Gene	Gene synonym	Ensembl	Gene description	Chromosome	Position	Protein class	Evidence	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Prognostic p-value	RNA cancer category	RNA tissue category	RNA TS	RNA TS TPM	TPM max in non-specific	RNA cell line category	RNA CS	RNA CS TPM
A3GALT2	A3GALT2P, IGB3S, IGBS3S	ENSG00000184389	Alpha 1,3-galactosyltransferase 2	1	33306766-33321098	Enzymes, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.6	Not detected		
A4GALT	A14GALT, Gb3S, P(k), P1	ENSG00000128274	Alpha 1,4-galactosyltransferase	22	42692121-42721298	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA001141, HPA076542			Supported	Mitochondria	Cervical cancer:2.48e-4 (favourable)	Expressed in all	Mixed			seminal vesicle: 30.5	Mixed		
AACS	ACSF1, FLJ12389, SUR-5	ENSG00000081760	Acetoacetyl-CoA synthetase	12	125065379-125143333	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA058815	Approved		Approved	Vesicles		Expressed in all	Expressed in all			breast: 55.0	Expressed in all		
AADACL3		ENSG00000188984	Arylacetamide deacetylase like 3	1	12716115-12728759	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		placenta: 1.3	skin: 0.7	Not detected		
AADACL4		ENSG00000204518	Arylacetamide deacetylase like 4	1	12644547-12667086	Predicted membrane proteins	Evidence at protein level	HPA043588	Uncertain					Not detected	Not detected			epididymis: 0.7	Not detected		
AASDH	ACSF4, LYS2, NRPS998	ENSG00000157426	Aminoadipate-semialdehyde dehydrogenase	4	56338287-56387508	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036472, HPA036473	Approved					Expressed in all	Mixed			parathyroid gland: 15.1	Expressed in all		
AATK	AATYK, AATYK1, KIAA0641, LMR1, LMTK1, PPP1R77	ENSG00000181409	Apoptosis associated tyrosine kinase	17	81117295-81166077	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009073	Enhanced		Uncertain	Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 36.4;duodenum: 23.4	small intestine: 18.3	Group enriched	5	CACO-2: 35.4;SH-SY5Y: 15.1
ABC7-42404400C24.1		ENSG00000277758		10	47750864-47763592	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA036971, HPA036972, HPA064559	Approved		Approved	Golgi apparatus		Not detected	Tissue enhanced		cerebral cortex: 13.8;lung: 19.3	skin: 5.7	Cell line enriched	7	SK-BR-3: 45.1
ABCA1	ABC1, HDLDT1, TGD	ENSG00000165029	ATP binding cassette subfamily A member 1	9	104781002-104928237	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA057283, CAB069889	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			adrenal gland: 38.0	Cell line enhanced		U-87 MG: 76.7
ABCA10	EST698739	ENSG00000154263	ATP binding cassette subfamily A member 10	17	69147214-69244846	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014535	Uncertain					Mixed	Mixed			ovary: 13.8	Cell line enhanced		HUVEC TERT2: 1.1;RT4: 1.0;U-2197: 1.8
ABCA12	DKFZP434G232, ICR2B, LI2	ENSG00000144452	ATP binding cassette subfamily A member 12	2	214931542-215138428	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA078239			Approved	Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Group enriched	6	breast: 7.7;skin: 25.2	tonsil: 2.5	Group enriched	6	hTCEpi: 28.4;SK-BR-3: 13.8;T-47d: 9.1
ABCA13	FLJ33876, FLJ33951	ENSG00000179869	ATP binding cassette subfamily A member 13	7	48171458-48647496	Predicted membrane proteins	Evidence at transcript level	HPA063601			Approved	Vesicles<br>Centrosome<br>Cytosol		Mixed	Tissue enriched	10	bone marrow: 29.4	testis: 3.0	Cell line enhanced		HDLM-2: 5.3;U-2 OS: 6.8
ABCA2	ABC2	ENSG00000107331	ATP binding cassette subfamily A member 2	9	137007227-137028922	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042886	Approved					Expressed in all	Tissue enriched	6	cerebral cortex: 97.9	thyroid gland: 17.1	Cell line enhanced		T-47d: 63.1
ABCA3	ABC-C, ABC3, EST111653, LBM180	ENSG00000167972	ATP binding cassette subfamily A member 3	16	2275881-2340746	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007884	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		lung: 135.5	cerebral cortex: 51.5	Cell line enhanced		SCLC-21H: 53.9;T-47d: 71.7
ABCA4	ABCR, ARMD2, CORD3, FFM, RP19, STGD, STGD1	ENSG00000198691	ATP binding cassette subfamily A member 4	1	93992835-94121132	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Lung cancer:2.45e-4 (favourable), Urothelial cancer:2.72e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		epididymis: 9.9	kidney: 4.2	Cell line enhanced		BEWO: 2.8;EFO-21: 6.2;SK-BR-3: 1.9
ABCA5	EST90625	ENSG00000154265	ATP binding cassette subfamily A member 5	17	69244311-69327244	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA022032, HPA062904	Approved		Approved	Nucleus	Pancreatic cancer:9.97e-5 (favourable)	Expressed in all	Expressed in all			skin: 28.0	Cell line enhanced		SiHa: 19.6
ABCA6	EST155051	ENSG00000154262	ATP binding cassette subfamily A member 6	17	69078702-69141888	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064878, HPA067180			Approved	Nucleoplasm	Liver cancer:3.29e-4 (favourable)	Tissue enriched	Tissue enhanced		liver: 41.4	ovary: 37.4	Cell line enhanced		ASC diff: 28.1;ASC TERT1: 41.4;HSkMC: 18.8;HUVEC TERT2: 47.8
ABCA7	ABCX	ENSG00000064687	ATP binding cassette subfamily A member 7	19	1040101-1065572	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041564	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:1.12e-4 (favourable), Colorectal cancer:7.26e-4 (unfavourable)	Expressed in all	Mixed			spleen: 25.3	Cell line enhanced		HMC-1: 52.2
ABCA8	KIAA0822	ENSG00000141338	ATP binding cassette subfamily A member 8	17	68867292-68955392	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044914	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			ovary: 67.5	Group enriched	6	ASC diff: 23.3;ASC TERT1: 52.5;HHSteC: 10.6;HSkMC: 41.5
ABCA9	EST640918	ENSG00000154258	ATP binding cassette subfamily A member 9	17	68974488-69061064	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052113, HPA054823	Uncertain		Approved	Endoplasmic reticulum		Mixed	Mixed			ovary: 32.5	Cell line enhanced		ASC diff: 14.7;ASC TERT1: 31.9;HSkMC: 11.9
ABCB1	ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1	ENSG00000085563	ATP binding cassette subfamily B member 1	7	87503633-87713323	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001716, HPA002199	Enhanced		Approved	Nucleoplasm<br>Focal adhesion sites<br>Cytosol	Renal cancer:2.95e-4 (favourable), Pancreatic cancer:3.33e-4 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 137.8;small intestine: 82.4	kidney: 37.3	Cell line enhanced		CACO-2: 56.6;HEL: 34.4;SH-SY5Y: 85.9
ABCB10	EST20237, M-ABC2, MTABC2	ENSG00000135776	ATP binding cassette subfamily B member 10	1	229516582-229558695	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB044063, CAB044065, HPA055175	Uncertain					Expressed in all	Expressed in all			bone marrow: 36.5	Expressed in all		
ABCB11	ABC16, BSEP, PFIC-2, PFIC2, PGY4, SPGP	ENSG00000073734	ATP binding cassette subfamily B member 11	2	168922938-169031322	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019035	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	13	liver: 19.1	testis: 1.4	Not detected		
ABCB4	GBD1, MDR2, MDR3, PFIC-3, PGY3	ENSG00000005471	ATP binding cassette subfamily B member 4	7	87401697-87480435	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049395, HPA053288	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites		Tissue enriched	Tissue enriched	6	liver: 69.3	adrenal gland: 10.7	Group enriched	6	SH-SY5Y: 14.2;WM-115: 25.6
ABCB5	ABCB5alpha, ABCB5beta, EST422562	ENSG00000004846	ATP binding cassette subfamily B member 5	7	20615207-20777038	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	7	epididymis: 32.3	gallbladder: 4.3	Cell line enriched	6	SK-MEL-30: 37.0
ABCB6	EST45597, MTABC3, umat	ENSG00000115657	ATP binding cassette subfamily B member 6 (Langereis blood group)	2	219209768-219218990	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046723, HPA058011	Approved		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Mitochondria<br>Cytosol	Renal cancer:1.52e-7 (unfavourable), Liver cancer:9.45e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 32.7	Mixed		
ABCB7	ABC7, ASAT, Atm1p, EST140535	ENSG00000131269	ATP binding cassette subfamily B member 7	X	75053172-75156732	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA034982	Approved		Supported	Mitochondria	Renal cancer:5.31e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.7	Expressed in all		
ABCB8	EST328128, M-ABC1, MABC1	ENSG00000197150	ATP binding cassette subfamily B member 8	7	151028422-151047782	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA045187	Approved		Supported	Nucleus<br>Mitochondria	Pancreatic cancer:3.34e-4 (favourable), Renal cancer:5.88e-4 (favourable), Head and neck cancer:5.91e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.1	Expressed in all		
ABCB9	EST122234	ENSG00000150967	ATP binding cassette subfamily B member 9	12	122920951-122981649	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB033052, HPA035113, HPA035114	Approved		Supported	Vesicles	Glioma:4.62e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 23.8	cerebral cortex: 12.0	Mixed		
ABCC1	GS-X, MRP, MRP1	ENSG00000103222	ATP binding cassette subfamily C member 1	16	15949577-16143074	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002380	Uncertain		Supported	Plasma membrane	Renal cancer:1.55e-6 (unfavourable), Liver cancer:5.42e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 18.6	Cell line enhanced		EFO-21: 84.1
ABCC10	EST182763, MRP7, SIMRP7	ENSG00000124574	ATP binding cassette subfamily C member 10	6	43427366-43450430	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041607, HPA045464	Approved				Renal cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 12.5	Expressed in all		
ABCC11	MRP8	ENSG00000121270	ATP binding cassette subfamily C member 11	16	48166910-48247568	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031980, HPA031981, HPA031982, CAB032513	Uncertain					Group enriched	Tissue enriched	11	breast: 64.4	prostate: 6.0	Cell line enriched	5	T-47d: 64.4
ABCC12	MRP9	ENSG00000140798	ATP binding cassette subfamily C member 12	16	48082973-48156018	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043100	Uncertain					Tissue enhanced	Tissue enhanced		testis: 2.9	breast: 0.6	Not detected		
ABCC2	CMOAT, cMRP, DJS, MRP2	ENSG00000023839	ATP binding cassette subfamily C member 2	10	99782732-99852192	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004860, CAB037271	Enhanced				Renal cancer:1.93e-5 (unfavourable)	Tissue enhanced	Group enriched	10	duodenum: 43.5;gallbladder: 42.7;kidney: 20.9;liver: 67.6;small intestine: 49.5	breast: 4.4	Cell line enhanced		A549: 203.8;Hep G2: 155.8
ABCC3	cMOAT2, EST90757, MLP2, MOAT-D, MRP3	ENSG00000108846	ATP binding cassette subfamily C member 3	17	50634777-50692252	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB037136, HPA048483	Enhanced		Approved	Plasma membrane	Renal cancer:4.68e-6 (unfavourable), Pancreatic cancer:9.57e-4 (unfavourable)	Mixed	Mixed			adrenal gland: 20.7	Cell line enhanced		A549: 69.8;CAPAN-2: 51.3
ABCC4	EST170205, MOAT-B, MOATB, MRP4	ENSG00000125257	ATP binding cassette subfamily C member 4	13	95019829-95301446	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002476	Enhanced				Renal cancer:2.25e-10 (favourable), Endometrial cancer:9.89e-4 (unfavourable)	Tissue enriched	Tissue enhanced		prostate: 70.4	epididymis: 23.6	Group enriched	5	HEL: 277.0;HMC-1: 278.6
ABCC5	EST277145, MOAT-C, MRP5, SMRP	ENSG00000114770	ATP binding cassette subfamily C member 5	3	183919934-184018015	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044067, HPA052295	Uncertain		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions	Liver cancer:6.78e-8 (unfavourable), Prostate cancer:3.40e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 72.6	Expressed in all		
ABCC6	ARA, EST349056, MLP1, MRP6, PXE, URG7	ENSG00000091262	ATP binding cassette subfamily C member 6	16	16148928-16223522	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038105			Supported	Plasma membrane	Liver cancer:3.82e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 16.9;liver: 23.4	duodenum: 13.0	Cell line enriched	6	Hep G2: 45.5
ABCC8	ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2	ENSG00000006071	ATP binding cassette subfamily C member 8	11	17392885-17476845	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB011451, HPA042318	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol		Tissue enriched	Tissue enhanced		cerebral cortex: 11.3	adrenal gland: 7.5	Cell line enhanced		A549: 1.7;AN3-CA: 1.8;SCLC-21H: 9.0
ABCC9	CMD1O, SUR2	ENSG00000069431	ATP binding cassette subfamily C member 9	12	21797401-21942529	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007279	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.85e-5 (unfavourable)	Mixed	Mixed			smooth muscle: 37.2	Cell line enhanced		ASC diff: 18.7;CACO-2: 21.7;HSkMC: 23.7;U-138 MG: 27.1
ABCD1	adrenoleukodystrophy, ALD, ALDP, AMN	ENSG00000101986	ATP binding cassette subfamily D member 1	X	153724868-153744762	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:5.50e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 19.3	Cell line enhanced		EFO-21: 65.5;PC-3: 46.4
ABCD2	ALDL1, ALDR, ALDRP	ENSG00000173208	ATP binding cassette subfamily D member 2	12	39550033-39619751	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enhanced		adipose tissue: 16.7	cervix, uterine: 8.5	Group enriched	6	ASC diff: 8.0;HDLM-2: 15.7;Karpas-707: 20.8;SH-SY5Y: 18.5;U-266/70: 7.4
ABCD3	PMP70, PXMP1, ZWS2	ENSG00000117528	ATP binding cassette subfamily D member 3	1	94418455-94518666	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032026, HPA032027, CAB032516, CAB075749	Enhanced		Enhanced	Peroxisomes	Colorectal cancer:1.16e-5 (favourable), Renal cancer:4.84e-5 (favourable)	Expressed in all	Expressed in all			liver: 66.4	Expressed in all		
ABCD4	EST352188, P70R, PMP69, PXMP1L	ENSG00000119688	ATP binding cassette subfamily D member 4	14	74285423-74303056	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003396	Approved					Expressed in all	Expressed in all			fallopian tube: 13.8	Expressed in all		
ABCG1	ABC8	ENSG00000160179	ATP binding cassette subfamily G member 1	21	42199689-42297244	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA031470, HPA031471	Approved		Supported	Golgi apparatus<br>Vesicles	Renal cancer:7.16e-6 (favourable)	Expressed in all	Expressed in all			lung: 43.5	Cell line enhanced		MCF7: 25.3;MOLT-4: 25.1;SCLC-21H: 26.2
ABCG2	ABCP, BCRP, CD338, EST157481, MXR	ENSG00000118777	ATP binding cassette subfamily G member 2 (Junior blood group)	4	88090264-88231322	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037299, HPA054719	Enhanced		Enhanced	Nucleus<br>Plasma membrane		Mixed	Tissue enhanced		small intestine: 113.8	seminal vesicle: 55.9	Cell line enhanced		A549: 47.2;BEWO: 80.5;RPMI-8226: 32.5
ABCG4	WHITE2	ENSG00000172350	ATP binding cassette subfamily G member 4	11	119149012-119162653	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA040312	Uncertain					Not detected	Group enriched	6	cerebral cortex: 6.6;parathyroid gland: 4.1;testis: 5.1	seminal vesicle: 0.8	Cell line enhanced		AN3-CA: 1.7;HAP1: 1.0
ABCG5	STSL	ENSG00000138075	ATP binding cassette subfamily G member 5	2	43812472-43838865	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016514			Approved	Nucleus	Liver cancer:2.60e-5 (favourable)	Tissue enriched	Group enriched	32	duodenum: 56.5;liver: 28.4;small intestine: 56.2	gallbladder: 1.4	Cell line enriched	37	Hep G2: 6.3
ABCG8	GBD4	ENSG00000143921	ATP binding cassette subfamily G member 8	2	43838964-43878466	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019556	Uncertain		Approved	Vesicles		Tissue enriched	Group enriched	25	duodenum: 50.0;liver: 34.0;small intestine: 55.5	gallbladder: 1.8	Cell line enriched	44	Hep G2: 6.9
ABHD1	FLJ36128, LABH1	ENSG00000143994	Abhydrolase domain containing 1	2	27123789-27130812	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044390	Uncertain					Mixed	Tissue enriched	17	testis: 30.0	liver: 1.7	Cell line enhanced		RPMI-8226: 1.1;T-47d: 3.0;U-266/70: 2.4;U-266/84: 1.9
ABHD12	ABHD12A, BEM46L2, C20orf22, dJ965G21.2, DKFZP434P106	ENSG00000100997	Abhydrolase domain containing 12	20	25294743-25390983	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026866	Uncertain				Cervical cancer:1.30e-5 (favourable), Breast cancer:3.81e-5 (unfavourable), Liver cancer:7.18e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 137.3	Expressed in all		
ABHD13	bA153I24.2, BEM46L1, C13orf6, FLJ14906	ENSG00000139826	Abhydrolase domain containing 13	13	108218379-108234255	Predicted membrane proteins	Evidence at protein level	HPA032143, HPA032144	Approved		Approved	Cytosol		Expressed in all	Mixed			thyroid gland: 12.7	Expressed in all		
ABHD14A	DKFZP564O243, DORZ1	ENSG00000248487	Abhydrolase domain containing 14A	3	51971426-51981199	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038153, HPA056913			Enhanced	Vesicles	Lung cancer:4.72e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 51.0	Expressed in all		
ABHD16A	BAT5, D6S82E, NG26	ENSG00000204427	Abhydrolase domain containing 16A	6	31686949-31703444	Predicted membrane proteins	Evidence at protein level	HPA058606	Approved				Endometrial cancer:2.63e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 1.7;testis: 1.2;thyroid gland: 1.4	esophagus: 0.9	Not detected		
ABHD2	LABH2	ENSG00000140526	Abhydrolase domain containing 2	15	89087459-89202360	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA005999	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.18e-7 (favourable)	Expressed in all	Expressed in all			testis: 93.8	Expressed in all		
ABHD3	LABH3	ENSG00000158201	Abhydrolase domain containing 3	18	21650897-21704805	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010729	Approved		Approved	Nucleus<br>Vesicles<br>Plasma membrane	Melanoma:8.52e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 71.5	Cell line enhanced		REH: 188.5;RPMI-8226: 159.6
ABHD6		ENSG00000163686	Abhydrolase domain containing 6	3	58237506-58295693	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA017283, HPA073225	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.11e-11 (favourable), Colorectal cancer:1.13e-4 (favourable)	Expressed in all	Mixed			small intestine: 50.9	Mixed		
ABO	A3GALNT, A3GALT1	ENSG00000175164	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	9	133250401-133275214	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		small intestine: 17.9	colon: 7.3	Group enriched	7	A-431: 4.5;CAPAN-2: 18.7;HaCaT: 14.1;K-562: 18.6;RT4: 6.3
AC004754.3		ENSG00000269881		16	249547-269943	Predicted membrane proteins	Evidence at transcript level	HPA011651, HPA071871	Uncertain		Uncertain	Nucleoplasm<br>Mitochondria		Not detected	Group enriched	5	duodenum: 14.2;small intestine: 7.8	testis: 2.0	Cell line enhanced		EFO-21: 1.5
AC006538.4		ENSG00000267001		19	2717769-2740048	Predicted membrane proteins	Evidence at protein level	HPA058526	Uncertain					Not detected	Mixed			testis: 3.9	Mixed		
AC007040.11		ENSG00000258881		2	70939318-70995336	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.1	skin: 0.7	Cell line enhanced		U-2 OS: 2.3
AC009014.3		ENSG00000271824		5	136191468-136193134	Predicted membrane proteins	Evidence at transcript level						Liver cancer:1.63e-4 (favourable), Pancreatic cancer:6.13e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 13.2;kidney: 22.7	small intestine: 6.8	Cell line enhanced		SCLC-21H: 2.0
AC009477.8		ENSG00000284479		2	131035092-131035262	Predicted membrane proteins	Evidence at transcript level								Tissue enriched	8	adipose tissue: 1.1	colon,small intestine: 0.1	Cell line enhanced		HEK93: 1.4
AC018755.18		ENSG00000268500		19	51612091-51646889	Predicted membrane proteins	Evidence at transcript level	HPA009085	Approved					Not detected	Tissue enhanced		appendix: 10.0;bone marrow: 17.4	spleen: 5.5	Group enriched	14	HMC-1: 68.6;U-937: 25.7
AC024592.12		ENSG00000267740		19	5866171-5903787	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA072209			Uncertain	Mitochondria		Not detected	Mixed			adrenal gland: 1.5	Mixed		
AC114783.1		ENSG00000237524		2	126898882-126902097	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	183	testis: 57.8	kidney: 0.3	Not detected		
AC136616.1		ENSG00000273554		Unmapped	1139577-1147868	Predicted membrane proteins	Evidence at transcript level								Group enriched	6	skin: 1.6;testis: 6.9	adrenal gland: 0.6	Cell line enriched	6	AN3-CA: 14.2
AC138517.6		ENSG00000283288		5	139470778-139474772	Predicted membrane proteins	Evidence at transcript level								Tissue enhanced		rectum: 2.6	colon: 1.6	Not detected		
AC138969.4		ENSG00000183889		16	16317444-16350590	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Expressed in all			skin: 116.2	Expressed in all		
AC171558.1		ENSG00000274792		Unmapped	386278-387620	Predicted membrane proteins	Evidence at transcript level	HPA057442	Uncertain		Uncertain	Centrosome			Tissue enriched	11	testis: 4.3	cerebral cortex: 0.4	Cell line enriched	29	U-2 OS: 3.3
AC171558.2		ENSG00000275249		Unmapped	372322-373405	Predicted membrane proteins	Evidence at transcript level	HPA058889	Uncertain						Tissue enriched	26	testis: 2.5	all non-specific tissues: 0.0	Not detected		
AC213203.1		ENSG00000277475		Unmapped	31698-32528	Predicted membrane proteins	Evidence at transcript level								Tissue enriched	11	testis: 24.2	lung: 2.2	Cell line enhanced		A549: 6.4;HMC-1: 4.8;SCLC-21H: 5.4
ACBD4	FLJ13322	ENSG00000181513	Acyl-CoA binding domain containing 4	17	45132600-45144181	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051772	Approved		Approved	Nucleus<br>Vesicles	Pancreatic cancer:4.64e-4 (favourable), Liver cancer:4.76e-4 (favourable), Urothelial cancer:6.53e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 30.3	Mixed		
ACBD5	DKFZp434A2417, KIAA1996	ENSG00000107897	Acyl-CoA binding domain containing 5	10	27195214-27242130	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011861, HPA012145	Enhanced		Enhanced	Peroxisomes	Renal cancer:4.68e-5 (favourable), Breast cancer:3.33e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 57.1	Expressed in all		
ACE	ACE1, CD143, DCP1	ENSG00000159640	Angiotensin I converting enzyme	17	63477061-63498380	Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002426, CAB002921, HPA029298, HPA069790	Enhanced		Approved	Vesicles		Expressed in all	Tissue enhanced		duodenum: 178.9;small intestine: 291.6	testis: 83.7	Cell line enhanced		ASC TERT1: 44.4;HUVEC TERT2: 28.2
ACE2		ENSG00000130234	Angiotensin I converting enzyme 2	X	15561033-15602148	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA000288, CAB026174	Enhanced				Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable)	Tissue enhanced	Group enriched	5	duodenum: 181.1;gallbladder: 100.2;kidney: 94.0;small intestine: 261.1;testis: 93.0	heart muscle: 27.9	Cell line enhanced		HaCaT: 1.1
ACER1	ASAH3	ENSG00000167769	Alkaline ceramidase 1	19	6306142-6333629	Enzymes, Predicted membrane proteins	Evidence at transcript level							Group enriched	Tissue enriched	6	skin: 67.8	esophagus: 11.4	Cell line enhanced		T-47d: 2.7
ACER2	ALKCDase2, ASAH3L, FLJ41587	ENSG00000177076	Alkaline ceramidase 2	9	19409059-19452020	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Group enriched	5	placenta: 14.8;stomach: 62.9;urinary bladder: 44.1	skin: 7.6	Group enriched	5	BEWO: 30.0;RT4: 62.6
ACER3	APHC, FLJ11238, PHCA	ENSG00000078124	Alkaline ceramidase 3	11	76860867-77026797	Predicted membrane proteins	Evidence at protein level	HPA070087	Approved				Liver cancer:2.49e-4 (unfavourable), Renal cancer:2.73e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 14.2	Mixed		
ACHE	YT	ENSG00000087085	Acetylcholinesterase (Cartwright blood group)	7	100889994-100896974	Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019704, HPA027098			Approved	Golgi apparatus<br>Vesicles	Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 58.5	cerebral cortex: 14.1	Cell line enhanced		BEWO: 11.7;CACO-2: 17.5;K-562: 20.7;Karpas-707: 25.8
ACKR1	CCBP1, CD234, DARC, Dfy, FY, GPD	ENSG00000213088	Atypical chemokine receptor 1 (Duffy blood group)	1	159203307-159206500	Blood group antigen proteins, CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA016421, HPA017672	Enhanced				Cervical cancer:2.52e-5 (favourable), Liver cancer:1.48e-4 (favourable), Thyroid cancer:9.76e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 112.8	Group enriched	6	HEL: 30.2;HSkMC: 23.2
ACKR2	CCBP2, CCR10, CCR9, CMKBR9, D6	ENSG00000144648	Atypical chemokine receptor 2	3	42804752-42887974	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013819, HPA073493	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol		Mixed	Tissue enhanced		placenta: 22.9	adipose tissue: 5.3	Cell line enhanced		BEWO: 50.1;HEL: 15.5;SK-BR-3: 21.0
ACKR3	CMKOR1, CXCR7, GPR159, RDC1	ENSG00000144476	Atypical chemokine receptor 3	2	236567787-236582358	Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA032003, HPA049718	Approved		Supported	Vesicles<br>Plasma membrane	Renal cancer:1.76e-6 (unfavourable), Stomach cancer:2.01e-4 (unfavourable), Urothelial cancer:2.93e-4 (unfavourable), Cervical cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 176.7	Cell line enhanced		RT4: 248.8;SiHa: 100.8;U-2197: 297.4
ACKR4	CCBP2, CCR11, CCRL1, CCX-CKR, PPR1, VSHK1	ENSG00000129048	Atypical chemokine receptor 4	3	132597237-132618967	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA054926			Approved	Vesicles<br>Mitochondria		Mixed	Mixed			duodenum: 19.1	Cell line enriched	6	BJ hTERT+: 281.6
ACP2	LAP	ENSG00000134575	Acid phosphatase 2, lysosomal	11	47239302-47248906	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 41.2	Expressed in all		
ACPP	ACP-3, ACP3, PAP	ENSG00000014257	Acid phosphatase, prostate	3	132317367-132368298	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000071, HPA004335, HPA063916	Enhanced					Tissue enriched	Tissue enriched	145	prostate: 6030.6	esophagus: 41.4	Cell line enhanced		BJ hTERT+: 14.1;RPMI-8226: 39.1;U-87 MG: 14.6
ACPT		ENSG00000142513	Acid phosphatase, testicular	19	50790415-50795224	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 1.4;testis: 2.2	parathyroid gland: 0.5	Cell line enhanced		HEK93: 1.3;U-266/84: 1.3
ACSBG2	BGR, DKFZp434K1635, PRTD-NY3	ENSG00000130377	Acyl-CoA synthetase bubblegum family member 2	19	6135247-6193094	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043421, HPA051013	Enhanced		Uncertain	Cytosol		Not detected	Tissue enriched	716	testis: 294.0	cerebral cortex: 0.4	Not detected		
ACSF2	ACSMW, FLJ20920	ENSG00000167107	Acyl-CoA synthetase family member 2	17	50426158-50474845	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA024693	Enhanced		Approved	Nucleoplasm<br>Microtubules<br>Cytosol	Renal cancer:2.17e-4 (unfavourable), Urothelial cancer:2.41e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 136.9	thyroid gland: 68.6	Expressed in all		
ACSF3		ENSG00000176715	Acyl-CoA synthetase family member 3	16	89088375-89155846	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:5.97e-6 (favourable), Pancreatic cancer:3.76e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 31.0	Expressed in all		
ACSL1	ACS1, FACL1, FACL2, LACS, LACS1, LACS2	ENSG00000151726	Acyl-CoA synthetase long-chain family member 1	4	184755595-184826818	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011316, HPA011964	Enhanced		Supported	Nucleus<br>Mitochondria	Renal cancer:1.25e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 824.0	Expressed in all		
ACSL3	ACS3, FACL3, PRO2194	ENSG00000123983	Acyl-CoA synthetase long-chain family member 3	2	222860934-222944639	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011315, HPA071021	Uncertain		Approved	Nucleoli<br>Lipid droplets	Liver cancer:2.75e-4 (unfavourable), Lung cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 682.1	Expressed in all		
ACSL4	ACS4, FACL4, LACS4, MRX63, MRX68	ENSG00000068366	Acyl-CoA synthetase long-chain family member 4	X	109624244-109733403	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000286, HPA005552	Enhanced		Approved	Golgi apparatus<br>Mitochondria	Urothelial cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 70.7	Cell line enhanced		HMC-1: 324.7
ACSL5	ACS2, ACS5, FACL5	ENSG00000197142	Acyl-CoA synthetase long-chain family member 5	10	112374018-112428380	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007162, CAB035986, CAB062546	Enhanced		Supported	Nucleus<br>Mitochondria	Endometrial cancer:1.13e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 460.3	Cell line enhanced		CAPAN-2: 121.7;RT4: 114.0
ACSL6	ACS2, FACL6, KIAA0837, LACS2, LACS5	ENSG00000164398	Acyl-CoA synthetase long-chain family member 6	5	131949973-132012243	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040470	Enhanced					Group enriched	Group enriched	6	bone marrow: 18.0;cerebral cortex: 61.9;parathyroid gland: 22.5;seminal vesicle: 29.0;testis: 51.4	adrenal gland: 6.4	Group enriched	6	SCLC-21H: 13.0;U-937: 5.2
ACSM1	BUCS1, MACS1	ENSG00000166743	Acyl-CoA synthetase medium-chain family member 1	16	20623237-20698890	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046291	Uncertain					Group enriched	Tissue enriched	49	breast: 298.7	prostate: 6.0	Group enriched	11	K-562: 3.2;NTERA-2: 15.6
ACSM2A	A-923A4.1, ACSM2, MGC150530	ENSG00000183747	Acyl-CoA synthetase medium-chain family member 2A	16	20451461-20487667	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057699	Supported				Liver cancer:1.41e-5 (favourable)	Group enriched	Group enriched	580	kidney: 285.2;liver: 185.7	cerebral cortex: 0.4	Cell line enhanced		Hep G2: 1.3
ACSM2B	ACSM2, HXMA, HYST1046	ENSG00000066813	Acyl-CoA synthetase medium-chain family member 2B	16	20536226-20576427	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057699	Supported				Liver cancer:3.31e-4 (favourable)	Group enriched	Group enriched	136	kidney: 426.7;liver: 262.0	thyroid gland: 2.5	Cell line enhanced		AF22: 2.8;Hep G2: 3.7
ACSM4		ENSG00000215009	Acyl-CoA synthetase medium-chain family member 4	12	7304284-7328724	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA049895	Uncertain					Not detected	Tissue enhanced		testis: 1.7	spleen: 0.7	Cell line enhanced		HDLM-2: 1.6;NB-4: 1.1;SH-SY5Y: 2.2;U-87 MG: 2.8
ACSM6	bA310E22.3, C10orf129	ENSG00000173124	Acyl-CoA synthetase medium-chain family member 6	10	95194200-95228928	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA044593	Uncertain				Urothelial cancer:7.71e-4 (favourable)	Tissue enriched	Tissue enhanced		stomach: 1.7	urinary bladder: 0.6	Cell line enriched	27	RT4: 3.0
ACSS1	ACAS2L, AceCS2L, dJ568C11.3, MGC33843	ENSG00000154930	Acyl-CoA synthetase short-chain family member 1	20	25006230-25058980	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041014, HPA043228	Enhanced				Lung cancer:8.33e-5 (favourable), Cervical cancer:9.37e-4 (favourable)	Expressed in all	Expressed in all			placenta: 166.2	Cell line enhanced		RPMI-8226: 51.0
ACSS2	ACAS2, AceCS, ACS, ACSA, dJ1161H23.1	ENSG00000131069	Acyl-CoA synthetase short-chain family member 2	20	34872146-34927962	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004141	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.04e-4 (favourable)	Expressed in all	Mixed			adipose tissue: 55.9	Mixed		
ACSS3	FLJ21963	ENSG00000111058	Acyl-CoA synthetase short-chain family member 3	12	80936414-81261205	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA039353, HPA047956, HPA061517	Approved		Approved	Mitochondria	Renal cancer:0.00e+0 (favourable)	Mixed	Mixed			parathyroid gland: 33.7	Cell line enhanced		Hep G2: 28.4;RH-30: 18.1;SK-BR-3: 13.2
ACVR1	ACVR1A, ACVRLK2, ALK2, SKR1	ENSG00000115170	Activin A receptor type 1	2	157736444-157875862	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007505, HPA046514	Approved		Approved	Nucleoli<br>Cytosol	Urothelial cancer:5.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.2	Mixed		
ACVR1B	ActRIB, ACVRLK4, ALK4, SKR2	ENSG00000135503	Activin A receptor type 1B	12	51951667-51997078	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026126, HPA063761	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 54.6	Expressed in all		
ACVR1C	ACVRLK7, ALK7	ENSG00000123612	Activin A receptor type 1C	2	157526767-157629005	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007982, HPA011933	Approved					Mixed	Tissue enriched	8	adipose tissue: 34.1	ovary: 4.3	Cell line enhanced		ASC diff: 7.5;HDLM-2: 4.8
ACVR2A	ACTRII, ACVR2	ENSG00000121989	Activin A receptor type 2A	2	147844517-147930826	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046997	Approved		Approved	Cytosol	Renal cancer:1.62e-4 (favourable)	Expressed in all	Mixed			skin: 22.5	Mixed		
ACVR2B	ActR-IIB	ENSG00000114739	Activin A receptor type 2B	3	38453851-38493142	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA007398, CAB025115, HPA040384	Approved		Approved	Nucleus<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 6.4	Cell line enhanced		AF22: 20.5;NTERA-2: 25.8
ACVRL1	ACVRLK1, ALK1, HHT, HHT2, ORW2	ENSG00000139567	Activin A receptor like type 1	12	51906908-51923361	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007041	Approved					Expressed in all	Tissue enhanced		placenta: 126.4	lung: 76.4	Cell line enhanced		ASC diff: 42.2;EFO-21: 52.0;HUVEC TERT2: 171.4;TIME: 130.8
ADAM10	CD156c, HsT18717, kuz, MADM	ENSG00000137845	ADAM metallopeptidase domain 10	15	58588807-58749978	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB001709, HPA050670	Approved		Supported	Vesicles<br>Plasma membrane	Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 47.9	Expressed in all		
ADAM11	MDC	ENSG00000073670	ADAM metallopeptidase domain 11	17	44759031-44781846	Predicted membrane proteins, Transporters	Evidence at protein level	HPA074550	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 19.8	heart muscle: 4.0	Cell line enhanced		HEK93: 18.5
ADAM12	MCMPMltna, MLTN	ENSG00000148848	ADAM metallopeptidase domain 12	10	126012381-126388455	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA030866, HPA030867, HPA030868	Enhanced		Supported	Plasma membrane	Renal cancer:2.39e-14 (unfavourable)	Mixed	Tissue enriched	8	placenta: 237.2	cervix, uterine: 29.7	Cell line enhanced		fHDF/TERT166: 119.5;hTEC/SVTERT24-B: 94.3;U-2197: 86.6;U-251 MG: 71.0
ADAM15	MDC15	ENSG00000143537	ADAM metallopeptidase domain 15	1	155050566-155062775	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011633, HPA072878	Uncertain		Uncertain	Vesicles	Renal cancer:5.64e-9 (unfavourable), Glioma:3.49e-5 (unfavourable), Liver cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 72.6	Cell line enhanced		PC-3: 305.3
ADAM17	CD156B, cSVP, TACE	ENSG00000151694	ADAM metallopeptidase domain 17	2	9488486-9555792	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA010738, CAB025906, HPA051575	Approved		Supported	Cytosol	Urothelial cancer:4.23e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 33.8	Expressed in all		
ADAM18	ADAM27, tMDCIII	ENSG00000168619	ADAM metallopeptidase domain 18	8	39584489-39730064	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	85	testis: 8.4	all non-specific tissues: 0.0	Not detected		
ADAM19	MLTNB	ENSG00000135074	ADAM metallopeptidase domain 19	5	157395534-157575775	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA055537			Approved	Vesicles	Renal cancer:3.90e-12 (unfavourable)	Expressed in all	Mixed			lymph node: 34.4	Cell line enhanced		HDLM-2: 101.7;U-251 MG: 170.3
ADAM2	CT15, FTNB, PH-30b, PH30	ENSG00000104755	ADAM metallopeptidase domain 2	8	39743735-39838289	Predicted membrane proteins	Evidence at protein level	CAB022390, HPA024621, HPA026581	Enhanced					Tissue enhanced	Tissue enriched	284	testis: 41.9	breast: 0.1	Not detected		
ADAM20		ENSG00000134007	ADAM metallopeptidase domain 20	14	70522358-70535015	Predicted membrane proteins	Evidence at protein level	HPA059377	Enhanced					Not detected	Tissue enriched	77	testis: 9.2	cerebral cortex,endometrium,epididymis,skin: 0.1	Not detected		
ADAM21	ADAM31	ENSG00000139985	ADAM metallopeptidase domain 21	14	70452157-70459899	Predicted membrane proteins	Evidence at protein level	HPA059016	Uncertain					Not detected	Tissue enriched	31	testis: 15.5	cerebral cortex: 0.5	Cell line enhanced		U-138 MG: 1.4;U-251 MG: 1.1
ADAM22	MDC2	ENSG00000008277	ADAM metallopeptidase domain 22	7	87934143-88202889	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050325			Approved	Cell Junctions		Mixed	Tissue enhanced		cerebral cortex: 47.6	prostate: 18.2	Cell line enhanced		Karpas-707: 58.7;SH-SY5Y: 81.7
ADAM23	MDC3	ENSG00000114948	ADAM metallopeptidase domain 23	2	206443539-206621130	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012130, CAB033276	Uncertain					Mixed	Group enriched	6	cerebral cortex: 55.4;parathyroid gland: 135.3	heart muscle: 16.5	Cell line enhanced		RH-30: 61.7;RPMI-8226: 120.2
ADAM28	ADAM23, eMDCII, MDC-Lm, MDC-Ls	ENSG00000042980	ADAM metallopeptidase domain 28	8	24294040-24359018	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA074034	Enhanced		Approved	Plasma membrane<br>Mitochondria	Endometrial cancer:3.17e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 435.5	stomach: 104.6	Cell line enriched	10	CAPAN-2: 24.6
ADAM29	CT73, svph1	ENSG00000168594	ADAM metallopeptidase domain 29	4	174829668-174978180	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	145	testis: 73.3	endometrium: 0.5	Not detected		
ADAM30	svph4	ENSG00000134249	ADAM metallopeptidase domain 30	1	119893533-119896495	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA026080	Uncertain					Not detected	Tissue enriched	471	testis: 47.0	all non-specific tissues: 0.0	Not detected		
ADAM32		ENSG00000197140	ADAM metallopeptidase domain 32	8	39106990-39284911	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044156, HPA062151	Enhanced		Approved	Nucleus<br>Vesicles		Not detected	Tissue enriched	35	testis: 28.7	skin: 0.8	Cell line enhanced		U-2 OS: 1.1
ADAM33	C20orf153, dJ964F7.1, DKFZp434K0521	ENSG00000149451	ADAM metallopeptidase domain 33	20	3667965-3682246	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA067152, HPA071758	Approved		Uncertain	Nuclear speckles<br>Plasma membrane		Mixed	Mixed			endometrium: 103.3	Cell line enhanced		ASC diff: 55.2;ASC TERT1: 72.4;BJ: 31.3;BJ hTERT+: 51.1;fHDF/TERT166: 29.6;U-2197: 46.1
ADAM7	EAPI, GP-83	ENSG00000069206	ADAM metallopeptidase domain 7	8	24440930-24526970	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008879	Enhanced					Group enriched	Tissue enriched	199	epididymis: 4534.6	seminal vesicle: 22.7	Group enriched	23	BEWO: 2.3;NB-4: 3.9;RPMI-8226: 1.1;SH-SY5Y: 1.9
ADAM8	CD156, CD156a, MS2	ENSG00000151651	ADAM metallopeptidase domain 8	10	133262403-133276868	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064637	Approved				Renal cancer:3.99e-10 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 43.8;spleen: 32.9	appendix: 30.1	Cell line enhanced		A-431: 51.7;BEWO: 78.4;CAPAN-2: 61.7;HaCaT: 61.1;HDLM-2: 42.3;U-87 MG: 33.6
ADAM9	CORD9, KIAA0021, MCMP, MDC9, Mltng	ENSG00000168615	ADAM metallopeptidase domain 9	8	38996869-39105144	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004000			Approved	Endoplasmic reticulum<br>Vesicles	Liver cancer:7.21e-6 (unfavourable), Pancreatic cancer:2.52e-5 (unfavourable), Breast cancer:1.14e-4 (unfavourable), Cervical cancer:2.25e-4 (unfavourable), Renal cancer:3.99e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 118.7	Expressed in all		
ADAMTS1	C3-C5, KIAA1346, METH1	ENSG00000154734	ADAM metallopeptidase with thrombospondin type 1 motif 1	21	26835747-26845409	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016394	Uncertain				Head and neck cancer:5.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		ovary: 412.9	adipose tissue: 279.9	Cell line enhanced		BJ: 346.6;hTEC/SVTERT24-B: 277.6
ADAMTS4	ADAMTS-2, ADMP-1, KIAA0688	ENSG00000158859	ADAM metallopeptidase with thrombospondin type 1 motif 4	1	161184308-161199056	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025876, HPA051296, HPA068374	Uncertain		Approved	Nuclear speckles	Renal cancer:7.27e-7 (unfavourable), Lung cancer:5.00e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 62.8	appendix: 22.9	Cell line enhanced		hTEC/SVTERT24-B: 11.8;HUVEC TERT2: 12.0;SH-SY5Y: 8.4;TIME: 9.9;U-251 MG: 9.0
ADCK2	MGC20727	ENSG00000133597	AarF domain containing kinase 2	7	140673153-140696261	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036036	Approved		Uncertain	Centrosome<br>Cytosol	Renal cancer:9.75e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.2	Mixed		
ADCK5	FLJ35454	ENSG00000173137	AarF domain containing kinase 5	8	144373101-144393242	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA025692, HPA028679	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Mixed			duodenum: 9.6	Mixed		
ADCY1	AC1, DFNB44	ENSG00000164742	Adenylate cyclase 1	7	45574140-45723116	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018364, HPA068274	Uncertain		Approved	Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 35.0	cervix, uterine: 8.2	Cell line enhanced		hTERT-HME1: 17.5;SCLC-21H: 16.1;SH-SY5Y: 27.5;SK-MEL-30: 23.8;WM-115: 17.1
ADCY10	HCA2, RP1-313L4.2, SAC, SACI, Sacy	ENSG00000143199	Adenylate cyclase 10, soluble	1	167809388-167914215	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015243, HPA017749	Approved					Tissue enhanced	Tissue enriched	11	testis: 33.1	liver: 3.1	Cell line enhanced		T-47d: 1.3
ADCY2	AC2, HBAC2, KIAA1060	ENSG00000078295	Adenylate cyclase 2	5	7396208-7830081	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB031482, HPA038015, HPA038483	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 57.2;skeletal muscle: 23.6	prostate: 8.4	Group enriched	7	AF22: 5.6;NTERA-2: 4.3;SK-MEL-30: 3.8
ADCY3	AC3	ENSG00000138031	Adenylate cyclase 3	2	24819169-24919839	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB010223	Approved				Renal cancer:1.32e-9 (unfavourable)	Expressed in all	Expressed in all			placenta: 122.5	Expressed in all		
ADCY4	AC4	ENSG00000129467	Adenylate cyclase 4	14	24318349-24335093	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB005070, HPA048344	Approved				Renal cancer:7.01e-4 (unfavourable), Endometrial cancer:8.20e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 21.1	lung: 11.6	Group enriched	6	HUVEC TERT2: 7.8;TIME: 3.1
ADCY5	AC5	ENSG00000173175	Adenylate cyclase 5	3	123282296-123449758	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017730, HPA077682	Uncertain		Enhanced	Intermediate filaments	Renal cancer:7.46e-6 (favourable)	Mixed	Tissue enhanced		heart muscle: 69.1	prostate,seminal vesicle: 30.0	Cell line enhanced		MCF7: 11.9;RPTEC TERT1: 4.0
ADCY6	AC6	ENSG00000174233	Adenylate cyclase 6	12	48766194-48789037	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018365	Approved		Approved	Golgi apparatus	Liver cancer:8.23e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 44.6	Mixed		
ADCY7	AC7, KIAA0037	ENSG00000121281	Adenylate cyclase 7	16	50246137-50318135	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041218, HPA048241	Uncertain		Approved	Cytosol	Cervical cancer:5.31e-4 (unfavourable)	Mixed	Mixed			spleen: 44.0	Cell line enhanced		HMC-1: 186.7;RPMI-8226: 76.6
ADCY8	AC8, ADCY3, HBAC1	ENSG00000155897	Adenylate cyclase 8	8	130780301-131042426	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018652, HPA024291	Supported					Group enriched	Group enriched	8	cerebral cortex: 12.9;epididymis: 27.8;fallopian tube: 6.2	seminal vesicle: 2.0	Group enriched	7	U-138 MG: 17.5;U-87 MG: 33.7
ADCY9	AC9	ENSG00000162104	Adenylate cyclase 9	16	3953387-4116185	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041328, HPA044225	Approved		Approved	Cytosol	Renal cancer:5.24e-8 (favourable), Endometrial cancer:2.55e-5 (unfavourable)	Expressed in all	Mixed			thyroid gland: 31.9	Mixed		
ADCYAP1R1	PAC1, PAC1R, PACAPR	ENSG00000078549	ADCYAP receptor type I	7	31052461-31111479	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA030739, HPA049877	Enhanced		Supported	Vesicles	Endometrial cancer:5.78e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 137.1;fallopian tube: 46.8	cervix, uterine: 20.7	Group enriched	6	AF22: 3.6;NTERA-2: 4.9;SCLC-21H: 4.8;SH-SY5Y: 7.8
ADGRA1	GPR123, KIAA1828	ENSG00000197177	Adhesion G protein-coupled receptor A1	10	133070929-133131675	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA042773	Approved					Tissue enriched	Tissue enhanced		adrenal gland: 4.9;cerebral cortex: 22.4	fallopian tube: 3.1	Cell line enriched	24	RH-30: 6.1
ADGRA2	DKFZp434C211, DKFZp434J0911, FLJ14390, GPR124, KIAA1531, TEM5	ENSG00000020181	Adhesion G protein-coupled receptor A2	8	37784191-37844896	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012393	Uncertain				Renal cancer:3.18e-7 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 89.6	Cell line enhanced		ASC diff: 66.7;ASC TERT1: 45.4;BJ hTERT+: 61.4;fHDF/TERT166: 60.9
ADGRA3	FLJ38547, GPR125, PGR21	ENSG00000152990	Adhesion G protein-coupled receptor A3	4	22345071-22516054	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008904	Uncertain					Expressed in all	Expressed in all			thyroid gland: 42.5	Mixed		
ADGRB1	BAI1	ENSG00000181790	Adhesion G protein-coupled receptor B1	8	142449430-142545009	Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	10	cerebral cortex: 22.0	spleen: 2.2	Cell line enhanced		AN3-CA: 10.7;RPMI-8226: 12.0;U-2 OS: 11.7
ADGRB2	BAI2	ENSG00000121753	Adhesion G protein-coupled receptor B2	1	31727117-31764893	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052612, HPA054617			Supported	Centrosome	Lung cancer:4.02e-5 (unfavourable), Breast cancer:6.46e-4 (favourable)	Tissue enhanced	Tissue enriched	14	cerebral cortex: 72.3	adrenal gland: 5.1	Cell line enhanced		SH-SY5Y: 26.4;T-47d: 27.3;U-2 OS: 28.9
ADGRB3	BAI3, KIAA0550	ENSG00000135298	Adhesion G protein-coupled receptor B3	6	68635367-69389511	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	10	cerebral cortex: 53.1	adrenal gland: 5.1	Group enriched	5	SCLC-21H: 10.4;SH-SY5Y: 20.2
ADGRD1	DKFZp434B1272, GPR133, PGR25	ENSG00000111452	Adhesion G protein-coupled receptor D1	12	130953907-131141469	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042395	Uncertain		Approved	Nucleus<br>Cytosol	Liver cancer:9.27e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 44.7	lung: 32.4	Cell line enhanced		BJ: 4.0;fHDF/TERT166: 4.1;HeLa: 6.4;HHSteC: 5.0;HMC-1: 11.4;U-2 OS: 6.6
ADGRD2	GPR144, PGR24	ENSG00000180264	Adhesion G protein-coupled receptor D2	9	124451425-124478589	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		seminal vesicle: 1.8	skin: 0.5	Not detected		
ADGRE1	EMR1, TM7LN3	ENSG00000174837	Adhesion G protein-coupled receptor E1	19	6887566-6940459	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA052809	Uncertain					Mixed	Tissue enhanced		appendix: 9.9;spleen: 19.7	lung: 6.8	Cell line enhanced		BJ hTERT+: 8.5;HDLM-2: 24.5;HMC-1: 15.9;Karpas-707: 16.0
ADGRE2	CD312, EMR2	ENSG00000127507	Adhesion G protein-coupled receptor E2	19	14732393-14778541	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA055200			Uncertain	Vesicles	Renal cancer:4.35e-6 (unfavourable)	Mixed	Tissue enhanced		appendix: 27.0;spleen: 15.4	adipose tissue: 6.0	Cell line enhanced		HEL: 10.6;HMC-1: 16.0;U-937: 11.8
ADGRE3	EMR3	ENSG00000131355	Adhesion G protein-coupled receptor E3	19	14619117-14690027	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA015638	Uncertain					Not detected	Tissue enhanced		appendix: 8.7;spleen: 8.6	lung: 3.9	Cell line enriched	50	HMC-1: 39.7
ADGRE5	CD97, TM7LN1	ENSG00000123146	Adhesion G protein-coupled receptor E5	19	14380501-14408725	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA013707	Enhanced		Approved	Cytosol	Renal cancer:1.87e-6 (unfavourable), Liver cancer:3.73e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 140.3	Mixed		
ADGRF1	GPR110, hGPCR36, PGR19	ENSG00000153292	Adhesion G protein-coupled receptor F1	6	46997703-47042363	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038438	Approved				Renal cancer:1.35e-5 (favourable)	Mixed	Tissue enhanced		esophagus: 14.6;kidney: 17.6;urinary bladder: 18.9	gallbladder: 9.4	Group enriched	9	A-431: 27.0;CAPAN-2: 99.3;HaCaT: 22.4;PC-3: 33.9;RPTEC TERT1: 38.6;RT4: 104.1
ADGRF2	GPR111, hGPCR35, PGR20	ENSG00000164393	Adhesion G protein-coupled receptor F2	6	47656436-47697797	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA035507	Uncertain					Not detected	Tissue enhanced		fallopian tube: 1.5;skin: 1.4	esophagus: 0.3	Not detected		
ADGRF3	GPR113, hGPCR37, PGR23	ENSG00000173567	Adhesion G protein-coupled receptor F3	2	26308173-26346817	G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA044500	Uncertain					Not detected	Not detected			kidney: 0.8	Mixed		
ADGRF4	FLJ38076, GPR115, PGR18	ENSG00000153294	Adhesion G protein-coupled receptor F4	6	47685864-47722021	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA007131, HPA007158	Enhanced		Uncertain	Mitochondria	Pancreatic cancer:5.52e-4 (unfavourable)	Mixed	Group enriched	8	esophagus: 12.1;skin: 45.8	tonsil: 3.7	Cell line enhanced		HaCaT: 11.5;HBEC3-KT: 14.9;hTCEpi: 22.8;U-87 MG: 25.8
ADGRF5	DKFZp564O1923, GPR116, KIAA0758	ENSG00000069122	Adhesion G protein-coupled receptor F5	6	46852512-46954943	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:8.84e-5 (favourable)	Expressed in all	Tissue enhanced		lung: 157.8	adipose tissue: 76.2	Group enriched	8	HUVEC TERT2: 20.7;TIME: 61.2
ADGRG1	GPR56, TM7LN4, TM7XN1	ENSG00000205336	Adhesion G protein-coupled receptor G1	16	57610652-57665580	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046065	Uncertain				Renal cancer:5.52e-7 (favourable), Head and neck cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 349.0	Cell line enhanced		SK-MEL-30: 229.9
ADGRG2	EDDM6, GPR64, HE6, TM7LN2	ENSG00000173698	Adhesion G protein-coupled receptor G2	X	18989309-19122637	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001478, HPA050029	Enhanced		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	6	epididymis: 1494.8	parathyroid gland: 240.0	Cell line enhanced		A549: 5.4;BEWO: 7.0;NTERA-2: 6.3;SH-SY5Y: 6.9;U-2197: 13.5
ADGRG3	GPR97, Pb99, PGR26	ENSG00000182885	Adhesion G protein-coupled receptor G3	16	57668187-57689378	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA040469	Uncertain					Mixed	Group enriched	5	appendix: 19.0;bone marrow: 86.6	adipose tissue: 9.8	Cell line enhanced		NB-4: 2.5;SK-MEL-30: 1.6
ADGRG4	GPR112, PGR17, RP1-299I16	ENSG00000156920	Adhesion G protein-coupled receptor G4	X	136300963-136416888	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA035324	Uncertain					Not detected	Tissue enhanced		duodenum: 2.5;small intestine: 1.7	fallopian tube: 0.5	Not detected		
ADGRG5	GPR114, PGR27	ENSG00000159618	Adhesion G protein-coupled receptor G5	16	57542421-57591681	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007133	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles	Cervical cancer:4.25e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 11.2;tonsil: 8.8	appendix,spleen: 5.9	Cell line enriched	8	HMC-1: 31.8
ADGRG6	FLJ14937, GPR126	ENSG00000112414	Adhesion G protein-coupled receptor G6	6	142301854-142446266	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017346	Approved				Pancreatic cancer:2.78e-5 (unfavourable), Lung cancer:8.78e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 67.2	liver: 36.9	Cell line enhanced		HUVEC TERT2: 133.3;MCF7: 118.0
ADGRG7	FLJ14454, GPR128	ENSG00000144820	Adhesion G protein-coupled receptor G7	3	100609589-100695479	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Group enriched	6	duodenum: 42.8;liver: 12.5;small intestine: 42.9	colon: 5.3	Not detected		
ADGRL1	CIRL1, KIAA0821, LEC2, LPHN1	ENSG00000072071	Adhesion G protein-coupled receptor L1	19	14147743-14206187	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037974	Uncertain				Pancreatic cancer:1.14e-4 (favourable), Renal cancer:4.45e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 60.1	parathyroid gland: 24.2	Cell line enhanced		AN3-CA: 66.4;SCLC-21H: 64.6
ADGRL2	KIAA0786, LEC1, LPHH1, LPHN2	ENSG00000117114	Adhesion G protein-coupled receptor L2	1	81306160-81992436	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA043447			Approved	Plasma membrane<br>Cell Junctions	Endometrial cancer:1.33e-4 (unfavourable), Stomach cancer:3.00e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 73.2	Cell line enhanced		AF22: 246.2;hTEC/SVTERT24-B: 124.0;SH-SY5Y: 176.4
ADGRL3	KIAA0768, LEC3, LPHN3	ENSG00000150471	Adhesion G protein-coupled receptor L3	4	61201258-62078335	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA015027, HPA015762, CAB022698	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 42.0;parathyroid gland: 30.6	cervix, uterine: 8.5	Cell line enhanced		AF22: 41.2;EFO-21: 10.2
ADGRL4	ELTD1, ETL	ENSG00000162618	Adhesion G protein-coupled receptor L4	1	78889764-79006718	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA025229	Supported				Renal cancer:1.60e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 67.7	Group enriched	5	HUVEC TERT2: 239.6;TIME: 288.6
ADGRV1	DKFZp761P0710, FEB4, GPR98, KIAA0686, MASS1, USH2C, VLGR1	ENSG00000164199	Adhesion G protein-coupled receptor V1	5	90529344-91164437	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA067503	Approved		Approved	Lipid droplets		Mixed	Tissue enriched	11	adrenal gland: 261.4	kidney: 22.9	Cell line enhanced		AF22: 15.3;HAP1: 23.8;NTERA-2: 11.7;SCLC-21H: 13.1
ADIG	MGC39724, RP5-1100H13.2, SMAF1	ENSG00000182035	Adipogenin	20	38581195-38588463	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA041124	Uncertain					Tissue enhanced	Group enriched	10	epididymis: 5.1;testis: 16.1;thyroid gland: 3.4	seminal vesicle: 0.8	Not detected		
ADIPOR1	ACDCR1, PAQR1	ENSG00000159346	Adiponectin receptor 1	1	202940823-202958572	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Ovarian cancer:5.27e-4 (favourable), Pancreatic cancer:5.50e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 136.6	Expressed in all		
ADIPOR2	ACDCR2, PAQR2	ENSG00000006831	Adiponectin receptor 2	12	1688574-1788678	Predicted membrane proteins	Evidence at protein level	HPA043737	Approved					Expressed in all	Expressed in all			adipose tissue: 77.1	Expressed in all		
ADORA1	RDC7	ENSG00000163485	Adenosine A1 receptor	1	203090654-203167405	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044383			Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 50.2;testis: 25.4	parathyroid gland: 18.9	Cell line enhanced		CACO-2: 33.2;RH-30: 62.4;RPTEC TERT1: 23.7;SK-BR-3: 26.3
ADORA2A	ADORA2, RDC8	ENSG00000128271	Adenosine A2a receptor	22	24417879-24442360	Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001943, HPA065566, HPA075997	Enhanced	Supported				Not detected	Tissue enhanced		bone marrow: 24.6;lymph node: 22.7	appendix: 17.8	Cell line enhanced		Karpas-707: 36.8;SK-BR-3: 55.0;U-266/70: 38.8;U-266/84: 50.0;U-698: 37.2
ADORA2B		ENSG00000170425	Adenosine A2b receptor	17	15944917-15975746	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA073747			Uncertain	Cytosol		Mixed	Mixed			colon: 8.5	Cell line enhanced		HMC-1: 142.9
ADORA3	AD026	ENSG00000282608	Adenosine A3 receptor	1	111499429-111503760	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level								Mixed			adrenal gland: 18.4	Cell line enriched	12	HMC-1: 89.3
ADPRM	C17orf48, MDS006	ENSG00000170222	ADP-ribose/CDP-alcohol diphosphatase, manganese dependent	17	10697594-10711233	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023265, HPA023820	Approved				Endometrial cancer:2.38e-5 (favourable), Cervical cancer:1.69e-4 (favourable)	Expressed in all	Expressed in all			prostate: 16.0	Expressed in all		
ADRA1A	ADRA1C, ADRA1L1	ENSG00000120907	Adrenoceptor alpha 1A	8	26748150-26867273	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029678, HPA029679	Approved					Tissue enhanced	Tissue enhanced		adipose tissue: 22.6;liver: 31.6;prostate: 20.8	seminal vesicle: 19.1	Not detected		
ADRA1B		ENSG00000170214	Adrenoceptor alpha 1B	5	159916783-159972544	Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA074416			Supported	Plasma membrane	Renal cancer:1.40e-6 (unfavourable), Thyroid cancer:3.19e-5 (favourable), Endometrial cancer:6.00e-5 (unfavourable), Ovarian cancer:2.67e-4 (favourable), Glioma:6.07e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 14.8;spleen: 17.0	ovary: 4.8	Cell line enhanced		EFO-21: 12.8;TIME: 10.9;U-2 OS: 9.6
ADRA1D	ADRA1, ADRA1A, ADRA1R	ENSG00000171873	Adrenoceptor alpha 1D	20	4220631-4249074	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA038789	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 4.3;prostate: 4.5	seminal vesicle: 2.6	Cell line enhanced		BJ: 6.7;CAPAN-2: 3.1;fHDF/TERT166: 3.7
ADRA2A	ADRA2, ADRA2R, ADRAR	ENSG00000150594	Adrenoceptor alpha 2A	10	111077163-111080907	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:8.06e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 33.2	Cell line enhanced		ASC diff: 7.4;ASC TERT1: 9.3;HEL: 18.7;HeLa: 7.4;HSkMC: 23.3
ADRA2B	ADRA2L1, ADRA2RL1, ADRARL1	ENSG00000274286	Adrenoceptor alpha 2B	2	96112875-96116245	Predicted membrane proteins	Evidence at transcript level	HPA066029	Approved					Mixed	Mixed			epididymis: 5.1	Cell line enhanced		BEWO: 1.5
ADRA2C	ADRA2L2, ADRA2RL2, ADRARL2	ENSG00000184160	Adrenoceptor alpha 2C	4	3766348-3768526	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA057688	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 20.9;endometrium: 26.0;seminal vesicle: 26.8	fallopian tube: 7.9	Cell line enhanced		Hep G2: 9.0;MCF7: 16.8;SCLC-21H: 9.5;SH-SY5Y: 10.3
ADRB1	ADRB1R	ENSG00000043591	Adrenoceptor beta 1	10	114044056-114046908	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA067972	Enhanced					Tissue enriched	Tissue enhanced		placenta: 45.4	heart muscle: 10.8	Cell line enhanced		HDLM-2: 6.7;THP-1: 3.2;TIME: 5.0
ADRB2	ADRB2R, ADRBR, B2AR, BAR	ENSG00000169252	Adrenoceptor beta 2	5	148825245-148828687	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003431, HPA075322	Uncertain		Uncertain	Cytosol	Renal cancer:3.15e-9 (favourable)	Mixed	Mixed			lung: 16.3	Cell line enhanced		hTCEpi: 28.8;hTERT-HME1: 31.6
ADRB3		ENSG00000188778	Adrenoceptor beta 3	8	37962991-37966965	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA061969	Uncertain					Not detected	Tissue enhanced		ovary: 8.9;placenta: 3.7	gallbladder: 2.2	Not detected		
ADTRP	AIG1L, C6orf105, dJ413H6.1	ENSG00000111863	Androgen dependent TFPI regulating protein	6	11712054-11807046	Predicted membrane proteins	Evidence at transcript level	HPA048113	Uncertain		Uncertain	Nucleoli	Renal cancer:1.13e-5 (unfavourable)	Mixed	Tissue enhanced		small intestine: 79.4	duodenum: 61.1	Cell line enhanced		HUVEC TERT2: 62.0;TIME: 33.0;U-138 MG: 25.7;U-266/84: 23.2
AFG3L2	SCA28, SPAX5	ENSG00000141385	AFG3 like matrix AAA peptidase subunit 2	18	12328944-12377314	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA004479, HPA004480	Enhanced		Enhanced	Mitochondria	Renal cancer:6.05e-14 (favourable), Endometrial cancer:8.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 123.6	Expressed in all		
AGER	RAGE, SCARJ1	ENSG00000204305	Advanced glycosylation end-product specific receptor	6	32180968-32184324	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB011682, HPA064436	Enhanced		Approved	Nucleoli fibrillar center<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.01e-7 (unfavourable), Urothelial cancer:2.74e-6 (favourable), Pancreatic cancer:3.41e-4 (favourable)	Expressed in all	Tissue enriched	181	lung: 889.2	thyroid gland: 4.9	Cell line enhanced		HEK93: 2.5;U-266/70: 2.6
AGL		ENSG00000162688	Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase	1	99850084-99924023	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA028498, HPA054340	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.73e-10 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 90.3	parathyroid gland: 35.1	Mixed		
AGMO	FLJ16237, TMEM195	ENSG00000187546	Alkylglycerol monooxygenase	7	15200318-15562015	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057900			Uncertain	Vesicles		Tissue enriched	Tissue enhanced		liver: 63.7	epididymis: 17.6	Cell line enhanced		Karpas-707: 5.6;SCLC-21H: 3.8;WM-115: 15.2
AGPAT1	LPAAT-alpha	ENSG00000204310	1-acylglycerol-3-phosphate O-acyltransferase 1	6	32168212-32178096	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA048478, HPA073355	Approved		Supported	Endoplasmic reticulum<br>Rods & Rings	Breast cancer:1.93e-4 (unfavourable), Endometrial cancer:5.21e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 52.2	Mixed		
AGPAT2	BSCL, LPAAT-beta	ENSG00000169692	1-acylglycerol-3-phosphate O-acyltransferase 2	9	136673143-136687423	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA019544	Uncertain		Approved	Centrosome		Expressed in all	Expressed in all			adipose tissue: 300.1	Mixed		
AGPAT3	LPAAT-gamma	ENSG00000160216	1-acylglycerol-3-phosphate O-acyltransferase 3	21	43865186-43986536	Enzymes, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.29e-4 (favourable), Cervical cancer:8.31e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 57.5	Mixed		
AGPAT4	dJ473J16.2, LPAAT-delta	ENSG00000026652	1-acylglycerol-3-phosphate O-acyltransferase 4	6	161129979-161274061	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053287, HPA060525	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Vesicles	Cervical cancer:1.45e-4 (unfavourable), Renal cancer:4.08e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 24.7	placenta: 12.3	Cell line enhanced		AF22: 25.4
AGPAT5	FLJ11210, LPAAT-e, LPAAT-epsilon	ENSG00000155189	1-acylglycerol-3-phosphate O-acyltransferase 5	8	6708357-6759666	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA010644, HPA010950	Approved				Liver cancer:4.57e-4 (unfavourable), Colorectal cancer:8.82e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.9	Expressed in all		
AGRN	AGRIN	ENSG00000188157	Agrin	1	1020123-1056118	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040090	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 33.2	Cell line enhanced		EFO-21: 223.9
AGTR1	AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R	ENSG00000144891	Angiotensin II receptor type 1	3	148697784-148743008	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003596	Enhanced		Uncertain	Vesicles		Group enriched	Tissue enhanced		placenta: 214.0	liver: 50.9	Cell line enhanced		ASC diff: 127.9;BJ hTERT+ SV40 Large T+: 33.9;HBF TERT88: 54.9;HSkMC: 24.7
AGTR2	AT2, MRX88	ENSG00000180772	Angiotensin II receptor type 2	X	116170722-116174972	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Group enriched	Group enriched	6	cervix, uterine: 6.8;endometrium: 13.9;fallopian tube: 3.8;lung: 12.6;smooth muscle: 17.6	adrenal gland: 1.9	Not detected		
AGTRAP	ATRAP	ENSG00000177674	Angiotensin II receptor associated protein	1	11736084-11754802	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044120	Approved		Supported	Vesicles	Liver cancer:6.57e-7 (unfavourable)	Expressed in all	Expressed in all			prostate: 92.6	Expressed in all		
AIFM1	AIF, CMTX4, NAMSD, PDCD8	ENSG00000156709	Apoptosis inducing factor mitochondria associated 1	X	130129362-130165887	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB003764, HPA030611	Enhanced				Renal cancer:4.42e-10 (favourable)	Expressed in all	Expressed in all			kidney: 158.1	Expressed in all		
AIG1	AIG-1, dJ95L4.1, FLJ10485	ENSG00000146416	Androgen induced 1	6	143060496-143340304	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA060766	Approved		Approved	Golgi apparatus	Head and neck cancer:3.25e-7 (unfavourable), Cervical cancer:3.26e-6 (unfavourable), Endometrial cancer:3.06e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 153.1	Expressed in all		
AJAP1	MOT8, SHREW-1, SHREW1	ENSG00000196581	Adherens junctions associated protein 1	1	4654732-4792534	Predicted membrane proteins	Evidence at protein level						Renal cancer:1.89e-7 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 11.3;ovary: 6.0	kidney,seminal vesicle: 3.2	Cell line enhanced		BEWO: 7.2;EFO-21: 6.2;RPTEC TERT1: 18.3
AKAP1	AKAP121, AKAP149, AKAP84, D-AKAP1, PPP1R43, PRKA1, S-AKAP84, SAKAP84, TDRD17	ENSG00000121057	A-kinase anchoring protein 1	17	57085092-57121349	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008620, HPA008691, CAB019286	Supported		Supported	Mitochondria	Renal cancer:7.86e-9 (favourable)	Expressed in all	Expressed in all			testis: 150.9	Expressed in all		
AKAP6	ADAP6, AKAP100, KIAA0311, mAKAP, PRKA6	ENSG00000151320	A-kinase anchoring protein 6	14	32329273-32837681	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB001983, HPA048741	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 49.0;heart muscle: 36.0	skeletal muscle: 16.6	Cell line enhanced		fHDF/TERT166: 12.2
AKAP9	AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO	ENSG00000127914	A-kinase anchoring protein 9	7	91940867-92110673	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008548, CAB012909, HPA026109	Enhanced		Enhanced	Golgi apparatus<br>Vesicles<br>Centrosome	Renal cancer:2.10e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 37.8	Expressed in all		
ALCAM	CD166, MEMD	ENSG00000170017	Activated leukocyte cell adhesion molecule	3	105366909-105576900	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002148, HPA010926	Approved				Renal cancer:3.15e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 471.5	lung: 111.2	Cell line enhanced		U-138 MG: 467.1
ALDH16A1	MGC10204	ENSG00000161618	Aldehyde dehydrogenase 16 family member A1	19	49453169-49471048	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA059488	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			spleen: 17.6	Mixed		
ALDH3A2	ALDH10, FALDH, SLS	ENSG00000072210	Aldehyde dehydrogenase 3 family member A2	17	19648136-19677598	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014769, CAB020692	Approved				Renal cancer:3.85e-8 (favourable)	Expressed in all	Expressed in all			adrenal gland: 179.0	Cell line enhanced		A549: 115.6
ALDH3B2	ALDH8	ENSG00000132746	Aldehyde dehydrogenase 3 family member B2	11	67662162-67681200	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045132	Enhanced					Mixed	Group enriched	6	breast: 89.9;esophagus: 103.4;skin: 122.2	tonsil: 19.0	Cell line enhanced		MCF7: 49.6;SK-BR-3: 48.3;T-47d: 12.2
ALDH6A1	MMSDH	ENSG00000119711	Aldehyde dehydrogenase 6 family member A1	14	74056850-74084493	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029072, HPA029073, HPA029074, HPA029075	Enhanced		Enhanced	Mitochondria	Renal cancer:2.00e-15 (favourable), Lung cancer:4.22e-4 (favourable)	Expressed in all	Expressed in all			kidney: 389.6	Expressed in all		
ALDOA		ENSG00000149925	Aldolase, fructose-bisphosphate A	16	30053090-30070457	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004177, CAB006252	Enhanced		Supported	Cytosol	Liver cancer:5.79e-5 (unfavourable), Lung cancer:7.32e-5 (unfavourable)	Expressed in all	Tissue enriched	7	skeletal muscle: 9377.0	esophagus: 1428.8	Expressed in all		
ALG1	CDG1K, HMAT1, HMT-1, Mat-1	ENSG00000033011	ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase	16	5033960-5087379	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA060392	Approved		Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum	Colorectal cancer:5.79e-4 (favourable), Testis cancer:6.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.4	Expressed in all		
ALG10	ALG10A, DIE2, FLJ14751	ENSG00000139133	ALG10, alpha-1,2-glucosyltransferase	12	34022281-34029694	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA043329, HPA063387	Approved		Approved	Endoplasmic reticulum		Mixed	Mixed			parathyroid gland: 4.6	Expressed in all		
ALG10B	KCR1	ENSG00000175548	ALG10B, alpha-1,2-glucosyltransferase	12	38316578-38329728	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA043329, HPA063387	Approved		Approved	Endoplasmic reticulum		Mixed	Mixed			parathyroid gland: 7.6	Expressed in all		
ALG11	CDG1P, KIAA0266	ENSG00000253710	ALG11, alpha-1,2-mannosyltransferase	13	52012398-52029664	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047214	Approved					Mixed	Expressed in all			thyroid gland: 23.6	Expressed in all		
ALG12	CDG1G, ECM39	ENSG00000182858	ALG12, alpha-1,6-mannosyltransferase	22	49900229-49918458	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA003076, HPA051665	Approved		Approved	Endoplasmic reticulum	Renal cancer:3.60e-5 (favourable), Endometrial cancer:6.09e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.2	Expressed in all		
ALG14	MGC19780	ENSG00000172339	ALG14, UDP-N-acetylglucosaminyltransferase subunit	1	94974407-95072945	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA031829	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			thyroid gland: 2.9	Mixed		
ALG2	CDG1I, CDGIi, FLJ14511, hALPG2, NET38	ENSG00000119523	ALG2, alpha-1,3/1,6-mannosyltransferase	9	99216426-99221956	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041512, HPA041601	Approved		Enhanced	Actin filaments<br>Cytosol	Renal cancer:2.28e-7 (favourable), Endometrial cancer:8.44e-5 (favourable), Head and neck cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 77.1	Expressed in all		
ALG3	CDGS4, D16Ertd36e, Not56, NOT56L	ENSG00000214160	ALG3, alpha-1,3- mannosyltransferase	3	184242301-184249548	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA045103	Approved				Liver cancer:1.58e-5 (unfavourable), Lung cancer:8.67e-5 (unfavourable), Renal cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.4	Expressed in all		
ALG5	bA421P11.2	ENSG00000120697	ALG5, dolichyl-phosphate beta-glucosyltransferase	13	36949775-37000261	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007989	Approved		Approved	Cytosol	Renal cancer:1.40e-5 (favourable), Head and neck cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 96.6	Expressed in all		
ALG6		ENSG00000088035	ALG6, alpha-1,3-glucosyltransferase	1	63367590-63438562	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA062536			Supported	Endoplasmic reticulum	Renal cancer:2.63e-6 (unfavourable), Colorectal cancer:4.86e-4 (favourable), Liver cancer:9.46e-4 (unfavourable)	Expressed in all	Mixed			placenta: 11.9	Expressed in all		
ALG8	MGC2840	ENSG00000159063	ALG8, alpha-1,3-glucosyltransferase	11	78100936-78139660	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA051898	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 86.2	Expressed in all		
ALG9	DIBD1	ENSG00000086848	ALG9, alpha-1,2-mannosyltransferase	11	111782195-111871581	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038575	Approved		Approved	Endoplasmic reticulum	Renal cancer:7.29e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
ALK	CD246	ENSG00000171094	Anaplastic lymphoma receptor tyrosine kinase	2	29192774-29921566	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010694	Approved		Supported	Plasma membrane		Group enriched	Tissue enhanced		cerebral cortex: 2.7;testis: 2.0	adrenal gland: 0.5	Cell line enriched	6	SH-SY5Y: 28.3
ALOX5AP	FLAP	ENSG00000132965	Arachidonate 5-lipoxygenase activating protein	13	30713478-30764426	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA026592	Enhanced				Renal cancer:5.68e-4 (unfavourable), Ovarian cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 301.7	Cell line enhanced		HDLM-2: 579.8;HL-60: 265.4;HMC-1: 899.6;THP-1: 279.0;U-937: 238.0
ALPK1	FLJ22670, KIAA1527, Lak	ENSG00000073331	Alpha kinase 1	4	112285509-112442620	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA027435, HPA027443	Approved		Approved	Centrosome	Renal cancer:5.82e-7 (unfavourable), Urothelial cancer:1.17e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.2	Mixed		
ALPL	HOPS, TNSALP	ENSG00000162551	Alkaline phosphatase, liver/bone/kidney	1	21509372-21578412	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007105, HPA008765, CAB020829	Enhanced		Approved	Cytosol	Melanoma:7.08e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 78.8	kidney: 47.2	Group enriched	8	HAP1: 31.9;HSkMC: 126.3;hTEC/SVTERT24-B: 139.0;LHCN-M2: 85.3;NTERA-2: 40.7;SCLC-21H: 103.8
AMFR	gp78, RNF45	ENSG00000159461	Autocrine motility factor receptor	16	56361452-56425538	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026381, HPA029018, HPA077835	Approved		Supported	Endoplasmic reticulum<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 154.7	Expressed in all		
AMHR2	MISR2, MISRII	ENSG00000135409	Anti-Mullerian hormone receptor type 2	12	53423855-53431534	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		adrenal gland: 32.1;ovary: 40.9	testis: 10.1	Group enriched	19	HEL: 36.1;K-562: 19.9
AMIGO1	AMIGO, KIAA1163	ENSG00000181754	Adhesion molecule with Ig like domain 1	1	109504175-109509738	Predicted membrane proteins	Evidence at protein level	HPA046152	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:1.21e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 24.6	Cell line enhanced		SCLC-21H: 9.8
AMIGO2	ALI1, DEGA	ENSG00000139211	Adhesion molecule with Ig like domain 2	12	47075707-47079951	Predicted membrane proteins	Evidence at protein level	HPA054004, HPA059601	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.80e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 55.1	Cell line enhanced		CAPAN-2: 184.4;fHDF/TERT166: 158.6;LHCN-M2: 167.5;RT4: 222.6;U-2 OS: 170.3
AMIGO3		ENSG00000176020	Adhesion molecule with Ig like domain 3	3	49716834-49719695	Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			skeletal muscle: 1.0	Cell line enhanced		CACO-2: 1.7;SH-SY5Y: 1.7
AMN	amnionless	ENSG00000166126	Amnion associated transmembrane protein	14	102922656-102933596	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000817	Approved				Renal cancer:9.62e-5 (favourable)	Mixed	Group enriched	6	colon: 20.0;duodenum: 34.2;kidney: 29.0;small intestine: 70.6	liver: 6.7	Cell line enhanced		CACO-2: 6.8;Hep G2: 5.6;U-698: 3.0
ANAPC1	APC1, MCPR, TSG24	ENSG00000153107	Anaphase promoting complex subunit 1	2	111766271-111884690	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036329, HPA036330, HPA042998	Approved		Approved	Vesicles	Endometrial cancer:1.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.6	Expressed in all		
ANKH	ANK, CCAL2, CMDJ, CPPDD, HANK	ENSG00000154122	ANKH inorganic pyrophosphate transport regulator	5	14704804-14871778	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA068104			Approved	Cytosol	Glioma:7.64e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 49.4	Mixed		
ANKLE1	ANKRD41, FLJ39369, LEMD6	ENSG00000160117	Ankyrin repeat and LEM domain containing 1	19	17281645-17287646	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026789, HPA073498	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:4.86e-5 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 13.7	lymph node: 3.6	Cell line enhanced		Daudi: 47.2;U-937: 40.1
ANKLE2	KIAA0692, Lem4, LEMD7	ENSG00000176915	Ankyrin repeat and LEM domain containing 2	12	132725503-132761888	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003602, HPA074838	Uncertain		Supported	Endoplasmic reticulum<br>Plasma membrane	Renal cancer:1.90e-8 (unfavourable), Liver cancer:3.97e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 80.4	Expressed in all		
ANKRD29	FLJ25053	ENSG00000154065	Ankyrin repeat domain 29	18	23598926-23662885	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041272, HPA049419	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Head and neck cancer:1.92e-5 (favourable), Lung cancer:5.98e-5 (favourable), Renal cancer:7.20e-5 (favourable)	Mixed	Mixed			lung: 47.4	Cell line enhanced		U-2197: 19.0;U-87 MG: 20.5
ANKRD46		ENSG00000186106	Ankyrin repeat domain 46	8	100509752-100559784	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013758	Approved		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 70.4	Expressed in all		
ANO1	DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A	ENSG00000131620	Anoctamin 1	11	70078302-70189528	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032148, HPA057356	Enhanced				Renal cancer:4.09e-6 (unfavourable), Endometrial cancer:4.58e-6 (favourable), Head and neck cancer:7.28e-5 (unfavourable), Pancreatic cancer:1.70e-4 (unfavourable), Lung cancer:2.40e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 220.9;seminal vesicle: 298.5	skin: 115.8	Group enriched	5	A-431: 121.8;CAPAN-2: 182.7;HaCaT: 224.5
ANO10	FLJ10375, MGC47890, SCAR10, TMEM16K	ENSG00000160746	Anoctamin 10	3	43354859-43691594	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051569	Approved				Renal cancer:6.41e-6 (favourable), Endometrial cancer:1.11e-4 (favourable), Liver cancer:3.19e-4 (unfavourable), Colorectal cancer:6.70e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 62.5	Mixed		
ANO2	C12orf3, TMEM16B	ENSG00000047617	Anoctamin 2	12	5531869-5946232	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036276, HPA057499	Supported		Supported	Nucleoplasm<br>Plasma membrane		Tissue enhanced	Tissue enhanced		testis: 17.8	placenta: 5.9	Cell line enhanced		BJ hTERT+: 7.8;HUVEC TERT2: 7.9;U-2 OS: 25.6
ANO3	C11orf25, DYT23, GENX-3947, TMEM16C	ENSG00000134343	Anoctamin 3	11	26309599-26663288	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041629	Uncertain					Not detected	Tissue enriched	6	epididymis: 62.2	cerebral cortex: 10.5	Cell line enhanced		HDLM-2: 5.9;U-2 OS: 1.7;U-2197: 4.2
ANO4	FLJ34221, FLJ34272, FLJ35277, TMEM16D	ENSG00000151572	Anoctamin 4	12	100717526-101128641	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA053412	Uncertain				Renal cancer:5.48e-5 (favourable)	Mixed	Group enriched	6	adrenal gland: 17.6;cerebral cortex: 10.0;cervix, uterine: 12.6;endometrium: 8.4;ovary: 10.9;prostate: 11.7;seminal vesicle: 11.4	testis: 2.0	Cell line enhanced		fHDF/TERT166: 14.2;SK-MEL-30: 13.3;TIME: 26.1;WM-115: 10.6
ANO5	GDD1, LGMD2L, TMEM16E	ENSG00000171714	Anoctamin 5	11	22193176-22283357	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA058857	Uncertain				Renal cancer:2.50e-7 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 56.1	skeletal muscle: 23.6	Cell line enhanced		A549: 4.5;HAP1: 5.6;HEK93: 6.2
ANO6	DKFZp313M0720, TMEM16F	ENSG00000177119	Anoctamin 6	12	45215987-45440404	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038958	Approved		Approved	Plasma membrane<br>Cytosol	Breast cancer:7.56e-5 (unfavourable), Cervical cancer:3.82e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 91.1	Expressed in all		
ANO7	IPCA-5, NGEP, PCANAP5, PCANAP5L, TMEM16G	ENSG00000146205	Anoctamin 7	2	241188509-241225377	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035730	Uncertain					Tissue enriched	Tissue enhanced		prostate: 100.6;stomach: 26.0	small intestine: 15.4	Cell line enhanced		BEWO: 2.1;Hep G2: 1.5
ANO8	KIAA1623, TMEM16H	ENSG00000074855	Anoctamin 8	19	17323223-17334829	Predicted membrane proteins	Evidence at protein level	HPA031787, HPA049206	Uncertain		Uncertain	Nucleoplasm<br>Nucleoli fibrillar center		Expressed in all	Tissue enhanced		cerebral cortex: 34.5	skin: 19.9	Mixed		
ANO9	PIG5, TMEM16J, TP53I5	ENSG00000185101	Anoctamin 9	11	417933-442011	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039948, HPA040112	Approved		Uncertain	Golgi apparatus	Urothelial cancer:8.81e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 31.6;small intestine: 30.9	skin: 21.6	Cell line enhanced		BEWO: 8.6;CAPAN-2: 24.1;HaCaT: 14.1;RPMI-8226: 13.6
ANPEP	CD13, gp150, LAP1, p150, PEPN	ENSG00000166825	Alanyl aminopeptidase, membrane	15	89784889-89815401	CD markers, Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002417, HPA004625	Enhanced		Supported	Plasma membrane		Expressed in all	Group enriched	9	duodenum: 2386.4;small intestine: 2133.7	kidney: 263.2	Cell line enhanced		BJ hTERT+: 958.3;HUVEC TERT2: 770.8;TIME: 760.6;U-2197: 926.0
ANTXR1	ATR, FLJ10601, FLJ21776, TEM8	ENSG00000169604	Anthrax toxin receptor 1	2	69013178-69249327	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054785			Uncertain	Vesicles	Thyroid cancer:1.22e-5 (unfavourable), Cervical cancer:5.76e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 180.5	Cell line enhanced		LHCN-M2: 286.7
ANTXR2	CMG-2, CMG2, FLJ31074	ENSG00000163297	Anthrax toxin receptor 2	4	79901149-80125454	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:3.34e-6 (unfavourable), Pancreatic cancer:1.33e-4 (unfavourable)	Expressed in all	Mixed			prostate: 139.5	Cell line enhanced		LHCN-M2: 147.2
ANTXRL		ENSG00000274209	Anthrax toxin receptor-like	10	46286345-46330207	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	23	testis: 15.5	bone marrow: 0.6	Not detected		
AP000322.53		ENSG00000243627		21	34418715-34423966	Predicted membrane proteins	Evidence at transcript level	HPA029085	Uncertain					Not detected	Group enriched	7	breast: 1.5;fallopian tube: 1.4;kidney: 4.3	skin: 0.3	Not detected		
AP000350.10		ENSG00000251357		22	23862188-23895223	Predicted membrane proteins	Evidence at transcript level	HPA042960	Uncertain					Not detected	Not detected			adrenal gland: 0.5	Cell line enhanced		SCLC-21H: 2.3
AP5S1	C20orf29, FLJ11168	ENSG00000125843	Adaptor related protein complex 5 sigma 1 subunit	20	3820524-3828837	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB034200, HPA043533, HPA048244	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:5.53e-5 (favourable)	Expressed in all	Expressed in all			testis: 12.4	Expressed in all		
APCDD1	B7323	ENSG00000154856	APC down-regulated 1	18	10454628-10489948	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:6.39e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 153.1	cerebral cortex: 60.6	Cell line enhanced		AF22: 31.6;BJ hTERT+: 56.8;HaCaT: 37.9;HSkMC: 28.6
APCDD1L	FLJ90166	ENSG00000198768	APC down-regulated 1 like	20	58459101-58515131	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067015	Uncertain		Uncertain	Mitochondria		Mixed	Tissue enhanced		breast: 6.5;salivary gland: 11.6	kidney: 2.9	Cell line enhanced		fHDF/TERT166: 88.4;hTEC/SVTERT24-B: 39.4;HUVEC TERT2: 33.7;TIME: 65.0;U-87 MG: 47.5
APH1A	APH-1A, CGI-78	ENSG00000117362	Aph-1 homolog A, gamma-secretase subunit	1	150265399-150269580	Predicted membrane proteins	Evidence at protein level	CAB037272	Approved					Expressed in all	Expressed in all			thyroid gland: 161.2	Expressed in all		
APH1B	APH-1B, DKFZp564D0372, PSFL	ENSG00000138613	Aph-1 homolog B, gamma-secretase subunit	15	63276018-63309126	Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:1.05e-4 (favourable), Renal cancer:2.25e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 153.4	thyroid gland: 32.1	Mixed		
APLF	C2orf13, MGC47799, Xip1, ZCCHH1	ENSG00000169621	Aprataxin and PNKP like factor	2	68467561-68655862	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029396, HPA034642, HPA034643	Uncertain		Supported	Nucleoplasm		Mixed	Mixed			skin: 3.3	Mixed		
APLNR	AGTRL1, APJ, APJR, FLJ90771	ENSG00000134817	Apelin receptor	11	57233577-57237314	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB025842	Approved					Expressed in all	Group enriched	5	cerebral cortex: 82.7;placenta: 146.8;spleen: 161.6	adipose tissue: 24.9	Group enriched	22	AF22: 6.2;HEL: 5.0;K-562: 1.5;NTERA-2: 1.8
APLP1	APLP	ENSG00000105290	Amyloid beta precursor like protein 1	19	35867899-35879791	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028970, HPA028971	Enhanced				Urothelial cancer:2.65e-5 (unfavourable), Endometrial cancer:3.87e-4 (unfavourable)	Tissue enhanced	Tissue enriched	13	cerebral cortex: 440.4	adrenal gland: 34.5	Cell line enhanced		AN3-CA: 137.3;SCLC-21H: 100.6;SH-SY5Y: 91.5
APLP2	APPH, APPL2	ENSG00000084234	Amyloid beta precursor like protein 2	11	130069837-130144811	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039319	Approved		Approved	Vesicles	Renal cancer:1.33e-9 (favourable), Thyroid cancer:2.90e-4 (favourable), Liver cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 1056.8	Expressed in all		
APMAP	BSCv, C20orf3	ENSG00000101474	Adipocyte plasma membrane associated protein	20	24962925-24992979	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012863, HPA064700	Uncertain		Approved	Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 323.5	Expressed in all		
APOC4-APOC2		ENSG00000224916	APOC4-APOC2 readthrough (NMD candidate)	19	44942238-44949565	Predicted membrane proteins	Evidence at protein level	HPA055877	Supported					Tissue enriched	Tissue enriched	102	liver: 109.7	cerebral cortex: 1.0	Cell line enhanced		HMC-1: 1.0;THP-1: 4.2
APOL1	APOL	ENSG00000100342	Apolipoprotein L1	22	36253010-36267530	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018885, CAB056156	Supported				Renal cancer:7.43e-6 (unfavourable), Urothelial cancer:2.01e-5 (favourable), Lung cancer:5.35e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 116.1	Cell line enhanced		EFO-21: 233.1;HDLM-2: 156.1;RT4: 120.9
APOL2	APOL-II	ENSG00000128335	Apolipoprotein L2	22	36226203-36239954	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001078	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.22e-7 (unfavourable), Urothelial cancer:5.06e-6 (favourable)	Expressed in all	Expressed in all			gallbladder: 64.8	Expressed in all		
APOL4	APOLIV	ENSG00000100336	Apolipoprotein L4	22	36189124-36204840	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049797, HPA055435	Approved		Supported	Vesicles	Urothelial cancer:2.40e-6 (favourable), Renal cancer:2.00e-5 (unfavourable), Ovarian cancer:3.45e-4 (favourable)	Expressed in all	Mixed			prostate: 26.7	Cell line enhanced		BEWO: 19.1;HDLM-2: 103.0;K-562: 21.3;SCLC-21H: 56.9
APOL6	APOL-VI, APOLVI	ENSG00000221963	Apolipoprotein L6	22	35648395-35668409	Predicted membrane proteins	Evidence at protein level	CAB028574, HPA029165, HPA029167	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Urothelial cancer:6.61e-4 (favourable)	Expressed in all	Mixed			adipose tissue: 25.4	Mixed		
APOLD1	DKFZP434F0318, FLJ25138	ENSG00000178878	Apolipoprotein L domain containing 1	12	12725917-12829975	Predicted membrane proteins	Evidence at protein level	HPA052462, HPA058882	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		adipose tissue: 142.9	placenta: 123.3	Cell line enhanced		AF22: 35.9;HDLM-2: 17.8
APOO	FAM121B, MGC4825, Mic23, MIC26, My025	ENSG00000184831	Apolipoprotein O	X	23833353-23907934	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003187	Supported		Approved	Mitochondria<br>Cytosol	Renal cancer:2.56e-6 (favourable), Cervical cancer:3.77e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 50.8	Expressed in all		
APP	AD1	ENSG00000142192	Amyloid beta precursor protein	21	25880550-26171128	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000157, HPA001462	Enhanced		Approved	Golgi apparatus<br>Vesicles	Renal cancer:2.79e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1203.4	Mixed		
AQP1	CHIP28, CO	ENSG00000240583	Aquaporin 1 (Colton blood group)	7	30911694-30925516	Blood group antigen proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001707, HPA019206	Enhanced		Supported	Plasma membrane	Renal cancer:1.32e-8 (favourable), Head and neck cancer:6.52e-4 (favourable)	Expressed in all	Expressed in all			kidney: 791.4	Cell line enhanced		EFO-21: 37.4;SH-SY5Y: 15.9;U-2 OS: 19.3;WM-115: 72.2
AQP10		ENSG00000143595	Aquaporin 10	1	154321090-154325325	Predicted membrane proteins, Transporters	Evidence at protein level	HPA065947	Enhanced					Not detected	Group enriched	8	duodenum: 68.4;small intestine: 48.7	fallopian tube: 7.2	Group enriched	27	HEL: 16.1;HMC-1: 6.3;K-562: 18.7;SH-SY5Y: 5.0
AQP11		ENSG00000178301	Aquaporin 11	11	77589391-77610355	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042879	Approved		Approved	Nucleoplasm<br>Vesicles	Ovarian cancer:9.89e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 24.1;small intestine: 23.1	adrenal gland: 10.0	Cell line enhanced		Hep G2: 7.7
AQP12A	AQP12	ENSG00000184945	Aquaporin 12A	2	240691845-240698483	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042216	Supported					Not detected	Tissue enriched	68	pancreas: 27.8	small intestine: 0.4	Not detected		
AQP12B	INSSA3	ENSG00000185176	Aquaporin 12B	2	240676418-240682906	Predicted membrane proteins	Evidence at protein level	HPA042216	Supported					Not detected	Tissue enriched	57	pancreas: 35.7	duodenum: 0.6	Not detected		
AQP2		ENSG00000167580	Aquaporin 2	12	49950741-49958881	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046834	Enhanced					Group enriched	Group enriched	132	kidney: 435.9;seminal vesicle: 302.5	testis: 2.8	Cell line enhanced		EFO-21: 3.0;HMC-1: 1.7
AQP3	GIL	ENSG00000165272	Aquaporin 3 (Gill blood group)	9	33441154-33447611	Blood group antigen proteins, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA014924	Enhanced		Supported	Nucleus<br>Plasma membrane	Cervical cancer:5.31e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 971.6	Cell line enhanced		HaCaT: 113.2;HeLa: 108.6;RT4: 167.6;SK-BR-3: 112.0;U-266/70: 114.3;U-266/84: 148.6
AQP4	MIWC	ENSG00000171885	Aquaporin 4	18	26852038-26865818	Predicted membrane proteins, Transporters	Evidence at protein level	CAB005079, HPA014784, CAB058689	Enhanced	Supported	Supported	Plasma membrane<br>Cell Junctions		Tissue enriched	Group enriched	16	cerebral cortex: 630.0;lung: 171.9	thyroid gland: 24.4	Cell line enhanced		AF22: 2.4;RPTEC TERT1: 1.0
AQP5		ENSG00000161798	Aquaporin 5	12	49961870-49965681	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA065008	Enhanced		Approved	Plasma membrane	Head and neck cancer:1.75e-5 (favourable)	Tissue enhanced	Group enriched	8	salivary gland: 255.6;stomach: 53.3;testis: 176.4	breast: 21.1	Group enriched	9	CAPAN-2: 7.6;REH: 9.2
AQP6	AQP2L	ENSG00000086159	Aquaporin 6	12	49967194-49977139	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015278	Enhanced					Tissue enriched	Tissue enriched	9	kidney: 20.8	cerebral cortex: 2.3	Not detected		
AQP7	AQP7L, AQP9, AQPap	ENSG00000165269	Aquaporin 7	9	33383179-33402682	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:9.21e-8 (favourable)	Mixed	Tissue enriched	5	adipose tissue: 355.1	parathyroid gland: 66.5	Cell line enriched	49	ASC diff: 181.4
AQP8		ENSG00000103375	Aquaporin 8	16	25215731-25228940	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046259	Enhanced					Group enriched	Group enriched	129	colon: 321.2;pancreas: 269.5;rectum: 166.5	smooth muscle: 1.9	Not detected		
AQP9	HsT17287, SSC1	ENSG00000103569	Aquaporin 9	15	58138169-58185911	Predicted membrane proteins	Evidence at protein level	HPA074762, CAB075684	Enhanced				Renal cancer:5.72e-11 (unfavourable)	Tissue enriched	Tissue enhanced		appendix: 102.4;liver: 353.0	epididymis: 50.3	Cell line enriched	37	U-87 MG: 27.9
AQR	fSAP164, IBP160, KIAA0560	ENSG00000021776	Aquarius intron-binding spliceosomal factor	15	34851782-34969839	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040624, HPA055647			Enhanced	Nucleoplasm	Renal cancer:4.83e-4 (favourable)	Expressed in all	Mixed			testis: 10.1	Expressed in all		
AREG	AREGB, SDGF	ENSG00000109321	Amphiregulin	4	74445134-74455009	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA008720, CAB023519	Approved		Approved	Mitochondria	Lung cancer:1.05e-5 (unfavourable), Head and neck cancer:2.61e-5 (unfavourable), Pancreatic cancer:8.32e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 463.5	gallbladder: 119.8	Cell line enhanced		CACO-2: 310.7;HBEC3-KT: 461.5;hTCEpi: 463.0;hTERT-HME1: 1044.5;MCF7: 315.9
AREL1	FIEL1, KIAA0317	ENSG00000119682	Apoptosis resistant E3 ubiquitin protein ligase 1	14	74653437-74713115	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051306	Uncertain				Renal cancer:4.67e-6 (favourable)	Expressed in all	Expressed in all			testis: 33.8	Expressed in all		
ARHGAP1	CDC42GAP, p50rhoGAP, RhoGAP	ENSG00000175220	Rho GTPase activating protein 1	11	46677080-46700615	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004689, HPA008285	Approved	Approved	Supported	Vesicles	Liver cancer:2.14e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 116.2	Expressed in all		
ARHGAP26	GRAF, KIAA0621, OPHN1L, OPHN1L1	ENSG00000145819	Rho GTPase activating protein 26	5	142770384-143229011	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035106, HPA035107	Enhanced		Approved	Cytosol	Urothelial cancer:2.88e-6 (favourable), Endometrial cancer:5.93e-6 (favourable), Cervical cancer:1.36e-4 (favourable), Breast cancer:2.05e-4 (favourable), Colorectal cancer:6.95e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 30.8	Cell line enhanced		Karpas-707: 61.5
ARIH2OS	C3orf71	ENSG00000221883	Ariadne homolog 2 opposite strand	3	48917788-48919385	Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			testis: 4.2	Mixed		
ARL10	ARL10A	ENSG00000175414	ADP ribosylation factor like GTPase 10	5	176365468-176401865	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047044	Approved					Mixed	Mixed			skin: 17.0	Mixed		
ARL6IP1	AIP1, ARL6IP, ARMER, KIAA0069, SPG61	ENSG00000170540	ADP ribosylation factor like GTPase 6 interacting protein 1	16	18791667-18801678	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045307	Uncertain		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			cerebral cortex: 386.9	Expressed in all		
ARL6IP5	DERP11, GTRAP3-18, HSPC127, JWA, PRAF3, Yip6b	ENSG00000144746	ADP ribosylation factor like GTPase 6 interacting protein 5	3	69084944-69106066	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015540, CAB019321	Supported		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			prostate: 214.1	Expressed in all		
ARL6IP6	MGC33864	ENSG00000177917	ADP ribosylation factor like GTPase 6 interacting protein 6	2	152717893-152761253	Predicted membrane proteins	Evidence at protein level	HPA014743	Enhanced		Approved	Nuclear membrane<br>Cytosol	Liver cancer:1.73e-4 (unfavourable), Renal cancer:2.14e-4 (unfavourable)	Expressed in all	Mixed			placenta: 7.5	Expressed in all		
ARMC10	MGC3195, SVH	ENSG00000170632	Armadillo repeat containing 10	7	103074881-103099764	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011036, HPA011057	Enhanced		Supported	Mitochondria	Pancreatic cancer:2.49e-6 (unfavourable), Glioma:6.98e-6 (unfavourable), Liver cancer:3.58e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 25.6	Expressed in all		
ARMCX1	ALEX1, GASP7	ENSG00000126947	Armadillo repeat containing, X-linked 1	X	101550531-101554700	Predicted membrane proteins	Evidence at protein level	HPA005685, CAB020695	Supported		Approved	Nucleus<br>Mitochondria<br>Cytosol	Pancreatic cancer:7.32e-5 (favourable), Cervical cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 59.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 75.6;RH-30: 84.3
ARMCX2	ALEX2, GASP9, KIAA0512	ENSG00000184867	Armadillo repeat containing, X-linked 2	X	101655281-101659891	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA005761	Enhanced		Approved	Nucleus<br>Mitochondria	Pancreatic cancer:3.45e-5 (favourable), Stomach cancer:2.69e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 202.3	thyroid gland: 107.5	Cell line enhanced		LHCN-M2: 146.0;NTERA-2: 125.3
ARMCX3	ALEX3, GASP6	ENSG00000102401	Armadillo repeat containing, X-linked 3	X	101622797-101627843	Predicted membrane proteins	Evidence at protein level	HPA000325, HPA000967, HPA001530	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.55e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 167.6	Mixed		
ARMCX6	FLJ20811, GASP10	ENSG00000198960	Armadillo repeat containing, X-linked 6	X	101615118-101618001	Predicted membrane proteins	Evidence at protein level	HPA043030, HPA048125	Approved		Supported	Nucleus<br>Nuclear membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 33.8	Mixed		
ARSD		ENSG00000006756	Arylsulfatase D	X	2903970-2929351	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004694, HPA063835	Approved		Approved	Vesicles<br>Lipid droplets	Renal cancer:1.97e-5 (favourable), Endometrial cancer:5.21e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 45.3	Cell line enhanced		EFO-21: 23.1
ARSE	CDPX, CDPX1	ENSG00000157399	Arylsulfatase E (chondrodysplasia punctata 1)	X	2934632-2968310	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA060518, HPA070651	Approved		Supported	Golgi apparatus	Colorectal cancer:8.95e-4 (favourable)	Mixed	Tissue enhanced		kidney: 41.3;liver: 49.3	pancreas: 23.9	Cell line enhanced		A549: 65.1;CACO-2: 37.1;Hep G2: 46.2;NTERA-2: 32.8
ARSF		ENSG00000062096	Arylsulfatase F	X	3041471-3112726	Predicted membrane proteins	Evidence at protein level	HPA000549			Uncertain	Cytosol		Tissue enhanced	Group enriched	6	adrenal gland: 4.0;cerebral cortex: 2.1;epididymis: 2.0;esophagus: 2.3;kidney: 8.0;skin: 6.7	liver: 0.6	Not detected		
ARSH		ENSG00000205667	Arylsulfatase family member H	X	3006613-3033571	Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.9	Not detected		
ART1	ART2, CD296	ENSG00000129744	ADP-ribosyltransferase 1	11	3645128-3664416	CD markers, Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA051148	Uncertain					Not detected	Tissue enriched	21	skeletal muscle: 16.4	esophagus: 0.7	Not detected		
ART3		ENSG00000156219	ADP-ribosyltransferase 3	4	76011184-76112802	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011268	Enhanced					Tissue enhanced	Tissue enhanced		skeletal muscle: 77.0;testis: 174.4	heart muscle: 29.1	Group enriched	7	NB-4: 3.4;NTERA-2: 14.0;SK-MEL-30: 4.9
ART4	CD297, DO, DOK1	ENSG00000111339	ADP-ribosyltransferase 4 (Dombrock blood group)	12	14825569-14843495	Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA075664			Approved	Rods & Rings		Tissue enhanced	Tissue enhanced		liver: 27.2;spleen: 26.9	gallbladder: 15.1	Cell line enhanced		AN3-CA: 5.6;HEL: 10.9;Hep G2: 4.9;HUVEC TERT2: 22.5
ARV1		ENSG00000173409	ARV1 homolog, fatty acid homeostasis modulator	1	230978981-231000595	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035709	Approved		Approved	Vesicles	Lung cancer:3.27e-5 (favourable), Colorectal cancer:1.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 61.9	Expressed in all		
ASB11	DKFZp779E2460	ENSG00000165192	Ankyrin repeat and SOCS box containing 11	X	15281697-15315656	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000238	Uncertain					Tissue enriched	Group enriched	6	heart muscle: 30.6;skeletal muscle: 42.1	stomach: 5.8	Not detected		
ASB18		ENSG00000182177	Ankyrin repeat and SOCS box containing 18	2	236194872-236264409	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068447	Approved					Not detected	Group enriched	8	heart muscle: 4.3;skeletal muscle: 3.6;testis: 1.0	cerebral cortex: 0.4	Not detected		
ASB5		ENSG00000164122	Ankyrin repeat and SOCS box containing 5	4	176213673-176277571	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA028870			Approved	Plasma membrane	Head and neck cancer:5.67e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		skeletal muscle: 75.7	prostate: 20.8	Cell line enriched	14	LHCN-M2: 986.5
ASGR2	CLEC4H2	ENSG00000161944	Asialoglycoprotein receptor 2	17	7101322-7115700	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014899, HPA015998	Enhanced		Supported	Endoplasmic reticulum<br>Plasma membrane		Tissue enriched	Tissue enriched	11	liver: 317.7	gallbladder: 28.1	Cell line enriched	7	Hep G2: 356.8
ASIC1	ACCN2, BNaC2, hBNaC2	ENSG00000110881	Acid sensing ion channel subunit 1	12	50057548-50083611	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA058870			Approved	Golgi apparatus<br>Plasma membrane		Tissue enhanced	Tissue enriched	10	cerebral cortex: 56.8	parathyroid gland: 5.7	Cell line enhanced		SH-SY5Y: 30.8
ASIC2	ACCN, ACCN1, ASIC2a, BNaC1, BNC1, hBNaC1, MDEG	ENSG00000108684	Acid sensing ion channel subunit 2	17	33013087-34174964	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA052112	Enhanced					Tissue enhanced	Group enriched	6	cerebral cortex: 8.6;cervix, uterine: 3.9;endometrium: 6.4;smooth muscle: 2.2	adrenal gland: 0.8	Cell line enhanced		NTERA-2: 1.1
ASIC3	ACCN3, DRASIC, TNaC1	ENSG00000213199	Acid sensing ion channel subunit 3	7	151048292-151052756	Predicted membrane proteins	Evidence at protein level	HPA049155, HPA054805	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		testis: 8.1	cerebral cortex: 5.8	Cell line enhanced		U-266/70: 13.4
ASIC4	ACCN4, BNAC4	ENSG00000072182	Acid sensing ion channel subunit family member 4	2	219514170-219538772	Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	8	cerebral cortex: 10.6	adrenal gland: 1.3	Group enriched	43	HEL: 17.6;HMC-1: 5.0;K-562: 10.2;SH-SY5Y: 5.4
ASIC5	ACCN5, HINAC, INAC	ENSG00000256394	Acid sensing ion channel subunit family member 5	4	155829729-155866273	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014903, HPA029444	Approved					Not detected	Group enriched	18	duodenum: 2.3;small intestine: 1.2	all non-specific tissues: 0.0	Not detected		
ASPH	BAH, CASQ2BP1, HAAH, JCTN	ENSG00000198363	Aspartate beta-hydroxylase	8	61500556-61714640	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA055161, HPA059303	Uncertain		Supported	Endoplasmic reticulum	Renal cancer:1.57e-5 (unfavourable), Cervical cancer:8.07e-5 (unfavourable), Pancreatic cancer:1.75e-4 (unfavourable), Lung cancer:3.61e-4 (unfavourable), Thyroid cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 403.5	Mixed		
ASPHD1		ENSG00000174939	Aspartate beta-hydroxylase domain containing 1	16	29900375-29919864	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045175	Uncertain				Pancreatic cancer:7.38e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 53.5	gallbladder: 11.9	Mixed		
ASPHD2	FLJ39838	ENSG00000128203	Aspartate beta-hydroxylase domain containing 2	22	26429273-26445015	Predicted membrane proteins	Evidence at protein level	HPA000820	Uncertain				Renal cancer:4.06e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 12.8	stomach: 7.8	Cell line enhanced		Karpas-707: 15.8
ASPRV1	FLJ25084, SASPase, Taps	ENSG00000244617	Aspartic peptidase, retroviral-like 1	2	69960089-69962265	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA034809, HPA034810	Enhanced					Group enriched	Tissue enriched	13	skin: 286.1	breast: 22.6	Cell line enhanced		REH: 4.5
ASTN1	ASTN	ENSG00000152092	Astrotactin 1	1	176857302-177164973	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA074112			Approved	Golgi apparatus<br>Vesicles		Tissue enriched	Group enriched	6	adrenal gland: 19.6;cerebral cortex: 66.8	ovary: 7.4	Cell line enhanced		Karpas-707: 4.1;NTERA-2: 4.4;SCLC-21H: 3.2;U-2 OS: 3.6;U-266/84: 14.7
ASTN2	KIAA0634	ENSG00000148219	Astrotactin 2	9	116425225-117415070	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027035	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.66e-16 (favourable)	Expressed in all	Expressed in all			prostate: 40.5	Cell line enhanced		SH-SY5Y: 39.4
ASZ1	ALP1, ANKL1, C7orf7, CT1.19, GASZ, Orf3	ENSG00000154438	Ankyrin repeat, SAM and basic leucine zipper domain containing 1	7	117363222-117428123	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020558	Enhanced		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	188	testis: 18.7	all non-specific tissues: 0.0	Not detected		
ATAD1	FLJ14600	ENSG00000138138	ATPase family, AAA domain containing 1	10	87751512-87841343	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA037569	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Renal cancer:3.98e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 29.0	Expressed in all		
ATF6	ATF6A	ENSG00000118217	Activating transcription factor 6	1	161766294-161964070	Disease related genes, Plasma proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA005935	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 41.3	Expressed in all		
ATF6B	CREBL1, G13	ENSG00000213676	Activating transcription factor 6 beta	6	32098176-32128253	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA046871	Uncertain		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 56.8	Expressed in all		
ATF7	ATFA	ENSG00000170653	Activating transcription factor 7	12	53507856-53626410	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA003384	Approved		Approved	Nucleus<br>Cytosol	Stomach cancer:2.10e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 40.3	Expressed in all		
ATG9A	APG9L1, FLJ22169	ENSG00000198925	Autophagy related 9A	2	219209772-219229717	Predicted membrane proteins	Evidence at protein level	HPA059551	Uncertain		Supported	Vesicles	Liver cancer:2.18e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 113.1	Expressed in all		
ATG9B	APG9L2, FLJ14885, NOS3AS, SONE	ENSG00000181652	Autophagy related 9B	7	151012209-151024499	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		esophagus: 9.2;placenta: 5.8;skin: 13.5	testis: 3.8	Cell line enhanced		BEWO: 12.5;CAPAN-2: 3.7
ATL1	AD-FSP, FSP1, SPG3, SPG3A	ENSG00000198513	Atlastin GTPase 1	14	50532509-50633068	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027550	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 96.9	smooth muscle: 22.0	Cell line enhanced		HDLM-2: 18.1;SCLC-21H: 20.2;SiHa: 19.9
ATL2	ARL6IP2	ENSG00000119787	Atlastin GTPase 2	2	38294880-38377285	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029108, HPA075302	Approved		Supported	Endoplasmic reticulum	Endometrial cancer:4.51e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 101.4	Expressed in all		
ATL3	DKFZP564J0863	ENSG00000184743	Atlastin GTPase 3	11	63624087-63671921	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065702, HPA076616			Enhanced	Endoplasmic reticulum	Pancreatic cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 65.6	Mixed		
ATM	ATA, ATC, ATD, ATDC, TEL1, TELO1	ENSG00000149311	ATM serine/threonine kinase	11	108222484-108369102	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000102, HPA067142	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 40.8	Expressed in all		
ATP10A	ATP10C, ATPVA, ATPVC, KIAA0566	ENSG00000206190	ATPase phospholipid transporting 10A (putative)	15	25677273-25865172	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA041496, HPA042509	Uncertain				Renal cancer:6.60e-5 (unfavourable)	Expressed in all	Mixed			lung: 10.6	Cell line enhanced		BJ: 16.3;fHDF/TERT166: 22.1;HMC-1: 16.2;SK-MEL-30: 20.1
ATP10B	ATPVB, FLJ21477, KIAA0715	ENSG00000118322	ATPase phospholipid transporting 10B (putative)	5	160563120-160852214	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034574	Uncertain					Group enriched	Tissue enhanced		colon: 36.0;rectum: 40.3	gallbladder: 21.4	Cell line enriched	23	WM-115: 13.6
ATP10D	ATPVD, KIAA1487	ENSG00000145246	ATPase phospholipid transporting 10D (putative)	4	47485288-47593486	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA050808	Approved		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:5.00e-8 (favourable)	Expressed in all	Mixed			parathyroid gland: 22.5	Cell line enhanced		HAP1: 43.0
ATP11A	ATPIH, ATPIS, KIAA1021	ENSG00000068650	ATPase phospholipid transporting 11A	13	112690329-112887168	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035583, HPA035584	Approved		Enhanced	Vesicles	Renal cancer:7.44e-4 (favourable)	Expressed in all	Expressed in all			lung: 59.1	Mixed		
ATP11B	ATPIF, ATPIR, KIAA0956	ENSG00000058063	ATPase phospholipid transporting 11B (putative)	3	182793500-182921635	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036237, HPA036238	Uncertain		Approved	Microtubule organizing center<br>Cytosol	Pancreatic cancer:1.09e-4 (unfavourable), Endometrial cancer:3.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 58.0	Expressed in all		
ATP11C	ATPIG, ATPIQ	ENSG00000101974	ATPase phospholipid transporting 11C	X	139726346-139945276	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030830	Approved					Expressed in all	Mixed			liver: 25.6	Mixed		
ATP12A	#945, 2, ATP1AL1, HK	ENSG00000075673	ATPase H+/K+ transporting non-gastric alpha2 subunit	13	24680411-24712493	Enzymes, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039526	Approved					Tissue enhanced	Tissue enhanced		esophagus: 12.7;placenta: 8.2;tonsil: 14.1	skin: 7.1	Not detected		
ATP13A1	ATP13A, CGI-152, FLJ31858, KIAA1825	ENSG00000105726	ATPase 13A1	19	19645198-19663693	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA031798, HPA049717	Approved		Approved	Vesicles	Renal cancer:6.51e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 52.5	Expressed in all		
ATP13A2	CLN12, HSA9947, PARK9	ENSG00000159363	ATPase 13A2	1	16985958-17011928	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB037038, CAB037111, HPA050910, HPA054717	Approved				Liver cancer:3.33e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.8	Expressed in all		
ATP13A3	AFURS1	ENSG00000133657	ATPase 13A3	3	194402672-194498364	Predicted membrane proteins	Evidence at protein level	HPA029471	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.60e-4 (unfavourable), Renal cancer:1.63e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 149.3	Expressed in all		
ATP13A4	DKFZp761I1011, FLJ37958	ENSG00000127249	ATPase 13A4	3	193402077-193593111	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA051932			Approved	Nucleoplasm	Head and neck cancer:3.91e-4 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 87.9;parathyroid gland: 131.5;thyroid gland: 68.5	lung: 53.7	Cell line enriched	7	SCLC-21H: 4.6
ATP13A5	FLJ16025	ENSG00000187527	ATPase 13A5	3	193274790-193378843	Predicted membrane proteins	Evidence at transcript level	HPA031771, HPA031774	Uncertain					Tissue enhanced	Tissue enhanced		breast: 17.7	salivary gland: 3.9	Cell line enhanced		SK-BR-3: 1.2
ATP1A1		ENSG00000163399	ATPase Na+/K+ transporting subunit alpha 1	1	116372668-116410261	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB018702, CAB069993	Enhanced				Renal cancer:8.98e-8 (favourable), Liver cancer:1.42e-4 (unfavourable), Urothelial cancer:4.01e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 2487.1	Expressed in all		
ATP1A2	FHM2, MHP2	ENSG00000018625	ATPase Na+/K+ transporting subunit alpha 2	1	160115759-160143591	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022230	Approved					Tissue enriched	Group enriched	6	cerebral cortex: 434.2;skeletal muscle: 307.0	heart muscle: 57.5	Cell line enhanced		AF22: 50.7;HHSteC: 12.3;RH-30: 16.2;U-87 MG: 10.1
ATP1A3	DYT12	ENSG00000105409	ATPase Na+/K+ transporting subunit alpha 3	19	41966582-41997497	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB033630, HPA045367, HPA056446	Enhanced				Renal cancer:3.02e-6 (unfavourable), Pancreatic cancer:6.15e-5 (favourable), Ovarian cancer:3.44e-4 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 378.4;heart muscle: 86.0	testis: 54.5	Cell line enhanced		Daudi: 39.5;SCLC-21H: 148.3;SH-SY5Y: 57.8
ATP1A4	ATP1AL2	ENSG00000132681	ATPase Na+/K+ transporting subunit alpha 4	1	160151570-160186977	Enzymes, Predicted membrane proteins	Evidence at protein level						Urothelial cancer:2.20e-4 (favourable)	Group enriched	Tissue enhanced		placenta: 10.2;testis: 18.2;urinary bladder: 8.6	lymph node: 4.1	Group enriched	11	BEWO: 19.2;HDLM-2: 48.0;RT4: 49.0
ATP1B1	ATP1B	ENSG00000143153	ATPase Na+/K+ transporting subunit beta 1	1	169105697-169132722	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012911	Enhanced				Renal cancer:7.08e-7 (favourable)	Expressed in all	Expressed in all			kidney: 1337.2	Cell line enhanced		RPTEC TERT1: 355.3;SH-SY5Y: 411.9
ATP1B2	AMOG	ENSG00000129244	ATPase Na+/K+ transporting subunit beta 2	17	7646627-7657768	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010698	Enhanced				Pancreatic cancer:1.05e-4 (favourable), Renal cancer:4.17e-4 (unfavourable)	Tissue enriched	Tissue enriched	9	cerebral cortex: 339.2	ovary: 36.7	Cell line enhanced		AF22: 9.7;HAP1: 3.1;K-562: 4.2
ATP1B3	CD298, FLJ29027	ENSG00000069849	ATPase Na+/K+ transporting subunit beta 3	3	141876124-141926514	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB020697, HPA048963	Enhanced		Supported	Plasma membrane	Liver cancer:6.32e-6 (unfavourable), Renal cancer:1.29e-5 (unfavourable), Endometrial cancer:5.19e-5 (favourable)	Expressed in all	Expressed in all			skin: 310.1	Expressed in all		
ATP1B4		ENSG00000101892	ATPase Na+/K+ transporting family member beta 4	X	120362085-120383249	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	9	skeletal muscle: 20.5	prostate: 2.3	Not detected		
ATP2A1	ATP2A, SERCA1	ENSG00000196296	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1	16	28878405-28904509	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002310, CAB032706	Enhanced		Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enriched	96	skeletal muscle: 2781.9	esophagus: 29.1	Mixed		
ATP2A2	ATP2B, DAR, SERCA2	ENSG00000174437	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2	12	110280756-110351093	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA062605, HPA067892	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			skeletal muscle: 1006.4	Expressed in all		
ATP2A3	SERCA3	ENSG00000074370	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	17	3923870-3964464	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007180, CAB010882	Approved				Cervical cancer:4.69e-5 (favourable), Head and neck cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 118.4	Cell line enhanced		Daudi: 133.8;HMC-1: 234.0;MOLT-4: 202.8;SK-BR-3: 146.3
ATP2B1	PMCA1	ENSG00000070961	ATPase plasma membrane Ca2+ transporting 1	12	89588049-89709300	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB005605, HPA011166, HPA012945	Enhanced		Supported	Plasma membrane	Liver cancer:7.74e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 143.6	Expressed in all		
ATP2B2	PMCA2	ENSG00000157087	ATPase plasma membrane Ca2+ transporting 2	3	10324023-10708031	Enzymes, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB005606	Enhanced					Tissue enhanced	Tissue enriched	7	cerebral cortex: 64.7	salivary gland: 9.7	Group enriched	7	EFO-21: 3.0;RPMI-8226: 5.4;SCLC-21H: 4.2;SH-SY5Y: 1.2
ATP2B3	CFAP39, CLA2, PMCA3, SCAX1	ENSG00000067842	ATPase plasma membrane Ca2+ transporting 3	X	153517676-153582939	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001583	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane		Not detected	Group enriched	8	adrenal gland: 12.1;cerebral cortex: 19.0	fallopian tube: 2.0	Cell line enhanced		SCLC-21H: 11.7;SH-SY5Y: 3.1;THP-1: 1.7;U-937: 1.9
ATP2B4	ATP2B2, MXRA1, PMCA4	ENSG00000058668	ATPase plasma membrane Ca2+ transporting 4	1	203626561-203744081	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016118, HPA040431	Enhanced		Supported	Plasma membrane	Renal cancer:1.21e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 254.6	Expressed in all		
ATP2C1	ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1	ENSG00000017260	ATPase secretory pathway Ca2+ transporting 1	3	130850595-131016712	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB010207, HPA035116, HPA069684	Supported		Enhanced	Golgi apparatus	Liver cancer:5.06e-6 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Renal cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			prostate: 138.3	Expressed in all		
ATP2C2	KIAA0703, SPCA2	ENSG00000064270	ATPase secretory pathway Ca2+ transporting 2	16	84368527-84464187	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052262, HPA075812	Approved		Approved	Plasma membrane<br>Focal adhesion sites	Endometrial cancer:6.20e-6 (favourable)	Mixed	Tissue enhanced		rectum: 38.4	skin: 30.0	Cell line enhanced		MCF7: 18.7;RT4: 15.1;SK-BR-3: 24.6;T-47d: 10.4
ATP4A	ATP6A	ENSG00000105675	ATPase H+/K+ transporting alpha subunit	19	35550043-35563658	Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039154	Enhanced					Tissue enriched	Tissue enriched	260	stomach: 557.9	pancreas: 2.1	Not detected		
ATP4B	ATP6B	ENSG00000186009	ATPase H+/K+ transporting beta subunit	13	113648804-113658186	Predicted membrane proteins, Transporters	Evidence at protein level	HPA045400, HPA052649	Enhanced					Tissue enriched	Tissue enriched	87	stomach: 953.2	fallopian tube: 10.9	Not detected		
ATP5F1		ENSG00000116459	ATP synthase, H+ transporting, mitochondrial Fo complex subunit B1	1	111448864-111462773	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046067, HPA057347	Enhanced		Supported	Mitochondria	Renal cancer:3.26e-9 (favourable), Stomach cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 50.4	Expressed in all		
ATP5G1	ATP5G	ENSG00000159199	ATP synthase, H+ transporting, mitochondrial Fo complex subunit C1 (subunit 9)	17	48892765-48895871	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:8.24e-6 (favourable), Cervical cancer:3.88e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 388.5	Expressed in all		
ATP5G2		ENSG00000135390	ATP synthase, H+ transporting, mitochondrial Fo complex subunit C2 (subunit 9)	12	53632726-53677408	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA051469	Approved					Expressed in all	Expressed in all			fallopian tube: 779.5	Expressed in all		
ATP5G3		ENSG00000154518	ATP synthase, H+ transporting, mitochondrial Fo complex subunit C3 (subunit 9)	2	175176258-175184607	Predicted membrane proteins	Evidence at transcript level						Renal cancer:2.31e-6 (favourable), Head and neck cancer:6.01e-4 (unfavourable), Colorectal cancer:9.90e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 534.0	Expressed in all		
ATP5J2	ATP5JL, F1Fo-ATPase	ENSG00000241468	ATP synthase, H+ transporting, mitochondrial Fo complex subunit F2	7	99448475-99466331	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067267, HPA070412	Approved		Supported	Mitochondria	Head and neck cancer:2.58e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 463.1	Expressed in all		
ATP5L	ATP5JG	ENSG00000167283	ATP synthase, H+ transporting, mitochondrial Fo complex subunit G	11	118401154-118431496	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044629	Approved		Supported	Mitochondria	Renal cancer:4.09e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 117.0	Expressed in all		
ATP6AP1	16A, Ac45, ATP6IP1, ATP6S1, CF2, ORF, VATPS1, XAP-3, XAP3	ENSG00000071553	ATPase H+ transporting accessory protein 1	X	154428632-154436516	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015218	Uncertain		Approved	Plasma membrane<br>Microtubules<br>Cytosol	Renal cancer:5.26e-8 (favourable), Breast cancer:2.40e-4 (unfavourable), Glioma:7.82e-4 (unfavourable), Pancreatic cancer:7.83e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 209.7	Expressed in all		
ATP6AP1L		ENSG00000205464	ATPase H+ transporting accessory protein 1 like	5	82279462-82386977	Predicted membrane proteins	Evidence at transcript level	HPA053771	Approved		Approved	Nucleoli<br>Cytosol		Mixed	Mixed			testis: 10.3	Cell line enhanced		MOLT-4: 14.2
ATP6AP2	APT6M8-9, ATP6IP2, ATP6M8-9, M8-9, PRR, RENR	ENSG00000182220	ATPase H+ transporting accessory protein 2	X	40579372-40606848	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA003156	Approved				Renal cancer:2.01e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 893.4	Expressed in all		
ATP6V0A1	a1, ATP6N1, ATP6N1A, Stv1, Vph1, VPP1	ENSG00000033627	ATPase H+ transporting V0 subunit a1	17	42458844-42522611	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA022144	Enhanced		Approved	Nuclear speckles<br>Golgi apparatus<br>Vesicles<br>Cytosol	Renal cancer:1.28e-4 (favourable), Pancreatic cancer:2.05e-4 (favourable), Urothelial cancer:6.90e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 200.9	Mixed		
ATP6V0A2	a2, ATP6a2, ATP6N1D, J6B7, Stv1, TJ6, TJ6M, TJ6s, Vph1	ENSG00000185344	ATPase H+ transporting V0 subunit a2	12	123712318-123761755	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044279	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			skin: 15.1	Expressed in all		
ATP6V0A4	a4, ATP6N1B, ATP6N2, RDRTA2, RTA1C, RTADR, Stv1, Vph1, VPP2	ENSG00000105929	ATPase H+ transporting V0 subunit a4	7	138706295-138799560	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018029, HPA064555	Enhanced		Approved	Cytosol	Renal cancer:1.32e-6 (favourable)	Tissue enriched	Group enriched	9	kidney: 69.6;salivary gland: 31.6	breast: 5.5	Cell line enriched	12	SK-BR-3: 42.2
ATP6V0B	ATP6F, HATPL, VMA16	ENSG00000117410	ATPase H+ transporting V0 subunit b	1	43974487-43978295	Predicted membrane proteins	Evidence at transcript level	HPA044281			Approved	Cytosol	Renal cancer:3.62e-6 (favourable), Pancreatic cancer:3.24e-4 (favourable), Liver cancer:4.79e-4 (unfavourable), Urothelial cancer:8.87e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 181.4	Expressed in all		
ATP6V0C	ATP6C, ATP6L, ATPL, VATL, Vma3	ENSG00000185883	ATPase H+ transporting V0 subunit c	16	2513870-2520218	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.07e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 422.8	Expressed in all		
ATP6V0E1	ATP6H, ATP6V0E, M9.2	ENSG00000113732	ATPase H+ transporting V0 subunit e1	5	172983757-173035445	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Expressed in all			epididymis: 772.1	Expressed in all		
ATP6V0E2	ATP6V0E2L, C7orf32	ENSG00000171130	ATPase H+ transporting V0 subunit e2	7	149872968-149880698	Predicted membrane proteins	Evidence at transcript level						Renal cancer:8.26e-7 (favourable), Pancreatic cancer:5.80e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 261.0	Expressed in all		
ATP7A	MNK	ENSG00000165240	ATPase copper transporting alpha	X	77910656-78050395	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012887, HPA048107	Approved		Supported	Golgi apparatus<br>Vesicles	Renal cancer:8.38e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.3	Mixed		
ATP7B	WND	ENSG00000123191	ATPase copper transporting beta	13	51930436-52012125	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA009137, HPA013187	Supported		Supported	Golgi apparatus	Endometrial cancer:5.01e-4 (unfavourable)	Mixed	Mixed			testis: 13.9	Cell line enhanced		BEWO: 31.8;HEL: 46.9;RPTEC TERT1: 22.2
ATP8A1	ATPIA	ENSG00000124406	ATPase phospholipid transporting 8A1	4	42408373-42657105	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052935	Enhanced		Supported	Vesicles	Renal cancer:5.54e-10 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 68.8;thyroid gland: 66.6	cerebral cortex: 58.2	Cell line enhanced		AN3-CA: 25.5;Daudi: 33.1
ATP8A2	ATPIB, ML-1	ENSG00000132932	ATPase phospholipid transporting 8A2	13	25372071-26025851	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA039926, HPA040033	Approved		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Group enriched	6	cerebral cortex: 26.4;testis: 10.7	adrenal gland: 2.9	Cell line enhanced		HMC-1: 19.3;SCLC-21H: 3.9
ATP8B1	ATPIC, BRIC, FIC1, PFIC, PFIC1	ENSG00000081923	ATPase phospholipid transporting 8B1	18	57646426-57803101	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018673, HPA018674	Enhanced				Colorectal cancer:2.60e-4 (favourable), Renal cancer:6.35e-4 (favourable)	Expressed in all	Expressed in all			colon: 94.6	Cell line enhanced		RT4: 171.8
ATP8B2	ATPID, KIAA1137	ENSG00000143515	ATPase phospholipid transporting 8B2	1	154325553-154351307	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046680	Approved				Urothelial cancer:5.29e-5 (unfavourable), Pancreatic cancer:1.60e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 61.1	Mixed		
ATP8B3	ATPIK	ENSG00000130270	ATPase phospholipid transporting 8B3	19	1782075-1812276	Enzymes, Predicted membrane proteins	Evidence at transcript level						Renal cancer:4.80e-9 (unfavourable)	Mixed	Tissue enriched	7	testis: 28.7	bone marrow: 4.0	Cell line enhanced		Karpas-707: 16.1;U-266/70: 14.2
ATP8B4	ATPIM, KIAA1939	ENSG00000104043	ATPase phospholipid transporting 8B4 (putative)	15	49858238-50182817	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040254	Approved		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		bone marrow: 23.0	endometrium: 9.3	Cell line enhanced		HMC-1: 32.2;THP-1: 16.5;U-937: 60.0
ATP9A	ATPIIA, KIAA0611	ENSG00000054793	ATPase phospholipid transporting 9A (putative)	20	51596514-51768634	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level	CAB020699, HPA035630	Approved				Renal cancer:5.67e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 155.8	Mixed		
ATP9B	ATPIIB	ENSG00000166377	ATPase phospholipid transporting 9B (putative)	18	79069285-79378283	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029364	Approved					Expressed in all	Expressed in all			testis: 39.0	Expressed in all		
ATR	FRP1, MEC1, SCKL, SCKL1	ENSG00000175054	ATR serine/threonine kinase	3	142449235-142578826	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054320			Supported	Nucleoplasm<br>Golgi apparatus	Pancreatic cancer:1.23e-5 (unfavourable), Liver cancer:8.39e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.4	Expressed in all		
ATRAID	APR3, C2orf28, HSPC013, p18	ENSG00000138085	All-trans retinoic acid induced differentiation factor	2	27212027-27217178	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051353	Uncertain					Expressed in all	Expressed in all			epididymis: 521.0	Expressed in all		
ATRN	DPPT-L, MGCA	ENSG00000088812	Attractin	20	3471040-3651122	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008853	Uncertain		Approved	Cytosol	Renal cancer:2.19e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.8	Mixed		
ATRNL1	ALP, FLJ45344, KIAA0534	ENSG00000107518	Attractin like 1	10	115093365-115948992	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038070	Uncertain		Approved	Nucleus<br>Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 33.9	testis: 22.7	Cell line enhanced		AN3-CA: 27.6;RH-30: 19.2
ATXN3	ATX3, JOS, MJD, SCA3	ENSG00000066427	Ataxin 3	14	92038652-92106621	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB021976, HPA024123, HPA069338	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane		Mixed	Mixed			testis: 18.6	Expressed in all		
AUP1		ENSG00000115307	Ancient ubiquitous protein 1	2	74526645-74529939	Predicted membrane proteins	Evidence at protein level	HPA007674	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:2.97e-9 (unfavourable), Liver cancer:2.29e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 58.2	Expressed in all		
AVL9	KIAA0241	ENSG00000105778	AVL9 cell migration associated	7	32495426-32588721	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050957	Approved		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			cerebral cortex: 25.5	Mixed		
AVPR1A	AVPR1	ENSG00000166148	Arginine vasopressin receptor 1A	12	63142759-63150942	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 77.8	adipose tissue: 20.0	Group enriched	8	ASC diff: 3.9;Karpas-707: 9.4;U-266/84: 6.8
AVPR1B	AVPR3	ENSG00000198049	Arginine vasopressin receptor 1B	1	206109692-206117699	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA075404	Supported					Tissue enhanced	Not detected			stomach: 0.3	Not detected		
AVPR2	DIR, DIR3, V2R	ENSG00000126895	Arginine vasopressin receptor 2	X	153902531-153907166	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046678	Approved					Mixed	Tissue enhanced		adipose tissue: 5.8	kidney: 2.8	Cell line enhanced		EFO-21: 3.0;SCLC-21H: 4.6;U-266/84: 2.7;U-698: 2.8
AWAT1	DGAT2L3	ENSG00000204195	Acyl-CoA wax alcohol acyltransferase 1	X	70234655-70240627	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA063412	Supported					Not detected	Not detected			breast: 0.8	Not detected		
AWAT2	DGAT2L4, MFAT	ENSG00000147160	Acyl-CoA wax alcohol acyltransferase 2	X	70040542-70049938	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA062748	Approved					Tissue enriched	Tissue enhanced		breast: 2.0;skin: 1.2	testis: 0.5	Not detected		
AXL	ARK, JTK11, Tyro7, UFO	ENSG00000167601	AXL receptor tyrosine kinase	19	41219203-41261766	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB032501, HPA037422, HPA037423	Uncertain				Renal cancer:2.53e-7 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 54.6	Mixed		
B3GALT2	beta3Gal-T2	ENSG00000162630	Beta-1,3-galactosyltransferase 2	1	193179045-193186654	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 29.0;gallbladder: 26.0	heart muscle: 14.9	Group enriched	5	AF22: 19.6;ASC TERT1: 6.1;LHCN-M2: 11.4;WM-115: 23.5
B3GAT2	GlcAT-S	ENSG00000112309	Beta-1,3-glucuronyltransferase 2	6	70856679-70957038	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA012059	Uncertain					Group enriched	Tissue enriched	10	cerebral cortex: 19.5	testis: 1.8	Cell line enriched	25	SCLC-21H: 25.9
B3GNT2	B3GN-T1, B3GN-T2, B3GNT-2, B3GNT1, BETA3GNT	ENSG00000170340	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	2	62196113-62224731	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA005997	Approved		Approved	Vesicles	Pancreatic cancer:1.62e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 51.0	Expressed in all		
B4GALNT2	Cad, GALGT2, Sda	ENSG00000167080	Beta-1,4-N-acetyl-galactosaminyltransferase 2	17	49132460-49176840	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015721	Approved				Renal cancer:1.29e-5 (favourable)	Mixed	Tissue enhanced		colon: 33.3	rectum: 14.9	Mixed		
B4GALT1	beta4Gal-T1, GGTB2	ENSG00000086062	Beta-1,4-galactosyltransferase 1	9	33104082-33167356	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA010806, HPA010807	Enhanced		Enhanced	Golgi apparatus	Endometrial cancer:6.85e-7 (favourable), Lung cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 140.5	Expressed in all		
B4GALT2	beta4Gal-T2	ENSG00000117411	Beta-1,4-galactosyltransferase 2	1	43978943-43991170	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007620, HPA047739	Enhanced		Supported	Golgi apparatus<br>Vesicles	Liver cancer:2.96e-5 (unfavourable), Renal cancer:3.62e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 49.4	Mixed		
BACE1	BACE	ENSG00000186318	Beta-secretase 1	11	117285207-117316259	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016358	Approved		Supported	Plasma membrane	Urothelial cancer:6.76e-4 (unfavourable)	Expressed in all	Expressed in all			pancreas: 100.7	Mixed		
BACE2	AEPLC, ALP56, CEAP1, DRAP	ENSG00000182240	Beta-site APP-cleaving enzyme 2	21	41167801-41282518	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035416	Approved				Cervical cancer:1.11e-4 (unfavourable), Glioma:8.13e-4 (unfavourable)	Expressed in all	Mixed			stomach: 30.5	Cell line enhanced		SK-BR-3: 43.8;WM-115: 41.2
BAK1	BAK, BCL2L7, CDN1	ENSG00000030110	BCL2 antagonist/killer 1	6	33572547-33580293	Predicted membrane proteins, Transporters	Evidence at protein level	CAB005029	Enhanced				Renal cancer:1.64e-5 (unfavourable), Endometrial cancer:1.71e-4 (unfavourable), Liver cancer:4.52e-4 (unfavourable), Lung cancer:5.64e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 47.9	Expressed in all		
BAMBI	NMA	ENSG00000095739	BMP and activin membrane bound inhibitor	10	28677342-28682939	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA010819, HPA010866	Approved		Approved	Nucleoli fibrillar center<br>Vesicles<br>Lipid droplets	Liver cancer:9.42e-6 (unfavourable), Renal cancer:5.25e-4 (favourable)	Expressed in all	Tissue enhanced		ovary: 87.8	adrenal gland: 50.0	Cell line enhanced		CACO-2: 120.2;SK-MEL-30: 134.8
BCAM	CD239, LU	ENSG00000187244	Basal cell adhesion molecule (Lutheran blood group)	19	44809059-44821420	Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005654	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:5.94e-6 (favourable), Endometrial cancer:1.24e-5 (unfavourable), Colorectal cancer:2.31e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 174.7	Cell line enhanced		HaCaT: 278.4;SK-BR-3: 217.2;T-47d: 152.4
BCAP29	BAP29, DKFZp686M2086	ENSG00000075790	B-cell receptor associated protein 29	7	107579977-107629170	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA029215, HPA049694	Enhanced		Approved	Cytosol	Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 93.0	Expressed in all		
BCAP31	6C6-Ag, BAP31, CDM, DXS1357E	ENSG00000185825	B-cell receptor-associated protein 31	X	153700497-153724697	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003906, CAB015350, CAB015424	Enhanced	Approved	Enhanced	Endoplasmic reticulum	Head and neck cancer:9.87e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 273.7	Expressed in all		
BCL2	Bcl-2, PPP1R50	ENSG00000171791	BCL2, apoptosis regulator	18	63123346-63320128	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000003, HPA055295	Enhanced		Supported	Nucleoplasm<br>Nuclear membrane	Renal cancer:1.29e-8 (favourable), Cervical cancer:5.13e-5 (favourable), Thyroid cancer:2.47e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 69.3	parathyroid gland: 35.3	Cell line enhanced		Karpas-707: 59.5;U-266/70: 217.8
BCL2L1	Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52	ENSG00000171552	BCL2 like 1	20	31664452-31723989	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters	Evidence at protein level	HPA035734, CAB072801	Approved		Approved	Mitochondria	Renal cancer:8.89e-5 (favourable), Pancreatic cancer:5.87e-4 (unfavourable), Endometrial cancer:9.10e-4 (unfavourable), Melanoma:9.57e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 100.5	Expressed in all		
BCL2L10	BCL-B, Boo, Diva	ENSG00000137875	BCL2 like 10	15	52109263-52112775	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042222	Approved					Mixed	Tissue enhanced		skin: 6.1	kidney: 3.3	Group enriched	8	NB-4: 21.5;SiHa: 4.5
BCL2L13	BCL-RAMBO, MIL1	ENSG00000099968	BCL2 like 13	22	17628855-17730855	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002052, HPA030994, HPA050377	Uncertain		Supported	Mitochondria	Renal cancer:1.96e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.7	Expressed in all		
BCL2L2	BCL-W, KIAA0271, PPP1R51	ENSG00000129473	BCL2 like 2	14	23298790-23311759	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB040539	Approved				Renal cancer:1.99e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 88.8	Expressed in all		
BCS1L	BCS, BJS, h-BCS, Hs.6719	ENSG00000074582	BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone	2	218658764-218663443	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037700, HPA037701	Enhanced				Urothelial cancer:3.31e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 31.2	Expressed in all		
BDKRB1	B1BKR, BKR1, bradyb1	ENSG00000100739	Bradykinin receptor B1	14	96255824-96268967	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA002935	Approved					Mixed	Tissue enhanced		gallbladder: 18.2	urinary bladder: 9.9	Cell line enhanced		BJ hTERT+: 19.8;HHSteC: 20.3;hTEC/SVTERT24-B: 23.1;U-2197: 23.8;U-87 MG: 82.4
BDKRB2	BK-2	ENSG00000168398	Bradykinin receptor B2	14	96204679-96244166	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA050841	Approved					Mixed	Mixed			gallbladder: 32.5	Cell line enhanced		ASC TERT1: 34.0;BJ hTERT+: 75.7;U-87 MG: 38.4
BDNF		ENSG00000176697	Brain derived neurotrophic factor	11	27654893-27722058	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009564, HPA031440, HPA056104	Enhanced		Supported	Nuclear speckles<br>Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 11.9	epididymis: 4.9	Cell line enhanced		BJ: 37.3;BJ hTERT+ SV40 Large T+: 30.7;HBF TERT88: 30.4;U-138 MG: 45.3
BEAN1	SCA31	ENSG00000166546	Brain expressed, associated with NEDD4, 1	16	66427297-66493529	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA053851	Uncertain		Uncertain	Nucleoplasm<br>Centrosome		Mixed	Mixed			cerebral cortex: 2.2	Cell line enhanced		AN3-CA: 5.5;BEWO: 2.9;RPTEC TERT1: 4.0;U-87 MG: 3.3
BEST1	BEST, BMD, RP50, VMD2	ENSG00000167995	Bestrophin 1	11	61949821-61965515	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA057464	Supported					Group enriched	Mixed			cerebral cortex: 17.0	Cell line enhanced		SK-MEL-30: 40.9;U-266/70: 10.4
BEST2	FLJ20132, VMD2L1	ENSG00000039987	Bestrophin 2	19	12751702-12758458	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA046229	Approved					Tissue enhanced	Tissue enhanced		colon: 15.4;rectum: 14.8	tonsil: 4.5	Mixed		
BEST3	MGC13168, MGC40411, VMD2L3	ENSG00000127325	Bestrophin 3	12	69643360-69699476	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA054582	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 16.3;skeletal muscle: 12.2	testis: 5.6	Group enriched	13	REH: 32.4;RPMI-8226: 26.4;U-698: 43.2
BEST4	VMD2L2	ENSG00000142959	Bestrophin 4	1	44783585-44787705	Predicted membrane proteins	Evidence at protein level	HPA058564	Uncertain					Mixed	Tissue enhanced		colon: 26.2;rectum: 21.3	duodenum: 11.3	Cell line enhanced		Hep G2: 2.1
BET1	hbet1	ENSG00000105829	Bet1 golgi vesicular membrane trafficking protein	7	93962762-94004382	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Glioma:9.38e-5 (unfavourable), Renal cancer:1.32e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 51.4	Expressed in all		
BET1L	GOLIM3, GS15	ENSG00000177951	Bet1 golgi vesicular membrane trafficking protein like	11	167784-207428	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039819	Approved		Approved	Nucleus<br>Golgi apparatus	Liver cancer:2.20e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 75.0	Expressed in all		
BFAR	BAR, RNF47	ENSG00000103429	Bifunctional apoptosis regulator	16	14632815-14669236	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:4.74e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 23.4	Expressed in all		
BIK	NBK	ENSG00000100290	BCL2 interacting killer	22	43110748-43129712	Predicted membrane proteins	Evidence at protein level	HPA051360	Approved				Renal cancer:7.45e-5 (favourable)	Mixed	Mixed			lymph node: 14.0	Cell line enhanced		A-431: 77.8;U-698: 117.1
BMPR1A	ACVRLK3, ALK3, CD292	ENSG00000107779	Bone morphogenetic protein receptor type 1A	10	86756601-86932838	Cancer-related genes, CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB019398	Approved		Approved	Cytosol	Liver cancer:8.93e-4 (unfavourable), Glioma:9.38e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 19.6	Mixed		
BMPR1B	ALK6, CDw293	ENSG00000138696	Bone morphogenetic protein receptor type 1B	4	94757968-95158448	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:2.84e-4 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 37.2;prostate: 37.0	seminal vesicle: 21.0	Cell line enhanced		A549: 21.1;SH-SY5Y: 20.1
BMPR2	BMPR-II, BMPR3, BRK-3, PPH1, T-ALK	ENSG00000204217	Bone morphogenetic protein receptor type 2	2	202376936-202567751	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA017385, HPA049014	Approved		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			placenta: 44.9	Mixed		
BMT2	C7orf60, DKFZp762M126, FLJ31818	ENSG00000164603	Base methyltransferase of 25S rRNA 2 homolog	7	112819147-112939916	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044405, HPA050733	Uncertain		Approved	Cytosol		Expressed in all	Mixed			testis: 14.9	Expressed in all		
BNIP1	Nip1, SEC20	ENSG00000113734	BCL2 interacting protein 1	5	173144442-173164387	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008009, HPA008149	Enhanced		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			testis: 27.0	Expressed in all		
BNIP2	BNIP-2, Nip2	ENSG00000140299	BCL2 interacting protein 2	15	59659146-59689534	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026843	Approved				Renal cancer:2.19e-5 (unfavourable), Endometrial cancer:8.42e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 84.4	Expressed in all		
BNIP3	Nip3	ENSG00000176171	BCL2 interacting protein 3	10	131966455-131982013	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003015, CAB011676	Supported		Uncertain	Cytosol	Renal cancer:4.55e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 84.1	Cell line enhanced		A-431: 338.9;U-87 MG: 339.6
BNIP3L	BNIP3a, Nix	ENSG00000104765	BCL2 interacting protein 3 like	8	26382898-26505636	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015652, CAB025371	Enhanced		Enhanced	Nuclear speckles<br>Mitochondria	Renal cancer:5.92e-5 (unfavourable), Thyroid cancer:3.95e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 147.5	Expressed in all		
BNIPL	BNIP-S, BNIP-Salpha, BNIP-Sbeta, BNIPl-1, BNIPL-2, PP753	ENSG00000163141	BCL2 interacting protein like	1	151036570-151047600	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019946			Approved	Cytosol	Thyroid cancer:4.32e-4 (favourable), Endometrial cancer:6.50e-4 (unfavourable)	Mixed	Group enriched	7	esophagus: 88.9;skin: 227.0	breast: 21.6	Cell line enriched	14	T-47d: 44.3
BOC	CDON2	ENSG00000144857	BOC cell adhesion associated, oncogene regulated	3	113211003-113287459	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025806, HPA060778, HPA061787	Uncertain		Supported	Nucleoplasm<br>Plasma membrane	Urothelial cancer:1.18e-5 (unfavourable), Head and neck cancer:4.89e-4 (favourable)	Mixed	Mixed			fallopian tube: 51.7	Cell line enhanced		AN3-CA: 73.4;ASC diff: 77.9;BJ hTERT+: 34.1
BOK	BCL2L9, BOKL, MGC4631	ENSG00000176720	BOK, BCL2 family apoptosis regulator	2	241558721-241574138	Plasma proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.09e-9 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 97.4	endometrium,seminal vesicle: 35.9	Mixed		
BPI	BPIFD1	ENSG00000101425	Bactericidal/permeability-increasing protein	20	38260149-38337505	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA061284	Enhanced					Not detected	Tissue enriched	37	bone marrow: 961.6	testis: 25.9	Group enriched	5	AF22: 2.3;ASC diff: 1.1;ASC TERT1: 3.1;BJ: 2.1;BJ hTERT+: 2.1;HL-60: 1.1
BRI3		ENSG00000164713	Brain protein I3	7	98252379-98310441	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042215	Uncertain				Head and neck cancer:3.35e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 119.1	Expressed in all		
BRI3BP	BNAS1, HCCR-2, HCCRBP-3, KG19	ENSG00000184992	BRI3 binding protein	12	124993700-125031231	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014957	Approved		Approved	Nucleoplasm<br>Mitochondria	Liver cancer:6.87e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 20.5	Expressed in all		
BRICD5	C16orf79, MGC21830	ENSG00000182685	BRICHOS domain containing 5	16	2209253-2211950	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019197, HPA063522	Uncertain		Approved	Nucleoplasm<br>Actin filaments	Urothelial cancer:8.06e-5 (favourable), Pancreatic cancer:7.01e-4 (favourable), Breast cancer:9.74e-4 (favourable)	Expressed in all	Mixed			testis: 10.6	Mixed		
BRS3	BB3, BB3R	ENSG00000102239	Bombesin receptor subtype 3	X	136487887-136493780	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	33	epididymis: 30.5	ovary: 0.9	Not detected		
BRSK1	KIAA1811	ENSG00000160469	BR serine/threonine kinase 1	19	55282072-55312533	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021212, HPA061719	Supported		Supported	Nucleoplasm	Renal cancer:7.98e-6 (unfavourable), Pancreatic cancer:1.02e-4 (favourable)	Expressed in all	Tissue enriched	6	cerebral cortex: 137.8	parathyroid gland: 24.6	Cell line enhanced		SCLC-21H: 65.8;SH-SY5Y: 53.1
BRSK2	C11orf7, PEN11B, STK29	ENSG00000174672	BR serine/threonine kinase 2	11	1389899-1462689	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA073690			Approved	Golgi apparatus		Tissue enhanced	Tissue enhanced		cerebral cortex: 61.7;pancreas: 19.2	testis: 9.5	Cell line enhanced		NTERA-2: 27.4;SCLC-21H: 74.9
BSCL2	GNG3LG, SPG17	ENSG00000168000	BSCL2, seipin lipid droplet biogenesis associated	11	62690275-62709845	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042394	Approved				Renal cancer:7.55e-5 (favourable)	Expressed in all	Expressed in all			testis: 250.5	Expressed in all		
BSG	CD147, EMMPRIN, OK	ENSG00000172270	Basigin (Ok blood group)	19	571277-583493	Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB002427, HPA036048, HPA074870	Enhanced		Approved	Vesicles	Renal cancer:1.95e-6 (favourable), Liver cancer:5.48e-6 (unfavourable), Endometrial cancer:2.59e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 593.5	Expressed in all		
BSND	BART, DFNB73	ENSG00000162399	Barttin CLCNK type accessory beta subunit	1	54998933-55010883	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA053836, HPA060617	Enhanced					Tissue enriched	Tissue enriched	7	kidney: 10.2	salivary gland: 1.5	Cell line enriched	15	RPMI-8226: 8.0
BST2	CD317, tetherin	ENSG00000130303	Bone marrow stromal cell antigen 2	19	17402939-17405648	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA017060	Approved		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:3.56e-9 (unfavourable), Testis cancer:4.22e-4 (unfavourable), Breast cancer:6.69e-4 (favourable)	Expressed in all	Expressed in all			ovary: 586.7	Mixed		
BTC		ENSG00000174808	Betacellulin	4	74744759-74794686	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:6.10e-5 (favourable)	Mixed	Mixed			skin: 15.4	Cell line enhanced		CAPAN-2: 13.5;RPTEC TERT1: 6.9
BTLA	BTLA1, CD272	ENSG00000186265	B and T lymphocyte associated	3	112463968-112499561	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047211, HPA062029	Enhanced					Mixed	Group enriched	7	appendix: 14.1;lymph node: 29.3;spleen: 14.6;tonsil: 24.7	urinary bladder: 3.0	Cell line enhanced		U-698: 1.3
BTN1A1	BT, BTN, BTN1	ENSG00000124557	Butyrophilin subfamily 1 member A1	6	26501221-26510422	Predicted membrane proteins	Evidence at protein level	HPA011126, CAB037340	Supported					Tissue enhanced	Tissue enriched	49	breast: 36.8	lymph node,tonsil: 0.7	Cell line enriched	5	CACO-2: 3.8
BTN2A1	BT2.1, BTF1, BTN2.1	ENSG00000112763	Butyrophilin subfamily 2 member A1	6	26457904-26476621	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019208	Approved		Approved	Plasma membrane	Urothelial cancer:4.52e-5 (favourable), Renal cancer:5.90e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 26.3	Expressed in all		
BTN2A2	BT2.2, BTF2, BTN2.2	ENSG00000124508	Butyrophilin subfamily 2 member A2	6	26383096-26394874	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051504	Uncertain		Supported	Mitochondria	Breast cancer:1.01e-4 (favourable)	Expressed in all	Mixed			lymph node: 37.6	Mixed		
BTN3A1	BT3.1, BTF5, BTN3.1, CD277	ENSG00000026950	Butyrophilin subfamily 3 member A1	6	26402237-26415216	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012565	Approved		Uncertain	Vesicles	Renal cancer:4.15e-5 (unfavourable), Urothelial cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			spleen: 112.6	Mixed		
BTN3A2	BTN3.2	ENSG00000186470	Butyrophilin subfamily 3 member A2	6	26365159-26378320	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB019392	Uncertain				Renal cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 129.4	Mixed		
BTN3A3	BTF3, BTN3.3	ENSG00000111801	Butyrophilin subfamily 3 member A3	6	26440472-26453415	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007904, HPA011871	Enhanced				Renal cancer:2.42e-5 (unfavourable), Ovarian cancer:1.80e-4 (favourable)	Expressed in all	Mixed			spleen: 64.0	Cell line enhanced		ASC TERT1: 43.5;BJ hTERT+ SV40 Large T+ RasG12V: 41.9
BTNL2	BTL-II, BTN7, HSBLMHC1	ENSG00000204290	Butyrophilin like 2	6	32393963-32407128	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			prostate: 0.2	Not detected		
BTNL3	BTN9.1, BTNLR	ENSG00000168903	Butyrophilin like 3	5	180988845-181006727	Predicted membrane proteins	Evidence at transcript level							Group enriched	Group enriched	25	colon: 24.5;duodenum: 115.1;rectum: 26.3;small intestine: 89.1	gallbladder: 2.5	Not detected		
BTNL8	BTN9.2, FLJ21458	ENSG00000113303	Butyrophilin like 8	5	180899077-180950906	Predicted membrane proteins	Evidence at protein level	HPA039738	Approved					Group enriched	Group enriched	6	colon: 26.1;duodenum: 117.4;rectum: 27.7;small intestine: 94.2	gallbladder: 10.4	Cell line enriched	26	CACO-2: 31.4
BTNL9	BTN8, FLJ32535	ENSG00000165810	Butyrophilin like 9	5	181040225-181061523	Predicted membrane proteins	Evidence at protein level	HPA043429			Approved	Nuclear membrane<br>Vesicles	Liver cancer:1.55e-9 (favourable), Endometrial cancer:7.51e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 166.9	lung: 55.8	Cell line enhanced		U-2 OS: 5.7;U-698: 25.5
BVES	HBVES, POP1, POPDC1	ENSG00000112276	Blood vessel epicardial substance	6	105096822-105137174	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014788, HPA018176	Enhanced		Supported	Plasma membrane<br>Cell Junctions		Mixed	Tissue enhanced		smooth muscle: 25.0	testis: 20.7	Cell line enhanced		RH-30: 28.7;WM-115: 29.8
C10orf128	Em:AC084727.5	ENSG00000204161	Chromosome 10 open reading frame 128	10	49154725-49188585	Predicted membrane proteins	Evidence at transcript level	HPA058166	Approved				Renal cancer:2.86e-5 (unfavourable)	Expressed in all	Mixed			lung: 40.6	Cell line enhanced		HDLM-2: 200.6;HEL: 46.6;K-562: 91.3;U-87 MG: 100.7;U-937: 72.4
C10orf35		ENSG00000171224	Chromosome 10 open reading frame 35	10	69630251-69633599	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034591	Enhanced		Approved	Nucleus<br>Centrosome<br>Cytosol	Liver cancer:1.03e-4 (unfavourable), Head and neck cancer:8.64e-4 (unfavourable), Urothelial cancer:9.72e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 27.6	testis: 20.2	Cell line enhanced		PC-3: 53.3
C11orf24	DM4E3	ENSG00000171067	Chromosome 11 open reading frame 24	11	68261335-68272001	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012748	Uncertain		Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:1.60e-9 (unfavourable), Lung cancer:6.05e-4 (unfavourable), Glioma:9.83e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 65.9	Expressed in all		
C11orf80	FLJ22531, TOPOVIBL	ENSG00000173715	Chromosome 11 open reading frame 80	11	66744451-66843328	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038932, HPA038933	Approved		Approved	Centrosome		Expressed in all	Tissue enhanced		skin: 48.2	testis: 26.7	Mixed		
C11orf87	LOC399947, LOH11CR1A, NEURIM1	ENSG00000185742	Chromosome 11 open reading frame 87	11	109422120-109429114	Predicted membrane proteins	Evidence at protein level	HPA034656	Approved					Tissue enhanced	Tissue enriched	20	cerebral cortex: 30.8	endometrium: 1.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 2.7;fHDF/TERT166: 9.0;SCLC-21H: 3.4
C12orf76	FLJ40142	ENSG00000174456	Chromosome 12 open reading frame 76	12	110027028-110073686	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA039713, HPA042013	Uncertain		Approved	Plasma membrane<br>Actin filaments	Renal cancer:5.74e-5 (unfavourable), Lung cancer:6.44e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 105.7	Expressed in all		
C14orf1	ERG28, NET51	ENSG00000133935	Chromosome 14 open reading frame 1	14	75649791-75661189	Predicted membrane proteins	Evidence at protein level	HPA043172, HPA063568	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.30e-5 (favourable)	Expressed in all	Expressed in all			testis: 77.2	Expressed in all		
C14orf132	C14orf88	ENSG00000227051	Chromosome 14 open reading frame 132	14	96039324-96093889	Predicted membrane proteins	Evidence at transcript level						Pancreatic cancer:3.54e-4 (favourable), Urothelial cancer:4.95e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 82.6	fallopian tube: 35.8	Cell line enhanced		SCLC-21H: 62.1;SH-SY5Y: 55.5;U-87 MG: 45.2
C14orf180	C14orf77, NRAC	ENSG00000184601	Chromosome 14 open reading frame 180	14	104579684-104590515	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Group enriched	19	adipose tissue: 34.5;heart muscle: 28.5	adrenal gland: 1.6	Cell line enriched	14	ASC diff: 2.0
C14orf2	MP68	ENSG00000156411	Chromosome 14 open reading frame 2	14	103912288-103928269	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058978, HPA060520	Enhanced		Supported	Nucleoli fibrillar center<br>Mitochondria	Ovarian cancer:6.80e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 209.1	Expressed in all		
C14orf37	UT2	ENSG00000139971	Chromosome 14 open reading frame 37	14	57999735-58298139	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001580, HPA001789	Enhanced		Approved	Plasma membrane		Mixed	Mixed			kidney: 8.8	Cell line enhanced		AF22: 9.6;fHDF/TERT166: 8.4
C16orf52		ENSG00000185716	Chromosome 16 open reading frame 52	16	22007638-22087534	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Mixed			parathyroid gland: 20.1	Expressed in all		
C16orf54	FLJ35681	ENSG00000185905	Chromosome 16 open reading frame 54	16	29742463-29746006	Predicted membrane proteins	Evidence at protein level	HPA060546	Uncertain					Expressed in all	Tissue enhanced		bone marrow: 26.0	lymph node: 23.9	Cell line enhanced		HEL: 16.6;HL-60: 15.0;HMC-1: 10.2;MOLT-4: 12.4;THP-1: 14.7
C16orf58	FLJ13868	ENSG00000140688	Chromosome 16 open reading frame 58	16	31489471-31509309	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024406	Uncertain		Approved	Nucleoplasm<br>Nucleoli<br>Golgi apparatus<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 77.4	Expressed in all		
C16orf62	MGC16824	ENSG00000103544	Chromosome 16 open reading frame 62	16	19555240-19706793	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042969, HPA053547	Uncertain		Approved	Mitochondria	Renal cancer:1.31e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 69.5	Mixed		
C16orf91	CCSMST1, gs103, URLC5	ENSG00000174109	Chromosome 16 open reading frame 91	16	1419744-1420800	Predicted membrane proteins	Evidence at protein level						Renal cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 11.9	Expressed in all		
C16orf92	FLJ25404	ENSG00000167194	Chromosome 16 open reading frame 92	16	30023334-30027736	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	7	testis: 22.9	cerebral cortex: 3.4	Cell line enhanced		RPMI-8226: 1.7;SCLC-21H: 9.5;SH-SY5Y: 1.9
C17orf62	FLJ90469, MGC4368	ENSG00000178927	Chromosome 17 open reading frame 62	17	82442589-82450829	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045696	Uncertain		Approved	Plasma membrane<br>Cell Junctions	Renal cancer:6.83e-11 (unfavourable)	Expressed in all	Expressed in all			lymph node: 127.0	Expressed in all		
C17orf74		ENSG00000184560	Chromosome 17 open reading frame 74	17	7425615-7427568	Predicted membrane proteins	Evidence at transcript level	HPA023649	Uncertain					Not detected	Tissue enriched	308	testis: 30.8	all non-specific tissues: 0.0	Not detected		
C17orf78	FLJ39647	ENSG00000278505	Chromosome 17 open reading frame 78	17	37375986-37392708	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Group enriched	Group enriched	74	duodenum: 99.1;small intestine: 50.9	testis: 1.0	Not detected		
C17orf80	FLJ20721, HLC-8, MIG3, SPEP1	ENSG00000141219	Chromosome 17 open reading frame 80	17	73232233-73248947	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012896	Uncertain		Approved	Nucleoplasm<br>Vesicles	Liver cancer:9.02e-6 (unfavourable), Colorectal cancer:1.43e-4 (favourable)	Expressed in all	Expressed in all			testis: 71.9	Expressed in all		
C18orf32	FLJ23458	ENSG00000177576	Chromosome 18 open reading frame 32	18	49477250-49487252	Predicted membrane proteins	Evidence at protein level	HPA040921	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:8.89e-9 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 119.6	Expressed in all		
C19orf18	MGC41906	ENSG00000177025	Chromosome 19 open reading frame 18	19	57958437-57974534	Predicted membrane proteins	Evidence at transcript level	HPA014527	Uncertain		Approved	Golgi apparatus	Endometrial cancer:5.07e-4 (favourable)	Mixed	Tissue enhanced		testis: 17.0	epididymis: 4.9	Cell line enhanced		HEK93: 2.7
C19orf24	FLJ20640	ENSG00000228300	Chromosome 19 open reading frame 24	19	1275438-1279249	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043279, HPA047026	Uncertain		Approved	Nuclear speckles<br>Golgi apparatus		Expressed in all	Expressed in all			spleen: 36.3	Expressed in all		
C19orf38	HIDE1	ENSG00000214212	Chromosome 19 open reading frame 38	19	10836575-10869790	Predicted membrane proteins	Evidence at protein level	HPA012150, HPA055027			Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.75e-7 (unfavourable), Cervical cancer:2.43e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 62.8	spleen: 17.4	Cell line enhanced		U-937: 39.3
C1GALT1C1	C1GALT2, COSMC	ENSG00000171155	C1GALT1 specific chaperone 1	X	120625793-120630150	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA015632	Approved		Approved	Cytosol	Breast cancer:5.66e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 44.5	Expressed in all		
C1GALT1C1L		ENSG00000223658	C1GALT1-specific chaperone 1 like	2	43675151-43676322	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 11.8	epididymis: 8.2	Cell line enhanced		SH-SY5Y: 15.3;U-2 OS: 9.4
C1orf101	MGC33370	ENSG00000179397	Chromosome 1 open reading frame 101	1	244454377-244641177	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	12	testis: 38.5	epididymis: 3.3	Not detected		
C1orf159	FLJ20584	ENSG00000131591	Chromosome 1 open reading frame 159	1	1081818-1116361	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010019	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:1.77e-6 (unfavourable), Liver cancer:9.58e-6 (unfavourable), Urothelial cancer:1.62e-4 (favourable)	Expressed in all	Mixed			skin: 15.3	Expressed in all		
C1orf162	MGC24133	ENSG00000143110	Chromosome 1 open reading frame 162	1	111473792-111478512	Predicted membrane proteins	Evidence at protein level	HPA026988	Approved				Renal cancer:3.14e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 129.3	Cell line enhanced		HDLM-2: 121.3;HL-60: 50.8;THP-1: 33.7;U-937: 81.9
C1orf185	FLJ27485	ENSG00000204006	Chromosome 1 open reading frame 185	1	51102234-51148086	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	243	testis: 43.0	adipose tissue,gallbladder,parathyroid gland: 0.1	Not detected		
C1orf186	FLJ16052	ENSG00000263961	Chromosome 1 open reading frame 186	1	206037231-206102459	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		cervix, uterine: 37.8	seminal vesicle: 28.9	Cell line enriched	7	HMC-1: 1374.2
C1orf210	MGC52423	ENSG00000253313	Chromosome 1 open reading frame 210	1	43281883-43285617	Predicted membrane proteins	Evidence at protein level	HPA013788	Uncertain		Uncertain	Nucleoli	Renal cancer:0.00e+0 (favourable)	Mixed	Mixed			duodenum: 44.3	Cell line enhanced		A-431: 10.7;BEWO: 12.7;CACO-2: 10.5;CAPAN-2: 35.4;T-47d: 14.3
C1orf27	FLJ20505, odr-4, TTG1	ENSG00000157181	Chromosome 1 open reading frame 27	1	186375838-186421378	Predicted membrane proteins	Evidence at protein level	HPA015988, HPA031352	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Ovarian cancer:9.92e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 76.3	Expressed in all		
C1orf43	DKFZp586G1722, NICE-3	ENSG00000143612	Chromosome 1 open reading frame 43	1	154206706-154220637	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010725	Approved				Liver cancer:6.57e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 194.9	Expressed in all		
C20orf141	dJ860F19.4	ENSG00000258713	Chromosome 20 open reading frame 141	20	2814987-2815833	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	105	testis: 97.0	placenta: 0.9	Group enriched	11	HDLM-2: 18.6;U-2197: 4.7
C20orf24	PNAS-11, RIP5	ENSG00000101084	Chromosome 20 open reading frame 24	20	36605734-36612557	Predicted membrane proteins	Evidence at protein level	HPA057387	Uncertain		Approved	Cytosol	Liver cancer:4.56e-6 (unfavourable), Renal cancer:2.46e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 83.2	Expressed in all		
C2CD2L	KIAA0285, TMEM24	ENSG00000172375	C2CD2 like	11	119102198-119118544	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA011044	Approved		Approved	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Cytosol	Renal cancer:1.75e-4 (unfavourable), Endometrial cancer:4.92e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.6	Expressed in all		
C2orf16	DKFZp434G118	ENSG00000221843	Chromosome 2 open reading frame 16	2	27537386-27582721	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052136, HPA056962	Uncertain		Uncertain	Nuclear bodies		Mixed	Tissue enriched	19	testis: 14.6	cerebral cortex,thyroid gland: 0.7	Cell line enhanced		SCLC-21H: 2.9;SiHa: 1.9
C2orf74	LOC339804	ENSG00000237651	Chromosome 2 open reading frame 74	2	61145068-61164829	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA026826	Approved		Approved	Centrosome		Mixed	Expressed in all			testis: 80.5	Mixed		
C2orf82	ASCL830, UNQ830	ENSG00000182600	Chromosome 2 open reading frame 82	2	232857270-232878708	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA052824	Uncertain		Approved	Nucleus<br>Nucleoli	Endometrial cancer:3.56e-4 (unfavourable)	Mixed	Tissue enhanced		breast: 5.1;testis: 4.1	cerebral cortex: 2.6	Cell line enriched	13	Hep G2: 40.1
C2orf83	DKFZp547H025	ENSG00000042304	Chromosome 2 open reading frame 83	2	227610090-227633320	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA030319	Approved					Not detected	Tissue enhanced		placenta: 2.9	testis: 0.9	Cell line enhanced		U-2197: 1.4
C3AR1	AZ3B, C3AR	ENSG00000171860	Complement C3a receptor 1	12	8058302-8066471	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB009405	Enhanced					Expressed in all	Tissue enhanced		appendix: 86.6	placenta: 49.5	Cell line enriched	9	HMC-1: 172.5
C3orf18	G20	ENSG00000088543	Chromosome 3 open reading frame 18	3	50558025-50571027	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA012105	Approved		Approved	Cytosol	Renal cancer:2.80e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 28.3	Cell line enhanced		HDLM-2: 45.2
C3orf35	APRG1	ENSG00000198590	Chromosome 3 open reading frame 35	3	37386269-37435497	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Mixed			testis: 4.4	Mixed		
C3orf52	FLJ23186, TTMP	ENSG00000114529	Chromosome 3 open reading frame 52	3	112086335-112131004	Predicted membrane proteins	Evidence at protein level	HPA008119, HPA011968	Uncertain				Pancreatic cancer:3.85e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 23.1	thyroid gland: 16.6	Cell line enhanced		U-698: 37.5
C3orf80		ENSG00000180044	Chromosome 3 open reading frame 80	3	160225496-160228213	Predicted membrane proteins	Evidence at transcript level	HPA047439	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 9.8	esophagus: 2.7	Cell line enriched	6	HMC-1: 126.0
C4orf3	HCVFTP1	ENSG00000164096	Chromosome 4 open reading frame 3	4	119296419-119304445	Predicted membrane proteins	Evidence at protein level	HPA026907	Approved		Approved	Endoplasmic reticulum	Renal cancer:3.46e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 150.6	Expressed in all		
C4orf32	FLJ39370	ENSG00000174749	Chromosome 4 open reading frame 32	4	112145397-112195256	Predicted membrane proteins	Evidence at protein level	HPA062443, HPA069294	Approved		Supported	Golgi apparatus	Stomach cancer:8.87e-4 (unfavourable)	Mixed	Mixed			adipose tissue: 18.6	Cell line enhanced		Daudi: 29.7
C5AR1	C5A, C5AR, C5R1, CD88	ENSG00000197405	Complement C5a receptor 1	19	47290023-47322066	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002720, HPA014520	Approved				Renal cancer:1.16e-4 (unfavourable), Cervical cancer:4.71e-4 (favourable), Testis cancer:7.99e-4 (unfavourable), Ovarian cancer:9.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 121.2	adipose tissue: 91.2	Cell line enhanced		HMC-1: 4.6;U-87 MG: 6.2;U-937: 5.1
C5AR2	C5L2, GPR77	ENSG00000134830	Complement component 5a receptor 2	19	47332147-47347327	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA016629	Uncertain					Tissue enhanced	Tissue enhanced		spleen: 9.7	appendix: 5.9	Group enriched	6	MCF7: 15.8;T-47d: 23.3
C5orf15	HTGN29, KCT2	ENSG00000113583	Chromosome 5 open reading frame 15	5	133955502-133968787	Predicted membrane proteins	Evidence at protein level	HPA011951, HPA039165	Uncertain		Approved	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 81.7	Expressed in all		
C5orf42	FLJ13231, Hug, JBTS17	ENSG00000197603	Chromosome 5 open reading frame 42	5	37106228-37249428	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036775, HPA036776	Approved		Approved	Cytosol		Mixed	Mixed			thyroid gland: 13.8	Cell line enhanced		SiHa: 60.3
C6orf1	LBH, MGC57858	ENSG00000186577	Chromosome 6 open reading frame 1	6	34246380-34249470	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA037659, HPA037660	Uncertain				Renal cancer:4.38e-4 (unfavourable), Pancreatic cancer:7.98e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 57.3	Expressed in all		
C6orf10	TSBP	ENSG00000204296	Chromosome 6 open reading frame 10	6	32288526-32371912	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	73	testis: 15.6	lymph node: 0.2	Not detected		
C6orf136	Em:AB023049.8	ENSG00000204564	Chromosome 6 open reading frame 136	6	30647039-30653210	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046804	Uncertain				Renal cancer:9.16e-8 (favourable), Urothelial cancer:7.51e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 8.0	Mixed		
C6orf47	D6S53E, G4	ENSG00000204439	Chromosome 6 open reading frame 47	6	31658298-31660772	Predicted membrane proteins	Evidence at protein level	HPA045281, HPA053373	Uncertain		Approved	Cytosol		Expressed in all	Mixed			skin: 5.4	Cell line enhanced		HBEC3-KT: 5.6;HEK93: 5.9;RT4: 5.8;U-2 OS: 5.7
C6orf89	BRAP, FLJ25357	ENSG00000198663	Chromosome 6 open reading frame 89	6	36871870-36928964	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012548	Uncertain				Renal cancer:5.77e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 97.2	Expressed in all		
C7orf34	CTM-1	ENSG00000165131	Chromosome 7 open reading frame 34	7	142939343-142940868	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	40	testis: 41.5	bone marrow: 1.0	Not detected		
C9orf57		ENSG00000204669	Chromosome 9 open reading frame 57	9	72051376-72072721	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	224	testis: 26.0	parathyroid gland: 0.1	Not detected		
C9orf69	bA83N9.1	ENSG00000238227	Chromosome 9 open reading frame 69	9	136114581-136118863	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066070	Supported		Supported	Nucleoplasm	Endometrial cancer:1.09e-4 (favourable)	Expressed in all	Expressed in all			skin: 23.7	Expressed in all		
C9orf84	FLJ32779	ENSG00000165181	Chromosome 9 open reading frame 84	9	111686173-111795008	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA032108			Approved	Vesicles<br>Cytosol		Mixed	Tissue enriched	10	testis: 31.0	adrenal gland: 3.1	Cell line enhanced		A-431: 4.3;SiHa: 5.3;U-2 OS: 23.4;U-266/84: 3.3
C9orf92	Em:AL513424.1	ENSG00000205549	Chromosome 9 open reading frame 92	9	16203935-16276313	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		thyroid gland: 1.3	testis: 1.0	Cell line enhanced		BJ hTERT+: 1.1;U-2197: 1.4
CA12	HsT18816	ENSG00000074410	Carbonic anhydrase 12	15	63321378-63382161	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA008773, CAB025181, CAB062549, CAB068179, HPA073203	Enhanced		Approved	Nucleus<br>Vesicles	Pancreatic cancer:3.80e-6 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 308.4;skin: 168.3	rectum: 102.9	Cell line enhanced		A549: 191.8;RT4: 180.0;T-47d: 269.1;U-138 MG: 295.7;U-87 MG: 352.6
CA14		ENSG00000118298	Carbonic anhydrase 14	1	150257159-150265078	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008482	Approved		Approved	Plasma membrane		Group enriched	Tissue enhanced		cerebral cortex: 10.6;seminal vesicle: 21.2	skeletal muscle: 9.4	Group enriched	23	AF22: 83.4;AN3-CA: 46.6;NTERA-2: 65.8;SK-MEL-30: 134.5
CA4	CAIV, Car4, RP17	ENSG00000167434	Carbonic anhydrase 4	17	60149936-60170899	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011089, HPA017258	Enhanced		Supported	Vesicles		Mixed	Tissue enhanced		colon: 253.5;rectum: 180.9	adipose tissue: 88.7	Not detected		
CA9	CAIX, MN	ENSG00000107159	Carbonic anhydrase 9	9	35673856-35681159	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005100, CAB017107, HPA055207	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:2.22e-7 (unfavourable), Liver cancer:1.71e-5 (unfavourable), Testis cancer:9.50e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 36.0;stomach: 93.6	small intestine: 14.5	Group enriched	11	A-431: 152.1;HDLM-2: 84.3;U-87 MG: 337.9
CABLES2	C20orf150, dJ908M14.2, ik3-2	ENSG00000149679	Cdk5 and Abl enzyme substrate 2	20	62388632-62407285	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052138			Approved	Nuclear bodies<br>Cell Junctions	Renal cancer:1.24e-6 (unfavourable), Endometrial cancer:5.26e-5 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 58.3	cerebral cortex: 9.0	Expressed in all		
CABP7	MGC57793	ENSG00000100314	Calcium binding protein 7	22	29720084-29731839	Predicted membrane proteins	Evidence at protein level	HPA016439	Uncertain					Tissue enhanced	Tissue enhanced		adrenal gland: 2.5;cerebral cortex: 3.4	small intestine: 1.4	Group enriched	13	HEL: 9.4;SCLC-21H: 11.7;SH-SY5Y: 3.3;U-2 OS: 3.4
CACFD1	C9orf7, D9S2135, flower	ENSG00000160325	Calcium channel flower domain containing 1	9	133459965-133470848	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015280			Approved	Nucleoplasm	Renal cancer:2.83e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 16.6	Mixed		
CACHD1	KIAA1573, VWCD1	ENSG00000158966	Cache domain containing 1	1	64470792-64693058	Predicted membrane proteins	Evidence at protein level	HPA017202	Uncertain		Uncertain	Nucleus<br>Nucleoli		Expressed in all	Mixed			ovary: 28.1	Cell line enhanced		AF22: 40.8;NTERA-2: 56.8
CACNA1A	APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6	ENSG00000141837	Calcium voltage-gated channel subunit alpha1 A	19	13206442-13633025	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA064258, HPA071902	Enhanced		Uncertain	Endoplasmic reticulum	Pancreatic cancer:4.32e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 15.1	stomach: 3.5	Group enriched	7	SCLC-21H: 56.1;U-87 MG: 26.1
CACNA1B	CACNL1A5, CACNN, Cav2.2	ENSG00000148408	Calcium voltage-gated channel subunit alpha1 B	9	137877789-138124624	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA044347	Uncertain					Tissue enhanced	Group enriched	8	adrenal gland: 3.7;cerebral cortex: 14.8;fallopian tube: 4.9;testis: 7.6	prostate: 0.9	Cell line enriched	6	SCLC-21H: 23.0
CACNA1C	CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS	ENSG00000151067	Calcium voltage-gated channel subunit alpha1 C	12	1970786-2697950	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA039796, CAB079031	Enhanced	Approved				Mixed	Tissue enhanced		smooth muscle: 30.9	endometrium: 26.2	Cell line enriched	17	HDLM-2: 188.9
CACNA1D	CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2	ENSG00000157388	Calcium voltage-gated channel subunit alpha1 D	3	53328963-53813733	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA020215	Uncertain		Approved	Nuclear membrane	Renal cancer:8.34e-8 (favourable)	Mixed	Mixed			fallopian tube: 13.5	Cell line enhanced		HMC-1: 19.6;RPMI-8226: 38.4;SK-BR-3: 7.4
CACNA1E	BII, CACH6, CACNL1A6, Cav2.3	ENSG00000198216	Calcium voltage-gated channel subunit alpha1 E	1	181413102-181808084	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA042515, CAB079032		Approved	Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Mixed	Tissue enriched	8	cerebral cortex: 10.3	adrenal gland: 1.3	Cell line enhanced		CACO-2: 1.2;U-266/70: 1.5
CACNA1F	AIED, Cav1.4, CORDX3, CSNB2, CSNB2A, CSNBX2, JM8, JMC8, OA2	ENSG00000102001	Calcium voltage-gated channel subunit alpha1 F	X	49205063-49233371	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA068379	Supported					Not detected	Mixed			lymph node: 1.6	Cell line enhanced		U-266/70: 1.0
CACNA1G	Cav3.1, NBR13	ENSG00000006283	Calcium voltage-gated channel subunit alpha1 G	17	50561068-50627474	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA004714	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 10.5;cervix, uterine: 8.5	endometrium: 5.2	Cell line enhanced		A549: 8.5;SCLC-21H: 3.3
CACNA1H	Cav3.2	ENSG00000196557	Calcium voltage-gated channel subunit alpha1 H	16	1153121-1221772	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA039125	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:3.12e-5 (favourable)	Expressed in all	Tissue enhanced		ovary: 44.9	seminal vesicle: 39.1	Cell line enhanced		A549: 16.1;AN3-CA: 23.5;MCF7: 36.8;T-47d: 13.0
CACNA1I	Cav3.3	ENSG00000100346	Calcium voltage-gated channel subunit alpha1 I	22	39570753-39689737	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 4.7;thyroid gland: 2.7	adrenal gland: 2.3	Cell line enhanced		SK-BR-3: 1.4;T-47d: 1.0
CACNA1S	CACNL1A3, Cav1.1, HOKPP, hypoPP, MHS5	ENSG00000081248	Calcium voltage-gated channel subunit alpha1 S	1	201039512-201112566	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	CAB009507, HPA048892, HPA056815	Enhanced					Tissue enhanced	Tissue enriched	34	skeletal muscle: 103.0	esophagus: 3.0	Group enriched	20	BEWO: 2.0;HSkMC: 1.9
CACNA2D1	CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3	ENSG00000153956	Calcium voltage-gated channel auxiliary subunit alpha2delta 1	7	81946444-82443798	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA008213, HPA008621	Enhanced				Renal cancer:1.16e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 35.4	Cell line enhanced		HUVEC TERT2: 45.6;SH-SY5Y: 66.1
CACNA2D3	HSA272268	ENSG00000157445	Calcium voltage-gated channel auxiliary subunit alpha2delta 3	3	54122547-55074557	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030849, HPA030850			Uncertain	Nucleus<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 16.2	adrenal gland: 5.4	Cell line enhanced		BJ hTERT+: 3.3;HAP1: 1.9;HeLa: 6.3
CACNA2D4		ENSG00000151062	Calcium voltage-gated channel auxiliary subunit alpha2delta 4	12	1791957-1918836	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031952	Uncertain					Mixed	Not detected			placenta,testis: 0.8	Cell line enhanced		Hep G2: 6.4;HL-60: 4.5;HMC-1: 24.8;NB-4: 8.3
CACNB4	EJM4	ENSG00000182389	Calcium voltage-gated channel auxiliary subunit beta 4	2	151832768-152099475	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015601	Approved					Mixed	Tissue enhanced		cerebral cortex: 25.9	skin: 8.0	Cell line enhanced		HMC-1: 17.7
CACNG1	CACNLG	ENSG00000108878	Calcium voltage-gated channel auxiliary subunit gamma 1	17	67044590-67056797	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	25	skeletal muscle: 113.4	esophagus: 4.4	Cell line enhanced		HSkMC: 2.2;SH-SY5Y: 1.0
CACNG2	MGC138502, MGC138504, stargazin	ENSG00000166862	Calcium voltage-gated channel auxiliary subunit gamma 2	22	36563921-36703558	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	13	cerebral cortex: 15.3	adrenal gland: 1.2	Group enriched	11	SCLC-21H: 3.3;SH-SY5Y: 1.3
CACNG3		ENSG00000006116	Calcium voltage-gated channel auxiliary subunit gamma 3	16	24255553-24362801	Predicted membrane proteins, Transporters	Evidence at protein level	HPA059010	Approved					Tissue enriched	Tissue enriched	28	cerebral cortex: 42.5	adrenal gland: 1.5	Not detected		
CACNG4	MGC11138, MGC24983	ENSG00000075461	Calcium voltage-gated channel auxiliary subunit gamma 4	17	66964910-67033398	Predicted membrane proteins, Transporters	Evidence at protein level	HPA005803, HPA065370	Enhanced		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 48.6;prostate: 20.3	lung: 9.2	Cell line enriched	7	SH-SY5Y: 436.5
CACNG5		ENSG00000075429	Calcium voltage-gated channel auxiliary subunit gamma 5	17	66835117-66885486	Predicted membrane proteins	Evidence at protein level	HPA050115	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 1.2	lymph node: 0.6	Not detected		
CACNG6		ENSG00000130433	Calcium voltage-gated channel auxiliary subunit gamma 6	19	53992288-54012669	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA056615			Approved	Nucleoli fibrillar center<br>Cytosol		Mixed	Group enriched	11	fallopian tube: 18.0;skeletal muscle: 33.9	lung: 2.3	Cell line enhanced		A549: 13.3;EFO-21: 23.7;HHSteC: 5.4
CACNG7		ENSG00000105605	Calcium voltage-gated channel auxiliary subunit gamma 7	19	53909335-53943941	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	101	cerebral cortex: 63.7	adrenal gland: 0.6	Cell line enhanced		AF22: 52.2;HMC-1: 36.0;NTERA-2: 14.0;SH-SY5Y: 34.2
CACNG8		ENSG00000142408	Calcium voltage-gated channel auxiliary subunit gamma 8	19	53963040-53990215	Predicted membrane proteins, Transporters	Evidence at protein level	HPA041351	Enhanced					Tissue enriched	Tissue enriched	34	cerebral cortex: 23.7	testis: 0.6	Cell line enhanced		AF22: 7.2;HMC-1: 21.1;TIME: 12.3
CADM1	BL2, IGSF4, IGSF4A, Necl-2, NECL2, RA175, ST17, SYNCAM, SYNCAM1, TSLC1	ENSG00000182985	Cell adhesion molecule 1	11	115169218-115504957	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037266	Enhanced		Supported	Cell Junctions	Endometrial cancer:1.32e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 151.6	Cell line enhanced		CACO-2: 245.0;WM-115: 185.3
CADM2	IGSF4D, Necl-3, NECL3, SynCAM2	ENSG00000175161	Cell adhesion molecule 2	3	84958981-86074429	Predicted membrane proteins	Evidence at protein level	HPA010024	Enhanced					Tissue enriched	Tissue enriched	14	cerebral cortex: 86.2	seminal vesicle: 6.2	Cell line enhanced		AF22: 10.8;AN3-CA: 29.1
CADM3	BIgR, FLJ10698, IGSF4B, Necl-1, NECL1, SynCAM3, TSLL1	ENSG00000162706	Cell adhesion molecule 3	1	159171609-159203313	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002981, CAB025746	Enhanced				Renal cancer:1.03e-5 (unfavourable), Urothelial cancer:5.75e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 278.5;placenta: 113.9	cervix, uterine: 44.7	Group enriched	7	HHSteC: 54.6;HSkMC: 158.9;hTERT-HME1: 91.2;U-2 OS: 34.5;WM-115: 59.5
CADM4	IGSF4C, Necl-4, SynCAM4, TSLL2	ENSG00000105767	Cell adhesion molecule 4	19	43622368-43639839	Predicted membrane proteins	Evidence at protein level	HPA012612	Enhanced		Approved	Nucleus<br>Nuclear membrane	Renal cancer:2.28e-6 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 163.6	parathyroid gland: 59.1	Cell line enriched	5	WM-115: 552.4
CALCR	CTR	ENSG00000004948	Calcitonin receptor	7	93424487-93574730	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA028962, HPA061428	Enhanced					Tissue enriched	Tissue enhanced		kidney: 2.1;testis: 1.4	placenta: 1.0	Cell line enhanced		RPTEC TERT1: 1.5;T-47d: 3.6
CALCRL	CGRPR, CRLR	ENSG00000064989	Calcitonin receptor like receptor	2	187343129-187448460	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA008070, HPA046515	Uncertain		Supported	Plasma membrane		Expressed in all	Tissue enhanced		lung: 114.3	adipose tissue: 76.8	Cell line enhanced		HUVEC TERT2: 145.5;RPTEC TERT1: 30.7;TIME: 20.7
CALHM1	FAM26C	ENSG00000185933	Calcium homeostasis modulator 1	10	103453387-103458888	Predicted membrane proteins, Transporters	Evidence at protein level	HPA018317	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.8	kidney: 0.6	Cell line enhanced		U-266/70: 1.0;U-266/84: 1.2
CALHM2	FAM26B	ENSG00000138172	Calcium homeostasis modulator 2	10	103446786-103452402	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014706	Approved		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:3.03e-6 (unfavourable)	Expressed in all	Mixed			ovary: 44.8	Mixed		
CALHM3	bA225H22.7, FAM26A	ENSG00000183128	Calcium homeostasis modulator 3	10	103472804-103479240	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA018205	Uncertain		Approved	Nucleoplasm		Tissue enhanced	Not detected			testis: 0.4	Cell line enhanced		CAPAN-2: 2.2;U-266/84: 10.0
CALN1		ENSG00000183166	Calneuron 1	7	71779491-72447151	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036278, HPA036708	Approved		Uncertain	Vesicles<br>Plasma membrane		Mixed	Group enriched	5	adrenal gland: 14.7;cerebral cortex: 46.4	testis: 6.0	Cell line enhanced		Karpas-707: 33.8;NTERA-2: 6.0;REH: 6.4;SCLC-21H: 7.8;U-2 OS: 7.6
CALY	CALCYON, DRD1IP, NSG3	ENSG00000130643	Calcyon neuron specific vesicular protein	10	133324072-133336935	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042283	Enhanced				Pancreatic cancer:3.54e-4 (favourable)	Group enriched	Group enriched	13	adrenal gland: 23.5;cerebral cortex: 77.1	testis: 3.8	Not detected		
CAMK1	CaMKI	ENSG00000134072	Calcium/calmodulin dependent protein kinase I	3	9757342-9769992	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB031904, HPA051409	Approved		Approved	Cytosol	Liver cancer:7.52e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 107.7	Cell line enhanced		HMC-1: 344.4
CAMK1D	CKLiK	ENSG00000183049	Calcium/calmodulin dependent protein kinase ID	10	12349482-12835545	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007266	Enhanced		Approved	Nucleus<br>Cytosol	Lung cancer:1.67e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 52.0	skin,thyroid gland: 21.9	Cell line enhanced		HDLM-2: 105.6;U-266/70: 38.2
CAMK1G	CLICKIII, dJ272L16.1, VWS1	ENSG00000008118	Calcium/calmodulin dependent protein kinase IG	1	209583717-209613938	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 32.3;ovary: 27.7	seminal vesicle: 7.4	Cell line enhanced		hTEC/SVTERT24-B: 7.0;SK-MEL-30: 1.6
CAMK2A	CAMKA, CaMKIINalpha, KIAA0968	ENSG00000070808	Calcium/calmodulin dependent protein kinase II alpha	5	150219491-150290291	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004330, HPA051783, HPA051785, HPA053973	Enhanced		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol		Tissue enriched	Tissue enriched	9	cerebral cortex: 283.6	skeletal muscle: 33.3	Cell line enhanced		SCLC-21H: 6.2;U-87 MG: 4.3
CAMK2B	CAM2, CAMK2, CAMKB	ENSG00000058404	Calcium/calmodulin dependent protein kinase II beta	7	44217150-44334577	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB006849, HPA026307, HPA051783, HPA051785, HPA053973	Enhanced	Supported	Supported	Plasma membrane<br>Cell Junctions<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 214.1	skeletal muscle: 46.1	Cell line enriched	12	SCLC-21H: 88.9
CAMK2D	CAMKD	ENSG00000145349	Calcium/calmodulin dependent protein kinase II delta	4	113451032-113761927	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026281, HPA051783, HPA051785, HPA053973	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			heart muscle: 110.3	Mixed		
CAMK2G	CAMKG	ENSG00000148660	Calcium/calmodulin dependent protein kinase II gamma	10	73812501-73874591	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040656, HPA051783, HPA051785, HPA053973	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 119.0	Expressed in all		
CAMK4	CaMK-GR	ENSG00000152495	Calcium/calmodulin dependent protein kinase IV	5	111223653-111494886	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004347, HPA011753, HPA017206	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center		Mixed	Tissue enhanced		cerebral cortex: 16.5;testis: 17.0	lymph node: 9.7	Cell line enhanced		HDLM-2: 83.9;SH-SY5Y: 35.7
CAMKK2	CAMKK, CAMKKB, KIAA0787, MGC15254	ENSG00000110931	Calcium/calmodulin dependent protein kinase kinase 2	12	121237691-121298308	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017389	Approved		Supported	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 102.8	Expressed in all		
CAMLG	CAML, GET2	ENSG00000164615	Calcium modulating ligand	5	134738501-134752160	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052636, HPA056472	Approved		Approved	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:1.09e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 99.6	Expressed in all		
CANT1	SCAN-1, SHAPY	ENSG00000171302	Calcium activated nucleotidase 1	17	78991717-79009867	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019627, HPA019639, HPA022818	Enhanced				Liver cancer:1.41e-4 (unfavourable), Lung cancer:2.90e-4 (unfavourable), Renal cancer:6.21e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 115.7	Expressed in all		
CANX	CNX, IP90, P90	ENSG00000127022	Calnexin	5	179678628-179730925	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004738, HPA009433, HPA009696	Enhanced		Enhanced	Endoplasmic reticulum	Colorectal cancer:1.38e-4 (favourable), Thyroid cancer:3.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 294.4	Expressed in all		
CARD19	bA370F5.1, BinCARD, C9orf89, MGC11115	ENSG00000165233	Caspase recruitment domain family member 19	9	93096218-93113283	Predicted membrane proteins	Evidence at protein level	HPA010921, HPA010990, HPA038297	Approved		Supported	Mitochondria	Liver cancer:1.32e-5 (unfavourable), Glioma:6.41e-5 (unfavourable)	Expressed in all	Mixed			testis: 11.1	Expressed in all		
CASD1	C7orf12, FLJ21213, FLJ21879	ENSG00000127995	CAS1 domain containing 1	7	94509219-94557019	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044404	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 38.8	Mixed		
CASK	CAGH39, FGS4, LIN2, TNRC8	ENSG00000147044	Calcium/calmodulin dependent serine protein kinase	X	41514934-41923463	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB001949, HPA023857	Enhanced		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:6.11e-5 (unfavourable)	Expressed in all	Expressed in all			small intestine: 34.5	Mixed		
CASR	FHH, GPRC2A, HHC, HHC1, NSHPT	ENSG00000036828	Calcium sensing receptor	3	122183683-122291629	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039686, HPA050335	Enhanced					Tissue enriched	Tissue enriched	58	parathyroid gland: 1441.4	kidney: 24.6	Not detected		
CATSPER1	CATSPER	ENSG00000175294	Cation channel sperm associated 1	11	66016752-66026517	Disease related genes, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	31	testis: 20.4	lung: 0.6	Cell line enhanced		CAPAN-2: 3.8;EFO-21: 3.7;HEL: 2.4;HMC-1: 4.4
CATSPER2		ENSG00000166762	Cation channel sperm associated 2	15	43628503-43668118	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enhanced		testis: 30.8	parathyroid gland: 6.5	Mixed		
CATSPER3	CACRC	ENSG00000152705	Cation channel sperm associated 3	5	134967906-135011707	Predicted membrane proteins, Transporters	Evidence at transcript level							Mixed	Tissue enriched	26	testis: 38.6	fallopian tube: 1.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 2.5
CATSPER4		ENSG00000188782	Cation channel sperm associated 4	1	26190561-26202968	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA045257	Enhanced					Not detected	Tissue enriched	97	testis: 9.6	all non-specific tissues: 0.0	Not detected		
CATSPERB	C14orf161, FLJ14298	ENSG00000133962	Cation channel sperm associated auxiliary subunit beta	14	91580696-91780707	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035134	Uncertain		Uncertain	Vesicles		Mixed	Mixed			skin: 2.7	Cell line enhanced		CAPAN-2: 1.1
CATSPERD	MGC39581, TMEM146	ENSG00000174898	Cation channel sperm associated auxiliary subunit delta	19	5720677-5778734	Predicted membrane proteins, Transporters	Evidence at protein level	HPA024056	Supported					Tissue enhanced	Tissue enriched	161	testis: 16.0	all non-specific tissues: 0.0	Cell line enriched	58	HEL: 6.9
CATSPERG	C19orf15, DKFZp434A1022, FLJ46353	ENSG00000099338	Cation channel sperm associated auxiliary subunit gamma	19	38335775-38370943	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052777			Approved	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Tissue enriched	41	testis: 48.6	skin: 1.1	Cell line enhanced		BEWO: 1.4;HMC-1: 1.6;MCF7: 1.2
CAV1	CAV	ENSG00000105974	Caveolin 1	7	116524785-116561184	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB003791, HPA049326	Enhanced		Supported	Golgi apparatus	Lung cancer:7.17e-5 (unfavourable), Renal cancer:1.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 859.9	adipose tissue: 640.4	Cell line enhanced		LHCN-M2: 1943.1
CAV2	CAV	ENSG00000105971	Caveolin 2	7	116287380-116508541	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013488, HPA044810	Enhanced		Approved	Vesicles	Head and neck cancer:5.80e-5 (unfavourable), Pancreatic cancer:1.21e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 233.6	Mixed		
CAV3	LGMD1C, LQT9, VIP-21, VIP21	ENSG00000182533	Caveolin 3	3	8733800-8841808	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB017518, CAB018557, HPA054488	Enhanced		Supported	Vesicles<br>Plasma membrane		Tissue enhanced	Group enriched	6	heart muscle: 14.0;skeletal muscle: 63.3	esophagus: 6.0	Group enriched	15	LHCN-M2: 19.0;RH-30: 91.1
CBARP	BARP, C19orf26, DOS, MGC40084	ENSG00000099625	CACN beta subunit associated regulatory protein	19	1228287-1238027	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012777			Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		adrenal gland: 2.4;cerebral cortex: 7.0	skin: 1.1	Cell line enhanced		SH-SY5Y: 5.6
CCDC107	MGC31967	ENSG00000159884	Coiled-coil domain containing 107	9	35658290-35661511	Predicted membrane proteins	Evidence at protein level	HPA016857, HPA050442			Enhanced	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			adipose tissue: 63.7	Expressed in all		
CCDC136	DKFZP434G156, KIAA1793, NAG6	ENSG00000128596	Coiled-coil domain containing 136	7	128790757-128822132	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010647, HPA071015	Enhanced		Approved	Nucleoli		Mixed	Tissue enriched	7	testis: 308.5	cerebral cortex: 44.2	Cell line enhanced		U-87 MG: 29.4;U-937: 36.3
CCDC144A	FLJ43983, KIAA0565	ENSG00000170160	Coiled-coil domain containing 144A	17	16689537-16777881	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022996, HPA047220, HPA047851	Approved		Approved	Nucleoplasm<br>Vesicles		Not detected	Tissue enhanced		testis: 16.6	endometrium: 6.1	Mixed		
CCDC155	FLJ32658, KASH5	ENSG00000161609	Coiled-coil domain containing 155	19	49388218-49417994	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019937, HPA019940	Enhanced					Tissue enhanced	Tissue enriched	135	testis: 56.9	pancreas: 0.4	Cell line enhanced		SCLC-21H: 1.5;U-266/70: 2.7
CCDC163	C1orf231, CCDC163P, LOC126661	ENSG00000280670	Coiled-coil domain containing 163	1	45493866-45500079	Predicted membrane proteins	Evidence at transcript level						Thyroid cancer:5.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 2.3	thyroid gland: 1.5	Cell line enhanced		U-266/70: 5.1
CCDC167	C6orf129, dJ153P14.2	ENSG00000198937	Coiled-coil domain containing 167	6	37482920-37499922	Predicted membrane proteins	Evidence at protein level	HPA045215	Uncertain		Approved	Cytosol	Renal cancer:1.71e-7 (unfavourable), Liver cancer:2.94e-4 (unfavourable), Cervical cancer:7.59e-4 (favourable)	Expressed in all	Expressed in all			tonsil: 55.0	Cell line enriched	7	U-698: 913.2
CCDC168	C13orf40, FLJ40176	ENSG00000175820	Coiled-coil domain containing 168	13	102729369-102759070	Predicted membrane proteins	Evidence at protein level	HPA048184, HPA058793	Uncertain					Not detected	Tissue enriched	47	testis: 7.6	epididymis: 0.1	Not detected		
CCDC188		ENSG00000234409	Coiled-coil domain containing 188	22	20148427-20151065	Predicted membrane proteins	Evidence at transcript level	HPA049901			Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enriched	10	testis: 18.1	spleen: 1.8	Cell line enhanced		AF22: 4.0;SCLC-21H: 6.6;SH-SY5Y: 7.6
CCDC47	GK001	ENSG00000108588	Coiled-coil domain containing 47	17	63745250-63776351	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029674, HPA072573	Approved		Enhanced	Endoplasmic reticulum	Colorectal cancer:2.17e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 161.4	Expressed in all		
CCDC51	FLJ12436	ENSG00000164051	Coiled-coil domain containing 51	3	48432164-48440456	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010980, HPA011408	Supported		Supported	Nucleoplasm<br>Centrosome<br>Mitochondria		Expressed in all	Mixed			thyroid gland: 17.3	Expressed in all		
CCDC90B	MDS011, MDS025	ENSG00000137500	Coiled-coil domain containing 90B	11	83259097-83286407	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011130, HPA011931	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			testis: 97.8	Expressed in all		
CCKAR		ENSG00000163394	Cholecystokinin A receptor	4	26481400-26490462	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	10	gallbladder: 47.2;stomach: 15.2	tonsil: 3.1	Not detected		
CCKBR		ENSG00000110148	Cholecystokinin B receptor	11	6259736-6272127	Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	13	cerebral cortex: 13.6;pancreas: 5.4;stomach: 16.4	prostate: 0.9	Cell line enriched	8	NTERA-2: 69.8
CCL5	D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228	ENSG00000271503	C-C motif chemokine ligand 5	17	35871491-35880793	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:3.61e-7 (unfavourable), Endometrial cancer:1.34e-5 (favourable), Melanoma:2.42e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 80.5	lymph node: 68.5	Group enriched	7	HL-60: 31.8;NB-4: 158.3;THP-1: 39.1;U-937: 41.8
CCL7	FIC, MARC, MCP-3, MCP3, NC28, SCYA6, SCYA7	ENSG00000108688	C-C motif chemokine ligand 7	17	34270221-34272242	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Group enriched	8	appendix: 3.6;bone marrow: 15.2	gallbladder,rectum: 1.1	Cell line enhanced		BJ hTERT+: 9.3;BJ hTERT+ SV40 Large T+: 2.2;BJ hTERT+ SV40 Large T+ RasG12V: 2.8;HSkMC: 2.4
CCPG1	CPR8, KIAA1254	ENSG00000260916	Cell cycle progression 1	15	55340032-55408510	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009432, HPA026861	Approved		Approved	Endoplasmic reticulum<br>Golgi apparatus	Stomach cancer:5.02e-5 (unfavourable), Renal cancer:5.07e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 140.4	Cell line enhanced		Karpas-707: 242.3
CCR1	CD191, CKR-1, CMKBR1, MIP1aR, SCYAR1	ENSG00000163823	C-C motif chemokine receptor 1	3	46201709-46208396	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.01e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 57.5	spleen: 41.1	Cell line enhanced		Karpas-707: 230.1;RPMI-8226: 105.8;U-266/84: 123.3
CCR10	GPR2	ENSG00000184451	C-C motif chemokine receptor 10	17	42678889-42683917	Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011684, HPA048007, HPA069188	Uncertain		Supported	Endoplasmic reticulum		Mixed	Mixed			adipose tissue: 4.4	Cell line enhanced		Karpas-707: 6.0;U-266/70: 13.0
CCR2	CC-CKR-2, CD192, CKR2, CMKBR2, FLJ78302, MCP-1-R	ENSG00000121807	C-C motif chemokine receptor 2	3	46353734-46360928	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB003793	Approved				Lung cancer:5.87e-4 (favourable)	Mixed	Tissue enhanced		appendix: 51.7	spleen: 20.5	Cell line enhanced		Karpas-707: 195.5;THP-1: 89.5;U-266/70: 473.3;U-266/84: 185.8
CCR3	CC-CKR-3, CD193, CKR3, CMKBR3	ENSG00000183625	C-C motif chemokine receptor 3	3	46163604-46266706	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB003795	Uncertain					Not detected	Mixed			small intestine: 2.9	Cell line enriched	9	RPMI-8226: 20.3
CCR4	CC-CKR-4, CD194, ChemR13, CKR4, CMKBR4, k5-5	ENSG00000183813	C-C motif chemokine receptor 4	3	32951574-32956349	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA031613	Approved					Mixed	Tissue enhanced		appendix: 11.5	urinary bladder: 8.9	Cell line enriched	17	HDLM-2: 187.8
CCR5	CC-CKR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22	ENSG00000160791	C-C motif chemokine receptor 5 (gene/pseudogene)	3	46370854-46376206	CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:7.42e-5 (favourable), Head and neck cancer:9.33e-5 (favourable)	Expressed in all	Mixed			appendix: 20.4	Group enriched	17	Karpas-707: 4.9;U-266/84: 2.1
CCR6	BN-1, CD196, CKR-L3, CMKBR6, DCR2, DRY-6, GPR-CY4, GPR29, STRL22	ENSG00000112486	C-C motif chemokine receptor 6	6	167111807-167139696	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB006820, HPA014488	Approved					Not detected	Tissue enhanced		lymph node: 20.4;tonsil: 32.4	spleen: 17.0	Cell line enriched	7	Hep G2: 6.2
CCR7	BLR2, CD197, CDw197, CMKBR7, EBI1	ENSG00000126353	C-C motif chemokine receptor 7	17	40553769-40565472	Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB003796, HPA031383, HPA074467	Enhanced		Supported	Mitochondria	Head and neck cancer:7.61e-7 (favourable), Cervical cancer:8.03e-6 (favourable), Breast cancer:3.84e-4 (favourable), Testis cancer:7.72e-4 (unfavourable)	Mixed	Group enriched	6	appendix: 88.8;lymph node: 97.1;spleen: 39.3;tonsil: 77.2	urinary bladder: 12.4	Cell line enriched	79	HDLM-2: 1284.5
CCR8	CDw198, CKR-L1, CMKBR8, CMKBRL2, CY6, GPR-CY6, TER1	ENSG00000179934	C-C motif chemokine receptor 8	3	39329706-39333511	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042383	Supported					Mixed	Tissue enhanced		urinary bladder: 2.3	appendix: 1.7	Cell line enriched	22	HDLM-2: 104.4
CCR9	CDw199, GPR-9-6, GPR28	ENSG00000173585	C-C motif chemokine receptor 9	3	45886504-45903177	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB006839	Uncertain					Not detected	Group enriched	6	appendix: 1.4;duodenum: 3.8;small intestine: 5.7;spleen: 1.2	lymph node,tonsil: 0.4	Cell line enriched	362	MOLT-4: 90.5
CCRL2	ACKR5, CKRX, CRAM-A, CRAM-B, HCR	ENSG00000121797	C-C motif chemokine receptor like 2	3	46407163-46412997	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA043238	Approved				Colorectal cancer:3.72e-5 (favourable), Urothelial cancer:9.67e-5 (favourable)	Mixed	Mixed			lung: 17.7	Cell line enhanced		HEL: 18.0;PC-3: 14.0;TIME: 12.2
CD101	IGSF2, V7	ENSG00000134256	CD101 molecule	1	117001750-117036476	CD markers, Predicted membrane proteins	Evidence at protein level	HPA049527, HPA057763	Approved		Uncertain	Mitochondria		Mixed	Tissue enhanced		lung: 9.6	small intestine: 6.8	Cell line enriched	8	HMC-1: 24.0
CD109	CPAMD7, DKFZp762L1111, FLJ38569	ENSG00000156535	CD109 molecule	6	73695785-73828316	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA015723	Enhanced				Stomach cancer:7.96e-5 (unfavourable), Renal cancer:2.65e-4 (unfavourable), Urothelial cancer:4.68e-4 (unfavourable)	Expressed in all	Tissue enriched	43	parathyroid gland: 967.3	skin: 22.4	Cell line enhanced		ASC TERT1: 162.5
CD151	PETA-3, RAPH, SFA-1, TSPAN24	ENSG00000177697	CD151 molecule (Raph blood group)	11	832843-839831	Blood group antigen proteins, CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002428, HPA011906	Supported				Liver cancer:5.58e-4 (unfavourable), Thyroid cancer:6.92e-4 (favourable), Lung cancer:9.46e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 361.3	Mixed		
CD163	M130, MM130, SCARI1	ENSG00000177575	CD163 molecule	12	7470813-7503893	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002432, HPA046404, HPA051974	Enhanced		Approved	Plasma membrane	Ovarian cancer:7.27e-4 (unfavourable)	Expressed in all	Mixed			appendix: 220.1	Cell line enhanced		HSkMC: 1.2
CD163L1	CD163B, M160, SCARI2	ENSG00000177675	CD163 molecule like 1	12	7346685-7479897	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015663	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Mixed	Tissue enhanced		spleen: 43.2	rectum: 24.1	Cell line enhanced		U-87 MG: 22.1
CD164	DFNA66, MGC-24, MUC-24	ENSG00000135535	CD164 molecule	6	109366514-109382457	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010636	Uncertain					Expressed in all	Expressed in all			thyroid gland: 613.1	Expressed in all		
CD164L2		ENSG00000174950	CD164 molecule like 2	1	27379176-27383380	Predicted membrane proteins	Evidence at protein level	HPA062915	Enhanced		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:1.64e-5 (favourable)	Mixed	Tissue enhanced		fallopian tube: 46.3	skin: 10.7	Cell line enhanced		CAPAN-2: 3.5;HaCaT: 1.6;HBEC3-KT: 1.4;hTCEpi: 2.0;SK-BR-3: 1.9
CD180	LY64, Ly78, RP105	ENSG00000134061	CD180 molecule	5	67179613-67196799	CD markers, Predicted membrane proteins	Evidence at protein level	HPA003740	Enhanced					Mixed	Tissue enhanced		lymph node: 27.4;tonsil: 21.3	spleen: 17.8	Group enriched	11	Daudi: 32.2;Karpas-707: 29.5;U-266/70: 25.3;U-266/84: 34.5;U-698: 8.6
CD19		ENSG00000177455	CD19 molecule	16	28931939-28939346	CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB016110	Enhanced					Mixed	Group enriched	11	appendix: 37.4;lymph node: 84.0;spleen: 47.4;tonsil: 68.3	urinary bladder: 5.5	Group enriched	40	Daudi: 103.6;REH: 70.5;U-698: 22.6
CD1A	CD1	ENSG00000158477	CD1a molecule	1	158254137-158258269	CD markers, Predicted membrane proteins	Evidence at protein level	CAB000009, HPA010734	Enhanced				Cervical cancer:6.37e-4 (favourable)	Mixed	Group enriched	6	esophagus: 9.5;skin: 27.0	lymph node,tonsil: 2.9	Cell line enriched	122	MOLT-4: 48.8
CD1B	CD1	ENSG00000158485	CD1b molecule	1	158327951-158331531	CD markers, Predicted membrane proteins	Evidence at protein level	HPA021824	Approved					Mixed	Tissue enhanced		rectum: 3.1;skin: 3.9	lymph node: 2.7	Cell line enriched	1556	MOLT-4: 465.4
CD1C	CD1	ENSG00000158481	CD1c molecule	1	158289786-158293630	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Cervical cancer:1.79e-5 (favourable)	Mixed	Tissue enhanced		spleen: 40.6;tonsil: 45.1	lymph node: 39.8	Cell line enriched	16	MOLT-4: 46.0
CD1D		ENSG00000158473	CD1d molecule	1	158179947-158184896	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	CAB016107, HPA072662	Uncertain		Supported	Endoplasmic reticulum	Renal cancer:2.12e-5 (unfavourable)	Mixed	Mixed			spleen: 20.6	Cell line enhanced		HBEC3-KT: 8.3;HHSteC: 14.4;MOLT-4: 19.6;THP-1: 9.9
CD1E		ENSG00000158488	CD1e molecule	1	158353696-158357553	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057769	Uncertain					Mixed	Tissue enhanced		skin: 18.3	tonsil: 10.4	Cell line enriched	980	MOLT-4: 1075.1
CD2	SRBC	ENSG00000116824	CD2 molecule	1	116754385-116769228	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002430, HPA003883	Enhanced				Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 131.1	tonsil: 70.8	Group enriched	27	HDLM-2: 201.2;MOLT-4: 129.2
CD200	MOX1, MOX2, MRC, OX-2	ENSG00000091972	CD200 molecule	3	112332347-112362812	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031149	Approved					Expressed in all	Mixed			cerebral cortex: 78.6	Cell line enhanced		AF22: 74.9;NTERA-2: 47.6;REH: 38.6;WM-115: 82.4
CD200R1	CD200R, HCRTR2, MOX2R, OX2R	ENSG00000163606	CD200 receptor 1	3	112921209-112975122	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA068512			Supported	Plasma membrane		Mixed	Tissue enhanced		spleen: 14.5	placenta: 10.2	Cell line enriched	8	HEL: 26.4
CD200R1L	CD200R2, CD200RLa	ENSG00000206531	CD200 receptor 1 like	3	112815709-112846856	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	46	testis: 4.9	epididymis: 0.1	Not detected		
CD207	CLEC4K, Langerin	ENSG00000116031	CD207 molecule	2	70830214-70835822	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB002222, HPA011216	Enhanced		Uncertain	Cytosol		Mixed	Tissue enriched	5	skin: 104.0	esophagus: 19.4	Cell line enhanced		AN3-CA: 8.3;HAP1: 2.2;SH-SY5Y: 1.3;T-47d: 1.5
CD209	CDSIGN, CLEC4L, DC-SIGN, DC-SIGN1	ENSG00000090659	CD209 molecule	19	7739994-7747564	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB032436, CAB033831	Supported				Renal cancer:1.15e-5 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 43.9	placenta: 33.0	Cell line enriched	9	THP-1: 2.3
CD22	SIGLEC-2, SIGLEC2	ENSG00000012124	CD22 molecule	19	35319261-35347355	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002418, HPA024353	Enhanced					Mixed	Tissue enhanced		lymph node: 264.4;ovary: 162.2;spleen: 151.7;tonsil: 210.1	appendix: 98.1	Group enriched	11	Daudi: 201.6;REH: 76.6;U-698: 153.7;WM-115: 49.6
CD226	DNAM-1, DNAM1, PTA1, TLiSA1	ENSG00000150637	CD226 molecule	18	69831158-69961803	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015715, HPA050348	Supported		Approved	Midbody		Not detected	Tissue enriched	11	parathyroid gland: 318.5	spleen: 28.4	Group enriched	7	HEL: 89.9;HMC-1: 37.6
CD244	2B4, NAIL, NKR2B4, Nmrk, SLAMF4	ENSG00000122223	CD244 molecule	1	160830160-160862855	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 23.5	bone marrow: 6.2	Cell line enhanced		HEL: 18.7;HMC-1: 61.7;U-937: 22.7
CD247	CD3H, CD3Q, CD3Z	ENSG00000198821	CD247 molecule	1	167430640-167518610	CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB004651, HPA008750	Enhanced				Endometrial cancer:8.63e-6 (favourable), Renal cancer:9.94e-6 (unfavourable), Head and neck cancer:3.98e-4 (favourable), Breast cancer:9.12e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 65.1;spleen: 48.6	tonsil: 33.6	Group enriched	34	HDLM-2: 144.2;MOLT-4: 133.0
CD248	CD164L1, TEM1	ENSG00000174807	CD248 molecule	11	66314487-66317044	CD markers, Predicted membrane proteins	Evidence at protein level	HPA051856	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:2.69e-7 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 136.8	placenta: 96.7	Cell line enhanced		ASC diff: 336.6;ASC TERT1: 336.4;BJ hTERT+: 268.5;fHDF/TERT166: 348.4;HSkMC: 374.9;U-2197: 735.8
CD27	S152, TNFRSF7, Tp55	ENSG00000139193	CD27 molecule	12	6444867-6451718	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002420, HPA038936	Enhanced				Head and neck cancer:6.65e-7 (favourable), Renal cancer:1.19e-6 (unfavourable), Cervical cancer:3.77e-5 (favourable), Endometrial cancer:2.90e-4 (favourable), Melanoma:5.50e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 140.5;tonsil: 85.8	spleen: 67.8	Group enriched	122	Daudi: 153.8;U-698: 81.7
CD274	B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1	ENSG00000120217	CD274 molecule	9	5450503-5470566	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB030018, CAB076385	Enhanced		Approved	Cytosol	Colorectal cancer:1.64e-5 (favourable), Breast cancer:8.89e-4 (favourable)	Mixed	Mixed			appendix: 14.0	Cell line enhanced		HDLM-2: 82.8;HHSteC: 46.6;U-251 MG: 80.8
CD276	B7-H3, B7H3, B7RP-2	ENSG00000103855	CD276 molecule	15	73683966-73714518	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009285, HPA017139, CAB017826	Enhanced		Approved	Vesicles	Renal cancer:6.31e-5 (unfavourable), Liver cancer:9.81e-4 (unfavourable)	Expressed in all	Mixed			placenta: 30.2	Cell line enhanced		U-2197: 176.1
CD28		ENSG00000178562	CD28 molecule	2	203706475-203738912	CD markers, Predicted membrane proteins	Evidence at protein level	HPA070003	Enhanced					Mixed	Tissue enhanced		lymph node: 32.4;placenta: 20.9	appendix: 18.6	Group enriched	12	Karpas-707: 257.5;RPMI-8226: 118.2;U-266/70: 222.7;U-266/84: 196.1
CD300A	CMRF-35-H9, CMRF35H, IGSF12, IRC1, IRC2, Irp60	ENSG00000167851	CD300a molecule	17	74466416-74484796	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011645	Approved				Renal cancer:1.91e-5 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 85.8	appendix: 40.0	Cell line enhanced		HMC-1: 88.9;NB-4: 27.4;RPMI-8226: 57.9
CD300C	CMRF-35A, CMRF35, CMRF35A, IGSF16, LIR	ENSG00000167850	CD300c molecule	17	74541108-74546143	CD markers, Predicted membrane proteins	Evidence at transcript level	HPA014523	Approved				Testis cancer:8.53e-5 (unfavourable)	Mixed	Tissue enhanced		lung: 12.4	appendix: 9.5	Cell line enhanced		HEL: 6.4;HMC-1: 29.3;U-937: 12.8
CD300E	CD300LE, CLM2, IREM2	ENSG00000186407	CD300e molecule	17	74609887-74623738	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015570	Uncertain					Mixed	Tissue enhanced		appendix: 52.8;bone marrow: 29.0	adipose tissue: 18.0	Not detected		
CD300LB	CLM7, TREM5	ENSG00000178789	CD300 molecule like family member b	17	74521174-74531474	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 11.4	spleen: 5.2	Cell line enhanced		HL-60: 1.5;NB-4: 1.5;THP-1: 1.3
CD300LD	CD300D, CMRF35A4	ENSG00000204345	CD300 molecule like family member d	17	74579365-74592283	CD markers, Predicted membrane proteins	Evidence at protein level	HPA027756	Uncertain					Not detected	Not detected			appendix: 0.9	Not detected		
CD300LF	CD300f, CLM1, IGSF13, IREM1, NKIR	ENSG00000186074	CD300 molecule like family member f	17	74694311-74712978	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013712	Supported					Expressed in all	Tissue enhanced		lung: 25.6;spleen: 28.0	appendix: 18.2	Group enriched	7	THP-1: 16.6;U-937: 37.2
CD300LG	CLM9, Trem4	ENSG00000161649	CD300 molecule like family member g	17	43847148-43863629	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Group enriched	5	adipose tissue: 143.0;placenta: 86.4;testis: 33.9	lung: 17.3	Not detected		
CD302	BIMLEC, CLEC13A, DCL-1, KIAA0022	ENSG00000241399	CD302 molecule	2	159768630-159798255	CD markers, Predicted membrane proteins	Evidence at protein level							Mixed	Expressed in all			liver: 104.7	Cell line enhanced		ASC diff: 178.2
CD320	8D6, 8D6A	ENSG00000167775	CD320 molecule	19	8302127-8308356	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014500, HPA073489	Approved		Approved	Cytosol	Liver cancer:4.02e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 77.2	Mixed		
CD33	FLJ00391, p67, SIGLEC-3, SIGLEC3	ENSG00000105383	CD33 molecule	19	51225064-51243860	CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011442, HPA035832, HPA064807	Approved		Supported	Nucleus<br>Plasma membrane		Mixed	Tissue enhanced		spleen: 33.1	bone marrow: 20.9	Cell line enhanced		HEL: 77.8;HL-60: 92.6;HMC-1: 72.6;RPMI-8226: 43.3;THP-1: 45.3;U-937: 66.2
CD34		ENSG00000174059	CD34 molecule	1	207880972-207911402	CD markers, Predicted membrane proteins	Evidence at protein level	CAB000018, HPA036722, HPA036723	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cell Junctions	Head and neck cancer:5.93e-5 (favourable), Renal cancer:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 316.6	Group enriched	7	HUVEC TERT2: 53.6;MOLT-4: 53.1
CD36	FAT, GP3B, GP4, GPIV, SCARB3	ENSG00000135218	CD36 molecule	7	80369575-80679277	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002018, CAB025866, HPA071026	Enhanced		Enhanced	Golgi apparatus	Stomach cancer:4.47e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 1617.9	Cell line enhanced		ASC diff: 218.9;HEL: 144.7
CD37	TSPAN26	ENSG00000104894	CD37 molecule	19	49335171-49343335	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002492, HPA032120, HPA032121	Enhanced				Endometrial cancer:4.51e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 241.4;spleen: 208.7	appendix: 129.0	Cell line enhanced		Daudi: 215.5;HMC-1: 252.2;RPMI-8226: 75.0;THP-1: 72.1
CD3D	T3D	ENSG00000167286	CD3d molecule	11	118338954-118342744	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013055	Enhanced				Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 199.3;tonsil: 119.1	appendix: 86.9	Cell line enriched	7	MOLT-4: 903.0
CD3E		ENSG00000198851	CD3e molecule	11	118304545-118316175	CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB000010, HPA040957, HPA043955, CAB072863, CAB072864	Enhanced				Endometrial cancer:2.30e-6 (favourable), Renal cancer:1.12e-5 (unfavourable), Melanoma:1.18e-4 (favourable), Head and neck cancer:1.32e-4 (favourable), Cervical cancer:1.62e-4 (favourable), Breast cancer:1.72e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 200.5;tonsil: 113.4	spleen: 95.0	Cell line enriched	92	MOLT-4: 531.3
CD3G		ENSG00000160654	CD3g molecule	11	118344344-118355161	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017520, HPA038494	Enhanced				Renal cancer:9.33e-5 (unfavourable), Cervical cancer:2.61e-4 (favourable), Head and neck cancer:3.00e-4 (favourable), Breast cancer:6.33e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 31.4;tonsil: 18.8	spleen: 16.1	Cell line enriched	69	MOLT-4: 160.9
CD4		ENSG00000010610	CD4 molecule	12	6786858-6820808	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000011, HPA004252, HPA004472, CAB068180	Enhanced		Supported	Plasma membrane	Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 549.0	spleen: 220.5	Group enriched	5	HEL: 90.7;HL-60: 32.7;NB-4: 37.0;THP-1: 77.1;U-937: 84.2
CD40	Bp50, p50, TNFRSF5	ENSG00000101017	CD40 molecule	20	46118272-46129863	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002495, HPA031567, HPA031568, CAB072868	Enhanced				Renal cancer:4.48e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 64.7	Cell line enhanced		CAPAN-2: 63.4;EFO-21: 116.6
CD40LG	CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP	ENSG00000102245	CD40 ligand	X	136648193-136660390	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA045827	Enhanced					Mixed	Tissue enhanced		lymph node: 18.8;tonsil: 14.1	appendix: 10.5	Cell line enriched	65	MOLT-4: 19.2
CD44	CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1	ENSG00000026508	CD44 molecule (Indian blood group)	11	35138870-35232402	Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000112, CAB000316, HPA005785	Enhanced		Enhanced	Golgi apparatus<br>Plasma membrane	Renal cancer:1.78e-8 (unfavourable)	Expressed in all	Expressed in all			skin: 530.1	Mixed		
CD46	MCP, MGC26544, MIC10, TLX, TRA2.10	ENSG00000117335	CD46 molecule	1	207752057-207795513	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB010401, HPA016903	Enhanced		Approved	Plasma membrane	Cervical cancer:8.54e-5 (unfavourable), Stomach cancer:2.38e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 489.1	Expressed in all		
CD47	IAP, MER6, OA3	ENSG00000196776	CD47 molecule	3	108043298-108091025	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016055, HPA044659	Approved		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane	Thyroid cancer:7.29e-5 (favourable), Renal cancer:1.69e-4 (unfavourable), Endometrial cancer:2.44e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 204.6	Expressed in all		
CD48	BCM1, BLAST, hCD48, mCD48, SLAMF2	ENSG00000117091	CD48 molecule	1	160678746-160711851	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002497, HPA055146	Enhanced		Supported	Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 311.4;spleen: 213.1;tonsil: 226.0	appendix: 148.5	Cell line enhanced		Daudi: 153.4;HMC-1: 202.6;U-266/70: 372.1;U-266/84: 244.7
CD5	LEU1, T1	ENSG00000110448	CD5 molecule	11	61102395-61127852	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015392, CAB020308, HPA043416, HPA060839	Enhanced				Head and neck cancer:7.41e-6 (favourable), Renal cancer:8.94e-5 (unfavourable), Endometrial cancer:9.00e-5 (favourable), Cervical cancer:9.16e-5 (favourable), Melanoma:3.93e-4 (favourable), Breast cancer:4.05e-4 (favourable)	Mixed	Tissue enhanced		appendix: 29.8;lymph node: 43.0	tonsil: 20.2	Cell line enriched	71	MOLT-4: 56.4
CD52	CDW52	ENSG00000169442	CD52 molecule	1	26317957-26320523	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level						Breast cancer:1.85e-5 (favourable), Endometrial cancer:2.06e-4 (favourable), Head and neck cancer:4.45e-4 (favourable), Renal cancer:5.85e-4 (unfavourable)	Expressed in all	Tissue enriched	35	epididymis: 43887.5	lymph node: 1251.0	Group enriched	8	Daudi: 505.6;REH: 946.6;U-266/84: 745.1;U-698: 783.6
CD53	MOX44, TSPAN25	ENSG00000143119	CD53 molecule	1	110873154-110899928	CD markers, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047216	Approved				Renal cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 462.7	Cell line enhanced		Daudi: 353.2;HDLM-2: 199.1;HMC-1: 262.4;U-266/70: 196.6
CD55	CR, CROM, DAF, TC	ENSG00000196352	CD55 molecule (Cromer blood group)	1	207321508-207386804	Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002190, CAB010454, HPA024386	Enhanced		Uncertain	Vesicles<br>Midbody ring	Renal cancer:9.36e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 324.4	Cell line enhanced		HMC-1: 495.0;U-2197: 364.6
CD58	LFA3	ENSG00000116815	CD58 molecule	1	116514535-116571039	CD markers, Predicted membrane proteins	Evidence at protein level						Liver cancer:2.32e-6 (unfavourable), Pancreatic cancer:5.60e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 42.7	Expressed in all		
CD59	16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20	ENSG00000085063	CD59 molecule	11	33698261-33736445	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB001448, HPA026494	Supported		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.39e-10 (favourable), Pancreatic cancer:2.92e-5 (unfavourable), Head and neck cancer:3.10e-5 (unfavourable), Cervical cancer:3.81e-5 (unfavourable), Stomach cancer:9.03e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 923.3	Cell line enhanced		TIME: 2367.1;U-2197: 2401.2
CD6	Tp120	ENSG00000013725	CD6 molecule	11	60971680-61020377	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002489, CAB016252	Enhanced				Head and neck cancer:5.10e-6 (favourable), Cervical cancer:1.57e-5 (favourable), Renal cancer:1.82e-4 (unfavourable), Breast cancer:1.95e-4 (favourable), Endometrial cancer:2.41e-4 (favourable)	Mixed	Tissue enhanced		appendix: 28.5;lymph node: 49.2	tonsil: 26.8	Cell line enriched	17	MOLT-4: 31.3
CD63	ME491, MLA1, TSPAN30	ENSG00000135404	CD63 molecule	12	55725323-55729707	CD markers, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010088, CAB026356	Supported		Supported	Vesicles	Liver cancer:1.37e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 1743.5	Expressed in all		
CD68	DKFZp686M18236, GP110, LAMP4, macrosialin, SCARD1	ENSG00000129226	CD68 molecule	17	7579467-7582113	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000051, CAB000066, HPA048982, CAB072861, CAB072862	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.14e-5 (unfavourable)	Mixed	Expressed in all			lung: 532.4	Expressed in all		
CD69	CLEC2C	ENSG00000110848	CD69 molecule	12	9752486-9760901	CD markers, Predicted membrane proteins	Evidence at protein level	CAB002503, HPA050525	Enhanced				Breast cancer:3.31e-5 (favourable), Renal cancer:7.87e-5 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 105.9;lymph node: 109.1	appendix: 64.1	Cell line enhanced		HL-60: 23.7;K-562: 52.0;U-937: 76.0
CD7	GP40, LEU-9, Tp40, TP41	ENSG00000173762	CD7 molecule	17	82314868-82317602	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002594, HPA039079	Enhanced				Renal cancer:7.75e-11 (unfavourable), Endometrial cancer:2.03e-5 (favourable), Melanoma:2.69e-4 (favourable), Cervical cancer:5.51e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 43.1;lymph node: 41.5;spleen: 43.1	small intestine: 17.0	Group enriched	5	Hep G2: 35.2;MOLT-4: 95.7
CD70	CD27L, CD27LG, TNFSF7	ENSG00000125726	CD70 molecule	19	6583183-6604103	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046582			Uncertain	Nucleoplasm	Renal cancer:3.22e-4 (unfavourable), Lung cancer:6.29e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 4.4	lymph node: 3.8	Cell line enhanced		SiHa: 200.2;U-251 MG: 192.3;U-266/70: 304.1;U-266/84: 216.7
CD72	CD72b, LYB2	ENSG00000137101	CD72 molecule	9	35609533-35646810	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002505, HPA044658	Enhanced		Approved	Nucleus<br>Mitochondria	Renal cancer:2.49e-8 (unfavourable)	Expressed in all	Group enriched	8	appendix: 25.1;lymph node: 71.1;spleen: 64.7;tonsil: 42.6	gallbladder: 6.2	Cell line enhanced		Daudi: 13.0;Karpas-707: 8.1;REH: 7.0;U-698: 27.7
CD74	DHLAG	ENSG00000019582	CD74 molecule	5	150401637-150412929	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB002506, HPA010592	Enhanced		Supported	Golgi apparatus	Endometrial cancer:6.53e-6 (favourable), Breast cancer:1.06e-4 (favourable)	Expressed in all	Expressed in all			spleen: 6545.9	Cell line enhanced		CAPAN-2: 1796.9;Daudi: 2297.1;HDLM-2: 4315.9;REH: 2549.8
CD79A	IGA, MB-1	ENSG00000105369	CD79a molecule	19	41877120-41881372	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000019	Enhanced				Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable)	Mixed	Group enriched	6	appendix: 263.8;lymph node: 515.1;spleen: 317.9;tonsil: 423.1	stomach: 63.3	Group enriched	23	Daudi: 1084.6;REH: 432.6;U-698: 905.8
CD79B	B29, IGB	ENSG00000007312	CD79b molecule	17	63928740-63932354	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA009178, CAB009751	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol	Head and neck cancer:2.35e-4 (favourable)	Expressed in all	Group enriched	5	appendix: 91.1;lymph node: 311.5;spleen: 157.4;tonsil: 189.1	bone marrow: 36.1	Group enriched	17	Daudi: 751.6;REH: 317.0;U-698: 986.5
CD80	B7-1, B7.1, CD28LG, CD28LG1	ENSG00000121594	CD80 molecule	3	119524293-119559602	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025368, HPA050092	Enhanced					Mixed	Tissue enhanced		appendix: 7.2;lymph node: 6.7;tonsil: 6.3	spleen: 4.7	Cell line enhanced		Daudi: 8.5;HDLM-2: 39.3;Karpas-707: 12.2;U-266/70: 5.5
CD81	TAPA-1, TAPA1, TSPAN28	ENSG00000110651	CD81 molecule	11	2376177-2397419	CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002507, HPA007234	Supported		Supported	Plasma membrane	Glioma:5.12e-5 (unfavourable), Pancreatic cancer:3.86e-4 (favourable), Colorectal cancer:7.56e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 2273.0	Cell line enhanced		ASC diff: 2031.3
CD82	IA4, KAI1, R2, ST6, TSPAN27	ENSG00000085117	CD82 molecule	11	44564427-44620363	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002508, HPA028900, HPA061418	Supported		Approved	Vesicles		Expressed in all	Expressed in all			esophagus: 131.5	Cell line enhanced		HMC-1: 349.6;U-87 MG: 273.7
CD83	BL11, HB15	ENSG00000112149	CD83 molecule	6	14117256-14136918	CD markers, Predicted membrane proteins	Evidence at protein level	CAB002509, HPA041454	Enhanced		Approved	Vesicles	Renal cancer:3.49e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 130.9	tonsil: 64.1	Cell line enhanced		Daudi: 54.6;HDLM-2: 64.1;U-698: 80.4
CD84	hCD84, mCD84, SLAMF5	ENSG00000066294	CD84 molecule	1	160541095-160579516	CD markers, Predicted membrane proteins	Evidence at protein level	HPA070502	Enhanced					Expressed in all	Tissue enhanced		lymph node: 28.4	appendix: 26.8	Cell line enhanced		Daudi: 17.1;HEL: 41.2;HMC-1: 44.1;U-698: 22.1
CD86	B7-2, B7.2, CD28LG2	ENSG00000114013	CD86 molecule	3	122055366-122121139	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004319	Uncertain				Renal cancer:9.83e-5 (unfavourable)	Expressed in all	Mixed			appendix: 47.8	Cell line enriched	10	HDLM-2: 275.8
CD8A	CD8	ENSG00000153563	CD8a molecule	2	86784610-86808396	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000012, HPA037756, CAB075722	Enhanced				Endometrial cancer:6.15e-6 (favourable), Renal cancer:1.91e-5 (unfavourable), Cervical cancer:4.54e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 161.9	lymph node: 46.9	Cell line enriched	5	MOLT-4: 11.7
CD8B	CD8B1	ENSG00000172116	CD8b molecule	2	86815339-86861924	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004353, HPA029164	Enhanced		Supported	Plasma membrane	Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 60.8;lymph node: 39.6	parathyroid gland: 22.7	Cell line enriched	50	RPMI-8226: 837.8
CD9	BA2, MIC3, MRP-1, P24, TSPAN29	ENSG00000010278	CD9 molecule	12	6199715-6238271	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002490	Supported		Supported	Plasma membrane	Renal cancer:6.49e-5 (favourable), Thyroid cancer:8.93e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 1013.7	Cell line enhanced		CAPAN-2: 1447.3;TIME: 1977.3
CD93	C1qR(P), C1QR1, C1qRP, CDw93, dJ737E23.1, ECSM3, MXRA4	ENSG00000125810	CD93 molecule	20	23079349-23086340	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA009300, HPA012368	Enhanced		Approved	Vesicles<br>Plasma membrane	Renal cancer:2.74e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 197.1	Group enriched	5	HUVEC TERT2: 286.2;TIME: 357.8;U-937: 464.4
CD96	TACTILE	ENSG00000153283	CD96 molecule	3	111292719-111665750	CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066754	Enhanced				Renal cancer:2.02e-6 (unfavourable), Urothelial cancer:5.23e-5 (favourable), Head and neck cancer:5.52e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 28.0	urinary bladder: 16.7	Group enriched	8	HEL: 13.0;MOLT-4: 51.4;RT4: 46.0;U-937: 40.7;WM-115: 10.8
CD99	MIC2	ENSG00000002586	CD99 molecule	X	2691179-2741309	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000020, HPA035304	Supported		Approved	Golgi apparatus	Renal cancer:5.87e-7 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 375.1	Mixed		
CD99L2	CD99B, MIC2L1	ENSG00000102181	CD99 molecule like 2	X	150766337-150898816	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038782, HPA038783, HPA061400	Enhanced		Supported	Plasma membrane	Pancreatic cancer:2.74e-5 (favourable), Lung cancer:4.96e-4 (favourable), Urothelial cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 143.5	Expressed in all		
CDAN1	CDA-I, CDAI	ENSG00000140326	Codanin 1	15	42723559-42737126	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039404, HPA040787	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:1.07e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 15.2	Expressed in all		
CDC14B	Cdc14B1, Cdc14B2, CDC14B3, hCDC14B	ENSG00000081377	Cell division cycle 14B	9	96490241-96619830	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013312, HPA064747	Approved		Supported	Nucleoplasm	Renal cancer:2.97e-10 (favourable), Thyroid cancer:2.82e-4 (unfavourable)	Expressed in all	Mixed			testis: 18.6	Cell line enhanced		ASC TERT1: 21.4
CDCP1	CD318, SIMA135	ENSG00000163814	CUB domain containing protein 1	3	45082278-45146422	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010978, HPA010979, CAB025637	Enhanced				Lung cancer:1.41e-5 (unfavourable), Pancreatic cancer:1.48e-4 (unfavourable)	Expressed in all	Mixed			skin: 27.7	Cell line enhanced		hTEC/SVTERT24-B: 263.4;hTERT-HME1: 135.9
CDCP2		ENSG00000157211	CUB domain containing protein 2	1	54132968-54153770	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA031143	Uncertain					Not detected	Not detected			breast,cervix, uterine,spleen: 0.1	Not detected		
CDH1	CD324, UVO, uvomorulin	ENSG00000039068	Cadherin 1	16	68737225-68835548	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Renal cancer:2.06e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 475.1	thyroid gland: 266.2	Cell line enhanced		BEWO: 645.6;CAPAN-2: 281.0;HaCaT: 273.9
CDH10		ENSG00000040731	Cadherin 10	5	24487100-24644978	Predicted membrane proteins	Evidence at protein level	HPA010651	Approved					Group enriched	Group enriched	20	cerebral cortex: 32.6;prostate: 7.5	adrenal gland: 1.0	Cell line enhanced		AF22: 7.0;HAP1: 4.8;U-138 MG: 1.5
CDH11	CAD11, OB	ENSG00000140937	Cadherin 11	16	64943753-65126112	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013072	Enhanced				Renal cancer:2.48e-9 (unfavourable)	Expressed in all	Tissue enhanced		ovary: 223.4	placenta: 173.7	Cell line enhanced		BJ: 205.7;fHDF/TERT166: 259.6;HSkMC: 159.5;PC-3: 262.9;U-2197: 178.5
CDH12	Br-cadherin, CDHB	ENSG00000154162	Cadherin 12	5	21750673-22853622	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA029325	Uncertain		Approved	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 3.6;cervix, uterine: 4.5;fallopian tube: 3.5	adrenal gland: 2.2	Group enriched	5	PC-3: 2.0;SCLC-21H: 3.7;U-2 OS: 1.3
CDH15	CDH14, CDH3	ENSG00000129910	Cadherin 15	16	89171767-89195492	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA009139, HPA070961	Enhanced		Supported	Golgi apparatus<br>Cytosol		Mixed	Tissue enriched	11	skeletal muscle: 13.0	placenta: 1.1	Cell line enriched	5	RH-30: 142.1
CDH16		ENSG00000166589	Cadherin 16	16	66908122-66918984	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013526, HPA036260	Enhanced				Renal cancer:1.02e-7 (favourable)	Tissue enriched	Group enriched	8	kidney: 231.3;thyroid gland: 58.0	fallopian tube: 17.2	Cell line enriched	78	RPTEC TERT1: 163.7
CDH17	cadherin, HPT-1	ENSG00000079112	Cadherin 17	8	94127171-94217303	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023614, HPA023616, CAB025143, HPA026556	Enhanced		Supported	Cell Junctions		Group enriched	Group enriched	8	colon: 256.9;duodenum: 314.3;rectum: 267.3;small intestine: 294.3	appendix: 37.5	Group enriched	6	CACO-2: 81.5;U-266/70: 121.0
CDH18	CDH14, EY-CADHERIN	ENSG00000145526	Cadherin 18	5	19472951-20575873	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014416	Uncertain					Mixed	Tissue enhanced		adrenal gland: 5.9;cerebral cortex: 19.0	testis: 3.2	Cell line enhanced		EFO-21: 4.1;U-2 OS: 7.1;U-2197: 5.6
CDH19	CDH7	ENSG00000071991	Cadherin 19	18	66501083-66604138	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056332	Uncertain					Tissue enriched	Mixed			heart muscle: 8.4	Group enriched	15	SK-MEL-30: 28.3;WM-115: 63.0
CDH2	CD325, CDHN, NCAD	ENSG00000170558	Cadherin 2	18	27950966-28177446	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000141, CAB018580, HPA058574, CAB078686	Enhanced		Supported	Plasma membrane<br>Cell Junctions		Expressed in all	Tissue enhanced		heart muscle: 123.5;parathyroid gland: 126.2	adrenal gland: 87.3	Cell line enhanced		AF22: 306.2;fHDF/TERT166: 367.9
CDH20	Cdh7, CDH7L3	ENSG00000101542	Cadherin 20	18	61333582-61555773	Predicted membrane proteins	Evidence at protein level	HPA015490	Uncertain					Tissue enriched	Tissue enriched	5	cerebral cortex: 26.8	adipose tissue: 4.9	Cell line enhanced		AF22: 1.8;ASC diff: 3.9;HHSteC: 2.2;SH-SY5Y: 4.1
CDH22	C20orf25, dJ998H6.1	ENSG00000149654	Cadherin 22	20	46173733-46308498	Predicted membrane proteins	Evidence at transcript level	HPA012164	Uncertain					Mixed	Group enriched	6	adrenal gland: 2.0;cerebral cortex: 10.2;fallopian tube: 2.3;skin: 5.1	prostate,seminal vesicle,testis: 0.7	Cell line enriched	23	SCLC-21H: 3.7
CDH23	CDHR23, DFNB12, USH1D	ENSG00000107736	Cadherin related 23	10	71396934-71815947	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017232	Approved				Urothelial cancer:3.40e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 30.2	ovary: 19.4	Cell line enhanced		RT4: 11.9;SCLC-21H: 6.6
CDH24	CDH11L	ENSG00000139880	Cadherin 24	14	23047062-23057538	Predicted membrane proteins	Evidence at protein level	HPA065233			Approved	Nucleoplasm<br>Cell Junctions<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.15e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 8.5	Cell line enhanced		SCLC-21H: 62.2
CDH26	VR20	ENSG00000124215	Cadherin 26	20	59958427-60034011	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA015722, HPA047578	Uncertain		Approved	Plasma membrane<br>Microtubules	Lung cancer:3.75e-4 (favourable), Cervical cancer:7.62e-4 (favourable)	Group enriched	Tissue enhanced		prostate: 19.1	urinary bladder: 6.1	Cell line enriched	6	RT4: 42.4
CDH3	CDHP, PCAD	ENSG00000062038	Cadherin 3	16	68636189-68722616	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001767, CAB002487	Enhanced		Uncertain	Cell Junctions<br>Cytosol	Pancreatic cancer:8.43e-4 (unfavourable), Lung cancer:8.53e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 31.9	ovary: 26.5	Cell line enhanced		A-431: 89.4;HaCaT: 243.8;HBEC3-KT: 95.6;hTCEpi: 75.4;RPTEC TERT1: 88.7
CDH4		ENSG00000179242	Cadherin 4	20	61252426-61940617	Predicted membrane proteins	Evidence at protein level	HPA015613			Enhanced	Plasma membrane		Group enriched	Tissue enhanced		cerebral cortex: 6.0;spleen: 4.8	seminal vesicle: 1.3	Cell line enhanced		AF22: 11.0;hTERT-HME1: 11.2;U-2 OS: 20.6;U-251 MG: 29.8
CDH5	7B4, CD144	ENSG00000179776	Cadherin 5	16	66366622-66404786	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB028366	Approved				Renal cancer:5.14e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 335.1	lung: 120.5	Group enriched	5	HUVEC TERT2: 616.7;TIME: 522.0
CDH6		ENSG00000113361	Cadherin 6	5	31193750-31329146	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007047, HPA007456, CAB025274	Enhanced					Group enriched	Tissue enhanced		kidney: 16.0	gallbladder: 14.7	Cell line enriched	7	EFO-21: 458.4
CDH7		ENSG00000081138	Cadherin 7	18	65750252-65890341	Predicted membrane proteins	Evidence at protein level	HPA061419	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 2.8;prostate: 1.3	testis: 0.7	Cell line enhanced		AF22: 15.0;Karpas-707: 4.0;RH-30: 7.0;U-87 MG: 3.3
CDH8		ENSG00000150394	Cadherin 8	16	61647242-62037035	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014908	Approved					Tissue enhanced	Group enriched	8	cerebral cortex: 27.8;seminal vesicle: 6.9	ovary: 2.1	Cell line enhanced		AF22: 6.9;fHDF/TERT166: 4.9;HaCaT: 12.6;LHCN-M2: 14.1
CDH9		ENSG00000113100	Cadherin 9	5	26880600-27121150	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007167	Approved					Not detected	Tissue enhanced		cerebral cortex: 11.4;kidney: 6.5	testis: 4.3	Cell line enhanced		K-562: 6.6;NTERA-2: 10.2
CDHR1	CORD15, KIAA1775, PCDH21, RP65	ENSG00000148600	Cadherin related family member 1	10	84194635-84219621	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036819	Supported					Tissue enhanced	Group enriched	5	rectum: 57.9;skin: 252.1	colon: 29.2	Cell line enhanced		HAP1: 10.5;HEK93: 4.8;HEL: 5.7;RPTEC TERT1: 12.5
CDHR2	FLJ20124, FLJ20383, PC-LKC, PCDH24, PCLKC	ENSG00000074276	Cadherin related family member 2	5	176542511-176595974	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA012569, HPA017053	Enhanced				Renal cancer:9.29e-4 (favourable)	Group enriched	Group enriched	12	duodenum: 276.5;small intestine: 260.3	colon: 22.6	Cell line enriched	12	Hep G2: 15.0
CDHR3	CDH28, FLJ23834, FLJ44366	ENSG00000128536	Cadherin related family member 3	7	105876796-106033773	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011218	Uncertain		Approved	Nucleoli fibrillar center		Mixed	Tissue enriched	8	fallopian tube: 147.1	lung: 19.1	Cell line enhanced		AF22: 4.9;Daudi: 4.7;WM-115: 4.3
CDHR4	CDH29, VLLR9392	ENSG00000187492	Cadherin related family member 4	3	49790732-49799835	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA076277	Enhanced					Tissue enriched	Tissue enriched	9	fallopian tube: 105.0	lung: 11.4	Cell line enhanced		ASC TERT1: 1.0
CDHR5	FLJ20219, MU-PCDH, MUCDHL, MUPCDH	ENSG00000099834	Cadherin related family member 5	11	616565-626078	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009081, HPA009173, CAB025004	Enhanced					Group enriched	Group enriched	9	colon: 41.7;duodenum: 82.7;kidney: 23.6;liver: 21.0;rectum: 54.3;small intestine: 64.3	gallbladder: 5.3	Cell line enhanced		CACO-2: 2.1
CDIP1	C16orf5, CDIP, LITAFL	ENSG00000089486	Cell death inducing p53 target 1	16	4510675-4538828	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049352	Approved		Supported	Nucleoplasm<br>Centrosome	Renal cancer:1.14e-6 (favourable), Pancreatic cancer:2.14e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 72.9	Cell line enhanced		RPMI-8226: 99.5
CDIPT	PIS, PIS1	ENSG00000103502	CDP-diacylglycerol--inositol 3-phosphatidyltransferase	16	29858357-29863736	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA056597	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Plasma membrane	Cervical cancer:9.40e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 112.7	Expressed in all		
CDKAL1	FLJ20342	ENSG00000145996	CDK5 regulatory subunit associated protein 1 like 1	6	20534457-21232404	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057474			Uncertain	Vesicles	Endometrial cancer:1.03e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 16.0	Cell line enriched	6	SCLC-21H: 222.3
CDON	CDO, CDON1, ORCAM	ENSG00000064309	Cell adhesion associated, oncogene regulated	11	125955796-126063335	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB012422, HPA017377	Uncertain				Renal cancer:1.78e-7 (unfavourable), Breast cancer:1.35e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 75.5	ovary: 53.5	Cell line enhanced		AF22: 55.0;ASC diff: 47.4;RH-30: 93.1
CDRT15L2		ENSG00000214819	CMT1A duplicated region transcript 15-like 2	17	20579724-20580911	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	11	testis: 13.2	epididymis: 1.2	Not detected		
CDS1		ENSG00000163624	CDP-diacylglycerol synthase 1	4	84582979-84651338	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA036187, HPA064546	Enhanced		Approved	Nucleus<br>Nuclear membrane	Renal cancer:0.00e+0 (favourable), Colorectal cancer:5.22e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 49.6	Cell line enhanced		CAPAN-2: 39.2;hTCEpi: 39.6;SK-BR-3: 44.9
CDS2		ENSG00000101290	CDP-diacylglycerol synthase 2	20	5126786-5197887	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA019698	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:3.53e-9 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 48.9	Expressed in all		
CEACAM1	BGP, BGP1, CD66a	ENSG00000079385	Carcinoembryonic antigen related cell adhesion molecule 1	19	42507304-42561234	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002146, HPA011041	Enhanced				Endometrial cancer:6.32e-7 (favourable)	Mixed	Tissue enhanced		colon: 202.3;rectum: 130.6	esophagus: 46.5	Cell line enhanced		CAPAN-2: 25.2;Hep G2: 56.7;RT4: 43.1;SK-MEL-30: 47.4
CEACAM19	CEAL1	ENSG00000186567	Carcinoembryonic antigen related cell adhesion molecule 19	19	44662278-44684359	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA014462, HPA052865	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Mixed			skin: 12.7	Cell line enhanced		RPTEC TERT1: 11.9;TIME: 16.9
CEACAM20	UNQ9366	ENSG00000273777	Carcinoembryonic antigen related cell adhesion molecule 20	19	44501677-44529788	Predicted membrane proteins	Evidence at transcript level							Group enriched	Group enriched	23	duodenum: 38.8;prostate: 14.3;small intestine: 42.7	gallbladder: 1.3	Cell line enriched	7	U-266/70: 1.0
CEACAM21	FLJ13540, R29124_1	ENSG00000007129	Carcinoembryonic antigen related cell adhesion molecule 21	19	41549518-41586844	Predicted membrane proteins	Evidence at transcript level	HPA043411	Uncertain				Endometrial cancer:1.89e-5 (favourable)	Mixed	Tissue enhanced		bone marrow: 11.0	spleen: 6.5	Cell line enhanced		HMC-1: 6.0;Karpas-707: 3.9;U-266/70: 4.6;U-937: 3.7
CEACAM3	CD66d, CGM1	ENSG00000170956	Carcinoembryonic antigen related cell adhesion molecule 3	19	41796437-41811553	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011041	Approved					Not detected	Tissue enriched	5	bone marrow: 28.5	appendix: 5.3	Not detected		
CEACAM4	CGM7	ENSG00000105352	Carcinoembryonic antigen related cell adhesion molecule 4	19	41618971-41627074	Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	6	appendix: 6.7;bone marrow: 13.9;spleen: 9.0	adipose tissue: 1.7	Cell line enriched	7	U-937: 3.2
CEACAM6	CD66c, NCA	ENSG00000086548	Carcinoembryonic antigen related cell adhesion molecule 6	19	41750977-41772208	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB008370, HPA011041	Enhanced					Mixed	Group enriched	6	bone marrow: 110.7;colon: 180.6;esophagus: 173.5;gallbladder: 189.0;lung: 405.6;rectum: 233.8	appendix: 37.6	Cell line enriched	9	A549: 140.1
CEACAM7	CEA, CGM2	ENSG00000007306	Carcinoembryonic antigen related cell adhesion molecule 7	19	41673307-41706976	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069621	Supported					Tissue enhanced	Group enriched	7	colon: 583.2;rectum: 691.9	appendix: 91.6	Not detected		
CEBPZOS	CEBPZ-AS1	ENSG00000218739	CEBPZ opposite strand	2	37196488-37216193	Predicted membrane proteins	Evidence at protein level	HPA053866	Uncertain		Approved	Nucleoplasm	Renal cancer:3.46e-7 (unfavourable), Liver cancer:1.72e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 47.1	Mixed		
CECR6		ENSG00000183307	Cat eye syndrome chromosome region, candidate 6	22	17116299-17121367	Predicted membrane proteins	Evidence at protein level	HPA068790	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane		Tissue enhanced	Group enriched	7	cerebral cortex: 15.0;prostate: 10.8	testis: 1.9	Cell line enhanced		AF22: 5.9;SCLC-21H: 16.7;THP-1: 8.0;U-937: 7.7
CELSR1	ADGRC1, CDHF9, FMI2, HFMI2, ME2	ENSG00000075275	Cadherin EGF LAG seven-pass G-type receptor 1	22	46360834-46537170	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052976, HPA060521			Supported	Plasma membrane		Expressed in all	Mixed			fallopian tube: 15.5	Cell line enhanced		A549: 38.6;T-47d: 28.3
CELSR2	ADGRC2, CDHF10, EGFL2, Flamingo1, KIAA0279, MEGF3	ENSG00000143126	Cadherin EGF LAG seven-pass G-type receptor 2	1	109250019-109275750	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013952	Uncertain		Approved	Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 45.1	skin: 31.0	Cell line enhanced		AF22: 49.6;HaCaT: 44.6;MCF7: 45.4
CELSR3	ADGRC3, CDHF11, EGFL1, FMI1, HFMI1, MEGF2	ENSG00000008300	Cadherin EGF LAG seven-pass G-type receptor 3	3	48636469-48662915	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA062866	Approved					Mixed	Group enriched	6	adrenal gland: 1.6;cerebral cortex: 5.9;testis: 3.5	parathyroid gland,stomach: 0.6	Cell line enhanced		SH-SY5Y: 19.4;SiHa: 17.5
CEND1	BM88, FLJ90066	ENSG00000184524	Cell cycle exit and neuronal differentiation 1	11	787104-790123	Predicted membrane proteins	Evidence at protein level	HPA042527	Enhanced		Approved	Mitochondria	Glioma:6.10e-5 (unfavourable)	Tissue enriched	Tissue enriched	16	cerebral cortex: 113.9	adrenal gland: 7.0	Cell line enhanced		Karpas-707: 21.5;SCLC-21H: 62.8;SH-SY5Y: 21.2;U-266/70: 15.9;U-87 MG: 27.1
CEP170	FAM68A, KAB, KIAA0470	ENSG00000143702	Centrosomal protein 170	1	243124428-243255348	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042151, HPA045597, HPA045787	Uncertain		Enhanced	Plasma membrane<br>Centrosome<br>Cytosol	Renal cancer:1.30e-9 (unfavourable)	Expressed in all	Tissue enhanced		testis: 130.5	cerebral cortex: 44.7	Expressed in all		
CEP95	CCDC45, DKFZp667E1824	ENSG00000258890	Centrosomal protein 95	17	64506588-64542461	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023654, HPA052426, HPA052428, HPA061371	Approved		Approved	Nucleoplasm<br>Vesicles<br>Mitotic spindle<br>Centrosome	Liver cancer:2.52e-5 (unfavourable), Renal cancer:5.76e-5 (unfavourable), Head and neck cancer:5.78e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 27.7	Expressed in all		
CEPT1		ENSG00000134255	Choline/ethanolamine phosphotransferase 1	1	111139627-111185102	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level						Glioma:6.43e-4 (favourable)	Expressed in all	Expressed in all			spleen: 37.1	Expressed in all		
CERS1	LAG1, LASS1, UOG1	ENSG00000223802	Ceramide synthase 1	19	18868545-18896727	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045724	Approved		Approved	Endoplasmic reticulum		Tissue enhanced	Group enriched	13	cerebral cortex: 136.3;testis: 28.0	skeletal muscle: 6.5	Cell line enhanced		AN3-CA: 28.0;HEK93: 28.4
CERS2	FLJ10243, LASS2, SP260	ENSG00000143418	Ceramide synthase 2	1	150960583-150975004	Predicted membrane proteins	Evidence at protein level	HPA027262	Approved		Supported	Nuclear membrane<br>Endoplasmic reticulum		Expressed in all	Expressed in all			liver: 410.7	Expressed in all		
CERS3	LASS3, MGC27091	ENSG00000154227	Ceramide synthase 3	15	100400395-100544995	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006092, HPA024356	Approved		Approved	Nucleoplasm		Tissue enhanced	Group enriched	9	esophagus: 48.1;skin: 60.5;testis: 32.3;tonsil: 14.3	breast: 4.3	Cell line enriched	6	hTCEpi: 47.1
CERS4	FLJ12089, LASS4, Trh1	ENSG00000090661	Ceramide synthase 4	19	8206736-8262421	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033734, HPA054729	Uncertain		Approved	Nucleus<br>Vesicles	Lung cancer:3.45e-5 (favourable), Renal cancer:9.63e-5 (favourable), Cervical cancer:2.71e-4 (favourable), Head and neck cancer:7.83e-4 (favourable), Pancreatic cancer:8.05e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 80.8	Cell line enhanced		NB-4: 63.0
CERS5	FLJ25304, LASS5, MGC45411, Trh4	ENSG00000139624	Ceramide synthase 5	12	50129306-50167533	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA026589	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:9.33e-11 (unfavourable), Liver cancer:4.63e-5 (unfavourable), Thyroid cancer:5.76e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.4	Expressed in all		
CERS6	LASS6	ENSG00000172292	Ceramide synthase 6	2	168455862-168775137	Predicted membrane proteins	Evidence at protein level	HPA044683, HPA063527	Approved		Supported	Nucleus	Liver cancer:1.10e-4 (unfavourable), Endometrial cancer:7.31e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 43.5	Mixed		
CES2	CE-2, CES2A1, iCE	ENSG00000172831	Carboxylesterase 2	16	66934444-66945096	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018897	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.50e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 527.2	Expressed in all		
CFAP46	bA288G11.4, bA288G11.5, bB137A17.2, bB137A17.3, C10orf123, C10orf124, C10orf92, C10orf93, DKFZp434A1721, FLJ25954, TTC40	ENSG00000171811	Cilia and flagella associated protein 46	10	132808392-132942823	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA037786, HPA038034, HPA038867, HPA038868	Uncertain					Mixed	Tissue enhanced		fallopian tube: 11.7;skeletal muscle: 11.4;testis: 23.8	thyroid gland: 4.5	Cell line enhanced		HAP1: 1.0;SH-SY5Y: 1.0
CFAP47	CHDC2, CXorf22, CXorf30, CXorf59, FLJ36601, MGC34831, RP13-11B7.1	ENSG00000165164	Cilia and flagella associated protein 47	X	35919734-36385319	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA044633, HPA054859	Uncertain					Tissue enhanced	Tissue enriched	5	fallopian tube: 7.5	testis: 1.3	Group enriched	6	Karpas-707: 1.1;U-266/70: 2.2
CFAP54	C12orf55, C12orf63, FLJ31514, FLJ44112	ENSG00000188596	Cilia and flagella associated protein 54	12	96489571-96875555	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039897	Enhanced		Approved	Microtubules<br>Cytosol		Not detected	Tissue enhanced		testis: 11.0	fallopian tube: 8.5	Cell line enhanced		TIME: 8.0
CFAP57	FLJ32000, WDR65	ENSG00000243710	Cilia and flagella associated protein 57	1	43172149-43254358	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002736, HPA028623	Enhanced		Approved	Cytosol	Endometrial cancer:6.02e-4 (favourable)	Mixed	Group enriched	8	fallopian tube: 35.6;testis: 27.7	lung: 3.7	Cell line enhanced		HaCaT: 2.5
CFAP61	C20orf26, CaM-IP3, dJ1002M8.3, DKFZP434K156	ENSG00000089101	Cilia and flagella associated protein 61	20	20052514-20360702	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA009079	Uncertain					Mixed	Group enriched	6	fallopian tube: 20.3;heart muscle: 8.5;testis: 29.5	skeletal muscle: 3.3	Cell line enhanced		HMC-1: 2.1;SCLC-21H: 6.6;U-87 MG: 4.1
CFTR	ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR	ENSG00000001626	Cystic fibrosis transmembrane conductance regulator	7	117465784-117715971	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001951, HPA021939	Enhanced				Liver cancer:9.44e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		gallbladder: 89.3	rectum: 49.0	Group enriched	19	CACO-2: 26.2;MOLT-4: 97.6;U-266/70: 47.9
CGRRF1	CGR19, RNF197	ENSG00000100532	Cell growth regulator with ring finger domain 1	14	54509812-54539309	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002930	Uncertain		Supported	Nucleoplasm<br>Vesicles	Renal cancer:2.57e-8 (favourable), Liver cancer:6.84e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.8	Expressed in all		
CH17-360D5.1		ENSG00000264717		10	47918739-47923524	Predicted membrane proteins	Evidence at transcript level	HPA027863	Uncertain					Not detected	Tissue enhanced		colon: 3.0;rectum: 2.4	skin: 2.0	Cell line enriched	12	A549: 17.8
CH25H		ENSG00000138135	Cholesterol 25-hydroxylase	10	89205629-89207314	Enzymes, Predicted membrane proteins	Evidence at protein level							Expressed in all	Mixed			gallbladder: 23.0	Cell line enhanced		ASC diff: 6.0;fHDF/TERT166: 25.5;HSkMC: 6.0
CH507-396I9.3		ENSG00000278961		21	7788703-7793954	Predicted membrane proteins	Evidence at transcript level	HPA029085	Uncertain					Not detected	Group enriched	7	breast: 1.5;fallopian tube: 1.4;kidney: 4.3	skin: 0.3	Not detected		
CH507-42P11.8		ENSG00000275993		21	6111134-6123739	Predicted membrane proteins	Evidence at transcript level	HPA038211	Uncertain					Expressed in all	Mixed			adrenal gland: 73.0	Cell line enhanced		HeLa: 61.0;Karpas-707: 90.2;LHCN-M2: 73.9;SiHa: 93.6
CH507-9B2.1		ENSG00000277117		21	5022493-5040666	Predicted membrane proteins	Evidence at protein level	HPA029179			Supported	Plasma membrane<br>Cytoplasmic bodies		Mixed	Mixed			cerebral cortex: 11.2	Cell line enhanced		BEWO: 20.4;REH: 15.6;SiHa: 15.3
CHEK2	bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53	ENSG00000183765	Checkpoint kinase 2	22	28687743-28742422	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001878, CAB002030	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:7.80e-9 (unfavourable)	Expressed in all	Mixed			testis: 13.4	Expressed in all		
CHIC1	BRX	ENSG00000204116	Cysteine rich hydrophobic domain 1	X	73563200-73687102	Predicted membrane proteins	Evidence at protein level	HPA026782, HPA052062	Uncertain		Approved	Nuclear speckles<br>Vesicles<br>Cytosol	Renal cancer:2.75e-4 (favourable)	Mixed	Mixed			cerebral cortex: 14.2	Mixed		
CHIC2	BTL	ENSG00000109220	Cysteine rich hydrophobic domain 2	4	54009789-54064690	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026782, HPA026784, HPA076603	Uncertain		Enhanced	Vesicles<br>Plasma membrane	Renal cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.2	Expressed in all		
CHL1	CALL, FLJ44930, L1CAM2, MGC132578	ENSG00000134121	Cell adhesion molecule L1 like	3	196596-409417	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003345, CAB026120	Enhanced				Renal cancer:1.21e-6 (favourable)	Tissue enhanced	Tissue enriched	5	cerebral cortex: 111.8	ovary: 20.9	Group enriched	6	SK-MEL-30: 73.7;WM-115: 29.2
CHML	REP-2	ENSG00000203668	CHM like, Rab escort protein 2	1	241628853-241640254	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029627, HPA029628, HPA062967	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.23e-5 (unfavourable)	Expressed in all	Mixed			placenta: 16.6	Expressed in all		
CHODL	C21orf68, FLJ12627, MT75, PRED12	ENSG00000154645	Chondrolectin	21	17901263-18267373	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017282	Enhanced	Supported			Endometrial cancer:1.18e-6 (unfavourable)	Mixed	Tissue enhanced		spleen: 19.5;testis: 57.6	prostate: 9.3	Cell line enhanced		U-266/70: 2.1;U-266/84: 5.1;U-87 MG: 7.6
CHPT1	CPT1	ENSG00000111666	Choline phosphotransferase 1	12	101696947-101744140	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA067643	Approved		Approved	Vesicles	Thyroid cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			breast: 125.6	Expressed in all		
CHRFAM7A	CHRNA7-DR1, D-10	ENSG00000166664	CHRNA7 (exons 5-10) and FAM7A (exons A-E) fusion	15	30357766-30393849	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		parathyroid gland: 5.0;testis: 5.4	thyroid gland: 2.5	Cell line enhanced		HAP1: 3.9;HEL: 3.3;RH-30: 2.7;SH-SY5Y: 3.8;U-937: 3.1
CHRM1		ENSG00000168539	Cholinergic receptor muscarinic 1	11	62908679-62921807	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014101, CAB022366	Enhanced		Approved	Nucleus<br>Cytosol		Tissue enriched	Group enriched	8	cerebral cortex: 39.9;prostate: 42.3;salivary gland: 11.0	adrenal gland: 3.8	Cell line enhanced		MCF7: 2.7;SK-BR-3: 1.2;T-47d: 1.0
CHRM2		ENSG00000181072	Cholinergic receptor muscarinic 2	7	136868669-137020255	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022338, HPA029795	Approved					Tissue enhanced	Tissue enhanced		gallbladder: 18.3;heart muscle: 25.8;smooth muscle: 13.7	urinary bladder: 5.9	Cell line enhanced		BJ: 14.1;BJ hTERT+: 15.2;fHDF/TERT166: 71.3;HHSteC: 10.8
CHRM3		ENSG00000133019	Cholinergic receptor muscarinic 3	1	239386565-239915452	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA024106, HPA048036	Approved		Supported	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 15.7	esophagus: 8.4	Cell line enhanced		RPMI-8226: 11.9;SH-SY5Y: 55.3;U-266/70: 16.6;U-266/84: 11.6
CHRM4		ENSG00000180720	Cholinergic receptor muscarinic 4	11	46385098-46386608	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022444, HPA072083	Uncertain		Uncertain	Nucleus<br>Golgi apparatus		Mixed	Tissue enhanced		cerebral cortex: 8.1;small intestine: 7.8;spleen: 21.4	testis: 6.9	Cell line enhanced		RH-30: 3.3;SCLC-21H: 11.7;U-2 OS: 3.0
CHRM5		ENSG00000184984	Cholinergic receptor muscarinic 5	15	33968720-34067457	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA013172	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 3.1;testis: 3.4	placenta: 2.3	Group enriched	7	BEWO: 4.5;HMC-1: 14.3
CHRNA1	CHRNA	ENSG00000138435	Cholinergic receptor nicotinic alpha 1 subunit	2	174747592-174787935	Disease related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071554	Enhanced		Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		prostate: 3.2;skeletal muscle: 7.2	colon: 1.5	Group enriched	23	LHCN-M2: 370.9;RH-30: 348.5
CHRNA10		ENSG00000129749	Cholinergic receptor nicotinic alpha 10 subunit	11	3665587-3671384	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	21	skeletal muscle: 16.6	appendix,lung: 0.7	Mixed		
CHRNA2		ENSG00000120903	Cholinergic receptor nicotinic alpha 2 subunit	8	27459761-27479883	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	24	prostate: 46.8	breast: 1.9	Not detected		
CHRNA3		ENSG00000080644	Cholinergic receptor nicotinic alpha 3 subunit	15	78593052-78621295	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029430	Approved					Mixed	Tissue enriched	8	adrenal gland: 48.0	appendix: 6.3	Group enriched	25	SCLC-21H: 72.3;SH-SY5Y: 343.0
CHRNA4	BFNC, EBN, EBN1	ENSG00000101204	Cholinergic receptor nicotinic alpha 4 subunit	20	63343223-63378401	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB034064	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 6.9;parathyroid gland: 17.4	liver: 3.9	Cell line enhanced		U-2 OS: 2.6
CHRNA5		ENSG00000169684	Cholinergic receptor nicotinic alpha 5 subunit	15	78565520-78595269	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054381	Approved		Approved	Plasma membrane<br>Focal adhesion sites	Lung cancer:3.64e-5 (unfavourable)	Mixed	Mixed			gallbladder: 6.9	Mixed		
CHRNA6		ENSG00000147434	Cholinergic receptor nicotinic alpha 6 subunit	8	42752620-42796392	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Not detected			adrenal gland,fallopian tube: 0.5	Cell line enhanced		Daudi: 3.0;HDLM-2: 2.5;HMC-1: 1.1;U-698: 2.5
CHRNA7		ENSG00000175344	Cholinergic receptor nicotinic alpha 7 subunit	15	31923438-32173018	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029422, CAB033624	Enhanced					Mixed	Tissue enhanced		adrenal gland: 9.4;small intestine: 10.4	stomach: 6.2	Cell line enhanced		AN3-CA: 5.8;RT4: 9.8;SH-SY5Y: 7.1;SK-BR-3: 10.0;U-2 OS: 11.2
CHRNA9	NACHRA9	ENSG00000174343	Cholinergic receptor nicotinic alpha 9 subunit	4	40335329-40355217	Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		fallopian tube: 1.1	cerebral cortex,skin: 0.4	Cell line enriched	10	U-87 MG: 15.6
CHRNB1	CHRNB	ENSG00000170175	Cholinergic receptor nicotinic beta 1 subunit	17	7445061-7457707	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005822, CAB011200	Approved					Expressed in all	Expressed in all			skeletal muscle: 21.9	Cell line enhanced		LHCN-M2: 28.7;RH-30: 68.7
CHRNB2		ENSG00000160716	Cholinergic receptor nicotinic beta 2 subunit	1	154567781-154580026	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	15	cerebral cortex: 21.2	adrenal gland: 1.4	Group enriched	7	SCLC-21H: 30.2;SH-SY5Y: 27.0
CHRNB3		ENSG00000147432	Cholinergic receptor nicotinic beta 3 subunit	8	42697376-42737407	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045555	Enhanced					Tissue enriched	Tissue enhanced		testis: 2.6	cerebral cortex: 0.6	Cell line enhanced		NTERA-2: 1.1;U-266/84: 1.8
CHRNB4		ENSG00000117971	Cholinergic receptor nicotinic beta 4 subunit	15	78624119-78727754	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		adrenal gland: 3.2;testis: 5.3	appendix: 0.8	Group enriched	23	SCLC-21H: 34.9;SH-SY5Y: 40.9
CHRND	ACHRD	ENSG00000135902	Cholinergic receptor nicotinic delta subunit	2	232525993-232536667	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA056404, HPA065404			Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	12	skeletal muscle: 9.6	prostate: 0.8	Cell line enriched	76	RH-30: 79.9
CHRNE	ACHRE	ENSG00000108556	Cholinergic receptor nicotinic epsilon subunit	17	4897774-4903074	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enriched	26	heart muscle: 33.9	epididymis: 1.3	Group enriched	15	HEL: 3.9;HMC-1: 9.2
CHRNG	ACHRG	ENSG00000196811	Cholinergic receptor nicotinic gamma subunit	2	232539727-232546403	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	17	skeletal muscle: 8.2	prostate: 0.4	Group enriched	21	HSkMC: 2.3;RH-30: 8.7
CHST10	HNK-1ST	ENSG00000115526	Carbohydrate sulfotransferase 10	2	100391860-100417656	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012884, HPA051545	Approved		Approved	Cytosol	Pancreatic cancer:4.05e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 46.4	endometrium: 19.4	Mixed		
CHST12	C4S-2, C4ST2	ENSG00000136213	Carbohydrate sulfotransferase 12	7	2403560-2448483	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA041680	Approved		Approved	Golgi apparatus	Pancreatic cancer:1.32e-5 (favourable)	Expressed in all	Expressed in all			spleen: 16.1	Cell line enhanced		U-266/70: 68.5
CHST14	D4ST-1, D4ST1, HD4ST	ENSG00000169105	Carbohydrate sulfotransferase 14	15	40470998-40474571	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA057697, HPA071601	Approved		Approved	Vesicles		Expressed in all	Expressed in all			placenta: 38.8	Expressed in all		
CHST15	BRAG, GALNAC4S-6ST, KIAA0598	ENSG00000182022	Carbohydrate sulfotransferase 15	10	124007666-124093607	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017584	Approved		Approved	Centrosome<br>Cytosol	Renal cancer:2.22e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 45.6	Cell line enhanced		REH: 82.5
CHST2	C6ST	ENSG00000175040	Carbohydrate sulfotransferase 2	3	143119331-143124014	Predicted membrane proteins	Evidence at protein level	HPA013620			Supported	Golgi apparatus		Expressed in all	Mixed			spleen: 15.2	Cell line enhanced		HHSteC: 89.5;HMC-1: 44.1
CHST3	C6ST, C6ST1	ENSG00000122863	Carbohydrate sulfotransferase 3	10	71964365-72013564	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA047523, HPA055704	Enhanced		Approved	Golgi apparatus<br>Cytosol		Expressed in all	Mixed			testis: 30.7	Mixed		
CHST5	FLJ22167, I-GLCNAC-6-ST	ENSG00000135702	Carbohydrate sulfotransferase 5	16	75528535-75535247	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043804	Enhanced					Group enriched	Group enriched	14	colon: 45.6;duodenum: 85.9;rectum: 59.7;small intestine: 83.5	stomach: 4.8	Mixed		
CHST9	GALNAC-4-ST2, GALNAC4ST-2	ENSG00000154080	Carbohydrate sulfotransferase 9	18	26906481-27185317	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011393	Uncertain					Mixed	Tissue enhanced		fallopian tube: 16.5;testis: 12.7	spleen: 7.8	Group enriched	7	CACO-2: 7.6;Hep G2: 9.4;RPTEC TERT1: 31.6;SCLC-21H: 10.6
CISD1	C10orf70, MDS029, mitoNEET, ZCD1	ENSG00000122873	CDGSH iron sulfur domain 1	10	58269058-58289586	Predicted membrane proteins	Evidence at protein level	HPA074383			Supported	Mitochondria	Breast cancer:1.11e-4 (unfavourable), Liver cancer:4.15e-4 (unfavourable), Urothelial cancer:6.69e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 118.3	cerebral cortex: 27.2	Expressed in all		
CISD2	ERIS, Miner1, NAF-1, WFS2, ZCD2	ENSG00000145354	CDGSH iron sulfur domain 2	4	102868978-102889242	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA015914	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			thyroid gland: 61.9	Expressed in all		
CKAP4	CLIMP-63, ERGIC-63, P63	ENSG00000136026	Cytoskeleton associated protein 4	12	106237877-106304279	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000278, HPA000792, HPA001225	Enhanced		Uncertain	Nuclear speckles<br>Cytosol<br>Cytoplasmic bodies	Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.61e-5 (unfavourable), Lung cancer:5.61e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 78.5	Cell line enhanced		BJ hTERT+: 563.9;fHDF/TERT166: 652.4
CKLF	C32, CKLF1, CKLF3, CKLF4, HSPC224, UCK-1	ENSG00000217555	Chemokine like factor	16	66552563-66566251	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA062779			Approved	Vesicles	Renal cancer:1.06e-9 (unfavourable), Liver cancer:5.67e-5 (unfavourable), Thyroid cancer:2.22e-4 (favourable)	Expressed in all	Expressed in all			testis: 90.9	Expressed in all		
CKLF-CMTM1		ENSG00000254788	CKLF-CMTM1 readthrough	16	66552587-66579135	Predicted membrane proteins	Evidence at transcript level	HPA017136	Approved					Mixed	Mixed			testis: 4.0	Mixed		
CLCA2	CLCRG2	ENSG00000137975	Chloride channel accessory 2	1	86424086-86456558	Predicted membrane proteins	Evidence at protein level	HPA047192	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions		Group enriched	Group enriched	5	esophagus: 126.4;skin: 102.7	tonsil: 22.5	Cell line enhanced		BEWO: 36.7;HBEC3-KT: 23.7;hTCEpi: 148.8
CLCA4	CaCC2	ENSG00000016602	Chloride channel accessory 4	1	86547078-86580754	Predicted membrane proteins	Evidence at protein level	HPA017045	Uncertain				Colorectal cancer:7.47e-4 (favourable), Head and neck cancer:8.63e-4 (favourable)	Tissue enhanced	Group enriched	6	colon: 249.5;esophagus: 365.5;rectum: 158.4	urinary bladder: 41.0	Cell line enriched	1215	RT4: 342.2
CLCC1	MCLC	ENSG00000121940	Chloride channel CLIC like 1	1	108929508-108963457	Predicted membrane proteins, Transporters	Evidence at protein level	HPA009087, HPA013210	Enhanced		Enhanced	Endoplasmic reticulum	Colorectal cancer:1.33e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.6	Expressed in all		
CLCN1	ClC-1, CLC1	ENSG00000188037	Chloride voltage-gated channel 1	7	143316126-143352083	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enriched	17	skeletal muscle: 22.9	testis: 1.3	Cell line enhanced		HSkMC: 1.1;PC-3: 1.0
CLCN2	ClC-2, CLC2, EJM6	ENSG00000114859	Chloride voltage-gated channel 2	3	184346185-184361651	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009397, HPA014545, HPA024108	Approved		Approved	Cytosol	Liver cancer:4.67e-8 (unfavourable)	Expressed in all	Mixed			testis: 17.7	Mixed		
CLCN3	ClC-3, CLC3	ENSG00000109572	Chloride voltage-gated channel 3	4	169612633-169723673	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044723	Approved		Approved	Cytosol	Renal cancer:1.10e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 104.1	Expressed in all		
CLCN4	ClC-4, CLC4	ENSG00000073464	Chloride voltage-gated channel 4	X	10156945-10237660	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031313, HPA063637	Enhanced		Approved	Vesicles	Endometrial cancer:2.13e-5 (unfavourable), Pancreatic cancer:9.55e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 49.1;epididymis: 28.1	skeletal muscle: 14.6	Cell line enhanced		HEL: 21.9;SCLC-21H: 28.6
CLCN5	ClC-5, CLC5, DENTS, hCIC-K2, hClC-K2, NPHL1, NPHL2, XLRH, XRN	ENSG00000171365	Chloride voltage-gated channel 5	X	49922615-50099235	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000401, HPA003213	Uncertain		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:2.05e-8 (favourable), Pancreatic cancer:5.20e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 33.7;kidney: 52.0	placenta: 9.6	Cell line enhanced		CACO-2: 44.1;RH-30: 76.7
CLCN6	CLC-6, KIAA0046	ENSG00000011021	Chloride voltage-gated channel 6	1	11806096-11843144	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA032097	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 31.2	Expressed in all		
CLCN7	CLC-7, CLC7, OPTA2, PPP1R63	ENSG00000103249	Chloride voltage-gated channel 7	16	1444934-1475580	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043019, HPA043586	Supported		Supported	Nucleoplasm	Testis cancer:3.21e-4 (unfavourable), Head and neck cancer:5.23e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 41.2	Expressed in all		
CLCNKA	hClC-Ka	ENSG00000186510	Chloride voltage-gated channel Ka	1	16018875-16034050	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA057717	Approved					Group enriched	Group enriched	9	kidney: 64.2;parathyroid gland: 40.4	thyroid gland: 5.5	Group enriched	11	RPMI-8226: 1.3;SK-BR-3: 1.4;U-266/70: 5.7
CLCNKB	hClC-Kb	ENSG00000184908	Chloride voltage-gated channel Kb	1	16043736-16057308	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057717	Approved				Renal cancer:1.27e-7 (favourable)	Tissue enriched	Tissue enhanced		kidney: 107.9	salivary gland: 22.0	Cell line enhanced		EFO-21: 1.5
CLDN1	ILVASC, SEMP1	ENSG00000163347	Claudin 1	3	190305701-190322475	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002602, HPA048319	Enhanced				Endometrial cancer:2.00e-4 (unfavourable), Pancreatic cancer:5.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 306.2;smooth muscle: 186.0	liver: 158.4	Cell line enhanced		EFO-21: 613.4;HaCaT: 206.6;hTCEpi: 206.7;RPTEC TERT1: 310.7;RT4: 210.1
CLDN10	CPETRL3, OSP-L	ENSG00000134873	Claudin 10	13	95433604-95579759	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB012969, HPA042348	Enhanced				Renal cancer:7.46e-5 (favourable), Thyroid cancer:2.13e-4 (favourable)	Mixed	Tissue enhanced		kidney: 163.5	cervix, uterine: 112.6	Cell line enhanced		EFO-21: 10.0;HUVEC TERT2: 11.9;NTERA-2: 28.0;RPTEC TERT1: 43.5
CLDN11	OSP, OTM	ENSG00000013297	Claudin 11	3	170418865-170860380	Predicted membrane proteins	Evidence at protein level	CAB009789, HPA013166	Enhanced				Breast cancer:6.31e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 89.0;testis: 183.6	ovary: 61.7	Cell line enhanced		ASC diff: 254.1;ASC TERT1: 324.5;EFO-21: 266.5;HUVEC TERT2: 345.5;TIME: 539.4
CLDN12		ENSG00000157224	Claudin 12	7	90383721-90513402	Predicted membrane proteins	Evidence at protein level	HPA026945	Approved				Cervical cancer:6.36e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 40.5	Mixed		
CLDN14	DFNB29	ENSG00000159261	Claudin 14	21	36460621-36576569	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA054707			Uncertain	Vesicles	Liver cancer:1.53e-4 (favourable)	Tissue enriched	Group enriched	11	kidney: 3.6;liver: 9.5	gallbladder: 0.6	Cell line enriched	18	HDLM-2: 205.9
CLDN15		ENSG00000106404	Claudin 15	7	101232092-101238820	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:5.31e-5 (unfavourable), Pancreatic cancer:2.56e-4 (favourable), Urothelial cancer:3.30e-4 (favourable)	Expressed in all	Group enriched	16	duodenum: 241.3;small intestine: 183.5	spleen: 13.3	Expressed in all		
CLDN16	HOMG3, PCLN1	ENSG00000113946	Claudin 16	3	190322541-190412143	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA056020	Enhanced				Endometrial cancer:1.99e-5 (unfavourable)	Group enriched	Tissue enriched	6	kidney: 51.7	thyroid gland: 8.7	Group enriched	135	EFO-21: 435.6;RPTEC TERT1: 123.6
CLDN17	MGC126552, MGC126554	ENSG00000156282	Claudin 17	21	30165564-30166756	Predicted membrane proteins, Transporters	Evidence at protein level	HPA045903	Enhanced					Tissue enhanced	Tissue enriched	5	esophagus: 6.6	tonsil: 1.2	Not detected		
CLDN18	SFTPJ	ENSG00000066405	Claudin 18	3	137998735-138033655	Predicted membrane proteins	Evidence at protein level	CAB013010, CAB013243, HPA018446	Enhanced					Group enriched	Group enriched	85	lung: 361.8;stomach: 689.7	heart muscle: 6.1	Not detected		
CLDN19		ENSG00000164007	Claudin 19	1	42733093-42740254	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Group enriched	12	kidney: 19.7;placenta: 14.5	breast: 1.4	Cell line enhanced		CACO-2: 2.4;Hep G2: 4.3
CLDN2		ENSG00000165376	Claudin 2	X	106900164-106930861	Predicted membrane proteins	Evidence at protein level	CAB002609, HPA051548	Enhanced		Supported	Nucleoplasm<br>Cell Junctions	Thyroid cancer:1.70e-4 (favourable)	Group enriched	Tissue enhanced		gallbladder: 159.0;kidney: 171.8;seminal vesicle: 129.3	epididymis: 41.1	Group enriched	23	A549: 24.6;CACO-2: 18.2;RPTEC TERT1: 35.1
CLDN20		ENSG00000171217	Claudin 20	6	155264013-155276548	Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			skin: 1.0	Mixed		
CLDN22	CLDN21	ENSG00000177300	Claudin 22	4	183318194-183320774	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 1.0	endometrium: 0.2	Not detected		
CLDN23	CLDNL	ENSG00000253958	Claudin 23	8	8701938-8704106	Predicted membrane proteins, Transporters	Evidence at protein level	HPA070578			Uncertain	Nucleus<br>Plasma membrane	Renal cancer:9.65e-8 (favourable), Colorectal cancer:3.46e-4 (favourable)	Expressed in all	Tissue enhanced		colon: 23.7;stomach: 24.5	small intestine: 16.5	Cell line enhanced		BEWO: 7.4
CLDN24	CLDN21	ENSG00000185758	Claudin 24	4	183321764-183322426	Predicted membrane proteins	No evidence							Not detected	Not detected			kidney: 0.8	Not detected		
CLDN25		ENSG00000228607	Claudin 25	11	113779747-113780500	Predicted membrane proteins	No evidence	HPA053555	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CLDN3	C7orf1, CPE-R2, CPETR2, HRVP1, RVP1	ENSG00000165215	Claudin 3	7	73768997-73770270	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002702, HPA014361	Supported		Supported	Cell Junctions	Renal cancer:3.39e-5 (favourable)	Mixed	Tissue enhanced		colon: 87.7;small intestine: 119.5	duodenum: 55.0	Cell line enhanced		MCF7: 175.3;PC-3: 44.1;SCLC-21H: 68.2;T-47d: 98.9
CLDN34		ENSG00000234469	Claudin 34	X	9967358-9968352	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	13	testis: 2.3	epididymis,kidney,ovary,placenta,prostate,skin,urinary bladder: 0.1	Not detected		
CLDN4	CPE-R, CPETR, CPETR1, hCPE-R, WBSCR8	ENSG00000189143	Claudin 4	7	73799542-73832693	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002610	Enhanced		Supported	Plasma membrane	Renal cancer:3.46e-10 (favourable), Ovarian cancer:3.28e-4 (unfavourable)	Mixed	Mixed			colon: 208.6	Cell line enhanced		A-431: 285.9;BEWO: 354.2;CAPAN-2: 613.4;MCF7: 279.4;PC-3: 419.8;SK-BR-3: 439.0
CLDN5	AWAL, BEC1, CPETRL1, TMVCF	ENSG00000184113	Claudin 5	22	19523024-19527545	Predicted membrane proteins, Transporters	Evidence at protein level	CAB002607	Approved					Expressed in all	Tissue enhanced		adipose tissue: 128.2	lung: 53.4	Group enriched	12	HUVEC TERT2: 71.6;SCLC-21H: 62.4
CLDN6		ENSG00000184697	Claudin 6	16	3014712-3020071	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:2.42e-6 (unfavourable), Urothelial cancer:1.78e-4 (unfavourable)	Group enriched	Tissue enhanced		placenta: 1.0;testis: 1.7	cerebral cortex,lung: 0.3	Group enriched	8	BEWO: 460.1;CACO-2: 110.7;NTERA-2: 441.6
CLDN7	CEPTRL2, CPETRL2, Hs.84359	ENSG00000181885	Claudin 7	17	7259903-7263983	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB013063, HPA014703, HPA073662	Enhanced		Approved	Vesicles<br>Cell Junctions	Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable)	Expressed in all	Mixed			small intestine: 350.1	Cell line enhanced		BEWO: 162.4;CAPAN-2: 304.6;HaCaT: 644.4;MCF7: 198.9;SK-BR-3: 225.1
CLDN8		ENSG00000156284	Claudin 8	21	30214006-30216073	Predicted membrane proteins, Transporters	Evidence at protein level	HPA060605	Supported				Renal cancer:3.32e-4 (favourable)	Tissue enhanced	Tissue enhanced		breast: 84.9;kidney: 76.1;rectum: 56.0	thyroid gland: 37.3	Cell line enriched	17	HaCaT: 30.1
CLDN9		ENSG00000213937	Claudin 9	16	3012456-3014505	Predicted membrane proteins	Evidence at protein level	HPA076613			Supported	Vesicles<br>Cell Junctions	Endometrial cancer:2.24e-6 (unfavourable), Stomach cancer:4.67e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 3.2	bone marrow: 1.7	Cell line enhanced		CAPAN-2: 5.5;MCF7: 16.8;SCLC-21H: 19.5
CLDND1	C3orf4	ENSG00000080822	Claudin domain containing 1	3	98497912-98523066	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA029841	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:5.84e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 399.9	Expressed in all		
CLDND2	MGC33839	ENSG00000160318	Claudin domain containing 2	19	51367098-51369003	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA056971	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 22.3	spleen: 6.2	Mixed		
CLEC10A	CD301, CLECSF13, CLECSF14, HML, HML2	ENSG00000132514	C-type lectin domain family 10 member A	17	7074537-7080307	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA021937	Approved				Head and neck cancer:1.26e-5 (favourable), Testis cancer:4.22e-4 (unfavourable), Lung cancer:9.24e-4 (favourable)	Expressed in all	Mixed			appendix: 38.9	Not detected		
CLEC12A	CD371, CLL-1, DCAL-2, MICL	ENSG00000172322	C-type lectin domain family 12 member A	12	9951316-9995694	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048515	Enhanced				Urothelial cancer:9.33e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 51.3	spleen: 26.6	Group enriched	7	HL-60: 17.3;U-937: 52.2
CLEC12B		ENSG00000256660	C-type lectin domain family 12 member B	12	10010627-10018619	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 27.0	skin: 5.5	Cell line enriched	14	U-937: 5.5
CLEC14A	C14orf27	ENSG00000176435	C-type lectin domain family 14 member A	14	38254103-38256369	Predicted membrane proteins	Evidence at protein level	HPA039468, HPA048119	Uncertain		Supported	Endoplasmic reticulum<br>Golgi apparatus	Head and neck cancer:4.13e-6 (favourable)	Expressed in all	Tissue enhanced		lung: 76.1	adipose tissue: 40.9	Cell line enhanced		fHDF/TERT166: 60.3;HUVEC TERT2: 345.4;TIME: 121.9
CLEC17A	FLJ45910	ENSG00000187912	C-type lectin domain family 17 member A	19	14583084-14611157	Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	10	appendix: 16.6;lymph node: 30.4;spleen: 19.2;tonsil: 28.4	urinary bladder: 2.3	Group enriched	11	Daudi: 6.8;U-698: 12.0
CLEC1A	CLEC1, MGC34328	ENSG00000150048	C-type lectin domain family 1 member A	12	10069554-10111627	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	5	placenta: 71.1	smooth muscle: 12.9	Cell line enhanced		BEWO: 20.5;HUVEC TERT2: 15.2;U-266/84: 8.0
CLEC1B	CLEC2	ENSG00000165682	C-type lectin domain family 1 member B	12	9985642-10013424	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	6	liver: 33.7	bone marrow: 5.6	Group enriched	5	Karpas-707: 8.1;U-266/84: 19.9
CLEC2A	INPE5792, KACL, PILAR, UNQ5792	ENSG00000188393	C-type lectin domain family 2 member A	12	9898673-9932381	Predicted membrane proteins	Evidence at protein level	HPA048530, HPA072407	Approved		Uncertain	Plasma membrane		Tissue enhanced	Tissue enriched	14	skin: 67.7	breast: 4.7	Cell line enhanced		BEWO: 5.9;fHDF/TERT166: 16.8;U-937: 42.5
CLEC2D	CLAX, LLT1, OCIL	ENSG00000069493	C-type lectin domain family 2 member D	12	9664969-9699555	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017649, HPA047584	Uncertain		Uncertain	Nucleoplasm<br>Golgi apparatus	Renal cancer:5.85e-11 (unfavourable), Urothelial cancer:1.68e-7 (favourable), Cervical cancer:1.37e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 63.4	tonsil: 38.0	Cell line enhanced		Daudi: 48.6;HDLM-2: 49.6;U-698: 71.5
CLEC2L	FLJ32986	ENSG00000236279	C-type lectin domain family 2 member L	7	139523856-139544984	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045050	Enhanced					Mixed	Group enriched	9	cerebral cortex: 21.0;parathyroid gland: 13.7	endometrium: 1.9	Cell line enhanced		NTERA-2: 1.3;U-266/70: 2.4;U-266/84: 8.8
CLEC4A	CD367, CLECSF6, DCIR, DDB27	ENSG00000111729	C-type lectin domain family 4 member A	12	8082269-8138607	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007842	Uncertain					Expressed in all	Tissue enhanced		appendix: 30.7	spleen: 17.1	Not detected		
CLEC4C	BDCA2, CD303, CLECSF11, CLECSF7, DLEC, HECL	ENSG00000198178	C-type lectin domain family 4 member C	12	7729415-7751605	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029432	Approved					Not detected	Tissue enhanced		lymph node: 6.0;spleen: 4.6;tonsil: 4.5	appendix,breast: 1.8	Cell line enhanced		HDLM-2: 1.9
CLEC4E	CLECSF9, mincle	ENSG00000166523	C-type lectin domain family 4 member E	12	8533305-8540963	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004935	Uncertain		Uncertain	Cytosol		Mixed	Tissue enhanced		appendix: 53.9;bone marrow: 49.6;spleen: 44.0	gallbladder: 18.9	Cell line enhanced		NB-4: 2.8;RPTEC TERT1: 9.2
CLEC4F	CLECSF13, FLJ39110, KCLR	ENSG00000152672	C-type lectin domain family 4 member F	2	70808643-70820600	Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			small intestine: 4.9	Cell line enhanced		AN3-CA: 1.7
CLEC4G	LSECtin, UNQ431	ENSG00000182566	C-type lectin domain family 4 member G	19	7728957-7733906	Predicted membrane proteins	Evidence at protein level	CAB003789, HPA014044	Enhanced					Mixed	Group enriched	6	adipose tissue: 18.7;liver: 27.6;lymph node: 16.8	urinary bladder: 3.4	Not detected		
CLEC4M	CD209L, CD299, DC-SIGN2, DC-SIGNR, DCSIGNR, HP10347, LSIGN	ENSG00000104938	C-type lectin domain family 4 member M	19	7763149-7769605	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033689, CAB033691, HPA042661	Supported					Not detected	Group enriched	8	liver: 34.7;lymph node: 20.3;placenta: 12.4	testis: 2.9	Not detected		
CLEC5A	CLECSF5, MDL-1	ENSG00000258227	C-type lectin domain family 5 member A	7	141927357-141947007	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054137			Supported	Plasma membrane<br>Cytosol	Ovarian cancer:2.21e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 10.6;bone marrow: 27.4	lung: 4.9	Group enriched	29	HL-60: 33.0;U-937: 123.1
CLEC6A	CLECSF10, dectin-2	ENSG00000205846	C-type lectin domain family 6 member A	12	8455926-8478330	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		appendix: 1.5;lung: 1.5	lymph node: 0.8	Cell line enhanced		NTERA-2: 3.3
CLEC7A	CD369, CLECSF12, dectin-1, hDectin-1, SCARE2	ENSG00000172243	C-type lectin domain family 7 member A	12	10116777-10130258	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043244, HPA050229			Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.31e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 65.6	bone marrow: 53.3	Group enriched	15	Karpas-707: 144.0;U-266/84: 116.1
CLEC9A	CD370, DNGR-1, HEEE9341, UNQ9341	ENSG00000197992	C-type lectin domain family 9 member A	12	10030677-10066027	Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		lymph node: 7.8;spleen: 6.6	testis: 5.5	Not detected		
CLECL1	DCAL1	ENSG00000184293	C-type lectin like 1	12	9715860-9733299	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		lymph node: 28.7;spleen: 22.6;tonsil: 28.3	appendix: 13.3	Group enriched	5	HEL: 44.5;Karpas-707: 47.7;U-698: 120.2;U-937: 75.2
CLGN		ENSG00000153132	Calmegin	4	140388455-140427968	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB020709, HPA048761, HPA058627	Enhanced		Enhanced	Endoplasmic reticulum		Tissue enhanced	Tissue enriched	5	testis: 186.4	heart muscle: 35.6	Cell line enhanced		U-251 MG: 54.9
CLK1		ENSG00000013441	CDC like kinase 1	2	200853009-200864744	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033141, HPA062405	Approved		Supported	Nucleoplasm<br>Nuclear membrane	Urothelial cancer:2.28e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 113.5	Expressed in all		
CLK4		ENSG00000113240	CDC like kinase 4	5	178602664-178630615	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043746	Approved		Approved	Actin filaments		Expressed in all	Expressed in all			testis: 22.5	Expressed in all		
CLMN	FLJ12383, KIAA0500, KIAA1188	ENSG00000165959	Calmin	14	95181940-95319906	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012634	Enhanced		Approved	Nuclear bodies<br>Cytosol	Renal cancer:2.68e-7 (favourable)	Expressed in all	Tissue enhanced		testis: 48.9	kidney: 14.5	Cell line enhanced		WM-115: 15.3
CLMP	ACAM, ASAM, FLJ22415	ENSG00000166250	CXADR like membrane protein	11	123069865-123195281	Disease related genes, Predicted membrane proteins	Evidence at protein level							Mixed	Mixed			adipose tissue: 65.1	Cell line enhanced		BJ: 143.8;U-138 MG: 227.7
CLN3	BTN1, BTS, JNCL	ENSG00000188603	CLN3, battenin	16	28474111-28495575	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA063280	Uncertain					Expressed in all	Expressed in all			placenta: 46.8	Expressed in all		
CLN5		ENSG00000102805	Ceroid-lipofuscinosis, neuronal 5	13	76990660-77019143	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041788	Approved				Renal cancer:1.52e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 127.1	Expressed in all		
CLN6	FLJ20561, HsT18960, nclf	ENSG00000128973	Ceroid-lipofuscinosis, neuronal 6, late infantile, variant	15	68206992-68257211	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066046, HPA074162	Approved		Approved	Vesicles	Renal cancer:4.87e-4 (favourable)	Expressed in all	Expressed in all			appendix: 19.8	Expressed in all		
CLN8	C8orf61, EPMR, FLJ39417	ENSG00000182372	Ceroid-lipofuscinosis, neuronal 8	8	1755778-1801711	Disease related genes, Predicted membrane proteins	Evidence at protein level						Renal cancer:4.36e-8 (favourable)	Expressed in all	Mixed			gallbladder: 7.5	Mixed		
CLPTM1		ENSG00000104853	CLPTM1, transmembrane protein	19	44954585-44993341	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068702			Approved	Nuclear membrane<br>Microtubule organizing center		Expressed in all	Expressed in all			parathyroid gland: 129.9	Expressed in all		
CLPTM1L	CRR9, FLJ14400	ENSG00000049656	CLPTM1 like	5	1317744-1345099	Predicted membrane proteins	Evidence at protein level	HPA014791	Approved		Approved	Endoplasmic reticulum	Liver cancer:3.75e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 54.1	Expressed in all		
CLRN1	RP61, USH3, USH3A	ENSG00000163646	Clarin 1	3	150926163-150972999	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA054636	Uncertain					Not detected	Group enriched	5	adrenal gland: 6.7;duodenum: 1.5	testis: 0.7	Cell line enriched	31	NTERA-2: 3.5
CLRN2		ENSG00000249581	Clarin 2	4	17515165-17527104	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA042407	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
CLRN3	MGC32871, TMEM12, USH3AL1	ENSG00000180745	Clarin 3	10	127877841-127892947	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014482	Approved				Stomach cancer:8.98e-4 (favourable)	Group enriched	Group enriched	8	colon: 69.9;duodenum: 73.3;gallbladder: 23.6;kidney: 44.3;liver: 40.4;rectum: 76.3;small intestine: 97.5	appendix: 7.2	Cell line enriched	6	CACO-2: 1.9
CLSTN1	CDHR12, CSTN1, KIAA0911	ENSG00000171603	Calsyntenin 1	1	9729026-9824526	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA012412	Approved				Renal cancer:4.10e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 381.7	Expressed in all		
CLSTN2	CDHR13, CS2, CSTN2, FLJ39113	ENSG00000158258	Calsyntenin 2	3	139935185-140577397	Predicted membrane proteins	Evidence at protein level	HPA031342	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Cell Junctions		Tissue enriched	Tissue enhanced		cerebral cortex: 34.6;ovary: 81.6	adipose tissue: 18.8	Cell line enhanced		AF22: 5.2;SCLC-21H: 17.0;THP-1: 6.3
CLSTN3	CDHR14, CSTN3, KIAA0726	ENSG00000139182	Calsyntenin 3	12	7129698-7158945	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.19e-5 (favourable), Renal cancer:4.49e-5 (unfavourable), Breast cancer:5.08e-4 (favourable), Urothelial cancer:8.07e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 126.6	parathyroid gland: 40.3	Mixed		
CLYBL	CLB	ENSG00000125246	Citrate lyase beta like	13	99606669-99897134	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039959, HPA040691	Enhanced		Approved	Cytosol	Renal cancer:6.66e-16 (favourable)	Expressed in all	Expressed in all			kidney: 67.5	Cell line enhanced		SCLC-21H: 62.6
CMKLR1	RVER1	ENSG00000174600	Chemerin chemokine-like receptor 1	12	108288044-108339341	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047865	Uncertain					Expressed in all	Mixed			spleen: 48.4	Group enriched	5	ASC diff: 9.6;ASC TERT1: 41.0;BJ hTERT+: 35.4;LHCN-M2: 11.1
CMTM1	CKLFH, CKLFH1a, CKLFSF1	ENSG00000089505	CKLF like MARVEL transmembrane domain containing 1	16	66566393-66579137	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013801, HPA017136	Uncertain		Approved	Nucleoplasm	Pancreatic cancer:5.68e-5 (unfavourable)	Mixed	Tissue enriched	6	testis: 28.7	spleen: 4.4	Mixed		
CMTM2	CKLFSF2, FLJ25732, MGC39436	ENSG00000140932	CKLF like MARVEL transmembrane domain containing 2	16	66579448-66588275	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	1018	testis: 712.6	appendix,bone marrow: 0.6	Cell line enriched	23	REH: 29.0
CMTM3	BNAS2, CKLFSF3, FLJ31762	ENSG00000140931	CKLF like MARVEL transmembrane domain containing 3	16	66603874-66613892	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013870, HPA072695	Approved		Approved	Nucleoplasm	Renal cancer:4.42e-6 (unfavourable), Stomach cancer:1.85e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 69.6	Mixed		
CMTM4	CKLFSF4	ENSG00000183723	CKLF like MARVEL transmembrane domain containing 4	16	66614750-66696707	Predicted membrane proteins	Evidence at protein level	HPA014704, HPA023890	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane	Renal cancer:4.72e-9 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 64.1	parathyroid gland: 47.8	Mixed		
CMTM5	CKLFSF5, FLJ37521	ENSG00000166091	CKLF like MARVEL transmembrane domain containing 5	14	23376808-23379772	Predicted membrane proteins	Evidence at protein level	HPA052338	Enhanced		Approved	Golgi apparatus<br>Vesicles		Group enriched	Tissue enriched	20	cerebral cortex: 81.3	seminal vesicle: 4.1	Cell line enriched	6	HEL: 73.9
CMTM6	CKLFSF6, FLJ20396	ENSG00000091317	CKLF like MARVEL transmembrane domain containing 6	3	32481312-32503408	Predicted membrane proteins	Evidence at protein level	HPA026980	Approved					Expressed in all	Expressed in all			fallopian tube: 238.0	Expressed in all		
CMTM7	CKLFSF7, FLJ30992	ENSG00000153551	CKLF like MARVEL transmembrane domain containing 7	3	32391671-32483067	Predicted membrane proteins, Transporters	Evidence at protein level	HPA077409			Approved	Plasma membrane	Renal cancer:1.00e-6 (unfavourable), Liver cancer:3.21e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 61.7	Mixed		
CMTM8	CKLFSF8	ENSG00000170293	CKLF like MARVEL transmembrane domain containing 8	3	32238679-32370325	Predicted membrane proteins	Evidence at protein level	HPA055077, HPA073258	Approved		Approved	Nucleoplasm	Renal cancer:2.80e-4 (favourable)	Expressed in all	Mixed			placenta: 24.8	Cell line enhanced		BEWO: 199.8
CMTR2	AFT, FLJ11171, FTSJD1, MTr2	ENSG00000180917	Cap methyltransferase 2	16	71281389-71289715	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041700, HPA048265	Uncertain		Approved	Nuclear speckles<br>Cell Junctions	Renal cancer:4.97e-5 (favourable)	Expressed in all	Expressed in all			testis: 18.9	Expressed in all		
CNEP1R1	C16orf69, FLJ38101, NEP1-R1, TMEM188	ENSG00000205423	CTD nuclear envelope phosphatase 1 regulatory subunit 1	16	50024410-50037088	Predicted membrane proteins	Evidence at protein level	HPA042815, HPA077906	Uncertain		Supported	Cytosol		Expressed in all	Mixed			testis: 32.8	Expressed in all		
CNGA1	CNCG, CNCG1, CNG1, RCNC1, RCNCa, RP49	ENSG00000198515	Cyclic nucleotide gated channel alpha 1	4	47935977-48016672	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Mixed			liver: 14.2	Cell line enhanced		CAPAN-2: 9.1;RT4: 6.7;U-2 OS: 3.3
CNGA2	CNCA, CNCA1, CNG2, FLJ46312, OCNC1, OCNCa, OCNCALPHA	ENSG00000183862	Cyclic nucleotide gated channel alpha 2	X	151738451-151745304	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA015065	Uncertain					Not detected	Not detected			testis: 0.4	Not detected		
CNGA3	ACHM2, CCNC1, CCNCa, CNCG3, CNG3	ENSG00000144191	Cyclic nucleotide gated channel alpha 3	2	98346155-98398601	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA049378, CAB079025	Approved	Approved				Tissue enriched	Mixed			esophagus: 1.9	Cell line enriched	7	U-87 MG: 6.9
CNGA4	CNCA2, CNG5, CNGB2, OCNC2, OCNCb	ENSG00000132259	Cyclic nucleotide gated channel alpha 4	11	6234765-6244429	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level						Endometrial cancer:1.48e-4 (favourable)	Tissue enriched	Group enriched	9	fallopian tube: 27.9;testis: 10.5	lung: 2.1	Not detected		
CNGB1	CNCG2, CNCG3L, CNGB1B, GAR1, GARP, RCNC2, RCNCb, RP45	ENSG00000070729	Cyclic nucleotide gated channel beta 1	16	57882340-57971116	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039159, HPA060355			Approved	Vesicles<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 1.6	appendix,cerebral cortex: 1.5	Cell line enhanced		SCLC-21H: 2.6;SiHa: 3.1
CNGB3	ACHM1, ACHM3, RMCH	ENSG00000170289	Cyclic nucleotide gated channel beta 3	8	86553977-86743675	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA057244	Enhanced					Not detected	Tissue enhanced		bone marrow: 2.7;testis: 3.9	fallopian tube: 2.1	Cell line enriched	19	SCLC-21H: 23.7
CNIH1	CNIH, CNIL, TGAM77	ENSG00000100528	Cornichon family AMPA receptor auxiliary protein 1	14	54423560-54441431	Predicted membrane proteins, Transporters	Evidence at protein level	HPA002544	Approved		Approved	Vesicles	Urothelial cancer:8.95e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 119.4	Expressed in all		
CNIH2	CNIH-2, Cnil, MGC50896	ENSG00000174871	Cornichon family AMPA receptor auxiliary protein 2	11	66278190-66285301	Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	11	cerebral cortex: 52.9	adrenal gland: 4.6	Cell line enhanced		SCLC-21H: 74.6;SH-SY5Y: 31.1
CNIH3	CNIH-3, FLJ38993	ENSG00000143786	Cornichon family AMPA receptor auxiliary protein 3	1	224434660-224740549	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		cerebral cortex: 14.7	testis: 4.2	Cell line enhanced		hTEC/SVTERT24-B: 46.6;NTERA-2: 17.2;U-266/70: 18.9;U-87 MG: 53.6
CNIH4	HSPC163	ENSG00000143771	Cornichon family AMPA receptor auxiliary protein 4	1	224356850-224379459	Predicted membrane proteins	Evidence at protein level	HPA044268	Approved				Renal cancer:4.27e-6 (unfavourable), Head and neck cancer:1.72e-4 (unfavourable), Pancreatic cancer:4.61e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 27.4	Expressed in all		
CNMD	BRICD3, CHM-I, CHM1, LECT1, MYETS1	ENSG00000136110	Chondromodulin	13	52703264-52739812	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010510	Uncertain					Group enriched	Tissue enhanced		salivary gland: 3.0;testis: 3.5;thyroid gland: 5.8	lung: 2.5	Cell line enriched	125	NTERA-2: 47.4
CNNM1	ACDP1	ENSG00000119946	Cyclin and CBS domain divalent metal cation transport mediator 1	10	99329099-99394330	Predicted membrane proteins	Evidence at protein level	HPA040408	Approved		Uncertain	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 10.2;testis: 16.8	ovary: 3.0	Cell line enhanced		A549: 16.9;BJ hTERT+ SV40 Large T+ RasG12V: 10.6;HAP1: 8.6
CNNM2	ACDP2	ENSG00000148842	Cyclin and CBS domain divalent metal cation transport mediator 2	10	102918293-103090221	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA059954, HPA071631			Enhanced	Vesicles	Renal cancer:2.39e-8 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 33.6	placenta: 12.4	Expressed in all		
CNNM3	ACDP3	ENSG00000168763	Cyclin and CBS domain divalent metal cation transport mediator 3	2	96816245-96833911	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016711	Supported		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 45.6	Expressed in all		
CNNM4	ACDP4, KIAA1592	ENSG00000158158	Cyclin and CBS domain divalent metal cation transport mediator 4	2	96760902-96811891	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017732	Enhanced		Uncertain	Plasma membrane<br>Actin filaments	Ovarian cancer:8.75e-4 (unfavourable), Endometrial cancer:9.14e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 36.9	Expressed in all		
CNOT1	AD-005, CDC39, KIAA1007, NOT1, NOT1H	ENSG00000125107	CCR4-NOT transcription complex subunit 1	16	58519951-58629886	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046577, HPA049664	Approved		Supported	Cytosol		Expressed in all	Expressed in all			testis: 196.3	Expressed in all		
CNPPD1	C2orf24, CGI-57	ENSG00000115649	Cyclin Pas1/PHO80 domain containing 1	2	219171897-219178106	Predicted membrane proteins	Evidence at transcript level	HPA049303	Uncertain				Renal cancer:1.62e-10 (favourable), Liver cancer:2.04e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 88.2	Expressed in all		
CNR1	CANN6, CB-R, CB1, CB1A, CB1K5, CNR	ENSG00000118432	Cannabinoid receptor 1	6	88139864-88166359	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enhanced		cerebral cortex: 32.1	adipose tissue: 12.2	Group enriched	7	ASC diff: 55.8;HSkMC: 39.1
CNR2	CB2	ENSG00000188822	Cannabinoid receptor 2	1	23870526-23913362	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009719	Uncertain					Tissue enriched	Group enriched	6	appendix: 3.1;lymph node: 8.7;spleen: 7.9;tonsil: 6.9	bone marrow: 1.0	Group enriched	5	Daudi: 3.8;HEL: 4.0;HMC-1: 17.3;U-698: 9.4
CNST	C1orf71, FLJ32001, PPP1R64	ENSG00000162852	Consortin, connexin sorting protein	1	246566444-246668584	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007225, HPA007226	Approved		Supported	Vesicles		Expressed in all	Expressed in all			cerebral cortex: 26.3	Expressed in all		
CNTD1	CNTD, FLJ40137	ENSG00000176563	Cyclin N-terminal domain containing 1	17	42798792-42811587	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA023324			Uncertain	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites		Mixed	Tissue enriched	25	testis: 73.1	stomach: 2.9	Cell line enhanced		A-431: 2.1;ASC diff: 1.0;SiHa: 1.3
CNTFR		ENSG00000122756	Ciliary neurotrophic factor receptor	9	34551432-34590140	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025310	Approved					Tissue enhanced	Tissue enhanced		adipose tissue: 62.6;cerebral cortex: 53.4	spleen: 27.5	Group enriched	9	AF22: 107.8;SH-SY5Y: 55.3
CNTN6	NB-3	ENSG00000134115	Contactin 6	3	1092576-1404217	Predicted membrane proteins	Evidence at protein level	HPA016645	Uncertain					Group enriched	Tissue enhanced		lung: 4.6;thyroid gland: 17.4	cerebral cortex: 4.0	Group enriched	22	AF22: 2.0;SH-SY5Y: 2.4
CNTNAP1	Caspr, CNTNAP, NRXN4, p190	ENSG00000108797	Contactin associated protein 1	17	42682613-42699814	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA011772	Approved		Approved	Nucleoplasm	Renal cancer:4.16e-14 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 61.8;smooth muscle: 38.9	endometrium: 19.2	Cell line enhanced		TIME: 59.4;U-138 MG: 80.6
CNTNAP2	Caspr2, KIAA0868, NRXN4	ENSG00000174469	Contactin associated protein-like 2	7	146116002-148420998	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002739	Enhanced					Tissue enhanced	Group enriched	11	cerebral cortex: 17.9;prostate: 6.0	fallopian tube: 1.0	Cell line enhanced		AF22: 7.9;CACO-2: 5.7;NTERA-2: 11.9;SCLC-21H: 28.5
CNTNAP3	CASPR3, CNTNAP3A, FLJ14195, KIAA1714	ENSG00000106714	Contactin associated protein-like 3	9	39072767-39288315	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA047731	Uncertain					Mixed	Mixed			esophagus: 8.2	Cell line enhanced		A549: 17.0;AF22: 22.2;WM-115: 37.4
CNTNAP3B		ENSG00000154529	Contactin associated protein-like 3B	9	41890314-42129510	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA047731	Uncertain					Not detected	Mixed			esophagus,skin: 10.4	Cell line enhanced		A549: 27.0;AF22: 41.2;WM-115: 28.0
CNTNAP4	CASPR4, KIAA1763	ENSG00000152910	Contactin associated protein like 4	16	76277278-76559238	Predicted membrane proteins	Evidence at protein level	HPA031859, HPA057342	Enhanced					Tissue enriched	Tissue enriched	21	cerebral cortex: 35.9	testis: 1.6	Group enriched	6	Daudi: 7.9;HSkMC: 3.0;Karpas-707: 2.6;RPMI-8226: 4.9
CNTNAP5	caspr5, FLJ31966	ENSG00000155052	Contactin associated protein like 5	2	124025287-124915287	Predicted membrane proteins	Evidence at protein level	HPA069095, HPA069356			Supported	Nucleus<br>Nucleoli fibrillar center<br>Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 5.8;gallbladder: 1.6	adrenal gland: 0.7	Cell line enhanced		AF22: 1.1;SH-SY5Y: 2.8
COA1	C7orf44, FLJ10803, MITRAC15	ENSG00000106603	Cytochrome c oxidase assembly factor 1 homolog	7	43608456-43729717	Predicted membrane proteins	Evidence at protein level	HPA011944	Approved		Supported	Mitochondria	Liver cancer:7.84e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 38.6	Expressed in all		
COA3	CCDC56, COX25, HSPC009, MITRAC12	ENSG00000183978	Cytochrome c oxidase assembly factor 3	17	42795147-42798704	Predicted membrane proteins	Evidence at protein level	HPA031966	Approved		Supported	Mitochondria	Cervical cancer:3.40e-4 (favourable), Renal cancer:6.62e-4 (favourable), Endometrial cancer:8.93e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 213.9	Expressed in all		
COL13A1		ENSG00000197467	Collagen type XIII alpha 1 chain	10	69801931-69964275	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050392	Approved					Mixed	Tissue enhanced		epididymis: 32.9	prostate: 20.4	Cell line enhanced		HUVEC TERT2: 78.6;PC-3: 69.5;TIME: 103.7
COL17A1	BP180, BPAG2	ENSG00000065618	Collagen type XVII alpha 1 chain	10	104031286-104086002	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043673, HPA052963	Enhanced		Supported	Golgi apparatus<br>Plasma membrane	Breast cancer:1.38e-4 (favourable), Pancreatic cancer:1.86e-4 (unfavourable)	Tissue enhanced	Tissue enriched	14	skin: 769.3	placenta: 53.1	Group enriched	6	CAPAN-2: 175.9;HaCaT: 403.2;HBEC3-KT: 525.2;hTCEpi: 673.0;hTERT-HME1: 604.3
COL25A1		ENSG00000188517	Collagen type XXV alpha 1 chain	4	108810721-109302657	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029107			Approved	Endoplasmic reticulum<br>Vesicles<br>Cytosol		Mixed	Tissue enhanced		testis: 20.4	adipose tissue: 7.5	Cell line enriched	6	HeLa: 37.1
COLEC12	CL-P1, SCARA4, SRCL	ENSG00000158270	Collectin subfamily member 12	18	316740-500722	Predicted membrane proteins	Evidence at protein level	HPA047917, HPA071056	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Cell Junctions	Thyroid cancer:8.10e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 28.2	lung: 16.7	Cell line enhanced		ASC TERT1: 16.8;BJ: 10.3;HSkMC: 14.5;U-2197: 29.2
COMT		ENSG00000093010	Catechol-O-methyltransferase	22	19941607-19969975	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001169, CAB011233	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Endometrial cancer:3.68e-4 (favourable), Prostate cancer:5.67e-4 (favourable), Renal cancer:9.76e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 172.6	Expressed in all		
COQ2	CL640, FLJ26072	ENSG00000173085	Coenzyme Q2, polyprenyltransferase	4	83261536-83284914	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA056599, HPA068727	Approved		Approved	Cytosol		Expressed in all	Expressed in all			adrenal gland: 18.4	Expressed in all		
COQ7	CAT5, CLK-1	ENSG00000167186	Coenzyme Q7, hydroxylase	16	19067599-19080095	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067252, HPA071922	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:8.23e-12 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.2	Expressed in all		
CORIN	ATC2, CRN, Lrp4, PRSC, TMPRSS10	ENSG00000145244	Corin, serine peptidase	4	47593998-47838106	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA070941			Approved	Nuclear bodies<br>Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		heart muscle: 38.6	skin: 9.4	Group enriched	6	ASC diff: 7.2;ASC TERT1: 31.6
COX10		ENSG00000006695	COX10, heme A:farnesyltransferase cytochrome c oxidase assembly factor	17	14069496-14208677	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA032005, HPA032006	Supported		Supported	Nucleoli<br>Mitochondria<br>Cytosol	Renal cancer:4.32e-6 (favourable), Stomach cancer:8.73e-4 (favourable)	Expressed in all	Expressed in all			testis: 43.1	Expressed in all		
COX11	COX11P	ENSG00000166260	COX11, cytochrome c oxidase copper chaperone	17	54951902-54968785	Predicted membrane proteins	Evidence at protein level	HPA044020	Approved				Colorectal cancer:4.30e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 60.8	Expressed in all		
COX14	C12orf62, MGC14288	ENSG00000178449	COX14, cytochrome c oxidase assembly factor	12	50111979-50120457	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA044618, HPA062014	Approved		Supported	Mitochondria	Melanoma:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 86.5	Expressed in all		
COX15	CEMCOX2	ENSG00000014919	COX15, cytochrome c oxidase assembly homolog	10	99711844-99732100	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA037727, HPA037728, HPA066096	Uncertain		Supported	Mitochondria	Renal cancer:9.21e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 36.0	Expressed in all		
COX18	FLJ38991	ENSG00000163626	COX18, cytochrome c oxidase assembly factor	4	73052362-73069755	Predicted membrane proteins	Evidence at protein level	HPA046772, HPA049489	Enhanced				Renal cancer:8.22e-7 (favourable), Colorectal cancer:6.31e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 5.4	Expressed in all		
COX20	FAM36A, FLJ43269	ENSG00000203667	COX20, cytochrome c oxidase assembly factor	1	244835322-244845057	Predicted membrane proteins	Evidence at protein level	HPA043617, HPA045490	Approved		Enhanced	Mitochondria	Ovarian cancer:3.13e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 51.7	Expressed in all		
COX4I1	COX4, COX4-1	ENSG00000131143	Cytochrome c oxidase subunit 4I1	16	85798633-85807044	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002485, CAB004080	Supported		Supported	Mitochondria	Renal cancer:2.56e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 1085.8	Expressed in all		
COX4I2	COX4-2, COX4B, COX4L2, COXIV-2, dJ857M17.2	ENSG00000131055	Cytochrome c oxidase subunit 4I2	20	31637888-31645006	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Head and neck cancer:6.04e-5 (favourable), Renal cancer:9.78e-4 (unfavourable)	Expressed in all	Group enriched	5	lung: 42.8;placenta: 157.5	thyroid gland: 19.3	Cell line enriched	5	SH-SY5Y: 1.8
COX6A1	COX6A	ENSG00000111775	Cytochrome c oxidase subunit 6A1	12	120438090-120440742	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA062394	Approved		Supported	Mitochondria	Renal cancer:6.50e-7 (favourable)	Expressed in all	Expressed in all			duodenum: 572.6	Expressed in all		
COX6C		ENSG00000164919	Cytochrome c oxidase subunit 6C	8	99873200-99894062	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA014295, CAB016244	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			duodenum: 339.6	Expressed in all		
COX7A1	COX7A, COX7AH	ENSG00000161281	Cytochrome c oxidase subunit 7A1	19	36150922-36152869	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Expressed in all	Group enriched	6	heart muscle: 357.0;skeletal muscle: 1077.7	adipose tissue: 117.8	Cell line enhanced		ASC diff: 34.1;ASC TERT1: 25.4;BJ: 29.4;BJ hTERT+: 23.3;fHDF/TERT166: 41.5;HHSteC: 27.7;HSkMC: 24.9
COX7A2	COX7AL, COXVIIa-L	ENSG00000112695	Cytochrome c oxidase subunit 7A2	6	75237675-75250323	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:3.43e-5 (favourable)	Expressed in all	Expressed in all			testis: 641.4	Expressed in all		
COX7A2L	COX7AR, COX7RP, EB1, SIG81	ENSG00000115944	Cytochrome c oxidase subunit 7A2 like	2	42333546-42425088	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059124, CAB073545			Enhanced	Nucleoli<br>Mitochondria	Liver cancer:4.13e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 254.6	Expressed in all		
COX7B		ENSG00000131174	Cytochrome c oxidase subunit 7B	X	77899438-77907373	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA058041	Uncertain				Renal cancer:6.80e-6 (favourable), Urothelial cancer:2.43e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 65.4	Expressed in all		
COX7B2		ENSG00000170516	Cytochrome c oxidase subunit 7B2	4	46734827-46909235	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enhanced	Tissue enriched	100	testis: 148.8	placenta: 1.4	Cell line enriched	12	Karpas-707: 25.2
COX7C		ENSG00000127184	Cytochrome c oxidase subunit 7C	5	86617904-86620962	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046647	Approved				Renal cancer:1.23e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 821.9	Expressed in all		
COX8A	COX, COX8, COX8-2, COX8L, VIII, VIII-L	ENSG00000176340	Cytochrome c oxidase subunit 8A	11	63974607-63976543	Predicted membrane proteins, Transporters	Evidence at protein level	HPA055942	Supported				Renal cancer:2.51e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 512.4	Expressed in all		
COX8C	COX8-3	ENSG00000187581	Cytochrome c oxidase subunit 8C	14	93347191-93348356	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA003127	Approved					Group enriched	Tissue enriched	51	testis: 29.7	fallopian tube: 0.5	Cell line enriched	7	U-937: 11.3
CPD	GP180	ENSG00000108582	Carboxypeptidase D	17	30378905-30469989	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052796, HPA055465	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Nuclear speckles		Expressed in all	Expressed in all			thyroid gland: 94.8	Expressed in all		
CPM		ENSG00000135678	Carboxypeptidase M	12	68842197-68971570	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002657, HPA077243	Uncertain		Uncertain	Vesicles	Endometrial cancer:1.00e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 164.0	placenta: 101.2	Cell line enhanced		ASC diff: 48.8;ASC TERT1: 35.1;HSkMC: 66.3;SiHa: 73.7
CPOX	CPO, CPX, HCP	ENSG00000080819	Coproporphyrinogen oxidase	3	98521132-98593723	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA015736, HPA054448			Enhanced	Mitochondria	Renal cancer:1.04e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 25.5	Expressed in all		
CPT1A	CPT1, CPT1-L, L-CPT1	ENSG00000110090	Carnitine palmitoyltransferase 1A	11	68754620-68844410	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008835	Enhanced		Supported	Mitochondria	Renal cancer:2.67e-7 (favourable), Breast cancer:3.84e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 78.9	Mixed		
CPT1B	CPT1-M, M-CPT1	ENSG00000205560	Carnitine palmitoyltransferase 1B	22	50568861-50578465	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA029583	Approved					Mixed	Expressed in all			heart muscle: 106.5	Mixed		
CPT1C	CPT1P, CPTIC, FLJ23809	ENSG00000169169	Carnitine palmitoyltransferase 1C	19	49690898-49713731	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014529, HPA063621	Approved		Approved	Centrosome	Pancreatic cancer:1.84e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 34.2	adrenal gland: 7.0	Cell line enhanced		AF22: 39.0;SH-SY5Y: 74.9
CR1	CD35, KN	ENSG00000203710	Complement C3b/C4b receptor 1 (Knops blood group)	1	207496147-207640647	Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002491, CAB016271, HPA042455, HPA043579, HPA049348	Enhanced					Mixed	Tissue enhanced		appendix: 37.5;spleen: 33.6	lymph node: 23.4	Group enriched	8	HL-60: 7.8;HMC-1: 19.1;NB-4: 5.8
CR2	C3DR, CD21	ENSG00000117322	Complement C3d receptor 2	1	207454230-207489895	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002659, HPA052942, HPA060715	Enhanced				Breast cancer:6.90e-4 (favourable)	Mixed	Group enriched	21	appendix: 68.3;lymph node: 206.0;spleen: 100.2;tonsil: 153.8	kidney: 6.2	Cell line enhanced		Daudi: 17.1;MOLT-4: 10.7;RPMI-8226: 3.2
CRB1	LCA8, RP12	ENSG00000134376	Crumbs 1, cell polarity complex component	1	197268204-197478455	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA061250, HPA063127	Approved		Uncertain	Vesicles		Tissue enriched	Group enriched	10	cerebral cortex: 12.2;testis: 5.0	ovary: 0.8	Cell line enriched	5	HeLa: 9.0
CRB2	FLJ16786, FLJ38464	ENSG00000148204	Crumbs 2, cell polarity complex component	9	123356170-123380324	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043674	Supported					Group enriched	Tissue enhanced		cerebral cortex: 9.4	kidney: 2.0	Cell line enriched	7	AF22: 32.2
CRB3	MGC17303	ENSG00000130545	Crumbs 3, cell polarity complex component	19	6463777-6467221	Predicted membrane proteins	Evidence at protein level	HPA013835	Enhanced		Supported	Cell Junctions	Renal cancer:0.00e+0 (favourable), Urothelial cancer:8.06e-5 (favourable), Endometrial cancer:4.54e-4 (favourable)	Mixed	Mixed			duodenum: 37.4	Cell line enhanced		A-431: 50.4;BEWO: 34.1;CACO-2: 31.7;HaCaT: 32.6
CREB3	Luman, LZIP, sLZIP	ENSG00000107175	CAMP responsive element binding protein 3	9	35732335-35737004	Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA030978			Supported	Cytosol	Renal cancer:3.77e-5 (favourable), Ovarian cancer:5.40e-4 (favourable), Liver cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 55.8	Expressed in all		
CREB3L1	OASIS	ENSG00000157613	CAMP responsive element binding protein 3 like 1	11	46277661-46321422	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA024069, CAB026151	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.97e-4 (unfavourable), Endometrial cancer:3.92e-4 (favourable), Thyroid cancer:8.59e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 66.0	Cell line enhanced		fHDF/TERT166: 248.2
CREB3L2	BBF2H7, TCAG_1951439	ENSG00000182158	CAMP responsive element binding protein 3 like 2	7	137874979-138002067	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA015068, HPA015534	Uncertain		Supported	Nucleoplasm<br>Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 110.9	Mixed		
CREB3L3	CREB-H	ENSG00000060566	CAMP responsive element binding protein 3 like 3	19	4153601-4173054	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA040671, HPA056228	Enhanced				Renal cancer:3.53e-6 (unfavourable)	Tissue enriched	Group enriched	104	duodenum: 241.6;liver: 61.0;small intestine: 278.7	colon,stomach: 1.8	Cell line enhanced		HDLM-2: 44.9;Hep G2: 10.3;U-266/70: 7.7
CREB3L4	AIbZIP, ATCE1, CREB3, CREB4, hJAL	ENSG00000143578	CAMP responsive element binding protein 3 like 4	1	153967534-153974363	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA038122	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane<br>Mitochondria	Endometrial cancer:7.21e-4 (favourable)	Group enriched	Expressed in all			prostate: 170.5	Expressed in all		
CRELD1	AVSD2	ENSG00000163703	Cysteine rich with EGF like domains 1	3	9933822-9945413	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026964	Uncertain		Approved	Nucleoli<br>Cytosol	Glioma:6.05e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 65.6	Expressed in all		
CRHR1	CRF-R, CRF1, CRHR	ENSG00000120088	Corticotropin releasing hormone receptor 1	17	45784280-45835828	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB025251	Approved					Mixed	Tissue enhanced		cerebral cortex: 4.0	endometrium: 0.8	Cell line enhanced		RT4: 2.7;SH-SY5Y: 2.2
CRHR2	CRF-RB, CRF2, HM-CRF	ENSG00000106113	Corticotropin releasing hormone receptor 2	7	30651943-30700129	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046683	Uncertain					Not detected	Tissue enhanced		seminal vesicle: 1.7	cerebral cortex: 1.2	Not detected		
CRIM1	S52	ENSG00000150938	Cysteine rich transmembrane BMP regulator 1	2	36355926-36551135	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000556	Enhanced				Renal cancer:9.51e-4 (favourable)	Expressed in all	Expressed in all			placenta: 239.7	Cell line enhanced		TIME: 540.0
CRLF2	CRL2, TSLPR	ENSG00000205755	Cytokine receptor-like factor 2	X	1187549-1212750	Cancer-related genes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		appendix: 2.1;gallbladder: 2.0	bone marrow: 1.0	Cell line enhanced		HMC-1: 13.5;RPMI-8226: 2.8;U-698: 2.4
CRLS1	C20orf155, CLS1, dJ967N21.6, GCD10	ENSG00000088766	Cardiolipin synthase 1	20	6006090-6040053	Enzymes, Predicted membrane proteins	Evidence at protein level						Urothelial cancer:8.02e-4 (favourable)	Expressed in all	Expressed in all			liver: 87.0	Expressed in all		
CRTAM	CD355	ENSG00000109943	Cytotoxic and regulatory T-cell molecule	11	122838500-122872639	CD markers, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 9.8	spleen: 5.0	Cell line enriched	45	SCLC-21H: 15.2
CRYAB	CRYA2, HSPB5	ENSG00000109846	Crystallin alpha B	11	111908565-111923722	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002053, CAB040560, HPA057100	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Urothelial cancer:1.70e-5 (unfavourable), Colorectal cancer:4.90e-5 (unfavourable)	Group enriched	Tissue enhanced		heart muscle: 3968.4	cerebral cortex: 1888.7	Cell line enhanced		ASC diff: 1679.2;fHDF/TERT166: 650.9;U-138 MG: 315.9
CS		ENSG00000062485	Citrate synthase	12	56271699-56300392	Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038460, HPA038461, CAB075750, CAB075751, CAB075752, CAB075753, CAB075754	Enhanced		Enhanced	Mitochondria	Renal cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 190.9	Expressed in all		
CSF1	M-CSF, MCSF, MGC31930	ENSG00000184371	Colony stimulating factor 1	1	109910242-109930992	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level						Renal cancer:1.00e-11 (unfavourable), Liver cancer:4.25e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 66.6	Cell line enhanced		ASC diff: 146.1;HHSteC: 271.2;HSkMC: 150.5
CSF1R	C-FMS, CD115, CSFR, FMS	ENSG00000182578	Colony stimulating factor 1 receptor	5	150053291-150113372	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB008970, HPA012323	Uncertain		Supported	Vesicles<br>Plasma membrane	Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable)	Expressed in all	Mixed			spleen: 147.7	Group enriched	6	BEWO: 118.6;SK-BR-3: 35.4
CSF2RA	CD116, CSF2R	ENSG00000198223	Colony stimulating factor 2 receptor alpha subunit	X	1268800-1310381	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016148	Uncertain				Cervical cancer:2.38e-5 (favourable), Head and neck cancer:2.81e-4 (favourable), Testis cancer:5.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 93.3	appendix: 34.6	Group enriched	8	BEWO: 187.1;HMC-1: 51.2;SK-MEL-30: 109.5
CSF2RB	CD131, IL3RB, IL5RB	ENSG00000100368	Colony stimulating factor 2 receptor beta common subunit	22	36913628-36940449	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA078677			Approved	Golgi apparatus	Head and neck cancer:7.47e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 89.7	tonsil: 57.2	Group enriched	7	HEL: 95.8;HMC-1: 281.8
CSF3R	CD114, GCSFR	ENSG00000119535	Colony stimulating factor 3 receptor	1	36466043-36483278	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017116, HPA048086	Enhanced				Testis cancer:3.79e-4 (unfavourable), Renal cancer:5.72e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 211.2;bone marrow: 243.4;placenta: 147.9	spleen: 96.5	Cell line enhanced		BEWO: 68.2;NB-4: 12.7;THP-1: 32.4;U-937: 36.3
CSMD1	KIAA1890, PPP1R24	ENSG00000183117	CUB and Sushi multiple domains 1	8	2935353-4994972	Predicted membrane proteins	Evidence at protein level	HPA074707			Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.2;testis: 4.7	fallopian tube: 1.1	Cell line enhanced		K-562: 4.4;U-2 OS: 2.3;U-266/70: 1.7;U-266/84: 1.5;U-698: 1.3
CSMD2	KIAA1884	ENSG00000121904	CUB and Sushi multiple domains 2	1	33513999-34165842	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008622	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 2.6;gallbladder: 1.8	testis: 1.0	Cell line enhanced		fHDF/TERT166: 5.3;HEL: 9.4;NTERA-2: 8.1;PC-3: 7.8;U-87 MG: 23.1
CSMD3		ENSG00000164796	CUB and Sushi multiple domains 3	8	112222928-113437099	Predicted membrane proteins	Evidence at transcript level	HPA029007	Uncertain					Not detected	Group enriched	7	cerebral cortex: 4.9;testis: 1.8	fallopian tube,prostate,spleen: 0.4	Not detected		
CSNK1G1	CK1gamma1	ENSG00000169118	Casein kinase 1 gamma 1	15	64165517-64356259	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018209			Supported	Cytosol		Expressed in all	Tissue enhanced		testis: 59.9	thyroid gland: 13.9	Expressed in all		
CSPG4	HMW-MAA, MCSP, MCSPG, MEL-CSPG, MSK16, NG2	ENSG00000173546	Chondroitin sulfate proteoglycan 4	15	75674322-75712848	Predicted membrane proteins	Evidence at protein level	HPA002951, CAB016189, HPA042785, HPA050008	Approved		Approved	Nucleus<br>Plasma membrane	Renal cancer:7.60e-6 (unfavourable), Urothelial cancer:4.93e-5 (unfavourable)	Expressed in all	Mixed			smooth muscle: 32.1	Cell line enhanced		SK-MEL-30: 115.3;U-138 MG: 90.7;WM-115: 136.7
CSPG5	NGC	ENSG00000114646	Chondroitin sulfate proteoglycan 5	3	47562239-47580792	Predicted membrane proteins	Evidence at protein level	HPA049529, HPA067818, HPA071779	Enhanced		Approved	Nucleoplasm<br>Mitochondria	Ovarian cancer:2.14e-4 (favourable)	Tissue enriched	Tissue enriched	56	cerebral cortex: 156.7	testis: 2.8	Cell line enhanced		AF22: 32.2
CTAGE1	CT21.1, CT21.2, CTAGE, cTAGE-1, cTAGE-2	ENSG00000212710	Cutaneous T-cell lymphoma-associated antigen 1	18	22413601-22417915	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922, CAB016204	Uncertain					Not detected	Tissue enriched	50	testis: 5.0	all non-specific tissues: 0.0	Not detected		
CTAGE15	CTAGE15P	ENSG00000271079	CTAGE family member 15	7	143571801-143574387	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain					Not detected	Tissue enhanced		testis: 7.3	thyroid gland: 1.6	Cell line enhanced		A-431: 2.8;RT4: 2.1;SiHa: 2.8;SK-BR-3: 1.8
CTAGE4	cTAGE-4, FLJ43692	ENSG00000225932	CTAGE family member 4	7	144183466-144186053	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain					Not detected	Tissue enhanced		thyroid gland: 16.4	testis: 13.6	Cell line enhanced		A-431: 16.9;hTCEpi: 10.1;RPTEC TERT1: 9.9;SiHa: 9.1
CTAGE5	cTAGE-5A, cTAGE-5B, cTAGE-5C, cTAGE-5D, MEA6, MGEA, MGEA11, MGEA6	ENSG00000150527	CTAGE family member 5, ER export factor	14	39265284-39388513	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain				Renal cancer:2.81e-4 (favourable)	Mixed	Expressed in all			thyroid gland: 77.4	Expressed in all		
CTAGE6	CTAGE6P, MGC41943	ENSG00000271321	CTAGE family member 6	7	143755089-143757696	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain					Not detected	Tissue enriched	38	testis: 9.9	skin: 0.2	Not detected		
CTAGE8		ENSG00000244693	CTAGE family member 8	7	144266701-144269288	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain					Not detected	Tissue enhanced		thyroid gland: 11.4	skin: 9.1	Cell line enhanced		A-431: 9.7;HaCaT: 5.8;RT4: 5.7;SiHa: 6.7
CTAGE9		ENSG00000236761	CTAGE family member 9	6	131708684-131711017	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain					Not detected	Tissue enriched	41	testis: 7.6	duodenum,small intestine: 0.1	Not detected		
CTB-133G6.1		ENSG00000263264		19	7348943-7383385	Predicted membrane proteins	Evidence at protein level	HPA049151	Uncertain					Mixed	Tissue enhanced		lymph node: 22.3;spleen: 16.5	appendix: 15.3	Cell line enhanced		Daudi: 38.3;HL-60: 18.6;MOLT-4: 18.2;REH: 18.9;THP-1: 15.0;U-698: 23.8;U-937: 14.2
CTC-260F20.3		ENSG00000258674		19	19516227-19536076	Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			cerebral cortex: 4.6	Cell line enhanced		BEWO: 23.4
CTCFL	BORIS, CT27, dJ579F20.2	ENSG00000124092	CCCTC-binding factor like	20	57495966-57525652	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA001472	Enhanced					Tissue enhanced	Tissue enriched	20	testis: 20.6	bone marrow: 1.0	Group enriched	41	HMC-1: 70.0;K-562: 103.5
CTD-2132N18.2		ENSG00000267221		17	42038232-42050614	Predicted membrane proteins	Evidence at transcript level						Renal cancer:4.24e-7 (favourable)	Mixed	Mixed			fallopian tube: 2.6	Mixed		
CTD-2370N5.3		ENSG00000265118		17	31305213-31318831	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045033	Uncertain					Not detected	Tissue enhanced		appendix: 5.1	tonsil: 3.0	Cell line enhanced		MOLT-4: 5.4;RPMI-8226: 3.7
CTD-2521M24.10		ENSG00000269035		19	17436611-17460804	Predicted membrane proteins	No evidence	HPA041580, HPA042010	Uncertain		Uncertain	Nuclear membrane		Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CTD-2568A17.1		ENSG00000261341		19	50776141-50793142	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	11	testis: 108.1	skin: 9.5	Cell line enhanced		AF22: 4.0;HEK93: 5.0
CTDNEP1	DULLARD, HSA011916, NET56	ENSG00000175826	CTD nuclear envelope phosphatase 1	17	7243591-7252491	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037439, HPA066466	Uncertain		Supported	Lipid droplets	Pancreatic cancer:1.81e-4 (favourable), Endometrial cancer:6.45e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 190.1	Expressed in all		
CTLA4	CD, CD152, CELIAC3, GSE, IDDM12	ENSG00000163599	Cytotoxic T-lymphocyte associated protein 4	2	203867786-203873960	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Head and neck cancer:4.48e-5 (favourable)	Mixed	Tissue enhanced		appendix: 23.5;lymph node: 31.9	tonsil: 15.3	Group enriched	5	SK-MEL-30: 2.4;U-266/70: 3.5;U-266/84: 9.7
CTNS	CTNS-LSB, PQLC4	ENSG00000040531	Cystinosin, lysosomal cystine transporter	17	3636468-3661542	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA046947			Supported	Vesicles<br>Intermediate filaments	Pancreatic cancer:6.39e-5 (favourable), Head and neck cancer:7.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 42.6	Expressed in all		
CTSK	CTSO, CTSO2, PKND, PYCD	ENSG00000143387	Cathepsin K	1	150796208-150808323	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050346			Supported	Vesicles	Renal cancer:7.12e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 575.0	Group enriched	6	ASC diff: 1592.3;ASC TERT1: 590.6;BJ hTERT+: 1576.7
CTXN1	FLJ25968	ENSG00000178531	Cortexin 1	19	7924485-7926166	Predicted membrane proteins	Evidence at transcript level	HPA016669	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cell Junctions		Expressed in all	Tissue enhanced		cerebral cortex: 100.4	endometrium: 22.7	Cell line enhanced		AN3-CA: 86.1;NTERA-2: 70.2;SCLC-21H: 63.8;SH-SY5Y: 96.5
CTXN2		ENSG00000233932	Cortexin 2	15	48191539-48203756	Predicted membrane proteins	Evidence at transcript level	HPA053168	Uncertain					Not detected	Group enriched	8	cerebral cortex: 1.9;testis: 1.5	fallopian tube: 0.2	Not detected		
CTXN3		ENSG00000205279	Cortexin 3	5	127649044-127658630	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	18	kidney: 78.6	skeletal muscle: 4.3	Not detected		
CUX1	CASP, CDP, CDP/Cut, CDP/Cux, CDP1, Clox, CUT, CUTL1, CUX, Cux/CDP, GOLIM6	ENSG00000257923	Cut like homeobox 1	7	101815904-102283957	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA003277, HPA003317	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:5.72e-7 (favourable), Glioma:9.90e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 82.5	Expressed in all		
CUX2	CDP2, CUTL2, KIAA0293	ENSG00000111249	Cut like homeobox 2	12	111034024-111350554	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 12.2;liver: 9.6;prostate: 18.0	thyroid gland: 6.8	Cell line enhanced		HBEC3-KT: 4.6;SCLC-21H: 7.5;SH-SY5Y: 14.5
CUZD1	ERG-1, UO-44	ENSG00000138161	CUB and zona pellucida like domains 1	10	122832149-122850793	Predicted membrane proteins	Evidence at protein level	HPA068479, HPA068660, HPA074117	Enhanced		Approved	Nucleoli<br>Vesicles		Tissue enriched	Tissue enriched	173	pancreas: 380.6	testis: 2.1	Mixed		
CWH43	CWH43-C, FLJ21511	ENSG00000109182	Cell wall biogenesis 43 C-terminal homolog	4	48986247-49062081	Predicted membrane proteins	Evidence at protein level	HPA042814, HPA048140	Uncertain				Renal cancer:2.29e-11 (favourable), Endometrial cancer:1.32e-4 (favourable)	Tissue enhanced	Tissue enhanced		prostate: 67.5	skin: 29.6	Not detected		
CX3CL1	ABCD-3, C3Xkine, CXC3, CXC3C, fractalkine, neurotactin, NTN, SCYD1	ENSG00000006210	C-X3-C motif chemokine ligand 1	16	57372458-57385048	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026192, HPA040361	Approved		Supported	Plasma membrane	Renal cancer:8.52e-7 (favourable), Cervical cancer:9.46e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 100.1	lung: 69.3	Cell line enhanced		EFO-21: 28.0;HDLM-2: 78.9;Hep G2: 42.9;RPTEC TERT1: 27.3
CX3CR1	CCRL1, CMKBRL1, CMKDR1, GPR13, V28	ENSG00000168329	C-X3-C motif chemokine receptor 1	3	39263494-39281735	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA030311, CAB032478, HPA046587, HPA077743	Approved		Approved	Nucleus		Tissue enhanced	Tissue enhanced		cerebral cortex: 59.2	spleen: 16.6	Cell line enriched	18	RPMI-8226: 409.2
CXADR	CAR	ENSG00000154639	Coxsackie virus and adenovirus receptor	21	17512382-17593579	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003342, CAB005103, HPA030411, HPA030412	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Head and neck cancer:3.50e-4 (favourable)	Expressed in all	Mixed			skin: 59.1	Cell line enhanced		CACO-2: 77.2;NTERA-2: 105.2;RT4: 82.7
CXCL16	CXCLG16, SR-PSOX, SRPSOX	ENSG00000161921	C-X-C motif chemokine ligand 16	17	4733526-4739922	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA053253, HPA066315	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			lung: 106.0	Cell line enhanced		A-431: 84.5;CACO-2: 54.2;HaCaT: 93.1
CXCR1	CD181, CDw128a, CKR-1, CMKAR1, IL8RA	ENSG00000163464	C-X-C motif chemokine receptor 1	2	218162845-218166995	Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA031991	Uncertain					Mixed	Tissue enhanced		appendix: 35.1;spleen: 25.0	adipose tissue: 15.7	Cell line enriched	32	HMC-1: 5.0
CXCR2	CD182, CMKAR2, IL8RB	ENSG00000180871	C-X-C motif chemokine receptor 2	2	218125289-218137253	Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB016268, HPA031999, HPA032017	Enhanced					Mixed	Tissue enhanced		appendix: 55.7;spleen: 36.7	esophagus: 29.9	Group enriched	10	BEWO: 13.6;HL-60: 6.5;HMC-1: 14.3;THP-1: 10.4;U-937: 11.8
CXCR3	CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR	ENSG00000186810	C-X-C motif chemokine receptor 3	X	71615916-71618517	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA045942	Enhanced				Renal cancer:1.67e-6 (unfavourable), Endometrial cancer:3.44e-6 (favourable), Melanoma:2.90e-4 (favourable), Head and neck cancer:3.35e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 17.9	spleen: 8.7	Cell line enriched	13	RPMI-8226: 32.7
CXCR4	CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R	ENSG00000121966	C-X-C motif chemokine receptor 4	2	136114349-136118165	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.41e-7 (unfavourable), Ovarian cancer:2.05e-4 (favourable), Stomach cancer:5.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 771.6	tonsil: 495.9	Cell line enhanced		Daudi: 410.1;MOLT-4: 425.1;REH: 252.8;U-266/70: 489.0;U-698: 459.8
CXCR5	BLR1, CD185, MDR15	ENSG00000160683	C-X-C motif chemokine receptor 5	11	118883766-118897799	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB026149, HPA042432	Enhanced					Not detected	Tissue enhanced		appendix: 14.5;lymph node: 32.5;spleen: 21.0;tonsil: 14.3	bone marrow: 6.4	Group enriched	8	Daudi: 12.9;U-698: 43.3
CXCR6	BONZO, CD186, STRL33, TYMSTR	ENSG00000172215	C-X-C motif chemokine receptor 6	3	45940933-45948353	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level						Endometrial cancer:6.74e-6 (favourable), Renal cancer:2.42e-5 (unfavourable), Head and neck cancer:2.16e-4 (favourable), Cervical cancer:4.92e-4 (favourable)	Mixed	Mixed			lymph node: 17.3	Group enriched	6	BEWO: 2.8;CAPAN-2: 9.8
CXorf66	RP11-35F15.2, SGPX	ENSG00000203933	Chromosome X open reading frame 66	X	139955725-139965520	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	76	testis: 24.3	liver: 0.3	Not detected		
CYB561	CYB561A1, FRRS2	ENSG00000008283	Cytochrome b561	17	63432304-63446378	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014753	Approved				Endometrial cancer:2.95e-5 (favourable), Breast cancer:8.89e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 163.4	Cell line enhanced		SH-SY5Y: 448.0
CYB561A3	CYBASC3	ENSG00000162144	Cytochrome b561 family member A3	11	61348745-61362299	Predicted membrane proteins	Evidence at protein level	HPA052548	Approved					Expressed in all	Expressed in all			adrenal gland: 187.1	Expressed in all		
CYB561D1	FLJ39035, FLJ44753	ENSG00000174151	Cytochrome b561 family member D1	1	109494052-109502932	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027028	Uncertain				Pancreatic cancer:5.16e-6 (favourable), Renal cancer:2.22e-4 (favourable), Head and neck cancer:4.68e-4 (favourable)	Expressed in all	Mixed			skin: 21.4	Expressed in all		
CYB561D2	101F6, TSP10	ENSG00000114395	Cytochrome b561 family member D2	3	50350695-50358460	Predicted membrane proteins	Evidence at protein level	HPA042817	Uncertain				Renal cancer:6.16e-5 (favourable), Pancreatic cancer:1.86e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 28.5	Expressed in all		
CYB5A	CYB5	ENSG00000166347	Cytochrome b5 type A	18	74250847-74292016	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB006333, HPA047548, HPA058547	Enhanced		Approved	Vesicles<br>Cytosol	Liver cancer:4.15e-4 (favourable), Colorectal cancer:5.23e-4 (favourable)	Expressed in all	Expressed in all			liver: 1260.1	Cell line enhanced		ASC diff: 766.9
CYB5B	CYB5-M	ENSG00000103018	Cytochrome b5 type B	16	69424525-69466266	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007893	Approved		Approved	Endoplasmic reticulum<br>Microtubule organizing center<br>Cytosol	Renal cancer:6.38e-5 (favourable), Head and neck cancer:2.51e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 398.0	Expressed in all		
CYB5R2		ENSG00000166394	Cytochrome b5 reductase 2	11	7665100-7677222	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038962, HPA061707	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enhanced		testis: 227.5	parathyroid gland: 72.2	Cell line enhanced		BJ hTERT+: 101.1;BJ hTERT+ SV40 Large T+: 61.1;BJ hTERT+ SV40 Large T+ RasG12V: 57.7;NTERA-2: 69.5;WM-115: 94.6
CYB5R3	DIA1	ENSG00000100243	Cytochrome b5 reductase 3	22	42617840-42649568	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001566	Approved		Enhanced	Endoplasmic reticulum	Liver cancer:2.13e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 339.4	Expressed in all		
CYBA	p22-PHOX	ENSG00000051523	Cytochrome b-245 alpha chain	16	88643283-88651152	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009492	Enhanced				Endometrial cancer:4.75e-5 (favourable), Renal cancer:1.83e-4 (unfavourable), Breast cancer:8.19e-4 (favourable)	Expressed in all	Expressed in all			spleen: 466.1	Cell line enhanced		RPMI-8226: 1035.0
CYBB	CGD, GP91-PHOX, NOX2	ENSG00000165168	Cytochrome b-245 beta chain	X	37780011-37813461	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051227	Enhanced					Expressed in all	Tissue enhanced		appendix: 215.6	lung: 132.2	Group enriched	5	Daudi: 37.3;NB-4: 40.0;REH: 49.1;RPMI-8226: 143.6
CYBRD1	CYB561A2, DCYTB, FLJ23462, FRRS3	ENSG00000071967	Cytochrome b reductase 1	2	171522247-171558133	Predicted membrane proteins	Evidence at protein level	HPA014757, HPA056736	Approved		Approved	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 381.1	Cell line enhanced		ASC diff: 712.0;ASC TERT1: 313.5;BJ hTERT+: 328.5
CYC1	UQCR4	ENSG00000179091	Cytochrome c1	8	144095027-144097525	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA001247	Supported		Supported	Mitochondria	Renal cancer:5.89e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 242.3	Expressed in all		
CYHR1	CHRP, KIAA0496, MGC13010	ENSG00000187954	Cysteine and histidine rich 1	8	144449582-144465677	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053653, HPA059543	Approved		Enhanced	Nucleoplasm	Colorectal cancer:1.05e-4 (unfavourable), Liver cancer:3.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.4	Expressed in all		
CYP19A1	ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM	ENSG00000137869	Cytochrome P450 family 19 subfamily A member 1	15	51208057-51338610	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000355, HPA051194	Enhanced		Approved	Mitochondria		Mixed	Tissue enriched	15	placenta: 174.5	adrenal gland: 11.9	Group enriched	6	ASC TERT1: 65.0;HDLM-2: 16.2;HSkMC: 22.8
CYP1A1	CP11, CYP1, P1-450, P450-C, P450DX	ENSG00000140465	Cytochrome P450 family 1 subfamily A member 1	15	74719542-74725610	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018654	Uncertain					Group enriched	Group enriched	8	liver: 33.9;small intestine: 20.5;urinary bladder: 80.8	breast: 5.7	Cell line enhanced		CACO-2: 30.3;hTCEpi: 14.0;HUVEC TERT2: 15.7
CYP1A2	CP12, P3-450	ENSG00000140505	Cytochrome P450 family 1 subfamily A member 2	15	74748844-74756202	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	CAB016531	Enhanced					Group enriched	Tissue enriched	170	liver: 268.6	thyroid gland: 1.5	Mixed		
CYP1B1	CP1B, GLC3A	ENSG00000138061	Cytochrome P450 family 1 subfamily B member 1	2	38066973-38109902	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB011705, HPA026863	Approved		Uncertain	Mitochondria	Renal cancer:4.39e-6 (unfavourable), Urothelial cancer:2.76e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 76.1	Cell line enhanced		HSkMC: 400.2;SiHa: 283.9;U-87 MG: 138.5
CYP20A1	CYP-M	ENSG00000119004	Cytochrome P450 family 20 subfamily A member 1	2	203238940-203305611	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055872, HPA058461	Uncertain		Approved	Plasma membrane<br>Cell Junctions<br>Actin filaments		Expressed in all	Mixed			thyroid gland: 16.4	Mixed		
CYP26C1		ENSG00000187553	Cytochrome P450 family 26 subfamily C member 1	10	93060808-93069536	Disease related genes, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			spleen: 0.2	Not detected		
CYP2D6	CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, P450-DB1, P450C2D	ENSG00000100197	Cytochrome P450 family 2 subfamily D member 6	22	42126499-42130906	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045223	Enhanced		Approved	Golgi apparatus		Tissue enriched	Group enriched	5	duodenum: 3.7;liver: 10.0;small intestine: 13.0	testis: 1.7	Cell line enhanced		Hep G2: 1.2;HMC-1: 2.2;REH: 1.4;U-266/70: 1.3
CYP2S1		ENSG00000167600	Cytochrome P450 family 2 subfamily S member 1	19	41193049-41207539	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049227, HPA069248	Approved		Approved	Endoplasmic reticulum	Renal cancer:1.60e-6 (unfavourable)	Expressed in all	Tissue enhanced		duodenum: 96.7;small intestine: 68.6;stomach: 111.7	colon: 25.9	Cell line enhanced		A549: 83.4;CACO-2: 39.6;HaCaT: 43.5;NTERA-2: 68.5
CYP2U1	SPG49	ENSG00000155016	Cytochrome P450 family 2 subfamily U member 1	4	107931369-107953457	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA041622, HPA046754, HPA064827	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:2.75e-5 (favourable), Stomach cancer:6.97e-4 (unfavourable)	Expressed in all	Mixed			prostate: 15.7	Mixed		
CYP39A1		ENSG00000146233	Cytochrome P450 family 39 subfamily A member 1	6	46549580-46652830	Enzymes, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.86e-4 (favourable)	Tissue enhanced	Tissue enhanced		liver: 56.8	epididymis: 28.9	Cell line enhanced		hTCEpi: 11.0;SiHa: 9.9;U-698: 7.7
CYP3A4	CYP3A3	ENSG00000160868	Cytochrome P450 family 3 subfamily A member 4	7	99756960-99784265	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033671, HPA072245	Enhanced		Uncertain	Cytosol		Tissue enriched	Group enriched	199	duodenum: 826.8;liver: 2451.8;small intestine: 971.1	adrenal gland: 7.1	Cell line enhanced		BEWO: 1.8;NB-4: 1.3;RPMI-8226: 2.2;SCLC-21H: 1.4;SH-SY5Y: 2.4
CYP3A43		ENSG00000021461	Cytochrome P450 family 3 subfamily A member 43	7	99828013-99866102	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066463, HPA072245	Supported		Uncertain	Cytosol	Liver cancer:3.41e-4 (favourable)	Tissue enriched	Tissue enriched	15	liver: 22.7	testis: 1.5	Not detected		
CYP3A5	CP35, P450PCN3, PCN3	ENSG00000106258	Cytochrome P450 family 3 subfamily A member 5	7	99648194-99679998	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA072245			Uncertain	Cytosol	Liver cancer:3.72e-5 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 114.8;liver: 93.2;small intestine: 187.6	stomach: 77.7	Cell line enhanced		A549: 2.5;CACO-2: 7.9;CAPAN-2: 5.7;Hep G2: 5.0
CYP3A7	CP37, P450-HFLA	ENSG00000160870	Cytochrome P450 family 3 subfamily A member 7	7	99705037-99735196	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA072245			Uncertain	Cytosol		Tissue enriched	Tissue enriched	15	liver: 143.3	kidney: 9.8	Cell line enhanced		Hep G2: 1.6;HHSteC: 1.0
CYP3A7-CYP3A51P		ENSG00000282301	CYP3A7-CYP3A51P readthrough	7	99684957-99735102	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA072245			Uncertain	Cytosol			Tissue enhanced		liver: 7.4	gallbladder: 1.9	Not detected		
CYP4A11	CYP4A2, CYP4AII	ENSG00000187048	Cytochrome P450 family 4 subfamily A member 11	1	46929177-46941484	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	183	kidney: 232.3;liver: 448.3	gallbladder: 1.8	Not detected		
CYP4A22		ENSG00000162365	Cytochrome P450 family 4 subfamily A member 22	1	47137435-47149741	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	16	kidney: 33.5;liver: 109.1	epididymis: 4.5	Cell line enriched	5	RH-30: 1.2
CYP4B1		ENSG00000142973	Cytochrome P450 family 4 subfamily B member 1	1	46757838-46819413	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004331	Approved		Supported	Vesicles	Cervical cancer:5.99e-4 (favourable)	Tissue enhanced	Tissue enhanced		lung: 382.2	fallopian tube: 79.0	Cell line enriched	9	RT4: 234.9
CYP4F12		ENSG00000186204	Cytochrome P450 family 4 subfamily F member 12	19	15672757-15697174	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058960	Approved				Cervical cancer:1.21e-4 (favourable), Urothelial cancer:2.33e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 36.2;small intestine: 42.3	skin: 22.3	Cell line enhanced		CAPAN-2: 14.8;HaCaT: 26.3;Karpas-707: 14.2;SiHa: 6.0
CYP4F2		ENSG00000186115	Cytochrome P450 family 4 subfamily F member 2	19	15878023-15898120	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014048, HPA017265, HPA058960	Supported					Tissue enriched	Group enriched	6	duodenum: 78.2;epididymis: 28.0;kidney: 39.3;liver: 84.6;small intestine: 84.3	prostate: 10.4	Cell line enhanced		Hep G2: 2.5
CYP4F22	FLJ39501	ENSG00000171954	Cytochrome P450 family 4 subfamily F member 22	19	15508493-15552317	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA058960	Uncertain					Group enriched	Tissue enhanced		esophagus: 14.0;skin: 34.3	seminal vesicle: 9.1	Cell line enhanced		MCF7: 1.3
CYP4F8		ENSG00000186526	Cytochrome P450 family 4 subfamily F member 8	19	15615218-15630638	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058960	Approved					Group enriched	Tissue enriched	54	seminal vesicle: 147.7	breast: 2.7	Not detected		
CYP4V2	CYP4AH1	ENSG00000145476	Cytochrome P450 family 4 subfamily V member 2	4	186191520-186213456	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA029122	Approved		Approved	Nuclear speckles	Renal cancer:1.49e-7 (favourable), Liver cancer:1.85e-4 (favourable), Endometrial cancer:5.86e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 65.1	liver: 47.4	Cell line enhanced		SK-MEL-30: 19.3
CYP4X1	MGC40051	ENSG00000186377	Cytochrome P450 family 4 subfamily X member 1	1	47023568-47050751	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA017661	Approved					Mixed	Tissue enhanced		cervix, uterine: 52.7	breast: 18.7	Cell line enhanced		CACO-2: 3.6;NTERA-2: 2.0;SCLC-21H: 3.0;T-47d: 8.7
CYP4Z1	CYP4A20	ENSG00000186160	Cytochrome P450 family 4 subfamily Z member 1	1	47067488-47118319	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		breast: 6.9	lung: 1.5	Group enriched	43	HDLM-2: 8.5;SK-BR-3: 2.8
CYP51A1	CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1	ENSG00000001630	Cytochrome P450 family 51 subfamily A member 1	7	92112151-92142952	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041325, HPA043508	Enhanced		Enhanced	Endoplasmic reticulum	Cervical cancer:6.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 174.1	Expressed in all		
CYP7B1	SPG5A	ENSG00000172817	Cytochrome P450 family 7 subfamily B member 1	8	64587763-64798761	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA017761	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 40.3	thyroid gland: 22.4	Cell line enhanced		HSkMC: 11.3;SH-SY5Y: 6.2;WM-115: 11.7
CYP8B1	CYP12	ENSG00000180432	Cytochrome P450 family 8 subfamily B member 1	3	42856005-42876165	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	14	liver: 190.6	kidney: 13.7	Cell line enhanced		BEWO: 2.2
CYSLTR1	CysLT(1), CysLT1, CYSLT1R	ENSG00000173198	Cysteinyl leukotriene receptor 1	X	78271464-78327691	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010546	Approved					Mixed	Mixed			spleen: 14.8	Cell line enhanced		HL-60: 16.0;NB-4: 17.8;RPMI-8226: 29.5;THP-1: 17.5;U-937: 22.4
CYSLTR2	CysLT(2), CYSLT2R	ENSG00000152207	Cysteinyl leukotriene receptor 2	13	48653711-48711226	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046528	Uncertain					Group enriched	Tissue enhanced		placenta: 36.7;seminal vesicle: 25.0	spleen: 11.4	Cell line enriched	64	HDLM-2: 83.3
CYYR1	C21orf95	ENSG00000166265	Cysteine and tyrosine rich 1	21	26466209-26573284	Predicted membrane proteins	Evidence at transcript level	CAB034921, HPA067685	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			adrenal gland: 60.2	Cell line enhanced		AF22: 13.8;NTERA-2: 39.4;RH-30: 16.1;SCLC-21H: 39.7
DAD1	OST2	ENSG00000129562	Defender against cell death 1	14	22564905-22589269	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA028882	Uncertain		Approved	Cytosol	Liver cancer:7.73e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 516.1	Expressed in all		
DAG1	156DAG, A3a, AGRNR, DAG	ENSG00000173402	Dystroglycan 1	3	49468703-49535618	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB001960, CAB016353	Enhanced		Supported	Vesicles	Renal cancer:2.59e-4 (favourable)	Expressed in all	Expressed in all			placenta: 109.3	Expressed in all		
DAGLA	C11orf11, DAGLALPHA, KIAA0659, NSDDR	ENSG00000134780	Diacylglycerol lipase alpha	11	61680433-61747001	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA062497	Approved				Endometrial cancer:1.13e-7 (unfavourable)	Expressed in all	Tissue enriched	6	cerebral cortex: 18.6	colon,testis: 3.0	Mixed		
DAGLB	DAGLBETA, KCCR13L	ENSG00000164535	Diacylglycerol lipase beta	7	6409126-6484190	Predicted membrane proteins	Evidence at protein level	HPA069377			Supported	Plasma membrane	Ovarian cancer:7.18e-5 (unfavourable), Renal cancer:1.54e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 20.6	Expressed in all		
DAPK1	DAPK	ENSG00000196730	Death associated protein kinase 1	9	87497228-87708633	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	CAB037302, HPA040472, HPA048436	Approved		Approved	Centrosome	Colorectal cancer:2.48e-5 (unfavourable)	Expressed in all	Mixed			lung: 56.3	Cell line enhanced		HMC-1: 85.8
DAPK2	DRP-1, MGC119312	ENSG00000035664	Death associated protein kinase 2	15	63907036-64072033	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA071581			Supported	Golgi apparatus<br>Vesicles	Lung cancer:5.63e-4 (favourable)	Tissue enriched	Tissue enhanced		thyroid gland: 49.1	lung: 29.9	Cell line enhanced		HMC-1: 16.0
DAPK3	ZIP, ZIPK	ENSG00000167657	Death associated protein kinase 3	19	3958453-3971123	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028569, HPA064809	Approved		Approved	Nucleus	Endometrial cancer:2.01e-5 (favourable), Renal cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 76.3	Expressed in all		
DAPL1		ENSG00000163331	Death associated protein like 1	2	158795317-158862781	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046937, HPA058635	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Microtubules	Cervical cancer:8.43e-4 (favourable)	Group enriched	Tissue enhanced		epididymis: 238.2;esophagus: 243.7;skin: 219.0	fallopian tube: 128.4	Group enriched	5	HaCaT: 3.5;hTCEpi: 16.6;SCLC-21H: 6.9;U-87 MG: 8.2
DCAF17	C2orf37, FLJ13096	ENSG00000115827	DDB1 and CUL4 associated factor 17	2	171434217-171485052	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053339, HPA055040	Uncertain		Supported	Nucleoplasm	Thyroid cancer:7.10e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 17.1	Expressed in all		
DCAKD	FLJ22955	ENSG00000172992	Dephospho-CoA kinase domain containing	17	45023340-45061109	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060997			Approved	Nucleus	Endometrial cancer:7.16e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 47.1	Expressed in all		
DCBLD1	dJ94G16.1, MGC46341	ENSG00000164465	Discoidin, CUB and LCCL domain containing 1	6	117453817-117569858	Predicted membrane proteins	Evidence at protein level	HPA059667	Approved				Renal cancer:8.57e-8 (unfavourable), Cervical cancer:6.44e-5 (unfavourable)	Expressed in all	Mixed			gallbladder: 14.3	Mixed		
DCBLD2	CLCP1, ESDN	ENSG00000057019	Discoidin, CUB and LCCL domain containing 2	3	98795941-98901689	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016909	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:3.32e-5 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Stomach cancer:2.87e-4 (unfavourable)	Expressed in all	Mixed			testis: 44.9	Cell line enhanced		LHCN-M2: 647.4;U-87 MG: 568.7
DCC	IGDCC1, NTN1R1	ENSG00000187323	DCC netrin 1 receptor	18	52340172-53535903	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055376, HPA069552	Supported		Supported	Golgi apparatus		Tissue enhanced	Tissue enhanced		cerebral cortex: 3.7;testis: 13.5	lung: 2.2	Cell line enhanced		AF22: 36.0;U-266/70: 85.8;U-266/84: 39.7
DCHS1	CDH25, CDHR6, FIB1, FLJ11790, KIAA1773, PCDH16	ENSG00000166341	Dachsous cadherin-related 1	11	6621323-6655854	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA017970, HPA050246	Approved		Approved	Plasma membrane	Renal cancer:9.32e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 29.6	Cell line enhanced		AF22: 32.9;HUVEC TERT2: 39.1;REH: 21.3;SH-SY5Y: 34.2
DCHS2	CDH27, CDHJ, CDHR7, FLJ20047, PCDH23, PCDHJ	ENSG00000197410	Dachsous cadherin-related 2	4	154232037-154491716	Predicted membrane proteins	Evidence at protein level	HPA064159	Uncertain		Approved	Vesicles<br>Plasma membrane		Not detected	Tissue enhanced		endometrium: 1.9	testis: 1.7	Cell line enriched	6	U-2 OS: 9.2
DCLK1	DCAMKL1, DCDC3A, DCLK, KIAA0369	ENSG00000133083	Doublecortin like kinase 1	13	35768652-36131306	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB012405, HPA015040, HPA015655	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.42e-4 (unfavourable)	Tissue enhanced	Tissue enriched	5	cerebral cortex: 140.5	smooth muscle: 27.3	Cell line enhanced		ASC diff: 19.8;ASC TERT1: 19.0;fHDF/TERT166: 18.2;HAP1: 18.4;HSkMC: 18.4;NTERA-2: 36.7
DCLK3	DCAMKL3, DCDC3C, KIAA1765	ENSG00000163673	Doublecortin like kinase 3	3	36712422-36764349	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA040685	Approved					Tissue enhanced	Tissue enhanced		testis: 4.9	cerebral cortex: 1.1	Cell line enhanced		SCLC-21H: 1.0
DCP1B	FLJ31638	ENSG00000151065	Decapping mRNA 1B	12	1946054-2004535	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039709, HPA058778	Approved		Supported	Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 36.7	Mixed		
DCST1	FLJ32785	ENSG00000163357	DC-STAMP domain containing 1	1	155033824-155050930	Predicted membrane proteins	Evidence at protein level	HPA060314	Uncertain					Not detected	Group enriched	5	skin: 3.7;testis: 6.1	small intestine: 0.9	Cell line enhanced		HaCaT: 1.8;RPMI-8226: 1.7
DCST2	FLJ32934	ENSG00000163354	DC-STAMP domain containing 2	1	155018520-155033781	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		skin: 5.0;testis: 4.2	duodenum,fallopian tube: 1.3	Cell line enhanced		U-266/70: 1.1
DCSTAMP	DC-STAMP, FIND, TM7SF4	ENSG00000164935	Dendrocyte expressed seven transmembrane protein	8	104339087-104356689	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Group enriched	10	epididymis: 2.4;lung: 5.6	cerebral cortex,cervix, uterine,lymph node,urinary bladder: 0.3	Not detected		
DCT	TYRP2	ENSG00000080166	Dopachrome tautomerase	13	94436808-94479682	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA010743, HPA010800, CAB017634	Enhanced					Tissue enriched	Tissue enriched	31	skin: 126.8	breast: 4.0	Cell line enriched	177	SK-MEL-30: 202.8
DDO		ENSG00000203797	D-aspartate oxidase	6	110391771-110415562	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA037525, HPA037526	Enhanced		Supported	Cytosol	Renal cancer:8.69e-5 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 24.3	heart muscle: 12.2	Cell line enhanced		RPMI-8226: 10.9;U-937: 13.6
DDOST	KIAA0115, OST, OST48, WBP1	ENSG00000244038	Dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	1	20651767-20661544	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009746, HPA046841, HPA052867	Supported		Supported	Endoplasmic reticulum	Renal cancer:9.05e-7 (unfavourable), Liver cancer:2.64e-5 (unfavourable), Head and neck cancer:4.88e-4 (unfavourable), Endometrial cancer:5.99e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 308.3	Expressed in all		
DDR1	CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6	ENSG00000204580	Discoidin domain receptor tyrosine kinase 1	6	30876421-30900156	CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010162, CAB025656, HPA057194	Approved		Approved	Nucleoplasm<br>Cell Junctions	Renal cancer:3.31e-10 (favourable)	Expressed in all	Mixed			cerebral cortex: 51.6	Cell line enhanced		HaCaT: 80.3;RT4: 74.6;T-47d: 96.8
DDR2	NTRKR3, TKT, TYRO10	ENSG00000162733	Discoidin domain receptor tyrosine kinase 2	1	162631373-162787400	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA070112			Supported	Plasma membrane<br>Actin filaments	Renal cancer:1.73e-7 (unfavourable)	Expressed in all	Mixed			adrenal gland: 93.5	Cell line enhanced		ASC diff: 203.0;ASC TERT1: 203.2;BJ hTERT+: 181.9
DEGS1	DEGS-1, Des-1, DES1, FADS7, MLD	ENSG00000143753	Delta 4-desaturase, sphingolipid 1	1	224175756-224193441	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA076422			Supported	Mitochondria	Renal cancer:6.83e-7 (unfavourable), Liver cancer:4.29e-5 (unfavourable), Endometrial cancer:7.74e-5 (unfavourable), Urothelial cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 616.3	Expressed in all		
DEGS2	C14orf66, DES2, FADS8	ENSG00000168350	Delta 4-desaturase, sphingolipid 2	14	100143957-100160163	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046644			Approved	Nucleus<br>Nucleoli	Renal cancer:7.94e-7 (favourable), Urothelial cancer:1.66e-4 (favourable)	Mixed	Tissue enhanced		skin: 31.4;small intestine: 38.7	duodenum: 24.8	Cell line enriched	16	T-47d: 98.2
DENND1A	FAM31A, FLJ21129, KIAA1608	ENSG00000119522	DENN domain containing 1A	9	123379654-123930152	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020481			Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:4.11e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.8	Expressed in all		
DENND1B	C1orf218, FAM31B, FLJ20054, MGC27044	ENSG00000213047	DENN domain containing 1B	1	197504748-197775696	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042586	Uncertain		Supported	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 11.1	Mixed		
DENND3	KIAA0870	ENSG00000105339	DENN domain containing 3	8	141117278-141195808	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024491, HPA041668		Approved	Approved	Vesicles<br>Cytosol		Expressed in all	Mixed			bone marrow: 68.5	Cell line enhanced		HDLM-2: 60.7;HeLa: 52.8
DENND4B	KIAA0476	ENSG00000198837	DENN domain containing 4B	1	153929501-153946696	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040188, HPA071133	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:9.27e-9 (unfavourable), Pancreatic cancer:3.18e-5 (favourable), Liver cancer:4.14e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 40.2	Expressed in all		
DENND4C	bA513M16.3, C9orf55, C9orf55B, FLJ20686, RAB10GEF	ENSG00000137145	DENN domain containing 4C	9	19230435-19373545	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014917, HPA015096	Approved		Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Renal cancer:3.51e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.6	Expressed in all		
DENND5A	FLJ22354, FLJ33829, FLJ43455, KIAA1091, RAB6IP1	ENSG00000184014	DENN domain containing 5A	11	9138825-9265390	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052923, HPA055009	Uncertain		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.14e-6 (unfavourable), Liver cancer:5.05e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 126.7	Mixed		
DENND5B	MGC24039	ENSG00000170456	DENN domain containing 5B	12	31382223-31591097	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038865	Approved		Approved	Nucleoli<br>Microtubules		Expressed in all	Mixed			testis: 29.6	Mixed		
DERL1	DER-1, DER1, derlin-1, FLJ13784, MGC3067, PRO2577	ENSG00000136986	Derlin 1	8	123013164-123042423	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016562, CAB037269	Enhanced		Enhanced	Endoplasmic reticulum	Endometrial cancer:5.66e-5 (unfavourable), Renal cancer:1.58e-4 (unfavourable), Breast cancer:2.43e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 76.8	Expressed in all		
DERL2	CGI-101, derlin-2, F-LAN-1, F-LANa, FLANa	ENSG00000072849	Derlin 2	17	5471251-5486811	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037287, HPA048957, HPA056551	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:6.49e-4 (unfavourable), Endometrial cancer:7.26e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 41.4	Expressed in all		
DERL3	C22orf14, derlin-3, FLJ43842, IZP6, MGC71803	ENSG00000099958	Derlin 3	22	23834503-23839128	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037234, HPA049306	Uncertain		Uncertain	Vesicles	Renal cancer:7.76e-13 (unfavourable), Cervical cancer:8.70e-5 (favourable), Head and neck cancer:8.01e-4 (favourable)	Expressed in all	Mixed			stomach: 39.0	Group enriched	5	Karpas-707: 58.5;RPMI-8226: 33.7;U-266/70: 66.4;U-698: 14.5
DEUP1	CCDC67, FLJ25393	ENSG00000165325	Deuterosome assembly protein 1	11	93329971-93438487	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010986	Uncertain					Not detected	Group enriched	11	fallopian tube: 7.6;testis: 29.8	thyroid gland: 1.6	Not detected		
DEXI	MYLE	ENSG00000182108	Dexi homolog	16	10928891-10942460	Predicted membrane proteins	Evidence at transcript level	HPA041511	Approved		Approved	Nuclear speckles<br>Cytosol	Pancreatic cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 45.0	Expressed in all		
DGAT1	ARGP1, DGAT	ENSG00000185000	Diacylglycerol O-acyltransferase 1	8	144314584-144326910	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB032853	Enhanced		Approved	Nucleoli<br>Endoplasmic reticulum		Expressed in all	Tissue enhanced		duodenum: 71.3;small intestine: 75.1	adipose tissue: 20.0	Cell line enhanced		PC-3: 35.6
DGAT2		ENSG00000062282	Diacylglycerol O-acyltransferase 2	11	75759512-75801535	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:2.84e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 493.2;liver: 170.9	skin: 116.1	Cell line enhanced		ASC diff: 55.2;HDLM-2: 57.8
DGAT2L6	DC3, FLJ25989	ENSG00000184210	Diacylglycerol O-acyltransferase 2 like 6	X	70177483-70205545	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Group enriched	22	breast: 2.8;skin: 1.6	all non-specific tissues: 0.0	Not detected		
DGCR2	DGS-C, IDD, KIAA0163, LAN, SEZ-12	ENSG00000070413	DiGeorge syndrome critical region gene 2	22	19036282-19122454	Predicted membrane proteins	Evidence at protein level	HPA000873, HPA075929	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:8.72e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 57.9	Expressed in all		
DGKE	DAGK6, DGK	ENSG00000153933	Diacylglycerol kinase epsilon	17	56834099-56869567	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017167	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:3.92e-5 (favourable)	Mixed	Mixed			testis: 12.1	Cell line enhanced		Karpas-707: 61.4
DHCR24	DCE, KIAA0018, seladin-1	ENSG00000116133	24-dehydrocholesterol reductase	1	54849633-54887218	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017981, CAB037247, HPA063005	Approved				Endometrial cancer:1.05e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 1094.6	Mixed		
DHCR7	SLOS	ENSG00000172893	7-dehydrocholesterol reductase	11	71428193-71452868	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA044280	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:6.93e-7 (favourable), Urothelial cancer:5.67e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 115.2	Expressed in all		
DHODH		ENSG00000102967	Dihydroorotate dehydrogenase (quinone)	16	72008588-72027664	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010123, HPA011942	Approved		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Mixed			liver: 21.4	Expressed in all		
DHRS3	RDH17, retSDR1, Rsdr1, SDR1, SDR16C1	ENSG00000162496	Dehydrogenase/reductase 3	1	12567910-12617731	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010844	Supported		Approved	Nucleoli<br>Mitochondria	Thyroid cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 99.9	Cell line enhanced		CAPAN-2: 219.3;WM-115: 228.2
DHRS7B	CGI-93, DKFZp566O084, MGC8916, SDR32C1	ENSG00000109016	Dehydrogenase/reductase 7B	17	21123364-21193265	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012132, HPA016873	Uncertain		Approved	Plasma membrane<br>Cell Junctions<br>Cytosol	Endometrial cancer:1.98e-8 (favourable), Renal cancer:3.95e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 51.2	Expressed in all		
DHRS9	3alpha-HSD, RDH15, RDHL, RETSDR8, SDR9C4	ENSG00000073737	Dehydrogenase/reductase 9	2	169064789-169096167	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036491, HPA036667	Approved				Pancreatic cancer:2.73e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 66.5;rectum: 48.1	esophagus: 30.1	Cell line enhanced		NB-4: 21.6;THP-1: 66.4;TIME: 35.4;U-2197: 29.3
DHX36	DDX36, KIAA1488, MLEL1	ENSG00000174953	DEAH-box helicase 36	3	154272546-154324497	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035399	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 63.3	Expressed in all		
DIABLO	DFNA64, DIABLO-S, FLJ10537, FLJ25049, SMAC	ENSG00000184047	Diablo IAP-binding mitochondrial protein	12	122207662-122227534	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001825, CAB003857, CAB016688	Enhanced		Enhanced	Mitochondria	Renal cancer:5.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 94.9	Expressed in all		
DIO1	TXDI1	ENSG00000211452	Iodothyronine deiodinase 1	1	53891239-53911086	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Thyroid cancer:5.44e-4 (unfavourable)	Group enriched	Group enriched	30	kidney: 147.5;liver: 94.9;thyroid gland: 434.9	fallopian tube: 7.5	Group enriched	20	Hep G2: 23.0;SK-BR-3: 59.3
DIO2	SelY, TXDI2	ENSG00000211448	Iodothyronine deiodinase 2	14	80197527-80387757	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029544, HPA048002			Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:4.62e-6 (favourable), Colorectal cancer:1.67e-4 (favourable)	Tissue enhanced	Group enriched	6	cervix, uterine: 269.4;thyroid gland: 601.2	esophagus: 70.3	Cell line enhanced		BJ: 70.1;HeLa: 63.5;SiHa: 184.0
DIO3	TXDI3	ENSG00000197406	Iodothyronine deiodinase 3	14	101561351-101563452	Enzymes, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cervix, uterine: 27.8;placenta: 25.4	ovary: 6.2	Cell line enriched	37	AF22: 53.5
DIP2A	C21orf106, Dip2, KIAA0184	ENSG00000160305	Disco interacting protein 2 homolog A	21	46458899-46569852	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052516	Uncertain		Approved	Nucleus	Head and neck cancer:9.35e-5 (favourable)	Expressed in all	Expressed in all			testis: 13.9	Expressed in all		
DIP2C	KIAA0934	ENSG00000151240	Disco interacting protein 2 homolog C	10	274190-689668	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030264, HPA059325	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.46e-6 (favourable), Endometrial cancer:8.92e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 23.4	Cell line enhanced		U-2197: 30.9
DIRC2	FLJ14784, RCC4	ENSG00000138463	Disrupted in renal carcinoma 2	3	122794795-122881139	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA072579			Supported	Vesicles	Renal cancer:8.81e-11 (favourable), Pancreatic cancer:5.81e-5 (unfavourable), Liver cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 16.2	Mixed		
DISP1	DISPA, DKFZP434I0428, MGC13130, MGC16796	ENSG00000154309	Dispatched RND transporter family member 1	1	222872271-223005995	Predicted membrane proteins	Evidence at protein level	HPA051411	Uncertain		Approved	Nuclear bodies	Renal cancer:3.86e-5 (favourable), Thyroid cancer:4.16e-4 (favourable), Pancreatic cancer:5.00e-4 (favourable)	Expressed in all	Mixed			lung: 15.8	Cell line enhanced		RH-30: 15.5
DISP2	C15orf36, DISPB, HsT16908, KIAA1742, LINC00594	ENSG00000140323	Dispatched RND transporter family member 2	15	40358235-40378639	Predicted membrane proteins	Evidence at protein level	HPA059903	Uncertain		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		cerebral cortex: 7.4	thyroid gland: 1.8	Group enriched	5	HaCaT: 5.9;SCLC-21H: 15.8
DISP3	KIAA1337, PTCHD2	ENSG00000204624	Dispatched RND transporter family member 3	1	11479166-11537584	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA054579	Uncertain		Uncertain	Nucleoplasm<br>Cytosol		Tissue enhanced	Group enriched	14	cerebral cortex: 8.6;testis: 4.3	adrenal gland,prostate: 0.4	Cell line enhanced		AF22: 4.8;NTERA-2: 2.1;SCLC-21H: 2.3;SH-SY5Y: 7.2
DLK1	Delta1, FA1, pG2, Pref-1, ZOG	ENSG00000185559	Delta like non-canonical Notch ligand 1	14	100725705-100738224	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005872, HPA053879, HPA062262	Supported		Approved	Golgi apparatus	Endometrial cancer:2.31e-4 (unfavourable)	Tissue enhanced	Group enriched	20	adrenal gland: 1591.0;placenta: 2331.6	ovary: 100.3	Group enriched	6	AF22: 118.4;Hep G2: 282.9;SH-SY5Y: 501.8
DLK2	EGFL9, MGC2487	ENSG00000171462	Delta like non-canonical Notch ligand 2	6	43450352-43456632	Predicted membrane proteins	Evidence at transcript level	HPA061223, HPA068672	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		prostate: 9.3;skin: 14.5	seminal vesicle: 7.5	Cell line enhanced		HaCaT: 21.0;hTCEpi: 27.7
DLL1		ENSG00000198719	Delta like canonical Notch ligand 1	6	170282206-170306565	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA078298			Uncertain	Nucleoplasm		Expressed in all	Mixed			spleen: 20.0	Cell line enhanced		HaCaT: 7.0;HBEC3-KT: 8.8;NB-4: 13.1;THP-1: 11.4
DLL3	SCDO1	ENSG00000090932	Delta like canonical Notch ligand 3	19	39498895-39508481	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056533			Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.94e-4 (unfavourable)	Group enriched	Tissue enriched	49	cerebral cortex: 51.3	testis: 1.0	Group enriched	6	SCLC-21H: 16.1;SH-SY5Y: 14.9;SK-MEL-30: 62.1
DLL4		ENSG00000128917	Delta like canonical Notch ligand 4	15	40929340-40939072	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA023392	Uncertain				Cervical cancer:3.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 28.6	lung: 16.4	Group enriched	14	BJ hTERT+: 48.7;HUVEC TERT2: 13.2;SCLC-21H: 37.4
DMPK	DM, DM1, DM1PK, DMK, MDPK, MT-PK	ENSG00000104936	Dystrophia myotonica protein kinase	19	45769717-45782552	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007164, HPA008905	Enhanced		Approved	Vesicles<br>Cytosol	Pancreatic cancer:9.39e-5 (favourable)	Expressed in all	Expressed in all			smooth muscle: 97.3	Cell line enhanced		RH-30: 99.0
DMRT2		ENSG00000173253	Doublesex and mab-3 related transcription factor 2	9	1049858-1057552	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at transcript level	HPA029297	Uncertain					Tissue enhanced	Tissue enriched	7	parathyroid gland: 108.9	kidney: 16.2	Cell line enhanced		HaCaT: 3.3;RH-30: 4.8;RPMI-8226: 13.4;SCLC-21H: 3.4;SK-MEL-30: 4.0;WM-115: 3.5
DMXL2	KIAA0856, RC3	ENSG00000104093	Dmx like 2	15	51447711-51622833	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039375	Approved				Renal cancer:7.50e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 26.3	Cell line enhanced		U-937: 50.3
DNAH2	DNHD3, FLJ46675, KIAA1503	ENSG00000183914	Dynein axonemal heavy chain 2	17	7717354-7833744	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067103	Enhanced		Approved	Microtubules		Mixed	Group enriched	8	fallopian tube: 20.9;parathyroid gland: 28.4;testis: 10.9	placenta: 2.5	Cell line enhanced		A-431: 2.2;CACO-2: 3.2;CAPAN-2: 2.1;SCLC-21H: 2.7;SiHa: 2.4
DNAJB12	DJ10, FLJ20027	ENSG00000148719	DnaJ heat shock protein family (Hsp40) member B12	10	72332830-72355230	Predicted membrane proteins	Evidence at protein level	HPA010642	Approved		Supported	Endoplasmic reticulum	Colorectal cancer:4.79e-4 (unfavourable), Head and neck cancer:8.17e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 48.0	Expressed in all		
DNAJB14	FLJ14281	ENSG00000164031	DnaJ heat shock protein family (Hsp40) member B14	4	99896248-99946726	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036016	Approved				Renal cancer:2.12e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 34.7	Expressed in all		
DNAJC1	DNAJL1, ERdj1, MTJ1	ENSG00000136770	DnaJ heat shock protein family (Hsp40) member C1	10	21756537-22003769	Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA013432	Approved		Approved	Endoplasmic reticulum	Liver cancer:1.96e-5 (unfavourable), Renal cancer:2.33e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 57.8	Expressed in all		
DNAJC10	ERdj5, PDIA19	ENSG00000077232	DnaJ heat shock protein family (Hsp40) member C10	2	182716041-182794464	Predicted membrane proteins	Evidence at protein level	HPA031111	Approved				Renal cancer:2.19e-7 (unfavourable), Endometrial cancer:6.42e-5 (favourable), Thyroid cancer:7.27e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 154.9	Expressed in all		
DNAJC11	FLJ10737	ENSG00000007923	DnaJ heat shock protein family (Hsp40) member C11	1	6634168-6701924	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028705	Uncertain		Approved	Cytosol	Renal cancer:2.63e-5 (favourable)	Expressed in all	Expressed in all			kidney: 38.4	Expressed in all		
DNAJC13	KIAA0678, RME8	ENSG00000138246	DnaJ heat shock protein family (Hsp40) member C13	3	132417526-132539032	Predicted membrane proteins	Evidence at protein level	HPA036923, HPA036924	Approved		Supported	Vesicles<br>Cytosol	Liver cancer:7.49e-4 (unfavourable), Pancreatic cancer:8.36e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.9	Expressed in all		
DNAJC14	DNAJ, DRIP78, FLJ32792, HDJ3, LIP6	ENSG00000135392	DnaJ heat shock protein family (Hsp40) member C14	12	55820960-55830824	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017653	Approved					Expressed in all	Expressed in all			parathyroid gland: 49.4	Expressed in all		
DNAJC15	DNAJD1, MCJ	ENSG00000120675	DnaJ heat shock protein family (Hsp40) member C15	13	43023203-43114224	Disease related genes, Predicted membrane proteins	Evidence at protein level							Expressed in all	Mixed			cerebral cortex: 11.4	Mixed		
DNAJC16	KIAA0962	ENSG00000116138	DnaJ heat shock protein family (Hsp40) member C16	1	15526813-15592379	Predicted membrane proteins	Evidence at protein level	HPA043643	Approved		Approved	Vesicles	Colorectal cancer:6.77e-4 (favourable), Renal cancer:7.24e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 16.8	Expressed in all		
DNAJC18	MGC29463	ENSG00000170464	DnaJ heat shock protein family (Hsp40) member C18	5	139408588-139444491	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036538, HPA060154	Approved		Supported	Cell Junctions	Pancreatic cancer:5.89e-4 (favourable)	Mixed	Group enriched	5	cerebral cortex: 30.2;testis: 115.6	ovary: 13.8	Mixed		
DNAJC22	FLJ13236, wus	ENSG00000178401	DnaJ heat shock protein family (Hsp40) member C22	12	49346917-49357546	Predicted membrane proteins	Evidence at protein level	HPA039953			Approved	Vesicles	Endometrial cancer:4.56e-5 (favourable), Melanoma:7.54e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 17.9	Cell line enhanced		CACO-2: 24.1;EFO-21: 28.4;MCF7: 19.7;T-47d: 21.2
DNAJC25	bA16L21.2.1	ENSG00000059769	DnaJ heat shock protein family (Hsp40) member C25	9	111631352-111654351	Predicted membrane proteins	Evidence at protein level	HPA019122	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:3.73e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 16.7	parathyroid gland: 7.9	Mixed		
DNAJC30	WBSCR18	ENSG00000176410	DnaJ heat shock protein family (Hsp40) member C30	7	73680969-73683453	Predicted membrane proteins	Evidence at protein level	HPA017318	Uncertain	Supported			Renal cancer:4.91e-8 (favourable), Glioma:6.59e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 11.3	Expressed in all		
DNAJC4	HSPF2, MCG18	ENSG00000110011	DnaJ heat shock protein family (Hsp40) member C4	11	64230278-64234286	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011947	Uncertain				Colorectal cancer:3.12e-4 (unfavourable), Renal cancer:6.21e-4 (favourable)	Expressed in all	Expressed in all			testis: 136.6	Expressed in all		
DNAJC5	CLN4, DNAJC5A, FLJ00118, FLJ13070	ENSG00000101152	DnaJ heat shock protein family (Hsp40) member C5	20	63895182-63936031	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA012737, HPA013154	Approved		Uncertain	Golgi apparatus	Renal cancer:7.70e-6 (favourable), Liver cancer:8.82e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 73.6	Expressed in all		
DNAJC5B	CSP-beta, MGC26226	ENSG00000147570	DnaJ heat shock protein family (Hsp40) member C5 beta	8	66021560-66100526	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA077389			Approved	Vesicles		Mixed	Tissue enriched	13	testis: 114.3	lung: 9.1	Group enriched	6	HDLM-2: 17.3;RPTEC TERT1: 15.6;THP-1: 8.8;U-266/70: 8.7;U-937: 8.8
DNAJC5G	CSP-gamma, FLJ40417	ENSG00000163793	DnaJ heat shock protein family (Hsp40) member C5 gamma	2	27275421-27281499	Predicted membrane proteins	Evidence at transcript level	HPA041445	Approved					Not detected	Group enriched	41	epididymis: 65.0;testis: 42.7	cerebral cortex: 1.3	Cell line enhanced		HAP1: 1.0
DNER	bet, UNQ26	ENSG00000187957	Delta/notch like EGF repeat containing	2	229357629-229714558	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA017320	Approved				Liver cancer:1.05e-4 (unfavourable), Renal cancer:3.42e-4 (unfavourable)	Tissue enriched	Group enriched	7	adrenal gland: 74.6;cerebral cortex: 176.0	salivary gland: 17.3	Cell line enhanced		hTERT-HME1: 115.0;U-138 MG: 248.6;U-87 MG: 146.3
DNPEP	ASPEP, DAP	ENSG00000123992	Aspartyl aminopeptidase	2	219373546-219400022	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036398, HPA044860	Enhanced		Supported	Cytosol		Expressed in all	Expressed in all			testis: 65.4	Expressed in all		
DOK7	C4orf25, Dok-7, FLJ33718, FLJ39137	ENSG00000175920	Docking protein 7	4	3463311-3494483	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059449, HPA062780	Approved		Supported	Nucleoplasm<br>Mitochondria	Breast cancer:8.45e-5 (favourable), Urothelial cancer:1.28e-4 (favourable), Endometrial cancer:2.19e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 6.7;heart muscle: 11.1	skeletal muscle: 4.7	Cell line enhanced		MCF7: 27.3;RH-30: 6.5;T-47d: 7.4
DOLK	DK1, KIAA1094, TMEM15	ENSG00000175283	Dolichol kinase	9	128945530-128947619	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA066767, HPA068706			Supported	Nucleus<br>Nucleoli	Thyroid cancer:6.88e-5 (favourable), Renal cancer:5.53e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 24.7	Expressed in all		
DOLPP1	LSFR2	ENSG00000167130	Dolichyldiphosphatase 1	9	129081100-129090438	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA019179	Approved		Approved	Vesicles<br>Intermediate filaments		Expressed in all	Expressed in all			duodenum: 25.8	Expressed in all		
DONSON	B17, C21orf60, C2TA, DKFZP434M035	ENSG00000159147	Downstream neighbor of SON	21	33559542-33588708	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039558, HPA049033	Uncertain		Approved	Nucleoplasm<br>Cell Junctions<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Ovarian cancer:2.17e-4 (favourable), Liver cancer:8.22e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 40.3	parathyroid gland: 15.4	Expressed in all		
DOPEY1	dJ202D23.2, KIAA1117	ENSG00000083097	Dopey family member 1	6	83067666-83171350	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027902, HPA027904	Enhanced		Approved	Nucleus<br>Vesicles	Pancreatic cancer:7.36e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 25.5	Mixed		
DPAGT1	ALG7, CDG-Ij, D11S366, DGPT, DPAGT, DPAGT2, GPT	ENSG00000172269	Dolichyl-phosphate N-acetylglucosaminephosphotransferase 1	11	119096503-119108331	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA053878	Approved				Liver cancer:2.03e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 25.5	Expressed in all		
DPCR1	bCX105N19.6, PBLT	ENSG00000168631	Diffuse panbronchiolitis critical region 1	6	30934523-30954221	Predicted membrane proteins	Evidence at protein level	HPA014036	Enhanced				Pancreatic cancer:6.58e-4 (unfavourable)	Group enriched	Tissue enriched	12	stomach: 191.3	gallbladder: 16.0	Not detected		
DPEP2		ENSG00000167261	Dipeptidase 2	16	67987394-68000586	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035644	Approved				Testis cancer:8.47e-4 (unfavourable)	Mixed	Tissue enhanced		spleen: 38.7	lung: 27.9	Cell line enhanced		HEL: 3.7;HMC-1: 16.1;U-937: 4.9
DPM2	MGC111193, MGC21559	ENSG00000136908	Dolichyl-phosphate mannosyltransferase subunit 2, regulatory	9	127935099-127938484	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA064623	Approved				Endometrial cancer:2.20e-4 (favourable), Liver cancer:7.08e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube,stomach: 24.8	Expressed in all		
DPM3	MGC125904, MGC125905, MGC34275	ENSG00000179085	Dolichyl-phosphate mannosyltransferase subunit 3	1	155139891-155140595	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014667	Approved				Endometrial cancer:7.09e-5 (favourable), Ovarian cancer:8.97e-5 (favourable), Urothelial cancer:8.64e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 78.5	Expressed in all		
DPP10	DPL2, DPPY, DPRP3	ENSG00000175497	Dipeptidyl peptidase like 10	2	114442299-115845752	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048767	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol		Mixed	Group enriched	7	adrenal gland: 14.1;cerebral cortex: 34.7	pancreas: 3.6	Cell line enhanced		AF22: 4.1;HAP1: 6.4;HMC-1: 3.8;NTERA-2: 3.7;RT4: 5.3;SCLC-21H: 11.4;SH-SY5Y: 4.1
DPP4	ADCP2, CD26, DPPIV	ENSG00000197635	Dipeptidyl peptidase 4	2	161992241-162074542	CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB045970	Enhanced				Renal cancer:1.35e-6 (favourable), Prostate cancer:1.98e-4 (unfavourable), Thyroid cancer:4.99e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 550.6	placenta: 169.1	Cell line enhanced		ASC diff: 115.0;ASC TERT1: 118.1;BJ hTERT+: 131.1;RPTEC TERT1: 175.8
DPP6	DPL1, DPPX	ENSG00000130226	Dipeptidyl peptidase like 6	7	153887097-154894285	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050509	Enhanced	Supported				Tissue enriched	Tissue enhanced		cerebral cortex: 51.1;endometrium: 27.6	smooth muscle: 15.4	Cell line enriched	9	NTERA-2: 5.5
DPY19L1	KIAA0877	ENSG00000173852	Dpy-19 like 1	7	34928876-35038271	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059139	Uncertain		Approved	Vesicles	Pancreatic cancer:2.99e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 69.5	Mixed		
DPY19L2	FLJ32949, SPATA34	ENSG00000177990	Dpy-19 like 2	12	63558913-63668939	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA071264			Approved	Nucleus<br>Mitochondria		Mixed	Tissue enriched	8	testis: 112.0	parathyroid gland: 14.4	Mixed		
DPY19L3		ENSG00000178904	Dpy-19 like 3 (C. elegans)	19	32405543-32485895	Predicted membrane proteins	Evidence at protein level	HPA008325	Approved		Approved	Microtubules	Pancreatic cancer:1.70e-4 (favourable), Head and neck cancer:5.55e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 20.3	Expressed in all		
DPY19L4		ENSG00000156162	Dpy-19 like 4 (C. elegans)	8	94719703-94793836	Predicted membrane proteins	Evidence at protein level	HPA024780	Approved		Approved	Vesicles	Endometrial cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.9	Expressed in all		
DRAM1	DRAM, FLJ11259	ENSG00000136048	DNA damage regulated autophagy modulator 1	12	101877351-102012130	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:6.52e-8 (favourable), Renal cancer:3.91e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 130.5	Cell line enhanced		BJ hTERT+: 400.1
DRAM2	MGC54289, PRO180, RP5-1180E21.1, TMEM77, WWFQ154	ENSG00000156171	DNA damage regulated autophagy modulator 2	1	111117333-111140216	Predicted membrane proteins	Evidence at protein level	HPA018036, HPA061701	Enhanced		Enhanced	Golgi apparatus<br>Vesicles	Liver cancer:3.45e-5 (unfavourable), Melanoma:6.43e-4 (unfavourable), Renal cancer:7.45e-4 (unfavourable)	Expressed in all	Mixed			spleen: 19.3	Mixed		
DRD1		ENSG00000184845	Dopamine receptor D1	5	175440039-175444208	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013393		Supported				Mixed	Tissue enhanced		cerebral cortex: 8.0	prostate: 1.7	Group enriched	10	RT4: 20.9;U-2 OS: 5.4
DRD2		ENSG00000149295	Dopamine receptor D2	11	113409615-113475691	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015139, HPA015691	Supported	Supported				Mixed	Tissue enhanced		adrenal gland: 11.2	smooth muscle: 2.2	Cell line enriched	10	SCLC-21H: 104.3
DRD3		ENSG00000151577	Dopamine receptor D3	3	114128652-114199407	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	13	testis: 1.3	all non-specific tissues: 0.0	Not detected		
DRD4		ENSG00000069696	Dopamine receptor D4	11	637293-640706	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Not detected			skin: 0.3	Not detected		
DRD5	DRD1B, DRD1L2	ENSG00000169676	Dopamine receptor D5	4	9781680-9784009	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA048930	Supported					Not detected	Tissue enhanced		appendix: 1.7;cerebral cortex: 2.0;stomach: 3.8	testis: 0.8	Not detected		
DSC1	CDHF1	ENSG00000134765	Desmocollin 1	18	31129236-31162856	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA075379	Enhanced					Group enriched	Tissue enriched	15	skin: 273.0	heart muscle: 17.8	Not detected		
DSC2	CDHF2, DSC3	ENSG00000134755	Desmocollin 2	18	31058840-31102415	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA011911, HPA012615	Enhanced				Urothelial cancer:3.01e-4 (unfavourable), Lung cancer:5.80e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 186.7	parathyroid gland: 62.0	Cell line enhanced		BEWO: 36.6;CAPAN-2: 44.0;HaCaT: 63.9;hTCEpi: 55.4;SK-BR-3: 33.9
DSC3	CDHF3, DSC, DSC1, DSC2, DSC4	ENSG00000134762	Desmocollin 3	18	30990008-31042815	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB037328, HPA049265, HPA073937	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Urothelial cancer:1.04e-5 (unfavourable)	Tissue enhanced	Group enriched	12	esophagus: 119.1;skin: 454.8	tonsil: 24.8	Cell line enhanced		HaCaT: 242.4;hTCEpi: 115.0;hTERT-HME1: 89.5
DSCAM	CHD2-42, CHD2-52	ENSG00000171587	DS cell adhesion molecule	21	40010999-40847139	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA019324	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	11	cerebral cortex: 12.4	placenta,spleen: 1.0	Cell line enhanced		HBEC3-KT: 2.6;MCF7: 6.2;NTERA-2: 2.2;SCLC-21H: 3.9;T-47d: 2.0
DSCAML1	KIAA1132	ENSG00000177103	DS cell adhesion molecule like 1	11	117427773-117817525	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035230	Uncertain				Renal cancer:8.37e-4 (favourable)	Group enriched	Tissue enhanced		cerebral cortex: 12.1	ovary: 4.4	Cell line enhanced		EFO-21: 6.2;RPTEC TERT1: 3.7;T-47d: 8.5
DSE	DSEPI, SART2	ENSG00000111817	Dermatan sulfate epimerase	6	116254173-116444860	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014764, HPA052151	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.50e-4 (unfavourable), Cervical cancer:3.36e-4 (unfavourable), Ovarian cancer:6.34e-4 (unfavourable)	Mixed	Mixed			appendix: 36.2	Mixed		
DSEL	C18orf4, FLJ11477, NCAG1	ENSG00000171451	Dermatan sulfate epimerase-like	18	67506582-67516980	Predicted membrane proteins	Evidence at protein level	HPA060942			Approved	Nucleoplasm<br>Plasma membrane		Tissue enhanced	Mixed			cerebral cortex: 5.2	Cell line enhanced		BJ: 31.6;LHCN-M2: 38.7;U-138 MG: 46.6
DSG1	CDHF4, DSG	ENSG00000134760	Desmoglein 1	18	31318089-31357029	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009394, HPA022128	Enhanced				Urothelial cancer:2.99e-4 (unfavourable)	Group enriched	Tissue enriched	20	skin: 725.7	esophagus: 36.4	Cell line enriched	17	hTCEpi: 6.6
DSG2	CDHF5	ENSG00000046604	Desmoglein 2	18	31498043-31549008	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004896, CAB025122	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Renal cancer:3.14e-10 (favourable), Pancreatic cancer:4.94e-5 (unfavourable), Lung cancer:2.43e-4 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable), Colorectal cancer:7.81e-4 (favourable), Cervical cancer:8.22e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 251.3	rectum: 106.9	Cell line enhanced		HaCaT: 233.0;hTERT-HME1: 159.3
DSG3	CDHF6	ENSG00000134757	Desmoglein 3	18	31447795-31478702	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA046864, HPA056863, CAB069880	Enhanced				Pancreatic cancer:1.43e-5 (unfavourable), Urothelial cancer:9.90e-4 (unfavourable)	Group enriched	Tissue enriched	5	esophagus: 349.5	tonsil: 66.0	Group enriched	7	HaCaT: 182.7;hTCEpi: 362.3
DSG4	CDHF13, LAH	ENSG00000175065	Desmoglein 4	18	31376777-31414912	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA059456	Supported					Not detected	Not detected			testis: 0.8	Cell line enriched	157	HaCaT: 37.3
DTNA	D18S892E, DRP3, DTN, DTN-1, DTN-2, DTN-3	ENSG00000134769	Dystrobrevin alpha	18	34493290-34891844	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB015196, HPA071177	Enhanced		Approved	Nucleoplasm<br>Cell Junctions<br>Intermediate filaments	Renal cancer:2.64e-7 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 197.2	heart muscle: 101.8	Cell line enhanced		NTERA-2: 42.7;SCLC-21H: 70.5;U-87 MG: 59.2
DUOX1	LNOX1, NOXEF1, THOX1	ENSG00000137857	Dual oxidase 1	15	45129933-45165576	Enzymes, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA023544	Approved				Cervical cancer:4.31e-6 (favourable)	Tissue enhanced	Tissue enhanced		skin: 96.9;thyroid gland: 92.6	esophagus: 73.2	Cell line enhanced		HaCaT: 56.9;hTCEpi: 22.1;RT4: 29.0
DUOX2	LNOX2, P138-TOX, P138(TOX), THOX2	ENSG00000140279	Dual oxidase 2	15	45092650-45114344	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enhanced		gallbladder: 446.7;thyroid gland: 124.8	urinary bladder: 87.1	Cell line enriched	8	HaCaT: 5.5
DUOXA1	FLJ32334, mol, NIP, NUMBIP	ENSG00000140254	Dual oxidase maturation factor 1	15	45117367-45129938	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041578	Approved					Tissue enhanced	Tissue enhanced		esophagus: 122.2;skin: 107.9;thyroid gland: 112.0	epididymis: 60.3	Cell line enriched	9	HaCaT: 92.0
DUOXA2		ENSG00000140274	Dual oxidase maturation factor 2	15	45114321-45118421	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA063548	Enhanced					Group enriched	Tissue enhanced		gallbladder: 97.3;urinary bladder: 24.7	thyroid gland: 13.6	Cell line enhanced		U-2 OS: 1.0
DUSP13	BEDP, DUSP13A, DUSP13B, FLJ32450, TMDP	ENSG00000079393	Dual specificity phosphatase 13	10	75094432-75109221	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	6	skeletal muscle: 84.9;testis: 47.5	heart muscle: 10.9	Cell line enhanced		BEWO: 4.2;EFO-21: 4.7;Hep G2: 7.4;K-562: 3.8;LHCN-M2: 7.9;RH-30: 7.7
DYM	DMC, FLJ20071, SMC	ENSG00000141627	Dymeclin	18	49041474-49461347	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043551, HPA049187	Approved		Supported	Golgi apparatus	Renal cancer:2.76e-5 (favourable), Urothelial cancer:5.26e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 80.2	Expressed in all		
DYNAP	C18orf26, FLJ39106	ENSG00000178690	Dynactin associated protein	18	54587757-54599493	Predicted membrane proteins	Evidence at protein level	HPA011148	Uncertain					Tissue enhanced	Tissue enriched	7	esophagus: 32.1	spleen: 4.3	Cell line enhanced		Karpas-707: 8.9
DYRK2		ENSG00000127334	Dual specificity tyrosine phosphorylation regulated kinase 2	12	67648338-67665406	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027230, HPA056902	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			small intestine: 31.0	Expressed in all		
DYSF	FER1L1, LGMD2B	ENSG00000135636	Dysferlin	2	71453722-71686768	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002510, HPA017071, HPA021945	Enhanced		Supported	Plasma membrane<br>Microtubule organizing center		Expressed in all	Mixed			skeletal muscle: 32.8	Group enriched	6	HUVEC TERT2: 69.0;LHCN-M2: 62.5;RH-30: 75.9;TIME: 44.6
DZIP3	hRUL138, PPP1R66	ENSG00000198919	DAZ interacting zinc finger protein 3	3	108589682-108694846	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035066, HPA049232	Approved		Approved	Vesicles	Renal cancer:3.65e-4 (favourable)	Expressed in all	Expressed in all			testis: 65.7	Mixed		
E2F5		ENSG00000133740	E2F transcription factor 5	8	85177225-85217158	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA055723			Supported	Nucleus<br>Nucleoli	Renal cancer:1.89e-6 (unfavourable)	Expressed in all	Mixed			lymph node: 30.9	Cell line enhanced		AF22: 76.4;Daudi: 112.8
EBLN1		ENSG00000223601	Endogenous Bornavirus-like nucleoprotein 1	10	22208814-22210021	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	43	testis: 4.2	all non-specific tissues: 0.0	Not detected		
EBP	CDPX2, CHO2, CPX, CPXD	ENSG00000147155	Emopamil binding protein (sterol isomerase)	X	48521158-48528716	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA003130	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			liver: 91.3	Expressed in all		
EBPL	EBRP	ENSG00000123179	Emopamil binding protein like	13	49660723-49691475	Predicted membrane proteins	Evidence at protein level	HPA049891	Approved		Supported	Endoplasmic reticulum	Renal cancer:7.18e-8 (unfavourable), Ovarian cancer:1.38e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 61.5	Expressed in all		
ECE1	ECE	ENSG00000117298	Endothelin converting enzyme 1	1	21217247-21345504	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001490, HPA013616	Approved					Expressed in all	Expressed in all			parathyroid gland: 436.1	Expressed in all		
ECE2	KIAA0604, MGC2408	ENSG00000145194	Endothelin converting enzyme 2	3	184249650-184293031	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043346, HPA062215	Enhanced		Approved	Nucleus<br>Cytosol	Endometrial cancer:8.41e-5 (unfavourable), Liver cancer:5.80e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 15.4	Expressed in all		
ECEL1	DINE, XCE	ENSG00000171551	Endothelin converting enzyme like 1	2	232479827-232487828	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067560, HPA069756		Supported	Approved	Nucleoplasm<br>Nuclear membrane<br>Nucleoli		Tissue enhanced	Tissue enriched	25	ovary: 111.9	spleen: 4.4	Group enriched	7	AN3-CA: 40.8;HeLa: 15.2
ECSCR	ARIA, ECSM2	ENSG00000249751	Endothelial cell surface expressed chemotaxis and apoptosis regulator	5	139448556-139462743	Predicted membrane proteins	Evidence at protein level	HPA063337			Enhanced	Nucleoplasm<br>Vesicles<br>Plasma membrane		Expressed in all	Mixed			placenta: 96.7	Group enriched	104	EFO-21: 322.5;HUVEC TERT2: 736.2;TIME: 536.3
EDA	ED1, ED1-A1, ED1-A2, EDA-A1, EDA-A2, EDA1, EDA2, HED, ODT1, XHED, XLHED	ENSG00000158813	Ectodysplasin A	X	69616067-70039469	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037972, HPA037973			Supported	Vesicles<br>Lipid droplets	Renal cancer:1.04e-9 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 19.4	thyroid gland: 10.0	Cell line enhanced		EFO-21: 5.0;Hep G2: 12.2
EDA2R	EDA-A2R, EDAA2R, TNFRSF27, XEDAR	ENSG00000131080	Ectodysplasin A2 receptor	X	66595637-66639298	Predicted membrane proteins	Evidence at protein level	HPA054522			Approved	Cell Junctions		Mixed	Mixed			thyroid gland: 9.5	Cell line enhanced		HSkMC: 24.5;LHCN-M2: 26.7
EDAR	DL, ED1R, ED3, ED5, EDA1R, EDA3, Edar	ENSG00000135960	Ectodysplasin A receptor	2	108894471-108989372	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA042292	Approved					Mixed	Mixed			esophagus: 2.8	Group enriched	7	CAPAN-2: 4.0;HaCaT: 8.7
EDNRA		ENSG00000151617	Endothelin receptor type A	4	147480917-147544954	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013774, CAB018957	Uncertain				Renal cancer:1.50e-7 (unfavourable), Stomach cancer:3.93e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 146.8	cervix, uterine: 83.0	Cell line enhanced		ASC TERT1: 11.8;LHCN-M2: 17.3;SH-SY5Y: 16.4
EDNRB	ETB, HSCR, HSCR2	ENSG00000136160	Endothelin receptor type B	13	77895481-77919768	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB017842, HPA027546	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.20e-5 (favourable)	Group enriched	Tissue enhanced		placenta: 180.2	cerebral cortex: 88.8	Cell line enhanced		AF22: 59.4;ASC diff: 35.4;SK-MEL-30: 42.0;U-266/70: 29.1;WM-115: 122.9
EDRF1	C10orf137, DKFZp586F1019, FLJ21617	ENSG00000107938	Erythroid differentiation regulatory factor 1	10	125719515-125764143	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031820			Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:3.16e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 28.2	Expressed in all		
EEF1E1	AIMP3, P18	ENSG00000124802	Eukaryotic translation elongation factor 1 epsilon 1	6	8073360-8102578	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027901, HPA057866	Approved		Supported	Nucleus<br>Cytosol	Liver cancer:1.55e-7 (unfavourable), Cervical cancer:3.16e-4 (favourable), Ovarian cancer:3.24e-4 (favourable)	Expressed in all	Expressed in all			testis: 101.7	Expressed in all		
EFCAB14	KIAA0494	ENSG00000159658	EF-hand calcium binding domain 14	1	46675159-46719064	Predicted membrane proteins	Evidence at protein level	HPA011224, HPA011938	Supported		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 305.3	Expressed in all		
EFNA3	Ehk1-L, EPLG3, LERK3	ENSG00000143590	Ephrin A3	1	155078872-155087538	Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB010494	Uncertain				Renal cancer:9.66e-10 (unfavourable), Liver cancer:2.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 51.3	cerebral cortex: 17.0	Cell line enhanced		HAP1: 19.5;SCLC-21H: 32.5;T-47d: 24.4
EFNA4	EPLG4, LERK4	ENSG00000243364	Ephrin A4	1	155063731-155069553	Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB021350, HPA064952	Approved		Uncertain	Nucleus<br>Vesicles	Liver cancer:1.00e-5 (unfavourable), Stomach cancer:3.60e-5 (favourable), Renal cancer:3.14e-4 (unfavourable)	Expressed in all	Mixed			skin: 24.5	Expressed in all		
EFNA5	AF1, EPLG7, LERK7	ENSG00000184349	Ephrin A5	5	107376889-107670895	Cancer-related genes, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB013282, HPA054047	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.92e-7 (unfavourable), Stomach cancer:3.77e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 17.1	Cell line enhanced		RPTEC TERT1: 43.4
EFNB1	CFNS, Elk-L, EPLG2, LERK2	ENSG00000090776	Ephrin B1	X	68828997-68842147	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB031489, HPA067188	Uncertain		Supported	Plasma membrane	Endometrial cancer:3.32e-5 (unfavourable), Pancreatic cancer:4.29e-4 (unfavourable), Melanoma:8.68e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 37.8	Mixed		
EFNB2	EPLG5, Htk-L, HTKL, LERK5, MGC126226, MGC126227, MGC126228	ENSG00000125266	Ephrin B2	13	106489731-106535114	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008999, CAB009368	Supported		Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:3.11e-6 (unfavourable), Pancreatic cancer:8.70e-5 (unfavourable), Lung cancer:8.43e-4 (unfavourable)	Expressed in all	Mixed			placenta: 48.4	Cell line enhanced		AF22: 180.7;SH-SY5Y: 87.9
EFNB3	EPLG8, LERK-8	ENSG00000108947	Ephrin B3	17	7705202-7711378	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA001623	Approved		Approved	Nucleoplasm	Endometrial cancer:5.52e-4 (unfavourable), Pancreatic cancer:8.21e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 48.7	endometrium: 17.4	Cell line enhanced		AF22: 53.1;AN3-CA: 29.8;SH-SY5Y: 29.8
EGF		ENSG00000138798	Epidermal growth factor	4	109912884-110012266	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level							Mixed	Tissue enriched	7	kidney: 122.1	pancreas: 18.5	Cell line enhanced		EFO-21: 5.9;SK-BR-3: 8.5;U-251 MG: 3.0
EGFR	ERBB, ERBB1	ENSG00000146648	Epidermal growth factor receptor	7	55019021-55211628	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000035, HPA001200, HPA018530, CAB068186, CAB073534	Enhanced		Enhanced	Plasma membrane	Urothelial cancer:2.04e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 100.0	skin: 58.7	Cell line enriched	15	A-431: 4682.9
EI24	EPG4, PIG8, TP53I8	ENSG00000149547	EI24, autophagy associated transmembrane protein	11	125569216-125584687	Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047165, HPA051029	Approved		Supported	Endoplasmic reticulum<br>Golgi apparatus<br>Cytosol	Pancreatic cancer:9.28e-4 (unfavourable)	Expressed in all	Tissue enriched	9	parathyroid gland: 1120.1	liver: 125.1	Expressed in all		
EIF2AK3	PEK, PERK	ENSG00000172071	Eukaryotic translation initiation factor 2 alpha kinase 3	2	88556741-88627576	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB009204, HPA015737	Enhanced					Expressed in all	Mixed			parathyroid gland: 37.3	Expressed in all		
EIF3L	EIF3EIP, EIF3S11, EIF3S6IP, HSPC021, HSPC025	ENSG00000100129	Eukaryotic translation initiation factor 3 subunit L	22	37848868-37889407	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003028	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:6.11e-4 (favourable)	Expressed in all	Expressed in all			breast: 179.8	Expressed in all		
ELFN1	PPP1R28	ENSG00000225968	Extracellular leucine rich repeat and fibronectin type III domain containing 1	7	1688119-1747954	Predicted membrane proteins	Evidence at protein level	HPA066382			Approved	Nucleoplasm<br>Cell Junctions	Liver cancer:9.68e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 3.5;liver: 3.7	endometrium: 1.7	Cell line enhanced		REH: 28.4;U-138 MG: 18.3;U-2 OS: 28.4;U-2197: 29.8
ELFN2	dJ63G5.3, KIAA1904, LRRC62, PPP1R29	ENSG00000166897	Extracellular leucine rich repeat and fibronectin type III domain containing 2	22	37367960-37427470	Predicted membrane proteins	Evidence at protein level	HPA000781	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:7.21e-4 (unfavourable)	Mixed	Tissue enriched	7	cerebral cortex: 24.3	testis: 3.4	Cell line enhanced		RPTEC TERT1: 16.3;U-2 OS: 25.4
ELMOD1	DKFZp547C176	ENSG00000110675	ELMO domain containing 1	11	107591091-107666779	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038434, HPA038435			Supported	Nucleoplasm<br>Cytosol		Tissue enriched	Group enriched	15	cerebral cortex: 71.3;skin: 36.7	adrenal gland,fallopian tube: 3.5	Cell line enhanced		HUVEC TERT2: 12.8;RH-30: 33.5
ELOVL1	Ssc1	ENSG00000066322	ELOVL fatty acid elongase 1	1	43363397-43368074	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB033426, HPA056557	Approved		Approved	Endoplasmic reticulum	Liver cancer:2.79e-7 (unfavourable), Cervical cancer:3.63e-5 (unfavourable), Pancreatic cancer:8.51e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 156.7	Expressed in all		
ELOVL2	Ssc2	ENSG00000197977	ELOVL fatty acid elongase 2	6	10980759-11044314	Enzymes, Predicted membrane proteins	Evidence at protein level						Breast cancer:6.73e-5 (favourable)	Group enriched	Tissue enhanced		liver: 27.6;parathyroid gland: 36.7;placenta: 50.2	cerebral cortex: 22.8	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 29.1;HBF TERT88: 28.0;RH-30: 30.7
ELOVL3	CIG-30	ENSG00000119915	ELOVL fatty acid elongase 3	10	102226328-102229589	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA036236	Supported		Approved	Vesicles<br>Cytosol	Endometrial cancer:6.25e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 3.6;breast: 4.4;skin: 3.4	testis: 2.3	Cell line enhanced		HSkMC: 10.4;SiHa: 24.5
ELOVL4	CT118, SCA34, STGD2, STGD3	ENSG00000118402	ELOVL fatty acid elongase 4	6	79914812-79947580	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Urothelial cancer:6.27e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 24.0;skin: 50.7	parathyroid gland: 15.7	Cell line enhanced		MOLT-4: 25.9
ELOVL5	dJ483K16.1, HELO1, SCA38	ENSG00000012660	ELOVL fatty acid elongase 5	6	53267398-53349179	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017042, HPA047752, HPA054197	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:1.94e-6 (unfavourable), Thyroid cancer:6.80e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 257.0	Expressed in all		
ELOVL6	FLJ23378, LCE, MGC5487	ENSG00000170522	ELOVL fatty acid elongase 6	4	110045846-110199199	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA042355	Uncertain				Colorectal cancer:6.74e-4 (favourable)	Expressed in all	Mixed			liver: 27.9	Mixed		
ELOVL7	FLJ23563	ENSG00000164181	ELOVL fatty acid elongase 7	5	60751791-60844389	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA036337	Approved				Renal cancer:1.54e-9 (favourable), Endometrial cancer:3.87e-5 (unfavourable)	Expressed in all	Mixed			prostate: 35.8	Cell line enhanced		HEL: 33.1
ELP6	C3orf75, FLJ20211, TMEM103	ENSG00000163832	Elongator acetyltransferase complex subunit 6	3	47495640-47513761	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046358, HPA064545	Uncertain		Approved	Nucleus<br>Centrosome<br>Cytosol	Renal cancer:3.42e-6 (favourable)	Expressed in all	Expressed in all			testis: 32.0	Expressed in all		
EMB	MGC71745	ENSG00000170571	Embigin	5	50396192-50443248	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:2.76e-5 (unfavourable)	Expressed in all	Mixed			bone marrow: 94.7	Cell line enhanced		THP-1: 182.2
EMC1	KIAA0090	ENSG00000127463	ER membrane protein complex subunit 1	1	19215664-19251552	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048904	Approved		Approved	Microtubules<br>Cytokinetic bridge	Liver cancer:8.56e-6 (unfavourable), Urothelial cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 34.4	Expressed in all		
EMC10	C19orf63, HSM1, HSS1, INM02	ENSG00000161671	ER membrane protein complex subunit 10	19	50476400-50490870	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053905	Uncertain				Renal cancer:6.64e-6 (favourable), Pancreatic cancer:4.39e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 63.8	Cell line enhanced		HEK93: 176.7
EMC3	TMEM111	ENSG00000125037	ER membrane protein complex subunit 3	3	9962537-10011116	Predicted membrane proteins	Evidence at protein level	HPA042372	Approved		Approved	Microtubules<br>Cytosol	Renal cancer:2.81e-6 (favourable)	Expressed in all	Expressed in all			testis: 90.8	Expressed in all		
EMC4	FLJ90746, MGC24415, PIG17, TMEM85	ENSG00000128463	ER membrane protein complex subunit 4	15	34224999-34230156	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026868, HPA053440	Approved		Approved	Cell Junctions<br>Focal adhesion sites		Expressed in all	Expressed in all			epididymis: 122.1	Expressed in all		
EMC6	MGC2963, TMEM93	ENSG00000127774	ER membrane protein complex subunit 6	17	3668815-3669668	Predicted membrane proteins	Evidence at protein level	HPA062681	Uncertain		Approved	Nucleus<br>Centrosome	Lung cancer:9.39e-5 (unfavourable), Cervical cancer:7.73e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 49.2	Expressed in all		
EMC7	C11orf3, C15orf24	ENSG00000134153	ER membrane protein complex subunit 7	15	34084017-34101948	Predicted membrane proteins	Evidence at protein level	HPA010029, HPA047572	Approved		Approved	Nucleoplasm	Endometrial cancer:4.68e-5 (favourable), Head and neck cancer:9.25e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 129.8	Expressed in all		
EMCN	MUC14	ENSG00000164035	Endomucin	4	100395341-100880126	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005928	Approved				Liver cancer:1.03e-4 (favourable), Renal cancer:2.25e-4 (favourable)	Expressed in all	Mixed			kidney: 83.7	Cell line enriched	6	HUVEC TERT2: 25.7
EMD	LEMD5, STA	ENSG00000102119	Emerin	X	154379197-154381523	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA000609, CAB001545, CAB002029, CAB062552	Enhanced		Enhanced	Nuclear membrane<br>Endoplasmic reticulum		Expressed in all	Expressed in all			fallopian tube: 32.7	Expressed in all		
EMP1	CL-20, TMP	ENSG00000134531	Epithelial membrane protein 1	12	13196716-13219939	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051931, HPA056250			Approved	Nucleoplasm	Ovarian cancer:2.26e-8 (unfavourable), Urothelial cancer:9.69e-8 (unfavourable), Pancreatic cancer:7.46e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 2199.3	Cell line enhanced		ASC TERT1: 819.4
EMP2	XMP	ENSG00000213853	Epithelial membrane protein 2	16	10528422-10580698	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014711	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.85e-8 (unfavourable), Glioma:1.93e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 343.9	skin: 166.6	Cell line enhanced		MCF7: 205.4;SK-BR-3: 191.4
EMP3	YMP	ENSG00000142227	Epithelial membrane protein 3	19	48321509-48330553	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.31e-7 (unfavourable), Stomach cancer:3.13e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 200.5	Mixed		
ENDOD1	KIAA0830	ENSG00000149218	Endonuclease domain containing 1	11	95089810-95132645	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008932, HPA010517	Enhanced		Approved	Nuclear membrane	Renal cancer:6.64e-7 (favourable), Urothelial cancer:3.27e-4 (unfavourable), Pancreatic cancer:8.86e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 99.6	Cell line enhanced		ASC diff: 132.3
ENG	CD105, END, HHT1, ORW, ORW1	ENSG00000106991	Endoglin	9	127815012-127854756	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB000096, HPA011862, HPA067440, CAB072873	Enhanced				Liver cancer:5.62e-6 (favourable), Renal cancer:4.26e-4 (unfavourable), Head and neck cancer:6.61e-4 (favourable)	Expressed in all	Expressed in all			spleen: 167.6	Cell line enhanced		HUVEC TERT2: 402.6;TIME: 810.4
ENPEP	CD249, gp160	ENSG00000138792	Glutamyl aminopeptidase	4	110365733-110565285	CD markers, Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA002821, HPA005128	Enhanced		Approved	Endoplasmic reticulum		Tissue enriched	Group enriched	5	duodenum: 36.5;kidney: 94.3;parathyroid gland: 160.7;small intestine: 180.3	placenta: 21.5	Cell line enhanced		BEWO: 2.6;HEK93: 6.8;MOLT-4: 1.4
ENPP1	M6S1, NPPS, PC-1, PCA1, PDNP1	ENSG00000197594	Ectonucleotide pyrophosphatase/phosphodiesterase 1	6	131808016-131895155	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB032904, HPA062066	Enhanced					Expressed in all	Tissue enhanced		parathyroid gland: 54.3;placenta: 62.9	thyroid gland: 34.1	Cell line enhanced		ASC diff: 23.4;U-138 MG: 27.3
ENPP2	ATX, PD-IALPHA, PDNP2	ENSG00000136960	Ectonucleotide pyrophosphatase/phosphodiesterase 2	8	119557086-119673453	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023700, HPA053652	Approved		Approved	Nucleus<br>Golgi apparatus<br>Actin filaments	Pancreatic cancer:2.07e-5 (favourable)	Expressed in all	Expressed in all			placenta: 376.2	Cell line enhanced		ASC TERT1: 231.1;BJ hTERT+: 160.8
ENPP4	KIAA0879, NPP4	ENSG00000001561	Ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative)	6	46129993-46146699	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA016594	Approved				Renal cancer:6.95e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.4	Cell line enhanced		SCLC-21H: 21.1
ENPP5		ENSG00000112796	Ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative)	6	46159187-46170971	Predicted membrane proteins	Evidence at protein level	HPA016902	Enhanced				Renal cancer:4.44e-13 (favourable), Pancreatic cancer:4.04e-4 (favourable), Lung cancer:4.57e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 296.6	thyroid gland: 85.6	Cell line enhanced		CAPAN-2: 9.8;SCLC-21H: 5.6;T-47d: 8.1;U-266/84: 5.5
ENTPD1	ATPDase, CD39, NTPDase-1, SPG64	ENSG00000138185	Ectonucleoside triphosphate diphosphohydrolase 1	10	95711779-95869695	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB002494, HPA014067	Enhanced		Uncertain	Microtubules	Renal cancer:5.33e-5 (unfavourable), Thyroid cancer:7.89e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 98.8	Group enriched	7	HDLM-2: 179.7;Karpas-707: 112.9
ENTPD2	CD39L1, NTPDase-2	ENSG00000054179	Ectonucleoside triphosphate diphosphohydrolase 2	9	137048098-137054045	Predicted membrane proteins	Evidence at protein level	HPA017676	Approved				Renal cancer:3.51e-6 (favourable), Liver cancer:2.48e-5 (unfavourable), Stomach cancer:1.38e-4 (favourable)	Expressed in all	Mixed			duodenum: 12.2	Cell line enhanced		Hep G2: 16.3;hTCEpi: 9.2;MCF7: 12.8;SK-BR-3: 16.1;T-47d: 22.0
ENTPD3	CD39L3, HB6, NTPDase-3	ENSG00000168032	Ectonucleoside triphosphate diphosphohydrolase 3	3	40387156-40428619	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA071802			Approved	Cytosol		Mixed	Tissue enhanced		cervix, uterine: 33.6	urinary bladder: 14.7	Cell line enhanced		HBEC3-KT: 9.3;hTCEpi: 6.3;RT4: 15.1
ENTPD4	KIAA0392, LALP70, LAP70, LYSAL1, NTPDase-4, UDPase	ENSG00000197217	Ectonucleoside triphosphate diphosphohydrolase 4	8	23385783-23457695	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017655	Supported		Supported	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 47.3	Expressed in all		
ENTPD6	CD39L2, dJ738P15.3, IL6ST2, NTPDase-6	ENSG00000197586	Ectonucleoside triphosphate diphosphohydrolase 6 (putative)	20	25195693-25226729	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015491, HPA069555	Approved		Supported	Golgi apparatus		Expressed in all	Expressed in all			cerebral cortex: 105.7	Expressed in all		
ENTPD7	FLJ30978, LALP1	ENSG00000198018	Ectonucleoside triphosphate diphosphohydrolase 7	10	99659506-99706240	Predicted membrane proteins	Evidence at protein level	HPA014351	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			small intestine: 23.7	Mixed		
ENTPD8	NTPDase-8, UNQ2492	ENSG00000188833	Ectonucleoside triphosphate diphosphohydrolase 8	9	137434364-137441816	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA021509	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Stomach cancer:7.17e-4 (favourable)	Mixed	Tissue enhanced		colon: 21.7;duodenum: 28.7;small intestine: 31.6	rectum: 12.5	Cell line enhanced		CAPAN-2: 4.8;RPMI-8226: 3.7;T-47d: 2.7
EOGT	AER61, C3orf64, FLJ33770	ENSG00000163378	EGF domain specific O-linked N-acetylglucosamine transferase	3	68975214-69013961	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019460	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Renal cancer:8.97e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 50.3	Mixed		
EPB41	4.1R, EL1	ENSG00000159023	Erythrocyte membrane protein band 4.1	1	28887091-29120046	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA028076, HPA028412, HPA028414	Supported		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.75e-6 (unfavourable), Endometrial cancer:4.58e-4 (unfavourable), Head and neck cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 50.6	Mixed		
EPB41L3	4.1B, DAL1, KIAA0987	ENSG00000082397	Erythrocyte membrane protein band 4.1 like 3	18	5392381-5630700	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028605	Enhanced		Enhanced	Plasma membrane		Mixed	Expressed in all			testis: 115.0	Cell line enhanced		SCLC-21H: 77.1;TIME: 134.0
EPCAM	17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1	ENSG00000119888	Epithelial cell adhesion molecule	2	47345158-47387601	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB003809, HPA026761, CAB030012, CAB055098, HPA067463	Enhanced		Supported	Plasma membrane	Renal cancer:1.04e-6 (favourable), Ovarian cancer:3.30e-4 (favourable)	Mixed	Tissue enhanced		rectum: 680.5;small intestine: 714.7	colon: 659.9	Cell line enhanced		A-431: 382.2;CACO-2: 461.4;CAPAN-2: 680.1;SCLC-21H: 345.3
EPGN	ALGV3072, EPG, epigen, PRO9904	ENSG00000182585	Epithelial mitogen	4	74308473-74315307	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014369			Approved	Nucleus<br>Nuclear membrane<br>Cytosol	Urothelial cancer:2.40e-4 (unfavourable)	Tissue enhanced	Tissue enriched	12	esophagus: 63.6	seminal vesicle: 5.4	Group enriched	7	hTCEpi: 132.6;U-2197: 76.6
EPHA1	EPH, EPHT, EPHT1	ENSG00000146904	EPH receptor A1	7	143390289-143408892	Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB026144	Uncertain				Renal cancer:1.14e-6 (favourable)	Mixed	Tissue enriched	24	parathyroid gland: 877.3	esophagus: 36.2	Cell line enhanced		CACO-2: 29.0;HaCaT: 28.6;NTERA-2: 106.2
EPHA10	FLJ16103, FLJ33655	ENSG00000183317	EPH receptor A10	1	37713880-37765133	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027497	Uncertain					Mixed	Tissue enhanced		testis: 20.4	colon: 7.9	Cell line enhanced		BEWO: 4.7;HDLM-2: 18.1;SCLC-21H: 10.2
EPHA2	ECK	ENSG00000142627	EPH receptor A2	1	16124337-16156087	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB010464			Supported	Nuclear speckles<br>Golgi apparatus<br>Plasma membrane<br>Cell Junctions		Expressed in all	Tissue enhanced		esophagus: 86.8	gallbladder: 44.5	Cell line enhanced		PC-3: 211.2;WM-115: 253.0
EPHA3	ETK, ETK1, HEK, HEK4, TYRO4	ENSG00000044524	EPH receptor A3	3	89107524-89482134	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010462	Approved		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:3.28e-7 (unfavourable)	Mixed	Tissue enhanced		prostate: 51.9	gallbladder: 29.8	Cell line enriched	7	AF22: 192.5
EPHA4	Hek8, TYRO1	ENSG00000116106	EPH receptor A4	2	221418027-221574202	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB028368	Enhanced				Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 41.6	testis: 22.2	Cell line enhanced		AF22: 77.5;CACO-2: 49.0;U-2197: 35.7
EPHA5	CEK7, EHK1, Hek7, TYRO4	ENSG00000145242	EPH receptor A5	4	65319563-65670495	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	5	cerebral cortex: 18.0	cervix, uterine: 3.3	Cell line enhanced		PC-3: 8.7;TIME: 10.3;U-138 MG: 25.1;U-2197: 14.6;U-251 MG: 17.0
EPHA6	FLJ35246	ENSG00000080224	EPH receptor A6	3	96814581-97752460	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007397, HPA058047	Uncertain		Enhanced	Nucleoplasm		Mixed	Tissue enhanced		ovary: 7.7;testis: 15.1	cerebral cortex: 3.6	Cell line enhanced		HEK93: 8.5;U-266/70: 21.4
EPHA7	Hek11	ENSG00000135333	EPH receptor A7	6	93240020-93419547	Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010496	Approved					Tissue enhanced	Tissue enriched	13	parathyroid gland: 253.5	prostate: 20.2	Cell line enhanced		AF22: 15.6;HEK93: 41.9;RH-30: 41.8;THP-1: 25.7
EPHA8	EEK, Hek3	ENSG00000070886	EPH receptor A8	1	22563564-22603594	Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009660, HPA031433	Uncertain					Mixed	Tissue enhanced		adrenal gland: 4.7;spleen: 2.6;testis: 1.9	cerebral cortex: 1.3	Cell line enriched	14	SCLC-21H: 70.4
EPHB1	EPHT2, Hek6	ENSG00000154928	EPH receptor B1	3	134597801-135260467	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067740	Enhanced		Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enhanced		cerebral cortex: 23.7;testis: 20.5	thyroid gland: 11.9	Cell line enhanced		HDLM-2: 59.3;HMC-1: 31.7
EPHB2	DRT, EPHT3, ERK, Hek5, Tyro5	ENSG00000133216	EPH receptor B2	1	22710839-22921500	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013647, HPA071200	Approved		Supported	Nucleus<br>Plasma membrane	Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable)	Tissue enhanced	Mixed			rectum: 27.3	Cell line enhanced		HUVEC TERT2: 71.2;TIME: 69.5
EPHB3	ETK2, Hek2, Tyro6	ENSG00000182580	EPH receptor B3	3	184561784-184582409	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	HPA007698, HPA008184, CAB034350	Enhanced				Renal cancer:7.88e-5 (unfavourable)	Expressed in all	Tissue enhanced		skin: 45.4	stomach: 18.1	Cell line enhanced		BEWO: 27.9;HaCaT: 35.7;SK-BR-3: 23.1;T-47d: 19.3
EPHB4	HTK, Tyro11	ENSG00000196411	EPH receptor B4	7	100802565-100827521	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013537	Uncertain				Colorectal cancer:4.33e-4 (unfavourable), Breast cancer:8.56e-4 (unfavourable), Urothelial cancer:8.84e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 50.6	Mixed		
EPHB6	HEP	ENSG00000106123	EPH receptor B6	7	142855061-142871094	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035784			Approved	Nuclear speckles	Urothelial cancer:4.68e-5 (favourable), Cervical cancer:1.80e-4 (favourable), Glioma:6.96e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 22.5;skin: 25.0	cervix, uterine: 7.6	Group enriched	5	MOLT-4: 25.8;RT4: 47.4
EPOR		ENSG00000187266	Erythropoietin receptor	19	11377205-11384342	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA077613			Supported	Vesicles	Pancreatic cancer:3.17e-5 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 53.1	thyroid gland: 18.0	Mixed		
EPSTI1	BRESI1, MGC29634	ENSG00000133106	Epithelial stromal interaction 1	13	42886388-42992271	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017362	Approved		Approved	Cytosol	Renal cancer:1.02e-5 (unfavourable), Pancreatic cancer:1.66e-4 (unfavourable)	Expressed in all	Mixed			spleen: 42.8	Cell line enhanced		BJ hTERT+ SV40 Large T+: 89.2;BJ hTERT+ SV40 Large T+ RasG12V: 97.1;HDLM-2: 68.7
EQTN	AFAF, C9orf11, equatorin, SPACA8	ENSG00000120160	Equatorin	9	27284659-27297139	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015089, HPA015504	Enhanced					Not detected	Tissue enriched	94	testis: 67.7	ovary: 0.7	Not detected		
ERBB2	CD340, HER-2, HER2, NEU, NGL	ENSG00000141736	Erb-b2 receptor tyrosine kinase 2	17	39687914-39730426	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 124.5	Cell line enriched	22	SK-BR-3: 2343.7
ERBB3	HER3, LCCS2	ENSG00000065361	Erb-b2 receptor tyrosine kinase 3	12	56079857-56103505	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025331, HPA045396	Uncertain		Approved	Plasma membrane<br>Actin filaments		Expressed in all	Mixed			small intestine: 86.8	Cell line enhanced		Hep G2: 79.5;SK-BR-3: 77.6;SK-MEL-30: 109.7;T-47d: 108.2;WM-115: 145.7
ERBB4	ALS19, HER4	ENSG00000178568	Erb-b2 receptor tyrosine kinase 4	2	211375717-212538841	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000276, HPA012016, CAB025522	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 17.8	cerebral cortex: 7.6	Group enriched	5	AF22: 6.8;EFO-21: 4.8;HEK93: 3.5;RPTEC TERT1: 4.2;SCLC-21H: 3.7;T-47d: 4.8
EREG	ER	ENSG00000124882	Epiregulin	4	74365143-74388751	Predicted membrane proteins	Evidence at protein level	HPA054373			Approved	Vesicles	Cervical cancer:1.67e-7 (unfavourable), Lung cancer:1.45e-5 (unfavourable), Pancreatic cancer:6.57e-5 (unfavourable)	Tissue enhanced	Tissue enriched	6	bone marrow: 82.3	appendix: 14.4	Cell line enhanced		BJ hTERT+: 218.4;U-2197: 168.6;U-87 MG: 300.8
ERGIC1	ERGIC-32, ERGIC32, KIAA1181, NET24	ENSG00000113719	Endoplasmic reticulum-golgi intermediate compartment 1	5	172834275-172952685	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018666, HPA018900	Enhanced		Enhanced	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			prostate: 238.2	Expressed in all		
ERGIC2	Erv41, PTX1	ENSG00000087502	ERGIC and golgi 2	12	29337352-29381189	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049695	Approved		Supported	Nucleoli<br>Vesicles	Renal cancer:3.76e-6 (unfavourable), Pancreatic cancer:7.02e-6 (unfavourable), Liver cancer:8.06e-6 (unfavourable), Ovarian cancer:8.18e-4 (favourable)	Expressed in all	Expressed in all			testis: 106.3	Expressed in all		
ERGIC3	C20orf47, CGI-54, Erv46, NY-BR-84, PRO0989, SDBCAG84	ENSG00000125991	ERGIC and golgi 3	20	35542021-35557634	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015242, HPA015968	Approved		Supported	Nucleoplasm	Liver cancer:2.20e-7 (unfavourable), Renal cancer:9.81e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 530.3	Expressed in all		
ERMAP	BTN5, RD, SC	ENSG00000164010	Erythroblast membrane associated protein (Scianna blood group)	1	42817124-42844989	Blood group antigen proteins, Predicted membrane proteins	Evidence at protein level	HPA042573	Uncertain					Expressed in all	Mixed			thyroid gland: 18.7	Cell line enhanced		HEL: 31.0
ERMARD	C6orf70, dJ266L20.3, FLJ11152	ENSG00000130023	ER membrane associated RNA degradation	6	169751622-169781584	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041741	Approved		Approved	Cytosol		Expressed in all	Expressed in all			testis: 33.2	Expressed in all		
ERMP1	FLJ23309, FXNA, KIAA1815	ENSG00000099219	Endoplasmic reticulum metallopeptidase 1	9	5765076-5833117	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA020584	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:5.83e-10 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 124.7	thyroid gland: 44.0	Cell line enhanced		RT4: 122.7
ERN1	IRE1, IRE1P	ENSG00000178607	Endoplasmic reticulum to nucleus signaling 1	17	64039142-64130819	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009495, HPA027730	Supported				Renal cancer:1.68e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 53.4	Cell line enhanced		Karpas-707: 74.5;U-266/70: 74.0
ERN2	IRE1b	ENSG00000134398	Endoplasmic reticulum to nucleus signaling 2	16	23690326-23713500	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016558	Uncertain					Mixed	Group enriched	7	cervix, uterine: 27.6;colon: 27.5;duodenum: 12.3;gallbladder: 25.1;rectum: 23.2;small intestine: 9.9;stomach: 49.1	appendix: 3.8	Cell line enriched	8	CAPAN-2: 5.9
ERVFRD-1	envFRD, ERVFRDE1, HERV-FRD, HERV-W/FRD, syncytin-2	ENSG00000244476	Endogenous retrovirus group FRD member 1	6	11102489-11111732	Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Group enriched	32	parathyroid gland: 30.4;placenta: 51.8	epididymis: 1.2	Cell line enriched	34	BEWO: 8.9
ERVMER34-1		ENSG00000226887	Endogenous retrovirus group MER34 member 1	4	52722618-52751640	Predicted membrane proteins	Evidence at protein level	HPA011423, HPA024053	Uncertain		Approved	Nucleus<br>Cytosol	Head and neck cancer:3.55e-4 (unfavourable)	Mixed	Group enriched	8	parathyroid gland: 48.2;placenta: 15.6	kidney: 3.7	Cell line enhanced		CACO-2: 38.7;hTCEpi: 23.6;RPTEC TERT1: 18.4
ERVV-1	ENVV1, FLJ32214, HERV-V1	ENSG00000269526	Endogenous retrovirus group V member 1	19	53013921-53016122	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	68	placenta: 22.1	prostate,urinary bladder: 0.3	Cell line enriched	8	BEWO: 7.4
ERVV-2		ENSG00000268964	Endogenous retrovirus group V member 2	19	53044738-53051076	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	101	placenta: 13.6	kidney,testis,thyroid gland: 0.1	Group enriched	5	BEWO: 18.5;T-47d: 5.1
ERVW-1	ERVWE1, HERV-7q, HERV-W, HERV-W-ENV, HERVW	ENSG00000242950	Endogenous retrovirus group W member 1	7	92468380-92477986	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	12	placenta: 77.2	testis: 6.5	Cell line enriched	48	BEWO: 81.7
ESAM	W117m	ENSG00000149564	Endothelial cell adhesion molecule	11	124752583-124762290	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA051043, HPA056293	Uncertain		Approved	Microtubules		Expressed in all	Expressed in all			placenta: 157.9	Group enriched	15	HEL: 198.2;HUVEC TERT2: 233.4;TIME: 115.5
ESPL1	ESP1, KIAA0165, SEPA	ENSG00000135476	Extra spindle pole bodies like 1, separase	12	53268299-53293643	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB012185	Uncertain		Supported	Nucleoplasm<br>Vesicles	Liver cancer:2.01e-5 (unfavourable), Endometrial cancer:5.32e-5 (unfavourable), Stomach cancer:7.10e-4 (favourable), Lung cancer:7.14e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 11.4;testis: 10.6	lymph node: 4.8	Mixed		
ESYT1	FAM62A, KIAA0747, MBC2	ENSG00000139641	Extended synaptotagmin 1	12	56118250-56144671	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016858, HPA076926	Approved		Supported	Endoplasmic reticulum	Renal cancer:3.86e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 114.6	Expressed in all		
ESYT2	CHR2SYT, FAM62B, KIAA1228	ENSG00000117868	Extended synaptotagmin 2	7	158730995-158830253	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002132	Approved		Uncertain	Cytosol	Urothelial cancer:2.81e-5 (unfavourable), Pancreatic cancer:5.73e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 80.2	Expressed in all		
ESYT3	CHR3SYT, FAM62C	ENSG00000158220	Extended synaptotagmin 3	3	138434586-138481686	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039200	Approved				Lung cancer:8.30e-4 (favourable)	Tissue enhanced	Tissue enhanced		lung: 8.4;skin: 7.5;thyroid gland: 8.5	endometrium: 3.7	Cell line enhanced		NTERA-2: 4.1;SCLC-21H: 5.2;SiHa: 1.9
ETFDH	ETFQO	ENSG00000171503	Electron transfer flavoprotein dehydrogenase	4	158672125-158709623	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041978	Enhanced				Renal cancer:5.76e-10 (favourable)	Expressed in all	Expressed in all			liver: 99.7	Expressed in all		
ETNK1	EKI, EKI1	ENSG00000139163	Ethanolamine kinase 1	12	22625075-22690665	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010712, HPA029407	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:1.75e-4 (favourable), Liver cancer:5.85e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 45.6	Expressed in all		
EVA1A	FAM176A, FLJ13391, TMEM166	ENSG00000115363	Eva-1 homolog A, regulator of programmed cell death	2	75469302-75569722	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008055	Approved		Supported	Vesicles<br>Plasma membrane	Ovarian cancer:5.67e-4 (favourable), Renal cancer:5.80e-4 (favourable)	Mixed	Tissue enhanced		liver: 98.9	lung: 31.1	Cell line enhanced		U-138 MG: 109.1
EVA1C	B18, B19, C21orf63, C21orf64, FAM176C, PRED34	ENSG00000166979	Eva-1 homolog C	21	32412006-32515397	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015720, HPA029944, CAB034174	Enhanced				Head and neck cancer:5.06e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 25.5	Cell line enhanced		A549: 16.5;CAPAN-2: 16.0;U-87 MG: 14.9
EVC	DWF-1	ENSG00000072840	EvC ciliary complex subunit 1	4	5711197-5814305	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA008703, HPA016046	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.60e-9 (favourable), Urothelial cancer:9.47e-5 (unfavourable)	Expressed in all	Mixed			ovary: 41.5	Mixed		
EVC2	LBN	ENSG00000173040	EvC ciliary complex subunit 2	4	5542772-5709548	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA040910, HPA048122	Uncertain		Approved	Mitochondria	Renal cancer:1.58e-4 (favourable)	Mixed	Mixed			ovary: 8.8	Cell line enhanced		HHSteC: 10.9
EVI2A	EVDA, EVI2	ENSG00000126860	Ecotropic viral integration site 2A	17	31317560-31321884	Predicted membrane proteins	Evidence at protein level	HPA045033, HPA057051	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.63e-6 (unfavourable), Melanoma:7.55e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 83.0	Cell line enhanced		Karpas-707: 71.2;RPMI-8226: 110.1
EVI2B	CD361, D17S376, EVDB	ENSG00000185862	Ecotropic viral integration site 2B	17	31303766-31314112	CD markers, Predicted membrane proteins	Evidence at protein level	HPA007436	Enhanced				Renal cancer:2.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 213.7	lymph node: 175.0	Cell line enhanced		HL-60: 77.7;HMC-1: 114.9;Karpas-707: 67.2;RPMI-8226: 98.3;THP-1: 81.9
EVI5	NB4S	ENSG00000067208	Ecotropic viral integration site 5	1	92508696-92792404	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027339, HPA053724	Approved		Supported	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			testis: 18.0	Mixed		
EVI5L		ENSG00000142459	Ecotropic viral integration site 5 like	19	7830233-7864976	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043099, HPA043563	Approved		Approved	Nuclear bodies	Renal cancer:2.18e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 41.6	Mixed		
EXD2	C14orf114, EXDL2, FLJ10738	ENSG00000081177	Exonuclease 3'-5' domain containing 2	14	69191511-69244020	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002906, HPA005848	Uncertain		Approved	Intermediate filaments<br>Mitochondria	Renal cancer:2.08e-9 (favourable), Liver cancer:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.6	Mixed		
EXT1	LGCR, LGS, ttv	ENSG00000182197	Exostosin glycosyltransferase 1	8	117794490-118111853	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044394	Uncertain				Lung cancer:1.20e-5 (unfavourable), Thyroid cancer:4.64e-4 (unfavourable), Cervical cancer:7.04e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 31.6	Cell line enhanced		BJ hTERT+: 193.5;fHDF/TERT166: 189.8
EXT2	SOTV	ENSG00000151348	Exostosin glycosyltransferase 2	11	44095549-44245429	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA078409			Supported	Golgi apparatus	Renal cancer:5.36e-6 (unfavourable), Head and neck cancer:2.50e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 90.7	Expressed in all		
EXTL3	botv, REGR	ENSG00000012232	Exostosin like glycosyltransferase 3	8	28600469-28755599	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025387	Approved				Liver cancer:1.14e-5 (unfavourable), Renal cancer:2.47e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.8	Expressed in all		
F11R	CD321, JAM-1, JAM-A, JAM1, JAMA, JCAM, PAM-1	ENSG00000158769	F11 receptor	1	160995211-161021348	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB004671, HPA043616, HPA061700	Enhanced		Supported	Cell Junctions<br>Microtubules		Expressed in all	Expressed in all			lung: 95.0	Cell line enhanced		HaCaT: 179.6
F2R	CF2R, PAR-1, PAR1, TR	ENSG00000181104	Coagulation factor II thrombin receptor	5	76716043-76735781	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB008973, CAB012962	Approved				Renal cancer:2.21e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 94.1	Cell line enhanced		HUVEC TERT2: 297.4;WM-115: 331.7
F2RL1	GPR11, PAR2	ENSG00000164251	F2R like trypsin receptor 1	5	76818933-76835315	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB012989, HPA014091	Approved		Approved	Plasma membrane	Renal cancer:5.86e-7 (favourable), Colorectal cancer:3.88e-4 (favourable), Head and neck cancer:5.88e-4 (unfavourable), Lung cancer:8.92e-4 (unfavourable)	Expressed in all	Mixed			colon: 58.9	Cell line enhanced		PC-3: 113.9;RPTEC TERT1: 152.3
F2RL2	PAR3	ENSG00000164220	Coagulation factor II thrombin receptor like 2	5	76615482-76623434	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Colorectal cancer:4.69e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 10.9	smooth muscle: 5.6	Cell line enhanced		BJ hTERT+: 43.2;HEL: 65.9;hTEC/SVTERT24-B: 34.7;U-138 MG: 52.8;WM-115: 67.6
F2RL3	PAR4	ENSG00000127533	F2R like thrombin/trypsin receptor 3	19	16888860-16892606	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:6.25e-4 (favourable)	Mixed	Mixed			thyroid gland: 7.7	Group enriched	8	HEL: 26.3;HMC-1: 10.0
F3	CD142, TF	ENSG00000117525	Coagulation factor III, tissue factor	1	94529225-94541800	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009438, HPA049292, HPA069132	Approved		Enhanced	Vesicles	Renal cancer:2.02e-8 (unfavourable), Pancreatic cancer:1.07e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 191.1	Cell line enhanced		A-431: 929.2;HaCaT: 433.2;HBEC3-KT: 914.1;U-2197: 442.4
FA2H	FAAH, FAXDC1, FLJ25287, SPG35	ENSG00000103089	Fatty acid 2-hydroxylase	16	74712955-74774831	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056614, HPA077840	Approved		Uncertain	Nuclear membrane	Renal cancer:5.01e-6 (favourable), Pancreatic cancer:3.74e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 51.6;stomach: 57.4	gallbladder: 28.6	Cell line enhanced		A549: 34.7;CAPAN-2: 18.4;HAP1: 50.4;SK-BR-3: 21.5
FAAH	FAAH-1	ENSG00000117480	Fatty acid amide hydrolase	1	46394265-46413848	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA007425	Approved		Uncertain	Cytosol	Stomach cancer:3.63e-5 (favourable), Renal cancer:4.25e-5 (favourable), Endometrial cancer:1.51e-4 (favourable)	Expressed in all	Expressed in all			prostate: 60.0	Cell line enhanced		BEWO: 34.8;RT4: 31.9
FADS1	D5D, FADS6, FADSD5, LLCDL1, TU12	ENSG00000149485	Fatty acid desaturase 1	11	61799625-61829318	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042705	Approved				Renal cancer:1.95e-9 (unfavourable), Urothelial cancer:1.33e-4 (unfavourable), Thyroid cancer:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 89.1	Expressed in all		
FADS2	D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13	ENSG00000134824	Fatty acid desaturase 2	11	61792980-61867354	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006741	Approved				Renal cancer:1.00e-7 (unfavourable), Urothelial cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 414.3	Expressed in all		
FADS3	CYB5RP, LLCDL3	ENSG00000221968	Fatty acid desaturase 3	11	61873519-61892051	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045224	Approved		Approved	Nucleoli fibrillar center	Renal cancer:1.50e-9 (unfavourable), Head and neck cancer:9.54e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 99.2	Expressed in all		
FADS6		ENSG00000172782	Fatty acid desaturase 6	17	74877299-74893781	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA016802	Uncertain					Tissue enhanced	Tissue enhanced		epididymis: 21.9	small intestine: 10.1	Mixed		
FAF2	ETEA, KIAA0887, UBXD8, UBXN3B	ENSG00000113194	Fas associated factor family member 2	5	176447628-176510074	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065968, HPA071246, HPA073828	Approved		Enhanced	Endoplasmic reticulum<br>Lipid droplets	Lung cancer:1.38e-4 (unfavourable), Liver cancer:1.79e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.0	Expressed in all		
FAIM2	KIAA0950, LFG, LFG2, LIFEGUARD, NMP35, TMBIM2	ENSG00000135472	Fas apoptotic inhibitory molecule 2	12	49866896-49904217	Predicted membrane proteins	Evidence at protein level	HPA018790, HPA048800	Enhanced		Approved	Intermediate filaments		Tissue enriched	Tissue enriched	7	cerebral cortex: 369.7	adrenal gland: 55.7	Cell line enhanced		HHSteC: 10.2;U-87 MG: 37.7
FAM105A	FLJ11127, NET20	ENSG00000145569	Family with sequence similarity 105 member A	5	14581775-14615007	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046638	Uncertain		Approved	Nucleoli<br>Cytosol	Pancreatic cancer:1.02e-4 (favourable), Testis cancer:7.62e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 35.5	Cell line enhanced		HMC-1: 87.0;U-937: 38.0
FAM122C	RP3-473B4.1	ENSG00000156500	Family with sequence similarity 122C	X	134796789-134854610	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA059961	Approved		Uncertain	Nucleoplasm		Mixed	Mixed			testis: 7.9	Mixed		
FAM134A	C2orf17, MAG-2, MGC3035	ENSG00000144567	Family with sequence similarity 134 member A	2	219176225-219185479	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011170, HPA011844	Approved		Approved	Cytosol	Liver cancer:1.49e-4 (unfavourable), Colorectal cancer:7.95e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 143.4	Expressed in all		
FAM134B	FLJ20152, JK1	ENSG00000154153	Family with sequence similarity 134 member B	5	16473038-16617058	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA012077			Supported	Endoplasmic reticulum	Renal cancer:5.25e-10 (favourable)	Expressed in all	Expressed in all			kidney: 62.2	Cell line enhanced		HSkMC: 20.3;RPTEC TERT1: 19.9;SCLC-21H: 20.1
FAM134C	DKFZp686B1036, FLJ33806	ENSG00000141699	Family with sequence similarity 134 member C	17	42579513-42610623	Predicted membrane proteins	Evidence at protein level	HPA016492	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Endometrial cancer:1.61e-4 (favourable), Renal cancer:6.82e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 48.2	Expressed in all		
FAM155A		ENSG00000204442	Family with sequence similarity 155 member A	13	107163510-107866735	Predicted membrane proteins	Evidence at protein level	HPA039453, HPA058768	Enhanced		Approved	Nucleus<br>Vesicles<br>Centrosome		Mixed	Tissue enriched	6	cerebral cortex: 15.6	seminal vesicle: 2.4	Cell line enhanced		RPTEC TERT1: 9.3;SCLC-21H: 8.9;SH-SY5Y: 18.1;U-87 MG: 10.5
FAM155B	CXorf63, TED, TMEM28	ENSG00000130054	Family with sequence similarity 155 member B	X	69505241-69532508	Predicted membrane proteins	Evidence at transcript level	HPA036093	Uncertain				Breast cancer:4.61e-5 (unfavourable), Prostate cancer:1.83e-4 (unfavourable), Renal cancer:6.63e-4 (favourable)	Mixed	Tissue enhanced		heart muscle: 10.8;seminal vesicle: 8.5;thyroid gland: 16.7	cerebral cortex: 2.5	Cell line enhanced		AN3-CA: 8.3;HAP1: 20.7;NTERA-2: 27.5;SCLC-21H: 15.3
FAM159A	MGC52498	ENSG00000182183	Family with sequence similarity 159 member A	1	52633344-52669683	Predicted membrane proteins	Evidence at transcript level	HPA030744	Uncertain					Mixed	Tissue enhanced		lymph node: 8.8;tonsil: 6.6	spleen: 4.5	Cell line enhanced		Daudi: 3.8;Karpas-707: 9.0;RPMI-8226: 11.8
FAM159B		ENSG00000145642	Family with sequence similarity 159 member B	5	64690308-64718090	Predicted membrane proteins	Evidence at protein level	HPA011778	Enhanced					Tissue enriched	Group enriched	8	pancreas: 1.0;stomach: 3.4	cerebral cortex,duodenum: 0.2	Group enriched	17	NTERA-2: 3.5;RPTEC TERT1: 5.5;SCLC-21H: 1.5
FAM160A2	C11orf56, DKFZP566M1046, FHIP, FLJ22665, KIAA1759	ENSG00000051009	Family with sequence similarity 160 member A2	11	6211335-6234711	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055994, HPA063987	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			testis: 42.0	Expressed in all		
FAM162A	C3orf28, E2IG5	ENSG00000114023	Family with sequence similarity 162 member A	3	122384176-122412334	Predicted membrane proteins	Evidence at protein level	HPA035856, HPA058113	Approved		Enhanced	Mitochondria<br>Cytosol	Urothelial cancer:3.93e-4 (favourable)	Expressed in all	Expressed in all			rectum: 162.9	Expressed in all		
FAM162B	bA86F4.2, C6orf189	ENSG00000183807	Family with sequence similarity 162 member B	6	116752197-116765723	Predicted membrane proteins	Evidence at protein level	HPA036112, HPA060342	Enhanced				Renal cancer:2.48e-4 (unfavourable)	Tissue enriched	Tissue enhanced		placenta: 94.0	lung: 27.0	Cell line enhanced		BJ: 7.3;BJ hTERT+: 19.0;BJ hTERT+ SV40 Large T+ RasG12V: 21.4;HSkMC: 5.6
FAM163A	C1orf76, MGC16664, NDSP	ENSG00000143340	Family with sequence similarity 163 member A	1	179743163-179816198	Predicted membrane proteins	Evidence at transcript level	HPA010778	Uncertain					Mixed	Tissue enhanced		adrenal gland: 7.6;testis: 8.7	gallbladder: 1.8	Cell line enriched	38	SH-SY5Y: 118.8
FAM163B	C9orf166	ENSG00000196990	Family with sequence similarity 163 member B	9	133578415-133586197	Predicted membrane proteins	Evidence at transcript level	HPA067336	Approved		Approved	Nuclear bodies<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	6	cerebral cortex: 103.5	adrenal gland: 16.4	Cell line enriched	19	SH-SY5Y: 72.4
FAM171A1	C10orf38, FLJ12884	ENSG00000148468	Family with sequence similarity 171 member A1	10	15211643-15371062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051345	Approved		Approved	Nucleoplasm<br>Plasma membrane	Thyroid cancer:4.90e-6 (unfavourable), Renal cancer:2.71e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 73.2	Cell line enhanced		TIME: 95.9
FAM171A2	MGC34829	ENSG00000161682	Family with sequence similarity 171 member A2	17	44353215-44363875	Predicted membrane proteins	Evidence at protein level	HPA019770	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 13.3	epididymis: 3.3	Cell line enhanced		REH: 20.9;SCLC-21H: 18.5
FAM171B	FLJ34104, KIAA1946	ENSG00000144369	Family with sequence similarity 171 member B	2	186693971-186765965	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010639, HPA013434	Approved		Approved	Nucleus<br>Mitochondria	Renal cancer:9.51e-7 (unfavourable), Urothelial cancer:5.03e-4 (unfavourable)	Tissue enriched	Tissue enriched	6	cerebral cortex: 114.5	parathyroid gland: 19.3	Mixed		
FAM173A	C16orf24, MGC2494	ENSG00000103254	Family with sequence similarity 173 member A	16	720581-722601	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046262	Enhanced		Approved	Cytosol	Renal cancer:4.24e-5 (favourable), Head and neck cancer:8.88e-4 (favourable)	Expressed in all	Mixed			spleen: 9.3	Cell line enhanced		U-266/70: 49.3
FAM173B	JS-2	ENSG00000150756	Family with sequence similarity 173 member B	5	10226330-10249897	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA074513			Approved	Nucleus<br>Vesicles	Breast cancer:1.32e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 26.2	Expressed in all		
FAM174A	NS5ATP6, TMEM157, UNQ1912	ENSG00000174132	Family with sequence similarity 174 member A	5	100535305-100586741	Predicted membrane proteins	Evidence at protein level	HPA019539	Approved		Approved	Golgi apparatus<br>Cytosol	Glioma:3.85e-6 (unfavourable), Renal cancer:5.48e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 51.5	Expressed in all		
FAM174B	LOC400451, MGC102891	ENSG00000185442	Family with sequence similarity 174 member B	15	92617443-92809884	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015306	Approved		Approved	Intermediate filaments	Endometrial cancer:9.03e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 61.3	Cell line enhanced		CACO-2: 61.8;MCF7: 69.4;RPMI-8226: 73.8;RT4: 176.5
FAM187A		ENSG00000214447	Family with sequence similarity 187 member A	17	44899712-44905390	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022794, HPA043131	Approved		Approved	Cytosol		Not detected	Tissue enhanced		fallopian tube: 24.6;testis: 17.2	thyroid gland: 5.3	Cell line enhanced		U-87 MG: 12.7
FAM187B	FLJ25660, TMEM162	ENSG00000177558	Family with sequence similarity 187 member B	19	35224800-35228729	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	202	testis: 44.2	spleen: 0.2	Not detected		
FAM189A1	KIAA0574, TMEM228	ENSG00000104059	Family with sequence similarity 189 member A1	15	29120254-29570723	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA009410, HPA010637	Uncertain		Supported	Nucleus		Mixed	Tissue enhanced		cerebral cortex: 2.2;parathyroid gland: 2.0	colon,testis: 0.8	Cell line enhanced		EFO-21: 4.4;HDLM-2: 11.1;REH: 2.6
FAM189A2	C9orf61, X123	ENSG00000135063	Family with sequence similarity 189 member A2	9	69324572-69392455	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029411, HPA057207	Approved				Endometrial cancer:1.16e-6 (favourable), Renal cancer:1.75e-5 (favourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 101.0	cervix, uterine: 64.4	Cell line enhanced		BEWO: 4.9;NTERA-2: 7.3;SK-MEL-30: 5.2
FAM189B	C1orf2, cote1	ENSG00000160767	Family with sequence similarity 189 member B	1	155247205-155255483	Predicted membrane proteins	Evidence at protein level	HPA006659, HPA050674	Uncertain		Supported	Nucleoplasm	Renal cancer:3.43e-7 (unfavourable), Endometrial cancer:9.59e-5 (unfavourable), Liver cancer:3.43e-4 (unfavourable), Cervical cancer:4.98e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 6.8	Expressed in all		
FAM198B	C4orf18, DKFZp434L142, ENED, FLJ38155	ENSG00000164125	Family with sequence similarity 198 member B	4	158124474-158173318	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007227	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus		Expressed in all	Expressed in all			adrenal gland: 271.5	Cell line enhanced		ASC TERT1: 100.6;HSkMC: 120.9;HUVEC TERT2: 160.0
FAM205A	C9orf144B	ENSG00000205108	Family with sequence similarity 205 member A	9	34723055-34729467	Predicted membrane proteins	Evidence at protein level	HPA071267	Enhanced					Not detected	Tissue enriched	321	testis: 39.5	skin: 0.1	Not detected		
FAM205C	FAM205CP	ENSG00000187791	Family with sequence similarity 205 member C	9	34889064-34895778	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	61	testis: 46.8	kidney: 0.7	Cell line enriched	84	THP-1: 9.8
FAM209A	C20orf106, dJ1153D9.3	ENSG00000124103	Family with sequence similarity 209 member A	20	56517187-56526142	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	10	testis: 100.6	bone marrow: 9.6	Cell line enhanced		HMC-1: 1.6;U-266/84: 1.0
FAM209B	C20orf107, dJ1153D9.4	ENSG00000213714	Family with sequence similarity 209 member B	20	56533246-56536520	Predicted membrane proteins	Evidence at protein level	HPA042144	Enhanced					Mixed	Tissue enriched	22	testis: 112.5	bone marrow: 5.0	Mixed		
FAM210A	C18orf19, HsT2329, MGC24180	ENSG00000177150	Family with sequence similarity 210 member A	18	13663347-13726663	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014324, HPA051564	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Mitochondria	Head and neck cancer:8.14e-4 (unfavourable)	Expressed in all	Mixed			testis: 15.7	Expressed in all		
FAM210B	C20orf108, dJ1167H4.1, DKFZP434A1114	ENSG00000124098	Family with sequence similarity 210 member B	20	56358915-56368663	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042652	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.44e-10 (favourable), Lung cancer:4.26e-4 (favourable), Cervical cancer:5.44e-4 (favourable)	Expressed in all	Expressed in all			ovary: 131.4	Cell line enhanced		SK-MEL-30: 224.0
FAM213A	Adrx, C10orf58, MGC4248, PAMM	ENSG00000122378	Family with sequence similarity 213 member A	10	80407829-80437115	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009025, HPA024565	Approved				Urothelial cancer:6.11e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 425.0	Cell line enhanced		ASC diff: 650.7;HUVEC TERT2: 365.0
FAM220A	ACPIN1, C7orf70, MGC12966, SIPAR	ENSG00000178397	Family with sequence similarity 220 member A	7	6329409-6348981	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA055050			Approved	Vesicles	Liver cancer:5.17e-6 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 102.3	Expressed in all		
FAM234A	C16orf9, DKFZP761D0211, FLJ32603, ITFG3	ENSG00000167930	Family with sequence similarity 234 member A	16	234546-268971	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011651, HPA071871	Uncertain		Uncertain	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 111.8	Expressed in all		
FAM234B	KIAA1467	ENSG00000084444	Family with sequence similarity 234 member B	12	13044284-13142521	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010803, HPA010850	Approved		Approved	Endoplasmic reticulum		Expressed in all	Tissue enhanced		cerebral cortex: 32.4	breast: 20.8	Expressed in all		
FAM26D	C6orf78, FLJ32239	ENSG00000164451	Family with sequence similarity 26 member D	6	116529013-116558868	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	46	placenta: 33.8	testis: 0.7	Not detected		
FAM26E	C6orf188, dJ493F7.3, MGC45451	ENSG00000178033	Family with sequence similarity 26 member E	6	116511646-116524792	Predicted membrane proteins	Evidence at protein level	HPA034969, HPA034970	Uncertain		Approved	Golgi apparatus		Mixed	Mixed			placenta: 6.4	Cell line enhanced		TIME: 7.3
FAM26F	C6orf187, dJ93H18.5, INAM, OTTHUMP00000017061, OTTHUMP00000017062, RP1-93H18.5	ENSG00000188820	Family with sequence similarity 26 member F	6	116461370-116463779	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:9.31e-10 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 170.6	appendix: 80.5	Cell line enhanced		Karpas-707: 33.4;RPMI-8226: 110.4;U-937: 46.8
FAM35A	bA163M19.1, FAM35A1, MGC5560	ENSG00000122376	Family with sequence similarity 35 member A	10	87094161-87191468	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036582	Uncertain		Approved	Nucleoplasm<br>Actin filaments	Glioma:5.44e-4 (favourable), Colorectal cancer:6.06e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 38.8	Expressed in all		
FAM3A	2-19, DXS560S, XAP-7	ENSG00000071889	Family with sequence similarity 3 member A	X	154506159-154516242	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025016, HPA056991	Uncertain		Approved	Nucleus<br>Nucleoli	Colorectal cancer:1.76e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 28.3	Expressed in all		
FAM3B	2-21, C21orf11, C21orf76, D21M16SJHU19e, ORF9, PANDER, PRED44	ENSG00000183844	Family with sequence similarity 3 member B	21	41304212-41357431	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015885, HPA029777	Approved		Approved	Vesicles		Tissue enhanced	Tissue enhanced		duodenum: 162.1;small intestine: 166.8	stomach: 124.0	Cell line enhanced		CACO-2: 16.2;CAPAN-2: 10.8;Hep G2: 22.1;RPMI-8226: 62.5
FAM3D	EF7, OIT1	ENSG00000198643	Family with sequence similarity 3 member D	3	58633946-58666848	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013844	Approved				Head and neck cancer:1.89e-4 (favourable), Breast cancer:7.51e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 318.5;rectum: 484.7	salivary gland: 191.6	Not detected		
FAM57A	CT120, FLJ22282	ENSG00000167695	Family with sequence similarity 57 member A	17	732412-742972	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:3.53e-6 (favourable), Renal cancer:1.44e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 82.7	esophagus: 25.9	Expressed in all		
FAM57B	DKFZP434I2117	ENSG00000149926	Family with sequence similarity 57 member B	16	30024427-30052978	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030837	Uncertain					Tissue enriched	Group enriched	12	cerebral cortex: 18.6;testis: 77.0	skeletal muscle: 3.9	Cell line enhanced		NTERA-2: 16.7;SCLC-21H: 105.0;SH-SY5Y: 35.9
FAM69A	FLJ23493	ENSG00000154511	Family with sequence similarity 69 member A	1	92832737-92961522	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015718, HPA017281	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:1.45e-7 (unfavourable), Breast cancer:8.96e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 44.7	Mixed		
FAM69B	C9orf136, MGC20262	ENSG00000165716	Family with sequence similarity 69 member B	9	136712570-136724050	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046812, HPA054443	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Vesicles	Colorectal cancer:1.77e-5 (unfavourable), Pancreatic cancer:9.48e-5 (favourable)	Expressed in all	Mixed			placenta: 29.6	Cell line enhanced		EFO-21: 67.2;HEK93: 59.7;HUVEC TERT2: 67.6
FAM76B	MGC33371	ENSG00000077458	Family with sequence similarity 76 member B	11	95768942-95790409	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036608	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:7.17e-5 (unfavourable), Urothelial cancer:2.72e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.9	Expressed in all		
FAM8A1	AHCP	ENSG00000137414	Family with sequence similarity 8 member A1	6	17600355-17611719	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044698, HPA073675	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			endometrium: 45.5	Expressed in all		
FAM98B	FLJ38426	ENSG00000171262	Family with sequence similarity 98 member B	15	38454127-38487710	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008320, HPA008502	Enhanced		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 32.1	Expressed in all		
FAM9C	TEX39C	ENSG00000187268	Family with sequence similarity 9 member C	X	13035618-13044682	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	7	spleen: 54.4	testis: 8.1	Cell line enriched	56	AN3-CA: 169.6
FANCA	FA-H, FAA, FACA, FAH, FANCH	ENSG00000187741	Fanconi anemia complementation group A	16	89737549-89816657	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA063236			Supported	Nucleus		Mixed	Mixed			testis: 19.5	Expressed in all		
FAR1	FLJ22728, MLSTD2, SDR10E1	ENSG00000197601	Fatty acyl-CoA reductase 1	11	13668670-13732346	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017322	Approved		Enhanced	Peroxisomes	Colorectal cancer:2.27e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 58.9	Mixed		
FAR2	FLJ10462, MLSTD1, SDR10E2	ENSG00000064763	Fatty acyl-CoA reductase 2	12	29149103-29340980	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015884	Approved		Approved	Nucleoli<br>Golgi apparatus	Renal cancer:4.93e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 43.9	Cell line enhanced		HUVEC TERT2: 69.5
FAS	APO-1, APT1, CD95, FAS1, TNFRSF6	ENSG00000026103	Fas cell surface death receptor	10	88990582-89015785	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027444	Enhanced		Approved	Plasma membrane<br>Cytosol		Expressed in all	Mixed			rectum: 32.9	Cell line enhanced		Karpas-707: 104.1
FASLG	APT1LG1, CD178, FasL, TNFSF6	ENSG00000117560	Fas ligand	1	172659018-172666874	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA054959	Approved				Renal cancer:1.59e-6 (unfavourable)	Mixed	Tissue enhanced		lymph node: 5.8	spleen: 5.1	Not detected		
FAT1	CDHF7, CDHR8, FAT	ENSG00000083857	FAT atypical cadherin 1	4	186587783-186726722	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001869, HPA023882	Approved				Lung cancer:4.22e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 37.6	Cell line enhanced		fHDF/TERT166: 221.3
FAT2	CDHF8, CDHR9, HFAT2, MEGF1	ENSG00000086570	FAT atypical cadherin 2	5	151504093-151568944	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB033680	Enhanced					Group enriched	Tissue enhanced		skin: 66.5	esophagus: 14.3	Group enriched	9	BEWO: 33.8;EFO-21: 19.8;HaCaT: 45.7;HBEC3-KT: 16.9;hTCEpi: 51.0
FAT3	CDHF15, CDHR10, KIAA1989	ENSG00000165323	FAT atypical cadherin 3	11	92352096-92896470	Predicted membrane proteins	Evidence at protein level	HPA026878	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 3.9;seminal vesicle: 2.6	prostate: 1.6	Cell line enhanced		AF22: 3.6;NTERA-2: 1.2;U-2 OS: 1.1;U-251 MG: 1.8
FAT4	CDHF14, CDHR11, FAT-J	ENSG00000196159	FAT atypical cadherin 4	4	125316399-125492932	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA052819	Approved		Approved	Cytosol	Renal cancer:1.89e-4 (favourable)	Mixed	Mixed			parathyroid gland: 9.6	Cell line enhanced		HUVEC TERT2: 11.5;TIME: 17.8
FATE1	CT43, FATE	ENSG00000147378	Fetal and adult testis expressed 1	X	151716035-151723194	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034604	Enhanced				Renal cancer:2.88e-4 (unfavourable)	Group enriched	Tissue enriched	314	testis: 308.4	cerebral cortex: 0.9	Not detected		
FAXDC2	C5orf4, FLJ13758	ENSG00000170271	Fatty acid hydroxylase domain containing 2	5	154818491-154859252	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Renal cancer:9.71e-10 (favourable), Liver cancer:3.87e-5 (favourable)	Expressed in all	Tissue enriched	6	parathyroid gland: 388.2	ovary: 66.6	Cell line enhanced		ASC diff: 22.0
FBXL17	DKFZP434C1715, Fbl17, Fbx13, FBXO13	ENSG00000145743	F-box and leucine rich repeat protein 17	5	107859035-108382098	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036410, HPA036411	Uncertain		Approved	Nucleus	Renal cancer:4.60e-8 (favourable), Thyroid cancer:3.27e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 44.2	Expressed in all		
FBXO18	FBH1, Fbx18, FLJ14590	ENSG00000134452	F-box protein, helicase, 18	10	5890203-5937594	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA002844	Supported				Liver cancer:7.73e-7 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 46.8	Expressed in all		
FBXO31	FBX14, Fbx31, FBXO14, MGC15419	ENSG00000103264	F-box protein 31	16	87326987-87392142	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030150	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Pancreatic cancer:9.16e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 24.8	Expressed in all		
FBXW12	Fbw12, FBXO35	ENSG00000164049	F-box and WD repeat domain containing 12	3	48372219-48401259	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037491, HPA037492	Uncertain					Not detected	Tissue enhanced		pancreas: 1.2;testis: 1.0	cerebral cortex: 0.2	Not detected		
FCAMR	CD351, FCA/MR, FKSG87	ENSG00000162897	Fc fragment of IgA and IgM receptor	1	206957965-206970625	CD markers, Predicted membrane proteins	Evidence at protein level	HPA056505	Enhanced					Tissue enhanced	Tissue enhanced		kidney: 32.1;lymph node: 14.0;tonsil: 11.3	appendix: 5.2	Not detected		
FCAR	CD89	ENSG00000186431	Fc fragment of IgA receptor	19	54874248-54890472	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014050	Approved		Supported	Plasma membrane		Not detected	Tissue enriched	15	bone marrow: 12.3	appendix: 0.8	Not detected		
FCER1A	FCE1A	ENSG00000179639	Fc fragment of IgE receptor Ia	1	159289714-159308224	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB022102, HPA036051, CAB055526	Approved				Renal cancer:1.20e-4 (favourable)	Expressed in all	Mixed			skin: 39.9	Cell line enriched	100	HEL: 401.2
FCER1G		ENSG00000158869	Fc fragment of IgE receptor Ig	1	161215234-161220699	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB022108, HPA026872	Supported				Renal cancer:1.83e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 462.9	Group enriched	5	HEL: 69.1;HMC-1: 265.2;THP-1: 185.7;U-266/84: 61.5;U-937: 67.6
FCER2	CD23, CD23A, CLEC4J, FCE2	ENSG00000104921	Fc fragment of IgE receptor II	19	7688758-7702146	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002624, HPA008928	Enhanced					Mixed	Group enriched	7	appendix: 21.9;lymph node: 47.4;spleen: 52.6;tonsil: 38.0	adipose tissue: 5.8	Cell line enriched	16	HDLM-2: 416.1
FCGR1A	CD64, CD64A	ENSG00000150337	Fc fragment of IgG receptor Ia	1	149782671-149792518	CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level						Renal cancer:4.83e-8 (unfavourable)	Tissue enhanced	Tissue enhanced		epididymis: 91.1	appendix: 48.9	Cell line enriched	5	THP-1: 113.9
FCGR1B	CD64b	ENSG00000198019	Fc fragment of IgG receptor Ib	1	121087345-121096310	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		appendix: 27.5;epididymis: 61.7	placenta: 17.0	Cell line enhanced		HMC-1: 6.6;NB-4: 12.8;THP-1: 51.9
FCGR2A	CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2	ENSG00000143226	Fc fragment of IgG receptor IIa	1	161505430-161524013	CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010718, HPA014730	Enhanced				Renal cancer:6.49e-7 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 160.6	appendix: 148.6	Cell line enhanced		HEL: 26.6;HMC-1: 50.4;K-562: 16.0;THP-1: 42.6;U-937: 21.3
FCGR2B	CD32, CD32B, FCG2, FCGR2	ENSG00000072694	Fc fragment of IgG receptor IIb	1	161663147-161678654	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB007796, HPA014730	Enhanced				Renal cancer:8.82e-4 (unfavourable)	Mixed	Tissue enriched	16	placenta: 576.7	adipose tissue: 36.6	Cell line enhanced		Daudi: 18.5;HMC-1: 27.5;RPMI-8226: 8.1
FCGR3A	CD16, CD16a, FCG3, FCGR3	ENSG00000203747	Fc fragment of IgG receptor IIIa	1	161541759-161550737	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB032435, HPA055431	Supported				Renal cancer:3.22e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 419.4	Not detected		
FCGR3B	CD16, CD16b, FCG3, FCGR3	ENSG00000162747	Fc fragment of IgG receptor IIIb	1	161623196-161631963	CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 118.1;spleen: 115.2	urinary bladder: 36.3	Not detected		
FCGRT	alpha-chain, FCRN	ENSG00000104870	Fc fragment of IgG receptor and transporter	19	49506816-49526333	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012122, HPA015130	Approved					Expressed in all	Expressed in all			small intestine: 312.0	Mixed		
FCMR	FAIM3, TOSO	ENSG00000162894	Fc fragment of IgM receptor	1	206904386-206923247	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003910	Approved		Approved	Nucleus<br>Focal adhesion sites<br>Cytosol	Breast cancer:4.23e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 175.8;spleen: 148.0;tonsil: 146.7	appendix: 88.1	Group enriched	5	RPMI-8226: 97.7;U-266/70: 51.8
FCN1	FCNM	ENSG00000085265	Ficolin 1	9	134905890-134917963	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000685, HPA001295, CAB016760	Enhanced				Renal cancer:3.98e-4 (unfavourable)	Mixed	Group enriched	5	appendix: 323.4;bone marrow: 634.5	spleen: 94.6	Group enriched	7	NB-4: 12.4;U-937: 22.6
FCRL1	CD307a, FCRH1, IFGP1, IRTA5	ENSG00000163534	Fc receptor like 1	1	157794403-157820105	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013323	Enhanced					Mixed	Tissue enhanced		lymph node: 30.3;spleen: 23.5;tonsil: 20.0	appendix: 12.5	Group enriched	31	Daudi: 3.7;U-698: 11.9
FCRL2	CD307b, FCRH2, IRTA4, SPAP1	ENSG00000132704	Fc receptor like 2	1	157745733-157777132	CD markers, Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	8	appendix: 16.3;lymph node: 28.4;spleen: 25.9;tonsil: 23.7	rectum: 3.0	Group enriched	27	Daudi: 9.2;U-266/70: 2.0;U-698: 7.2
FCRL3	CD307c, FCRH3, IFGP3, IRTA3, SPAP2, SPAP2a, SPAP2b, SPAP2c, SPAP2d, SPAP2e	ENSG00000160856	Fc receptor like 3	1	157674321-157700857	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048022	Enhanced					Mixed	Group enriched	13	appendix: 18.1;lymph node: 55.9;spleen: 36.7;tonsil: 32.3	urinary bladder: 2.8	Cell line enriched	7	Daudi: 6.9
FCRL4	CD307d, FCRH4, IGFP2, IRTA1	ENSG00000163518	Fc receptor like 4	1	157573749-157598080	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA054030	Approved					Not detected	Tissue enhanced		appendix: 3.6;lymph node: 4.4;tonsil: 9.6	spleen: 1.1	Cell line enriched	36	U-266/70: 3.5
FCRL5	BXMAS1, CD307e, FCRH5, IRTA2	ENSG00000143297	Fc receptor like 5	1	157513377-157552520	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 28.7;spleen: 20.5;tonsil: 32.8	appendix: 17.9	Cell line enhanced		U-266/70: 2.5;U-698: 5.1
FCRL6	FcRH6, FLJ16056, IFGP6	ENSG00000181036	Fc receptor like 6	1	159800511-159816251	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 18.4	lung: 8.9	Not detected		
FCRLA	FCRL, FCRLa, FCRLb, FCRLc1, FCRLc2, FCRLd, FCRLe, FCRLM1, FCRLX, FREB, MGC4595	ENSG00000132185	Fc receptor like A	1	161706972-161714352	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016545	Enhanced					Tissue enriched	Group enriched	10	appendix: 31.2;lymph node: 80.5;spleen: 56.4;tonsil: 86.7	urinary bladder: 6.2	Cell line enhanced		Daudi: 338.0;SK-MEL-30: 150.5;U-698: 179.6
FDFT1		ENSG00000079459	Farnesyl-diphosphate farnesyltransferase 1	8	11795573-11839309	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008874	Approved		Supported	Endoplasmic reticulum	Renal cancer:6.59e-9 (favourable), Colorectal cancer:4.92e-5 (favourable)	Expressed in all	Expressed in all			testis: 215.0	Expressed in all		
FER1L5	DKFZp434I0121	ENSG00000249715	Fer-1 like family member 5	2	96642737-96704885	Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.5	Not detected		
FER1L6	C8ORFK23	ENSG00000214814	Fer-1 like family member 6	8	123851987-124120061	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA054117	Uncertain					Group enriched	Group enriched	5	rectum: 12.0;stomach: 42.4	small intestine: 5.1	Cell line enhanced		AF22: 1.0;ASC TERT1: 1.3;BJ hTERT+: 1.0;PC-3: 1.6;U-87 MG: 1.6
FFAR1	FFA1R, GPR40	ENSG00000126266	Free fatty acid receptor 1	19	35351552-35353862	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		bone marrow: 1.9	ovary: 1.2	Cell line enhanced		U-698: 1.1
FFAR2	FFA2R, GPR43	ENSG00000126262	Free fatty acid receptor 2	19	35443907-35451767	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA023985	Approved					Tissue enhanced	Tissue enhanced		appendix: 25.5;bone marrow: 13.3	spleen: 10.8	Cell line enhanced		HMC-1: 3.5;U-937: 1.3
FFAR3	FFA3R, GPR41	ENSG00000185897	Free fatty acid receptor 3	19	35358460-35360485	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA044681	Uncertain					Not detected	Tissue enhanced		adipose tissue: 2.5;appendix: 3.5;smooth muscle: 2.2	gallbladder: 0.8	Not detected		
FFAR4	GPR120, GPR129, O3FAR1, PGR4	ENSG00000186188	Free fatty acid receptor 4	10	93566665-93604480	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA042563	Uncertain		Uncertain	Plasma membrane		Tissue enhanced	Tissue enhanced		colon: 8.4;rectum: 12.4	lung: 5.4	Cell line enhanced		A549: 1.2;HaCaT: 2.0;NB-4: 1.6
FGFR1	BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM	ENSG00000077782	Fibroblast growth factor receptor 1	8	38411138-38468834	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB033614, HPA056402, HPA076274	Approved		Supported	Nucleoli		Expressed in all	Expressed in all			cervix, uterine: 109.5	Cell line enhanced		AN3-CA: 602.2
FGFR2	BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25	ENSG00000066468	Fibroblast growth factor receptor 2	10	121478334-121598458	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010886, HPA035305, HPA056562	Uncertain		Approved	Vesicles	Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)	Expressed in all	Mixed			skin: 129.4	Cell line enhanced		AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4
FGFR3	ACH, CD333, CEK2, JTK4	ENSG00000068078	Fibroblast growth factor receptor 3	4	1793307-1808872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB004231, HPA067204	Enhanced		Supported	Endoplasmic reticulum	Endometrial cancer:3.77e-4 (unfavourable)	Expressed in all	Tissue enriched	7	skin: 333.1	cerebral cortex: 49.4	Cell line enhanced		CACO-2: 41.4;Hep G2: 56.1;NTERA-2: 37.4;RT4: 81.0
FGFR4	CD334, JTK2	ENSG00000160867	Fibroblast growth factor receptor 4	5	177086886-177098144	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005196, HPA027273, HPA027369, HPA028251	Approved					Mixed	Tissue enhanced		lung: 38.9	duodenum: 21.4	Cell line enhanced		CACO-2: 142.3;Hep G2: 118.3;RH-30: 260.0
FGFRL1		ENSG00000127418	Fibroblast growth factor receptor-like 1	4	1009936-1026897	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB026019, HPA068828	Approved		Supported	Vesicles		Expressed in all	Expressed in all			thyroid gland: 67.6	Mixed		
FIG4	ALS11, CMT4J, dJ249I4.1, hSac3, KIAA0274, SAC3	ENSG00000112367	FIG4 phosphoinositide 5-phosphatase	6	109691312-109825428	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017823, HPA068859	Approved		Approved	Vesicles<br>Lipid droplets	Liver cancer:4.73e-4 (unfavourable), Breast cancer:5.91e-4 (unfavourable), Renal cancer:8.19e-4 (favourable), Colorectal cancer:8.42e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 33.1	Expressed in all		
FIS1	CGI-135, Fis1, H_NH0132A01.6, TTC11	ENSG00000214253	Fission, mitochondrial 1	7	101239458-101252316	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017430	Approved		Enhanced	Mitochondria	Renal cancer:1.08e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 269.9	Expressed in all		
FITM1	FIT1	ENSG00000139914	Fat storage inducing transmembrane protein 1	14	24131275-24132849	Predicted membrane proteins	Evidence at protein level	HPA019842	Uncertain				Liver cancer:1.00e-3 (favourable)	Mixed	Group enriched	15	heart muscle: 45.8;skeletal muscle: 113.0	spleen: 5.4	Cell line enriched	23	RH-30: 60.8
FITM2	C20orf142, dJ881L22.2, FIT2	ENSG00000197296	Fat storage inducing transmembrane protein 2	20	44302838-44311169	Predicted membrane proteins	Evidence at protein level						Renal cancer:8.98e-12 (favourable)	Expressed in all	Tissue enhanced		heart muscle: 40.1	parathyroid gland: 24.1	Mixed		
FKBP11	FKBP19	ENSG00000134285	FK506 binding protein 11	12	48921518-48926474	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041709	Enhanced		Approved	Centrosome	Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:7.09e-4 (favourable)	Expressed in all	Mixed			pancreas: 60.7	Mixed		
FKBP1A	FKBP-12, FKBP1, FKBP12, FKBP12C, PKC12, PPIASE	ENSG00000088832	FK506 binding protein 1A	20	1368978-1393172	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004639, HPA051798	Uncertain				Liver cancer:3.44e-7 (unfavourable), Renal cancer:6.69e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 369.7	Expressed in all		
FKBP8	FKBP38, FKBPr38	ENSG00000105701	FK506 binding protein 8	19	18531751-18544077	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025346, HPA045177	Supported		Supported	Endoplasmic reticulum<br>Mitochondria<br>Cytosol	Colorectal cancer:1.24e-4 (unfavourable), Pancreatic cancer:7.76e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 354.7	Expressed in all		
FKRP	LGMD2I, MDC1C	ENSG00000181027	Fukutin related protein	19	46746046-46776988	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043115, HPA060454	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Pancreatic cancer:8.98e-4 (favourable)	Expressed in all	Expressed in all			placenta: 14.9	Expressed in all		
FLRT1	MGC21624, SPG68	ENSG00000126500	Fibronectin leucine rich transmembrane protein 1	11	64103188-64119173	Predicted membrane proteins	Evidence at protein level	HPA054589	Uncertain					Mixed	Tissue enhanced		adrenal gland: 5.9;cerebral cortex: 12.5	cervix, uterine: 4.0	Cell line enhanced		SCLC-21H: 6.4;SH-SY5Y: 14.3;THP-1: 7.6
FLRT2		ENSG00000185070	Fibronectin leucine rich transmembrane protein 2	14	85530144-85654426	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		ovary: 36.4	cervix, uterine: 16.7	Cell line enhanced		hTERT-HME1: 46.2;TIME: 45.0;U-138 MG: 57.9;U-2197: 39.9
FLRT3		ENSG00000125848	Fibronectin leucine rich transmembrane protein 3	20	14322988-14337616	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB026166, HPA056033	Enhanced		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.49e-7 (favourable), Lung cancer:9.85e-5 (unfavourable), Pancreatic cancer:1.54e-4 (unfavourable)	Expressed in all	Mixed			lung: 32.3	Cell line enhanced		AF22: 32.9;hTCEpi: 45.3;WM-115: 75.5
FLT1	FLT, VEGFR1	ENSG00000102755	Fms related tyrosine kinase 1	13	28300344-28495145	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA011740, HPA014290, CAB068189, CAB068190	Enhanced		Supported	Plasma membrane<br>Actin filaments	Renal cancer:2.19e-4 (unfavourable)	Expressed in all	Tissue enriched	8	placenta: 622.5	thyroid gland: 81.9	Cell line enhanced		BJ: 61.1;HMC-1: 308.1;WM-115: 126.2
FLT3	CD135, FLK2, STK1	ENSG00000122025	Fms related tyrosine kinase 3	13	28003274-28100592	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA047539			Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		lymph node: 7.0;spleen: 7.7	appendix: 3.9	Group enriched	14	REH: 38.7;THP-1: 17.4
FLT3LG		ENSG00000090554	Fms related tyrosine kinase 3 ligand	19	49474207-49486231	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Cervical cancer:2.17e-5 (favourable)	Mixed	Mixed			lymph node: 27.7	Mixed		
FLT4	PCL, VEGFR3	ENSG00000037280	Fms related tyrosine kinase 4	5	180601506-180649624	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000099, HPA046519, HPA067906	Approved		Enhanced	Nuclear speckles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			spleen: 18.3	Cell line enhanced		BEWO: 11.8;HEK93: 14.1;T-47d: 13.7;TIME: 12.7
FLVCR1	AXPC1, FLVCR, MFSD7B, PCA	ENSG00000162769	Feline leukemia virus subgroup C cellular receptor 1	1	212858255-212899363	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046646	Approved		Approved	Cell Junctions	Renal cancer:1.06e-5 (unfavourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:3.50e-4 (favourable)	Expressed in all	Tissue enhanced		small intestine: 21.4	duodenum: 9.8	Expressed in all		
FLVCR2	C14orf58, FLJ20371, MFSD7C	ENSG00000119686	Feline leukemia virus subgroup C cellular receptor family member 2	14	75578617-75663214	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037984	Enhanced				Renal cancer:2.53e-5 (favourable)	Expressed in all	Tissue enhanced		testis: 38.8	small intestine: 26.9	Cell line enhanced		ASC diff: 37.0;BEWO: 71.0
FMNL1	C17orf1, C17orf1B, FMNL	ENSG00000184922	Formin like 1	17	45221444-45247320	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008129, HPA028288	Enhanced		Approved	Cytosol	Renal cancer:4.23e-8 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 175.0	Cell line enhanced		Karpas-707: 137.1;MOLT-4: 110.5;U-266/70: 120.6
FMO1		ENSG00000010932	Flavin containing monooxygenase 1	1	171248471-171285978	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA023680	Uncertain				Renal cancer:2.81e-4 (favourable)	Tissue enriched	Tissue enriched	9	kidney: 203.2	small intestine: 22.8	Cell line enriched	8	HSkMC: 14.8
FMO2		ENSG00000094963	Flavin containing monooxygenase 2	1	171185208-171211230	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA028261	Approved					Mixed	Tissue enhanced		adipose tissue: 98.3;esophagus: 102.9;lung: 158.2	breast: 55.8	Group enriched	48	ASC diff: 27.9;ASC TERT1: 12.9;HSkMC: 35.2
FMO3		ENSG00000007933	Flavin containing monooxygenase 3	1	171090877-171117819	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013750	Enhanced				Lung cancer:5.60e-5 (favourable), Renal cancer:1.13e-4 (unfavourable), Liver cancer:3.46e-4 (favourable)	Tissue enriched	Tissue enriched	24	liver: 556.7	fallopian tube: 22.8	Group enriched	13	ASC diff: 23.4;ASC TERT1: 17.9;HSkMC: 5.1
FMO4	FMO2	ENSG00000076258	Flavin containing monooxygenase 4	1	171314208-171342084	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA049100	Uncertain				Liver cancer:1.09e-4 (favourable), Renal cancer:6.96e-4 (favourable), Lung cancer:7.45e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 48.2;liver: 30.1	parathyroid gland: 10.9	Cell line enhanced		EFO-21: 5.2
FMO5		ENSG00000131781	Flavin containing monooxygenase 5	1	147175351-147243050	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012373	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.34e-6 (favourable)	Tissue enriched	Tissue enhanced		liver: 324.7	small intestine: 75.4	Cell line enhanced		Hep G2: 26.6;HMC-1: 7.7;THP-1: 6.7
FMR1NB	CT37, FLJ25736, NY-SAR-35	ENSG00000176988	Fragile X mental retardation 1 neighbor	X	147981329-148026667	Predicted membrane proteins	Evidence at protein level	HPA011284, CAB026403	Enhanced					Tissue enhanced	Tissue enriched	415	testis: 86.9	epididymis: 0.2	Group enriched	24	U-266/70: 50.9;U-266/84: 39.2
FNDC10	C1orf233	ENSG00000228594	Fibronectin type III domain containing 10	1	1598012-1600096	Predicted membrane proteins	Evidence at protein level						Renal cancer:1.11e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 12.7	cerebral cortex: 9.4	Cell line enhanced		HMC-1: 24.9
FNDC3A	bA203I16.5, FNDC3, KIAA0970	ENSG00000102531	Fibronectin type III domain containing 3A	13	48975912-49209779	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008927, HPA012825	Approved		Approved	Endoplasmic reticulum	Renal cancer:4.25e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 85.7	Expressed in all		
FNDC3B	DKFZp762K137, FAD104, FLJ23399, PRO4979, YVTM2421	ENSG00000075420	Fibronectin type III domain containing 3B	3	172039628-172401665	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007859	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:5.65e-7 (unfavourable), Cervical cancer:2.41e-5 (unfavourable), Pancreatic cancer:9.06e-5 (unfavourable), Liver cancer:9.85e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 77.5	Expressed in all		
FNDC4	FLJ22362, FRCP1	ENSG00000115226	Fibronectin type III domain containing 4	2	27491883-27495245	Predicted membrane proteins	Evidence at transcript level	HPA051804, HPA063581	Uncertain		Approved	Nucleoplasm<br>Aggresome<br>Cytosol	Endometrial cancer:5.07e-4 (unfavourable), Urothelial cancer:6.11e-4 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 72.5	cerebral cortex: 35.9	Cell line enhanced		AN3-CA: 31.3;HUVEC TERT2: 34.8;SH-SY5Y: 33.9;TIME: 31.2
FNDC5	FRCP2	ENSG00000160097	Fibronectin type III domain containing 5	1	32862268-32872482	Predicted membrane proteins	Evidence at protein level	HPA051290	Approved					Group enriched	Tissue enhanced		skeletal muscle: 110.2	heart muscle: 26.5	Cell line enhanced		RH-30: 45.0;SCLC-21H: 9.3
FNDC9	C5orf40, MGC27121	ENSG00000172568	Fibronectin type III domain containing 9	5	157341600-157345721	Predicted membrane proteins	Evidence at transcript level	HPA011115, HPA017291	Approved					Tissue enriched	Group enriched	18	adrenal gland: 6.2;cerebral cortex: 20.7	appendix: 0.7	Not detected		
FOCAD	FLJ20375, KIAA1797	ENSG00000188352	Focadhesin	9	20658309-20995955	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055015	Uncertain		Uncertain	Mitochondria	Renal cancer:3.09e-8 (favourable), Liver cancer:4.41e-5 (unfavourable), Colorectal cancer:3.25e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 34.2	Mixed		
FOLH1	FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA	ENSG00000086205	Folate hydrolase 1	11	49146635-49208670	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB001451, HPA010593	Enhanced				Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable)	Tissue enriched	Group enriched	6	duodenum: 298.8;prostate: 136.6;small intestine: 90.8	cerebral cortex: 31.0	Mixed		
FOLR1	FOLR	ENSG00000110195	Folate receptor 1	11	72189558-72196323	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA077030			Approved	Nuclear membrane	Liver cancer:2.50e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 166.6;fallopian tube: 275.8;lung: 267.5	kidney: 152.7	Group enriched	6	HeLa: 298.2;RPTEC TERT1: 350.8
FOLR2		ENSG00000165457	Folate receptor beta	11	72216601-72221950	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Thyroid cancer:8.41e-4 (favourable), Colorectal cancer:8.42e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 235.4	Group enriched	6	Daudi: 2.6;U-698: 12.5
FPR1	FMLP, FPR	ENSG00000171051	Formyl peptide receptor 1	19	51745172-51804110	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA046550, HPA061744	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Renal cancer:2.21e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 177.8	bone marrow: 95.0	Cell line enriched	6	U-87 MG: 51.5
FPR2	ALXR, FMLP-R-II, FMLPX, FPR2A, FPRH2, FPRL1, HM63, LXA4R	ENSG00000171049	Formyl peptide receptor 2	19	51752026-51770526	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029154	Approved					Mixed	Tissue enhanced		appendix: 69.7	spleen: 19.7	Cell line enriched	21	U-937: 23.5
FPR3	FMLPY, FPRH1, FPRL2, RMLP-R-I	ENSG00000187474	Formyl peptide receptor 3	19	51795163-51826189	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level						Testis cancer:9.13e-4 (unfavourable)	Expressed in all	Mixed			lung: 41.2	Cell line enriched	9	HEL: 9.0
FRAS1	FLJ14927, FLJ22031, KIAA1500	ENSG00000138759	Fraser extracellular matrix complex subunit 1	4	78057570-78544269	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011281, HPA051601	Approved		Approved	Nucleoli fibrillar center	Renal cancer:4.69e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 20.2	kidney,placenta: 8.2	Cell line enhanced		fHDF/TERT166: 28.1;RH-30: 19.7;SiHa: 23.0
FREM2	DKFZp686J0811	ENSG00000150893	FRAS1 related extracellular matrix protein 2	13	38687129-38887131	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA028831	Uncertain		Approved	Cytosol	Renal cancer:2.23e-7 (favourable)	Mixed	Tissue enhanced		kidney: 8.2;thyroid gland: 8.3	lung: 3.3	Cell line enhanced		AF22: 15.4;HAP1: 10.9;MCF7: 6.0;RT4: 5.7;WM-115: 5.8
FRMD3	EPB41L4O, MGC20553	ENSG00000172159	FERM domain containing 3	9	83242990-83538546	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017285	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane	Thyroid cancer:1.79e-4 (favourable), Renal cancer:7.24e-4 (favourable)	Tissue enhanced	Tissue enhanced		heart muscle: 56.5	skeletal muscle: 28.5	Cell line enhanced		HEL: 21.0;RPMI-8226: 54.8;SCLC-21H: 32.9
FRMD5	MGC14161	ENSG00000171877	FERM domain containing 5	15	43870761-44195252	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011746, HPA013961			Uncertain	Golgi apparatus<br>Centrosome	Pancreatic cancer:5.89e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 20.4;heart muscle: 29.4	adrenal gland: 7.2	Cell line enhanced		WM-115: 59.3
FRRS1	SDFR2, SDR2	ENSG00000156869	Ferric chelate reductase 1	1	99708703-99766631	Predicted membrane proteins	Evidence at protein level	HPA017883	Approved				Renal cancer:6.53e-4 (unfavourable)	Expressed in all	Mixed			placenta: 15.8	Cell line enhanced		HEL: 33.4
FRRS1L	C9orf4, CG-6	ENSG00000260230	Ferric chelate reductase 1 like	9	109130293-109167291	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA071086	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 47.7	ovary: 14.2	Cell line enhanced		AF22: 1.6;SH-SY5Y: 4.3
FSD1L	CCDC10, CSDUFD1, FSD1CL, FSD1NL	ENSG00000106701	Fibronectin type III and SPRY domain containing 1 like	9	105447796-105552433	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035138	Approved		Approved	Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		cerebral cortex: 17.8	testis: 13.5	Mixed		
FSHR	FSHRO, LGR1, ODG1	ENSG00000170820	Follicle stimulating hormone receptor	2	48962157-49154537	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Group enriched	9	ovary: 2.5;testis: 4.3	gallbladder: 0.3	Not detected		
FURIN	FUR, PACE, PCSK3, SPC1	ENSG00000140564	Furin, paired basic amino acid cleaving enzyme	15	90868592-90883458	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009499	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Lung cancer:1.58e-4 (unfavourable)	Expressed in all	Expressed in all			salivary gland: 92.8	Expressed in all		
FUT1	H, HSC	ENSG00000174951	Fucosyltransferase 1 (H blood group)	19	48748011-48755390	Blood group antigen proteins, Enzymes, Predicted membrane proteins	Evidence at protein level						Renal cancer:3.99e-4 (favourable)	Mixed	Mixed			stomach: 7.1	Cell line enhanced		HEL: 8.6;SCLC-21H: 8.1
FUT2	SE, Se2, SEC2, sej	ENSG00000176920	Fucosyltransferase 2	19	48695971-48705950	Blood group antigen proteins, Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014402	Uncertain		Uncertain	Plasma membrane<br>Cytosol	Head and neck cancer:5.83e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 51.4	stomach: 32.2	Cell line enriched	6	CAPAN-2: 68.6
FUT3	CD174, LE	ENSG00000171124	Fucosyltransferase 3 (Lewis blood group)	19	5842888-5851474	Blood group antigen proteins, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046966	Supported				Renal cancer:8.22e-7 (favourable), Breast cancer:6.86e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 68.0;esophagus: 83.0;small intestine: 63.1	rectum: 49.4	Group enriched	5	A-431: 40.5;RH-30: 14.4
FUT4	CD15, ELFT, FCT3A, FUC-TIV	ENSG00000196371	Fucosyltransferase 4	11	94543840-94549898	Predicted membrane proteins	Evidence at protein level	CAB000014, CAB016129	Enhanced		Enhanced	Vesicles	Lung cancer:3.64e-4 (unfavourable)	Expressed in all	Tissue enriched	5	bone marrow: 62.9	duodenum: 12.4	Cell line enhanced		HL-60: 29.6;THP-1: 31.3;U-937: 25.8
FUT5	FUC-TV	ENSG00000130383	Fucosyltransferase 5	19	5865826-5870540	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA046966	Uncertain					Not detected	Not detected			bone marrow,testis: 0.3	Not detected		
FUT6	FCT3A, FLJ40754, FT1A, FucT-VI	ENSG00000156413	Fucosyltransferase 6	19	5830610-5839731	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043707, HPA046966	Approved		Supported	Golgi apparatus	Renal cancer:3.17e-8 (favourable), Head and neck cancer:2.12e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 49.8;kidney: 34.5	small intestine: 30.6	Group enriched	5	Hep G2: 7.2;RPMI-8226: 2.7
FUT8		ENSG00000033170	Fucosyltransferase 8	14	65410592-65744121	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017129, HPA040863, HPA043410	Enhanced		Enhanced	Golgi apparatus<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 31.5	Expressed in all		
FUT9	Fuc-TIX	ENSG00000172461	Fucosyltransferase 9	6	96015984-96215612	Predicted membrane proteins	Evidence at protein level	HPA070923			Approved	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge<br>Cytosol		Tissue enhanced	Group enriched	12	cerebral cortex: 28.1;stomach: 22.4	duodenum: 2.0	Cell line enhanced		MCF7: 2.2;RT4: 5.1;SCLC-21H: 7.5;SK-BR-3: 2.7
FUZ	FLJ22688, Fy	ENSG00000010361	Fuzzy planar cell polarity protein	19	49806869-49817376	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041779, HPA042196	Uncertain		Approved	Cytosol	Renal cancer:1.50e-5 (favourable)	Expressed in all	Expressed in all			testis: 52.0	Mixed		
FXYD1	PLM	ENSG00000266964	FXYD domain containing ion transport regulator 1	19	35138808-35143109	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026873			Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:7.59e-8 (unfavourable), Glioma:9.67e-4 (unfavourable)	Tissue enhanced	Expressed in all			skeletal muscle: 469.1	Cell line enhanced		ASC diff: 30.9;ASC TERT1: 9.1;HSkMC: 13.6
FXYD2	ATP1G1, HOMG2, MGC12372	ENSG00000137731	FXYD domain containing ion transport regulator 2	11	117800844-117828698	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064218, HPA068838	Supported		Approved	Mitochondria	Renal cancer:3.23e-9 (favourable)	Tissue enriched	Group enriched	6	gallbladder: 571.3;kidney: 1433.1;salivary gland: 380.4	pancreas: 134.6	Group enriched	24	MOLT-4: 1801.2;RPTEC TERT1: 3683.4
FXYD3	MAT-8, PLML	ENSG00000089356	FXYD domain containing ion transport regulator 3	19	35115879-35124324	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010856	Enhanced				Renal cancer:1.15e-6 (unfavourable)	Expressed in all	Tissue enhanced		colon: 1455.6;rectum: 1952.1	stomach: 557.3	Cell line enhanced		HaCaT: 792.6;hTCEpi: 1156.1;RT4: 686.4;SK-BR-3: 621.3;WM-115: 590.3
FXYD4	CHIF	ENSG00000150201	FXYD domain containing ion transport regulator 4	10	43371642-43376335	Predicted membrane proteins	Evidence at protein level	HPA058421	Enhanced					Group enriched	Tissue enriched	26	kidney: 127.4	stomach: 4.8	Not detected		
FXYD5	OIT2	ENSG00000089327	FXYD domain containing ion transport regulator 5	19	35154730-35169883	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010817	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:3.71e-9 (unfavourable)	Expressed in all	Expressed in all			spleen: 237.1	Mixed		
FXYD6		ENSG00000137726	FXYD domain containing ion transport regulator 6	11	117836976-117877486	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041334, HPA042284	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:1.05e-5 (unfavourable), Renal cancer:4.38e-5 (favourable), Urothelial cancer:1.60e-4 (unfavourable), Liver cancer:5.87e-4 (favourable), Pancreatic cancer:5.97e-4 (favourable)	Tissue enriched	Expressed in all			cerebral cortex: 696.9	Cell line enhanced		AF22: 128.6;HAP1: 89.7;SCLC-21H: 231.1;SH-SY5Y: 118.8
FXYD6-FXYD2		ENSG00000255245	FXYD6-FXYD2 readthrough	11	117820163-117876667	Predicted membrane proteins	Evidence at transcript level	HPA068838, HPA075209	Approved		Approved	Nuclear membrane<br>Vesicles		Not detected	Tissue enhanced		kidney: 5.6	salivary gland: 2.1	Group enriched	6	MOLT-4: 5.2;RPTEC TERT1: 5.3
FXYD7		ENSG00000221946	FXYD domain containing ion transport regulator 7	19	35143250-35154301	Predicted membrane proteins	Evidence at protein level	HPA026916	Approved					Tissue enhanced	Tissue enriched	35	cerebral cortex: 105.8	lymph node: 3.0	Cell line enhanced		HAP1: 1.8;HMC-1: 4.5;WM-115: 3.1
FZD1	DKFZp564G072	ENSG00000157240	Frizzled class receptor 1	7	91264364-91271326	Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB013008	Approved		Supported	Plasma membrane	Renal cancer:8.87e-7 (favourable)	Expressed in all	Mixed			thyroid gland: 32.4	Mixed		
FZD10	CD350	ENSG00000111432	Frizzled class receptor 10	12	130162459-130165740	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014484, HPA014485	Uncertain		Supported	Nucleoplasm	Endometrial cancer:5.05e-7 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 9.4;esophagus: 8.8	skin: 5.6	Cell line enhanced		AF22: 5.4;BEWO: 6.1;hTCEpi: 2.6;RT4: 2.5
FZD2		ENSG00000180340	Frizzled class receptor 2	17	44557459-44559570	Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA057667	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Cell Junctions		Expressed in all	Mixed			placenta: 4.9	Mixed		
FZD3		ENSG00000104290	Frizzled class receptor 3	8	28494205-28574268	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB024995	Approved				Colorectal cancer:1.17e-4 (favourable), Ovarian cancer:3.71e-4 (favourable)	Mixed	Mixed			cerebral cortex: 16.4	Cell line enhanced		AF22: 53.7;SCLC-21H: 46.9
FZD4	CD344, EVR1	ENSG00000174804	Frizzled class receptor 4	11	86945679-86955391	CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA042328, HPA074833	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.60e-5 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 127.3	seminal vesicle: 42.3	Cell line enhanced		ASC diff: 43.7;Hep G2: 57.9;HUVEC TERT2: 78.0;TIME: 37.7
FZD5	C2orf31, DKFZP434E2135, HFZ5	ENSG00000163251	Frizzled class receptor 5	2	207762586-207769563	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA052361	Approved					Expressed in all	Mixed			duodenum: 19.6	Cell line enhanced		BEWO: 105.1;NTERA-2: 32.1
FZD6	Hfz6	ENSG00000164930	Frizzled class receptor 6	8	103298433-103332866	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA017991	Approved		Approved	Plasma membrane	Pancreatic cancer:1.20e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 45.5	Mixed		
FZD7	FzE3	ENSG00000155760	Frizzled class receptor 7	2	202034587-202038445	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA069165	Approved		Approved	Nucleoplasm	Liver cancer:7.71e-5 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 39.1	Cell line enhanced		CAPAN-2: 63.3
FZD8		ENSG00000177283	Frizzled class receptor 8	10	35638249-35642278	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA045025, HPA071142	Approved		Approved	Endoplasmic reticulum	Pancreatic cancer:8.21e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 15.9	lung: 6.6	Cell line enhanced		PC-3: 37.6;U-138 MG: 14.7
FZD9	CD349, FZD3	ENSG00000188763	Frizzled class receptor 9	7	73433783-73436120	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Mixed			skeletal muscle,testis: 1.5	Cell line enhanced		HEK93: 4.1;NTERA-2: 3.5
G6PC	G6PT, GSD1a	ENSG00000131482	Glucose-6-phosphatase catalytic subunit	17	42900797-42913369	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA052324	Enhanced				Renal cancer:3.79e-5 (favourable), Liver cancer:5.42e-5 (favourable)	Tissue enriched	Tissue enhanced		kidney: 89.1;liver: 147.3	small intestine: 33.2	Not detected		
G6PC2	IGRP	ENSG00000152254	Glucose-6-phosphatase catalytic subunit 2	2	168901240-168910000	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	12	pancreas: 2.9	testis: 0.2	Not detected		
G6PC3	UGRP	ENSG00000141349	Glucose-6-phosphatase catalytic subunit 3	17	44070735-44076344	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067052			Supported	Endoplasmic reticulum	Endometrial cancer:1.11e-4 (favourable), Liver cancer:9.61e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 84.3	Expressed in all		
GABBR1	GPRC3A, hGB1a	ENSG00000204681	Gamma-aminobutyric acid type B receptor subunit 1	6	29555629-29633976	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050483, HPA058459	Uncertain		Approved	Centrosome	Renal cancer:3.77e-10 (unfavourable), Pancreatic cancer:2.54e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 20.8	spleen: 13.1	Cell line enhanced		U-2 OS: 6.7
GABBR2	GABABR2, GPR51, GPRC3B, HG20	ENSG00000136928	Gamma-aminobutyric acid type B receptor subunit 2	9	98288082-98709197	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013820, HPA031684, CAB079065	Enhanced	Approved				Group enriched	Tissue enriched	18	cerebral cortex: 77.9	adrenal gland: 4.3	Cell line enhanced		BJ: 11.3;HUVEC TERT2: 22.8;U-138 MG: 10.3
GABRA1	EJM5	ENSG00000022355	Gamma-aminobutyric acid type A receptor alpha1 subunit	5	161847063-161899981	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022502, HPA055746	Enhanced					Tissue enriched	Tissue enriched	46	cerebral cortex: 85.0	adrenal gland: 1.8	Not detected		
GABRA2		ENSG00000151834	Gamma-aminobutyric acid type A receptor alpha2 subunit	4	46248427-46475230	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB079061		Supported				Tissue enhanced	Tissue enriched	7	cerebral cortex: 74.3	epididymis: 11.3	Cell line enhanced		U-2 OS: 4.9;U-87 MG: 2.2;WM-115: 2.5
GABRA3		ENSG00000011677	Gamma-aminobutyric acid type A receptor alpha3 subunit	X	152166234-152451358	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA000839	Approved	Supported				Tissue enriched	Tissue enriched	7	cerebral cortex: 28.8	placenta: 4.1	Cell line enhanced		HMC-1: 7.4;Karpas-707: 10.3;PC-3: 7.8;U-2 OS: 7.3;U-266/84: 9.5;U-87 MG: 8.1
GABRA4		ENSG00000109158	Gamma-aminobutyric acid type A receptor alpha4 subunit	4	46918900-46994407	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	9	cerebral cortex: 15.1	heart muscle: 1.6	Cell line enriched	127	REH: 12.7
GABRA5		ENSG00000186297	Gamma-aminobutyric acid type A receptor alpha5 subunit	15	26866363-26949207	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA077031, CAB079022		Supported	Supported	Plasma membrane		Mixed	Tissue enriched	43	cerebral cortex: 81.6	esophagus: 1.8	Group enriched	10	A549: 32.7;HAP1: 12.7;NTERA-2: 14.6;U-2 OS: 13.1
GABRA6		ENSG00000145863	Gamma-aminobutyric acid type A receptor alpha6 subunit	5	161547063-161702593	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	CAB022462	Approved					Not detected	Tissue enhanced		testis: 1.1	cerebral cortex: 0.3	Not detected		
GABRB1		ENSG00000163288	Gamma-aminobutyric acid type A receptor beta1 subunit	4	46993723-47426444	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051297	Uncertain					Tissue enhanced	Tissue enriched	12	cerebral cortex: 19.7	heart muscle: 1.5	Cell line enhanced		REH: 1.4;U-87 MG: 2.4
GABRB2		ENSG00000145864	Gamma-aminobutyric acid type A receptor beta2 subunit	5	161288429-161549044	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001964, HPA067632	Enhanced					Tissue enriched	Tissue enriched	12	cerebral cortex: 62.8	epididymis: 5.2	Cell line enriched	17	SCLC-21H: 27.6
GABRB3		ENSG00000166206	Gamma-aminobutyric acid type A receptor beta3 subunit	15	26543546-26939539	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 78.3	gallbladder: 21.5	Cell line enhanced		A549: 61.5;HAP1: 28.7;NTERA-2: 48.0;SCLC-21H: 51.8
GABRD		ENSG00000187730	Gamma-aminobutyric acid type A receptor delta subunit	1	2019298-2030758	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044371	Enhanced		Uncertain	Golgi apparatus<br>Vesicles	Renal cancer:4.12e-8 (unfavourable)	Expressed in all	Tissue enriched	12	cerebral cortex: 34.0	testis: 2.7	Cell line enhanced		EFO-21: 1.3;MCF7: 3.1;NB-4: 1.6;SH-SY5Y: 1.6
GABRE		ENSG00000102287	Gamma-aminobutyric acid type A receptor epsilon subunit	X	151953124-151974680	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level	HPA045918	Uncertain				Renal cancer:4.05e-11 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 10.1	heart muscle: 6.4	Cell line enhanced		EFO-21: 10.9;HeLa: 3.5;SiHa: 5.9
GABRG1		ENSG00000163285	Gamma-aminobutyric acid type A receptor gamma1 subunit	4	46035769-46124081	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level	HPA035622	Approved					Tissue enriched	Tissue enriched	17	cerebral cortex: 26.0	ovary: 1.5	Cell line enhanced		U-266/70: 1.1
GABRG2		ENSG00000113327	Gamma-aminobutyric acid type A receptor gamma2 subunit	5	162000057-162162977	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB079060		Supported				Tissue enhanced	Tissue enriched	12	cerebral cortex: 66.5	adrenal gland: 5.3	Cell line enhanced		CACO-2: 11.6;U-266/70: 17.2;U-266/84: 13.6
GABRG3		ENSG00000182256	Gamma-aminobutyric acid type A receptor gamma3 subunit	15	26971282-27541991	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054010	Supported					Tissue enhanced	Tissue enhanced		prostate: 10.6;testis: 16.5	cerebral cortex: 4.2	Cell line enhanced		K-562: 4.0;PC-3: 5.1;U-87 MG: 14.0
GABRP		ENSG00000094755	Gamma-aminobutyric acid type A receptor pi subunit	5	170763350-170814047	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB014883	Uncertain				Cervical cancer:3.37e-4 (favourable)	Mixed	Expressed in all			breast: 177.0	Cell line enhanced		A-431: 184.7;EFO-21: 182.4;PC-3: 293.8
GABRQ	THETA	ENSG00000268089	Gamma-aminobutyric acid type A receptor theta subunit	X	152638183-152657534	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		cerebral cortex: 6.6;cervix, uterine: 12.9	adrenal gland: 3.0	Group enriched	7	HeLa: 8.2;SiHa: 12.7;U-87 MG: 37.4
GABRR1		ENSG00000146276	Gamma-aminobutyric acid type A receptor rho1 subunit	6	89177501-89231278	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	6	testis: 1.8	placenta: 0.3	Cell line enhanced		NTERA-2: 1.2
GABRR2		ENSG00000111886	Gamma-aminobutyric acid type A receptor rho2 subunit	6	89257208-89315299	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			adrenal gland,appendix,cerebral cortex,endometrium,gallbladder,lymph node,skin,spleen,testis,thyroid gland: 0.1	Not detected		
GABRR3		ENSG00000183185	Gamma-aminobutyric acid type A receptor rho3 subunit (gene/pseudogene)	3	97986673-98035304	FDA approved drug targets, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
GAL3ST4	FLJ12116	ENSG00000197093	Galactose-3-O-sulfotransferase 4	7	100159244-100168750	Predicted membrane proteins	Evidence at protein level	HPA038137, HPA038138	Uncertain		Approved	Nucleoplasm<br>Cytosol	Ovarian cancer:2.57e-4 (unfavourable), Renal cancer:4.14e-4 (unfavourable), Colorectal cancer:5.44e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 32.6	smooth muscle: 14.7	Cell line enhanced		WM-115: 42.3
GALC		ENSG00000054983	Galactosylceramidase	14	87837820-87993665	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB022196	Approved					Expressed in all	Expressed in all			testis: 44.0	Cell line enhanced		CAPAN-2: 72.3;HMC-1: 67.2
GALNT1	GalNAc-T1	ENSG00000141429	Polypeptide N-acetylgalactosaminyltransferase 1	18	35581117-35711834	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012628	Uncertain					Expressed in all	Expressed in all			urinary bladder: 85.6	Expressed in all		
GALNT11	GalNAc-T11	ENSG00000178234	Polypeptide N-acetylgalactosaminyltransferase 11	7	152025674-152122347	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA039330	Uncertain				Renal cancer:2.24e-6 (favourable), Glioma:8.42e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 242.9	Mixed		
GALNT14	FLJ12691, GalNac-T10, GalNac-T14	ENSG00000158089	Polypeptide N-acetylgalactosaminyltransferase 14	2	30910467-31155202	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030138			Approved	Nucleus<br>Golgi apparatus		Tissue enriched	Tissue enhanced		kidney: 40.3	parathyroid gland: 12.8	Cell line enhanced		RPTEC TERT1: 29.5;RT4: 23.6;SCLC-21H: 25.2
GALNT18	GalNAc-T18, GALNT15, GALNTL4, MGC71806	ENSG00000110328	Polypeptide N-acetylgalactosaminyltransferase 18	11	11270876-11622005	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA012955	Approved		Approved	Mitochondria	Endometrial cancer:1.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 59.3	lung: 43.2	Cell line enhanced		A-431: 36.5;HaCaT: 46.1;PC-3: 33.7;SK-BR-3: 35.3;U-87 MG: 32.9
GALNT3	GalNAc-T3, HFTC, HHS	ENSG00000115339	Polypeptide N-acetylgalactosaminyltransferase 3	2	165747591-165794682	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007613	Enhanced		Supported	Golgi apparatus	Cervical cancer:2.08e-4 (unfavourable), Head and neck cancer:4.10e-4 (unfavourable)	Expressed in all	Mixed			stomach: 86.1	Cell line enhanced		CAPAN-2: 92.9;HaCaT: 108.1;hTCEpi: 82.6
GALNT8	GALNAC-T8	ENSG00000130035	Polypeptide N-acetylgalactosaminyltransferase 8	12	4720341-4851927	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012638, HPA014418, HPA073461	Approved		Approved	Vesicles		Tissue enhanced	Group enriched	7	cerebral cortex: 19.4;colon: 17.6;duodenum: 8.1;rectum: 40.6;small intestine: 18.9;testis: 26.5	appendix: 3.2	Cell line enhanced		Karpas-707: 24.5;NTERA-2: 12.1;U-2 OS: 4.6;U-266/84: 7.3
GALNT9	GALNAC-T9	ENSG00000182870	Polypeptide N-acetylgalactosaminyltransferase 9	12	132196372-132329349	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA075016			Approved	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 29.4	thyroid gland: 6.3	Cell line enriched	6	U-87 MG: 30.6
GALNTL5	GalNAc-T5L, GALNT15	ENSG00000106648	Polypeptide N-acetylgalactosaminyltransferase-like 5	7	151956379-152019934	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA011140	Enhanced					Not detected	Tissue enriched	14	testis: 11.1	cerebral cortex: 0.8	Not detected		
GALR1	GALNR, GALNR1	ENSG00000166573	Galanin receptor 1	18	77250549-77277896	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		adrenal gland: 2.1;cerebral cortex: 1.7	prostate,seminal vesicle,testis: 0.4	Not detected		
GALR2	GALNR2	ENSG00000182687	Galanin receptor 2	17	76074794-76077541	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA044513	Approved					Mixed	Tissue enhanced		smooth muscle: 2.4	bone marrow: 0.6	Cell line enhanced		NTERA-2: 2.0;THP-1: 2.0
GALR3		ENSG00000128310	Galanin receptor 3	22	37823382-37825495	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			cerebral cortex,testis: 0.2	Not detected		
GCGR	GGR	ENSG00000215644	Glucagon receptor	17	81804132-81814013	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071228			Approved	Golgi apparatus		Tissue enhanced	Group enriched	7	adrenal gland: 6.6;kidney: 8.4;liver: 20.8;parathyroid gland: 8.0	skin: 1.6	Cell line enhanced		HeLa: 1.2;MCF7: 2.2;SK-BR-3: 1.8;U-87 MG: 2.7
GCLC	GCS, GLCL, GLCLC	ENSG00000001084	Glutamate-cysteine ligase catalytic subunit	6	53497341-53616970	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009569, HPA036359, HPA036360	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.83e-6 (favourable), Thyroid cancer:8.24e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 80.9	Expressed in all		
GCNT2	bA360O19.2, bA421M1.1, CCAT, GCNT5, IGNT, II, NACGT1, NAGCT1, ULG3	ENSG00000111846	Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)	6	10492223-10629368	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026776	Approved		Supported	Golgi apparatus		Mixed	Tissue enhanced		prostate: 55.7	breast: 13.9	Cell line enhanced		CACO-2: 39.6;EFO-21: 67.0
GCNT3	C2/4GnT, C2GnT-M, C2GnT2	ENSG00000140297	Glucosaminyl (N-acetyl) transferase 3, mucin type	15	59594875-59640239	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA011154	Enhanced		Approved	Golgi apparatus<br>Vesicles	Liver cancer:6.49e-5 (unfavourable), Endometrial cancer:1.78e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 142.2;gallbladder: 118.0;rectum: 134.6;small intestine: 138.4	duodenum: 97.7	Cell line enriched	6	A549: 133.3
GDAP1	CMT2K, CMT4, CMT4A	ENSG00000104381	Ganglioside induced differentiation associated protein 1	8	74321130-74488872	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014266, HPA024334	Enhanced		Supported	Mitochondria<br>Cytosol	Endometrial cancer:1.82e-4 (unfavourable), Lung cancer:2.68e-4 (favourable), Thyroid cancer:4.54e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 76.7	parathyroid gland: 18.3	Cell line enhanced		SH-SY5Y: 49.8
GDAP1L1		ENSG00000124194	Ganglioside induced differentiation associated protein 1 like 1	20	44247099-44280917	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054182, HPA063265	Approved		Approved	Endoplasmic reticulum		Tissue enriched	Tissue enriched	20	cerebral cortex: 55.6	adrenal gland: 2.8	Group enriched	6	NTERA-2: 11.9;SCLC-21H: 34.5;SH-SY5Y: 15.2
GDE1	MIR16	ENSG00000006007	Glycerophosphodiester phosphodiesterase 1	16	19501689-19522145	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA074747			Approved	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:3.12e-5 (favourable), Liver cancer:7.52e-5 (unfavourable), Colorectal cancer:3.12e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 67.9	Expressed in all		
GDPD1	FLJ37451, GDE4	ENSG00000153982	Glycerophosphodiester phosphodiesterase domain containing 1	17	59220467-59275967	Predicted membrane proteins	Evidence at protein level						Lung cancer:2.98e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 27.9	testis: 20.0	Cell line enhanced		HEL: 27.1;SCLC-21H: 21.6
GDPD2	FLJ20207, GDE3, OBDPF	ENSG00000130055	Glycerophosphodiester phosphodiesterase domain containing 2	X	70423031-70433390	Enzymes, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		skin: 50.8;spleen: 60.0	small intestine: 20.0	Group enriched	8	AF22: 8.8;NTERA-2: 19.3
GDPD3	MGC4171	ENSG00000102886	Glycerophosphodiester phosphodiesterase domain containing 3	16	30104810-30113856	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041148, HPA041470	Uncertain		Approved	Nucleoplasm<br>Cytokinetic bridge<br>Cytosol	Renal cancer:5.89e-9 (unfavourable)	Expressed in all	Mixed			esophagus: 23.1	Cell line enhanced		MCF7: 24.3;SK-BR-3: 81.3
GDPD4	GDE6	ENSG00000178795	Glycerophosphodiester phosphodiesterase domain containing 4	11	77216558-77301687	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	12	testis: 4.7	placenta: 0.3	Not detected		
GDPD5	GDE2, PP1665	ENSG00000158555	Glycerophosphodiester phosphodiesterase domain containing 5	11	75434640-75525903	Predicted membrane proteins	Evidence at protein level	HPA065257, HPA066762, HPA069281	Uncertain		Approved	Golgi apparatus	Renal cancer:6.59e-9 (unfavourable), Endometrial cancer:1.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 67.0	testis: 31.2	Cell line enhanced		HDLM-2: 62.5
GFPT1	GFA, GFAT, GFAT1, GFPT	ENSG00000198380	Glutamine--fructose-6-phosphate transaminase 1	2	69319769-69387254	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047240			Approved	Nucleus<br>Nucleoli	Colorectal cancer:7.13e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 81.8	Expressed in all		
GFPT2	GFAT2	ENSG00000131459	Glutamine-fructose-6-phosphate transaminase 2	5	180300690-180353387	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056892, HPA059910	Uncertain		Supported	Vesicles	Renal cancer:2.58e-14 (unfavourable), Lung cancer:2.95e-4 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable), Cervical cancer:9.09e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 90.9	appendix: 25.7	Cell line enhanced		ASC TERT1: 138.7;hTEC/SVTERT24-B: 242.9;U-87 MG: 409.1
GFRA1	GDNFR, GDNFRA, GFR-ALPHA-1, RET1L, RETL1, TRNR1	ENSG00000151892	GDNF family receptor alpha 1	10	116056925-116273467	Predicted membrane proteins	Evidence at protein level	HPA043829	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Tissue enriched	Mixed			breast: 30.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 41.6;BJ hTERT+ SV40 Large T+ RasG12V: 75.3;EFO-21: 44.6;fHDF/TERT166: 68.9;HBF TERT88: 62.5;MCF7: 45.6;U-251 MG: 45.6
GFRA3	GFRa-3	ENSG00000146013	GDNF family receptor alpha 3	5	138252379-138274671	Predicted membrane proteins	Evidence at protein level	HPA020731	Approved		Uncertain	Plasma membrane<br>Cytosol		Mixed	Mixed			seminal vesicle: 8.1	Cell line enriched	21	SH-SY5Y: 33.1
GFRAL	bA360D14.1, C6orf144, GRAL, UNQ9356	ENSG00000187871	GDNF family receptor alpha like	6	55327469-55402493	Predicted membrane proteins	Evidence at protein level	HPA047372	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
GFY	Goofy	ENSG00000261949	Golgi associated olfactory signaling regulator	19	49423749-49428818	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 1.0	cerebral cortex: 0.2	Group enriched	6	HEK93: 1.7;SCLC-21H: 5.3;T-47d: 1.1;U-266/84: 2.0
GGCX	VKCFD1	ENSG00000115486	Gamma-glutamyl carboxylase	2	85544723-85561547	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA018284	Approved				Endometrial cancer:1.82e-6 (unfavourable)	Expressed in all	Expressed in all			liver: 61.3	Expressed in all		
GGT1	CD224, D22S672, D22S732, GGT	ENSG00000100031	Gamma-glutamyltransferase 1	22	24583750-24629005	Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045635, HPA047534, HPA065444	Supported		Approved	Vesicles	Renal cancer:4.83e-4 (favourable), Ovarian cancer:7.44e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 161.2	small intestine: 95.9	Cell line enhanced		HDLM-2: 148.2;Karpas-707: 162.6;RPMI-8226: 159.9;RPTEC TERT1: 155.8
GGT2	GGT	ENSG00000133475	Gamma-glutamyltransferase 2	22	21207973-21227637	Predicted membrane proteins	Evidence at protein level	HPA045635, HPA047534, HPA065444	Supported		Approved	Vesicles		Tissue enhanced	Tissue enhanced		lung: 1.3;thyroid gland: 1.5	breast,salivary gland: 0.9	Cell line enhanced		HDLM-2: 1.5;HeLa: 2.0;U-2197: 8.2
GGT6	FLJ90165	ENSG00000167741	Gamma-glutamyltransferase 6	17	4556927-4560818	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023362, HPA027213	Approved				Renal cancer:9.42e-7 (favourable), Lung cancer:4.35e-4 (favourable)	Mixed	Mixed			colon: 54.8	Group enriched	8	RT4: 48.3;SK-BR-3: 15.2;T-47d: 59.4
GGT7	D20S101, dJ18C9.2, GGTL3, GGTL5	ENSG00000131067	Gamma-glutamyltransferase 7	20	34844720-34872860	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013204, HPA013339	Approved		Approved	Nucleus<br>Vesicles	Endometrial cancer:1.26e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex,parathyroid gland: 50.0	Mixed		
GHITM	DERP2, HSPC282, My021, PTD010, TMBIM5	ENSG00000165678	Growth hormone inducible transmembrane protein	10	84139440-84153245	Predicted membrane proteins	Evidence at protein level	HPA016464, HPA061664	Approved		Supported	Mitochondria	Renal cancer:2.32e-10 (favourable), Head and neck cancer:1.76e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 352.9	Expressed in all		
GHR	GHBP	ENSG00000112964	Growth hormone receptor	5	42423777-42721878	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA045339, HPA057705	Enhanced		Supported	Plasma membrane<br>Cytosol<br>Cytoplasmic bodies	Liver cancer:2.73e-6 (favourable)	Mixed	Group enriched	6	adipose tissue: 91.4;liver: 110.5	prostate: 18.0	Group enriched	7	HSkMC: 15.4;T-47d: 52.5
GHRHR		ENSG00000106128	Growth hormone releasing hormone receptor	7	30938669-30993254	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enhanced	Not detected			adrenal gland: 0.5	Not detected		
GHSR		ENSG00000121853	Growth hormone secretagogue receptor	3	172445133-172448456	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			adrenal gland: 0.3	Not detected		
GIMAP1	HIMAP1, IAN2, IMAP1, IMAP38	ENSG00000213203	GTPase, IMAP family member 1	7	150716557-150724284	Predicted membrane proteins	Evidence at protein level	HPA044887, HPA053441	Uncertain		Supported	Endoplasmic reticulum	Liver cancer:1.09e-4 (favourable), Testis cancer:6.12e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 32.8	lymph node: 21.3	Group enriched	10	HUVEC TERT2: 12.1;MOLT-4: 7.0;TIME: 3.1
GIMAP1-GIMAP5		ENSG00000281887	GIMAP1-GIMAP5 readthrough	7	150716668-150743646	Predicted membrane proteins	Evidence at protein level	HPA053441			Supported	Endoplasmic reticulum		Not detected	Tissue enhanced		spleen: 17.9	appendix: 14.9	Group enriched	9	HUVEC TERT2: 5.3;MOLT-4: 8.3;THP-1: 1.7;TIME: 3.9
GIMAP2	DKFZp586D0824, HIMAP2, IAN12, IMAP2	ENSG00000106560	GTPase, IMAP family member 2	7	150685697-150693641	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013589	Approved				Renal cancer:1.29e-4 (unfavourable), Breast cancer:3.50e-4 (favourable)	Expressed in all	Mixed			lymph node: 88.0	Cell line enhanced		HUVEC TERT2: 52.1;MOLT-4: 63.1;REH: 30.9
GIMAP5	HIMAP3, IAN4L1, IAN5	ENSG00000196329	GTPase, IMAP family member 5	7	150722253-150750033	Predicted membrane proteins	Evidence at protein level							Mixed	Expressed in all			lymph node: 80.5	Cell line enhanced		HDLM-2: 3.4;MOLT-4: 23.3;U-937: 5.3
GINM1	C6orf72, dJ12G14.2	ENSG00000055211	Glycoprotein integral membrane 1	6	149566294-149591748	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017210, HPA041679	Approved		Approved	Nucleoli fibrillar center<br>Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 118.5	Expressed in all		
GIPR		ENSG00000010310	Gastric inhibitory polypeptide receptor	19	45668244-45683724	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022710	Uncertain					Tissue enriched	Tissue enhanced		stomach: 22.4	parathyroid gland: 12.1	Cell line enhanced		HDLM-2: 9.1;HMC-1: 18.5;SCLC-21H: 16.5;U-266/70: 13.1
GJA1	CX43, GJAL, ODD, ODDD, ODOD, SDTY3	ENSG00000152661	Gap junction protein alpha 1	6	121435692-121449727	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB010753, HPA035097, HPA047551, HPA069245	Enhanced	Supported	Supported	Nucleoplasm<br>Vesicles<br>Cell Junctions	Stomach cancer:4.99e-5 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 651.5	skin: 469.0	Cell line enhanced		HUVEC TERT2: 306.6;NTERA-2: 370.8;U-87 MG: 348.4
GJA10	CX62	ENSG00000135355	Gap junction protein alpha 10	6	89894469-89921760	Predicted membrane proteins	Evidence at protein level	HPA021145	Uncertain					Tissue enriched	Not detected			testis: 0.4	Not detected		
GJA3	CX46, CZP3	ENSG00000121743	Gap junction protein alpha 3	13	20138255-20161049	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014821	Supported					Tissue enhanced	Tissue enhanced		heart muscle: 5.1;parathyroid gland: 5.9;placenta: 3.5	testis: 2.4	Cell line enhanced		CAPAN-2: 6.8;HL-60: 5.2
GJA4	CX37	ENSG00000187513	Gap junction protein alpha 4	1	34792998-34795747	Predicted membrane proteins, Transporters	Evidence at protein level	HPA047981	Approved				Liver cancer:3.28e-4 (favourable), Renal cancer:7.44e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 89.3	fallopian tube: 48.2	Cell line enriched	8	EFO-21: 70.4
GJA5	CX40	ENSG00000265107	Gap junction protein alpha 5	1	147756199-147773362	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB013080	Uncertain					Expressed in all	Tissue enhanced		placenta: 123.0	lung: 39.9	Cell line enriched	10	SK-BR-3: 100.3
GJA8	CAE, CAE1, CX50, CZP1	ENSG00000121634	Gap junction protein alpha 8	1	147907956-147909257	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014715, HPA062940	Enhanced					Not detected	Tissue enriched	86	testis: 11.4	kidney,smooth muscle: 0.1	Not detected		
GJA9	CX58, CX59, GJA10	ENSG00000131233	Gap junction protein alpha 9	1	38874451-38881587	Predicted membrane proteins	Evidence at transcript level	HPA067850	Uncertain					Not detected	Tissue enhanced		testis: 2.0	skin: 0.5	Not detected		
GJB1	CMTX, CMTX1, CX32	ENSG00000169562	Gap junction protein beta 1	X	71215194-71225516	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB012994	Uncertain				Renal cancer:2.85e-6 (favourable)	Tissue enhanced	Tissue enhanced		liver: 159.4	gallbladder: 59.2	Group enriched	6	Hep G2: 94.2;SK-MEL-30: 123.7
GJB2	CX26, DFNA3, DFNB1, NSRD1	ENSG00000165474	Gap junction protein beta 2	13	20187470-20192898	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB013093, HPA014362	Uncertain		Approved	Mitochondria	Renal cancer:2.53e-6 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable), Glioma:5.98e-4 (unfavourable), Lung cancer:6.25e-4 (unfavourable)	Expressed in all	Tissue enriched	9	esophagus: 725.5	tonsil: 81.3	Cell line enhanced		CAPAN-2: 129.4;hTCEpi: 78.0;RT4: 137.8
GJB3	CX31, DFNA2, EKV	ENSG00000188910	Gap junction protein beta 3	1	34781189-34786369	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA074472			Supported	Vesicles<br>Cell Junctions	Pancreatic cancer:7.56e-5 (unfavourable), Lung cancer:4.56e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 33.6;skin: 77.3	tonsil: 11.6	Cell line enhanced		A-431: 76.8;CAPAN-2: 106.8;HaCaT: 87.5;HBEC3-KT: 60.8;hTCEpi: 98.5
GJB4	CX30.3	ENSG00000189433	Gap junction protein beta 4	1	34759741-34763724	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA055112			Supported	Cell Junctions	Pancreatic cancer:3.24e-5 (unfavourable), Cervical cancer:5.48e-4 (favourable)	Group enriched	Tissue enriched	6	skin: 27.7	epididymis: 4.6	Cell line enhanced		A-431: 4.0;HaCaT: 5.8;HBEC3-KT: 3.1;hTCEpi: 2.0;RPTEC TERT1: 1.9;RT4: 2.4
GJB5	CX31.1	ENSG00000189280	Gap junction protein beta 5	1	34755047-34758512	Cancer-related genes, Predicted membrane proteins	Evidence at transcript level	HPA038146	Uncertain				Pancreatic cancer:1.54e-4 (unfavourable)	Group enriched	Group enriched	6	esophagus: 56.4;skin: 77.4	tonsil: 11.4	Cell line enhanced		A-431: 25.3;HaCaT: 80.2;HBEC3-KT: 29.1;hTCEpi: 106.2;RT4: 40.6
GJB6	CX30, DFNA3, ED2, EDH, HED	ENSG00000121742	Gap junction protein beta 6	13	20221971-20232395	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014846			Supported	Cell Junctions		Tissue enhanced	Group enriched	5	bone marrow: 48.1;cerebral cortex: 39.4;esophagus: 150.1;skin: 32.1	tonsil: 12.2	Cell line enriched	9	RT4: 133.4
GJB7	bA136M9.1, CX25	ENSG00000164411	Gap junction protein beta 7	6	87282978-87329278	Predicted membrane proteins	Evidence at transcript level							Mixed	Group enriched	7	fallopian tube: 11.1;placenta: 3.8	lung: 1.0	Cell line enhanced		BEWO: 4.3;HDLM-2: 7.0;MCF7: 3.1;RT4: 2.9
GJC1	CX45, GJA7	ENSG00000182963	Gap junction protein gamma 1	17	44798448-44830816	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071788			Uncertain	Nucleoli<br>Cell Junctions<br>Cytosol	Renal cancer:3.55e-8 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 44.3;placenta: 51.5;smooth muscle: 49.2	seminal vesicle: 27.2	Mixed		
GJC2	CX46.6, CX47, GJA12, SPG44	ENSG00000198835	Gap junction protein gamma 2	1	228149852-228159826	Disease related genes, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 11.5	fallopian tube: 3.7	Cell line enhanced		EFO-21: 5.1;SCLC-21H: 3.4
GJC3	CX30.2, GJE1	ENSG00000176402	Gap junction protein gamma 3	7	99923269-99929620	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015024	Uncertain					Group enriched	Tissue enhanced		breast: 8.7;prostate: 5.3	testis: 2.7	Cell line enhanced		SK-MEL-30: 1.8;U-2197: 1.7
GJD2	CX36, GJA9	ENSG00000159248	Gap junction protein delta 2	15	34751032-34754965	Predicted membrane proteins	Evidence at protein level	HPA014355	Uncertain					Tissue enriched	Group enriched	6	adrenal gland: 7.9;cerebral cortex: 1.9	pancreas: 0.8	Not detected		
GJD3	Cx30.2, CX31.9, GJA11, GJC1	ENSG00000183153	Gap junction protein delta 3	17	40362931-40363815	Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		spleen: 7.0	stomach: 2.7	Cell line enhanced		BEWO: 14.7
GJD4	CX40.1, FLJ90023	ENSG00000177291	Gap junction protein delta 4	10	35605410-35608935	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA038266	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.7	skin: 1.0	Cell line enhanced		RH-30: 1.6
GJE1	CX23	ENSG00000203733	Gap junction protein epsilon 1	6	142133090-142135151	Predicted membrane proteins	No evidence	HPA014916	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GK	GK1, GKD	ENSG00000198814	Glycerol kinase	X	30653359-30731456	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060687	Supported				Renal cancer:3.24e-9 (favourable)	Expressed in all	Tissue enhanced		kidney: 111.0	small intestine: 98.6	Mixed		
GK2	GKP2, GKTA	ENSG00000196475	Glycerol kinase 2	4	79406352-79408293	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA060687	Uncertain					Not detected	Tissue enriched	1527	testis: 152.6	all non-specific tissues: 0.0	Cell line enriched	45	SCLC-21H: 4.4
GK3P	GKP3, GKTB	ENSG00000229894	Glycerol kinase 3 pseudogene	4	165277812-165279679	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA060687	Uncertain					Not detected	Tissue enriched	79	testis: 23.9	bone marrow: 0.3	Not detected		
GLCCI1	FAM117C, GIG18, TSSN1	ENSG00000106415	Glucocorticoid induced 1	7	7968794-8094272	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001674, HPA005987	Approved		Uncertain	Nucleoli		Expressed in all	Mixed			thyroid gland: 28.1	Cell line enhanced		U-266/70: 66.1
GLG1	CFR-1, ESL-1, MG-160	ENSG00000090863	Golgi glycoprotein 1	16	74447427-74607144	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010815	Supported		Enhanced	Golgi apparatus	Renal cancer:1.56e-7 (favourable), Cervical cancer:1.99e-4 (unfavourable), Urothelial cancer:7.97e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 167.1	Expressed in all		
GLIPR1	GliPR, RTVP1	ENSG00000139278	GLI pathogenesis related 1	12	75480680-75503853	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011014	Approved				Renal cancer:8.69e-9 (unfavourable)	Expressed in all	Mixed			appendix: 64.9	Cell line enhanced		hTEC/SVTERT24-B: 189.5;U-138 MG: 359.6
GLIPR1L2	MGC39497	ENSG00000180481	GLI pathogenesis related 1 like 2	12	75391070-75432688	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039795, HPA039866	Enhanced					Mixed	Tissue enriched	8	testis: 84.9	parathyroid gland: 10.9	Cell line enhanced		SK-BR-3: 4.4;U-2 OS: 7.8
GLMP	C1orf85, MGC31963, NCU-G1	ENSG00000198715	Glycosylated lysosomal membrane protein	1	156290089-156295689	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029121	Uncertain				Liver cancer:6.35e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 96.6	Mixed		
GLP1R		ENSG00000112164	Glucagon like peptide 1 receptor	6	39048798-39087743	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 1.9;heart muscle: 1.8	pancreas: 1.5	Cell line enhanced		NTERA-2: 1.3;SCLC-21H: 3.7
GLP2R		ENSG00000065325	Glucagon like peptide 2 receptor	17	9822206-9892102	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022690, HPA049244	Supported		Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		gallbladder: 19.3	duodenum: 10.1	Cell line enhanced		A549: 15.1;HeLa: 54.7;SiHa: 8.7
GLRA1	STHE	ENSG00000145888	Glycine receptor alpha 1	5	151822513-151924842	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016502, CAB079042	Uncertain	Supported				Not detected	Not detected			adrenal gland: 0.4	Not detected		
GLRA2	GLR	ENSG00000101958	Glycine receptor alpha 2	X	14529298-14731812	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB070422	Approved					Mixed	Group enriched	10	cerebral cortex: 6.1;colon: 1.4;rectum: 4.3	testis: 0.3	Cell line enriched	41	AN3-CA: 16.1
GLRA3		ENSG00000145451	Glycine receptor alpha 3	4	174636914-174829314	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Group enriched	6	breast: 2.6;cerebral cortex: 9.1	adrenal gland: 1.0	Cell line enhanced		Karpas-707: 1.4
GLRA4		ENSG00000188828	Glycine receptor alpha 4	X	103707224-103728655	Predicted membrane proteins	Evidence at transcript level	HPA044759	Uncertain					Not detected	Tissue enhanced		smooth muscle: 2.8	parathyroid gland: 1.0	Cell line enriched	18	SCLC-21H: 2.8
GLRB		ENSG00000109738	Glycine receptor beta	4	157076057-157172090	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052363	Approved				Renal cancer:4.89e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 62.0;parathyroid gland: 63.1	cervix, uterine: 14.1	Mixed		
GLT8D1	AD-017, FLJ14611	ENSG00000016864	Glycosyltransferase 8 domain containing 1	3	52694488-52706032	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010588	Approved		Approved	Mitochondria	Endometrial cancer:2.76e-4 (favourable)	Expressed in all	Expressed in all			testis: 116.9	Expressed in all		
GNE	IBM2, Uae1	ENSG00000159921	Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	9	36214441-36277056	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007045, HPA027258	Approved		Supported	Cytosol	Renal cancer:9.28e-11 (favourable)	Expressed in all	Expressed in all			rectum: 53.4	Cell line enhanced		RPTEC TERT1: 82.9
GNPTAB	GNPTA, KIAA1208, MGC4170	ENSG00000111670	N-acetylglucosamine-1-phosphate transferase alpha and beta subunits	12	101745497-101830938	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014558, HPA042343	Approved		Supported	Golgi apparatus	Endometrial cancer:8.48e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.1	Expressed in all		
GNRHR	GRHR, LHRHR	ENSG00000109163	Gonadotropin releasing hormone receptor	4	67739328-67754360	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013424	Supported					Not detected	Tissue enhanced		adrenal gland: 1.0	cerebral cortex: 0.6	Not detected		
GOLGA5	golgin-84, GOLIM5, ret-II, rfg5	ENSG00000066455	Golgin A5	14	92794231-92839963	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000992, HPA063876	Enhanced	Supported	Supported	Golgi apparatus		Expressed in all	Expressed in all			epididymis: 65.3	Expressed in all		
GOLGB1	GCP, GCP372, giantin, GOLIM1	ENSG00000173230	Golgin B1	3	121663199-121749767	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011008, HPA011555	Enhanced		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			prostate: 41.9	Expressed in all		
GOLIM4	GIMPC, GOLPH4, GPP130, P138	ENSG00000173905	Golgi integral membrane protein 4	3	168008677-168095975	Predicted membrane proteins	Evidence at protein level	HPA001677, HPA002315	Enhanced		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			small intestine: 93.8	Mixed		
GOLT1A	CGI-141, FLJ42654, GOT1, MGC62027, YMR292W	ENSG00000174567	Golgi transport 1A	1	204198160-204214092	Predicted membrane proteins	Evidence at protein level						Renal cancer:6.35e-5 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Glioma:5.49e-4 (unfavourable)	Tissue enriched	Tissue enhanced		duodenum: 40.3;liver: 79.1;small intestine: 42.3	parathyroid gland: 28.1	Cell line enhanced		CACO-2: 12.3;CAPAN-2: 14.9;Hep G2: 14.6;MCF7: 27.7;RT4: 18.6;SK-BR-3: 17.2
GOLT1B	CGI-141, GOT1, YMR292W	ENSG00000111711	Golgi transport 1B	12	21501781-21518408	Predicted membrane proteins	Evidence at protein level	HPA055909, HPA066383	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:4.83e-10 (unfavourable), Liver cancer:1.99e-8 (unfavourable), Pancreatic cancer:2.32e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 42.4	Expressed in all		
GOSR1	GOLIM2, GOS-28, GOS28, GS28, P28	ENSG00000108587	Golgi SNAP receptor complex member 1	17	30477362-30527592	Predicted membrane proteins	Evidence at protein level	HPA020590	Uncertain				Renal cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 55.5	Expressed in all		
GOSR2	Bos1, GS27	ENSG00000108433	Golgi SNAP receptor complex member 2	17	46923075-46975524	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017456, HPA048956, HPA054472	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:3.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.6	Expressed in all		
GP1BA	CD42b, GP1B, GPIbalpha	ENSG00000185245	Glycoprotein Ib platelet alpha subunit	17	4932297-4935030	CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002496, HPA013316	Supported					Mixed	Tissue enhanced		lymph node: 17.3	tonsil: 7.1	Cell line enriched	23	HEL: 64.4
GP1BB	CD42c, GPIbbeta	ENSG00000203618	Glycoprotein Ib platelet beta subunit	22	19722945-19724771	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	6	skin: 2.8	spleen: 0.4	Cell line enhanced		K-562: 8.8;NB-4: 5.1;REH: 8.9;SH-SY5Y: 4.7;U-2 OS: 9.7
GP2	ZAP75	ENSG00000169347	Glycoprotein 2	16	20309572-20327808	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015739, HPA016668	Enhanced					Tissue enriched	Tissue enriched	206	pancreas: 7530.3	duodenum: 36.5	Not detected		
GP5	CD42d	ENSG00000178732	Glycoprotein V platelet	3	194394821-194398354	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		lymph node: 1.3	fallopian tube: 1.1	Cell line enriched	10	HEL: 14.6
GP6	GPVI	ENSG00000088053	Glycoprotein VI platelet	19	55013705-55038264	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA066482	Approved		Approved	Nucleoplasm		Not detected	Tissue enhanced		testis: 1.2	skin: 0.7	Group enriched	12	HEL: 8.5;K-562: 3.7;U-2 OS: 2.7
GP9	CD42a, GPIX	ENSG00000169704	Glycoprotein IX platelet	3	129060767-129062406	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA063182	Enhanced					Not detected	Tissue enhanced		bone marrow: 2.9;spleen: 2.7	testis: 1.2	Cell line enriched	19	HEL: 75.1
GPA33	A33	ENSG00000143167	Glycoprotein A33	1	167052836-167166479	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018858, CAB025943	Enhanced					Tissue enriched	Group enriched	8	colon: 183.6;duodenum: 130.8;rectum: 188.7;small intestine: 131.3	appendix: 19.0	Cell line enhanced		NTERA-2: 1.0
GPAA1	GAA1, hGAA1	ENSG00000197858	Glycosylphosphatidylinositol anchor attachment 1	8	144082590-144086216	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 70.1	Expressed in all		
GPAM	GPAT1, KIAA1560, MGC26846	ENSG00000119927	Glycerol-3-phosphate acyltransferase, mitochondrial	10	112149864-112215377	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046339, HPA060090	Approved		Approved	Mitochondria	Renal cancer:4.54e-6 (favourable)	Tissue enriched	Expressed in all			adipose tissue: 315.8	Expressed in all		
GPAT2	CT123	ENSG00000186281	Glycerol-3-phosphate acyltransferase 2, mitochondrial	2	96021946-96039451	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036841	Uncertain		Approved	Mitochondria		Mixed	Mixed			testis: 7.2	Cell line enhanced		BJ: 6.9;BJ hTERT+ SV40 Large T+: 18.2;BJ hTERT+ SV40 Large T+ RasG12V: 11.3;U-2 OS: 11.7
GPAT3	AGPAT10, AGPAT9, HMFN0839, LPAAT-theta, MAG1, MGC11324	ENSG00000138678	Glycerol-3-phosphate acyltransferase 3	4	83535914-83605875	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA029414, CAB033749	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:2.71e-9 (favourable), Urothelial cancer:8.21e-4 (unfavourable)	Mixed	Tissue enhanced		kidney: 89.9	duodenum: 40.7	Cell line enhanced		CAPAN-2: 141.3;U-87 MG: 67.1;WM-115: 52.9
GPAT4	AGPAT6, DKFZp586M1819, LPAAT-zeta, TSARG7	ENSG00000158669	Glycerol-3-phosphate acyltransferase 4	8	41577187-41625001	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA016471	Approved				Ovarian cancer:2.20e-4 (unfavourable), Prostate cancer:4.15e-4 (favourable), Urothelial cancer:5.65e-4 (favourable), Endometrial cancer:9.37e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 80.3	Expressed in all		
GPBAR1	BG37, GPCR, GPCR19, GPR131, M-BAR, MGC40597, TGR5	ENSG00000179921	G protein-coupled bile acid receptor 1	2	218259496-218263859	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA062890	Enhanced					Tissue enhanced	Tissue enhanced		gallbladder: 26.9;smooth muscle: 14.0	adipose tissue: 9.9	Cell line enhanced		HHSteC: 1.5;SCLC-21H: 1.1;U-937: 1.4
GPC1	glypican	ENSG00000063660	Glypican 1	2	240435671-240468078	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030571	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:2.44e-6 (unfavourable), Colorectal cancer:5.78e-5 (unfavourable), Endometrial cancer:1.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 265.8	prostate: 67.5	Mixed		
GPC3	DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1	ENSG00000147257	Glypican 3	X	133535745-133985895	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006316			Approved	Plasma membrane	Stomach cancer:4.83e-4 (unfavourable)	Expressed in all	Tissue enriched	6	placenta: 845.0	lung: 130.6	Group enriched	6	HAP1: 539.0;Hep G2: 1445.8
GPC4	K-glypican	ENSG00000076716	Glypican 4	X	133300103-133415490	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA030836	Approved		Approved	Vesicles	Renal cancer:1.25e-5 (favourable), Lung cancer:3.51e-4 (favourable)	Expressed in all	Mixed			placenta: 41.7	Cell line enhanced		AF22: 206.9;HAP1: 125.3;NTERA-2: 110.1;RPTEC TERT1: 208.8
GPER1	CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER, GPR30, LERGU, LERGU2, LyGPR	ENSG00000164850	G protein-coupled estrogen receptor 1	7	1082208-1093815	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA027052	Approved				Endometrial cancer:1.17e-4 (favourable)	Expressed in all	Mixed			placenta: 9.1	Cell line enhanced		AN3-CA: 10.6;Hep G2: 15.3
GPI	AMF, NLK	ENSG00000105220	Glucose-6-phosphate isomerase	19	34359480-34402156	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018655, HPA024305, CAB040563, HPA052171	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 314.1	Expressed in all		
GPM6A	GPM6	ENSG00000150625	Glycoprotein M6A	4	175632934-176002664	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017338	Supported					Tissue enriched	Tissue enriched	36	cerebral cortex: 1104.1	lung: 30.7	Group enriched	9	AF22: 49.3;Daudi: 30.7;HAP1: 18.0;U-251 MG: 42.1
GPM6B	M6B, MGC17150, MGC54284	ENSG00000046653	Glycoprotein M6B	X	13771031-13938638	Predicted membrane proteins	Evidence at protein level	HPA002913	Approved				Ovarian cancer:2.67e-4 (favourable)	Group enriched	Tissue enriched	17	cerebral cortex: 835.8	seminal vesicle: 48.6	Cell line enhanced		AF22: 147.7;AN3-CA: 138.3;HSkMC: 79.6;SK-MEL-30: 117.9
GPNMB	HGFIN, NMB	ENSG00000136235	Glycoprotein nmb	7	23235967-23275108	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Expressed in all			skin: 654.6	Cell line enriched	5	ASC diff: 3230.9
GPR1		ENSG00000183671	G protein-coupled receptor 1	2	206175316-206218047	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010525	Uncertain		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		placenta: 5.6	esophagus: 2.7	Cell line enhanced		HHSteC: 112.4;hTCEpi: 44.7
GPR101		ENSG00000165370	G protein-coupled receptor 101	X	137030148-137031674	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001084	Uncertain					Not detected	Not detected			cerebral cortex: 0.1	Not detected		
GPR107	FLJ20998, KIAA1624, LUSTR1, RP11-88G17	ENSG00000148358	G protein-coupled receptor 107	9	130053426-130140169	Predicted membrane proteins	Evidence at protein level	HPA031704	Supported		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.87e-5 (favourable), Breast cancer:3.56e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 55.3	Expressed in all		
GPR108	LUSTR2	ENSG00000125734	G protein-coupled receptor 108	19	6729914-6737603	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041924, HPA041951, HPA063863	Uncertain		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.29e-9 (favourable), Endometrial cancer:1.04e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 75.1	Mixed		
GPR119	GPCR2, hGPCR2	ENSG00000147262	G protein-coupled receptor 119	X	130384440-130385447	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:6.93e-4 (favourable)	Tissue enriched	Not detected			pancreas: 0.6	Cell line enhanced		Hep G2: 1.1
GPR12	GPCR21, PPP1R84	ENSG00000132975	G protein-coupled receptor 12	13	26755200-26760785	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA050972	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 7.9	breast: 1.7	Cell line enriched	8	SCLC-21H: 16.7
GPR132	G2A	ENSG00000183484	G protein-coupled receptor 132	14	105049389-105065445	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029694, HPA029695	Supported				Renal cancer:1.71e-5 (unfavourable), Cervical cancer:3.21e-4 (favourable), Head and neck cancer:6.44e-4 (favourable)	Mixed	Mixed			appendix: 9.4	Group enriched	6	HDLM-2: 24.9;Karpas-707: 19.2;THP-1: 5.6
GPR135	HUMNPIIY20, PAFR	ENSG00000181619	G protein-coupled receptor 135	14	59429022-59465342	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA045337	Uncertain					Mixed	Tissue enhanced		testis: 9.1	fallopian tube,parathyroid gland: 5.0	Mixed		
GPR137	C11orf4, GPR137A, TM7SF1L1	ENSG00000173264	G protein-coupled receptor 137	11	64270062-64289500	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA062871	Uncertain		Approved	Nucleus<br>Nucleoli<br>Actin filaments	Liver cancer:5.34e-4 (unfavourable), Pancreatic cancer:6.18e-4 (favourable)	Expressed in all	Expressed in all			testis: 146.5	Expressed in all		
GPR137B	TM7SF1	ENSG00000077585	G protein-coupled receptor 137B	1	236142505-236221865	Predicted membrane proteins, Transporters	Evidence at protein level	HPA026422	Approved				Colorectal cancer:1.63e-4 (unfavourable)	Expressed in all	Mixed			kidney: 70.7	Cell line enhanced		SK-MEL-30: 165.8
GPR137C	DKFZp762F0713, TM7SF1L2	ENSG00000180998	G protein-coupled receptor 137C	14	52553148-52637713	Predicted membrane proteins	Evidence at transcript level	HPA003640, HPA030763	Uncertain		Approved	Vesicles		Mixed	Group enriched	6	cerebral cortex: 18.0;epididymis: 10.8;testis: 6.8	gallbladder: 2.1	Mixed		
GPR139	PGR3	ENSG00000180269	G protein-coupled receptor 139	16	20031485-20073917	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA046596	Uncertain					Not detected	Not detected			endometrium: 0.3	Not detected		
GPR141	PGR13	ENSG00000187037	G protein-coupled receptor 141	7	37683796-37833788	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		bone marrow: 18.5	appendix: 5.6	Cell line enhanced		HEL: 11.8;HMC-1: 43.8;NTERA-2: 27.0;U-937: 17.1
GPR142	PGR2	ENSG00000257008	G protein-coupled receptor 142	17	74367407-74372622	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA031392	Uncertain		Uncertain	Plasma membrane<br>Cell Junctions<br>Cytosol		Tissue enhanced	Not detected			appendix: 0.1	Not detected		
GPR143	OA1	ENSG00000101850	G protein-coupled receptor 143	X	9725346-9786297	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003648	Enhanced				Renal cancer:2.45e-5 (favourable), Cervical cancer:8.73e-4 (favourable)	Tissue enriched	Mixed			skin: 10.3	Cell line enriched	7	SK-MEL-30: 119.4
GPR146	PGR8	ENSG00000164849	G protein-coupled receptor 146	7	1044576-1059261	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Expressed in all			adipose tissue: 33.6	Cell line enhanced		BEWO: 22.4
GPR148	PGR6	ENSG00000173302	G protein-coupled receptor 148	2	130729070-130730336	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA060527	Uncertain					Not detected	Not detected			stomach: 0.4	Not detected		
GPR149	IEDA, PGR10	ENSG00000174948	G protein-coupled receptor 149	3	154337672-154429715	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA018020	Uncertain					Not detected	Tissue enriched	6	seminal vesicle: 2.9	testis: 0.4	Not detected		
GPR15		ENSG00000154165	G protein-coupled receptor 15	3	98531899-98533150	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA013775	Approved					Mixed	Tissue enhanced		colon: 25.0;rectum: 46.8	urinary bladder: 18.4	Group enriched	22	HDLM-2: 5.6;U-266/70: 1.9
GPR150	PGR11	ENSG00000178015	G protein-coupled receptor 150	5	95620078-95622142	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA026635	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 1.3;parathyroid gland: 2.0	pancreas: 1.0	Cell line enhanced		ASC diff: 1.0;SiHa: 1.3;TIME: 2.2
GPR151	GALR4, PGR7	ENSG00000173250	G protein-coupled receptor 151	5	146513103-146516190	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex: 0.2	Not detected		
GPR152	PGR5	ENSG00000175514	G protein-coupled receptor 152	11	67451301-67452729	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA035078	Uncertain					Not detected	Not detected			spleen: 0.1	Not detected		
GPR153	PGR1	ENSG00000158292	G protein-coupled receptor 153	1	6247346-6260975	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA007159	Approved				Endometrial cancer:3.07e-4 (unfavourable), Lung cancer:3.75e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 17.4	Cell line enhanced		PC-3: 65.6;RH-30: 32.1;SCLC-21H: 39.5
GPR155	DEP.7, DEPDC3, FLJ31819, PGR22	ENSG00000163328	G protein-coupled receptor 155	2	174431571-174487094	Predicted membrane proteins	Evidence at protein level	HPA036159, HPA057384	Approved		Approved	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			stomach: 45.4	Cell line enhanced		U-266/70: 11.3;WM-115: 9.8
GPR156	GABABL, PGR28	ENSG00000175697	G protein-coupled receptor 156	3	120164645-120285094	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA028642, HPA028644	Uncertain		Supported	Plasma membrane		Mixed	Tissue enhanced		testis: 5.0	fallopian tube: 1.8	Cell line enhanced		SiHa: 3.8;U-2 OS: 2.0
GPR157	FLJ12132	ENSG00000180758	G protein-coupled receptor 157	1	9100305-9129170	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA028697	Uncertain		Uncertain	Nucleoli<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			parathyroid gland: 24.2	Cell line enhanced		SK-BR-3: 46.8
GPR158	KIAA1136	ENSG00000151025	G protein-coupled receptor 158	10	25175062-25602226	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013185	Uncertain		Approved	Cytosol		Mixed	Tissue enriched	17	cerebral cortex: 17.9	testis: 1.0	Cell line enhanced		HEL: 18.7;T-47d: 5.2
GPR160	GPCR1, GPCR150	ENSG00000173890	G protein-coupled receptor 160	3	170037929-170085403	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006970	Approved		Supported	Plasma membrane	Renal cancer:4.93e-7 (favourable), Lung cancer:1.21e-4 (favourable), Urothelial cancer:3.61e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 435.1	small intestine: 109.0	Cell line enhanced		THP-1: 130.2;U-266/70: 156.8
GPR161	RE2	ENSG00000143147	G protein-coupled receptor 161	1	168079543-168137667	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA015576, HPA072047	Uncertain		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		smooth muscle: 40.3	endometrium: 28.6	Mixed		
GPR162	A-2, GRCA	ENSG00000250510	G protein-coupled receptor 162	12	6821545-6829972	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055135	Enhanced		Approved	Microtubule organizing center	Renal cancer:1.37e-6 (unfavourable), Pancreatic cancer:4.29e-5 (favourable)	Tissue enriched	Group enriched	6	cerebral cortex: 84.3;fallopian tube: 29.4	lung: 9.5	Cell line enhanced		AF22: 17.4;AN3-CA: 19.5;NTERA-2: 19.7;SH-SY5Y: 14.2;U-2 OS: 17.2
GPR17		ENSG00000144230	G protein-coupled receptor 17	2	127645864-127652639	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029766	Enhanced	Supported	Approved	Vesicles		Tissue enriched	Mixed			spleen: 9.6	Cell line enhanced		HeLa: 1.7;REH: 4.0;TIME: 3.5;U-2 OS: 1.8;U-2197: 1.8;U-251 MG: 2.1
GPR171	H963	ENSG00000174946	G protein-coupled receptor 171	3	151197832-151203201	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA062429	Approved					Mixed	Tissue enhanced		appendix: 29.8	lymph node: 21.5	Cell line enriched	21	U-266/70: 21.2
GPR173	SREB3	ENSG00000184194	G protein-coupled receptor 173	X	53049091-53080615	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA003905			Approved	Plasma membrane<br>Cytosol	Endometrial cancer:2.88e-6 (unfavourable), Pancreatic cancer:2.33e-5 (favourable), Renal cancer:2.47e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 19.1	ovary: 8.9	Cell line enhanced		HAP1: 10.2
GPR174	FKSG79	ENSG00000147138	G protein-coupled receptor 174	X	79170972-79172229	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA041025	Enhanced		Uncertain	Vesicles		Mixed	Tissue enhanced		lymph node: 29.8;spleen: 16.7;tonsil: 17.2	appendix: 12.6	Cell line enriched	8	MOLT-4: 85.1
GPR176	Gm1012	ENSG00000166073	G protein-coupled receptor 176	15	39799032-39920892	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA039943, HPA039979	Approved				Renal cancer:9.38e-7 (unfavourable), Stomach cancer:6.84e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 18.4	Cell line enhanced		BJ hTERT+: 243.3;fHDF/TERT166: 159.0
GPR179	CSNB1E, GPR158L1	ENSG00000277399	G protein-coupled receptor 179	17	38325530-38343847	Predicted membrane proteins	No evidence	HPA017885	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GPR18		ENSG00000125245	G protein-coupled receptor 18	13	99254714-99261744	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013873	Enhanced					Mixed	Tissue enhanced		lymph node: 51.5;testis: 25.3;tonsil: 31.5	appendix: 16.4	Cell line enhanced		Daudi: 6.1;THP-1: 13.5;U-937: 2.6
GPR180	ITR	ENSG00000152749	G protein-coupled receptor 180	13	94601903-94634645	Predicted membrane proteins	Evidence at protein level	HPA047250	Approved		Approved	Vesicles	Renal cancer:3.18e-5 (unfavourable)	Expressed in all	Mixed			adipose tissue: 6.3	Mixed		
GPR182	ADMR, AM-R, G10D, hrhAMR	ENSG00000166856	G protein-coupled receptor 182	12	56994446-56998441	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027037	Enhanced					Not detected	Tissue enhanced		spleen: 12.2;testis: 6.7	liver: 2.0	Cell line enhanced		RH-30: 1.8
GPR183	EBI2	ENSG00000169508	G protein-coupled receptor 183	13	99294530-99307405	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA028847, CAB033690	Uncertain		Approved	Nuclear membrane<br>Vesicles	Cervical cancer:9.77e-4 (favourable)	Expressed in all	Mixed			appendix: 114.8	Group enriched	49	HDLM-2: 144.6;HL-60: 85.1
GPR19		ENSG00000183150	G protein-coupled receptor 19	12	12660891-12696207	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013955	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 8.4;testis: 7.8	appendix: 2.7	Cell line enhanced		HDLM-2: 37.0;NTERA-2: 39.8
GPR20		ENSG00000204882	G protein-coupled receptor 20	8	141356500-141367267	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Mixed			smooth muscle: 1.2	Cell line enhanced		EFO-21: 2.1
GPR21		ENSG00000188394	G protein-coupled receptor 21	9	123034527-123035696	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA041651	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 2.1	endometrium: 0.9	Cell line enriched	6	HBEC3-KT: 2.2
GPR22		ENSG00000172209	G protein-coupled receptor 22	7	107470018-107475659	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Group enriched	13	adrenal gland: 1.2;cerebral cortex: 4.7;cervix, uterine: 3.2;endometrium: 2.5;heart muscle: 5.4	smooth muscle: 0.2	Cell line enriched	29	SH-SY5Y: 2.9
GPR25		ENSG00000170128	G protein-coupled receptor 25	1	200872955-200874178	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		stomach: 1.7	appendix,lung: 0.6	Cell line enriched	6	U-266/70: 1.0
GPR26		ENSG00000154478	G protein-coupled receptor 26	10	123666355-123694607	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA062736	Enhanced					Tissue enriched	Tissue enriched	16	cerebral cortex: 4.3	testis: 0.2	Cell line enriched	15	SCLC-21H: 1.4
GPR27	SREB1	ENSG00000170837	G protein-coupled receptor 27	3	71754050-71756496	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029395	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Actin filaments<br>Cytosol	Ovarian cancer:1.21e-6 (favourable), Breast cancer:5.63e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 46.5	cerebral cortex: 24.9	Cell line enhanced		EFO-21: 17.2;HL-60: 14.7;NTERA-2: 30.5;SH-SY5Y: 12.3
GPR3	ACCA	ENSG00000181773	G protein-coupled receptor 3	1	27392644-27395814	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB006254	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 5.2	thyroid gland: 1.3	Cell line enhanced		U-2197: 21.6
GPR31	12-HETER, HETER1	ENSG00000120436	G protein-coupled receptor 31	6	167156271-167158329	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA014014, HPA027108	Uncertain					Not detected	Tissue enhanced		lymph node: 1.6	spleen: 0.9	Not detected		
GPR32	RVDR1	ENSG00000142511	G protein-coupled receptor 32	19	50770464-50771732	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	99	parathyroid gland: 260.1	placenta: 2.6	Cell line enriched	361	BEWO: 36.0
GPR33		ENSG00000214943	G protein-coupled receptor 33 (gene/pseudogene)	14	31482875-31488142	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			spleen: 0.3	Not detected		
GPR34		ENSG00000171659	G protein-coupled receptor 34	X	41688973-41697277	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA010668, CAB025490	Uncertain		Uncertain	Nucleus<br>Cytosol		Expressed in all	Mixed			placenta: 60.9	Cell line enhanced		HMC-1: 1.1
GPR35		ENSG00000178623	G protein-coupled receptor 35	2	240605431-240631259	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level						Renal cancer:2.59e-5 (unfavourable), Lung cancer:5.86e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		duodenum: 41.4;small intestine: 42.3	colon: 18.4	Cell line enhanced		CACO-2: 17.1;CAPAN-2: 45.0;HDLM-2: 16.3;Hep G2: 22.7;HMC-1: 27.8
GPR37	EDNRBL, hET(B)R-LP, PAELR	ENSG00000170775	G protein-coupled receptor 37	7	124745997-124765627	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA042903, HPA068009	Approved		Approved	Nuclear membrane<br>Cytosol	Lung cancer:6.00e-5 (unfavourable), Ovarian cancer:7.26e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 78.7;testis: 27.6	placenta: 12.8	Cell line enhanced		AF22: 12.8;fHDF/TERT166: 24.0;TIME: 17.5
GPR37L1	ETBR-LP-2	ENSG00000170075	G protein-coupled receptor 37 like 1	1	202122858-202133592	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA064454	Enhanced					Tissue enriched	Tissue enriched	65	cerebral cortex: 34.1	seminal vesicle: 0.5	Cell line enhanced		HaCaT: 1.1;MCF7: 1.1;T-47d: 3.6
GPR39		ENSG00000183840	G protein-coupled receptor 39	2	132416574-132646559	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA022111	Approved				Pancreatic cancer:7.50e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 18.5	cervix, uterine,colon: 6.0	Cell line enhanced		A-431: 25.5;hTEC/SVTERT24-B: 28.7
GPR4		ENSG00000177464	G protein-coupled receptor 4	19	45589764-45602208	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014278	Uncertain				Renal cancer:2.07e-5 (unfavourable), Lung cancer:9.19e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 10.3	Group enriched	11	HUVEC TERT2: 15.6;TIME: 25.6
GPR42	FFAR3L, GPR41L, GPR42P	ENSG00000126251	G protein-coupled receptor 42 (gene/pseudogene)	19	35370929-35372962	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA044681	Uncertain					Not detected	Not detected			appendix,small intestine: 0.3	Not detected		
GPR45	PSP24, PSP24A	ENSG00000135973	G protein-coupled receptor 45	2	105241743-105243049	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA055940	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.8	testis: 0.4	Group enriched	14	BEWO: 1.3;U-2 OS: 4.5
GPR50	H9, Mel1c	ENSG00000102195	G protein-coupled receptor 50	X	151176653-151181465	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA049862, HPA054678	Supported		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Not detected			placenta: 0.6	Cell line enriched	7	HEK93: 4.8
GPR52		ENSG00000203737	G protein-coupled receptor 52	1	174448111-174449198	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA028575	Uncertain					Not detected	Tissue enriched	7	cerebral cortex: 2.6	bone marrow: 0.3	Not detected		
GPR55		ENSG00000135898	G protein-coupled receptor 55	2	230907318-230961066	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 5.8;testis: 9.0	tonsil: 4.4	Cell line enhanced		HDLM-2: 6.0;Karpas-707: 23.3;SK-MEL-30: 4.7
GPR6		ENSG00000146360	G protein-coupled receptor 6	6	109978256-109980718	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	16	cerebral cortex: 1.5	all non-specific tissues: 0.0	Cell line enriched	11	SCLC-21H: 1.1
GPR61	BALGR	ENSG00000156097	G protein-coupled receptor 61	1	109539872-109548406	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA007326, HPA026088	Approved					Not detected	Tissue enhanced		adrenal gland: 1.0;cerebral cortex: 3.4;thyroid gland: 1.2	testis: 0.5	Not detected		
GPR62		ENSG00000180929	G protein-coupled receptor 62	3	51955314-51957504	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	14	cerebral cortex: 8.0	ovary: 0.5	Cell line enriched	6	SCLC-21H: 2.2
GPR63	PSP24(beta), PSP24B	ENSG00000112218	G protein-coupled receptor 63	6	96794126-96837463	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA039103	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Mixed	Mixed			testis: 4.6	Cell line enhanced		HHSteC: 11.3;Karpas-707: 15.0
GPR65	hTDAG8, TDAG8	ENSG00000140030	G protein-coupled receptor 65	14	88005124-88014811	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA054454			Approved	Cytosol	Renal cancer:4.99e-4 (unfavourable)	Mixed	Mixed			spleen: 13.3	Cell line enhanced		Daudi: 4.0;HEL: 5.5;HL-60: 5.9;HMC-1: 7.9;RH-30: 11.1
GPR68	OGR1	ENSG00000119714	G protein-coupled receptor 68	14	91232532-91253925	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:3.06e-5 (favourable)	Mixed	Mixed			appendix: 8.1	Cell line enhanced		U-87 MG: 31.4
GPR75	WI-31133	ENSG00000119737	G protein-coupled receptor 75	2	53852913-53859989	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 17.8	parathyroid gland: 6.5	Mixed		
GPR78		ENSG00000155269	G protein-coupled receptor 78	4	8558725-8619761	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013209	Uncertain					Tissue enhanced	Not detected			all non-specific tissues: 0.0	Cell line enriched	194	BEWO: 19.5
GPR82		ENSG00000171657	G protein-coupled receptor 82	X	41724155-41730135	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA035914	Approved					Mixed	Tissue enhanced		tonsil: 6.3	lymph node: 3.7	Cell line enriched	16	HMC-1: 3.6
GPR83	GPR72	ENSG00000123901	G protein-coupled receptor 83	11	94377311-94401419	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Group enriched	6	adrenal gland: 1.0;cerebral cortex: 4.6;thyroid gland: 5.1	skin,testis: 0.5	Cell line enhanced		CACO-2: 1.4
GPR84	EX33	ENSG00000139572	G protein-coupled receptor 84	12	54362445-54364487	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA027603	Enhanced					Mixed	Tissue enhanced		appendix: 11.6;bone marrow: 14.7	adipose tissue: 6.0	Cell line enhanced		HL-60: 10.3;NB-4: 25.5;U-937: 4.0
GPR85	SREB2	ENSG00000164604	G protein-coupled receptor 85	7	113078331-113087778	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 16.7	skeletal muscle: 11.4	Cell line enriched	6	HEL: 99.3
GPR87	GPR95	ENSG00000138271	G protein-coupled receptor 87	3	151294086-151316952	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA066313			Approved	Nucleoplasm<br>Lipid droplets<br>Mitochondria	Pancreatic cancer:4.62e-6 (unfavourable)	Group enriched	Tissue enhanced		esophagus: 29.3;skin: 29.8	placenta: 12.0	Cell line enhanced		A-431: 87.7;HaCaT: 68.9;HBEC3-KT: 74.5;hTCEpi: 98.3;hTERT-HME1: 43.6
GPR88		ENSG00000181656	G protein-coupled receptor 88	1	100538137-100542018	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at transcript level	HPA007488		Approved				Tissue enriched	Group enriched	11	breast: 9.4;cerebral cortex: 3.1;liver: 4.9;ovary: 3.1;parathyroid gland: 4.9;spleen: 14.4	prostate: 0.6	Group enriched	8	HSkMC: 1.1;SCLC-21H: 2.3
GPR89A	UNQ192	ENSG00000117262	G protein-coupled receptor 89A	1	145607990-145670648	Predicted membrane proteins	Evidence at protein level	HPA076096			Approved	Endoplasmic reticulum		Mixed	Mixed			kidney: 21.0	Expressed in all		
GPR89B	GPR89, GPR89C, SH120	ENSG00000188092	G protein-coupled receptor 89B	1	147928393-147993521	Predicted membrane proteins	Evidence at protein level	HPA076096			Approved	Endoplasmic reticulum		Mixed	Expressed in all			kidney: 31.2	Expressed in all		
GPRC5A	PEIG-1, RAI3, RAIG1, TIG1	ENSG00000013588	G protein-coupled receptor class C group 5 member A	12	12890782-12917937	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007928, HPA046526	Enhanced		Enhanced	Vesicles<br>Plasma membrane	Pancreatic cancer:4.63e-6 (unfavourable), Renal cancer:9.02e-5 (unfavourable)	Mixed	Tissue enhanced		lung: 302.0	thyroid gland: 91.3	Cell line enhanced		CAPAN-2: 1167.5;SiHa: 520.3
GPRC5B	RAIG-2	ENSG00000167191	G protein-coupled receptor class C group 5 member B	16	19856691-19886167	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015247	Enhanced		Supported	Nucleus<br>Nucleoli<br>Vesicles	Colorectal cancer:9.27e-5 (unfavourable), Renal cancer:6.30e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 308.3	testis: 66.2	Cell line enhanced		EFO-21: 84.6;HHSteC: 50.7
GPRC5C	RAIG-3	ENSG00000170412	G protein-coupled receptor class C group 5 member C	17	74424851-74451653	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029776	Enhanced		Uncertain	Nucleus<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.58e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 104.0	Cell line enhanced		HMC-1: 144.5;RPTEC TERT1: 168.2;T-47d: 118.6
GPRC5D		ENSG00000111291	G protein-coupled receptor class C group 5 member D	12	12940775-12952147	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA071909	Approved				Head and neck cancer:5.09e-4 (favourable)	Mixed	Mixed			testis: 4.9	Group enriched	10	Karpas-707: 60.7;RPMI-8226: 58.9;U-266/84: 17.2
GPRC6A	bA86F4.3	ENSG00000173612	G protein-coupled receptor class C group 6 member A	6	116792085-116829037	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Not detected			kidney: 0.7	Cell line enhanced		U-266/70: 1.2
GPSM2	DFNB82, LGN, Pins	ENSG00000121957	G-protein signaling modulator 2	1	108875350-108934545	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007327, HPA008408, CAB018962	Uncertain		Supported	Cytosol	Colorectal cancer:7.86e-5 (favourable), Renal cancer:3.02e-4 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable)	Mixed	Mixed			skin: 49.3	Expressed in all		
GRAMD1A	FLJ90346, KIAA1533	ENSG00000089351	GRAM domain containing 1A	19	34994784-35026471	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008852, HPA012570	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:7.95e-12 (unfavourable)	Expressed in all	Expressed in all			lung: 36.5	Expressed in all		
GRAMD1B	KIAA1201	ENSG00000023171	GRAM domain containing 1B	11	123358428-123627774	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008557	Approved		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments	Renal cancer:4.30e-7 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 135.1	cerebral cortex: 39.5	Cell line enhanced		A549: 57.9;HDLM-2: 155.3
GRAMD1C	DKFZp434C0328	ENSG00000178075	GRAM domain containing 1C	3	113828182-113947174	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012316	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:4.22e-15 (favourable)	Mixed	Mixed			testis: 28.1	Cell line enhanced		CAPAN-2: 11.4;HUVEC TERT2: 8.3
GRAMD2		ENSG00000175318	GRAM domain containing 2	15	72159807-72197785	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA029435	Uncertain		Approved	Nucleoli<br>Nuclear speckles<br>Cytosol	Thyroid cancer:7.01e-4 (unfavourable)	Mixed	Tissue enhanced		epididymis: 43.8;placenta: 69.9	lung: 22.8	Group enriched	15	BEWO: 159.8;SK-BR-3: 56.9
GRAMD3	FLJ21313, NS3TP2	ENSG00000155324	GRAM domain containing 3	5	126360132-126496494	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009678, HPA010095	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Expressed in all	Mixed			thyroid gland: 69.1	Cell line enhanced		BJ hTERT+: 93.5
GRAMD4	DIP, KIAA0767	ENSG00000075240	GRAM domain containing 4	22	46576012-46679790	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Head and neck cancer:3.04e-4 (favourable)	Expressed in all	Expressed in all			skin: 53.4	Expressed in all		
GREB1	KIAA0575	ENSG00000196208	Growth regulation by estrogen in breast cancer 1	2	11482341-11642788	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024616, HPA027843, HPA028416	Uncertain		Approved	Mitochondria<br>Cytosol	Endometrial cancer:1.05e-4 (favourable)	Tissue enhanced	Tissue enhanced		ovary: 156.8	prostate: 57.1	Cell line enhanced		AF22: 39.6;MCF7: 47.1;SH-SY5Y: 42.6;T-47d: 129.7
GRIA1	GluA1, GLUR1, GLURA	ENSG00000155511	Glutamate ionotropic receptor AMPA type subunit 1	5	153489615-153813869	FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB001965, HPA035202	Supported					Tissue enriched	Tissue enriched	6	cerebral cortex: 67.1	lung: 10.6	Cell line enhanced		AF22: 11.5;BJ: 4.7;LHCN-M2: 6.9;U-266/70: 4.4
GRIA2	GluA2, GLUR2, GLURB	ENSG00000120251	Glutamate ionotropic receptor AMPA type subunit 2	4	157204182-157366075	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB007812, HPA008441	Enhanced					Group enriched	Tissue enriched	7	cerebral cortex: 206.6	endometrium: 27.5	Cell line enriched	8	SCLC-21H: 19.9
GRIA3	GluA3, GLUR3, GLURC, MRX94	ENSG00000125675	Glutamate ionotropic receptor AMPA type subunit 3	X	123184153-123490915	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA058659	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 56.6	adrenal gland: 11.3	Cell line enhanced		BJ: 20.3;BJ hTERT+: 28.1;fHDF/TERT166: 35.8;U-2197: 14.1
GRIA4	GluA4, GLUR4, GLURD	ENSG00000152578	Glutamate ionotropic receptor AMPA type subunit 4	11	105609994-105982092	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	10	cerebral cortex: 73.2	adrenal gland: 7.3	Cell line enhanced		AF22: 11.9;NTERA-2: 4.0;SCLC-21H: 5.1
GRID1	GluD1, KIAA1220	ENSG00000182771	Glutamate ionotropic receptor delta type subunit 1	10	85599555-86366493	Predicted membrane proteins	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 7.7	thyroid gland: 3.4	Cell line enhanced		Daudi: 1.8;HEL: 2.3;SH-SY5Y: 1.0
GRID2	GluD2, GluR-delta-2	ENSG00000152208	Glutamate ionotropic receptor delta type subunit 2	4	92303622-93810157	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056253, HPA058538	Enhanced					Tissue enriched	Tissue enriched	10	testis: 60.4	cerebral cortex: 6.2	Cell line enhanced		SCLC-21H: 1.4;U-2 OS: 8.2;U-266/70: 2.7;WM-115: 1.3
GRIK1	GluK1, GLUR5	ENSG00000171189	Glutamate ionotropic receptor kainate type subunit 1	21	29536933-29940033	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA014623	Uncertain				Glioma:9.12e-4 (unfavourable)	Group enriched	Tissue enhanced		adrenal gland: 16.3;cerebral cortex: 9.0	prostate: 4.0	Not detected		
GRIK2	GluK2, GLUR6, MRT6	ENSG00000164418	Glutamate ionotropic receptor kainate type subunit 2	6	101398788-102070083	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014395, HPA014623, CAB022463	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 22.5	thyroid gland: 6.3	Cell line enhanced		BJ: 14.3;BJ hTERT+: 22.6;fHDF/TERT166: 16.5;WM-115: 25.2
GRIK3	GluK3, GLUR7	ENSG00000163873	Glutamate ionotropic receptor kainate type subunit 3	1	36795527-37034129	Plasma proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	6	cerebral cortex: 19.8	seminal vesicle: 3.5	Group enriched	5	SCLC-21H: 11.4;T-47d: 37.2
GRIK4	GluK4, GRIK, KA1	ENSG00000149403	Glutamate ionotropic receptor kainate type subunit 4	11	120511700-120988904	Predicted membrane proteins, Transporters	Evidence at protein level	HPA074453	Enhanced					Tissue enriched	Tissue enhanced		cerebral cortex: 11.3	ovary,thyroid gland: 3.5	Group enriched	5	HDLM-2: 5.7;HEL: 16.7;T-47d: 4.4
GRIK5	GluK5, GRIK2, KA2	ENSG00000105737	Glutamate ionotropic receptor kainate type subunit 5	19	41998321-42069498	Predicted membrane proteins	Evidence at protein level	HPA074001			Supported	Nucleus<br>Plasma membrane	Pancreatic cancer:7.23e-4 (favourable), Renal cancer:9.32e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 30.8;parathyroid gland: 22.1	testis: 18.8	Cell line enhanced		HEL: 12.3;NTERA-2: 13.1;REH: 34.1;SCLC-21H: 12.1;SH-SY5Y: 24.1
GRIN1	GluN1, NMDAR1	ENSG00000176884	Glutamate ionotropic receptor NMDA type subunit 1	9	137138390-137168762	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters	Evidence at protein level	CAB006831	Approved					Mixed	Tissue enriched	208	cerebral cortex: 151.8	prostate: 0.7	Cell line enhanced		RPMI-8226: 1.8;SCLC-21H: 6.7;SH-SY5Y: 4.2
GRIN2A	GluN2A, NMDAR2A	ENSG00000183454	Glutamate ionotropic receptor NMDA type subunit 2A	16	9753404-10182754	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB022725	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 25.8	testis: 6.1	Cell line enhanced		fHDF/TERT166: 3.3;U-138 MG: 4.4
GRIN2B	GluN2B, NMDAR2B	ENSG00000273079	Glutamate ionotropic receptor NMDA type subunit 2B	12	13437942-13981957	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA069762	Approved					Not detected	Tissue enriched	23	cerebral cortex: 13.1	adipose tissue,testis: 0.5	Cell line enhanced		AF22: 1.2;CACO-2: 1.2;NTERA-2: 1.8;RPTEC TERT1: 1.3
GRIN2C	GluN2C, NMDAR2C	ENSG00000161509	Glutamate ionotropic receptor NMDA type subunit 2C	17	74842023-74861504	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 9.5;thyroid gland: 14.1	heart muscle: 6.1	Cell line enhanced		BEWO: 6.1;SCLC-21H: 3.3
GRIN2D	EB11, GluN2D, NMDAR2D, NR2D	ENSG00000105464	Glutamate ionotropic receptor NMDA type subunit 2D	19	48394875-48444931	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 2.3	placenta: 1.3	Cell line enhanced		A549: 16.7;HMC-1: 27.0
GRIN3A	GluN3A	ENSG00000198785	Glutamate ionotropic receptor NMDA type subunit 3A	9	101569353-101738580	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	5	cerebral cortex: 12.3;cervix, uterine: 2.5	seminal vesicle: 1.3	Cell line enriched	6	SCLC-21H: 2.1
GRIN3B	GluN3B	ENSG00000116032	Glutamate ionotropic receptor NMDA type subunit 3B	19	1000419-1009732	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		fallopian tube: 2.1;spleen: 1.2	lung: 0.7	Cell line enhanced		U-266/70: 2.6
GRINA	HNRGW, LFG1, NMDARA1, TMBIM3	ENSG00000178719	Glutamate ionotropic receptor NMDA type subunit associated protein 1	8	143990058-143993415	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA036980, HPA036981	Approved		Approved	Nucleoli fibrillar center<br>Cytosol		Expressed in all	Expressed in all			seminal vesicle: 264.5	Expressed in all		
GRM1	GPRC1A, mGlu1, MGLUR1, PPP1R85	ENSG00000152822	Glutamate metabotropic receptor 1	6	146027646-146437598	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015701	Approved		Approved	Vesicles		Not detected	Group enriched	5	cerebral cortex: 7.0;heart muscle: 1.7	kidney: 0.8	Not detected		
GRM2	GPRC1B, mGlu2, MGLUR2	ENSG00000164082	Glutamate metabotropic receptor 2	3	51707070-51718613	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027868, HPA065166	Approved	Supported				Tissue enhanced	Tissue enriched	10	cerebral cortex: 4.4	testis: 0.4	Cell line enriched	7	SCLC-21H: 7.3
GRM3	GPRC1C, mGlu3, MGLUR3	ENSG00000198822	Glutamate metabotropic receptor 3	7	86643914-86864884	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	43	cerebral cortex: 62.3	testis: 1.4	Cell line enriched	8	AF22: 35.5
GRM4	GPRC1D, mGlu4, MGLUR4	ENSG00000124493	Glutamate metabotropic receptor 4	6	34018645-34155622	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB022096	Enhanced					Tissue enhanced	Tissue enhanced		cerebral cortex: 2.9	testis: 0.7	Group enriched	11	BEWO: 7.2;SCLC-21H: 35.0
GRM5	GPRC1E, mGlu5, MGLUR5, PPP1R86	ENSG00000168959	Glutamate metabotropic receptor 5	11	88504576-89065945	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	8	cerebral cortex: 27.2	testis: 3.2	Not detected		
GRM6	CSNB1B, GPRC1F, mGlu6, MGLUR6	ENSG00000113262	Glutamate metabotropic receptor 6	5	178978327-178996206	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA014511	Supported					Not detected	Not detected			testis: 0.7	Not detected		
GRM7	GLUR7, GPRC1G, mGlu7, MGLUR7, PPP1R87	ENSG00000196277	Glutamate metabotropic receptor 7	3	6770001-7741533	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015964			Uncertain	Cytosol		Not detected	Tissue enhanced		cerebral cortex: 10.1;parathyroid gland: 7.2	smooth muscle: 3.4	Cell line enriched	12	SH-SY5Y: 5.0
GRM8	GLUR8, GPRC1H, mGlu8, MGLUR8	ENSG00000179603	Glutamate metabotropic receptor 8	7	126438598-127253294	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA051481	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 4.1	testis: 3.0	Group enriched	6	HAP1: 3.1;HEK93: 1.4;NTERA-2: 3.9;RH-30: 2.2;SCLC-21H: 4.1;SH-SY5Y: 2.0;U-2 OS: 1.3
GRPR	BB2, BB2R	ENSG00000126010	Gastrin releasing peptide receptor	X	16123556-16153021	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA069604			Enhanced	Plasma membrane		Tissue enhanced	Tissue enhanced		pancreas: 4.2	breast,epididymis: 2.6	Group enriched	10	PC-3: 30.0;T-47d: 37.9;U-138 MG: 53.4
GS1-259H13.2		ENSG00000244219		7	99598066-99610813	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	54	testis: 234.7	epididymis: 4.3	Cell line enhanced		Karpas-707: 8.5
GSG1	MGC3146	ENSG00000111305	Germ cell associated 1	12	13083560-13103683	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	377	testis: 574.9	duodenum: 1.5	Cell line enhanced		fHDF/TERT166: 6.7;LHCN-M2: 8.2;RPTEC TERT1: 9.2;U-2 OS: 6.4
GSG1L	KTSR5831, MGC18079, PRO19651	ENSG00000169181	GSG1 like	16	27787535-28063509	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014479	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 11.7;heart muscle: 7.3	fallopian tube: 2.7	Group enriched	7	HMC-1: 7.3;THP-1: 2.1
GSG1L2		ENSG00000214978	GSG1 like 2	17	9802386-9822071	Predicted membrane proteins	Evidence at transcript level	HPA059428	Uncertain					Tissue enriched	Group enriched	13	cerebral cortex: 1.5;testis: 1.0	all non-specific tissues: 0.0	Not detected		
GSTCD	FLJ13273	ENSG00000138780	Glutathione S-transferase C-terminal domain containing	4	105708778-105847728	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046160, HPA061782	Approved		Supported	Nucleus		Expressed in all	Mixed			testis: 19.5	Expressed in all		
GTF3C1	TFIIIC220	ENSG00000077235	General transcription factor IIIC subunit 1	16	27459555-27549913	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051617	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.25e-4 (favourable), Liver cancer:8.73e-4 (unfavourable), Pancreatic cancer:9.56e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 49.8	Expressed in all		
GTF3C3	TFIIIC102, TFiiiC2-102	ENSG00000119041	General transcription factor IIIC subunit 3	2	196763032-196799725	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069179			Supported	Nucleus<br>Nuclear membrane	Liver cancer:1.26e-6 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 37.4	Expressed in all		
GUCY2C	GUC2C, STAR	ENSG00000070019	Guanylate cyclase 2C	12	14612632-14696585	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037655, HPA073759	Uncertain		Uncertain	Vesicles	Liver cancer:1.37e-5 (unfavourable)	Group enriched	Group enriched	13	colon: 37.0;duodenum: 68.7;rectum: 45.4;small intestine: 73.2	appendix: 4.4	Cell line enhanced		AN3-CA: 1.2;CAPAN-2: 1.4;SiHa: 1.6
GUCY2D	CORD6, CYGD, GUC1A4, GUC2D, LCA, LCA1, retGC, RETGC-1, ROS-GC1	ENSG00000132518	Guanylate cyclase 2D, retinal	17	8002594-8020339	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enhanced		testis: 1.4	lymph node: 0.3	Cell line enriched	6	HMC-1: 1.1
GUCY2F	CYGF, GC-F, GUC2DL, RetGC-2, ROS-GC2	ENSG00000101890	Guanylate cyclase 2F, retinal	X	109372906-109482072	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			fallopian tube,testis: 0.4	Not detected		
GULP1	CED-6, CED6, GULP	ENSG00000144366	GULP, engulfment adaptor PTB domain containing 1	2	188291669-188595931	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020587	Enhanced		Approved	Vesicles	Renal cancer:4.25e-6 (favourable), Stomach cancer:6.17e-4 (unfavourable)	Mixed	Mixed			epididymis: 99.9	Cell line enhanced		AF22: 114.8;WM-115: 252.9
GYPA	CD235a, GPA, MN, MNS	ENSG00000170180	Glycophorin A (MNS blood group)	4	144109303-144140751	Blood group antigen proteins, CD markers, Predicted membrane proteins	Evidence at protein level	CAB002658, HPA014811	Enhanced					Not detected	Tissue enriched	16	bone marrow: 84.6	placenta: 5.4	Group enriched	264	HEL: 127.3;K-562: 31.3
GYPB	CD235b, GPB, MNS, SS	ENSG00000250361	Glycophorin B (MNS blood group)	4	143996104-144019345	Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	5	bone marrow: 37.2	placenta: 7.3	Cell line enriched	5	HEL: 225.3
GYPC	CD236, CD236R, Ge, GPC, GYPD	ENSG00000136732	Glycophorin C (Gerbich blood group)	2	126655933-126696675	Blood group antigen proteins, CD markers, Predicted membrane proteins	Evidence at protein level	HPA008965, CAB009445	Enhanced		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 229.7	Cell line enhanced		HHSteC: 315.4;SK-MEL-30: 452.6
GYPE	GPE, MNS	ENSG00000197465	Glycophorin E (MNS blood group)	4	143870867-143905563	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		bone marrow: 8.1	lung: 4.5	Group enriched	14	HEL: 108.6;K-562: 35.5
HACD1	CAP, PTPLA	ENSG00000165996	3-hydroxyacyl-CoA dehydratase 1	10	17589032-17617377	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		heart muscle: 42.0	smooth muscle: 36.3	Mixed		
HACD2	PTPLB	ENSG00000206527	3-hydroxyacyl-CoA dehydratase 2	3	123490820-123585185	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB019282	Approved				Pancreatic cancer:9.59e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 68.9	Expressed in all		
HACD3	B-ind1, HSPC121, PTPLAD1	ENSG00000074696	3-hydroxyacyl-CoA dehydratase 3	15	65530418-65578352	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014837, HPA060347	Enhanced		Enhanced	Nuclear membrane<br>Endoplasmic reticulum<br>Mitochondria<br>Cytosol	Renal cancer:3.09e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 138.9	Expressed in all		
HACD4	Em:AL662879.1, PTPLAD2	ENSG00000188921	3-hydroxyacyl-CoA dehydratase 4	9	20999515-21031636	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA058666	Uncertain				Ovarian cancer:3.14e-4 (favourable), Renal cancer:6.77e-4 (unfavourable)	Mixed	Mixed			lung: 12.6	Cell line enhanced		BJ hTERT+: 14.0;HDLM-2: 10.0;U-937: 10.5
HAPLN3	EXLD1, HsT19883	ENSG00000140511	Hyaluronan and proteoglycan link protein 3	15	88877288-88895626	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039237	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.18e-13 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 13.8;lymph node: 10.8	spleen: 4.0	Cell line enhanced		HDLM-2: 29.8;U-2 OS: 31.7
HAS1	HAS	ENSG00000105509	Hyaluronan synthase 1	19	51713112-51723994	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA067602	Approved		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		adipose tissue: 27.0	appendix: 8.9	Group enriched	12	hTEC/SVTERT24-B: 27.0;U-87 MG: 110.6
HAS2		ENSG00000170961	Hyaluronan synthase 2	8	121612116-121641390	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA052060			Approved	Nuclear speckles		Mixed	Tissue enhanced		adipose tissue: 27.9	gallbladder: 12.7	Cell line enhanced		HBF TERT88: 154.7;hTEC/SVTERT24-B: 155.8;LHCN-M2: 174.3;U-138 MG: 396.2;U-251 MG: 103.0
HAS3		ENSG00000103044	Hyaluronan synthase 3	16	69105564-69118719	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA031554, CAB033850	Supported		Approved	Microtubules	Pancreatic cancer:5.36e-4 (unfavourable)	Group enriched	Tissue enhanced		lung: 29.9;urinary bladder: 36.4	stomach: 11.8	Cell line enhanced		HaCaT: 46.5;PC-3: 257.9;RT4: 89.2
HAVCR1	CD365, HAVCR, HAVCR-1, KIM1, TIM-1, TIM1, TIMD1	ENSG00000113249	Hepatitis A virus cellular receptor 1	5	157029413-157059119	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007173, CAB075697	Approved		Approved	Vesicles	Urothelial cancer:1.32e-4 (favourable), Stomach cancer:7.81e-4 (unfavourable)	Tissue enriched	Group enriched	6	colon: 4.8;kidney: 8.3;rectum: 4.1;testis: 1.7	gallbladder: 0.8	Group enriched	5	A549: 86.4;CACO-2: 95.7;RPTEC TERT1: 33.8
HAVCR2	CD366, FLJ14428, Tim-3, TIM3, TIMD3	ENSG00000135077	Hepatitis A virus cellular receptor 2	5	157085832-157142869	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026003	Enhanced					Expressed in all	Mixed			lung: 24.0	Cell line enhanced		HDLM-2: 16.9;RPMI-8226: 10.3
HBD		ENSG00000223609	Hemoglobin subunit delta	11	5232678-5235370	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037087, HPA043234	Supported		Approved	Vesicles		Not detected	Tissue enriched	64	bone marrow: 1221.3	placenta: 19.0	Cell line enhanced		HEL: 13.7;HMC-1: 14.7;U-266/70: 73.6;U-266/84: 12.8
HBEGF	DTR, DTS, HEGFL	ENSG00000113070	Heparin binding EGF like growth factor	5	140332843-140346631	Predicted membrane proteins	Evidence at protein level	HPA053243	Uncertain				Head and neck cancer:2.41e-4 (unfavourable), Prostate cancer:6.00e-4 (favourable), Pancreatic cancer:7.09e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 89.0	Cell line enhanced		U-698: 63.3
HBS1L	DKFZp434g247, EF-1a, eRF3c, ERFS, HBS1, HSPC276, KIAA1038	ENSG00000112339	HBS1 like translational GTPase	6	134960378-135103056	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029728, HPA029729	Approved		Approved	Nuclear bodies<br>Cytosol	Colorectal cancer:6.77e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 73.2	Expressed in all		
HCAR1	FKSG80, GPR104, GPR81, HCA1, LACR1, TA-GPCR	ENSG00000196917	Hydroxycarboxylic acid receptor 1	12	122726076-122730843	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level						Breast cancer:3.61e-5 (unfavourable)	Mixed	Tissue enriched	8	parathyroid gland: 115.0	breast: 15.1	Cell line enhanced		CAPAN-2: 10.9;MCF7: 6.3;RT4: 28.4
HCAR2	GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG	ENSG00000182782	Hydroxycarboxylic acid receptor 2	12	122701293-122703343	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA028660	Approved		Approved	Cell Junctions		Group enriched	Tissue enhanced		spleen: 36.0	esophagus: 25.5	Cell line enriched	7	HaCaT: 105.3
HCAR3	GPR109B, HCA3, HM74	ENSG00000255398	Hydroxycarboxylic acid receptor 3	12	122714756-122716892	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA028660	Approved		Approved	Cell Junctions		Mixed	Tissue enhanced		bone marrow: 16.6;spleen: 21.7	appendix: 12.4	Group enriched	6	HaCaT: 8.1;RT4: 28.3
HCN1	BCNG-1, BCNG1, HAC-2	ENSG00000164588	Hyperpolarization activated cyclic nucleotide gated potassium channel 1	5	45254950-45696498	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA019195	Enhanced					Not detected	Tissue enriched	8	cerebral cortex: 4.9	heart muscle: 0.6	Cell line enhanced		WM-115: 1.0
HCN2	BCNG-2, BCNG2, HAC-1	ENSG00000099822	Hyperpolarization activated cyclic nucleotide gated potassium channel 2	19	589893-617159	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Renal cancer:6.99e-5 (unfavourable)	Group enriched	Tissue enriched	5	cerebral cortex: 38.3	heart muscle: 7.0	Cell line enhanced		A549: 27.1;MCF7: 21.7;U-138 MG: 20.0;U-87 MG: 40.9
HCN3	KIAA1535	ENSG00000143630	Hyperpolarization activated cyclic nucleotide gated potassium channel 3	1	155277583-155289848	Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level	HPA026584	Approved				Urothelial cancer:6.93e-4 (favourable), Renal cancer:7.49e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex,skin: 2.9	Cell line enhanced		K-562: 5.7
HCN4		ENSG00000138622	Hyperpolarization activated cyclic nucleotide gated potassium channel 4	15	73319859-73369264	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Group enriched	Group enriched	6	cerebral cortex: 1.4;heart muscle: 1.5;testis: 6.7	adrenal gland: 0.5	Cell line enhanced		AF22: 1.2;CACO-2: 1.3;NTERA-2: 4.7;U-2 OS: 2.1
HCRTR1	OX1R	ENSG00000121764	Hypocretin receptor 1	1	31617686-31632518	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014018	Approved					Not detected	Tissue enhanced		adrenal gland: 1.2	cerebral cortex: 0.9	Not detected		
HCRTR2	OX2R	ENSG00000137252	Hypocretin receptor 2	6	55106460-55282620	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA054516	Supported					Not detected	Not detected			kidney: 0.6	Cell line enriched	7	AF22: 1.0
HCST	DAP10, DKFZP586C1522, KAP10, PIK3AP	ENSG00000126264	Hematopoietic cell signal transducer	19	35902480-35904377	Predicted membrane proteins	Evidence at protein level	CAB034435, HPA063026	Enhanced		Uncertain	Vesicles	Renal cancer:1.59e-10 (unfavourable), Melanoma:6.70e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 154.3	Cell line enhanced		HEL: 207.8;HL-60: 107.2;HMC-1: 130.2;THP-1: 117.5;U-937: 204.7
HDAC10	DKFZP761B039	ENSG00000100429	Histone deacetylase 10	22	50245183-50251405	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB045977, HPA056514	Supported		Approved	Nucleoli fibrillar center	Renal cancer:4.74e-11 (unfavourable), Endometrial cancer:2.45e-5 (favourable), Cervical cancer:4.46e-4 (favourable), Pancreatic cancer:9.25e-4 (favourable)	Expressed in all	Mixed			spleen: 9.8	Mixed		
HEATR5A	C14orf125, DKFZP434I1735	ENSG00000129493	HEAT repeat containing 5A	14	31291791-31420582	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049539	Uncertain				Renal cancer:1.11e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 18.2	Expressed in all		
HECTD4	C12orf51, FLJ34154, KIAA0614	ENSG00000173064	HECT domain E3 ubiquitin protein ligase 4	12	112160188-112382439	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041062, HPA045473	Uncertain		Approved	Nucleoplasm<br>Vesicles	Head and neck cancer:2.97e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.4	Expressed in all		
HEG1	HEG, KIAA1237	ENSG00000173706	Heart development protein with EGF like domains 1	3	124965710-125055958	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA010952, HPA011559	Approved		Approved	Vesicles	Renal cancer:1.93e-5 (unfavourable), Urothelial cancer:1.16e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 65.0	Cell line enhanced		HHSteC: 134.6
HELZ	DHRC, HUMORF5, KIAA0054	ENSG00000198265	Helicase with zinc finger	17	67070438-67245989	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028276	Approved		Approved	Nucleoli<br>Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			parathyroid gland: 32.9	Expressed in all		
HEPACAM	FLJ25530, GLIALCAM, hepaCAM	ENSG00000165478	Hepatic and glial cell adhesion molecule	11	124919193-124936412	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017613, CAB025486	Enhanced		Approved	Vesicles		Tissue enriched	Tissue enriched	5	cerebral cortex: 80.7	adipose tissue: 15.1	Cell line enriched	27	Hep G2: 18.8
HEPACAM2	FLJ38683	ENSG00000188175	HEPACAM family member 2	7	93188586-93226524	Predicted membrane proteins	Evidence at protein level						Colorectal cancer:9.73e-5 (favourable)	Mixed	Tissue enhanced		colon: 64.3;rectum: 103.1;small intestine: 53.6	duodenum: 30.2	Cell line enriched	47	SCLC-21H: 202.2
HEPH	CPL, KIAA0698	ENSG00000089472	Hephaestin	X	66162549-66268867	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005824	Approved				Renal cancer:7.00e-6 (unfavourable), Glioma:6.23e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 119.0	Cell line enhanced		AF22: 28.1;HEL: 22.8;HSkMC: 26.1;K-562: 64.5;LHCN-M2: 23.8
HEPHL1	DKFZp686F22190	ENSG00000181333	Hephaestin like 1	11	94021361-94113751	Predicted membrane proteins	Evidence at protein level	HPA031517	Uncertain				Cervical cancer:4.94e-4 (unfavourable)	Tissue enriched	Group enriched	11	esophagus: 3.2;tonsil: 9.4	testis: 0.5	Cell line enhanced		HaCaT: 1.4;HBEC3-KT: 2.0
HERC2	D15F37S1, jdf2, p528	ENSG00000128731	HECT and RLD domain containing E3 ubiquitin protein ligase 2	15	28111040-28322152	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017188, HPA048389	Approved		Approved	Vesicles	Renal cancer:1.41e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.1	Cell line enhanced		HEL: 48.6
HERC4	DKFZP564G092, KIAA1593	ENSG00000148634	HECT and RLD domain containing E3 ubiquitin protein ligase 4	10	67921899-68075348	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045453, HPA070301	Uncertain		Supported	Nucleoli fibrillar center<br>Cytosol	Renal cancer:3.86e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 32.5	Expressed in all		
HERC5	CEB1	ENSG00000138646	HECT and RLD domain containing E3 ubiquitin protein ligase 5	4	88457117-88506163	Predicted membrane proteins	Evidence at protein level	HPA043929	Supported				Endometrial cancer:4.46e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 106.5	endometrium: 25.6	Cell line enhanced		BJ hTERT+ SV40 Large T+: 83.8;BJ hTERT+ SV40 Large T+ RasG12V: 120.3
HERC6	FLJ20637	ENSG00000138642	HECT and RLD domain containing E3 ubiquitin protein ligase family member 6	4	88378739-88443111	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035846	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:7.14e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 22.8	Group enriched	5	BJ hTERT+ SV40 Large T+: 108.0;BJ hTERT+ SV40 Large T+ RasG12V: 83.5
HERPUD1	HERP, KIAA0025, Mif1, SUP	ENSG00000051108	Homocysteine inducible ER protein with ubiquitin like domain 1	16	56932048-56944863	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037041, CAB037104, HPA040754, HPA041219	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.41e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 358.8	Expressed in all		
HERPUD2	FLJ22313	ENSG00000122557	HERPUD family member 2	7	35632659-35695571	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015630, HPA076087	Approved		Approved	Nucleoli		Expressed in all	Expressed in all			testis: 48.2	Expressed in all		
HFE	HLA-H	ENSG00000010704	Hemochromatosis	6	26087281-26098343	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA017276, HPA053470	Approved		Approved	Nuclear membrane<br>Mitochondria		Expressed in all	Mixed			parathyroid gland: 27.9	Cell line enhanced		T-47d: 50.9
HFE2	haemojuvelin, hemojuvelin, HFE2A, HJV, JH, RGMC	ENSG00000168509	Hemochromatosis type 2 (juvenile)	1	146017468-146036746	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	15	heart muscle: 45.4;liver: 123.4;skeletal muscle: 212.6	esophagus: 8.6	Cell line enhanced		HSkMC: 1.1;K-562: 1.4
HGSNAT	FLJ32731, HGNAT, TMEM76	ENSG00000165102	Heparan-alpha-glucosaminide N-acetyltransferase	8	43140455-43202855	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA029578	Approved				Ovarian cancer:6.33e-5 (favourable), Glioma:7.02e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 49.2	Expressed in all		
HHAT	FLJ10724, GUP2, MART-2, MART2, rasp, sit, ski, Skn	ENSG00000054392	Hedgehog acyltransferase	1	210328252-210676296	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016462	Approved		Approved	Golgi apparatus	Renal cancer:8.47e-7 (favourable)	Expressed in all	Mixed			thyroid gland: 7.8	Cell line enhanced		HMC-1: 11.9;RH-30: 12.0
HHATL	C3orf3, GUP1, KIAA1173, MBOAT3, MSTP002, OACT3	ENSG00000010282	Hedgehog acyltransferase-like	3	42692663-42702827	Predicted membrane proteins	Evidence at protein level	HPA018174	Enhanced					Tissue enhanced	Tissue enhanced		heart muscle: 333.1;skeletal muscle: 97.6	cerebral cortex: 53.3	Not detected		
HHIP	FLJ20992, HIP	ENSG00000164161	Hedgehog interacting protein	4	144646021-144745271	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012616	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		lung: 24.2	cerebral cortex: 10.8	Group enriched	6	HUVEC TERT2: 269.0;RH-30: 62.9;TIME: 306.5
HHLA2	B7-H5, B7H7, B7y	ENSG00000114455	HERV-H LTR-associating 2	3	108296490-108378285	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055478	Enhanced					Group enriched	Group enriched	10	colon: 87.7;duodenum: 87.1;gallbladder: 46.0;rectum: 90.5;small intestine: 143.9	stomach: 9.2	Cell line enhanced		HDLM-2: 3.7;Karpas-707: 2.0
HIGD1A	DKFZP564K247, HIG1, RCF1A	ENSG00000181061	HIG1 hypoxia inducible domain family member 1A	3	42784298-42804531	Predicted membrane proteins	Evidence at protein level	HPA043336	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.99e-8 (favourable), Colorectal cancer:2.12e-4 (favourable)	Expressed in all	Expressed in all			rectum: 328.9	Expressed in all		
HIGD1B	CLST11240, CLST11240-15	ENSG00000131097	HIG1 hypoxia inducible domain family member 1B	17	44846353-44850480	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Group enriched	6	lung: 55.4;placenta: 153.8	gallbladder: 18.2	Mixed		
HIGD1C	Gm921	ENSG00000214511	HIG1 hypoxia inducible domain family member 1C	12	50953922-50970506	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 2.9	parathyroid gland: 2.1	Cell line enhanced		BEWO: 1.2;Karpas-707: 1.1
HIGD2A	MGC2198, RCF1B	ENSG00000146066	HIG1 hypoxia inducible domain family member 2A	5	176388747-176389771	Predicted membrane proteins	Evidence at protein level	HPA042715	Uncertain		Supported	Mitochondria<br>Cytosol	Liver cancer:9.47e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 170.9	Expressed in all		
HIGD2B	HIGD2BP	ENSG00000175202	HIG1 hypoxia inducible domain family member 2B	15	72675783-72686149	Predicted membrane proteins	Evidence at protein level	HPA019016, HPA042715	Uncertain		Supported	Mitochondria<br>Cytosol		Not detected	Tissue enriched	14	testis: 6.7	epididymis,thyroid gland: 0.4	Not detected		
HILPDA	C7orf68, FLJ21076, HIG-2, HIG2	ENSG00000135245	Hypoxia inducible lipid droplet associated	7	128455849-128458418	Predicted membrane proteins	Evidence at protein level	HPA010515	Approved		Supported	Nucleoplasm<br>Lipid droplets	Liver cancer:4.30e-11 (unfavourable), Renal cancer:2.05e-7 (unfavourable)	Expressed in all	Expressed in all			esophagus: 107.8	Expressed in all		
HIPK1	KIAA0630, MGC26642, MGC33446, MGC33548, Myak, Nbak2	ENSG00000163349	Homeodomain interacting protein kinase 1	1	113929192-113977869	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016664	Approved		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 89.7	Expressed in all		
HIPK2		ENSG00000064393	Homeodomain interacting protein kinase 2	7	139561570-139777778	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007611	Supported		Supported	Nucleus	Renal cancer:9.99e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 61.3	Cell line enhanced		HDLM-2: 113.5
HIPK3	DYRK6, FIST3, PKY, YAK1	ENSG00000110422	Homeodomain interacting protein kinase 3	11	33256672-33357023	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028069	Approved		Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 126.8	Expressed in all		
HLA-A		ENSG00000206503	Major histocompatibility complex, class I, A	6	29941260-29945884	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB078470			Supported	Golgi apparatus<br>Plasma membrane	Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable)	Expressed in all	Mixed			gallbladder: 340.9	Cell line enhanced		A-431: 1127.9
HLA-B	AS	ENSG00000234745	Major histocompatibility complex, class I, B	6	31269491-31357188	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB015418	Enhanced				Melanoma:2.90e-4 (favourable)	Expressed in all	Mixed			lung: 1241.8	Cell line enhanced		A-431: 553.0;EFO-21: 516.7;U-266/70: 1064.3
HLA-C	D6S204, HLA-JY3, PSORS1	ENSG00000204525	Major histocompatibility complex, class I, C	6	31268749-31272130	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		lung: 744.7	small intestine: 396.9	Cell line enhanced		A-431: 660.6;EFO-21: 748.1;RPTEC TERT1: 346.0;U-266/70: 367.3;U-266/84: 281.2
HLA-DMA	D6S222E, RING6	ENSG00000204257	Major histocompatibility complex, class II, DM alpha	6	32948613-32969094	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012750, HPA017295	Enhanced		Approved	Vesicles	Endometrial cancer:4.64e-5 (favourable), Lung cancer:4.59e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 65.0	fallopian tube: 41.9	Cell line enhanced		U-266/70: 22.0;U-266/84: 9.5;U-698: 52.4
HLA-DMB	D6S221E, RING7	ENSG00000242574	Major histocompatibility complex, class II, DM beta	6	32934629-32941070	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012298	Supported				Endometrial cancer:3.89e-5 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 29.3	spleen: 12.0	Group enriched	11	CAPAN-2: 5.2;Daudi: 6.1;EFO-21: 3.6;U-266/70: 2.3;U-698: 7.1
HLA-DOA	HLA-D0-alpha, HLA-DNA, HLA-DZA	ENSG00000204252	Major histocompatibility complex, class II, DO alpha	6	33004178-33009612	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045038	Enhanced					Expressed in all	Tissue enhanced		spleen: 14.4	tonsil: 8.9	Cell line enhanced		Daudi: 4.6;HDLM-2: 4.3;REH: 19.0;U-698: 3.4
HLA-DOB		ENSG00000241106	Major histocompatibility complex, class II, DO beta	6	32812763-32817048	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013846	Enhanced				Renal cancer:3.15e-5 (unfavourable), Ovarian cancer:4.17e-5 (favourable), Breast cancer:4.29e-4 (favourable)	Expressed in all	Group enriched	5	lymph node: 19.6;spleen: 18.6;tonsil: 30.7;urinary bladder: 8.3	colon: 3.5	Cell line enhanced		Daudi: 37.8;U-698: 12.8;U-937: 6.1
HLA-DPA1	HLA-DP1A	ENSG00000231389	Major histocompatibility complex, class II, DP alpha 1	6	33064569-33080775	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017967	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			lung: 120.6	Cell line enhanced		Daudi: 26.7;HDLM-2: 107.3;REH: 26.8
HLA-DPB1	HLA-DP1B	ENSG00000223865	Major histocompatibility complex, class II, DP beta 1	6	33075926-33087201	Predicted membrane proteins	Evidence at protein level	HPA011078, HPA058509	Approved		Approved	Nucleus<br>Cell Junctions	Endometrial cancer:3.38e-4 (favourable)	Expressed in all	Expressed in all			spleen: 170.6	Group enriched	7	HDLM-2: 102.6;REH: 48.0
HLA-DQA1	CELIAC1, HLA-DQA	ENSG00000196735	Major histocompatibility complex, class II, DQ alpha 1	6	32628179-32647062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012315	Enhanced					Expressed in all	Tissue enhanced		lung: 504.8	lymph node: 338.6	Cell line enriched	9	HDLM-2: 1315.9
HLA-DQA2	HLA-DXA	ENSG00000237541	Major histocompatibility complex, class II, DQ alpha 2	6	32741342-32747215	Predicted membrane proteins	Evidence at protein level							Expressed in all	Not detected			tonsil: 0.3	Not detected		
HLA-DQB1	CELIAC1, HLA-DQB, IDDM1	ENSG00000179344	Major histocompatibility complex, class II, DQ beta 1	6	32659467-32668383	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013667	Uncertain		Supported	Golgi apparatus<br>Rods & Rings		Expressed in all	Tissue enhanced		lymph node: 287.3	lung: 268.5	Cell line enriched	8	HDLM-2: 555.8
HLA-DQB2	HLA-DXB	ENSG00000232629	Major histocompatibility complex, class II, DQ beta 2	6	32756098-32763534	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Breast cancer:5.55e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 8.1;skin: 13.3	tonsil: 5.9	Not detected		
HLA-DRA	HLA-DRA1	ENSG00000204287	Major histocompatibility complex, class II, DR alpha	6	32439842-32445046	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002798, CAB015402, HPA050162, HPA053176	Enhanced				Colorectal cancer:5.30e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 731.8;lymph node: 894.1	tonsil: 476.7	Cell line enhanced		Daudi: 254.2;HDLM-2: 588.3;REH: 234.5;U-698: 247.8;U-87 MG: 236.0
HLA-DRB1	HLA-DR1B	ENSG00000196126	Major histocompatibility complex, class II, DR beta 1	6	32578769-32589848	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB015400, CAB034021, HPA043151	Enhanced					Expressed in all	Tissue enhanced		lung: 868.4	lymph node: 619.6	Cell line enhanced		HDLM-2: 1095.2;U-87 MG: 302.0
HLA-DRB5		ENSG00000198502	Major histocompatibility complex, class II, DR beta 5	6	32517343-32530287	Predicted membrane proteins	Evidence at protein level	HPA043151	Supported				Endometrial cancer:7.89e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 530.8	lymph node: 397.6	Group enriched	7	HDLM-2: 589.3;HMC-1: 134.7;U-698: 129.3;U-87 MG: 232.1
HLA-E		ENSG00000204592	Major histocompatibility complex, class I, E	6	30489467-30494205	Predicted membrane proteins	Evidence at protein level	CAB024589, HPA031454	Enhanced		Approved	Vesicles	Renal cancer:3.86e-4 (unfavourable)	Expressed in all	Mixed			skin: 153.4	Cell line enhanced		U-266/70: 73.1
HLA-F		ENSG00000204642	Major histocompatibility complex, class I, F	6	29722775-29738528	Plasma proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 41.2	stomach: 28.7	Group enriched	7	A-431: 31.2;HEK93: 11.2;HEL: 7.8;HHSteC: 8.5;U-266/70: 6.4;U-937: 10.5
HLA-G		ENSG00000204632	Major histocompatibility complex, class I, G	6	29826967-29831125	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	CAB016158	Enhanced				Melanoma:3.91e-5 (favourable)	Expressed in all	Tissue enriched	23	placenta: 14.9	duodenum,testis: 0.6	Not detected		
HM13	dJ324O17.1, H13, IMP1, IMPAS, PSENL3, PSL3, SPP, SPPL1	ENSG00000101294	Histocompatibility minor 13	20	31514428-31577923	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA045089, HPA056062	Approved		Supported	Endoplasmic reticulum	Renal cancer:4.64e-12 (unfavourable), Liver cancer:1.95e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 154.2	Expressed in all		
HMGCR		ENSG00000113161	3-hydroxy-3-methylglutaryl-CoA reductase	5	75336329-75362104	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008338, CAB016797	Approved				Renal cancer:9.42e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 87.5	Expressed in all		
HMOX1	bK286B10, HO-1	ENSG00000100292	Heme oxygenase 1	22	35380361-35394214	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000635, CAB017444	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane	Liver cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 428.5	Cell line enhanced		BEWO: 701.9;U-138 MG: 414.7;U-87 MG: 399.9
HMOX2	HO-2	ENSG00000103415	Heme oxygenase 2	16	4474690-4510347	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025464, HPA040611	Supported		Approved	Vesicles<br>Cytosol	Renal cancer:8.98e-6 (favourable), Endometrial cancer:7.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 97.6	Expressed in all		
HMP19		ENSG00000170091	HMP19 protein	5	174045604-174243501	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046531, HPA056191	Enhanced		Supported	Golgi apparatus		Tissue enriched	Tissue enriched	7	cerebral cortex: 288.5	adrenal gland: 42.0	Group enriched	84	SCLC-21H: 45.2;SH-SY5Y: 65.3
HOXC11	HOX3H	ENSG00000123388	Homeobox C11	12	53973126-53977643	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA038291	Uncertain		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		skin: 2.2	testis: 1.1	Cell line enhanced		AN3-CA: 32.1;BJ hTERT+: 14.2;T-47d: 25.7
HPN	TMPRSS1	ENSG00000105707	Hepsin	19	35040506-35066571	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006804	Approved				Renal cancer:5.45e-5 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 99.7;liver: 155.4	prostate: 31.6	Group enriched	7	EFO-21: 29.1;Hep G2: 31.2;T-47d: 20.3
HPS3	BLOC2S1, SUTAL	ENSG00000163755	HPS3, biogenesis of lysosomal organelles complex 2 subunit 1	3	149129584-149173732	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046281, HPA052778	Approved		Approved	Golgi apparatus<br>Plasma membrane	Renal cancer:4.38e-4 (unfavourable), Liver cancer:6.04e-4 (unfavourable)	Expressed in all	Mixed			spleen: 22.0	Expressed in all		
HRASLS	H-REV107, HRASLS1	ENSG00000127252	HRAS like suppressor	3	193241125-193277738	Predicted membrane proteins	Evidence at transcript level	HPA051179	Uncertain		Approved	Focal adhesion sites<br>Cytosol	Testis cancer:4.36e-4 (favourable)	Mixed	Group enriched	6	skeletal muscle: 27.2;testis: 95.8	thyroid gland: 10.0	Cell line enhanced		HAP1: 11.5;PC-3: 20.0;SCLC-21H: 22.9;U-2 OS: 12.2;U-251 MG: 12.7
HRASLS2	FLJ20556	ENSG00000133328	HRAS like suppressor 2	11	63552770-63563383	Predicted membrane proteins	Evidence at protein level	HPA058997	Approved		Approved	Mitochondria	Pancreatic cancer:5.27e-5 (unfavourable), Cervical cancer:6.87e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 67.6;small intestine: 46.5	rectum: 14.4	Cell line enriched	7	U-266/70: 97.6
HRH1		ENSG00000196639	Histamine receptor H1	3	11137093-11263557	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029740	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:1.27e-5 (unfavourable)	Mixed	Mixed			cerebral cortex: 12.4	Mixed		
HRH2		ENSG00000113749	Histamine receptor H2	5	175658030-175710756	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013770	Approved					Tissue enhanced	Tissue enhanced		bone marrow: 23.5	appendix: 16.7	Cell line enhanced		RPMI-8226: 45.4;SK-MEL-30: 15.0;THP-1: 12.1;U-937: 16.9
HRH3	GPCR97	ENSG00000101180	Histamine receptor H3	20	62214970-62220267	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	17	cerebral cortex: 11.1	adrenal gland: 0.6	Cell line enriched	7	SCLC-21H: 18.6
HRH4	AXOR35, GPCR105, GPRv53, H4R, HH4R	ENSG00000134489	Histamine receptor H4	18	24460629-24479957	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA035009	Uncertain					Not detected	Not detected			skin: 0.7	Cell line enhanced		HL-60: 1.1
HRK	DP5	ENSG00000135116	Harakiri, BCL2 interacting protein	12	116856144-116881441	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025973	Uncertain					Mixed	Group enriched	9	cerebral cortex: 13.3;thyroid gland: 6.4	testis: 1.1	Cell line enhanced		Daudi: 7.9;SCLC-21H: 10.7;SH-SY5Y: 8.3;SK-MEL-30: 16.7;U-698: 25.7
HS3ST4	3OST4	ENSG00000182601	Heparan sulfate-glucosamine 3-sulfotransferase 4	16	25692026-26137688	Enzymes, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	7	cerebral cortex: 18.7	breast: 2.8	Cell line enhanced		NTERA-2: 1.4
HS6ST2		ENSG00000171004	Heparan sulfate 6-O-sulfotransferase 2	X	132626016-132961395	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA034625, HPA034626	Uncertain		Supported	Nucleoplasm	Urothelial cancer:6.03e-4 (favourable)	Mixed	Tissue enhanced		kidney: 15.0;ovary: 17.6	placenta: 11.9	Cell line enhanced		HEK93: 42.3;RH-30: 63.9;SH-SY5Y: 87.0
HSD11B1L	SCDR10, SDR26C2	ENSG00000167733	Hydroxysteroid 11-beta dehydrogenase 1 like	19	5680604-5688523	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA049078			Approved	Vesicles	Head and neck cancer:4.38e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 25.6	fallopian tube: 7.9	Cell line enhanced		SH-SY5Y: 20.1
HSD11B2	SDR9C3	ENSG00000176387	Hydroxysteroid 11-beta dehydrogenase 2	16	67430652-67437553	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB032443, HPA042186, HPA056385	Enhanced		Approved	Vesicles	Renal cancer:9.51e-5 (favourable)	Expressed in all	Tissue enhanced		colon: 151.6;kidney: 173.3	salivary gland: 122.5	Cell line enhanced		NTERA-2: 11.4;RPMI-8226: 9.6;RT4: 11.0;SCLC-21H: 17.5;SK-BR-3: 10.0
HSD17B12	KAR, SDR12C1	ENSG00000149084	Hydroxysteroid 17-beta dehydrogenase 12	11	43680558-43856617	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016427	Approved				Renal cancer:2.10e-8 (favourable), Liver cancer:2.76e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 196.5	Expressed in all		
HSD17B2	HSD17, SDR9C2	ENSG00000086696	Hydroxysteroid 17-beta dehydrogenase 2	16	82035004-82098534	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021826, HPA050235	Enhanced		Approved	Endoplasmic reticulum	Urothelial cancer:3.83e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 430.9;placenta: 552.6	small intestine: 199.4	Cell line enhanced		BJ hTERT+: 47.0;Hep G2: 32.2;RT4: 77.0;TIME: 44.0
HSD17B3	SDR12C2	ENSG00000130948	Hydroxysteroid 17-beta dehydrogenase 3	9	96235306-96302152	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056833	Enhanced		Supported	Vesicles		Mixed	Tissue enriched	15	testis: 74.9	thyroid gland: 4.8	Cell line enhanced		HBEC3-KT: 2.6;HEL: 3.2;U-2 OS: 5.8
HSD17B7	PRAP, SDR37C1	ENSG00000132196	Hydroxysteroid 17-beta dehydrogenase 7	1	162790702-162812817	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047496	Approved				Renal cancer:8.47e-5 (unfavourable)	Expressed in all	Mixed			liver: 16.9	Expressed in all		
HSD3B1	HSD3B, HSDB3, SDR11E1	ENSG00000203857	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	1	119507198-119515054	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043261, HPA043264, HPA044028	Supported				Urothelial cancer:4.59e-5 (favourable)	Tissue enhanced	Tissue enriched	13	placenta: 110.5	small intestine: 8.7	Cell line enriched	7	CACO-2: 52.9
HSD3B2	SDR11E2	ENSG00000203859	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	1	119414931-119423035	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043261, HPA043264, HPA044028	Supported					Tissue enhanced	Tissue enriched	433	adrenal gland: 2384.5	testis: 5.5	Cell line enhanced		SK-MEL-30: 1.2
HSD3B7	C(27)-3BETA-HSD, SDR11E3	ENSG00000099377	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7	16	30985207-30989152	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050521, HPA060847	Uncertain		Supported	Lipid droplets	Renal cancer:1.60e-6 (unfavourable), Colorectal cancer:5.95e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 21.9	Cell line enhanced		HDLM-2: 83.9;HMC-1: 85.9;U-2197: 89.0
HSDL1	SDR12C3	ENSG00000103160	Hydroxysteroid dehydrogenase like 1	16	84122146-84145192	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:4.20e-7 (favourable), Liver cancer:3.50e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 45.8	Expressed in all		
HTATIP2	CC3, FLJ26963, SDR44U1, TIP30	ENSG00000109854	HIV-1 Tat interactive protein 2	11	20363685-20383783	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006417, HPA024321	Approved		Supported	Cytosol	Liver cancer:2.86e-4 (unfavourable), Pancreatic cancer:6.18e-4 (unfavourable), Renal cancer:8.01e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 135.2	Mixed		
HTR1A	5-HT1A, ADRB2RL1, ADRBRL1	ENSG00000178394	5-hydroxytryptamine receptor 1A	5	63960356-63962507	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018073	Uncertain					Not detected	Group enriched	10	cerebral cortex: 1.9;ovary: 3.9	testis: 0.2	Group enriched	16	NTERA-2: 1.6;SCLC-21H: 1.5
HTR1B	5-HT1B, 5-HT1DB, HTR1D2, S12	ENSG00000135312	5-hydroxytryptamine receptor 1B	6	77461753-77463773	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA028808	Enhanced		Uncertain	Plasma membrane		Mixed	Tissue enhanced		placenta: 10.0;stomach: 4.7	cerebral cortex: 2.4	Group enriched	16	HUVEC TERT2: 68.8;TIME: 29.9
HTR1D	5-HT1D, HT1DA, HTRL, RDC4	ENSG00000179546	5-hydroxytryptamine receptor 1D	1	23191895-23194729	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Liver cancer:1.86e-4 (unfavourable), Pancreatic cancer:5.30e-4 (unfavourable)	Mixed	Group enriched	8	duodenum: 9.4;gallbladder: 2.5;small intestine: 9.1	fallopian tube: 0.9	Cell line enhanced		A549: 9.5;SiHa: 7.5;TIME: 21.6;U-2 OS: 9.0
HTR1E	5-HT1E	ENSG00000168830	5-hydroxytryptamine receptor 1E	6	86937306-87016683	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA004931	Approved					Not detected	Tissue enhanced		endometrium: 2.4;ovary: 4.9	cerebral cortex: 1.8	Group enriched	19	PC-3: 1.4;SH-SY5Y: 6.2
HTR1F	5-HT1F, HTR1EL	ENSG00000179097	5-hydroxytryptamine receptor 1F	3	87990696-87993835	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA005555	Uncertain					Not detected	Tissue enhanced		placenta: 2.7	cerebral cortex: 1.0	Cell line enhanced		K-562: 1.1;LHCN-M2: 1.0
HTR2A	5-HT2A, HTR2	ENSG00000102468	5-hydroxytryptamine receptor 2A	13	46831550-46897076	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014011	Enhanced					Not detected	Tissue enriched	8	cerebral cortex: 32.2	smooth muscle: 3.9	Cell line enhanced		ASC diff: 1.3;ASC TERT1: 3.2;BEWO: 1.4;HEL: 1.3;U-138 MG: 2.3;U-2 OS: 1.6
HTR2B	5-HT(2B), 5-HT2B	ENSG00000135914	5-hydroxytryptamine receptor 2B	2	231108230-231125118	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012867, HPA063658	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		cervix, uterine: 31.2;endometrium: 30.1;smooth muscle: 23.2	adrenal gland: 19.1	Cell line enhanced		HHSteC: 7.0;HSkMC: 11.5;SK-MEL-30: 23.9
HTR2C	5-HT2C, 5HTR2C, HTR1C	ENSG00000147246	5-hydroxytryptamine receptor 2C	X	114584078-114910061	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	6	cerebral cortex: 3.1	cervix, uterine: 0.5	Cell line enhanced		EFO-21: 2.5;U-266/70: 3.6;U-266/84: 2.8
HTR3A	5-HT3A, 5-HT3R, HTR3	ENSG00000166736	5-hydroxytryptamine receptor 3A	11	113974881-113990313	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA069442	Supported				Endometrial cancer:1.26e-4 (unfavourable), Cervical cancer:6.26e-4 (favourable)	Tissue enriched	Group enriched	5	appendix: 2.8;lymph node: 7.8;tonsil: 7.2	small intestine: 1.1	Cell line enhanced		CAPAN-2: 5.3;Daudi: 4.2;NTERA-2: 3.6;SCLC-21H: 22.1
HTR3B	5-HT3B	ENSG00000149305	5-hydroxytryptamine receptor 3B	11	113904677-113946565	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039559	Approved					Not detected	Tissue enhanced		cerebral cortex: 2.7	testis: 1.1	Not detected		
HTR3C		ENSG00000178084	5-hydroxytryptamine receptor 3C	3	184053047-184060671	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		lung: 1.9	duodenum: 0.4	Not detected		
HTR3D		ENSG00000186090	5-hydroxytryptamine receptor 3D	3	184031544-184039369	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HTR3E		ENSG00000186038	5-hydroxytryptamine receptor 3E	3	184097064-184106995	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049764	Enhanced					Not detected	Tissue enhanced		duodenum: 1.0	small intestine: 0.8	Cell line enriched	6	RH-30: 1.3
HTR4	5-HT4	ENSG00000164270	5-hydroxytryptamine receptor 4	5	148451032-148677235	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040591	Approved					Not detected	Tissue enhanced		duodenum: 4.8;small intestine: 10.0	rectum: 3.1	Not detected		
HTR5A	5-HT5A	ENSG00000157219	5-hydroxytryptamine receptor 5A	7	155070324-155085749	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	CAB017467	Approved					Not detected	Tissue enriched	11	cerebral cortex: 8.6	testis: 0.7	Not detected		
HTR6	5-HT6, 5-HT6R	ENSG00000158748	5-hydroxytryptamine receptor 6	1	19665287-19679562	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Not detected			cerebral cortex: 0.8	Cell line enhanced		SH-SY5Y: 2.1
HTR7	5-HT7	ENSG00000148680	5-hydroxytryptamine receptor 7	10	90740823-90857698	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB022708, HPA073617	Approved		Supported	Nuclear speckles<br>Plasma membrane<br>Cytosol		Group enriched	Group enriched	8	parathyroid gland: 44.8;testis: 16.1	urinary bladder: 3.8	Cell line enhanced		hTERT-HME1: 25.8;LHCN-M2: 11.4;WM-115: 12.9
HTRA2	OMI, PARK13, PRSS25	ENSG00000115317	HtrA serine peptidase 2	2	74529377-74533348	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB004004, HPA006602, HPA027366	Uncertain		Supported	Mitochondria	Liver cancer:7.77e-8 (unfavourable)	Expressed in all	Mixed			spleen: 9.0	Expressed in all		
HTT	HD, IT15	ENSG00000197386	Huntingtin	4	3074681-3243959	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002756, HPA026114	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.41e-12 (favourable), Head and neck cancer:3.26e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.3	Expressed in all		
HUWE1	Ib772, KIAA0312, UREB1	ENSG00000086758	HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase	X	53532096-53686729	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002548, CAB022718	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 96.6	Expressed in all		
HVCN1	Hv1, MGC15619, VSOP	ENSG00000122986	Hydrogen voltage gated channel 1	12	110627841-110704950	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039329	Enhanced					Expressed in all	Mixed			testis: 82.5	Cell line enhanced		HL-60: 35.4;NB-4: 182.9;U-698: 61.5
HYAL2	LuCa-2, LUCA2	ENSG00000068001	Hyaluronoglucosaminidase 2	3	50317790-50322906	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036436	Uncertain					Expressed in all	Expressed in all			spleen: 214.2	Expressed in all		
HYAL4		ENSG00000106302	Hyaluronoglucosaminidase 4	7	123828983-123877478	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029453	Uncertain					Tissue enriched	Tissue enhanced		placenta: 5.9;testis: 4.0	skin,spleen: 1.1	Cell line enhanced		BEWO: 3.5;CAPAN-2: 5.2;RT4: 11.2
ICA1	ICA69, ICAp69	ENSG00000003147	Islet cell autoantigen 1	7	8113184-8262687	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017646, HPA061452	Approved		Supported	Vesicles<br>Cytosol	Renal cancer:4.23e-8 (favourable)	Expressed in all	Mixed			testis: 42.6	Cell line enhanced		SCLC-21H: 73.0;SH-SY5Y: 109.7
ICAM1	BB2, CD54	ENSG00000090339	Intercellular adhesion molecule 1	19	10270835-10286615	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002126, CAB002142, HPA004877	Enhanced		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			lung: 255.9	Cell line enhanced		Karpas-707: 302.5
ICAM2	CD102	ENSG00000108622	Intercellular adhesion molecule 2	17	64002594-64020634	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071155			Uncertain	Cytosol		Expressed in all	Expressed in all			spleen: 200.5	Group enriched	7	HUVEC TERT2: 1043.9;TIME: 259.9
ICAM3	CD50, CDW50, ICAM-R	ENSG00000076662	Intercellular adhesion molecule 3	19	10333776-10339823	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002498, HPA049820	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Mitochondria		Mixed	Expressed in all			bone marrow: 111.9	Cell line enhanced		Karpas-707: 205.5;NB-4: 121.3;RPMI-8226: 154.3;U-937: 121.2
ICAM4	CD242, LW	ENSG00000105371	Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)	19	10286967-10288522	Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		bone marrow: 8.7;lung: 14.5	epididymis: 2.9	Cell line enhanced		HEL: 67.4;K-562: 35.3;NB-4: 20.5
ICAM5	TLCN, TLN	ENSG00000105376	Intercellular adhesion molecule 5	19	10289981-10296778	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008943, HPA009083, CAB025178	Enhanced					Tissue enhanced	Tissue enriched	10	cerebral cortex: 21.6	lung: 2.0	Cell line enhanced		HEL: 14.8;K-562: 12.0;RPMI-8226: 10.5;U-266/70: 13.3;U-87 MG: 10.1
ICMT	HSTE14, PCCMT, PPMT	ENSG00000116237	Isoprenylcysteine carboxyl methyltransferase	1	6221193-6235972	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA032024, HPA032025	Uncertain				Liver cancer:1.79e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 45.1	Expressed in all		
ICOS	AILIM, CD278	ENSG00000163600	Inducible T-cell costimulator	2	203936748-203961577	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB032575	Approved				Head and neck cancer:1.80e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 10.9;lymph node: 16.9;tonsil: 14.8	appendix: 10.2	Group enriched	69	HEL: 4.0;MOLT-4: 9.6
ICOSLG	B7-H2, B7H2, B7RP-1, B7RP1, CD275, GL50, ICOS-L, ICOSL, KIAA0653	ENSG00000160223	Inducible T-cell costimulator ligand	21	44222991-44240966	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB026037, HPA029179	Uncertain		Supported	Plasma membrane<br>Cytoplasmic bodies		Not detected	Mixed			bone marrow: 10.3	Mixed		
IER3	DIF-2, IEX-1, IEX-1L, PRG1	ENSG00000137331	Immediate early response 3	6	30743199-30744554	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043847	Approved				Renal cancer:3.10e-7 (unfavourable), Liver cancer:6.36e-5 (unfavourable), Head and neck cancer:5.57e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 20.7	adipose tissue: 11.4	Group enriched	6	A-431: 133.8;EFO-21: 51.6;HBEC3-KT: 133.4;RPTEC TERT1: 150.4
IER3IP1		ENSG00000134049	Immediate early response 3 interacting protein 1	18	47152834-47176374	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010027	Supported		Supported	Endoplasmic reticulum	Liver cancer:6.47e-6 (unfavourable), Ovarian cancer:8.59e-4 (favourable)	Expressed in all	Expressed in all			kidney: 32.8	Expressed in all		
IFI27	FAM14D, ISG12, P27	ENSG00000165949	Interferon alpha inducible protein 27	14	94104836-94116698	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028875	Uncertain				Ovarian cancer:8.80e-4 (favourable)	Expressed in all	Expressed in all			spleen: 729.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 1891.1;BJ hTERT+ SV40 Large T+ RasG12V: 1737.9;EFO-21: 516.8
IFI30	GILT, IFI-30, IP-30, IP30, MGC32056	ENSG00000216490	IFI30, lysosomal thiol reductase	19	18173162-18178117	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026650	Approved		Supported	Vesicles<br>Cytosol		Mixed	Expressed in all			appendix: 828.7	Cell line enhanced		Daudi: 385.9;RPMI-8226: 408.1;U-266/84: 467.0
IFI6	6-16, FAM14C, G1P3, IFI-6-16, IFI616	ENSG00000126709	Interferon alpha inducible protein 6	1	27666061-27672218	Predicted membrane proteins	Evidence at transcript level	HPA005543	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			placenta: 413.9	Group enriched	6	BJ hTERT+ SV40 Large T+: 1217.0;BJ hTERT+ SV40 Large T+ RasG12V: 1476.2;EFO-21: 494.2;SK-MEL-30: 747.5
IFITM1	9-27, CD225, IFI17	ENSG00000185885	Interferon induced transmembrane protein 1	11	313506-315272	CD markers, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004810, CAB017615	Enhanced		Supported	Cytosol	Renal cancer:5.77e-9 (unfavourable)	Expressed in all	Expressed in all			epididymis: 918.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 1313.0;BJ hTERT+ SV40 Large T+ RasG12V: 2441.8
IFITM10		ENSG00000244242	Interferon induced transmembrane protein 10	11	1732410-1750591	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Tissue enhanced		adrenal gland: 3.4	bone marrow,seminal vesicle: 0.7	Cell line enhanced		CAPAN-2: 2.6;MCF7: 3.3;SH-SY5Y: 10.4;U-87 MG: 5.6
IFITM2	1-8D	ENSG00000185201	Interferon induced transmembrane protein 2	11	307631-315272	Predicted membrane proteins, Transporters	Evidence at protein level	HPA004337	Uncertain				Renal cancer:2.37e-9 (unfavourable)	Expressed in all	Expressed in all			appendix: 705.4	Cell line enhanced		HMC-1: 1031.9;HSkMC: 907.1
IFITM3	1-8U	ENSG00000142089	Interferon induced transmembrane protein 3	11	319669-327537	Predicted membrane proteins, Transporters	Evidence at protein level	HPA004337	Uncertain				Renal cancer:5.78e-7 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1037.8	Cell line enhanced		BJ hTERT+ SV40 Large T+: 1986.9;BJ hTERT+ SV40 Large T+ RasG12V: 2628.1;HHSteC: 2049.3
IFITM5	BRIL, fragilis4, Hrmp1	ENSG00000206013	Interferon induced transmembrane protein 5	11	298200-299526	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA039258	Uncertain					Mixed	Not detected			bone marrow: 0.5	Not detected		
IFNAR1	IFNAR, IFRC	ENSG00000142166	Interferon alpha and beta receptor subunit 1	21	33324477-33359862	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018015, HPA029226	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 61.3	Expressed in all		
IFNAR2	IFNABR	ENSG00000159110	Interferon alpha and beta receptor subunit 2	21	33229901-33265675	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.54e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 58.7	Expressed in all		
IFNGR1	CD119, IFNGR	ENSG00000027697	Interferon gamma receptor 1	6	137197484-137219449	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025889, HPA063871	Approved				Renal cancer:5.48e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 221.9	Expressed in all		
IFNGR2	AF-1, IFNGT1	ENSG00000159128	Interferon gamma receptor 2	21	33402896-33479348	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA001535	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.13e-10 (unfavourable), Liver cancer:3.25e-4 (unfavourable)	Expressed in all	Mixed			spleen: 10.0	Mixed		
IFNLR1	CRF2/12, IFNLR, IL-28R1, IL28RA	ENSG00000185436	Interferon lambda receptor 1	1	24154157-24187959	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017319	Uncertain		Approved	Cytosol	Breast cancer:5.12e-4 (favourable)	Expressed in all	Mixed			small intestine: 10.1	Cell line enhanced		U-266/70: 39.6;U-698: 28.0
IFRD1	PC4, TIS7	ENSG00000006652	Interferon related developmental regulator 1	7	112422968-112481017	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024122	Approved		Approved	Plasma membrane<br>Cytosol	Ovarian cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 129.9	Expressed in all		
IFRD2	IFNRP, SKMc15, SM15	ENSG00000214706	Interferon related developmental regulator 2	3	50287732-50292918	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068560	Approved		Approved	Nucleoplasm	Renal cancer:2.50e-4 (favourable), Breast cancer:7.22e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.9	Expressed in all		
IGDCC3	HsT18880, PUNC	ENSG00000174498	Immunoglobulin superfamily DCC subclass member 3	15	65327127-65378040	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA015246	Approved					Tissue enhanced	Group enriched	5	cerebral cortex: 3.3;parathyroid gland: 14.6;placenta: 8.5;testis: 5.0	thyroid gland: 1.5	Cell line enhanced		AF22: 103.7;CACO-2: 22.5;Hep G2: 58.8
IGDCC4	LOC57722, NOPE	ENSG00000103742	Immunoglobulin superfamily DCC subclass member 4	15	65381464-65423072	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008510, HPA008576	Approved	Approved	Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Mixed			ovary: 9.0	Cell line enhanced		AF22: 8.1;CAPAN-2: 6.4;NTERA-2: 6.2
IGF1R	CD221, IGFIR, IGFR, JTK13, MGC18216	ENSG00000140443	Insulin like growth factor 1 receptor	15	98648971-98964530	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB010268, HPA045563	Uncertain		Uncertain	Vesicles	Renal cancer:3.75e-7 (favourable)	Expressed in all	Mixed			prostate: 25.0	Mixed		
IGF2	C11orf43, FLJ44734, IGF-II	ENSG00000167244	Insulin like growth factor 2	11	2129112-2141238	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007556, HPA007993	Enhanced		Approved	Nucleoplasm<br>Vesicles	Liver cancer:7.12e-4 (favourable)	Group enriched	Tissue enriched	18	placenta: 3962.9	fallopian tube: 217.6	Cell line enhanced		CACO-2: 711.5;Hep G2: 406.1;LHCN-M2: 277.7;RH-30: 396.9;SH-SY5Y: 525.9
IGF2R	CD222, CI-M6PR, CI-MPR, CIMPR, M6P-R, MPR1, MPR300, MPRI	ENSG00000197081	Insulin like growth factor 2 receptor	6	159969099-160113507	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009661, HPA011332	Supported		Enhanced	Golgi apparatus<br>Vesicles	Cervical cancer:2.92e-5 (unfavourable), Breast cancer:3.01e-4 (unfavourable), Urothelial cancer:6.08e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.5	Expressed in all		
IGFALS	ALS	ENSG00000099769	Insulin like growth factor binding protein acid labile subunit	16	1790413-1794971	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040692, HPA040948	Approved		Supported	Nucleoplasm	Liver cancer:5.97e-4 (favourable), Endometrial cancer:6.06e-4 (unfavourable)	Tissue enhanced	Group enriched	6	liver: 25.0;stomach: 6.6	gallbladder: 2.5	Cell line enhanced		Hep G2: 1.2;U-266/70: 1.3
IGFLR1	FLJ22573, TMEM149, U2AF1L4	ENSG00000126246	IGF like family receptor 1	19	35738801-35742453	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012369	Uncertain		Approved	Focal adhesion sites	Ovarian cancer:1.59e-5 (favourable), Cervical cancer:6.55e-4 (favourable)	Expressed in all	Mixed			lymph node: 37.8	Cell line enhanced		HMC-1: 29.7;U-266/70: 26.0
IGSF1	IGCD1, IGDC1, INHBP, KIAA0364, MGC75490, PGSF2	ENSG00000147255	Immunoglobulin superfamily member 1	X	131273506-131578899	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012732, HPA035582	Enhanced		Approved	Cytosol	Endometrial cancer:4.25e-8 (unfavourable)	Tissue enriched	Tissue enhanced		testis: 20.0	adrenal gland: 13.1	Cell line enhanced		Hep G2: 22.7;SH-SY5Y: 30.6
IGSF11	BT-IgSF, CT119, Igsf13, MGC35227, VSIG3	ENSG00000144847	Immunoglobulin superfamily member 11	3	118900557-119146068	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046377	Uncertain		Approved	Nucleus<br>Cell Junctions<br>Cytosol		Group enriched	Tissue enhanced		cerebral cortex: 31.0;testis: 64.9	ovary: 20.1	Cell line enhanced		A549: 7.2;SK-MEL-30: 26.9;U-266/70: 8.9;U-266/84: 10.2
IGSF23		ENSG00000216588	Immunoglobulin superfamily member 23	19	44613630-44636781	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA051811, HPA054591	Uncertain		Approved	Nucleus<br>Cell Junctions	Liver cancer:7.20e-6 (favourable)	Tissue enriched	Group enriched	7	duodenum: 15.2;liver: 13.0;small intestine: 17.4	testis: 2.3	Cell line enhanced		CACO-2: 9.0;Hep G2: 4.4;SiHa: 5.2
IGSF3	EWI-3, MGC117164, V8	ENSG00000143061	Immunoglobulin superfamily member 3	1	116574399-116667755	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036305, HPA036306	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.87e-6 (favourable), Liver cancer:4.03e-6 (unfavourable), Endometrial cancer:1.98e-4 (unfavourable), Pancreatic cancer:2.03e-4 (unfavourable)	Expressed in all	Mixed			skin: 21.5	Cell line enhanced		HDLM-2: 237.0;WM-115: 235.3
IGSF5	JAM4	ENSG00000183067	Immunoglobulin superfamily member 5	21	39745407-39802096	Predicted membrane proteins	Evidence at transcript level	HPA057282	Uncertain					Tissue enhanced	Mixed			placenta: 3.6	Cell line enhanced		T-47d: 5.4
IGSF6	DORA	ENSG00000140749	Immunoglobulin superfamily member 6	16	21639537-21652660	Predicted membrane proteins	Evidence at protein level	HPA041023, HPA041072	Uncertain				Endometrial cancer:1.54e-5 (favourable), Cervical cancer:4.92e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 15.2;spleen: 18.1	lung: 8.0	Not detected		
IGSF8	CD316, CD81P3, EWI2, PGRL	ENSG00000162729	Immunoglobulin superfamily member 8	1	160091340-160098943	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011917	Uncertain				Cervical cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 107.8	Expressed in all		
IGSF9	IGSF9A, KIAA1355, Nrt1	ENSG00000085552	Immunoglobulin superfamily member 9	1	159927039-159945604	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA037753	Uncertain				Endometrial cancer:5.16e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 28.1	stomach: 13.2	Cell line enhanced		BEWO: 25.2;HaCaT: 34.4;SCLC-21H: 40.2
IGSF9B	KIAA1030	ENSG00000080854	Immunoglobulin superfamily member 9B	11	133908564-133956985	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA010744, HPA010802	Uncertain		Approved	Cytosol		Mixed	Mixed			cerebral cortex: 9.0	Cell line enhanced		SCLC-21H: 19.6;SH-SY5Y: 9.0
IKBIP	FLJ31051, IKIP	ENSG00000166130	IKBKB interacting protein	12	98613405-98645113	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038677, HPA038678, HPA061541	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:4.60e-9 (unfavourable), Liver cancer:4.00e-5 (unfavourable)	Expressed in all	Mixed			placenta: 36.6	Expressed in all		
IKZF1	hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1	ENSG00000185811	IKAROS family zinc finger 1	7	50304124-50405101	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	CAB009247, HPA035221, HPA035222	Enhanced		Supported	Nucleoplasm	Cervical cancer:2.02e-4 (favourable), Breast cancer:4.28e-4 (favourable), Head and neck cancer:8.63e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 83.0	tonsil: 55.9	Cell line enhanced		HDLM-2: 172.0;HMC-1: 152.5;MOLT-4: 116.9;REH: 122.5;U-698: 108.4
IL10RA	CD210, CD210a, CDW210A, HIL-10R, IL10R	ENSG00000110324	Interleukin 10 receptor subunit alpha	11	117986348-118003037	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.45e-5 (unfavourable), Head and neck cancer:4.47e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 86.2	lymph node: 56.0	Cell line enhanced		Daudi: 21.3;HDLM-2: 69.7;Karpas-707: 19.5;RPMI-8226: 23.7
IL10RB	CDW210B, CRF2-4, CRFB4, D21S58, D21S66, IL-10R2	ENSG00000243646	Interleukin 10 receptor subunit beta	21	33266358-33310187	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB020670, HPA047550	Approved		Approved	Cytosol	Renal cancer:5.62e-9 (unfavourable)	Expressed in all	Expressed in all			placenta: 90.0	Expressed in all		
IL11RA		ENSG00000137070	Interleukin 11 receptor subunit alpha	9	34650702-34661892	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013162, CAB032830, HPA036652	Supported				Renal cancer:6.56e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 72.6	Mixed		
IL12A	CLMF, IL-12A, NFSK, NKSF1, p35	ENSG00000168811	Interleukin 12A	3	159988750-159996019	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA001886	Uncertain					Mixed	Tissue enhanced		esophagus: 4.0	fallopian tube: 3.2	Cell line enhanced		HDLM-2: 11.1;SK-BR-3: 12.8
IL12RB1	CD212, IL12RB	ENSG00000096996	Interleukin 12 receptor subunit beta 1	19	18058995-18098944	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074414			Approved	Plasma membrane	Renal cancer:5.90e-5 (unfavourable), Cervical cancer:3.41e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 25.9	spleen: 20.6	Cell line enhanced		Daudi: 13.1;HDLM-2: 28.9;Karpas-707: 36.8
IL12RB2		ENSG00000081985	Interleukin 12 receptor subunit beta 2	1	67307364-67396900	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA024168	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		placenta: 11.8	cerebral cortex: 4.4	Cell line enhanced		HMC-1: 4.6;SCLC-21H: 12.2;SK-MEL-30: 21.0;THP-1: 10.6
IL13RA1	CD213a1, IL-13Ra, NR4	ENSG00000131724	Interleukin 13 receptor subunit alpha 1	X	118727572-118794539	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000293			Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.19e-8 (unfavourable)	Expressed in all	Expressed in all			lung: 72.0	Mixed		
IL13RA2	CD213a2, CT19, IL-13R, IL13BP	ENSG00000123496	Interleukin 13 receptor subunit alpha 2	X	115003975-115019977	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level						Liver cancer:3.55e-4 (favourable)	Tissue enhanced	Tissue enriched	8	testis: 52.8	prostate: 6.8	Group enriched	9	PC-3: 120.8;U-2197: 386.1;U-251 MG: 238.2;U-87 MG: 159.9
IL15RA	CD215, IL-15RA	ENSG00000134470	Interleukin 15 receptor subunit alpha	10	5943639-5978187	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026215	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.27e-12 (unfavourable), Liver cancer:2.67e-6 (unfavourable), Pancreatic cancer:5.35e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 33.5	Cell line enhanced		CAPAN-2: 59.4;HDLM-2: 70.4
IL17RA	CD217, CDw217, hIL-17R, IL-17RA, IL17R	ENSG00000177663	Interleukin 17 receptor A	22	17084954-17115694	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024996	Enhanced		Approved	Nucleoplasm<br>Cytosol	Stomach cancer:8.35e-4 (favourable)	Expressed in all	Mixed			bone marrow: 20.6	Cell line enhanced		HL-60: 47.4;THP-1: 50.1
IL17RB	CRL4, EVI27, IL17BR, IL17RH1	ENSG00000056736	Interleukin 17 receptor B	3	53846580-53865800	Predicted membrane proteins	Evidence at protein level	HPA005482	Supported				Renal cancer:6.61e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 61.7	cervix, uterine: 29.4	Cell line enhanced		Hep G2: 40.4
IL17RC	IL17-RL	ENSG00000163702	Interleukin 17 receptor C	3	9917074-9933630	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019885, CAB026255	Approved				Endometrial cancer:1.38e-4 (favourable)	Expressed in all	Expressed in all			prostate: 24.2	Mixed		
IL17RD	FLJ35755, IL-17RD, IL17RLM, SEF	ENSG00000144730	Interleukin 17 receptor D	3	57089982-57170306	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039577, HPA043550	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:2.92e-9 (favourable)	Mixed	Mixed			parathyroid gland: 26.8	Group enriched	7	AF22: 24.6;AN3-CA: 62.9;NTERA-2: 39.0;SH-SY5Y: 108.1
IL17RE	FLJ23658	ENSG00000163701	Interleukin 17 receptor E	3	9902612-9916402	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019011	Uncertain					Expressed in all	Mixed			small intestine: 22.6	Cell line enhanced		ASC TERT1: 27.7;BEWO: 14.7;T-47d: 18.4
IL18R1	CD218a, IL-1Rrp, IL1RRP	ENSG00000115604	Interleukin 18 receptor 1	2	102311529-102398775	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007615	Approved		Approved	Mitochondria	Renal cancer:4.52e-4 (unfavourable)	Mixed	Mixed			placenta: 14.4	Cell line enhanced		HDLM-2: 28.1;HHSteC: 51.3;HMC-1: 36.8;U-937: 54.3
IL18RAP	AcPL, CD218b	ENSG00000115607	Interleukin 18 receptor accessory protein	2	102418689-102452565	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025270	Enhanced					Mixed	Tissue enhanced		bone marrow: 70.9	appendix: 16.9	Cell line enriched	10	U-937: 42.2
IL19	IL-10C, IL-19, MDA1, NG.1, ZMDA1	ENSG00000142224	Interleukin 19	1	206798870-206842981	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	cervix, uterine: 21.0	salivary gland: 2.3	Cell line enriched	11	BJ hTERT+: 4.9
IL1R1	CD121A, D2S1473, IL1R, IL1RA	ENSG00000115594	Interleukin 1 receptor type 1	2	102064544-102179874	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005823, CAB007779, HPA029560	Approved				Renal cancer:6.92e-6 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 246.0	Cell line enhanced		ASC diff: 431.3;ASC TERT1: 195.1;HHSteC: 165.4;HSkMC: 562.6
IL1R2	CD121b, IL1RB	ENSG00000115590	Interleukin 1 receptor type 2	2	101991844-102028544	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027597, HPA027598	Uncertain				Renal cancer:5.58e-12 (unfavourable)	Mixed	Mixed			appendix: 50.3	Cell line enriched	24	HDLM-2: 436.8
IL1RAP	C3orf13, IL-1RAcP, IL1R3	ENSG00000196083	Interleukin 1 receptor accessory protein	3	190514051-190659750	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035293	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:2.16e-7 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable), Urothelial cancer:6.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 113.0;placenta: 53.7	gallbladder: 19.8	Cell line enhanced		SK-MEL-30: 193.6
IL1RAPL1	IL1R8, IL1RAPL, MRX10, MRX21, MRX34, OPHN4, TIGIRR-2	ENSG00000169306	Interleukin 1 receptor accessory protein like 1	X	28587399-29956723	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	11	cerebral cortex: 5.1	ovary,prostate,seminal vesicle: 0.4	Cell line enhanced		WM-115: 2.5
IL1RAPL2	IL-1R9, IL1R9, IL1RAPL-2, TIGIRR-1	ENSG00000189108	Interleukin 1 receptor accessory protein like 2	X	104566315-105767829	Predicted membrane proteins	Evidence at protein level	HPA036128, HPA036129	Uncertain					Not detected	Tissue enhanced		parathyroid gland: 4.8	adrenal gland: 1.9	Cell line enhanced		fHDF/TERT166: 1.1;hTERT-HME1: 4.3;NTERA-2: 1.0;RT4: 1.6
IL1RL1	DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1	ENSG00000115602	Interleukin 1 receptor like 1	2	102311502-102352037	Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007406, HPA007917	Uncertain		Approved	Vesicles		Tissue enhanced	Tissue enriched	12	placenta: 289.6	gallbladder: 23.7	Group enriched	6	HHSteC: 206.0;HMC-1: 327.3;HUVEC TERT2: 154.2
IL1RL2	IL1R-rp2, IL1RRP2	ENSG00000115598	Interleukin 1 receptor like 2	2	102186973-102240002	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015485	Uncertain					Mixed	Tissue enhanced		skin: 15.5	parathyroid gland: 8.5	Cell line enhanced		A-431: 7.2;ASC TERT1: 3.6;HaCaT: 3.3;HSkMC: 3.1
IL20RA	IL-20R1, ZCYTOR7	ENSG00000016402	Interleukin 20 receptor subunit alpha	6	136999971-137045180	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024990, HPA042281	Approved		Approved	Cytosol	Endometrial cancer:1.43e-6 (favourable), Head and neck cancer:2.29e-5 (favourable)	Mixed	Tissue enhanced		skin: 45.0	breast: 33.5	Group enriched	7	CAPAN-2: 8.4;HaCaT: 6.1;RT4: 9.2;SH-SY5Y: 11.4;T-47d: 10.0
IL20RB	DIRS1, FNDC6, IL-20R2, MGC34923	ENSG00000174564	Interleukin 20 receptor subunit beta	3	136946230-137011085	Predicted membrane proteins	Evidence at protein level	HPA063914			Approved	Vesicles<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.44e-4 (unfavourable)	Group enriched	Group enriched	9	esophagus: 56.6;skin: 165.5	breast: 12.4	Cell line enhanced		HaCaT: 70.0;HBEC3-KT: 93.7;HHSteC: 70.6;hTCEpi: 372.4;hTERT-HME1: 73.1
IL21R	CD360	ENSG00000103522	Interleukin 21 receptor	16	27402162-27452042	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA042296	Uncertain		Uncertain	Plasma membrane<br>Cytosol	Head and neck cancer:7.29e-4 (favourable)	Mixed	Tissue enhanced		appendix: 15.8;lymph node: 28.8;tonsil: 17.4	spleen: 7.5	Cell line enhanced		HDLM-2: 102.6;Karpas-707: 35.4;RH-30: 36.0;RPMI-8226: 42.7
IL22RA1	CRF2-9, IL22R	ENSG00000142677	Interleukin 22 receptor subunit alpha 1	1	24119771-24143121	Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	5	colon: 11.3;duodenum: 20.2;esophagus: 10.1;pancreas: 26.1;rectum: 10.9;skin: 38.7;small intestine: 31.3	gallbladder: 4.0	Cell line enhanced		CACO-2: 9.3;HaCaT: 4.5;Hep G2: 5.5
IL23R	IL-23R	ENSG00000162594	Interleukin 23 receptor	1	67138907-67259979	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056427	Uncertain					Not detected	Tissue enhanced		adrenal gland: 2.1;testis: 2.8	rectum: 1.0	Cell line enhanced		HMC-1: 8.0;K-562: 3.2;U-2197: 12.8
IL27RA	CRL1, IL-27R, TCCR, WSX-1, WSX1, zcytor1	ENSG00000104998	Interleukin 27 receptor subunit alpha	19	14031748-14053216	Predicted membrane proteins	Evidence at protein level						Renal cancer:2.58e-10 (unfavourable), Breast cancer:1.74e-6 (favourable)	Expressed in all	Mixed			tonsil: 30.4	Mixed		
IL2RA	CD25, IDDM10, IL2R	ENSG00000134460	Interleukin 2 receptor subunit alpha	10	6010689-6062325	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002419, HPA054622	Enhanced				Renal cancer:2.08e-9 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 24.2;appendix: 19.8;lymph node: 20.4	tonsil: 12.0	Cell line enriched	80	HDLM-2: 1041.6
IL2RB	CD122, IL15RB	ENSG00000100385	Interleukin 2 receptor subunit beta	22	37125838-37175054	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062657	Enhanced				Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 52.7;spleen: 67.1	lymph node: 39.8	Cell line enriched	10	HDLM-2: 476.9
IL2RG	CD132, CIDX, IMD4, SCIDX1	ENSG00000147168	Interleukin 2 receptor subunit gamma	X	71107404-71112108	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046641, HPA049691	Enhanced		Approved	Vesicles	Renal cancer:2.28e-7 (unfavourable), Endometrial cancer:1.73e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 273.3;tonsil: 279.4	appendix: 182.3	Cell line enriched	5	Karpas-707: 1646.4
IL31RA	CRL, CRL3, GLM-R, Glmr, IL-31RA	ENSG00000164509	Interleukin 31 receptor A	5	55851379-55922853	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051532, HPA068114	Approved		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		testis: 3.6	bone marrow: 1.2	Cell line enhanced		hTERT-HME1: 10.7;U-2 OS: 21.6;U-87 MG: 23.4
IL3RA	CD123	ENSG00000185291	Interleukin 3 receptor subunit alpha	X	1336616-1382689	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003539, CAB018374	Approved				Cervical cancer:4.27e-4 (favourable), Breast cancer:9.78e-4 (favourable)	Expressed in all	Mixed			lung: 33.2	Cell line enhanced		HDLM-2: 109.2;RPMI-8226: 33.2
IL4R	CD124	ENSG00000077238	Interleukin 4 receptor	16	27313668-27364778	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004451, HPA050124	Enhanced				Renal cancer:1.23e-5 (unfavourable), Endometrial cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 137.6	Mixed		
IL5RA	CD125, CDw125, IL5R	ENSG00000091181	Interleukin 5 receptor subunit alpha	3	3066326-3126613	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		fallopian tube: 22.7	lung: 4.9	Cell line enriched	28	HMC-1: 66.2
IL6R	CD126	ENSG00000160712	Interleukin 6 receptor	1	154405193-154469450	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.65e-4 (favourable)	Expressed in all	Mixed			appendix: 33.4	Cell line enhanced		THP-1: 147.4;U-266/84: 186.8
IL6ST	CD130, GP130	ENSG00000134352	Interleukin 6 signal transducer	5	55935095-55994993	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010558, CAB025784	Uncertain		Supported	Golgi apparatus<br>Plasma membrane	Renal cancer:5.05e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 329.8	Expressed in all		
IL7R	CD127	ENSG00000168685	Interleukin 7 receptor	5	35852695-35879603	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010215	Approved		Approved	Plasma membrane<br>Microtubule organizing center		Expressed in all	Tissue enhanced		appendix: 182.9;lymph node: 158.5	tonsil: 112.9	Cell line enhanced		fHDF/TERT166: 149.9;HBF TERT88: 165.6;REH: 372.0
IL9R	CD129	ENSG00000124334	Interleukin 9 receptor	X	155997581-156010817	CD markers, Predicted membrane proteins	Evidence at protein level	HPA063240, HPA064557	Approved				Urothelial cancer:1.90e-7 (favourable)	Tissue enhanced	Tissue enhanced		urinary bladder: 8.4	lymph node: 2.8	Cell line enriched	10	HMC-1: 217.8
ILDR1	DFNB42, MGC50831	ENSG00000145103	Immunoglobulin like domain containing receptor 1	3	121987323-122022204	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018207	Approved				Renal cancer:5.79e-9 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 35.1	cervix, uterine: 20.0	Cell line enhanced		CAPAN-2: 6.5;HDLM-2: 10.3;MCF7: 5.7;RT4: 7.7;T-47d: 6.4;U-266/70: 5.6
ILDR2	C1orf32	ENSG00000143195	Immunoglobulin like domain containing receptor 2	1	166895711-166975482	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012545	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 11.3;testis: 17.4	kidney: 3.1	Cell line enhanced		AF22: 7.8;U-2 OS: 10.6;U-251 MG: 4.6
ILVBL	209L8, AHAS, FLJ39061, HACL1L, ILV2H, MGC1269, MGC19535	ENSG00000105135	IlvB acetolactate synthase like	19	15114984-15125785	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA067682	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.91e-8 (favourable), Endometrial cancer:1.52e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 80.2	Expressed in all		
IMMP2L	IMMP2L-IT1, IMP2	ENSG00000184903	Inner mitochondrial membrane peptidase subunit 2	7	110663051-111562517	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026711	Approved		Approved	Mitochondria	Head and neck cancer:1.89e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 39.4	Expressed in all		
IMPAD1	FLJ20421, gPAPP, IMPA3	ENSG00000104331	Inositol monophosphatase domain containing 1	8	56957933-56993844	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009411	Supported		Supported	Nucleus<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 52.7	Expressed in all		
IMPG2	IPM200, RP56	ENSG00000081148	Interphotoreceptor matrix proteoglycan 2	3	101222546-101320560	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA008779, HPA015907	Supported					Tissue enriched	Tissue enriched	45	fallopian tube: 15.7	appendix,lymph node,spleen: 0.3	Not detected		
INAFM2	LINC00984, OGU1	ENSG00000259330	InaF motif containing 2	15	40323664-40326715	Predicted membrane proteins	Evidence at transcript level						Renal cancer:1.88e-7 (unfavourable), Stomach cancer:5.01e-4 (unfavourable), Lung cancer:7.87e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 44.5	Expressed in all		
INO80C	C18orf37, FLJ38183, hIes6, IES6	ENSG00000153391	INO80 complex subunit C	18	35452230-35497991	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049060	Approved		Supported	Nucleoli fibrillar center	Endometrial cancer:2.62e-5 (unfavourable), Cervical cancer:3.58e-4 (favourable)	Expressed in all	Expressed in all			testis: 166.3	Expressed in all		
INPP4A	INPP4	ENSG00000040933	Inositol polyphosphate-4-phosphatase type I A	2	98444854-98594390	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001628	Approved		Approved	Nucleus<br>Nuclear membrane	Endometrial cancer:3.70e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 38.7	Expressed in all		
INPP4B		ENSG00000109452	Inositol polyphosphate-4-phosphatase type II B	4	142023160-142847432	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037681, HPA037682	Approved		Approved	Centrosome	Pancreatic cancer:1.03e-4 (unfavourable)	Mixed	Mixed			testis: 33.2	Cell line enhanced		CAPAN-2: 132.1
INPP5F	hSac2, KIAA0966, SAC2	ENSG00000198825	Inositol polyphosphate-5-phosphatase F	10	119726097-119829278	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			cerebral cortex: 132.0	Expressed in all		
INPP5J	INPP5, PIB5PA, PIPP	ENSG00000185133	Inositol polyphosphate-5-phosphatase J	22	31122731-31134696	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034539			Approved	Nucleoli<br>Cytosol	Renal cancer:1.12e-7 (favourable), Lung cancer:1.47e-5 (favourable)	Tissue enriched	Group enriched	10	parathyroid gland: 215.4;thyroid gland: 242.1	small intestine: 22.4	Cell line enhanced		HL-60: 15.5;SK-BR-3: 30.3;T-47d: 24.0
INSIG1	CL-6, MGC1405	ENSG00000186480	Insulin induced gene 1	7	155297776-155310235	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA071524			Approved	Vesicles	Thyroid cancer:9.62e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 281.7	Cell line enhanced		Karpas-707: 871.4
INSIG2		ENSG00000125629	Insulin induced gene 2	2	118088452-118110997	Predicted membrane proteins	Evidence at protein level	CAB033861	Uncertain				Pancreatic cancer:2.19e-6 (unfavourable), Renal cancer:4.11e-6 (unfavourable), Head and neck cancer:7.10e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.4	Expressed in all		
INSR	CD220	ENSG00000171105	Insulin receptor	19	7112255-7294034	CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA036302, HPA036303	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			ovary: 35.5	Cell line enhanced		Karpas-707: 42.9
INSRR	IRR	ENSG00000027644	Insulin receptor related receptor	1	156840063-156859018	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA025285	Uncertain					Not detected	Tissue enhanced		adrenal gland: 1.8;kidney: 1.4;testis: 2.2	prostate: 0.6	Group enriched	10	SCLC-21H: 5.5;SH-SY5Y: 17.2
INTS1	DKFZp586J0619, INT1, KIAA1440, NET28	ENSG00000164880	Integrator complex subunit 1	7	1470277-1504367	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021658, HPA053009	Approved		Approved	Nucleoplasm	Liver cancer:1.66e-4 (unfavourable), Pancreatic cancer:4.83e-4 (favourable)	Expressed in all	Expressed in all			testis: 41.8	Expressed in all		
INTS14	C15orf44, DKFZP564O1664, VWA9	ENSG00000138614	Integrator complex subunit 14	15	65578753-65611289	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040255, HPA040651	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Nuclear bodies<br>Mitochondria		Expressed in all	Expressed in all			fallopian tube: 39.1	Expressed in all		
INTS2	INT2, KIAA1287	ENSG00000108506	Integrator complex subunit 2	17	61865367-61928016	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049524	Uncertain				Thyroid cancer:2.20e-4 (unfavourable), Liver cancer:4.37e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.5	Expressed in all		
IQCF1	MGC39725	ENSG00000173389	IQ motif containing F1	3	51894876-51903335	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	574	testis: 57.4	all non-specific tissues: 0.0	Not detected		
IQCF3		ENSG00000229972	IQ motif containing F3	3	51817604-51830856	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	242	testis: 72.6	epididymis: 0.3	Not detected		
IQCF5		ENSG00000214681	IQ motif containing F5	3	51873721-51875584	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	708	testis: 70.8	all non-specific tissues: 0.0	Not detected		
ISLR2	KIAA1465	ENSG00000167178	Immunoglobulin superfamily containing leucine rich repeat 2	15	74100311-74138540	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012930, HPA067333	Uncertain					Mixed	Group enriched	5	cerebral cortex: 31.1;testis: 14.8	endometrium: 4.5	Group enriched	13	SCLC-21H: 68.2;SH-SY5Y: 91.6
ITFG1	CDA08, LNKN-1, TIP	ENSG00000129636	Integrin alpha FG-GAP repeat containing 1	16	47154387-47464149	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015590, HPA019728	Approved		Approved	Intermediate filaments<br>Aggresome	Renal cancer:1.95e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 110.1	Expressed in all		
ITGA1	CD49a, VLA1	ENSG00000213949	Integrin subunit alpha 1	5	52787896-52959210	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042555	Uncertain				Renal cancer:2.24e-4 (unfavourable)	Expressed in all	Mixed			spleen: 78.0	Cell line enhanced		fHDF/TERT166: 28.9;HHSteC: 36.5;WM-115: 32.9
ITGA10		ENSG00000143127	Integrin subunit alpha 10	1	145891208-145910189	Plasma proteins, Predicted membrane proteins	Evidence at transcript level						Breast cancer:7.18e-4 (favourable)	Tissue enhanced	Mixed			cervix, uterine: 8.1	Cell line enhanced		ASC TERT1: 35.3;HSkMC: 33.5;hTERT-HME1: 31.5;LHCN-M2: 60.2;TIME: 100.9
ITGA11	HsT18964	ENSG00000137809	Integrin subunit alpha 11	15	68296533-68432162	Predicted membrane proteins	Evidence at protein level	HPA051813	Uncertain				Renal cancer:3.22e-7 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 54.7;endometrium: 52.4;smooth muscle: 75.7	epididymis: 22.9	Cell line enhanced		fHDF/TERT166: 203.4;U-138 MG: 173.0;WM-115: 98.4
ITGA2	CD49B	ENSG00000164171	Integrin subunit alpha 2	5	52989326-53094779	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB017690, HPA060991, HPA063556	Enhanced		Approved	Nucleus<br>Cytosol	Pancreatic cancer:1.02e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 24.5	Cell line enhanced		BJ hTERT+: 74.4;HaCaT: 82.1
ITGA2B	CD41, CD41B, GP2B, PPP1R93	ENSG00000005961	Integrin subunit alpha 2b	17	44372180-44389505	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018611, HPA031168, HPA031169, HPA031170, HPA031171	Enhanced					Mixed	Tissue enhanced		bone marrow: 11.2;epididymis: 29.3	testis: 4.4	Group enriched	18	HEL: 396.8;HMC-1: 636.9
ITGA3	CD49c, GAP-B3, MSK18, VCA-2, VLA3a	ENSG00000005884	Integrin subunit alpha 3	17	50055968-50090481	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008572, CAB018594	Enhanced		Supported	Plasma membrane	Pancreatic cancer:5.95e-5 (unfavourable), Head and neck cancer:1.36e-4 (unfavourable), Cervical cancer:6.75e-4 (unfavourable)	Expressed in all	Mixed			lung: 99.0	Cell line enhanced		U-87 MG: 917.0
ITGA4	CD49D	ENSG00000115232	Integrin subunit alpha 4	2	181457202-181536187	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074961			Approved	Plasma membrane	Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable)	Mixed	Tissue enhanced		spleen: 67.6	appendix: 49.6	Cell line enhanced		fHDF/TERT166: 148.2;HEL: 275.3;MOLT-4: 291.8
ITGA5	CD49e, FNRA	ENSG00000161638	Integrin subunit alpha 5	12	54395261-54419460	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA002642, CAB009008	Enhanced				Renal cancer:1.32e-8 (unfavourable), Cervical cancer:4.07e-6 (unfavourable), Liver cancer:2.23e-5 (unfavourable), Lung cancer:2.44e-4 (unfavourable), Head and neck cancer:2.91e-4 (unfavourable), Colorectal cancer:8.43e-4 (unfavourable), Thyroid cancer:8.89e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 489.0	Cell line enhanced		HUVEC TERT2: 1106.4;TIME: 1039.6;U-87 MG: 602.5
ITGA6	CD49f	ENSG00000091409	Integrin subunit alpha 6	2	172427354-172506282	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009009, HPA012696, HPA027582	Enhanced				Renal cancer:2.35e-11 (favourable), Head and neck cancer:1.03e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 114.9	Cell line enhanced		HaCaT: 319.9;HBEC3-KT: 511.4
ITGA7		ENSG00000135424	Integrin subunit alpha 7	12	55684568-55716043	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008427	Uncertain		Approved	Plasma membrane<br>Cytosol	Urothelial cancer:9.59e-5 (unfavourable), Pancreatic cancer:1.75e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 154.7	smooth muscle: 136.8	Cell line enhanced		ASC diff: 46.9;hTEC/SVTERT24-B: 66.1;SK-MEL-30: 38.6;U-87 MG: 57.9
ITGA8		ENSG00000077943	Integrin subunit alpha 8	10	15513949-15720125	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA003432	Approved					Mixed	Tissue enhanced		prostate: 59.5	seminal vesicle: 40.5	Cell line enhanced		HEK93: 7.4;HMC-1: 17.0;HSkMC: 6.1;U-266/84: 6.6
ITGA9	ALPHA-RLC, ITGA4L, RLC	ENSG00000144668	Integrin subunit alpha 9	3	37452115-37823514	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030609	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			thyroid gland: 34.7	Cell line enhanced		CACO-2: 8.3;HEL: 7.3;SH-SY5Y: 12.3;WM-115: 6.1
ITGAD	ADB2, CD11d	ENSG00000156886	Integrin subunit alpha D	16	31393312-31426505	CD markers, Predicted membrane proteins	Evidence at protein level	HPA026786	Uncertain					Mixed	Tissue enriched	5	spleen: 27.9	lymph node: 5.1	Not detected		
ITGAE	CD103, HUMINAE	ENSG00000083457	Integrin subunit alpha E	17	3714628-3801243	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026461, HPA036313	Approved				Renal cancer:1.13e-8 (unfavourable), Endometrial cancer:1.04e-4 (favourable), Urothelial cancer:3.56e-4 (favourable), Pancreatic cancer:5.78e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 9.5	small intestine: 6.2	Cell line enriched	22	MOLT-4: 9.6
ITGAL	CD11A, LFA-1	ENSG00000005844	Integrin subunit alpha L	16	30472658-30523185	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025011	Enhanced				Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 79.0;spleen: 80.9	appendix: 52.5	Cell line enriched	5	HMC-1: 570.1
ITGAM	CD11B, CR3A, MAC-1	ENSG00000169896	Integrin subunit alpha M	16	31259990-31332892	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002274, CAB025091, CAB072870	Enhanced				Renal cancer:6.93e-5 (unfavourable), Liver cancer:3.43e-4 (unfavourable), Testis cancer:6.93e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 130.2	appendix: 36.3	Cell line enhanced		HMC-1: 47.6;NB-4: 12.7;U-937: 18.8
ITGAV	CD51, MSK8, VNRA, VTNR	ENSG00000138448	Integrin subunit alpha V	2	186590065-186680901	Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002499, HPA004856	Supported		Approved	Focal adhesion sites<br>Cytosol	Stomach cancer:1.05e-6 (unfavourable), Liver cancer:2.08e-4 (unfavourable), Pancreatic cancer:5.07e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 191.2	Cell line enhanced		RT4: 294.1
ITGAX	CD11C	ENSG00000140678	Integrin subunit alpha X	16	31355134-31382997	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004458, HPA004723, CAB072871	Enhanced				Renal cancer:1.37e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 58.3;spleen: 59.0	bone marrow: 30.4	Cell line enriched	5	HMC-1: 92.2
ITGB1	CD29, FNRB, GPIIA, MDF2, MSK12	ENSG00000150093	Integrin subunit beta 1	10	32900319-33005792	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB003434, HPA059297, HPA069003	Enhanced		Supported	Endoplasmic reticulum<br>Plasma membrane<br>Focal adhesion sites	Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1069.5	Expressed in all		
ITGB2	CD18, LFA-1, MAC-1, MFI7	ENSG00000160255	Integrin subunit beta 2	21	44885953-44931989	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008877, HPA016894	Enhanced		Approved	Plasma membrane		Expressed in all	Expressed in all			appendix: 239.2	Cell line enhanced		EFO-21: 120.5;THP-1: 518.6;U-937: 447.2
ITGB3	CD61, GP3A, GPIIIa	ENSG00000259207	Integrin subunit beta 3	17	47253846-47311816	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027852	Supported					Group enriched	Tissue enhanced		thyroid gland: 95.6	smooth muscle: 36.8	Cell line enhanced		EFO-21: 179.0;HEL: 158.0;WM-115: 275.8
ITGB4	CD104	ENSG00000132470	Integrin subunit beta 4	17	75721328-75757818	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002422, CAB005258, HPA036348, HPA036349	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Pancreatic cancer:6.39e-4 (unfavourable), Lung cancer:7.18e-4 (unfavourable)	Expressed in all	Mixed			skin: 84.3	Cell line enhanced		CAPAN-2: 787.0;HaCaT: 304.0;HBEC3-KT: 550.4
ITGB5		ENSG00000082781	Integrin subunit beta 5	3	124761948-124901418	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001820, CAB022050	Approved		Approved	Plasma membrane<br>Mitochondria	Pancreatic cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 117.5	Cell line enhanced		WM-115: 463.5
ITGB6		ENSG00000115221	Integrin subunit beta 6	2	160099666-160271888	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA023626, CAB073536	Approved		Approved	Nucleoplasm<br>Cell Junctions<br>Centrosome	Pancreatic cancer:5.03e-6 (unfavourable)	Mixed	Tissue enhanced		lung: 66.9	urinary bladder: 30.3	Cell line enhanced		CAPAN-2: 122.2;RPTEC TERT1: 206.4
ITGB7		ENSG00000139626	Integrin subunit beta 7	12	53191318-53207307	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042277			Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			spleen: 32.5	Group enriched	97	Karpas-707: 3399.5;RPMI-8226: 2658.1
ITGB8		ENSG00000105855	Integrin subunit beta 8	7	20330702-20415754	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA027796, HPA027797	Supported		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.77e-4 (favourable)	Mixed	Mixed			cerebral cortex: 30.8	Cell line enhanced		AF22: 45.0;EFO-21: 54.7;RPTEC TERT1: 68.8;WM-115: 130.0
ITM2A	BRICD2A, E25A	ENSG00000078596	Integral membrane protein 2A	X	79360384-79367667	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002918			Uncertain	Nucleoplasm	Liver cancer:3.66e-6 (favourable)	Expressed in all	Expressed in all			ovary: 220.1	Cell line enriched	6	MOLT-4: 1365.5
ITM2B	BRI, BRI2, BRICD2B, E25B, E3-16	ENSG00000136156	Integral membrane protein 2B	13	48233158-48270357	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA029292, HPA071992	Approved		Enhanced	Golgi apparatus<br>Vesicles	Renal cancer:3.73e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 1855.0	Expressed in all		
ITM2C	BRI3, BRICD2C, E25, hRPC.1050_D_4, ITM3	ENSG00000135916	Integral membrane protein 2C	2	230864639-230879248	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:1.81e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 852.3	Mixed		
ITPR1	ACV, Insp3r1, IP3R1, PPP1R94, SCA15, SCA16, SCA29	ENSG00000150995	Inositol 1,4,5-trisphosphate receptor type 1	3	4493348-4847840	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014765, HPA016487	Approved		Approved	Vesicles	Thyroid cancer:3.43e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 106.8	thyroid gland: 47.4	Cell line enhanced		HDLM-2: 75.1;HeLa: 38.4;U-87 MG: 44.6
ITPR2	CFAP48, IP3R2	ENSG00000123104	Inositol 1,4,5-trisphosphate receptor type 2	12	26336515-26833198	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059144, HPA062260	Uncertain		Supported	Nucleus<br>Endoplasmic reticulum		Expressed in all	Mixed			parathyroid gland: 26.2	Cell line enhanced		TIME: 55.9
ITPR3	IP3R3	ENSG00000096433	Inositol 1,4,5-trisphosphate receptor type 3	6	33620365-33696574	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA003915, HPA064704	Approved		Uncertain	Vesicles		Expressed in all	Mixed			skin: 65.1	Mixed		
ITPRIP	bA127L20.2, DANGER, KIAA1754	ENSG00000148841	Inositol 1,4,5-trisphosphate receptor interacting protein	10	104309698-104338404	Predicted membrane proteins	Evidence at protein level	HPA043626			Uncertain	Vesicles	Lung cancer:3.59e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 135.2	Mixed		
ITPRIPL1	KIAA1754L	ENSG00000198885	Inositol 1,4,5-trisphosphate receptor interacting protein-like 1	2	96325331-96330517	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	6	testis: 27.3	lymph node: 4.8	Mixed		
ITPRIPL2	FLJ22994, LOC162073, MGC126798, MGC126800	ENSG00000205730	Inositol 1,4,5-trisphosphate receptor interacting protein like 2	16	19113932-19121629	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042011			Approved	Centrosome		Expressed in all	Expressed in all			skin: 27.8	Mixed		
ITSN1	ITSN, MGC134948, MGC134949, SH3D1A, SH3P17	ENSG00000205726	Intersectin 1	21	33642400-33899861	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018007	Approved		Supported	Plasma membrane		Expressed in all	Expressed in all			adipose tissue: 61.5	Expressed in all		
IYD	C6orf71, DEHAL1, dJ422F24.1	ENSG00000009765	Iodotyrosine deiodinase	6	150368892-150405969	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA059627	Enhanced		Supported	Plasma membrane	Liver cancer:6.22e-4 (favourable)	Tissue enriched	Tissue enriched	28	thyroid gland: 794.5	kidney: 27.9	Cell line enhanced		CACO-2: 1.1;SK-BR-3: 2.4
IZUMO1	IZUMO, MGC34799, OBF	ENSG00000182264	Izumo sperm-egg fusion 1	19	48740852-48746909	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038104	Enhanced					Not detected	Tissue enriched	22	testis: 19.0	lung: 0.8	Not detected		
IZUMO2	C19orf41, MGC33947, SCRL	ENSG00000161652	IZUMO family member 2	19	50152548-50163195	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA042143	Uncertain					Not detected	Tissue enriched	250	testis: 56.1	prostate,skin,thyroid gland: 0.2	Not detected		
IZUMO3	bA20A20.1, C9orf134	ENSG00000205442	IZUMO family member 3	9	24542952-24545946	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	215	testis: 21.5	all non-specific tissues: 0.0	Cell line enriched	33	SCLC-21H: 3.3
JAG1	AGS, AHD, AWS, CD339, HJ1, JAGL1	ENSG00000101384	Jagged 1	20	10637684-10674107	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB010343, HPA021555	Enhanced		Supported	Golgi apparatus<br>Plasma membrane	Pancreatic cancer:4.10e-6 (unfavourable)	Expressed in all	Expressed in all			placenta: 97.1	Cell line enhanced		HBEC3-KT: 150.8;hTERT-HME1: 96.7;U-251 MG: 151.3
JAG2		ENSG00000184916	Jagged 2	14	105140981-105168824	Predicted membrane proteins	Evidence at protein level	CAB025481, HPA030636, HPA050567	Approved		Supported	Vesicles<br>Cytosol		Expressed in all	Tissue enhanced		skin: 22.5	adipose tissue: 6.5	Cell line enhanced		HaCaT: 54.2;SCLC-21H: 36.3
JAGN1	FLJ14602, GL009	ENSG00000171135	Jagunal homolog 1	3	9890554-9894349	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA067610			Approved	Vesicles		Expressed in all	Expressed in all			epididymis: 37.9	Expressed in all		
JAKMIP1	FLJ31564, Gababrbp, JAMIP1, MARLIN1	ENSG00000152969	Janus kinase and microtubule interacting protein 1	4	6026199-6200591	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044570	Uncertain					Mixed	Tissue enriched	6	cerebral cortex: 38.7	prostate: 6.9	Cell line enhanced		Daudi: 11.3;MOLT-4: 36.1;SCLC-21H: 22.4;U-266/70: 20.1
JAKMIP2	JAMIP2, KIAA0555	ENSG00000176049	Janus kinase and microtubule interacting protein 2	5	147585439-147782848	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046929, HPA065023	Approved		Supported	Golgi apparatus		Tissue enriched	Tissue enriched	6	cerebral cortex: 32.7	testis: 5.3	Cell line enhanced		AF22: 19.7;Karpas-707: 34.1;RH-30: 46.3;SCLC-21H: 26.3
JAKMIP3	bA140A10.5, C10orf14, C10orf39, FLJ37857, KIAA4091, NECC2	ENSG00000188385	Janus kinase and microtubule interacting protein 3	10	132104671-132184809	Predicted membrane proteins	Evidence at protein level	HPA022872	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 5.8	prostate: 2.2	Cell line enhanced		A549: 2.2;U-266/84: 4.1
JAM2	C21orf43, CD322, JAM-B, JAMB, VE-JAM	ENSG00000154721	Junctional adhesion molecule 2	21	25639272-25717562	CD markers, Predicted membrane proteins	Evidence at protein level	HPA028789, HPA077346			Supported	Nucleoplasm<br>Plasma membrane		Tissue enriched	Tissue enhanced		placenta: 92.9	cerebral cortex: 34.2	Cell line enhanced		AF22: 25.3;BJ hTERT+: 13.4;HDLM-2: 15.5;U-138 MG: 18.0;U-87 MG: 13.2
JAM3	JAM-C, JAMC	ENSG00000166086	Junctional adhesion molecule 3	11	134068925-134152001	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003417, HPA050434	Uncertain		Enhanced	Golgi apparatus	Urothelial cancer:2.68e-4 (unfavourable), Renal cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 144.4	Cell line enhanced		RH-30: 119.8
JAML	AMICA, AMICA1, Gm638	ENSG00000160593	Junction adhesion molecule like	11	118193740-118225094	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047919	Approved				Head and neck cancer:3.11e-4 (favourable), Lung cancer:3.92e-4 (favourable)	Mixed	Tissue enhanced		appendix: 82.3	spleen: 67.0	Cell line enhanced		CACO-2: 4.8;HMC-1: 24.2
JKAMP	C14orf100, CDA06, HSPC213, HSPC327, JAMP	ENSG00000050130	JNK1/MAPK8-associated membrane protein	14	59484443-59505410	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA031172, HPA071650	Supported		Approved	Nucleoplasm<br>Vesicles	Liver cancer:3.09e-6 (unfavourable), Renal cancer:1.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 76.2	Expressed in all		
JPH1	JP-1	ENSG00000104369	Junctophilin 1	8	74234700-74321328	Predicted membrane proteins	Evidence at protein level	HPA008996, HPA009413, CAB013461	Enhanced		Supported	Nucleus	Lung cancer:5.77e-5 (favourable)	Mixed	Tissue enriched	10	skeletal muscle: 88.0	cerebral cortex: 8.6	Cell line enhanced		SK-BR-3: 27.1;T-47d: 24.2
JPH2	JP-2	ENSG00000149596	Junctophilin 2	20	44111695-44187578	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052646	Approved					Mixed	Tissue enhanced		skeletal muscle: 72.1;smooth muscle: 56.0	seminal vesicle: 47.8	Cell line enhanced		EFO-21: 21.6;fHDF/TERT166: 18.5;SiHa: 16.8
JPH3	CAGL237, HDL2, JP-3, JP3, TNRC22	ENSG00000154118	Junctophilin 3	16	87601835-87698156	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA076304			Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	22	cerebral cortex: 43.3	adrenal gland: 2.0	Cell line enhanced		MCF7: 5.8;NTERA-2: 6.6;SH-SY5Y: 8.9;SiHa: 5.9;U-2 OS: 27.3
JPH4	JPHL1, KIAA1831	ENSG00000092051	Junctophilin 4	14	23568035-23578800	Predicted membrane proteins	Evidence at transcript level	CAB013492			Uncertain	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 107.1;seminal vesicle: 51.9	endometrium: 28.1	Group enriched	7	SCLC-21H: 16.8;SH-SY5Y: 37.5;U-2 OS: 27.7
JTB	hJT, PAR	ENSG00000143543	Jumping translocation breakpoint	1	153974269-153977688	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA006514	Approved		Approved	Vesicles<br>Actin filaments	Renal cancer:6.65e-9 (unfavourable), Ovarian cancer:7.87e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 116.4	Expressed in all		
KALRN	ARHGEF24, DUET, duo, HAPIP, Hs.8004, Kalirin, TRAD	ENSG00000160145	Kalirin, RhoGEF kinase	3	124080023-124726325	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011913, CAB026456	Approved		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 51.3	spleen: 11.8	Cell line enhanced		CACO-2: 47.6;HEL: 31.9;SH-SY5Y: 16.9
KANSL1L	C2orf67, FLJ23861, FLJ32349, KIAA1267L, MSL1v2	ENSG00000144445	KAT8 regulatory NSL complex subunit 1 like	2	210021423-210171383	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043102, HPA046790	Uncertain		Approved	Cytosol		Expressed in all	Tissue enriched	13	parathyroid gland: 585.1	testis: 46.0	Expressed in all		
KCNA1	AEMK, HUK1, Kv1.1, MBK1, RBK1	ENSG00000111262	Potassium voltage-gated channel subfamily A member 1	12	4909893-4918256	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	CAB022365	Uncertain					Not detected	Tissue enriched	6	cerebral cortex: 13.4	parathyroid gland: 2.1	Cell line enhanced		SCLC-21H: 1.2;U-2 OS: 1.0
KCNA10	Kv1.8	ENSG00000143105	Potassium voltage-gated channel subfamily A member 10	1	110517217-110519175	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA015061, CAB022564			Uncertain	Nucleoplasm<br>Cytosol		Not detected	Not detected			testis: 0.8	Not detected		
KCNA2	HK4, Kv1.2	ENSG00000177301	Potassium voltage-gated channel subfamily A member 2	1	110519837-110631474	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB001976	Enhanced					Tissue enhanced	Tissue enriched	6	cerebral cortex: 23.2	thyroid gland: 4.1	Cell line enhanced		Karpas-707: 4.4;SCLC-21H: 1.8;U-2 OS: 1.4;U-266/70: 1.5;U-266/84: 2.3;WM-115: 1.6
KCNA3	HLK3, HPCN3, Kv1.3, MK3	ENSG00000177272	Potassium voltage-gated channel subfamily A member 3	1	110672465-110675033	FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA016625	Approved					Mixed	Mixed			lymph node: 10.5	Cell line enhanced		HDLM-2: 20.5;Karpas-707: 31.5;U-266/70: 23.9;U-266/84: 21.1
KCNA4	HK1, HPCN2, KCNA4L, Kv1.4	ENSG00000182255	Potassium voltage-gated channel subfamily A member 4	11	30009741-30017023	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	CAB001977, HPA016422	Approved					Not detected	Tissue enhanced		adrenal gland: 7.9;cerebral cortex: 4.3	heart muscle: 1.4	Not detected		
KCNA5	HK2, HPCN1, Kv1.5	ENSG00000130037	Potassium voltage-gated channel subfamily A member 5	12	5043989-5046788	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA021516, CAB022562	Approved					Mixed	Tissue enhanced		heart muscle: 16.1	esophagus: 5.6	Cell line enriched	20	NTERA-2: 4.3
KCNA6	HBK2, Kv1.6, PPP1R96	ENSG00000151079	Potassium voltage-gated channel subfamily A member 6	12	4809176-4813412	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level	CAB011539, HPA014418	Approved					Not detected	Not detected			appendix,duodenum,lymph node: 0.1	Not detected		
KCNA7	HAK6, Kv1.7	ENSG00000104848	Potassium voltage-gated channel subfamily A member 7	19	49067418-49072941	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level							Not detected	Tissue enriched	37	skeletal muscle: 26.2	esophagus: 0.7	Not detected		
KCNB1	Kv2.1	ENSG00000158445	Potassium voltage-gated channel subfamily B member 1	20	49293394-49484297	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB001979, HPA042434	Enhanced					Mixed	Tissue enhanced		adipose tissue: 10.9;cerebral cortex: 21.6	fallopian tube,smooth muscle: 7.4	Cell line enhanced		CACO-2: 1.8;U-2 OS: 1.8
KCNB2	Kv2.2	ENSG00000182674	Potassium voltage-gated channel subfamily B member 2	8	72537391-72938349	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA065970			Approved	Nucleoli<br>Plasma membrane<br>Midbody		Not detected	Tissue enhanced		cerebral cortex: 3.2;spleen: 3.3	fallopian tube,testis: 0.7	Cell line enhanced		HaCaT: 1.3;HDLM-2: 1.4;HEK93: 3.2;SCLC-21H: 3.4
KCNC1	Kv3.1	ENSG00000129159	Potassium voltage-gated channel subfamily C member 1	11	17734774-17856804	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA047634, HPA048249	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Vesicles<br>Cytosol		Tissue enhanced	Tissue enriched	8	cerebral cortex: 18.6	testis: 2.2	Cell line enhanced		RH-30: 3.6;SCLC-21H: 4.2;SH-SY5Y: 2.3
KCNC2	Kv3.2	ENSG00000166006	Potassium voltage-gated channel subfamily C member 2	12	75040077-75209868	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA019664, CAB022571	Uncertain		Supported	Plasma membrane<br>Cytosol		Group enriched	Tissue enriched	11	cerebral cortex: 46.4	prostate: 4.3	Not detected		
KCNC3	Kv3.3, SCA13	ENSG00000131398	Potassium voltage-gated channel subfamily C member 3	19	50311937-50333515	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA018041	Approved				Renal cancer:1.23e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 39.9	cerebral cortex: 19.8	Cell line enhanced		HMC-1: 26.4;SK-BR-3: 15.3;T-47d: 18.4;U-2 OS: 13.8
KCNC4	C1orf30, HKSHIIIC, Kv3.4	ENSG00000116396	Potassium voltage-gated channel subfamily C member 4	1	110211343-110283100	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA014740			Approved	Nucleoli<br>Cytosol		Mixed	Mixed			parathyroid gland: 13.6	Cell line enhanced		HDLM-2: 17.2;U-87 MG: 15.3
KCND1	Kv4.1	ENSG00000102057	Potassium voltage-gated channel subfamily D member 1	X	48961378-48971569	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA000524, HPA001066	Approved		Approved	Nucleus	Pancreatic cancer:2.66e-6 (favourable)	Mixed	Mixed			gallbladder: 3.9	Mixed		
KCND2	KIAA1044, Kv4.2, RK5	ENSG00000184408	Potassium voltage-gated channel subfamily D member 2	7	120273668-120750331	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA029068	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 20.7	gallbladder: 6.8	Cell line enhanced		ASC TERT1: 3.5;SCLC-21H: 15.6
KCND3	KSHIVB, Kv4.3, SCA19, SCA22	ENSG00000171385	Potassium voltage-gated channel subfamily D member 3	1	111770662-111989155	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA029452	Approved					Mixed	Mixed			cerebral cortex: 26.7	Cell line enhanced		SCLC-21H: 14.0;WM-115: 2.8
KCNE1	ISK, JLNS2, LQT5, minK	ENSG00000180509	Potassium voltage-gated channel subfamily E regulatory subunit 1	21	34446688-34512275	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		fallopian tube: 16.6	heart muscle: 3.6	Cell line enhanced		BJ hTERT+ SV40 Large T+: 1.2;CACO-2: 3.3
KCNE1B		ENSG00000276289	Potassium voltage-gated channel subfamily E regulatory subunit 1B	21	7816675-7829926	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 9.1;heart muscle: 4.0	kidney: 2.9	Cell line enhanced		CACO-2: 1.5
KCNE2	LQT6, MiRP1	ENSG00000159197	Potassium voltage-gated channel subfamily E regulatory subunit 2	21	34364024-34371389	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA029706, HPA051553	Enhanced					Tissue enriched	Tissue enriched	25	stomach: 175.3	duodenum: 7.0	Cell line enhanced		SCLC-21H: 2.3
KCNE3	HOKPP, MiRP2	ENSG00000175538	Potassium voltage-gated channel subfamily E regulatory subunit 3	11	74454841-74467729	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014849	Approved				Liver cancer:2.28e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 70.1	Cell line enhanced		CACO-2: 18.7;EFO-21: 19.5;HEL: 61.5;NB-4: 27.5;THP-1: 21.7
KCNE4	MiRP3	ENSG00000152049	Potassium voltage-gated channel subfamily E regulatory subunit 4	2	223051814-223198399	Predicted membrane proteins	Evidence at protein level	HPA011420	Approved		Approved	Nuclear bodies<br>Microtubules	Renal cancer:2.02e-7 (unfavourable), Colorectal cancer:9.42e-5 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 54.0	endometrium: 33.5	Cell line enriched	6	AN3-CA: 152.4
KCNE5	KCNE1L	ENSG00000176076	Potassium voltage-gated channel subfamily E regulatory subunit 5	X	109623700-109625172	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA042316	Uncertain		Uncertain	Cytosol		Group enriched	Tissue enhanced		cerebral cortex: 2.1	adipose tissue: 1.1	Cell line enhanced		hTEC/SVTERT24-B: 2.0
KCNF1	IK8, KCNF, kH1, Kv5.1	ENSG00000162975	Potassium voltage-gated channel modifier subfamily F member 1	2	10911937-10914225	Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014738, HPA062278	Enhanced		Approved	Golgi apparatus		Tissue enriched	Tissue enriched	32	cerebral cortex: 37.5	endometrium: 1.1	Cell line enhanced		A549: 12.9;MCF7: 3.9;T-47d: 5.7
KCNG1	K13, KCNG, kH2, Kv6.1	ENSG00000026559	Potassium voltage-gated channel modifier subfamily G member 1	20	51003656-51023129	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA039530, HPA040024	Approved		Approved	Vesicles		Tissue enhanced	Tissue enhanced		endometrium: 23.4;seminal vesicle: 18.1	placenta: 10.1	Cell line enhanced		hTCEpi: 38.3;U-138 MG: 39.5
KCNG2	KCNF2, Kv6.2	ENSG00000178342	Potassium voltage-gated channel modifier subfamily G member 2	18	79863668-79900184	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA048628	Approved					Not detected	Not detected			cerebral cortex: 0.4	Not detected		
KCNG3	Kv6.3	ENSG00000171126	Potassium voltage-gated channel modifier subfamily G member 3	2	42442017-42494097	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA041625			Approved	Cytoplasmic bodies		Mixed	Tissue enhanced		adrenal gland: 1.2;cerebral cortex: 1.3;testis: 1.1	colon,endometrium: 0.4	Cell line enhanced		HAP1: 4.9;HMC-1: 14.2;NTERA-2: 10.3
KCNG4	Kv6.4	ENSG00000168418	Potassium voltage-gated channel modifier subfamily G member 4	16	84218667-84239750	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Not detected	Not detected			adrenal gland: 0.6	Not detected		
KCNH1	eag, eag1, h-eag, Kv10.1	ENSG00000143473	Potassium voltage-gated channel subfamily H member 1	1	210676823-211134180	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014551, HPA019445	Enhanced		Approved	Vesicles		Not detected	Tissue enriched	6	cerebral cortex: 6.2	testis: 1.0	Cell line enhanced		RH-30: 4.9;SH-SY5Y: 6.8;SK-MEL-30: 4.8;T-47d: 4.3
KCNH2	erg1, HERG, Kv11.1, LQT2	ENSG00000055118	Potassium voltage-gated channel subfamily H member 2	7	150944961-150978315	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Endometrial cancer:6.06e-5 (unfavourable), Pancreatic cancer:5.61e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 24.1;testis: 27.3	parathyroid gland: 13.2	Group enriched	6	K-562: 170.9;NB-4: 59.5;SH-SY5Y: 79.9
KCNH3	BEC1, elk2, Kv12.2	ENSG00000135519	Potassium voltage-gated channel subfamily H member 3	12	49539157-49558308	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA051088	Uncertain		Approved	Nucleus<br>Mitochondria		Tissue enhanced	Group enriched	5	cerebral cortex: 24.2;fallopian tube: 7.1;parathyroid gland: 4.9	adrenal gland: 2.2	Cell line enhanced		A549: 7.6;RPTEC TERT1: 7.7;U-2 OS: 11.2
KCNH4	elk1, Kv12.3	ENSG00000089558	Potassium voltage-gated channel subfamily H member 4	17	42156891-42181278	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 1.8	appendix: 0.7	Cell line enhanced		HDLM-2: 4.2;K-562: 3.8;RPMI-8226: 5.6;RT4: 2.3;U-266/70: 3.1
KCNH5	eag2, H-EAG2, Kv10.2	ENSG00000140015	Potassium voltage-gated channel subfamily H member 5	14	62699454-63102037	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA030487	Uncertain		Uncertain	Microtubules<br>Mitotic spindle		Not detected	Tissue enhanced		adrenal gland: 1.4;cerebral cortex: 3.6	testis: 0.7	Cell line enhanced		BEWO: 1.5;HeLa: 5.0;RT4: 7.9
KCNH6	erg2, HERG2, Kv11.2	ENSG00000173826	Potassium voltage-gated channel subfamily H member 6	17	63523334-63548977	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enhanced		kidney: 6.1;prostate: 5.4;small intestine: 5.5	duodenum: 2.2	Group enriched	6	SCLC-21H: 4.0;SH-SY5Y: 1.4
KCNH7	erg3, HERG3, Kv11.3	ENSG00000184611	Potassium voltage-gated channel subfamily H member 7	2	162371407-162838730	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA018039	Uncertain					Not detected	Tissue enriched	7	cerebral cortex: 4.7	stomach,testis: 0.6	Group enriched	12	SCLC-21H: 7.7;SK-BR-3: 4.4
KCNH8	elk3, Kv12.1	ENSG00000183960	Potassium voltage-gated channel subfamily H member 8	3	19148454-19535646	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA016586			Supported	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 4.8	adrenal gland: 2.3	Cell line enhanced		HAP1: 1.0;SH-SY5Y: 4.4
KCNIP4	CALP, KCHIP4, MGC44947	ENSG00000185774	Potassium voltage-gated channel interacting protein 4	4	20728616-21948799	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA022862		Supported				Mixed	Tissue enhanced		cerebral cortex: 57.3	cervix, uterine: 18.9	Cell line enhanced		RPTEC TERT1: 4.6;SCLC-21H: 5.6
KCNJ1	Kir1.1, ROMK1	ENSG00000151704	Potassium voltage-gated channel subfamily J member 1	11	128836315-128867373	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA026962	Enhanced					Tissue enriched	Tissue enriched	117	kidney: 210.8	epididymis: 1.7	Cell line enriched	42	RPTEC TERT1: 87.0
KCNJ10	Kir1.2, Kir4.1	ENSG00000177807	Potassium voltage-gated channel subfamily J member 10	1	159998651-160070483	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA078302	Enhanced					Tissue enriched	Group enriched	5	cerebral cortex: 124.7;kidney: 30.6	spleen: 14.5	Cell line enhanced		Hep G2: 4.5;SK-MEL-30: 1.6;U-266/70: 1.6
KCNJ11	BIR, Kir6.2	ENSG00000187486	Potassium voltage-gated channel subfamily J member 11	11	17385859-17389331	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA048891	Approved				Renal cancer:1.56e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 32.7	cerebral cortex: 10.2	Cell line enhanced		HEK93: 12.0;MCF7: 8.2;SCLC-21H: 10.3
KCNJ12	hIRK1, IRK2, KCNJN1, Kir2.2, Kir2.2v	ENSG00000184185	Potassium voltage-gated channel subfamily J member 12	17	21376197-21419872	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA027021	Approved		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Endometrial cancer:7.84e-5 (unfavourable)	Mixed	Group enriched	5	parathyroid gland: 19.2;skeletal muscle: 23.1	heart muscle: 3.9	Cell line enhanced		HeLa: 2.6;PC-3: 3.9;SCLC-21H: 5.6;SiHa: 2.6;U-2197: 3.9
KCNJ13	Kir1.4, Kir7.1, LCA16	ENSG00000115474	Potassium voltage-gated channel subfamily J member 13	2	232766464-232776568	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Tissue enriched	Group enriched	5	parathyroid gland: 25.8;small intestine: 112.2	thyroid gland: 12.5	Cell line enhanced		U-2197: 1.2
KCNJ14	IRK4, Kir2.4	ENSG00000182324	Potassium voltage-gated channel subfamily J member 14	19	48455509-48466980	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA071765			Approved	Nucleoli		Mixed	Mixed			skin,testis: 2.1	Mixed		
KCNJ15	IRKK, Kir1.3, Kir4.2	ENSG00000157551	Potassium voltage-gated channel subfamily J member 15	21	38157034-38307357	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA016702	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:4.09e-10 (favourable), Urothelial cancer:1.95e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 261.3;thyroid gland: 216.3	lung: 63.4	Cell line enhanced		ASC TERT1: 48.4;HBEC3-KT: 50.0;RPTEC TERT1: 51.4;RT4: 65.6
KCNJ16	BIR9, Kir5.1	ENSG00000153822	Potassium voltage-gated channel subfamily J member 16	17	70053429-70135608	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA059563	Approved		Uncertain	Vesicles	Renal cancer:9.61e-7 (favourable), Thyroid cancer:6.58e-4 (favourable)	Group enriched	Group enriched	8	kidney: 209.1;parathyroid gland: 269.7;thyroid gland: 235.1	seminal vesicle: 31.5	Cell line enriched	18	RPTEC TERT1: 211.8
KCNJ18	KIR2.6, TTPP2	ENSG00000260458	Potassium voltage-gated channel subfamily J member 18	17	21692523-21704612	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA027021	Uncertain		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Tissue enhanced	Group enriched	8	skin: 3.8;tonsil: 1.3	testis: 0.3	Not detected		
KCNJ2	IRK1, Kir2.1, LQT7	ENSG00000123700	Potassium voltage-gated channel subfamily J member 2	17	70168673-70180048	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA029109	Approved					Mixed	Tissue enhanced		parathyroid gland: 44.6	fallopian tube: 10.6	Cell line enhanced		REH: 6.8;RH-30: 28.3;U-138 MG: 10.5
KCNJ3	GIRK1, KGA, Kir3.1	ENSG00000162989	Potassium voltage-gated channel subfamily J member 3	2	154698299-154858352	Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA024231	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 25.4;parathyroid gland: 39.8	seminal vesicle: 14.1	Cell line enhanced		BJ: 1.2
KCNJ4	HIR, hIRK2, HRK1, IRK3, Kir2.3	ENSG00000168135	Potassium voltage-gated channel subfamily J member 4	22	38426327-38455199	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Group enriched	25	cerebral cortex: 40.9;heart muscle: 11.4	gallbladder: 1.0	Cell line enriched	8	SCLC-21H: 13.4
KCNJ5	CIR, GIRK4, KATP1, Kir3.4, LQT13	ENSG00000120457	Potassium voltage-gated channel subfamily J member 5	11	128891356-128921035	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014722, HPA017353, CAB022569	Enhanced					Mixed	Tissue enhanced		adrenal gland: 84.8	spleen: 18.8	Cell line enriched	12	HBEC3-KT: 9.5
KCNJ6	BIR1, GIRK2, hiGIRK2, KATP2, KCNJ7, Kir3.2	ENSG00000157542	Potassium voltage-gated channel subfamily J member 6	21	37607376-37916446	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Not detected	Tissue enriched	9	cerebral cortex: 2.6	spleen,stomach,testis: 0.2	Cell line enhanced		LHCN-M2: 7.1;TIME: 1.8
KCNJ8	Kir6.1	ENSG00000121361	Potassium voltage-gated channel subfamily J member 8	12	21764955-21775581	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA031066	Uncertain				Renal cancer:1.62e-6 (unfavourable), Colorectal cancer:9.29e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 32.0	Cell line enhanced		CACO-2: 71.9;SH-SY5Y: 31.1
KCNJ9	GIRK3, Kir3.3	ENSG00000162728	Potassium voltage-gated channel subfamily J member 9	1	160081570-160090563	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA070478	Enhanced					Tissue enriched	Tissue enriched	113	cerebral cortex: 52.3	adrenal gland,testis: 0.4	Not detected		
KCNK1	DPK, K2p1.1, TWIK-1	ENSG00000135750	Potassium two pore domain channel subfamily K member 1	1	233614004-233672512	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA016049, CAB022588	Approved		Approved	Vesicles	Renal cancer:8.69e-8 (unfavourable), Liver cancer:3.84e-4 (favourable), Pancreatic cancer:7.29e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 46.4	Cell line enhanced		SCLC-21H: 70.2;U-266/70: 104.5;U-266/84: 92.8
KCNK10	K2p10.1, PPP1R97, TREK-2, TREK2	ENSG00000100433	Potassium two pore domain channel subfamily K member 10	14	88180103-88326907	Predicted membrane proteins	Evidence at protein level	HPA030462	Approved					Mixed	Tissue enhanced		cerebral cortex: 5.6;duodenum: 5.1	small intestine,stomach: 2.7	Cell line enhanced		AF22: 1.0;REH: 1.6;SCLC-21H: 3.7
KCNK12	K2p12.1, THIK-2, THIK2	ENSG00000184261	Potassium two pore domain channel subfamily K member 12	2	47516581-47570939	Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level							Tissue enriched	Tissue enriched	17	cerebral cortex: 5.3	placenta,testis: 0.3	Group enriched	6	REH: 21.5;SCLC-21H: 10.5
KCNK13	K2p13.1, THIK-1, THIK1	ENSG00000152315	Potassium two pore domain channel subfamily K member 13	14	90061765-90185857	Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level	HPA003514	Approved		Approved	Nuclear speckles<br>Cell Junctions		Mixed	Tissue enhanced		parathyroid gland: 14.6;testis: 14.4	kidney: 3.3	Cell line enhanced		RT4: 1.4
KCNK15	dJ781B1.1, K2p15.1, KCNK11, KCNK14, KIAA0237, KT3.3, TASK-5, TASK5	ENSG00000124249	Potassium two pore domain channel subfamily K member 15	20	44745780-44752313	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA064861	Uncertain				Cervical cancer:3.68e-4 (unfavourable)	Tissue enriched	Tissue enhanced		fallopian tube: 8.0	testis: 2.9	Cell line enriched	8	MCF7: 35.7
KCNK16	K2p16.1, TALK-1, TALK1	ENSG00000095981	Potassium two pore domain channel subfamily K member 16	6	39314698-39322968	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Tissue enriched	Tissue enhanced		duodenum: 3.8;pancreas: 5.4;stomach: 12.4	thyroid gland: 1.7	Cell line enriched	511	SCLC-21H: 157.3
KCNK17	K2p17.1, TALK-2, TALK2, TASK-4, TASK4	ENSG00000124780	Potassium two pore domain channel subfamily K member 17	6	39299001-39314553	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at transcript level	HPA043892	Uncertain					Mixed	Tissue enhanced		lung: 5.6	placenta: 5.3	Cell line enriched	9	SCLC-21H: 91.6
KCNK18	K2p18.1, TRESK, TRESK-2, TRESK2, TRIK	ENSG00000186795	Potassium two pore domain channel subfamily K member 18	10	117197489-117210299	Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA044739	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
KCNK2	K2p2.1, TREK-1	ENSG00000082482	Potassium two pore domain channel subfamily K member 2	1	215005775-215237093	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 75.2	thyroid gland: 17.0	Cell line enhanced		ASC TERT1: 58.1;fHDF/TERT166: 59.9;T-47d: 108.4;U-2197: 38.1
KCNK3	K2p3.1, TASK, TASK-1	ENSG00000171303	Potassium two pore domain channel subfamily K member 3	2	26692690-26733420	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Renal cancer:2.37e-7 (unfavourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 111.8;placenta: 35.8	lung: 19.9	Group enriched	6	EFO-21: 10.3;SCLC-21H: 30.6
KCNK4	K2p4.1, TRAAK	ENSG00000182450	Potassium two pore domain channel subfamily K member 4	11	64291302-64300031	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Not detected	Tissue enriched	12	cerebral cortex: 4.3	cervix, uterine: 0.3	Not detected		
KCNK5	K2p5.1, TASK-2	ENSG00000164626	Potassium two pore domain channel subfamily K member 5	6	39188973-39229450	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA059148	Uncertain		Approved	Nucleus	Renal cancer:4.98e-7 (favourable), Cervical cancer:3.29e-4 (favourable), Urothelial cancer:4.45e-4 (favourable), Pancreatic cancer:5.85e-4 (unfavourable)	Mixed	Tissue enhanced		small intestine: 39.3	gallbladder: 29.5	Cell line enhanced		CACO-2: 28.9;HEL: 32.6;HMC-1: 28.2;K-562: 30.8
KCNK6	K2p6.1, TWIK-2	ENSG00000099337	Potassium two pore domain channel subfamily K member 6	19	38319844-38332076	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB022637, HPA040184	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Endometrial cancer:1.45e-6 (favourable), Renal cancer:1.04e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 22.6	Cell line enhanced		HEL: 33.9;HMC-1: 35.7
KCNK7	K2p7.1	ENSG00000173338	Potassium two pore domain channel subfamily K member 7	11	65592855-65595996	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Voltage-gated ion channels	Evidence at transcript level	HPA077577			Approved	Plasma membrane		Tissue enhanced	Tissue enriched	7	skin: 53.2	esophagus: 7.9	Cell line enhanced		SCLC-21H: 8.4
KCNK9	K2p9.1, TASK-3, TASK3	ENSG00000169427	Potassium two pore domain channel subfamily K member 9	8	139600838-139703056	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Group enriched	7	adrenal gland: 4.7;cerebral cortex: 4.8	cervix, uterine: 0.7	Cell line enhanced		PC-3: 2.0;SCLC-21H: 1.1
KCNMA1	KCa1.1, mSLO1, SLO	ENSG00000156113	Potassium calcium-activated channel subfamily M alpha 1	10	76869601-77638369	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA054648	Approved					Mixed	Tissue enhanced		smooth muscle: 137.0	endometrium: 109.5	Cell line enhanced		PC-3: 148.0;U-138 MG: 111.0;U-87 MG: 107.5
KCNMB1	hslo-beta	ENSG00000145936	Potassium calcium-activated channel subfamily M regulatory beta subunit 1	5	170374671-170389677	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:4.13e-6 (unfavourable)	Mixed	Tissue enhanced		seminal vesicle: 64.2;smooth muscle: 69.7	endometrium: 42.0	Cell line enhanced		REH: 7.4;U-937: 2.6
KCNMB2		ENSG00000197584	Potassium calcium-activated channel subfamily M regulatory beta subunit 2	3	178272932-178844429	Predicted membrane proteins, Transporters	Evidence at protein level	CAB022649	Uncertain					Mixed	Tissue enhanced		epididymis: 43.1;fallopian tube: 22.3;ovary: 19.0	adrenal gland: 7.6	Cell line enhanced		BJ hTERT+: 2.5;SCLC-21H: 4.7
KCNMB3	KCNMB2, KCNMBL	ENSG00000171121	Potassium calcium-activated channel subfamily M regulatory beta subunit 3	3	179236691-179267002	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015665, HPA019185	Approved		Approved	Nucleus<br>Mitochondria		Not detected	Mixed			placenta: 6.1	Cell line enhanced		HEL: 7.2
KCNMB4		ENSG00000135643	Potassium calcium-activated channel subfamily M regulatory beta subunit 4	12	70366276-70434292	Predicted membrane proteins	Evidence at protein level	HPA072287	Enhanced		Approved	Cytosol		Mixed	Group enriched	8	adrenal gland: 19.5;cerebral cortex: 38.1	placenta: 3.7	Cell line enhanced		NTERA-2: 7.7;RH-30: 8.0;RT4: 7.4
KCNN1	hSK1, KCa2.1	ENSG00000105642	Potassium calcium-activated channel subfamily N member 1	19	17951293-18000080	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA065938			Approved	Actin filaments<br>Cytosol		Tissue enhanced	Tissue enriched	10	cerebral cortex: 21.4	testis: 2.0	Cell line enriched	13	REH: 141.4
KCNN2	hSK2, KCa2.2	ENSG00000080709	Potassium calcium-activated channel subfamily N member 2	5	114360945-114496500	Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA038221	Uncertain		Uncertain	Nucleoplasm<br>Cytosol		Group enriched	Tissue enhanced		adrenal gland: 27.3	prostate: 15.9	Cell line enhanced		BJ: 14.7;NTERA-2: 6.4;SK-MEL-30: 9.7;THP-1: 15.0;U-937: 6.2
KCNN3	hSK3, KCa2.3, SKCA3	ENSG00000143603	Potassium calcium-activated channel subfamily N member 3	1	154697455-154870280	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA017990, HPA057127	Uncertain		Approved	Nucleoplasm	Renal cancer:1.97e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 25.4	fallopian tube: 9.4	Cell line enhanced		Daudi: 28.1;HMC-1: 23.0;Karpas-707: 46.9;U-266/70: 47.5
KCNN4	hIKCa1, hKCa4, hSK4, IK, KCa3.1	ENSG00000104783	Potassium calcium-activated channel subfamily N member 4	19	43766533-43781257	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA053841, HPA059622	Approved				Renal cancer:1.05e-14 (unfavourable), Urothelial cancer:1.75e-4 (favourable), Glioma:3.77e-4 (unfavourable), Pancreatic cancer:4.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		salivary gland: 73.7	stomach: 36.6	Cell line enhanced		CAPAN-2: 93.3;WM-115: 264.9
KCNQ1	JLNS1, KCNA8, KCNA9, Kv7.1, KVLQT1, LQT, LQT1	ENSG00000053918	Potassium voltage-gated channel subfamily Q member 1	11	2444684-2849109	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB018656, HPA048553	Enhanced				Stomach cancer:9.85e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 133.6;thyroid gland: 102.7	seminal vesicle: 60.6	Cell line enhanced		HMC-1: 25.7;RPMI-8226: 14.2;U-266/70: 8.9;U-937: 8.8
KCNQ2	BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2	ENSG00000075043	Potassium voltage-gated channel subfamily Q member 2	20	63400210-63472677	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA016642, HPA057112	Enhanced		Approved	Endoplasmic reticulum		Tissue enriched	Tissue enriched	7	cerebral cortex: 57.2	testis: 8.2	Cell line enhanced		AN3-CA: 32.4;SCLC-21H: 79.6;SH-SY5Y: 126.1
KCNQ3	EBN2, Kv7.3	ENSG00000184156	Potassium voltage-gated channel subfamily Q member 3	8	132120858-132481019	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enriched	14	cerebral cortex: 26.7	adrenal gland: 1.9	Cell line enhanced		hTERT-HME1: 5.1;U-2 OS: 4.5;U-87 MG: 3.5
KCNQ4	DFNA2, Kv7.4	ENSG00000117013	Potassium voltage-gated channel subfamily Q member 4	1	40784012-40840452	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA018305	Uncertain					Mixed	Mixed			smooth muscle: 2.5	Cell line enhanced		HAP1: 1.9;HEK93: 2.5;K-562: 2.6
KCNQ5	Kv7.5	ENSG00000185760	Potassium voltage-gated channel subfamily Q member 5	6	72621792-73198851	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA016655	Enhanced		Approved	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 22.3	thyroid gland: 7.9	Cell line enhanced		BJ: 29.6
KCNS1	Kv9.1	ENSG00000124134	Potassium voltage-gated channel modifier subfamily S member 1	20	45092310-45101112	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Ovarian cancer:6.45e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 9.3;gallbladder: 3.8;seminal vesicle: 4.2	testis: 1.7	Cell line enhanced		HBF TERT88: 1.3;HHSteC: 1.8;THP-1: 1.2;U-87 MG: 3.0
KCNS2	Kv9.2	ENSG00000156486	Potassium voltage-gated channel modifier subfamily S member 2	8	98427022-98432848	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA051417	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 7.2	placenta: 2.2	Group enriched	9	HSkMC: 1.5;SCLC-21H: 7.5
KCNS3	Kv9.3	ENSG00000170745	Potassium voltage-gated channel modifier subfamily S member 3	2	17877847-18361616	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014864	Approved		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 35.5	skeletal muscle: 29.6	Cell line enhanced		RH-30: 66.9;RT4: 38.5
KCNT1	KCa4.1, KIAA1422, SLACK, Slo2.2	ENSG00000107147	Potassium sodium-activated channel subfamily T member 1	9	135702185-135795508	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA059880	Uncertain					Tissue enhanced	Group enriched	5	cerebral cortex: 11.6;ovary: 3.9;skeletal muscle: 3.8;spleen: 6.8	testis: 1.2	Cell line enhanced		RPMI-8226: 1.2;SCLC-21H: 3.0
KCNT2	KCa4.2, SLICK, SLO2.1	ENSG00000162687	Potassium sodium-activated channel subfamily T member 2	1	196225779-196609225	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA051218	Uncertain		Approved	Vesicles	Renal cancer:1.67e-5 (unfavourable)	Mixed	Tissue enhanced		ovary: 6.0	cerebral cortex: 3.5	Cell line enhanced		HHSteC: 2.7;NTERA-2: 2.6;SCLC-21H: 8.5;SH-SY5Y: 6.9
KCNU1	KCa5.1, Kcnma3, KCNMC1, Slo3	ENSG00000215262	Potassium calcium-activated channel subfamily U member 1	8	36784324-36936128	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA063317			Uncertain	Plasma membrane		Tissue enhanced	Tissue enriched	28	testis: 13.5	adipose tissue,epididymis: 0.4	Cell line enriched	6	HDLM-2: 7.3
KCNV1	Kv8.1	ENSG00000164794	Potassium voltage-gated channel modifier subfamily V member 1	8	109963645-109975847	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enriched	32	cerebral cortex: 21.8	epididymis,skin,thyroid gland: 0.6	Not detected		
KCNV2	Kv8.2	ENSG00000168263	Potassium voltage-gated channel modifier subfamily V member 2	9	2717502-2730037	Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA031131	Supported					Tissue enriched	Tissue enriched	44	testis: 6.6	skin: 0.1	Not detected		
KCTD7	CLN14, EPM3, FLJ32069	ENSG00000243335	Potassium channel tetramerization domain containing 7	7	66628767-66649067	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:3.26e-4 (favourable), Colorectal cancer:8.07e-4 (unfavourable)	Expressed in all	Mixed			testis: 32.9	Expressed in all		
KCTD8		ENSG00000183783	Potassium channel tetramerization domain containing 8	4	44173909-44448807	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031562	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 11.5;thyroid gland: 5.2	testis: 2.4	Cell line enhanced		HAP1: 2.2;NTERA-2: 1.5;SCLC-21H: 6.8;U-2 OS: 1.8
KDELR1	ERD2, ERD2.1, HDEL	ENSG00000105438	KDEL endoplasmic reticulum protein retention receptor 1	19	48382570-48391553	Predicted membrane proteins, Transporters	Evidence at protein level	CAB017455	Approved		Supported	Golgi apparatus<br>Vesicles	Liver cancer:1.61e-4 (unfavourable), Head and neck cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 264.3	Expressed in all		
KDELR2	ELP-1, ERD2.2	ENSG00000136240	KDEL endoplasmic reticulum protein retention receptor 2	7	6445953-6484242	Predicted membrane proteins	Evidence at protein level	HPA016459	Approved				Renal cancer:6.79e-8 (unfavourable), Head and neck cancer:1.03e-5 (unfavourable), Glioma:8.16e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 204.0	Expressed in all		
KDELR3		ENSG00000100196	KDEL endoplasmic reticulum protein retention receptor 3	22	38468062-38483447	Predicted membrane proteins	Evidence at protein level	HPA043477, HPA076405	Uncertain		Enhanced	Endoplasmic reticulum	Renal cancer:6.05e-10 (unfavourable), Liver cancer:1.19e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 46.5	Cell line enhanced		ASC TERT1: 179.3;fHDF/TERT166: 214.6
KDR	CD309, FLK1, VEGFR, VEGFR2	ENSG00000128052	Kinase insert domain receptor	4	55078477-55125589	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB004028	Enhanced		Supported	Plasma membrane	Renal cancer:7.26e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 119.2	thyroid gland: 54.7	Group enriched	9	HUVEC TERT2: 178.6;TIME: 148.0
KDSR	DHSR, FVT1, SDR35C1	ENSG00000119537	3-ketodihydrosphingosine reductase	18	63327726-63367510	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB003673, HPA044884	Approved				Renal cancer:9.53e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 45.5	Expressed in all		
KEL	CD238, ECE3	ENSG00000197993	Kell blood group, metallo-endopeptidase	7	142941114-142962681	Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 14.5;testis: 19.5	lymph node: 6.4	Group enriched	14	HEL: 12.2;K-562: 10.7
KHDC1	bA257K9.4, C6orf147, C6orf148, Em:AC019205.8, MGC10818, NDG1	ENSG00000135314	KH homology domain containing 1	6	73241314-73310365	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA029032			Approved	Mitochondria<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 9.9	testis: 6.8	Mixed		
KIAA0319	NMIG	ENSG00000137261	KIAA0319	6	24544104-24646155	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015607, HPA076313	Enhanced		Uncertain	Vesicles		Mixed	Tissue enriched	6	cerebral cortex: 15.8	fallopian tube: 2.8	Cell line enhanced		HDLM-2: 2.6;SCLC-21H: 5.1;U-266/84: 2.6
KIAA0319L	KIAA1837	ENSG00000142687	KIAA0319 like	1	35433490-35557950	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA072692			Approved	Nucleoli<br>Golgi apparatus	Liver cancer:5.92e-5 (unfavourable), Renal cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.6	Expressed in all		
KIAA0922	DKFZp586H1322, TMEM131L	ENSG00000121210	KIAA0922	4	153466346-153636711	Predicted membrane proteins	Evidence at protein level	HPA043472, HPA048443	Uncertain		Approved	Nucleoli fibrillar center<br>Vesicles	Cervical cancer:6.69e-6 (favourable)	Expressed in all	Expressed in all			lymph node: 56.4	Cell line enhanced		Daudi: 75.0;MOLT-4: 79.8;U-698: 85.3
KIAA1024		ENSG00000169330	KIAA1024	15	79432516-79472290	Predicted membrane proteins	Evidence at protein level	HPA011545	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enriched	11	adrenal gland: 14.0	prostate,salivary gland: 1.2	Cell line enhanced		U-138 MG: 9.2
KIAA1024L		ENSG00000186367	KIAA1024 like	5	129748079-129766732	Predicted membrane proteins	Evidence at transcript level	HPA013760	Uncertain					Not detected	Tissue enriched	12	skeletal muscle: 11.5	testis: 0.9	Cell line enhanced		SH-SY5Y: 1.5
KIAA1109	FLJ21404, FSA, KIAA1371, Tweek	ENSG00000138688	KIAA1109	4	122152333-122362758	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038076	Approved		Approved	Nucleoplasm<br>Centrosome	Renal cancer:4.33e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 130.9	Expressed in all		
KIAA1161	NET37	ENSG00000164976	KIAA1161	9	34366670-34376853	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060533, HPA067487	Approved		Approved	Mitochondria	Renal cancer:1.20e-13 (favourable), Endometrial cancer:6.96e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 29.4	Cell line enhanced		SK-BR-3: 43.1;T-47d: 50.4
KIAA1324	EIG121, maba1	ENSG00000116299	KIAA1324	1	109113679-109206781	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029869, HPA070749	Enhanced		Supported	Plasma membrane	Endometrial cancer:2.14e-7 (favourable), Lung cancer:5.69e-5 (favourable), Ovarian cancer:2.16e-4 (favourable)	Mixed	Mixed			cervix, uterine: 129.0	Cell line enhanced		MCF7: 21.5;SCLC-21H: 20.3;SK-BR-3: 15.8;T-47d: 68.2;U-87 MG: 13.3
KIAA1324L	EIG121L, FLJ31340	ENSG00000164659	KIAA1324 like	7	86876906-87059699	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044527, HPA076093	Uncertain		Approved	Endoplasmic reticulum		Mixed	Tissue enhanced		lung: 32.2	cerebral cortex: 21.7	Cell line enhanced		K-562: 44.1;SCLC-21H: 45.6
KIAA1468	FLJ33841, HsT3308, HsT885	ENSG00000134444	KIAA1468	18	62187258-62307829	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039708, HPA040038	Approved		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			skin: 24.6	Expressed in all		
KIAA1524	CIP2A	ENSG00000163507	KIAA1524	3	108549869-108589644	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039570	Approved		Supported	Plasma membrane<br>Cytosol	Endometrial cancer:6.24e-5 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:9.18e-4 (unfavourable)	Expressed in all	Mixed			testis: 10.3	Mixed		
KIAA1549		ENSG00000122778	KIAA1549	7	138831381-138981318	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA019560	Approved		Approved	Nuclear membrane<br>Intermediate filaments	Renal cancer:3.93e-7 (favourable)	Mixed	Mixed			seminal vesicle: 10.5	Cell line enhanced		SH-SY5Y: 29.9
KIAA1549L	C11orf41, C11orf69, G2, MGC34830	ENSG00000110427	KIAA1549 like	11	33542072-33674102	Predicted membrane proteins	Evidence at protein level	HPA051594			Approved	Nucleoplasm		Mixed	Group enriched	41	cerebral cortex: 34.9;parathyroid gland: 146.2	skin: 2.2	Cell line enhanced		TIME: 43.4;U-138 MG: 64.2;WM-115: 44.5
KIAA1644		ENSG00000138944	KIAA1644	22	44243667-44312851	Predicted membrane proteins	Evidence at transcript level	HPA051178	Uncertain		Approved	Vesicles<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 27.6;endometrium: 42.8;smooth muscle: 44.6	cervix, uterine: 19.2	Cell line enhanced		SiHa: 38.9;U-2197: 76.1;U-87 MG: 46.0;WM-115: 27.3
KIAA2013	MGC33867, RP5-1077B9.1	ENSG00000116685	KIAA2013	1	11919591-11926428	Predicted membrane proteins	Evidence at protein level	HPA052677, HPA060536	Uncertain		Approved	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			small intestine: 68.1	Expressed in all		
KIDINS220	ARMS	ENSG00000134313	Kinase D interacting substrate 220	2	8721081-8837630	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014790	Supported		Approved	Nucleoplasm	Renal cancer:9.29e-6 (favourable), Lung cancer:9.64e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 101.6	Expressed in all		
KIR2DL1	47.11, CD158A, cl-42, nkat1, p58.1	ENSG00000125498	Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1	19	54769811-54784322	CD markers, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KIR2DL3	CD158B2, cl-6, nkat2, nkat2a, nkat2b, p58	ENSG00000243772	Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3	19	54738515-54753052	CD markers, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KIR2DL4	103AS, 15.212, CD158D	ENSG00000189013	Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4	19	54803535-54814517	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Not detected			all non-specific tissues: 0.0	Not detected		
KIR3DL1	AMB11, CD158E1, CD158e1/2, CD158e2, cl-11, cl-2, KIR, nkat3, NKB1, NKB1B	ENSG00000167633	Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1	19	54816468-54830778	CD markers, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			bone marrow: 0.1	Not detected		
KIR3DL2	CD158K, cl-5, nkat4, nkat4a, nkat4b	ENSG00000240403	Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2	19	54850443-54867207	CD markers, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			bone marrow: 0.1	Not detected		
KIR3DL3	CD158z, KIR3DL7, KIR44, KIRC1	ENSG00000242019	Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 3	19	54724479-54736536	Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KIRREL	NEPH1	ENSG00000183853	Kin of IRRE like (Drosophila)	1	157993273-158100262	Predicted membrane proteins	Evidence at protein level	HPA030458	Approved				Renal cancer:1.12e-8 (unfavourable), Cervical cancer:1.87e-4 (unfavourable), Urothelial cancer:2.85e-4 (unfavourable)	Expressed in all	Mixed			placenta: 47.1	Cell line enhanced		WM-115: 333.0
KIRREL2	DKFZp564A1164, FILTRIN, MGC15718, NEPH3, NLG1	ENSG00000126259	Kin of IRRE like 2 (Drosophila)	19	35855861-35867109	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071587, HPA074326			Supported	Microtubule organizing center		Mixed	Tissue enriched	8	pancreas: 11.6	cerebral cortex: 1.4	Cell line enhanced		HDLM-2: 20.2;HMC-1: 29.3
KIRREL3	KIAA1867, KIRRE, NEPH2	ENSG00000149571	Kin of IRRE like 3 (Drosophila)	11	126423359-127003460	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA053324, HPA056320	Enhanced					Tissue enhanced	Tissue enriched	11	cerebral cortex: 20.4	adrenal gland: 1.9	Cell line enhanced		BJ: 21.4;BJ hTERT+: 12.0;fHDF/TERT166: 14.2;U-138 MG: 11.2;U-251 MG: 11.6
KISS1R	AXOR12, GPR54, HOT7T175	ENSG00000116014	KISS1 receptor	19	917287-921015	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071913			Supported	Vesicles<br>Plasma membrane	Renal cancer:3.33e-6 (unfavourable)	Tissue enhanced	Tissue enriched	5	cerebral cortex: 1.2	appendix,lymph node,placenta: 0.2	Cell line enhanced		K-562: 14.0;RPMI-8226: 26.1;SCLC-21H: 8.9;SH-SY5Y: 21.3
KIT	C-Kit, CD117, PBT, SCFR	ENSG00000157404	KIT proto-oncogene receptor tyrosine kinase	4	54657918-54740715	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB003288, HPA004471, CAB068253, CAB072867, HPA073252	Enhanced	Supported	Supported	Plasma membrane	Renal cancer:5.63e-4 (favourable)	Mixed	Tissue enhanced		breast: 133.6	thyroid gland: 78.7	Group enriched	14	HEL: 220.1;HMC-1: 434.1
KITLG	FPH2, Kitl, KL-1, MGF, SCF, SF	ENSG00000049130	KIT ligand	12	88492793-88580851	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA070395	Approved		Approved	Vesicles	Renal cancer:5.81e-7 (favourable), Liver cancer:4.01e-4 (unfavourable)	Expressed in all	Mixed			lung: 23.5	Cell line enhanced		CACO-2: 199.5
KL		ENSG00000133116	Klotho	13	33016433-33066145	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.29e-9 (favourable), Pancreatic cancer:4.44e-4 (favourable)	Group enriched	Group enriched	5	kidney: 136.6;parathyroid gland: 346.4	placenta: 44.1	Cell line enhanced		HMC-1: 2.1;SK-BR-3: 3.4
KLB		ENSG00000134962	Klotho beta	4	39406853-39451536	Predicted membrane proteins, Transporters	Evidence at protein level	HPA021136	Uncertain					Tissue enriched	Tissue enhanced		adipose tissue: 20.6;liver: 9.1	testis: 5.0	Group enriched	19	ASC diff: 4.5;Hep G2: 17.2
KLHL5		ENSG00000109790	Kelch like family member 5	4	39045039-39126857	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013958	Approved					Expressed in all	Expressed in all			seminal vesicle: 91.0	Expressed in all		
KLRB1	CD161, CLEC5B, hNKR-P1A, NKR, NKR-P1, NKR-P1A	ENSG00000111796	Killer cell lectin like receptor B1	12	9594551-9607886	CD markers, Predicted membrane proteins	Evidence at protein level	HPA039113	Approved		Uncertain	Nucleoplasm<br>Cytosol	Endometrial cancer:1.42e-5 (favourable), Breast cancer:3.51e-5 (favourable), Head and neck cancer:6.99e-5 (favourable), Thyroid cancer:5.61e-4 (favourable)	Mixed	Mixed			spleen: 40.7	Not detected		
KLRC1	CD159a, NKG2, NKG2-A, NKG2-B	ENSG00000134545	Killer cell lectin like receptor C1	12	10442264-10454685	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058052			Approved	Plasma membrane		Mixed	Mixed			spleen: 9.9	Cell line enhanced		HeLa: 3.5
KLRC2	CD159c, NKG2-C	ENSG00000205809	Killer cell lectin like receptor C2	12	10426854-10442300	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058052			Approved	Plasma membrane		Tissue enriched	Group enriched	6	cerebral cortex: 17.3;spleen: 8.1	stomach: 2.1	Cell line enhanced		HEL: 5.2;HeLa: 11.9;HSkMC: 3.0;U-87 MG: 2.8
KLRC3	NKG2-E	ENSG00000205810	Killer cell lectin like receptor C3	12	10412312-10420595	Predicted membrane proteins	Evidence at transcript level	HPA039910, HPA062570	Approved		Uncertain	Vesicles		Tissue enriched	Tissue enhanced		cerebral cortex: 9.2;spleen: 6.2	lymph node: 2.3	Cell line enhanced		HEL: 1.1;HeLa: 4.5;U-698: 1.3
KLRC4	NKG2-F	ENSG00000183542	Killer cell lectin like receptor C4	12	10407382-10409757	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		spleen: 13.1	lymph node: 5.6	Cell line enhanced		HeLa: 3.1;U-698: 1.1
KLRD1	CD94	ENSG00000134539	Killer cell lectin like receptor D1	12	10226058-10329600	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069688	Uncertain					Mixed	Tissue enhanced		spleen: 18.8	lymph node: 6.7	Mixed		
KLRF1	CLEC5C, NKp80	ENSG00000150045	Killer cell lectin like receptor F1	12	9827481-9845007	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 24.9	bone marrow: 7.2	Cell line enhanced		BJ hTERT+: 1.2;HAP1: 1.4;U-937: 3.5
KLRF2	NKp65	ENSG00000256797	Killer cell lectin like receptor F2	12	9881489-9895833	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	16	skin: 14.1	tonsil: 0.8	Cell line enriched	40	U-937: 24.5
KLRG1	2F1, CLEC15A, MAFA, MAFA-L	ENSG00000139187	Killer cell lectin like receptor G1	12	8950044-9010760	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051403, HPA076494			Supported	Vesicles		Mixed	Tissue enhanced		spleen: 15.8	lymph node: 13.5	Cell line enhanced		HEL: 29.9;NTERA-2: 22.2;U-937: 16.1
KLRG2	CLEC15B, FLJ44186	ENSG00000188883	Killer cell lectin like receptor G2	7	139452690-139483712	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018199	Uncertain				Lung cancer:8.61e-4 (favourable)	Tissue enriched	Tissue enhanced		lung: 4.4;parathyroid gland: 5.7;thyroid gland: 6.8	kidney: 2.7	Cell line enhanced		BEWO: 14.0;HAP1: 15.9;SCLC-21H: 8.6;SK-BR-3: 23.3
KLRK1	CD314, D12S2489E, KLR, NKG2-D, NKG2D	ENSG00000213809	Killer cell lectin like receptor K1	12	10372353-10391874	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	CAB021896, HPA068877	Enhanced		Supported	Plasma membrane		Not detected	Tissue enhanced		lymph node: 35.1;spleen: 52.8	tonsil: 16.2	Cell line enriched	8	U-698: 41.6
KMO		ENSG00000117009	Kynurenine 3-monooxygenase	1	241532134-241595642	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA031115, HPA056942	Enhanced				Renal cancer:6.49e-8 (unfavourable)	Mixed	Tissue enhanced		kidney: 32.3;liver: 47.7	spleen: 10.8	Cell line enhanced		RPMI-8226: 6.1;RPTEC TERT1: 16.3;SK-BR-3: 8.4;U-698: 6.4
KMT2E	HDCMC04P, MLL5	ENSG00000005483	Lysine methyltransferase 2E	7	105014179-105114361	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022812, HPA056125	Approved	Approved			Renal cancer:3.80e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 51.7	Expressed in all		
KNCN	FLJ32011, KINO, L5	ENSG00000162456	Kinocilin	1	46545644-46551527	Predicted membrane proteins	Evidence at transcript level	HPA046357	Uncertain					Not detected	Not detected			testis: 0.6	Not detected		
KREMEN1	KREMEN, KRM1	ENSG00000183762	Kringle containing transmembrane protein 1	22	29073078-29168333	Predicted membrane proteins	Evidence at protein level	HPA058513			Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Not detected	Mixed			skin: 43.4	Cell line enhanced		U-2197: 55.3
KREMEN2	KRM2, MGC10791	ENSG00000131650	Kringle containing transmembrane protein 2	16	2963944-2968383	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA003223	Uncertain		Approved	Nucleoli	Lung cancer:8.98e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 6.9	cerebral cortex: 2.1	Cell line enhanced		HMC-1: 24.6;RPMI-8226: 19.1
KRTCAP2	KCP2	ENSG00000163463	Keratinocyte associated protein 2	1	155169408-155173475	Predicted membrane proteins	Evidence at protein level						Renal cancer:9.70e-11 (unfavourable)	Expressed in all	Expressed in all			epididymis: 241.8	Expressed in all		
KRTCAP3	KCP3	ENSG00000157992	Keratinocyte associated protein 3	2	27442366-27446481	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047136, HPA060203	Enhanced		Approved	Nucleus<br>Cytosol	Breast cancer:2.67e-5 (favourable)	Expressed in all	Mixed			small intestine: 34.8	Cell line enhanced		A-431: 53.9;CAPAN-2: 60.3;SCLC-21H: 37.2
KTN1	CG1, KIAA0004, KNT	ENSG00000126777	Kinectin 1	14	55559072-55701526	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003178, CAB015331, HPA017876	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:1.01e-6 (favourable), Head and neck cancer:6.83e-5 (unfavourable), Liver cancer:3.76e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 268.4	Expressed in all		
L1CAM	CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1	ENSG00000198910	L1 cell adhesion molecule	X	153861514-153909223	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010896	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Endometrial cancer:8.51e-10 (unfavourable), Lung cancer:2.36e-6 (unfavourable), Renal cancer:1.17e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 36.0;cerebral cortex: 66.9	seminal vesicle: 12.8	Cell line enhanced		BJ hTERT+: 303.8;BJ hTERT+ SV40 Large T+ RasG12V: 195.5;HeLa: 182.1
LAG3	CD223	ENSG00000089692	Lymphocyte activating 3	12	6772512-6778455	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002301, HPA013967	Enhanced				Renal cancer:4.62e-11 (unfavourable), Cervical cancer:3.89e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 32.0	lymph node: 17.6	Cell line enriched	140	HDLM-2: 136.0
LAIR1	CD305	ENSG00000167613	Leukocyte associated immunoglobulin like receptor 1	19	54351384-54370558	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011155	Enhanced		Supported	Plasma membrane	Renal cancer:5.01e-5 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 7.1	appendix: 4.2	Cell line enhanced		HMC-1: 6.6;Karpas-707: 14.1;THP-1: 15.4
LAMP1	CD107a	ENSG00000185896	Lysosomal associated membrane protein 1	13	113297241-113323672	CD markers, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB004260, HPA014750	Enhanced				Renal cancer:4.15e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 211.6	Expressed in all		
LAMP2	CD107b	ENSG00000005893	Lysosomal associated membrane protein 2	X	120427827-120469365	CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB005272, HPA029100	Enhanced					Expressed in all	Expressed in all			gallbladder: 223.2	Expressed in all		
LAMP3	CD208, DC-LAMP, DCLAMP, LAMP, TSC403	ENSG00000078081	Lysosomal associated membrane protein 3	3	183122213-183163839	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025133, HPA051467	Enhanced		Enhanced	Vesicles	Renal cancer:1.89e-7 (unfavourable), Ovarian cancer:9.90e-4 (favourable)	Mixed	Tissue enriched	7	lung: 319.3	appendix: 44.9	Group enriched	8	EFO-21: 154.0;HDLM-2: 40.5;HHSteC: 50.0;hTCEpi: 40.3
LAMP5	BAD-LAMP, C20orf103, dJ1119D9.3, UNC-46	ENSG00000125869	Lysosomal associated membrane protein family member 5	20	9514358-9530524	Predicted membrane proteins	Evidence at protein level	HPA004802, HPA070765	Uncertain		Approved	Mitotic spindle<br>Microtubule organizing center<br>Cytosol	Renal cancer:6.46e-6 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 44.9;ovary: 24.6	fallopian tube: 14.9	Group enriched	9	Karpas-707: 298.2;SH-SY5Y: 80.2;THP-1: 100.4
LAPTM4A	HUMORF13, KIAA0108, LAPTM4, MBNT, Mtrp	ENSG00000068697	Lysosomal protein transmembrane 4 alpha	2	20032650-20052028	Predicted membrane proteins	Evidence at protein level	HPA031402, HPA031404, HPA068554	Approved		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane	Pancreatic cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 635.0	Expressed in all		
LAPTM4B	LC27	ENSG00000104341	Lysosomal protein transmembrane 4 beta	8	97775057-97853013	Predicted membrane proteins, Transporters	Evidence at protein level	CAB020782, HPA068830	Uncertain		Approved	Golgi apparatus	Liver cancer:2.70e-6 (unfavourable), Breast cancer:5.63e-4 (unfavourable), Head and neck cancer:5.70e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 133.2	Mixed		
LAPTM5		ENSG00000162511	Lysosomal protein transmembrane 5	1	30732469-30757820	Predicted membrane proteins, Transporters	Evidence at protein level	HPA051293	Approved		Approved	Cytosol	Renal cancer:5.89e-5 (unfavourable), Cervical cancer:3.40e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 799.7	Cell line enhanced		HEL: 921.8;HMC-1: 2049.8;REH: 698.6;U-698: 604.9
LARP4B	KIAA0217, LARP5	ENSG00000107929	La ribonucleoprotein domain family member 4B	10	806914-931705	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036566, HPA042738	Approved		Enhanced	Cytosol	Liver cancer:1.70e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 38.1	Expressed in all		
LAT	LAT1	ENSG00000213658	Linker for activation of T-cells	16	28984826-28990783	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB002223, HPA011157, CAB012978	Enhanced		Supported	Golgi apparatus<br>Plasma membrane		Not detected	Tissue enhanced		lymph node: 75.3	appendix: 31.8	Group enriched	8	HEL: 173.8;HMC-1: 690.0;MOLT-4: 227.5
LAX1	FLJ20340, LAX	ENSG00000122188	Lymphocyte transmembrane adaptor 1	1	203765176-203776233	Predicted membrane proteins	Evidence at protein level	HPA002461, HPA003887, CAB025358	Enhanced		Enhanced	Golgi apparatus<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		tonsil: 15.3	lymph node: 10.3	Cell line enhanced		Karpas-707: 14.1;U-266/70: 18.2;U-266/84: 40.4;U-698: 14.6
LAYN	FLJ30977, FLJ31092	ENSG00000204381	Layilin	11	111540280-111561745	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040087	Approved		Approved	Cytosol		Expressed in all	Mixed			ovary: 49.6	Cell line enhanced		BJ: 126.5;BJ hTERT+: 131.6;BJ hTERT+ SV40 Large T+ RasG12V: 98.0;U-138 MG: 107.5
LBR	DHCR14B, TDRD18	ENSG00000143815	Lamin B receptor	1	225401502-225428925	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049840, HPA062236	Enhanced		Enhanced	Nuclear membrane	Liver cancer:7.30e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 98.6	Expressed in all		
LCLAT1	AGPAT8, ALCAT1, FLJ37965, LYCAT	ENSG00000172954	Lysocardiolipin acyltransferase 1	2	30447226-30644225	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA031880, HPA049217	Uncertain		Supported	Endoplasmic reticulum<br>Cytosol	Liver cancer:8.72e-4 (unfavourable), Head and neck cancer:9.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 18.8	Expressed in all		
LCT		ENSG00000115850	Lactase	2	135787840-135837180	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Group enriched	631	duodenum: 223.1;small intestine: 142.8	appendix,lymph node: 0.2	Cell line enhanced		MOLT-4: 3.9;RPMI-8226: 6.7
LCTL	FLJ33279, KLG, KLPH	ENSG00000188501	Lactase like	15	66547179-66565979	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA071640			Approved	Endoplasmic reticulum<br>Plasma membrane		Group enriched	Mixed			cerebral cortex: 1.0	Cell line enhanced		EFO-21: 5.3;NTERA-2: 5.2;U-2 OS: 15.2;U-251 MG: 5.3
LDAH	C2orf43, FLJ21820	ENSG00000118961	Lipid droplet associated hydrolase	2	20684014-20823130	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034729, HPA034730	Approved		Uncertain	Nuclear speckles<br>Cytosol	Liver cancer:6.09e-6 (unfavourable), Renal cancer:1.18e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 20.6	Mixed		
LDLR	LDLCQ2	ENSG00000130164	Low density lipoprotein receptor	19	11089362-11133816	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009647, HPA013159	Approved				Pancreatic cancer:6.60e-5 (unfavourable), Urothelial cancer:3.43e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 87.6	Expressed in all		
LDLRAD1		ENSG00000203985	Low density lipoprotein receptor class A domain containing 1	1	54007299-54018186	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052489	Enhanced		Uncertain	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:9.21e-4 (favourable)	Tissue enhanced	Tissue enriched	22	fallopian tube: 256.4	lung: 11.7	Cell line enhanced		CAPAN-2: 2.2;Hep G2: 7.0
LDLRAD3	LRAD3	ENSG00000179241	Low density lipoprotein receptor class A domain containing 3	11	35943981-36232136	Predicted membrane proteins	Evidence at protein level	HPA038251	Approved		Supported	Cell Junctions	Renal cancer:5.05e-8 (unfavourable), Lung cancer:9.34e-6 (unfavourable), Urothelial cancer:2.14e-5 (unfavourable), Cervical cancer:2.24e-4 (unfavourable)	Expressed in all	Mixed			breast: 23.0	Mixed		
LDLRAD4	C18orf1	ENSG00000168675	Low density lipoprotein receptor class A domain containing 4	18	13217498-13652755	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047633, HPA054556, HPA065246	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:4.58e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 27.5	Cell line enhanced		HEL: 34.2;MOLT-4: 94.8;REH: 32.0
LEMD1	CT50, LEMP-1	ENSG00000186007	LEM domain containing 1	1	205381378-205457091	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA045425			Approved	Nucleoli<br>Cytosol	Ovarian cancer:1.26e-4 (favourable), Pancreatic cancer:1.70e-4 (unfavourable)	Tissue enhanced	Group enriched	16	epididymis: 18.1;testis: 71.4	fallopian tube: 2.7	Group enriched	6	CAPAN-2: 34.9;NTERA-2: 7.0
LEMD2	dJ482C21.1, NET25	ENSG00000161904	LEM domain containing 2	6	33771202-33789136	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017340	Supported		Enhanced	Nuclear membrane	Renal cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 69.8	Expressed in all		
LEMD3	MAN1	ENSG00000174106	LEM domain containing 3	12	65169571-65248327	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA025078, HPA076986	Uncertain		Supported	Nuclear membrane	Renal cancer:2.30e-4 (favourable)	Expressed in all	Expressed in all			testis: 28.9	Expressed in all		
LENG8	KIAA1932, MGC40108, pp13842	ENSG00000167615	Leukocyte receptor cluster member 8	19	54448887-54462037	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042004, HPA042056, HPA061571	Uncertain		Supported	Nucleus	Renal cancer:3.30e-7 (unfavourable), Urothelial cancer:2.73e-6 (favourable), Head and neck cancer:7.59e-4 (favourable)	Expressed in all	Expressed in all			spleen: 165.7	Expressed in all		
LEPR	CD295, OBR	ENSG00000116678	Leptin receptor	1	65420652-65641559	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA030899	Approved		Approved	Vesicles		Tissue enriched	Mixed			liver: 67.9	Cell line enhanced		K-562: 102.4;RPTEC TERT1: 39.6
LEPROT	FLJ90360, OB-RGRP, OBRGRP, VPS55	ENSG00000213625	Leptin receptor overlapping transcript	1	65420587-65436007	Predicted membrane proteins	Evidence at protein level	HPA069444			Approved	Centrosome		Expressed in all	Expressed in all			placenta: 80.3	Expressed in all		
LEPROTL1	my047, Vps55	ENSG00000104660	Leptin receptor overlapping transcript-like 1	8	30095398-30177208	Predicted membrane proteins	Evidence at protein level	HPA047911	Uncertain				Renal cancer:1.94e-5 (unfavourable), Colorectal cancer:9.04e-4 (favourable)	Expressed in all	Expressed in all			placenta: 120.0	Expressed in all		
LETM1		ENSG00000168924	Leucine zipper and EF-hand containing transmembrane protein 1	4	1811479-1856247	Predicted membrane proteins, Transporters	Evidence at protein level	HPA011029, HPA011100	Enhanced		Enhanced	Mitochondria	Prostate cancer:1.77e-4 (unfavourable), Liver cancer:1.79e-4 (unfavourable), Renal cancer:8.90e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 16.3	Expressed in all		
LETM2	FLJ25409	ENSG00000165046	Leucine zipper and EF-hand containing transmembrane protein 2	8	38386207-38409527	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA025032	Approved		Approved	Nucleus<br>Nuclear bodies<br>Cytosol		Mixed	Tissue enriched	9	testis: 39.5	cerebral cortex: 4.2	Mixed		
LETMD1	HCCR, HCCR-1, HCCR-2, HCCR1, HCCR2	ENSG00000050426	LETM1 domain containing 1	12	51047962-51060424	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA074361			Supported	Nucleoplasm<br>Mitochondria	Urothelial cancer:3.16e-4 (favourable), Renal cancer:3.26e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 61.7	Expressed in all		
LGR4	GPR48	ENSG00000205213	Leucine rich repeat containing G protein-coupled receptor 4	11	27365961-27472775	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030267, HPA054350	Uncertain		Approved	Microtubule organizing center	Renal cancer:2.00e-7 (favourable)	Expressed in all	Expressed in all			kidney: 56.2	Cell line enhanced		HAP1: 86.6
LGR5	FEX, GPR49, GPR67, HG38	ENSG00000139292	Leucine rich repeat containing G protein-coupled receptor 5	12	71439770-71586310	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA012530	Approved				Lung cancer:5.09e-4 (favourable)	Group enriched	Tissue enhanced		fallopian tube: 26.6;placenta: 26.9	seminal vesicle: 9.8	Group enriched	6	Hep G2: 25.0;SH-SY5Y: 110.2
LGR6	FLJ14471	ENSG00000133067	Leucine rich repeat containing G protein-coupled receptor 6	1	202193901-202319781	G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008556	Approved		Approved	Nucleoplasm<br>Plasma membrane	Glioma:2.00e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 14.3	gallbladder: 9.6	Cell line enhanced		A549: 15.6;CAPAN-2: 13.4;HaCaT: 7.3
LHCGR	HHG, LCGR, LGR2, LHR, ULG5	ENSG00000138039	Luteinizing hormone/choriogonadotropin receptor	2	48686775-48755730	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009814	Uncertain					Not detected	Tissue enhanced		ovary: 1.6;testis: 4.3	adipose tissue: 1.3	Not detected		
LHFP	MGC22429	ENSG00000183722	Lipoma HMGIC fusion partner	13	39342892-39603528	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA058975	Approved		Approved	Nucleoli	Renal cancer:1.20e-7 (unfavourable), Urothelial cancer:2.30e-4 (unfavourable)	Expressed in all	Mixed			placenta: 196.1	Cell line enhanced		ASC diff: 177.4;HSkMC: 137.4
LHFPL1		ENSG00000182508	Lipoma HMGIC fusion partner-like 1	X	112630648-112680054	Predicted membrane proteins	Evidence at transcript level	HPA003029	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 1.8	seminal vesicle: 1.3	Cell line enhanced		SK-MEL-30: 1.9
LHFPL2	KIAA0206	ENSG00000145685	Lipoma HMGIC fusion partner-like 2	5	78485215-78770021	Predicted membrane proteins	Evidence at protein level	HPA042402	Uncertain		Approved	Vesicles<br>Actin filaments	Renal cancer:3.45e-7 (unfavourable), Liver cancer:2.73e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 36.4	Mixed		
LHFPL3	LHFPL4	ENSG00000187416	Lipoma HMGIC fusion partner-like 3	7	104328656-104907232	Predicted membrane proteins	Evidence at transcript level	HPA069691			Approved	Vesicles		Tissue enriched	Tissue enriched	10	cerebral cortex: 48.7	cervix, uterine: 4.6	Cell line enhanced		SCLC-21H: 1.8;SH-SY5Y: 2.1;SK-BR-3: 1.3
LHFPL4		ENSG00000156959	Lipoma HMGIC fusion partner-like 4	3	9498361-9553802	Predicted membrane proteins	Evidence at protein level	HPA041421	Uncertain		Approved	Nucleus<br>Golgi apparatus		Group enriched	Tissue enriched	9	cerebral cortex: 23.1	adrenal gland: 2.6	Cell line enhanced		NTERA-2: 4.4;SCLC-21H: 11.9;SH-SY5Y: 13.4;U-266/84: 7.9;WM-115: 3.9
LHFPL5	DFNB67, dJ510O8.8, MGC33835, Tmhs	ENSG00000197753	Lipoma HMGIC fusion partner-like 5	6	35805293-35833874	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA055110	Uncertain					Not detected	Tissue enhanced		epididymis: 10.8	bone marrow: 4.2	Mixed		
LIFR	CD118	ENSG00000113594	Leukemia inhibitory factor receptor alpha	5	38474963-38608354	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004478, CAB010252	Approved		Approved	Nuclear speckles<br>Golgi apparatus	Renal cancer:1.40e-7 (favourable), Lung cancer:1.92e-4 (favourable)	Mixed	Mixed			thyroid gland: 68.0	Cell line enhanced		AF22: 93.6;SCLC-21H: 72.8
LILRA1	CD85i, LIR-6, LIR6	ENSG00000104974	Leukocyte immunoglobulin like receptor A1	19	54593582-54602090	CD markers, Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			appendix: 0.8	Not detected		
LILRA2	CD85h, ILT1, LIR-7, LIR7	ENSG00000239998	Leukocyte immunoglobulin like receptor A2	19	54572920-54590287	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 9.9;spleen: 7.0	appendix: 4.0	Cell line enhanced		REH: 1.8;THP-1: 2.7;U-937: 7.1
LILRA4	CD85g, ILT7	ENSG00000239961	Leukocyte immunoglobulin like receptor A4	19	54333185-54339150	CD markers, Predicted membrane proteins	Evidence at protein level	HPA049418	Approved					Mixed	Tissue enhanced		spleen: 2.1;tonsil: 2.5	lymph node: 0.9	Not detected		
LILRA5	CD85, CD85f, ILT11, LILRB7, LIR9	ENSG00000187116	Leukocyte immunoglobulin like receptor A5	19	54307070-54313139	CD markers, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.78e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 13.9;bone marrow: 10.3;spleen: 7.5	urinary bladder: 2.4	Not detected		
LILRA6	CD85b, ILT8, LILRB6	ENSG00000244482	Leukocyte immunoglobulin like receptor A6	19	54236592-54242791	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		adipose tissue: 1.9;appendix: 1.9;smooth muscle: 1.9;spleen: 1.9	bone marrow: 1.0	Not detected		
LILRB1	CD85, CD85j, ILT2, LIR-1, LIR1, MIR-7, PIR-B, PIRB	ENSG00000104972	Leukocyte immunoglobulin like receptor B1	19	54617158-54637528	Predicted membrane proteins	Evidence at transcript level						Renal cancer:3.08e-6 (unfavourable)	Mixed	Tissue enhanced		appendix: 8.6;lymph node: 6.2;spleen: 9.9	smooth muscle: 3.7	Group enriched	17	Daudi: 4.0;THP-1: 1.9
LILRB2	CD85d, ILT4, LIR-2, LIR2, MIR-10, MIR10	ENSG00000131042	Leukocyte immunoglobulin like receptor B2	19	54273821-54281184	CD markers, Predicted membrane proteins	Evidence at protein level						Renal cancer:5.45e-7 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 8.7;bone marrow: 20.5;spleen: 10.4	lung: 3.9	Not detected		
LILRB3	CD85a, HL9, ILT5, LIR-3, LIR3, PIR-B, PIRB	ENSG00000204577	Leukocyte immunoglobulin like receptor B3	19	54216278-54223506	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Group enriched	5	adipose tissue: 5.4;appendix: 11.3;bone marrow: 9.9;lung: 9.2;spleen: 11.1;urinary bladder: 6.8	placenta: 1.7	Not detected		
LILRB4	CD85k, HM18, ILT3, LIR-5, LIR5	ENSG00000186818	Leukocyte immunoglobulin like receptor B4	19	54643889-54670359	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052807	Approved					Expressed in all	Tissue enhanced		appendix: 14.6;lymph node: 13.4	lung: 8.3	Cell line enriched	33	Karpas-707: 293.0
LILRB5	CD85c, LIR-8, LIR8	ENSG00000105609	Leukocyte immunoglobulin like receptor B5	19	54249431-54257301	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA012069	Approved					Mixed	Tissue enhanced		spleen: 26.1	adipose tissue: 11.4	Not detected		
LIM2	MP17, MP19	ENSG00000105370	Lens intrinsic membrane protein 2	19	51379909-51387960	Disease related genes, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Not detected			testis: 0.4	Not detected		
LINC00116	NCRNA00116	ENSG00000175701	Long intergenic non-protein coding RNA 116	2	110211529-110245420	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			skeletal muscle: 257.6	Mixed		
LINC00282	FLJ37307, NCRNA00282	ENSG00000281106	Long intergenic non-protein coding RNA 282	13	51813347-51845175	Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			lymph node: 3.3	Cell line enhanced		BEWO: 1.0;SK-MEL-30: 2.7
LINC00493	LOC388789	ENSG00000232388	Long intergenic non-protein coding RNA 493	20	18567347-18569563	Predicted membrane proteins	Evidence at transcript level	HPA068733			Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:7.84e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 157.9	Expressed in all		
LINC00672		ENSG00000263874	Long intergenic non-protein coding RNA 672	17	38925168-38929384	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	6	cerebral cortex: 20.1	endometrium: 3.3	Cell line enhanced		NTERA-2: 6.4
LINC00675		ENSG00000263429	Long intergenic non-protein coding RNA 675	17	10794913-10804099	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		colon: 36.9;rectum: 40.8;stomach: 44.3	duodenum,small intestine: 18.3	Cell line enriched	8	RT4: 3.2
LINC00890		ENSG00000260802	Long intergenic non-protein coding RNA 890	X	111511662-111522399	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		endometrium: 44.1;epididymis: 51.0;seminal vesicle: 107.2	prostate: 15.9	Cell line enhanced		HMC-1: 14.8;NTERA-2: 2.9;SCLC-21H: 3.3
LINC00998		ENSG00000214194	Long intergenic non-protein coding RNA 998	7	113116718-113118613	Predicted membrane proteins	Evidence at transcript level						Liver cancer:1.02e-4 (unfavourable), Renal cancer:7.21e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 123.3	Mixed		
LINC01125		ENSG00000228486	Long intergenic non-protein coding RNA 1125	2	97664217-97703064	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 11.7	skin: 2.4	Cell line enhanced		AF22: 1.7;HDLM-2: 1.8
LINC01314		ENSG00000259417	Long intergenic non-protein coding RNA 1314	15	80195484-80252213	Predicted membrane proteins	Evidence at transcript level							Group enriched	Tissue enhanced		cerebral cortex: 5.7;epididymis: 6.6	liver: 4.8	Group enriched	7	SK-MEL-30: 1.2;WM-115: 4.7
LINC02210-CRHR1		ENSG00000263715	LINC02210-CRHR1 readthrough	17	45620344-45835826	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	9	cerebral cortex: 1.1	fallopian tube: 0.1	Not detected		
LINGO1	FLJ14594, LERN1, LRRN6A	ENSG00000169783	Leucine rich repeat and Ig domain containing 1	15	77613027-77820900	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074653	Enhanced		Approved	Plasma membrane	Renal cancer:3.23e-7 (unfavourable)	Expressed in all	Tissue enriched	13	cerebral cortex: 130.8	placenta: 9.8	Cell line enhanced		AF22: 23.6;AN3-CA: 18.6;HAP1: 31.4;HEK93: 19.6;NTERA-2: 56.8
LINGO2	LERN3, LRRN6C	ENSG00000174482	Leucine rich repeat and Ig domain containing 2	9	27948078-28670286	Predicted membrane proteins	Evidence at transcript level	HPA016633, CAB025361	Approved					Mixed	Tissue enhanced		endometrium: 11.9;smooth muscle: 12.9	thyroid gland: 5.0	Cell line enhanced		AN3-CA: 2.0;SH-SY5Y: 9.6;WM-115: 4.0
LINGO3	LERN2, LRRN6B	ENSG00000220008	Leucine rich repeat and Ig domain containing 3	19	2289784-2292024	Predicted membrane proteins	Evidence at protein level	HPA043781, HPA055932, HPA059558	Uncertain		Approved	Mitochondria		Tissue enhanced	Tissue enhanced		appendix: 1.6;cerebral cortex: 1.6;spleen: 3.7	lymph node: 1.2	Group enriched	6	HMC-1: 15.2;RPMI-8226: 3.0
LINGO4	LRRN6D	ENSG00000213171	Leucine rich repeat and Ig domain containing 4	1	151800264-151806154	Predicted membrane proteins	Evidence at transcript level	HPA060781	Uncertain					Mixed	Tissue enhanced		adrenal gland: 2.2;skeletal muscle: 4.1	fallopian tube,prostate: 1.0	Not detected		
LITAF	FLJ38636, PIG7, SIMPLE, TP53I7	ENSG00000189067	Lipopolysaccharide induced TNF factor	16	11547722-11636381	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006960	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Glioma:1.78e-4 (unfavourable), Testis cancer:6.25e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 225.8	Mixed		
LLNLR-275H8.1		ENSG00000283758		19	35586260-35587296	Predicted membrane proteins	Evidence at transcript level								Tissue enriched	17	testis: 1.7	all non-specific tissues: 0.0	Not detected		
LMAN1	ERGIC-53, ERGIC53, F5F8D, FMFD1, gp58, MCFD1, MR60	ENSG00000074695	Lectin, mannose binding 1	18	59327823-59359962	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA002320, CAB037163	Supported		Uncertain	Cytosol		Expressed in all	Expressed in all			thyroid gland: 125.2	Expressed in all		
LMAN1L	ERGIC-53L, ERGL	ENSG00000140506	Lectin, mannose binding 1 like	15	74812716-74825758	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		prostate: 91.3;spleen: 31.7	heart muscle: 12.7	Not detected		
LMAN2	C5orf8, GP36B, VIP36	ENSG00000169223	Lectin, mannose binding 2	5	177331562-177351852	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003927	Approved				Renal cancer:8.53e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 164.8	Expressed in all		
LMAN2L	DKFZp564L2423, VIPL	ENSG00000114988	Lectin, mannose binding 2 like	2	96705929-96740064	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA026600	Approved					Expressed in all	Mixed			fallopian tube: 28.0	Expressed in all		
LMBR1	ACHP, C7orf2, FLJ11665, ZRS	ENSG00000105983	Limb development membrane protein 1	7	156668946-156893230	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016592	Approved		Approved	Cytosol	Renal cancer:1.44e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.3	Expressed in all		
LMBR1L	FLJ10494, KIAA1174	ENSG00000139636	Limb development membrane protein 1 like	12	49096551-49110900	Predicted membrane proteins	Evidence at protein level						Renal cancer:4.45e-7 (unfavourable), Colorectal cancer:1.04e-4 (unfavourable), Pancreatic cancer:3.50e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 27.9	endometrium: 9.1	Expressed in all		
LMBRD1	bA810I22.1, C6orf209, cblF, FLJ11240	ENSG00000168216	LMBR1 domain containing 1	6	69675802-69797111	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019547	Uncertain				Renal cancer:1.07e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 173.4	Expressed in all		
LMBRD2	DKFZp434H2226	ENSG00000164187	LMBR1 domain containing 2	5	36098412-36151961	Predicted membrane proteins	Evidence at protein level	HPA012165	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 25.4	Mixed		
LMF1	C16orf26, FLJ12681, FLJ22302, JFP11, TMEM112, TMEM112A	ENSG00000103227	Lipase maturation factor 1	16	853634-981318	Disease related genes, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.95e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.2	Mixed		
LMF2	TMEM112B, TMEM153	ENSG00000100258	Lipase maturation factor 2	22	50502949-50507691	Predicted membrane proteins	Evidence at protein level	HPA062626	Approved		Approved	Centrosome	Cervical cancer:3.47e-4 (favourable)	Expressed in all	Expressed in all			pancreas: 38.1	Expressed in all		
LMLN	Gp63, Msp	ENSG00000185621	Leishmanolysin like peptidase	3	197960200-198043720	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016481, HPA028844	Uncertain		Supported	Focal adhesion sites<br>Cytosol	Endometrial cancer:6.77e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 18.6	epididymis: 13.0	Mixed		
LMO7	FBX20, FBXO20, KIAA0858	ENSG00000136153	LIM domain 7	13	75620434-75859870	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020923, HPA050184	Approved		Supported	Actin filaments<br>Cytosol	Renal cancer:7.75e-12 (favourable), Pancreatic cancer:3.51e-4 (unfavourable), Endometrial cancer:5.12e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 269.4	Cell line enhanced		fHDF/TERT166: 440.3;LHCN-M2: 438.5
LMTK2	AATYK2, BREK, cprk, KIAA1079, KPI-2, KPI2, LMR2, PPP1R100	ENSG00000164715	Lemur tyrosine kinase 2	7	98106885-98209633	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA010657, HPA041836	Uncertain		Approved	Nuclear speckles<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.12e-7 (favourable), Ovarian cancer:8.03e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 27.9	Expressed in all		
LMTK3	KIAA1883, LMR3, PPP1R101, TYKLM3	ENSG00000142235	Lemur tyrosine kinase 3	19	48485271-48513189	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA040203, HPA077070	Enhanced		Approved	Nucleoplasm<br>Cell Junctions	Renal cancer:3.18e-8 (favourable)	Mixed	Group enriched	6	cerebral cortex: 20.3;parathyroid gland: 4.9	duodenum: 2.2	Cell line enhanced		HMC-1: 6.1;SK-BR-3: 6.2;U-266/70: 5.9
LNPEP	CAP, IRAP, P-LAP, PLAP	ENSG00000113441	Leucyl and cystinyl aminopeptidase	5	96935394-97037515	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA043642	Approved					Expressed in all	Mixed			parathyroid gland: 23.3	Expressed in all		
LNPK	KIAA1715, LNP, LNP1, Ul	ENSG00000144320	Lunapark, ER junction formation factor	2	175923892-176002839	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014205	Approved		Supported	Nucleoplasm<br>Endoplasmic reticulum		Expressed in all	Expressed in all			testis: 44.7	Expressed in all		
LPAR1	edg-2, EDG2, Gpcr26, GPR26, LPA1, Mrec1.3, rec.1.3, vzg-1	ENSG00000198121	Lysophosphatidic acid receptor 1	9	110873263-111038458	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA050667			Approved	Nuclear speckles<br>Plasma membrane		Expressed in all	Mixed			cervix, uterine: 91.5	Cell line enhanced		ASC diff: 399.3;ASC TERT1: 236.2;BJ hTERT+: 345.8
LPAR2	EDG-4, EDG4, LPA2	ENSG00000064547	Lysophosphatidic acid receptor 2	19	19623668-19628930	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019616	Approved				Renal cancer:1.61e-7 (unfavourable), Stomach cancer:1.43e-4 (favourable)	Expressed in all	Mixed			testis: 40.7	Cell line enhanced		HMC-1: 64.8
LPAR3	Edg-7, EDG7, HOFNH30, LP-A3, LPA3, RP4-678I3	ENSG00000171517	Lysophosphatidic acid receptor 3	1	84811602-84893213	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013421			Supported	Plasma membrane	Ovarian cancer:4.31e-5 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 66.9	prostate: 23.3	Cell line enhanced		HAP1: 22.1;HBEC3-KT: 18.9;hTCEpi: 20.1;NTERA-2: 23.5;PC-3: 24.6;SK-MEL-30: 19.8
LPAR4	GPR23, LPA4, P2RY9, P2Y5-LIKE, P2Y9	ENSG00000147145	Lysophosphatidic acid receptor 4	X	78747709-78757094	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046563, HPA054951, HPA055571	Uncertain		Supported	Nuclear bodies<br>Vesicles<br>Plasma membrane		Tissue enhanced	Tissue enhanced		ovary: 4.5	cerebral cortex: 2.2	Cell line enhanced		AF22: 9.2;NTERA-2: 15.2;RH-30: 6.2
LPAR5	GPR92, GPR93, KPG_010, LPA5	ENSG00000184574	Lysophosphatidic acid receptor 5	12	6618835-6636447	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013170	Approved				Thyroid cancer:6.56e-5 (favourable)	Mixed	Mixed			tonsil: 10.6	Cell line enhanced		HEL: 16.4;HMC-1: 22.4;K-562: 12.4
LPAR6	P2RY5, P2Y5	ENSG00000139679	Lysophosphatidic acid receptor 6	13	48389567-48444704	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA028934, HPA076273	Approved		Supported	Vesicles<br>Plasma membrane	Renal cancer:3.60e-4 (unfavourable), Lung cancer:6.22e-4 (favourable)	Expressed in all	Expressed in all			placenta: 100.9	Cell line enhanced		AF22: 19.1;HUVEC TERT2: 26.4
LPCAT1	AGPAT10, AGPAT9, AYTL2, FLJ12443	ENSG00000153395	Lysophosphatidylcholine acyltransferase 1	5	1456480-1523977	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA012501, HPA022268	Enhanced		Supported	Endoplasmic reticulum<br>Lipid droplets	Liver cancer:1.88e-8 (unfavourable), Renal cancer:2.64e-7 (unfavourable), Pancreatic cancer:4.90e-5 (favourable), Cervical cancer:7.11e-5 (unfavourable), Endometrial cancer:3.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 19.0;spleen: 14.7	cerebral cortex: 4.4	Cell line enhanced		BEWO: 80.0;EFO-21: 74.7;PC-3: 52.0
LPCAT2	AGPAT11, AYTL1, FLJ20481, LysoPAFAT	ENSG00000087253	Lysophosphatidylcholine acyltransferase 2	16	55508998-55586670	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007891, HPA008433	Enhanced	Supported	Enhanced	Endoplasmic reticulum<br>Lipid droplets	Endometrial cancer:8.03e-6 (favourable), Colorectal cancer:3.43e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 142.6	bone marrow: 56.4	Cell line enhanced		CAPAN-2: 100.9;HMC-1: 141.4;WM-115: 114.8
LPCAT3	C3F, MBOAT5, nessy, OACT5	ENSG00000111684	Lysophosphatidylcholine acyltransferase 3	12	6976186-7018510	Enzymes, Predicted membrane proteins	Evidence at protein level						Renal cancer:4.89e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 123.0	Expressed in all		
LPCAT4	AGPAT7, AYTL3, FLJ10257, LPAAT-eta, LPEAT2	ENSG00000176454	Lysophosphatidylcholine acyltransferase 4	15	34358618-34367278	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030719	Uncertain				Liver cancer:9.99e-4 (unfavourable)	Expressed in all	Mixed			rectum: 38.6	Expressed in all		
LPGAT1	FAM34A, FAM34A1, KIAA0205, NET8	ENSG00000123684	Lysophosphatidylglycerol acyltransferase 1	1	211743457-211830772	Predicted membrane proteins	Evidence at protein level	HPA008304	Approved					Expressed in all	Expressed in all			thyroid gland: 43.1	Mixed		
LRAT	LCA14	ENSG00000121207	Lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase)	4	154626945-154753118	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA070726			Uncertain	Endoplasmic reticulum<br>Golgi apparatus		Mixed	Tissue enhanced		thyroid gland: 2.3	testis: 1.6	Cell line enriched	11	NTERA-2: 11.7
LRBA	BGL, CDC4L, LAB300, LBA	ENSG00000198589	LPS responsive beige-like anchor protein	4	150264531-151015727	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019366, HPA023597	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:2.22e-16 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 62.7	Expressed in all		
LRCH1	CHDC1, KIAA1016	ENSG00000136141	Leucine rich repeats and calponin homology domain containing 1	13	46553168-46753040	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021536	Uncertain		Approved	Nucleoli<br>Actin filaments<br>Cytosol	Renal cancer:1.04e-4 (favourable), Ovarian cancer:5.75e-4 (unfavourable), Cervical cancer:6.24e-4 (unfavourable), Lung cancer:6.67e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 26.8	Expressed in all		
LRCH3	MGC4126	ENSG00000186001	Leucine rich repeats and calponin homology domain containing 3	3	197791226-197888436	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012380, HPA017299	Uncertain		Enhanced	Cytosol	Liver cancer:2.95e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 26.2	Expressed in all		
LRCH4	LRN, LRRN1	ENSG00000077454	Leucine rich repeats and calponin homology domain containing 4	7	100574011-100586153	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037667, HPA037668	Enhanced		Approved	Nucleoplasm<br>Focal adhesion sites<br>Cytosol	Colorectal cancer:1.61e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 105.8	Expressed in all		
LRFN1	KIAA1484, SALM2	ENSG00000128011	Leucine rich repeat and fibronectin type III domain containing 1	19	39306568-39315336	Predicted membrane proteins	Evidence at protein level						Endometrial cancer:3.31e-5 (unfavourable), Ovarian cancer:3.13e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 5.5	spleen: 2.2	Cell line enhanced		CACO-2: 14.4;HEK93: 19.2
LRFN2	FIGLER2, KIAA1246, SALM1	ENSG00000156564	Leucine rich repeat and fibronectin type III domain containing 2	6	40391586-40587465	Predicted membrane proteins	Evidence at protein level	HPA076660	Enhanced		Supported	Vesicles		Not detected	Tissue enriched	5	cerebral cortex: 6.8	testis: 1.3	Cell line enhanced		REH: 1.5;SH-SY5Y: 5.0
LRFN3	FIGLER1, MGC2656, SALM4	ENSG00000126243	Leucine rich repeat and fibronectin type III domain containing 3	19	35935358-35945767	Predicted membrane proteins	Evidence at transcript level	HPA048923	Approved				Renal cancer:8.46e-7 (favourable)	Expressed in all	Mixed			cerebral cortex: 8.2	Mixed		
LRFN4	FIGLER6, MGC3103, SALM3.	ENSG00000173621	Leucine rich repeat and fibronectin type III domain containing 4	11	66856647-66860475	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Mixed			cerebral cortex: 13.3	Mixed		
LRFN5	C14orf146, FIGLER8, SALM5	ENSG00000165379	Leucine rich repeat and fibronectin type III domain containing 5	14	41607570-41904549	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001177	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 52.3	cervix, uterine: 16.8	Cell line enhanced		AN3-CA: 16.8;RPTEC TERT1: 4.6;SCLC-21H: 11.1;U-138 MG: 11.4
LRIG1	DKFZP586O1624, LIG-1, LIG1	ENSG00000144749	Leucine rich repeats and immunoglobulin like domains 1	3	66378797-66501263	Predicted membrane proteins	Evidence at protein level	HPA011846	Approved		Approved	Cytosol	Lung cancer:3.01e-5 (favourable), Urothelial cancer:1.50e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 59.6	Cell line enhanced		Daudi: 28.6;hTEC/SVTERT24-B: 30.3
LRIG2	KIAA0806	ENSG00000198799	Leucine rich repeats and immunoglobulin like domains 2	1	113073209-113132260	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA015538	Uncertain		Approved	Nucleus<br>Golgi apparatus	Endometrial cancer:9.37e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland,thyroid gland: 5.6	Mixed		
LRIG3	FLJ90440, KIAA3016	ENSG00000139263	Leucine rich repeats and immunoglobulin like domains 3	12	58872149-58920522	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010773	Approved		Approved	Cytosol		Expressed in all	Tissue enhanced		thyroid gland: 97.8	skin: 33.0	Mixed		
LRIT1	DKFZP434K091, FIGLER9, LRRC21, PAL	ENSG00000148602	Leucine rich repeat, Ig-like and transmembrane domains 1	10	84231593-84241461	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	69	testis: 6.8	all non-specific tissues: 0.0	Not detected		
LRIT2	AC022389.4, LRRC22	ENSG00000204033	Leucine rich repeat, Ig-like and transmembrane domains 2	10	84220495-84225589	Predicted membrane proteins	Evidence at protein level	HPA037788	Supported					Not detected	Group enriched	11	cerebral cortex: 1.0;skin: 3.1	colon,esophagus,small intestine,spleen,testis: 0.1	Not detected		
LRIT3	CSNB1F, FIGLER4, FLJ44691	ENSG00000183423	Leucine rich repeat, Ig-like and transmembrane domains 3	4	109848202-109872315	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA013454	Supported		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Not detected	Not detected			kidney: 0.9	Not detected		
LRMP	JAW1	ENSG00000118308	Lymphoid restricted membrane protein	12	25004342-25108334	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002967, HPA018505	Enhanced		Supported	Nucleus<br>Vesicles<br>Cytosol		Mixed	Tissue enhanced		lymph node: 207.1;tonsil: 185.6	appendix: 63.4	Group enriched	7	Daudi: 453.9;REH: 202.5;U-698: 497.6
LRP1	A2MR, APOER, APR, CD91, LRP, LRP1A	ENSG00000123384	LDL receptor related protein 1	12	57128493-57213351	Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004182, CAB018621, HPA022903	Supported		Supported	Nucleoplasm<br>Vesicles	Urothelial cancer:1.29e-5 (unfavourable), Renal cancer:1.52e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 123.8	Cell line enhanced		ASC diff: 333.3;ASC TERT1: 342.9;HSkMC: 232.4
LRP10	DKFZP564C1940, LRP9, MGC8675, MST087, MSTP087	ENSG00000197324	LDL receptor related protein 10	14	22871613-22881580	Predicted membrane proteins	Evidence at protein level	HPA000932			Approved	Nucleus<br>Nucleoli	Liver cancer:3.54e-7 (unfavourable), Renal cancer:6.31e-5 (favourable), Lung cancer:9.17e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 179.5	Expressed in all		
LRP11	bA350J20.3, MANSC3	ENSG00000120256	LDL receptor related protein 11	6	149818798-149864026	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064002			Approved	Mitochondria	Breast cancer:2.31e-8 (unfavourable), Liver cancer:2.01e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 89.2	Mixed		
LRP12	FLJ12929, ST7	ENSG00000147650	LDL receptor related protein 12	8	104489231-104589024	Predicted membrane proteins	Evidence at protein level	HPA017245	Uncertain		Approved	Nucleoli fibrillar center<br>Plasma membrane<br>Mitochondria	Endometrial cancer:2.67e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 27.8	Mixed		
LRP1B	LRP-DIT, LRPDIT	ENSG00000168702	LDL receptor related protein 1B	2	140231423-142131701	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069094, HPA074788	Approved		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 16.4;thyroid gland: 9.6	epididymis: 2.7	Cell line enhanced		ASC diff: 1.0;HEK93: 1.5;U-138 MG: 1.8
LRP2	DBS, gp330	ENSG00000081479	LDL receptor related protein 2	2	169127109-169362685	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005980, HPA064792	Enhanced		Approved	Vesicles<br>Mitochondria	Renal cancer:3.43e-5 (favourable)	Group enriched	Group enriched	6	kidney: 49.8;parathyroid gland: 155.8;thyroid gland: 37.0	breast: 14.2	Group enriched	11	AF22: 39.4;CACO-2: 56.2
LRP3	hLRp105, LRP-3	ENSG00000130881	LDL receptor related protein 3	19	33177603-33208867	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Pancreatic cancer:6.12e-7 (favourable)	Expressed in all	Mixed			ovary: 63.4	Mixed		
LRP4	CLSS, LRP-4, MEGF7, SOST2	ENSG00000134569	LDL receptor related protein 4	11	46856868-46918642	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011934, HPA012300	Approved		Uncertain	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Tissue enhanced		cerebral cortex: 35.4;skin: 37.9	parathyroid gland: 13.1	Cell line enhanced		AF22: 21.2
LRP5	BMND1, EVR1, EVR4, HBM, LR3, LRP7, OPPG, OPS, OPTA1, VBCH2	ENSG00000162337	LDL receptor related protein 5	11	68312609-68449275	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013001, HPA030505	Approved				Renal cancer:3.55e-10 (favourable)	Expressed in all	Expressed in all			small intestine: 49.8	Mixed		
LRP6	ADCAD2	ENSG00000070018	LDL receptor related protein 6	12	12116025-12267012	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004490, HPA029925	Enhanced					Expressed in all	Mixed			parathyroid gland: 16.4	Mixed		
LRP8	APOER2, HSZ75190, LRP-8, MCI1	ENSG00000157193	LDL receptor related protein 8	1	53242364-53328070	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA073031	Enhanced				Endometrial cancer:3.46e-6 (unfavourable), Lung cancer:7.02e-4 (unfavourable)	Mixed	Group enriched	7	cerebral cortex: 25.2;testis: 46.9;thyroid gland: 87.5	appendix: 7.7	Expressed in all		
LRRC15	LIB	ENSG00000172061	Leucine rich repeat containing 15	3	194355247-194369743	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA035503	Uncertain		Approved	Vesicles<br>Plasma membrane		Tissue enhanced	Mixed			cervix, uterine: 4.7	Group enriched	8	fHDF/TERT166: 93.4;U-138 MG: 22.2;U-87 MG: 61.4
LRRC19	FLJ21302	ENSG00000184434	Leucine rich repeat containing 19	9	26993136-27005693	Predicted membrane proteins	Evidence at protein level						Renal cancer:7.08e-8 (favourable)	Group enriched	Group enriched	9	colon: 35.9;duodenum: 23.7;gallbladder: 9.4;kidney: 45.1;rectum: 35.3;small intestine: 34.7	appendix: 3.5	Not detected		
LRRC24	LRRC14OS	ENSG00000254402	Leucine rich repeat containing 24	8	144522377-144527032	Predicted membrane proteins	Evidence at protein level	HPA028171, HPA052250	Enhanced		Approved	Vesicles		Not detected	Tissue enhanced		parathyroid gland: 3.6;prostate: 4.5	cerebral cortex: 3.1	Cell line enhanced		SCLC-21H: 3.2;SH-SY5Y: 7.9
LRRC25	FLJ38116, MAPA	ENSG00000175489	Leucine rich repeat containing 25	19	18391144-18397617	Predicted membrane proteins	Evidence at protein level	HPA029459	Approved				Testis cancer:6.93e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 30.4;spleen: 40.6	bone marrow: 20.7	Cell line enhanced		HMC-1: 1.6;THP-1: 1.2;U-937: 1.1
LRRC26	bA350O14.10	ENSG00000184709	Leucine rich repeat containing 26	9	137168758-137170051	Predicted membrane proteins	Evidence at protein level	HPA056312	Approved		Supported	Nucleoli fibrillar center<br>Plasma membrane	Endometrial cancer:4.82e-6 (favourable), Stomach cancer:3.48e-4 (favourable)	Tissue enriched	Group enriched	7	colon: 10.2;prostate: 35.5;salivary gland: 26.5	small intestine: 3.5	Group enriched	10	REH: 18.9;RPMI-8226: 87.4
LRRC3	C21orf102	ENSG00000160233	Leucine rich repeat containing 3	21	44455486-44462196	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA017975	Uncertain					Mixed	Mixed			liver: 4.1	Cell line enhanced		BEWO: 8.4;U-2 OS: 6.7
LRRC32	D11S833E, GARP	ENSG00000137507	Leucine rich repeat containing 32	11	76657524-76670747	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055775, HPA058434			Supported	Nucleoplasm	Renal cancer:3.93e-5 (unfavourable), Urothelial cancer:2.64e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 76.4	Group enriched	5	ASC diff: 78.8;ASC TERT1: 49.2;HSkMC: 32.0;HUVEC TERT2: 43.0;U-2197: 100.6
LRRC37A	KIAA0563	ENSG00000176681	Leucine rich repeat containing 37A	17	46292733-46337794	Predicted membrane proteins	Evidence at protein level	HPA042121, HPA042701, HPA043056, HPA045090, HPA049080	Supported		Approved	Vesicles		Not detected	Tissue enriched	8	testis: 13.4	skeletal muscle: 1.6	Cell line enhanced		Daudi: 2.8
LRRC37A2	FLJ45049	ENSG00000238083	Leucine rich repeat containing 37 member A2	17	46511511-46555650	Predicted membrane proteins	Evidence at protein level	HPA042121, HPA042701, HPA043056, HPA045090, HPA049080	Supported		Approved	Vesicles		Mixed	Tissue enriched	25	testis: 13.0	breast,lung: 0.5	Not detected		
LRRC37A3	FLJ34306, KIAA0563	ENSG00000176809	Leucine rich repeat containing 37 member A3	17	64854312-64919480	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042121, HPA042701, HPA043056, HPA045090	Supported		Approved	Vesicles	Renal cancer:3.25e-6 (unfavourable)	Mixed	Tissue enhanced		testis: 31.6	thyroid gland: 12.5	Mixed		
LRRC37B		ENSG00000185158	Leucine rich repeat containing 37B	17	32007872-32053504	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015135	Approved		Approved	Cytosol		Mixed	Mixed			testis: 32.4	Expressed in all		
LRRC38		ENSG00000162494	Leucine rich repeat containing 38	1	13474977-13514048	Predicted membrane proteins	Evidence at protein level	HPA038778	Approved					Mixed	Group enriched	19	adrenal gland: 19.9;skeletal muscle: 10.5	placenta: 0.8	Cell line enhanced		MOLT-4: 13.0;PC-3: 10.4;U-138 MG: 17.5
LRRC3B	LRP15	ENSG00000179796	Leucine rich repeat containing 3B	3	26622806-26710776	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015568	Approved					Group enriched	Group enriched	7	cerebral cortex: 19.2;skeletal muscle: 3.9;testis: 13.0	endometrium,ovary: 1.6	Cell line enhanced		NTERA-2: 1.6
LRRC3C		ENSG00000204913	Leucine rich repeat containing 3C	17	39941474-39944747	Predicted membrane proteins	Evidence at protein level	HPA071271	Uncertain					Not detected	Not detected			testis: 0.9	Not detected		
LRRC4	NAG14	ENSG00000128594	Leucine rich repeat containing 4	7	128027071-128032107	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051100			Approved	Golgi apparatus	Renal cancer:6.98e-4 (favourable), Endometrial cancer:8.19e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 52.8	parathyroid gland: 13.1	Group enriched	9	AF22: 16.3;NTERA-2: 36.7;REH: 32.0;SCLC-21H: 22.0;SH-SY5Y: 12.3
LRRC4B	DKFZp761A179, HSM, LRIG4	ENSG00000131409	Leucine rich repeat containing 4B	19	50516892-50568045	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA058986	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 61.4	cervix, uterine: 12.9	Cell line enhanced		HMC-1: 29.7;SH-SY5Y: 31.3;U-2 OS: 28.7
LRRC4C	KIAA1580, NGL-1	ENSG00000148948	Leucine rich repeat containing 4C	11	40114203-41459773	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051335, HPA054800	Approved		Approved	Cytosol		Tissue enhanced	Tissue enriched	7	cerebral cortex: 34.4	cervix, uterine: 4.7	Group enriched	9	AF22: 18.9;U-2 OS: 21.7
LRRC52	FLJ25811	ENSG00000162763	Leucine rich repeat containing 52	1	165544007-165563961	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	26	testis: 18.6	parathyroid gland: 0.7	Not detected		
LRRC53		ENSG00000162621	Leucine rich repeat containing 53	1	74469878-74512614	Predicted membrane proteins	No evidence	HPA054062	Uncertain					Not detected	Not detected			cerebral cortex: 0.5	Not detected		
LRRC55	FLJ45686	ENSG00000183908	Leucine rich repeat containing 55	11	57181747-57191717	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014053	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 6.6	lymph node: 2.4	Group enriched	33	AF22: 19.1;NTERA-2: 4.6
LRRC59	FLJ21675, PRO1855	ENSG00000108829	Leucine rich repeat containing 59	17	50375059-50397553	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030827, HPA030829	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:1.19e-6 (unfavourable), Liver cancer:3.12e-6 (unfavourable), Head and neck cancer:1.00e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Colorectal cancer:2.60e-4 (favourable), Pancreatic cancer:6.87e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 92.0	Expressed in all		
LRRC66		ENSG00000188993	Leucine rich repeat containing 66	4	51993702-52017620	Predicted membrane proteins	Evidence at transcript level	HPA014549, HPA027839	Uncertain					Mixed	Tissue enhanced		duodenum: 22.5;small intestine: 20.5	rectum: 6.4	Cell line enhanced		ASC TERT1: 1.0;CAPAN-2: 1.8
LRRC70	LOC100130733, SLRN	ENSG00000186105	Leucine rich repeat containing 70	5	62578735-62581448	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013409	Uncertain					Mixed	Mixed			thyroid gland: 6.4	Group enriched	16	HUVEC TERT2: 13.7;TIME: 7.3
LRRC8A	FLJ10337, KIAA1437, LRRC8, SWELL1	ENSG00000136802	Leucine rich repeat containing 8 family member A	9	128882112-128918039	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:5.27e-5 (favourable), Pancreatic cancer:3.83e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 89.7	Expressed in all		
LRRC8B	KIAA0231, TA-LRRP	ENSG00000197147	Leucine rich repeat containing 8 family member B	1	89524836-89597864	Predicted membrane proteins, Transporters	Evidence at protein level	HPA017950	Uncertain		Approved	Nuclear speckles	Colorectal cancer:7.15e-4 (favourable), Endometrial cancer:9.99e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 37.6	testis: 28.8	Mixed		
LRRC8C	AD158	ENSG00000171488	Leucine rich repeat containing 8 family member C	1	89633072-89769903	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029347	Uncertain		Approved	Golgi apparatus	Renal cancer:3.75e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 22.7	Mixed		
LRRC8D	FLJ10470, LRRC5	ENSG00000171492	Leucine rich repeat containing 8 family member D	1	89821014-89936611	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014745			Approved	Nucleoplasm<br>Mitochondria	Endometrial cancer:3.21e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 35.9	Expressed in all		
LRRC8E	FLJ23420	ENSG00000171017	Leucine rich repeat containing 8 family member E	19	7888505-7902021	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020466	Uncertain					Mixed	Mixed			skin: 11.0	Cell line enhanced		U-87 MG: 35.6
LRRN1	FIGLER3	ENSG00000175928	Leucine rich repeat neuronal 1	3	3799437-3847703	Predicted membrane proteins	Evidence at protein level	HPA011071	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 44.3	parathyroid gland: 18.3	Cell line enhanced		AF22: 159.4;CAPAN-2: 50.8;HAP1: 50.2;NTERA-2: 96.1
LRRN2	FIGLER7, GAC1, LRANK1, LRRN5	ENSG00000170382	Leucine rich repeat neuronal 2	1	204617170-204685733	Predicted membrane proteins	Evidence at transcript level	HPA029124	Uncertain		Approved	Endoplasmic reticulum	Endometrial cancer:2.59e-7 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 23.4;parathyroid gland: 21.2	fallopian tube: 11.5	Cell line enhanced		HEL: 8.3;NTERA-2: 17.9;RPMI-8226: 20.1;T-47d: 9.4
LRRN3	FIGLER5, FLJ11129, NLRR3	ENSG00000173114	Leucine rich repeat neuronal 3	7	111091006-111125454	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA043820, HPA046792	Uncertain		Approved	Nucleus<br>Cytosol		Group enriched	Tissue enhanced		adrenal gland: 30.8;cerebral cortex: 31.2;testis: 29.1;thyroid gland: 33.6	lung: 11.6	Cell line enhanced		AF22: 24.9;BJ hTERT+: 25.6;SH-SY5Y: 47.7;T-47d: 23.4
LRRN4	C20orf75, dJ1056H1.1, NLRR4	ENSG00000125872	Leucine rich repeat neuronal 4	20	6040778-6054049	Predicted membrane proteins	Evidence at protein level	HPA075974			Approved	Nucleoli<br>Cytosol		Group enriched	Tissue enriched	10	lung: 13.5	fallopian tube: 1.2	Cell line enriched	12	RPTEC TERT1: 53.0
LRRN4CL		ENSG00000177363	LRRN4 C-terminal like	11	62686402-62689899	Predicted membrane proteins	Evidence at protein level	HPA050317	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies		Tissue enriched	Mixed			endometrium: 16.8	Cell line enhanced		ASC TERT1: 15.0;HHSteC: 14.1;HSkMC: 6.6;LHCN-M2: 9.5
LRRTM1	FLJ32082	ENSG00000162951	Leucine rich repeat transmembrane neuronal 1	2	80288351-80304749	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA062660	Approved					Group enriched	Tissue enhanced		cerebral cortex: 13.3;salivary gland: 4.9	thyroid gland: 2.2	Cell line enhanced		SH-SY5Y: 1.4
LRRTM2	KIAA0416	ENSG00000146006	Leucine rich repeat transmembrane neuronal 2	5	138868923-138875368	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	10	cerebral cortex: 29.0	placenta: 3.0	Group enriched	7	HDLM-2: 14.6;SCLC-21H: 5.8
LRRTM3		ENSG00000198739	Leucine rich repeat transmembrane neuronal 3	10	66926006-67099830	Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	5	cerebral cortex: 22.6	ovary: 4.2	Cell line enhanced		AF22: 1.9;HAP1: 5.7;NTERA-2: 1.2
LRRTM4	FLJ12568	ENSG00000176204	Leucine rich repeat transmembrane neuronal 4	2	76747719-77593319	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	cerebral cortex: 21.3	epididymis: 2.4	Cell line enriched	7	Karpas-707: 91.1
LRTM1	HT017	ENSG00000144771	Leucine rich repeats and transmembrane domains 1	3	54918237-54967088	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		skeletal muscle: 9.3;spleen: 8.9	esophagus: 4.3	Cell line enhanced		HEL: 1.0
LRTM2		ENSG00000166159	Leucine rich repeats and transmembrane domains 2	12	1820267-1836752	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055094	Uncertain					Not detected	Tissue enriched	47	cerebral cortex: 8.3	testis: 0.1	Group enriched	12	HEL: 7.7;SCLC-21H: 5.2
LRTOMT	CFAP111, COMT2, DFNB63, LRRC51	ENSG00000184154	Leucine rich transmembrane and O-methyltransferase domain containing	11	72080331-72110782	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039949	Approved		Approved	Nucleoli<br>Microtubules	Ovarian cancer:5.36e-4 (favourable), Endometrial cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			testis: 136.6	Expressed in all		
LSAMP	IGLON3, LAMP	ENSG00000185565	Limbic system-associated membrane protein	3	115802363-117139389	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054051, HPA076122			Approved	Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 102.7	prostate: 43.6	Group enriched	6	AF22: 11.1;SH-SY5Y: 24.0;WM-115: 55.4
LSMEM1	C7orf53, FLJ39575	ENSG00000181016	Leucine rich single-pass membrane protein 1	7	112480853-112491062	Predicted membrane proteins	Evidence at protein level	HPA013753, HPA047988	Uncertain		Supported	Cytosol		Mixed	Tissue enriched	11	skeletal muscle: 31.8	testis: 2.8	Cell line enhanced		HeLa: 4.9
LSMEM2	C3orf45, FLJ38608	ENSG00000179564	Leucine rich single-pass membrane protein 2	3	50279027-50288114	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		heart muscle: 15.4;skeletal muscle: 5.4	testis: 2.8	Not detected		
LSR	ILDR3, LISCH7	ENSG00000105699	Lipolysis stimulated lipoprotein receptor	19	35248330-35267964	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007270	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.09e-4 (favourable)	Expressed in all	Expressed in all			stomach: 128.7	Cell line enhanced		A-431: 435.7
LST1	B144, D6S49E, LST-1	ENSG00000204482	Leukocyte specific transcript 1	6	31586124-31588909	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.97e-5 (unfavourable), Testis cancer:7.62e-4 (unfavourable), Cervical cancer:7.89e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 68.7;spleen: 48.9	appendix: 32.1	Cell line enhanced		HMC-1: 64.7;NB-4: 50.8;THP-1: 128.8;U-937: 79.6
LTB4R	BLTR, CMKRL1, GPR16, LTB4R1, P2RY7, P2Y7	ENSG00000213903	Leukotriene B4 receptor	14	24311450-24318036	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003873	Approved				Renal cancer:3.44e-15 (unfavourable), Pancreatic cancer:1.85e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 165.8	esophagus: 42.6	Expressed in all		
LTB4R2	BLT2, BLTR2, JULF2, NOP9	ENSG00000213906	Leukotriene B4 receptor 2	14	24305734-24312053	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022689, HPA029680, HPA072921	Uncertain		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		skin: 40.5	spleen: 10.3	Cell line enhanced		HaCaT: 24.8
LTBR	D12S370, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP, TNFRSF3	ENSG00000111321	Lymphotoxin beta receptor	12	6375045-6391571	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026202, HPA061617	Uncertain		Supported	Golgi apparatus	Liver cancer:5.13e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 89.5	Cell line enhanced		HHSteC: 330.0
LTC4S	MGC33147	ENSG00000213316	Leukotriene C4 synthase	5	179793980-179796647	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		fallopian tube: 3.7	adipose tissue,adrenal gland: 2.0	Cell line enriched	6	HMC-1: 59.7
LTK	TYK1	ENSG00000062524	Leukocyte receptor tyrosine kinase	15	41503638-41513887	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059545	Uncertain		Approved	Vesicles		Mixed	Mixed			placenta: 15.2	Cell line enhanced		HEL: 4.4;NB-4: 6.1;RH-30: 4.4;THP-1: 9.9
LTN1	C21orf10, C21orf98, FLJ11053, KIAA0714, LISTERIN, RNF160, ZNF294	ENSG00000198862	Listerin E3 ubiquitin protein ligase 1	21	28928144-28992956	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029143, CAB034164, HPA055604	Uncertain		Enhanced	Cytosol		Expressed in all	Expressed in all			placenta: 26.6	Expressed in all		
LY6D	E48	ENSG00000167656	Lymphocyte antigen 6 family member D	8	142784880-142786592	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA024755, HPA064317	Enhanced				Pancreatic cancer:1.94e-6 (unfavourable), Renal cancer:1.20e-4 (unfavourable)	Group enriched	Group enriched	11	esophagus: 631.6;skin: 717.0	tonsil: 61.0	Cell line enriched	26	A-431: 128.0
LY6E	RIG-E, SCA-2, TSA-1	ENSG00000160932	Lymphocyte antigen 6 family member E	8	143017982-143023832	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level						Renal cancer:6.74e-8 (unfavourable)	Expressed in all	Expressed in all			lung: 109.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 564.1;MCF7: 492.5
LY6G5C	C6orf20, G5c, NG33	ENSG00000204428	Lymphocyte antigen 6 family member G5C	6	31676684-31684040	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038690	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:1.07e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 1.5	testis: 0.9	Not detected		
LY6G6C	C6orf24, G6c, NG24	ENSG00000204421	Lymphocyte antigen 6 family member G6C	6	31718648-31721845	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	8	skin: 64.3	esophagus: 7.5	Not detected		
LY6G6D	C6orf23, G6D, Ly6-D, MEGT1, NG25	ENSG00000244355	Lymphocyte antigen 6 family member G6D	6	31715356-31717804	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054412	Uncertain					Tissue enriched	Tissue enhanced		seminal vesicle: 2.0	prostate: 0.8	Cell line enhanced		HEL: 1.6
LY6G6F	C6orf21, G6f, LY6G6D, NG32	ENSG00000204424	Lymphocyte antigen 6 family member G6F	6	31706885-31710595	Predicted membrane proteins	Evidence at protein level	HPA008053	Uncertain					Not detected	Not detected			bone marrow: 0.4	Cell line enriched	79	HEL: 7.9
LY6K	CT97, FLJ35226, HSJ001348	ENSG00000160886	Lymphocyte antigen 6 family member K	8	142700111-142705127	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017770, CAB075742, CAB075743	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Lung cancer:9.17e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 29.0	adipose tissue: 5.9	Cell line enhanced		A-431: 108.7;BJ: 111.4;HeLa: 95.9;SiHa: 218.6;U-2197: 254.2
LY75	CD205, CLEC13B, DEC-205	ENSG00000054219	Lymphocyte antigen 75	2	159803355-159904749	CD markers, Predicted membrane proteins	Evidence at protein level	CAB001450, HPA049108, HPA054073	Enhanced		Approved	Golgi apparatus	Renal cancer:2.39e-5 (unfavourable), Urothelial cancer:3.86e-4 (favourable)	Mixed	Mixed			lymph node: 35.5	Cell line enhanced		CAPAN-2: 19.4;HDLM-2: 19.8;Karpas-707: 62.7;RT4: 24.1
LY75-CD302		ENSG00000248672	LY75-CD302 readthrough	2	159771851-159904710	Predicted membrane proteins	Evidence at protein level	HPA049108	Uncertain					Not detected	Mixed			appendix: 2.5	Cell line enhanced		CACO-2: 5.5;HDLM-2: 6.5;Karpas-707: 18.3;RT4: 8.7
LY9	CD229, hly9, mLY9, SLAMF3	ENSG00000122224	Lymphocyte antigen 9	1	160796074-160828261	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050917	Approved					Mixed	Tissue enhanced		lymph node: 34.5;spleen: 28.2;tonsil: 28.3	appendix: 17.8	Cell line enhanced		Daudi: 10.2;Karpas-707: 20.1;U-266/70: 53.8;U-266/84: 20.4
LYNX1	SLURP2	ENSG00000180155	Ly6/neurotoxin 1	8	142771197-142777810	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:2.82e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 94.6	parathyroid gland: 58.6	Cell line enhanced		BJ: 6.9;fHDF/TERT166: 7.9;HHSteC: 6.9;T-47d: 6.7
LYPD3	C4.4A	ENSG00000124466	LY6/PLAUR domain containing 3	19	43460787-43465660	Predicted membrane proteins	Evidence at protein level	HPA041529, HPA041797, HPA077859	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Lung cancer:7.86e-5 (unfavourable)	Tissue enhanced	Group enriched	6	esophagus: 673.8;skin: 593.4	tonsil: 114.6	Cell line enhanced		HaCaT: 85.1;MCF7: 84.1;RT4: 83.0;SK-BR-3: 114.6
LYPD5	FLJ30469	ENSG00000159871	LY6/PLAUR domain containing 5	19	43795929-43827206	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042511, HPA054670	Approved		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:5.84e-4 (favourable)	Tissue enhanced	Tissue enhanced		skin: 43.7	testis: 12.3	Cell line enhanced		A-431: 3.3;BEWO: 5.5;HaCaT: 5.3
LYPLA1	LPL1	ENSG00000120992	Lysophospholipase I	8	54046367-54102017	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050941, HPA063151	Enhanced		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.34e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 118.6	Expressed in all		
LYSMD3	FLJ13542	ENSG00000176018	LysM domain containing 3	5	90515611-90529584	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018024	Approved		Approved	Cytosol	Colorectal cancer:3.83e-4 (favourable), Renal cancer:9.25e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.7	Expressed in all		
LYSMD4	FLJ33008	ENSG00000183060	LysM domain containing 4	15	99715697-99733561	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA029152, HPA059824	Approved		Approved	Actin filaments<br>Cytosol		Expressed in all	Mixed			skin: 18.3	Mixed		
LYVE1	LYVE-1, XLKD1	ENSG00000133800	Lymphatic vessel endothelial hyaluronan receptor 1	11	10556966-10611689	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB025860, HPA042953	Supported				Renal cancer:6.98e-5 (unfavourable), Ovarian cancer:1.07e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 157.5;placenta: 213.1	smooth muscle: 95.3	Cell line enriched	11	HUVEC TERT2: 67.8
LYZL1	LYC2, MGC33408	ENSG00000120563	Lysozyme like 1	10	29289061-29318328	Enzymes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	480	testis: 53.4	parathyroid gland: 0.1	Not detected		
LYZL2		ENSG00000151033	Lysozyme like 2	10	30611779-30629762	Enzymes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	670	testis: 67.0	all non-specific tissues: 0.0	Cell line enriched	6	SK-BR-3: 2.2
M6PR	CD-M6PR, CD-MPR	ENSG00000003056	Mannose-6-phosphate receptor, cation dependent	12	8940363-8949955	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034464, HPA040445	Approved				Liver cancer:3.89e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 175.3	Expressed in all		
MACF1	ABP620, ACF7, FLJ45612, FLJ46776, KIAA0465, KIAA1251, MACF	ENSG00000127603	Microtubule-actin crosslinking factor 1	1	39081316-39487177	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013713, HPA068064, HPA068103	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Actin filaments	Renal cancer:2.77e-5 (favourable)	Expressed in all	Expressed in all			lung: 137.2	Expressed in all		
MADCAM1	MACAM1	ENSG00000099866	Mucosal vascular addressin cell adhesion molecule 1	19	489176-505342	Predicted membrane proteins	Evidence at protein level	CAB075699	Enhanced					Mixed	Tissue enhanced		appendix: 17.8;spleen: 11.4	gallbladder: 3.3	Mixed		
MADD	DENN, KIAA0358, RAB3GEP	ENSG00000110514	MAP kinase activating death domain	11	47269161-47330031	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038568	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:5.69e-5 (favourable), Endometrial cancer:6.62e-5 (favourable), Urothelial cancer:8.25e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 103.9	Expressed in all		
MAG	GMA, S-MAG, SIGLEC-4A, SIGLEC4A	ENSG00000105695	Myelin associated glycoprotein	19	35292125-35313804	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009345, HPA012499	Enhanced					Tissue enriched	Tissue enriched	6	cerebral cortex: 163.6	ovary: 27.5	Cell line enriched	31	WM-115: 35.4
MAGEA4	CT1.4, MAGE-41, MAGE-X2, MAGE4, MAGE4A, MAGE4B, MGC21336	ENSG00000147381	MAGE family member A4	X	151912509-151925170	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021942, CAB040535	Enhanced		Approved	Nuclear speckles<br>Cytosol		Mixed	Tissue enriched	7	testis: 44.7	placenta: 6.3	Cell line enhanced		A-431: 382.3;AN3-CA: 243.7;HMC-1: 436.2;U-266/84: 580.0
MAGED4	KIAA1859, MAGE-E1, MAGE1, MGC3210	ENSG00000154545	MAGE family member D4	X	52184823-52192268	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003554	Uncertain					Not detected	Not detected			cerebral cortex: 0.7	Cell line enhanced		A549: 2.7;ASC TERT1: 1.8;Hep G2: 5.3
MAGED4B		ENSG00000187243	MAGE family member D4B	X	52061827-52069248	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003554	Approved					Not detected	Tissue enhanced		cerebral cortex: 35.1	endometrium: 13.8	Cell line enhanced		AF22: 48.8;NTERA-2: 40.6
MAGEH1	APR1	ENSG00000187601	MAGE family member H1	X	55452105-55453566	Predicted membrane proteins	Evidence at protein level	HPA011324	Uncertain		Approved	Nucleoli	Endometrial cancer:1.37e-4 (unfavourable), Pancreatic cancer:2.60e-4 (favourable)	Expressed in all	Tissue enriched	5	epididymis: 616.6	cerebral cortex: 115.7	Mixed		
MAGT1	DKFZp564K142, IAP, MRX95, OST3B	ENSG00000102158	Magnesium transporter 1	X	77826364-77895593	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049851	Approved				Breast cancer:1.30e-4 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable), Melanoma:8.98e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 137.3	Expressed in all		
MAL		ENSG00000172005	Mal, T-cell differentiation protein	2	95025677-95053996	Predicted membrane proteins	Evidence at protein level	HPA065691			Approved	Golgi apparatus<br>Centrosome	Renal cancer:3.96e-9 (favourable), Endometrial cancer:5.18e-6 (unfavourable)	Mixed	Tissue enriched	8	esophagus: 2449.8	tonsil: 315.5	Group enriched	6	HDLM-2: 467.4;MOLT-4: 571.7;RPTEC TERT1: 1845.6
MAL2		ENSG00000147676	Mal, T-cell differentiation protein 2 (gene/pseudogene)	8	119165034-119245673	Predicted membrane proteins	Evidence at protein level	HPA043831	Uncertain				Breast cancer:4.57e-6 (unfavourable), Renal cancer:2.39e-5 (favourable), Endometrial cancer:8.44e-5 (unfavourable), Pancreatic cancer:3.98e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 266.5	Cell line enhanced		A-431: 909.7;HaCaT: 399.9;SK-BR-3: 1080.1
MALL	BENE	ENSG00000144063	Mal, T-cell differentiation protein like	2	110083870-110116566	Predicted membrane proteins	Evidence at protein level	HPA051410	Uncertain				Pancreatic cancer:1.23e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 222.2;parathyroid gland: 321.0	small intestine: 182.4	Cell line enhanced		A-431: 176.6;A549: 174.8;CAPAN-2: 233.6;fHDF/TERT166: 228.9;HaCaT: 183.5
MALRD1	bA265G8.2, C10orf112, Diet1	ENSG00000204740	MAM and LDL receptor class A domain containing 1	10	19048771-19790401	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035732, HPA038106, HPA046848	Uncertain		Enhanced	Golgi apparatus		Tissue enhanced	Group enriched	8	duodenum: 30.8;small intestine: 34.4	testis: 3.9	Cell line enriched	9	Karpas-707: 31.8
MAMDC4	AEGP, DKFZp434M1411	ENSG00000177943	MAM domain containing 4	9	136850943-136860799	Predicted membrane proteins	Evidence at protein level	CAB026377, HPA059977	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.88e-6 (favourable)	Expressed in all	Mixed			spleen: 5.6	Cell line enhanced		BEWO: 16.2
MAN1A1		ENSG00000111885	Mannosidase alpha class 1A member 1	6	119177209-119349761	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB037058, HPA053198, HPA063561	Uncertain		Supported	Golgi apparatus		Expressed in all	Expressed in all			placenta: 112.4	Cell line enhanced		ASC diff: 187.5;Karpas-707: 157.8;U-266/70: 224.6
MAN1A2	MAN1B	ENSG00000198162	Mannosidase alpha class 1A member 2	1	117367449-117528872	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034559, HPA057364	Enhanced		Enhanced	Golgi apparatus	Ovarian cancer:4.08e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.3	Expressed in all		
MAN1B1	ERManI, MANA-ER, MRT15	ENSG00000177239	Mannosidase alpha class 1B member 1	9	137086927-137109187	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051516	Approved		Uncertain	Vesicles	Liver cancer:1.45e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 33.4	Expressed in all		
MAN1C1	HMIC	ENSG00000117643	Mannosidase alpha class 1C member 1	1	25617468-25786207	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048352	Uncertain		Uncertain	Nucleus<br>Vesicles	Pancreatic cancer:4.79e-4 (favourable), Lung cancer:7.55e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 40.7	Cell line enhanced		AF22: 28.0;HSkMC: 74.2
MAN2A1	GOLIM7, MANA2	ENSG00000112893	Mannosidase alpha class 2A member 1	5	109689366-109869625	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB022377, HPA026896	Enhanced		Supported	Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 40.5	Expressed in all		
MAN2A2	HsT19662, MANA2X	ENSG00000196547	Mannosidase alpha class 2A member 2	15	90902218-90922584	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017226, HPA077930	Approved		Approved	Cytoplasmic bodies	Renal cancer:8.95e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 46.3	Expressed in all		
MANBAL	dJ1141E15.2	ENSG00000101363	Mannosidase beta like	20	37289638-37317260	Predicted membrane proteins	Evidence at protein level	HPA052348	Uncertain		Approved	Nucleus<br>Mitochondria	Renal cancer:3.62e-4 (favourable), Liver cancer:7.07e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 96.2	Expressed in all		
MANEA	FLJ12838, mandaselin	ENSG00000172469	Mannosidase endo-alpha	6	95577543-95609457	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011046, HPA011069	Enhanced		Supported	Golgi apparatus	Colorectal cancer:3.04e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 19.4	Expressed in all		
MANSC1	FLJ10298, LOH12CR3	ENSG00000111261	MANSC domain containing 1	12	12326056-12350541	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007955, HPA007956	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:3.30e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 24.7	Cell line enhanced		HUVEC TERT2: 42.6
MANSC4		ENSG00000205693	MANSC domain containing 4	12	27762738-27771276	Predicted membrane proteins	Evidence at transcript level	HPA039454, HPA039682	Uncertain					Not detected	Tissue enhanced		testis: 3.2	placenta: 0.8	Cell line enhanced		HUVEC TERT2: 1.2
MAOA		ENSG00000189221	Monoamine oxidase A	X	43654907-43746824	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB009437, HPA054807, HPA059299	Enhanced		Enhanced	Mitochondria		Expressed in all	Mixed			small intestine: 248.3	Cell line enhanced		ASC diff: 108.7;HHSteC: 249.1;hTCEpi: 61.9;RT4: 102.5
MAOB		ENSG00000069535	Monoamine oxidase B	X	43766611-43882447	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA002328, CAB037200	Enhanced		Approved	Nucleoli<br>Mitochondria		Expressed in all	Mixed			seminal vesicle: 215.4	Group enriched	9	Hep G2: 28.1;SiHa: 82.8
MAP3K1	MAPKKK1, MEKK, MEKK1	ENSG00000095015	Mitogen-activated protein kinase kinase kinase 1	5	56815574-56896152	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB004500, HPA046509	Approved		Approved	Cytosol		Expressed in all	Mixed			spleen: 28.3	Cell line enhanced		SH-SY5Y: 55.9
MAPKAPK2		ENSG00000162889	Mitogen-activated protein kinase-activated protein kinase 2	1	206684944-206734283	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	CAB010297, HPA045556, HPA063708, HPA064435	Approved		Supported	Nucleoplasm<br>Centrosome	Renal cancer:4.58e-6 (unfavourable), Liver cancer:1.93e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 113.0	Expressed in all		
MAPKAPK3	3pK, MAPKAP3	ENSG00000114738	Mitogen-activated protein kinase-activated protein kinase 3	3	50611520-50649297	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058275			Supported	Nucleoplasm	Renal cancer:1.90e-8 (favourable), Colorectal cancer:8.08e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 117.6	Expressed in all		
MAPKAPK5	PRAK	ENSG00000089022	Mitogen-activated protein kinase-activated protein kinase 5	12	111841978-111902238	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004546, HPA015515	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.98e-8 (unfavourable)	Expressed in all	Expressed in all			rectum: 33.8	Expressed in all		
MARC2	FLJ20605, MOSC2	ENSG00000117791	Mitochondrial amidoxime reducing component 2	1	220748225-220784815	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015085, HPA017572	Enhanced				Liver cancer:1.40e-10 (favourable), Renal cancer:3.09e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 338.5	kidney: 139.5	Cell line enhanced		T-47d: 33.9
MARCH1	FLJ20668, MARCH-I, RNF171	ENSG00000145416	Membrane associated ring-CH-type finger 1	4	163524298-164384050	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014600	Uncertain		Supported	Mitochondria		Mixed	Mixed			lymph node: 36.0	Mixed		
MARCH11	MARCH-XI	ENSG00000183654	Membrane associated ring-CH-type finger 11	5	16067139-16180762	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	20	testis: 90.3	cerebral cortex: 4.5	Cell line enriched	13	SH-SY5Y: 89.2
MARCH2	HSPC240, MARCH-II, RNF172	ENSG00000099785	Membrane associated ring-CH-type finger 2	19	8413270-8439017	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014063	Approved		Approved	Cytosol	Endometrial cancer:1.05e-5 (favourable), Pancreatic cancer:6.21e-4 (favourable), Colorectal cancer:6.48e-4 (unfavourable), Head and neck cancer:8.29e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 64.8	Mixed		
MARCH3	MARCH-III, MGC48332, RNF173	ENSG00000173926	Membrane associated ring-CH-type finger 3	5	126867714-127030808	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043406	Uncertain		Supported	Vesicles		Mixed	Mixed			testis: 10.9	Cell line enhanced		hTEC/SVTERT24-B: 41.0;TIME: 27.2
MARCH4	KIAA1399, MARCH-IV, RNF174	ENSG00000144583	Membrane associated ring-CH-type finger 4	2	216257865-216372027	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014348	Approved					Mixed	Tissue enriched	6	cerebral cortex: 9.1	stomach: 1.6	Cell line enhanced		BJ: 63.3;fHDF/TERT166: 37.3
MARCH5	FLJ20445, MARCH-V, MITOL, RNF153	ENSG00000198060	Membrane associated ring-CH-type finger 5	10	92291163-92353964	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA056596			Supported	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 28.7	Expressed in all		
MARCH6	MARCH-VI, RNF176, TEB4	ENSG00000145495	Membrane associated ring-CH-type finger 6	5	10353703-10440388	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040841, HPA063246	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 96.8	Expressed in all		
MARCH8	c-MIR, CMIR, MARCH-VIII, MIR, RNF178	ENSG00000165406	Membrane associated ring-CH-type finger 8	10	45454585-45594906	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014597	Approved				Pancreatic cancer:2.71e-4 (favourable), Renal cancer:6.64e-4 (favourable)	Expressed in all	Expressed in all			testis: 104.6	Expressed in all		
MARCH9	FLJ36578, RNF179	ENSG00000139266	Membrane associated ring-CH-type finger 9	12	57755098-57760407	Enzymes, Predicted membrane proteins	Evidence at protein level						Lung cancer:1.54e-5 (favourable), Renal cancer:2.98e-5 (favourable), Ovarian cancer:1.59e-4 (favourable), Endometrial cancer:3.07e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.3	Cell line enriched	16	RH-30: 498.8
MARCO	SCARA2	ENSG00000019169	Macrophage receptor with collagenous structure	2	118942166-118994660	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA063793	Enhanced		Approved	Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		appendix: 123.2;lung: 288.2	adipose tissue: 78.0	Cell line enhanced		HaCaT: 1.5;THP-1: 1.7;U-2 OS: 2.7;U-266/70: 1.1
MARK3	CTAK1, KP78, PAR-1A	ENSG00000075413	Microtubule affinity regulating kinase 3	14	103385392-103503831	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024652	Approved		Approved	Nuclear membrane	Melanoma:1.14e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 64.0	Expressed in all		
MARK4	FLJ90097, KIAA1860, MARKL1, Nbla00650, PAR-1D	ENSG00000007047	Microtubule affinity regulating kinase 4	19	45079288-45305283	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039186	Approved		Approved	Cytosol	Endometrial cancer:8.31e-8 (unfavourable), Head and neck cancer:3.05e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 51.2	Expressed in all		
MARS	CMT2U, MetRS, SPG70	ENSG00000166986	Methionyl-tRNA synthetase	12	57475445-57517569	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004125, CAB017097	Supported	Approved	Enhanced	Cytosol	Liver cancer:4.55e-7 (unfavourable), Renal cancer:1.59e-4 (unfavourable), Breast cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 66.7	Expressed in all		
MARVELD1	bA548K23.8, FLJ22343, FLJ23440, GB14, MGC4415, MRVLDC1	ENSG00000155254	MARVEL domain containing 1	10	97713173-97718152	Predicted membrane proteins	Evidence at protein level						Renal cancer:8.89e-7 (unfavourable), Lung cancer:5.85e-5 (unfavourable)	Expressed in all	Mixed			smooth muscle: 69.3	Mixed		
MARVELD2	DFNB49, FLJ30532, MRVLDC2, TRIC	ENSG00000152939	MARVEL domain containing 2	5	69415112-69444330	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018119, HPA061726	Uncertain		Supported	Cell Junctions	Renal cancer:2.84e-13 (favourable)	Mixed	Tissue enhanced		thyroid gland: 19.7	small intestine: 8.7	Cell line enhanced		BEWO: 30.0;CAPAN-2: 22.9;HaCaT: 17.6;RT4: 17.7;SCLC-21H: 32.0;T-47d: 18.4
MARVELD3	MRVLDC3	ENSG00000140832	MARVEL domain containing 3	16	71626161-71642114	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043514, HPA045471			Approved	Vesicles<br>Intermediate filaments	Renal cancer:6.80e-10 (favourable)	Mixed	Tissue enhanced		small intestine: 37.1	duodenum: 31.5	Cell line enhanced		BEWO: 29.9;CAPAN-2: 19.9;MCF7: 31.1;T-47d: 24.8
MAS1		ENSG00000130368	MAS1 proto-oncogene, G protein-coupled receptor	6	159906690-159916530	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 1.8	cervix, uterine: 0.7	Cell line enriched	9	HMC-1: 6.7
MAS1L	dJ994E9.2, MAS-L, MRG	ENSG00000204687	MAS1 proto-oncogene like, G protein-coupled receptor	6	29486697-29487956	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA017983	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		cervix, uterine: 5.1	epididymis: 2.3	Not detected		
MAST1	KIAA0973, SAST	ENSG00000105613	Microtubule associated serine/threonine kinase 1	19	12833951-12874951	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028181, HPA073106	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enriched	12	cerebral cortex: 35.2	testis: 3.0	Cell line enhanced		AN3-CA: 21.6;SCLC-21H: 47.7;SH-SY5Y: 21.4
MAST2	KIAA0807, MAST205	ENSG00000086015	Microtubule associated serine/threonine kinase 2	1	45786987-46036124	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	HPA039722, HPA040155	Approved		Approved	Cytosol	Renal cancer:6.85e-13 (unfavourable), Liver cancer:4.31e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 78.6	Expressed in all		
MAVS	Cardif, IPS-1, KIAA1271, VISA	ENSG00000088888	Mitochondrial antiviral signaling protein	20	3846799-3876123	Predicted membrane proteins	Evidence at protein level	CAB009187, HPA049850, HPA053524	Enhanced		Enhanced	Mitochondria	Renal cancer:4.13e-5 (favourable), Pancreatic cancer:3.81e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.6	Expressed in all		
MBOAT1	dJ434O11.1, LPEAT1, MGC44669, OACT1	ENSG00000172197	Membrane bound O-acyltransferase domain containing 1	6	20102145-20212399	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA052996			Approved	Mitochondria	Pancreatic cancer:9.15e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 55.7	Cell line enhanced		HaCaT: 55.4;HEL: 47.2
MBOAT2	FLJ14415, FLJ90298, OACT2	ENSG00000143797	Membrane bound O-acyltransferase domain containing 2	2	8852690-9003813	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014836	Uncertain		Approved	Vesicles	Endometrial cancer:2.13e-9 (unfavourable), Urothelial cancer:5.32e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 50.1	cerebral cortex: 29.7	Mixed		
MBOAT4	FKSG89, GOAT, OACT4	ENSG00000177669	Membrane bound O-acyltransferase domain containing 4	8	30131824-30144686	Predicted membrane proteins	Evidence at protein level	HPA044509			Supported	Golgi apparatus		Tissue enhanced	Tissue enhanced		fallopian tube: 2.9;stomach: 3.5	gallbladder: 1.6	Cell line enhanced		Hep G2: 2.1
MBOAT7	BB1, hMBOA-7, LENG4, LPIAT	ENSG00000125505	Membrane bound O-acyltransferase domain containing 7	19	54173412-54189882	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA055967	Approved		Approved	Cytosol	Liver cancer:5.55e-6 (unfavourable), Renal cancer:6.62e-5 (unfavourable), Urothelial cancer:4.31e-4 (favourable), Lung cancer:5.13e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 24.3	Cell line enhanced		HMC-1: 150.7
MBTPS1	KIAA0091, PCSK8, S1P, SKI-1	ENSG00000140943	Membrane bound transcription factor peptidase, site 1	16	84053761-84116906	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056109	Supported				Renal cancer:2.21e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 118.5	Expressed in all		
MBTPS2	KFSD, S2P	ENSG00000012174	Membrane bound transcription factor peptidase, site 2	X	21839636-21885424	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA005494, CAB009486	Approved		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 19.3	Expressed in all		
MC1R	MSH-R	ENSG00000258839	Melanocortin 1 receptor	16	89912119-89920977	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:7.88e-4 (favourable)	Tissue enhanced	Tissue enhanced		testis: 13.7	skin: 6.9	Cell line enhanced		SK-MEL-30: 28.3
MC2R	ACTHR	ENSG00000185231	Melanocortin 2 receptor	18	13882044-13915707	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	23	adrenal gland: 50.6	epididymis: 2.1	Not detected		
MC3R	MC3	ENSG00000124089	Melanocortin 3 receptor	20	56248732-56249815	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
MC4R		ENSG00000166603	Melanocortin 4 receptor	18	60371110-60372775	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016719	Uncertain					Tissue enhanced	Group enriched	10	cerebral cortex: 2.9;fallopian tube: 5.0	epididymis: 0.4	Cell line enriched	64	fHDF/TERT166: 75.8
MC5R		ENSG00000176136	Melanocortin 5 receptor	18	13824149-13827323	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA042365	Approved					Not detected	Tissue enriched	7	epididymis: 3.0	esophagus,testis: 0.4	Cell line enhanced		U-138 MG: 1.8
MCAM	CD146, MUC18	ENSG00000076706	Melanoma cell adhesion molecule	11	119308529-119321521	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002147, HPA008848	Enhanced		Enhanced	Plasma membrane	Renal cancer:5.14e-4 (unfavourable), Cervical cancer:7.61e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 367.1	Cell line enhanced		HUVEC TERT2: 935.6;TIME: 901.7;WM-115: 859.1
MCEMP1	C19orf59, MGC132456	ENSG00000183019	Mast cell expressed membrane protein 1	19	7676628-7679826	Predicted membrane proteins	Evidence at protein level	HPA014731	Enhanced					Mixed	Group enriched	9	appendix: 27.9;bone marrow: 43.9;lung: 110.4	smooth muscle: 7.0	Group enriched	5	THP-1: 36.2;U-937: 130.3
MCHR1	GPR24, MCH1R, SLC1	ENSG00000128285	Melanin concentrating hormone receptor 1	22	40678750-40682814	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.49e-6 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 8.6	ovary: 2.1	Cell line enhanced		NTERA-2: 1.2;RH-30: 1.6;T-47d: 1.3;U-87 MG: 1.5
MCHR2	GPR145, MCH2, MCH2R, SLT	ENSG00000152034	Melanin concentrating hormone receptor 2	6	99919910-99994247	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Group enriched	47	cerebral cortex: 8.6;testis: 4.3	colon,small intestine: 0.1	Not detected		
MCL1	BCL2L3, Mcl-1	ENSG00000143384	BCL2 family apoptosis regulator	1	150574551-150579738	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002781, HPA008455, HPA031125, CAB068195	Approved		Enhanced	Mitochondria	Renal cancer:7.16e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 661.4	Cell line enriched	11	U-698: 3345.2
MCOLN1	ML4, MLIV, MST080, MSTP080, TRPM-L1, TRPML1	ENSG00000090674	Mucolipin 1	19	7522626-7534009	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA031763, CAB032637	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:5.60e-5 (favourable), Renal cancer:5.67e-4 (favourable)	Expressed in all	Expressed in all			spleen: 48.2	Expressed in all		
MCOLN2	FLJ36691, TRP-ML2, TRPML2	ENSG00000153898	Mucolipin 2	1	84925583-84997113	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA019114, HPA048999	Uncertain		Supported	Intermediate filaments	Lung cancer:2.56e-4 (favourable)	Mixed	Mixed			rectum: 17.2	Cell line enhanced		Daudi: 14.8;HAP1: 14.9;HDLM-2: 23.0;THP-1: 19.8;U-698: 12.6
MCOLN3	FLJ11006, TRP-ML3, TRPML3	ENSG00000055732	Mucolipin 3	1	85018082-85048499	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA018106, HPA062137	Enhanced		Approved	Nucleoli<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 57.8;parathyroid gland: 42.8	epididymis: 17.5	Cell line enhanced		HAP1: 13.4;RH-30: 15.2;SK-MEL-30: 22.2
MCTP1	FLJ22344	ENSG00000175471	Multiple C2 and transmembrane domain containing 1	5	94703741-95284575	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019018	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			bone marrow: 29.0	Mixed		
MCTP2	FLJ11175, FLJ33303	ENSG00000140563	Multiple C2 and transmembrane domain containing 2	15	94231538-94483952	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051176, HPA070541	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.18e-5 (unfavourable)	Mixed	Mixed			placenta: 28.6	Cell line enhanced		HEL: 19.0;U-698: 15.8;U-87 MG: 24.4
MCU	C10orf42, CCDC109A, FLJ46135	ENSG00000156026	Mitochondrial calcium uniporter	10	72692131-72887694	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016480	Approved		Supported	Mitochondria	Liver cancer:6.06e-5 (unfavourable), Renal cancer:5.07e-4 (favourable)	Expressed in all	Expressed in all			stomach: 40.7	Expressed in all		
MCUB	CCDC109B, FLJ20647	ENSG00000005059	Mitochondrial calcium uniporter dominant negative beta subunit	4	109560205-109688726	Predicted membrane proteins, Transporters	Evidence at protein level	HPA048776	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.35e-6 (unfavourable)	Expressed in all	Mixed			lymph node: 36.2	Mixed		
MCUR1	C6orf79, CCDC90A, FLJ20958	ENSG00000050393	Mitochondrial calcium uniporter regulator 1	6	13786557-13814568	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:3.32e-4 (favourable), Ovarian cancer:5.51e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.9	Expressed in all		
MDFIC	HIC	ENSG00000135272	MyoD family inhibitor domain containing	7	114922154-115019202	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030716	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:3.65e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 48.0	Cell line enhanced		U-2197: 101.4
MDGA2	MAMDC1	ENSG00000139915	MAM domain containing glycosylphosphatidylinositol anchor 2	14	46839629-47674954	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003084	Uncertain					Tissue enhanced	Group enriched	15	cerebral cortex: 6.2;testis: 6.9	skin: 0.4	Cell line enhanced		AF22: 5.0;T-47d: 2.4;U-138 MG: 5.6;U-2 OS: 4.3;WM-115: 3.4
MDM1		ENSG00000111554	Mdm1 nuclear protein	12	68272443-68332381	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040411, HPA041594	Uncertain		Supported	Centrosome<br>Cytosol	Cervical cancer:6.01e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.5	Expressed in all		
MED17	CRSP6, CRSP77, DRIP80, TRAP80	ENSG00000042429	Mediator complex subunit 17	11	93784227-93814963	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA064236			Approved	Nucleoplasm<br>Vesicles	Liver cancer:4.04e-6 (unfavourable), Breast cancer:4.94e-4 (unfavourable)	Expressed in all	Mixed			spleen: 3.2	Mixed		
MED23	CRSP130, CRSP3, DRIP130, Sur2	ENSG00000112282	Mediator complex subunit 23	6	131573966-131628229	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA070341			Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 32.2	Expressed in all		
MED24	CRSP100, CRSP4, DRIP100, KIAA0130, MED5, THRAP4, TRAP100	ENSG00000008838	Mediator complex subunit 24	17	40019097-40061215	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			testis: 64.3	Expressed in all		
MEGF10	KIAA1780	ENSG00000145794	Multiple EGF like domains 10	5	127290831-127465737	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	7	cerebral cortex: 15.8	adrenal gland: 2.2	Cell line enhanced		AF22: 31.3;RH-30: 37.5
MEGF11	DKFZp434L121, KIAA1781	ENSG00000157890	Multiple EGF like domains 11	15	65895079-66253747	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA017982	Uncertain					Tissue enhanced	Group enriched	6	cerebral cortex: 13.0;fallopian tube: 12.3	testis: 1.9	Cell line enhanced		AN3-CA: 3.1;HEK93: 2.4;RPTEC TERT1: 7.0;SCLC-21H: 8.5
MEGF8	C19orf49, EGFL4, FLJ22365, SBP1	ENSG00000105429	Multiple EGF like domains 8	19	42325609-42378769	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049248	Approved				Renal cancer:2.17e-7 (favourable), Pancreatic cancer:6.03e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 38.0	Expressed in all		
MEGF9	EGFL5	ENSG00000106780	Multiple EGF like domains 9	9	120600813-120714470	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA014319, HPA050238	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:5.48e-11 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.2	Mixed		
MELK	KIAA0175	ENSG00000165304	Maternal embryonic leucine zipper kinase	9	36572862-36677683	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017214	Uncertain				Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.91e-7 (unfavourable), Lung cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.58e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 16.9	lymph node: 11.7	Expressed in all		
MEMO1	C2orf4, CGI-27, MEMO	ENSG00000162959	Mediator of cell motility 1	2	31865060-32011230	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042603, HPA057952	Approved		Approved	Vesicles		Mixed	Expressed in all			testis: 116.1	Expressed in all		
MEP1A	PPHA	ENSG00000112818	Meprin A subunit alpha	6	46793390-46839782	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB025163, HPA029416	Enhanced					Tissue enriched	Group enriched	42	colon: 117.8;duodenum: 282.2;rectum: 114.3;small intestine: 538.5	appendix: 6.2	Cell line enhanced		BEWO: 1.2;CACO-2: 2.4;RPMI-8226: 1.0
MEP1B		ENSG00000141434	Meprin A subunit beta	18	32185069-32220404	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029119	Enhanced					Group enriched	Group enriched	37	duodenum: 251.4;small intestine: 402.2	colon: 8.7	Cell line enhanced		SCLC-21H: 6.6
MERTK	c-Eyk, mer, RP38, Tyro12	ENSG00000153208	MER proto-oncogene, tyrosine kinase	2	111898479-112029561	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036196, HPA075622	Approved		Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:4.43e-5 (favourable), Lung cancer:4.74e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 77.2	Cell line enhanced		CACO-2: 31.5;Hep G2: 27.2;HUVEC TERT2: 32.3
MET	DFNB97, HGFR, RCCP2	ENSG00000105976	MET proto-oncogene, receptor tyrosine kinase	7	116672390-116798386	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005282, CAB018577, HPA055607	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 39.0	Mixed		
METTL21A	FAM119A, HCA557b, HSPA-KMT, LOC151194	ENSG00000144401	Methyltransferase like 21A	2	207580631-207625928	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034712	Uncertain		Approved	Nucleus<br>Cytosol	Liver cancer:1.87e-5 (unfavourable), Renal cancer:5.43e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 22.3	Expressed in all		
METTL2B	FLJ11350, METL, METTL2	ENSG00000165055	Methyltransferase like 2B	7	128476729-128506602	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			skin: 12.9	Expressed in all		
METTL7A	DKFZP586A0522	ENSG00000185432	Methyltransferase like 7A	12	50923472-50932517	Predicted membrane proteins	Evidence at protein level	HPA017434			Supported	Lipid droplets	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			thyroid gland: 400.8	Cell line enhanced		ASC diff: 267.0;Karpas-707: 287.8;RPMI-8226: 158.7
MFAP3		ENSG00000037749	Microfibrillar associated protein 3	5	154038906-154220478	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015883, HPA049198	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Cervical cancer:4.28e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 74.8	Expressed in all		
MFAP3L	KIAA0626, NYD-sp9	ENSG00000198948	Microfibrillar associated protein 3 like	4	169986597-170033031	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017986	Approved				Renal cancer:1.42e-8 (favourable)	Expressed in all	Tissue enhanced		testis: 74.1	epididymis: 47.4	Cell line enhanced		HMC-1: 19.9;RT4: 30.4;SK-BR-3: 25.8
MFF	C2orf33, GL004	ENSG00000168958	Mitochondrial fission factor	2	227325151-227357836	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010968, HPA074625	Approved		Supported	Mitochondria	Liver cancer:1.20e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 353.8	Expressed in all		
MFN1	FLJ20693	ENSG00000171109	Mitofusin 1	3	179347692-179394931	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033437, HPA059230	Approved		Supported	Mitochondria	Liver cancer:8.08e-5 (unfavourable), Endometrial cancer:6.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.4	Expressed in all		
MFN2	CMT2A2, CPRP1, KIAA0214, MARF	ENSG00000116688	Mitofusin 2	1	11980181-12013514	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030554	Uncertain				Renal cancer:2.36e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 200.3	Expressed in all		
MFRP	C1QTNF5, FLJ30570, NNO2, rd6	ENSG00000235718	Membrane frizzled-related protein	11	119338942-119346673	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			parathyroid gland: 0.2	Not detected		
MFSD1	FLJ14153, UG0581B09	ENSG00000118855	Major facilitator superfamily domain containing 1	3	158732198-158829719	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057924, HPA065858	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:5.60e-5 (favourable)	Expressed in all	Expressed in all			spleen: 35.2	Expressed in all		
MFSD10	IT10C3, TETRAN	ENSG00000109736	Major facilitator superfamily domain containing 10	4	2930561-2934859	Predicted membrane proteins	Evidence at protein level	HPA043209	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:5.68e-5 (unfavourable), Liver cancer:4.49e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 41.2	Expressed in all		
MFSD11	FLJ20226, FLJ22196	ENSG00000092931	Major facilitator superfamily domain containing 11	17	76735865-76781449	Predicted membrane proteins	Evidence at protein level	HPA022001	Uncertain		Approved	Nuclear speckles	Endometrial cancer:7.69e-4 (unfavourable), Urothelial cancer:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.5	Expressed in all		
MFSD12	C19orf28, MGC20700, PP3501	ENSG00000161091	Major facilitator superfamily domain containing 12	19	3538261-3574290	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042149, HPA043088	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Endometrial cancer:5.66e-6 (favourable), Lung cancer:2.34e-4 (unfavourable), Liver cancer:6.61e-4 (unfavourable), Stomach cancer:7.70e-4 (favourable)	Tissue enriched	Expressed in all			skin: 64.2	Expressed in all		
MFSD13A	bA18I14.8, C10orf77, FLJ22529, TMEM180	ENSG00000138111	Major facilitator superfamily domain containing 13A	10	102461395-102477045	Predicted membrane proteins, Transporters	Evidence at protein level	HPA018031	Uncertain		Approved	Golgi apparatus<br>Cytosol	Cervical cancer:8.29e-4 (favourable), Renal cancer:8.51e-4 (unfavourable)	Expressed in all	Mixed			lung: 11.5	Mixed		
MFSD14A	DKFZP564L0864, HIAT1	ENSG00000156875	Major facilitator superfamily domain containing 14A	1	100038097-100083377	Predicted membrane proteins	Evidence at protein level	HPA073681			Approved	Vesicles	Liver cancer:2.08e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 195.0	Expressed in all		
MFSD14B	FLJ14753, HIATL1	ENSG00000148110	Major facilitator superfamily domain containing 14B	9	94374551-94461042	Predicted membrane proteins, Transporters	Evidence at protein level	HPA017978			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enriched	5	parathyroid gland: 255.7	skin: 50.6	Expressed in all		
MFSD14C	HIATL2, MGC12945	ENSG00000196312	Major facilitator superfamily domain containing 14C	9	96897917-97013708	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Mixed			testis: 13.9	Cell line enhanced		HAP1: 27.3
MFSD2A	FLJ14490, MFSD2	ENSG00000168389	Major facilitator superfamily domain containing 2A	1	39955112-39969968	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043107	Uncertain		Approved	Plasma membrane<br>Cytosol<br>Cytoplasmic bodies	Renal cancer:4.22e-6 (unfavourable), Urothelial cancer:2.33e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 116.7;seminal vesicle: 110.9	testis: 63.4	Cell line enhanced		THP-1: 112.5
MFSD2B		ENSG00000205639	Major facilitator superfamily domain containing 2B	2	24010081-24063321	Predicted membrane proteins	Evidence at protein level	HPA044145	Enhanced					Not detected	Tissue enriched	9	bone marrow: 7.2	placenta: 0.7	Group enriched	16	HEL: 7.5;K-562: 3.3
MFSD3		ENSG00000167700	Major facilitator superfamily domain containing 3	8	144509074-144511213	Predicted membrane proteins	Evidence at protein level	HPA056013	Uncertain		Approved	Vesicles	Renal cancer:5.44e-7 (favourable), Cervical cancer:5.08e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 14.5	Mixed		
MFSD4A	DKFZp761N1114, FLJ25004, FLJ34577, MFSD4, UNQ3064	ENSG00000174514	Major facilitator superfamily domain containing 4A	1	205568885-205602918	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.27e-13 (favourable), Lung cancer:4.59e-4 (favourable), Cervical cancer:7.54e-4 (favourable)	Mixed	Tissue enhanced		kidney: 75.4;stomach: 111.7	cerebral cortex: 50.6	Cell line enhanced		HMC-1: 1.3;SCLC-21H: 1.9
MFSD4B	KIAA1919, MGC33953	ENSG00000173214	Major facilitator superfamily domain containing 4B	6	111259348-111271167	Predicted membrane proteins	Evidence at protein level	HPA031784	Approved		Uncertain	Intermediate filaments		Expressed in all	Mixed			placenta: 5.0	Mixed		
MFSD5	MGC11308	ENSG00000182544	Major facilitator superfamily domain containing 5	12	53251251-53254405	Predicted membrane proteins	Evidence at protein level	HPA039773	Uncertain				Liver cancer:1.43e-6 (unfavourable)	Expressed in all	Expressed in all			skin: 49.6	Expressed in all		
MFSD6	FLJ20160	ENSG00000151690	Major facilitator superfamily domain containing 6	2	190408355-190509205	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022274	Approved		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:1.05e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 79.0	Cell line enhanced		HDLM-2: 73.8
MFSD6L	FLJ35773	ENSG00000185156	Major facilitator superfamily domain containing 6 like	17	8797162-8799349	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA023164	Uncertain				Breast cancer:1.84e-4 (favourable)	Mixed	Tissue enhanced		testis: 29.8	parathyroid gland: 8.4	Cell line enriched	5	HMC-1: 7.5
MFSD7	FLJ22269, LP2561	ENSG00000169026	Major facilitator superfamily domain containing 7	4	681829-689441	Predicted membrane proteins	Evidence at transcript level	HPA043593	Uncertain				Renal cancer:2.66e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 13.0	Cell line enhanced		BEWO: 7.9;T-47d: 24.0
MFSD8	CLN7, MGC33302	ENSG00000164073	Major facilitator superfamily domain containing 8	4	127917805-127965995	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044802	Approved		Supported	Nucleoplasm<br>Vesicles	Urothelial cancer:2.21e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 12.5	Mixed		
MFSD9	MGC11332	ENSG00000135953	Major facilitator superfamily domain containing 9	2	102715840-102736888	Predicted membrane proteins	Evidence at protein level	HPA055293, HPA061859	Approved		Approved	Nucleoli	Glioma:7.48e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 9.8	Expressed in all		
MGAM	MGA	ENSG00000257335	Maltase-glucoamylase	7	141907813-142106747	Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA002270	Enhanced				Renal cancer:6.16e-5 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 59.4;small intestine: 97.2	epididymis: 31.1	Cell line enhanced		A549: 1.6;BJ hTERT+: 1.3;HL-60: 2.2;U-937: 3.4
MGAM2		ENSG00000257743	Maltase-glucoamylase 2 (putative)	7	142111749-142222324	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA055697	Enhanced		Approved	Vesicles<br>Cytosol		Group enriched	Group enriched	5	duodenum: 11.8;small intestine: 10.4	salivary gland: 2.1	Cell line enriched	7	RH-30: 1.1
MGARP	C4orf49, CESP-1, HUMMR, OSAP	ENSG00000137463	Mitochondria localized glutamic acid rich protein	4	139266163-139280338	Predicted membrane proteins	Evidence at protein level	HPA015994	Enhanced		Supported	Mitochondria		Tissue enhanced	Tissue enriched	10	adrenal gland: 267.2	ovary: 27.1	Cell line enhanced		BJ: 15.5;fHDF/TERT166: 21.3;HHSteC: 17.8;HUVEC TERT2: 46.0
MGAT1	GLCNAC-TI, GLYT1, GNT-1, GnTI, MGAT	ENSG00000131446	Mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase	5	180784782-180815652	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017432	Approved				Renal cancer:8.65e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 118.4	Expressed in all		
MGAT4C	HGNT-IV-H	ENSG00000182050	MGAT4 family member C	12	85955666-86838904	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA016418	Approved					Tissue enriched	Group enriched	5	cerebral cortex: 5.9;epididymis: 6.7;testis: 5.5;thyroid gland: 15.9	adrenal gland: 1.6	Group enriched	13	NTERA-2: 8.7;SCLC-21H: 4.4
MGAT5	GNT-V	ENSG00000152127	Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase	2	134119983-134454621	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA010919	Approved					Expressed in all	Mixed			parathyroid gland: 32.6	Expressed in all		
MGAT5B	FLJ25132, GnT-IX, GnT-VB	ENSG00000167889	Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B	17	76868456-76950393	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011082			Approved	Nucleoplasm<br>Cytokinetic bridge<br>Mitotic spindle		Group enriched	Tissue enriched	14	cerebral cortex: 23.1	testis: 1.6	Cell line enhanced		A549: 28.7;SCLC-21H: 18.6;U-138 MG: 18.3;U-2 OS: 21.0
MGST1	GST12, MGST-I	ENSG00000008394	Microsomal glutathione S-transferase 1	12	16347142-16609259	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044840	Enhanced		Approved	Endoplasmic reticulum<br>Mitochondria	Thyroid cancer:1.97e-4 (favourable), Renal cancer:7.45e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 1602.4	Cell line enhanced		ASC diff: 3718.8
MGST2	MGST-II	ENSG00000085871	Microsomal glutathione S-transferase 2	4	139665768-139740745	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010707	Approved		Approved	Nucleoplasm	Renal cancer:3.22e-9 (favourable), Endometrial cancer:5.26e-5 (favourable)	Expressed in all	Expressed in all			liver: 178.3	Mixed		
MGST3	GST-III	ENSG00000143198	Microsomal glutathione S-transferase 3	1	165630861-165661796	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA053311			Approved	Nucleus		Expressed in all	Expressed in all			epididymis: 629.7	Expressed in all		
MIA3	FLJ39207, KIAA0268, TANGO, TANGO1, UNQ6077	ENSG00000154305	MIA family member 3, ER export factor	1	222618086-222668012	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055922, HPA056816	Enhanced		Enhanced	Vesicles	Renal cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 81.5	Expressed in all		
MICA	PERB11.1	ENSG00000204520	MHC class I polypeptide-related sequence A	6	31399784-31415315	Predicted membrane proteins	Evidence at protein level						Cervical cancer:5.88e-4 (unfavourable)	Expressed in all	Mixed			lung: 11.2	Cell line enhanced		A-431: 36.1;HAP1: 29.8;HSkMC: 44.2;RPTEC TERT1: 30.9
MICAL2	KIAA0750	ENSG00000133816	Microtubule associated monooxygenase, calponin and LIM domain containing 2	11	12094008-12263789	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030437	Approved		Approved	Golgi apparatus	Renal cancer:3.63e-5 (unfavourable)	Expressed in all	Mixed			testis: 79.8	Cell line enhanced		U-138 MG: 131.4
MICAL3	KIAA0819	ENSG00000243156	Microtubule associated monooxygenase, calponin and LIM domain containing 3	22	17787649-18024559	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000639, HPA003421, HPA034882	Uncertain		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 71.2	Expressed in all		
MICB	PERB11.2	ENSG00000204516	MHC class I polypeptide-related sequence B	6	31494881-31511124	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA064618			Approved	Golgi apparatus<br>Vesicles	Renal cancer:4.94e-9 (unfavourable), Liver cancer:7.04e-5 (unfavourable)	Mixed	Tissue enhanced		lymph node: 3.2	spleen: 2.8	Cell line enhanced		U-266/84: 26.2
MICU3	DKFZp313A0139, EFHA2	ENSG00000155970	Mitochondrial calcium uptake family member 3	8	17027238-17122644	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024048, HPA024771, HPA024779	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 34.8	parathyroid gland: 14.2	Cell line enhanced		HBF TERT88: 12.3
MID1	FXY, OS, RNF59, TRIM18	ENSG00000101871	Midline 1	X	10445310-10833654	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003715	Approved				Liver cancer:3.06e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 20.7	Cell line enhanced		A549: 168.3;AF22: 136.2
MIEF1	FLJ20232, MiD51, SMCR7L	ENSG00000100335	Mitochondrial elongation factor 1	22	39499432-39518132	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA061059			Approved	Intermediate filaments<br>Mitochondria	Renal cancer:3.96e-5 (favourable)	Expressed in all	Expressed in all			testis: 22.1	Expressed in all		
MIEF2	MGC23130, MiD49, SMCR7	ENSG00000177427	Mitochondrial elongation factor 2	17	18260534-18266552	Predicted membrane proteins	Evidence at protein level	HPA042334	Uncertain				Renal cancer:1.75e-7 (favourable)	Expressed in all	Mixed			skeletal muscle: 7.0	Mixed		
MIGA1	FAM73A, FLJ35093	ENSG00000180488	Mitoguardin 1	1	77779624-77879539	Predicted membrane proteins	Evidence at protein level	HPA017589	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 32.7	Expressed in all		
MIGA2	C9orf54, FAM73B, FLJ00199, FLJ14596	ENSG00000148343	Mitoguardin 2	9	129036621-129072082	Predicted membrane proteins	Evidence at protein level	HPA041363	Approved		Approved	Cell Junctions<br>Cytosol	Pancreatic cancer:3.04e-6 (favourable)	Expressed in all	Mixed			small intestine: 15.5	Expressed in all		
MILR1	Allergin-1, C17orf60, MCA-32	ENSG00000271605	Mast cell immunoglobulin like receptor 1	17	64449037-64468643	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014347	Enhanced				Renal cancer:5.07e-6 (unfavourable)	Expressed in all	Mixed			appendix: 41.7	Cell line enhanced		CAPAN-2: 114.8;Daudi: 46.7;REH: 47.7;U-698: 47.8
MINOS1	C1orf151, FLJ36999, Mic10, MIO10, RP5-1056L3.2	ENSG00000173436	Mitochondrial inner membrane organizing system 1	1	19596977-19629821	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059930	Enhanced		Supported	Mitochondria	Liver cancer:7.23e-4 (unfavourable), Urothelial cancer:8.11e-4 (favourable)	Expressed in all	Expressed in all			prostate: 13.1	Expressed in all		
MIP	AQP0, LIM1, MP26	ENSG00000135517	Major intrinsic protein of lens fiber	12	56449502-56469166	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014940	Supported					Not detected	Tissue enhanced		testis: 1.2	cerebral cortex,liver: 0.2	Not detected		
MKKS	BBS6	ENSG00000125863	McKusick-Kaufman syndrome	20	10401009-10434222	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041071, HPA044233	Enhanced		Supported	Centrosome	Renal cancer:3.79e-9 (favourable), Liver cancer:9.84e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 70.6	Expressed in all		
MKNK1	MNK1	ENSG00000079277	MAP kinase interacting serine/threonine kinase 1	1	46557408-46616843	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB027355, CAB037310, HPA071293	Approved		Supported	Nucleoplasm	Liver cancer:1.24e-5 (unfavourable), Renal cancer:1.51e-5 (unfavourable), Cervical cancer:7.05e-4 (favourable)	Expressed in all	Expressed in all			appendix: 35.8	Expressed in all		
MLANA	MART1	ENSG00000120215	Melan-A	9	5890802-5910606	Predicted membrane proteins	Evidence at protein level	CAB000057, HPA048662	Enhanced					Tissue enriched	Tissue enriched	25	skin: 50.4	breast: 1.9	Cell line enriched	330	SK-MEL-30: 523.2
MLC1	KIAA0027, LVM, MLC, VL	ENSG00000100427	Megalencephalic leukoencephalopathy with subcortical cysts 1	22	50059391-50085902	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003040, HPA067533	Enhanced					Tissue enriched	Tissue enriched	8	cerebral cortex: 180.8	bone marrow: 23.0	Cell line enhanced		HL-60: 182.4;NB-4: 133.9;THP-1: 267.0;U-266/70: 101.9;U-266/84: 85.6
MLEC	KIAA0152	ENSG00000110917	Malectin	12	120686869-120701864	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:9.60e-6 (favourable), Stomach cancer:8.77e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 162.3	Expressed in all		
MLLT10	AF10	ENSG00000078403	Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 10	10	21524675-21743630	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA005747	Supported		Supported	Nucleoplasm	Head and neck cancer:8.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 177.6	Expressed in all		
MLNR	GPR38	ENSG00000102539	Motilin receptor	13	49220338-49222377	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		thyroid gland: 2.8	bone marrow: 0.8	Cell line enhanced		NTERA-2: 1.3;THP-1: 2.7
MMD	MMA, PAQR11	ENSG00000108960	Monocyte to macrophage differentiation associated	17	55392613-55421992	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA026978			Approved	Vesicles	Colorectal cancer:3.52e-5 (favourable), Liver cancer:6.39e-5 (unfavourable), Renal cancer:2.85e-4 (unfavourable), Endometrial cancer:3.88e-4 (unfavourable), Thyroid cancer:8.62e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 141.5	cerebral cortex: 73.0	Expressed in all		
MMD2	PAQR10	ENSG00000136297	Monocyte to macrophage differentiation associated 2	7	4905989-4959213	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Group enriched	83	cerebral cortex: 41.2;testis: 12.4	adrenal gland: 0.3	Not detected		
MME	CALLA, CD10, NEP	ENSG00000196549	Membrane metalloendopeptidase	3	155024124-155183729	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000013, HPA052583, HPA056072	Enhanced					Mixed	Tissue enhanced		duodenum: 428.2;kidney: 384.2;small intestine: 401.5	prostate: 162.5	Cell line enhanced		ASC TERT1: 595.9;BJ hTERT+: 1084.7;HSkMC: 604.7
MMGT1	EMC5, TMEM32	ENSG00000169446	Membrane magnesium transporter 1	X	135962070-135974063	Predicted membrane proteins	Evidence at protein level	HPA032037	Approved				Renal cancer:1.94e-5 (favourable), Breast cancer:8.54e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 34.5	Expressed in all		
MMP14	MT1-MMP	ENSG00000157227	Matrix metallopeptidase 14	14	22836557-22849027	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009918, HPA051432	Approved		Approved	Intermediate filaments<br>Cytosol	Renal cancer:1.34e-4 (unfavourable), Ovarian cancer:9.48e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 236.6	Cell line enhanced		HHSteC: 664.7
MMP15	MT2-MMP, MTMMP2, SMCP-2	ENSG00000102996	Matrix metallopeptidase 15	16	58025566-58046901	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002611, HPA040390	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 70.1	placenta: 39.3	Cell line enhanced		BEWO: 86.0;WM-115: 73.7
MMP16	C8orf57, DKFZp761D112, MT3-MMP	ENSG00000156103	Matrix metallopeptidase 16	8	88032009-88328025	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023693	Uncertain		Approved	Vesicles<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 9.6	gallbladder: 4.2	Cell line enhanced		AN3-CA: 27.2;SH-SY5Y: 17.2;WM-115: 28.4
MMP24	MT5-MMP	ENSG00000125966	Matrix metallopeptidase 24	20	35226654-35277000	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level	HPA049280			Approved	Nucleoli<br>Plasma membrane	Renal cancer:8.17e-11 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 10.6	lung: 7.0	Cell line enhanced		A549: 32.8;CACO-2: 46.1;RPTEC TERT1: 18.5;U-2 OS: 18.9
MOG	BTN6, BTNL11	ENSG00000204655	Myelin oligodendrocyte glycoprotein	6	29656981-29672372	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA021873	Enhanced					Tissue enriched	Not detected			cerebral cortex: 0.8	Not detected		
MOGAT1	DGAT2L, DGAT2L1, MGAT1	ENSG00000124003	Monoacylglycerol O-acyltransferase 1	2	222671786-222709930	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA049944	Uncertain					Tissue enhanced	Tissue enriched	10	gallbladder: 30.7	parathyroid gland: 2.9	Not detected		
MOGAT2	DGAT2L5, FLJ22644, MGAT2	ENSG00000166391	Monoacylglycerol O-acyltransferase 2	11	75717819-75732958	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028834	Uncertain					Tissue enhanced	Group enriched	12	colon: 12.5;duodenum: 37.2;liver: 12.1;rectum: 12.5;small intestine: 43.6	appendix: 1.9	Group enriched	6	Hep G2: 2.7;RPMI-8226: 1.8
MOGAT3	DC7, DGAT2L2, MGAT3	ENSG00000106384	Monoacylglycerol O-acyltransferase 3	7	101195007-101201021	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA011940	Uncertain		Approved	Centrosome		Tissue enhanced	Group enriched	6	colon: 11.3;duodenum: 30.4;rectum: 11.9;small intestine: 33.6	liver: 3.4	Cell line enhanced		CACO-2: 2.9;Hep G2: 8.1
MOGS	CWH41, DER7, GCS1	ENSG00000115275	Mannosyl-oligosaccharide glucosidase	2	74461057-74465410	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011322, HPA011969	Approved		Enhanced	Endoplasmic reticulum	Renal cancer:2.79e-8 (unfavourable), Liver cancer:2.34e-6 (unfavourable), Colorectal cancer:5.33e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 63.1	Expressed in all		
MOSPD1	dJ473B4	ENSG00000101928	Motile sperm domain containing 1	X	134887626-134915267	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031158	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			fallopian tube: 42.4	Expressed in all		
MOSPD2	MGC26706	ENSG00000130150	Motile sperm domain containing 2	X	14873441-14922327	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003334	Uncertain		Approved	Endoplasmic reticulum	Liver cancer:8.91e-4 (unfavourable)	Expressed in all	Mixed			skin: 28.6	Expressed in all		
MOSPD3	CDS3, NET30	ENSG00000106330	Motile sperm domain containing 3	7	100612102-100615384	Predicted membrane proteins	Evidence at protein level	HPA041137, HPA048240	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 29.6	Expressed in all		
MOXD1	dJ248E1.1, DKFZP564G202, MOX	ENSG00000079931	Monooxygenase DBH like 1	6	132296055-132401545	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035740	Approved		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:7.09e-5 (favourable), Stomach cancer:3.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 106.1;smooth muscle: 114.5	seminal vesicle: 53.7	Cell line enhanced		ASC diff: 111.5;fHDF/TERT166: 149.9;HBF TERT88: 116.1;U-2197: 280.6
MPC1	BRP44L, CGI-129, dJ68L15.3	ENSG00000060762	Mitochondrial pyruvate carrier 1	6	166364919-166383013	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA045119, HPA055790	Enhanced		Enhanced	Mitochondria	Renal cancer:4.79e-11 (favourable), Lung cancer:1.29e-4 (favourable), Cervical cancer:1.45e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 432.9	Expressed in all		
MPC1L		ENSG00000238205	Mitochondrial pyruvate carrier 1-like	X	40623566-40624136	Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	67	testis: 12.0	epididymis,lung,lymph node: 0.1	Not detected		
MPC2	BRP44, DKFZP564B167	ENSG00000143158	Mitochondrial pyruvate carrier 2	1	167916729-167937040	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA056091	Uncertain					Expressed in all	Expressed in all			testis: 355.9	Expressed in all		
MPDU1	CDGIf, Lec35, PQLC5, SL15	ENSG00000129255	Mannose-P-dolichol utilization defect 1	17	7583529-7592789	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014845	Uncertain		Supported	Endoplasmic reticulum<br>Mitochondria		Expressed in all	Expressed in all			rectum: 67.3	Expressed in all		
MPEG1	MPG1	ENSG00000197629	Macrophage expressed 1	11	59208510-59212951	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046801	Approved					Expressed in all	Tissue enhanced		spleen: 283.2	appendix: 152.1	Not detected		
MPHOSPH10	CT90, MPP10, MPP10P, PPP1R106	ENSG00000124383	M-phase phosphoprotein 10	2	71130314-71150101	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035059, HPA035060, HPA049907	Enhanced		Enhanced	Nucleoli	Renal cancer:3.89e-7 (unfavourable)	Expressed in all	Expressed in all			prostate: 35.3	Expressed in all		
MPIG6B	C6orf25, G6b, G6b-B, NG31	ENSG00000204420	Megakaryocyte and platelet inhibitory receptor G6b	6	31718594-31726714	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA073017			Uncertain	Golgi apparatus		Mixed	Not detected			skin: 0.8	Cell line enriched	16	HEL: 5.4
MPL	CD110, TPOR	ENSG00000117400	MPL proto-oncogene, thrombopoietin receptor	1	43337849-43352772	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Mixed			ovary: 1.3	Cell line enriched	97	HEL: 51.8
MPPE1		ENSG00000154889	Metallophosphoesterase 1	18	11882622-11909223	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012639	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:6.45e-7 (favourable), Melanoma:1.35e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 78.0	Expressed in all		
MPV17	SYM1	ENSG00000115204	MPV17, mitochondrial inner membrane protein	2	27309492-27325680	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Liver cancer:6.99e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 84.3	Expressed in all		
MPV17L	FLJ39599, MLPH1, MLPH2, MPV17L1	ENSG00000156968	MPV17 mitochondrial inner membrane protein like	16	15395754-15413268	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041180	Uncertain		Supported	Vesicles	Renal cancer:1.48e-11 (favourable)	Mixed	Mixed			breast: 10.3	Cell line enhanced		HMC-1: 35.5
MPV17L2	FKSG24, MGC12972	ENSG00000254858	MPV17 mitochondrial inner membrane protein like 2	19	18193182-18196948	Predicted membrane proteins	Evidence at protein level	HPA043111	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.30e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 16.3	Expressed in all		
MPZ	CMT1, CMT1B, CMT2I, CMT2J, HMSNIB	ENSG00000158887	Myelin protein zero	1	161304735-161309972	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068925	Supported					Tissue enriched	Mixed			seminal vesicle: 16.7	Cell line enriched	8	WM-115: 201.9
MPZL1	FLJ21047, PZR	ENSG00000197965	Myelin protein zero like 1	1	167721192-167791919	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026966, HPA063538	Approved		Supported	Vesicles<br>Plasma membrane	Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 111.6	Expressed in all		
MPZL2	EVA, EVA1	ENSG00000149573	Myelin protein zero like 2	11	118253403-118264536	Predicted membrane proteins	Evidence at protein level	HPA060740	Approved		Approved	Cell Junctions	Pancreatic cancer:1.14e-4 (unfavourable), Thyroid cancer:1.62e-4 (favourable)	Expressed in all	Tissue enhanced		esophagus: 209.1	urinary bladder: 118.1	Cell line enhanced		CAPAN-2: 107.3;EFO-21: 123.8;HaCaT: 149.0;RT4: 257.4;TIME: 288.5
MPZL3		ENSG00000160588	Myelin protein zero like 3	11	118226690-118252350	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029116			Approved	Golgi apparatus	Thyroid cancer:3.64e-4 (favourable), Pancreatic cancer:4.98e-4 (unfavourable)	Expressed in all	Mixed			skin: 25.8	Cell line enhanced		CAPAN-2: 23.2;HMC-1: 25.7
MR1	HLALS	ENSG00000153029	Major histocompatibility complex, class I-related	1	181033425-181061938	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048304			Supported	Plasma membrane		Expressed in all	Mixed			thyroid gland: 28.2	Mixed		
MRAP	B27, C21orf61, FALP	ENSG00000170262	Melanocortin 2 receptor accessory protein	21	32291813-32314784	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA011024	Uncertain					Not detected	Group enriched	8	adipose tissue: 52.7;adrenal gland: 65.2	breast: 7.5	Cell line enhanced		Hep G2: 1.0;HSkMC: 1.2
MRAP2	bA51G5.2, C6orf117	ENSG00000135324	Melanocortin 2 receptor accessory protein 2	6	84033756-84090881	Disease related genes, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:1.66e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 21.0	fallopian tube: 13.4	Group enriched	5	K-562: 81.0;SCLC-21H: 35.1
MRC1	bA541I19.1, CD206, CLEC13D, CLEC13DL, MRC1L1	ENSG00000260314	Mannose receptor C-type 1	10	17809344-17911170	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA004114, HPA045134, CAB068203	Enhanced					Expressed in all	Tissue enhanced		lung: 179.9	placenta: 77.6	Group enriched	22	MOLT-4: 15.4;TIME: 14.0
MRC2	CD280, CLEC13E, ENDO180, KIAA0709	ENSG00000011028	Mannose receptor C type 2	17	62627401-62693597	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041991	Enhanced				Renal cancer:4.94e-7 (unfavourable), Ovarian cancer:1.68e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 39.7	Cell line enhanced		BJ: 151.9;U-138 MG: 176.9
MRGPRD	mrgD	ENSG00000172938	MAS related GPR family member D	11	68980021-68980986	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA031346	Uncertain					Not detected	Not detected			seminal vesicle: 0.3	Not detected		
MRGPRE	GPR167, mrgE	ENSG00000184350	MAS related GPR family member E	11	3227698-3232386	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA046556	Uncertain					Tissue enhanced	Tissue enhanced		cervix, uterine: 1.0	endometrium: 0.7	Cell line enhanced		RPMI-8226: 1.5;SCLC-21H: 4.1
MRGPRF	GPR140, GPR168, MGC21621, mrgF	ENSG00000172935	MAS related GPR family member F	11	69004395-69013409	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA028811	Approved		Supported	Nuclear membrane<br>Plasma membrane		Expressed in all	Mixed			smooth muscle: 78.8	Cell line enhanced		ASC diff: 43.0;BJ: 31.1;BJ hTERT+: 74.9;BJ hTERT+ SV40 Large T+: 31.7;U-2197: 40.5
MRGPRG	GPR169, mrgG	ENSG00000182170	MAS related GPR family member G	11	3217944-3218813	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA058909	Uncertain					Not detected	Tissue enriched	15	testis: 1.5	all non-specific tissues: 0.0	Cell line enhanced		SCLC-21H: 1.0
MRGPRX1	MRGX1	ENSG00000170255	MAS related GPR family member X1	11	18933813-18939507	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MRGPRX2	MRGX2	ENSG00000183695	MAS related GPR family member X2	11	19054455-19060681	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA055220	Approved					Not detected	Tissue enhanced		breast: 1.2;skin: 1.2	cervix, uterine: 0.6	Not detected		
MRGPRX3	MRGX3	ENSG00000179826	MAS related GPR family member X3	11	18120955-18138480	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		salivary gland: 1.3	breast,testis: 0.7	Cell line enriched	7	HBEC3-KT: 10.4
MRGPRX4	MRGX4	ENSG00000179817	MAS related GPR family member X4	11	18172837-18174280	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Not detected			all non-specific tissues: 0.0	Cell line enhanced		SK-MEL-30: 1.1;WM-115: 1.8
MRLN	Linc-RAM, LINC00948, M1, MLN, MUSER1	ENSG00000227877	Myoregulin	10	59736692-59756041	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enhanced	Tissue enhanced		skeletal muscle: 65.4	kidney: 13.8	Cell line enriched	12	RH-30: 21.4
MRS2	MRS2L	ENSG00000124532	MRS2, magnesium transporter	6	24402908-24426194	Predicted membrane proteins	Evidence at protein level	HPA017642	Uncertain				Ovarian cancer:5.14e-11 (favourable), Endometrial cancer:5.32e-4 (unfavourable), Thyroid cancer:8.03e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 29.8	Mixed		
MRVI1	IRAG, JAW1L	ENSG00000072952	Murine retrovirus integration site 1 homolog	11	10573091-10693988	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008704	Uncertain		Approved	Nuclear bodies<br>Cytosol	Endometrial cancer:5.78e-4 (favourable), Renal cancer:9.70e-4 (unfavourable)	Mixed	Mixed			smooth muscle: 99.6	Cell line enhanced		ASC diff: 14.2;BJ: 12.9;BJ hTERT+: 14.3
MS4A1	B1, Bp35, CD20, MS4A2	ENSG00000156738	Membrane spanning 4-domains A1	11	60455752-60470760	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000015, HPA014341, HPA014391	Enhanced		Supported	Plasma membrane	Breast cancer:4.34e-5 (favourable)	Mixed	Group enriched	15	appendix: 240.0;lymph node: 770.3;spleen: 468.8;tonsil: 789.8	urinary bladder: 38.3	Group enriched	19	Daudi: 534.8;U-698: 258.0
MS4A10	CD20L7, MS4A9	ENSG00000172689	Membrane spanning 4-domains A10	11	60785348-60801305	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA014778	Uncertain					Not detected	Group enriched	193	duodenum: 74.2;small intestine: 95.8	kidney: 0.4	Not detected		
MS4A12	FLJ20217, Ms4a10	ENSG00000071203	Membrane spanning 4-domains A12	11	60492778-60507430	Predicted membrane proteins	Evidence at protein level	HPA057657	Enhanced					Tissue enriched	Group enriched	19	colon: 235.5;rectum: 280.6	appendix: 13.2	Cell line enhanced		RH-30: 1.1
MS4A13		ENSG00000204979	Membrane spanning 4-domains A13	11	60515413-60542721	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA045017, HPA063626	Uncertain					Not detected	Tissue enriched	54	testis: 5.3	all non-specific tissues: 0.0	Cell line enhanced		U-266/70: 1.4
MS4A14	DKFZp434H092, FLJ32856, MS4A16, NYD-SP21	ENSG00000166928	Membrane spanning 4-domains A14	11	60378530-60417756	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level							Mixed	Tissue enriched	12	testis: 91.8	spleen: 7.6	Cell line enriched	23	THP-1: 6.3
MS4A15		ENSG00000166961	Membrane spanning 4-domains A15	11	60756953-60776732	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	11	lung: 71.4	endometrium: 6.2	Cell line enhanced		HEL: 6.6;MOLT-4: 2.7;U-266/70: 7.9;U-266/84: 3.3
MS4A18		ENSG00000214782	Membrane spanning 4-domains A18	11	60729304-60744212	Predicted membrane proteins	Evidence at transcript level	HPA045121	Approved					Not detected	Tissue enhanced		breast: 10.3;duodenum: 23.9	small intestine: 4.0	Not detected		
MS4A2	APY, FCER1B, IGER, MS4A1	ENSG00000149534	Membrane spanning 4-domains A2	11	60088261-60098466	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA059967	Enhanced					Mixed	Tissue enhanced		lung: 24.8	gallbladder: 18.4	Cell line enhanced		HEL: 2.4;THP-1: 1.0
MS4A3	CD20L, HTM4	ENSG00000149516	Membrane spanning 4-domains A3	11	60056587-60071128	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019210	Supported					Not detected	Tissue enriched	256	bone marrow: 305.3	skin,spleen: 1.1	Cell line enhanced		HEL: 172.0;K-562: 132.6;NB-4: 69.9;THP-1: 214.5;U-937: 98.3
MS4A4A	CD20L1, MS4A4, MS4A7	ENSG00000110079	Membrane spanning 4-domains A4A	11	60280541-60308972	Predicted membrane proteins	Evidence at transcript level	HPA029323	Approved					Expressed in all	Tissue enhanced		placenta: 102.2	adipose tissue: 63.4	Cell line enriched	24	K-562: 118.6
MS4A4E		ENSG00000214787	Membrane spanning 4-domains A4E	11	60201253-60243088	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040075	Uncertain					Mixed	Mixed			adipose tissue: 5.9	Cell line enhanced		K-562: 1.9;THP-1: 2.0
MS4A5	CD20L2	ENSG00000166930	Membrane spanning 4-domains A5	11	60429589-60455214	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA043732	Uncertain					Not detected	Tissue enriched	280	testis: 73.1	duodenum: 0.2	Not detected		
MS4A6A	CD20L3, MS4A6	ENSG00000110077	Membrane spanning 4-domains A6A	11	60172014-60184666	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA011391	Approved				Cervical cancer:6.33e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 113.5	Cell line enriched	6	THP-1: 32.2
MS4A6E		ENSG00000166926	Membrane spanning 4-domains A6E	11	60334831-60396596	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	37	testis: 61.9	appendix: 1.6	Not detected		
MS4A7	CD20L4, CFFM4, MS4A8	ENSG00000166927	Membrane spanning 4-domains A7	11	60378482-60395951	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017418, CAB026387	Approved					Expressed in all	Tissue enhanced		spleen: 316.0	lung: 125.0	Cell line enriched	25	THP-1: 78.2
MS4A8	CD20L5, MS4A4, MS4A8B	ENSG00000166959	Membrane spanning 4-domains A8	11	60699574-60715811	Predicted membrane proteins	Evidence at protein level	HPA007318, HPA007319	Enhanced					Tissue enhanced	Tissue enhanced		duodenum: 186.5;fallopian tube: 226.5;small intestine: 210.9	stomach: 49.1	Cell line enhanced		SCLC-21H: 1.1
MSANTD3-TMEFF1	C9orf30-TMEFF1	ENSG00000251349	MSANTD3-TMEFF1 readthrough	9	100442271-100577636	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 48.0	testis: 10.2	Cell line enhanced		AF22: 98.5;NTERA-2: 50.5;SCLC-21H: 63.0
MSLN	CAK1, MPF	ENSG00000102854	Mesothelin	16	760762-768865	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002216, HPA017172	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.91e-4 (favourable), Pancreatic cancer:6.66e-4 (unfavourable)	Tissue enhanced	Group enriched	9	fallopian tube: 445.8;lung: 105.4	epididymis: 29.1	Cell line enhanced		CAPAN-2: 448.3;EFO-21: 72.6;HeLa: 104.4;hTCEpi: 80.2
MSLNL	C16orf37, MPFL	ENSG00000162006	Mesothelin-like	16	769428-783370	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Not detected			epididymis: 0.8	Group enriched	5	CAPAN-2: 9.8;HeLa: 4.3
MSMO1	DESP4, ERG25, SC4MOL	ENSG00000052802	Methylsterol monooxygenase 1	4	165327623-165343160	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA056127	Approved				Cervical cancer:2.97e-4 (unfavourable), Renal cancer:9.21e-4 (favourable)	Expressed in all	Expressed in all			liver: 297.1	Expressed in all		
MSR1	CD204, SCARA1	ENSG00000038945	Macrophage scavenger receptor 1	8	16107878-16567490	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000272, CAB032491	Enhanced					Expressed in all	Tissue enhanced		lung: 187.7	gallbladder: 50.2	Group enriched	6	BJ hTERT+: 86.3;REH: 37.8
MST1R	CD136, CDw136, PTK8, RON	ENSG00000164078	Macrophage stimulating 1 receptor	3	49887002-49903873	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007657, HPA008180, CAB008972	Enhanced		Approved	Cytosol	Urothelial cancer:2.33e-5 (favourable)	Mixed	Tissue enhanced		skin: 69.4	stomach: 37.2	Cell line enhanced		CAPAN-2: 84.1;HaCaT: 46.9;HBEC3-KT: 41.5;hTCEpi: 57.4;RT4: 49.8
MT-ATP6	ATP6, ATPase-6, MTATP6, RP, Su6m	ENSG00000198899	Mitochondrially encoded ATP synthase 6	MT	8527-9207	Disease related genes, Predicted membrane proteins	Evidence at protein level						Liver cancer:3.79e-4 (favourable), Pancreatic cancer:7.64e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 42788.3	Expressed in all		
MT-ATP8	A6L, ATP8, MTATP8	ENSG00000228253	Mitochondrially encoded ATP synthase 8	MT	8366-8572	Disease related genes, Predicted membrane proteins	Evidence at protein level						Liver cancer:7.56e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 66363.2	Expressed in all		
MT-CO1	COI, COX1, MTCO1	ENSG00000198804	Mitochondrially encoded cytochrome c oxidase I	MT	5904-7445	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016241, HPA069328	Enhanced		Supported	Mitochondria	Liver cancer:2.29e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 79421.5	Expressed in all		
MT-CO2	CO2, COX2, MTCO2	ENSG00000198712	Mitochondrially encoded cytochrome c oxidase II	MT	7586-8269	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016243, HPA051505, HPA054758	Enhanced				Liver cancer:2.89e-4 (favourable), Pancreatic cancer:7.10e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 40900.1	Expressed in all		
MT-CO3	CO3, COIII, COX3, MTCO3	ENSG00000198938	Mitochondrially encoded cytochrome c oxidase III	MT	9207-9990	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042788	Approved		Approved	Nucleoplasm	Pancreatic cancer:1.04e-4 (favourable), Liver cancer:2.01e-4 (favourable)	Expressed in all	Expressed in all			kidney: 54081.3	Expressed in all		
MT-CYB	COB, CYTB, MTCYB, UQCR3	ENSG00000198727	Mitochondrially encoded cytochrome b	MT	14747-15887	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB032215, HPA068400	Enhanced		Approved	Mitochondria	Liver cancer:5.96e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 23224.8	Expressed in all		
MT-ND1	MTND1, NAD1, ND1	ENSG00000198888	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	MT	3307-4262	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB033779	Approved				Pancreatic cancer:3.26e-4 (favourable), Breast cancer:3.63e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 23817.4	Expressed in all		
MT-ND2	MTND2, NAD2, ND2	ENSG00000198763	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	MT	4470-5511	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			heart muscle: 24880.0	Expressed in all		
MT-ND3	MTND3, NAD3, ND3	ENSG00000198840	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	MT	10059-10404	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA063296	Enhanced		Approved	Cytosol	Liver cancer:4.63e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 30083.4	Expressed in all		
MT-ND4	LHON, MTND4, NAD4, ND4	ENSG00000198886	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	MT	10760-12137	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA053928	Approved				Ovarian cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 36982.3	Expressed in all		
MT-ND4L	MTND4L, NAD4L, ND4L	ENSG00000212907	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	MT	10470-10766	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA075648			Supported	Mitochondria	Liver cancer:4.47e-4 (favourable)	Expressed in all	Expressed in all			kidney: 23320.0	Expressed in all		
MT-ND5	MTND5, NAD5, ND5	ENSG00000198786	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	MT	12337-14148	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.31e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 13037.2	Expressed in all		
MT-ND6	MTND6, NAD6, ND6	ENSG00000198695	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	MT	14149-14673	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Renal cancer:8.91e-6 (favourable)	Expressed in all	Expressed in all			heart muscle: 22714.1	Expressed in all		
MTCH1	CGI-64, PSAP, SLC25A49	ENSG00000137409	Mitochondrial carrier 1	6	36968141-36986298	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015971	Approved				Renal cancer:1.16e-7 (favourable), Liver cancer:1.17e-4 (unfavourable), Endometrial cancer:2.06e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 569.1	Expressed in all		
MTCH2	SLC25A50	ENSG00000109919	Mitochondrial carrier 2	11	47617315-47642623	Predicted membrane proteins, Transporters	Evidence at protein level	HPA038390	Approved		Supported	Mitochondria	Renal cancer:9.05e-6 (favourable)	Expressed in all	Expressed in all			testis: 138.3	Expressed in all		
MTDH	3D3, AEG-1, LYRIC	ENSG00000147649	Metadherin	8	97644179-97728770	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010932, HPA015104, CAB068204, CAB068205	Supported		Enhanced	Endoplasmic reticulum	Renal cancer:3.82e-4 (unfavourable), Pancreatic cancer:5.36e-4 (unfavourable), Lung cancer:7.76e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 104.4	Expressed in all		
MTFP1	HSPC242, MTP18	ENSG00000242114	Mitochondrial fission process 1	22	30425530-30429053	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA077396			Approved	Mitochondria		Expressed in all	Expressed in all			epididymis: 19.2	Expressed in all		
MTFR2	DUFD1, FAM54A	ENSG00000146410	Mitochondrial fission regulator 2	6	136231024-136250335	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029792, HPA029794	Approved		Uncertain	Vesicles	Lung cancer:8.28e-4 (unfavourable), Endometrial cancer:9.64e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 12.7	bone marrow: 10.2	Mixed		
MTHFD1	MTHFC, MTHFD	ENSG00000100714	Methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1	14	64388031-64463457	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000704, HPA001290, HPA015006, HPA050052	Approved		Enhanced	Cytosol	Renal cancer:5.93e-5 (favourable), Pancreatic cancer:6.96e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 198.5	Expressed in all		
MTHFD1L	DKFZP586G1517, FLJ21145, FTHFSDC1	ENSG00000120254	Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like	6	150865549-151101887	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015006, HPA029040, HPA029041, HPA050052, HPA074911	Approved		Supported	Mitochondria	Cervical cancer:1.68e-5 (unfavourable), Liver cancer:8.33e-5 (unfavourable), Urothelial cancer:8.69e-5 (unfavourable), Head and neck cancer:5.10e-4 (unfavourable), Endometrial cancer:7.28e-4 (unfavourable)	Expressed in all	Mixed			placenta: 20.6	Expressed in all		
MTNR1A	MEL-1A-R	ENSG00000168412	Melatonin receptor 1A	4	186533655-186555567	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		kidney: 2.2;testis: 1.9	colon: 1.2	Not detected		
MTNR1B		ENSG00000134640	Melatonin receptor 1B	11	92969720-92985066	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		placenta: 1.4	testis: 0.8	Not detected		
MTUS1	ATBP, ATIP1, DKFZp586D1519, FLJ14295, ICIS, KIAA1288, MP44, MTSG1	ENSG00000129422	Microtubule associated tumor suppressor 1	8	17643795-17800917	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067903, HPA069795			Enhanced	Nucleoli<br>Microtubules	Colorectal cancer:1.05e-4 (favourable), Renal cancer:2.76e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 128.1	Cell line enhanced		A549: 104.4;AN3-CA: 92.7;HUVEC TERT2: 247.3
MTX1	MTX, MTXN	ENSG00000173171	Metaxin 1	1	155208699-155213824	Predicted membrane proteins	Evidence at protein level	HPA011543	Uncertain		Supported	Mitochondria	Renal cancer:3.39e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 71.8	Expressed in all		
MUC1	ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM	ENSG00000185499	Mucin 1, cell surface associated	1	155185824-155192916	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000036, CAB001986, HPA004179, HPA007235, HPA008855	Enhanced				Pancreatic cancer:4.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 448.0;stomach: 654.1	cervix, uterine: 288.9	Group enriched	7	CAPAN-2: 1005.2;RPTEC TERT1: 654.7;T-47d: 360.0
MUC12	MUC11	ENSG00000205277	Mucin 12, cell surface associated	7	100969623-101018949	Predicted membrane proteins	Evidence at protein level	HPA023835	Enhanced					Tissue enriched	Group enriched	24	colon: 49.6;rectum: 74.4	appendix: 2.5	Not detected		
MUC13	DRCC1	ENSG00000173702	Mucin 13, cell surface associated	3	124905442-124953819	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045163	Enhanced				Renal cancer:9.73e-5 (unfavourable)	Tissue enhanced	Group enriched	6	colon: 301.8;duodenum: 614.7;rectum: 330.1;small intestine: 555.7	appendix: 79.5	Cell line enhanced		A549: 6.6;CACO-2: 5.3;CAPAN-2: 11.9;Karpas-707: 5.6
MUC15		ENSG00000169550	Mucin 15, cell surface associated	11	26559033-26572233	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA026110	Approved					Tissue enriched	Tissue enriched	18	epididymis: 2826.7	thyroid gland: 159.3	Cell line enhanced		BEWO: 9.4;K-562: 11.5;SK-BR-3: 15.6;U-266/70: 6.2;U-266/84: 16.2
MUC16	CA125, FLJ14303	ENSG00000181143	Mucin 16, cell surface associated	19	8848844-8981342	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB055172, HPA065600	Enhanced					Tissue enhanced	Tissue enhanced		cervix, uterine: 24.0;fallopian tube: 9.4	endometrium: 3.5	Cell line enhanced		A-431: 20.2;CAPAN-2: 7.0;HaCaT: 6.8;HeLa: 26.2
MUC17		ENSG00000169876	Mucin 17, cell surface associated	7	101020072-101058745	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA031634	Enhanced					Group enriched	Group enriched	8	duodenum: 21.8;small intestine: 42.5	rectum: 3.8	Not detected		
MUC21	bCX31G15.2, C6orf205	ENSG00000204544	Mucin 21, cell surface associated	6	30983718-30989903	Predicted membrane proteins	Evidence at protein level	HPA052028	Enhanced					Group enriched	Tissue enriched	49	esophagus: 596.4	tonsil: 12.2	Not detected		
MUC22	PBMUCL1	ENSG00000261272	Mucin 22	6	31010474-31035402	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	116	esophagus: 20.2	testis,tonsil: 0.1	Not detected		
MUC3A	MUC3	ENSG00000169894	Mucin 3A, cell surface associated	7	100949555-100968346	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010871	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 41.6;gallbladder: 21.8;small intestine: 37.1	rectum: 13.1	Cell line enhanced		CACO-2: 6.0;CAPAN-2: 2.1;U-2 OS: 1.4
MUC4		ENSG00000145113	Mucin 4, cell surface associated	3	195746765-195812277	Predicted membrane proteins	Evidence at protein level	HPA005895, CAB013536	Approved					Tissue enhanced	Tissue enhanced		colon: 1.0	esophagus: 0.4	Not detected		
MUL1	C1orf166, FLJ12875, GIDE, MAPL, MULAN, RNF218	ENSG00000090432	Mitochondrial E3 ubiquitin protein ligase 1	1	20499448-20508161	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA026827			Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:6.15e-14 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.7	Expressed in all		
MUSK		ENSG00000030304	Muscle associated receptor tyrosine kinase	9	110668771-110801620	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Mixed			testis: 3.0	Group enriched	19	LHCN-M2: 20.0;RH-30: 23.3
MVD	MPD	ENSG00000167508	Mevalonate diphosphate decarboxylase	16	88651935-88663161	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041404, HPA048250	Uncertain		Approved	Cell Junctions<br>Cytosol	Endometrial cancer:2.17e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 33.9	Expressed in all		
MXRA8	DKFZp586E2023	ENSG00000162576	Matrix remodeling associated 8	1	1352689-1361777	Predicted membrane proteins	Evidence at protein level	HPA053958, HPA055780	Uncertain		Approved	Nucleoli	Renal cancer:3.43e-6 (unfavourable), Urothelial cancer:9.87e-4 (unfavourable), Stomach cancer:9.93e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 57.4	endometrium: 44.5	Cell line enhanced		BJ: 122.4;BJ hTERT+: 55.0;fHDF/TERT166: 56.2
MYADM		ENSG00000179820	Myeloid associated differentiation marker	19	53866223-53876437	Predicted membrane proteins, Transporters	Evidence at protein level	HPA056301			Approved	Nuclear speckles	Renal cancer:7.71e-7 (unfavourable), Lung cancer:8.15e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 260.7	Mixed		
MYADML2	LOC255275	ENSG00000185105	Myeloid associated differentiation marker like 2	17	81939645-81947233	Predicted membrane proteins	Evidence at transcript level	HPA041856, HPA048476	Uncertain					Tissue enhanced	Tissue enriched	17	skeletal muscle: 28.8	heart muscle: 1.6	Cell line enriched	8	SCLC-21H: 3.6
MYCT1	FLJ21269, MTLC	ENSG00000120279	Myc target 1	6	152697895-152724567	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047992			Uncertain	Nucleoplasm	Renal cancer:4.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 69.0	placenta: 29.9	Cell line enhanced		HEL: 20.7;HUVEC TERT2: 103.9;TIME: 85.0
MYEOV	OCIM	ENSG00000172927	Myeloma overexpressed	11	69294138-69367726	Predicted membrane proteins	Evidence at transcript level	HPA012949	Uncertain		Approved	Nucleus<br>Vesicles	Pancreatic cancer:1.54e-7 (unfavourable), Renal cancer:1.48e-5 (unfavourable), Lung cancer:2.00e-4 (unfavourable)	Mixed	Group enriched	5	adipose tissue: 4.0;breast: 5.8;esophagus: 9.2;skin: 1.8;stomach: 6.8	appendix: 1.0	Cell line enhanced		A-431: 154.1;A549: 74.9;U-2 OS: 38.7
MYLK	MLCK, MLCK1, MYLK1, smMLCK	ENSG00000065534	Myosin light chain kinase	3	123610049-123884331	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB020789, HPA031677, HPA048055	Enhanced		Enhanced	Plasma membrane<br>Actin filaments	Renal cancer:2.04e-6 (unfavourable), Urothelial cancer:4.46e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 3002.5	Cell line enhanced		BJ: 144.8;BJ hTERT+: 209.1;fHDF/TERT166: 165.3;RPTEC TERT1: 207.7
MYLK3	caMLCK, MLCK	ENSG00000140795	Myosin light chain kinase 3	16	46703369-46790407	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA073447	Enhanced					Not detected	Tissue enhanced		heart muscle: 69.4;skeletal muscle: 16.9	testis: 11.7	Cell line enhanced		BEWO: 12.5;HEL: 36.3;K-562: 5.8;SK-BR-3: 6.2
MYLK4	SgK085	ENSG00000145949	Myosin light chain kinase family member 4	6	2663629-2750966	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA015860	Uncertain					Mixed	Tissue enhanced		skeletal muscle: 9.8	kidney: 3.1	Cell line enriched	7	HEL: 6.4
MYOF	FER1L3, KIAA1207	ENSG00000138119	Myoferlin	10	93306429-93482317	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014245	Enhanced		Supported	Vesicles<br>Plasma membrane	Pancreatic cancer:1.40e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 101.2	Mixed		
MYRF	C11orf9, MRF, Ndt80, pqn-47	ENSG00000124920	Myelin regulatory factor	11	61752642-61788518	Plasma proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA018310			Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.01e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 67.4;stomach: 62.1	gallbladder: 38.3	Cell line enhanced		A549: 36.8;CACO-2: 56.7;CAPAN-2: 34.1;EFO-21: 48.7
MYRFL	bcm1377, C12orf15, C12orf28, FLJ25056	ENSG00000166268	Myelin regulatory factor-like	12	69825304-69959097	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA049340	Approved		Approved	Nucleoli		Mixed	Group enriched	5	duodenum: 23.7;small intestine: 24.0	testis: 4.3	Cell line enhanced		NTERA-2: 5.2;T-47d: 11.1
N4BP2L2	CG005, PFAAP5	ENSG00000244754	NEDD4 binding protein 2 like 2	13	32432417-32538885	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039338, HPA039434, HPA059327	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 57.6	Expressed in all		
NAA25	C12orf30, FLJ13089	ENSG00000111300	N(alpha)-acetyltransferase 25, NatB auxiliary subunit	12	112026689-112109022	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039322	Approved		Supported	Golgi apparatus<br>Cytosol	Renal cancer:1.32e-8 (unfavourable), Liver cancer:5.53e-5 (unfavourable), Endometrial cancer:2.26e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 9.5	Expressed in all		
NAALAD2	GCPIII, NAALADASE2	ENSG00000077616	N-acetylated alpha-linked acidic dipeptidase 2	11	90131515-90192894	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060820, HPA065419	Approved		Approved	Nucleus		Tissue enhanced	Tissue enhanced		testis: 27.2	adrenal gland: 13.7	Group enriched	5	CACO-2: 31.5;SH-SY5Y: 13.2
NAALADL2		ENSG00000177694	N-acetylated alpha-linked acidic dipeptidase like 2	3	174438573-175810552	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012413, HPA017425, CAB025586	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		parathyroid gland: 28.0	cervix, uterine: 9.9	Cell line enhanced		ASC TERT1: 10.1;fHDF/TERT166: 5.0;WM-115: 5.8
NAGPA	APAA, UCE	ENSG00000103174	N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase	16	5024844-5034141	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA064055	Approved				Renal cancer:2.67e-5 (unfavourable), Liver cancer:4.67e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 9.6	Mixed		
NALCN	bA430M15.1, CanIon, VGCNL1	ENSG00000102452	Sodium leak channel, non-selective	13	101053776-101416492	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031889, HPA031890, HPA031958	Approved					Mixed	Tissue enhanced		cerebral cortex: 28.1	adrenal gland: 6.0	Cell line enhanced		HaCaT: 12.6;HHSteC: 12.3;TIME: 15.4;U-87 MG: 11.1
NAT14	KLP1	ENSG00000090971	N-acetyltransferase 14 (putative)	19	55485004-55487568	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047187			Approved	Mitochondria	Renal cancer:3.61e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 26.7	Expressed in all		
NAT8	ATase2, GLA, Hcml1, TSC501	ENSG00000144035	N-acetyltransferase 8 (putative)	2	73640832-73642393	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA067855, HPA074519	Enhanced		Approved	Endoplasmic reticulum		Tissue enriched	Tissue enriched	18	kidney: 891.8	liver: 49.4	Cell line enriched	12	Hep G2: 8.7
NAT8L	FLJ37478, Hcml3	ENSG00000185818	N-acetyltransferase 8 like	4	2059512-2069089	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040677			Supported	Mitochondria	Endometrial cancer:1.01e-5 (unfavourable)	Group enriched	Group enriched	7	adipose tissue: 48.6;cerebral cortex: 64.9;testis: 19.0	kidney: 6.7	Cell line enhanced		SCLC-21H: 32.4
NAV3	KIAA0938, POMFIL1	ENSG00000067798	Neuron navigator 3	12	77324641-78213008	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA032111, HPA032112, CAB037063	Uncertain		Approved	Nuclear membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 27.2;ovary: 24.6	spleen: 12.3	Cell line enhanced		hTEC/SVTERT24-B: 46.2;WM-115: 38.6
NBAS	NAG	ENSG00000151779	Neuroblastoma amplified sequence	2	15166909-15561330	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036817	Approved		Approved	Nuclear membrane<br>Nucleoli<br>Golgi apparatus	Urothelial cancer:5.84e-5 (unfavourable), Liver cancer:1.10e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.6	Expressed in all		
NBEA	BCL8B, FLJ10197, KIAA1544, LYST2	ENSG00000172915	Neurobeachin	13	34942287-35673022	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039730, HPA040385	Enhanced		Supported	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol	Renal cancer:7.86e-8 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 30.3	seminal vesicle: 12.2	Cell line enriched	5	SH-SY5Y: 83.5
NCAM1	CD56, NCAM	ENSG00000149294	Neural cell adhesion molecule 1	11	112961247-113278436	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000142, CAB018071, HPA039835	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 334.9	heart muscle: 87.5	Cell line enhanced		RH-30: 128.0;SCLC-21H: 126.2;U-138 MG: 71.8;WM-115: 77.9
NCAM2	MGC51008, NCAM21	ENSG00000154654	Neural cell adhesion molecule 2	21	20998315-21543329	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA030900, HPA030901	Supported		Supported	Nuclear bodies<br>Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 68.8	adrenal gland: 15.8	Cell line enhanced		T-47d: 86.4;WM-115: 22.5
NCEH1	AADACL1, KIAA1363, NCEH	ENSG00000144959	Neutral cholesterol ester hydrolase 1	3	172630249-172711218	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026888	Supported		Approved	Endoplasmic reticulum	Pancreatic cancer:8.25e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 35.0	Cell line enhanced		CAPAN-2: 250.8
NCKAP1	HEM2, Nap1, NAP125	ENSG00000061676	NCK associated protein 1	2	182909115-183038858	Predicted membrane proteins	Evidence at protein level	HPA020449	Enhanced		Approved	Cytosol	Pancreatic cancer:3.81e-4 (unfavourable), Lung cancer:9.71e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 145.1	Mixed		
NCKAP1L	HEM1	ENSG00000123338	NCK associated protein 1 like	12	54497711-54548238	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA039490, HPA040772	Approved		Uncertain	Plasma membrane<br>Cytosol		Expressed in all	Mixed			spleen: 54.9	Cell line enhanced		HL-60: 89.0;HMC-1: 98.8;THP-1: 81.4;U-937: 55.5
NCKIPSD	AF3P21, DIP1, ORF1, SPIN90, WASLBP, WISH	ENSG00000213672	NCK interacting protein with SH3 domain	3	48673844-48686364	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB019267, HPA050005			Enhanced	Plasma membrane<br>Cytosol	Renal cancer:1.20e-5 (favourable), Liver cancer:8.57e-4 (unfavourable)	Expressed in all	Tissue enriched	9	parathyroid gland: 306.0	cerebral cortex: 35.0	Expressed in all		
NCLN	NET59, NICALIN	ENSG00000125912	Nicalin	19	3185563-3209575	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006625	Approved		Uncertain	Nucleoplasm<br>Lipid droplets	Renal cancer:8.37e-5 (unfavourable), Stomach cancer:8.82e-5 (favourable), Endometrial cancer:1.19e-4 (favourable), Liver cancer:2.15e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 33.9	Expressed in all		
NCMAP	C1orf130, FLJ42528, MP11	ENSG00000184454	Non-compact myelin associated protein	1	24556111-24609328	Predicted membrane proteins	Evidence at transcript level	HPA013656	Uncertain				Endometrial cancer:2.83e-6 (favourable)	Mixed	Tissue enhanced		gallbladder: 11.5	thyroid gland: 7.1	Cell line enhanced		A549: 1.8;T-47d: 3.7;U-266/70: 2.3
NCR1	CD335, LY94, NK-p46, NKP46	ENSG00000189430	Natural cytotoxicity triggering receptor 1	19	54906150-54916140	CD markers, Predicted membrane proteins	Evidence at protein level	HPA049311			Approved	Endoplasmic reticulum		Tissue enhanced	Not detected			spleen: 0.6	Not detected		
NCR2	CD336, LY95, NK-p44	ENSG00000096264	Natural cytotoxicity triggering receptor 2	6	41335655-41350887	CD markers, Predicted membrane proteins	Evidence at protein level	HPA067249	Uncertain					Not detected	Not detected			duodenum: 0.5	Not detected		
NCR3	1C7, CD337, LY117, NKp30	ENSG00000204475	Natural cytotoxicity triggering receptor 3	6	31588895-31592985	CD markers, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 1.7;spleen: 1.5;tonsil: 1.1	appendix: 1.0	Cell line enhanced		NB-4: 2.6
NCR3LG1	B7-H6, DKFZp686O24166	ENSG00000188211	Natural killer cell cytotoxicity receptor 3 ligand 1	11	17351726-17377341	Predicted membrane proteins	Evidence at protein level	HPA024137	Uncertain				Renal cancer:4.21e-12 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 12.9	rectum: 5.6	Cell line enhanced		HL-60: 42.1
NCSTN	APH2, KIAA0253	ENSG00000162736	Nicastrin	1	160343272-160358952	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB021982, HPA054846, HPA070642	Approved		Approved	Cytosol	Renal cancer:7.75e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 143.2	Expressed in all		
NDC1	FLJ10407, NET3, TMEM48	ENSG00000058804	NDC1 transmembrane nucleoporin	1	53765460-53838860	Predicted membrane proteins, Transporters	Evidence at protein level	HPA069751, HPA070882	Approved		Supported	Nuclear membrane<br>Plasma membrane<br>Actin filaments	Liver cancer:7.52e-7 (unfavourable), Colorectal cancer:4.48e-5 (favourable), Pancreatic cancer:3.58e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 16.4	Expressed in all		
NDFIP1	MGC10924, N4WBP5	ENSG00000131507	Nedd4 family interacting protein 1	5	142108505-142154443	Predicted membrane proteins	Evidence at protein level	HPA009682	Approved				Head and neck cancer:2.33e-7 (unfavourable), Renal cancer:2.39e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 246.0	Expressed in all		
NDFIP2	KIAA1165, N4wbp5a	ENSG00000102471	Nedd4 family interacting protein 2	13	79481124-79556075	Predicted membrane proteins	Evidence at protein level	HPA009160	Uncertain		Enhanced	Vesicles	Renal cancer:4.18e-5 (favourable), Head and neck cancer:5.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 96.0	Mixed		
NDN	HsT16328, PWCR	ENSG00000182636	Necdin, MAGE family member	15	23685400-23687330	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA074457			Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.52e-4 (unfavourable)	Expressed in all	Mixed			ovary: 85.0	Cell line enhanced		AF22: 53.6;HSkMC: 51.0;NTERA-2: 43.3;U-2 OS: 83.1
NDRG2	KIAA1248, SYLD	ENSG00000165795	NDRG family member 2	14	21016763-21070872	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002896, HPA003590, CAB017491	Enhanced		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.43e-12 (favourable), Liver cancer:6.71e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1029.5	Cell line enhanced		Hep G2: 38.7
NDRG4	KIAA1180, SMAP-8	ENSG00000103034	NDRG family member 4	16	58462846-58513628	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015313, HPA017587	Enhanced		Uncertain	Nucleus<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 146.6;cerebral cortex: 420.0;heart muscle: 150.6	testis: 72.0	Cell line enhanced		EFO-21: 30.7;SCLC-21H: 58.1
NDST1	HSST, NST1	ENSG00000070614	N-deacetylase and N-sulfotransferase 1	5	150485818-150558211	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060532	Approved				Ovarian cancer:5.13e-4 (unfavourable), Endometrial cancer:6.99e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 59.7	Expressed in all		
NDST2	HSST2, NST2	ENSG00000166507	N-deacetylase and N-sulfotransferase 2	10	73801911-73811798	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051515	Approved		Approved	Cytosol		Mixed	Expressed in all			spleen: 44.9	Expressed in all		
NDUFA1	CI-MWFE, MWFE	ENSG00000125356	NADH:ubiquinone oxidoreductase subunit A1	X	119871487-119876662	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA029768, HPA054359	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:3.48e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 224.8	Expressed in all		
NDUFA11	B14.7	ENSG00000174886	NADH:ubiquinone oxidoreductase subunit A11	19	5891276-5904006	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA072209			Uncertain	Mitochondria	Endometrial cancer:3.38e-5 (favourable), Cervical cancer:4.54e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 309.7	Expressed in all		
NDUFA13	B16.6, CDA016, CGI-39, GRIM-19, GRIM19	ENSG00000186010	NADH:ubiquinone oxidoreductase subunit A13	19	19515736-19529054	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA041213	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			heart muscle: 226.3	Expressed in all		
NDUFA3	B9	ENSG00000170906	NADH:ubiquinone oxidoreductase subunit A3	19	54102728-54109257	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046976	Supported				Urothelial cancer:4.80e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable)	Expressed in all	Expressed in all			skin: 16.0	Expressed in all		
NDUFA4	CI-9k, MLRQ	ENSG00000189043	NDUFA4, mitochondrial complex associated	7	10931951-10940256	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA055323			Supported	Mitochondria	Renal cancer:4.61e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 251.7	Expressed in all		
NDUFA4L2	FLJ26118, NUOMS	ENSG00000185633	NDUFA4, mitochondrial complex associated like 2	12	57234903-57240715	Predicted membrane proteins	Evidence at protein level	HPA055323			Approved	Mitochondria	Renal cancer:1.37e-5 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 152.3;skin: 191.7	placenta: 104.2	Cell line enriched	8	AN3-CA: 123.9
NDUFA9	CI-39k, NDUFS2L, SDR22E1	ENSG00000139180	NADH:ubiquinone oxidoreductase subunit A9	12	4649095-4694317	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042268, HPA073212	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:2.57e-7 (favourable), Urothelial cancer:5.75e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 38.4	Expressed in all		
NDUFB1	CI-MNLL, MNLL	ENSG00000183648	NADH:ubiquinone oxidoreductase subunit B1	14	92116122-92121917	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA063737			Supported	Nuclear speckles<br>Mitochondria	Renal cancer:1.31e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 278.8	Expressed in all		
NDUFB11	ESSS, Np15, NP17.3	ENSG00000147123	NADH:ubiquinone oxidoreductase subunit B11	X	47142216-47145504	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA030367	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 129.1	Expressed in all		
NDUFB3	B12	ENSG00000119013	NADH:ubiquinone oxidoreductase subunit B3	2	201071433-201085750	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034596	Approved				Head and neck cancer:7.24e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 180.0	Expressed in all		
NDUFB4	B15	ENSG00000065518	NADH:ubiquinone oxidoreductase subunit B4	3	120596309-120602500	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051739	Enhanced		Supported	Nuclear membrane<br>Mitochondria	Urothelial cancer:1.79e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 364.4	Expressed in all		
NDUFB5	CI-SGDH, MGC12314, SGDH	ENSG00000136521	NADH:ubiquinone oxidoreductase subunit B5	3	179604690-179627647	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005640	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.32e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 136.7	Expressed in all		
NDUFB6	B17, CI	ENSG00000165264	NADH:ubiquinone oxidoreductase subunit B6	9	32552999-32573184	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044001, HPA053334	Supported		Enhanced	Mitochondria	Renal cancer:7.47e-10 (favourable), Cervical cancer:3.18e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 70.2	Expressed in all		
NDUFB8	ASHI, CI-ASHI	ENSG00000166136	NADH:ubiquinone oxidoreductase subunit B8	10	100523740-100530000	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA003886	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			heart muscle: 306.4	Expressed in all		
NDUFC1	KFYI	ENSG00000109390	NADH:ubiquinone oxidoreductase subunit C1	4	139266880-139302551	Predicted membrane proteins	Evidence at protein level	HPA044556	Approved		Supported	Mitochondria	Endometrial cancer:8.23e-5 (favourable), Urothelial cancer:7.25e-4 (favourable), Renal cancer:9.96e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 86.7	Expressed in all		
NDUFC2	B14.5b, HLC-1	ENSG00000151366	NADH:ubiquinone oxidoreductase subunit C2	11	78068304-78080219	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038873, HPA056195	Approved		Supported	Mitochondria	Renal cancer:5.00e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 370.1	Expressed in all		
NDUFC2-KCTD14		ENSG00000259112	NDUFC2-KCTD14 readthrough	11	78016971-78079865	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038873, HPA056195	Approved		Supported	Mitochondria		Not detected	Tissue enhanced		duodenum: 5.0	stomach: 2.5	Cell line enhanced		CACO-2: 7.9;EFO-21: 7.0;U-2 OS: 12.0
NECTIN1	CD111, CLPED1, ED4, HIgR, HVEC, OFC7, PRR, PRR1, PVRL1, PVRR1, SK-12	ENSG00000110400	Nectin cell adhesion molecule 1	11	119623408-119729084	CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016135, HPA026846	Approved					Expressed in all	Tissue enhanced		esophagus: 108.6;skin: 161.7	cerebral cortex: 50.3	Cell line enhanced		HaCaT: 203.5
NECTIN2	CD112, HVEB, PRR2, PVRL2, PVRR2	ENSG00000130202	Nectin cell adhesion molecule 2	19	44846175-44889228	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012759, CAB026138, HPA073459	Enhanced		Approved	Nucleoli fibrillar center<br>Cell Junctions		Expressed in all	Expressed in all			placenta: 111.4	Mixed		
NECTIN3	CD113, CDw113, DKFZP566B0846, nectin-3, PPR3, PVRL3, PVRR3	ENSG00000177707	Nectin cell adhesion molecule 3	3	111070071-111275563	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009869, HPA011038	Approved		Approved	Microtubule organizing center	Renal cancer:9.82e-7 (favourable)	Expressed in all	Tissue enhanced		testis: 99.5	thyroid gland: 73.7	Cell line enhanced		TIME: 138.4
NECTIN4	LNIR, nectin-4, PRR4, PVRL4	ENSG00000143217	Nectin cell adhesion molecule 4	1	161070995-161089599	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA010775	Enhanced		Supported	Plasma membrane		Mixed	Tissue enhanced		esophagus: 45.9;skin: 79.5	breast,placenta: 17.1	Cell line enhanced		BEWO: 53.8;HaCaT: 32.5;SK-BR-3: 35.3;T-47d: 28.8
NEGR1	IGLON4, KILON, MGC46680, Ntra	ENSG00000172260	Neuronal growth regulator 1	1	71395940-72282734	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA011894	Uncertain		Approved	Vesicles<br>Actin filaments<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 54.3	gallbladder: 16.9	Mixed		
NELL2	NRP2	ENSG00000184613	Neural EGFL like 2	12	44508275-44921848	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035714, HPA035715	Uncertain		Approved	Vesicles	Pancreatic cancer:5.56e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 204.1;fallopian tube: 96.7	prostate: 46.5	Cell line enhanced		AF22: 102.5;NTERA-2: 41.0;SCLC-21H: 88.2
NEMP1	KIAA0286, TMEM194, TMEM194A	ENSG00000166881	Nuclear envelope integral membrane protein 1	12	57055643-57088063	Predicted membrane proteins	Evidence at protein level	HPA014394	Uncertain		Approved	Nucleoplasm	Renal cancer:1.09e-5 (unfavourable), Liver cancer:1.93e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 14.5	Expressed in all		
NEMP2	TMEM194B	ENSG00000189362	Nuclear envelope integral membrane protein 2	2	190504342-190534722	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057719			Approved	Nucleoplasm	Renal cancer:6.42e-4 (unfavourable)	Expressed in all	Mixed			testis: 5.6	Mixed		
NEO1	HsT17534, IGDCC2, NGN, NTN1R2	ENSG00000067141	Neogenin 1	15	73051710-73305206	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB009320, HPA027804, HPA027805, HPA027806	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane	Renal cancer:4.39e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 102.7	Mixed		
NEPRO	C3orf17, DKFZP434F2021, NET17	ENSG00000163608	Nucleolus and neural progenitor protein	3	113002440-113019861	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069654			Supported	Nucleus<br>Nucleoli	Endometrial cancer:1.13e-4 (unfavourable), Liver cancer:4.25e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 20.8	Expressed in all		
NETO1	BCTL1, BTCL1	ENSG00000166342	Neuropilin and tolloid like 1	18	72742314-72868146	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA064630			Approved	Golgi apparatus		Tissue enhanced	Tissue enriched	16	cerebral cortex: 64.0	spleen: 4.1	Cell line enhanced		MOLT-4: 22.4;REH: 24.8;RPMI-8226: 30.0;RT4: 22.5;SCLC-21H: 43.0
NETO2	FLJ10430, NEOT2	ENSG00000171208	Neuropilin and tolloid like 2	16	47077703-47143997	Predicted membrane proteins, Transporters	Evidence at protein level	HPA013180	Uncertain		Approved	Golgi apparatus	Renal cancer:5.53e-6 (unfavourable)	Mixed	Tissue enhanced		spleen: 31.5	cerebral cortex: 20.9	Mixed		
NF1		ENSG00000196712	Neurofibromin 1	17	31094927-31382116	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA045502	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 33.0	Expressed in all		
NFAM1	CNAIP	ENSG00000235568	NFAT activating protein with ITAM motif 1	22	42380410-42432395	Predicted membrane proteins	Evidence at protein level	HPA031812	Uncertain				Endometrial cancer:6.16e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 17.2;bone marrow: 20.2	spleen: 14.5	Cell line enhanced		NB-4: 5.5;SCLC-21H: 6.8;THP-1: 25.4
NFASC	FLJ46866, KIAA0756, NF, NRCAML	ENSG00000163531	Neurofascin	1	204828651-205022822	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008832	Enhanced				Renal cancer:2.93e-5 (unfavourable), Pancreatic cancer:3.21e-5 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 55.7	seminal vesicle: 22.4	Cell line enhanced		BJ: 23.3;fHDF/TERT166: 39.1;SCLC-21H: 26.9;U-138 MG: 62.0;U-87 MG: 30.5
NFXL1	HOZFP	ENSG00000170448	Nuclear transcription factor, X-box binding like 1	4	47847233-47914667	Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA059132	Approved		Approved	Nucleoplasm	Liver cancer:9.28e-4 (unfavourable)	Expressed in all	Mixed			testis: 24.9	Expressed in all		
NGFR	CD271, p75NTR, TNFRSF16	ENSG00000064300	Nerve growth factor receptor	17	49495293-49515017	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB000143, CAB001995, HPA004765	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Urothelial cancer:3.40e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 32.4	Group enriched	8	RH-30: 193.0;WM-115: 221.3
NGLY1	FLJ11005, PNG1	ENSG00000151092	N-glycanase 1	3	25718944-25790039	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036825	Approved				Liver cancer:1.96e-6 (unfavourable), Colorectal cancer:1.17e-5 (favourable)	Expressed in all	Expressed in all			testis: 116.0	Expressed in all		
NIF3L1	ALS2CR1, CALS-7, MDS015	ENSG00000196290	NGG1 interacting factor 3 like 1	2	200889327-200903930	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036335, HPA036336, HPA061466	Enhanced		Approved	Vesicles	Liver cancer:2.51e-6 (unfavourable), Endometrial cancer:9.52e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 40.6	Expressed in all		
NIM1K	MGC42105, NIM1	ENSG00000177453	NIM1 serine/threonine protein kinase	5	43192071-43280850	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA007695	Uncertain		Approved	Cytosol		Tissue enriched	Tissue enriched	8	cerebral cortex: 16.3	lung: 2.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 1.9;HDLM-2: 2.1;PC-3: 2.4;U-87 MG: 2.6
NINJ1	NIN1	ENSG00000131669	Ninjurin 1	9	93121489-93134288	Predicted membrane proteins	Evidence at protein level	HPA045063	Uncertain					Expressed in all	Expressed in all			bone marrow: 158.2	Mixed		
NINJ2		ENSG00000171840	Ninjurin 2	12	564296-663779	Predicted membrane proteins	Evidence at protein level	HPA058980			Approved	Endoplasmic reticulum	Head and neck cancer:5.31e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 55.6	bone marrow: 23.9	Cell line enhanced		HEL: 137.2;MOLT-4: 210.8
NIPA1	MGC35570, SPG6	ENSG00000170113	Non imprinted in Prader-Willi/Angelman syndrome 1	15	22773063-22829791	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA023269	Uncertain					Expressed in all	Tissue enhanced		cerebral cortex: 38.2	parathyroid gland: 16.8	Mixed		
NIPA2		ENSG00000140157	Non imprinted in Prader-Willi/Angelman syndrome 2	15	22838641-22868384	Predicted membrane proteins, Transporters	Evidence at protein level	HPA067160, HPA071342	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			appendix: 44.4	Expressed in all		
NIPAL1	DKFZp686A06115, NPAL1	ENSG00000163293	NIPA like domain containing 1	4	47914142-48040173	Predicted membrane proteins	Evidence at transcript level	HPA036765	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enhanced		esophagus: 24.0;skin: 30.8	rectum: 14.6	Cell line enhanced		A-431: 11.6;HaCaT: 13.6;RT4: 14.3
NIPAL2	FLJ13955, NPAL2	ENSG00000104361	NIPA like domain containing 2	8	98189833-98294393	Predicted membrane proteins	Evidence at transcript level	HPA071759	Uncertain					Expressed in all	Mixed			skin: 62.2	Cell line enhanced		ASC diff: 30.5
NIPAL3	DJ462O23.2, NPAL3	ENSG00000001461	NIPA like domain containing 3	1	24415794-24472976	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039978	Approved		Approved	Nucleoplasm	Renal cancer:3.03e-7 (favourable), Thyroid cancer:3.95e-4 (favourable)	Expressed in all	Expressed in all			prostate: 97.4	Mixed		
NIPAL4	ICHYN	ENSG00000172548	NIPA like domain containing 4	5	157460019-157474717	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038259	Approved				Urothelial cancer:6.82e-4 (favourable)	Tissue enhanced	Tissue enhanced		skin: 41.9	esophagus: 10.2	Group enriched	10	hTCEpi: 21.3;RT4: 80.1
NKAIN1	FAM77C, FLJ12650	ENSG00000084628	Sodium/potassium transporting ATPase interacting 1	1	31179745-31239554	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA006873	Uncertain					Group enriched	Group enriched	5	adrenal gland: 13.9;cerebral cortex: 13.1;epididymis: 4.4;skeletal muscle: 7.4	prostate: 1.9	Cell line enhanced		AF22: 23.5;AN3-CA: 36.7;NTERA-2: 101.7;SCLC-21H: 35.5;SH-SY5Y: 50.9
NKAIN2	FAM77B, TCBA1	ENSG00000188580	Sodium/potassium transporting ATPase interacting 2	6	123804141-124825657	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA045860			Approved	Cytosol		Mixed	Tissue enriched	44	cerebral cortex: 46.1	adipose tissue,skeletal muscle: 1.0	Cell line enhanced		HEK93: 4.5;HEL: 5.8;Karpas-707: 7.5
NKAIN3	FAM77D, FLJ39630	ENSG00000185942	Sodium/potassium transporting ATPase interacting 3	8	62248591-62999652	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA018833	Uncertain					Tissue enhanced	Not detected			adrenal gland: 0.4	Cell line enhanced		SCLC-21H: 1.7
NKAIN4	bA261N11.2, C20orf58, FAM77A	ENSG00000101198	Sodium/potassium transporting ATPase interacting 4	20	63240784-63272694	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA029876	Approved				Endometrial cancer:3.14e-4 (unfavourable)	Tissue enriched	Tissue enriched	13	cerebral cortex: 71.8	kidney: 5.5	Cell line enhanced		BEWO: 23.2;MOLT-4: 33.2
NKG7	GIG1, GMP-17	ENSG00000105374	Natural killer cell granule protein 7	19	51371606-51372715	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071454			Approved	Vesicles	Renal cancer:3.32e-6 (unfavourable), Endometrial cancer:7.42e-6 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 351.3;spleen: 151.2	lymph node: 122.0	Cell line enhanced		NB-4: 109.5;THP-1: 34.5;U-937: 34.9
NKPD1	FLJ33600	ENSG00000179846	NTPase KAP family P-loop domain containing 1	19	45149750-45158737	Predicted membrane proteins	Evidence at protein level	HPA043339	Uncertain					Mixed	Tissue enriched	18	skin: 14.8	seminal vesicle: 0.8	Cell line enhanced		hTCEpi: 1.1;SiHa: 1.5;U-266/70: 2.2
NLGN1	KIAA1070	ENSG00000169760	Neuroligin 1	3	173396284-174286644	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006572, HPA006680	Approved		Uncertain	Nuclear bodies<br>Plasma membrane		Group enriched	Tissue enhanced		cerebral cortex: 25.4	testis: 12.5	Cell line enhanced		fHDF/TERT166: 20.1;HUVEC TERT2: 20.7;RH-30: 25.4;WM-115: 26.7
NLGN2	KIAA1366	ENSG00000169992	Neuroligin 2	17	7404874-7419860	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055321, HPA069278	Enhanced		Approved	Mitochondria	Renal cancer:3.44e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 40.7	endometrium: 21.8	Cell line enhanced		AF22: 43.3
NLGN3	ASPGX1, AUTSX1, HNL3, KIAA1480	ENSG00000196338	Neuroligin 3	X	71144831-71171201	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003183, HPA004066	Enhanced		Supported	Golgi apparatus<br>Cell Junctions		Tissue enriched	Tissue enhanced		cerebral cortex: 62.2	seminal vesicle: 17.3	Cell line enhanced		AF22: 6.8;NTERA-2: 5.0;SH-SY5Y: 2.9
NLGN4X	HLNX, KIAA1260, NLGN, NLGN4	ENSG00000146938	Neuroligin 4, X-linked	X	5840637-6228863	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA001651	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 20.1	ovary: 12.9	Group enriched	5	AF22: 51.1;NTERA-2: 42.7
NLGN4Y	KIAA0951	ENSG00000165246	Neuroligin 4, Y-linked	Y	14522638-14845650	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA001651	Approved					Mixed	Tissue enhanced		prostate: 11.4;seminal vesicle: 12.5	cerebral cortex: 7.5	Cell line enhanced		BJ hTERT+: 28.5;fHDF/TERT166: 21.5;HDLM-2: 30.2;hTCEpi: 16.2;U-138 MG: 23.0
NMBR	BB1, BB1R	ENSG00000135577	Neuromedin B receptor	6	142058330-142088799	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA026665			Supported	Plasma membrane<br>Cytosol		Not detected	Group enriched	5	fallopian tube: 1.4;testis: 2.6	cerebral cortex: 0.3	Not detected		
NMUR1	FM-3, GPC-R, GPR66, NMU1R	ENSG00000171596	Neuromedin U receptor 1	2	231523160-231530495	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA027895	Uncertain					Mixed	Mixed			adipose tissue: 5.5	Not detected		
NMUR2	NMU2R	ENSG00000132911	Neuromedin U receptor 2	5	152391532-152433368	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA045836	Enhanced					Group enriched	Tissue enhanced		stomach: 1.1;testis: 2.2	thyroid gland: 0.9	Cell line enriched	10	EFO-21: 8.9
NNAT	Peg5	ENSG00000053438	Neuronatin	20	37521215-37523693	Predicted membrane proteins	Evidence at transcript level							Group enriched	Group enriched	5	cerebral cortex: 157.6;placenta: 147.3	adipose tissue: 27.9	Cell line enriched	28	SH-SY5Y: 735.9
NNT		ENSG00000112992	Nicotinamide nucleotide transhydrogenase	5	43602692-43707405	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004829, CAB004975	Enhanced		Enhanced	Mitochondria	Renal cancer:1.22e-15 (favourable)	Expressed in all	Expressed in all			heart muscle: 130.6	Expressed in all		
NOL6	bA311H10.1, FLJ21959, MGC14896, MGC14921, MGC20838, Nrap, UTP22	ENSG00000165271	Nucleolar protein 6	9	33461441-33473930	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055891, HPA061002	Supported		Enhanced	Nucleus<br>Nucleoli<br>Mitochondria	Liver cancer:4.83e-5 (unfavourable), Thyroid cancer:9.49e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Expressed in all		
NOMO1	PM5	ENSG00000103512	NODAL modulator 1	16	14833681-14896160	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025192, HPA046697, HPA061174	Approved		Approved	Endoplasmic reticulum	Urothelial cancer:3.15e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 11.9	Cell line enhanced		Hep G2: 80.5;SiHa: 142.9
NOMO2	NOMO, PM5	ENSG00000185164	NODAL modulator 2	16	18417325-18562211	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046697, HPA061174	Approved					Expressed in all	Expressed in all			parathyroid gland: 157.3	Expressed in all		
NOMO3		ENSG00000103226	NODAL modulator 3	16	16232495-16294814	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046697, HPA061174	Approved					Mixed	Mixed			skin: 1.9	Mixed		
NOTCH1	TAN1	ENSG00000148400	Notch 1	9	136494444-136545862	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB008112, CAB022466, HPA067168	Supported		Approved	Nucleoplasm	Renal cancer:5.45e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 24.0	Cell line enhanced		MOLT-4: 77.4
NOTCH2		ENSG00000134250	Notch 2	1	119911553-120069626	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048743	Approved		Supported	Nucleoplasm<br>Plasma membrane	Ovarian cancer:5.24e-4 (unfavourable), Pancreatic cancer:9.48e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 46.7	Mixed		
NOTCH3	CADASIL, CASIL	ENSG00000074181	Notch 3	19	15159038-15200981	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005393, HPA044392	Approved		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:2.53e-7 (unfavourable), Endometrial cancer:5.92e-4 (unfavourable)	Expressed in all	Mixed			skin: 93.6	Cell line enhanced		AF22: 65.5;MCF7: 51.9
NOTCH4	INT3	ENSG00000204301	Notch 4	6	32194843-32224067	Predicted membrane proteins	Evidence at protein level						Renal cancer:3.84e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 12.1	thyroid gland: 4.2	Not detected		
NOX1	GP91-2, MOX1, NOH-1, NOH1	ENSG00000007952	NADPH oxidase 1	X	100843324-100874345	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Colorectal cancer:9.71e-4 (favourable)	Tissue enriched	Group enriched	17	colon: 58.7;rectum: 79.9	appendix: 3.9	Cell line enriched	19	CACO-2: 25.5
NOX3	GP91-3	ENSG00000074771	NADPH oxidase 3	6	155395370-155455903	Predicted membrane proteins, Transporters	Evidence at protein level	HPA073837			Uncertain	Vesicles		Not detected	Not detected			adrenal gland: 0.1	Cell line enriched	7	MCF7: 2.9
NOX4	KOX, KOX-1	ENSG00000086991	NADPH oxidase 4	11	89324356-89498187	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015475			Approved	Nucleus	Renal cancer:6.14e-4 (favourable)	Mixed	Tissue enriched	12	kidney: 134.7	parathyroid gland: 10.9	Group enriched	6	HUVEC TERT2: 22.0;TIME: 48.5
NOX5	NOX5A, NOX5B	ENSG00000255346	NADPH oxidase 5	15	68930525-69062743	Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		spleen: 13.2	testis: 3.5	Not detected		
NPBWR1	GPR7	ENSG00000183729	Neuropeptides B and W receptor 1	8	52938431-52941117	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Not detected			cerebral cortex: 0.7	Cell line enhanced		SiHa: 1.2
NPBWR2	GPR8	ENSG00000125522	Neuropeptides B and W receptor 2	20	64105820-64107171	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			adrenal gland,cerebral cortex: 0.1	Not detected		
NPC1		ENSG00000141458	NPC intracellular cholesterol transporter 1	18	23506184-23586898	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026618, CAB070132, HPA077445	Approved		Supported	Nucleus<br>Vesicles	Liver cancer:2.26e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 110.1	Expressed in all		
NPC1L1		ENSG00000015520	NPC1 like intracellular cholesterol transporter 1	7	44512535-44541315	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB070127, CAB070128	Enhanced					Group enriched	Tissue enhanced		duodenum: 57.1;small intestine: 57.9	liver: 14.2	Group enriched	7	CACO-2: 5.9;Hep G2: 12.2;SCLC-21H: 17.4
NPDC1	CAB-, CAB1, DKFZp586J0523	ENSG00000107281	Neural proliferation, differentiation and control 1	9	137039470-137046203	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008189	Approved		Approved	Nucleus<br>Cytosol	Colorectal cancer:2.01e-5 (unfavourable), Endometrial cancer:6.19e-5 (favourable), Pancreatic cancer:3.18e-4 (favourable)	Expressed in all	Expressed in all			prostate: 124.2	Mixed		
NPFFR1	GPR147, NPFF1R1, OT7T022	ENSG00000148734	Neuropeptide FF receptor 1	10	70247329-70283676	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA037521	Uncertain					Tissue enhanced	Tissue enhanced		testis: 2.1	cerebral cortex,lymph node: 0.8	Cell line enhanced		U-2 OS: 1.0
NPFFR2	GPR74, NPFF2, NPGPR	ENSG00000056291	Neuropeptide FF receptor 2	4	72031804-72148067	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026825			Approved	Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		placenta: 2.3;seminal vesicle: 4.6	epididymis: 1.1	Group enriched	11	NTERA-2: 9.2;RPTEC TERT1: 9.0;SH-SY5Y: 14.9;U-2 OS: 14.5
NPHP4	KIAA0673, POC10, SLSN4	ENSG00000131697	Nephrocystin 4	1	5862811-5992473	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065526	Approved					Mixed	Mixed			fallopian tube: 12.5	Mixed		
NPHS1	CNF, NPHN	ENSG00000161270	NPHS1, nephrin	19	35825964-35869287	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB035555	Enhanced					Mixed	Tissue enhanced		kidney: 17.7;lymph node: 5.4;pancreas: 5.5	tonsil: 2.3	Cell line enhanced		HMC-1: 1.1
NPHS2	PDCN, SRN1	ENSG00000116218	NPHS2, podocin	1	179550539-179575952	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB037267, HPA049486	Enhanced					Not detected	Tissue enriched	87	kidney: 93.6	testis: 1.0	Cell line enriched	12	NTERA-2: 1.1
NPIPA1	morpheus, NPIP	ENSG00000183426	Nuclear pore complex interacting protein family member A1	16	14922802-14952060	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA053611	Supported		Approved	Nucleoplasm		Mixed	Mixed			ovary: 68.6	Mixed		
NPIPA2		ENSG00000254852	Nuclear pore complex interacting protein family member A2	16	14748066-14765413	Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Tissue enhanced		testis: 3.6	cerebral cortex: 1.8	Cell line enhanced		BEWO: 6.5
NPIPA3		ENSG00000224712	Nuclear pore complex interacting protein family member A3	16	14708944-14726338	Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Mixed			parathyroid gland: 4.3	Cell line enhanced		NB-4: 6.7;SK-MEL-30: 11.7
NPIPA5		ENSG00000183793	Nuclear pore complex interacting protein family member A5	16	15363624-15381047	Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Mixed			testis: 17.2	Mixed		
NPIPA7		ENSG00000214967	Nuclear pore complex interacting protein family member A7	16	16379055-16393954	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Expressed in all			parathyroid gland: 48.8	Expressed in all		
NPIPA8	LCR16a9	ENSG00000214940	Nuclear pore complex interacting protein family member A8	16	18317942-18336736	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Mixed			cerebral cortex: 21.8	Cell line enhanced		EFO-21: 55.7;HMC-1: 196.9;SCLC-21H: 63.6
NPIPB11		ENSG00000254206	Nuclear pore complex interacting protein family member B11	16	29381354-29404029	Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Mixed			skin: 8.1	Mixed		
NPIPB12		ENSG00000169203	Nuclear pore complex interacting protein family, member B12	16	29483642-29505999	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Expressed in all			skin: 133.9	Expressed in all		
NPIPB13		ENSG00000198064	Nuclear pore complex interacting protein family, member B13	16	30222937-30254510	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Mixed			skin: 9.1	Mixed		
NPIPB15	LOC440348, NPIPL2	ENSG00000196436	Nuclear pore complex interacting protein family member B15	16	74377878-74392080	Predicted membrane proteins	Evidence at protein level	HPA011188, HPA053611	Supported		Approved	Nucleoplasm		Expressed in all	Tissue enhanced		testis: 39.2	rectum: 13.2	Cell line enhanced		T-47d: 11.2
NPIPB2		ENSG00000234719	Nuclear pore complex interacting protein family, member B2	16	11927373-11976643	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Supported		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 14.8	parathyroid gland: 8.8	Cell line enhanced		RPMI-8226: 10.3;U-266/70: 19.3
NPIPB3	KIAA0220, NPIPL3	ENSG00000169246	Nuclear pore complex interacting protein family member B3	16	21402237-21448567	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Expressed in all			skin: 189.3	Expressed in all		
NPIPB4		ENSG00000185864	Nuclear pore complex interacting protein family member B4	16	21834569-21880827	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Expressed in all			skin: 124.6	Expressed in all		
NPIPB5		ENSG00000243716	Nuclear pore complex interacting protein family member B5	16	22479121-22536521	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Expressed in all			skin: 261.4	Expressed in all		
NPIPB6		ENSG00000198156	Nuclear pore complex interacting protein family member B6	16	28342555-28363508	Predicted membrane proteins	Evidence at protein level	HPA011188, HPA053611	Approved		Approved	Nucleoplasm		Not detected	Tissue enriched	24	testis: 54.8	skin: 2.3	Mixed		
NPIPB7	LOC440350, NPIPL1	ENSG00000233232	Nuclear pore complex interacting protein family member B7	16	28456372-28471175	Predicted membrane proteins	Evidence at protein level	HPA011188, HPA053611	Approved		Approved	Nucleoplasm		Not detected	Tissue enriched	32	testis: 15.3	skin: 0.4	Cell line enhanced		BEWO: 1.7
NPIPB8		ENSG00000255524	Nuclear pore complex interacting protein family member B8	16	28637654-28658682	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011188, HPA053611	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enriched	12	testis: 12.8	small intestine: 1.1	Cell line enriched	23	hTCEpi: 15.2
NPIPB9		ENSG00000196993	Nuclear pore complex interacting protein family member B9	16	28751787-28772807	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011188, HPA053611	Approved		Approved	Nucleoplasm		Not detected	Tissue enriched	8	testis: 14.5	skin: 1.9	Cell line enhanced		hTCEpi: 3.1
NPR1	ANPa, ANPRA, GUCY2A, NPRA	ENSG00000169418	Natriuretic peptide receptor 1	1	153678637-153693992	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA031087			Approved	Nucleus<br>Nucleoli<br>Plasma membrane	Pancreatic cancer:2.49e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 72.0;fallopian tube: 58.2	placenta: 25.4	Cell line enriched	6	ASC diff: 107.2
NPR2	AMDM, ANPb, ANPRB, GUCY2B, NPRB	ENSG00000159899	Natriuretic peptide receptor 2	9	35792154-35809732	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Expressed in all	Mixed			endometrium: 31.1	Cell line enhanced		ASC diff: 37.7
NPR3	ANPRC, C5orf23, FLJ14054, GUCY2B, NPRC	ENSG00000113389	Natriuretic peptide receptor 3	5	32689070-32791724	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052702	Supported		Approved	Cytosol	Renal cancer:5.43e-6 (favourable)	Tissue enhanced	Tissue enriched	5	kidney: 114.1	adipose tissue: 21.9	Cell line enhanced		ASC TERT1: 24.8;HeLa: 53.7;HSkMC: 36.4;U-138 MG: 21.1
NPSR1	GPR154, GPRA, PGR14	ENSG00000187258	Neuropeptide S receptor 1	7	34658239-34878332	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA007489	Supported					Tissue enhanced	Not detected			stomach: 0.5	Cell line enhanced		HAP1: 1.1
NPTN	GP55, GP65, np55, np65, SDFR1, SDR1	ENSG00000156642	Neuroplastin	15	73560014-73634134	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051497, HPA072453	Approved		Approved	Cytokinetic bridge<br>Mitochondria		Expressed in all	Expressed in all			smooth muscle: 433.8	Expressed in all		
NPY1R	NPYR	ENSG00000164128	Neuropeptide Y receptor Y1	4	163323961-163344832	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029903			Approved	Nucleus<br>Mitochondria<br>Cytosol	Breast cancer:7.68e-5 (favourable)	Tissue enriched	Tissue enhanced		spleen: 151.8	breast: 39.6	Cell line enriched	16	HEL: 105.6
NPY2R		ENSG00000185149	Neuropeptide Y receptor Y2	4	155208629-155217078	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		breast: 1.0;cerebral cortex: 1.7;testis: 1.0	rectum: 0.6	Cell line enriched	6	SH-SY5Y: 8.0
NPY4R	PP1, PPYR1, Y4	ENSG00000204174	Neuropeptide Y receptor Y4	10	46461099-46465881	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA027863	Approved					Tissue enhanced	Tissue enhanced		colon: 5.1;rectum: 6.9	skin: 3.6	Cell line enriched	5	A549: 26.3
NPY5R	NPYR5	ENSG00000164129	Neuropeptide Y receptor Y5	4	163343939-163351934	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		spleen: 12.3;testis: 9.7	adipose tissue: 7.7	Not detected		
NRCAM	Bravo, KIAA0343	ENSG00000091129	Neuronal cell adhesion molecule	7	108147623-108456717	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012606	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 180.4	adrenal gland: 49.5	Cell line enhanced		A549: 90.2;AF22: 93.7;EFO-21: 165.3;HMC-1: 165.2;SH-SY5Y: 122.8
NRDE2	C14orf102, FLJ14051	ENSG00000119720	NRDE-2, necessary for RNA interference, domain containing	14	90267856-90332137	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047050, HPA050583	Uncertain		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Mixed			parathyroid gland: 2.9	Mixed		
NRG1	GGF, HGL, HRG, NDF, NRG1-IT2	ENSG00000157168	Neuregulin 1	8	31639386-32767959	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010964	Uncertain		Approved	Nucleoplasm		Tissue enhanced	Mixed			thyroid gland: 20.0	Cell line enhanced		A549: 130.4;hTEC/SVTERT24-B: 101.2
NRG2	Don-1, HRG2, NTAK	ENSG00000158458	Neuregulin 2	5	139846779-140043299	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA038935, HPA047973	Uncertain		Supported	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		parathyroid gland: 13.3	ovary: 10.2	Cell line enhanced		AN3-CA: 7.0;PC-3: 12.4;SCLC-21H: 5.8
NRG3		ENSG00000185737	Neuregulin 3	10	81875314-82987179	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA075789			Approved	Vesicles		Group enriched	Tissue enhanced		cerebral cortex: 30.3	fallopian tube: 7.3	Cell line enhanced		HEK93: 1.4;SK-MEL-30: 2.6;U-2 OS: 2.9
NRG4	HRG4	ENSG00000169752	Neuregulin 4	15	75935969-76059795	Predicted membrane proteins	Evidence at protein level	HPA010957	Uncertain					Mixed	Tissue enhanced		fallopian tube: 1.0;testis: 1.3	stomach: 0.8	Cell line enhanced		HeLa: 2.9;HL-60: 1.3;SiHa: 1.2;U-937: 2.1
NRK	DKFZp686A17109	ENSG00000123572	Nik related kinase	X	105822543-105958610	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017238	Uncertain		Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enhanced		ovary: 39.8;placenta: 34.3	adrenal gland: 21.0	Cell line enhanced		fHDF/TERT166: 45.0;RH-30: 12.4;RPTEC TERT1: 26.3
NRM	NRM29	ENSG00000137404	Nurim (nuclear envelope membrane protein)	6	30688047-30691420	Predicted membrane proteins	Evidence at protein level	HPA072545, HPA073982			Enhanced	Nuclear membrane	Renal cancer:3.52e-8 (unfavourable)	Expressed in all	Mixed			skin,smooth muscle: 1.6	Mixed		
NRN1	NRN	ENSG00000124785	Neuritin 1	6	5997999-6007605	Predicted membrane proteins	Evidence at protein level						Renal cancer:4.79e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 152.5	adipose tissue: 61.5	Cell line enhanced		fHDF/TERT166: 111.6;REH: 174.8
NRP1	CD304, NRP, VEGF165R	ENSG00000099250	Neuropilin 1	10	33177492-33336262	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004511, HPA030278	Approved		Uncertain	Mitochondria	Stomach cancer:1.22e-5 (unfavourable), Cervical cancer:7.10e-5 (unfavourable), Renal cancer:3.87e-4 (unfavourable), Glioma:7.78e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 194.1	Cell line enhanced		U-87 MG: 437.4
NRP2	VEGF165R2	ENSG00000118257	Neuropilin 2	2	205681990-205798133	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039980, HPA054974	Enhanced		Supported	Vesicles<br>Plasma membrane	Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable)	Expressed in all	Mixed			smooth muscle: 84.4	Cell line enhanced		CAPAN-2: 119.6;U-251 MG: 195.9
NRROS	ELLP3030, GARPL1, LRRC33, MGC50789, UNQ3030	ENSG00000174004	Negative regulator of reactive oxygen species	3	196639686-196662004	Predicted membrane proteins	Evidence at protein level	HPA031586	Uncertain				Ovarian cancer:9.63e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 19.8	Cell line enhanced		HMC-1: 93.4;NB-4: 87.0;U-937: 59.2
NRSN1	p24, VMP	ENSG00000152954	Neurensin 1	6	24126122-24154900	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA061006	Approved		Approved	Nucleus<br>Vesicles		Tissue enriched	Tissue enriched	14	cerebral cortex: 96.3	adrenal gland: 6.6	Cell line enhanced		SCLC-21H: 14.0;SH-SY5Y: 10.0
NRSN2	C20orf98, dJ1103G7.6	ENSG00000125841	Neurensin 2	20	346782-359660	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015967	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Pancreatic cancer:1.61e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 126.1	parathyroid gland: 69.0	Mixed		
NRXN1	Hs.22998, KIAA0578	ENSG00000179915	Neurexin 1	2	49918505-51225575	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA071400			Approved	Nucleoli<br>Plasma membrane		Tissue enriched	Tissue enriched	12	cerebral cortex: 154.0	seminal vesicle: 12.9	Cell line enriched	9	SCLC-21H: 42.8
NRXN2		ENSG00000110076	Neurexin 2	11	64606174-64723188	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	8	cerebral cortex: 142.6	testis: 17.0	Cell line enhanced		REH: 43.5;SCLC-21H: 27.0;U-2 OS: 27.6;U-87 MG: 18.3
NRXN3	C14orf60, KIAA0743	ENSG00000021645	Neurexin 3	14	78170373-79868290	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002727	Approved				Renal cancer:1.83e-7 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 43.0;smooth muscle: 28.9	seminal vesicle: 15.3	Cell line enhanced		BJ hTERT+ SV40 Large T+: 8.7;RT4: 19.0
NSDHL	H105e3, SDR31E1, XAP104	ENSG00000147383	NAD(P) dependent steroid dehydrogenase-like	X	152830967-152869729	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000248, HPA000571	Enhanced		Enhanced	Endoplasmic reticulum<br>Lipid droplets	Renal cancer:6.09e-5 (favourable), Liver cancer:5.04e-4 (unfavourable), Cervical cancer:5.65e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 54.1	Expressed in all		
NSG1		ENSG00000168824	Neuron-specific protein family member 1 	4	4348140-4419058	Predicted membrane proteins	Evidence at protein level	HPA035775			Approved	Mitochondria	Pancreatic cancer:9.49e-4 (favourable)	Tissue enhanced	Tissue enhanced		skin: 143.1	cerebral cortex: 68.6	Group enriched	8	HAP1: 87.0;SCLC-21H: 199.6;SH-SY5Y: 87.5;SK-MEL-30: 63.7;TIME: 166.8;U-698: 51.3
NT5E	CALJA, CD73, eN, eNT, NT5	ENSG00000135318	5'-nucleotidase ecto	6	85449584-85495791	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017357	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 172.7	smooth muscle: 106.3	Cell line enhanced		LHCN-M2: 772.3;U-87 MG: 800.0
NTM	HNT, IGLON2, NTRI	ENSG00000182667	Neurotrimin	11	131370478-132336822	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024875	Enhanced				Renal cancer:1.10e-8 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 116.0	lung: 39.1	Cell line enhanced		LHCN-M2: 102.1;U-2 OS: 86.6;WM-115: 164.5
NTRK1	MTC, TRK, TRKA	ENSG00000198400	Neurotrophic receptor tyrosine kinase 1	1	156815640-156881850	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB004606, HPA035799, HPA076570	Approved		Uncertain	Vesicles<br>Cytosol		Tissue enhanced	Tissue enriched	6	adrenal gland: 9.5	testis: 1.6	Cell line enhanced		HDLM-2: 10.4;HEL: 11.9;HMC-1: 69.1;SH-SY5Y: 19.1
NTRK2	TRKB	ENSG00000148053	Neurotrophic receptor tyrosine kinase 2	9	84668551-85027070	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA007637, CAB010346	Enhanced		Approved	Cytosol		Group enriched	Tissue enhanced		cerebral cortex: 439.6;thyroid gland: 215.7	breast: 82.1	Group enriched	5	AF22: 9.4;HaCaT: 3.1;RPTEC TERT1: 8.1;SH-SY5Y: 12.9;WM-115: 2.8
NTRK3	TRKC	ENSG00000140538	Neurotrophic receptor tyrosine kinase 3	15	87859751-88256768	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009233, HPA027484, HPA048065	Enhanced		Supported	Nuclear membrane<br>Nucleoli		Tissue enhanced	Tissue enhanced		cerebral cortex: 39.6	testis: 15.2	Cell line enriched	8	U-138 MG: 99.2
NTSR1	NTR	ENSG00000101188	Neurotensin receptor 1	20	62708837-62762771	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050299			Supported	Plasma membrane		Tissue enhanced	Not detected			cerebral cortex: 0.5	Cell line enriched	6	PC-3: 53.5
NTSR2	NTR2	ENSG00000169006	Neurotensin receptor 2	2	11658178-11670164	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	25	cerebral cortex: 25.0	ovary: 0.9	Not detected		
NUAK2	FLJ90349, SNARK	ENSG00000163545	NUAK family kinase 2	1	205302059-205321791	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA008958	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Endometrial cancer:3.01e-7 (unfavourable), Pancreatic cancer:7.94e-6 (favourable)	Expressed in all	Mixed			esophagus: 22.0	Cell line enhanced		BEWO: 42.0;RPTEC TERT1: 30.2
NUDC	NudC	ENSG00000090273	Nuclear distribution C, dynein complex regulator	1	26900238-26946862	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027183, HPA028105	Enhanced		Enhanced	Cytosol	Liver cancer:1.21e-6 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 150.6	Expressed in all		
NUP107	NUP84	ENSG00000111581	Nucleoporin 107	12	68686734-68745809	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031679			Uncertain	Nucleoplasm<br>Nuclear membrane<br>Centrosome	Liver cancer:3.12e-9 (unfavourable), Renal cancer:1.28e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 38.1	Expressed in all		
NUP188	KIAA0169	ENSG00000095319	Nucleoporin 188	9	128947699-129007096	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA061750, HPA063942	Approved		Supported	Nucleus	Endometrial cancer:5.20e-5 (favourable)	Expressed in all	Expressed in all			testis: 104.6	Expressed in all		
NUP205	C7orf14, KIAA0225	ENSG00000155561	Nucleoporin 205	7	135557919-135648757	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Liver cancer:1.90e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.3	Expressed in all		
NUP210	FLJ22389, GP210, KIAA0906, POM210	ENSG00000132182	Nucleoporin 210	3	13316235-13420309	Predicted membrane proteins, Transporters	Evidence at protein level	HPA066888	Approved				Liver cancer:6.03e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 48.6	Mixed		
NUP210L		ENSG00000143552	Nucleoporin 210 like	1	153992685-154155116	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA047195, HPA064245, HPA066707	Enhanced		Approved	Nuclear bodies		Not detected	Tissue enriched	100	testis: 47.8	seminal vesicle,smooth muscle,thyroid gland: 0.4	Cell line enriched	42	MCF7: 12.0
NUP93	KIAA0095	ENSG00000102900	Nucleoporin 93	16	56730105-56850286	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017937	Uncertain				Liver cancer:1.72e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 74.6	Expressed in all		
NUS1	C6orf68, MGC7199, NgBR, TANGO14	ENSG00000153989	NUS1 dehydrodolichyl diphosphate synthase subunit	6	117675502-117710640	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA027504	Supported		Approved	Vesicles<br>Plasma membrane	Cervical cancer:6.99e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 92.2	Expressed in all		
NXPE1	FAM55A, MGC34290	ENSG00000095110	Neurexophilin and PC-esterase domain family member 1	11	114521715-114559895	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049133	Enhanced					Tissue enriched	Group enriched	13	colon: 111.8;rectum: 165.9	appendix: 10.5	Not detected		
OCA2	BEY, BEY1, BEY2, D15S12, EYCL, EYCL2, EYCL3, P	ENSG00000104044	OCA2 melanosomal transmembrane protein	15	27754875-28099358	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enhanced		skin: 7.4;thyroid gland: 5.8	testis: 2.5	Group enriched	6	SH-SY5Y: 6.3;SK-MEL-30: 18.3
OCIAD1	Asrij, FLJ20455, OCIA, TPA018	ENSG00000109180	OCIA domain containing 1	4	48805212-48861817	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044803	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 325.6	Expressed in all		
OCLM		ENSG00000262180	Oculomedin	1	186400572-186401455	Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			epididymis: 2.4	Mixed		
OCLN	PPP1R115	ENSG00000197822	Occludin	5	69492292-69558104	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005933, CAB013075, CAB068212, CAB068213, CAB068214	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:6.59e-11 (favourable)	Mixed	Tissue enhanced		thyroid gland: 78.7	lung: 39.8	Cell line enhanced		CAPAN-2: 60.2;HaCaT: 48.8
OCSTAMP	C20orf123, dJ257E24.3	ENSG00000149635	Osteoclast stimulatory transmembrane protein	20	46540946-46550574	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA031116	Uncertain					Not detected	Not detected			testis: 0.2	Cell line enhanced		AF22: 1.1;HMC-1: 2.0;NB-4: 1.6;U-266/84: 1.7
ODF4	CT136, OPPO1	ENSG00000184650	Outer dense fiber of sperm tails 4	17	8339864-8346048	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	172	testis: 17.1	all non-specific tissues: 0.0	Not detected		
OFCC1	MRDS1	ENSG00000181355	Orofacial cleft 1 candidate 1	6	9596110-10211608	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035725, HPA050619	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enhanced		testis: 2.8	cervix, uterine,duodenum,placenta: 0.7	Cell line enhanced		CACO-2: 2.5;K-562: 4.4;SK-MEL-30: 2.7
OGFOD3	C17orf101, FLJ22222	ENSG00000181396	2-oxoglutarate and iron dependent oxygenase domain containing 3	17	82389223-82418637	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052099	Uncertain		Approved	Nucleoplasm	Renal cancer:5.72e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.4	Expressed in all		
OLR1	CLEC8A, LOX-1, SCARE1	ENSG00000173391	Oxidized low density lipoprotein receptor 1	12	10158301-10172138	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050798			Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Head and neck cancer:8.24e-5 (unfavourable)	Expressed in all	Group enriched	6	appendix: 41.3;cerebral cortex: 32.7;lung: 146.3;placenta: 160.9	bone marrow: 15.8	Cell line enhanced		CACO-2: 102.6;HHSteC: 104.1;SiHa: 261.9;SK-BR-3: 72.4
OMA1	FLJ33782, MPRP-1, YKR087C, ZMPOMA1	ENSG00000162600	OMA1 zinc metallopeptidase	1	58415384-58546802	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055120	Approved		Approved	Nucleoplasm<br>Mitochondria	Breast cancer:1.63e-4 (favourable), Colorectal cancer:7.70e-4 (favourable), Lung cancer:8.52e-4 (favourable)	Expressed in all	Expressed in all			prostate: 31.9	Expressed in all		
OPA3	FLJ22187, MGA3	ENSG00000125741	OPA3, outer mitochondrial membrane lipid metabolism regulator	19	45527427-45602212	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA044881	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.30e-12 (favourable), Liver cancer:5.60e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 18.0	Expressed in all		
OPALIN	HTMP10, TMEM10, TMP10	ENSG00000197430	Oligodendrocytic myelin paranodal and inner loop protein	10	96343216-96359365	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014372	Supported					Tissue enriched	Tissue enriched	864	cerebral cortex: 86.3	all non-specific tissues: 0.0	Not detected		
OPN1LW	CBBM, CBP, COD5, RCP	ENSG00000102076	Opsin 1, long wave sensitive	X	154144224-154159032	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
OPN1MW	CBBM, CBD, COD5, GCP, OPN1MW1	ENSG00000268221	Opsin 1, medium wave sensitive	X	154182596-154196135	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			appendix: 0.1	Not detected		
OPN1MW2		ENSG00000166160	Opsin 1, medium wave sensitive 2	X	154219756-154233286	Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OPN1MW3		ENSG00000269433	Opsin 1, medium wave sensitive 3	X	154257538-154271805	Predicted membrane proteins	No evidence							Not detected	Not detected			skin: 0.1	Not detected		
OPN1SW	BCP, BOP, CBT	ENSG00000128617	Opsin 1, short wave sensitive	7	128772491-128775790	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA013562, HPA014083	Enhanced				Renal cancer:2.26e-8 (unfavourable), Stomach cancer:5.98e-8 (unfavourable), Liver cancer:8.50e-5 (unfavourable), Urothelial cancer:9.33e-4 (unfavourable)	Expressed in all	Mixed			heart muscle: 6.7	Cell line enhanced		U-87 MG: 64.7
OPN3	ECPN, encephalopsin, ERO, NMO-1, PPP1R116	ENSG00000054277	Opsin 3	1	241590102-241677376	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB013682, HPA064443	Uncertain		Approved	Nucleoplasm	Cervical cancer:3.17e-5 (unfavourable), Glioma:2.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 26.9	lung: 12.8	Cell line enhanced		ASC TERT1: 51.2
OPN4	melanopsin, MOP	ENSG00000122375	Opsin 4	10	86654557-86666848	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039147	Approved					Not detected	Tissue enhanced		cerebral cortex: 2.2;parathyroid gland: 1.4	skeletal muscle: 0.9	Not detected		
OPN5	dJ402H5.1, neuropsin, TMEM13	ENSG00000124818	Opsin 5	6	47781982-47832780	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA026084	Supported					Not detected	Tissue enriched	36	testis: 4.1	heart muscle: 0.1	Not detected		
OPRD1		ENSG00000116329	Opioid receptor delta 1	1	28812142-28871267	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA070831	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 2.6	adrenal gland: 0.8	Group enriched	12	RH-30: 15.8;SCLC-21H: 7.6;SH-SY5Y: 6.9;WM-115: 21.7
OPRK1	KOR, OPRK	ENSG00000082556	Opioid receptor kappa 1	8	53225716-53251697	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022595, HPA067549	Uncertain		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Tissue enhanced	Group enriched	7	cerebral cortex: 3.6;prostate: 2.8;testis: 1.3	placenta,skeletal muscle: 0.3	Group enriched	7	AF22: 4.5;U-937: 17.3
OPRL1	KOR-3, NOCIR, NOPr, OOR, ORL1	ENSG00000125510	Opioid related nociceptin receptor 1	20	64080173-64100643	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 12.3	testis: 4.7	Cell line enhanced		REH: 4.4;SCLC-21H: 9.4;U-937: 7.1
OPRM1	MOR1	ENSG00000112038	Opioid receptor mu 1	6	154010496-154246867	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014509, HPA067435	Enhanced	Supported				Not detected	Tissue enhanced		testis: 4.1	adrenal gland,esophagus: 1.2	Cell line enriched	29	SH-SY5Y: 7.7
OR10A2	OR10A2P, OST363	ENSG00000170790	Olfactory receptor family 10 subfamily A member 2	11	6869693-6870745	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10A3	HSHTPCRX12, HTPCRX12	ENSG00000170683	Olfactory receptor family 10 subfamily A member 3	11	7938534-7939594	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10A4	OR10A4P	ENSG00000170782	Olfactory receptor family 10 subfamily A member 4	11	6876625-6877619	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10A5	JCG6, OR10A1, OR11-403	ENSG00000166363	Olfactory receptor family 10 subfamily A member 5	11	6845652-6846705	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10A7		ENSG00000179919	Olfactory receptor family 10 subfamily A member 7	12	55221025-55221975	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA055111	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10AD1	OR10AD1P	ENSG00000172640	Olfactory receptor family 10 subfamily AD member 1	12	48202083-48203387	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA049913	Uncertain					Not detected	Not detected			testis: 0.9	Not detected		
OR10AG1		ENSG00000174970	Olfactory receptor family 10 subfamily AG member 1	11	55967558-55968463	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10C1	hs6M1-17, OR10C1P, OR10C2	ENSG00000206474	Olfactory receptor family 10 subfamily C member 1 (gene/pseudogene)	6	29439306-29440977	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA049336	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10D3	HTPCRX09, OR10D3P	ENSG00000197309	Olfactory receptor family 10 subfamily D member 3 (putative)	11	124185216-124186245	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049991	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
OR10G2		ENSG00000255582	Olfactory receptor family 10 subfamily G member 2	14	21633836-21634940	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			lymph node: 0.2	Not detected		
OR10G3		ENSG00000169208	Olfactory receptor family 10 subfamily G member 3	14	21569803-21570744	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA019766	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10G4		ENSG00000254737	Olfactory receptor family 10 subfamily G member 4	11	124015575-124016510	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			pancreas,rectum: 0.1	Not detected		
OR10G6	OR10G6P, OR10G6Q	ENSG00000198674	Olfactory receptor family 10 subfamily G member 6	11	123994163-123995161	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10G7		ENSG00000182634	Olfactory receptor family 10 subfamily G member 7	11	124038066-124039010	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10G8		ENSG00000234560	Olfactory receptor family 10 subfamily G member 8	11	124029590-124030634	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10G9	OR10G10P	ENSG00000236981	Olfactory receptor family 10 subfamily G member 9	11	124023013-124023948	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10H1		ENSG00000186723	Olfactory receptor family 10 subfamily H member 1	19	15807003-15808126	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			urinary bladder: 0.7	Cell line enriched	6	RT4: 2.9
OR10H2		ENSG00000171942	Olfactory receptor family 10 subfamily H member 2	19	15728020-15729060	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10H3		ENSG00000171936	Olfactory receptor family 10 subfamily H member 3	19	15741393-15742343	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10H4		ENSG00000176231	Olfactory receptor family 10 subfamily H member 4	19	15949008-15949958	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10H5		ENSG00000172519	Olfactory receptor family 10 subfamily H member 5	19	15793951-15795082	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10J1	HGMP07J, HSHGMP07J	ENSG00000196184	Olfactory receptor family 10 subfamily J member 1	1	159439722-159440811	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	102	testis: 10.2	all non-specific tissues: 0.0	Not detected		
OR10J3	OR10J3P	ENSG00000196266	Olfactory receptor family 10 subfamily J member 3	1	159313670-159314659	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA042963	Uncertain					Not detected	Not detected			placenta: 0.6	Cell line enriched	7	LHCN-M2: 1.1
OR10J5		ENSG00000184155	Olfactory receptor family 10 subfamily J member 5	1	159535078-159536007	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10K1		ENSG00000173285	Olfactory receptor family 10 subfamily K member 1	1	158465562-158466503	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA059125	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10K2		ENSG00000180708	Olfactory receptor family 10 subfamily K member 2	1	158419928-158420866	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA059125	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10P1	OR10P1P, OR10P2P, OR10P3P, OST701	ENSG00000175398	Olfactory receptor family 10 subfamily P member 1	12	55636860-55637854	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			heart muscle: 0.2	Not detected		
OR10Q1		ENSG00000180475	Olfactory receptor family 10 subfamily Q member 1	11	58227882-58228918	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA046968	Uncertain					Not detected	Not detected			placenta: 0.1	Not detected		
OR10R2	OR10R2Q	ENSG00000198965	Olfactory receptor family 10 subfamily R member 2	1	158479878-158480885	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA059775, HPA060399	Uncertain					Not detected	Not detected			thyroid gland: 0.1	Cell line enriched	9	MOLT-4: 26.2
OR10S1		ENSG00000196248	Olfactory receptor family 10 subfamily S member 1	11	123976661-123977781	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA019038	Uncertain					Not detected	Not detected			thyroid gland: 0.1	Not detected		
OR10T2		ENSG00000186306	Olfactory receptor family 10 subfamily T member 2	1	158398522-158399466	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		SCLC-21H: 1.0
OR10V1		ENSG00000172289	Olfactory receptor family 10 subfamily V member 1	11	59712823-59713864	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA060076	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10W1	OR10W1P	ENSG00000172772	Olfactory receptor family 10 subfamily W member 1	11	58266792-58268260	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10Z1		ENSG00000198967	Olfactory receptor family 10 subfamily Z member 1	1	158606439-158607380	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA058072	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR11A1	hs6M1-18, OR11A2	ENSG00000204694	Olfactory receptor family 11 subfamily A member 1	6	29425504-29457071	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR11G2		ENSG00000196832	Olfactory receptor family 11 subfamily G member 2	14	20197336-20198446	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	19	HEL: 1.9
OR11H1	OR22-1	ENSG00000130538	Olfactory receptor family 11 subfamily H member 1	22	15528158-15529139	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA047370	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR11H12		ENSG00000257115	Olfactory receptor family 11 subfamily H member 12	14	18601045-18602129	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047370	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR11H2	C14orf15, OR11H2P, OR11H8P	ENSG00000258453	Olfactory receptor family 11 subfamily H member 2	14	19712936-19713920	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA047370	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR11H4		ENSG00000176198	Olfactory receptor family 11 subfamily H member 4	14	20242739-20243820	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA052790	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR11H6		ENSG00000176219	Olfactory receptor family 11 subfamily H member 6	14	20223632-20224805	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR11L1		ENSG00000197591	Olfactory receptor family 11 subfamily L member 1	1	247840928-247841896	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			thyroid gland: 0.3	Not detected		
OR12D3	hs6M1-27	ENSG00000112462	Olfactory receptor family 12 subfamily D member 3	6	29373423-29375291	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR13A1		ENSG00000256574	Olfactory receptor family 13 subfamily A member 1	10	45302654-45315608	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA057237	Uncertain					Tissue enhanced	Not detected			urinary bladder: 0.5	Group enriched	16	Daudi: 5.8;U-698: 5.1
OR13C2		ENSG00000276119	Olfactory receptor family 13 subfamily C member 2	9	104604671-104605627	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex,fallopian tube,thyroid gland: 0.1	Not detected		
OR13C3		ENSG00000204246	Olfactory receptor family 13 subfamily C member 3	9	104535749-104536856	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA053978	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
OR13C4		ENSG00000148136	Olfactory receptor family 13 subfamily C member 4	9	104526253-104527209	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR13C5		ENSG00000277556	Olfactory receptor family 13 subfamily C member 5	9	104598457-104599413	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			adrenal gland,fallopian tube,seminal vesicle,testis,thyroid gland: 0.1	Not detected		
OR13C8		ENSG00000186943	Olfactory receptor family 13 subfamily C member 8	9	104569168-104570130	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR13C9		ENSG00000136839	Olfactory receptor family 13 subfamily C member 9	9	104617248-104618204	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR13D1		ENSG00000179055	Olfactory receptor family 13 subfamily D member 1	9	104694422-104695462	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA055921	Uncertain					Not detected	Not detected			testis: 0.4	Not detected		
OR13F1		ENSG00000186881	Olfactory receptor family 13 subfamily F member 1	9	104504263-104505222	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR13G1		ENSG00000197437	Olfactory receptor family 13 subfamily G member 1	1	247672118-247673041	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Not detected		
OR13H1		ENSG00000171054	Olfactory receptor family 13 subfamily H member 1	X	131544074-131545000	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR13J1		ENSG00000168828	Olfactory receptor family 13 subfamily J member 1	9	35869263-35870601	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex: 0.3	Not detected		
OR14A16	OR5AT1	ENSG00000196772	Olfactory receptor family 14 subfamily A member 16	1	247814800-247815729	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
OR14A2	OR5AX1, OR5AX1P	ENSG00000241128	Olfactory receptor family 14 subfamily A member 2	1	247723099-247724043	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA052685	Uncertain					Not detected	Tissue enriched	51	testis: 5.0	all non-specific tissues: 0.0	Not detected		
OR14C36	OR5BF1	ENSG00000177174	Olfactory receptor family 14 subfamily C member 36	1	248348775-248349713	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			prostate: 0.1	Not detected		
OR14I1	OR5BU1, OR5BU1P	ENSG00000189181	Olfactory receptor family 14 subfamily I member 1	1	248681369-248682304	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	5	cerebral cortex: 3.4	prostate: 0.6	Not detected		
OR14J1	hs6M1-28, OR5U1	ENSG00000204695	Olfactory receptor family 14 subfamily J member 1	6	29306690-29307655	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA045575	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR14K1	OR5AY1	ENSG00000153230	Olfactory receptor family 14 subfamily K member 1	1	247738615-247739559	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA016643	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
OR1A1	OR17-7	ENSG00000172146	Olfactory receptor family 1 subfamily A member 1	17	3215621-3216550	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR1A2	OR17-6	ENSG00000172150	Olfactory receptor family 1 subfamily A member 2	17	3197519-3198448	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR1C1	HSTPCR27, TPCR27	ENSG00000221888	Olfactory receptor family 1 subfamily C member 1	1	247757462-247758406	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	22	testis: 2.2	all non-specific tissues: 0.0	Not detected		
OR1D2	OLFR1, OR17-4	ENSG00000184166	Olfactory receptor family 1 subfamily D member 2	17	3092058-3092996	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
OR1D5	OR17-31	ENSG00000262628	Olfactory receptor family 1 subfamily D member 5	17	3062669-3063607	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR1E1	HGM071, OR13-66, OR17-2, OR17-32, OR1E5, OR1E6, OR1E9P	ENSG00000180016	Olfactory receptor family 1 subfamily E member 1	17	3397104-3398410	G-protein coupled receptors, Predicted membrane proteins, Transporters	No evidence							Not detected	Not detected			placenta,spleen,testis: 0.1	Not detected		
OR1E2	OR17-135, OR17-93, OR1E4	ENSG00000127780	Olfactory receptor family 1 subfamily E member 2	17	3432870-3433841	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR1F1	Olfmf, OR16-36, OR16-37, OR16-88, OR16-89, OR16-90, OR1F10, OR1F13P, OR1F4, OR1F5, OR1F6, OR1F7, OR1F8, OR1F9, OR3-145	ENSG00000168124	Olfactory receptor family 1 subfamily F member 1	16	3204247-3205188	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.7	Not detected		
OR1G1	OR17-209, OR1G2	ENSG00000183024	Olfactory receptor family 1 subfamily G member 1	17	3126584-3127581	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
OR1I1	OR19-20, OR1I1P, OR1I1Q	ENSG00000094661	Olfactory receptor family 1 subfamily I member 1	19	15086980-15088221	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR1J1	hg32	ENSG00000136834	Olfactory receptor family 1 subfamily J member 1	9	122476958-122477926	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR1J2	OR1J3, OR1J5, OST044	ENSG00000197233	Olfactory receptor family 1 subfamily J member 2	9	122510802-122511743	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			urinary bladder: 0.2	Not detected		
OR1J4	HSHTPCRX01, HTPCRX01	ENSG00000239590	Olfactory receptor family 1 subfamily J member 4	9	122519141-122520082	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.2	Not detected		
OR1K1	hg99, MNAB	ENSG00000165204	Olfactory receptor family 1 subfamily K member 1	9	122800123-122801073	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
OR1L1	OR1L2, OR9-C	ENSG00000173679	Olfactory receptor family 1 subfamily L member 1	9	122661566-122662648	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			urinary bladder: 0.1	Not detected		
OR1L3	OR9-D	ENSG00000171481	Olfactory receptor family 1 subfamily L member 3	9	122675130-122676104	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058878	Uncertain					Not detected	Not detected			cerebral cortex: 0.1	Not detected		
OR1L4	OR1L5, OR9-E	ENSG00000136939	Olfactory receptor family 1 subfamily L member 4	9	122723990-122724925	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR1L6	OR1L7	ENSG00000171459	Olfactory receptor family 1 subfamily L member 6	9	122749740-122750783	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR1L8		ENSG00000171496	Olfactory receptor family 1 subfamily L member 8	9	122567548-122568477	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		spleen: 1.2	testis: 0.8	Cell line enriched	7	RT4: 5.5
OR1M1	OR19-6	ENSG00000170929	Olfactory receptor family 1 subfamily M member 1	19	9093179-9094213	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			fallopian tube: 0.1	Not detected		
OR1N1	OR1-26, OR1N3	ENSG00000171505	Olfactory receptor family 1 subfamily N member 1	9	122526358-122527296	G-protein coupled receptors, Predicted membrane proteins	No evidence							Group enriched	Not detected			cervix, uterine,testis: 0.1	Not detected		
OR1N2		ENSG00000171501	Olfactory receptor family 1 subfamily N member 2	9	122553112-122555173	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR1Q1	HSTPCR106, OR1Q2, OR1Q3, OR9-A, OST226, OST226OR9-A, TPCR106	ENSG00000165202	Olfactory receptor family 1 subfamily Q member 1	9	122614738-122615682	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA044828	Uncertain					Not detected	Not detected			epididymis: 0.9	Not detected		
OR1S2		ENSG00000197887	Olfactory receptor family 1 subfamily S member 2	11	58203202-58204181	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049304	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2A1		ENSG00000221970	Olfactory receptor family 2 subfamily A member 1	7	144318125-144319057	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058272	Uncertain					Not detected	Tissue enhanced		thyroid gland: 2.8	ovary: 1.1	Not detected		
OR2A12	OR2A12P	ENSG00000221858	Olfactory receptor family 2 subfamily A member 12	7	144095048-144096093	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2A14	OR2A14P, OR2A6, OST182	ENSG00000221938	Olfactory receptor family 2 subfamily A member 14	7	144129058-144130069	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2A2	OR2A17P, OR2A2P, OST008	ENSG00000221989	Olfactory receptor family 2 subfamily A member 2	7	144109514-144110564	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2A25	OR2A25P, OR2A27	ENSG00000221933	Olfactory receptor family 2 subfamily A member 25	7	144074182-144075195	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058272	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2A4	OR2A10	ENSG00000180658	Olfactory receptor family 2 subfamily A member 4	6	131700469-131701401	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058272	Uncertain					Tissue enriched	Not detected			testis: 0.2	Not detected		
OR2A42		ENSG00000212807	Olfactory receptor family 2 subfamily A member 42	7	144231911-144232843	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA058272	Uncertain					Not detected	Not detected			thyroid gland: 0.6	Not detected		
OR2A5	OR2A26, OR2A8, OR7-138, OR7-141	ENSG00000221836	Olfactory receptor family 2 subfamily A member 5	7	144050368-144051380	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2A7	HSDJ0798C17	ENSG00000243896	Olfactory receptor family 2 subfamily A member 7	7	144258607-144259722	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058272	Uncertain					Mixed	Mixed			thyroid gland: 19.9	Cell line enhanced		A-431: 12.2;hTCEpi: 5.6;RT4: 5.8;SK-BR-3: 4.8
OR2AE1	OR2AE2	ENSG00000244623	Olfactory receptor family 2 subfamily AE member 1	7	99875987-99877057	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA042957	Uncertain					Not detected	Not detected			parathyroid gland: 0.2	Not detected		
OR2AG1	OR2AG3	ENSG00000279486	Olfactory receptor family 2 subfamily AG member 1 (gene/pseudogene)	11	6785017-6786014	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2AG2	OR2AG2P	ENSG00000188124	Olfactory receptor family 2 subfamily AG member 2	11	6767987-6769055	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.3	Not detected		
OR2AJ1	OR2AJ1P, OR2AJ1Q	ENSG00000177275	Olfactory receptor family 2 subfamily AJ member 1	1	247933769-247934755	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			spleen: 0.1	Not detected		
OR2AK2	OR2AK1P	ENSG00000187080	Olfactory receptor family 2 subfamily AK member 2	1	247965233-247966386	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA052544	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
OR2AP1	OR2AP1P	ENSG00000179615	Olfactory receptor family 2 subfamily AP member 1	12	55574415-55575344	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2AT4		ENSG00000171561	Olfactory receptor family 2 subfamily AT member 4	11	75088713-75089754	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA060357	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	12	K-562: 2.6
OR2B11		ENSG00000177535	Olfactory receptor family 2 subfamily B member 11	1	247451029-247451982	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047459	Uncertain					Not detected	Not detected			bone marrow: 0.4	Not detected		
OR2B2	hs6M1-10, OR2B2Q, OR2B9, OR6-1	ENSG00000168131	Olfactory receptor family 2 subfamily B member 2	6	27911185-27912396	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2B3	OR2B3P, OR6-4	ENSG00000204703	Olfactory receptor family 2 subfamily B member 3	6	29086208-29087313	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2B6	dJ408B20.2, OR2B1, OR2B1P, OR2B5, OR2B6P, OR5-40, OR5-41, OR6-31	ENSG00000124657	Olfactory receptor family 2 subfamily B member 6	6	27957241-27958182	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			testis: 0.3	Cell line enhanced		K-562: 1.4;SCLC-21H: 1.5;U-266/84: 2.9;U-937: 1.5
OR2C1	OLFmf3, OR2C2P	ENSG00000168158	Olfactory receptor family 2 subfamily C member 1	16	3355889-3357294	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 1.1	parathyroid gland: 0.4	Not detected		
OR2C3	OR2C4, OR2C5P, OST742	ENSG00000196242	Olfactory receptor family 2 subfamily C member 3	1	247530132-247533839	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA053920, HPA058578	Uncertain		Enhanced	Plasma membrane		Not detected	Expressed in all			parathyroid gland: 27.0	Expressed in all		
OR2D2	hg27, OR11-610, OR2D1	ENSG00000166368	Olfactory receptor family 2 subfamily D member 2	11	6891490-6892599	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2D3		ENSG00000178358	Olfactory receptor family 2 subfamily D member 3	11	6920974-6922043	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA052551	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2F2	OR7-1	ENSG00000221910	Olfactory receptor family 2 subfamily F member 2	7	143935166-143936279	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2G2		ENSG00000177489	Olfactory receptor family 2 subfamily G member 2	1	247588360-247589313	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2G3		ENSG00000177476	Olfactory receptor family 2 subfamily G member 3	1	247605586-247606515	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2G6		ENSG00000188558	Olfactory receptor family 2 subfamily G member 6	1	248521647-248522597	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			kidney: 0.1	Not detected		
OR2H1	OR2H6, OR2H8, OR6-2	ENSG00000204688	Olfactory receptor family 2 subfamily H member 1	6	29457181-29464328	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.9	Not detected		
OR2H2	hs6M1-12	ENSG00000204657	Olfactory receptor family 2 subfamily H member 2	6	29587455-29589038	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2J2	dJ80I19.4, hs6M1-6, OR6-8	ENSG00000204700	Olfactory receptor family 2 subfamily J member 2	6	29173303-29174574	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2J3	OR6-6	ENSG00000204701	Olfactory receptor family 2 subfamily J member 3	6	29111891-29112826	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
OR2K2	HSHTPCRH06, HTPCRH06, OR2AR1P	ENSG00000171133	Olfactory receptor family 2 subfamily K member 2	9	111327483-111328520	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA024261	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
OR2L13	OR2L14	ENSG00000196071	Olfactory receptor family 2 subfamily L member 13	1	248098649-248100922	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 4.0	prostate: 1.0	Not detected		
OR2L2	HSHTPCRH07, HTPCRH07, OR2L12, OR2L4P	ENSG00000203663	Olfactory receptor family 2 subfamily L member 2	1	248038268-248039206	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	7	testis: 2.6	cerebral cortex,spleen: 0.3	Not detected		
OR2L3		ENSG00000198128	Olfactory receptor family 2 subfamily L member 3	1	248060682-248061620	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			thyroid gland: 0.3	Not detected		
OR2L5	OR2L11, OR2L5P	ENSG00000197454	Olfactory receptor family 2 subfamily L member 5	1	248021948-248022886	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2M2	OR2M2Q, OST423	ENSG00000198601	Olfactory receptor family 2 subfamily M member 2	1	248179986-248181029	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2M3	OR2M3P, OR2M6, OST003	ENSG00000228198	Olfactory receptor family 2 subfamily M member 3	1	248203068-248204006	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2M4	HSHTPCRX18, HTPCRX18, OST710, TPCR100	ENSG00000171180	Olfactory receptor family 2 subfamily M member 4	1	248238929-248239864	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA051308	Uncertain					Not detected	Not detected			cerebral cortex: 0.2	Not detected		
OR2M5	OR2M5P	ENSG00000162727	Olfactory receptor family 2 subfamily M member 5	1	248145148-248146086	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2M7		ENSG00000177186	Olfactory receptor family 2 subfamily M member 7	1	248323630-248324568	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2S2		ENSG00000278889	Olfactory receptor family 2 subfamily S member 2 (gene/pseudogene)	9	35957108-35958154	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2T1	OR1-25	ENSG00000175143	Olfactory receptor family 2 subfamily T member 1	1	248405995-248407104	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA063064	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2T10		ENSG00000184022	Olfactory receptor family 2 subfamily T member 10	1	248592830-248593768	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA052019	Uncertain					Tissue enhanced	Tissue enriched	18	kidney: 7.1	prostate: 0.3	Not detected		
OR2T12		ENSG00000177201	Olfactory receptor family 2 subfamily T member 12	1	248294616-248295578	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2T2	OR2T2P	ENSG00000196240	Olfactory receptor family 2 subfamily T member 2	1	248452798-248453772	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2T27		ENSG00000187701	Olfactory receptor family 2 subfamily T member 27	1	248649931-248650884	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2T29		ENSG00000182783	Olfactory receptor family 2 subfamily T member 29	1	248558544-248559491	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2T3		ENSG00000196539	Olfactory receptor family 2 subfamily T member 3	1	248473351-248474307	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2T33		ENSG00000177212	Olfactory receptor family 2 subfamily T member 33	1	248272852-248273814	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			bone marrow,testis: 0.2	Not detected		
OR2T34		ENSG00000183310	Olfactory receptor family 2 subfamily T member 34	1	248573801-248574757	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2T35		ENSG00000177151	Olfactory receptor family 2 subfamily T member 35	1	248638287-248639258	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2T4	OR2T4Q	ENSG00000196944	Olfactory receptor family 2 subfamily T member 4	1	248361581-248362627	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			cervix, uterine,prostate: 0.1	Not detected		
OR2T5		ENSG00000203661	Olfactory receptor family 2 subfamily T member 5	1	248488589-248489536	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2T6	OR2T6P, OR2T9, OST703	ENSG00000198104	Olfactory receptor family 2 subfamily T member 6	1	248387609-248388535	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2T8	OR2T8P	ENSG00000177462	Olfactory receptor family 2 subfamily T member 8	1	247921018-247921956	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		thyroid gland: 1.2	testis: 0.4	Not detected		
OR2V1	OR2V1P, OST265	ENSG00000185372	Olfactory receptor family 2 subfamily V member 1	5	181124357-181125304	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049953	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2V2	OR2V3, OST713	ENSG00000182613	Olfactory receptor family 2 subfamily V member 2	5	181154943-181155890	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049953	Uncertain					Not detected	Not detected			fallopian tube: 0.4	Not detected		
OR2W1	hs6M1-15	ENSG00000204704	Olfactory receptor family 2 subfamily W member 1	6	29044213-29045240	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2W3	OR2W3P, OR2W8P, OST718	ENSG00000238243	Olfactory receptor family 2 subfamily W member 3	1	247895587-247896531	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA045594	Uncertain					Tissue enhanced	Tissue enhanced		bone marrow: 7.8;thyroid gland: 10.5	cerebral cortex: 2.9	Cell line enhanced		HEL: 12.1;PC-3: 12.2;U-2 OS: 8.8;WM-115: 9.3
OR2Y1		ENSG00000174339	Olfactory receptor family 2 subfamily Y member 1	5	180739042-180740099	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2Z1	OR2Z2	ENSG00000181733	Olfactory receptor family 2 subfamily Z member 1	19	8730954-8732009	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA048760	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR3A1	OLFRA03, OR17-40, OR40	ENSG00000180090	Olfactory receptor family 3 subfamily A member 1	17	3291635-3292600	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.7	epididymis: 0.3	Cell line enriched	21	HDLM-2: 20.9
OR3A2	OLFRA04, OR17-228, OR228	ENSG00000221882	Olfactory receptor family 3 subfamily A member 2	17	3277899-3278974	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	6	testis: 5.3	epididymis: 0.9	Cell line enriched	6	HDLM-2: 10.0
OR3A3	OR17-137, OR17-16, OR17-201, OR3A6, OR3A7, OR3A8P	ENSG00000159961	Olfactory receptor family 3 subfamily A member 3	17	3420568-3421533	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			gallbladder,lymph node,tonsil: 0.1	Cell line enriched	10	HDLM-2: 1.5
OR4A15		ENSG00000181958	Olfactory receptor family 4 subfamily A member 15	11	55367884-55368918	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4A16	OR4A16Q	ENSG00000181961	Olfactory receptor family 4 subfamily A member 16	11	55343201-55344187	Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
OR4A47		ENSG00000237388	Olfactory receptor family 4 subfamily A member 47	11	48488717-48489780	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA059763	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4A5		ENSG00000221840	Olfactory receptor family 4 subfamily A member 5	11	54706885-54707832	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4B1	OST208	ENSG00000175619	Olfactory receptor family 4 subfamily B member 1	11	48216792-48217762	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA059443	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4C11	OR4C11P	ENSG00000172188	Olfactory receptor family 4 subfamily C member 11	11	55603354-55604398	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4C12		ENSG00000221954	Olfactory receptor family 4 subfamily C member 12	11	49981473-49982535	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4C13		ENSG00000258817	Olfactory receptor family 4 subfamily C member 13	11	49952391-49953419	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4C15		ENSG00000181939	Olfactory receptor family 4 subfamily C member 15	11	55554307-55555419	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA061939	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4C3		ENSG00000176547	Olfactory receptor family 4 subfamily C member 3	11	48324920-48328471	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA049116	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4C46		ENSG00000185926	Olfactory receptor family 4 subfamily C member 46	11	54603069-54603998	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4C5	OR4C5P, OR4C5Q	ENSG00000176540	Olfactory receptor family 4 subfamily C member 5 (gene/pseudogene)	11	48365485-48366465	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049516	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4C6		ENSG00000181903	Olfactory receptor family 4 subfamily C member 6	11	55665167-55666096	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			lymph node,tonsil: 0.1	Group enriched	7	CAPAN-2: 3.3;Karpas-707: 2.9
OR4D1	OR4D3, TPCR16	ENSG00000141194	Olfactory receptor family 4 subfamily D member 1	17	58155133-58156156	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			lymph node,testis: 0.1	Not detected		
OR4D10	OR4D10P, OST711	ENSG00000254466	Olfactory receptor family 4 subfamily D member 10	11	59477373-59478396	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
OR4D11	OR4D11P	ENSG00000176200	Olfactory receptor family 4 subfamily D member 11	11	59503576-59504511	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4D2		ENSG00000255713	Olfactory receptor family 4 subfamily D member 2	17	58169656-58170579	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4D5		ENSG00000171014	Olfactory receptor family 4 subfamily D member 5	11	123939543-123940637	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA045005	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4D6		ENSG00000166884	Olfactory receptor family 4 subfamily D member 6	11	59456938-59457991	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
OR4D9		ENSG00000172742	Olfactory receptor family 4 subfamily D member 9	11	59514913-59515857	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4E2		ENSG00000221977	Olfactory receptor family 4 subfamily E member 2	14	21665083-21666024	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
OR4F15		ENSG00000182854	Olfactory receptor family 4 subfamily F member 15	15	101818163-101819147	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4F16		ENSG00000273547	Olfactory receptor family 4 subfamily F member 16	1	685716-686654	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047705	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4F17	OR4F11P, OR4F18, OR4F19	ENSG00000176695	Olfactory receptor family 4 subfamily F member 17	19	107461-111696	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4F21	OR4F21P	ENSG00000176269	Olfactory receptor family 4 subfamily F member 21	8	166049-167043	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047705	Uncertain					Not detected	Not detected			testis: 0.2	Cell line enriched	6	BEWO: 1.3
OR4F29		ENSG00000278566	Olfactory receptor family 4 subfamily F member 29	1	450740-451678	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047705	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4F3		ENSG00000230178	Olfactory receptor family 4 subfamily F member 3	5	181367268-181368262	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047705	Uncertain					Not detected	Not detected			testis: 0.5	Not detected		
OR4F4	OR4F18	ENSG00000177693	Olfactory receptor family 4 subfamily F member 4	15	101922042-101923095	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4F5		ENSG00000186092	Olfactory receptor family 4 subfamily F member 5	1	69091-70008	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4F6	OR4F12	ENSG00000184140	Olfactory receptor family 4 subfamily F member 6	15	101805699-101806686	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4K1		ENSG00000155249	Olfactory receptor family 4 subfamily K member 1	14	19935608-19936683	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA028877	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
OR4K13		ENSG00000176253	Olfactory receptor family 4 subfamily K member 13	14	20033844-20034760	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4K14		ENSG00000169484	Olfactory receptor family 4 subfamily K member 14	14	20014260-20015193	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4K15	OR4K15Q	ENSG00000169488	Olfactory receptor family 4 subfamily K member 15	14	19975444-19976659	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA055732	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4K17		ENSG00000176230	Olfactory receptor family 4 subfamily K member 17	14	20117407-20118438	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4K2		ENSG00000165762	Olfactory receptor family 4 subfamily K member 2	14	19876232-19877309	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4K5		ENSG00000176281	Olfactory receptor family 4 subfamily K member 5	14	19920582-19921659	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4L1	OR4L2P	ENSG00000176246	Olfactory receptor family 4 subfamily L member 1	14	20060045-20060983	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4M1		ENSG00000176299	Olfactory receptor family 4 subfamily M member 1	14	19780242-19781357	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058889	Uncertain					Not detected	Not detected			testis: 0.6	Not detected		
OR4M2		ENSG00000274102	Olfactory receptor family 4 subfamily M member 2	15	22080527-22081659	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058889	Uncertain					Not detected	Tissue enriched	10	testis: 1.2	cerebral cortex: 0.1	Not detected		
OR4N2		ENSG00000176294	Olfactory receptor family 4 subfamily N member 2	14	19719015-19828372	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	14	testis: 24.3	cerebral cortex: 1.7	Cell line enhanced		U-2 OS: 4.7
OR4N4		ENSG00000183706	Olfactory receptor family 4 subfamily N member 4	15	22094431-22095556	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA057442	Uncertain		Uncertain	Centrosome		Not detected	Tissue enriched	103	testis: 10.4	cervix, uterine: 0.1	Not detected		
OR4N5		ENSG00000184394	Olfactory receptor family 4 subfamily N member 5	14	20143736-20144662	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	71	HEL: 7.0
OR4P4	OR4P3P	ENSG00000181927	Olfactory receptor family 4 subfamily P member 4	11	55638358-55639296	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA059458	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4Q3	C14orf13, OR4Q4	ENSG00000182652	Olfactory receptor family 4 subfamily Q member 3	14	19747428-19748369	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049924	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
OR4S1		ENSG00000176555	Olfactory receptor family 4 subfamily S member 1	11	48306223-48307152	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4S2	OR4S2P, OST725	ENSG00000174982	Olfactory receptor family 4 subfamily S member 2	11	55650904-55651839	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4X1		ENSG00000176567	Olfactory receptor family 4 subfamily X member 1 (gene/pseudogene)	11	48263861-48264778	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51A2		ENSG00000205496	Olfactory receptor family 51 subfamily A member 2	11	4954772-4955713	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51A4		ENSG00000205497	Olfactory receptor family 51 subfamily A member 4	11	4946159-4947100	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51A7		ENSG00000176895	Olfactory receptor family 51 subfamily A member 7	11	4907370-4908308	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA061356	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
OR51B4		ENSG00000183251	Olfactory receptor family 51 subfamily B member 4	11	5301014-5301996	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Group enriched	8	K-562: 3.2;U-2197: 4.1
OR51B5		ENSG00000242180	Olfactory receptor family 51 subfamily B member 5	11	5342586-5343524	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA063124	Uncertain					Not detected	Not detected			epididymis,testis: 0.2	Group enriched	7	K-562: 5.4;U-2197: 1.5
OR51B6		ENSG00000176239	Olfactory receptor family 51 subfamily B member 6	11	5351508-5352446	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51D1	OR51D1Q	ENSG00000197428	Olfactory receptor family 51 subfamily D member 1	11	4639715-4640838	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA061240	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51E1	GPR136, GPR164, OR51E1P, OR52A3P	ENSG00000180785	Olfactory receptor family 51 subfamily E member 1	11	4643420-4655488	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	CAB019995, HPA051439	Approved				Renal cancer:1.23e-6 (unfavourable)	Tissue enriched	Tissue enhanced		adipose tissue: 6.4;placenta: 9.6;prostate: 9.0	smooth muscle,urinary bladder: 1.7	Cell line enriched	96	SCLC-21H: 10.5
OR51E2	PSGR	ENSG00000167332	Olfactory receptor family 51 subfamily E member 2	11	4680171-4697854	Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	8	prostate: 45.9	placenta: 5.8	Cell line enhanced		ASC TERT1: 1.3
OR51F2		ENSG00000176925	Olfactory receptor family 51 subfamily F member 2	11	4821386-4822414	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51G2		ENSG00000176893	Olfactory receptor family 51 subfamily G member 2	11	4914719-4915663	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51H1	OR51H1P	ENSG00000176904	Olfactory receptor family 51 subfamily H member 1	11	4859656-4860564	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.5	Not detected		
OR51I1		ENSG00000167359	Olfactory receptor family 51 subfamily I member 1	11	5440570-5441514	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.1	Not detected		
OR51I2		ENSG00000187918	Olfactory receptor family 51 subfamily I member 2	11	5453489-5454427	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51J1	OR51J1P, OR51J2	ENSG00000184321	Olfactory receptor family 51 subfamily J member 1 (gene/pseudogene)	11	5402597-5403547	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA017605	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51L1		ENSG00000176798	Olfactory receptor family 51 subfamily L member 1	11	4998983-4999930	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51M1		ENSG00000184698	Olfactory receptor family 51 subfamily M member 1	11	5389399-5390379	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA056773	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51Q1		ENSG00000167360	Olfactory receptor family 51 subfamily Q member 1 (gene/pseudogene)	11	5422111-5423206	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA044998	Uncertain					Not detected	Not detected			epididymis: 0.1	Cell line enriched	23	RT4: 2.2
OR51S1		ENSG00000176922	Olfactory receptor family 51 subfamily S member 1	11	4848237-4849208	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
OR51T1		ENSG00000176900	Olfactory receptor family 51 subfamily T member 1	11	4881819-4882883	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA046877	Uncertain					Not detected	Not detected			prostate: 0.1	Not detected		
OR51V1	OR51A12	ENSG00000176742	Olfactory receptor family 51 subfamily V member 1	11	5199735-5200700	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52A1	HPFH1OR	ENSG00000182070	Olfactory receptor family 52 subfamily A member 1	11	5151009-5186382	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52A5		ENSG00000171944	Olfactory receptor family 52 subfamily A member 5	11	5131692-5132642	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			bone marrow: 0.1	Not detected		
OR52B2		ENSG00000255307	Olfactory receptor family 52 subfamily B member 2	11	6169330-6170408	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52B6		ENSG00000187747	Olfactory receptor family 52 subfamily B member 6	11	5580877-5581884	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52D1		ENSG00000181609	Olfactory receptor family 52 subfamily D member 1	11	5488685-5489749	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA046965	Uncertain					Not detected	Tissue enriched	13	testis: 1.2	all non-specific tissues: 0.0	Not detected		
OR52E2		ENSG00000176787	Olfactory receptor family 52 subfamily E member 2	11	5058650-5059627	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA045748	Uncertain					Not detected	Not detected			testis: 0.4	Not detected		
OR52E4		ENSG00000180974	Olfactory receptor family 52 subfamily E member 4	11	5884271-5885300	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
OR52E5		ENSG00000277932	Olfactory receptor family 52 subfamily E member 5	11	5900777-5902090	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
OR52E6		ENSG00000205409	Olfactory receptor family 52 subfamily E member 6	11	5840928-5841952	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
OR52E8		ENSG00000183269	Olfactory receptor family 52 subfamily E member 8	11	5856674-5857734	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52H1		ENSG00000181616	Olfactory receptor family 52 subfamily H member 1	11	5544561-5545523	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52I1		ENSG00000232268	Olfactory receptor family 52 subfamily I member 1	11	4593750-4595013	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52I2		ENSG00000226288	Olfactory receptor family 52 subfamily I member 2	11	4586791-4587905	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA049343	Uncertain					Not detected	Not detected			epididymis: 0.2	Not detected		
OR52J3		ENSG00000205495	Olfactory receptor family 52 subfamily J member 3	11	5046526-5047461	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52K1		ENSG00000196778	Olfactory receptor family 52 subfamily K member 1	11	4488879-4489908	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			appendix: 0.1	Not detected		
OR52K2		ENSG00000181963	Olfactory receptor family 52 subfamily K member 2	11	4449295-4450361	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			bone marrow: 0.1	Not detected		
OR52L1		ENSG00000183313	Olfactory receptor family 52 subfamily L member 1	11	5985892-5986985	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
OR52M1	OR52M1P	ENSG00000197790	Olfactory receptor family 52 subfamily M member 1	11	4545191-4546144	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52N1		ENSG00000181001	Olfactory receptor family 52 subfamily N member 1	11	5787854-5788816	Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA054028	Uncertain					Not detected	Not detected			adipose tissue: 0.1	Not detected		
OR52N2		ENSG00000180988	Olfactory receptor family 52 subfamily N member 2	11	5820314-5821348	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.8	Not detected		
OR52N4		ENSG00000181074	Olfactory receptor family 52 subfamily N member 4 (gene/pseudogene)	11	5754693-5755729	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			spleen: 2.4	Not detected		
OR52N5	OR52N5Q	ENSG00000181009	Olfactory receptor family 52 subfamily N member 5	11	5777634-5778667	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			adipose tissue: 0.1	Not detected		
OR52W1	OR52W1P	ENSG00000175485	Olfactory receptor family 52 subfamily W member 1	11	6199146-6200259	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			bone marrow: 0.1	Not detected		
OR56A1		ENSG00000180934	Olfactory receptor family 56 subfamily A member 1	11	6026671-6027741	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.4	Not detected		
OR56A3	OR56A3P, OR56A6	ENSG00000184478	Olfactory receptor family 56 subfamily A member 3	11	5947340-5948361	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
OR56A4		ENSG00000183389	Olfactory receptor family 56 subfamily A member 4	11	6001986-6003194	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR56A5	OR56A5P	ENSG00000188691	Olfactory receptor family 56 subfamily A member 5	11	5967177-5968494	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
OR56B1	OR56B1P	ENSG00000181023	Olfactory receptor family 56 subfamily B member 1	11	5736517-5737491	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA045043	Uncertain					Not detected	Not detected			parathyroid gland: 0.3	Not detected		
OR56B4		ENSG00000180919	Olfactory receptor family 56 subfamily B member 4	11	6107684-6108835	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			appendix,spleen,thyroid gland: 0.1	Not detected		
OR5A1	OR5A1P, OST181	ENSG00000172320	Olfactory receptor family 5 subfamily A member 1	11	59443144-59444194	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
OR5A2		ENSG00000172324	Olfactory receptor family 5 subfamily A member 2	11	59421943-59422976	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047135, HPA049575	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5AC2	HSA1	ENSG00000196578	Olfactory receptor family 5 subfamily AC member 2	3	98087173-98088102	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.4	Not detected		
OR5AK2		ENSG00000181273	Olfactory receptor family 5 subfamily AK member 2	11	56988872-56989867	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	68	spleen: 7.2	lung: 0.1	Not detected		
OR5AN1		ENSG00000176495	Olfactory receptor family 5 subfamily AN member 1	11	59364412-59365448	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5AP2		ENSG00000172464	Olfactory receptor family 5 subfamily AP member 2	11	56641466-56642471	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5AS1		ENSG00000181785	Olfactory receptor family 5 subfamily AS member 1	11	56030419-56031393	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5AU1		ENSG00000169327	Olfactory receptor family 5 subfamily AU member 1	14	21154865-21156063	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			seminal vesicle: 0.2	Not detected		
OR5B12	OR5B12P, OR5B16, OST743	ENSG00000172362	Olfactory receptor family 5 subfamily B member 12	11	58439120-58440173	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5B17	OR5B20P	ENSG00000197786	Olfactory receptor family 5 subfamily B member 17	11	58358124-58359069	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5B2	OST073	ENSG00000172365	Olfactory receptor family 5 subfamily B member 2	11	58422265-58423313	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
OR5B21		ENSG00000198283	Olfactory receptor family 5 subfamily B member 21	11	58507175-58508105	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
OR5B3	OR5B13, OST129	ENSG00000172769	Olfactory receptor family 5 subfamily B member 3	11	58402464-58403409	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5C1	hRPK-465_F_21, OR5C2P, OR9-F	ENSG00000148215	Olfactory receptor family 5 subfamily C member 1	9	122788933-122789895	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5D14		ENSG00000186113	Olfactory receptor family 5 subfamily D member 14	11	55795556-55796500	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5D16		ENSG00000205029	Olfactory receptor family 5 subfamily D member 16	11	55838752-55839738	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA046711	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5D18		ENSG00000186119	Olfactory receptor family 5 subfamily D member 18	11	55819630-55820571	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5F1	OR11-10	ENSG00000149133	Olfactory receptor family 5 subfamily F member 1	11	55993681-55994625	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA059360	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5H1	HSHTPCRX14, HTPCRX14	ENSG00000231192	Olfactory receptor family 5 subfamily H member 1	3	98132698-98133639	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5H14		ENSG00000236032	Olfactory receptor family 5 subfamily H member 14	3	98149326-98150405	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			placenta,testis: 0.2	Not detected		
OR5H15		ENSG00000233412	Olfactory receptor family 5 subfamily H member 15	3	98168700-98169733	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5H2		ENSG00000197938	Olfactory receptor family 5 subfamily H member 2	3	98282888-98283832	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5H6		ENSG00000230301	Olfactory receptor family 5 subfamily H member 6 (gene/pseudogene)	3	98264244-98265356	Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
OR5I1	HSOlf1, OLF1	ENSG00000167825	Olfactory receptor family 5 subfamily I member 1	11	55935456-55936400	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5J2		ENSG00000174957	Olfactory receptor family 5 subfamily J member 2	11	56176618-56177556	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA059466	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5K1	HSHTPCRX10, HTPCRX10	ENSG00000232382	Olfactory receptor family 5 subfamily K member 1	3	98469480-98470576	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5K2		ENSG00000231861	Olfactory receptor family 5 subfamily K member 2	3	98497604-98498663	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			lung,skeletal muscle,skin,spleen: 0.3	Not detected		
OR5K3		ENSG00000206536	Olfactory receptor family 5 subfamily K member 3	3	98390666-98391631	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5K4		ENSG00000196098	Olfactory receptor family 5 subfamily K member 4	3	98353854-98354819	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5L2	HSHTPCRX16, HTPCRX16	ENSG00000205030	Olfactory receptor family 5 subfamily L member 2	11	55827219-55828154	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047524	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5M1	OST050	ENSG00000255012	Olfactory receptor family 5 subfamily M member 1	11	56612555-56613502	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5M10		ENSG00000254834	Olfactory receptor family 5 subfamily M member 10	11	56576774-56577721	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5M11	OR11-199	ENSG00000255223	Olfactory receptor family 5 subfamily M member 11	11	56542340-56543257	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
OR5M3		ENSG00000174937	Olfactory receptor family 5 subfamily M member 3	11	56469574-56470497	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5M8		ENSG00000181371	Olfactory receptor family 5 subfamily M member 8	11	56490435-56491370	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
OR5M9		ENSG00000150269	Olfactory receptor family 5 subfamily M member 9	11	56462469-56463401	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5P2	JCG3	ENSG00000183303	Olfactory receptor family 5 subfamily P member 2	11	7795905-7796973	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			skin: 0.1	Not detected		
OR5P3	JCG1	ENSG00000182334	Olfactory receptor family 5 subfamily P member 3	11	7825037-7825972	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA060787	Uncertain					Not detected	Not detected			epididymis,skin: 0.1	Not detected		
OR5T1	OR5T1P	ENSG00000181698	Olfactory receptor family 5 subfamily T member 1	11	56275639-56276619	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA050952	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5T2		ENSG00000181718	Olfactory receptor family 5 subfamily T member 2	11	56232106-56233185	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5T3	OR5T3Q	ENSG00000172489	Olfactory receptor family 5 subfamily T member 3	11	56252200-56253222	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA044986	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5V1	hs6M1-21	ENSG00000243729	Olfactory receptor family 5 subfamily V member 1	6	29355230-29431967	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA046707	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5W2	OR5W2P, OR5W3P	ENSG00000187612	Olfactory receptor family 5 subfamily W member 2	11	55913650-55914582	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6A2	OR11-55, OR6A1, OR6A2P	ENSG00000184933	Olfactory receptor family 6 subfamily A member 2	11	6794627-6795783	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6B1	OR7-3	ENSG00000221813	Olfactory receptor family 6 subfamily B member 1	7	144003929-144004983	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA053164	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
OR6B2	OR6B2P	ENSG00000182083	Olfactory receptor family 6 subfamily B member 2	2	240028965-240030456	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047529	Uncertain					Not detected	Not detected			testis: 0.5	Not detected		
OR6B3	OR6B3P, OR6B3Q	ENSG00000178586	Olfactory receptor family 6 subfamily B member 3	2	240045077-240046072	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047529	Uncertain					Not detected	Tissue enhanced		epididymis: 1.9	testis: 0.7	Not detected		
OR6C1	OST267	ENSG00000205330	Olfactory receptor family 6 subfamily C member 1	12	55320561-55321624	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6C2	OR6C67	ENSG00000179695	Olfactory receptor family 6 subfamily C member 2	12	55452214-55453152	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			epididymis,testis: 0.2	Not detected		
OR6C3	OST709	ENSG00000205329	Olfactory receptor family 6 subfamily C member 3	12	55331701-55332636	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6C4		ENSG00000179626	Olfactory receptor family 6 subfamily C member 4	12	55551199-55552244	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6C6		ENSG00000188324	Olfactory receptor family 6 subfamily C member 6	12	55294288-55295232	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA051090	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6C65		ENSG00000205328	Olfactory receptor family 6 subfamily C member 65	12	55400430-55401505	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6C68		ENSG00000205327	Olfactory receptor family 6 subfamily C member 68	12	55492378-55493316	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			heart muscle: 0.2	Not detected		
OR6C70		ENSG00000184954	Olfactory receptor family 6 subfamily C member 70	12	55469200-55470138	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	6	Karpas-707: 1.6
OR6C74		ENSG00000197706	Olfactory receptor family 6 subfamily C member 74	12	55247198-55248302	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6C75		ENSG00000187857	Olfactory receptor family 6 subfamily C member 75	12	55365111-55366049	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6C76		ENSG00000185821	Olfactory receptor family 6 subfamily C member 76	12	55426254-55427192	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6F1	OST731	ENSG00000169214	Olfactory receptor family 6 subfamily F member 1	1	247711829-247712755	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	21	testis: 2.1	all non-specific tissues: 0.0	Not detected		
OR6J1	OR6J1P, OR6J2	ENSG00000255804	Olfactory receptor family 6 subfamily J member 1 (gene/pseudogene)	14	22633768-22634811	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6K2		ENSG00000196171	Olfactory receptor family 6 subfamily K member 2	1	158699678-158700652	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6K3		ENSG00000203757	Olfactory receptor family 6 subfamily K member 3	1	158717168-158718163	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA055949	Uncertain					Not detected	Not detected			bone marrow: 0.8	Not detected		
OR6K6		ENSG00000180433	Olfactory receptor family 6 subfamily K member 6	1	158754720-158755891	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6M1		ENSG00000196099	Olfactory receptor family 6 subfamily M member 1	11	123805335-123806387	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA048674	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
OR6N1		ENSG00000197403	Olfactory receptor family 6 subfamily N member 1	1	158765744-158766682	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			bone marrow: 0.6	Not detected		
OR6N2		ENSG00000188340	Olfactory receptor family 6 subfamily N member 2	1	158776682-158777635	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA056637	Uncertain					Not detected	Tissue enriched	12	bone marrow: 1.1	all non-specific tissues: 0.0	Not detected		
OR6P1		ENSG00000186440	Olfactory receptor family 6 subfamily P member 1	1	158562651-158563604	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA047466	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6Q1		ENSG00000279051	Olfactory receptor family 6 subfamily Q member 1 (gene/pseudogene)	11	58030930-58031931	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6S1	OR6S1Q	ENSG00000181803	Olfactory receptor family 6 subfamily S member 1	14	20640696-20641691	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6T1		ENSG00000181499	Olfactory receptor family 6 subfamily T member 1	11	123942785-123943873	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA060893	Uncertain					Not detected	Not detected			testis: 0.6	Not detected		
OR6V1	GPR138	ENSG00000225781	Olfactory receptor family 6 subfamily V member 1	7	143052320-143053347	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6X1		ENSG00000221931	Olfactory receptor family 6 subfamily X member 1	11	123753488-123754545	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.1	Not detected		
OR6Y1	OR6Y2	ENSG00000197532	Olfactory receptor family 6 subfamily Y member 1	1	158547128-158548105	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR7A10		ENSG00000127515	Olfactory receptor family 7 subfamily A member 10	19	14840948-14841877	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR7A17	HTPCRX19	ENSG00000185385	Olfactory receptor family 7 subfamily A member 17	19	14880426-14881452	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			skin,thyroid gland: 0.4	Not detected		
OR7A5	HTPCR2	ENSG00000188269	Olfactory receptor family 7 subfamily A member 5	19	14792490-14835376	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA053823	Uncertain					Tissue enriched	Tissue enhanced		epididymis: 5.5;parathyroid gland: 5.4;testis: 2.8	breast,seminal vesicle: 0.9	Not detected		
OR7C1	OR19-5, OR7C4	ENSG00000127530	Olfactory receptor family 7 subfamily C member 1	19	14799146-14800211	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047127	Uncertain					Tissue enriched	Tissue enhanced		epididymis: 3.5;parathyroid gland: 5.0;testis: 3.9	seminal vesicle: 1.5	Not detected		
OR7C2	OR19-18, OR7C3	ENSG00000127529	Olfactory receptor family 7 subfamily C member 2	19	14941489-14942448	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA047295	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR7D2	FLJ38149, HTPCRH03, OR19-4	ENSG00000188000	Olfactory receptor family 7 subfamily D member 2	19	9185594-9188817	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			testis: 1.8	Cell line enhanced		HEL: 1.6
OR7D4	hg105, OR19-B, OR7D4P	ENSG00000174667	Olfactory receptor family 7 subfamily D member 4	19	9213850-9214871	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
OR7E24	HSHT2, OR19-8, OR7E24P, OR7E24Q	ENSG00000237521	Olfactory receptor family 7 subfamily E member 24	19	9250930-9252479	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	25	testis: 2.5	all non-specific tissues: 0.0	Not detected		
OR7G1	OR19-15, OR7G1P	ENSG00000161807	Olfactory receptor family 7 subfamily G member 1	19	9114828-9115763	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR7G2	OST260	ENSG00000170923	Olfactory receptor family 7 subfamily G member 2	19	9102269-9103306	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR7G3	OST085	ENSG00000170920	Olfactory receptor family 7 subfamily G member 3	19	9126012-9126950	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8A1	OST025	ENSG00000196119	Olfactory receptor family 8 subfamily A member 1	11	124569997-124571142	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.4	Not detected		
OR8B12		ENSG00000170953	Olfactory receptor family 8 subfamily B member 12	11	124542682-124543679	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Not detected		
OR8B2		ENSG00000204293	Olfactory receptor family 8 subfamily B member 2	11	124382395-124383362	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	26	testis: 2.5	all non-specific tissues: 0.0	Not detected		
OR8B3		ENSG00000196661	Olfactory receptor family 8 subfamily B member 3	11	124396382-124397368	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.5	Not detected		
OR8B4	OR8B4P	ENSG00000280090	Olfactory receptor family 8 subfamily B member 4 (gene/pseudogene)	11	124423904-124424893	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8B8	TPCR85	ENSG00000197125	Olfactory receptor family 8 subfamily B member 8	11	124440126-124441158	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8D1	OR8D3, OST004	ENSG00000196341	Olfactory receptor family 8 subfamily D member 1	11	124309812-124310837	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA059510	Uncertain					Not detected	Tissue enriched	13	testis: 1.3	all non-specific tissues: 0.0	Not detected		
OR8D4		ENSG00000181518	Olfactory receptor family 8 subfamily D member 4	11	123906146-123907476	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8G1	HSTPCR25, OR8G1P, TPCR25	ENSG00000197849	Olfactory receptor family 8 subfamily G member 1 (gene/pseudogene)	11	124249676-124250611	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.6	Not detected		
OR8G5	OR8G5P, OR8G6	ENSG00000255298	Olfactory receptor family 8 subfamily G member 5	11	124264827-124265867	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	31	testis: 6.2	placenta: 0.2	Cell line enhanced		K-562: 2.3;PC-3: 1.1;T-47d: 1.9
OR8H1		ENSG00000181693	Olfactory receptor family 8 subfamily H member 1	11	56290053-56291090	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8H2		ENSG00000181767	Olfactory receptor family 8 subfamily H member 2	11	56105018-56106055	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8H3		ENSG00000181761	Olfactory receptor family 8 subfamily H member 3	11	56122373-56123311	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8I2		ENSG00000172154	Olfactory receptor family 8 subfamily I member 2	11	56093308-56094240	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8J1		ENSG00000172487	Olfactory receptor family 8 subfamily J member 1	11	56360215-56361288	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8J3		ENSG00000167822	Olfactory receptor family 8 subfamily J member 3	11	56136771-56137718	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8K1		ENSG00000150261	Olfactory receptor family 8 subfamily K member 1	11	56346039-56346998	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA055233	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8K5		ENSG00000181752	Olfactory receptor family 8 subfamily K member 5	11	56159394-56160317	G-protein coupled receptors, Predicted membrane proteins	No evidence							Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
OR8S1		ENSG00000197376	Olfactory receptor family 8 subfamily S member 1	12	48507354-48529897	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA045595	Uncertain		Approved	Plasma membrane		Not detected	Not detected			testis: 0.1	Not detected		
OR8U1		ENSG00000172199	Olfactory receptor family 8 subfamily U member 1	11	56375624-56376553	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR9A2		ENSG00000179468	Olfactory receptor family 9 subfamily A member 2	7	143026158-143027195	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR9A4		ENSG00000258083	Olfactory receptor family 9 subfamily A member 4	7	141918817-141919909	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Cell line enriched	7	U-937: 1.0
OR9G1	OR9G5	ENSG00000174914	Olfactory receptor family 9 subfamily G member 1	11	56700388-56701305	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR9G4		ENSG00000172457	Olfactory receptor family 9 subfamily G member 4	11	56742827-56743811	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR9I1		ENSG00000172377	Olfactory receptor family 9 subfamily I member 1	11	58118500-58119444	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR9K2		ENSG00000170605	Olfactory receptor family 9 subfamily K member 2	12	55129681-55130802	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA015808	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR9Q1		ENSG00000186509	Olfactory receptor family 9 subfamily Q member 1	11	58023881-58181616	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			skeletal muscle,skin,testis: 0.1	Not detected		
OR9Q2	OR9Q2P	ENSG00000186513	Olfactory receptor family 9 subfamily Q member 2	11	58190434-58191518	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
ORAI1	CRACM1, FLJ14466, TMEM142A	ENSG00000276045	ORAI calcium release-activated calcium modulator 1	12	121626550-121642677	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016583, HPA061823	Approved		Supported	Cytosol	Ovarian cancer:4.30e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.9	Expressed in all		
ORAI2	C7orf19, CBCIP2, FLJ12474, FLJ14733, H_NH0514P08.8, TMEM142B	ENSG00000160991	ORAI calcium release-activated calcium modulator 2	7	102433106-102456821	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055137, HPA065937	Uncertain		Approved	Nucleus	Pancreatic cancer:8.49e-5 (favourable), Thyroid cancer:6.65e-4 (favourable)	Expressed in all	Mixed			appendix: 41.9	Expressed in all		
ORAI3	MGC13024, TMEM142C	ENSG00000175938	ORAI calcium release-activated calcium modulator 3	16	30949066-30956461	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015022	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.87e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 27.1	Cell line enhanced		HHSteC: 79.5
ORC3	IMAGE50150, LATHEO, ORC3L	ENSG00000135336	Origin recognition complex subunit 3	6	87590067-87667453	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039553, HPA053748	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:2.89e-5 (unfavourable), Renal cancer:7.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 48.9	Expressed in all		
ORMDL1		ENSG00000128699	ORMDL sphingolipid biosynthesis regulator 1	2	189770323-189784371	Predicted membrane proteins	Evidence at protein level	HPA065643			Supported	Endoplasmic reticulum	Renal cancer:5.84e-9 (unfavourable), Urothelial cancer:1.49e-5 (favourable), Ovarian cancer:3.04e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 155.0	Expressed in all		
ORMDL2	adoplin-2, HSPC160, MST095, MSTP095	ENSG00000123353	ORMDL sphingolipid biosynthesis regulator 2	12	55817919-55821879	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA065643			Supported	Endoplasmic reticulum	Endometrial cancer:3.30e-5 (favourable), Liver cancer:9.75e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 62.6	Expressed in all		
ORMDL3		ENSG00000172057	ORMDL sphingolipid biosynthesis regulator 3	17	39921041-39927601	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA065643			Supported	Endoplasmic reticulum	Urothelial cancer:5.18e-4 (favourable), Lung cancer:9.29e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 164.7	Expressed in all		
OSBPL5	KIAA1534, ORP5	ENSG00000021762	Oxysterol binding protein like 5	11	3087116-3166739	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038335, HPA038712, HPA058727	Approved		Enhanced	Vesicles		Expressed in all	Mixed			spleen: 19.8	Cell line enhanced		NB-4: 47.3
OSBPL8	MST120, MSTP120, ORP8, OSBP10	ENSG00000091039	Oxysterol binding protein like 8	12	76351797-76559809	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA001309	Uncertain		Approved	Vesicles<br>Cytosol	Pancreatic cancer:9.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.5	Expressed in all		
OSCAR		ENSG00000170909	Osteoclast associated, immunoglobulin-like receptor	19	54094668-54102692	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.71e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 9.0;lung: 14.1	appendix: 3.3	Cell line enhanced		EFO-21: 13.1;HHSteC: 7.9;U-937: 14.0
OSMR	OSMRB	ENSG00000145623	Oncostatin M receptor	5	38845858-38945596	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017278	Approved		Approved	Nucleoli	Renal cancer:3.96e-6 (unfavourable), Cervical cancer:4.87e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 55.1	Mixed		
OST4		ENSG00000228474	Oligosaccharyltransferase complex subunit 4, non-catalytic	2	27070472-27071773	Predicted membrane proteins	Evidence at protein level						Renal cancer:7.35e-5 (unfavourable), Liver cancer:5.11e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 344.8	Expressed in all		
OSTC	DC2	ENSG00000198856	Oligosaccharyltransferase complex non-catalytic subunit	4	108650584-108667820	Predicted membrane proteins	Evidence at protein level	HPA065174			Approved	Nucleoplasm	Renal cancer:2.31e-8 (unfavourable), Endometrial cancer:1.44e-4 (favourable), Lung cancer:2.84e-4 (unfavourable), Head and neck cancer:6.66e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 215.1	Expressed in all		
OSTM1	GL, HSPC019	ENSG00000081087	Osteopetrosis associated transmembrane protein 1	6	108041409-108165854	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA010851	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:1.34e-6 (unfavourable), Stomach cancer:1.20e-4 (unfavourable), Liver cancer:4.26e-4 (unfavourable), Breast cancer:4.36e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 33.6	Expressed in all		
OTOF	DFNB6, DFNB9, FER1L2	ENSG00000115155	Otoferlin	2	26457203-26558698	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012410	Approved					Not detected	Tissue enhanced		bone marrow: 4.3	cerebral cortex: 1.1	Cell line enriched	20	HDLM-2: 30.8
OTOP1		ENSG00000163982	Otopetrin 1	4	4188803-4226889	Predicted membrane proteins	Evidence at transcript level	HPA035599	Uncertain					Not detected	Not detected			skin: 0.2	Not detected		
OTOP2		ENSG00000183034	Otopetrin 2	17	74924275-74933912	Predicted membrane proteins	Evidence at transcript level	HPA024524, HPA053090	Uncertain					Not detected	Tissue enhanced		colon: 20.0;rectum: 11.4	testis: 3.9	Cell line enriched	50	HDLM-2: 9.6
OTOP3		ENSG00000182938	Otopetrin 3	17	74935719-74949992	Predicted membrane proteins	Evidence at protein level						Head and neck cancer:3.86e-4 (favourable)	Tissue enhanced	Not detected			small intestine: 0.5	Not detected		
OXA1L	MGC133129, OXA1	ENSG00000155463	OXA1L, mitochondrial inner membrane protein	14	22766522-22773041	Predicted membrane proteins, Transporters	Evidence at protein level	HPA003531	Approved		Supported	Mitochondria	Renal cancer:4.82e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 142.6	Expressed in all		
OXER1	GPCR, GPR170, TG1019	ENSG00000162881	Oxoeicosanoid receptor 1	2	42762481-42764261	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA051433	Uncertain					Expressed in all	Mixed			small intestine: 9.2	Cell line enhanced		CACO-2: 5.4;Hep G2: 5.1;HMC-1: 5.4;REH: 2.9
OXGR1	aKGR, GPR80, GPR99, P2RY15, P2Y15	ENSG00000165621	Oxoglutarate receptor 1	13	96985719-96994730	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA067673			Supported	Plasma membrane		Mixed	Tissue enhanced		breast: 5.1	kidney: 4.6	Cell line enhanced		RT4: 2.6;SK-BR-3: 1.1;U-2 OS: 1.7
OXTR		ENSG00000180914	Oxytocin receptor	3	8750408-8769628	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enriched	13	breast: 65.4	fallopian tube: 4.9	Cell line enhanced		BJ: 357.1;BJ hTERT+: 104.6;BJ hTERT+ SV40 Large T+: 111.8;fHDF/TERT166: 330.6
P2RX1	P2X1	ENSG00000108405	Purinergic receptor P2X 1	17	3896592-3916500	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		seminal vesicle: 46.2;urinary bladder: 41.9	bone marrow: 26.3	Cell line enhanced		HEL: 12.5;HMC-1: 7.5;Karpas-707: 12.1;THP-1: 9.6;U-937: 5.8
P2RX2	DFNA41, P2X2	ENSG00000187848	Purinergic receptor P2X 2	12	132618780-132622386	Disease related genes, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		epididymis: 26.6;seminal vesicle: 12.7	prostate: 9.7	Cell line enhanced		MCF7: 3.9;T-47d: 10.5
P2RX3	P2X3	ENSG00000109991	Purinergic receptor P2X 3	11	57338374-57370600	Predicted membrane proteins, Transporters	Evidence at protein level	HPA057776	Uncertain					Not detected	Tissue enhanced		heart muscle: 2.5;testis: 6.1	liver: 0.9	Not detected		
P2RX4	P2X4	ENSG00000135124	Purinergic receptor P2X 4	12	121209857-121234106	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039494	Enhanced		Approved	Actin filaments<br>Cytosol	Endometrial cancer:6.30e-10 (favourable)	Expressed in all	Mixed			placenta: 33.8	Mixed		
P2RX5	LRH-1, P2X5	ENSG00000083454	Purinergic receptor P2X 5	17	3672199-3696404	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021948, HPA067827	Supported		Supported	Cytosol		Mixed	Group enriched	10	appendix: 40.9;lymph node: 89.8;spleen: 74.3;tonsil: 47.1	bone marrow: 6.2	Cell line enhanced		Daudi: 36.5;RPMI-8226: 40.2;U-698: 32.6
P2RX6	MGC129625, P2RXL1, P2X6, P2XM	ENSG00000099957	Purinergic receptor P2X 6	22	21009808-21028830	Predicted membrane proteins	Evidence at protein level	HPA028776, HPA028777	Approved		Approved	Nucleoli<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 3.4;skeletal muscle: 3.0	spleen: 2.3	Cell line enhanced		LHCN-M2: 5.6;RH-30: 4.0;U-87 MG: 11.5
P2RX7	MGC20089, P2X7	ENSG00000089041	Purinergic receptor P2X 7	12	121132819-121188032	Predicted membrane proteins, Transporters	Evidence at protein level	HPA034967, HPA034968, HPA042013, HPA044141	Approved		Approved	Golgi apparatus	Renal cancer:2.92e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 21.0	Cell line enhanced		Karpas-707: 28.5;RPMI-8226: 16.7;SK-MEL-30: 31.3;U-266/70: 16.4;U-266/84: 14.0
P2RY1	P2Y1	ENSG00000169860	Purinergic receptor P2Y1	3	152834693-152841439	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA015577	Enhanced				Renal cancer:2.04e-7 (unfavourable)	Mixed	Tissue enhanced		placenta: 34.0	esophagus: 19.9	Cell line enriched	6	HEL: 38.5
P2RY10	P2Y10	ENSG00000078589	Purinergic receptor P2Y10	X	78945332-78961954	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA036757, HPA065766	Enhanced				Renal cancer:3.63e-4 (unfavourable)	Mixed	Tissue enhanced		lymph node: 33.1;spleen: 22.6;tonsil: 24.0	appendix: 19.4	Group enriched	5	Karpas-707: 90.1;U-266/70: 20.1
P2RY11	P2Y11	ENSG00000244165	Purinergic receptor P2Y11	19	10111538-10115372	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014232	Approved				Urothelial cancer:1.77e-4 (favourable)	Expressed in all	Mixed			lymph node: 7.2	Mixed		
P2RY12	HORK3, P2Y12, SP1999	ENSG00000169313	Purinergic receptor P2Y12	3	151337380-151384812	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013796, HPA014518	Enhanced					Tissue enriched	Tissue enriched	6	cerebral cortex: 83.8	lymph node: 13.1	Not detected		
P2RY13	FKSG77, GPR86, GPR94, P2Y13	ENSG00000181631	Purinergic receptor P2Y13	3	151326312-151329548	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA049047	Enhanced					Expressed in all	Tissue enhanced		spleen: 51.2	appendix: 27.9	Not detected		
P2RY14	GPR105, KIAA0001	ENSG00000174944	Purinergic receptor P2Y14	3	151212117-151278467	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	CAB022646	Uncertain				Renal cancer:1.72e-5 (unfavourable)	Mixed	Tissue enhanced		placenta: 45.9	esophagus: 23.3	Cell line enriched	77	HMC-1: 60.0
P2RY2	P2U	ENSG00000175591	Purinergic receptor P2Y2	11	73218298-73236352	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022642	Uncertain		Uncertain	Cytosol	Pancreatic cancer:2.19e-5 (unfavourable)	Mixed	Tissue enhanced		esophagus: 18.9	skeletal muscle: 14.9	Cell line enhanced		HaCaT: 31.0;HL-60: 27.2;THP-1: 53.1
P2RY4	NRU, P2P, P2Y4, UNR	ENSG00000186912	Pyrimidinergic receptor P2Y4	X	70258170-70259764	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022644	Uncertain					Not detected	Tissue enriched	5	small intestine: 3.1	rectum,skin: 0.6	Not detected		
P2RY6	P2Y6	ENSG00000171631	Pyrimidinergic receptor P2Y6	11	73264505-73298617	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022740	Uncertain				Renal cancer:2.50e-7 (unfavourable)	Mixed	Tissue enhanced		placenta: 16.8;spleen: 35.6	appendix: 10.8	Cell line enhanced		AN3-CA: 64.0;EFO-21: 20.2;MCF7: 25.4;SK-BR-3: 41.5
P2RY8	P2Y8	ENSG00000182162	Purinergic receptor P2Y8	X	1462572-1537107	Cancer-related genes, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003631	Enhanced				Head and neck cancer:7.80e-5 (favourable), Liver cancer:1.73e-4 (favourable), Pancreatic cancer:6.54e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 47.6	tonsil: 31.3	Cell line enhanced		Daudi: 87.1;U-266/70: 75.0;U-698: 136.4
P4HTM	EGLN4, FLJ20262, HIFPH4, P4H-TM, PH-4, PH4, PHD4	ENSG00000178467	Prolyl 4-hydroxylase, transmembrane	3	48989886-49007154	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007199	Supported		Uncertain	Vesicles<br>Cytosol	Renal cancer:3.28e-5 (favourable), Endometrial cancer:8.18e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 50.0	Mixed		
PAAF1	FLJ11848, Rpn14, WDR71	ENSG00000175575	Proteasomal ATPase associated factor 1	11	73876699-73931124	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039952, HPA040020	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 53.1	Expressed in all		
PACRG	FLJ32724, Glup, HAK005771, PARK2CRG	ENSG00000112530	PARK2 coregulated	6	162727132-163315492	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066293	Enhanced				Renal cancer:2.55e-6 (favourable)	Mixed	Tissue enhanced		fallopian tube: 57.1;testis: 53.0	cerebral cortex,epididymis: 11.8	Cell line enhanced		SCLC-21H: 8.2
PALD1	KIAA1274, PALD	ENSG00000107719	Phosphatase domain containing, paladin 1	10	70478821-70568449	Predicted membrane proteins	Evidence at protein level	HPA015696, HPA017343	Uncertain					Expressed in all	Mixed			lung: 15.0	Cell line enhanced		AN3-CA: 20.7;Daudi: 19.8;RPMI-8226: 23.0
PAM	PAL, PHM	ENSG00000145730	Peptidylglycine alpha-amidating monooxygenase	5	102753981-103031105	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026119, HPA042260	Enhanced		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:1.63e-4 (favourable), Liver cancer:6.20e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 947.8	Cell line enhanced		fHDF/TERT166: 553.5
PANX1	MRS1, PX1, UNQ2529	ENSG00000110218	Pannexin 1	11	94128928-94181972	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016930	Uncertain		Enhanced	Plasma membrane	Renal cancer:1.49e-7 (unfavourable), Lung cancer:7.09e-5 (unfavourable), Endometrial cancer:1.13e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 19.5	Expressed in all		
PANX2	hPANX2, PX2	ENSG00000073150	Pannexin 2	22	50170731-50180294	Predicted membrane proteins, Transporters	Evidence at protein level	HPA004624, HPA039117	Enhanced		Approved	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 8.7	seminal vesicle: 2.1	Cell line enhanced		HDLM-2: 15.5;Hep G2: 13.2;SCLC-21H: 11.5
PANX3	Px3	ENSG00000154143	Pannexin 3	11	124611490-124620356	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Not detected			testis: 0.4	Not detected		
PAPD7	LAK-1, POLK, POLS, TRF4, TRF4-1	ENSG00000112941	Poly(A) RNA polymerase D7, non-canonical	5	6713007-6757048	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045487, HPA046742	Enhanced		Supported	Nucleoplasm<br>Nuclear membrane<br>Golgi apparatus	Renal cancer:7.99e-5 (unfavourable), Urothelial cancer:8.55e-4 (favourable)	Expressed in all	Expressed in all			testis: 19.1	Expressed in all		
PAPOLA	PAP	ENSG00000090060	Poly(A) polymerase alpha	14	96501433-96567111	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001788	Supported		Enhanced	Nucleoplasm	Liver cancer:2.41e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 166.9	Expressed in all		
PAPOLG	FLJ12972	ENSG00000115421	Poly(A) polymerase gamma	2	60756230-60802085	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017795, HPA035349, HPA035350	Approved		Enhanced	Nucleoplasm	Renal cancer:4.21e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 22.2	Expressed in all		
PAPPA2	PAPP-A2, PAPPE, PLAC3	ENSG00000116183	Pappalysin 2	1	176463171-176845605	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018412, HPA018430	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles		Mixed	Tissue enriched	8	placenta: 82.7	cervix, uterine: 10.8	Cell line enriched	6	U-87 MG: 19.4
PAQR3		ENSG00000163291	Progestin and adipoQ receptor family member 3	4	78887127-78939438	Predicted membrane proteins	Evidence at protein level	HPA058453	Uncertain					Expressed in all	Not detected			testis: 0.7	Not detected		
PAQR4	FLJ30002	ENSG00000162073	Progestin and adipoQ receptor family member 4	16	2969245-2973489	Predicted membrane proteins	Evidence at protein level	HPA068394			Approved	Vesicles	Renal cancer:3.01e-6 (unfavourable), Stomach cancer:1.70e-4 (favourable), Liver cancer:6.86e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 54.0;parathyroid gland: 65.2	prostate,skin: 19.2	Mixed		
PAQR5	FLJ20190, MPRG	ENSG00000137819	Progestin and adipoQ receptor family member 5	15	69298947-69407780	Predicted membrane proteins	Evidence at protein level	HPA076729			Approved	Vesicles	Renal cancer:1.47e-14 (favourable), Pancreatic cancer:2.15e-5 (unfavourable)	Mixed	Tissue enhanced		kidney: 55.8	adrenal gland: 20.8	Cell line enhanced		A549: 34.9;CAPAN-2: 40.4;HMC-1: 69.7
PAQR6	FLJ22672, PRdelta	ENSG00000160781	Progestin and adipoQ receptor family member 6	1	156243321-156248117	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA073505			Approved	Nucleus<br>Nucleoli	Renal cancer:1.58e-8 (unfavourable), Colorectal cancer:1.60e-5 (unfavourable), Urothelial cancer:1.86e-4 (favourable), Prostate cancer:1.99e-4 (unfavourable)	Tissue enriched	Tissue enriched	9	cerebral cortex: 97.5	skin: 10.7	Cell line enhanced		U-266/70: 19.6
PAQR7	MPRA, mSR	ENSG00000182749	Progestin and adipoQ receptor family member 7	1	25861210-25871253	Predicted membrane proteins	Evidence at protein level	HPA046936	Approved		Approved	Cytosol	Renal cancer:1.05e-5 (favourable), Liver cancer:1.14e-4 (unfavourable)	Expressed in all	Mixed			testis: 51.0	Cell line enhanced		CAPAN-2: 54.0
PAQR8	C6orf33, LMPB1, MPRB	ENSG00000170915	Progestin and adipoQ receptor family member 8	6	52361421-52407777	Predicted membrane proteins	Evidence at protein level	HPA064625			Supported	Golgi apparatus<br>Plasma membrane	Breast cancer:4.61e-4 (favourable), Urothelial cancer:6.40e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 64.9	Cell line enhanced		Hep G2: 28.4
PAQR9	FLJ41938	ENSG00000188582	Progestin and adipoQ receptor family member 9	3	142949164-142963682	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052798	Uncertain					Tissue enriched	Tissue enhanced		heart muscle: 5.6;liver: 6.8;testis: 19.3	bone marrow: 3.4	Cell line enhanced		A549: 3.0;AF22: 2.0;HEL: 2.1;NTERA-2: 2.5;U-266/70: 4.6;U-266/84: 2.4
PARL	PRO2207, PSARL, PSARL1, RHBDS1	ENSG00000175193	Presenilin associated rhomboid like	3	183829271-183884933	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019545	Approved		Approved	Mitochondria	Urothelial cancer:9.11e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 71.1	Expressed in all		
PARM1	Cipar1, DKFZP564O0823, WSC4	ENSG00000169116	Prostate androgen-regulated mucin-like protein 1	4	74933095-75050115	Predicted membrane proteins	Evidence at protein level	HPA038236	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol	Thyroid cancer:1.78e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 206.6	Cell line enhanced		ASC diff: 30.6;Karpas-707: 32.2;U-266/70: 37.9
PARP16	C15orf30, FLJ20509, FLJ25281, pART15	ENSG00000138617	Poly(ADP-ribose) polymerase family member 16	15	65234460-65300618	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA017081	Approved					Expressed in all	Expressed in all			ovary: 13.0	Expressed in all		
PARVA	FLJ10793, FLJ12254, MXRA2	ENSG00000197702	Parvin alpha	11	12377185-12530801	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA005964	Approved		Supported	Actin filaments<br>Focal adhesion sites<br>Cytosol	Endometrial cancer:1.76e-4 (favourable), Lung cancer:8.19e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 145.8	Mixed		
PARVB	CGI-56	ENSG00000188677	Parvin beta	22	43999211-44172949	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062601			Approved	Cytosol		Expressed in all	Expressed in all			skeletal muscle: 68.6	Mixed		
PARVG		ENSG00000138964	Parvin gamma	22	44172956-44219533	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031833, HPA031834	Uncertain				Renal cancer:3.43e-6 (unfavourable), Endometrial cancer:4.44e-6 (favourable)	Expressed in all	Tissue enhanced		spleen: 38.4	appendix: 35.4	Cell line enhanced		HL-60: 92.2;NB-4: 28.2;THP-1: 43.6;U-937: 42.1
PAX6	AN, AN2, D11S812E, WAGR	ENSG00000007372	Paired box 6	11	31784779-31818062	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA030775, CAB034143	Supported		Enhanced	Nucleoplasm		Tissue enhanced	Group enriched	7	cerebral cortex: 22.3;stomach: 11.2	testis: 2.5	Cell line enhanced		AF22: 15.6;AN3-CA: 19.1;HEK93: 17.3;U-251 MG: 14.4
PBXIP1	HPIP	ENSG00000163346	PBX homeobox interacting protein 1	1	154944076-154956123	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006949	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:9.22e-6 (favourable), Pancreatic cancer:2.64e-4 (favourable), Colorectal cancer:2.73e-4 (unfavourable), Head and neck cancer:7.19e-4 (favourable), Lung cancer:8.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 138.8	Cell line enriched	7	Karpas-707: 788.8
PCDH1	pc42	ENSG00000156453	Protocadherin 1	5	141853111-141879246	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047720, HPA050538	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cell Junctions	Liver cancer:4.96e-5 (unfavourable), Renal cancer:7.55e-5 (favourable), Pancreatic cancer:3.61e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 40.3	Cell line enhanced		CAPAN-2: 75.4;HaCaT: 95.1;RT4: 59.1;TIME: 60.2;WM-115: 51.1
PCDH10	KIAA1400, OL-PCDH	ENSG00000138650	Protocadherin 10	4	133149315-133208606	Predicted membrane proteins	Evidence at protein level	HPA011220, HPA073462	Approved		Approved	Nucleus<br>Golgi apparatus<br>Vesicles		Tissue enhanced	Group enriched	5	cerebral cortex: 62.0;placenta: 36.7;prostate: 17.6;seminal vesicle: 24.5	adrenal gland: 6.8	Cell line enhanced		HUVEC TERT2: 23.1;MOLT-4: 19.4;TIME: 45.4;U-138 MG: 14.3
PCDH11X	PCDH-X, PCDH11, PCDHX, PPP1R119	ENSG00000102290	Protocadherin 11 X-linked	X	91779261-92623230	Predicted membrane proteins	Evidence at transcript level	HPA000432	Approved					Not detected	Tissue enhanced		cerebral cortex: 4.6;ovary: 8.9;parathyroid gland: 4.9	cervix, uterine: 1.5	Cell line enhanced		AF22: 1.4;AN3-CA: 2.1
PCDH11Y	PCDH22, PCDHY	ENSG00000099715	Protocadherin 11 Y-linked	Y	5000226-5742224	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000432	Uncertain					Not detected	Tissue enriched	6	cerebral cortex: 4.4	placenta,seminal vesicle: 0.7	Not detected		
PCDH12	VE-cadherin-2	ENSG00000113555	Protocadherin 12	5	141943585-141969741	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051242	Uncertain				Renal cancer:2.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 38.5	spleen: 22.5	Cell line enhanced		HUVEC TERT2: 19.4;Karpas-707: 41.2;U-937: 7.5
PCDH15	CDHR15, DFNB23, USH1F	ENSG00000150275	Protocadherin related 15	10	53802771-55627942	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074437		Supported				Tissue enriched	Tissue enhanced		adrenal gland: 25.0;cerebral cortex: 12.2	kidney: 8.1	Cell line enhanced		U-2 OS: 1.1;U-266/70: 2.5
PCDH17	PCDH68, PCH68	ENSG00000118946	Protocadherin 17	13	57631810-57729311	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026817	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:3.31e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 25.8;spleen: 33.8	lung: 18.3	Cell line enhanced		AF22: 13.8;HEK93: 8.1;U-87 MG: 5.1
PCDH18	KIAA1562, PCDH68L	ENSG00000189184	Protocadherin 18	4	137518918-137532494	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017976	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:3.21e-4 (unfavourable), Urothelial cancer:4.71e-4 (unfavourable)	Mixed	Mixed			placenta: 64.5	Cell line enhanced		AF22: 148.8;ASC diff: 122.0;ASC TERT1: 137.4;fHDF/TERT166: 114.4;HHSteC: 109.9;HSkMC: 146.3
PCDH19	EFMR, EIEE9, KIAA1313	ENSG00000165194	Protocadherin 19	X	100291644-100410273	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027533	Approved		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 11.3	cervix, uterine: 2.6	Cell line enriched	7	AF22: 17.7
PCDH20	FLJ22218, PCDH13	ENSG00000280165	Protocadherin 20	13	61409685-61415522	Predicted membrane proteins	Evidence at protein level	HPA062669			Approved	Vesicles<br>Cytokinetic bridge		Not detected	Tissue enhanced		cerebral cortex: 14.5;smooth muscle: 13.0	lung: 5.0	Cell line enriched	12	RPTEC TERT1: 39.0
PCDH7	BH-Pcdh, PPP1R120	ENSG00000169851	Protocadherin 7	4	30720415-31146805	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011866, HPA046521	Uncertain		Enhanced	Plasma membrane<br>Cell Junctions	Lung cancer:6.46e-5 (unfavourable), Stomach cancer:6.42e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 46.0	Cell line enhanced		RH-30: 116.4;RT4: 51.9
PCDH8	ARCADLIN, PAPC	ENSG00000136099	Protocadherin 8	13	52842889-52848641	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA010509	Uncertain		Uncertain	Golgi apparatus<br>Cytosol		Tissue enhanced	Tissue enriched	8	cerebral cortex: 5.7	testis: 0.7	Group enriched	7	AF22: 23.5;NTERA-2: 4.9;SCLC-21H: 6.4
PCDH9		ENSG00000184226	Protocadherin 9	13	66302834-67230445	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA015581			Approved	Nucleoplasm<br>Centrosome		Tissue enriched	Tissue enriched	11	cerebral cortex: 68.8	seminal vesicle: 6.1	Cell line enhanced		AF22: 24.9;LHCN-M2: 34.9;TIME: 40.1;U-698: 44.9
PCDHA1		ENSG00000204970	Protocadherin alpha 1	5	140786136-141012347	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035969	Enhanced		Approved	Plasma membrane		Not detected	Tissue enhanced		cerebral cortex: 2.8;testis: 1.4	adrenal gland: 0.4	Cell line enriched	6	T-47d: 8.6
PCDHA10	CNR8, CNRN8, CNRS8, CRNR8, PCDH-ALPHA10	ENSG00000250120	Protocadherin alpha 10	5	140855883-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		cerebral cortex: 17.5	thyroid gland: 4.3	Cell line enriched	10	EFO-21: 16.6
PCDHA11	CNR7, CNRN7, CNRS7, CRNR7, PCDH-ALPHA11	ENSG00000249158	Protocadherin alpha 11	5	140868183-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA077160			Approved	Vesicles<br>Cell Junctions<br>Cytoplasmic bodies		Not detected	Tissue enhanced		cerebral cortex: 7.6;parathyroid gland: 3.8	testis: 1.8	Cell line enhanced		AN3-CA: 14.0;EFO-21: 7.3;T-47d: 5.0
PCDHA12	PCDH-ALPHA12	ENSG00000251664	Protocadherin alpha 12	5	140875302-141012344	Predicted membrane proteins	Evidence at transcript level	HPA035812	Approved		Approved	Cytosol		Not detected	Tissue enhanced		lung: 2.7	cerebral cortex: 1.8	Cell line enhanced		A549: 6.8;hTCEpi: 3.3;PC-3: 5.3;RT4: 4.6;SH-SY5Y: 3.3
PCDHA13	CNR5, CNRN5, CNRS5, CRNR5, PCDH-ALPHA13	ENSG00000239389	Protocadherin alpha 13	5	140882208-141012344	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	6	parathyroid gland: 6.8	cerebral cortex,testis: 1.0	Cell line enhanced		AN3-CA: 1.0;PC-3: 3.5;WM-115: 1.1
PCDHA2		ENSG00000204969	Protocadherin alpha 2	5	140794852-141012344	Predicted membrane proteins	Evidence at protein level	HPA035653	Uncertain					Not detected	Not detected			cerebral cortex: 0.9	Cell line enhanced		AF22: 4.4;SH-SY5Y: 1.3;T-47d: 1.1;WM-115: 1.0
PCDHA3	PCDH-ALPHA3	ENSG00000255408	Protocadherin alpha 3	5	140801028-141012344	Predicted membrane proteins	Evidence at transcript level	HPA035667	Uncertain					Not detected	Mixed			endometrium: 2.5	Cell line enhanced		T-47d: 8.9;WM-115: 2.4
PCDHA4	CNR1, CNRN1, CRNR1, PCDH-ALPHA4	ENSG00000204967	Protocadherin alpha 4	5	140806929-141012344	Predicted membrane proteins	Evidence at protein level	HPA043180, HPA073478	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		cerebral cortex: 4.4	gallbladder: 2.5	Cell line enhanced		A549: 5.9;AF22: 6.1;EFO-21: 5.0;T-47d: 5.1
PCDHA5	CNR6, CNRN6, CNRS6, CRNR6, PCDH-ALPHA5	ENSG00000204965	Protocadherin alpha 5	5	140821604-141012344	Predicted membrane proteins	Evidence at transcript level	HPA044557	Approved					Not detected	Tissue enriched	10	cerebral cortex: 4.1	endometrium: 0.4	Cell line enhanced		A549: 1.2;EFO-21: 3.4;T-47d: 3.5;WM-115: 1.4
PCDHA6	CNR2, CNRS2, CRNR2, PCDH-ALPHA6	ENSG00000081842	Protocadherin alpha 6	5	140827958-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059326, HPA078110	Enhanced		Approved	Vesicles		Not detected	Tissue enhanced		cerebral cortex: 4.8	parathyroid gland: 1.9	Cell line enhanced		AF22: 2.0;EFO-21: 8.1;U-2 OS: 3.7;WM-115: 5.1
PCDHA7	CNR4, CNRS4, CRNR4	ENSG00000204963	Protocadherin alpha 7	5	140834248-141012344	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.6;testis: 1.0	endometrium,gallbladder,smooth muscle: 0.3	Cell line enhanced		NTERA-2: 1.0;WM-115: 1.0
PCDHA8		ENSG00000204962	Protocadherin alpha 8	5	140841187-141012344	Predicted membrane proteins	Evidence at protein level	HPA044585	Uncertain					Not detected	Not detected			cerebral cortex: 0.7	Group enriched	5	AN3-CA: 13.9;SCLC-21H: 4.9
PCDHA9	KIAA0345, PCDH-ALPHA9	ENSG00000204961	Protocadherin alpha 9	5	140847463-141012344	Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.2	cerebral cortex: 0.6	Cell line enriched	8	SCLC-21H: 6.7
PCDHAC1		ENSG00000248383	Protocadherin alpha subfamily C, 1	5	140926369-141012344	Predicted membrane proteins	Evidence at transcript level	HPA052775			Approved	Nucleus<br>Nucleoli<br>Vesicles		Not detected	Tissue enriched	27	parathyroid gland: 69.4	cerebral cortex: 2.5	Cell line enhanced		A549: 5.7;hTCEpi: 5.8;PC-3: 4.2;SCLC-21H: 4.1
PCDHAC2	PCDH-ALPHA-C2	ENSG00000243232	Protocadherin alpha subfamily C, 2	5	140966235-141012344	Predicted membrane proteins	Evidence at transcript level	HPA076190			Approved	Nucleoplasm<br>Mitochondria		Mixed	Tissue enriched	7	parathyroid gland: 92.5	cerebral cortex: 14.1	Cell line enhanced		A549: 11.3;AN3-CA: 57.4;SH-SY5Y: 11.6
PCDHB1	PCDH-BETA1	ENSG00000171815	Protocadherin beta 1	5	141051135-141059344	Predicted membrane proteins	Evidence at protein level	HPA053921	Uncertain					Not detected	Not detected			fallopian tube,testis: 0.7	Not detected		
PCDHB10		ENSG00000120324	Protocadherin beta 10	5	141192353-141195642	Predicted membrane proteins	Evidence at protein level	HPA013445	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 8.3	endometrium: 5.1	Cell line enhanced		EFO-21: 13.2
PCDHB11	ME2, PCDH-BETA11	ENSG00000197479	Protocadherin beta 11	5	141199582-141203779	Predicted membrane proteins	Evidence at transcript level	HPA045042	Uncertain		Approved	Plasma membrane		Mixed	Tissue enhanced		parathyroid gland: 8.2	endometrium: 2.5	Cell line enhanced		AN3-CA: 5.1;EFO-21: 7.4
PCDHB12	PCDH-BETA12	ENSG00000120328	Protocadherin beta 12	5	141208697-141212571	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045042	Uncertain		Approved	Plasma membrane		Mixed	Mixed			endometrium: 3.6	Cell line enhanced		EFO-21: 2.8;RH-30: 3.1
PCDHB13	PCDH-BETA13	ENSG00000187372	Protocadherin beta 13	5	141213919-141218979	Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			endometrium,gallbladder: 2.5	Cell line enhanced		EFO-21: 6.9;T-47d: 13.5;U-2197: 10.8
PCDHB14	PCDH-BETA14	ENSG00000120327	Protocadherin beta 14	5	141222932-141227759	Predicted membrane proteins	Evidence at protein level	HPA007692, HPA045248	Uncertain		Approved	Vesicles	Renal cancer:6.09e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 7.6	Cell line enhanced		SH-SY5Y: 15.2;SiHa: 12.6
PCDHB15	PCDH-BETA15	ENSG00000113248	Protocadherin beta 15	5	141245349-141249365	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007172, CAB026471, HPA074676	Uncertain		Approved	Mitochondria		Mixed	Mixed			cerebral cortex: 12.7	Cell line enhanced		AF22: 5.7;LHCN-M2: 4.0;WM-115: 4.7
PCDHB16	KIAA1621, ME1, PCDH-BETA16, PCDH3X, PCDHB8a	ENSG00000272674	Protocadherin beta 16	5	141181399-141186399	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014668			Approved	Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		parathyroid gland: 10.8	ovary: 7.3	Cell line enhanced		AN3-CA: 15.6;U-138 MG: 35.8
PCDHB2	PCDH-BETA2	ENSG00000112852	Protocadherin beta 2	5	141094578-141098703	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007548	Enhanced		Approved	Nucleoplasm	Urothelial cancer:4.84e-4 (unfavourable), Renal cancer:6.99e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 7.7	testis: 7.5	Cell line enhanced		AF22: 23.3;AN3-CA: 47.2;EFO-21: 26.8
PCDHB3	PCDH-BETA3	ENSG00000113205	Protocadherin beta 3	5	141100473-141103827	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050296	Uncertain		Supported	Vesicles		Mixed	Tissue enhanced		testis: 6.9	endometrium,prostate: 2.4	Cell line enhanced		EFO-21: 10.7;SH-SY5Y: 16.1;U-138 MG: 5.2
PCDHB4	PCDH-BETA4	ENSG00000081818	Protocadherin beta 4	5	141121799-141125623	Predicted membrane proteins	Evidence at transcript level	HPA014466	Approved		Uncertain	Plasma membrane<br>Intermediate filaments<br>Cytosol		Mixed	Mixed			endometrium: 8.9	Group enriched	6	SCLC-21H: 10.2;SH-SY5Y: 6.2
PCDHB5	DKFZp586B0217, PCDH-BETA5	ENSG00000113209	Protocadherin beta 5	5	141135218-141138625	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA013191	Approved					Mixed	Mixed			ovary: 7.3	Cell line enhanced		AF22: 18.5;NTERA-2: 17.7;SCLC-21H: 19.4;T-47d: 16.6;U-138 MG: 32.0;U-2 OS: 15.2
PCDHB6	PCDH-BETA6	ENSG00000113211	Protocadherin beta 6	5	141150022-141153287	Predicted membrane proteins	Evidence at transcript level	HPA029566	Uncertain		Uncertain	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:5.52e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 7.1	testis: 3.5	Cell line enhanced		EFO-21: 15.4;SH-SY5Y: 7.4;T-47d: 5.0;U-2197: 7.0;WM-115: 10.2
PCDHB7	PCDH-BETA7	ENSG00000113212	Protocadherin beta 7	5	141172619-141176383	Plasma proteins, Predicted membrane proteins	Evidence at transcript level	HPA059271	Approved					Tissue enhanced	Tissue enhanced		endometrium: 6.6	smooth muscle: 4.5	Cell line enhanced		EFO-21: 4.4;U-138 MG: 3.1;U-2197: 8.8;U-87 MG: 3.2;WM-115: 3.2
PCDHB8	PCDH-BETA8, PCDH3I	ENSG00000120322	Protocadherin beta 8	5	141177790-141180529	Predicted membrane proteins	Evidence at transcript level	HPA057773	Uncertain					Mixed	Mixed			endometrium: 2.1	Cell line enhanced		EFO-21: 19.7;T-47d: 29.4;U-138 MG: 12.0;U-2197: 31.8
PCDHB9	PCDH-BETA9, PCDH3H	ENSG00000177839	Protocadherin beta 9	5	141187127-141191541	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA013445	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 7.9	epididymis,ovary: 2.5	Cell line enhanced		ASC diff: 7.0;SH-SY5Y: 15.3
PCDHGA1	PCDH-GAMMA-A1	ENSG00000204956	Protocadherin gamma subfamily A, 1	5	141330571-141512981	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA036547	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 3.2	testis: 1.3	Cell line enhanced		LHCN-M2: 3.7;T-47d: 6.9
PCDHGA10	PCDH-GAMMA-A10	ENSG00000253846	Protocadherin gamma subfamily A, 10	5	141412987-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	5	cerebral cortex: 28.0	placenta: 5.1	Cell line enhanced		AF22: 14.4;T-47d: 18.5
PCDHGA11	PCDH-GAMMA-A11	ENSG00000253873	Protocadherin gamma subfamily A, 11	5	141421047-141512979	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			cerebral cortex,placenta: 3.2	Cell line enhanced		ASC diff: 16.8;ASC TERT1: 18.5;SK-MEL-30: 16.7;WM-115: 43.4
PCDHGA12	CDH21, FIB3, KIAA0588, PCDH-GAMMA-A12	ENSG00000253159	Protocadherin gamma subfamily A, 12	5	141430589-141512979	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 8.1	Cell line enhanced		BJ: 8.3;BJ hTERT+: 13.2;fHDF/TERT166: 18.9;HSkMC: 12.6
PCDHGA2	PCDH-GAMMA-A2	ENSG00000081853	Protocadherin gamma subfamily A, 2	5	141338760-141512979	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA038625	Approved		Approved	Nucleus<br>Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			cerebral cortex: 8.4	Cell line enhanced		ASC TERT1: 4.3;BJ: 3.0;fHDF/TERT166: 3.3
PCDHGA3	PCDH-GAMMA-A3	ENSG00000254245	Protocadherin gamma subfamily A, 3	5	141343829-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		cerebral cortex: 6.5	ovary: 3.1	Group enriched	7	AF22: 7.0;BJ: 2.0;EFO-21: 5.4
PCDHGA4	PCDH-GAMMA-A4	ENSG00000262576	Protocadherin gamma subfamily A, 4	5	141355025-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			cerebral cortex: 5.7	Cell line enhanced		ASC TERT1: 5.2;U-87 MG: 5.9
PCDHGA5	CDH-GAMMA-A5, ME3, PCDH-GAMMA-A5	ENSG00000253485	Protocadherin gamma subfamily A, 5	5	141364232-141512979	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 3.8	Group enriched	6	ASC diff: 10.8;ASC TERT1: 4.3
PCDHGA6	PCDH-GAMMA-A6	ENSG00000253731	Protocadherin gamma subfamily A, 6	5	141373914-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			endometrium,ovary: 3.8	Cell line enhanced		SCLC-21H: 11.4;WM-115: 12.0
PCDHGA7	PCDH-GAMMA-A7	ENSG00000253537	Protocadherin gamma subfamily A, 7	5	141382739-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 7.4	thyroid gland: 3.3	Cell line enhanced		BJ hTERT+: 17.1;SH-SY5Y: 19.7
PCDHGA8	KIAA0327, PCDH-GAMMA-A8	ENSG00000253767	Protocadherin gamma subfamily A, 8	5	141390157-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Not detected	Not detected			thyroid gland: 0.7	Not detected		
PCDHGA9	PCDH-GAMMA-A9	ENSG00000261934	Protocadherin gamma subfamily A, 9	5	141402932-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 9.6	endometrium: 4.1	Cell line enhanced		EFO-21: 3.4;TIME: 3.7;U-87 MG: 5.0
PCDHGB1	PCDH-GAMMA-B1	ENSG00000254221	Protocadherin gamma subfamily B, 1	5	141350102-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA076182	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Focal adhesion sites<br>Midbody<br>Cytosol		Mixed	Tissue enriched	11	cerebral cortex: 23.8	endometrium: 2.0	Cell line enhanced		ASC diff: 8.8;T-47d: 8.1
PCDHGB2	PCDH-GAMMA-B2	ENSG00000253910	Protocadherin gamma subfamily B, 2	5	141360042-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA077526	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enriched	Mixed			cerebral cortex: 6.5	Cell line enhanced		ASC diff: 9.2
PCDHGB3	PCDH-GAMMA-B3	ENSG00000262209	Protocadherin gamma subfamily B, 3	5	141370264-141512979	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA035823	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			endometrium: 1.5	Cell line enhanced		ASC diff: 7.2;ASC TERT1: 5.9;TIME: 4.5
PCDHGB4	CDH20, FIB2, PCDH-GAMMA-B4	ENSG00000253953	Protocadherin gamma subfamily B, 4	5	141387698-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			placenta: 4.3	Cell line enhanced		BJ hTERT+: 35.5;TIME: 18.0
PCDHGB5	PCDH-GAMMA-B5	ENSG00000276547	Protocadherin gamma subfamily B, 5	5	141397987-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		parathyroid gland: 19.8	thyroid gland: 7.6	Cell line enhanced		ASC diff: 45.6;ASC TERT1: 34.8;BJ hTERT+ SV40 Large T+: 27.3;BJ hTERT+ SV40 Large T+ RasG12V: 31.8
PCDHGB6	PCDH-GAMMA-B6	ENSG00000253305	Protocadherin gamma subfamily B, 6	5	141408021-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 20.8	parathyroid gland: 11.9	Cell line enhanced		AF22: 15.8;EFO-21: 5.1
PCDHGB7	ME6, PCDH-GAMMA-B7	ENSG00000254122	Protocadherin gamma subfamily B, 7	5	141417645-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Mixed			ovary: 10.2	Cell line enhanced		AN3-CA: 80.7;HSkMC: 19.4
PCDHGC3	PC-43, PC43, PCDH-GAMMA-C3, PCDH2	ENSG00000240184	Protocadherin gamma subfamily C, 3	5	141475947-141512979	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA077289	Approved		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol	Urothelial cancer:6.00e-4 (unfavourable), Ovarian cancer:6.19e-4 (unfavourable), Renal cancer:8.18e-4 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 376.0	cervix, uterine: 93.8	Cell line enhanced		U-138 MG: 264.5;WM-115: 404.1
PCDHGC4	PCDH-GAMMA-C4	ENSG00000242419	Protocadherin gamma subfamily C, 4	5	141484997-141512979	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	11	cerebral cortex: 16.3	adrenal gland: 1.4	Cell line enhanced		REH: 8.3;SCLC-21H: 8.7;SH-SY5Y: 15.1
PCDHGC5	PCDH-GAMMA-C5	ENSG00000240764	Protocadherin gamma subfamily C, 5	5	141489121-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA051540	Uncertain		Approved	Nucleus<br>Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol		Group enriched	Tissue enriched	43	cerebral cortex: 50.6	smooth muscle: 1.1	Cell line enhanced		U-138 MG: 14.5;U-251 MG: 5.4;U-87 MG: 8.8
PCLO	ACZ, DKFZp779G1236, KIAA0559	ENSG00000186472	Piccolo presynaptic cytomatrix protein	7	82754013-83162930	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015858, HPA029579, CAB079012	Approved	Approved	Approved	Nuclear speckles<br>Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 17.4	parathyroid gland: 9.8	Group enriched	36	REH: 239.6;U-2 OS: 298.6
PCMT1		ENSG00000120265	Protein-L-isoaspartate (D-aspartate) O-methyltransferase	6	149749443-149811420	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003239	Approved		Supported	Cytosol	Breast cancer:4.02e-7 (unfavourable), Head and neck cancer:1.88e-4 (unfavourable), Liver cancer:2.58e-4 (unfavourable), Endometrial cancer:4.27e-4 (unfavourable), Urothelial cancer:6.38e-4 (unfavourable), Cervical cancer:9.58e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 194.7	Expressed in all		
PCNX1	KIAA0805, KIAA0995, PCNX, PCNXL1, pecanex	ENSG00000100731	Pecanex homolog 1 (Drosophila)	14	70907405-71115382	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053532			Approved	Nucleoplasm	Renal cancer:4.05e-5 (favourable)	Expressed in all	Expressed in all			testis: 38.2	Expressed in all		
PCNX2	FLJ11383, KIAA0435, PCNXL2	ENSG00000135749	Pecanex homolog 2 (Drosophila)	1	232983435-233295713	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013815, HPA014427	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:2.27e-5 (unfavourable)	Mixed	Mixed			cerebral cortex: 14.0	Mixed		
PCNX3	FLJ22427, PCNXL3	ENSG00000197136	Pecanex homolog 3 (Drosophila)	11	65615773-65637439	Predicted membrane proteins	Evidence at protein level	HPA018084	Uncertain		Approved	Cytosol		Expressed in all	Mixed			testis: 17.2	Expressed in all		
PCNX4	C14orf135, PCNXL4	ENSG00000126773	Pecanex homolog 4 (Drosophila)	14	60091911-60169133	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002076, HPA003390	Uncertain		Approved	Cytosol	Renal cancer:6.84e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.2	Expressed in all		
PCSK4	DKFZp434B217, MGC34749, PC4, SPC5	ENSG00000115257	Proprotein convertase subtilisin/kexin type 4	19	1481428-1490752	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005572	Uncertain				Endometrial cancer:9.45e-5 (favourable)	Expressed in all	Tissue enriched	9	testis: 41.3	fallopian tube: 4.8	Cell line enhanced		AN3-CA: 6.5;HMC-1: 3.2;U-266/70: 5.8
PCSK5	PC5, PC6, SPC6	ENSG00000099139	Proprotein convertase subtilisin/kexin type 5	9	75890644-76362339	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031072	Enhanced		Supported	Golgi apparatus	Renal cancer:9.61e-5 (unfavourable)	Mixed	Mixed			small intestine: 28.1	Cell line enhanced		BEWO: 31.5;HaCaT: 41.2;RPTEC TERT1: 32.1;U-2 OS: 68.5
PCSK7	LPC, PC7, PC8, SPC7	ENSG00000160613	Proprotein convertase subtilisin/kexin type 7	11	117204337-117232525	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043181, HPA052957			Uncertain	Nucleus<br>Nuclear membrane<br>Nucleoli		Expressed in all	Expressed in all			endometrium: 75.4	Expressed in all		
PDCD1	CD279, hSLE1, PD-1, PD1, SLEB2	ENSG00000188389	Programmed cell death 1	2	241849881-241858908	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035981, CAB038418, CAB076386	Enhanced				Renal cancer:3.48e-7 (unfavourable), Endometrial cancer:9.44e-5 (favourable)	Mixed	Tissue enhanced		lymph node: 12.0	appendix: 3.3	Group enriched	13	MOLT-4: 4.6;RPMI-8226: 4.0
PDCD1LG2	B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2	ENSG00000197646	Programmed cell death 1 ligand 2	9	5510570-5571254	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	HPA013411	Approved		Approved	Cytosol	Renal cancer:1.15e-4 (unfavourable)	Mixed	Tissue enhanced		spleen: 21.5	lymph node: 12.0	Cell line enhanced		BJ: 62.0;BJ hTERT+: 93.1;HDLM-2: 83.9
PDE3A	CGI-PDE	ENSG00000172572	Phosphodiesterase 3A	12	20369245-20684381	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA014492	Uncertain		Supported	Cytosol	Renal cancer:1.72e-6 (unfavourable)	Expressed in all	Mixed			heart muscle: 35.4	Group enriched	8	AF22: 15.4;HEL: 26.9;HeLa: 53.3;HUVEC TERT2: 11.9;SH-SY5Y: 31.0;U-138 MG: 22.1
PDE3B	HcGIP1	ENSG00000152270	Phosphodiesterase 3B	11	14643723-14872044	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA056111			Approved	Endoplasmic reticulum	Pancreatic cancer:7.91e-4 (favourable)	Mixed	Tissue enhanced		adipose tissue: 65.4	testis: 17.4	Mixed		
PDGFRA	CD140a, GAS9, PDGFR2	ENSG00000134853	Platelet derived growth factor receptor alpha	4	54229097-54298247	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA004947, CAB018143	Supported		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable)	Expressed in all	Expressed in all			ovary: 222.6	Cell line enhanced		ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0
PDGFRB	CD140b, JTK12, PDGFR, PDGFR1	ENSG00000113721	Platelet derived growth factor receptor beta	5	150113837-150155872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB003842, CAB018144, HPA028499	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 193.8	Cell line enhanced		ASC diff: 923.6;ASC TERT1: 324.4
PDIA6	ERp5, P5, TXNDC7	ENSG00000143870	Protein disulfide isomerase family A member 6	2	10783391-10837977	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034347, HPA034652, HPA034653	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.51e-6 (unfavourable), Liver cancer:3.63e-5 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable), Cervical cancer:1.80e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 591.9	Expressed in all		
PDIK1L	CLIK1L	ENSG00000175087	PDLIM1 interacting kinase 1 like	1	26111165-26125543	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA064157			Supported	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 27.4	Expressed in all		
PDLIM5	Enh, LIM	ENSG00000163110	PDZ and LIM domain 5	4	94451857-94668227	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013511, HPA016740, HPA020026	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites		Tissue enriched	Expressed in all			heart muscle: 424.8	Expressed in all		
PDPN	aggrus, Gp38, GP40, PA2.26, T1A-2	ENSG00000162493	Podoplanin	1	13583465-13617957	Predicted membrane proteins	Evidence at protein level	HPA007534, CAB008376	Enhanced					Tissue enhanced	Tissue enhanced		placenta: 194.0	appendix: 78.6	Cell line enhanced		AF22: 148.2;EFO-21: 336.7;HAP1: 260.6;HHSteC: 181.4;TIME: 199.2
PDZK1IP1	DD96, MAP17, SPAP	ENSG00000162366	PDZK1 interacting protein 1	1	47183593-47191044	Predicted membrane proteins	Evidence at protein level	HPA014907	Enhanced		Approved	Nuclear speckles<br>Cytosol	Pancreatic cancer:3.45e-4 (unfavourable), Glioma:9.46e-4 (unfavourable)	Expressed in all	Group enriched	6	gallbladder: 297.8;kidney: 1052.9	esophagus: 121.2	Group enriched	5	EFO-21: 138.3;RPTEC TERT1: 370.1
PEAR1	FLJ00193, JEDI, MEGF12	ENSG00000187800	Platelet endothelial aggregation receptor 1	1	156893698-156916434	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035217	Approved		Approved	Nucleoplasm<br>Cell Junctions<br>Centrosome	Renal cancer:4.31e-4 (unfavourable)	Expressed in all	Mixed			placenta: 16.9	Cell line enhanced		HBEC3-KT: 21.4;HUVEC TERT2: 43.6;TIME: 69.3
PECAM1	CD31	ENSG00000261371	Platelet and endothelial cell adhesion molecule 1	17	64319415-64413776	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004690	Supported				Renal cancer:8.98e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 659.7	Cell line enhanced		HUVEC TERT2: 644.6;TIME: 437.4
PEMT	PEMPT, PEMT2	ENSG00000133027	Phosphatidylethanolamine N-methyltransferase	17	17505563-17591708	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA042375	Approved		Approved	Cytosol	Endometrial cancer:6.77e-6 (favourable)	Expressed in all	Expressed in all			epididymis: 208.8	Expressed in all		
PERP	dJ496H19.1, KCP1, KRTCAP1, PIGPC1, THW	ENSG00000112378	PERP, TP53 apoptosis effector	6	138088505-138107511	Predicted membrane proteins	Evidence at protein level	HPA022269	Enhanced				Pancreatic cancer:1.05e-5 (unfavourable), Lung cancer:3.73e-4 (unfavourable), Breast cancer:5.46e-4 (unfavourable)	Expressed in all	Group enriched	6	esophagus: 571.9;skin: 1235.5	breast: 151.1	Cell line enhanced		hTCEpi: 661.0
PEX10	RNF69	ENSG00000157911	Peroxisomal biogenesis factor 10	1	2403964-2413797	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049458, HPA049755	Approved		Approved	Nucleoplasm	Renal cancer:4.16e-6 (favourable), Breast cancer:4.50e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.2	Expressed in all		
PEX11A	MGC119947, MGC138534, PEX11-ALPHA	ENSG00000166821	Peroxisomal biogenesis factor 11 alpha	15	89677764-89690783	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Head and neck cancer:2.57e-4 (unfavourable)	Expressed in all	Mixed			prostate: 29.3	Cell line enhanced		SK-BR-3: 40.6
PEX11B		ENSG00000131779	Peroxisomal biogenesis factor 11 beta	1	145911350-145918837	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA050104	Supported				Liver cancer:2.67e-4 (unfavourable), Lung cancer:6.85e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 44.8	Expressed in all		
PEX11G		ENSG00000104883	Peroxisomal biogenesis factor 11 gamma	19	7476875-7497449	Predicted membrane proteins	Evidence at protein level	HPA069817	Uncertain				Renal cancer:1.83e-9 (favourable), Liver cancer:3.27e-4 (favourable), Endometrial cancer:3.60e-4 (favourable)	Expressed in all	Mixed			testis: 15.6	Mixed		
PEX12		ENSG00000108733	Peroxisomal biogenesis factor 12	17	35574795-35578863	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA069386	Enhanced				Renal cancer:3.58e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 17.3	Mixed		
PEX13		ENSG00000162928	Peroxisomal biogenesis factor 13	2	61017225-61051990	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032141, HPA032142, CAB032689	Enhanced		Supported	Vesicles	Pancreatic cancer:8.07e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 27.5	Expressed in all		
PEX14		ENSG00000142655	Peroxisomal biogenesis factor 14	1	10472288-10630758	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046104, HPA049231	Supported		Supported	Nucleoli fibrillar center<br>Peroxisomes		Expressed in all	Expressed in all			seminal vesicle: 32.7	Expressed in all		
PEX16		ENSG00000121680	Peroxisomal biogenesis factor 16	11	45909669-45918812	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043286	Approved				Urothelial cancer:9.06e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 27.5	Expressed in all		
PEX2	PAF-1, PMP35, PXMP3, RNF72, ZWS3	ENSG00000164751	Peroxisomal biogenesis factor 2	8	76980258-77001044	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010983, HPA011410, HPA027729	Approved		Supported	Vesicles		Expressed in all	Expressed in all			seminal vesicle: 111.5	Expressed in all		
PEX26	FLJ20695	ENSG00000215193	Peroxisomal biogenesis factor 26	22	18077920-18131138	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB070429	Approved				Renal cancer:1.38e-4 (favourable), Liver cancer:3.10e-4 (unfavourable), Colorectal cancer:9.92e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 34.1	Expressed in all		
PEX3		ENSG00000034693	Peroxisomal biogenesis factor 3	6	143450807-143490010	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042830, HPA058006	Enhanced		Supported	Nucleoplasm<br>Peroxisomes	Renal cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 54.3	Expressed in all		
PFDN1	PFD1	ENSG00000113068	Prefoldin subunit 1	5	140245039-140303121	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006499	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Liver cancer:8.81e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 106.3	Expressed in all		
PFN2		ENSG00000070087	Profilin 2	3	149964904-150050788	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035611, CAB037073	Enhanced				Liver cancer:2.19e-7 (unfavourable), Endometrial cancer:2.93e-4 (unfavourable), Head and neck cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 419.6	Mixed		
PGAP1	Bst1, FLJ12377, SPG67	ENSG00000197121	Post-GPI attachment to proteins 1	2	196833004-196927796	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069704	Uncertain					Mixed	Mixed			skin: 14.6	Mixed		
PGAP2	CWH43-N, FRAG1, MRT21	ENSG00000148985	Post-GPI attachment to proteins 2	11	3797724-3826371	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA063099	Approved		Approved	Microtubules	Liver cancer:7.49e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 263.3	Expressed in all		
PGAP3	CAB2, MGC9753, PER1, PERLD1, PP1498	ENSG00000161395	Post-GPI attachment to proteins 3	17	39671122-39696797	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016591	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.89e-4 (favourable), Liver cancer:3.94e-4 (favourable), Ovarian cancer:6.82e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 35.6	Cell line enhanced		SK-BR-3: 99.2
PGLYRP2	PGLYRPL, PGRP-L, PGRPL, tagL, tagL-alpha, tagl-beta, TAGL-like	ENSG00000161031	Peptidoglycan recognition protein 2	19	15468645-15498956	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033468, HPA043568, HPA046311, HPA075237	Approved		Approved	Cell Junctions		Tissue enriched	Tissue enriched	17	liver: 133.2	testis: 7.8	Group enriched	8	MCF7: 5.7;T-47d: 6.8
PGRMC1	HPR6.6	ENSG00000101856	Progesterone receptor membrane component 1	X	119236245-119244466	Predicted membrane proteins	Evidence at protein level	HPA002877	Enhanced		Approved	Nucleoli<br>Endoplasmic reticulum	Head and neck cancer:3.02e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 339.9	Expressed in all		
PGRMC2	DG6, PMBP	ENSG00000164040	Progesterone receptor membrane component 2	4	128269237-128288829	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041172, HPA058652	Approved		Approved	Nuclear bodies<br>Plasma membrane<br>Cytosol	Endometrial cancer:3.62e-4 (favourable), Renal cancer:9.60e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 133.4	Expressed in all		
PHEX	HPDR, HPDR1, HYP, HYP1, PEX, XLH	ENSG00000102174	Phosphate regulating endopeptidase homolog, X-linked	X	22032441-22251310	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Thyroid cancer:2.51e-4 (favourable)	Tissue enhanced	Tissue enhanced		endometrium: 3.5	lung: 2.9	Cell line enhanced		PC-3: 2.8;U-87 MG: 6.5;WM-115: 2.8
PHKG1	PHKG	ENSG00000164776	Phosphorylase kinase catalytic subunit gamma 1	7	56080283-56092996	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012057	Enhanced					Tissue enriched	Tissue enriched	7	skeletal muscle: 100.5	cerebral cortex: 14.2	Mixed		
PHKG2		ENSG00000156873	Phosphorylase kinase catalytic subunit gamma 2	16	30748270-30761176	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065618, HPA068751			Supported	Cytosol	Lung cancer:1.90e-4 (favourable), Cervical cancer:7.90e-4 (favourable), Pancreatic cancer:8.02e-4 (favourable), Colorectal cancer:9.92e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 149.4	Expressed in all		
PHLDB2	FLJ21791, LL5b, LL5beta	ENSG00000144824	Pleckstrin homology like domain family B member 2	3	111732497-111976517	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035146, HPA035147	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.03e-8 (favourable), Head and neck cancer:2.59e-4 (unfavourable)	Expressed in all	Mixed			placenta: 59.0	Mixed		
PHTF1	PHTF	ENSG00000116793	Putative homeodomain transcription factor 1	1	113696831-113759489	Plasma proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA059486			Approved	Nucleoli<br>Nuclear bodies	Renal cancer:1.21e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 54.4	parathyroid gland: 19.0	Mixed		
PHTF2	DKFZp434D166	ENSG00000006576	Putative homeodomain transcription factor 2	7	77798792-77957503	Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA012312	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.09e-7 (unfavourable), Thyroid cancer:2.78e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 62.0	Expressed in all		
PI16	CD364, dJ90K10.5, MGC45378, MSMBBP	ENSG00000164530	Peptidase inhibitor 16	6	36948263-36964837	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA076574	Approved					Tissue enhanced	Tissue enhanced		cervix, uterine: 199.5	urinary bladder: 78.6	Cell line enhanced		Daudi: 3.7;fHDF/TERT166: 3.6;U-2197: 1.0
PI4KA	PI4K-ALPHA, pi4K230, PIK4CA	ENSG00000241973	Phosphatidylinositol 4-kinase alpha	22	20707691-20859417	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009092, HPA075515	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:7.22e-5 (favourable), Lung cancer:5.24e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 113.6	Expressed in all		
PIANP	C12orf53, DKFZp547D2210, PANP	ENSG00000139200	PILR alpha associated neural protein	12	6693792-6700800	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010631	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 64.3	endometrium: 13.4	Cell line enhanced		NTERA-2: 20.8;SH-SY5Y: 20.6;U-2 OS: 11.2
PIAS2	miz, PIASX-ALPHA, PIASX-BETA, ZMIZ4	ENSG00000078043	Protein inhibitor of activated STAT 2	18	46803224-46920160	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068792	Enhanced		Supported	Nucleoplasm	Thyroid cancer:1.27e-4 (unfavourable)	Expressed in all	Group enriched	5	parathyroid gland: 28.5;testis: 119.6	cerebral cortex,thyroid gland: 13.8	Mixed		
PIEZO1	FAM38A, KIAA0233	ENSG00000103335	Piezo type mechanosensitive ion channel component 1	16	88715343-88785211	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047185	Uncertain				Renal cancer:8.89e-7 (unfavourable), Lung cancer:2.36e-5 (unfavourable), Cervical cancer:2.37e-4 (unfavourable), Ovarian cancer:3.78e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 42.0	Expressed in all		
PIEZO2	C18orf30, C18orf58, FAM38B, FAM38B2, FLJ23144, FLJ23403, FLJ34907, HsT748, HsT771	ENSG00000154864	Piezo type mechanosensitive ion channel component 2	18	10666483-11148762	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015986, HPA031974, HPA031975, HPA040616	Enhanced		Approved	Vesicles	Renal cancer:9.57e-7 (unfavourable)	Mixed	Mixed			lung: 12.8	Cell line enhanced		AF22: 17.1;BJ hTERT+ SV40 Large T+ RasG12V: 24.8;HeLa: 26.7;U-266/70: 19.5
PIGA	GPI3	ENSG00000165195	Phosphatidylinositol glycan anchor biosynthesis class A	X	15319451-15335580	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001174	Approved				Pancreatic cancer:7.64e-4 (unfavourable)	Expressed in all	Mixed			lung: 9.8	Expressed in all		
PIGB		ENSG00000069943	Phosphatidylinositol glycan anchor biosynthesis class B	15	55318960-55355648	Predicted membrane proteins	Evidence at protein level	HPA039929	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 22.8	Expressed in all		
PIGC		ENSG00000135845	Phosphatidylinositol glycan anchor biosynthesis class C	1	172370189-172444086	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA036663	Uncertain				Renal cancer:1.43e-8 (unfavourable), Liver cancer:4.49e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 47.7	Expressed in all		
PIGF		ENSG00000151665	Phosphatidylinositol glycan anchor biosynthesis class F	2	46580937-46617119	Predicted membrane proteins	Evidence at protein level	HPA051389	Uncertain				Liver cancer:1.39e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 47.1	Expressed in all		
PIGG	FLJ20265, GPI7, LAS21	ENSG00000174227	Phosphatidylinositol glycan anchor biosynthesis class G	4	499210-540196	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015997	Uncertain		Uncertain	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 35.6	Expressed in all		
PIGH	GPI-H	ENSG00000100564	Phosphatidylinositol glycan anchor biosynthesis class H	14	67581955-67600287	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031624	Approved				Renal cancer:2.68e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 107.3	Expressed in all		
PIGK	GPI8, hGPI8	ENSG00000142892	Phosphatidylinositol glycan anchor biosynthesis class K	1	77088990-77219430	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056383, HPA057040	Uncertain				Liver cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.4	Expressed in all		
PIGM	GPI-MT-I	ENSG00000143315	Phosphatidylinositol glycan anchor biosynthesis class M	1	160027673-160031991	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA047418	Uncertain				Ovarian cancer:3.27e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 16.3	Mixed		
PIGN	MDC4, PIG-N	ENSG00000197563	Phosphatidylinositol glycan anchor biosynthesis class N	18	61905255-62187118	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039922, HPA040374	Approved		Supported	Plasma membrane<br>Cytosol	Colorectal cancer:6.51e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 33.4	Expressed in all		
PIGO	DKFZp434M222, FLJ00135	ENSG00000165282	Phosphatidylinositol glycan anchor biosynthesis class O	9	35088688-35096601	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014905			Approved	Nucleus<br>Nucleoli	Renal cancer:3.05e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 74.6	Expressed in all		
PIGP	DCRC, DSCR5, DSRC	ENSG00000185808	Phosphatidylinositol glycan anchor biosynthesis class P	21	37059170-37073170	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026921	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			epididymis: 125.7	Expressed in all		
PIGQ	GPI1, hGPI1	ENSG00000007541	Phosphatidylinositol glycan anchor biosynthesis class Q	16	566995-584136	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039105, HPA039828, HPA061414	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:2.53e-6 (favourable)	Expressed in all	Expressed in all			bone marrow: 17.5	Expressed in all		
PIGR		ENSG00000162896	Polymeric immunoglobulin receptor	1	206928518-206946466	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA006154, CAB009454, HPA012012	Enhanced				Breast cancer:1.22e-5 (favourable), Renal cancer:5.08e-5 (favourable), Endometrial cancer:2.57e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 1688.0;duodenum: 2659.3	rectum: 1335.9	Cell line enriched	7	EFO-21: 33.8
PIGS		ENSG00000087111	Phosphatidylinositol glycan anchor biosynthesis class S	17	28553383-28571872	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA018149	Approved				Liver cancer:1.86e-4 (unfavourable), Urothelial cancer:5.31e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 13.5	Expressed in all		
PIGT		ENSG00000124155	Phosphatidylinositol glycan anchor biosynthesis class T	20	45416067-45456934	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 123.1	Expressed in all		
PIGU	bA346K17.2, CDC91L1, GAB1	ENSG00000101464	Phosphatidylinositol glycan anchor biosynthesis class U	20	34560542-34698790	Predicted membrane proteins	Evidence at protein level	HPA041706, HPA046766	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.49e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 48.2	Expressed in all		
PIGV	FLJ20477	ENSG00000060642	Phosphatidylinositol glycan anchor biosynthesis class V	1	26787472-26798398	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054181			Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:7.60e-7 (favourable)	Expressed in all	Expressed in all			testis: 79.6	Expressed in all		
PIGW	FLJ37433, Gwt1	ENSG00000277161	Phosphatidylinositol glycan anchor biosynthesis class W	17	36535020-36539310	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA023499			Approved	Plasma membrane		Expressed in all	Mixed			appendix: 5.1	Expressed in all		
PIGX	FLJ20522	ENSG00000163964	Phosphatidylinositol glycan anchor biosynthesis class X	3	196639775-196736007	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029409	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:7.45e-5 (unfavourable), Cervical cancer:2.12e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.5	Expressed in all		
PIGY	MGC14156	ENSG00000255072	Phosphatidylinositol glycan anchor biosynthesis class Y	4	88521573-88521789	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA059018	Uncertain					Not detected	Tissue enriched	11	colon: 1.0	all non-specific tissues: 0.0	Group enriched	10	AF22: 7.5;hTEC/SVTERT24-B: 10.7;MOLT-4: 13.8
PIGZ	FLJ12768, MGC52163, SMP3	ENSG00000119227	Phosphatidylinositol glycan anchor biosynthesis class Z	3	196946343-196969060	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA058599, HPA059920	Approved		Uncertain	Vesicles	Renal cancer:5.60e-5 (unfavourable)	Expressed in all	Tissue enhanced		colon: 18.5;rectum: 18.1	cerebral cortex: 10.9	Mixed		
PIK3IP1	HGFL, MGC17330	ENSG00000100100	Phosphoinositide-3-kinase interacting protein 1	22	31281593-31292534	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 121.1	Cell line enhanced		U-698: 23.5
PILRA	FDF03	ENSG00000085514	Paired immunoglobin like type 2 receptor alpha	7	100367530-100400099	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056132	Approved				Renal cancer:1.61e-4 (unfavourable), Cervical cancer:2.99e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 52.4	lung: 43.8	Cell line enhanced		ASC diff: 18.7;HMC-1: 21.9;NB-4: 12.4
PILRB	FDFACT1, FDFACT2	ENSG00000121716	Paired immunoglobin-like type 2 receptor beta	7	100352176-100367733	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026750	Approved		Approved	Mitochondria	Renal cancer:1.42e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 166.9	Expressed in all		
PIM2		ENSG00000102096	Pim-2 proto-oncogene, serine/threonine kinase	X	48913182-48919024	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000285			Approved	Cytosol	Renal cancer:1.17e-11 (unfavourable), Cervical cancer:4.05e-5 (favourable)	Tissue enriched	Mixed			lymph node: 128.7	Expressed in all		
PIRT		ENSG00000233670	Phosphoinositide interacting regulator of transient receptor potential channels	17	10822475-10838445	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA042337	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 3.1;cerebral cortex: 2.6;rectum: 2.7	colon: 2.1	Not detected		
PISD	dJ858B16.2, PSDC	ENSG00000241878	Phosphatidylserine decarboxylase	22	31618491-31662432	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031090, HPA031091	Approved		Approved	Golgi apparatus<br>Cytosol	Urothelial cancer:5.27e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 35.9	Expressed in all		
PKD1	PBP, Pc-1, TRPP1	ENSG00000008710	Polycystin 1, transient receptor potential channel interacting	16	2088710-2135898	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB046448	Approved				Pancreatic cancer:3.38e-5 (favourable), Head and neck cancer:3.35e-4 (favourable), Colorectal cancer:7.43e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 21.6	Expressed in all		
PKD1L1	PRO19563	ENSG00000158683	Polycystin 1 like 1, transient receptor potential channel interacting	7	47774652-47948491	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020422, HPA022424	Uncertain					Tissue enhanced	Tissue enhanced		testis: 2.4	adipose tissue: 1.8	Group enriched	8	T-47d: 5.0;U-266/70: 10.5;U-266/84: 3.7
PKD1L3		ENSG00000277481	Polycystin 1 like 3, transient receptor potential channel interacting	16	71929538-71999978	Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			testis: 0.7	Not detected		
PKD2	Pc-2, PC2, PKD4, TRPP2	ENSG00000118762	Polycystin 2, transient receptor potential cation channel	4	88007668-88077777	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB004544, HPA015794	Approved		Enhanced	Endoplasmic reticulum		Expressed in all	Expressed in all			endometrium: 101.0	Cell line enhanced		BJ hTERT+: 167.9
PKD2L1	PCL, PKD2L, PKDL, TRPP3	ENSG00000107593	Polycystin 2 like 1, transient receptor potential cation channel	10	100288154-100330486	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB022621	Uncertain					Mixed	Tissue enhanced		spleen: 9.8	lung: 3.4	Not detected		
PKD2L2	TRPP5	ENSG00000078795	Polycystin 2 like 2, transient receptor potential cation channel	5	137887968-137942747	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level	HPA041903, HPA043634	Approved		Approved	Plasma membrane<br>Cytosol		Not detected	Tissue enriched	12	testis: 14.9	adrenal gland,thyroid gland: 1.2	Mixed		
PKDREJ		ENSG00000130943	Polycystin (PKD) family receptor for egg jelly	22	46255663-46263355	Predicted membrane proteins	Evidence at protein level	HPA034587	Enhanced					Not detected	Tissue enriched	9	testis: 6.2	skin: 0.7	Not detected		
PKHD1	ARPKD, FCYT, TIGM1	ENSG00000170927	Polycystic kidney and hepatic disease 1 (autosomal recessive)	6	51615300-52087625	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031227	Approved				Renal cancer:9.74e-8 (favourable)	Group enriched	Group enriched	5	epididymis: 5.7;kidney: 15.3	pancreas: 1.9	Cell line enriched	7	RPTEC TERT1: 8.1
PKHD1L1		ENSG00000205038	Polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1	8	109362477-109530330	Predicted membrane proteins	Evidence at protein level	HPA044458	Uncertain				Endometrial cancer:7.61e-4 (favourable)	Group enriched	Group enriched	6	cervix, uterine: 21.3;fallopian tube: 19.7;thyroid gland: 57.2	endometrium: 5.5	Cell line enhanced		HHSteC: 1.2;TIME: 1.3;U-266/70: 1.1
PKMYT1	MYT1, PPP1R126	ENSG00000127564	Protein kinase, membrane associated tyrosine/threonine 1	16	2968024-2980539	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068860			Supported	Nucleus<br>Nucleoli<br>Golgi apparatus	Lung cancer:3.37e-4 (unfavourable), Liver cancer:8.33e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 17.0;testis: 27.7	lymph node: 9.7	Mixed		
PKN2	Pak-2, PRK2, PRKCL2, STK7	ENSG00000065243	Protein kinase N2	1	88684222-88836255	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034861, HPA057913	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Intermediate filaments<br>Cytosol	Colorectal cancer:5.67e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 48.8	Expressed in all		
PLA2G15	GXVPLA2, LLPL, LYPLA3	ENSG00000103066	Phospholipase A2 group XV	16	68245304-68261062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041702, HPA041727	Enhanced		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			placenta: 37.5	Expressed in all		
PLA2G16	AdPLA, H-REV107-1, HRASLS3, HREV107, HREV107-3, MGC118754.	ENSG00000176485	Phospholipase A2 group XVI	11	63573195-63616883	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA058997	Uncertain		Approved	Mitochondria	Pancreatic cancer:5.58e-6 (unfavourable), Thyroid cancer:2.54e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 327.7	Cell line enhanced		CAPAN-2: 206.7
PLA2G2F		ENSG00000158786	Phospholipase A2 group IIF	1	20139326-20150386	Enzymes, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level						Urothelial cancer:3.86e-4 (favourable)	Tissue enriched	Group enriched	11	skin: 11.3;tonsil: 7.2;urinary bladder: 3.9	gallbladder: 0.6	Cell line enriched	57	RT4: 110.7
PLA2G6	iPLA2, iPLA2beta, NBIA2, PARK14, PNPLA9	ENSG00000184381	Phospholipase A2 group VI	22	38111495-38205690	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA001171	Approved		Approved	Microtubule organizing center<br>Cytosol	Urothelial cancer:1.55e-4 (favourable), Cervical cancer:7.29e-4 (favourable)	Expressed in all	Expressed in all			testis: 60.2	Cell line enhanced		HEL: 55.1
PLA2R1	CLEC13C, PLA2-R, PLA2G1R, PLA2IR	ENSG00000153246	Phospholipase A2 receptor 1	2	159932006-160062610	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB068217, CAB068218	Approved		Approved	Cytosol	Stomach cancer:3.08e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 70.6	parathyroid gland: 34.5	Cell line enhanced		ASC TERT1: 13.7;BJ hTERT+: 13.1;SiHa: 12.5;TIME: 38.6
PLAUR	CD87, UPAR, URKR	ENSG00000011422	Plasminogen activator, urokinase receptor	19	43646095-43670547	Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050843, CAB073533	Uncertain		Supported	Plasma membrane	Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 428.5	Cell line enhanced		U-251 MG: 341.1;U-87 MG: 336.6;WM-115: 338.6
PLB1	FLJ30866, PLB	ENSG00000163803	Phospholipase B1	2	28457145-28643788	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014045			Approved	Cytosol		Mixed	Group enriched	7	skin: 9.4;small intestine: 45.7	testis: 4.2	Cell line enhanced		BEWO: 3.5
PLD3	HU-K4	ENSG00000105223	Phospholipase D family member 3	19	40348456-40380439	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012800, CAB020812	Approved				Renal cancer:2.21e-4 (favourable), Pancreatic cancer:6.44e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 494.9	Expressed in all		
PLD4	C14orf175	ENSG00000166428	Phospholipase D family member 4	14	104924816-104937790	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051512	Approved					Mixed	Mixed			lymph node: 13.9	Cell line enhanced		HMC-1: 99.3;RPMI-8226: 58.9;THP-1: 143.6
PLD5	FLJ40773	ENSG00000180287	Phospholipase D family member 5	1	242082986-242524696	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA028389, HPA050367	Uncertain		Approved	Vesicles<br>Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		seminal vesicle: 4.2	cerebral cortex: 4.1	Cell line enhanced		AF22: 10.2;HDLM-2: 5.0;SH-SY5Y: 3.0;U-2 OS: 3.6
PLD6		ENSG00000179598	Phospholipase D family member 6	17	17200995-17206315	Predicted membrane proteins	Evidence at protein level	HPA049345	Approved				Pancreatic cancer:1.05e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 29.3	ovary: 8.9	Cell line enhanced		HAP1: 42.7
PLET1	C11orf34	ENSG00000188771	Placenta expressed transcript 1	11	112248479-112260860	Predicted membrane proteins	Evidence at transcript level	HPA040237	Uncertain					Not detected	Not detected			skin: 0.4	Not detected		
PLIN1	PLIN	ENSG00000166819	Perilipin 1	15	89664365-89679427	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024299, CAB033821, CAB037333	Enhanced		Uncertain	Peroxisomes		Tissue enhanced	Tissue enriched	10	adipose tissue: 1012.5	breast: 100.6	Cell line enriched	157	ASC diff: 142.8
PLLP	PMLP, TM4SF11	ENSG00000102934	Plasmolipin	16	57248547-57284687	Predicted membrane proteins	Evidence at protein level	HPA041862	Enhanced				Renal cancer:6.21e-9 (favourable), Endometrial cancer:2.80e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 118.0	Cell line enhanced		EFO-21: 25.9;Hep G2: 54.1;RPTEC TERT1: 24.7
PLN	CMD1P, PLB	ENSG00000198523	Phospholamban	6	118548298-118560730	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB005597, HPA026900	Enhanced				Renal cancer:4.11e-4 (unfavourable), Urothelial cancer:5.59e-4 (unfavourable)	Mixed	Tissue enriched	5	heart muscle: 1461.9	smooth muscle: 270.2	Not detected		
PLOD2	LH2	ENSG00000152952	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2	3	146069440-146163653	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025898, HPA069126	Approved		Uncertain	Nucleoli<br>Cytosol	Renal cancer:4.99e-11 (unfavourable), Liver cancer:7.64e-10 (unfavourable), Lung cancer:1.42e-4 (unfavourable), Cervical cancer:1.97e-4 (unfavourable), Stomach cancer:2.83e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 150.8	Cell line enhanced		HBF TERT88: 615.2;U-87 MG: 554.9
PLP1	GPM6C, PLP, SPG2	ENSG00000123560	Proteolipid protein 1	X	103773718-103792619	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA004128	Enhanced					Group enriched	Tissue enriched	30	cerebral cortex: 3216.6	parathyroid gland: 107.9	Group enriched	6	NTERA-2: 37.4;SK-MEL-30: 184.2;WM-115: 137.4
PLP2	A4, A4-LSB, MGC126187	ENSG00000102007	Proteolipid protein 2	X	49171926-49175239	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042415	Approved				Renal cancer:5.55e-10 (unfavourable), Endometrial cancer:3.32e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 480.2	Mixed		
PLPP1	LPP1, PAP-2a, PPAP2A	ENSG00000067113	Phospholipid phosphatase 1	5	55424854-55535050	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB033331, HPA047815	Enhanced		Supported	Plasma membrane	Stomach cancer:5.77e-4 (unfavourable), Liver cancer:6.06e-4 (favourable)	Expressed in all	Mixed			prostate: 339.9	Cell line enhanced		ASC diff: 295.0;HMC-1: 201.8
PLPP2	LPP2, PAP-2c, PPAP2C	ENSG00000141934	Phospholipid phosphatase 2	19	281040-291504	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA055540	Uncertain		Approved	Mitochondria	Endometrial cancer:3.21e-8 (favourable), Breast cancer:4.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 128.6	cervix, uterine: 92.0	Cell line enhanced		A549: 122.2;CAPAN-2: 128.0
PLPP3	LPP3, PAP-2b, PPAP2B	ENSG00000162407	Phospholipid phosphatase 3	1	56494747-56645301	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA028892, HPA072751	Uncertain		Supported	Golgi apparatus	Renal cancer:4.59e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 546.5	Group enriched	8	ASC diff: 484.3;ASC TERT1: 245.1;HSkMC: 316.7;U-138 MG: 173.1;U-2197: 610.0
PLPP4	DPPL2, PPAPDC1, PPAPDC1A	ENSG00000203805	Phospholipid phosphatase 4	10	120456954-120589855	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045188	Approved		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		cerebral cortex: 17.1;gallbladder: 10.4;testis: 12.7	kidney: 7.8	Cell line enhanced		BJ: 30.3;U-251 MG: 92.6
PLPP5	DPPL1, HTPAP, PPAPDC1B	ENSG00000147535	Phospholipid phosphatase 5	8	38263130-38269243	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA055777			Approved	Vesicles	Renal cancer:8.33e-10 (unfavourable), Endometrial cancer:1.48e-5 (favourable), Ovarian cancer:2.42e-5 (favourable), Lung cancer:8.72e-5 (favourable)	Expressed in all	Expressed in all			prostate: 120.8	Mixed		
PLPP6	FLJ46512, FLJ90191, PDP1, PPAPDC2	ENSG00000205808	Phospholipid phosphatase 6	9	4662315-4665258	Predicted membrane proteins	Evidence at protein level	HPA018096	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:3.99e-4 (favourable)	Expressed in all	Mixed			prostate: 26.7	Cell line enhanced		HDLM-2: 92.6
PLPP7	C9orf67, FLJ14662, MGC12921, NET39, PPAPDC3	ENSG00000160539	Phospholipid phosphatase 7 (inactive)	9	131289694-131309262	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA070252	Uncertain		Approved	Nucleus<br>Vesicles		Mixed	Group enriched	5	heart muscle: 32.6;skeletal muscle: 72.2	cerebral cortex: 10.1	Cell line enhanced		AN3-CA: 10.2;ASC diff: 7.8;SCLC-21H: 13.4;SH-SY5Y: 9.1
PLPPR1	FLJ20300, LPPR1, MGC26189, PRG-3	ENSG00000148123	Phospholipid phosphatase related 1	9	101028709-101325135	Predicted membrane proteins	Evidence at protein level	HPA014760, HPA014968, HPA014979	Supported		Supported	Nucleoplasm	Lung cancer:1.37e-4 (favourable)	Group enriched	Group enriched	6	cerebral cortex: 23.8;kidney: 15.8	epididymis: 3.3	Cell line enhanced		Hep G2: 2.1;SCLC-21H: 6.4
PLPPR2	LPPR2, PRG-4	ENSG00000105520	Phospholipid phosphatase related 2	19	11355386-11365698	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA048973	Uncertain		Approved	Nucleoplasm	Renal cancer:7.46e-11 (unfavourable), Colorectal cancer:6.45e-4 (unfavourable), Pancreatic cancer:6.82e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 77.2	Cell line enhanced		U-2197: 88.4
PLPPR3	FLJ11535, LPPR3, PRG-2, PRG2	ENSG00000129951	Phospholipid phosphatase related 3	19	812488-821977	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA052293, HPA057034	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Tissue enhanced	Tissue enhanced		bone marrow: 6.1;cerebral cortex: 9.6;fallopian tube: 8.9	testis: 2.1	Cell line enhanced		NB-4: 38.6;THP-1: 86.0
PLPPR4	KIAA0455, LPPR4, PHP1, PRG-1	ENSG00000117600	Phospholipid phosphatase related 4	1	99263953-99309590	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	10	cerebral cortex: 88.6	testis: 9.0	Cell line enhanced		BJ hTERT+: 21.8;BJ hTERT+ SV40 Large T+ RasG12V: 10.0;SH-SY5Y: 21.1;U-138 MG: 9.8;U-87 MG: 16.4
PLPPR5	LPPR5, PAP2, PAP2D, PRG5	ENSG00000117598	Phospholipid phosphatase related 5	1	98890245-99005032	Predicted membrane proteins	Evidence at transcript level	HPA018072, HPA059085	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:6.22e-4 (unfavourable)	Group enriched	Group enriched	11	cerebral cortex: 12.0;testis: 4.0	adrenal gland: 0.7	Group enriched	7	PC-3: 12.4;SH-SY5Y: 25.0
PLSCR3		ENSG00000187838	Phospholipid scramblase 3	17	7389727-7394843	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048387, HPA068609	Supported		Supported	Mitochondria		Mixed	Mixed			smooth muscle: 19.5	Mixed		
PLSCR4		ENSG00000114698	Phospholipid scramblase 4	3	146192339-146251179	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002276	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:3.90e-4 (unfavourable), Renal cancer:4.13e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 80.2	Cell line enhanced		ASC diff: 41.7;HUVEC TERT2: 42.5;TIME: 86.2
PLSCR5		ENSG00000231213	Phospholipid scramblase family member 5	3	146576555-146606216	Predicted membrane proteins	Evidence at transcript level	HPA047249	Uncertain					Not detected	Tissue enriched	7	parathyroid gland: 1.8	testis: 0.2	Not detected		
PLVAP	FELS, gp68, PV-1, PV1	ENSG00000130300	Plasmalemma vesicle associated protein	19	17351448-17377350	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002279	Supported					Expressed in all	Expressed in all			thyroid gland: 329.1	Cell line enriched	31	EFO-21: 506.3
PLXDC1	TEM3, TEM7	ENSG00000161381	Plexin domain containing 1	17	39063303-39154394	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012805	Approved				Renal cancer:9.15e-8 (unfavourable)	Expressed in all	Mixed			gallbladder: 22.8	Cell line enhanced		BJ hTERT+: 7.5;U-87 MG: 5.7
PLXDC2	FLJ14623, TEM7R	ENSG00000120594	Plexin domain containing 2	10	19816239-20289856	Predicted membrane proteins	Evidence at protein level	HPA017268, HPA070793	Approved		Supported	Nuclear bodies		Expressed in all	Mixed			gallbladder: 25.0	Cell line enhanced		HHSteC: 14.9;U-2197: 40.1
PLXNA1	NOV, PLXN1	ENSG00000114554	Plexin A1	3	126988594-127037392	Predicted membrane proteins	Evidence at protein level	HPA007499, CAB012483	Uncertain		Enhanced	Nucleus<br>Cytosol	Liver cancer:4.13e-6 (unfavourable), Renal cancer:5.64e-5 (unfavourable), Ovarian cancer:1.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 43.5	skin: 16.8	Mixed		
PLXNA2	FLJ11751, FLJ30634, KIAA0463, OCT, PLXN2	ENSG00000076356	Plexin A2	1	208022242-208244320	Predicted membrane proteins	Evidence at protein level	CAB009763	Approved					Expressed in all	Mixed			ovary: 17.0	Cell line enhanced		BEWO: 51.1;HaCaT: 49.2;HUVEC TERT2: 58.9;TIME: 133.3
PLXNA3	6.3, Plxn3, PLXN4, SEX, XAP-6	ENSG00000130827	Plexin A3	X	154458281-154477779	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA058989			Supported	Vesicles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			skin: 12.0	Mixed		
PLXNA4	DKFZp434G0625PRO34003, FAYV2820, KIAA1550, PLXNA4A, PLXNA4B	ENSG00000221866	Plexin A4	7	132123332-132648688	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029919, HPA052141, HPA075592	Approved		Approved	Plasma membrane	Endometrial cancer:1.61e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 15.2;cervix, uterine: 12.5	cerebral cortex: 10.4	Cell line enhanced		ASC diff: 17.3;HMC-1: 15.0;RH-30: 17.9;TIME: 46.9
PLXNB1	KIAA0407, PLXN5, SEP	ENSG00000164050	Plexin B1	3	48403854-48430051	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA040586	Enhanced				Renal cancer:2.77e-5 (favourable), Head and neck cancer:5.03e-4 (favourable), Urothelial cancer:7.60e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 36.7	Mixed		
PLXNB2	KIAA0315, MM1, PLEXB2	ENSG00000196576	Plexin B2	22	50274979-50307627	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003100	Uncertain				Stomach cancer:4.75e-4 (favourable), Ovarian cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 120.9	Mixed		
PLXNB3	PLEXB3, PLEXR, PLXN6	ENSG00000198753	Plexin B3	X	153764196-153779346	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048046	Enhanced				Breast cancer:6.13e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 67.3	adrenal gland: 19.7	Cell line enhanced		WM-115: 69.8
PLXNC1	CD232, VESPR	ENSG00000136040	Plexin C1	12	94148723-94307675	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026155, HPA066899	Uncertain		Approved	Mitochondria		Expressed in all	Mixed			testis: 28.5	Cell line enhanced		HAP1: 34.3;SK-MEL-30: 32.7;U-266/70: 49.2;U-266/84: 50.5
PLXND1	KIAA0620	ENSG00000004399	Plexin D1	3	129555175-129606818	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB020819	Approved				Renal cancer:5.93e-7 (unfavourable)	Expressed in all	Expressed in all			placenta: 161.3	Cell line enhanced		ASC diff: 268.0;HSkMC: 206.8;HUVEC TERT2: 287.4;TIME: 332.2
PMEL	D12S53E, gp100, Pmel17, SI, SIL, SILV	ENSG00000185664	Premelanosome protein	12	55954105-55973317	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031649	Enhanced				Renal cancer:3.70e-4 (favourable)	Tissue enriched	Tissue enriched	12	skin: 133.4	breast: 10.6	Cell line enriched	55	SK-MEL-30: 6730.3
PMEPA1	STAG1, TMEPAI	ENSG00000124225	Prostate transmembrane protein, androgen induced 1	20	57648392-57711536	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA072291			Supported	Vesicles	Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 146.1;prostate: 179.6	endometrium: 60.3	Cell line enhanced		SiHa: 218.5;U-251 MG: 397.1;WM-115: 233.9
PMP22	GAS3, HNPP, Sp110	ENSG00000109099	Peripheral myelin protein 22	17	15229777-15265326	Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 316.4	Cell line enhanced		ASC diff: 277.3;HMC-1: 278.9;WM-115: 491.1
PNKD	BRP17, DKFZp564N1362, DYT8, FKSG19, FPD1, KIAA1184, KIPP1184, MGC31943, MR-1, PDC, PKND1, TAHCCP2	ENSG00000127838	Paroxysmal nonkinesigenic dyskinesia	2	218270392-218346793	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010134, HPA017068	Approved		Enhanced	Mitochondria	Renal cancer:5.13e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 119.5	Expressed in all		
PNLDC1	dJ195P10.2, FLJ40240	ENSG00000146453	PARN like, ribonuclease domain containing 1	6	159800249-159820704	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA052026	Uncertain					Mixed	Tissue enriched	5	testis: 12.2	fallopian tube: 2.4	Not detected		
PNPLA6	iPLA2delta, NTE, SPG39, sws	ENSG00000032444	Patatin like phospholipase domain containing 6	19	7534004-7561764	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007522	Uncertain				Pancreatic cancer:3.51e-5 (favourable), Head and neck cancer:5.25e-4 (favourable), Renal cancer:7.53e-4 (favourable)	Expressed in all	Expressed in all			testis: 49.1	Expressed in all		
PNPLA7	C9orf111, FLJ31318, FLJ43070, FLJ44279, NTE-R1, NTEL1, RP11-48C7.2	ENSG00000130653	Patatin like phospholipase domain containing 7	9	137459953-137550534	Predicted membrane proteins	Evidence at protein level	HPA009130	Uncertain		Uncertain	Microtubule organizing center<br>Cytosol	Pancreatic cancer:2.24e-5 (favourable)	Tissue enhanced	Mixed			prostate: 17.6	Cell line enriched	21	HMC-1: 72.0
PNPLA8	IPLA2-2, IPLA2G, iPLA2gamma	ENSG00000135241	Patatin like phospholipase domain containing 8	7	108470422-108569666	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020083	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.86e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 63.1	Expressed in all		
PODXL	Gp200, PC, PCLP	ENSG00000128567	Podocalyxin like	7	131500262-131558217	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA002110, CAB016169, HPA045507, CAB062558, CAB068219, CAB068220	Enhanced		Approved	Vesicles<br>Plasma membrane<br>Microtubule organizing center	Renal cancer:2.89e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 29.6	Cell line enhanced		fHDF/TERT166: 106.7;NTERA-2: 181.6;TIME: 168.8
PODXL2	endoglycan, PODLX2	ENSG00000114631	Podocalyxin like 2	3	127629181-127672809	Predicted membrane proteins	Evidence at protein level	CAB024934, HPA042265	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Tissue enhanced		cerebral cortex: 77.1	testis: 35.9	Cell line enhanced		SCLC-21H: 195.4
POLR1E	FLJ13390, FLJ13970, PAF53, PRAF1	ENSG00000137054	RNA polymerase I subunit E	9	37485935-37503697	Predicted intracellular proteins, Predicted membrane proteins, RNA polymerase related proteins	Evidence at protein level	HPA022527, HPA052400	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Breast cancer:2.27e-4 (favourable)	Expressed in all	Expressed in all			ovary: 51.5	Expressed in all		
POMGNT1	FLJ20277, LGMD2O, MEB, MGAT1.2	ENSG00000085998	Protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-)	1	46188682-46220305	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA044518	Approved				Liver cancer:3.52e-4 (unfavourable), Pancreatic cancer:4.27e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 123.1	Expressed in all		
POMK	FLJ23356, SgK196	ENSG00000185900	Protein-O-mannose kinase	8	43093506-43123434	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA013321	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Mixed			cerebral cortex: 6.2	Expressed in all		
POMT1	LGMD2K	ENSG00000130714	Protein O-mannosyltransferase 1	9	131502902-131523806	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA065252			Approved	Golgi apparatus	Pancreatic cancer:3.90e-5 (favourable), Renal cancer:4.68e-5 (favourable)	Expressed in all	Expressed in all			testis: 62.7	Expressed in all		
POMT2	LGMD2N	ENSG00000009830	Protein O-mannosyltransferase 2	14	77274956-77320884	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA003663	Uncertain				Liver cancer:2.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.9	Expressed in all		
POPDC2	POP2	ENSG00000121577	Popeye domain containing 2	3	119636457-119665324	Predicted membrane proteins	Evidence at protein level	HPA024255	Enhanced					Mixed	Tissue enhanced		heart muscle: 197.3;seminal vesicle: 64.1	smooth muscle: 35.3	Cell line enriched	31	SH-SY5Y: 30.8
POPDC3	bA355M14.1, MGC22671, POP3	ENSG00000132429	Popeye domain containing 3	6	105158280-105179995	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012514			Approved	Nucleoli<br>Cytosol	Head and neck cancer:4.43e-4 (unfavourable), Lung cancer:5.79e-4 (unfavourable)	Mixed	Group enriched	7	cerebral cortex: 8.8;heart muscle: 19.8;skeletal muscle: 41.8;testis: 9.1	epididymis: 2.9	Cell line enhanced		RH-30: 20.5
POR	CYPOR, FLJ26468	ENSG00000127948	Cytochrome p450 oxidoreductase	7	75899200-75986855	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004372, HPA010136	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Glioma:5.23e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 220.8	Expressed in all		
PORCN	DHOF, MG61, por, PORC, PPN	ENSG00000102312	Porcupine homolog (Drosophila)	X	48508962-48520814	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA049215, HPA058413	Enhanced		Approved	Vesicles		Expressed in all	Mixed			adrenal gland: 31.4	Cell line enhanced		HBEC3-KT: 126.7
PPAN-P2RY11		ENSG00000243207	PPAN-P2RY11 readthrough	19	10106223-10114780	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014232	Uncertain					Not detected	Mixed			fallopian tube: 2.4	Mixed		
PPFIA1	LIP.1, LIPRIN	ENSG00000131626	PTPRF interacting protein alpha 1	11	70270700-70384403	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008272, CAB017032, HPA042271	Uncertain		Enhanced	Focal adhesion sites<br>Cytosol	Renal cancer:3.76e-4 (favourable), Head and neck cancer:5.58e-4 (unfavourable), Pancreatic cancer:8.26e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 57.2	Expressed in all		
PPIL3	CyPJ	ENSG00000240344	Peptidylprolyl isomerase like 3	2	200870907-200889303	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040765, HPA062187	Approved		Supported	Nucleus	Ovarian cancer:1.19e-4 (favourable), Renal cancer:5.16e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 45.3	Expressed in all		
PPM1L	PP2CE	ENSG00000163590	Protein phosphatase, Mg2+/Mn2+ dependent 1L	3	160755602-161078907	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019891, HPA019953	Approved		Approved	Nucleoplasm<br>Cytosol	Breast cancer:4.90e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 39.6	cerebral cortex: 27.9	Group enriched	5	HDLM-2: 73.7;U-266/70: 57.7
PPP1R3A	GM, PPP1R3	ENSG00000154415	Protein phosphatase 1 regulatory subunit 3A	7	113876777-114075920	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Group enriched	18	heart muscle: 26.6;skeletal muscle: 53.1	prostate: 2.2	Cell line enriched	59	THP-1: 9.8
PPP1R3F	Hb2E	ENSG00000049769	Protein phosphatase 1 regulatory subunit 3F	X	49269843-49301461	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000244, HPA000918	Approved		Approved	Nucleoplasm	Pancreatic cancer:1.85e-6 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 26.8	epididymis: 14.6	Mixed		
PQLC1	FLJ22378	ENSG00000122490	PQ loop repeat containing 1	18	79902420-79951664	Predicted membrane proteins	Evidence at protein level	HPA051666	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			adipose tissue: 40.6	Expressed in all		
PQLC2	FLJ20320	ENSG00000040487	PQ loop repeat containing 2	1	19312326-19329300	Predicted membrane proteins, Transporters	Evidence at protein level	HPA057810	Approved		Enhanced	Vesicles	Liver cancer:2.64e-5 (unfavourable), Endometrial cancer:3.50e-4 (favourable)	Expressed in all	Expressed in all			testis: 16.3	Expressed in all		
PQLC2L	C3orf55	ENSG00000174899	PQ loop repeat containing 2 like	3	157543246-157677749	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054395	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		adipose tissue: 21.6;thyroid gland: 16.0	breast: 6.1	Cell line enhanced		ASC diff: 45.0;ASC TERT1: 25.3;EFO-21: 23.8;LHCN-M2: 28.4
PQLC3	C2orf22, MGC33602	ENSG00000162976	PQ loop repeat containing 3	2	11155198-11178874	Predicted membrane proteins	Evidence at protein level	HPA061607			Approved	Cytosol		Expressed in all	Expressed in all			cervix, uterine,epididymis: 54.6	Mixed		
PRAC2	C17orf93, HOXB-AS5, HOXB13-AS1, NCRNA00253	ENSG00000229637	Prostate cancer susceptibility candidate 2	17	48723168-48724758	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		prostate: 16.8;rectum: 10.1	colon: 4.5	Group enriched	5	PC-3: 44.6;REH: 17.6
PRAF2	JM4, Yip6a	ENSG00000243279	PRA1 domain family member 2	X	49071156-49074071	Predicted membrane proteins, Transporters	Evidence at protein level	HPA002859, HPA005504, CAB011655	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Liver cancer:1.66e-6 (unfavourable), Pancreatic cancer:4.88e-6 (favourable), Renal cancer:5.83e-6 (unfavourable), Lung cancer:2.81e-4 (favourable), Cervical cancer:7.42e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 185.0	Expressed in all		
PREB	SEC12	ENSG00000138073	Prolactin regulatory element binding	2	27130756-27134675	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013582, HPA014133	Uncertain		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			epididymis: 107.6	Expressed in all		
PRIMA1	PRIMA	ENSG00000175785	Proline rich membrane anchor 1	14	93718298-93788481	Predicted membrane proteins	Evidence at protein level	HPA046671, HPA060047	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:2.62e-7 (unfavourable), Endometrial cancer:6.99e-5 (unfavourable)	Mixed	Mixed			smooth muscle: 11.7	Cell line enhanced		HAP1: 5.8;SCLC-21H: 11.6;SH-SY5Y: 5.9
PRKAA2	AMPK, AMPKa2, PRKAA	ENSG00000162409	Protein kinase AMP-activated catalytic subunit alpha 2	1	56645322-56715335	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA044540	Approved		Supported	Nuclear speckles<br>Golgi apparatus	Renal cancer:4.95e-5 (favourable), Endometrial cancer:4.80e-4 (unfavourable), Liver cancer:5.30e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 26.5	parathyroid gland: 15.0	Cell line enhanced		RPTEC TERT1: 10.7
PRLHR	GPR10, PrRPR	ENSG00000119973	Prolactin releasing hormone receptor	10	118589989-118595699	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA039361	Supported					Not detected	Group enriched	6	adrenal gland: 6.7;cerebral cortex: 3.7;endometrium: 4.0;smooth muscle: 5.5	seminal vesicle: 0.7	Not detected		
PRLR		ENSG00000113494	Prolactin receptor	5	35048756-35230589	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		placenta: 70.9	kidney: 33.1	Cell line enriched	22	T-47d: 356.8
PRND	dJ1068H6.4, DOPPEL, DPL, PrPLP	ENSG00000171864	Prion protein 2 (dublet)	20	4721910-4728460	Predicted membrane proteins, Transporters	Evidence at protein level	HPA043373	Enhanced					Tissue enhanced	Tissue enriched	22	testis: 136.5	endometrium: 6.0	Not detected		
PRNP	AltPrP, CD230, CJD, GSS, PRIP, PRP	ENSG00000171867	Prion protein	20	4686236-4701590	CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA042754, HPA043398	Enhanced		Approved	Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:7.41e-5 (unfavourable), Glioma:1.99e-4 (unfavourable), Colorectal cancer:2.96e-4 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 619.4	Cell line enhanced		WM-115: 985.1
PROCR	CCD41, CD201, EPCR	ENSG00000101000	Protein C receptor	20	35172073-35216240	Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039461	Enhanced				Renal cancer:7.62e-6 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 63.0	Cell line enhanced		HMC-1: 339.1;HUVEC TERT2: 510.3;TIME: 297.7
PROKR1	GPR73, GPR73a, PKR1, ZAQ	ENSG00000169618	Prokineticin receptor 1	2	68643589-68658247	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029396	Uncertain					Not detected	Group enriched	8	adipose tissue: 1.7;adrenal gland: 1.4;epididymis: 4.3	testis: 0.3	Cell line enhanced		NTERA-2: 2.0
PROKR2	dJ680N4.3, GPR73b, GPR73L1, GPRg2, KAL3, PKR2	ENSG00000101292	Prokineticin receptor 2	20	5302040-5314369	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA047281	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 3.0	bone marrow: 0.8	Cell line enhanced		NTERA-2: 1.1;SH-SY5Y: 2.2
PROM1	AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4	ENSG00000007062	Prominin 1	4	15963076-16084378	CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004922, CAB011525, HPA031053	Enhanced				Renal cancer:2.56e-5 (favourable)	Expressed in all	Tissue enhanced		cervix, uterine: 67.2	gallbladder: 47.5	Cell line enhanced		AF22: 36.7;CACO-2: 58.5;EFO-21: 62.9;NTERA-2: 99.9;RPTEC TERT1: 69.7
PROM2		ENSG00000155066	Prominin 2	2	95274453-95291308	Predicted membrane proteins	Evidence at protein level	CAB046005, HPA063728	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Renal cancer:1.55e-6 (unfavourable), Breast cancer:2.16e-4 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 71.1	esophagus: 44.6	Cell line enhanced		A-431: 69.3;CAPAN-2: 119.5;HaCaT: 65.0;hTCEpi: 56.7;RT4: 66.9;SK-BR-3: 88.2
PROS1	PROS	ENSG00000184500	Protein S (alpha)	3	93873033-93974066	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007724, HPA023974	Enhanced				Urothelial cancer:4.42e-5 (unfavourable), Stomach cancer:8.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 177.6	heart muscle: 78.3	Cell line enhanced		ASC diff: 98.8;SK-MEL-30: 127.4
PRPH2	CACD2, rd2, RDS, RP7, TSPAN22	ENSG00000112619	Peripherin 2	6	42696600-42722574	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029458	Supported					Mixed	Mixed			parathyroid gland: 8.6	Cell line enhanced		ASC TERT1: 2.4;fHDF/TERT166: 4.1;HHSteC: 6.6;HSkMC: 4.4;LHCN-M2: 3.0
PRRC1	FLJ32875	ENSG00000164244	Proline rich coiled-coil 1	5	127517609-127555089	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039212	Supported		Approved	Vesicles	Breast cancer:9.35e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 54.1	Expressed in all		
PRRG1	PRGP1	ENSG00000130962	Proline rich and Gla domain 1	X	37349275-37457295	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056029, HPA078129	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane	Renal cancer:2.05e-7 (favourable), Pancreatic cancer:1.22e-4 (unfavourable), Cervical cancer:4.65e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 21.6	Cell line enhanced		RPTEC TERT1: 59.3
PRRG2	PRGP2	ENSG00000126460	Proline rich and Gla domain 2	19	49580646-49591015	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010702	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.82e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 29.5	Cell line enhanced		CAPAN-2: 13.1;T-47d: 13.6;U-266/84: 12.9
PRRG3	TMG3	ENSG00000130032	Proline rich and Gla domain 3	X	151695124-151705924	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060566	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 8.9	cervix, uterine: 7.5	Cell line enhanced		NTERA-2: 1.0
PRRG4	TMG4	ENSG00000135378	Proline rich and Gla domain 4	11	32829943-32858123	Predicted membrane proteins	Evidence at protein level	HPA009040, HPA024566	Uncertain		Approved	Golgi apparatus		Expressed in all	Mixed			skin: 25.1	Cell line enhanced		HaCaT: 47.2;hTCEpi: 20.5
PRRT1	C6orf31, IFITMD7, NG5	ENSG00000204314	Proline rich transmembrane protein 1	6	32148359-32154373	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055149, HPA059099	Enhanced					Mixed	Tissue enriched	8	cerebral cortex: 4.5	ovary: 0.6	Cell line enhanced		SK-MEL-30: 1.1
PRRT2	DKFZp547J199, DSPB3, DYT10, EKD1, FICCA, FLJ25513, ICCA, IFITMD1, PKC	ENSG00000167371	Proline rich transmembrane protein 2	16	29811382-29815892	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014447, HPA019203	Enhanced		Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 98.1	ovary: 54.6	Cell line enhanced		AF22: 26.4;REH: 19.4;U-138 MG: 18.0
PRRT3	FLJ33674	ENSG00000163704	Proline rich transmembrane protein 3	3	9945542-9952394	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035127, HPA035128	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 19.4;parathyroid gland: 27.8	fallopian tube: 12.2	Cell line enhanced		MCF7: 17.7;SK-BR-3: 25.1
PRRT4		ENSG00000224940	Proline rich transmembrane protein 4	7	128350325-128361685	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046373, HPA052681	Uncertain		Approved	Nucleoplasm<br>Peroxisomes<br>Plasma membrane		Mixed	Group enriched	12	adipose tissue: 15.7;bone marrow: 41.2	cerebral cortex: 2.2	Cell line enriched	8	SH-SY5Y: 239.1
PRSS48	ESSPL	ENSG00000189099	Protease, serine 48	4	151277171-151291453	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA053801	Uncertain					Not detected	Tissue enhanced		testis: 1.4	skin: 0.4	Not detected		
PRSS8		ENSG00000052344	Protease, serine 8	16	31131433-31135762	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030436, HPA063533	Uncertain		Uncertain	Cytosol	Renal cancer:2.05e-10 (favourable)	Mixed	Mixed			small intestine: 164.8	Cell line enhanced		BEWO: 230.2;CACO-2: 133.7;CAPAN-2: 96.1;hTCEpi: 111.3;SK-BR-3: 136.6
PRTG	FLJ25756, IGDCC5	ENSG00000166450	Protogenin	15	55611546-55743090	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA032138	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		thyroid gland: 18.2	testis: 6.7	Cell line enriched	6	AF22: 148.8
PRUNE2	A214N16.3, bA214N16.3, BMCC1, BNIPXL, C9orf65, KIAA0367	ENSG00000106772	Prune homolog 2	9	76611376-76906087	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022470, HPA031079	Uncertain				Renal cancer:1.37e-6 (favourable)	Mixed	Mixed			seminal vesicle: 89.8	Cell line enhanced		LHCN-M2: 69.0;RH-30: 68.7
PSCA		ENSG00000167653	Prostate stem cell antigen	8	142670308-142682724	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030783, HPA056418	Approved		Supported	Plasma membrane	Pancreatic cancer:5.60e-5 (unfavourable)	Tissue enriched	Group enriched	8	prostate: 344.6;stomach: 1648.5;urinary bladder: 343.4	esophagus: 101.7	Cell line enhanced		CAPAN-2: 18.6;HeLa: 27.5;RT4: 47.1
PSEN1	AD3, FAD, PS1, S182	ENSG00000080815	Presenilin 1	14	73136418-73223691	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB006844, HPA030760, HPA067496	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cell Junctions	Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 66.0	Expressed in all		
PSEN2	AD3L, AD4, PS2, STM2	ENSG00000143801	Presenilin 2	1	226870184-226896105	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB013634, HPA038005			Supported	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 28.8	Mixed		
PSENEN	PEN2	ENSG00000205155	Presenilin enhancer gamma-secretase subunit	19	35745114-35747519	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA047435	Approved				Renal cancer:8.70e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 375.2	Expressed in all		
PSG9	PSG11, PSGII	ENSG00000183668	Pregnancy specific beta-1-glycoprotein 9	19	43211791-43269530	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Not detected	Tissue enriched	118	placenta: 147.0	smooth muscle: 1.2	Cell line enhanced		BJ: 4.4;BJ hTERT+ SV40 Large T+: 4.2;HBF TERT88: 9.0;T-47d: 4.0;U-2197: 9.0
PSKH1		ENSG00000159792	Protein serine kinase H1	16	67893272-67929678	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA053927	Approved		Approved	Nucleoplasm	Renal cancer:4.28e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 49.5	Expressed in all		
PSKH2		ENSG00000147613	Protein serine kinase H2	8	86048373-86088621	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA015095	Uncertain					Tissue enhanced	Not detected			testis: 0.4	Cell line enriched	21	HEL: 8.2
PSMD1	P112, Rpn2, S1	ENSG00000173692	Proteasome 26S subunit, non-ATPase 1	2	231056864-231172827	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB021092, HPA036736, HPA036737	Enhanced		Approved	Nucleoplasm<br>Actin filaments	Liver cancer:8.63e-12 (unfavourable), Lung cancer:2.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 204.0	Expressed in all		
PSMD2	MGC14274, P97, Rpn1, S2, TRAP2	ENSG00000175166	Proteasome 26S subunit, non-ATPase 2	3	184298709-184309054	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045192	Approved				Liver cancer:6.63e-7 (unfavourable), Lung cancer:1.55e-4 (unfavourable), Head and neck cancer:9.98e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 163.6	Expressed in all		
PTAFR		ENSG00000169403	Platelet activating factor receptor	1	28147166-28193936	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA027543	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane		Expressed in all	Tissue enhanced		appendix: 41.1	bone marrow: 26.2	Cell line enhanced		HBEC3-KT: 26.0;HMC-1: 113.4
PTCH1	BCNS, NBCCS, PTCH	ENSG00000185920	Patched 1	9	95442980-95517057	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013717, HPA075072	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enhanced		cervix, uterine: 41.7	endometrium: 27.2	Cell line enhanced		WM-115: 70.2
PTCH2		ENSG00000117425	Patched 2	1	44819844-44843063	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Pancreatic cancer:5.74e-5 (favourable)	Tissue enhanced	Tissue enriched	6	parathyroid gland: 203.9	salivary gland: 32.2	Cell line enhanced		U-266/84: 8.0
PTCHD1	FLJ30296	ENSG00000165186	Patched domain containing 1	X	23334016-23404372	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA046110	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 4.6;seminal vesicle: 5.1	endometrium: 2.6	Cell line enhanced		HEK93: 1.5;RT4: 1.3;WM-115: 5.3
PTCHD3	FLJ44037, PTR	ENSG00000182077	Patched domain containing 3	10	27398187-27414368	Predicted membrane proteins	Evidence at protein level	HPA044613	Enhanced					Not detected	Tissue enriched	9	testis: 4.1	adipose tissue: 0.4	Not detected		
PTCHD4	C6orf138, dJ402H5.2, FLJ41841	ENSG00000244694	Patched domain containing 4	6	47878028-48068689	Predicted membrane proteins	Evidence at transcript level	HPA041276	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.49e-6 (favourable)	Group enriched	Mixed			seminal vesicle: 2.8	Cell line enhanced		AF22: 17.0;BEWO: 22.0;Hep G2: 27.0;LHCN-M2: 15.3;TIME: 16.1;WM-115: 16.7
PTCRA	PT-ALPHA, PTA	ENSG00000171611	Pre T-cell antigen receptor alpha	6	42915989-42925835	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 3.2;spleen: 4.8	lung: 2.1	Group enriched	12	MOLT-4: 33.3;SK-MEL-30: 10.7
PTDSS1	KIAA0024, PSS1, PSSA	ENSG00000156471	Phosphatidylserine synthase 1	8	96261715-96336995	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA016852	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum	Liver cancer:1.08e-5 (unfavourable), Lung cancer:9.83e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 14.1	Expressed in all		
PTDSS2	PSS2	ENSG00000174915	Phosphatidylserine synthase 2	11	448268-491399	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA038928, HPA038929	Approved				Liver cancer:5.12e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 25.5	Expressed in all		
PTGDR	DP, DP1, PTGDR1	ENSG00000168229	Prostaglandin D2 receptor	14	52267713-52276724	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		rectum: 8.6;spleen: 8.7	colon: 5.6	Not detected		
PTGDR2	CD294, CRTH2, DP2, GPR44	ENSG00000183134	Prostaglandin D2 receptor 2	11	60850940-60855971	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014259	Uncertain					Mixed	Tissue enhanced		small intestine: 7.1;stomach: 7.5	parathyroid gland: 5.0	Cell line enhanced		HEL: 8.5;Hep G2: 3.2;HMC-1: 5.1;K-562: 3.6;NB-4: 8.7
PTGER1	EP1	ENSG00000160951	Prostaglandin E receptor 1	19	14472466-14475362	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enhanced	Tissue enhanced		kidney: 2.9;spleen: 2.5	lung: 0.7	Cell line enhanced		HEL: 2.2;PC-3: 2.9;SH-SY5Y: 1.9
PTGER2	EP2	ENSG00000125384	Prostaglandin E receptor 2	14	52314305-52328606	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level						Renal cancer:4.16e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 27.3	Cell line enhanced		ASC TERT1: 50.0;HHSteC: 38.3;HSkMC: 41.8
PTGER3	EP3	ENSG00000050628	Prostaglandin E receptor 3	1	70852353-71047808	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA010689	Uncertain				Renal cancer:3.50e-4 (unfavourable)	Group enriched	Group enriched	7	adipose tissue: 58.6;endometrium: 115.3;kidney: 88.3;smooth muscle: 105.2	skin: 13.9	Group enriched	5	ASC diff: 19.6;HAP1: 21.6;HDLM-2: 30.4;HEL: 14.0;T-47d: 68.0
PTGER4	EP4	ENSG00000171522	Prostaglandin E receptor 4	5	40679498-40693735	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA011226, HPA012756	Approved				Urothelial cancer:2.48e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 48.1	Cell line enhanced		HDLM-2: 33.9;RT4: 28.7;TIME: 37.0
PTGES	MGST-IV, MGST1-L1, MGST1L1, PIG12, TP53I12	ENSG00000148344	Prostaglandin E synthase	9	129738331-129753047	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045064	Enhanced		Supported	Endoplasmic reticulum	Pancreatic cancer:7.97e-5 (unfavourable), Colorectal cancer:2.32e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 82.9;seminal vesicle: 119.5	urinary bladder: 36.3	Cell line enhanced		BEWO: 155.0;HaCaT: 189.3;U-2197: 372.3
PTGFR	FP	ENSG00000122420	Prostaglandin F receptor	1	78303884-78539749	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		endometrium: 30.5;smooth muscle: 25.7	urinary bladder: 12.9	Group enriched	7	ASC TERT1: 193.6;HSkMC: 63.3
PTGFRN	CD315, CD9P-1, EWI-F, FLJ11001, FPRP, KIAA1436, SMAP-6	ENSG00000134247	Prostaglandin F2 receptor inhibitor	1	116910057-116990358	CD markers, Predicted membrane proteins	Evidence at protein level	HPA017074	Approved				Renal cancer:3.98e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 69.3	Cell line enhanced		U-87 MG: 146.9
PTGIR	IP	ENSG00000160013	Prostaglandin I2 (prostacyclin) receptor (IP)	19	46620468-46625118	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.09e-8 (unfavourable), Testis cancer:1.74e-4 (unfavourable)	Mixed	Tissue enhanced		lung: 13.9	appendix: 8.2	Cell line enhanced		BJ: 9.0;BJ hTERT+: 9.8;fHDF/TERT166: 11.8;HEL: 25.3
PTGIS	CYP8A1, PGIS	ENSG00000124212	Prostaglandin I2 synthase	20	49503874-49568146	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB009517, HPA014193, HPA052244	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:4.74e-8 (unfavourable), Urothelial cancer:9.99e-5 (unfavourable)	Expressed in all	Mixed			fallopian tube: 78.2	Cell line enhanced		ASC diff: 30.9;ASC TERT1: 31.6;U-2197: 133.1
PTH1R	PTHR, PTHR1	ENSG00000160801	Parathyroid hormone 1 receptor	3	46877746-46903799	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007978	Approved				Renal cancer:6.79e-6 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 158.9	adrenal gland: 36.7	Cell line enriched	8	RPTEC TERT1: 88.0
PTH2R	PTHR2	ENSG00000144407	Parathyroid hormone 2 receptor	2	208359714-208854503	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA010655	Approved					Tissue enhanced	Mixed			bone marrow: 2.9	Group enriched	9	EFO-21: 10.1;HEL: 14.3;HL-60: 3.1;SH-SY5Y: 6.7
PTK7	CCK4	ENSG00000112655	Protein tyrosine kinase 7 (inactive)	6	43076268-43161719	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003222	Approved					Expressed in all	Mixed			endometrium: 117.3	Mixed		
PTPMT1	DUSP23, MOSP, PLIP	ENSG00000110536	Protein tyrosine phosphatase, mitochondrial 1	11	47565430-47573461	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040348, HPA043932	Approved		Supported	Mitochondria	Liver cancer:3.04e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 92.8	Expressed in all		
PTPN1	PTP1B	ENSG00000196396	Protein tyrosine phosphatase, non-receptor type 1	20	50510321-50585241	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB009329, HPA012542, CAB015217	Enhanced		Enhanced	Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 62.6	Expressed in all		
PTPN2	PTPT, TC-PTP, TCELLPTP, TCPTP	ENSG00000175354	Protein tyrosine phosphatase, non-receptor type 2	18	12785478-12929643	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015004, HPA046176	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.20e-8 (unfavourable), Ovarian cancer:1.37e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 52.5	Expressed in all		
PTPN5	PTPSTEP, STEP, STEP61	ENSG00000110786	Protein tyrosine phosphatase, non-receptor type 5	11	18727928-18792721	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031014, HPA072091	Supported		Approved	Endoplasmic reticulum		Group enriched	Tissue enriched	15	cerebral cortex: 58.8	testis: 3.8	Cell line enhanced		NTERA-2: 1.7
PTPRA	HLPR, HPTPA, LRP, PTPA, PTPRL2, RPTPA	ENSG00000132670	Protein tyrosine phosphatase, receptor type A	20	2864184-3039076	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029412, CAB034366, HPA069480	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:3.29e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 167.4	Expressed in all		
PTPRB	PTPB	ENSG00000127329	Protein tyrosine phosphatase, receptor type B	12	70515866-70637440	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004782, HPA067868	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:1.02e-4 (favourable), Liver cancer:6.05e-4 (favourable)	Expressed in all	Mixed			lung: 54.0	Cell line enhanced		EFO-21: 22.9;HUVEC TERT2: 51.3;TIME: 74.1
PTPRC	CD45, GP180, LCA, T200	ENSG00000081237	Protein tyrosine phosphatase, receptor type C	1	198638671-198757283	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000052, HPA000440, CAB002800, CAB056154, CAB068221	Enhanced				Renal cancer:2.42e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 372.4	Cell line enhanced		Daudi: 151.8;HEL: 73.7;HL-60: 73.8;MOLT-4: 105.0;U-698: 84.9;U-937: 62.5
PTPRD	HPTP, PTPD	ENSG00000153707	Protein tyrosine phosphatase, receptor type D	9	8314246-10612723	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054829	Uncertain		Approved	Vesicles	Renal cancer:7.45e-6 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 32.7;parathyroid gland: 47.0	ovary: 11.7	Cell line enhanced		AF22: 27.3;RH-30: 9.9
PTPRE	PTPE	ENSG00000132334	Protein tyrosine phosphatase, receptor type E	10	127907061-128085855	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015870, HPA021872	Supported		Approved	Intermediate filaments	Renal cancer:4.08e-5 (unfavourable)	Expressed in all	Mixed			appendix: 34.8	Cell line enhanced		HUVEC TERT2: 34.9;TIME: 64.9
PTPRF	LAR	ENSG00000142949	Protein tyrosine phosphatase, receptor type F	1	43525187-43623666	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012710	Uncertain		Approved	Golgi apparatus	Liver cancer:3.47e-4 (unfavourable), Stomach cancer:7.03e-4 (favourable)	Expressed in all	Mixed			skin: 128.2	Mixed		
PTPRG	PTPG, RPTPG	ENSG00000144724	Protein tyrosine phosphatase, receptor type G	3	61561569-62297613	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA064237	Uncertain				Renal cancer:3.10e-6 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 73.5	thyroid gland: 22.8	Mixed		
PTPRH	SAP-1	ENSG00000080031	Protein tyrosine phosphatase, receptor type H	19	55181248-55209506	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA042300			Approved	Mitochondria		Mixed	Tissue enhanced		duodenum: 68.9;small intestine: 77.0	gallbladder: 38.6	Cell line enhanced		HHSteC: 10.1;K-562: 13.5;SK-MEL-30: 17.2
PTPRJ	CD148, DEP1, HPTPeta	ENSG00000149177	Protein tyrosine phosphatase, receptor type J	11	47980558-48170841	CD markers, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006026	Approved				Renal cancer:1.13e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 38.6	Mixed		
PTPRK	R-PTP-kappa	ENSG00000152894	Protein tyrosine phosphatase, receptor type K	6	127968779-128520674	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054056, HPA054822	Uncertain		Supported	Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.33e-5 (favourable), Pancreatic cancer:1.99e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 27.8	Mixed		
PTPRM	hR-PTPu, PTPRL1, RPTPU	ENSG00000173482	Protein tyrosine phosphatase, receptor type M	18	7566782-8406861	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003891, CAB022442, CAB022443	Supported		Approved	Plasma membrane	Cervical cancer:8.65e-5 (unfavourable), Urothelial cancer:1.07e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 91.6	Mixed		
PTPRN	IA-2	ENSG00000054356	Protein tyrosine phosphatase, receptor type N	2	219289623-219309648	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007152, HPA007179	Enhanced		Approved	Endoplasmic reticulum	Glioma:2.45e-7 (unfavourable)	Group enriched	Tissue enriched	5	cerebral cortex: 183.1	adrenal gland: 35.0	Group enriched	8	U-2 OS: 70.1;U-87 MG: 244.6
PTPRN2	IA-2beta, ICAAR, KIAA0387, phogrin	ENSG00000155093	Protein tyrosine phosphatase, receptor type N2	7	157539056-158587788	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006900, HPA026656	Approved		Supported	Vesicles	Glioma:7.72e-5 (unfavourable), Renal cancer:8.68e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 82.3	stomach: 38.9	Cell line enhanced		AF22: 28.0;HDLM-2: 38.8;NB-4: 27.1;SCLC-21H: 26.6;SH-SY5Y: 24.3;U-87 MG: 27.1
PTPRO	GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2	ENSG00000151490	Protein tyrosine phosphatase, receptor type O	12	15322397-15597399	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA034525	Enhanced					Tissue enhanced	Tissue enhanced		rectum: 33.0	cerebral cortex: 21.7	Cell line enhanced		NTERA-2: 6.6;SCLC-21H: 4.7;SH-SY5Y: 8.4
PTPRQ	DFNB84	ENSG00000139304	Protein tyrosine phosphatase, receptor type Q	12	80402178-80680234	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053245	Uncertain		Approved	Cytosol		Not detected	Tissue enhanced		testis: 4.9	lung: 3.4	Cell line enhanced		ASC TERT1: 3.4;BJ: 3.3;HBF TERT88: 2.6;RH-30: 2.8;RT4: 2.7;U-2197: 2.9
PTPRR	EC-PTP, PCPTP1, PTP-SL, PTPBR7, PTPRQ	ENSG00000153233	Protein tyrosine phosphatase, receptor type R	12	70638073-70920843	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB011461, HPA011851, HPA071067	Uncertain		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol	Urothelial cancer:1.40e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 20.8	endometrium: 9.0	Group enriched	11	HDLM-2: 18.5;RT4: 29.7;SH-SY5Y: 6.2
PTPRS		ENSG00000105426	Protein tyrosine phosphatase, receptor type S	19	5158495-5340803	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054747			Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:1.07e-4 (favourable), Renal cancer:1.70e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 70.7	Cell line enhanced		AN3-CA: 112.7;HaCaT: 110.4
PTPRT	KIAA0283, RPTPrho	ENSG00000196090	Protein tyrosine phosphatase, receptor type T	20	42072752-43189970	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017336, CAB069423	Approved					Tissue enhanced	Group enriched	5	cerebral cortex: 24.3;fallopian tube: 17.4	placenta: 4.0	Cell line enhanced		BEWO: 1.1
PTPRU	FMI, hPTP-J, PCP-2, PTP, PTPRO	ENSG00000060656	Protein tyrosine phosphatase, receptor type U	1	29236516-29326813	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011476, HPA039832	Approved				Head and neck cancer:8.32e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 28.0	Cell line enhanced		BEWO: 92.2
PTPRZ1	phosphacan, PTP18, PTPRZ, PTPZ, RPTPB	ENSG00000106278	Protein tyrosine phosphatase, receptor type Z1	7	121873089-122062036	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA015103, CAB025106, HPA071024	Enhanced	Supported	Supported	Cytosol	Urothelial cancer:9.36e-4 (unfavourable)	Tissue enriched	Tissue enriched	9	cerebral cortex: 257.9	skin: 30.1	Group enriched	12	AF22: 420.6;NTERA-2: 119.0;WM-115: 185.9
PTRH2	BIT1, CFAP37, CGI-147, PTH2	ENSG00000141378	Peptidyl-tRNA hydrolase 2	17	59674636-59707626	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA012897	Supported		Supported	Mitochondria	Renal cancer:1.01e-8 (unfavourable), Liver cancer:1.50e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 43.9	Expressed in all		
PTTG1IP	C21orf1, C21orf3, PBF	ENSG00000183255	Pituitary tumor-transforming 1 interacting protein	21	44849585-44873903	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034146, HPA061827	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:2.28e-4 (unfavourable), Stomach cancer:5.40e-4 (unfavourable), Cervical cancer:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 243.5	Expressed in all		
PVR	CD155, HVED, Necl-5, NECL5, PVS, Tage4	ENSG00000073008	Poliovirus receptor	19	44643798-44663583	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012568	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Cervical cancer:1.29e-4 (unfavourable), Urothelial cancer:2.75e-4 (unfavourable), Lung cancer:9.30e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 17.0	Cell line enhanced		TIME: 147.4
PVRIG	C7orf15, MGC2463	ENSG00000213413	Poliovirus receptor related immunoglobulin domain containing	7	100218241-100221490	Predicted membrane proteins	Evidence at protein level	HPA047497	Uncertain		Approved	Nucleoli<br>Endoplasmic reticulum		Not detected	Tissue enhanced		lymph node: 20.5;spleen: 11.0	appendix: 8.4	Group enriched	23	Daudi: 69.1;MOLT-4: 86.0;U-698: 21.4
PXMP2	PMP22	ENSG00000176894	Peroxisomal membrane protein 2	12	132687606-132704991	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:2.75e-4 (favourable), Head and neck cancer:9.84e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 120.3	Expressed in all		
PXMP4	PMP24	ENSG00000101417	Peroxisomal membrane protein 4	20	33702754-33720319	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050077	Approved		Approved	Nucleoli fibrillar center<br>Peroxisomes	Renal cancer:4.03e-10 (favourable), Lung cancer:3.88e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.1	Cell line enhanced		SK-BR-3: 56.7;T-47d: 60.1
QARS		ENSG00000172053	Glutaminyl-tRNA synthetase	3	49095932-49105135	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036986, HPA036987	Enhanced		Enhanced	Cytosol	Renal cancer:5.60e-6 (favourable), Breast cancer:1.43e-4 (favourable)	Expressed in all	Expressed in all			rectum: 117.0	Expressed in all		
QRFPR	GPR103	ENSG00000186867	Pyroglutamylated RFamide peptide receptor	4	121329312-121381059	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA014300	Uncertain				Renal cancer:3.09e-4 (favourable)	Tissue enriched	Not detected			heart muscle: 0.6	Cell line enhanced		HL-60: 2.6;hTERT-HME1: 3.2;RPTEC TERT1: 2.0;SCLC-21H: 2.0;U-2 OS: 4.7;WM-115: 2.5
QSOX1	QSCN6	ENSG00000116260	Quiescin sulfhydryl oxidase 1	1	180154834-180204030	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042127, HPA056243	Uncertain		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.86e-5 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 233.0	Expressed in all		
QSOX2	DKFZp762A2013, QSCN6L1, SOXN	ENSG00000165661	Quiescin sulfhydryl oxidase 2	9	136206333-136245841	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012716, HPA017280	Uncertain		Enhanced	Nucleoplasm<br>Golgi apparatus	Renal cancer:9.64e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 20.7	Expressed in all		
RAB18		ENSG00000099246	RAB18, member RAS oncogene family	10	27504174-27542237	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA025928	Uncertain					Expressed in all	Expressed in all			cerebral cortex: 87.9	Expressed in all		
RABAC1	PRA1, PRAF1, YIP3	ENSG00000105404	Rab acceptor 1	19	41956681-41959390	Predicted membrane proteins, Transporters	Evidence at protein level	CAB019320, HPA029171	Enhanced		Approved	Nuclear membrane<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			cerebral cortex: 107.2	Expressed in all		
RABGAP1	GAPCenA, TBC1D11	ENSG00000011454	RAB GTPase activating protein 1	9	122940833-123104866	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041651, HPA064860, HPA072273	Enhanced		Enhanced	Cytosol	Renal cancer:6.06e-6 (favourable), Breast cancer:8.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 65.6	Expressed in all		
RABGAP1L	FLJ38519, HHL, KIAA0471, TBC1D18	ENSG00000152061	RAB GTPase activating protein 1 like	1	174159410-174995308	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054695	Uncertain		Approved	Nucleoli<br>Cytosol	Lung cancer:1.16e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 76.6	Expressed in all		
RAD51B	hREC2, R51H2, RAD51L1, REC2	ENSG00000182185	RAD51 paralog B	14	67819779-68730218	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB016191, HPA051869	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Mixed			epididymis: 11.0	Expressed in all		
RAET1E	bA350J20.7, LETAL, ULBP4	ENSG00000164520	Retinoic acid early transcript 1E	6	149883375-149898102	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054022			Approved	Focal adhesion sites<br>Cytosol		Tissue enhanced	Tissue enhanced		esophagus: 70.8;skin: 29.0	tonsil: 10.3	Cell line enhanced		HBEC3-KT: 15.9;HeLa: 20.3;hTCEpi: 15.6;SiHa: 11.2;U-87 MG: 9.0
RAET1G	ULBP5	ENSG00000203722	Retinoic acid early transcript 1G	6	149916878-149923121	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062673			Approved	Vesicles	Lung cancer:5.35e-4 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 8.2;esophagus: 9.5	skin: 3.4	Cell line enhanced		HeLa: 21.4;hTCEpi: 18.1;SiHa: 13.3;U-87 MG: 9.8
RAET1L		ENSG00000155918	Retinoic acid early transcript 1L	6	150018334-150025532	Predicted membrane proteins	Evidence at protein level						Lung cancer:4.09e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	esophagus: 38.9	tonsil: 5.9	Cell line enriched	6	HaCaT: 15.6
RALGAPA1	DKFZp667F074, GARNL1, GRIPE, KIAA0884, RalGAPalpha1, Tulip1	ENSG00000174373	Ral GTPase activating protein catalytic alpha subunit 1	14	35538352-35809304	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000851	Approved		Approved	Mitochondria<br>Cytosol	Renal cancer:9.76e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 53.4	Expressed in all		
RALGAPA2	AS250, C20orf74, dJ1049G11.4, KIAA1272, RapGAPalpha2	ENSG00000188559	Ral GTPase activating protein catalytic alpha subunit 2	20	20389552-20712488	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042707, HPA043622	Uncertain		Supported	Plasma membrane<br>Cytosol	Renal cancer:3.77e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Group enriched	5	RT4: 88.7;SCLC-21H: 71.2
RAMP1		ENSG00000132329	Receptor activity modifying protein 1	2	237858893-237912114	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA057814			Supported	Nucleoplasm<br>Nuclear membrane	Stomach cancer:1.68e-4 (unfavourable), Liver cancer:7.61e-4 (favourable)	Expressed in all	Tissue enhanced		endometrium: 234.1	smooth muscle: 171.5	Cell line enhanced		HDLM-2: 126.9;PC-3: 142.8;SH-SY5Y: 202.6
RAMP2		ENSG00000131477	Receptor activity modifying protein 2	17	42758447-42763041	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052020			Approved	Vesicles		Expressed in all	Mixed			lung: 178.6	Cell line enhanced		ASC diff: 78.4;EFO-21: 72.9;HUVEC TERT2: 29.7
RAMP3		ENSG00000122679	Receptor activity modifying protein 3	7	45157791-45186302	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level						Liver cancer:2.50e-6 (favourable), Cervical cancer:2.89e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 120.2	thyroid gland: 66.3	Cell line enhanced		Karpas-707: 1.8
RANBP17		ENSG00000204764	RAN binding protein 17	5	170861870-171300015	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029568, HPA029569	Uncertain		Approved	Nuclear membrane<br>Nuclear bodies<br>Cytosol		Mixed	Mixed			testis: 2.2	Mixed		
RARRES3	HRASLS4, TIG3	ENSG00000133321	Retinoic acid receptor responder 3	11	63536809-63546462	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:6.26e-6 (unfavourable), Breast cancer:1.35e-5 (favourable), Cervical cancer:4.00e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 166.5	Cell line enhanced		CAPAN-2: 203.5;RPTEC TERT1: 87.4;SK-BR-3: 131.4
RASGEF1B	FLJ31695, GPIG4	ENSG00000138670	RasGEF domain family member 1B	4	81426393-82044244	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044574	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:4.21e-6 (favourable), Head and neck cancer:1.49e-5 (favourable), Cervical cancer:6.40e-4 (favourable)	Expressed in all	Mixed			skin: 31.6	Cell line enhanced		CACO-2: 12.9;Daudi: 13.1;Karpas-707: 9.0;NTERA-2: 11.1;SCLC-21H: 10.7
RB1	OSRC, PPP1R130, RB	ENSG00000139687	RB transcriptional corepressor 1	13	48303751-48481986	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB000095, CAB016687, HPA050082	Supported		Enhanced	Nucleoplasm	Ovarian cancer:6.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 36.1	Mixed		
RBL1	cp107, p107, PRB1	ENSG00000080839	RB transcriptional corepressor like 1	20	36996349-37095995	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054962, HPA056525	Enhanced		Enhanced	Nucleoplasm	Renal cancer:2.52e-6 (unfavourable)	Expressed in all	Mixed			bone marrow: 9.2	Expressed in all		
RCAN2	DSCR1L1, ZAKI-4	ENSG00000172348	Regulator of calcineurin 2	6	46220736-46491972	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053880	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.12e-6 (favourable), Pancreatic cancer:2.48e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 145.4	Group enriched	6	fHDF/TERT166: 49.1;HDLM-2: 120.1
RCE1	FACE-2, FACE2, hRCE1, RCE1A, RCE1B	ENSG00000173653	Ras converting CAAX endopeptidase 1	11	66842835-66846546	Enzymes, Predicted membrane proteins	Evidence at protein level							Expressed in all	Mixed			skin: 23.3	Expressed in all		
RCN3	RLP49	ENSG00000142552	Reticulocalbin 3	19	49527618-49546962	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043134, HPA050402	Uncertain		Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:5.80e-12 (unfavourable)	Expressed in all	Expressed in all			small intestine: 45.0	Cell line enhanced		ASC diff: 170.1;BJ: 238.6;fHDF/TERT166: 192.6
RDH10	SDR16C4	ENSG00000121039	Retinol dehydrogenase 10	8	73294612-73325281	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049199			Approved	Lipid droplets		Expressed in all	Expressed in all			placenta: 51.8	Expressed in all		
RDH16	RODH-4, SDR9C8	ENSG00000139547	Retinol dehydrogenase 16 (all-trans)	12	56951431-56959374	Predicted membrane proteins	Evidence at protein level	HPA038518	Enhanced				Liver cancer:2.16e-5 (favourable)	Tissue enriched	Tissue enriched	85	liver: 278.6	prostate: 3.2	Cell line enhanced		HaCaT: 1.1;hTCEpi: 2.0
RDM1	MGC33977, RAD52B	ENSG00000278023	RAD52 motif containing 1	17	35918066-35930773	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024794, HPA067546	Enhanced		Supported	Nucleoli<br>Cytosol		Mixed	Tissue enriched	6	testis: 9.7	tonsil: 1.6	Cell line enhanced		T-47d: 17.4
RECK	hRECK, ST15	ENSG00000122707	Reversion inducing cysteine rich protein with kazal motifs	9	36036433-36124451	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB025109, HPA071729	Supported		Supported	Plasma membrane	Stomach cancer:7.31e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 21.4	Group enriched	5	ASC diff: 122.8;ASC TERT1: 99.6;BJ: 49.1;BJ hTERT+: 67.5;fHDF/TERT166: 40.1;HSkMC: 46.5;TIME: 32.3
REEP1	C2orf23, FLJ13110, SPG31, Yip2a	ENSG00000068615	Receptor accessory protein 1	2	86213993-86338083	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA058061	Enhanced					Mixed	Tissue enhanced		testis: 92.3	cerebral cortex: 54.1	Cell line enhanced		BEWO: 65.9;SCLC-21H: 38.4
REEP2	C5orf19, SGC32445, SPG72, Yip2d	ENSG00000132563	Receptor accessory protein 2	5	138439017-138446969	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA031813	Enhanced				Breast cancer:7.83e-5 (favourable), Glioma:3.43e-4 (unfavourable), Melanoma:9.31e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 90.1	smooth muscle: 18.0	Cell line enhanced		AN3-CA: 89.1;SCLC-21H: 46.8;SH-SY5Y: 47.6
REEP3	C10orf74, Yip2b	ENSG00000165476	Receptor accessory protein 3	10	63521363-63625123	Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:1.32e-4 (unfavourable), Liver cancer:3.19e-4 (unfavourable), Head and neck cancer:7.83e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 56.9	Mixed		
REEP4	C8orf20, FLJ22246, FLJ22277, PP432, Yip2c	ENSG00000168476	Receptor accessory protein 4	8	22138020-22141951	Predicted membrane proteins	Evidence at protein level	HPA042683	Approved		Approved	Cytosol	Renal cancer:2.88e-5 (unfavourable), Liver cancer:4.14e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 66.4	Expressed in all		
REEP5	C5orf18, D5S346, DP1, TB2, Yip2e	ENSG00000129625	Receptor accessory protein 5	5	112876379-112922539	Predicted membrane proteins	Evidence at protein level	HPA003895, HPA069960	Approved		Approved	Endoplasmic reticulum	Endometrial cancer:5.23e-6 (favourable), Renal cancer:2.05e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 343.0	Expressed in all		
REEP6	C19orf32, DP1L1, FLJ25383, Yip2f	ENSG00000115255	Receptor accessory protein 6	19	1490747-1497927	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA003895, HPA048015	Enhanced		Supported	Endoplasmic reticulum		Expressed in all	Group enriched	7	adrenal gland: 48.2;duodenum: 166.1;liver: 76.1;small intestine: 167.0;testis: 181.2	prostate: 19.3	Cell line enhanced		K-562: 101.6;T-47d: 84.9
RELL1		ENSG00000181826	RELT like 1	4	37590800-37686376	Predicted membrane proteins	Evidence at protein level	HPA013377	Approved		Supported	Plasma membrane<br>Microtubules		Expressed in all	Mixed			thyroid gland: 27.7	Cell line enhanced		RH-30: 57.4
RELL2	C5orf16, FLJ90583	ENSG00000164620	RELT like 2	5	141636950-141641077	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA077928			Uncertain	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 13.2;parathyroid gland: 23.3	testis: 4.3	Mixed		
RELT	FLJ14993, TNFRSF19L	ENSG00000054967	RELT tumor necrosis factor receptor	11	73376264-73397474	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062824, HPA071518			Supported	Nucleus	Renal cancer:4.07e-11 (unfavourable)	Mixed	Tissue enriched	6	bone marrow: 95.8	spleen: 17.2	Mixed		
RER1		ENSG00000157916	Retention in endoplasmic reticulum sorting receptor 1	1	2391775-2405444	Predicted membrane proteins, Transporters	Evidence at protein level	CAB037240, HPA051400	Supported		Enhanced	Golgi apparatus	Renal cancer:8.23e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 186.8	Expressed in all		
RET	CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51	ENSG00000165731	Ret proto-oncogene	10	43077027-43130351	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002581, HPA008356, HPA008495, CAB018342	Approved	Supported	Supported	Vesicles<br>Plasma membrane<br>Cytosol	Endometrial cancer:5.02e-4 (unfavourable)	Tissue enhanced	Tissue enriched	5	parathyroid gland: 154.5	adrenal gland: 29.8	Cell line enriched	5	SH-SY5Y: 404.3
RETSAT	FLJ20296	ENSG00000042445	Retinol saturase	2	85342088-85354620	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007961, HPA046513	Uncertain		Approved	Nucleoli	Renal cancer:1.95e-10 (favourable), Liver cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 265.4	Expressed in all		
RFT1	CDG1N	ENSG00000163933	RFT1 homolog	3	53088483-53130462	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA060327, HPA069022	Approved		Approved	Vesicles	Liver cancer:1.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
RGMB	DRAGON, FLJ90406	ENSG00000174136	Repulsive guidance molecule family member b	5	98768650-98798643	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016993			Approved	Nucleoplasm		Expressed in all	Mixed			cerebral cortex: 43.6	Cell line enhanced		BJ: 267.0;HBF TERT88: 210.1
RGR	RP44	ENSG00000148604	Retinal G protein coupled receptor	10	84245053-84259960	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	13	cerebral cortex: 16.1	testis: 1.2	Not detected		
RGS9BP	FLJ45744, PERRS, R9AP, RGS9	ENSG00000186326	Regulator of G-protein signaling 9 binding protein	19	32675407-32678300	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA049791	Supported					Not detected	Tissue enriched	6	skeletal muscle: 2.6	lung: 0.4	Cell line enhanced		HEL: 4.7
RGSL1	RGSL2	ENSG00000121446	Regulator of G-protein signaling like 1	1	182409192-182560599	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	6	testis: 9.1	epididymis: 1.4	Not detected		
RHAG	CD241, RH50A, SLC42A1	ENSG00000112077	Rh-associated glycoprotein	6	49605158-49636839	CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046051, HPA055331	Approved		Uncertain	Endoplasmic reticulum		Not detected	Tissue enriched	24	bone marrow: 73.7	placenta: 3.1	Group enriched	223	HEL: 448.1;K-562: 429.7
RHBDD1	DKFZp547E052	ENSG00000144468	Rhomboid domain containing 1	2	226835581-226999215	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013972, HPA057125	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			testis: 32.2	Mixed		
RHBDD2	NPD007, RHBDL7	ENSG00000005486	Rhomboid domain containing 2	7	75842602-75888926	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045074, HPA051960	Uncertain		Enhanced	Golgi apparatus	Renal cancer:8.68e-6 (favourable), Colorectal cancer:3.31e-5 (unfavourable), Glioma:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 258.6	Expressed in all		
RHBDD3	C22orf3, PTAG	ENSG00000100263	Rhomboid domain containing 3	22	29259852-29268209	Predicted membrane proteins	Evidence at protein level	HPA043979	Approved		Approved	Microtubules	Endometrial cancer:2.67e-6 (favourable), Renal cancer:2.24e-4 (unfavourable)	Expressed in all	Mixed			testis: 10.5	Mixed		
RHBDF1	C16orf8, Dist1, EGFR-RS, FLJ2235, iRhom1	ENSG00000007384	Rhomboid 5 homolog 1	16	58059-76355	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA077399			Uncertain	Vesicles	Renal cancer:2.49e-5 (unfavourable)	Expressed in all	Mixed			placenta: 39.8	Mixed		
RHBDF2	FLJ22341, iRhom2, RHBDL5, RHBDL6, TOC, TOCG	ENSG00000129667	Rhomboid 5 homolog 2	17	76470891-76501790	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018080	Uncertain				Renal cancer:3.96e-11 (unfavourable)	Expressed in all	Expressed in all			appendix: 49.4	Mixed		
RHBDL1	RHBDL, RRP	ENSG00000103269	Rhomboid like 1	16	675666-678268	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA030359, HPA030360, HPA046593	Uncertain		Approved	Nucleoplasm	Breast cancer:8.12e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 8.0	adrenal gland: 3.3	Mixed		
RHBDL2	FLJ20435	ENSG00000158315	Rhomboid like 2	1	38885807-38941799	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA043807	Approved					Mixed	Mixed			skin: 22.1	Cell line enhanced		CAPAN-2: 40.9;HaCaT: 21.4;RT4: 37.8
RHBDL3	RHBDL4, VRHO	ENSG00000141314	Rhomboid like 3	17	32266176-32324661	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA059607	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 20.7	adrenal gland: 5.5	Cell line enhanced		A549: 4.0;AF22: 4.3;HDLM-2: 5.7;NTERA-2: 6.4;U-2 OS: 4.6
RHBG	SLC42A2	ENSG00000132677	Rh family B glycoprotein (gene/pseudogene)	1	156369212-156385219	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042726, HPA048489	Enhanced		Approved	Nucleoplasm	Urothelial cancer:8.06e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 3.5;ovary: 2.1	esophagus,liver: 0.6	Group enriched	28	CACO-2: 2.1;Hep G2: 2.0;RT4: 4.3
RHCE	CD240CE, RH	ENSG00000188672	Rh blood group CcEe antigens	1	25362249-25430192	Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enriched	6	bone marrow: 28.8	epididymis: 5.2	Group enriched	12	HEL: 76.1;K-562: 16.0
RHCG	C15orf6, PDRC2, RHGK, SLC42A3	ENSG00000140519	Rh family C glycoprotein	15	89471398-89496613	Predicted membrane proteins, Transporters	Evidence at protein level	HPA041874, HPA043317	Enhanced				Lung cancer:3.80e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	esophagus: 2901.8	tonsil: 420.3	Cell line enhanced		A549: 3.3;hTCEpi: 1.4;RT4: 1.6;SK-MEL-30: 1.0
RHD	CD240D, DIIIc, RH, Rh30a, Rh4, RhII, RhPI	ENSG00000187010	Rh blood group D antigen	1	25272393-25330445	Blood group antigen proteins, CD markers, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		bone marrow: 9.2	skin: 2.5	Group enriched	5	HEL: 33.3;K-562: 10.3
RHO	CSNBAD1, OPN2, RP4	ENSG00000163914	Rhodopsin	3	129528640-129535169	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013440, CAB022486, CAB034887, CAB034888	Supported					Not detected	Not detected			cerebral cortex: 0.3	Not detected		
RHOT1	ARHT1, FLJ11040, MIRO-1	ENSG00000126858	Ras homolog family member T1	17	32142454-32253374	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010687, CAB068223, CAB068224	Enhanced					Expressed in all	Expressed in all			parathyroid gland: 48.8	Expressed in all		
RHOT2	ARHT2, C16orf39, MIRO-2	ENSG00000140983	Ras homolog family member T2	16	668086-674174	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012624, HPA012895	Approved		Supported	Cytosol	Head and neck cancer:5.01e-4 (favourable), Renal cancer:5.43e-4 (favourable)	Expressed in all	Expressed in all			spleen: 31.2	Expressed in all		
RIC1	bA207C16.1, KIAA1432	ENSG00000107036	RIC1 homolog, RAB6A GEF complex partner 1	9	5629025-5776557	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051578	Supported					Expressed in all	Expressed in all			testis: 21.4	Expressed in all		
RIC3	AYST720, FLJ11608, PRO1385	ENSG00000166405	RIC3 acetylcholine receptor chaperone	11	8106093-8169055	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA065016	Approved					Mixed	Mixed			parathyroid gland: 28.2	Cell line enhanced		NTERA-2: 5.0;SCLC-21H: 9.9;SH-SY5Y: 6.2
RMDN2	FAM82A, FAM82A1, FLJ32954, RMD2	ENSG00000115841	Regulator of microtubule dynamics 2	2	37923187-38067142	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034705, HPA034706	Approved		Supported	Golgi apparatus<br>Mitotic spindle<br>Cytosol	Lung cancer:2.63e-4 (favourable)	Mixed	Expressed in all			adrenal gland: 68.9	Mixed		
RMDN3	FAM82A2, FAM82C, FLJ10579, PTPIP51, RMD3	ENSG00000137824	Regulator of microtubule dynamics 3	15	40735884-40755851	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009975	Supported		Enhanced	Mitochondria	Renal cancer:6.70e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 58.1	Expressed in all		
RMND1	bA351K16.3, C6orf96, FLJ20627, RMD1	ENSG00000155906	Required for meiotic nuclear division 1 homolog	6	151404763-151452181	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031397, HPA031398, HPA031399	Approved		Supported	Mitochondria	Head and neck cancer:6.96e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 44.1	Expressed in all		
RNASEK	MGC71993	ENSG00000219200	Ribonuclease K	17	7012417-7014532	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA044708	Uncertain				Pancreatic cancer:1.92e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 468.1	Expressed in all		
RNASEK-C17orf49		ENSG00000161939	RNASEK-C17orf49 readthrough	17	7012635-7017520	Predicted membrane proteins	Evidence at protein level	HPA022961, HPA024457	Uncertain		Uncertain	Nucleoplasm<br>Cytosol		Not detected	Not detected			endometrium,small intestine,testis: 0.6	Cell line enhanced		U-87 MG: 3.6
RNF103	hkf-1, KF1, ZFP103	ENSG00000239305	Ring finger protein 103	2	86603393-86623866	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA057922	Approved				Urothelial cancer:6.77e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 55.3	Expressed in all		
RNF112	BFP, ZNF179	ENSG00000128482	Ring finger protein 112	17	19411125-19417276	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA015970	Approved		Approved	Nuclear speckles		Tissue enriched	Tissue enhanced		cerebral cortex: 33.0	prostate: 11.0	Cell line enhanced		SCLC-21H: 7.1;SH-SY5Y: 11.1;U-87 MG: 33.6
RNF121	FLJ11099	ENSG00000137522	Ring finger protein 121	11	71928701-71997597	Predicted membrane proteins	Evidence at protein level	HPA046041	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Renal cancer:2.72e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.5	Expressed in all		
RNF122	FLJ12526	ENSG00000133874	Ring finger protein 122	8	33547755-33567125	Predicted membrane proteins	Evidence at transcript level	HPA003888	Uncertain				Renal cancer:4.50e-7 (unfavourable), Thyroid cancer:1.88e-4 (unfavourable), Prostate cancer:5.37e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 21.6	Cell line enhanced		HEK93: 76.9;Karpas-707: 38.8
RNF128	FLJ23516, GRAIL	ENSG00000133135	Ring finger protein 128, E3 ubiquitin protein ligase	X	106693794-106796993	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA019675	Uncertain				Renal cancer:1.07e-7 (unfavourable)	Mixed	Mixed			small intestine: 66.9	Cell line enhanced		BEWO: 40.1;CAPAN-2: 30.6;RT4: 70.6;WM-115: 52.6
RNF13	RZF	ENSG00000082996	Ring finger protein 13	3	149812708-149962139	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA064784	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.00e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 94.4	Expressed in all		
RNF130	G1RZFP, GOLIATH, GP	ENSG00000113269	Ring finger protein 130	5	179911651-180072118	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014499	Approved				Cervical cancer:6.32e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 74.8	Mixed		
RNF133		ENSG00000188050	Ring finger protein 133	7	122697712-122699156	Enzymes, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	182	testis: 60.9	lung: 0.3	Not detected		
RNF139	HRCA1, RCA1, TRC8	ENSG00000170881	Ring finger protein 139	8	124474738-124487914	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001202	Approved				Pancreatic cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 114.8	Expressed in all		
RNF144A	KIAA0161, RNF144, UBCE7IP4	ENSG00000151692	Ring finger protein 144A	2	6917392-7068286	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049939	Approved		Approved	Vesicles	Stomach cancer:7.32e-5 (unfavourable), Endometrial cancer:6.00e-4 (unfavourable), Head and neck cancer:6.96e-4 (favourable)	Expressed in all	Mixed			endometrium: 43.1	Cell line enhanced		HMC-1: 112.4
RNF144B	bA528A10.3, IBRDC2	ENSG00000137393	Ring finger protein 144B	6	18387350-18468874	Predicted membrane proteins	Evidence at protein level	CAB046013, HPA054127, HPA072469	Uncertain		Approved	Nucleoli<br>Mitochondria		Expressed in all	Tissue enhanced		thyroid gland: 68.1	breast: 35.0	Cell line enhanced		Daudi: 137.5;U-698: 110.9
RNF145	FLJ31951	ENSG00000145860	Ring finger protein 145	5	159157409-159210053	Predicted membrane proteins	Evidence at protein level	HPA036562	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.64e-6 (unfavourable)	Expressed in all	Expressed in all			lung: 109.0	Expressed in all		
RNF148	MGC35222	ENSG00000235631	Ring finger protein 148	7	122701664-122702967	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	228	testis: 73.5	lung: 0.3	Cell line enhanced		Karpas-707: 1.9
RNF149	FLJ90504	ENSG00000163162	Ring finger protein 149	2	101271219-101308701	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA011424	Approved		Approved	Vesicles<br>Plasma membrane	Renal cancer:2.04e-8 (unfavourable), Urothelial cancer:2.91e-4 (favourable)	Expressed in all	Expressed in all			appendix: 67.8	Mixed		
RNF150	KIAA1214	ENSG00000170153	Ring finger protein 150	4	140859807-141212877	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA037987	Uncertain				Breast cancer:1.41e-4 (favourable)	Mixed	Mixed			endometrium,fallopian tube: 21.3	Cell line enhanced		fHDF/TERT166: 21.9;SH-SY5Y: 42.3
RNF152	FLJ39176	ENSG00000176641	Ring finger protein 152	18	61808063-61894247	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.13e-8 (favourable), Stomach cancer:2.85e-5 (unfavourable)	Expressed in all	Tissue enriched	5	kidney: 56.6	liver: 10.3	Cell line enhanced		HaCaT: 18.4;SH-SY5Y: 13.4;U-138 MG: 20.3
RNF167	DKFZP566H073	ENSG00000108523	Ring finger protein 167	17	4940008-4945222	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049810	Approved		Approved	Cytosol	Pancreatic cancer:2.03e-6 (favourable), Renal cancer:4.47e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 116.9	Expressed in all		
RNF170	ADSA, DKFZP564A022, SNAX1	ENSG00000120925	Ring finger protein 170	8	42849637-42897290	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA050931, HPA054621	Uncertain					Expressed in all	Expressed in all			thyroid gland: 47.9	Expressed in all		
RNF175	FLJ34190	ENSG00000145428	Ring finger protein 175	4	153710125-153760235	Predicted membrane proteins	Evidence at protein level	HPA035837	Uncertain				Glioma:4.15e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 13.2	seminal vesicle: 4.1	Cell line enhanced		AF22: 6.9;REH: 5.6;SH-SY5Y: 6.3;THP-1: 10.0;U-87 MG: 3.4
RNF180		ENSG00000164197	Ring finger protein 180	5	64165844-64372869	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006897	Approved		Approved	Cytosol	Renal cancer:6.81e-5 (favourable)	Tissue enhanced	Tissue enhanced		parathyroid gland: 62.4	thyroid gland: 24.8	Cell line enriched	5	RPMI-8226: 20.6
RNF182	MGC33993	ENSG00000180537	Ring finger protein 182	6	13924446-13980302	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012309	Approved		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Endometrial cancer:4.66e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 14.6	testis: 6.9	Cell line enhanced		HeLa: 57.3;RPTEC TERT1: 51.0
RNF183	MGC4734	ENSG00000165188	Ring finger protein 183	9	113297093-113303376	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA057675	Uncertain				Endometrial cancer:7.95e-6 (favourable), Renal cancer:3.51e-4 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 20.0;gallbladder: 9.0	kidney: 4.3	Cell line enriched	10	SCLC-21H: 22.2
RNF185	FLJ38628	ENSG00000138942	Ring finger protein 185	22	31160183-31207019	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:4.82e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 86.7	Expressed in all		
RNF186	FLJ20225	ENSG00000178828	Ring finger protein 186	1	19814029-19815278	Predicted membrane proteins	Evidence at protein level	HPA034547, HPA035558	Enhanced					Tissue enhanced	Tissue enhanced		duodenum: 132.4;epididymis: 82.2;small intestine: 46.5	kidney: 26.2	Cell line enhanced		RPMI-8226: 1.2
RNF19A	DKFZp566B1346, dorfin, RNF19	ENSG00000034677	Ring finger protein 19A, RBR E3 ubiquitin protein ligase	8	100257060-100336218	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB011455, HPA023652	Approved				Urothelial cancer:3.28e-5 (favourable), Renal cancer:7.99e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 95.3	Expressed in all		
RNF19B	FLJ90005, IBRDC3	ENSG00000116514	Ring finger protein 19B	1	32936445-32964685	Predicted membrane proteins	Evidence at protein level	HPA049587	Approved		Approved	Cytosol	Liver cancer:5.41e-6 (unfavourable), Renal cancer:4.39e-5 (favourable), Head and neck cancer:3.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 155.3	Expressed in all		
RNF213	C17orf27, KIAA1554, KIAA1618, MYMY2, NET57	ENSG00000173821	Ring finger protein 213	17	80260866-80398786	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003347, HPA026790	Approved		Supported	Cytosol	Endometrial cancer:4.65e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.3	Expressed in all		
RNF215		ENSG00000099999	Ring finger protein 215	22	30368811-30421771	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA029427, HPA056498	Approved		Approved	Nucleoli<br>Microtubules	Renal cancer:6.37e-10 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 19.2	Expressed in all		
RNF217	C6orf172, dJ84N20.1, IBRDC1, MGC26996	ENSG00000146373	Ring finger protein 217	6	124962545-125092633	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029598	Uncertain				Renal cancer:4.60e-5 (unfavourable), Urothelial cancer:1.92e-4 (unfavourable)	Expressed in all	Tissue enriched	8	parathyroid gland: 95.7	testis: 12.5	Mixed		
RNF222		ENSG00000189051	Ring finger protein 222	17	8390704-8397826	Predicted membrane proteins	Evidence at transcript level	HPA048916	Uncertain					Tissue enhanced	Group enriched	6	esophagus: 9.7;skin: 4.1;tonsil: 2.0	bone marrow: 0.9	Cell line enriched	7	SK-BR-3: 5.1
RNF223		ENSG00000237330	Ring finger protein 223	1	1070966-1074307	Predicted membrane proteins	Evidence at transcript level						Endometrial cancer:8.08e-5 (favourable), Pancreatic cancer:6.53e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 5.3;stomach: 3.6	skin: 2.0	Cell line enhanced		A-431: 13.3;CAPAN-2: 9.8;HaCaT: 6.2;MCF7: 18.6;SK-BR-3: 12.0;T-47d: 9.8
RNF225		ENSG00000269855	Ring finger protein 225	19	58396090-58397079	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		esophagus: 2.0;skin: 1.7	prostate: 0.6	Not detected		
RNF24	G1L	ENSG00000101236	Ring finger protein 24	20	3927309-4015582	Predicted membrane proteins	Evidence at protein level	HPA011900	Approved		Supported	Golgi apparatus	Renal cancer:2.67e-7 (unfavourable), Liver cancer:3.81e-5 (unfavourable)	Expressed in all	Mixed			bone marrow: 34.2	Expressed in all		
RNF26	MGC2642	ENSG00000173456	Ring finger protein 26	11	119334527-119337313	Predicted membrane proteins	Evidence at transcript level	HPA027620	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:3.45e-6 (favourable), Liver cancer:3.19e-4 (unfavourable), Urothelial cancer:7.73e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.9	Mixed		
RNF43	DKFZp781H0392, FLJ20315, URCC	ENSG00000108375	Ring finger protein 43	17	58352500-58417595	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA008079	Uncertain				Renal cancer:6.04e-9 (favourable)	Tissue enhanced	Mixed			duodenum: 23.4	Cell line enhanced		CACO-2: 20.6;Hep G2: 33.5
RNF5	G16, NG2, RING5, RMA1	ENSG00000204308	Ring finger protein 5	6	32178354-32180793	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB034107, HPA065032	Uncertain		Supported	Endoplasmic reticulum	Ovarian cancer:2.44e-4 (favourable)	Expressed in all	Mixed			kidney: 18.6	Mixed		
RNFT1	PTD016	ENSG00000189050	Ring finger protein, transmembrane 1	17	59952240-59964761	Predicted membrane proteins	Evidence at protein level	HPA013739			Approved	Nucleoli	Thyroid cancer:2.57e-4 (favourable), Colorectal cancer:6.57e-4 (favourable), Lung cancer:7.48e-4 (favourable)	Expressed in all	Tissue enriched	9	testis: 114.0	epididymis: 12.6	Expressed in all		
RNFT2	FLJ14627, TMEM118	ENSG00000135119	Ring finger protein, transmembrane 2	12	116738178-116853631	Predicted membrane proteins	Evidence at protein level	HPA064161	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 15.3	testis: 6.0	Mixed		
ROBO1	DUTT1, FLJ21882, SAX3	ENSG00000169855	Roundabout guidance receptor 1	3	78597240-79767815	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013524, HPA052968, HPA074461	Uncertain		Enhanced	Plasma membrane	Liver cancer:9.88e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 32.9	Mixed		
ROBO2	KIAA1568	ENSG00000185008	Roundabout guidance receptor 2	3	75906695-77649964	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013371	Approved		Approved	Nucleus<br>Microtubule organizing center		Tissue enhanced	Tissue enhanced		cerebral cortex: 33.8	lung: 15.1	Cell line enhanced		BJ hTERT+: 24.2;HEL: 75.2
ROBO3	FLJ21044, HGPPS, HGPS, RBIG1	ENSG00000154134	Roundabout guidance receptor 3	11	124865386-124881470	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		smooth muscle: 1.2	cerebral cortex: 0.8	Cell line enriched	11	AF22: 17.9
ROBO4	ECSM4, FLJ20798, MRB	ENSG00000154133	Roundabout guidance receptor 4	11	124883691-124898500	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA065212			Approved	Plasma membrane	Liver cancer:4.85e-4 (favourable), Stomach cancer:8.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 58.2	adipose tissue: 45.1	Group enriched	9	HUVEC TERT2: 203.4;TIME: 180.3
ROM1	ROM, TSPAN23	ENSG00000149489	Retinal outer segment membrane protein 1	11	62611722-62615120	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028910	Supported		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.85e-6 (unfavourable), Lung cancer:2.20e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 25.4	ovary: 13.3	Mixed		
ROR1	NTRKR1	ENSG00000185483	Receptor tyrosine kinase like orphan receptor 1	1	63774022-64181498	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057016			Uncertain	Microtubules<br>Cytokinetic bridge		Mixed	Tissue enhanced		parathyroid gland: 52.0	endometrium: 12.1	Cell line enhanced		ASC TERT1: 35.2;NTERA-2: 43.3
ROR2	BDB, BDB1, NTRKR2	ENSG00000169071	Receptor tyrosine kinase like orphan receptor 2	9	91563091-91950162	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA021868	Uncertain				Thyroid cancer:4.28e-8 (unfavourable), Renal cancer:9.86e-7 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 35.1	endometrium: 21.4	Cell line enhanced		AF22: 25.3;HHSteC: 55.3;HSkMC: 39.9;U-266/70: 29.6
ROS1	c-ros-1, MCF3, ROS	ENSG00000047936	ROS proto-oncogene 1, receptor tyrosine kinase	6	117288300-117425855	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049098, HPA072424	Uncertain		Approved	Vesicles		Tissue enriched	Group enriched	18	epididymis: 70.9;lung: 47.2	seminal vesicle: 3.2	Cell line enhanced		HSkMC: 7.5;hTCEpi: 15.7;LHCN-M2: 12.7
RP11-1035H13.3		ENSG00000260342		16	18788063-18801519	Predicted membrane proteins	Evidence at transcript level	HPA045307	Uncertain		Approved	Endoplasmic reticulum		Mixed	Tissue enhanced		testis: 25.8	cerebral cortex: 7.0	Cell line enhanced		HDLM-2: 82.4
RP11-104H15.12		ENSG00000283439		17	7428903-7432762	Predicted membrane proteins	Evidence at transcript level								Tissue enriched	285	testis: 28.5	all non-specific tissues: 0.0	Not detected		
RP11-108O10.8		ENSG00000258529		11	111786286-111879425	Predicted membrane proteins	Evidence at protein level	HPA038575	Uncertain		Approved	Endoplasmic reticulum		Not detected	Tissue enhanced		testis: 1.7	skin: 0.9	Cell line enhanced		CACO-2: 2.3
RP11-1212A22.4		ENSG00000233024		16	18358086-18379331	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Uncertain	Nucleoplasm		Not detected	Expressed in all			parathyroid gland: 131.8	Expressed in all		
RP11-20I23.1		ENSG00000260272		16	2496032-2520218	Predicted membrane proteins	Evidence at transcript level	HPA044712	Uncertain					Not detected	Not detected			cerebral cortex: 0.7	Cell line enhanced		HEK93: 1.5;SCLC-21H: 1.9;SH-SY5Y: 1.9
RP11-215A19.2		ENSG00000272297		4	186426546-186555328	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	16	testis: 54.0	prostate: 3.3	Group enriched	5	A-431: 2.2;T-47d: 1.2
RP11-226E21.4		ENSG00000283208		13	76992078-77129589	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level								Tissue enhanced		bone marrow: 2.8	cerebral cortex,thyroid gland: 0.9	Not detected		
RP11-235D19.4		ENSG00000283324		1	150887136-150913292	Predicted membrane proteins	Evidence at transcript level								Not detected			fallopian tube: 0.8	Cell line enriched	6	BEWO: 1.1
RP11-240B13.2		ENSG00000258417		8	132024238-132085655	Predicted membrane proteins	No evidence							Not detected	Not detected			cerebral cortex,testis: 0.1	Not detected		
RP11-244E17.1		ENSG00000283654		14	23099065-23104992	Predicted membrane proteins	Evidence at transcript level								Not detected			testis: 0.7	Cell line enriched	10	HSkMC: 2.2
RP11-277P12.6		ENSG00000255641		12	10412312-10436001	Predicted membrane proteins	Evidence at transcript level	HPA062570	Uncertain					Not detected	Group enriched	7	cerebral cortex: 8.2;spleen: 6.1	bone marrow: 1.0	Cell line enriched	5	HeLa: 5.8
RP11-294C11.1		ENSG00000182974		15	21637909-21638992	Predicted membrane proteins	Evidence at transcript level	HPA058889	Uncertain					Not detected	Tissue enriched	24	testis: 2.3	all non-specific tissues: 0.0	Not detected		
RP11-294C11.3		ENSG00000279408		15	21651844-21653039	Predicted membrane proteins	Evidence at transcript level	HPA057442	Uncertain		Uncertain	Centrosome		Not detected	Tissue enriched	17	testis: 14.6	cerebral cortex: 0.8	Cell line enriched	42	U-2 OS: 6.9
RP11-295K3.1		ENSG00000250644		11	1734821-1763954	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003001	Uncertain					Mixed	Tissue enhanced		adrenal gland: 83.1	cerebral cortex: 29.6	Cell line enhanced		CAPAN-2: 196.3;SH-SY5Y: 53.0;U-87 MG: 58.5
RP11-303E16.8		ENSG00000260643		16	81053587-81096296	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041368	Approved		Approved	Vesicles		Mixed	Tissue enhanced		thyroid gland: 17.3	cerebral cortex: 11.3	Mixed		
RP11-310K10.1		ENSG00000197991		13	61409858-61427849	Predicted membrane proteins	No evidence	HPA062669			Approved	Vesicles<br>Cytokinetic bridge		Not detected	Not detected			testis: 0.5	Not detected		
RP11-330H6.5		ENSG00000173366		3	52221081-52231190	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		lymph node: 3.7;tonsil: 2.3	appendix,spleen: 1.9	Cell line enhanced		Daudi: 9.9;RPMI-8226: 18.1;U-698: 8.8
RP11-360D2.1		ENSG00000232113		1	173635333-173637134	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	244	testis: 24.4	all non-specific tissues: 0.0	Not detected		
RP11-385J1.3		ENSG00000275163		3	178419123-178843300	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	6	fallopian tube: 8.8	kidney: 1.5	Cell line enriched	10	HSkMC: 1.0
RP11-407N17.3		ENSG00000258941	CTAGE family member 5 isoform 8 precursor 	14	39233902-39350423	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922, HPA054066, HPA055459	Uncertain		Approved	Endoplasmic reticulum		Not detected	Tissue enhanced		duodenum: 23.9;liver: 22.8;parathyroid gland: 44.1;small intestine: 29.5	kidney: 19.0	Cell line enhanced		CAPAN-2: 17.3;EFO-21: 5.5;Hep G2: 8.5;RPTEC TERT1: 7.0
RP11-407P15.2		ENSG00000259916		2	94588522-94604573	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	13	adipose tissue: 7.6	kidney: 0.5	Cell line enriched	9	ASC diff: 1.3
RP11-40A7.2		ENSG00000283526		9	131545514-131558620	Predicted membrane proteins	Evidence at transcript level								Tissue enhanced		fallopian tube: 10.2;lung: 6.2	prostate: 4.0	Group enriched	11	A549: 13.2;BEWO: 9.2;MCF7: 3.0;T-47d: 6.8
RP11-434N15.2		ENSG00000284299		1	210858125-211134146	Predicted membrane proteins	Evidence at transcript level								Not detected			cerebral cortex: 0.6	Cell line enhanced		SH-SY5Y: 1.3
RP11-435I10.4		ENSG00000261832		16	28456371-28492098	Predicted membrane proteins	Evidence at protein level	HPA053611	Uncertain		Approved	Nucleoplasm		Not detected	Not detected			smooth muscle: 0.1	Not detected		
RP11-449K6.5		ENSG00000283765		3	183815568-183884889	Predicted membrane proteins	Evidence at protein level	HPA019545	Uncertain		Approved	Mitochondria			Tissue enhanced		cerebral cortex: 3.4;testis: 2.1	adrenal gland,esophagus,skeletal muscle: 0.6	Cell line enhanced		T-47d: 7.0
RP11-451G4.2		ENSG00000240045		3	155290229-155293775	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	25	skeletal muscle: 400.8	prostate: 15.8	Not detected		
RP11-468E2.1		ENSG00000254692		14	24189157-24213473	Predicted membrane proteins	Evidence at protein level	HPA059249	Approved		Approved	Golgi apparatus		Not detected	Expressed in all			parathyroid gland: 54.2	Mixed		
RP11-468E2.6		ENSG00000259371		14	24120956-24131829	Predicted membrane proteins	No evidence							Not detected	Not detected			small intestine,testis: 0.5	Not detected		
RP11-49P4.7		ENSG00000282881		1	46532166-46533614	Predicted membrane proteins	No evidence								Not detected			cerebral cortex: 0.3	Not detected		
RP11-540D14.8		ENSG00000251246		1	155063748-155086807	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.2	testis: 0.7	Cell line enhanced		RPMI-8226: 2.2;U-266/70: 2.0
RP11-545J16.1		ENSG00000257046		12	20815674-21090245	Predicted membrane proteins	Evidence at transcript level	HPA050892	Uncertain					Not detected	Tissue enriched	13	breast: 26.9	liver: 2.0	Cell line enhanced		A-431: 1.4;CAPAN-2: 1.4;HeLa: 1.8
RP11-566K11.2		ENSG00000198211		16	89919165-89936092	Predicted membrane proteins	Evidence at protein level	CAB011512, HPA043640, HPA046280	Uncertain					Not detected	Tissue enhanced		skin: 1.0	testis: 0.6	Cell line enriched	7	SK-MEL-30: 12.4
RP11-599B13.6		ENSG00000263620		17	8150816-8162975	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		colon: 5.2;spleen: 5.1;stomach: 4.5	adipose tissue: 3.8	Cell line enhanced		HDLM-2: 28.8;HEK93: 11.5;REH: 14.0
RP11-680F20.6		ENSG00000283703		11	125946056-125956319	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level								Tissue enriched	9	skin: 20.9	breast: 2.2	Not detected		
RP11-6L6.2		ENSG00000250673		4	146214515-146230878	Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			skin: 0.4	Cell line enriched	89	HDLM-2: 8.9
RP11-77H9.1		ENSG00000283516		16	8881634-8885351	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level								Tissue enriched	6	testis: 6.9	skin: 1.1	Not detected		
RP11-77K12.1		ENSG00000261717		16	75412684-75464706	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA041316, HPA055071	Uncertain					Not detected	Not detected			testis: 0.8	Cell line enhanced		REH: 4.3;U-698: 13.9
RP11-872D17.8		ENSG00000254979		11	57387365-57424059	Predicted membrane proteins	Evidence at protein level	HPA038515	Supported					Mixed	Tissue enhanced		bone marrow: 7.7;placenta: 10.5	skin: 5.8	Cell line enriched	7	HMC-1: 162.8
RP11-96L14.7		ENSG00000236782		1	26169516-26171821	Predicted membrane proteins	No evidence							Not detected	Not detected			endometrium,ovary,testis: 0.4	Not detected		
RP3-422G23.4		ENSG00000262543		6	138377905-138383075	Predicted membrane proteins	No evidence							Not detected	Not detected			appendix,rectum: 0.8	Not detected		
RP4-539M6.19		ENSG00000249590		22	30409255-30428990	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			duodenum: 3.6	Cell line enhanced		HBEC3-KT: 13.6;HUVEC TERT2: 10.7
RP4-583P15.15		ENSG00000273154		20	63708864-63739103	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		adrenal gland: 1.2;appendix: 1.0	duodenum,prostate: 0.5	Mixed		
RP4-714D9.5		ENSG00000283761		1	99970011-100083321	Predicted membrane proteins	Evidence at transcript level	HPA073681			Approved	Vesicles			Mixed			lung: 1.0	Mixed		
RP5-860F19.8		ENSG00000241690		20	2814968-2818066	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	43	testis: 10.6	epididymis,placenta: 0.2	Cell line enriched	5	HDLM-2: 9.0
RP5-877J2.1		ENSG00000250424		7	30852273-30923812	Predicted membrane proteins	Evidence at protein level	HPA019206, HPA030130	Approved		Approved	Plasma membrane		Not detected	Tissue enhanced		gallbladder: 1.5	fallopian tube: 1.2	Not detected		
RP5-972B16.2		ENSG00000250349		X	37349330-38687674	Predicted membrane proteins	Evidence at protein level	HPA003140	Uncertain					Not detected	Not detected			skeletal muscle: 0.9	Not detected		
RPAP1	DKFZP727M111, FLJ12732, KIAA1403, MGC858	ENSG00000103932	RNA polymerase II associated protein 1	15	41517176-41544269	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041739	Approved		Approved	Nucleoplasm<br>Cytosol	Thyroid cancer:9.32e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 13.3	Expressed in all		
RPAP2	C1orf82, FLJ13150, Rtr1	ENSG00000122484	RNA polymerase II associated protein 2	1	92298965-92402056	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046443	Approved		Supported	Nucleoli<br>Cytosol		Expressed in all	Mixed			thyroid gland: 4.8	Expressed in all		
RPGR	COD1, CORDX1, CRD, RP15, RP3	ENSG00000156313	Retinitis pigmentosa GTPase regulator	X	38269163-38327564	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001593, HPA073455	Approved		Supported	Golgi apparatus		Expressed in all	Expressed in all			fallopian tube: 22.9	Mixed		
RPN1	OST1	ENSG00000163902	Ribophorin I	3	128619970-128681075	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB009748, HPA026828, HPA051520	Enhanced		Enhanced	Endoplasmic reticulum	Liver cancer:4.80e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 422.3	Expressed in all		
RPN2	RIBIIR, RPN-II, RPNII, SWP1	ENSG00000118705	Ribophorin II	20	37178410-37241623	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008297, CAB019277, HPA025922	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:1.44e-10 (unfavourable), Liver cancer:1.38e-4 (unfavourable), Urothelial cancer:2.44e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 364.2	Expressed in all		
RPRM	FLJ90327, REPRIMO	ENSG00000177519	Reprimo, TP53 dependent G2 arrest mediator candidate	2	153477338-153478808	Predicted membrane proteins	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 21.2;endometrium: 21.8	smooth muscle: 17.4	Group enriched	6	HEK93: 22.9;MCF7: 21.9;NTERA-2: 19.8;SCLC-21H: 8.5;SH-SY5Y: 8.7
RPRML	MGC43894	ENSG00000179673	Reprimo like	17	46978156-46979248	Predicted membrane proteins	Evidence at transcript level	HPA062668	Uncertain					Tissue enhanced	Tissue enriched	11	cerebral cortex: 8.6	epididymis: 0.7	Cell line enhanced		AF22: 1.9;Daudi: 8.9;HEK93: 3.5;NTERA-2: 1.9;SCLC-21H: 2.2
RPS15A	S15A	ENSG00000134419	Ribosomal protein S15a	16	18781295-18790383	Predicted intracellular proteins, Predicted membrane proteins, Ribosomal proteins	Evidence at protein level	HPA047103	Supported				Renal cancer:7.29e-7 (unfavourable)	Expressed in all	Expressed in all			breast: 4784.5	Expressed in all		
RPTOR	KIAA1303, KOG1, Mip1, raptor	ENSG00000141564	Regulatory associated protein of MTOR complex 1	17	80544819-80966371	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013514, HPA064306	Approved		Enhanced	Nucleoplasm<br>Lysosomes<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 11.2	Expressed in all		
RRBP1	ES/130, hES	ENSG00000125844	Ribosome binding protein 1	20	17613678-17682295	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009026, HPA011924	Enhanced		Enhanced	Endoplasmic reticulum	Endometrial cancer:1.41e-4 (favourable), Urothelial cancer:9.38e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 218.2	Expressed in all		
RRH	peropsin	ENSG00000180245	Retinal pigment epithelium-derived rhodopsin homolog	4	109827994-109844604	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			breast,cerebral cortex,skin: 0.5	Cell line enhanced		U-266/84: 1.0
RRM2		ENSG00000171848	Ribonucleotide reductase regulatory subunit M2	2	10122328-10131419	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056994	Enhanced		Supported	Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Pancreatic cancer:1.62e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 47.5	Mixed		
RRM2B	p53R2	ENSG00000048392	Ribonucleotide reductase regulatory TP53 inducible subunit M2B	8	102204502-102239118	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB006854, HPA028812	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 75.1	Expressed in all		
RRNAD1	C1orf66, CGI-41, METTL25B	ENSG00000143303	Ribosomal RNA adenine dimethylase domain containing 1	1	156728442-156736960	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA047426	Approved		Approved	Nucleoli<br>Cytosol	Colorectal cancer:5.60e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 49.2	Expressed in all		
RRP12	KIAA0690	ENSG00000052749	Ribosomal RNA processing 12 homolog	10	97356358-97426076	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049945			Supported	Nucleoli	Liver cancer:3.12e-8 (unfavourable), Renal cancer:2.54e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 58.2	Expressed in all		
RTBDN	FLJ36353	ENSG00000132026	Retbindin	19	12825478-12835428	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052511			Approved	Endoplasmic reticulum		Mixed	Group enriched	6	adrenal gland: 4.6;cerebral cortex: 14.6;testis: 3.5	stomach: 1.2	Cell line enhanced		SCLC-21H: 9.8;SH-SY5Y: 5.8;U-266/84: 16.0
RTL1	Mar1, MART1, PEG11	ENSG00000254656	Retrotransposon-like 1	14	100880655-100884847	Predicted membrane proteins	Evidence at protein level	HPA066979			Approved	Cytosol		Tissue enhanced	Group enriched	9	adrenal gland: 2.4;placenta: 4.5	cerebral cortex,testis: 0.3	Cell line enriched	35	SH-SY5Y: 664.4
RTN1	NSP	ENSG00000139970	Reticulon 1	14	59595976-59870966	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002745, HPA040945, HPA044249	Enhanced		Enhanced	Endoplasmic reticulum	Pancreatic cancer:3.69e-4 (favourable)	Tissue enhanced	Tissue enriched	8	cerebral cortex: 411.6	parathyroid gland: 49.6	Cell line enhanced		HEL: 54.3;SCLC-21H: 84.4;SH-SY5Y: 121.8
RTN2	NSP2, NSPL1, SPG12	ENSG00000125744	Reticulon 2	19	45485289-45497061	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA034941, HPA034948	Approved		Approved	Nuclear speckles	Renal cancer:5.58e-6 (unfavourable)	Expressed in all	Tissue enriched	6	skeletal muscle: 175.3	placenta: 27.5	Mixed		
RTN3	ASYIP, HAP, NSPL2, NSPLII, RTN3-A1	ENSG00000133318	Reticulon 3	11	63681446-63759891	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015649, HPA015650	Enhanced		Supported	Endoplasmic reticulum	Liver cancer:1.30e-6 (unfavourable), Renal cancer:9.87e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1030.6	Expressed in all		
RTN4	ASY, KIAA0886, NOGO, NSP-CL	ENSG00000115310	Reticulon 4	2	54972187-55112621	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB005388, HPA023977	Supported		Enhanced	Endoplasmic reticulum	Head and neck cancer:1.00e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 636.8	Expressed in all		
RTN4R	NOGOR	ENSG00000040608	Reticulon 4 receptor	22	20241415-20283246	Predicted membrane proteins	Evidence at protein level	CAB012443			Supported	Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Head and neck cancer:7.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 23.8	spleen: 5.0	Cell line enhanced		NB-4: 24.1;REH: 48.8;SCLC-21H: 36.8
RTP1	MGC35450, Z3CXXC1	ENSG00000175077	Receptor transporter protein 1	3	187197486-187201465	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.3	testis: 0.7	Cell line enriched	24	T-47d: 2.4
RTP2	MGC78665, Z3CXXC2	ENSG00000198471	Receptor transporter protein 2	3	187698259-187702557	Predicted membrane proteins	Evidence at protein level	HPA026875	Uncertain					Not detected	Not detected			testis: 0.9	Cell line enriched	12	SK-BR-3: 1.3
RTP3	LTM1, TMEM7, Z3CXXC3	ENSG00000163825	Receptor transporter protein 3	3	46497491-46500949	Predicted membrane proteins	Evidence at protein level	HPA075932			Uncertain	Mitochondria	Liver cancer:3.11e-6 (favourable)	Group enriched	Tissue enriched	24	liver: 33.8	testis: 1.4	Cell line enriched	11	SiHa: 10.7
RTP4	IFRG28, Z3CXXC4	ENSG00000136514	Receptor transporter protein 4	3	187368332-187372076	Predicted membrane proteins	Evidence at protein level	HPA064887, HPA071189	Uncertain		Supported	Nucleus	Urothelial cancer:1.45e-4 (favourable), Thyroid cancer:4.35e-4 (favourable), Pancreatic cancer:6.83e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 16.7	Cell line enhanced		CAPAN-2: 9.2;HDLM-2: 11.0;SK-MEL-30: 14.0
RTP5	C2orf85, CXXC11, FLJ33590, Z3CXXC5	ENSG00000188011	Receptor transporter protein 5 (putative)	2	241869600-241873823	Predicted membrane proteins	Evidence at protein level	HPA050902	Approved					Tissue enriched	Tissue enriched	9	cerebral cortex: 5.3	lymph node: 0.5	Group enriched	21	MOLT-4: 1.1;SCLC-21H: 3.0
RUFY2	FLJ10063, KIAA1537, RABIP4R, ZFYVE13	ENSG00000204130	RUN and FYVE domain containing 2	10	68341107-68407294	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039792	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 36.8	Expressed in all		
RXFP1	LGR7, RXFPR1	ENSG00000171509	Relaxin/insulin like family peptide receptor 1	4	158315311-158653372	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA027067	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 21.6;endometrium: 10.1	adrenal gland: 5.7	Group enriched	6	EFO-21: 26.8;HEL: 8.8;RPTEC TERT1: 10.0
RXFP2	GPR106, GREAT, INSL3R, LGR8, RXFPR2	ENSG00000133105	Relaxin/insulin like family peptide receptor 2	13	31739542-31803388	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			endometrium: 0.8	Not detected		
RXFP3	GPCR135, RLN3R1, RXFPR3, SALPR	ENSG00000182631	Relaxin/insulin like family peptide receptor 3	5	33936386-33938237	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA027833	Uncertain					Not detected	Not detected			adrenal gland: 0.3	Not detected		
RXFP4	GPCR142, GPR100, RLN3R2, RXFPR4	ENSG00000173080	Relaxin/insulin like family peptide receptor 4	1	155941710-155942949	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		colon: 2.0;duodenum: 1.4;rectum: 2.2	small intestine: 1.1	Not detected		
RYK	D3S3195, JTK5, JTK5A, RYK1	ENSG00000163785	Receptor-like tyrosine kinase	3	134065303-134250744	Predicted membrane proteins	Evidence at protein level	CAB034117, HPA045503, HPA075430	Uncertain		Approved	Golgi apparatus<br>Cytosol	Liver cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 101.1	Expressed in all		
RYR1	CCO, MHS, MHS1, PPP1R137, RYR	ENSG00000196218	Ryanodine receptor 1	19	38433699-38587564	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA056416	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Cytosol		Mixed	Tissue enriched	31	skeletal muscle: 572.4	esophagus: 18.6	Cell line enhanced		HaCaT: 16.8;RH-30: 14.8;SiHa: 32.7;U-2 OS: 13.2
RYR2	ARVC2, ARVD2, VTSIP	ENSG00000198626	Ryanodine receptor 2	1	237042205-237833988	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020028	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	8	heart muscle: 65.9	cerebral cortex: 7.9	Cell line enhanced		HDLM-2: 4.8;HEK93: 6.3;K-562: 2.0;NTERA-2: 2.5;U-937: 2.5
RYR3		ENSG00000198838	Ryanodine receptor 3	15	33310945-33866121	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA062004			Approved	Vesicles		Tissue enhanced	Tissue enhanced		parathyroid gland: 29.1	cerebral cortex: 7.0	Cell line enhanced		A549: 3.9;RH-30: 6.3;RPTEC TERT1: 2.3
S100A10	42C, ANX2LG, CAL1L, CLP11, P11	ENSG00000197747	S100 calcium binding protein A10	1	151982915-151994390	Predicted membrane proteins, Transporters	Evidence at protein level	HPA003340, CAB025484	Enhanced		Approved	Mitochondria	Renal cancer:3.80e-8 (unfavourable), Lung cancer:2.66e-5 (unfavourable), Liver cancer:1.00e-4 (unfavourable), Head and neck cancer:3.33e-4 (unfavourable), Urothelial cancer:3.84e-4 (unfavourable), Pancreatic cancer:3.88e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 974.3	Mixed		
S1PR1	CD363, D1S3362, edg-1, EDG1	ENSG00000170989	Sphingosine-1-phosphate receptor 1	1	101236888-101241518	Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB010104, HPA075568	Supported		Supported	Vesicles	Urothelial cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 86.8	Cell line enhanced		BJ: 53.9;HUVEC TERT2: 149.1;TIME: 81.9;U-251 MG: 103.4
S1PR2	AGR16, DFNB68, EDG5, Gpcr13, H218	ENSG00000267534	Sphingosine-1-phosphate receptor 2	19	10221435-10231272	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA014255, HPA014307	Approved		Uncertain	Nuclear speckles<br>Golgi apparatus	Renal cancer:4.36e-10 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 27.0	lymph node: 13.3	Cell line enhanced		Daudi: 38.8;U-698: 40.3;WM-115: 38.8
S1PR3	EDG-3, EDG3	ENSG00000213694	Sphingosine-1-phosphate receptor 3	9	88991447-89005010	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.91e-6 (unfavourable), Colorectal cancer:1.30e-4 (unfavourable), Breast cancer:5.91e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 52.4	Cell line enhanced		AF22: 117.8;ASC diff: 111.7;ASC TERT1: 114.8
S1PR4	EDG6	ENSG00000125910	Sphingosine-1-phosphate receptor 4	19	3172346-3180332	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA060601, HPA067232			Uncertain	Mitochondria	Head and neck cancer:1.45e-6 (favourable), Cervical cancer:1.33e-4 (favourable), Endometrial cancer:2.22e-4 (favourable), Renal cancer:2.87e-4 (unfavourable), Breast cancer:3.13e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 18.1;spleen: 26.4	appendix: 14.0	Cell line enhanced		HDLM-2: 22.2;HL-60: 25.5;NB-4: 19.9;REH: 81.1;U-937: 23.6
S1PR5	Edg-8, EDG8	ENSG00000180739	Sphingosine-1-phosphate receptor 5	19	10512742-10517931	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029683	Enhanced				Renal cancer:6.71e-7 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 14.9;skin: 22.1	spleen: 12.0	Cell line enhanced		HaCaT: 25.0;RT4: 14.8;T-47d: 10.9;U-2 OS: 10.7
SAA2-SAA4		ENSG00000255071	SAA2-SAA4 readthrough	11	18231423-18248635	Predicted membrane proteins	Evidence at transcript level	HPA060139	Uncertain				Renal cancer:2.92e-8 (unfavourable), Breast cancer:4.56e-4 (favourable), Glioma:9.87e-4 (unfavourable)	Tissue enriched	Tissue enhanced		adipose tissue: 27.9;cervix, uterine: 22.6;liver: 15.0	breast: 5.4	Cell line enhanced		A-431: 2.3;EFO-21: 1.4
SACM1L	KIAA0851, SAC1	ENSG00000211456	SAC1 suppressor of actin mutations 1-like (yeast)	3	45689056-45745424	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039573, HPA069869	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:5.47e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 67.5	Expressed in all		
SAMD5	dJ875H10.1	ENSG00000203727	Sterile alpha motif domain containing 5	6	147508927-147737547	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067811	Uncertain		Supported	Vesicles	Liver cancer:2.23e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 22.5	placenta: 18.1	Cell line enhanced		Hep G2: 44.5;K-562: 40.0;RH-30: 28.7;WM-115: 20.8
SAMD8	FLJ25082, SMSr	ENSG00000156671	Sterile alpha motif domain containing 8	10	75099586-75182123	Predicted membrane proteins	Evidence at protein level	HPA044402			Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			cerebral cortex: 43.1	Expressed in all		
SARAF	MGC8721, TMEM66	ENSG00000133872	Store-operated calcium entry associated regulatory factor	8	30063012-30083208	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040400			Supported	Endoplasmic reticulum<br>Rods & Rings	Lung cancer:5.28e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 287.0	Expressed in all		
SAYSD1	C6orf64, FLJ11101	ENSG00000112167	SAYSVFN motif domain containing 1	6	39104064-39115189	Predicted membrane proteins	Evidence at protein level	HPA007959		Approved	Enhanced	Vesicles		Expressed in all	Tissue enriched	6	testis: 85.8	prostate: 14.6	Mixed		
SBK1	Sbk	ENSG00000188322	SH3 domain binding kinase 1	16	28292519-28323849	Enzymes, Predicted membrane proteins	Evidence at transcript level						Cervical cancer:6.88e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 10.9;skeletal muscle: 12.0	parathyroid gland: 4.1	Cell line enhanced		AF22: 27.9;NTERA-2: 29.2;REH: 29.2;SCLC-21H: 52.5;SH-SY5Y: 44.5
SBK2	SGK069	ENSG00000187550	SH3 domain binding kinase family member 2	19	55529733-55537089	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA030631	Uncertain					Tissue enhanced	Tissue enriched	30	heart muscle: 24.2	testis: 0.8	Group enriched	5	A549: 2.5;Hep G2: 1.4;MCF7: 2.2;NTERA-2: 5.5;RH-30: 4.9;U-2 OS: 3.1
SBK3	SgK110	ENSG00000231274	SH3 domain binding kinase family member 3	19	55540656-55545543	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA078322			Approved	Mitochondria		Not detected	Tissue enriched	6	heart muscle: 17.8	adipose tissue: 2.7	Cell line enhanced		A549: 4.5;CACO-2: 1.4;CAPAN-2: 2.6;RH-30: 2.1
SC5D	SC5DL	ENSG00000109929	Sterol-C5-desaturase	11	121292453-121308694	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA066283, HPA070248	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:1.07e-7 (favourable), Head and neck cancer:3.30e-4 (unfavourable), Melanoma:3.98e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 193.5	Expressed in all		
SCAF11	CASP11, SFRS2IP, SIP1, SRRP129, SRSF2IP	ENSG00000139218	SR-related CTD associated factor 11	12	45919131-45992120	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038862, HPA045456, HPA046345	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 84.9	Expressed in all		
SCAMP1	SCAMP37	ENSG00000085365	Secretory carrier membrane protein 1	5	78360583-78479071	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044753, CAB079009		Approved	Approved	Nucleoplasm<br>Vesicles<br>Cell Junctions	Renal cancer:1.92e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 69.2	Expressed in all		
SCAMP2		ENSG00000140497	Secretory carrier membrane protein 2	15	74843730-74873365	Predicted membrane proteins	Evidence at protein level	HPA014699, HPA019194	Approved		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.12e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 128.7	Expressed in all		
SCAMP3	C1orf3	ENSG00000116521	Secretory carrier membrane protein 3	1	155255979-155262430	Predicted membrane proteins	Evidence at protein level	HPA071167			Supported	Vesicles	Liver cancer:2.92e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 46.9	Expressed in all		
SCAMP4	FLJ33847	ENSG00000227500	Secretory carrier membrane protein 4	19	1905214-1926013	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043284	Approved		Approved	Golgi apparatus<br>Vesicles<br>Lipid droplets<br>Plasma membrane	Endometrial cancer:4.40e-6 (favourable), Liver cancer:1.92e-5 (unfavourable), Renal cancer:3.56e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 59.3	Expressed in all		
SCAMP5	MGC24969	ENSG00000198794	Secretory carrier membrane protein 5	15	74957219-75021496	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046645	Enhanced				Renal cancer:1.34e-6 (favourable), Pancreatic cancer:5.67e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 275.5	parathyroid gland: 81.7	Cell line enhanced		SCLC-21H: 103.1;SH-SY5Y: 51.9
SCAP	KIAA0199	ENSG00000114650	SREBF chaperone	3	47413694-47477126	Predicted membrane proteins	Evidence at protein level	HPA004713	Approved				Renal cancer:4.33e-5 (favourable), Pancreatic cancer:7.14e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 67.0	Expressed in all		
SCARA3	APC7, CSR, CSR1, MSLR1, MSRL1	ENSG00000168077	Scavenger receptor class A member 3	8	27633868-27676776	Predicted membrane proteins	Evidence at protein level	HPA029861, HPA047386	Uncertain		Supported	Endoplasmic reticulum		Expressed in all	Tissue enhanced		fallopian tube: 151.9	smooth muscle: 108.4	Cell line enhanced		ASC TERT1: 137.0;HeLa: 151.4;HUVEC TERT2: 130.0;U-2 OS: 147.0
SCARA5	FLJ23907, MGC45780, NET33	ENSG00000168079	Scavenger receptor class A member 5	8	27869882-27992727	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024661	Approved					Mixed	Mixed			adipose tissue: 66.0	Cell line enriched	19	ASC diff: 157.1
SCARB1	CD36L1, CLA-1, CLA1, SR-BI, SRB1	ENSG00000073060	Scavenger receptor class B member 1	12	124776856-124882668	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA066285, CAB070124, HPA072449	Enhanced		Approved	Vesicles	Renal cancer:1.49e-5 (unfavourable), Liver cancer:1.83e-5 (unfavourable), Lung cancer:4.02e-4 (unfavourable)	Expressed in all	Group enriched	7	adrenal gland: 758.4;placenta: 287.5	liver: 72.3	Mixed		
SCARB2	CD36L2, HLGP85, LIMP-2, LIMPII, SR-BII	ENSG00000138760	Scavenger receptor class B member 2	4	76158733-76234536	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB015415, HPA018014	Supported		Approved	Cytosol	Breast cancer:2.82e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 112.1	Mixed		
SCARF2	HUMZD58C02, SREC-II, SREC2	ENSG00000244486	Scavenger receptor class F member 2	22	20424815-20437826	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA035079	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:2.78e-5 (unfavourable), Urothelial cancer:4.28e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 6.7	Cell line enhanced		SH-SY5Y: 30.9;U-138 MG: 39.3;U-2 OS: 43.6
SCART1		ENSG00000214279	Scavenger receptor protein family member	10	133453928-133523558	Predicted membrane proteins	Evidence at protein level	HPA043101	Supported					Not detected	Not detected			endometrium: 0.2	Cell line enhanced		HMC-1: 3.4;NB-4: 2.3;U-266/84: 2.8
SCCPDH	CGI-49, NET11	ENSG00000143653	Saccharopine dehydrogenase (putative)	1	246724047-246768137	Predicted membrane proteins	Evidence at protein level	HPA050775	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			testis: 241.5	Mixed		
SCD	FADS5, SCDOS	ENSG00000099194	Stearoyl-CoA desaturase	10	100347124-100364834	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA012107, HPA063921	Uncertain		Enhanced	Endoplasmic reticulum	Renal cancer:7.56e-5 (unfavourable), Urothelial cancer:7.79e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 1255.0	Expressed in all		
SCD5	ACOD4, FADS4, FLJ21032, HSCD5, SCD4	ENSG00000145284	Stearoyl-CoA desaturase 5	4	82629539-82798857	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA042380	Uncertain				Renal cancer:2.32e-5 (favourable)	Group enriched	Tissue enhanced		adrenal gland: 200.6;cerebral cortex: 500.3	epididymis: 117.0	Mixed		
SCIMP	C17orf87, DTFT5783, FLJ32580, MGC163426, MGC163428, UNQ5783	ENSG00000161929	SLP adaptor and CSK interacting membrane protein	17	5208961-5234860	Predicted membrane proteins	Evidence at protein level	HPA006117	Enhanced					Mixed	Tissue enhanced		spleen: 68.5	lymph node: 45.9	Cell line enhanced		U-698: 7.7
SCN10A	hPN3, Nav1.8, PN3, SNS	ENSG00000185313	Sodium voltage-gated channel alpha subunit 10	3	38696802-38794010	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Not detected	Not detected			testis: 0.3	Not detected		
SCN11A	NaN, Nav1.9, SCN12A, SNS-2	ENSG00000168356	Sodium voltage-gated channel alpha subunit 11	3	38845769-38950561	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA036746, HPA036747	Uncertain					Not detected	Tissue enhanced		placenta: 3.7;spleen: 5.3	testis: 2.0	Cell line enhanced		HDLM-2: 1.1
SCN1A	FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI	ENSG00000144285	Sodium voltage-gated channel alpha subunit 1	2	165989160-166149214	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA078664			Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane		Tissue enriched	Group enriched	41	cerebral cortex: 10.3;fallopian tube: 2.9;lung: 2.2	adrenal gland,placenta,testis: 0.1	Cell line enhanced		AF22: 1.1;ASC TERT1: 4.4;Hep G2: 1.1
SCN1B		ENSG00000105711	Sodium voltage-gated channel beta subunit 1	19	35030466-35040449	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.38e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 145.1	cerebral cortex: 52.4	Cell line enhanced		A549: 15.7;TIME: 21.3
SCN2A	HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2	ENSG00000136531	Sodium voltage-gated channel alpha subunit 2	2	165194993-165392310	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB022567	Enhanced					Tissue enhanced	Tissue enriched	26	cerebral cortex: 56.6	kidney: 2.1	Cell line enhanced		U-138 MG: 3.6;U-266/84: 5.7;U-87 MG: 2.2
SCN2B		ENSG00000149575	Sodium voltage-gated channel beta subunit 2	11	118161951-118176673	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Group enriched	9	cerebral cortex: 34.7;heart muscle: 7.1	smooth muscle: 2.4	Cell line enhanced		U-2197: 1.6
SCN3A	Nav1.3	ENSG00000153253	Sodium voltage-gated channel alpha subunit 3	2	165087522-165204067	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA035396	Approved					Tissue enriched	Tissue enriched	7	cerebral cortex: 13.6	adrenal gland: 1.9	Cell line enhanced		Karpas-707: 7.8;MOLT-4: 26.0;RPTEC TERT1: 11.6;SH-SY5Y: 7.3
SCN3B	HSA243396	ENSG00000166257	Sodium voltage-gated channel beta subunit 3	11	123629187-123655244	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041707			Approved	Intermediate filaments<br>Cytosol		Tissue enhanced	Tissue enriched	11	cerebral cortex: 132.1	adrenal gland: 11.5	Cell line enhanced		hTCEpi: 4.6;RH-30: 2.8;SCLC-21H: 7.5;SH-SY5Y: 5.0
SCN4A	HYKPP, HYPP, Nav1.4, SkM1	ENSG00000007314	Sodium voltage-gated channel alpha subunit 4	17	63938554-63972918	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA053992			Approved	Nucleoplasm<br>Microtubule organizing center		Tissue enhanced	Group enriched	9	adipose tissue: 12.4;skeletal muscle: 47.2	thyroid gland: 3.3	Group enriched	13	REH: 13.6;RH-30: 43.5
SCN4B	LQT10	ENSG00000177098	Sodium voltage-gated channel beta subunit 4	11	118133377-118152888	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017293	Approved					Mixed	Tissue enhanced		adipose tissue: 25.0	thyroid gland: 17.0	Cell line enhanced		AN3-CA: 1.2;NTERA-2: 1.4;U-2 OS: 1.4
SCN5A	CDCD2, CMD1E, CMPD2, HB1, HB2, HBBD, HH1, ICCD, IVF, LQT3, Nav1.5, PFHB1, SSS1	ENSG00000183873	Sodium voltage-gated channel alpha subunit 5	3	38548057-38649673	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enriched	18	heart muscle: 27.8	cervix, uterine: 1.5	Cell line enhanced		LHCN-M2: 23.1;RH-30: 22.0
SCN7A	NaG, Nav2.1, Nav2.2, SCN6A	ENSG00000136546	Sodium voltage-gated channel alpha subunit 7	2	166403573-166494247	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA004879	Uncertain					Mixed	Tissue enhanced		ovary: 63.2	lung: 41.1	Not detected		
SCN8A	CerIII, MED, NaCh6, Nav1.6, PN4	ENSG00000196876	Sodium voltage-gated channel alpha subunit 8	12	51590266-51812864	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enriched	7	cerebral cortex: 22.1	testis: 3.1	Mixed		
SCN9A	ETHA, Nav1.7, NE-NA, NENA, PN1	ENSG00000169432	Sodium voltage-gated channel alpha subunit 9	2	166195185-166375993	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB013679, HPA061843	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Renal cancer:2.30e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 9.1	placenta: 5.9	Cell line enhanced		BJ: 20.5;BJ hTERT+: 13.6;HHSteC: 13.7
SCNN1A	ENaCalpha, SCNN1	ENSG00000111319	Sodium channel epithelial 1 alpha subunit	12	6346843-6377730	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012743	Enhanced				Renal cancer:9.21e-8 (favourable), Pancreatic cancer:2.30e-4 (unfavourable), Ovarian cancer:8.86e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 95.1	Cell line enhanced		CAPAN-2: 264.6;HBEC3-KT: 145.5;RPTEC TERT1: 78.8;RT4: 91.1;SK-BR-3: 72.7
SCNN1B	ENaCbeta	ENSG00000168447	Sodium channel epithelial 1 beta subunit	16	23278231-23381299	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015612	Uncertain				Renal cancer:2.09e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 72.0	esophagus: 44.8	Cell line enhanced		hTCEpi: 24.0;RT4: 14.6;U-266/70: 41.7;U-266/84: 14.3
SCNN1D	dNaCh, ENaCdelta	ENSG00000162572	Sodium channel epithelial 1 delta subunit	1	1280436-1292029	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026884	Enhanced		Supported	Plasma membrane<br>Actin filaments	Renal cancer:6.67e-5 (unfavourable), Pancreatic cancer:1.32e-4 (favourable), Head and neck cancer:1.60e-4 (favourable)	Mixed	Tissue enhanced		testis: 13.8	cerebral cortex: 7.3	Mixed		
SCNN1G	ENaCgamma, SCNEG	ENSG00000166828	Sodium channel epithelial 1 gamma subunit	16	23182715-23216883	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071194			Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:3.20e-7 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 24.6;kidney: 46.7	thyroid gland: 9.5	Group enriched	5	hTCEpi: 33.4;RT4: 17.1
SCO1	SCOD1	ENSG00000133028	SCO1, cytochrome c oxidase assembly protein	17	10672474-10698375	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA021565, HPA021579	Enhanced				Renal cancer:9.69e-7 (favourable), Thyroid cancer:7.44e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 22.5	Expressed in all		
SCO2	MYP6, SCO1L	ENSG00000130489	SCO2, cytochrome c oxidase assembly protein	22	50523568-50525606	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA046943, HPA056254	Approved		Approved	Mitochondria	Renal cancer:1.67e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 47.1	Expressed in all		
SCO2		ENSG00000284194	SCO2, cytochrome c oxidase assembly protein	22	50523568-50526439	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046943, HPA056254	Uncertain		Approved	Mitochondria			Tissue enhanced		bone marrow: 5.3	spleen: 2.7	Mixed		
SCTR		ENSG00000080293	Secretin receptor	2	119439843-119525301	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA007269	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 26.7;lung: 12.7;pancreas: 14.4	stomach: 4.1	Cell line enhanced		Karpas-707: 2.2
SDC1	CD138, SDC, SYND1, syndecan	ENSG00000115884	Syndecan 1	2	20200797-20225433	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB002424, HPA006185	Approved		Supported	Focal adhesion sites	Breast cancer:2.22e-4 (unfavourable), Glioma:8.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 250.7;skin: 287.9	liver: 144.7	Cell line enhanced		U-266/84: 739.8
SDC2	CD362, fibroglycan, HSPG, HSPG1, SYND2	ENSG00000169439	Syndecan 2	8	96493351-96611780	CD markers, Predicted membrane proteins	Evidence at protein level	CAB025123, HPA044416	Uncertain		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 712.7	Cell line enhanced		AF22: 646.8;U-138 MG: 309.2
SDC3	N-syndecan, SYND3	ENSG00000162512	Syndecan 3	1	30869467-30908761	Predicted membrane proteins	Evidence at protein level	HPA017087, CAB025786, HPA048085	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.71e-4 (unfavourable), Melanoma:2.36e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 136.4	Cell line enhanced		SK-MEL-30: 167.1;WM-115: 290.3
SDC4	amphiglycan, ryudocan, SYND4	ENSG00000124145	Syndecan 4	20	45325288-45348424	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA005716, CAB013240	Supported		Approved	Golgi apparatus<br>Plasma membrane	Renal cancer:2.44e-7 (favourable), Thyroid cancer:2.67e-4 (favourable), Pancreatic cancer:4.20e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 250.2	Mixed		
SDHC	CYB560, cybL, PGL3	ENSG00000143252	Succinate dehydrogenase complex subunit C	1	161314257-161375340	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.20e-4 (favourable)	Expressed in all	Expressed in all			kidney: 188.8	Expressed in all		
SDHD	cybS, PGL, PGL1	ENSG00000204370	Succinate dehydrogenase complex subunit D	11	112086773-112120013	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045727	Approved				Renal cancer:1.99e-10 (favourable)	Expressed in all	Expressed in all			kidney: 305.5	Expressed in all		
SDHD	cybS, PGL, PGL1	ENSG00000255292	Succinate dehydrogenase complex subunit D	11	112086824-112193805	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA045727	Uncertain					Not detected	Tissue enriched	13	colon: 7.8	parathyroid gland: 0.5	Cell line enhanced		A549: 23.8;CACO-2: 57.0;Hep G2: 19.6;hTEC/SVTERT24-B: 20.1;RT4: 30.5
SDK1	FLJ31425	ENSG00000146555	Sidekick cell adhesion molecule 1	7	3301448-4269000	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011392	Approved		Approved	Cytosol	Pancreatic cancer:4.08e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 15.0	spleen: 6.0	Cell line enhanced		BEWO: 10.1;RT4: 8.9;U-2 OS: 13.6
SDK2	FLJ10832, KIAA1514	ENSG00000069188	Sidekick cell adhesion molecule 2	17	73334384-73644089	Predicted membrane proteins	Evidence at protein level	HPA014725			Approved	Nucleoplasm		Mixed	Tissue enhanced		cervix, uterine: 9.0;testis: 18.6	fallopian tube: 4.0	Cell line enhanced		AF22: 13.8;BEWO: 11.0;U-2 OS: 5.0
SDR16C5	EPHD-2, RDH-E2, RDHE2	ENSG00000170786	Short chain dehydrogenase/reductase family 16C member 5	8	56300010-56320776	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA025224	Enhanced				Head and neck cancer:7.88e-4 (favourable)	Mixed	Group enriched	6	breast: 15.2;esophagus: 36.3;lung: 40.3;skin: 72.9;small intestine: 21.7;stomach: 21.0;tonsil: 25.3	cervix, uterine: 5.6	Cell line enhanced		CAPAN-2: 22.6;HaCaT: 11.3;hTCEpi: 15.1;T-47d: 9.2
SDR42E1	HSPC105	ENSG00000184860	Short chain dehydrogenase/reductase family 42E, member 1	16	81988855-82011488	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA014388	Uncertain					Mixed	Mixed			skin: 10.7	Cell line enhanced		hTCEpi: 8.4;RT4: 15.4;SCLC-21H: 9.5
SDR42E2		ENSG00000183921	Short chain dehydrogenase/reductase family 42E, member 2	16	22165583-22191754	Predicted membrane proteins	No evidence	HPA061278	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
SDSL	cSDH, SDS-RS1	ENSG00000139410	Serine dehydratase like	12	113422237-113438276	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA005740	Approved		Approved	Cytosol	Renal cancer:3.09e-5 (favourable), Pancreatic cancer:8.58e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 35.2	Cell line enhanced		MCF7: 64.8
SEC11A	SEC11L1, sid2895, SPC18, SPCS4A	ENSG00000140612	SEC11 homolog A, signal peptidase complex subunit	15	84669538-84716716	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047533			Approved	Nuclear membrane<br>Golgi apparatus	Endometrial cancer:1.94e-5 (favourable), Head and neck cancer:5.99e-5 (unfavourable), Thyroid cancer:2.95e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 211.1	Expressed in all		
SEC11C	SEC11L3, SPC21, SPCS4C	ENSG00000166562	SEC11 homolog C, signal peptidase complex subunit	18	59139477-59158836	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA026816, HPA047533	Approved		Approved	Nuclear membrane<br>Golgi apparatus		Expressed in all	Expressed in all			prostate: 271.8	Expressed in all		
SEC22A	SEC22L2	ENSG00000121542	SEC22 homolog A, vesicle trafficking protein	3	123201927-123274130	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 48.7	Expressed in all		
SEC22B	ERS-24, sec22b, SEC22L1	ENSG00000265808	SEC22 homolog B, vesicle trafficking protein (gene/pseudogene)	1	120150898-120176515	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB079017		Approved			Renal cancer:3.34e-4 (unfavourable), Ovarian cancer:4.58e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 43.3	Expressed in all		
SEC22C	MGC13261, MGC5373, SEC22L3	ENSG00000093183	SEC22 homolog C, vesicle trafficking protein	3	42547969-42601080	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055594			Approved	Golgi apparatus	Renal cancer:1.35e-7 (favourable), Liver cancer:3.04e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 63.7	Expressed in all		
SEC61A1		ENSG00000058262	Sec61 translocon alpha 1 subunit	3	128051641-128071683	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022076			Supported	Endoplasmic reticulum	Renal cancer:6.84e-9 (unfavourable), Liver cancer:1.07e-6 (unfavourable), Endometrial cancer:7.82e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 218.2	Expressed in all		
SEC61A2	FLJ10578	ENSG00000065665	Sec61 translocon alpha 2 subunit	10	12129637-12169961	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:1.08e-5 (favourable), Urothelial cancer:8.75e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 51.3	testis: 32.5	Expressed in all		
SEC61B		ENSG00000106803	Sec61 translocon beta subunit	9	99222064-99230615	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049407	Approved		Enhanced	Endoplasmic reticulum	Endometrial cancer:1.26e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 339.1	Expressed in all		
SEC61G	SSS1	ENSG00000132432	Sec61 translocon gamma subunit	7	54752250-54759974	Predicted membrane proteins, Transporters	Evidence at protein level	HPA053196	Uncertain				Renal cancer:6.60e-8 (unfavourable), Head and neck cancer:4.64e-7 (unfavourable), Liver cancer:3.85e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 408.8	Expressed in all		
SEC62	Dtrp1, HTP1, TLOC1	ENSG00000008952	SEC62 homolog, preprotein translocation factor	3	169966635-169998373	Predicted membrane proteins	Evidence at protein level	HPA014059, HPA061450	Approved		Approved	Endoplasmic reticulum<br>Intermediate filaments		Expressed in all	Expressed in all			thyroid gland: 203.0	Expressed in all		
SEC63	DNAJC23, ERdj2, PRO2507, SEC63L	ENSG00000025796	SEC63 homolog, protein translocation regulator	6	107867756-107958189	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA053295, HPA060535	Enhanced		Supported	Endoplasmic reticulum	Breast cancer:3.32e-4 (unfavourable), Cervical cancer:4.01e-4 (unfavourable), Renal cancer:6.16e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 87.4	Expressed in all		
SECTM1	K12	ENSG00000141574	Secreted and transmembrane 1	17	82321024-82334074	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051214	Approved					Expressed in all	Tissue enhanced		small intestine: 96.6	duodenum: 64.4	Cell line enhanced		SiHa: 125.5;U-2197: 82.3
SEL1L	IBD2, SEL1L1	ENSG00000071537	SEL1L ERAD E3 ligase adaptor subunit	14	81471549-81533861	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA024267	Approved					Expressed in all	Expressed in all			thyroid gland: 90.5	Expressed in all		
SEL1L2	C20orf50, DKFZp434C1826	ENSG00000101251	SEL1L2 ERAD E3 ligase adaptor subunit	20	13849247-13996443	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA059121	Approved					Not detected	Tissue enriched	63	testis: 12.6	endometrium: 0.2	Not detected		
SEL1L3	KIAA0746	ENSG00000091490	SEL1L family member 3	4	25747427-25863760	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040045, HPA058792	Approved		Enhanced	Nucleus	Urothelial cancer:4.33e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 146.6	Cell line enhanced		Daudi: 205.7
SELE	CD62E, ELAM, ELAM1, ESEL	ENSG00000007908	Selectin E	1	169722641-169764705	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002143	Enhanced					Mixed	Tissue enhanced		parathyroid gland: 45.2;prostate: 46.4	urinary bladder: 27.8	Cell line enriched	6	HUVEC TERT2: 1.0
SELENOI	EPT1, KIAA1724, SELI, SEPI	ENSG00000138018	Selenoprotein I	2	26308547-26395891	Enzymes, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 33.7	Expressed in all		
SELENOK	SELK	ENSG00000113811	Selenoprotein K	3	53884410-53891988	Predicted membrane proteins	Evidence at protein level	HPA008196	Uncertain		Approved	Nucleoplasm<br>Cytosol	Lung cancer:3.76e-4 (favourable), Endometrial cancer:7.18e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 75.4	Expressed in all		
SELENOP	SELP, SeP, SEPP, SEPP1	ENSG00000250722	Selenoprotein P	5	42799880-42887392	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036287	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:6.97e-6 (favourable)	Expressed in all	Expressed in all			liver: 2947.1	Cell line enhanced		Hep G2: 350.2;HSkMC: 307.3;T-47d: 109.6
SELENOS	AD-015, MGC2553, SBBI8, SELS, SEPS1, VIMP	ENSG00000131871	Selenoprotein S	15	101270817-101277500	Predicted membrane proteins	Evidence at protein level	HPA010025	Approved		Enhanced	Endoplasmic reticulum	Endometrial cancer:1.33e-4 (favourable), Ovarian cancer:5.19e-4 (favourable)	Expressed in all	Expressed in all			testis: 141.8	Expressed in all		
SELENOT	SELT	ENSG00000198843	Selenoprotein T	3	150602875-150630445	Predicted membrane proteins	Evidence at protein level	HPA039780	Approved					Expressed in all	Expressed in all			thyroid gland: 109.3	Expressed in all		
SELL	CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR	ENSG00000188404	Selectin L	1	169690667-169711698	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002144, HPA051972	Enhanced		Approved	Cytosol	Renal cancer:4.96e-5 (unfavourable), Cervical cancer:2.25e-4 (favourable), Ovarian cancer:3.14e-4 (favourable), Breast cancer:3.76e-4 (favourable), Head and neck cancer:6.43e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 254.9;spleen: 219.3;tonsil: 179.1	appendix: 152.7	Cell line enhanced		EFO-21: 9.7;MOLT-4: 16.7;U-266/70: 28.0;U-698: 12.2
SELP	CD62, CD62P, GMP140, GRMP, PADGEM, PSEL	ENSG00000174175	Selectin P	1	169588849-169630193	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002145, HPA002655, HPA005990	Enhanced				Head and neck cancer:3.12e-4 (favourable)	Mixed	Mixed			smooth muscle: 20.6	Group enriched	46	EFO-21: 34.2;HEL: 30.9
SELPLG	CD162, PSGL-1	ENSG00000110876	Selectin P ligand	12	108622277-108633959	Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002431	Enhanced				Cervical cancer:1.46e-4 (favourable), Thyroid cancer:2.74e-4 (favourable), Melanoma:2.92e-4 (favourable), Renal cancer:5.86e-4 (unfavourable), Head and neck cancer:6.94e-4 (favourable)	Expressed in all	Mixed			spleen: 85.3	Cell line enhanced		HDLM-2: 137.1;HMC-1: 120.1;Karpas-707: 155.1;RPMI-8226: 215.5;U-266/70: 266.2;U-266/84: 163.2
SEMA4A	CORD10, FLJ12287, SEMAB, SemB	ENSG00000196189	Semaphorin 4A	1	156147366-156177752	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053726, HPA066006, HPA069136	Supported		Enhanced	Nucleus	Head and neck cancer:1.09e-4 (favourable), Renal cancer:8.20e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 62.3	Cell line enhanced		Karpas-707: 108.3;U-698: 46.5
SEMA4B	KIAA1745, MGC131831, SEMAC, SemC	ENSG00000185033	Semaphorin 4B	15	90160604-90229679	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013372	Approved				Renal cancer:3.33e-8 (unfavourable), Lung cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 49.3	Expressed in all		
SEMA4C	Semacl1, Semaf, SEMAI	ENSG00000168758	Semaphorin 4C	2	96859716-96870757	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011090	Approved				Renal cancer:9.50e-7 (unfavourable), Colorectal cancer:3.53e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 62.9	Cell line enriched	6	BEWO: 298.1
SEMA4D	C9orf164, CD100, coll-4, FLJ39737, SEMAJ	ENSG00000187764	Semaphorin 4D	9	89360787-89498130	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015662, HPA023277	Approved		Supported	Endoplasmic reticulum<br>Vesicles	Urothelial cancer:4.06e-5 (favourable), Cervical cancer:4.17e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 72.4	Cell line enhanced		HDLM-2: 124.4;HMC-1: 86.7;MOLT-4: 98.7
SEMA4F	SEMAM, SEMAW	ENSG00000135622	Ssemaphorin 4F	2	74654228-74683853	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064095, HPA065969	Approved		Approved	Nucleus<br>Plasma membrane<br>Centrosome	Renal cancer:9.74e-6 (unfavourable), Endometrial cancer:5.94e-5 (unfavourable), Glioma:3.18e-4 (unfavourable), Thyroid cancer:6.94e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 14.1	Mixed		
SEMA4G	FLJ20590, KIAA1619	ENSG00000095539	Semaphorin 4G	10	100969518-100985871	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038362, HPA077752	Uncertain		Uncertain	Vesicles<br>Lipid droplets		Mixed	Tissue enhanced		rectum: 92.7	duodenum: 53.8	Cell line enhanced		A549: 28.9;CACO-2: 25.3;Hep G2: 76.9
SEMA5A	SEMAF, semF	ENSG00000112902	Semaphorin 5A	5	9035026-9546075	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004632	Approved				Renal cancer:3.66e-8 (favourable), Head and neck cancer:2.45e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 19.3	Cell line enhanced		BJ hTERT+: 52.1;fHDF/TERT166: 29.1;RT4: 54.3
SEMA5B	FLJ10372, KIAA1445, SEMAG, SemG	ENSG00000082684	Semaphorin 5B	3	122909193-123028605	Predicted membrane proteins	Evidence at protein level	HPA066548	Enhanced		Supported	Cytosol	Renal cancer:7.57e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 11.4	heart muscle: 4.2	Cell line enhanced		AF22: 79.6;NTERA-2: 15.7;SH-SY5Y: 22.6
SEMA6A	HT018, KIAA1368, SEMA, SEMA6A1, SEMAQ	ENSG00000092421	Semaphorin 6A	5	116443616-116574934	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031265, HPA031267	Approved		Supported	Nucleus<br>Intermediate filaments	Liver cancer:4.39e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 49.1	Cell line enhanced		AF22: 36.5;AN3-CA: 41.0;BEWO: 36.9;HAP1: 53.6;NTERA-2: 115.0
SEMA6B	SEM-SEMA-Y, SEMA-VIB, SEMAN, semaZ	ENSG00000167680	Semaphorin 6B	19	4542593-4559808	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB025157, HPA055778, HPA058523	Enhanced				Renal cancer:3.29e-5 (unfavourable), Thyroid cancer:1.45e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 65.5	spleen: 24.5	Cell line enhanced		Hep G2: 88.4;HMC-1: 180.6;HUVEC TERT2: 71.3;TIME: 88.7
SEMA6C	KIAA1869	ENSG00000143434	Semaphorin 6C	1	151131685-151146664	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA076150, HPA077625			Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Pancreatic cancer:3.06e-5 (favourable), Endometrial cancer:3.27e-4 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 111.3	testis: 33.8	Cell line enhanced		AF22: 13.8;HUVEC TERT2: 20.6
SEMA6D	FLJ11598, KIAA1479	ENSG00000137872	Semaphorin 6D	15	47184101-47774223	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043109			Approved	Golgi apparatus<br>Plasma membrane	Renal cancer:5.96e-5 (favourable)	Tissue enhanced	Tissue enhanced		placenta: 63.6	small intestine: 44.3	Cell line enhanced		BJ hTERT+: 12.7;SCLC-21H: 16.1;SH-SY5Y: 13.4
SEMA7A	CD108, H-Sema-L, SEMAL	ENSG00000138623	Semaphorin 7A (John Milton Hagen blood group)	15	74409289-74434467	Blood group antigen proteins, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008210, HPA042273	Uncertain		Uncertain	Vesicles	Renal cancer:2.45e-11 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 59.6;testis: 56.9	placenta: 44.8	Cell line enhanced		HMC-1: 510.6;hTEC/SVTERT24-B: 213.0;U-251 MG: 310.7
SERAC1	FLJ14917	ENSG00000122335	Serine active site containing 1	6	158109515-158168270	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA025715, HPA025716	Enhanced					Expressed in all	Expressed in all			testis: 16.5	Expressed in all		
SERF1A	4F5, FAM2A, H4F5, SERF1, SMAM1	ENSG00000172058	Small EDRK-rich factor 1A	5	70900665-70918530	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA075271			Approved	Nuclear bodies		Not detected	Mixed			cerebral cortex: 9.1	Mixed		
SERF1B	FAM2B, H4F5C	ENSG00000205572	Small EDRK-rich factor 1B	5	70025247-70043113	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA075271			Approved	Nuclear bodies		Mixed	Tissue enhanced		testis: 48.0	epididymis: 31.8	Cell line enhanced		SiHa: 111.5
SERINC1	KIAA1253, TDE1L, TDE2, TMS-2	ENSG00000111897	Serine incorporator 1	6	122443354-122471822	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA035738, HPA035739	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 615.4	Expressed in all		
SERINC2	FKSG84, PRO0899, TDE2, TDE2L	ENSG00000168528	Serine incorporator 2	1	31409565-31434680	Predicted membrane proteins	Evidence at protein level	HPA005974	Enhanced				Endometrial cancer:1.69e-7 (favourable), Liver cancer:2.11e-4 (unfavourable), Lung cancer:5.70e-4 (unfavourable)	Expressed in all	Mixed			urinary bladder: 133.9	Cell line enhanced		HaCaT: 290.8;HBEC3-KT: 373.3;RT4: 285.7
SERINC3	AIGP1, DIFF33, SBBI99, TDE, TDE1, TMS-1	ENSG00000132824	Serine incorporator 3	20	44496221-44522109	Predicted membrane proteins, Transporters	Evidence at protein level	HPA048116	Uncertain				Cervical cancer:1.01e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 201.7	Expressed in all		
SERINC4	FLJ40363	ENSG00000184716	Serine incorporator 4	15	43794162-43800221	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	10	testis: 2.3	endometrium: 0.2	Not detected		
SERINC5	C5orf12, TPO1	ENSG00000164300	Serine incorporator 5	5	80111651-80256079	Predicted membrane proteins	Evidence at protein level	HPA037898, HPA037899	Supported		Uncertain	Nucleus<br>Golgi apparatus<br>Vesicles		Expressed in all	Mixed			testis: 55.4	Mixed		
SERP1	FLJ43424, RAMP4	ENSG00000120742	Stress associated endoplasmic reticulum protein 1	3	150541994-150603228	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038970	Approved		Approved	Endoplasmic reticulum	Pancreatic cancer:1.03e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 182.5	Expressed in all		
SERP2	bA269C23.1, C13orf21	ENSG00000151778	Stress associated endoplasmic reticulum protein family member 2	13	44373665-44397714	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038970	Uncertain				Renal cancer:1.94e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 52.7;testis: 23.7	epididymis: 11.3	Cell line enhanced		LHCN-M2: 3.2;SH-SY5Y: 5.6;U-2197: 4.5
SERPINA10	PZI, ZPI	ENSG00000140093	Serpin family A member 10	14	94280455-94293271	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048739			Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.00e-4 (favourable)	Tissue enriched	Tissue enriched	89	liver: 193.7	bone marrow: 2.1	Cell line enriched	6	Hep G2: 13.4
SERPINB13	headpin, HUR7, hurpin, PI13	ENSG00000197641	Serpin family B member 13	18	63586989-63604639	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052630, HPA057129	Enhanced		Approved	Nuclear speckles<br>Cytosol		Tissue enhanced	Tissue enriched	9	esophagus: 184.6	tonsil: 20.7	Group enriched	137	HaCaT: 177.0;hTCEpi: 54.2
SERTM1	C13orf36	ENSG00000180440	Serine rich and transmembrane domain containing 1	13	36673912-36697839	Predicted membrane proteins	Evidence at protein level	HPA054814, HPA070485	Uncertain		Supported	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 47.6;endometrium: 37.7;fallopian tube: 29.6	smooth muscle: 24.8	Cell line enhanced		HAP1: 1.2;HEK93: 1.3;NTERA-2: 3.5;SH-SY5Y: 2.1
SETDB1	ESET, KG1T, KIAA0067, KMT1E, TDRD21	ENSG00000143379	SET domain bifurcated 1	1	150926263-150964744	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018142, HPA058484	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:4.25e-4 (unfavourable), Liver cancer:8.88e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 46.3	Expressed in all		
SEZ6		ENSG00000063015	Seizure related 6 homolog	17	28954901-29006440	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011777	Enhanced		Uncertain	Intermediate filaments		Tissue enriched	Tissue enriched	53	cerebral cortex: 54.3	duodenum: 1.0	Cell line enriched	6	SCLC-21H: 69.9
SEZ6L		ENSG00000100095	Seizure related 6 homolog like	22	26169474-26383597	Predicted membrane proteins	Evidence at protein level	HPA045135			Approved	Vesicles		Group enriched	Tissue enriched	7	cerebral cortex: 89.2	adrenal gland: 13.6	Group enriched	8	SCLC-21H: 49.2;SH-SY5Y: 11.9
SEZ6L2	FLJ90517, PSK-1	ENSG00000174938	Seizure related 6 homolog like 2	16	29871159-29899547	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064471	Enhanced				Colorectal cancer:1.31e-4 (unfavourable), Glioma:7.27e-4 (unfavourable), Cervical cancer:7.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 82.4;parathyroid gland: 58.4	adrenal gland: 30.6	Cell line enhanced		EFO-21: 72.2
SF3B1	Hsh155, Prp10, PRPF10, SAP155, SF3b155	ENSG00000115524	Splicing factor 3b subunit 1	2	197389784-197435091	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050275	Approved		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			endometrium: 348.2	Expressed in all		
SFT2D1	C6orf83, MGC19825, pRGR1	ENSG00000198818	SFT2 domain containing 1	6	166319728-166342591	Predicted membrane proteins	Evidence at protein level	HPA014677	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:2.19e-5 (unfavourable), Renal cancer:3.59e-4 (unfavourable), Thyroid cancer:5.90e-4 (favourable), Head and neck cancer:7.47e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 78.5	Expressed in all		
SFT2D2	dJ747L4.C1.2, UNQ512	ENSG00000213064	SFT2 domain containing 2	1	168225938-168253025	Predicted membrane proteins	Evidence at protein level	HPA042207	Approved				Liver cancer:4.86e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 21.1	Expressed in all		
SFT2D3	MGC5391	ENSG00000173349	SFT2 domain containing 3	2	127701508-127705242	Predicted membrane proteins	Evidence at protein level							Not detected	Mixed			parathyroid gland: 7.9	Cell line enhanced		ASC diff: 5.1;hTCEpi: 5.1
SFXN1	FLJ12876	ENSG00000164466	Sideroflexin 1	5	175477062-175529742	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019543, HPA063745	Uncertain		Enhanced	Mitochondria		Expressed in all	Expressed in all			liver: 51.7	Expressed in all		
SFXN2		ENSG00000156398	Sideroflexin 2	10	102714538-102743492	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018150, HPA026834	Enhanced		Approved	Mitochondria	Renal cancer:2.28e-5 (favourable), Cervical cancer:2.28e-4 (favourable), Urothelial cancer:6.52e-4 (favourable), Liver cancer:9.95e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 18.7	parathyroid gland: 12.4	Cell line enhanced		T-47d: 35.9
SFXN3	SFX3	ENSG00000107819	Sideroflexin 3	10	101031234-101041244	Predicted membrane proteins	Evidence at protein level	HPA008028, HPA048105	Approved		Enhanced	Mitochondria	Head and neck cancer:3.79e-4 (unfavourable), Renal cancer:4.94e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 41.4	Mixed		
SFXN4		ENSG00000183605	Sideroflexin 4	10	119140767-119165667	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018028, HPA020872	Approved		Supported	Vesicles		Expressed in all	Expressed in all			thyroid gland: 47.3	Expressed in all		
SFXN5	BBG-TCC	ENSG00000144040	Sideroflexin 5	2	72942036-73075619	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015473, HPA056866	Approved		Approved	Nucleoplasm<br>Mitochondria	Pancreatic cancer:2.26e-6 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 39.4	epididymis: 18.6	Mixed		
SGCA	A2, adhalin, ADL, DMDA2, LGMD2D, SCARMD1	ENSG00000108823	Sarcoglycan alpha	17	50164214-50175931	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007537	Uncertain					Mixed	Tissue enhanced		heart muscle: 79.5;skeletal muscle: 181.4	seminal vesicle: 38.3	Cell line enriched	13	LHCN-M2: 65.0
SGCB	A3b, LGMD2E, SGC	ENSG00000163069	Sarcoglycan beta	4	52020706-52038482	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA011422, HPA058656	Enhanced		Approved	Cytosol	Renal cancer:5.53e-6 (favourable), Urothelial cancer:7.61e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 75.4	Mixed		
SGCD	CMD1L, DAGD, LGMD2F	ENSG00000170624	Sarcoglycan delta	5	155870344-156767788	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA026969	Uncertain					Tissue enhanced	Mixed			thyroid gland: 37.4	Cell line enhanced		BJ: 19.4;fHDF/TERT166: 28.5;RH-30: 26.8;SK-MEL-30: 28.7;U-138 MG: 34.9
SGCE	DYT11	ENSG00000127990	Sarcoglycan epsilon	7	94585230-94656209	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA074790			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles<br>Plasma membrane	Head and neck cancer:1.61e-5 (unfavourable), Stomach cancer:1.35e-4 (unfavourable)	Expressed in all	Mixed			ovary: 133.2	Mixed		
SGCG	A4, DAGA4, DMDA, DMDA1, LGMD2C, MAM, MGC130048, SCARMD2, SCG3, TYPE	ENSG00000102683	Sarcoglycan gamma	13	23180952-23325165	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007476, HPA011922	Enhanced		Supported	Nucleoplasm		Mixed	Tissue enhanced		heart muscle: 74.9;skeletal muscle: 54.0	adipose tissue: 14.5	Cell line enriched	5	fHDF/TERT166: 50.4
SGCZ	ZSG1	ENSG00000185053	Sarcoglycan zeta	8	14089864-15238339	Predicted membrane proteins	Evidence at transcript level	HPA017585	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.3;ovary: 3.4	breast: 0.7	Not detected		
SGMS1	MGC17342, MOB, SMS1, TMEM23	ENSG00000198964	Sphingomyelin synthase 1	10	50305586-50625163	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045191	Approved		Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus<br>Cytosol	Renal cancer:1.95e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 116.7	Expressed in all		
SGMS2	MGC26963, SMS2	ENSG00000164023	Sphingomyelin synthase 2	4	107824563-107915047	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015076	Enhanced				Renal cancer:1.37e-4 (favourable)	Expressed in all	Mixed			gallbladder: 64.4	Mixed		
SGPL1	SPL	ENSG00000166224	Sphingosine-1-phosphate lyase 1	10	70815961-70881173	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021125, HPA023086	Enhanced		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			skin: 34.5	Expressed in all		
SGPP1		ENSG00000126821	Sphingosine-1-phosphate phosphatase 1	14	63684214-63728039	Predicted membrane proteins	Evidence at protein level	HPA053149, HPA064908	Approved		Supported	Nucleus		Expressed in all	Expressed in all			placenta: 34.7	Mixed		
SGPP2	FLJ39004, SPP2	ENSG00000163082	Sphingosine-1-phosphate phosphatase 2	2	222424517-222560948	Predicted membrane proteins	Evidence at transcript level						Renal cancer:1.28e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 59.2	thyroid gland: 33.7	Cell line enhanced		CAPAN-2: 13.9;EFO-21: 12.7;hTCEpi: 31.0;RPTEC TERT1: 32.2;SCLC-21H: 20.4
SGSM3	DJ1042K10.2, RabGAP-5, RABGAP5, RUSC3, RUTBC3	ENSG00000100359	Small G protein signaling modulator 3	22	40370591-40410289	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048980	Approved		Supported	Golgi apparatus	Endometrial cancer:4.47e-5 (favourable)	Expressed in all	Expressed in all			stomach: 75.9	Expressed in all		
SH3TC1	FLJ20356	ENSG00000125089	SH3 domain and tetratricopeptide repeats 1	4	8182072-8241803	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038132, HPA056807	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Mixed			spleen: 12.5	Cell line enhanced		HUVEC TERT2: 20.1;MOLT-4: 35.0;SK-MEL-30: 19.0
SHISA2	bA398O19.2, C13orf13, hShisa, PRO28631, TMEM46, WGAR9166	ENSG00000180730	Shisa family member 2	13	26044597-26051031	Predicted membrane proteins	Evidence at protein level	HPA049752, HPA050172	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Renal cancer:2.43e-4 (favourable), Lung cancer:3.30e-4 (favourable)	Mixed	Tissue enhanced		breast: 22.3;thyroid gland: 48.3	epididymis: 13.1	Cell line enhanced		LHCN-M2: 21.2;NTERA-2: 18.4;RH-30: 56.6;U-2197: 34.1
SHISA3	hShisa3	ENSG00000178343	Shisa family member 3	4	42397839-42402487	Predicted membrane proteins	Evidence at protein level	HPA054754			Approved	Lipid droplets<br>Cytosol		Mixed	Tissue enhanced		kidney: 25.1	lymph node: 8.7	Group enriched	6	AN3-CA: 231.0;PC-3: 134.3
SHISA4	C1orf40, hShisa4, TMEM58	ENSG00000198892	Shisa family member 4	1	201888680-201892306	Predicted membrane proteins	Evidence at protein level	HPA061273	Uncertain					Expressed in all	Tissue enhanced		cerebral cortex: 45.3;skeletal muscle: 94.4	adrenal gland: 23.6	Mixed		
SHISA5	hShisa5, SCOTIN	ENSG00000164054	Shisa family member 5	3	48467798-48504826	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042295	Approved				Liver cancer:3.72e-6 (unfavourable), Renal cancer:8.64e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 199.1	Expressed in all		
SHISA6	FLJ45455	ENSG00000188803	Shisa family member 6	17	11241263-11564063	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA023440	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 24.7	seminal vesicle: 10.2	Cell line enriched	8	NTERA-2: 2.2
SHISA7		ENSG00000187902	Shisa family member 7	19	55428740-55442863	Predicted membrane proteins	Evidence at protein level	HPA058935	Uncertain					Tissue enriched	Tissue enriched	13	cerebral cortex: 18.2	testis: 1.4	Cell line enhanced		HEL: 2.7;HMC-1: 2.7;THP-1: 1.1
SHISA8	C22orf17, Orf26	ENSG00000234965	Shisa family member 8	22	41909554-41914667	Predicted membrane proteins	Evidence at transcript level	HPA059173	Uncertain				Endometrial cancer:2.76e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 4.3	lymph node,spleen: 1.4	Cell line enriched	7	HEK93: 17.7
SHISA9		ENSG00000237515	Shisa family member 9	16	12901620-13240413	Predicted membrane proteins	Evidence at transcript level						Renal cancer:1.53e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 22.8	prostate: 7.2	Cell line enhanced		EFO-21: 46.5;LHCN-M2: 33.9
SI		ENSG00000090402	Sucrase-isomaltase	3	164978898-165078495	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA011897	Enhanced					Tissue enhanced	Group enriched	15	duodenum: 547.3;small intestine: 493.2	rectum: 34.5	Cell line enhanced		BEWO: 1.0;CACO-2: 1.3;RPMI-8226: 1.3;SH-SY5Y: 1.2
SIDT1	FLJ20174, SID-1	ENSG00000072858	SID1 transmembrane family member 1	3	113532296-113629578	Predicted membrane proteins, Transporters	Evidence at protein level	HPA035862	Enhanced				Urothelial cancer:4.09e-5 (favourable), Cervical cancer:3.78e-4 (favourable)	Mixed	Mixed			cerebral cortex: 10.6	Cell line enhanced		MCF7: 11.1;PC-3: 18.4;RT4: 11.2;T-47d: 12.3
SIDT2	CGI-40	ENSG00000149577	SID1 transmembrane family member 2	11	117178733-117197445	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052352	Approved				Renal cancer:4.18e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 60.8	Expressed in all		
SIGIRR	IL-1R8, TIR8	ENSG00000185187	Single Ig and TIR domain containing	11	405716-417455	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023188	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:7.61e-6 (favourable), Endometrial cancer:1.34e-5 (favourable), Urothelial cancer:1.54e-5 (favourable), Cervical cancer:7.44e-5 (favourable), Head and neck cancer:9.08e-4 (favourable)	Expressed in all	Expressed in all			spleen: 64.7	Cell line enhanced		CAPAN-2: 119.6
SIGLEC1	CD169, dJ1009E24.1, FLJ00051, FLJ00055, FLJ00073, FLJ32150, sialoadhesin, SIGLEC-1, SN	ENSG00000088827	Sialic acid binding Ig like lectin 1	20	3686970-3707128	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053457	Supported				Renal cancer:8.69e-5 (unfavourable), Testis cancer:4.36e-4 (unfavourable)	Expressed in all	Mixed			placenta: 27.3	Cell line enriched	14	THP-1: 1.4
SIGLEC10	MGC126774, PRO940, SIGLEC-10, SLG2	ENSG00000142512	Sialic acid binding Ig like lectin 10	19	51410021-51417803	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025807, HPA027093	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:4.74e-5 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 48.4;spleen: 36.9	lymph node: 22.1	Cell line enhanced		Daudi: 21.0;HEL: 13.5;HMC-1: 10.2;U-698: 14.8;U-937: 9.7
SIGLEC11		ENSG00000161640	Sialic acid binding Ig like lectin 11	19	49948985-49961172	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA060278	Approved					Mixed	Group enriched	7	ovary: 80.0;spleen: 31.7	adrenal gland: 8.1	Cell line enriched	15	HEL: 9.4
SIGLEC12	S2V, Siglec-12, Siglec-L1, Siglec-XII, SIGLECL1, SLG	ENSG00000254521	Sialic acid binding Ig like lectin 12 (gene/pseudogene)	19	51491357-51501789	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		appendix: 6.4;spleen: 12.8	smooth muscle: 3.7	Group enriched	9	HMC-1: 124.2;U-937: 61.4
SIGLEC14		ENSG00000254415	Sialic acid binding Ig like lectin 14	19	51642553-51646801	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA014377	Uncertain					Mixed	Tissue enhanced		appendix: 34.8;spleen: 55.2	bone marrow: 18.3	Group enriched	10	HMC-1: 87.0;U-937: 19.3
SIGLEC15	CD33L3, HsT1361	ENSG00000197046	Sialic acid binding Ig like lectin 15	18	45825512-45844080	Predicted membrane proteins	Evidence at protein level	HPA053509			Supported	Nucleoplasm<br>Golgi apparatus	Urothelial cancer:9.14e-5 (favourable)	Mixed	Not detected			spleen: 0.6	Group enriched	8	PC-3: 9.6;U-87 MG: 30.2
SIGLEC5	CD170, CD33L2, OB-BP2, SIGLEC-5	ENSG00000105501	Sialic acid binding Ig like lectin 5	19	51611927-51645545	CD markers, Predicted membrane proteins	Evidence at protein level	HPA009085, CAB024900	Supported					Tissue enhanced	Tissue enhanced		appendix: 9.3;bone marrow: 9.7;spleen: 8.8	lymph node: 3.5	Group enriched	7	HMC-1: 52.0;U-937: 19.9
SIGLEC6	CD327, CD33L, CD33L1, OB-BP1, SIGLEC-6	ENSG00000105492	Sialic acid binding Ig like lectin 6	19	51519525-51531856	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009084, HPA018198	Enhanced					Tissue enhanced	Tissue enriched	25	placenta: 147.9	lung: 6.0	Cell line enriched	7	HMC-1: 401.5
SIGLEC7	CD328, p75/AIRM1, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2	ENSG00000168995	Sialic acid binding Ig like lectin 7	19	51142299-51153526	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 21.0	appendix: 14.4	Group enriched	10	Karpas-707: 39.7;RPMI-8226: 23.1;U-937: 27.4
SIGLEC8	MGC59785, SAF2, SIGLEC-8, SIGLEC8L	ENSG00000105366	Sialic acid binding Ig like lectin 8	19	51450847-51458456	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA012556	Approved		Uncertain	Cytosol		Tissue enhanced	Mixed			lymph node: 7.5	Cell line enriched	60	HMC-1: 129.9
SIGLEC9	CD329	ENSG00000129450	Sialic acid binding Ig like lectin 9	19	51124908-51136651	Predicted membrane proteins	Evidence at protein level	HPA010682	Uncertain				Renal cancer:6.17e-5 (unfavourable)	Mixed	Tissue enhanced		appendix: 24.7;spleen: 23.5	lung: 12.2	Group enriched	7	Karpas-707: 16.8;RPMI-8226: 11.4
SIGLECL1	C19orf75, FLJ40235, SIGLEC23P, SIGLECP7	ENSG00000179213	SIGLEC family like 1	19	51246348-51269330	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	86	testis: 40.1	cervix, uterine: 0.4	Not detected		
SIGMAR1	OPRS1, SR-BP1	ENSG00000147955	Sigma non-opioid intracellular receptor 1	9	34634722-34637809	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB013470, HPA018002, HPA024071	Approved				Urothelial cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 67.8	Expressed in all		
SIK1	msk, SNF1LK	ENSG00000142178	Salt inducible kinase 1	21	43414515-43427128	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB023801, HPA038211	Approved		Supported	Cytosol		Mixed	Mixed			seminal vesicle: 13.9	Cell line enhanced		HaCaT: 18.5;HBEC3-KT: 22.7;HeLa: 32.3;hTCEpi: 25.9;SiHa: 16.7;U-266/84: 20.5
SIK2	DKFZp434K1115, KIAA0781, LOH11CR1I, QIK, SNF1LK2	ENSG00000170145	Salt inducible kinase 2	11	111602391-111730853	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA016026	Approved		Approved	Golgi apparatus	Renal cancer:1.17e-9 (favourable), Liver cancer:4.93e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 32.1	Expressed in all		
SIK3	FLJ12240, KIAA0999, L19, QSK	ENSG00000160584	SIK family kinase 3	11	116843402-117098437	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045245, HPA048161	Enhanced		Approved	Nucleoplasm	Renal cancer:1.12e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 42.9	Expressed in all		
SIRPA	BIT, CD172a, MFR, MYD-1, P84, PTPNS1, SHPS-1, SHPS1, SIRP, SIRP-ALPHA-1, SIRPalpha, SIRPalpha2	ENSG00000198053	Signal regulatory protein alpha	20	1894167-1940592	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002776, CAB015122, HPA054437, HPA058511	Enhanced					Expressed in all	Expressed in all			cerebral cortex: 207.9	Cell line enhanced		fHDF/TERT166: 110.5
SIRPB1	CD172b, SIRP-BETA-1	ENSG00000101307	Signal regulatory protein beta 1	20	1563521-1620061	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047463	Uncertain		Uncertain	Vesicles		Mixed	Tissue enhanced		appendix: 38.7;bone marrow: 33.7	lung: 28.0	Cell line enhanced		HMC-1: 46.6;NB-4: 46.7;THP-1: 38.2
SIRPB2	dJ776F14.2, PTPN1L, PTPNS1L3	ENSG00000196209	Signal regulatory protein beta 2	20	1470741-1491587	Predicted membrane proteins	Evidence at protein level	HPA011548, HPA048032	Uncertain		Approved	Nuclear bodies		Mixed	Tissue enhanced		appendix: 17.0	placenta: 10.9	Cell line enhanced		A-431: 4.2;HMC-1: 7.0;hTCEpi: 6.2;THP-1: 5.3;U-937: 6.6
SIRPG	bA77C3.1, CD172g, SIRP-B2, SIRPB2, SIRPgamma	ENSG00000089012	Signal regulatory protein gamma	20	1629152-1657779	CD markers, Predicted membrane proteins	Evidence at protein level						Melanoma:7.36e-7 (favourable), Endometrial cancer:1.05e-6 (favourable), Renal cancer:1.47e-6 (unfavourable), Head and neck cancer:2.24e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 38.8;tonsil: 25.8	appendix: 16.9	Cell line enhanced		NB-4: 8.6;RT4: 2.8;THP-1: 1.6
SIT1	SIT	ENSG00000137078	Signaling threshold regulating transmembrane adaptor 1	9	35649295-35650950	Predicted membrane proteins	Evidence at protein level	HPA018506	Enhanced				Endometrial cancer:1.94e-6 (favourable), Renal cancer:1.75e-5 (unfavourable), Head and neck cancer:1.14e-4 (favourable), Cervical cancer:6.56e-4 (favourable), Melanoma:8.17e-4 (favourable)	Mixed	Group enriched	5	appendix: 24.6;lymph node: 56.1;spleen: 21.9;tonsil: 29.6	urinary bladder: 6.0	Cell line enhanced		Daudi: 80.3;HDLM-2: 65.0;U-698: 70.1
SLAMF1	CD150, SLAM	ENSG00000117090	Signaling lymphocytic activation molecule family member 1	1	160608100-160647295	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002438, HPA069319	Enhanced					Mixed	Tissue enhanced		appendix: 15.4;lymph node: 21.1;tonsil: 14.3	spleen: 7.9	Cell line enriched	134	HDLM-2: 142.1
SLAMF6	CD352, KALI, KALIb, Ly108, NTB-A, NTBA, SF2000	ENSG00000162739	SLAM family member 6	1	160485030-160523262	CD markers, Predicted membrane proteins	Evidence at protein level	HPA051363, HPA051903	Uncertain				Renal cancer:2.09e-6 (unfavourable), Head and neck cancer:7.34e-5 (favourable), Melanoma:1.25e-4 (favourable), Cervical cancer:2.78e-4 (favourable), Breast cancer:9.42e-4 (favourable), Endometrial cancer:9.53e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 70.8;spleen: 43.3;tonsil: 44.6	appendix: 27.2	Cell line enhanced		Daudi: 63.2;MOLT-4: 17.4;U-698: 89.3
SLAMF7	19A, CD319, CRACC, CS1	ENSG00000026751	SLAM family member 7	1	160739057-160754821	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015445, HPA055945, HPA061654	Enhanced		Approved	Vesicles	Renal cancer:8.57e-5 (unfavourable), Ovarian cancer:3.93e-4 (favourable)	Mixed	Mixed			spleen: 58.3	Group enriched	7	SK-MEL-30: 45.6;U-266/70: 216.2
SLAMF8	BLAME, CD353, SBBI42	ENSG00000158714	SLAM family member 8	1	159826750-159837249	CD markers, Predicted membrane proteins	Evidence at protein level	HPA067601	Enhanced				Renal cancer:5.42e-5 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 39.3	lymph node: 36.1	Cell line enhanced		ASC TERT1: 1.1;HL-60: 1.0;U-138 MG: 2.0;U-87 MG: 1.3
SLAMF9	CD2F-10, CD84-H1, SF2001	ENSG00000162723	SLAM family member 9	1	159951492-159954254	Predicted membrane proteins	Evidence at transcript level	HPA035153	Uncertain					Mixed	Tissue enhanced		testis: 1.1	appendix: 0.6	Cell line enhanced		HBEC3-KT: 2.6;HEL: 4.6;PC-3: 1.9;SK-MEL-30: 1.7
SLC10A1	NTCP	ENSG00000100652	Solute carrier family 10 member 1	14	69775417-69797289	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042727	Approved				Liver cancer:9.53e-6 (favourable)	Tissue enriched	Tissue enriched	394	liver: 212.4	gallbladder: 0.5	Not detected		
SLC10A2	ASBT, ISBT	ENSG00000125255	Solute carrier family 10 member 2	13	103043998-103066846	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004795	Approved				Renal cancer:5.78e-5 (favourable)	Tissue enriched	Group enriched	31	duodenum: 21.0;kidney: 15.4;small intestine: 51.4	gallbladder: 0.9	Not detected		
SLC10A3	DXS253E, P3	ENSG00000126903	Solute carrier family 10 member 3	X	154487306-154490690	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA021656	Approved		Approved	Intermediate filaments	Colorectal cancer:4.15e-5 (unfavourable), Cervical cancer:4.53e-4 (favourable), Pancreatic cancer:7.22e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 33.0	Expressed in all		
SLC10A4	MGC29802	ENSG00000145248	Solute carrier family 10 member 4	4	48483343-48489196	Predicted membrane proteins, Transporters	Evidence at protein level	HPA028835	Uncertain	Supported				Tissue enhanced	Tissue enhanced		adrenal gland: 6.2;cerebral cortex: 4.0	cervix, uterine: 1.5	Cell line enhanced		HAP1: 15.2;K-562: 13.9;SH-SY5Y: 41.0
SLC10A5		ENSG00000253598	Solute carrier family 10 member 5	8	81693607-81696174	Predicted membrane proteins, Transporters	Evidence at protein level	HPA025966	Uncertain		Approved	Plasma membrane		Mixed	Mixed			liver: 3.0	Not detected		
SLC10A6	SOAT	ENSG00000145283	Solute carrier family 10 member 6	4	86823468-86849263	Predicted membrane proteins	Evidence at protein level	HPA016662	Enhanced					Group enriched	Tissue enhanced		esophagus: 11.0;skin: 17.3	adipose tissue: 6.2	Cell line enhanced		BJ: 1.4;BJ hTERT+: 1.0;HaCaT: 1.1
SLC10A7	C4orf13, DKFZp313H0531, DKFZp566M114, DKFZp779O2438, MGC25043	ENSG00000120519	Solute carrier family 10 member 7	4	146253975-146521964	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039996, HPA057906	Uncertain		Approved	Nucleoli		Expressed in all	Mixed			epididymis: 16.2	Expressed in all		
SLC11A1	LSH, NRAMP, NRAMP1	ENSG00000018280	Solute carrier family 11 member 1	2	218382029-218396894	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029590	Uncertain				Renal cancer:2.58e-8 (unfavourable)	Mixed	Tissue enhanced		appendix: 9.1;lung: 13.0	spleen: 4.6	Not detected		
SLC11A2	DCT1, DMT1, NRAMP2	ENSG00000110911	Solute carrier family 11 member 2	12	50979401-51028566	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032139, HPA032140	Uncertain		Supported	Mitochondria	Lung cancer:3.07e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 75.1	Expressed in all		
SLC12A1	NKCC2	ENSG00000074803	Solute carrier family 12 member 1	15	48191664-48304078	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014967, HPA018107	Enhanced		Approved	Nucleus<br>Vesicles		Tissue enhanced	Tissue enriched	477	kidney: 780.2	testis: 1.6	Cell line enriched	19	RPTEC TERT1: 19.2
SLC12A2	BSC, BSC2, NKCC1, PPP1R141	ENSG00000064651	Solute carrier family 12 member 2	5	128083766-128189688	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020130, HPA063697	Approved		Approved	Vesicles<br>Plasma membrane	Renal cancer:7.09e-4 (favourable), Endometrial cancer:8.60e-4 (favourable)	Expressed in all	Expressed in all			rectum: 65.4	Expressed in all		
SLC12A3	NCCT	ENSG00000070915	Solute carrier family 12 member 3	16	56865207-56915850	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA028748	Enhanced					Tissue enhanced	Tissue enriched	109	kidney: 109.8	lymph node: 1.0	Group enriched	11	BEWO: 7.0;HAP1: 4.1;HeLa: 5.5
SLC12A4	KCC1	ENSG00000124067	Solute carrier family 12 member 4	16	67943474-67969601	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041138	Approved		Approved	Endosomes	Renal cancer:2.25e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.9	Mixed		
SLC12A5	KCC2, KIAA1176	ENSG00000124140	Solute carrier family 12 member 5	20	46021690-46060152	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA072058	Enhanced				Glioma:8.45e-4 (unfavourable)	Mixed	Tissue enriched	8	cerebral cortex: 94.2	adrenal gland: 11.9	Cell line enhanced		NB-4: 32.3;U-2 OS: 29.1
SLC12A6	ACCPN, KCC3	ENSG00000140199	Solute carrier family 12 member 6	15	34229996-34338060	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA034563	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:3.33e-6 (favourable)	Expressed in all	Mixed			testis: 46.4	Cell line enhanced		HaCaT: 38.6
SLC12A7	DKFZP434F076, KCC4	ENSG00000113504	Solute carrier family 12 member 7	5	1050376-1112035	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041652	Approved		Uncertain	Cytosol	Liver cancer:2.12e-6 (unfavourable), Urothelial cancer:3.16e-5 (favourable)	Expressed in all	Mixed			duodenum: 24.3	Cell line enhanced		REH: 40.1
SLC12A8	CCC9	ENSG00000221955	Solute carrier family 12 member 8	3	125082636-125212864	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031123	Uncertain		Supported	Nucleoplasm	Renal cancer:5.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 39.6	gallbladder: 16.2	Cell line enhanced		HHSteC: 28.8;U-2197: 63.6
SLC12A9	CIP1	ENSG00000146828	Solute carrier family 12 member 9	7	100826820-100867009	Predicted membrane proteins, Transporters	Evidence at protein level	HPA067536	Approved				Ovarian cancer:4.00e-4 (unfavourable), Renal cancer:4.92e-4 (unfavourable), Lung cancer:5.97e-4 (favourable)	Expressed in all	Mixed			placenta: 20.2	Expressed in all		
SLC13A1	NAS1, NaSi-1	ENSG00000081800	Solute carrier family 13 member 1	7	123113531-123199986	Predicted membrane proteins, Transporters	Evidence at protein level	HPA053615, HPA062714	Enhanced				Renal cancer:8.95e-5 (favourable)	Tissue enriched	Tissue enriched	6	kidney: 85.0	small intestine: 14.1	Not detected		
SLC13A2	NaDC-1	ENSG00000007216	Solute carrier family 13 member 2	17	28473293-28497781	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014963	Enhanced				Renal cancer:9.00e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 68.7;small intestine: 54.3	kidney: 19.7	Not detected		
SLC13A3	NADC3, SDCT2	ENSG00000158296	Solute carrier family 13 member 3	20	46557823-46684467	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014333, HPA014353, HPA014736	Enhanced		Supported	Plasma membrane		Mixed	Tissue enriched	7	kidney: 431.7	placenta: 60.9	Cell line enhanced		EFO-21: 17.7;Hep G2: 38.2
SLC13A4	SUT-1, SUT1	ENSG00000164707	Solute carrier family 13 member 4	7	135681237-135729258	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA048582	Approved					Mixed	Tissue enriched	10	placenta: 76.8	testis: 7.4	Cell line enriched	6	HDLM-2: 28.0
SLC13A5	NACT	ENSG00000141485	Solute carrier family 13 member 5	17	6684713-6713567	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044343, HPA057088	Approved		Uncertain	Nucleoplasm		Tissue enriched	Tissue enriched	9	liver: 118.4	salivary gland: 12.8	Cell line enriched	65	Hep G2: 39.1
SLC14A1	HsT1341, JK, RACH1, RACH2	ENSG00000141469	Solute carrier family 14 member 1 (Kidd blood group)	18	45724127-45752520	Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA058353, HPA059570	Supported		Supported	Vesicles		Group enriched	Group enriched	5	prostate: 137.8;urinary bladder: 49.9	cerebral cortex: 18.1	Cell line enriched	14	RT4: 97.7
SLC14A2	HUT2, UT2	ENSG00000132874	Solute carrier family 14 member 2	18	45212995-45683686	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enhanced		kidney: 4.0	adipose tissue: 1.6	Cell line enriched	5	U-266/70: 3.4
SLC15A1	HPECT1, HPEPT1, PEPT1	ENSG00000088386	Solute carrier family 15 member 1	13	98683801-98752654	Predicted membrane proteins, Transporters	Evidence at protein level	HPA002827	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	5	duodenum: 153.2;gallbladder: 67.7;small intestine: 225.0	skin: 27.8	Group enriched	6	CAPAN-2: 49.1;SK-BR-3: 41.2
SLC15A2	PEPT2	ENSG00000163406	Solute carrier family 15 member 2	3	121894089-121944102	Predicted membrane proteins, Transporters	Evidence at protein level						Cervical cancer:2.37e-4 (favourable), Lung cancer:6.74e-4 (favourable), Endometrial cancer:6.96e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 78.5;prostate: 64.9	epididymis: 47.8	Mixed		
SLC15A3	hPTR3, PHT2	ENSG00000110446	Solute carrier family 15 member 3	11	60937084-60952530	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA047880, HPA057642	Approved		Supported	Vesicles	Cervical cancer:4.07e-5 (favourable)	Expressed in all	Expressed in all			lung: 102.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 91.0;BJ hTERT+ SV40 Large T+ RasG12V: 114.5;HHSteC: 47.3
SLC15A4	PHT1, PTR4	ENSG00000139370	Solute carrier family 15 member 4	12	128793191-128823983	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016713	Approved		Supported	Nucleoplasm	Renal cancer:7.56e-6 (unfavourable), Liver cancer:6.78e-4 (unfavourable), Head and neck cancer:8.45e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium,testis: 20.2	Mixed		
SLC15A5		ENSG00000188991	Solute carrier family 15 member 5	12	16188485-16277685	Predicted membrane proteins, Transporters	No evidence	HPA041638	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
SLC16A1	MCT, MCT1	ENSG00000155380	Solute carrier family 16 member 1	1	112911847-112957013	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003324, CAB017489, HPA071055, CAB079035	Enhanced	Supported	Enhanced	Plasma membrane<br>Cell Junctions	Renal cancer:6.78e-8 (unfavourable), Endometrial cancer:8.37e-6 (unfavourable), Pancreatic cancer:2.10e-4 (unfavourable), Lung cancer:4.05e-4 (unfavourable)	Expressed in all	Mixed			testis: 31.4	Mixed		
SLC16A10	MCT10, TAT1	ENSG00000112394	Solute carrier family 16 member 10	6	111087503-111231194	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016860	Approved		Approved	Vesicles<br>Cell Junctions		Tissue enriched	Tissue enhanced		placenta: 38.6	skin: 22.4	Cell line enhanced		HAP1: 53.9;HEK93: 20.6;RPMI-8226: 30.8
SLC16A11	FLJ90193, MCT11	ENSG00000174326	Solute carrier family 16 member 11	17	7041630-7043923	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level						Renal cancer:3.19e-7 (favourable), Pancreatic cancer:1.45e-5 (favourable), Liver cancer:2.56e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 8.9;parathyroid gland: 11.0	seminal vesicle: 3.8	Not detected		
SLC16A12	MCT12	ENSG00000152779	Solute carrier family 16 member 12	10	89430299-89556641	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA037587			Approved	Mitochondria	Renal cancer:4.50e-12 (favourable)	Tissue enriched	Tissue enhanced		epididymis: 63.5;kidney: 93.5	seminal vesicle: 20.2	Cell line enhanced		ASC TERT1: 16.2;HSkMC: 6.0
SLC16A13	MCT13	ENSG00000174327	Solute carrier family 16 member 13	17	7036075-7040121	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA065245			Supported	Golgi apparatus	Pancreatic cancer:1.50e-4 (favourable)	Expressed in all	Mixed			liver: 15.4	Cell line enhanced		A549: 21.3
SLC16A14	FLJ30794, MCT14	ENSG00000163053	Solute carrier family 16 member 14	2	230034974-230068999	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA040518	Uncertain		Approved	Endoplasmic reticulum		Mixed	Mixed			parathyroid gland: 14.7	Cell line enhanced		HL-60: 16.9;Karpas-707: 10.1;REH: 16.6;RPMI-8226: 11.3
SLC16A2	AHDS, DXS128, MCT7, MCT8, MRX22, XPCT	ENSG00000147100	Solute carrier family 16 member 2	X	74421461-74533917	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA072719			Approved	Plasma membrane	Breast cancer:8.88e-5 (unfavourable), Renal cancer:1.83e-4 (unfavourable), Urothelial cancer:3.16e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 24.0	Cell line enhanced		BJ: 73.2
SLC16A3	MCT3, MCT4	ENSG00000141526	Solute carrier family 16 member 3	17	82228397-82261129	Predicted membrane proteins, Transporters	Evidence at protein level	CAB017490, HPA021451	Approved		Supported	Nuclear membrane<br>Plasma membrane	Liver cancer:1.19e-7 (unfavourable), Renal cancer:3.71e-7 (unfavourable), Lung cancer:2.02e-5 (unfavourable), Cervical cancer:6.07e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 74.3	Mixed		
SLC16A4	MCT4, MCT5	ENSG00000168679	Solute carrier family 16 member 4	1	110362848-110391082	Predicted membrane proteins	Evidence at transcript level	HPA046986, HPA060163	Approved		Approved	Microtubules<br>Cytokinetic bridge<br>Cytosol	Renal cancer:1.69e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 125.2	placenta: 39.9	Cell line enhanced		BEWO: 19.0;CAPAN-2: 26.1;SK-MEL-30: 24.1
SLC16A5	MCT5, MCT6	ENSG00000170190	Solute carrier family 16 member 5	17	75087727-75106162	Predicted membrane proteins, Transporters	Evidence at transcript level							Expressed in all	Mixed			duodenum: 34.5	Cell line enhanced		A549: 59.5;RPTEC TERT1: 52.1;RT4: 111.4
SLC16A6	MCT6, MCT7	ENSG00000108932	Solute carrier family 16 member 6	17	68267026-68291267	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA054459, HPA066328	Uncertain		Approved	Vesicles		Group enriched	Tissue enhanced		epididymis: 39.4	esophagus: 12.1	Cell line enriched	11	SK-MEL-30: 392.2
SLC16A7	MCT2	ENSG00000118596	Solute carrier family 16 member 7	12	59596067-59789855	Predicted membrane proteins, Transporters	Evidence at protein level	HPA005911	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:8.85e-5 (favourable)	Mixed	Mixed			adipose tissue,heart muscle: 24.9	Mixed		
SLC16A8	MCT3, REMP	ENSG00000100156	Solute carrier family 16 member 8	22	38078134-38084093	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA075017	Supported		Approved	Intermediate filaments<br>Focal adhesion sites		Mixed	Mixed			prostate: 3.9	Cell line enhanced		BEWO: 4.3;SiHa: 5.2;T-47d: 5.5;U-266/70: 6.4
SLC16A9	C10orf36, FLJ43803, MCT9	ENSG00000165449	Solute carrier family 16 member 9	10	59650761-59736002	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049286	Approved		Approved	Nucleus<br>Cell Junctions	Renal cancer:2.56e-6 (favourable)	Mixed	Tissue enhanced		adrenal gland: 198.5;kidney: 201.0	spleen: 56.3	Cell line enhanced		HAP1: 11.1;NTERA-2: 20.0;U-937: 14.6
SLC17A1	NAPI-1, NPT1	ENSG00000124568	Solute carrier family 17 member 1	6	25782897-25832059	Predicted membrane proteins, Transporters	Evidence at protein level	HPA050513			Approved	Golgi apparatus		Group enriched	Tissue enriched	7	kidney: 174.5	liver: 25.1	Cell line enriched	490	RPTEC TERT1: 48.9
SLC17A2	NPT3	ENSG00000112337	Solute carrier family 17 member 2	6	25912754-25930726	Predicted membrane proteins, Transporters	Evidence at protein level	HPA038270	Uncertain				Liver cancer:8.54e-4 (favourable)	Tissue enriched	Tissue enriched	85	liver: 40.8	kidney,testis: 0.4	Cell line enriched	12	Hep G2: 2.5
SLC17A3	NPT4	ENSG00000124564	Solute carrier family 17 member 3	6	25833066-25882286	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	9	kidney: 168.7	liver: 18.6	Cell line enriched	177	RPTEC TERT1: 87.1
SLC17A4	KIAA2138	ENSG00000146039	Solute carrier family 17 member 4	6	25754699-25781191	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA055564	Approved					Group enriched	Group enriched	6	colon: 20.4;duodenum: 28.6;gallbladder: 25.4;liver: 22.3;rectum: 28.9;small intestine: 35.0	pancreas: 4.2	Cell line enriched	5	RPTEC TERT1: 1.1
SLC17A5	AST, ISSD, NSD, SD, SIALIN, SIASD, SLD	ENSG00000119899	Solute carrier family 17 member 5	6	73593379-73654155	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA044479			Supported	Plasma membrane<br>Cytosol	Thyroid cancer:3.52e-4 (favourable)	Expressed in all	Tissue enriched	9	parathyroid gland: 652.6	thyroid gland: 70.0	Expressed in all		
SLC17A6	DNPI, VGLUT2	ENSG00000091664	Solute carrier family 17 member 6	11	22338097-22379503	Predicted membrane proteins, Transporters	Evidence at protein level	CAB037130, HPA039226, CAB078204	Enhanced	Supported				Not detected	Tissue enriched	65	cerebral cortex: 6.5	all non-specific tissues: 0.0	Cell line enriched	263	SCLC-21H: 35.7
SLC17A7	BNPI, VGLUT1	ENSG00000104888	Solute carrier family 17 member 7	19	49429401-49442360	Predicted membrane proteins, Transporters	Evidence at protein level	CAB037183, HPA050458, HPA063679	Enhanced	Supported				Tissue enriched	Tissue enriched	177	cerebral cortex: 584.4	adipose tissue: 3.3	Cell line enhanced		HMC-1: 18.2;K-562: 6.2;SCLC-21H: 5.7
SLC17A8	DFNA25, VGLUT3	ENSG00000179520	Solute carrier family 17 member 8	12	100357079-100422059	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB079058		Supported				Tissue enhanced	Tissue enhanced		small intestine: 5.8	cerebral cortex: 1.2	Not detected		
SLC17A9	C20orf59, FLJ23412, VNUT	ENSG00000101194	Solute carrier family 17 member 9	20	62952647-62969585	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047470, HPA056499	Uncertain		Approved	Nucleoplasm	Renal cancer:2.78e-15 (unfavourable)	Mixed	Mixed			stomach: 8.6	Cell line enhanced		Hep G2: 46.7;U-937: 33.7
SLC18A1	CGAT, VAT1, VMAT1	ENSG00000036565	Solute carrier family 18 member A1	8	20144855-20183206	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006877, HPA063797	Enhanced					Tissue enhanced	Tissue enriched	11	adrenal gland: 32.6	rectum: 3.0	Cell line enriched	9	SH-SY5Y: 70.0
SLC18A2	SVAT, SVMT, VMAT2	ENSG00000165646	Solute carrier family 18 member A2	10	117241093-117279430	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA073224	Approved					Mixed	Tissue enhanced		cervix, uterine: 47.6	adrenal gland: 19.0	Cell line enriched	18	HMC-1: 308.7
SLC18A3	VACHT	ENSG00000187714	Solute carrier family 18 member A3	10	49610301-49612720	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB037102, CAB079011	Uncertain	Supported				Mixed	Not detected			placenta: 0.6	Group enriched	6	SCLC-21H: 2.0;SH-SY5Y: 7.6
SLC18B1	C6orf192, dJ55C23.6	ENSG00000146409	Solute carrier family 18 member B1	6	132769370-132798553	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029747, HPA049659	Approved		Supported	Golgi apparatus<br>Cytosol	Head and neck cancer:3.55e-4 (favourable), Liver cancer:7.90e-4 (unfavourable), Renal cancer:9.24e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 37.5	Mixed		
SLC19A1	FOLT, RFC1	ENSG00000173638	Solute carrier family 19 member 1	21	45493572-45544411	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA024802	Approved		Approved	Plasma membrane	Renal cancer:1.07e-10 (unfavourable), Cervical cancer:4.15e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 22.0	Expressed in all		
SLC19A2	THTR1, TRMA	ENSG00000117479	Solute carrier family 19 member 2	1	169463909-169486003	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006119, HPA016599	Uncertain		Approved	Cytosol	Renal cancer:2.70e-5 (favourable), Glioma:2.11e-4 (favourable), Breast cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 49.2	Mixed		
SLC19A3	THTR2	ENSG00000135917	Solute carrier family 19 member 3	2	227685210-227718012	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038898	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		adipose tissue: 50.2;placenta: 35.3	duodenum: 12.3	Cell line enhanced		ASC diff: 6.9;BEWO: 6.1;CACO-2: 12.7
SLC1A1	EAAC1, EAAT3	ENSG00000106688	Solute carrier family 1 member 1	9	4490444-4587469	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB015466, HPA020086	Approved				Renal cancer:2.86e-8 (favourable)	Expressed in all	Tissue enhanced		small intestine: 71.2	epididymis: 54.5	Cell line enhanced		HDLM-2: 65.4;RPTEC TERT1: 50.1
SLC1A2	EAAT2, GLT-1	ENSG00000110436	Solute carrier family 1 member 2	11	35251206-35420063	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002574, HPA009172	Enhanced					Tissue enriched	Tissue enriched	30	cerebral cortex: 365.8	liver: 12.2	Cell line enhanced		fHDF/TERT166: 1.5;NTERA-2: 2.4;SCLC-21H: 1.5
SLC1A3	EA6, EAAT1, GLAST	ENSG00000079215	Solute carrier family 1 member 3	5	36606355-36688334	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002573, HPA037467, HPA037468	Enhanced		Approved	Nucleoli<br>Mitochondria		Tissue enriched	Tissue enriched	16	cerebral cortex: 518.2	adipose tissue: 31.9	Cell line enhanced		AF22: 49.5;CACO-2: 68.8;HaCaT: 55.0
SLC1A4	ASCT1, SATT	ENSG00000115902	Solute carrier family 1 member 4	2	64988477-65023865	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA034963, HPA034964	Approved		Supported	Centrosome	Liver cancer:4.23e-5 (unfavourable), Cervical cancer:3.59e-4 (favourable), Renal cancer:4.87e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 79.1	Expressed in all		
SLC1A5	AAAT, ASCT2, M7V1, RDRC	ENSG00000105281	Solute carrier family 1 member 5	19	46774883-46788594	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035239, HPA035240	Enhanced		Enhanced	Plasma membrane	Liver cancer:1.66e-8 (unfavourable), Renal cancer:1.18e-7 (unfavourable)	Expressed in all	Expressed in all			epididymis: 119.2	Expressed in all		
SLC1A6	EAAT4	ENSG00000105143	Solute carrier family 1 member 6	19	14950034-15022990	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041505, HPA044066	Enhanced		Uncertain	Intermediate filaments	Urothelial cancer:6.88e-6 (unfavourable)	Tissue enriched	Group enriched	5	cerebral cortex: 16.2;skin: 8.9;testis: 36.9	epididymis: 3.7	Group enriched	5	HAP1: 7.6;NTERA-2: 6.0;U-698: 19.3
SLC1A7	EAAT5	ENSG00000162383	Solute carrier family 1 member 7	1	53087179-53142632	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049124	Supported					Tissue enhanced	Tissue enhanced		gallbladder: 8.5	small intestine: 3.5	Cell line enriched	8	HHSteC: 21.0
SLC20A1	Glvr-1, GLVR1, PiT-1	ENSG00000144136	Solute carrier family 20 member 1	2	112645857-112663827	Predicted membrane proteins, Transporters	Evidence at protein level	CAB019279, HPA035834	Approved		Approved	Vesicles	Renal cancer:3.44e-5 (unfavourable), Head and neck cancer:6.56e-5 (unfavourable)	Expressed in all	Expressed in all			colon: 51.1	Expressed in all		
SLC20A2	Glvr-2, GLVR2, MLVAR, PiT-2, Ram-1	ENSG00000168575	Solute carrier family 20 member 2	8	42416475-42541926	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026540	Approved				Renal cancer:1.01e-4 (favourable), Breast cancer:7.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 138.4	Expressed in all		
SLC22A1	OCT1	ENSG00000175003	Solute carrier family 22 member 1	6	160121789-160158718	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029846	Approved				Liver cancer:1.35e-5 (favourable)	Tissue enriched	Tissue enriched	253	liver: 286.8	gallbladder: 1.1	Not detected		
SLC22A10	hOAT5, OAT5	ENSG00000184999	Solute carrier family 22 member 10	11	63137867-63369718	Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enriched	Tissue enriched	106	liver: 36.2	epididymis: 0.3	Not detected		
SLC22A11	OAT4	ENSG00000168065	Solute carrier family 22 member 11	11	64555626-64572875	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026076	Approved				Renal cancer:3.68e-5 (favourable)	Group enriched	Group enriched	114	epididymis: 10.0;kidney: 26.0;placenta: 44.8	seminal vesicle: 0.2	Cell line enhanced		BEWO: 1.2
SLC22A12	OAT4L, RST, URAT1	ENSG00000197891	Solute carrier family 22 member 12	11	64590641-64602353	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA024575	Enhanced				Renal cancer:2.63e-4 (favourable)	Group enriched	Tissue enriched	198	kidney: 105.0	adipose tissue: 0.5	Not detected		
SLC22A13	OAT10, OCTL1, OCTL3, ORCTL3	ENSG00000172940	Solute carrier family 22 member 13	3	38265812-38278315	Predicted membrane proteins, Transporters	Evidence at protein level	HPA035603, HPA035962	Enhanced					Tissue enriched	Tissue enriched	39	kidney: 10.7	testis: 0.2	Not detected		
SLC22A14	OCTL2, ORCTL4	ENSG00000144671	Solute carrier family 22 member 14	3	38282294-38318575	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	20	testis: 13.5	kidney: 0.6	Not detected		
SLC22A15	FLIPT1	ENSG00000163393	Solute carrier family 22 member 15	1	115976498-116070054	Predicted membrane proteins, Transporters	Evidence at protein level	HPA019785	Approved					Expressed in all	Tissue enhanced		bone marrow: 20.5	skin: 11.1	Cell line enhanced		hTCEpi: 26.0;hTERT-HME1: 36.4
SLC22A16	CT2, FLIPT2, OAT6, OKB1	ENSG00000004809	Solute carrier family 22 member 16	6	110424687-110476641	Predicted membrane proteins	Evidence at protein level	HPA036902	Uncertain					Tissue enriched	Group enriched	8	bone marrow: 12.9;parathyroid gland: 16.3;testis: 38.6	smooth muscle: 2.7	Group enriched	16	NB-4: 10.5;REH: 14.0;THP-1: 35.6;U-937: 24.4
SLC22A17	BOCT, BOIT, NGALR	ENSG00000092096	Solute carrier family 22 member 17	14	23346306-23352912	Predicted membrane proteins, Transporters	Evidence at protein level	HPA002728	Uncertain				Pancreatic cancer:1.73e-4 (favourable), Stomach cancer:5.95e-4 (unfavourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 275.0	prostate: 52.6	Cell line enhanced		AN3-CA: 35.6;SH-SY5Y: 46.8
SLC22A18	BWR1A, BWSCR1A, IMPT1, ITM, ORCTL2, SLC22A1L, TSSC5	ENSG00000110628	Solute carrier family 22 member 18	11	2899721-2925246	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA067812, HPA071461	Enhanced					Expressed in all	Tissue enhanced		duodenum: 43.2;small intestine: 31.7	colon: 10.3	Cell line enhanced		CAPAN-2: 28.3;Karpas-707: 21.3
SLC22A2	OCT2	ENSG00000112499	Solute carrier family 22 member 2	6	160171061-160277638	Predicted membrane proteins, Transporters	Evidence at protein level	HPA008567, CAB068236, CAB068237	Enhanced				Renal cancer:1.85e-7 (favourable)	Tissue enriched	Tissue enriched	83	kidney: 150.3	seminal vesicle: 1.8	Not detected		
SLC22A23	C6orf85, FLJ22174	ENSG00000137266	Solute carrier family 22 member 23	6	3268962-3457022	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014697	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.39e-4 (unfavourable), Endometrial cancer:6.57e-4 (favourable)	Expressed in all	Expressed in all			stomach: 27.9	Mixed		
SLC22A24	MGC34821, NET46	ENSG00000197658	Solute carrier family 22 member 24	11	63079940-63144221	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA045015	Uncertain					Tissue enriched	Tissue enriched	47	kidney: 4.6	all non-specific tissues: 0.0	Not detected		
SLC22A25	HIMTP, MGC120420, UST6	ENSG00000196600	Solute carrier family 22 member 25	11	63163776-63229652	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA039390	Uncertain				Liver cancer:7.04e-4 (favourable)	Tissue enriched	Tissue enriched	58	liver: 5.7	all non-specific tissues: 0.0	Not detected		
SLC22A3	EMT, OCT3	ENSG00000146477	Solute carrier family 22 member 3	6	160348268-160452581	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029750	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Cervical cancer:7.19e-5 (unfavourable), Urothelial cancer:7.26e-4 (unfavourable)	Mixed	Mixed			seminal vesicle: 70.8	Cell line enhanced		A549: 24.2;HeLa: 24.0;Hep G2: 15.5;RPTEC TERT1: 10.1
SLC22A31		ENSG00000259803	Solute carrier family 22 member 31	16	89195761-89201664	Predicted membrane proteins	Evidence at transcript level							Group enriched	Tissue enriched	7	lung: 23.0	pancreas: 3.4	Cell line enhanced		BEWO: 33.0;Hep G2: 19.4;NB-4: 9.3;RPMI-8226: 11.9
SLC22A4	DFNB60, MGC34546, OCTN1	ENSG00000197208	Solute carrier family 22 member 4	5	132294443-132344206	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB015468, HPA036974	Approved		Approved	Mitochondria		Mixed	Tissue enhanced		fallopian tube: 18.4	bone marrow: 13.2	Cell line enhanced		BJ hTERT+: 48.5;U-138 MG: 24.5
SLC22A5	CDSP, OCTN2, SCD	ENSG00000197375	Solute carrier family 22 member 5	5	132369752-132395614	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA063062			Approved	Mitochondria	Endometrial cancer:2.87e-5 (favourable), Pancreatic cancer:7.36e-4 (favourable), Renal cancer:8.36e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 32.1	Cell line enhanced		SiHa: 40.6
SLC22A6	OAT1, PAHT, ROAT1	ENSG00000197901	Solute carrier family 22 member 6	11	62936385-62984983	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA074559, CAB075704	Enhanced					Tissue enriched	Tissue enriched	64	kidney: 200.2	cerebral cortex: 3.1	Not detected		
SLC22A7	NLT, OAT2	ENSG00000137204	Solute carrier family 22 member 7	6	43295694-43305538	Predicted membrane proteins, Transporters	Evidence at protein level	HPA030220	Approved				Liver cancer:5.48e-6 (favourable), Renal cancer:8.98e-4 (favourable)	Tissue enriched	Group enriched	73	kidney: 50.3;liver: 167.8	testis: 1.4	Cell line enriched	14	Hep G2: 6.7
SLC22A8	OAT3	ENSG00000149452	Solute carrier family 22 member 8	11	62989154-63015839	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044174	Enhanced					Tissue enhanced	Tissue enriched	395	kidney: 339.8	cerebral cortex: 0.8	Not detected		
SLC22A9	FLJ23666, OAT4, OAT7, UST3	ENSG00000149742	Solute carrier family 22 member 9	11	63369789-63410294	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	30	liver: 22.8	skeletal muscle: 0.7	Not detected		
SLC23A1	SLC23A2, SVCT1, YSPL3	ENSG00000170482	Solute carrier family 23 member 1	5	139367196-139384553	Predicted membrane proteins, Transporters	Evidence at protein level	HPA047612	Enhanced					Group enriched	Group enriched	5	duodenum: 26.7;fallopian tube: 86.2;kidney: 41.9;small intestine: 72.0	liver: 10.7	Cell line enhanced		CACO-2: 7.7;HDLM-2: 7.6;Hep G2: 9.2;Karpas-707: 7.8;RPMI-8226: 7.6;U-266/70: 12.7
SLC23A2	KIAA0238, SLC23A1, SVCT2, YSPL2	ENSG00000089057	Solute carrier family 23 member 2	20	4852356-5010293	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052825, HPA059314	Approved		Supported	Golgi apparatus<br>Vesicles	Urothelial cancer:6.08e-5 (favourable), Pancreatic cancer:7.14e-5 (favourable), Liver cancer:3.35e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 98.2	Expressed in all		
SLC23A3	FLJ31168, SVCT3, Yspl1	ENSG00000213901	Solute carrier family 23 member 3	2	219161465-219170095	Predicted membrane proteins, Transporters	Evidence at protein level	HPA019059			Approved	Nucleus<br>Cell Junctions		Tissue enriched	Tissue enhanced		kidney: 53.1;small intestine: 22.9	duodenum: 8.7	Cell line enhanced		hTCEpi: 3.5
SLC24A1	CSNB1D, HsT17412, KIAA0702, NCKX, NCKX1, RODX	ENSG00000074621	Solute carrier family 24 member 1	15	65611366-65660995	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039370	Supported		Approved	Microtubules	Renal cancer:2.33e-6 (favourable)	Expressed in all	Mixed			fallopian tube: 8.5	Mixed		
SLC24A2	NCKX2	ENSG00000155886	Solute carrier family 24 member 2	9	19507452-19786928	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	7	cerebral cortex: 51.6	adrenal gland: 7.9	Cell line enhanced		K-562: 2.3;SCLC-21H: 2.6;U-87 MG: 2.9
SLC24A3		ENSG00000185052	Solute carrier family 24 member 3	20	19212646-19722937	Predicted membrane proteins, Transporters	Evidence at protein level	HPA043400, HPA045497	Uncertain				Thyroid cancer:6.08e-4 (unfavourable)	Mixed	Mixed			endometrium: 47.7	Cell line enhanced		BJ hTERT+: 10.7;HEL: 16.2;HMC-1: 68.3;T-47d: 15.9
SLC24A4	NCKX4	ENSG00000140090	Solute carrier family 24 member 4	14	92322581-92501483	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 7.1	spleen: 2.7	Cell line enhanced		SCLC-21H: 1.5
SLC24A5	JSX, OCA6	ENSG00000188467	Solute carrier family 24 member 5	15	48120972-48142672	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Group enriched	21	skin: 9.6;testis: 2.9	breast: 0.3	Cell line enriched	760	SK-MEL-30: 193.4
SLC25A10	DIC	ENSG00000183048	Solute carrier family 25 member 10	17	81712236-81721016	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA023048	Supported		Supported	Nucleoplasm<br>Mitochondria	Urothelial cancer:1.31e-4 (favourable), Head and neck cancer:2.56e-4 (favourable), Ovarian cancer:8.14e-4 (favourable)	Expressed in all	Mixed			kidney: 35.4	Expressed in all		
SLC25A11	OGC, SLC20A4	ENSG00000108528	Solute carrier family 25 member 11	17	4937130-4940251	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA021167	Approved				Renal cancer:2.84e-9 (favourable), Pancreatic cancer:6.41e-6 (favourable)	Expressed in all	Expressed in all			heart muscle: 152.4	Expressed in all		
SLC25A14	BMCP1, UCP5	ENSG00000102078	Solute carrier family 25 member 14	X	130339888-130373361	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA060316			Approved	Mitochondria	Renal cancer:5.52e-6 (unfavourable), Urothelial cancer:1.39e-5 (favourable), Cervical cancer:1.72e-5 (favourable), Pancreatic cancer:1.78e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 20.4	Expressed in all		
SLC25A15	D13S327, HHH, ORC1, ORNT1	ENSG00000102743	Solute carrier family 25 member 15	13	40789412-40810111	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042146	Approved				Renal cancer:1.74e-4 (favourable), Liver cancer:2.16e-4 (favourable), Urothelial cancer:5.46e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 49.6	Expressed in all		
SLC25A16	D10S105E, GDA, HGT.1, ML7	ENSG00000122912	Solute carrier family 25 member 16	10	68477999-68527474	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036243, HPA044580	Uncertain		Approved	Mitochondria		Expressed in all	Mixed			prostate: 13.4	Mixed		
SLC25A17	PMP34	ENSG00000100372	Solute carrier family 25 member 17	22	40769630-40819399	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052708, HPA060972	Approved		Supported	Peroxisomes		Expressed in all	Expressed in all			ovary: 24.1	Expressed in all		
SLC25A18		ENSG00000182902	Solute carrier family 25 member 18	22	17563439-17590994	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 74.5;liver: 25.2	adipose tissue: 13.8	Cell line enhanced		BEWO: 8.2
SLC25A19	DNC, MCPHA, MUP1, TPC	ENSG00000125454	Solute carrier family 25 member 19	17	75272981-75289510	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Liver cancer:1.21e-7 (unfavourable), Endometrial cancer:8.72e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 49.2	Expressed in all		
SLC25A2	ORNT2	ENSG00000120329	Solute carrier family 25 member 2	5	141302629-141304045	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042146	Uncertain					Not detected	Tissue enriched	117	testis: 11.6	all non-specific tissues: 0.0	Not detected		
SLC25A20	CAC, CACT	ENSG00000178537	Solute carrier family 25 member 20	3	48856931-48898993	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016862, HPA029863	Approved		Supported	Mitochondria<br>Cytosol		Expressed in all	Expressed in all			liver: 70.9	Cell line enhanced		RPMI-8226: 88.8
SLC25A22	EIEE3, FLJ13044, GC1, NET44	ENSG00000177542	Solute carrier family 25 member 22	11	790475-798333	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014662	Approved		Enhanced	Nucleoplasm<br>Mitochondria		Expressed in all	Tissue enriched	6	cerebral cortex: 89.6	testis: 15.2	Expressed in all		
SLC25A23	APC2, FLJ30339, MGC2615	ENSG00000125648	Solute carrier family 25 member 23	19	6436079-6465203	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA009675, HPA050883	Approved		Supported	Mitochondria	Renal cancer:1.10e-12 (favourable), Endometrial cancer:1.29e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 141.3	Mixed		
SLC25A26		ENSG00000144741	Solute carrier family 25 member 26	3	66133610-66388116	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026887	Enhanced		Supported	Mitochondria	Renal cancer:1.73e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.5	Expressed in all		
SLC25A3	PHC	ENSG00000075415	Solute carrier family 25 member 3	12	98593591-98606379	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA045709			Supported	Mitochondria	Renal cancer:8.11e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 595.7	Expressed in all		
SLC25A31	ANT4, DKFZP434N1235	ENSG00000151475	Solute carrier family 25 member 31	4	127730378-127774299	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015064, HPA016841, HPA046835, HPA071684	Uncertain		Enhanced	Mitochondria		Not detected	Tissue enriched	852	testis: 85.1	all non-specific tissues: 0.0	Not detected		
SLC25A33	BMSC-MCP, MGC4399, PNC1	ENSG00000171612	Solute carrier family 25 member 33	1	9539482-9585179	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049982	Uncertain				Cervical cancer:4.86e-4 (favourable), Lung cancer:7.02e-4 (favourable)	Expressed in all	Mixed			testis: 22.1	Expressed in all		
SLC25A34	DKFZp781A10161	ENSG00000162461	Solute carrier family 25 member 34	1	15736405-15741396	Predicted membrane proteins, Transporters	Evidence at protein level	HPA069806			Supported	Mitochondria		Mixed	Tissue enhanced		duodenum: 14.5;small intestine: 15.2	skeletal muscle: 8.2	Mixed		
SLC25A35	FLJ40217	ENSG00000125434	Solute carrier family 25 member 35	17	8287763-8295343	Predicted membrane proteins, Transporters	Evidence at protein level	HPA051720	Uncertain		Approved	Vesicles<br>Mitochondria	Endometrial cancer:3.37e-7 (favourable), Renal cancer:1.14e-6 (favourable), Urothelial cancer:1.91e-5 (favourable)	Expressed in all	Mixed			testis: 19.3	Mixed		
SLC25A36	FLJ10618, PNC2	ENSG00000114120	Solute carrier family 25 member 36	3	140941830-140979933	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA027036	Approved		Approved	Nucleus<br>Mitochondria<br>Cytosol	Urothelial cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 69.5	Expressed in all		
SLC25A38	FLJ20551	ENSG00000144659	Solute carrier family 25 member 38	3	39383348-39397351	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041027	Approved				Renal cancer:1.58e-5 (favourable), Urothelial cancer:7.29e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 65.9	Expressed in all		
SLC25A39	CGI-69, FLJ22407	ENSG00000013306	Solute carrier family 25 member 39	17	44319625-44324870	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA026785	Approved				Renal cancer:3.58e-5 (favourable), Liver cancer:5.90e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 181.1	Expressed in all		
SLC25A4	ANT1, PEO2, PEO3, T1	ENSG00000151729	Solute carrier family 25 member 4	4	185143241-185150382	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046835, HPA071684	Approved		Enhanced	Mitochondria	Renal cancer:0.00e+0 (favourable), Pancreatic cancer:3.41e-4 (favourable)	Expressed in all	Tissue enhanced		heart muscle: 122.1;skeletal muscle: 66.2	cerebral cortex: 38.1	Mixed		
SLC25A40	MCFP	ENSG00000075303	Solute carrier family 25 member 40	7	87833568-87876357	Predicted membrane proteins, Transporters	Evidence at protein level	HPA055197	Uncertain				Renal cancer:1.52e-5 (favourable), Liver cancer:1.93e-4 (unfavourable)	Expressed in all	Mixed			prostate: 14.1	Expressed in all		
SLC25A42	MGC26694	ENSG00000181035	Solute carrier family 25 member 42	19	19063999-19112888	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049449	Approved		Supported	Mitochondria	Lung cancer:4.11e-4 (favourable), Cervical cancer:5.04e-4 (favourable)	Expressed in all	Expressed in all			kidney: 28.8	Mixed		
SLC25A43		ENSG00000077713	Solute carrier family 25 member 43	X	119399060-119454478	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA035188	Uncertain		Approved	Nucleus	Renal cancer:5.06e-8 (unfavourable), Endometrial cancer:3.76e-5 (unfavourable)	Expressed in all	Mixed			esophagus: 20.5	Mixed		
SLC25A44	FLJ90431, KIAA0446	ENSG00000160785	Solute carrier family 25 member 44	1	156193932-156212796	Predicted membrane proteins, Transporters	Evidence at protein level	HPA065411			Approved	Nucleus<br>Mitochondria	Pancreatic cancer:2.49e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 43.0	Expressed in all		
SLC25A45		ENSG00000162241	Solute carrier family 25 member 45	11	65375192-65383701	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050821	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.83e-4 (favourable)	Expressed in all	Expressed in all			spleen: 12.4	Cell line enhanced		HDLM-2: 16.2;Karpas-707: 16.4
SLC25A46		ENSG00000164209	Solute carrier family 25 member 46	5	110738136-110765161	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039601, HPA071582	Approved		Supported	Mitochondria	Thyroid cancer:2.52e-4 (unfavourable), Colorectal cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.6	Expressed in all		
SLC25A47	C14orf68	ENSG00000140107	Solute carrier family 25 member 47	14	100323337-100330378	Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enriched	Tissue enriched	171	liver: 101.0	duodenum,small intestine: 0.5	Cell line enhanced		Hep G2: 1.1
SLC25A48	FLJ44862, HDMCP	ENSG00000145832	Solute carrier family 25 member 48	5	135834649-135888637	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014674	Uncertain		Approved	Intermediate filaments<br>Actin filaments		Mixed	Tissue enhanced		cerebral cortex: 17.7;kidney: 7.3	skeletal muscle: 2.7	Cell line enhanced		HAP1: 2.4;HEK93: 1.6;SCLC-21H: 2.0;U-2 OS: 2.3
SLC25A5	2F1, ANT2, T2, T3	ENSG00000005022	Solute carrier family 25 member 5	X	119468400-119471319	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046835, HPA071684	Approved		Supported	Mitochondria	Renal cancer:8.06e-6 (favourable), Cervical cancer:7.35e-4 (favourable), Colorectal cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 769.6	Expressed in all		
SLC25A51	CG7943, MCART1, MGC14836	ENSG00000122696	Solute carrier family 25 member 51	9	37879400-37904353	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046388, HPA058261	Uncertain		Approved	Mitochondria	Liver cancer:5.67e-5 (unfavourable), Renal cancer:1.52e-4 (favourable), Thyroid cancer:2.21e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.4	Expressed in all		
SLC25A52	MCART2	ENSG00000141437	Solute carrier family 25 member 52	18	31759562-31760880	Predicted membrane proteins	Evidence at transcript level	HPA046388, HPA058261	Uncertain		Approved	Mitochondria		Not detected	Tissue enriched	64	testis: 15.4	adipose tissue,skin: 0.2	Not detected		
SLC25A53	MCART6	ENSG00000269743	Solute carrier family 25 member 53	X	104099214-104157027	Predicted membrane proteins	Evidence at protein level	HPA034959	Uncertain					Mixed	Mixed			cerebral cortex: 2.5	Cell line enhanced		Daudi: 4.3;Karpas-707: 10.0
SLC25A6	ANT3, ANT3Y, MGC17525	ENSG00000169100	Solute carrier family 25 member 6	X	1386152-1392724	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046835, HPA071684	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			ovary: 291.7	Expressed in all		
SLC26A1	EDM4, SAT-1	ENSG00000145217	Solute carrier family 26 member 1	4	979073-993440	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041654	Uncertain		Approved	Microtubules	Renal cancer:1.19e-4 (favourable)	Mixed	Mixed			adrenal gland,kidney: 6.0	Mixed		
SLC26A10		ENSG00000135502	Solute carrier family 26 member 10	12	57619527-57626151	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA044719	Uncertain					Tissue enhanced	Mixed			endometrium: 1.7	Cell line enhanced		NTERA-2: 3.0;RH-30: 2.2;SH-SY5Y: 4.4;U-266/70: 2.2
SLC26A11		ENSG00000181045	Solute carrier family 26 member 11	17	80219699-80253500	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029893	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Liver cancer:1.82e-6 (unfavourable), Pancreatic cancer:1.43e-5 (favourable), Endometrial cancer:1.55e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 34.4	Mixed		
SLC26A2	DTD, DTDST	ENSG00000155850	Solute carrier family 26 member 2	5	149960737-149993455	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041957, HPA058090	Enhanced		Approved	Vesicles	Renal cancer:3.27e-4 (unfavourable), Liver cancer:4.66e-4 (unfavourable), Endometrial cancer:7.29e-4 (favourable)	Expressed in all	Tissue enhanced		colon: 213.0;rectum: 207.1	parathyroid gland: 82.7	Expressed in all		
SLC26A3	CLD, DRA	ENSG00000091138	Solute carrier family 26 member 3	7	107765467-107803225	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036055	Approved					Tissue enriched	Tissue enhanced		colon: 1075.0;duodenum: 577.9;rectum: 961.7	seminal vesicle: 185.8	Cell line enhanced		RPMI-8226: 1.9
SLC26A4	DFNB4, PDS	ENSG00000091137	Solute carrier family 26 member 4	7	107660635-107717809	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042860	Approved					Tissue enriched	Tissue enriched	28	thyroid gland: 419.0	cerebral cortex: 15.1	Cell line enhanced		LHCN-M2: 3.7;SCLC-21H: 1.9
SLC26A5	DFNB61, PRES	ENSG00000170615	Solute carrier family 26 member 5	7	103352730-103446177	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level							Mixed	Not detected			breast,parathyroid gland: 0.9	Not detected		
SLC26A6	DKFZp586E1422	ENSG00000225697	Solute carrier family 26 member 6	3	48625723-48635493	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA048363	Approved		Uncertain	Cytosol	Renal cancer:1.53e-5 (unfavourable), Liver cancer:3.92e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 24.0	Expressed in all		
SLC26A7	SUT2	ENSG00000147606	Solute carrier family 26 member 7	8	91209494-91398152	Predicted membrane proteins	Evidence at transcript level							Group enriched	Tissue enriched	21	thyroid gland: 550.6	kidney: 26.3	Not detected		
SLC26A8		ENSG00000112053	Solute carrier family 26 member 8	6	35943514-36024868	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038081	Enhanced					Not detected	Tissue enriched	27	testis: 76.1	bone marrow: 2.8	Not detected		
SLC26A9		ENSG00000174502	Solute carrier family 26 member 9	1	205913048-205943460	Predicted membrane proteins, Transporters	Evidence at protein level	HPA051485	Enhanced		Approved	Nucleus<br>Cell Junctions	Head and neck cancer:8.55e-5 (favourable)	Tissue enhanced	Group enriched	5	lung: 11.4;salivary gland: 31.5;stomach: 30.8	tonsil: 4.8	Group enriched	12	CAPAN-2: 11.8;Hep G2: 3.4
SLC27A1	ACSVL5, FATP, FATP1, FLJ00336, MGC71751	ENSG00000130304	Solute carrier family 27 member 1	19	17468769-17506168	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA076520			Approved	Plasma membrane<br>Mitochondria<br>Cytosol	Renal cancer:4.70e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 34.5	Cell line enhanced		SK-MEL-30: 36.4
SLC27A2	ACSVL1, FACVL1, FATP2, hFACVL1, HsT17226, VLACS, VLCS	ENSG00000140284	Solute carrier family 27 member 2	15	50182196-50236395	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026089	Enhanced				Renal cancer:7.48e-6 (favourable), Urothelial cancer:6.40e-4 (favourable)	Tissue enhanced	Group enriched	5	epididymis: 80.1;kidney: 162.3;liver: 145.5	placenta: 24.7	Cell line enhanced		HaCaT: 78.4;HL-60: 52.3;SCLC-21H: 47.4
SLC27A3	ACSVL3, FATP3, MGC4365	ENSG00000143554	Solute carrier family 27 member 3	1	153774354-153780157	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006935, HPA067508	Uncertain		Supported	Endoplasmic reticulum	Pancreatic cancer:5.23e-4 (favourable), Renal cancer:6.33e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 43.9	lung: 20.9	Cell line enhanced		ASC diff: 42.9;MCF7: 27.0
SLC27A4	ACSVL4, FATP4	ENSG00000167114	Solute carrier family 27 member 4	9	128340646-128361470	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007293, CAB009771	Approved		Supported	Vesicles	Renal cancer:2.61e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 72.1	Expressed in all		
SLC27A5	ACSB, ACSVL6, FACVL3, FATP5, FLJ22987, VLACSR, VLCS-H2, VLCSH2	ENSG00000083807	Solute carrier family 27 member 5	19	58479512-58512413	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007292, CAB056160, CAB068239	Enhanced				Liver cancer:1.57e-4 (favourable)	Tissue enriched	Tissue enriched	23	liver: 337.5	fallopian tube: 14.7	Mixed		
SLC27A6	ACSVL2, FACVL2, FATP6, VLCS-H1	ENSG00000113396	Solute carrier family 27 member 6	5	128538013-129033642	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008987	Approved		Approved	Nuclear bodies		Tissue enriched	Tissue enhanced		adrenal gland: 32.6;fallopian tube: 34.0	testis: 24.3	Cell line enriched	9	BEWO: 42.4
SLC28A1	CNT1	ENSG00000156222	Solute carrier family 28 member 1	15	84884654-84945796	Predicted membrane proteins, Transporters	Evidence at protein level	HPA019551	Enhanced					Group enriched	Group enriched	26	duodenum: 37.9;kidney: 49.4;liver: 35.4;small intestine: 53.6	placenta: 1.7	Not detected		
SLC28A2	CNT2, HCNT2, HsT17153, SPNT1	ENSG00000137860	Solute carrier family 28 member 2	15	45252230-45277845	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046068, HPA055623	Enhanced					Tissue enhanced	Tissue enhanced		duodenum: 64.9;rectum: 37.1;small intestine: 97.9	stomach: 21.0	Not detected		
SLC28A3	CNT3	ENSG00000197506	Solute carrier family 28 member 3	9	84275457-84340683	Predicted membrane proteins, Transporters	Evidence at protein level	HPA023311, HPA024729	Approved				Breast cancer:3.37e-4 (favourable)	Mixed	Tissue enhanced		breast: 10.7;gallbladder: 11.7;skin: 9.8	bone marrow: 6.2	Cell line enriched	8	HMC-1: 51.9
SLC29A1	ENT1	ENSG00000112759	Solute carrier family 29 member 1 (Augustine blood group)	6	44219505-44234151	Predicted membrane proteins, Transporters	Evidence at protein level	HPA012384	Approved				Renal cancer:2.96e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 124.4	Expressed in all		
SLC29A2	DER12, ENT2, HNP36	ENSG00000174669	Solute carrier family 29 member 2	11	66362521-66372214	Predicted membrane proteins, Transporters	Evidence at protein level	HPA018168	Approved		Uncertain	Nucleoplasm	Endometrial cancer:2.04e-4 (unfavourable), Renal cancer:2.78e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 36.4	parathyroid gland: 21.9	Cell line enhanced		CAPAN-2: 37.2;T-47d: 48.0
SLC29A3	ENT3, FLJ11160	ENSG00000198246	Solute carrier family 29 member 3	10	71319258-71363385	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046085, HPA054976, HPA057905	Approved		Supported	Golgi apparatus<br>Vesicles	Liver cancer:6.07e-6 (unfavourable), Renal cancer:5.53e-5 (unfavourable), Thyroid cancer:1.16e-4 (favourable)	Expressed in all	Mixed			placenta: 18.8	Cell line enhanced		BEWO: 35.2
SLC29A4	ENT4, FLJ34923	ENSG00000164638	Solute carrier family 29 member 4	7	5274369-5306870	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052829			Supported	Microtubules<br>Cytokinetic bridge	Pancreatic cancer:4.52e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 44.2	cerebral cortex: 12.0	Cell line enhanced		AN3-CA: 45.6;SH-SY5Y: 74.8
SLC2A1	CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR	ENSG00000117394	Solute carrier family 2 member 1	1	42925375-42959173	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002759, HPA031345, HPA058494	Enhanced	Supported	Enhanced	Plasma membrane	Renal cancer:4.55e-9 (unfavourable), Liver cancer:3.65e-8 (unfavourable), Pancreatic cancer:4.39e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Urothelial cancer:4.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 293.0	skin: 59.3	Expressed in all		
SLC2A10	GLUT10	ENSG00000197496	Solute carrier family 2 member 10	20	46709487-46736347	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041015	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			prostate: 49.3	Cell line enhanced		SK-MEL-30: 45.7
SLC2A11	GLUT10, GLUT11	ENSG00000133460	Solute carrier family 2 member 11	22	23856703-23886309	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA042960, HPA071184	Uncertain		Uncertain	Nucleus<br>Cell Junctions	Renal cancer:5.77e-7 (favourable), Pancreatic cancer:3.83e-4 (favourable)	Mixed	Mixed			parathyroid gland: 10.9	Mixed		
SLC2A12	GLUT12, GLUT8	ENSG00000146411	Solute carrier family 2 member 12	6	133988697-134052636	Predicted membrane proteins, Transporters	Evidence at protein level	HPA031593, HPA031594	Approved		Enhanced	Plasma membrane<br>Cell Junctions		Tissue enriched	Tissue enhanced		prostate: 43.3	endometrium: 16.1	Cell line enhanced		CAPAN-2: 8.0;HaCaT: 6.1;U-2 OS: 10.1
SLC2A13	HMIT	ENSG00000151229	Solute carrier family 2 member 13	12	39755021-40106089	Predicted membrane proteins, Transporters	Evidence at protein level	HPA006584	Approved		Approved	Nuclear membrane		Mixed	Tissue enhanced		cerebral cortex: 49.3;parathyroid gland: 74.7	cervix, uterine: 20.4	Mixed		
SLC2A14	GLUT14, SLC2A3P3	ENSG00000173262	Solute carrier family 2 member 14	12	7812512-7891148	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006539	Supported		Approved	Plasma membrane		Tissue enriched	Tissue enriched	35	testis: 148.8	ovary: 4.2	Cell line enhanced		BEWO: 17.9;CACO-2: 25.7
SLC2A2	GLUT2	ENSG00000163581	Solute carrier family 2 member 2	3	170996348-171026750	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB010444, HPA028997, HPA028998	Enhanced		Approved	Nucleoplasm	Liver cancer:2.63e-5 (favourable)	Tissue enriched	Tissue enriched	7	liver: 433.0	duodenum: 65.7	Group enriched	61	CACO-2: 6.7;Hep G2: 18.6
SLC2A3	GLUT3	ENSG00000059804	Solute carrier family 2 member 3	12	7919230-7936275	Predicted membrane proteins, Transporters	Evidence at protein level	CAB002763, HPA006539	Approved		Approved	Plasma membrane	Renal cancer:6.36e-8 (unfavourable), Stomach cancer:2.89e-5 (unfavourable), Colorectal cancer:8.58e-4 (unfavourable)	Tissue enriched	Tissue enhanced		bone marrow: 271.2	placenta: 138.7	Group enriched	7	BEWO: 1387.7;CACO-2: 1315.8;NTERA-2: 293.2
SLC2A4	GLUT4	ENSG00000181856	Solute carrier family 2 member 4	17	7281667-7288257	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016544	Enhanced					Mixed	Tissue enhanced		heart muscle: 32.6;skeletal muscle: 45.0	adipose tissue: 21.8	Cell line enhanced		Hep G2: 3.7
SLC2A5	GLUT5	ENSG00000142583	Solute carrier family 2 member 5	1	9035107-9088478	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005449	Enhanced				Renal cancer:5.44e-5 (unfavourable)	Group enriched	Tissue enhanced		duodenum: 109.0;small intestine: 92.6;testis: 139.9	bone marrow: 64.4	Cell line enhanced		Daudi: 134.4;U-266/70: 111.0;U-698: 121.2;U-937: 52.9
SLC2A6	GLUT6, GLUT9, HSA011372	ENSG00000160326	Solute carrier family 2 member 6	9	133471095-133479137	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042272, CAB046014	Uncertain				Renal cancer:1.02e-11 (unfavourable), Glioma:1.94e-4 (unfavourable), Liver cancer:8.82e-4 (unfavourable)	Expressed in all	Mixed			appendix: 6.1	Cell line enhanced		HMC-1: 57.7
SLC2A7	GLUT7	ENSG00000197241	Solute carrier family 2 member 7	1	9003300-9026345	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039931	Uncertain					Not detected	Group enriched	8	duodenum: 3.0;small intestine: 3.1	epididymis,testis: 0.3	Not detected		
SLC2A8	GLUT8, GLUTX1	ENSG00000136856	Solute carrier family 2 member 8	9	127397138-127408424	Predicted membrane proteins, Transporters	Evidence at protein level	HPA011935	Uncertain		Approved	Vesicles	Cervical cancer:2.57e-6 (favourable), Renal cancer:6.55e-6 (favourable), Pancreatic cancer:9.86e-6 (favourable)	Expressed in all	Expressed in all			testis: 50.0	Cell line enhanced		CACO-2: 101.8
SLC2A9	Glut9, GLUTX, URATv1	ENSG00000109667	Solute carrier family 2 member 9	4	9771153-10054936	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA066229	Enhanced				Renal cancer:1.32e-11 (favourable)	Mixed	Tissue enhanced		kidney: 30.8;seminal vesicle: 27.2	placenta: 11.1	Cell line enhanced		HBEC3-KT: 34.8;Hep G2: 16.1;hTCEpi: 14.4;THP-1: 13.9;U-937: 10.7
SLC30A1	ZNT1, ZRC1	ENSG00000170385	Solute carrier family 30 member 1	1	211571568-211578742	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015275, HPA049000	Uncertain		Supported	Vesicles<br>Plasma membrane		Expressed in all	Mixed			liver: 47.3	Expressed in all		
SLC30A10	DKFZp547M236, ZnT-10, ZNT8, ZRC1	ENSG00000196660	Solute carrier family 30 member 10	1	219685427-219958647	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064547	Enhanced					Tissue enriched	Tissue enhanced		duodenum: 2.1;liver: 2.3	testis: 1.2	Cell line enhanced		HEK93: 1.2
SLC30A2	ZNT2	ENSG00000158014	Solute carrier family 30 member 2	1	26037252-26046133	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017979			Approved	Vesicles	Renal cancer:2.86e-6 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 22.0;thyroid gland: 42.4	pancreas: 16.5	Group enriched	5	BEWO: 2.4;RPTEC TERT1: 4.3;WM-115: 3.5
SLC30A3	ZNT3	ENSG00000115194	Solute carrier family 30 member 3	2	27253684-27275817	Predicted membrane proteins, Transporters	Evidence at protein level	HPA060505, HPA067637, CAB079044	Enhanced	Approved	Approved	Nucleus<br>Nucleoli<br>Vesicles<br>Cytosol		Mixed	Group enriched	12	cerebral cortex: 36.6;epididymis: 55.4;testis: 43.5	heart muscle: 3.6	Cell line enhanced		HAP1: 10.6;Hep G2: 9.5;REH: 20.7;RH-30: 11.0
SLC30A4	ZNT4	ENSG00000104154	Solute carrier family 30 member 4	15	45479611-45522807	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018178	Uncertain				Pancreatic cancer:6.02e-4 (favourable)	Tissue enriched	Tissue enriched	5	prostate: 64.5	testis: 11.8	Mixed		
SLC30A5	FLJ12496, FLJ12756, MGC5499, ZnT-5, ZNT5, ZNTL1, ZTL1	ENSG00000145740	Solute carrier family 30 member 5	5	69093646-69131069	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035373	Approved		Supported	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 61.7	Expressed in all		
SLC30A6	FLJ31101, ZNT6	ENSG00000152683	Solute carrier family 30 member 6	2	32165841-32224379	Predicted membrane proteins, Transporters	Evidence at protein level	HPA055032, HPA057328	Uncertain		Enhanced	Golgi apparatus	Liver cancer:9.58e-6 (unfavourable), Endometrial cancer:6.55e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 19.8	Expressed in all		
SLC30A7	ZNT7, ZnTL2	ENSG00000162695	Solute carrier family 30 member 7	1	100896076-100981753	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018034	Uncertain		Supported	Golgi apparatus		Expressed in all	Mixed			parathyroid gland: 20.9	Expressed in all		
SLC30A8	ZnT-8, ZNT8	ENSG00000164756	Solute carrier family 30 member 8	8	116950273-117176714	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA076165	Enhanced					Group enriched	Tissue enhanced		pancreas: 13.2	salivary gland: 4.9	Group enriched	27	U-266/70: 36.7;U-266/84: 25.2
SLC30A9	C4orf1, GAC63, HUEL, ZNT9	ENSG00000014824	Solute carrier family 30 member 9	4	41990472-42090457	Predicted membrane proteins, Transporters	Evidence at protein level	HPA004014	Approved				Renal cancer:2.86e-14 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.1	Expressed in all		
SLC31A1	COPT1, CTR1, hCTR1	ENSG00000136868	Solute carrier family 31 member 1	9	113221562-113264492	Predicted membrane proteins, Transporters	Evidence at protein level	HPA013810	Approved				Renal cancer:2.20e-6 (favourable), Thyroid cancer:2.03e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 56.5	Expressed in all		
SLC31A2	COPT2, CTR2, hCTR2	ENSG00000136867	Solute carrier family 31 member 2	9	113150942-113164137	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014861	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Intermediate filaments		Mixed	Expressed in all			salivary gland: 169.9	Cell line enhanced		hTCEpi: 59.3
SLC32A1	bA122O1.1, VGAT, VIAAT	ENSG00000101438	Solute carrier family 32 member 1	20	38724462-38729372	Predicted membrane proteins, Transporters	Evidence at protein level	CAB037156, HPA058859, HPA059985	Enhanced	Supported				Tissue enhanced	Tissue enriched	35	cerebral cortex: 15.9	testis: 0.4	Cell line enhanced		MOLT-4: 1.1
SLC33A1	ACATN, AT-1, AT1, SPG42	ENSG00000169359	Solute carrier family 33 member 1	3	155821024-155854429	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042430, HPA060345	Uncertain		Approved	Nucleus		Expressed in all	Expressed in all			thyroid gland: 67.3	Expressed in all		
SLC34A1	NAPI-3, NPT2, NPTIIa, SLC11, SLC17A2	ENSG00000131183	Solute carrier family 34 member 1	5	177379235-177398848	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051255	Approved		Supported	Nuclear speckles<br>Plasma membrane<br>Mitotic spindle		Tissue enriched	Tissue enriched	164	kidney: 161.7	liver: 0.9	Group enriched	12	HEL: 2.1;U-937: 1.2
SLC34A2	NAPI-3B	ENSG00000157765	Solute carrier family 34 member 2	4	25655301-25678748	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037989	Enhanced					Tissue enhanced	Tissue enriched	10	lung: 1121.1	fallopian tube: 111.8	Group enriched	76	BEWO: 31.0;EFO-21: 114.1;RPTEC TERT1: 66.5
SLC34A3	FLJ38680, NPTIIc	ENSG00000198569	Solute carrier family 34 member 3	9	137230757-137236554	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA023776	Enhanced					Mixed	Group enriched	15	kidney: 11.8;small intestine: 9.1	testis: 0.7	Cell line enhanced		CAPAN-2: 2.9;MCF7: 4.2
SLC35A1	CMPST, hCST	ENSG00000164414	Solute carrier family 35 member A1	6	87470623-87512336	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:2.70e-6 (unfavourable)	Expressed in all	Expressed in all			prostate: 59.5	Expressed in all		
SLC35A2	UGALT, UGAT, UGT, UGT1, UGT2, UGTL	ENSG00000102100	Solute carrier family 35 member A2	X	48903180-48911958	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036087	Approved		Supported	Golgi apparatus	Liver cancer:9.64e-5 (unfavourable), Breast cancer:3.16e-4 (unfavourable), Stomach cancer:8.23e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 45.0	Expressed in all		
SLC35A3		ENSG00000117620	Solute carrier family 35 member A3	1	99969351-100035637	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015253	Uncertain					Expressed in all	Expressed in all			rectum: 58.7	Expressed in all		
SLC35A4		ENSG00000176087	Solute carrier family 35 member A4	5	140564456-140569103	Predicted membrane proteins, Transporters	Evidence at protein level	HPA062210			Approved	Nucleoplasm	Renal cancer:4.56e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 113.2	Mixed		
SLC35A5	FLJ20730	ENSG00000138459	Solute carrier family 35 member A5	3	112561709-112585577	Predicted membrane proteins, Transporters	Evidence at protein level	HPA035519, HPA057964	Uncertain		Approved	Golgi apparatus	Renal cancer:4.10e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 43.9	Expressed in all		
SLC35B1	UGTREL1	ENSG00000121073	Solute carrier family 35 member B1	17	49700943-49709014	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA048655, HPA057418	Approved		Approved	Nucleus<br>Endoplasmic reticulum<br>Vesicles	Renal cancer:5.69e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 52.2	Expressed in all		
SLC35B2	UGTrel4	ENSG00000157593	Solute carrier family 35 member B2	6	44254096-44257890	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029638	Approved		Approved	Vesicles	Liver cancer:8.59e-5 (unfavourable), Prostate cancer:6.07e-4 (favourable), Breast cancer:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.2	Expressed in all		
SLC35B3	C6orf196, CGI-19, dJ453H5.1, PAPST2	ENSG00000124786	Solute carrier family 35 member B3	6	8413068-8435483	Predicted membrane proteins, Transporters	Evidence at protein level	HPA054661, HPA057801	Approved					Expressed in all	Expressed in all			epididymis: 63.2	Expressed in all		
SLC35B4	FLJ14697, YEA4	ENSG00000205060	Solute carrier family 35 member B4	7	134289332-134317051	Predicted membrane proteins	Evidence at protein level	HPA049779	Approved					Expressed in all	Mixed			cerebral cortex: 17.8	Expressed in all		
SLC35C1	FLJ11320, FUCT1	ENSG00000181830	Solute carrier family 35 member C1	11	45804072-45813015	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064001	Enhanced		Supported	Golgi apparatus	Thyroid cancer:3.64e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 29.4	Expressed in all		
SLC35C2	bA394O2.1, C20orf5, CGI-15, OVCOV1	ENSG00000080189	Solute carrier family 35 member C2	20	46345980-46364458	Predicted membrane proteins, Transporters	Evidence at protein level	HPA027011	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:1.08e-4 (unfavourable), Renal cancer:8.68e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 37.0	Expressed in all		
SLC35D1	KIAA0260, UGTREL7	ENSG00000116704	Solute carrier family 35 member D1	1	66999332-67054099	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Lung cancer:6.55e-4 (unfavourable), Endometrial cancer:7.47e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 38.5	Expressed in all		
SLC35D2	SQV7L, UGTrel8	ENSG00000130958	Solute carrier family 35 member D2	9	96320706-96383710	Predicted membrane proteins, Transporters	Evidence at protein level	HPA064047	Approved		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			small intestine: 72.4	Mixed		
SLC35D3	FRCL1	ENSG00000182747	Solute carrier family 35 member D3	6	136922264-136925639	Predicted membrane proteins, Transporters	Evidence at protein level	HPA030431, HPA067497	Uncertain		Approved	Microtubule organizing center		Tissue enhanced	Tissue enhanced		adrenal gland: 1.2	lung,stomach: 0.6	Group enriched	16	SCLC-21H: 4.2;SH-SY5Y: 16.3
SLC35E1	FLJ14251	ENSG00000127526	Solute carrier family 35 member E1	19	16549831-16572382	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016570, HPA062214	Approved		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 28.5	Expressed in all		
SLC35E2	KIAA0447	ENSG00000215790	Solute carrier family 35 member E2	1	1724838-1745992	Predicted membrane proteins	Evidence at transcript level	HPA062711	Uncertain		Uncertain	Nucleus		Mixed	Mixed			thyroid gland: 7.5	Mixed		
SLC35E2B		ENSG00000189339	Solute carrier family 35 member E2B	1	1659529-1692728	Predicted membrane proteins, Transporters	Evidence at protein level	HPA045641, HPA062711	Uncertain		Uncertain	Nucleus	Urothelial cancer:5.15e-4 (favourable), Head and neck cancer:7.64e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 47.2	Expressed in all		
SLC35E3	BLOV1	ENSG00000175782	Solute carrier family 35 member E3	12	68746106-68793964	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level	HPA049403	Uncertain				Endometrial cancer:1.78e-4 (favourable)	Expressed in all	Mixed			skin: 6.1	Mixed		
SLC35E4		ENSG00000100036	Solute carrier family 35 member E4	22	30635652-30669016	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA049558	Approved		Approved	Cytosol		Mixed	Tissue enhanced		testis: 17.6	cerebral cortex: 5.1	Mixed		
SLC35F1	C6orf169, dJ230I3.1	ENSG00000196376	Solute carrier family 35 member F1	6	117907526-118317676	Predicted membrane proteins, Transporters	Evidence at protein level	HPA019576	Enhanced		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol		Group enriched	Tissue enriched	12	cerebral cortex: 45.4	epididymis: 3.7	Group enriched	10	AF22: 47.2;WM-115: 80.1
SLC35F2	FLJ13018	ENSG00000110660	Solute carrier family 35 member F2	11	107790991-107928293	Predicted membrane proteins, Transporters	Evidence at protein level	HPA048185, HPA050695	Uncertain		Approved	Mitochondria	Pancreatic cancer:5.92e-6 (unfavourable), Lung cancer:4.03e-4 (unfavourable), Glioma:7.31e-4 (favourable)	Expressed in all	Mixed			prostate: 33.8	Cell line enhanced		PC-3: 166.4
SLC35F3	FLJ37712	ENSG00000183780	Solute carrier family 35 member F3	1	233904933-234324516	Predicted membrane proteins, Transporters	Evidence at protein level	HPA051327, HPA061582	Uncertain		Approved	Nucleoli<br>Golgi apparatus		Mixed	Tissue enhanced		cerebral cortex: 10.1	breast: 3.0	Cell line enriched	7	HDLM-2: 103.6
SLC35F4	C14orf36, FLJ37712	ENSG00000151812	Solute carrier family 35 member F4	14	57563922-57982194	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA043853	Uncertain		Approved	Nucleoli fibrillar center		Not detected	Tissue enhanced		prostate: 1.9;seminal vesicle: 4.9;testis: 1.8	thyroid gland: 1.1	Cell line enhanced		RPMI-8226: 1.0;U-87 MG: 2.0
SLC35F5	FLJ22004	ENSG00000115084	Solute carrier family 35 member F5	2	113705011-113756823	Predicted membrane proteins, Transporters	Evidence at protein level	HPA034828, HPA049229	Uncertain		Uncertain	Plasma membrane	Renal cancer:1.71e-5 (favourable), Cervical cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 97.7	Expressed in all		
SLC35F6	ANT2BP, C2orf18, FLJ20555, TANGO9	ENSG00000213699	Solute carrier family 35 member F6	2	26764284-26781231	Predicted membrane proteins, Transporters	Evidence at protein level	HPA034655	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:1.11e-4 (unfavourable), Lung cancer:3.71e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 26.2	Expressed in all		
SLC35G1	C10orf60, FLJ33990, TMEM20	ENSG00000176273	Solute carrier family 35 member G1	10	93893973-93956062	Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Group enriched	8	duodenum: 86.0;small intestine: 44.8	rectum,testis: 7.8	Mixed		
SLC35G2	DKFZp564K2464, MGC3295, TMEM22	ENSG00000168917	Solute carrier family 35 member G2	3	136818647-136855892	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052054, HPA064728	Approved		Supported	Plasma membrane	Renal cancer:1.16e-7 (unfavourable)	Mixed	Mixed			testis: 21.3	Cell line enhanced		BJ hTERT+: 59.1
SLC35G3	AMAC1, FLJ40154, TMEM21A	ENSG00000164729	Solute carrier family 35 member G3	17	35192520-35194523	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	15	testis: 1.6	lymph node,skeletal muscle,spleen: 0.1	Not detected		
SLC35G4	AMAC1L1, SLC35G4P	ENSG00000236396	Solute carrier family 35 member G4	18	11609596-11610612	Predicted membrane proteins, Transporters	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
SLC35G5	AMAC, AMAC1L2	ENSG00000177710	Solute carrier family 35 member G5	8	11330888-11332208	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.4	appendix,skin: 0.4	Not detected		
SLC35G6	AMAC1L3, TMEM21B	ENSG00000259224	Solute carrier family 35 member G6	17	7481332-7483496	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	17	testis: 1.7	all non-specific tissues: 0.0	Not detected		
SLC36A1	LYAAT-1, PAT1, TRAMD3	ENSG00000123643	Solute carrier family 36 member 1	5	151437046-151492381	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035937	Approved				Renal cancer:1.83e-6 (unfavourable), Liver cancer:6.30e-5 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 65.4	duodenum: 44.3	Mixed		
SLC36A2	PAT2, TRAMD1, tramdorin	ENSG00000186335	Solute carrier family 36 member 2	5	151314978-151347590	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044002, HPA062229	Enhanced					Tissue enriched	Group enriched	27	kidney: 67.7;skeletal muscle: 28.0	testis: 1.7	Not detected		
SLC36A3	PAT3, TRAMD2, tramdorin2	ENSG00000186334	Solute carrier family 36 member 3	5	151276762-151303766	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	60	testis: 14.5	epididymis: 0.2	Not detected		
SLC36A4	FLJ38932, PAT4	ENSG00000180773	Solute carrier family 36 member 4	11	93144171-93197964	Predicted membrane proteins, Transporters	Evidence at protein level	HPA017887	Enhanced		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			thyroid gland: 14.8	Mixed		
SLC37A1		ENSG00000160190	Solute carrier family 37 member 1	21	42496008-42581440	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030418, CAB034154	Approved				Thyroid cancer:3.43e-5 (favourable), Endometrial cancer:9.22e-5 (favourable)	Expressed in all	Mixed			duodenum: 45.6	Cell line enhanced		HEL: 112.3
SLC37A2	FLJ00171	ENSG00000134955	Solute carrier family 37 member 2	11	125063067-125090312	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014948	Uncertain					Expressed in all	Mixed			adrenal gland: 24.7	Cell line enhanced		A-431: 23.5;CAPAN-2: 49.0;hTERT-HME1: 45.0;U-138 MG: 41.2
SLC37A3	DKFZp761N0624	ENSG00000157800	Solute carrier family 37 member 3	7	140293693-140404433	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014713, HPA061841			Supported	Cytosol	Liver cancer:4.78e-5 (unfavourable), Cervical cancer:9.54e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 73.0	Mixed		
SLC37A4	G6PT1, G6PT2, G6PT3, GSD1b, GSD1c, GSD1d	ENSG00000137700	Solute carrier family 37 member 4	11	119024114-119030906	Predicted membrane proteins	Evidence at protein level	HPA038939, HPA038940	Enhanced		Approved	Mitochondria		Expressed in all	Tissue enhanced		kidney: 36.6	duodenum: 30.8	Cell line enhanced		HEK93: 24.3
SLC38A1	ATA1, NAT2, SAT1	ENSG00000111371	Solute carrier family 38 member 1	12	46183063-46270017	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039460, HPA052272	Uncertain	Supported			Liver cancer:6.95e-8 (unfavourable), Endometrial cancer:4.76e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 154.6	Mixed		
SLC38A10	MGC15523, PP1744	ENSG00000157637	Solute carrier family 38 member 10	17	81245000-81295547	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA021374, HPA023161, HPA024631	Enhanced		Enhanced	Golgi apparatus	Renal cancer:5.34e-7 (unfavourable), Pancreatic cancer:2.92e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 44.6	Expressed in all		
SLC38A11	AVT2, FLJ39822	ENSG00000169507	Solute carrier family 38 member 11	2	164896186-164955525	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA043432	Uncertain				Renal cancer:2.00e-8 (favourable)	Tissue enriched	Tissue enhanced		epididymis: 47.1;gallbladder: 28.2	seminal vesicle: 23.5	Cell line enriched	8	BJ hTERT+: 202.7
SLC38A2	ATA2, KIAA1382, SAT2, SNAT2	ENSG00000134294	Solute carrier family 38 member 2	12	46358189-46372867	Predicted membrane proteins	Evidence at protein level	HPA035180	Approved		Approved	Vesicles		Expressed in all	Expressed in all			skin: 238.8	Mixed		
SLC38A3	G17, SN1	ENSG00000188338	Solute carrier family 38 member 3	3	50205246-50221486	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031871			Approved	Microtubules<br>Cytosol		Tissue enriched	Tissue enriched	7	liver: 174.0	cerebral cortex: 25.4	Cell line enhanced		Hep G2: 33.9;SCLC-21H: 18.6
SLC38A4	ATA3, NAT3, PAAT	ENSG00000139209	Solute carrier family 38 member 4	12	46764761-46832408	Predicted membrane proteins, Transporters	Evidence at protein level						Liver cancer:5.37e-4 (favourable)	Tissue enriched	Tissue enriched	40	liver: 346.9	smooth muscle: 8.7	Cell line enhanced		LHCN-M2: 37.9;RH-30: 14.5;RT4: 71.7
SLC38A5	JM24, SN2	ENSG00000017483	Solute carrier family 38 member 5	X	48458537-48470256	Predicted membrane proteins, Transporters	Evidence at protein level	HPA047411	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:2.13e-4 (unfavourable)	Expressed in all	Mixed			pancreas: 50.0	Cell line enhanced		HBEC3-KT: 233.9;HeLa: 214.9;RPMI-8226: 374.4
SLC38A6	NAT-1	ENSG00000139974	Solute carrier family 38 member 6	14	60981114-61083733	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018508	Approved		Approved	Plasma membrane<br>Cell Junctions<br>Microtubules	Liver cancer:9.47e-6 (unfavourable), Renal cancer:1.37e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 24.7	Mixed		
SLC38A7	FLJ10815	ENSG00000103042	Solute carrier family 38 member 7	16	58665109-58685104	Predicted membrane proteins, Transporters	Evidence at protein level	HPA041777	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.87e-4 (favourable), Endometrial cancer:6.87e-4 (favourable)	Expressed in all	Mixed			testis: 34.7	Expressed in all		
SLC38A8		ENSG00000166558	Solute carrier family 38 member 8	16	84009667-84042636	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Not detected			testis: 0.9	Cell line enriched	5	SCLC-21H: 4.0
SLC38A9	FLJ90709	ENSG00000177058	Solute carrier family 38 member 9	5	55625845-55773194	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043785	Uncertain		Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:7.24e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 80.4	Expressed in all		
SLC39A1	ZIP1, ZIRTL	ENSG00000143570	Solute carrier family 39 member 1	1	153959099-153968184	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016506			Uncertain	Cytosol	Liver cancer:4.12e-7 (unfavourable), Head and neck cancer:5.26e-5 (unfavourable), Cervical cancer:4.83e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 134.2	Expressed in all		
SLC39A10	DKFZp564L2123, FLJ90515, KIAA1265	ENSG00000196950	Solute carrier family 39 member 10	2	195575977-195737702	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA036512, HPA036513, HPA066087	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Glioma:2.05e-5 (favourable), Liver cancer:4.39e-5 (unfavourable), Pancreatic cancer:3.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 77.7;thyroid gland: 79.2	prostate: 30.8	Expressed in all		
SLC39A11	C17orf26	ENSG00000133195	Solute carrier family 39 member 11	17	72645949-73092712	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA021455			Approved	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 60.1	Expressed in all		
SLC39A12	FLJ30499	ENSG00000148482	Solute carrier family 39 member 12	10	17951839-18043292	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	28	cerebral cortex: 25.3	breast: 0.8	Not detected		
SLC39A13	FLJ25785	ENSG00000165915	Solute carrier family 39 member 13	11	47407132-47416501	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043971	Approved		Uncertain	Cytosol	Ovarian cancer:2.73e-5 (unfavourable), Renal cancer:1.96e-4 (favourable), Colorectal cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 58.3	Expressed in all		
SLC39A14	KIAA0062, NET34, ZIP14	ENSG00000104635	Solute carrier family 39 member 14	8	22367249-22434129	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016508	Approved		Approved	Endoplasmic reticulum<br>Golgi apparatus<br>Plasma membrane	Renal cancer:3.79e-7 (unfavourable), Colorectal cancer:5.00e-5 (favourable)	Expressed in all	Mixed			liver: 203.0	Expressed in all		
SLC39A2	ZIP2	ENSG00000165794	Solute carrier family 39 member 2	14	20999255-21001871	Predicted membrane proteins	Evidence at protein level	HPA030489	Uncertain					Mixed	Group enriched	11	esophagus: 19.0;prostate: 19.2;seminal vesicle: 46.9;skin: 34.1	breast: 2.6	Cell line enriched	67	HaCaT: 20.5
SLC39A3	ZIP3	ENSG00000141873	Solute carrier family 39 member 3	19	2732204-2740152	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042139, HPA058526	Uncertain		Approved	Vesicles	Endometrial cancer:9.76e-5 (favourable)	Expressed in all	Expressed in all			testis: 110.2	Cell line enhanced		U-937: 326.0
SLC39A4	AEZ, AWMS2, ZIP4	ENSG00000147804	Solute carrier family 39 member 4	8	144409742-144416895	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:9.04e-4 (favourable)	Expressed in all	Group enriched	8	duodenum: 134.2;small intestine: 95.7	kidney: 14.3	Group enriched	9	CAPAN-2: 50.5;Hep G2: 102.1
SLC39A5		ENSG00000139540	Solute carrier family 39 member 5	12	56230049-56237846	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018423			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:5.05e-4 (favourable)	Tissue enhanced	Group enriched	12	colon: 73.2;duodenum: 240.2;kidney: 115.0;liver: 86.0;pancreas: 53.1;rectum: 48.9;small intestine: 240.4	gallbladder: 10.0	Group enriched	62	CACO-2: 33.1;Hep G2: 39.7
SLC39A6	LIV-1	ENSG00000141424	Solute carrier family 39 member 6	18	36108532-36129385	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042377	Approved				Liver cancer:5.33e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 209.2	Expressed in all		
SLC39A7	D6S2244E, H2-KE4, HKE4, KE4, RING5, ZIP7	ENSG00000112473	Solute carrier family 39 member 7	6	33200445-33204439	Predicted membrane proteins, Transporters	Evidence at protein level	HPA053999	Approved		Supported	Endoplasmic reticulum	Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 41.1	Expressed in all		
SLC39A8	BIGM103	ENSG00000138821	Solute carrier family 39 member 8	4	102251041-102431258	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038832, HPA038833	Approved				Renal cancer:6.34e-6 (favourable), Colorectal cancer:1.34e-4 (favourable), Breast cancer:6.69e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 257.0	cervix, uterine: 129.4	Cell line enhanced		BJ hTERT+: 128.9;Karpas-707: 123.0
SLC39A9	FLJ11274	ENSG00000029364	Solute carrier family 39 member 9	14	69398015-69462388	Predicted membrane proteins, Transporters	Evidence at protein level	HPA007921, HPA075390	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:1.05e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 45.0	Expressed in all		
SLC3A1	ATR1, CSNU1, D2H, NBAT, RBAT	ENSG00000138079	Solute carrier family 3 member 1	2	44275458-44321494	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA038360, HPA071102	Enhanced		Approved	Nuclear bodies<br>Mitochondria	Renal cancer:3.67e-7 (favourable)	Tissue enriched	Tissue enhanced		kidney: 688.2	small intestine: 148.9	Cell line enriched	14	RPTEC TERT1: 80.7
SLC3A2	4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE	ENSG00000168003	Solute carrier family 3 member 2	11	62856102-62888875	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB010455, HPA017980	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Urothelial cancer:1.48e-4 (unfavourable), Liver cancer:8.17e-4 (unfavourable), Renal cancer:8.22e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 431.9	Expressed in all		
SLC40A1	FPN1, HFE4, IREG1, MTP1, SLC11A3	ENSG00000138449	Solute carrier family 40 member 1	2	189560579-189583758	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA065634	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.55e-5 (favourable)	Expressed in all	Expressed in all			spleen: 489.1	Group enriched	6	ASC diff: 336.9;CACO-2: 97.8;HEL: 380.0;HMC-1: 94.0;T-47d: 188.1
SLC41A1	MgtE	ENSG00000133065	Solute carrier family 41 member 1	1	205789093-205813748	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014721, HPA015138	Uncertain		Approved	Mitochondria	Cervical cancer:1.48e-4 (unfavourable)	Expressed in all	Tissue enhanced		heart muscle: 66.8	testis: 37.3	Mixed		
SLC41A2	DKFZP434K0427	ENSG00000136052	Solute carrier family 41 member 2	12	104802553-104958744	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038658	Approved				Renal cancer:3.35e-4 (unfavourable), Liver cancer:9.94e-4 (favourable)	Expressed in all	Mixed			liver: 60.0	Cell line enhanced		HDLM-2: 52.1
SLC41A3	FLJ20473	ENSG00000114544	Solute carrier family 41 member 3	3	126006355-126101561	Predicted membrane proteins, Transporters	Evidence at protein level	HPA045847	Approved		Supported	Plasma membrane	Liver cancer:1.49e-7 (unfavourable), Renal cancer:6.04e-7 (favourable)	Expressed in all	Expressed in all			testis: 77.4	Expressed in all		
SLC43A1	PB39, POV1, R00504	ENSG00000149150	Solute carrier family 43 member 1	11	57484534-57515786	Predicted membrane proteins, Transporters	Evidence at protein level	HPA018813, HPA018826	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane	Renal cancer:2.97e-5 (unfavourable), Endometrial cancer:3.19e-4 (favourable), Thyroid cancer:5.27e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 50.0	Mixed		
SLC43A2	MGC34680	ENSG00000167703	Solute carrier family 43 member 2	17	1569267-1628886	Predicted membrane proteins, Transporters	Evidence at protein level	HPA021564	Enhanced				Pancreatic cancer:1.05e-6 (favourable), Renal cancer:5.40e-5 (favourable)	Expressed in all	Tissue enhanced		placenta: 31.7	appendix: 17.0	Cell line enhanced		CACO-2: 14.8
SLC43A3	DKFZp762A227, Eeg1, FOAP-13, PRO1659, SEEEG-1	ENSG00000134802	Solute carrier family 43 member 3	11	57406954-57427580	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030551, HPA077244	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane	Renal cancer:3.97e-13 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 122.3	Cell line enhanced		WM-115: 524.5
SLC44A1	CD92, CDW92, CHTL1, CTL1	ENSG00000070214	Solute carrier family 44 member 1	9	105244622-105439171	CD markers, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064714			Supported	Nucleoplasm<br>Mitochondria	Renal cancer:1.85e-4 (favourable), Lung cancer:4.49e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 107.5	Expressed in all		
SLC44A2	CTL2	ENSG00000129353	Solute carrier family 44 member 2	19	10602457-10644559	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003228, HPA070799	Approved		Approved	Vesicles<br>Cell Junctions	Renal cancer:1.71e-5 (favourable), Pancreatic cancer:6.01e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 226.1	Mixed		
SLC44A3	CTL3, MGC45474	ENSG00000143036	Solute carrier family 44 member 3	1	94820342-94895246	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047433	Enhanced				Renal cancer:7.63e-5 (favourable)	Expressed in all	Mixed			rectum: 38.5	Cell line enhanced		RPTEC TERT1: 76.8;RT4: 55.4
SLC44A4	C6orf29, CTL4, FLJ14491, NG22, TPPT	ENSG00000204385	Solute carrier family 44 member 4	6	31863192-31879046	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046977, HPA054176	Enhanced				Renal cancer:1.06e-6 (favourable), Head and neck cancer:3.54e-4 (favourable), Urothelial cancer:6.06e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 35.1	colon: 28.7	Cell line enhanced		Hep G2: 1.0
SLC44A5	CTL5, MGC34032	ENSG00000137968	Solute carrier family 44 member 5	1	75202131-75611116	Predicted membrane proteins, Transporters	Evidence at protein level	HPA047455, HPA051011	Uncertain		Approved	Cytosol	Renal cancer:6.52e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 12.6	parathyroid gland: 8.1	Cell line enhanced		SH-SY5Y: 12.2;TIME: 11.9
SLC45A1	DNB5	ENSG00000162426	Solute carrier family 45 member 1	1	8317826-8344167	Predicted membrane proteins, Transporters	Evidence at transcript level							Mixed	Tissue enhanced		cerebral cortex: 11.7	endometrium: 3.2	Cell line enhanced		HHSteC: 4.1;U-87 MG: 6.3
SLC45A2	AIM-1, MATP, OCA4	ENSG00000164175	Solute carrier family 45 member 2	5	33944616-33984730	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enhanced		skin: 1.2;testis: 1.2	prostate,rectum: 0.3	Cell line enriched	43	SK-MEL-30: 48.5
SLC45A3	IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein	ENSG00000158715	Solute carrier family 45 member 3	1	205657851-205680459	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019073, HPA019075	Enhanced		Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:4.04e-5 (unfavourable), Urothelial cancer:7.33e-5 (favourable)	Tissue enriched	Tissue enriched	30	prostate: 505.2	stomach: 16.5	Cell line enriched	28	HMC-1: 749.2
SLC45A4	KIAA1126	ENSG00000022567	Solute carrier family 45 member 4	8	141207166-141308305	Predicted membrane proteins, Transporters	Evidence at protein level	HPA023154	Uncertain		Approved	Plasma membrane	Renal cancer:1.73e-6 (favourable)	Expressed in all	Mixed			testis: 21.0	Mixed		
SLC46A1	HCP1, MGC9564, PCFT	ENSG00000076351	Solute carrier family 46 member 1	17	28394756-28407197	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB011614	Approved		Supported	Plasma membrane<br>Cytosol	Glioma:3.90e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 95.1	Cell line enhanced		CACO-2: 169.5
SLC46A2	Ly110, TSCOT	ENSG00000119457	Solute carrier family 46 member 2	9	112878920-112890913	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA020098	Approved					Tissue enhanced	Group enriched	6	cervix, uterine: 23.3;endometrium: 5.5;epididymis: 5.7;lung: 15.1;skin: 11.3	seminal vesicle: 2.1	Not detected		
SLC46A3	DKFZp686A1775, FLJ42613	ENSG00000139508	Solute carrier family 46 member 3	13	28700064-28718970	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039930	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Lung cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 87.7	Cell line enhanced		RPTEC TERT1: 22.1
SLC47A1	FLJ10847, MATE1	ENSG00000142494	Solute carrier family 47 member 1	17	19495385-19579034	Predicted membrane proteins, Transporters	Evidence at protein level	HPA021987	Enhanced				Endometrial cancer:5.54e-8 (favourable), Renal cancer:1.06e-5 (favourable), Lung cancer:1.88e-5 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 138.3;kidney: 105.1	liver: 53.8	Cell line enhanced		A549: 19.2;AN3-CA: 15.5;Hep G2: 28.2;U-266/70: 23.7
SLC47A2	FLJ31196, MATE2, MATE2-K	ENSG00000180638	Solute carrier family 47 member 2	17	19678288-19718979	Predicted membrane proteins, Transporters	Evidence at protein level						Glioma:7.41e-4 (unfavourable)	Tissue enhanced	Group enriched	5	fallopian tube: 16.5;kidney: 49.3	epididymis: 6.4	Cell line enhanced		hTCEpi: 1.5
SLC48A1	FLJ20489, hHRG-1, HRG1	ENSG00000211584	Solute carrier family 48 member 1	12	47753916-47782753	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA073994			Supported	Vesicles	Renal cancer:1.34e-6 (favourable), Liver cancer:9.39e-5 (unfavourable), Cervical cancer:4.27e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 79.5	Expressed in all		
SLC4A1	AE1, CD233, DI, EPB3, FR, RTA1A, SW, WD, WR	ENSG00000004939	Solute carrier family 4 member 1 (Diego blood group)	17	44248385-44268141	Blood group antigen proteins, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015584, CAB034438, HPA063911	Enhanced					Tissue enriched	Tissue enriched	8	bone marrow: 238.0	kidney: 30.0	Mixed		
SLC4A10	NBCn2, NCBE	ENSG00000144290	Solute carrier family 4 member 10	2	161424332-161985282	Predicted membrane proteins, Transporters	Evidence at protein level	HPA034755	Supported					Tissue enhanced	Tissue enriched	22	cerebral cortex: 57.5	adrenal gland: 2.6	Cell line enriched	10	Karpas-707: 6.1
SLC4A11	BTR1, CDPD1, CHED2, dJ794I6.2, FECD4, NaBC1	ENSG00000088836	Solute carrier family 4 member 11	20	3227417-3239190	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018120, HPA058377	Uncertain		Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:6.21e-6 (favourable), Cervical cancer:9.03e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 27.7	salivary gland: 19.2	Cell line enhanced		HaCaT: 55.7
SLC4A2	AE2, BND3L, EPB3L1, HKB3, NBND3	ENSG00000164889	Solute carrier family 4 member 2	7	151057210-151076527	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019339	Enhanced		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Liver cancer:9.04e-6 (unfavourable), Renal cancer:1.26e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 89.3	Expressed in all		
SLC4A3	AE3, SLC2C	ENSG00000114923	Solute carrier family 4 member 3	2	219627327-219641980	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA063498			Approved	Nucleoplasm	Urothelial cancer:4.12e-4 (unfavourable)	Expressed in all	Group enriched	6	cerebral cortex: 30.0;heart muscle: 119.1;ovary: 47.7	testis: 10.9	Mixed		
SLC4A4	hhNMC, HNBC1, NBC1, NBC2, pNBC, SLC4A5	ENSG00000080493	Solute carrier family 4 member 4	4	71186757-71572087	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022493, HPA035628, HPA035629	Enhanced				Renal cancer:1.18e-4 (favourable), Colorectal cancer:7.69e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 125.8	cerebral cortex: 59.3	Cell line enhanced		BJ: 12.5;RPTEC TERT1: 11.7;U-138 MG: 8.0
SLC4A5	NBC4	ENSG00000188687	Solute carrier family 4 member 5	2	74216242-74343414	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036621	Approved					Tissue enriched	Group enriched	6	testis: 30.9;thyroid gland: 44.9	skin: 6.3	Cell line enhanced		U-266/70: 7.2
SLC4A7	NBC3, SBC2, SLC4A6	ENSG00000033867	Solute carrier family 4 member 7	3	27372721-27484420	Predicted membrane proteins, Transporters	Evidence at protein level	CAB022494, HPA035857	Enhanced		Supported	Plasma membrane<br>Focal adhesion sites<br>Cytosol	Renal cancer:7.91e-6 (unfavourable)	Expressed in all	Tissue enhanced		duodenum: 57.7	breast: 23.8	Expressed in all		
SLC4A8	NBC3	ENSG00000050438	Solute carrier family 4 member 8	12	51391317-51515763	Predicted membrane proteins	Evidence at protein level	HPA031536			Uncertain	Actin filaments		Group enriched	Tissue enhanced		cerebral cortex: 14.5;testis: 15.4	ovary: 4.2	Cell line enhanced		BEWO: 20.3;SCLC-21H: 18.5
SLC4A9	AE4	ENSG00000113073	Solute carrier family 4 member 9	5	140360202-140375143	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA051307	Uncertain					Tissue enriched	Tissue enriched	19	kidney: 12.2	seminal vesicle,testis: 0.6	Not detected		
SLC50A1	HsSWEET1, RAG1AP1, RP11-540D14.5, RZPDo834D038D, SCP, slv, SWEET1	ENSG00000169241	Solute carrier family 50 member 1	1	155135344-155138857	Predicted membrane proteins, Transporters	Evidence at protein level	HPA018095	Approved				Renal cancer:3.88e-7 (unfavourable)	Expressed in all	Expressed in all			epididymis: 135.2	Expressed in all		
SLC51A	OSTalpha	ENSG00000163959	Solute carrier family 51 alpha subunit	3	196211487-196243178	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA039123	Enhanced				Liver cancer:7.54e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 29.3;liver: 35.1;small intestine: 71.3	colon: 9.9	Cell line enhanced		REH: 3.4
SLC51B	OSTbeta	ENSG00000186198	Solute carrier family 51 beta subunit	15	65045370-65053396	Predicted membrane proteins, Transporters	Evidence at protein level	HPA008398, HPA008533	Enhanced		Approved	Vesicles<br>Mitochondria	Renal cancer:8.46e-5 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 59.7;duodenum: 85.4;small intestine: 118.4	colon: 40.7	Group enriched	9	CACO-2: 15.0;EFO-21: 11.0;Hep G2: 10.4
SLC52A1	FLJ10060, GPCR42, GPR172B, hRFT1, PAR2, RFVT1	ENSG00000132517	Solute carrier family 52 member 1	17	5032600-5052009	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB011449	Uncertain				Cervical cancer:9.54e-4 (favourable)	Mixed	Group enriched	10	duodenum: 36.1;placenta: 26.1;skin: 13.2;small intestine: 26.3	parathyroid gland: 2.6	Cell line enhanced		A549: 2.1;BEWO: 1.9;HMC-1: 4.1;SK-BR-3: 2.0
SLC52A2	D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2	ENSG00000185803	Solute carrier family 52 member 2	8	144354135-144361272	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA063036	Approved				Liver cancer:2.04e-6 (unfavourable), Renal cancer:1.23e-4 (unfavourable), Cervical cancer:7.55e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 20.8	Expressed in all		
SLC52A3	bA371L19.1, C20orf54, hRFT2, RFVT3	ENSG00000101276	Solute carrier family 52 member 3	20	760080-776015	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049391, HPA059078	Approved				Stomach cancer:5.51e-6 (favourable)	Expressed in all	Tissue enhanced		testis: 62.3	small intestine: 18.1	Cell line enhanced		CAPAN-2: 33.7;SK-BR-3: 10.4;T-47d: 16.0
SLC5A1	D22S675, NAGT, SGLT1	ENSG00000100170	Solute carrier family 5 member 1	22	32043032-32113029	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB015467, HPA051805, HPA055106	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:6.97e-7 (favourable), Endometrial cancer:2.59e-4 (favourable)	Mixed	Group enriched	10	duodenum: 505.0;small intestine: 313.4	gallbladder: 40.2	Cell line enhanced		CACO-2: 2.1;RPMI-8226: 1.3;SH-SY5Y: 1.0
SLC5A10	SGLT5	ENSG00000154025	Solute carrier family 5 member 10	17	18950345-19022595	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052014	Uncertain					Tissue enriched	Tissue enriched	25	kidney: 43.9	bone marrow: 1.7	Cell line enhanced		U-937: 4.4
SLC5A11	KST1, SGLT6, SMIT2	ENSG00000158865	Solute carrier family 5 member 11	16	24845841-24911628	Predicted membrane proteins	Evidence at protein level	HPA035331	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Group enriched	5	cerebral cortex: 10.5;duodenum: 6.6;kidney: 6.1;small intestine: 15.2	breast: 1.7	Cell line enhanced		BEWO: 1.7;Hep G2: 11.2;Karpas-707: 3.2
SLC5A12	MGC52019, SMCT2	ENSG00000148942	Solute carrier family 5 member 12	11	26667019-26723427	Predicted membrane proteins, Transporters	Evidence at protein level	HPA060904	Enhanced					Tissue enriched	Tissue enhanced		epididymis: 58.2;kidney: 173.7	small intestine: 33.4	Cell line enhanced		Karpas-707: 1.6;NTERA-2: 1.7;T-47d: 1.1
SLC5A2	SGLT2	ENSG00000140675	Solute carrier family 5 member 2	16	31483002-31490860	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041603	Enhanced					Not detected	Tissue enriched	10	kidney: 26.5	testis: 2.7	Not detected		
SLC5A3	SMIT, SMIT1	ENSG00000198743	Solute carrier family 5 member 3	21	34073570-34106262	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029791			Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:1.98e-5 (unfavourable), Renal cancer:4.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 42.2	kidney: 33.1	Expressed in all		
SLC5A4	DJ90G24.4, SAAT1, SGLT3	ENSG00000100191	Solute carrier family 5 member 4	22	32218476-32255341	Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enriched	Group enriched	8	duodenum: 18.0;small intestine: 21.3	lung: 2.3	Cell line enriched	15	SK-MEL-30: 21.9
SLC5A5	NIS	ENSG00000105641	Solute carrier family 5 member 5	19	17871973-17895174	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022364, HPA049055	Enhanced					Mixed	Tissue enhanced		salivary gland: 28.3;stomach: 56.1;thyroid gland: 20.7	cervix, uterine: 8.3	Cell line enriched	5	BEWO: 10.8
SLC5A6	SMVT	ENSG00000138074	Solute carrier family 5 member 6	2	27199587-27212958	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA036958	Approved		Approved	Cell Junctions	Renal cancer:3.60e-7 (unfavourable)	Expressed in all	Expressed in all			epididymis: 81.3	Expressed in all		
SLC5A7	CHT1, hCHT	ENSG00000115665	Solute carrier family 5 member 7	2	107986523-108013994	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046105			Approved	Nuclear bodies<br>Cell Junctions<br>Intermediate filaments		Tissue enhanced	Mixed			thyroid gland: 2.0	Group enriched	21	RT4: 2.9;SCLC-21H: 1.2
SLC5A8	AIT	ENSG00000256870	Solute carrier family 5 member 8	12	101155493-101210407	Predicted membrane proteins	Evidence at protein level						Breast cancer:9.04e-6 (favourable), Renal cancer:1.97e-4 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 15.0;thyroid gland: 14.7	kidney: 3.5	Cell line enriched	6	SK-BR-3: 2.3
SLC5A9	SGLT4	ENSG00000117834	Solute carrier family 5 member 9	1	48222685-48248644	Predicted membrane proteins, Transporters	Evidence at protein level	HPA050263			Approved	Actin filaments<br>Cytosol	Renal cancer:1.84e-5 (unfavourable)	Tissue enhanced	Group enriched	9	duodenum: 42.6;small intestine: 45.5	lung: 4.6	Cell line enriched	7	Hep G2: 10.2
SLC6A1	GABATHG, GABATR, GAT1	ENSG00000157103	Solute carrier family 6 member 1	3	10992724-11039247	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013341, CAB022293	Enhanced		Uncertain	Mitochondria	Renal cancer:5.05e-6 (unfavourable), Liver cancer:3.20e-4 (favourable)	Group enriched	Group enriched	5	cerebral cortex: 119.4;liver: 50.4	parathyroid gland: 16.0	Not detected		
SLC6A11	GAT3	ENSG00000132164	Solute carrier family 6 member 11	3	10816200-10940733	Predicted membrane proteins, Transporters	Evidence at protein level	HPA037981	Supported	Supported				Tissue enhanced	Tissue enhanced		cerebral cortex: 18.1;skin: 6.7	esophagus: 5.5	Cell line enhanced		HaCaT: 11.8;Hep G2: 10.7;hTCEpi: 8.5;NTERA-2: 6.6
SLC6A12	BGT-1	ENSG00000111181	Solute carrier family 6 member 12	12	190077-214570	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA034973	Approved		Approved	Vesicles	Renal cancer:2.70e-6 (favourable), Endometrial cancer:1.59e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		kidney: 29.5;liver: 43.6	cerebral cortex: 14.8	Group enriched	10	Hep G2: 4.9;RPTEC TERT1: 10.5
SLC6A13	GAT2	ENSG00000010379	Solute carrier family 6 member 13	12	220621-262873	Predicted membrane proteins, Transporters	Evidence at protein level	HPA036449, HPA052726			Approved	Nucleus<br>Nucleoli<br>Mitochondria<br>Cytosol		Tissue enriched	Tissue enriched	14	kidney: 154.0	fallopian tube: 11.3	Cell line enriched	7	RPTEC TERT1: 3.5
SLC6A14		ENSG00000268104	Solute carrier family 6 member 14	X	116436622-116461458	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA003193	Uncertain		Approved	Vesicles	Pancreatic cancer:9.74e-4 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 11.0;lung: 23.9	breast: 9.1	Cell line enhanced		HeLa: 1.0;Hep G2: 2.3
SLC6A15	FLJ10316, hv7-3, NTT73, SBAT1, V7-3	ENSG00000072041	Solute carrier family 6 member 15	12	84859488-84913615	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008609	Uncertain		Approved	Nucleoli<br>Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 23.0	placenta: 5.5	Cell line enhanced		ASC diff: 62.0;hTERT-HME1: 99.4;SCLC-21H: 104.6
SLC6A16	NTT5	ENSG00000063127	Solute carrier family 6 member 16	19	49289638-49325225	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA076812			Supported	Golgi apparatus		Mixed	Tissue enriched	18	testis: 162.8	lymph node: 8.8	Cell line enhanced		AF22: 18.0
SLC6A17		ENSG00000197106	Solute carrier family 6 member 17	1	110150486-110202202	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007663, HPA008044	Enhanced		Approved	Nucleus<br>Golgi apparatus		Tissue enriched	Tissue enriched	10	cerebral cortex: 75.4	adrenal gland: 7.9	Cell line enhanced		SiHa: 6.6;SK-MEL-30: 28.5;U-87 MG: 7.0
SLC6A18	FLJ31236, Xtrp2	ENSG00000164363	Solute carrier family 6 member 18	5	1225355-1246189	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA011885	Enhanced					Tissue enriched	Tissue enriched	83	kidney: 8.2	all non-specific tissues: 0.0	Not detected		
SLC6A19		ENSG00000174358	Solute carrier family 6 member 19	5	1201595-1225117	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037415, HPA043207	Enhanced		Approved	Nucleoli	Renal cancer:4.14e-6 (favourable)	Tissue enhanced	Group enriched	21	duodenum: 139.5;kidney: 91.8;small intestine: 156.9	rectum: 6.2	Group enriched	6	BEWO: 13.7;HEL: 16.3
SLC6A2	NAT1, NET, NET1, SLC6A5	ENSG00000103546	Solute carrier family 6 member 2	16	55655604-55706192	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004057, HPA076311, CAB078195	Enhanced	Supported	Approved	Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		adrenal gland: 29.2;placenta: 18.4;skin: 15.7	testis: 11.4	Cell line enriched	35	SH-SY5Y: 519.4
SLC6A20	XT3, Xtrp3	ENSG00000163817	Solute carrier family 6 member 20	3	45755450-45796535	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029873	Uncertain				Renal cancer:1.55e-5 (favourable)	Mixed	Tissue enhanced		duodenum: 24.4;small intestine: 19.3	gallbladder: 10.9	Cell line enhanced		HaCaT: 1.5
SLC6A3	DAT, DAT1	ENSG00000142319	Solute carrier family 6 member 3	5	1392790-1445430	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012763, HPA013602, CAB016249, CAB078172	Supported	Supported	Approved	Vesicles	Renal cancer:3.40e-7 (unfavourable)	Tissue enriched	Not detected			thyroid gland: 0.3	Not detected		
SLC6A4	5-HTT, HTT, OCD1, SERT1	ENSG00000108576	Solute carrier family 6 member 4	17	30194319-30236002	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071354, HPA074728		Supported	Supported	Golgi apparatus<br>Vesicles		Tissue enhanced	Group enriched	10	duodenum: 10.4;lung: 44.2;placenta: 26.4;small intestine: 45.3	esophagus: 3.1	Cell line enhanced		BEWO: 1.9;CACO-2: 3.2;Hep G2: 7.1
SLC6A5	GLYT2, NET1	ENSG00000165970	Solute carrier family 6 member 5	11	20599400-20659285	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		lung: 1.4	testis: 0.6	Not detected		
SLC6A6	TAUT	ENSG00000131389	Solute carrier family 6 member 6	3	14402576-14489349	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015028, HPA016488	Enhanced		Approved	Cell Junctions<br>Cytosol	Glioma:1.09e-7 (unfavourable), Endometrial cancer:5.22e-5 (favourable), Liver cancer:8.78e-4 (unfavourable)	Expressed in all	Mixed			ovary: 50.8	Mixed		
SLC6A7	PROT	ENSG00000011083	Solute carrier family 6 member 7	5	150189957-150222788	Predicted membrane proteins, Transporters	Evidence at protein level	HPA028907	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 16.9;rectum: 4.2	colon: 2.9	Not detected		
SLC6A8	CRTR, CT1	ENSG00000130821	Solute carrier family 6 member 8	X	153688099-153696593	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.53e-4 (unfavourable), Thyroid cancer:7.39e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 89.2	Mixed		
SLC6A9	GLYT1	ENSG00000196517	Solute carrier family 6 member 9	1	43991500-44031467	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA013977	Uncertain		Approved	Nucleus<br>Golgi apparatus	Renal cancer:5.93e-4 (unfavourable), Endometrial cancer:9.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 49.7	adrenal gland: 30.8	Cell line enhanced		hTCEpi: 77.6
SLC7A1	ATRC1, CAT-1, ERR, HCAT1, REC1L	ENSG00000139514	Solute carrier family 7 member 1	13	29509410-29595688	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039721	Approved				Renal cancer:1.32e-5 (unfavourable)	Expressed in all	Mixed			esophagus: 41.8	Expressed in all		
SLC7A10	asc-1	ENSG00000130876	Solute carrier family 7 member 10	19	33208664-33225850	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA041884, HPA057036	Uncertain		Uncertain	Nucleus<br>Nucleoli		Mixed	Group enriched	24	adipose tissue: 31.6;cerebral cortex: 6.5	breast: 0.8	Cell line enhanced		BEWO: 1.8;HSkMC: 1.2;THP-1: 2.6;U-2 OS: 1.1
SLC7A11	xCT	ENSG00000151012	Solute carrier family 7 member 11	4	138164097-138242349	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064215			Supported	Vesicles	Ovarian cancer:1.77e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 22.4	epididymis: 8.2	Expressed in all		
SLC7A13	AGT-1, XAT2	ENSG00000164893	Solute carrier family 7 member 13	8	86214052-86321146	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	170	kidney: 42.9	breast,testis: 0.2	Not detected		
SLC7A14	KIAA1613, PPP1R142	ENSG00000013293	Solute carrier family 7 member 14	3	170459584-170586074	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA045929	Approved					Group enriched	Tissue enriched	8	cerebral cortex: 26.7	adrenal gland: 3.1	Cell line enhanced		LHCN-M2: 2.7;SCLC-21H: 3.7
SLC7A2	ATRC2, CAT-2, HCAT2	ENSG00000003989	Solute carrier family 7 member 2	8	17497088-17570573	Predicted membrane proteins, Transporters	Evidence at protein level	HPA009277			Supported	Plasma membrane<br>Cell Junctions	Renal cancer:2.65e-7 (unfavourable), Stomach cancer:3.08e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 380.7	liver: 92.6	Cell line enhanced		HHSteC: 171.6
SLC7A3	ATRC3, CAT-3, FLJ14541	ENSG00000165349	Solute carrier family 7 member 3	X	70925582-70931125	Predicted membrane proteins, Transporters	Evidence at protein level	HPA003629	Approved					Tissue enriched	Tissue enhanced		endometrium: 7.8;prostate: 9.9;seminal vesicle: 7.5	smooth muscle: 4.1	Cell line enhanced		HAP1: 66.1;NTERA-2: 130.6;REH: 25.9
SLC7A4	CAT-4, HCAT3, VH	ENSG00000099960	Solute carrier family 7 member 4	22	21028718-21032840	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031023	Enhanced					Mixed	Tissue enhanced		testis: 22.5	esophagus: 6.0	Cell line enriched	24	BEWO: 135.5
SLC7A5	CD98, D16S469E, E16, LAT1, MPE16	ENSG00000103257	Solute carrier family 7 member 5	16	87830023-87869488	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052673, HPA056077	Approved		Supported	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Lung cancer:2.43e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 90.3;testis: 84.3	bone marrow: 66.1	Expressed in all		
SLC7A6	KIAA0245, LAT-2, LAT3, y+LAT-2	ENSG00000103064	Solute carrier family 7 member 6	16	68264516-68301823	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050713	Uncertain		Approved	Vesicles<br>Plasma membrane	Urothelial cancer:1.84e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 35.7	Expressed in all		
SLC7A7	LPI, y+LAT-1	ENSG00000155465	Solute carrier family 7 member 7	14	22773222-22829820	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036227	Enhanced				Renal cancer:6.28e-6 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 281.9	parathyroid gland: 162.5	Group enriched	5	BEWO: 191.5;CACO-2: 274.5;EFO-21: 65.6
SLC7A8	LAT2, LPI-PC1	ENSG00000092068	Solute carrier family 7 member 8	14	23125295-23183674	Predicted membrane proteins, Transporters	Evidence at protein level	CAB046015, HPA051950, HPA060672	Enhanced				Urothelial cancer:1.52e-4 (unfavourable), Liver cancer:1.97e-4 (unfavourable), Lung cancer:3.15e-4 (favourable)	Expressed in all	Tissue enriched	8	parathyroid gland: 1094.9	kidney: 135.4	Cell line enhanced		BEWO: 118.7;K-562: 122.1
SLC7A9	CSNU3	ENSG00000021488	Solute carrier family 7 member 9	19	32830509-32869766	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042591	Enhanced					Group enriched	Group enriched	10	duodenum: 79.0;kidney: 70.1;small intestine: 123.5	liver: 8.9	Group enriched	20	BEWO: 3.3;CACO-2: 6.7;Hep G2: 5.4
SLC8A1	NCX1	ENSG00000183023	Solute carrier family 8 member A1	2	40097270-40611053	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022694, HPA070007	Uncertain		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		heart muscle: 78.0	seminal vesicle: 37.6	Cell line enhanced		BJ: 24.4;fHDF/TERT166: 54.5
SLC8A2	KIAA1087, NCX2	ENSG00000118160	Solute carrier family 8 member A2	19	47428017-47472168	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050818, HPA054671	Enhanced					Mixed	Tissue enriched	11	cerebral cortex: 68.2	endometrium: 6.3	Group enriched	8	NTERA-2: 3.2;SCLC-21H: 10.8;SH-SY5Y: 5.2;SiHa: 4.1;U-2 OS: 6.2
SLC8A3	NCX3	ENSG00000100678	Solute carrier family 8 member A3	14	70044217-70189070	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Group enriched	6	cerebral cortex: 16.3;skeletal muscle: 6.1	adrenal gland: 1.7	Cell line enhanced		AF22: 4.3;LHCN-M2: 6.7;SH-SY5Y: 27.3
SLC8B1	FLJ22233, NCKX6, NCLX, SLC24A6	ENSG00000089060	Solute carrier family 8 member B1	12	113298759-113359493	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA040668	Approved				Urothelial cancer:5.02e-4 (favourable), Breast cancer:9.52e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 48.4	Mixed		
SLC9A1	APNH, NHE1, PPP1R143	ENSG00000090020	Solute carrier family 9 member A1	1	27098815-27166981	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022371, HPA048532, HPA052891	Enhanced		Supported	Plasma membrane	Glioma:6.32e-4 (unfavourable), Ovarian cancer:7.10e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 65.5	Expressed in all		
SLC9A2	NHE2	ENSG00000115616	Solute carrier family 9 member A2	2	102619707-102711318	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035121, HPA035122	Approved		Supported	Cell Junctions		Mixed	Tissue enhanced		colon: 20.5;rectum: 23.3;stomach: 25.7	testis: 10.7	Cell line enhanced		A-431: 8.9;RT4: 13.9;SK-BR-3: 11.4;T-47d: 18.0
SLC9A3	NHE3	ENSG00000066230	Solute carrier family 9 member A3	5	473310-524332	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036493, HPA036669	Enhanced		Supported	Plasma membrane	Melanoma:8.49e-4 (unfavourable)	Mixed	Tissue enhanced		colon: 80.9;gallbladder: 66.1;small intestine: 72.6	kidney: 57.3	Cell line enhanced		HDLM-2: 30.4
SLC9A4	NHE4	ENSG00000180251	Solute carrier family 9 member A4	2	102473303-102533972	Predicted membrane proteins, Transporters	Evidence at protein level	HPA036096	Supported		Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	5	stomach: 51.3	kidney: 9.5	Cell line enhanced		EFO-21: 1.3;HDLM-2: 2.2;RT4: 3.4
SLC9A5	NHE5	ENSG00000135740	Solute carrier family 9 member A5	16	67237683-67272190	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041004, HPA041329	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		spleen: 7.8	cerebral cortex: 2.5	Cell line enhanced		U-138 MG: 5.9
SLC9A6	KIAA0267, NHE6	ENSG00000198689	Solute carrier family 9 member A6	X	135973841-136047269	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA059445, HPA059590	Enhanced		Supported	Vesicles		Expressed in all	Tissue enhanced		cerebral cortex: 67.9	parathyroid gland: 16.6	Mixed		
SLC9A7	NHE7	ENSG00000065923	Solute carrier family 9 member A7	X	46599252-46759172	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA048938, HPA075385	Approved		Supported	Vesicles	Endometrial cancer:8.58e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 14.4	Mixed		
SLC9A8	KIAA0939, NHE8	ENSG00000197818	Solute carrier family 9 member A8	20	49812713-49892242	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB033682	Approved					Expressed in all	Expressed in all			bone marrow: 13.2	Expressed in all		
SLC9A9	FLJ35613, NHE9	ENSG00000181804	Solute carrier family 9 member A9	3	143265222-143848531	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA058234	Approved				Renal cancer:5.57e-7 (unfavourable), Lung cancer:8.18e-4 (favourable)	Expressed in all	Mixed			placenta: 22.3	Cell line enhanced		ASC TERT1: 17.2;Karpas-707: 44.4;RPMI-8226: 20.5;U-266/70: 21.8
SLC9B1	NHA1, NHEDC1	ENSG00000164037	Solute carrier family 9 member B1	4	102885048-103019739	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA058971, HPA065520			Supported	Microtubule organizing center<br>Mitochondria		Mixed	Tissue enriched	28	testis: 72.9	epididymis: 2.6	Mixed		
SLC9B2	FLJ23984, NHA2, NHEDC2	ENSG00000164038	Solute carrier family 9 member B2	4	103019868-103085829	Predicted membrane proteins, Transporters	Evidence at protein level	HPA047008	Uncertain		Approved	Nucleoplasm<br>Cell Junctions		Expressed in all	Tissue enhanced		cerebral cortex: 32.5	liver: 20.4	Mixed		
SLC9C1	NHE, SLC9A10	ENSG00000172139	Solute carrier family 9 member C1	3	112140887-112294258	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Group enriched	10	skin: 2.9;testis: 14.1	thyroid gland: 0.8	Not detected		
SLC9C2	MGC43026, SLC9A11	ENSG00000162753	Solute carrier family 9 member C2 (putative)	1	173500464-173603094	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	12	testis: 10.6	fallopian tube: 0.8	Not detected		
SLCO1A2	OATP, OATP-A, OATP1A2, SLC21A3	ENSG00000084453	Solute carrier organic anion transporter family member 1A2	12	21264600-21419594	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA071152			Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 28.7	salivary gland: 6.6	Cell line enhanced		NTERA-2: 16.5;RPMI-8226: 8.3;U-266/70: 18.6
SLCO1B1	LST-1, OATP-C, OATP1B1, SLC21A6	ENSG00000134538	Solute carrier organic anion transporter family member 1B1	12	21131202-21239246	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050892	Supported					Tissue enriched	Tissue enriched	248	liver: 308.0	breast: 1.2	Not detected		
SLCO1B3	OATP1B3, OATP8, SLC21A8	ENSG00000111700	Solute carrier organic anion transporter family member 1B3	12	20810702-20916911	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004943, HPA050892	Enhanced		Supported	Plasma membrane		Tissue enhanced	Tissue enriched	7	liver: 138.9	cervix, uterine: 19.5	Cell line enhanced		A-431: 56.7;A549: 15.8;CAPAN-2: 11.0;PC-3: 16.0;U-2 OS: 15.2
SLCO1B7	LST3, SLC21A21	ENSG00000205754	Solute carrier organic anion transporter family member 1B7 (putative)	12	21015696-21092745	Predicted membrane proteins	Evidence at transcript level	HPA050892	Uncertain					Not detected	Tissue enriched	17	breast: 43.2	liver: 2.4	Cell line enhanced		A-431: 2.3;A549: 1.6;CAPAN-2: 1.6;HeLa: 1.1;U-2 OS: 1.3
SLCO1C1	OATP-F, OATP1, OATP1C1, SLC21A14	ENSG00000139155	Solute carrier organic anion transporter family member 1C1	12	20695355-20753386	Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enriched	Tissue enriched	10	cerebral cortex: 27.5	testis: 2.6	Cell line enriched	9	HeLa: 2.7
SLCO2A1	MATR1, OATP2A1, PGT, SLC21A2	ENSG00000174640	Solute carrier organic anion transporter family member 2A1	3	133932696-134052184	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013742	Enhanced				Liver cancer:9.24e-5 (favourable), Stomach cancer:3.25e-4 (unfavourable), Endometrial cancer:9.69e-4 (favourable)	Expressed in all	Tissue enhanced		seminal vesicle: 114.6	thyroid gland: 71.3	Group enriched	5	EFO-21: 83.6;TIME: 17.5
SLCO2B1	OATP-B, OATP2B1, SLC21A9	ENSG00000137491	Solute carrier organic anion transporter family member 2B1	11	75100563-75206549	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020659	Uncertain					Expressed in all	Expressed in all			liver: 123.1	Cell line enhanced		CACO-2: 75.7;HEL: 13.5;Hep G2: 14.2;HMC-1: 23.5
SLCO3A1	OATP-D, OATP3A1, SLC21A11	ENSG00000176463	Solute carrier organic anion transporter family member 3A1	15	91853695-92172435	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA066327	Approved				Endometrial cancer:6.57e-6 (unfavourable), Cervical cancer:8.61e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 27.0	Cell line enhanced		CAPAN-2: 55.3;HaCaT: 84.3;HMC-1: 48.5
SLCO4A1	OATP-E, OATP4A1, SLC21A12	ENSG00000101187	Solute carrier organic anion transporter family member 4A1	20	62642445-62685785	Predicted membrane proteins, Transporters	Evidence at protein level	HPA030669, HPA030670	Uncertain		Supported	Cell Junctions	Lung cancer:4.74e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 10.5	Cell line enhanced		PC-3: 178.2;RPTEC TERT1: 137.9
SLCO4C1	OATP-H, OATP4C1, OATPX, SLC21A20	ENSG00000173930	Solute carrier organic anion transporter family member 4C1	5	102233986-102296549	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.12e-4 (favourable)	Tissue enriched	Tissue enhanced		kidney: 42.4	lung: 11.2	Cell line enhanced		Karpas-707: 12.0;RPTEC TERT1: 70.8;U-937: 19.1
SLCO5A1	OATP-J, OATP5A1, OATPRP4, SLC21A15	ENSG00000137571	Solute carrier organic anion transporter family member 5A1	8	69667047-69835064	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA025062	Uncertain					Mixed	Tissue enhanced		prostate: 3.6	skeletal muscle: 2.6	Cell line enhanced		HAP1: 5.7;NTERA-2: 3.6;RPMI-8226: 2.5;SCLC-21H: 4.6
SLCO6A1	CT48, MGC26949, OATP6A1, OATPY	ENSG00000205359	Solute carrier organic anion transporter family member 6A1	5	102371782-102499016	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA054126	Enhanced					Not detected	Tissue enriched	136	testis: 54.0	placenta: 0.3	Not detected		
SLF1	ANKRD32, BRCTD1, BRCTx, DKFZp564C0469, DKFZp761C121	ENSG00000133302	SMC5-SMC6 complex localization factor 1	5	94618347-94739436	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040793, HPA054213	Uncertain		Approved	Nucleus		Expressed in all	Tissue enhanced		testis: 12.9	cerebral cortex: 4.4	Cell line enhanced		HeLa: 34.7
SLF2	C10orf6, FAM178A, FLJ10512, FLJ25012	ENSG00000119906	SMC5-SMC6 complex localization factor 2	10	100912569-100965136	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038499, HPA057568	Approved		Supported	Nucleus<br>Vesicles		Expressed in all	Expressed in all			epididymis: 56.9	Expressed in all		
SLFN12L		ENSG00000205045	Schlafen family member 12 like	17	35464249-35537861	Predicted membrane proteins	Evidence at protein level	HPA024447	Uncertain					Mixed	Mixed			spleen: 7.3	Cell line enhanced		HDLM-2: 20.4;Karpas-707: 10.7
SLIT2	SLIL3, Slit-2	ENSG00000145147	Slit guidance ligand 2	4	20253260-20620561	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB007590, HPA019511, HPA023088	Uncertain				Renal cancer:6.51e-4 (favourable)	Mixed	Mixed			lung: 49.5	Cell line enhanced		BJ hTERT+: 175.8;BJ hTERT+ SV40 Large T+: 96.6;fHDF/TERT166: 96.4;HBF TERT88: 115.2
SLITRK1	KIAA1910, LRRC12	ENSG00000178235	SLIT and NTRK like family member 1	13	83877205-83882393	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA012414	Enhanced					Tissue enriched	Tissue enriched	81	cerebral cortex: 23.8	adrenal gland,cervix, uterine,pancreas,seminal vesicle: 0.2	Cell line enhanced		A-431: 2.6;AF22: 1.1
SLITRK2	CXorf2, KIAA1854, SLITL1	ENSG00000185985	SLIT and NTRK like family member 2	X	145817832-145825842	Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 25.7	seminal vesicle: 7.4	Cell line enriched	39	HAP1: 36.6
SLITRK3	KIAA0848	ENSG00000121871	SLIT and NTRK like family member 3	3	165186720-165197109	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017636, HPA048042	Enhanced		Approved	Mitochondria		Tissue enriched	Tissue enhanced		cerebral cortex: 17.3;endometrium: 12.3	fallopian tube: 9.8	Cell line enhanced		AF22: 2.6;HAP1: 2.3;SCLC-21H: 1.7
SLITRK4	DKFZp547M2010	ENSG00000179542	SLIT and NTRK like family member 4	X	143622790-143635777	Predicted membrane proteins	Evidence at protein level	HPA000431	Enhanced		Uncertain	Microtubules		Tissue enhanced	Tissue enhanced		adrenal gland: 13.9;cerebral cortex: 12.8	cervix, uterine: 8.4	Cell line enhanced		HeLa: 3.9;HHSteC: 2.5;T-47d: 8.3;U-2 OS: 3.5
SLITRK5	bA364G4.2, KIAA0918, LRRC11	ENSG00000165300	SLIT and NTRK like family member 5	13	87672615-87696272	Predicted membrane proteins	Evidence at protein level	HPA013843	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus		Not detected	Tissue enhanced		cerebral cortex: 4.9;fallopian tube: 4.7	seminal vesicle: 1.8	Cell line enhanced		AF22: 6.9
SLITRK6	FLJ22774	ENSG00000184564	SLIT and NTRK like family member 6	13	85792790-85799488	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014491, HPA014513	Uncertain		Supported	Plasma membrane	Head and neck cancer:8.52e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		urinary bladder: 19.6	prostate: 12.1	Group enriched	12	hTCEpi: 19.1;RT4: 76.0;WM-115: 21.9
SLMAP	KIAA1601, SLAP	ENSG00000163681	Sarcolemma associated protein	3	57755450-57929168	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002357, HPA002358	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:1.58e-6 (favourable), Lung cancer:7.98e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 265.6	Expressed in all		
SLN	MGC12301, MGC125854, MGC125855	ENSG00000170290	Sarcolipin	11	107707378-107719693	Predicted membrane proteins, Transporters	Evidence at protein level	CAB011628			Approved	Microtubules	Renal cancer:3.52e-9 (unfavourable)	Group enriched	Tissue enriched	17	skeletal muscle: 2802.0	heart muscle: 162.9	Cell line enhanced		BEWO: 1.1;HSkMC: 1.8;PC-3: 1.0;U-2 OS: 1.2
SMAD2	JV18-1, MADH2, MADR2	ENSG00000175387	SMAD family member 2	18	47808957-47931146	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	CAB025507, HPA067203, CAB073546	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:9.44e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 126.7	Expressed in all		
SMAGP	hSMAGP, MGC149453, MGC149454	ENSG00000170545	Small cell adhesion glycoprotein	12	51244558-51270890	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039711	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:2.24e-4 (favourable), Pancreatic cancer:4.38e-4 (unfavourable), Glioma:7.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 145.7	esophagus: 83.3	Cell line enhanced		BEWO: 126.2
SMCO2	C12orf70, LOC341346	ENSG00000165935	Single-pass membrane protein with coiled-coil domains 2	12	27466810-27502185	Predicted membrane proteins	Evidence at protein level	HPA014366	Uncertain					Mixed	Tissue enhanced		testis: 1.3	skin: 0.6	Cell line enhanced		HDLM-2: 2.0
SMCO3	C12orf69, LOC440087	ENSG00000179256	Single-pass membrane protein with coiled-coil domains 3	12	14804650-14814182	Predicted membrane proteins	Evidence at protein level	HPA040574, HPA047804	Uncertain					Tissue enhanced	Tissue enhanced		cervix, uterine: 5.6	gallbladder,kidney: 3.0	Cell line enhanced		AN3-CA: 1.8
SMCO4	C11orf75, FN5	ENSG00000166002	Single-pass membrane protein with coiled-coil domains 4	11	93478472-93543508	Predicted membrane proteins	Evidence at protein level	HPA041120	Uncertain				Renal cancer:5.81e-7 (unfavourable)	Expressed in all	Expressed in all			salivary gland: 97.5	Cell line enhanced		Karpas-707: 102.3
SMDT1	C22orf32, DDDD, dJ186O1.1, EMRE	ENSG00000183172	Single-pass membrane protein with aspartate rich tail 1	22	42079691-42084284	Predicted membrane proteins, Transporters	Evidence at protein level	HPA032117, HPA060340	Uncertain		Supported	Nucleus<br>Mitochondria	Renal cancer:2.36e-9 (favourable), Endometrial cancer:5.32e-8 (favourable), Pancreatic cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 7.8	Mixed		
SMG5	EST1B, KIAA1089, LPTS-RP1, LPTSRP1, RP11-54H19.7, SMG-5	ENSG00000198952	SMG5, nonsense mediated mRNA decay factor	1	156249224-156282825	Predicted membrane proteins	Evidence at protein level	HPA072651			Uncertain	Cytoplasmic bodies	Liver cancer:6.70e-9 (unfavourable), Endometrial cancer:3.39e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 76.0	Expressed in all		
SMG8	C17orf71, FLJ10587, FLJ23205	ENSG00000167447	SMG8, nonsense mediated mRNA decay factor	17	59209400-59215247	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024841	Approved		Approved	Nucleoplasm	Liver cancer:3.72e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 13.9	Expressed in all		
SMG9	C19orf61, FLJ12886	ENSG00000105771	SMG9, nonsense mediated mRNA decay factor	19	43727992-43754990	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041763, HPA042096	Uncertain		Approved	Mitochondria<br>Cytosol	Liver cancer:2.15e-5 (unfavourable), Renal cancer:1.71e-4 (unfavourable), Urothelial cancer:8.09e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 48.9	lymph node: 14.8	Expressed in all		
SMIM1	Vel	ENSG00000235169	Small integral membrane protein 1 (Vel blood group)	1	3772788-3775982	Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069088	Uncertain					Expressed in all	Tissue enhanced		bone marrow: 17.5;testis: 24.6	seminal vesicle: 7.5	Group enriched	6	HEL: 58.5;Hep G2: 21.1;K-562: 28.8
SMIM10	CXorf69	ENSG00000184785	Small integral membrane protein 10	X	134990938-134992473	Predicted membrane proteins	Evidence at transcript level						Renal cancer:3.69e-6 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 63.4;testis: 50.6	fallopian tube: 17.7	Mixed		
SMIM10L2A	LED, LINC00086, MGC39606, NCRNA00086	ENSG00000178947	Small integral membrane protein 10 like 2A	X	135421943-135428074	Predicted membrane proteins	Evidence at transcript level						Renal cancer:8.28e-8 (favourable), Endometrial cancer:6.78e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 21.8;cerebral cortex: 22.5	epididymis: 17.6	Cell line enhanced		AN3-CA: 4.8;HAP1: 10.7;hTCEpi: 3.9
SMIM10L2B	LINC00087, NCRNA00087, RP11-85L21.2	ENSG00000196972	Small integral membrane protein 10 like 2B	X	135094987-135098634	Predicted membrane proteins	Evidence at transcript level						Renal cancer:2.41e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 23.9	parathyroid gland: 7.4	Cell line enhanced		HHSteC: 1.6;HSkMC: 2.2;NTERA-2: 1.6
SMIM11A	C21orf51, FAM165B, SMIM11	ENSG00000205670	Small integral membrane protein 11A	21	34375480-34407866	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051321	Uncertain		Approved	Focal adhesion sites		Not detected	Mixed			thyroid gland: 32.1	Mixed		
SMIM11B		ENSG00000273590	Small integral membrane protein 11B	21	7744962-7777853	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA051321	Uncertain		Approved	Focal adhesion sites		Not detected	Expressed in all			epididymis: 24.8	Mixed		
SMIM12	C1orf212, FLJ90372	ENSG00000163866	Small integral membrane protein 12	1	34712737-34859816	Predicted membrane proteins	Evidence at protein level	HPA065331	Approved		Approved	Mitochondria	Renal cancer:1.15e-5 (favourable), Liver cancer:1.18e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 45.3	Expressed in all		
SMIM13	C6orf228	ENSG00000224531	Small integral membrane protein 13	6	11094033-11138733	Predicted membrane proteins	Evidence at protein level	HPA065706	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Golgi apparatus	Renal cancer:1.03e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 47.1	placenta: 18.9	Expressed in all		
SMIM14	C4orf34, FLJ13289	ENSG00000163683	Small integral membrane protein 14	4	39546330-39639090	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051299	Uncertain				Head and neck cancer:3.00e-6 (favourable), Renal cancer:2.07e-4 (favourable), Endometrial cancer:2.63e-4 (favourable), Liver cancer:3.47e-4 (favourable)	Expressed in all	Expressed in all			liver: 54.3	Cell line enhanced		Daudi: 189.5
SMIM17		ENSG00000268182	Small integral membrane protein 17	19	56643145-56655766	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA071857, HPA071861	Enhanced		Approved	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 8.7	epididymis: 2.0	Cell line enhanced		AF22: 2.3;HEK93: 2.1;SCLC-21H: 2.5
SMIM18		ENSG00000253457	Small integral membrane protein 18	8	30638600-30646064	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066648	Supported		Uncertain	Nucleus<br>Centrosome		Tissue enriched	Tissue enriched	9	cerebral cortex: 11.1	adrenal gland: 1.3	Cell line enriched	6	SH-SY5Y: 9.9
SMIM19	C8orf40	ENSG00000176209	Small integral membrane protein 19	8	42541155-42555193	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011145	Uncertain				Renal cancer:1.74e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 123.2	Expressed in all		
SMIM2	C13orf44, MGC5590	ENSG00000139656	Small integral membrane protein 2	13	44143543-44161257	Predicted membrane proteins	Evidence at protein level	HPA026891	Enhanced					Not detected	Tissue enriched	8	testis: 30.0	epididymis: 3.6	Cell line enhanced		BJ hTERT+: 2.1;SiHa: 2.1
SMIM20	C4orf52	ENSG00000250317	Small integral membrane protein 20	4	25861830-25929874	Predicted membrane proteins	Evidence at protein level	HPA016552	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:8.97e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 88.0	Expressed in all		
SMIM21	C18orf62	ENSG00000206026	Small integral membrane protein 21	18	75409476-75427703	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041686	Enhanced					Not detected	Tissue enriched	52	testis: 5.2	all non-specific tissues: 0.0	Cell line enhanced		U-87 MG: 1.1
SMIM22		ENSG00000267795	Small integral membrane protein 22	16	4788397-4796491	Predicted membrane proteins	Evidence at transcript level	HPA077331			Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			colon: 225.6	Group enriched	8	CAPAN-2: 277.9;RT4: 94.2;SCLC-21H: 95.4;SK-BR-3: 176.3
SMIM24	C19orf77, HSPC323	ENSG00000095932	Small integral membrane protein 24	19	3473986-3480542	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045046, HPA056027	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.13e-10 (favourable)	Tissue enhanced	Group enriched	8	duodenum: 758.8;epididymis: 1928.7;kidney: 835.9;small intestine: 682.3	stomach: 140.0	Group enriched	8	CACO-2: 128.5;HEL: 66.3;Hep G2: 79.7;MOLT-4: 90.8;REH: 56.0;U-937: 68.2
SMIM3	C5orf62, MSTP150, NID67	ENSG00000256235	Small integral membrane protein 3	5	150777946-150796734	Predicted membrane proteins	Evidence at protein level	HPA075345			Approved	Vesicles	Renal cancer:1.15e-8 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 109.0	Cell line enhanced		ASC diff: 172.4;U-87 MG: 184.9
SMIM4	C3orf78	ENSG00000168273	Small integral membrane protein 4	3	52534013-52579237	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047771	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Lung cancer:1.78e-5 (favourable), Renal cancer:1.63e-4 (favourable), Pancreatic cancer:5.00e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 102.2	Expressed in all		
SMIM5	C17orf109	ENSG00000204323	Small integral membrane protein 5	17	75633434-75641404	Predicted membrane proteins	Evidence at protein level	HPA065332, HPA071268	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.12e-4 (favourable), Cervical cancer:5.52e-4 (favourable)	Mixed	Mixed			thyroid gland: 14.3	Cell line enhanced		MCF7: 8.0;SK-BR-3: 3.4
SMIM6	C17orf110	ENSG00000259120	Small integral membrane protein 6	17	75646243-75647977	Predicted membrane proteins	Evidence at transcript level	HPA065721	Uncertain		Approved	Nucleus	Endometrial cancer:1.49e-4 (favourable), Urothelial cancer:1.64e-4 (favourable), Renal cancer:4.09e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 40.3;stomach: 34.4	testis: 22.6	Cell line enhanced		A549: 10.7;EFO-21: 8.5;HEL: 6.1
SMIM7	C19orf42, MGC2747	ENSG00000214046	Small integral membrane protein 7	19	16630751-16660442	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043127	Uncertain		Approved	Golgi apparatus		Expressed in all	Expressed in all			epididymis: 55.4	Expressed in all		
SMIM8	C6orf162, dJ102H19.2, DKFZP586E1923	ENSG00000111850	Small integral membrane protein 8	6	87322583-87399749	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007401, HPA067453	Approved		Approved	Vesicles		Expressed in all	Mixed			cerebral cortex: 13.9	Expressed in all		
SMIM9	CXorf68	ENSG00000203870	Small integral membrane protein 9	X	154823348-154834662	Predicted membrane proteins	Evidence at transcript level	HPA060970	Uncertain					Not detected	Tissue enriched	5	testis: 1.3	placenta: 0.2	Not detected		
SMLR1		ENSG00000256162	Small leucine rich protein 1	6	130827406-130837135	Predicted membrane proteins	Evidence at protein level	HPA066060	Uncertain					Tissue enriched	Group enriched	5	duodenum: 12.2;liver: 28.9;small intestine: 11.4	kidney: 3.2	Cell line enriched	10	Hep G2: 55.1
SMO	FZD11, SMOH	ENSG00000128602	Smoothened, frizzled class receptor	7	129188872-129213545	Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011446	Approved					Expressed in all	Mixed			ovary: 30.4	Cell line enhanced		AN3-CA: 84.8;NTERA-2: 69.7
SMOC2	SMAP2	ENSG00000112562	SPARC related modular calcium binding 2	6	168441151-168673445	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033979	Uncertain				Renal cancer:1.16e-6 (unfavourable)	Expressed in all	Mixed			endometrium: 183.6	Cell line enhanced		AF22: 8.0;EFO-21: 2.6;RPMI-8226: 7.7;RPTEC TERT1: 2.8
SMPD2	ISC1, nSMase	ENSG00000135587	Sphingomyelin phosphodiesterase 2	6	109440763-109443919	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018110, HPA018125	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cell Junctions	Liver cancer:1.17e-4 (unfavourable), Urothelial cancer:1.70e-4 (favourable), Pancreatic cancer:1.00e-3 (favourable)	Expressed in all	Mixed			testis: 55.8	Expressed in all		
SMPD3	NSMASE2	ENSG00000103056	Sphingomyelin phosphodiesterase 3	16	68358325-68448688	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033885, HPA065535, HPA069383	Approved		Supported	Endoplasmic reticulum	Endometrial cancer:3.86e-4 (favourable), Cervical cancer:7.72e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 61.0;small intestine: 62.9	stomach: 22.6	Cell line enhanced		HMC-1: 8.5;MOLT-4: 11.7;RPMI-8226: 8.3;SCLC-21H: 15.6
SMPD4	FLJ20297, FLJ20756, KIAA1418, NET13, nSMase-3, NSMASE3	ENSG00000136699	Sphingomyelin phosphodiesterase 4	2	130151392-130182750	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046279, HPA049426	Approved		Approved	Nuclear membrane<br>Cytosol	Renal cancer:8.16e-8 (unfavourable), Liver cancer:8.37e-6 (unfavourable), Endometrial cancer:7.47e-5 (unfavourable), Prostate cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.0	Expressed in all		
SMYD4	KIAA1936, ZMYND21	ENSG00000186532	SET and MYND domain containing 4	17	1779485-1830634	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030059	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 10.8	Expressed in all		
SNAP23	HsT17016, SNAP23A, SNAP23B	ENSG00000092531	Synaptosome associated protein 23	15	42491233-42545356	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA001214, CAB037083, CAB037317	Approved		Supported	Plasma membrane		Expressed in all	Expressed in all			spleen: 86.7	Expressed in all		
SNN		ENSG00000184602	Stannin	16	11668414-11679159	Predicted membrane proteins	Evidence at protein level	HPA011055	Approved		Approved	Cytosol	Liver cancer:1.85e-6 (unfavourable), Renal cancer:1.83e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 150.6	Expressed in all		
SNPH	bA314N13.5	ENSG00000101298	Syntaphilin	20	1266316-1309328	Predicted membrane proteins	Evidence at protein level	HPA049393	Approved		Uncertain	Cytokinetic bridge<br>Mitochondria	Pancreatic cancer:6.97e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 33.6	seminal vesicle: 15.6	Mixed		
SNRNP40	HPRP8BP, PRP8BP, PRPF8BP, SPF38, WDR57	ENSG00000060688	Small nuclear ribonucleoprotein U5 subunit 40	1	31259568-31296782	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026527, HPA027345	Supported		Supported	Nuclear speckles	Liver cancer:4.73e-6 (unfavourable), Glioma:9.74e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 40.9	Expressed in all		
SNRPF	Sm-F	ENSG00000139343	Small nuclear ribonucleoprotein polypeptide F	12	95858928-95903828	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.11e-6 (unfavourable)	Expressed in all	Expressed in all			appendix: 36.8	Expressed in all		
SNX13	KIAA0713, RGS-PX1	ENSG00000071189	Sorting nexin 13	7	17790761-17940501	Predicted membrane proteins	Evidence at protein level						Renal cancer:5.98e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.3	Expressed in all		
SNX14	RGS-PX2	ENSG00000135317	Sorting nexin 14	6	85505496-85594156	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017639	Approved		Supported	Cytosol	Head and neck cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 156.6	Expressed in all		
SNX19	CHET8, KIAA0254	ENSG00000120451	Sorting nexin 19	11	130875436-130916509	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013447	Uncertain		Supported	Mitochondria	Renal cancer:3.56e-5 (favourable)	Expressed in all	Expressed in all			testis: 50.8	Mixed		
SOAT1	ACAT, SOAT, STAT	ENSG00000057252	Sterol O-acyltransferase 1	1	179293714-179358680	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB009533, HPA047171	Enhanced		Enhanced	Endoplasmic reticulum		Expressed in all	Tissue enhanced		adrenal gland: 218.2	prostate: 45.1	Expressed in all		
SOAT2	ACAT2	ENSG00000167780	Sterol O-acyltransferase 2	12	53103518-53124538	Enzymes, Predicted membrane proteins	Evidence at protein level							Group enriched	Group enriched	5	duodenum: 12.1;small intestine: 22.0	spleen: 3.2	Cell line enhanced		CACO-2: 8.8;Hep G2: 15.8;U-266/70: 5.6
SOGA3	C6orf174, dJ403A15.3	ENSG00000214338	SOGA family member 3	6	127472794-127519191	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035388, HPA035389	Uncertain		Approved	Nucleus<br>Cytosol		Not detected	Tissue enriched	7	cerebral cortex: 10.1	ovary,stomach: 1.5	Cell line enhanced		SCLC-21H: 36.7;SH-SY5Y: 18.9
SORCS1	sorCS1	ENSG00000108018	Sortilin related VPS10 domain containing receptor 1	10	106573663-107164534	Predicted membrane proteins	Evidence at protein level	HPA011948	Approved		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 12.2;thyroid gland: 18.1	kidney: 4.8	Group enriched	12	RH-30: 78.2;SH-SY5Y: 111.4
SORCS2	KIAA1329	ENSG00000184985	Sortilin related VPS10 domain containing receptor 2	4	7192538-7742836	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA061916			Approved	Nucleus<br>Cytosol	Renal cancer:3.09e-4 (unfavourable), Ovarian cancer:3.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 19.3	cervix, uterine: 10.4	Cell line enhanced		HaCaT: 17.3;HMC-1: 12.7;SiHa: 15.0
SORCS3	KIAA1059, SORCS	ENSG00000156395	Sortilin related VPS10 domain containing receptor 3	10	104641101-105265235	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Renal cancer:5.72e-4 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 11.9	adrenal gland: 2.6	Not detected		
SORL1	C11orf32, gp250, LR11, LRP9, SorLA, SorLA-1	ENSG00000137642	Sortilin related receptor 1	11	121452203-121633693	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011500, HPA031321	Uncertain		Approved	Nucleoplasm<br>Cell Junctions	Renal cancer:1.80e-7 (favourable)	Expressed in all	Mixed			cervix, uterine: 67.8	Cell line enhanced		CAPAN-2: 125.3;RT4: 81.2;U-698: 97.2
SORT1	Gp95, NT3	ENSG00000134243	Sortilin 1	1	109309568-109397951	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006889, CAB011498	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Colorectal cancer:7.74e-6 (favourable), Liver cancer:1.23e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 169.5	Mixed		
SPACA1	SAMP32	ENSG00000118434	Sperm acrosome associated 1	6	88047789-88066832	Predicted membrane proteins	Evidence at protein level	HPA026744, HPA043297	Enhanced					Not detected	Tissue enriched	512	testis: 51.2	all non-specific tissues: 0.0	Not detected		
SPACA3	ALLP17, CT54, LYC3, LYZL3, SLLP1	ENSG00000141316	Sperm acrosome associated 3	17	32970376-32997877	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023633	Enhanced					Tissue enhanced	Tissue enriched	17	testis: 77.5	pancreas: 4.5	Cell line enriched	17	U-266/70: 72.1
SPACA6	LET7EH, LINC00085, NCRNA00085, SPACA6P	ENSG00000182310	Sperm acrosome associated 6	19	51693340-51712387	Predicted membrane proteins	Evidence at protein level						Renal cancer:1.98e-10 (unfavourable), Endometrial cancer:2.73e-4 (unfavourable)	Mixed	Tissue enriched	19	testis: 4.0	adipose tissue: 0.2	Not detected		
SPAG4	CT127, SUN4	ENSG00000061656	Sperm associated antigen 4	20	35615892-35621049	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048393, HPA061789	Approved				Endometrial cancer:9.52e-8 (favourable), Colorectal cancer:1.09e-5 (unfavourable), Glioma:8.89e-5 (unfavourable), Renal cancer:1.28e-4 (unfavourable), Urothelial cancer:6.66e-4 (favourable)	Expressed in all	Mixed			testis: 22.5	Cell line enhanced		EFO-21: 25.0;U-87 MG: 46.8
SPAG9	CT89, FLJ13450, FLJ14006, FLJ26141, FLJ34602, HLC4, HSS, JIP-4, JIP4, JLP, KIAA0516, MGC117291, MGC14967, MGC74461, PHET, PIG6, SYD1	ENSG00000008294	Sperm associated antigen 9	17	50962174-51120865	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040446, HPA061458	Approved		Enhanced	Microtubule organizing center<br>Cytosol	Urothelial cancer:8.10e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 106.2	Expressed in all		
SPAM1	HYAL5, PH-20, SPAG15	ENSG00000106304	Sperm adhesion molecule 1	7	123925237-123971414	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017984	Enhanced					Not detected	Tissue enriched	66	testis: 30.2	duodenum,small intestine: 0.4	Not detected		
SPAST	ADPSP, FSP2, KIAA1083, SPG4	ENSG00000021574	Spastin	2	32063611-32157637	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017311	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.62e-4 (unfavourable), Renal cancer:4.15e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 20.0	Expressed in all		
SPATA3	TSARG1	ENSG00000173699	Spermatogenesis associated 3	2	230996121-231025055	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018254	Enhanced					Not detected	Tissue enriched	448	testis: 160.1	cerebral cortex: 0.3	Not detected		
SPATA31A1	C9orf36, C9orf36A, DKFZP434B204, FAM75A1, FAM75A2, SPATA31A2	ENSG00000204849	SPATA31 subfamily A member 1	9	39355669-39361959	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	81	testis: 8.0	all non-specific tissues: 0.0	Not detected		
SPATA31A3	DKFZp434B204, FAM75A3	ENSG00000275969	SPATA31 subfamily A member 3	9	66986304-66992583	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	52	testis: 5.1	all non-specific tissues: 0.0	Not detected		
SPATA31A5	FAM75A5	ENSG00000276581	SPATA31 subfamily A member 5	9	60914374-60920650	Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.7	Not detected		
SPATA31A6	FAM75A6	ENSG00000185775	SPATA31 subfamily A member 6	9	42183659-42189882	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	16	testis: 1.5	all non-specific tissues: 0.0	Not detected		
SPATA31A7	FAM75A4, FAM75A7, SPATA31A4	ENSG00000276040	SPATA31 subfamily A member 7	9	61190003-61196280	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	26	testis: 2.6	all non-specific tissues: 0.0	Not detected		
SPATA31D1	FAM75D1, FLJ46321	ENSG00000214929	SPATA31 subfamily D member 1	9	81988772-81995256	Predicted membrane proteins	Evidence at transcript level	HPA047897	Uncertain					Not detected	Tissue enriched	100	testis: 9.9	all non-specific tissues: 0.0	Not detected		
SPATA31D3	FAM75D3, FLJ44082	ENSG00000186788	SPATA31 subfamily D member 3	9	81943586-81950038	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	78	testis: 7.8	all non-specific tissues: 0.0	Not detected		
SPATA31D4	FAM75D4, FLJ43859	ENSG00000189357	SPATA31 subfamily D member 4	9	81928514-81934948	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	49	testis: 4.8	all non-specific tissues: 0.0	Not detected		
SPATA31E1	C9orf79, FAM75E1, FLJ35866	ENSG00000177992	SPATA31 subfamily E member 1	9	87882826-87888899	Predicted membrane proteins	Evidence at protein level	HPA024253	Enhanced					Not detected	Tissue enriched	99	testis: 9.9	all non-specific tissues: 0.0	Cell line enhanced		ASC TERT1: 1.1;SCLC-21H: 1.6
SPATA9	FLJ35906, NYD-SP16	ENSG00000145757	Spermatogenesis associated 9	5	95652181-95698711	Predicted membrane proteins	Evidence at protein level	HPA010848	Uncertain		Approved	Mitochondria		Not detected	Tissue enriched	39	testis: 53.6	adipose tissue: 1.3	Not detected		
SPCS1	HSPC033, SPC1, SPC12, YJR010C-A	ENSG00000114902	Signal peptidase complex subunit 1	3	52704955-52711146	Predicted membrane proteins	Evidence at protein level	HPA046091, HPA055273	Supported		Approved	Golgi apparatus<br>Vesicles	Renal cancer:2.90e-4 (favourable), Colorectal cancer:9.28e-4 (favourable)	Expressed in all	Expressed in all			testis: 216.1	Expressed in all		
SPCS2	KIAA0102	ENSG00000118363	Signal peptidase complex subunit 2	11	74949247-74979031	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013386	Approved		Approved	Nucleus		Expressed in all	Expressed in all			epididymis: 269.1	Expressed in all		
SPEM1	C17orf83, FLJ40081	ENSG00000181323	Spermatid maturation 1	17	7420360-7421632	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	321	testis: 32.0	all non-specific tissues: 0.0	Not detected		
SPG11	FLJ21439, KIAA1840	ENSG00000104133	SPG11, spatacsin vesicle trafficking associated	15	44562696-44663678	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040412, HPA040947	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:6.28e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland,thyroid gland: 48.3	Expressed in all		
SPG7	CAR, CMAR, SPG5C	ENSG00000197912	SPG7, paraplegin matrix AAA peptidase subunit	16	89490917-89557768	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:2.22e-4 (favourable), Urothelial cancer:4.25e-4 (favourable), Pancreatic cancer:4.91e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.2	Expressed in all		
SPI1	OF, PU.1, SFPI1, SPI-1, SPI-A	ENSG00000066336	Spi-1 proto-oncogene	11	47354860-47378576	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	CAB004079, HPA044653	Enhanced		Supported	Nucleoplasm	Renal cancer:2.07e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 212.5	Cell line enhanced		HL-60: 125.6;HMC-1: 245.7;NB-4: 167.8;THP-1: 137.9;U-937: 90.6
SPIN3	TDRD27	ENSG00000204271	Spindlin family member 3	X	56818298-56995827	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000727	Uncertain		Approved	Nucleoplasm	Endometrial cancer:3.49e-4 (unfavourable), Urothelial cancer:6.30e-4 (favourable), Lung cancer:6.79e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 13.2	Mixed		
SPINT1	HAI, MANSC2	ENSG00000166145	Serine peptidase inhibitor, Kunitz type 1	15	40844018-40858207	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006903, HPA031178	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.37e-7 (favourable), Breast cancer:6.97e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 217.3	Cell line enhanced		BEWO: 311.8;HaCaT: 333.0;RT4: 245.6;SK-BR-3: 418.2;T-47d: 251.3
SPINT2	HAI-2, Kop	ENSG00000167642	Serine peptidase inhibitor, Kunitz type 2	19	38244035-38292614	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011101, CAB018969	Approved		Uncertain	Plasma membrane<br>Intermediate filaments<br>Cytosol	Renal cancer:3.41e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 539.2	Cell line enhanced		A-431: 736.5;CAPAN-2: 1060.7
SPN	CD43, GPL115, LSN	ENSG00000197471	Sialophorin	16	29662979-29670876	CD markers, Predicted membrane proteins	Evidence at protein level	CAB002666, HPA055244	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 38.6;lung: 33.3	lymph node: 25.4	Cell line enhanced		HEL: 209.9;HL-60: 167.0;HMC-1: 98.8;U-937: 115.3
SPNS1	HSpin1, LAT, nrs, PP2030, SPIN1, SPINL	ENSG00000169682	Sphingolipid transporter 1 (putative)	16	28974221-28984548	Predicted membrane proteins, Transporters	Evidence at protein level	HPA041995, HPA042988	Enhanced		Approved	Nucleoli fibrillar center<br>Golgi apparatus<br>Vesicles<br>Cytosol		Mixed	Expressed in all			parathyroid gland: 37.1	Expressed in all		
SPNS2		ENSG00000183018	Sphingolipid transporter 2	17	4498838-4539035	Predicted membrane proteins, Transporters	Evidence at protein level	HPA068717	Uncertain					Expressed in all	Tissue enhanced		esophagus: 46.4	kidney: 30.0	Group enriched	6	BEWO: 29.2;RPTEC TERT1: 120.6;SK-BR-3: 55.8
SPNS3	MGC29671	ENSG00000182557	Sphingolipid transporter 3 (putative)	17	4433688-4488208	Predicted membrane proteins	Evidence at protein level	HPA023928	Uncertain				Renal cancer:8.09e-4 (unfavourable)	Mixed	Tissue enriched	6	bone marrow: 12.4	spleen: 2.1	Group enriched	10	HL-60: 3.0;MOLT-4: 4.9;NB-4: 12.9;THP-1: 14.7;U-698: 3.6;U-937: 13.1
SPPL2A	IMP3, PSL2	ENSG00000138600	Signal peptide peptidase like 2A	15	50702266-50765808	Enzymes, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036062, HPA067304	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 291.5	Expressed in all		
SPPL2B	IMP4, KIAA1532, PSL1	ENSG00000005206	Signal peptide peptidase like 2B	19	2328615-2354806	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB005592, HPA039292	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Centrosome	Endometrial cancer:5.00e-5 (favourable), Pancreatic cancer:1.33e-4 (favourable), Renal cancer:6.45e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.1	Expressed in all		
SPPL2C	IMP5	ENSG00000185294	Signal peptide peptidase like 2C	17	45844835-45847072	Enzymes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	21	testis: 2.1	all non-specific tissues: 0.0	Not detected		
SPPL3	DKFZP586C1324, IMP2, MGC126674, MGC126676, MGC90402, PSL4	ENSG00000157837	Signal peptide peptidase like 3	12	120762510-120904371	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA004194, HPA059958	Uncertain		Supported	Vesicles<br>Plasma membrane	Liver cancer:1.29e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 84.1	Mixed		
SPRED1	FLJ33903, PPP1R147	ENSG00000166068	Sprouty related EVH1 domain containing 1	15	38252326-38357249	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042193, HPA061805	Approved		Supported	Nucleus	Renal cancer:7.37e-5 (unfavourable), Stomach cancer:8.29e-5 (unfavourable), Endometrial cancer:7.08e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 48.2	Mixed		
SPRED2	FLJ21897, FLJ31917, Spred-2	ENSG00000198369	Sprouty related EVH1 domain containing 2	2	65310851-65432637	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038256, HPA064394	Approved		Uncertain	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 44.0	Expressed in all		
SPRED3		ENSG00000188766	Sprouty related EVH1 domain containing 3	19	38388421-38399587	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA071521			Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.6	parathyroid gland: 2.6	Cell line enhanced		TIME: 12.9
SPRY1	hSPRY1	ENSG00000164056	Sprouty RTK signaling antagonist 1	4	123396795-123403760	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013538, HPA051369, HPA070554	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			gallbladder: 132.0	Cell line enhanced		AF22: 94.2;AN3-CA: 180.0
SPRY2	hSPRY2	ENSG00000136158	Sprouty RTK signaling antagonist 2	13	80335976-80340951	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB037205, HPA042198	Approved		Supported	Microtubules		Expressed in all	Expressed in all			adipose tissue: 69.7	Cell line enhanced		AN3-CA: 269.3
SPRY3	HSPRY3	ENSG00000168939	Sprouty RTK signaling antagonist 3	X	155767812-155782459	Predicted membrane proteins	Evidence at transcript level	CAB013505	Uncertain		Approved	Nucleoli<br>Cytosol		Mixed	Mixed			epididymis: 2.6	Cell line enhanced		AN3-CA: 3.4
SPRY4		ENSG00000187678	Sprouty RTK signaling antagonist 4	5	142310427-142326455	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB008086, HPA055471, HPA072661	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:2.20e-4 (unfavourable), Cervical cancer:7.12e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 26.9	Cell line enhanced		AN3-CA: 111.1;WM-115: 158.0
SPTLC1	hLCB1, HSAN1, HSN1, LCB1, SPTI	ENSG00000090054	Serine palmitoyltransferase long chain base subunit 1	9	92031999-92115384	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA010860, CAB018747, HPA063907	Supported		Supported	Endoplasmic reticulum	Renal cancer:1.36e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 108.3	Expressed in all		
SPTLC2	hLCB2a, KIAA0526, LCB2, LCB2A	ENSG00000100596	Serine palmitoyltransferase long chain base subunit 2	14	77505997-77616773	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA027552			Approved	Mitochondria	Renal cancer:6.69e-8 (favourable), Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 29.0	Expressed in all		
SPTLC3	C20orf38, FLJ11112, hLCB2b, LCB2B, SPTLC2L	ENSG00000172296	Serine palmitoyltransferase long chain base subunit 3	20	13008979-13169103	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044247, HPA048079	Enhanced		Approved	Microtubules	Renal cancer:4.51e-7 (favourable), Pancreatic cancer:6.02e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 40.8	Cell line enhanced		RPTEC TERT1: 33.2;U-87 MG: 56.0
SPTSSA	C14orf147, ssSPTa	ENSG00000165389	Serine palmitoyltransferase small subunit A	14	34432789-34462356	Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			adrenal gland: 90.1	Expressed in all		
SPTSSB	ADMP, C3orf57, ssSPTb	ENSG00000196542	Serine palmitoyltransferase small subunit B	3	161344792-161372880	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047712			Approved	Nuclear speckles		Tissue enhanced	Tissue enhanced		skin: 48.3;stomach: 59.4;urinary bladder: 36.3	prostate: 23.4	Group enriched	9	MCF7: 892.8;RT4: 244.7
SPTY2D1-AS1		ENSG00000247595	SPTY2D1 antisense RNA 1	11	18588781-18610255	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	21	testis: 366.7	skin: 17.2	Mixed		
SQLE		ENSG00000104549	Squalene epoxidase	8	124998497-125022283	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018038, HPA020762	Enhanced		Uncertain	Vesicles<br>Cytosol	Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable)	Expressed in all	Mixed			testis: 107.8	Expressed in all		
SRD5A1		ENSG00000145545	Steroid 5 alpha-reductase 1	5	6633343-6674386	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA051402	Approved				Endometrial cancer:8.73e-6 (unfavourable)	Expressed in all	Mixed			skin: 16.8	Mixed		
SRD5A2		ENSG00000277893	Steroid 5 alpha-reductase 2	2	31522480-31581067	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Group enriched	Group enriched	11	epididymis: 27.9;fallopian tube: 31.6;liver: 30.6;prostate: 26.6;seminal vesicle: 24.5	testis: 2.5	Cell line enhanced		RT4: 1.2
SRD5A3	FLJ13352, SRD5A2L, SRD5A2L1	ENSG00000128039	Steroid 5 alpha-reductase 3	4	55346109-55373096	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA027006	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.85e-10 (unfavourable), Liver cancer:1.80e-6 (unfavourable), Endometrial cancer:9.39e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 28.2	Expressed in all		
SREBF1	bHLHd1, SREBP-1c, SREBP1, SREBP1a	ENSG00000072310	Sterol regulatory element binding transcription factor 1	17	17810399-17837002	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	CAB005406, HPA043343, HPA043878	Uncertain		Supported	Golgi apparatus<br>Cytosol	Endometrial cancer:2.66e-4 (favourable), Pancreatic cancer:9.05e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 92.4	Expressed in all		
SREBF2	bHLHd2, SREBP2	ENSG00000198911	Sterol regulatory element binding transcription factor 2	22	41833079-41907308	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA031962, HPA031963	Approved		Supported	Nucleoplasm<br>Vesicles<br>Mitochondria	Renal cancer:1.37e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 118.4	Expressed in all		
SRPRB	APMCF1, SR-beta	ENSG00000144867	SRP receptor beta subunit	3	133784033-133825772	Predicted membrane proteins	Evidence at protein level	HPA011173	Approved		Approved	Plasma membrane	Liver cancer:3.12e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 52.0	Expressed in all		
SSBP2	HSPC116	ENSG00000145687	Single stranded DNA binding protein 2	5	81413021-81751797	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB020834, HPA068605	Approved		Supported	Nucleoplasm		Mixed	Expressed in all			parathyroid gland: 76.2	Cell line enhanced		REH: 178.5
SSMEM1	C7orf45, FLJ40316	ENSG00000165120	Serine rich single-pass membrane protein 1	7	130207860-130216843	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	199	testis: 57.1	lung,placenta: 0.2	Not detected		
SSPN	KRAG, SPN1, SPN2	ENSG00000123096	Sarcospan	12	26121991-26299290	Predicted membrane proteins	Evidence at protein level	HPA066432			Approved	Nucleus<br>Nuclear membrane	Renal cancer:2.77e-5 (unfavourable)	Mixed	Mixed			cervix, uterine: 64.4	Cell line enhanced		ASC diff: 18.2
SSR1	TRAPA	ENSG00000124783	Signal sequence receptor subunit 1	6	7268306-7347446	Predicted membrane proteins	Evidence at protein level	HPA011276, HPA017062	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:5.79e-6 (unfavourable), Liver cancer:4.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 141.0	Expressed in all		
SSR2	TLAP, TRAPB	ENSG00000163479	Signal sequence receptor subunit 2	1	156009048-156020959	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.00e-7 (unfavourable), Liver cancer:2.86e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 551.1	Expressed in all		
SSR3	TRAPG	ENSG00000114850	Signal sequence receptor subunit 3	3	156540140-156555184	Predicted membrane proteins	Evidence at protein level	HPA014906	Approved	Approved	Uncertain	Cytosol	Liver cancer:4.46e-7 (unfavourable), Renal cancer:2.84e-4 (unfavourable), Head and neck cancer:3.43e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 204.7	Expressed in all		
SSR4	TRAPD	ENSG00000180879	Signal sequence receptor subunit 4	X	153793516-153798505	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA045209	Enhanced				Renal cancer:5.51e-6 (unfavourable), Endometrial cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 979.6	Expressed in all		
SSTR1		ENSG00000139874	Somatostatin receptor 1	14	38207999-38213067	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA031506	Approved				Renal cancer:4.28e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 13.6;duodenum: 14.2;stomach: 21.4	small intestine: 9.1	Cell line enhanced		BJ: 102.5;BJ hTERT+: 27.1;fHDF/TERT166: 56.0
SSTR2		ENSG00000180616	Somatostatin receptor 2	17	73165012-73176633	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA007264	Uncertain		Supported	Cytosol	Renal cancer:9.04e-7 (unfavourable), Pancreatic cancer:6.63e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 22.9	spleen: 5.8	Cell line enriched	9	SCLC-21H: 14.9
SSTR3		ENSG00000278195	Somatostatin receptor 3	22	37204238-37212322	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022647	Approved					Tissue enhanced	Tissue enhanced		testis: 10.9	cerebral cortex: 3.9	Group enriched	12	RPMI-8226: 16.5;SCLC-21H: 10.1
SSTR4		ENSG00000132671	Somatostatin receptor 4	20	23035386-23036812	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA064252	Uncertain					Not detected	Not detected			cerebral cortex: 0.8	Not detected		
SSTR5		ENSG00000162009	Somatostatin receptor 5	16	1078781-1080142	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA066503			Supported	Plasma membrane		Mixed	Tissue enhanced		adrenal gland: 1.2	kidney: 0.5	Group enriched	15	Hep G2: 10.4;PC-3: 50.7
ST14	HAI, MT-SP1, PRSS14, SNC19, TMPRSS14	ENSG00000149418	Suppression of tumorigenicity 14	11	130159562-130210376	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA047014			Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.03e-11 (favourable)	Expressed in all	Mixed			small intestine: 149.0	Cell line enhanced		CAPAN-2: 361.3;HaCaT: 255.1;RPMI-8226: 192.2;T-47d: 268.8
ST3GAL2	SIAT4B, ST3GalA.2, ST3GALII	ENSG00000157350	ST3 beta-galactoside alpha-2,3-sialyltransferase 2	16	70375978-70439237	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA017270	Approved		Approved	Vesicles	Renal cancer:3.34e-6 (unfavourable), Pancreatic cancer:2.33e-4 (favourable), Liver cancer:2.79e-4 (unfavourable)	Expressed in all	Mixed			appendix: 15.2	Mixed		
ST3GAL3	MRT12, SIAT6	ENSG00000126091	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	1	43705824-43931165	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051102	Uncertain					Expressed in all	Expressed in all			skeletal muscle: 30.5	Mixed		
ST3GAL4	CGS23, FLJ11867, NANTA3, SAT3, SIAT4, SIAT4C, STZ	ENSG00000110080	ST3 beta-galactoside alpha-2,3-sialyltransferase 4	11	126355640-126440344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049827	Approved					Expressed in all	Mixed			epididymis: 106.8	Expressed in all		
ST3GAL5	SIAT9, SIATGM3S, ST3GalV	ENSG00000115525	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	2	85837120-85905199	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034708, HPA040425, HPA068928	Uncertain		Approved	Vesicles	Renal cancer:2.25e-7 (unfavourable), Urothelial cancer:4.48e-4 (favourable), Thyroid cancer:4.99e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 44.7	cerebral cortex: 40.7	Cell line enhanced		AN3-CA: 50.3;RT4: 37.4
ST3GAL6	SIAT10, ST3GALVI	ENSG00000064225	ST3 beta-galactoside alpha-2,3-sialyltransferase 6	3	98732236-98821201	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018792	Approved					Tissue enhanced	Mixed			liver: 28.4	Cell line enhanced		RPMI-8226: 65.1;SK-MEL-30: 85.2
ST6GAL2	KIAA1877, SIAT2, St6gal2, St6GalII	ENSG00000144057	ST6 beta-galactoside alpha-2,6-sialyltransferase 2	2	106801600-106887108	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014459	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Tissue enriched	Tissue enhanced		cerebral cortex: 22.1;thyroid gland: 47.9	testis: 9.8	Cell line enhanced		A549: 4.8;PC-3: 5.5;RPMI-8226: 6.7;SCLC-21H: 7.2;U-138 MG: 7.4;U-266/70: 7.5
ST6GALNAC1	SIAT7A, ST6GalNAcI	ENSG00000070526	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1	17	76624761-76643838	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014975	Uncertain				Head and neck cancer:2.54e-5 (favourable)	Mixed	Tissue enhanced		colon: 162.6;rectum: 235.5	cervix, uterine: 90.7	Cell line enhanced		EFO-21: 9.1;HaCaT: 9.7;HEL: 16.1;K-562: 48.8
ST6GALNAC3	SIAT7C	ENSG00000184005	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3	1	76074719-76634601	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054566, HPA055399	Uncertain		Supported	Nucleoplasm		Mixed	Tissue enhanced		thyroid gland: 22.4	parathyroid gland: 11.1	Cell line enhanced		AF22: 35.4;HUVEC TERT2: 38.4;SK-MEL-30: 49.6;TIME: 16.7
ST6GALNAC4	SIAT3C, SIAT7D, ST6GALNACIV	ENSG00000136840	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4	9	127907886-127917038	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009042			Approved	Nucleus<br>Golgi apparatus	Liver cancer:8.63e-7 (unfavourable), Ovarian cancer:5.12e-4 (unfavourable), Renal cancer:8.39e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 24.4	Cell line enhanced		HDLM-2: 98.1;RPMI-8226: 103.5
ST6GALNAC6	SIAT7F, ST6GALNACVI	ENSG00000160408	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 6	9	127885321-127905408	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018890	Approved		Approved	Nucleus		Expressed in all	Expressed in all			rectum: 154.1	Expressed in all		
ST7	ETS7q, FAM4A, FAM4A1, HELG, RAY1, SEN4, TSG7	ENSG00000004866	Suppression of tumorigenicity 7	7	116953238-117230103	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038325, HPA038326	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.39e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 51.0	Mixed		
ST7L	FAM4B, FLJ20284, ST7R, STLR	ENSG00000007341	Suppression of tumorigenicity 7 like	1	112523518-112620825	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA042324, HPA075418	Uncertain		Approved	Centrosome	Ovarian cancer:3.04e-5 (favourable), Colorectal cancer:8.34e-5 (favourable), Melanoma:5.16e-4 (unfavourable), Endometrial cancer:8.96e-4 (unfavourable)	Expressed in all	Tissue enriched	5	testis: 65.0	thyroid gland: 12.4	Mixed		
ST8SIA1	SIAT8, SIAT8A	ENSG00000111728	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1	12	22063773-22437041	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026775	Approved					Mixed	Mixed			cerebral cortex: 9.0	Cell line enhanced		AF22: 6.4;SK-MEL-30: 4.8;WM-115: 6.4
ST8SIA3	SIAT8C	ENSG00000177511	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3	18	57350813-57371731	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA063398, HPA066783	Supported		Supported	Golgi apparatus		Group enriched	Tissue enriched	7	cerebral cortex: 31.8	adrenal gland: 4.8	Group enriched	67	NTERA-2: 4.3;SCLC-21H: 8.6;SH-SY5Y: 8.7
ST8SIA5	SIAT8E	ENSG00000101638	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5	18	46667821-46759257	Predicted membrane proteins	Evidence at protein level	HPA043813, HPA046771	Approved		Approved	Plasma membrane<br>Midbody		Tissue enriched	Tissue enhanced		adrenal gland: 5.5;cerebral cortex: 11.4	parathyroid gland: 3.4	Cell line enriched	7	WM-115: 121.0
STAB1	CLEVER-1, FEEL-1, FELE-1, FEX1, KIAA0246, SCARH2, STAB-1	ENSG00000010327	Stabilin 1	3	52495338-52524495	Predicted membrane proteins	Evidence at protein level	HPA005434	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:3.88e-7 (unfavourable), Colorectal cancer:7.59e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 123.3	Group enriched	38	HUVEC TERT2: 86.2;NB-4: 93.1;TIME: 104.8
STAB2	DKFZP434E0321, FEEL-2, FELL, HARE, SCARH1, STAB-2	ENSG00000136011	Stabilin 2	12	103587273-103766727	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026871	Enhanced		Uncertain	Cytosol		Not detected	Tissue enriched	6	spleen: 48.3	liver: 7.8	Cell line enhanced		BEWO: 11.1;HaCaT: 2.8
STARD3	es64, MLN64	ENSG00000131748	StAR related lipid transfer domain containing 3	17	39637065-39663484	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	CAB017021	Uncertain				Liver cancer:3.60e-5 (unfavourable), Renal cancer:7.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.3	Expressed in all		
STARD3NL	MENTHO, MGC3251	ENSG00000010270	STARD3 N-terminal like	7	38178222-38230671	Predicted membrane proteins	Evidence at protein level	HPA019204	Enhanced		Supported	Vesicles	Liver cancer:1.44e-5 (unfavourable), Head and neck cancer:2.20e-4 (unfavourable), Pancreatic cancer:8.48e-4 (favourable)	Expressed in all	Expressed in all			placenta: 70.6	Expressed in all		
STEAP1	PRSS24, STEAP	ENSG00000164647	STEAP family member 1	7	90154375-90164829	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030985	Uncertain					Tissue enriched	Tissue enhanced		prostate: 119.0	appendix: 40.6	Cell line enhanced		CAPAN-2: 106.6;U-138 MG: 147.9
STEAP1B		ENSG00000105889	STEAP family member 1B	7	22419444-22632925	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 5.3	spleen: 3.4	Cell line enhanced		hTEC/SVTERT24-B: 75.9;HUVEC TERT2: 72.0;K-562: 46.3;WM-115: 93.7
STEAP2	IPCA-1, PCANAP1, STAMP1, STMP	ENSG00000157214	STEAP2 metalloreductase	7	90167590-90238137	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029115, HPA055603	Uncertain		Supported	Vesicles		Tissue enriched	Tissue enriched	11	prostate: 208.0	parathyroid gland: 18.7	Cell line enhanced		A549: 20.3;CAPAN-2: 42.2;U-138 MG: 26.9
STEAP3	dudlin-2, STMP3, TSAP6	ENSG00000115107	STEAP3 metalloreductase	2	119223831-119265652	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA050510	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:0.00e+0 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 194.5	liver: 53.0	Cell line enhanced		U-87 MG: 145.7
STEAP4	FLJ23153, STAMP2, TIARP, TNFAIP9	ENSG00000127954	STEAP4 metalloreductase	7	88270892-88306891	Predicted membrane proteins, Transporters	Evidence at protein level	HPA075871			Supported	Golgi apparatus	Liver cancer:2.97e-4 (favourable), Stomach cancer:5.77e-4 (unfavourable)	Tissue enhanced	Expressed in all			adipose tissue: 130.7	Group enriched	6	HSkMC: 88.7;SiHa: 126.7;U-2197: 154.7
STIM1	D11S4896E, GOK	ENSG00000167323	Stromal interaction molecule 1	11	3854527-4093210	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA011088, HPA012123, CAB037128, CAB037288	Enhanced		Enhanced	Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 86.8	Expressed in all		
STIM2		ENSG00000109689	Stromal interaction molecule 2	4	26857678-27025381	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036933, CAB037196, HPA057511	Supported				Liver cancer:3.97e-5 (unfavourable), Pancreatic cancer:5.01e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 45.8	Expressed in all		
STK17A	DRAK1	ENSG00000164543	Serine/threonine kinase 17a	7	43582758-43626786	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA018138, HPA037979	Uncertain		Approved	Nuclear speckles<br>Plasma membrane		Expressed in all	Expressed in all			lymph node: 49.2	Expressed in all		
STK17B	DRAK2	ENSG00000081320	Serine/threonine kinase 17b	2	196133566-196176503	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034858	Enhanced		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:5.72e-8 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 248.5	lymph node: 133.3	Expressed in all		
STK36	FU, KIAA1278	ENSG00000163482	Serine/threonine kinase 36	2	218672026-218702716	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027409, HPA027453, HPA030058	Approved		Supported	Cytosol	Liver cancer:5.20e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.0	Expressed in all		
STK40	MGC4796, SgK495	ENSG00000196182	Serine/threonine kinase 40	1	36339624-36385896	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA008026	Uncertain		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.59e-4 (favourable)	Expressed in all	Expressed in all			testis: 57.0	Expressed in all		
STKLD1	C9orf96, MGC43306, SGK071	ENSG00000198870	Serine/threonine kinase like domain containing 1	9	133376367-133406096	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA029902	Uncertain					Mixed	Tissue enriched	14	testis: 5.7	cerebral cortex,epididymis: 0.3	Not detected		
STOM	BND7, EPB7, EPB72	ENSG00000148175	Stomatin	9	121338988-121370304	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010961, HPA011419	Approved		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			adipose tissue: 463.6	Cell line enhanced		ASC diff: 468.5;hTCEpi: 411.2
STOML1	FLJ36370, hUNC-24, SLP-1, STORP	ENSG00000067221	Stomatin like 1	15	73978923-73994622	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042353	Approved		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 43.7	Expressed in all		
STOML3	Epb7.2l, SRO	ENSG00000133115	Stomatin like 3	13	38965925-38991066	Predicted membrane proteins, Transporters	Evidence at protein level	HPA012892, HPA071011	Enhanced		Enhanced	Plasma membrane	Endometrial cancer:1.49e-4 (favourable)	Tissue enhanced	Tissue enriched	18	fallopian tube: 50.3	lung: 2.8	Cell line enriched	33	AF22: 15.4
STON2	STN2, STNB2	ENSG00000140022	Stonin 2	14	81260656-81436465	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003086	Enhanced		Supported	Nucleoli<br>Cytosol	Endometrial cancer:4.96e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 34.2	Cell line enhanced		HEL: 130.5;HMC-1: 63.9
STRA6	FLJ12541	ENSG00000137868	Stimulated by retinoic acid 6	15	74179466-74212267	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA040839	Approved		Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		cervix, uterine: 37.0;placenta: 20.4	endometrium: 13.2	Cell line enhanced		CAPAN-2: 162.1;SH-SY5Y: 119.5;WM-115: 273.5
STRN4	PPP2R6C, ZIN	ENSG00000090372	Striatin 4	19	46719507-46746994	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043051, HPA043527, HPA056706	Enhanced		Approved	Cytosol	Liver cancer:6.06e-8 (unfavourable), Ovarian cancer:2.98e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 104.8	Expressed in all		
STS	ARSC, ARSC1	ENSG00000101846	Steroid sulfatase	X	7219456-7354810	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA002904	Enhanced				Pancreatic cancer:3.47e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 36.5	adipose tissue: 18.9	Cell line enhanced		U-266/70: 79.0
STT3A	ITM1, MGC9042, STT3-A, TMC	ENSG00000134910	STT3A, catalytic subunit of the oligosaccharyltransferase complex	11	125591712-125625215	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA030735	Approved		Uncertain	Nucleoplasm<br>Vesicles<br>Cytosol	Endometrial cancer:1.32e-4 (favourable), Liver cancer:3.57e-4 (unfavourable), Renal cancer:4.96e-4 (unfavourable)	Expressed in all	Tissue enriched	7	parathyroid gland: 1131.8	epididymis: 173.0	Expressed in all		
STT3B	FLJ90106, SIMP, STT3-B	ENSG00000163527	STT3B, catalytic subunit of the oligosaccharyltransferase complex	3	31532638-31637622	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA036448, HPA036646	Approved		Supported	Endoplasmic reticulum	Colorectal cancer:7.91e-5 (favourable)	Expressed in all	Expressed in all			testis: 165.5	Expressed in all		
STUM	C1orf95, DKFZp761P211	ENSG00000203685	Stum, mechanosensory transduction mediator homolog	1	226548800-226609214	Predicted membrane proteins	Evidence at protein level	HPA074381			Approved	Cytosol	Renal cancer:6.40e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 35.7	smooth muscle: 8.4	Cell line enriched	5	HEL: 26.9
STX10	hsyn10, SYN10	ENSG00000104915	Syntaxin 10	19	13144058-13150383	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035303, HPA056439	Approved		Approved	Golgi apparatus	Renal cancer:1.69e-7 (unfavourable), Lung cancer:8.26e-4 (favourable)	Expressed in all	Expressed in all			skin: 57.0	Expressed in all		
STX12	STX13, STX14	ENSG00000117758	Syntaxin 12	1	27773183-27824452	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041038, HPA055300	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			thyroid gland: 156.0	Expressed in all		
STX16	hsyn16, SYN16	ENSG00000124222	Syntaxin 16	20	58651253-58679526	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041019, HPA042033	Uncertain		Enhanced	Vesicles	Renal cancer:1.11e-16 (unfavourable), Liver cancer:4.18e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 63.9	Expressed in all		
STX17	FLJ20651	ENSG00000136874	Syntaxin 17	9	99906633-99970341	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001204	Approved		Uncertain	Nucleoli<br>Cytosol	Renal cancer:1.62e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.7	Expressed in all		
STX18	Ufe1	ENSG00000168818	Syntaxin 18	4	4415742-4542346	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003019	Approved		Approved	Plasma membrane	Endometrial cancer:6.33e-8 (favourable), Colorectal cancer:2.84e-4 (favourable), Urothelial cancer:4.69e-4 (favourable), Renal cancer:7.03e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 180.1	Expressed in all		
STX1A	HPC-1, p35-1, STX1	ENSG00000106089	Syntaxin 1A	7	73699206-73719672	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB008372, HPA069176	Enhanced				Endometrial cancer:1.94e-5 (unfavourable), Cervical cancer:3.63e-4 (unfavourable)	Expressed in all	Tissue enriched	15	cerebral cortex: 166.6	gallbladder: 10.8	Cell line enhanced		SCLC-21H: 164.0;U-87 MG: 90.3
STX1B	STX1B1, STX1B2	ENSG00000099365	Syntaxin 1B	16	30989256-31010661	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069176, CAB079008	Supported	Supported				Tissue enriched	Tissue enriched	22	cerebral cortex: 108.6	testis: 4.8	Cell line enhanced		hTEC/SVTERT24-B: 11.1
STX2	EPIM, EPM, STX2A, STX2B, STX2C	ENSG00000111450	Syntaxin 2	12	130789600-130839266	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA038189, HPA069176, CAB079007	Uncertain	Supported	Approved	Nucleus<br>Cytosol	Renal cancer:5.15e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 35.2	Expressed in all		
STX3	STX3A	ENSG00000166900	Syntaxin 3	11	59755059-59805882	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002191, HPA069176	Approved		Approved	Nucleus<br>Nuclear bodies<br>Golgi apparatus<br>Cytosol	Liver cancer:8.41e-7 (unfavourable), Renal cancer:1.14e-6 (favourable)	Expressed in all	Expressed in all			placenta: 72.4	Mixed		
STX4	p35-2, STX4A	ENSG00000103496	Syntaxin 4	16	31032889-31042975	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA001330	Approved		Enhanced	Plasma membrane	Renal cancer:2.88e-9 (unfavourable), Cervical cancer:3.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 64.5	Expressed in all		
STX5	SED5, STX5A	ENSG00000162236	Syntaxin 5	11	62806897-62832088	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001358	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 59.1	Expressed in all		
STX6		ENSG00000135823	Syntaxin 6	1	180972712-181023121	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA038557, HPA038558	Approved		Enhanced	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.93e-8 (unfavourable), Liver cancer:6.24e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 30.2	Expressed in all		
STX7		ENSG00000079950	Syntaxin 7	6	132445867-132513198	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001467, CAB062564	Enhanced		Enhanced	Lysosomes	Liver cancer:1.60e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 91.4	Expressed in all		
STX8	CARB	ENSG00000170310	Syntaxin 8	17	9250471-9576591	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001540	Approved		Uncertain	Nuclear bodies<br>Golgi apparatus<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			testis: 96.6	Expressed in all		
STYK1	DKFZp761P1010, NOK, SuRTK106	ENSG00000060140	Serine/threonine/tyrosine kinase 1	12	10618939-10674318	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040468, HPA048569	Uncertain		Approved	Nucleus<br>Plasma membrane		Mixed	Mixed			rectum: 17.4	Cell line enhanced		CAPAN-2: 23.5;HUVEC TERT2: 20.0;TIME: 18.2
SUCNR1	GPR91	ENSG00000198829	Succinate receptor 1	3	151873643-151884619	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022745	Uncertain					Mixed	Tissue enhanced		kidney: 42.3	thyroid gland: 15.9	Group enriched	6	HEL: 47.7;NB-4: 19.6;U-937: 41.3
SUCO	C1orf9, CH1, OPT, SLP1	ENSG00000094975	SUN domain containing ossification factor	1	172532349-172611833	Predicted membrane proteins	Evidence at protein level	HPA047251	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Liver cancer:2.86e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 75.9	Expressed in all		
SUN1	FLJ12407, KIAA0810, UNC84A	ENSG00000164828	Sad1 and UNC84 domain containing 1	7	816615-896435	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008346, HPA008461	Enhanced		Enhanced	Nuclear membrane		Expressed in all	Expressed in all			endometrium: 120.7	Expressed in all		
SUN2	UNC84B	ENSG00000100242	Sad1 and UNC84 domain containing 2	22	38734725-38794143	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001209	Supported		Supported	Nuclear membrane		Expressed in all	Expressed in all			lymph node: 118.9	Expressed in all		
SUN3	MGC33329, SUNC1	ENSG00000164744	Sad1 and UNC84 domain containing 3	7	47987148-48029119	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008344			Approved	Golgi apparatus		Tissue enhanced	Tissue enriched	156	testis: 74.6	placenta: 0.4	Cell line enriched	8	U-2 OS: 21.7
SUN5	dJ726C3.1, SPAG4L, TSARG4	ENSG00000167098	Sad1 and UNC84 domain containing 5	20	32983773-33004433	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048529	Enhanced					Not detected	Tissue enriched	411	testis: 41.0	all non-specific tissues: 0.0	Not detected		
SURF1		ENSG00000148290	SURF1, cytochrome c oxidase assembly factor	9	133351755-133356676	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB033946	Uncertain				Renal cancer:6.92e-9 (favourable)	Expressed in all	Expressed in all			epididymis: 46.8	Expressed in all		
SURF4	ERV29, FLJ22993, MGC102753	ENSG00000148248	Surfeit 4	9	133361449-133376166	Predicted membrane proteins, Transporters	Evidence at protein level	HPA064613	Approved				Head and neck cancer:1.47e-5 (unfavourable), Breast cancer:5.85e-4 (unfavourable), Liver cancer:8.11e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 82.7	Expressed in all		
SUSD1	DKFZP761E1824	ENSG00000106868	Sushi domain containing 1	9	112040785-112175408	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048554	Approved		Approved	Nucleoplasm	Renal cancer:3.63e-6 (favourable)	Expressed in all	Mixed			placenta: 21.5	Cell line enhanced		HEL: 50.2
SUSD2	BK65A6.2, FLJ22778	ENSG00000099994	Sushi domain containing 2	22	24181259-24189110	Predicted membrane proteins	Evidence at protein level	HPA004117	Enhanced		Approved	Plasma membrane	Renal cancer:3.29e-5 (unfavourable)	Expressed in all	Tissue enhanced		lung: 139.3	small intestine: 35.2	Cell line enriched	33	SK-BR-3: 622.4
SUSD3	MGC26847	ENSG00000157303	Sushi domain containing 3	9	93058688-93085138	Predicted membrane proteins	Evidence at protein level	HPA042310	Uncertain		Approved	Nucleus	Breast cancer:5.13e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 91.6	lymph node: 66.4	Cell line enhanced		Daudi: 107.9;NB-4: 49.1;RPMI-8226: 56.9
SUSD4	FLJ10052	ENSG00000143502	Sushi domain containing 4	1	223220819-223364202	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058296	Uncertain		Approved	Vesicles	Endometrial cancer:4.28e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 42.4	cerebral cortex: 38.5	Cell line enriched	5	SCLC-21H: 46.1
SUSD5	KIAA0527	ENSG00000173705	Sushi domain containing 5	3	33150042-33219215	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052788	Uncertain		Uncertain	Golgi apparatus<br>Vesicles		Tissue enhanced	Mixed			cerebral cortex: 11.0	Cell line enhanced		BJ hTERT+ SV40 Large T+: 26.7;HUVEC TERT2: 60.2;LHCN-M2: 23.3;TIME: 23.4
SUSD6	KIAA0247	ENSG00000100647	Sushi domain containing 6	14	69611596-69715142	Predicted membrane proteins	Evidence at protein level	HPA030464	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments	Renal cancer:2.16e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 52.4	Expressed in all		
SV2A	KIAA0736, SV2	ENSG00000159164	Synaptic vesicle glycoprotein 2A	1	149903318-149917882	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB002226, HPA007863	Enhanced		Approved	Cytosol	Renal cancer:3.22e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 166.9;parathyroid gland: 72.0	epididymis: 28.2	Cell line enhanced		NTERA-2: 65.6;SCLC-21H: 63.2
SV2B	HsT19680, KIAA0735	ENSG00000185518	Synaptic vesicle glycoprotein 2B	15	91099950-91301309	Predicted membrane proteins	Evidence at protein level	HPA046247	Approved					Mixed	Tissue enriched	23	cerebral cortex: 47.9	adipose tissue: 2.1	Group enriched	6	RPMI-8226: 1.4;SCLC-21H: 4.6
SV2C		ENSG00000122012	Synaptic vesicle glycoprotein 2C	5	76083172-76353939	Predicted membrane proteins	Evidence at protein level	HPA040722, HPA040770	Supported		Supported	Nucleoplasm<br>Vesicles		Not detected	Tissue enhanced		adrenal gland: 1.6;cerebral cortex: 3.4	fallopian tube,ovary: 0.6	Cell line enhanced		Karpas-707: 6.5;SCLC-21H: 4.3;SH-SY5Y: 9.0
SVOP	DKFZp761H039	ENSG00000166111	SV2 related protein	12	108907741-109021240	Predicted membrane proteins	Evidence at protein level	HPA016573	Uncertain					Group enriched	Tissue enriched	15	cerebral cortex: 32.2	adrenal gland: 2.0	Cell line enhanced		Karpas-707: 2.0;RPMI-8226: 2.0;SCLC-21H: 1.8;SH-SY5Y: 1.4
SVOPL	MGC46715	ENSG00000157703	SVOP like	7	138594285-138701352	Predicted membrane proteins	Evidence at transcript level	HPA018035	Uncertain					Mixed	Tissue enriched	5	parathyroid gland: 14.3	fallopian tube: 2.6	Cell line enhanced		HMC-1: 3.7;NTERA-2: 1.2;T-47d: 4.1
SYBU	FLJ20366, GOLSYN, KIAA1472, OCSYN, SNPHL	ENSG00000147642	Syntabulin	8	109573978-109691791	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053057	Uncertain		Supported	Vesicles	Liver cancer:7.74e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 76.0	adrenal gland: 40.7	Cell line enhanced		HaCaT: 20.2;PC-3: 23.7;SCLC-21H: 20.0;SK-BR-3: 38.8
SYNDIG1	C20orf39, FLJ14220, IFITMD5, SynDIG1, TMEM90B	ENSG00000101463	Synapse differentiation inducing 1	20	24469199-24666616	Predicted membrane proteins	Evidence at protein level	HPA044271, HPA059267			Supported	Vesicles	Thyroid cancer:6.16e-6 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 26.9	heart muscle: 14.4	Group enriched	9	Karpas-707: 9.0;RH-30: 34.5;RPMI-8226: 24.4;SCLC-21H: 9.7;U-87 MG: 21.0
SYNDIG1L	capucin, IFITMD4, TMEM90A	ENSG00000183379	Synapse differentiation inducing 1 like	14	74405893-74426102	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA042594, HPA048487	Uncertain					Mixed	Tissue enriched	10	epididymis: 13.4	lung: 1.3	Not detected		
SYNE1	8B, ARCA1, C6orf98, CPG2, dJ45H2.2, enaptin, KIAA0796, MYNE1, Nesp1, Nesprin-1, SCAR8, SYNE-1B	ENSG00000131018	Spectrin repeat containing nuclear envelope protein 1	6	152121684-152637801	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019113	Approved		Supported	Nucleoplasm<br>Nuclear membrane		Mixed	Expressed in all			parathyroid gland: 59.2	Mixed		
SYNE2	DKFZP434H2235, KIAA1011, Nesp2, Nesprin-2, NUA, NUANCE, SYNE-2	ENSG00000054654	Spectrin repeat containing nuclear envelope protein 2	14	63852983-64226433	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003435, HPA050204	Enhanced		Enhanced	Nuclear membrane	Renal cancer:3.56e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 197.1	Cell line enhanced		Daudi: 72.6
SYNE3	C14orf139, C14orf49, FLJ25605, LINC00341, NCRNA00341, Nesp3, Nesprin-3, NET53	ENSG00000176438	Spectrin repeat containing nuclear envelope family member 3	14	95407266-95475836	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055227, HPA077140	Approved		Enhanced	Nuclear membrane		Mixed	Mixed			adipose tissue: 14.7	Cell line enhanced		ASC diff: 31.9;REH: 31.6
SYNE4	C19orf46, DFNB76, FLJ36445, Nesp4, Nesprin-4	ENSG00000181392	Spectrin repeat containing nuclear envelope family member 4	19	36003307-36008793	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060253	Uncertain				Renal cancer:8.64e-9 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 18.7	prostate: 11.8	Cell line enhanced		CACO-2: 27.6;Hep G2: 20.0;MCF7: 26.0;SK-BR-3: 30.3;T-47d: 29.1
SYNGR1		ENSG00000100321	Synaptogyrin 1	22	39349925-39385588	Predicted membrane proteins	Evidence at protein level	HPA029673, CAB034277	Enhanced		Supported	Cytosol	Renal cancer:4.98e-7 (favourable), Pancreatic cancer:2.41e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 175.4	Mixed		
SYNGR2		ENSG00000108639	Synaptogyrin 2	17	78168558-78173527	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014742	Approved		Approved	Golgi apparatus	Renal cancer:5.37e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 154.3	Mixed		
SYNGR3		ENSG00000127561	Synaptogyrin 3	16	1989660-1994275	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB034278, HPA042842	Enhanced		Approved	Plasma membrane	Renal cancer:7.12e-7 (favourable), Cervical cancer:6.92e-4 (favourable)	Mixed	Tissue enriched	7	cerebral cortex: 82.6	parathyroid gland: 12.6	Cell line enhanced		HDLM-2: 45.7;HMC-1: 26.7;U-266/70: 30.7
SYNGR4		ENSG00000105467	Synaptogyrin 4	19	48364395-48376376	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030075, HPA059286	Enhanced		Approved	Golgi apparatus		Mixed	Tissue enriched	10	testis: 46.8	parathyroid gland: 4.5	Group enriched	6	A549: 9.0;SCLC-21H: 28.5
SYNJ2BP	Arip2	ENSG00000213463	Synaptojanin 2 binding protein	14	70366496-70417061	Predicted membrane proteins	Evidence at protein level	HPA000866	Approved	Supported	Approved	Mitochondria	Renal cancer:1.11e-16 (favourable)	Expressed in all	Mixed			parathyroid gland: 40.9	Mixed		
SYNPR	MGC26651, SPO	ENSG00000163630	Synaptoporin	3	63228315-63616921	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051368, HPA061671	Enhanced					Tissue enhanced	Tissue enriched	27	cerebral cortex: 78.2	heart muscle: 2.9	Cell line enhanced		SCLC-21H: 1.2
SYP	MRX96	ENSG00000102003	Synaptophysin	X	49187804-49200259	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000076, HPA002858, CAB055505, CAB078999	Enhanced	Supported				Group enriched	Tissue enriched	11	cerebral cortex: 571.4	adrenal gland: 51.1	Cell line enhanced		SCLC-21H: 116.7;SH-SY5Y: 38.0
SYPL1	SYPL	ENSG00000008282	Synaptophysin like 1	7	106090503-106112576	Predicted membrane proteins	Evidence at protein level	HPA014141	Approved				Renal cancer:1.25e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 194.9	Mixed		
SYPL2	Mg29	ENSG00000143028	Synaptophysin like 2	1	109466628-109482137	Predicted membrane proteins	Evidence at protein level	HPA018032			Approved	Nucleoplasm	Renal cancer:3.05e-4 (favourable)	Mixed	Tissue enriched	7	skeletal muscle: 129.4	parathyroid gland: 17.4	Cell line enhanced		ASC diff: 22.2;BJ: 12.2;BJ hTERT+: 36.7;fHDF/TERT166: 18.3;HAP1: 12.5
SYS1	C20orf169, dJ453C12.4	ENSG00000204070	SYS1, golgi trafficking protein	20	45361937-45376798	Predicted membrane proteins	Evidence at protein level	HPA046716	Approved				Liver cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 51.8	Expressed in all		
SYT1	P65, SVP65, SYT	ENSG00000067715	Synaptotagmin 1	12	78863993-79452008	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008394, HPA064788	Enhanced	Supported				Mixed	Tissue enriched	13	cerebral cortex: 476.5	smooth muscle: 36.7	Cell line enhanced		hTERT-HME1: 29.8;LHCN-M2: 26.5;SH-SY5Y: 32.1;WM-115: 28.3
SYT10		ENSG00000110975	Synaptotagmin 10	12	33374238-33439819	Predicted membrane proteins	Evidence at transcript level	HPA055426	Uncertain		Approved	Nucleoplasm<br>Vesicles		Tissue enriched	Tissue enhanced		fallopian tube: 3.5	seminal vesicle: 1.1	Cell line enhanced		AF22: 1.6;MCF7: 2.7;RT4: 1.1;SCLC-21H: 2.0
SYT14	FLJ34198, sytXIV	ENSG00000143469	Synaptotagmin 14	1	209938174-210171389	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036963			Supported	Vesicles		Tissue enhanced	Group enriched	5	cerebral cortex: 3.0;testis: 6.7;thyroid gland: 9.8	adrenal gland: 1.3	Cell line enhanced		BJ hTERT+: 10.5;SCLC-21H: 7.8;TIME: 8.9;U-138 MG: 7.9
SYT15	CHR10SYT	ENSG00000204176	Synaptotagmin 15	10	46578217-46594173	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA036971, HPA036972, HPA064559	Uncertain		Approved	Golgi apparatus		Not detected	Mixed			lung: 21.1	Cell line enhanced		SK-BR-3: 23.7
SYT16	CHR14SYT, Strep14, SYT14L, yt14r	ENSG00000139973	Synaptotagmin 16	14	61811974-62112550	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004199, HPA076871	Uncertain		Approved	Cytosol		Mixed	Group enriched	8	cerebral cortex: 18.0;prostate: 3.6;testis: 6.9	stomach: 1.2	Cell line enhanced		A-431: 9.4;PC-3: 5.0;RPTEC TERT1: 4.7;RT4: 13.5;U-2 OS: 6.9
SYT2		ENSG00000143858	Synaptotagmin 2	1	202590596-202710417	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA030372, HPA063655	Enhanced	Supported	Approved	Vesicles		Tissue enriched	Tissue enhanced		adrenal gland: 1.8;cerebral cortex: 2.1	epididymis,testis: 1.0	Cell line enhanced		AF22: 8.4;NTERA-2: 5.8;U-2 OS: 1.8
SYT3		ENSG00000213023	Synaptotagmin 3	19	50621307-50639827	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	10	cerebral cortex: 17.1	testis: 1.7	Cell line enhanced		HEK93: 7.1;HMC-1: 4.7;NTERA-2: 5.5;SH-SY5Y: 6.6;U-2 OS: 4.0
SYT5		ENSG00000129990	Synaptotagmin 5	19	55171199-55180441	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA078390	Enhanced				Pancreatic cancer:5.54e-4 (favourable), Glioma:8.26e-4 (unfavourable)	Mixed	Tissue enriched	10	cerebral cortex: 131.4	adrenal gland: 12.7	Cell line enhanced		EFO-21: 25.6;HMC-1: 53.1;K-562: 20.2;SCLC-21H: 18.7
SYT6		ENSG00000134207	Synaptotagmin 6	1	114089291-114153919	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058362			Uncertain	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.5	kidney: 1.5	Group enriched	7	NTERA-2: 23.0;WM-115: 16.3
SYT7	IPCA-7, MGC150517, PCANAP7, SYT-VII	ENSG00000011347	Synaptotagmin 7	11	61515313-61581148	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012869	Enhanced				Renal cancer:1.16e-4 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 108.7;prostate: 84.8	placenta: 26.6	Cell line enhanced		hTERT-HME1: 68.9;RT4: 30.1;SCLC-21H: 34.3;SK-BR-3: 31.0;T-47d: 38.2
SYT8	DKFZp434K0322	ENSG00000149043	Synaptotagmin 8	11	1828307-1837521	Predicted membrane proteins	Evidence at transcript level	HPA052700	Uncertain		Approved	Nucleoplasm<br>Cell Junctions		Tissue enhanced	Group enriched	5	gallbladder: 26.5;skin: 80.2;urinary bladder: 24.5	seminal vesicle: 8.6	Group enriched	6	CAPAN-2: 56.5;hTCEpi: 72.7;T-47d: 25.8
SYT9		ENSG00000170743	Synaptotagmin 9	11	7238778-7469042	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		cerebral cortex: 6.1;seminal vesicle: 5.1	adrenal gland: 2.7	Cell line enhanced		HEK93: 9.6;RT4: 14.7;SH-SY5Y: 14.3;TIME: 16.8
SYVN1	DER3, HRD1	ENSG00000162298	Synoviolin 1	11	65121780-65134533	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA005480, HPA024300, CAB037030	Enhanced		Supported	Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane	Head and neck cancer:6.88e-4 (favourable)	Expressed in all	Expressed in all			tonsil: 73.8	Expressed in all		
TAAR1	TA1, TAR1, TRAR1	ENSG00000146399	Trace amine associated receptor 1	6	132644984-132646003	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA055614	Approved					Tissue enhanced	Group enriched	17	fallopian tube: 2.2;stomach: 7.8	duodenum,endometrium,prostate,urinary bladder: 0.2	Not detected		
TAAR2	GPR58	ENSG00000146378	Trace amine associated receptor 2 (gene/pseudogene)	6	132617022-132624275	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.4	Not detected		
TAAR5	PNR	ENSG00000135569	Trace amine associated receptor 5	6	132588673-132589686	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA051703	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAAR6	TA4, TRAR4	ENSG00000146383	Trace amine associated receptor 6	6	132570322-132571359	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			kidney: 0.1	Not detected		
TAAR8	GPR102, TA5, TAR5, TRAR5	ENSG00000146385	Trace amine associated receptor 8	6	132552693-132553721	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAAR9	TA3, TAR3, TRAR3	ENSG00000237110	Trace amine associated receptor 9 (gene/pseudogene)	6	132538290-132539336	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TACR1	NK1R, NKIR, SPR, TAC1R	ENSG00000115353	Tachykinin receptor 1	2	75046463-75199700	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA074573	Enhanced					Mixed	Tissue enhanced		cervix, uterine: 7.3	fallopian tube: 4.7	Not detected		
TACR2	NK2R, NKNAR, SKR, TAC2R	ENSG00000075073	Tachykinin receptor 2	10	69403903-69416867	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA076573			Approved	Plasma membrane		Tissue enhanced	Tissue enhanced		smooth muscle: 67.2	esophagus: 23.1	Cell line enhanced		SK-MEL-30: 3.2;U-87 MG: 2.3
TACR3	NK3R	ENSG00000169836	Tachykinin receptor 3	4	103586031-103719816	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA009418	Uncertain					Not detected	Not detected			cerebral cortex: 0.5	Cell line enriched	13	BEWO: 6.9
TACSTD2	EGP-1, GA733-1, M1S1, TROP2	ENSG00000184292	Tumor-associated calcium signal transducer 2	1	58575423-58577773	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA043104, HPA055067, CAB072852	Enhanced		Supported	Nucleoli<br>Vesicles<br>Plasma membrane	Renal cancer:3.99e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 313.8	skin: 209.6	Cell line enhanced		A-431: 502.8;CAPAN-2: 665.4;HaCaT: 672.0
TAF15	hTAFII68, Npl3, RBP56, TAF2N	ENSG00000270647	TATA-box binding protein associated factor 15	17	35713791-35864615	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052059, HPA063647	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 61.1	Expressed in all		
TAF1B	RAF1B, RAFI63, SL1, TAFI63	ENSG00000115750	TATA-box binding protein associated factor, RNA polymerase I subunit B	2	9843354-9934416	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA071254			Supported	Nucleus<br>Nucleoli	Liver cancer:6.94e-7 (unfavourable), Colorectal cancer:8.58e-5 (favourable), Renal cancer:8.55e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 23.9	Expressed in all		
TAF1D	JOSD3, MGC5306, TAF(I)41	ENSG00000166012	TATA-box binding protein associated factor, RNA polymerase I subunit D	11	93729948-93784391	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055935, HPA060385	Uncertain		Supported	Nucleoplasm<br>Microtubule organizing center	Renal cancer:3.17e-7 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 13.8	Expressed in all		
TANGO6	FLJ12688, KIAA1746, TMCO7	ENSG00000103047	Transport and golgi organization 6 homolog	16	68843604-69085180	Predicted membrane proteins	Evidence at protein level	HPA041312	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:3.20e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.2	Expressed in all		
TAOK2	KIAA0881, MAP3K17, PSK, PSK1, TAO1, TAO2	ENSG00000149930	TAO kinase 2	16	29973641-29992261	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010650	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Endometrial cancer:3.87e-5 (favourable), Colorectal cancer:2.51e-4 (unfavourable), Renal cancer:3.66e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable)	Expressed in all	Expressed in all			testis: 36.9	Expressed in all		
TAP1	ABCB2, D6S114E, PSF1, RING4	ENSG00000168394	Transporter 1, ATP binding cassette subfamily B member	6	32845209-32853978	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009516, HPA072354	Approved		Supported	Endoplasmic reticulum<br>Microtubule organizing center	Renal cancer:6.58e-5 (unfavourable), Ovarian cancer:4.07e-4 (favourable), Colorectal cancer:9.01e-4 (favourable)	Expressed in all	Mixed			appendix: 19.9	Mixed		
TAP2	ABCB3, D6S217E, PSF2, RING11	ENSG00000204267	Transporter 2, ATP binding cassette subfamily B member	6	32821833-32838780	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA001312	Approved		Approved	Nuclear speckles<br>Endoplasmic reticulum	Renal cancer:5.22e-8 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable)	Expressed in all	Mixed			urinary bladder: 15.1	Cell line enhanced		U-251 MG: 53.5
TAPBP	TAPA	ENSG00000231925	TAP binding protein	6	33299694-33314387	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007066	Approved				Breast cancer:2.76e-4 (favourable), Melanoma:6.29e-4 (favourable)	Expressed in all	Expressed in all			spleen: 30.7	Cell line enhanced		CAPAN-2: 67.6
TAPBPL	FLJ10143, TAPBP-R, TAPBPR	ENSG00000139192	TAP binding protein like	12	6451690-6466517	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039545	Uncertain				Renal cancer:6.04e-5 (favourable), Breast cancer:1.98e-4 (favourable), Urothelial cancer:7.86e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.2	Cell line enhanced		CAPAN-2: 58.5
TAPT1	FLJ90013	ENSG00000169762	Transmembrane anterior posterior transformation 1	4	16160505-16227410	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA042567, HPA048658	Approved		Approved	Vesicles	Urothelial cancer:4.18e-4 (favourable), Pancreatic cancer:5.34e-4 (favourable), Renal cancer:8.52e-4 (favourable), Endometrial cancer:9.75e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 21.5	Expressed in all		
TARM1		ENSG00000248385	T-cell-interacting, activating receptor on myeloid cells 1	19	54069895-54081365	Predicted membrane proteins	Evidence at transcript level	HPA051022, HPA054401	Uncertain					Not detected	Not detected			gallbladder,spleen: 0.2	Not detected		
TAS1R1	GPR70, T1R1, TR1	ENSG00000173662	Taste 1 receptor member 1	1	6555181-6579757	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA034579, HPA034580	Approved					Mixed	Tissue enriched	7	testis: 4.1	gallbladder,skin: 0.5	Cell line enhanced		HDLM-2: 1.6;Hep G2: 1.1;LHCN-M2: 1.1
TAS1R2	GPR71, T1R2, TR2	ENSG00000179002	Taste 1 receptor member 2	1	18839599-18859682	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS1R3	T1R3	ENSG00000169962	Taste 1 receptor member 3	1	1331314-1335306	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA053439	Uncertain					Mixed	Group enriched	5	epididymis: 14.9;salivary gland: 3.3	appendix: 1.7	Cell line enhanced		Karpas-707: 1.8
TAS2R1	T2R1, TRB7	ENSG00000169777	Taste 2 receptor member 1	5	9628997-9712378	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA051879	Uncertain					Not detected	Tissue enriched	40	testis: 13.1	fallopian tube: 0.3	Not detected		
TAS2R10	T2R10, TRB2	ENSG00000121318	Taste 2 receptor member 10	12	10825317-10826358	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			breast,epididymis: 0.2	Not detected		
TAS2R13	T2R13, TRB3	ENSG00000212128	Taste 2 receptor member 13	12	10907926-10909562	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R14	T2R14, TRB1	ENSG00000212127	Taste 2 receptor member 14	12	10937406-11171573	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Mixed			epididymis: 1.2	Not detected		
TAS2R16	T2R16	ENSG00000128519	Taste 2 receptor member 16	7	122994704-122995700	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R19	T2R19, T2R23, TAS2R23, TAS2R48	ENSG00000212124	Taste 2 receptor member 19	12	11021619-11022620	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enhanced	Not detected			ovary: 0.2	Not detected		
TAS2R20	T2R20, T2R56, TAS2R49	ENSG00000255837	Taste 2 receptor member 20	12	10996495-10997875	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			skin: 0.8	Not detected		
TAS2R3	T2R3	ENSG00000127362	Taste 2 receptor member 3	7	141764097-141765197	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			ovary: 0.5	Not detected		
TAS2R30	T2R30, TAS2R47	ENSG00000256188	Taste 2 receptor member 30	12	11132958-11134644	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			endometrium,ovary,parathyroid gland,testis,thyroid gland: 0.2	Not detected		
TAS2R31	T2R31, T2R53, TAS2R44	ENSG00000256436	Taste 2 receptor member 31	12	11030387-11031407	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			endometrium,parathyroid gland: 0.3	Not detected		
TAS2R38	PTC, T2R61	ENSG00000257138	Taste 2 receptor member 38	7	141972631-141973773	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA043862, HPA054366	Uncertain					Not detected	Not detected			rectum,small intestine: 0.3	Not detected		
TAS2R39		ENSG00000236398	Taste 2 receptor member 39	7	143183419-143184435	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA053456, HPA060680	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R4	T2R4	ENSG00000127364	Taste 2 receptor member 4	7	141778442-141780819	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Mixed			skin: 1.7	Not detected		
TAS2R40	GPR60	ENSG00000221937	Taste 2 receptor member 40	7	143222037-143223079	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			appendix: 0.9	Not detected		
TAS2R41	T2R59	ENSG00000221855	Taste 2 receptor member 41	7	143477873-143478796	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA057063	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R42	hT2R55, T2R24, T2R55, TAS2R55	ENSG00000186136	Taste 2 receptor member 42	12	11185993-11186937	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA036149	Uncertain		Approved	Nucleoplasm<br>Actin filaments<br>Focal adhesion sites		Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R43	T2R52	ENSG00000255374	Taste 2 receptor member 43	12	11091287-11092313	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R46	T2R54	ENSG00000226761	Taste 2 receptor member 46	12	11061365-11062294	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R5	T2R5	ENSG00000127366	Taste 2 receptor member 5	7	141790217-141791367	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 5.0	epididymis: 3.4	Cell line enhanced		hTCEpi: 3.8
TAS2R50	T2R51	ENSG00000212126	Taste 2 receptor member 50	12	10985913-10986912	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R60	T2R60	ENSG00000185899	Taste 2 receptor member 60	7	143443453-143444409	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA030416	Uncertain					Not detected	Not detected			appendix,bone marrow,liver,parathyroid gland,placenta: 0.1	Not detected		
TAS2R7	T2R7, TRB4	ENSG00000121377	Taste 2 receptor member 7	12	10801532-10802627	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R8	T2R8, TRB5	ENSG00000121314	Taste 2 receptor member 8	12	10806051-10807293	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R9	T2R9, TRB6	ENSG00000121381	Taste 2 receptor member 9	12	10809094-10810168	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TATDN1	CDA11	ENSG00000147687	TatD DNase domain containing 1	8	124488485-124539458	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023634, HPA053045	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 62.1	Expressed in all		
TAX1BP1	CALCOCO3, TXBP151	ENSG00000106052	Tax1 binding protein 1	7	27739331-27844564	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024432	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.80e-6 (favourable), Pancreatic cancer:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 184.5	Expressed in all		
TAZ	BTHS, CMD3A, EFE, EFE2, G4.5, TAZ1, XAP-2	ENSG00000102125	Tafazzin	X	154411518-154421726	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039557	Approved		Approved	Plasma membrane	Renal cancer:1.22e-7 (unfavourable), Cervical cancer:5.70e-4 (favourable)	Expressed in all	Expressed in all			bone marrow,spleen: 20.8	Expressed in all		
TBC1D10C	Carabin, EPI64C, FLJ00332	ENSG00000175463	TBC1 domain family member 10C	11	67403915-67410089	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069743	Enhanced		Approved	Nuclear bodies	Renal cancer:4.35e-7 (unfavourable), Head and neck cancer:1.86e-5 (favourable), Breast cancer:3.83e-4 (favourable), Cervical cancer:4.20e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 45.6;spleen: 37.9	appendix: 22.0	Cell line enhanced		MOLT-4: 34.1;NB-4: 32.0;U-937: 16.2
TBC1D19	FLJ11082	ENSG00000109680	TBC1 domain family member 19	4	26576437-26755351	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039592	Approved		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:1.21e-7 (favourable), Thyroid cancer:4.06e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 23.2	Cell line enhanced		LHCN-M2: 64.6
TBC1D20	C20orf140, dJ852M4.2	ENSG00000125875	TBC1 domain family member 20	20	435480-462553	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA043613	Approved					Expressed in all	Expressed in all			parathyroid gland: 31.2	Expressed in all		
TBC1D23	FLJ11046	ENSG00000036054	TBC1 domain family member 23	3	100261000-100325251	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038151, HPA038152	Approved		Enhanced	Golgi apparatus	Endometrial cancer:5.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 32.9	Expressed in all		
TBC1D2B	KIAA1055	ENSG00000167202	TBC1 domain family member 2B	15	77984036-78077724	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041833, HPA048174, HPA052663	Approved		Supported	Cytosol		Expressed in all	Expressed in all			ovary: 57.3	Expressed in all		
TBC1D3	DKFZp434P2235, PRC17, TBC1D3A	ENSG00000274611	TBC1 domain family member 3	17	38181659-38192541	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		small intestine: 4.0;testis: 6.8	endometrium: 3.6	Cell line enhanced		AF22: 7.5;REH: 4.5;U-138 MG: 6.4;U-266/70: 7.8;U-266/84: 3.0;U-698: 3.6
TBC1D30	KIAA0984	ENSG00000111490	TBC1 domain family member 30	12	64781193-64881032	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039772, HPA040043	Approved		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:3.61e-5 (favourable), Lung cancer:5.08e-4 (favourable)	Mixed	Mixed			parathyroid gland: 12.5	Cell line enhanced		MCF7: 33.4;RT4: 26.3;SCLC-21H: 35.3;SK-BR-3: 23.3
TBC1D32	bA57L9.1, BROMI, C6orf170, C6orf171, dJ310J6.1, FLJ30899, FLJ34235	ENSG00000146350	TBC1 domain family member 32	6	121079494-121334745	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013413	Uncertain		Approved	Mitochondria		Mixed	Mixed			testis: 6.1	Cell line enhanced		HDLM-2: 20.6
TBC1D3B	PRC17, TBC1D3I	ENSG00000274808	TBC1 domain family member 3B	17	36165681-36176636	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		skin: 6.3;testis: 6.0	spleen: 2.9	Cell line enhanced		CAPAN-2: 7.5;T-47d: 5.6
TBC1D3C	MGC44903	ENSG00000278299	TBC1 domain family member 3C	17	38057693-38068592	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		testis: 3.3	skin: 2.1	Cell line enhanced		CAPAN-2: 30.1;HeLa: 4.4;T-47d: 6.5
TBC1D3D		ENSG00000274419	TBC1 domain family member 3D	17	38003976-38014902	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		small intestine: 5.5;testis: 3.4	skin: 3.2	Cell line enhanced		CAPAN-2: 8.4;HaCaT: 6.1;HeLa: 5.2;RT4: 3.7
TBC1D3E		ENSG00000278599	TBC1 domain family member 3E	17	38127951-38138862	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		bone marrow: 1.1;gallbladder: 1.8;testis: 3.1	lymph node: 0.9	Cell line enhanced		HHSteC: 3.4
TBC1D3F		ENSG00000275954	TBC1 domain family member 3F	17	36428618-36439566	Predicted membrane proteins	Evidence at protein level	HPA046969			Uncertain	Vesicles		Not detected	Tissue enriched	14	testis: 1.9	bone marrow,gallbladder: 0.1	Not detected		
TBC1D3G		ENSG00000260287	TBC1 domain family member 3G	17	36323884-36334759	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Supported		Approved	Vesicles		Not detected	Tissue enriched	33	testis: 6.1	duodenum: 0.1	Cell line enhanced		SiHa: 1.4
TBC1D3H		ENSG00000274226	TBC1 domain family member 3H	17	36377531-36388423	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Approved	Vesicles		Not detected	Tissue enhanced		testis: 2.7;urinary bladder: 1.1	cervix, uterine: 0.6	Cell line enriched	10	CAPAN-2: 5.1
TBC1D3I		ENSG00000274933	TBC1 domain family member 3I	17	36253456-36264553	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		testis: 1.1	skin: 0.3	Cell line enriched	6	CAPAN-2: 4.7
TBC1D3K		ENSG00000273513	TBC1 domain family member 3K	17	37924415-37935365	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		testis: 1.6	lymph node: 0.3	Cell line enhanced		T-47d: 1.3
TBC1D3L		ENSG00000274512	TBC1 domain family member 3L	17	37977972-37989048	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Mixed	Mixed			skin: 42.2	Cell line enhanced		BEWO: 37.5
TBC1D5	KIAA0210	ENSG00000131374	TBC1 domain family member 5	3	17157162-18444817	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035125, HPA035126	Uncertain		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.75e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.9	Expressed in all		
TBC1D7	dJ257A7.3, FLJ32666	ENSG00000145979	TBC1 domain family member 7	6	13266542-13328583	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034748	Approved				Renal cancer:2.03e-7 (unfavourable), Ovarian cancer:4.98e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 24.4	Expressed in all		
TBC1D8	AD3, GRAMD8, HBLP1, VRP	ENSG00000204634	TBC1 domain family member 8	2	101007617-101252866	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB015211, HPA037496	Uncertain		Supported	Nucleus	Colorectal cancer:6.73e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 45.1	Cell line enhanced		ASC diff: 59.6
TBCD		ENSG00000141556	Tubulin folding cofactor D	17	82752064-82945922	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045200	Approved				Liver cancer:2.39e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 58.6	Expressed in all		
TBXA2R		ENSG00000006638	Thromboxane A2 receptor	19	3594506-3606840	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA077366			Supported	Nuclear speckles<br>Plasma membrane	Renal cancer:1.45e-4 (unfavourable), Pancreatic cancer:7.17e-4 (favourable)	Expressed in all	Mixed			spleen: 5.2	Cell line enhanced		HeLa: 6.4;U-2197: 6.3
TBXAS1	CYP5, CYP5A1, THAS, TS, TXAS, TXS	ENSG00000059377	Thromboxane A synthase 1	7	139777051-140020325	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031257, HPA031258, HPA031259	Enhanced		Supported	Vesicles	Renal cancer:1.14e-4 (unfavourable)	Expressed in all	Mixed			spleen: 56.3	Cell line enhanced		NB-4: 48.5;PC-3: 22.1;U-937: 48.2
TCEANC2	C1orf83, FLJ32112	ENSG00000116205	Transcription elongation factor A N-terminal and central domain containing 2	1	54053587-54112519	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046918	Uncertain		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			testis: 12.5	Expressed in all		
TCIRG1	a3, Atp6i, ATP6N1C, ATP6V0A3, OC-116, OC116, TIRC7	ENSG00000110719	T-cell immune regulator 1, ATPase H+ transporting V0 subunit a3	11	68039016-68050895	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038742	Approved		Approved	Mitochondria	Renal cancer:1.50e-11 (unfavourable), Urothelial cancer:9.45e-6 (favourable)	Expressed in all	Expressed in all			spleen: 82.0	Mixed		
TCTA		ENSG00000145022	T-cell leukemia translocation altered	3	49412206-49416475	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA007342	Approved		Approved	Cytosol	Renal cancer:5.00e-15 (favourable), Lung cancer:6.76e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 76.2	Expressed in all		
TCTN2	C12orf38, FLJ12975, JBTS24, MKS8, TECT2	ENSG00000168778	Tectonic family member 2	12	123671113-123708403	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA039900	Enhanced		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			fallopian tube: 46.6	Mixed		
TCTN3	C10orf61, DKFZP564D116, JBTS18, TECT3	ENSG00000119977	Tectonic family member 3	10	95663396-95694143	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026987	Approved		Approved	Microtubules	Endometrial cancer:5.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 138.1	Expressed in all		
TDRKH	TDRD2	ENSG00000182134	Tudor and KH domain containing	1	151770107-151791416	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016419, HPA019625	Approved		Approved	Centrosome<br>Cytosol	Endometrial cancer:1.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 76.8;testis: 40.1	cerebral cortex: 13.0	Mixed		
TECR	GPSN2, MRT14, SC2, TER	ENSG00000099797	Trans-2,3-enoyl-CoA reductase	19	14517085-14565980	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029780, HPA056488	Supported		Supported	Endoplasmic reticulum	Urothelial cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 404.6	Expressed in all		
TECRL	DKFZp313B2333, DKFZp313D0829, GPSN2L, SRD5A2L2, TERL	ENSG00000205678	Trans-2,3-enoyl-CoA reductase-like	4	64275257-64409468	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	18	heart muscle: 371.9	skeletal muscle: 20.5	Not detected		
TECTA	DFNA12, DFNA8, DFNB21	ENSG00000109927	Tectorin alpha	11	121101173-121191493	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA018870	Approved					Mixed	Tissue enhanced		cerebral cortex: 2.7	parathyroid gland: 2.0	Cell line enhanced		SH-SY5Y: 1.5
TECTB		ENSG00000119913	Tectorin beta	10	112283735-112305035	Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.6	Cell line enhanced		Hep G2: 1.7
TEDDM1	EDDM9, Epdd1, HE9, TMEM45C	ENSG00000203730	Transmembrane epididymal protein 1	1	182398117-182400616	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	447	epididymis: 716.9	seminal vesicle: 1.6	Not detected		
TEK	CD202b, TIE-2, TIE2, VMCM, VMCM1	ENSG00000120156	TEK receptor tyrosine kinase	9	27109141-27230175	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010359, HPA073265	Approved		Supported	Plasma membrane<br>Microtubule organizing center	Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 65.9	lung: 42.6	Group enriched	8	HUVEC TERT2: 74.6;NTERA-2: 44.2;TIME: 80.0
TELO2	hCLK2, KIAA0683, TEL2	ENSG00000100726	Telomere maintenance 2	16	1493344-1510457	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041348, HPA041473	Approved		Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			spleen: 15.5	Expressed in all		
TENM1	ODZ1, ODZ3, TEN-M1, TNM	ENSG00000009694	Teneurin transmembrane protein 1	X	124375903-124963817	Predicted membrane proteins	Evidence at protein level	HPA002848	Uncertain					Group enriched	Mixed			prostate: 4.0	Cell line enhanced		MOLT-4: 4.7;RPTEC TERT1: 1.5;SCLC-21H: 2.3;U-138 MG: 3.2
TENM2	KIAA1127, ODZ2, Ten-M2	ENSG00000145934	Teneurin transmembrane protein 2	5	167284799-168264157	Predicted membrane proteins	Evidence at protein level	HPA038018, HPA038420, HPA068691	Uncertain		Approved	Nucleoli	Urothelial cancer:7.52e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 9.0;heart muscle: 17.1	prostate: 3.6	Cell line enhanced		fHDF/TERT166: 51.2;HBEC3-KT: 30.8;HDLM-2: 40.1;U-138 MG: 73.5;U-2 OS: 67.5;U-251 MG: 41.3
TENM3	KIAA1455, ODZ3, Ten-M3	ENSG00000218336	Teneurin transmembrane protein 3	4	182143987-182803024	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047043	Approved		Approved	Nucleoplasm		Mixed	Tissue enhanced		placenta: 18.7	parathyroid gland: 13.4	Cell line enhanced		HDLM-2: 83.6;T-47d: 80.9
TENM4	KIAA1302, ODZ4, Ten-M4	ENSG00000149256	Teneurin transmembrane protein 4	11	78652831-79440948	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019521, HPA065961	Approved					Mixed	Tissue enhanced		ovary: 20.8;parathyroid gland: 54.0	thyroid gland: 9.7	Cell line enhanced		PC-3: 9.9;SH-SY5Y: 18.6
TERT	EST2, hEST2, TCS1, TP2, TRT	ENSG00000164362	Telomerase reverse transcriptase	5	1253147-1295069	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA054641, HPA065897	Supported		Enhanced	Nucleoplasm<br>Nuclear speckles<br>Cytosol		Mixed	Not detected			lymph node,testis: 0.5	Cell line enhanced		ASC TERT1: 349.5;fHDF/TERT166: 388.9;HBEC3-KT: 725.5;hTEC/SVTERT24-B: 626.8;TIME: 672.9
TEX10	bA208F1.2, FLJ20287, Ipi1	ENSG00000136891	Testis expressed 10	9	100302077-100352939	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Liver cancer:4.46e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 41.6	Expressed in all		
TEX101	CT131, MGC4766, SGRG, SPATA44	ENSG00000131126	Testis expressed 101	19	43401496-43418597	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041915, HPA042513	Enhanced					Mixed	Tissue enriched	108	testis: 173.9	skin: 1.6	Not detected		
TEX2	HT008, KIAA1738, TMEM96	ENSG00000136478	Testis expressed 2	17	64147227-64263301	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020648, HPA057116	Approved		Approved	Nucleus	Colorectal cancer:3.90e-6 (favourable)	Expressed in all	Expressed in all			testis: 99.6	Expressed in all		
TEX261	MGC32043, TEG-261	ENSG00000144043	Testis expressed 261	2	70985938-70994945	Predicted membrane proteins	Evidence at transcript level	HPA016631	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:4.23e-4 (unfavourable), Endometrial cancer:6.17e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 93.1	Expressed in all		
TEX264	FLJ13935, ZSIG11	ENSG00000164081	Testis expressed 264	3	51662693-51704323	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005002, HPA017739	Enhanced		Supported	Nucleoli<br>Cytosol	Renal cancer:7.95e-9 (favourable), Pancreatic cancer:5.67e-4 (favourable)	Expressed in all	Expressed in all			testis: 113.1	Expressed in all		
TEX28	CXorf2, fTEX	ENSG00000278057	Testis expressed 28	X	154271265-154295853	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	33	testis: 6.2	bone marrow,skin: 0.1	Not detected		
TEX29	bA474D23.1, C13orf16, MGC35169	ENSG00000153495	Testis expressed 29	13	111316184-111344249	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	15	testis: 46.8	cerebral cortex: 3.0	Cell line enriched	42	U-698: 15.3
TEX38	ATPAF1-AS1, C1orf223, LOC374973, THEG4	ENSG00000186118	Testis expressed 38	1	46668855-46673594	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	125	testis: 260.8	parathyroid gland: 2.0	Not detected		
TFR2	HFE3, TFRC2	ENSG00000106327	Transferrin receptor 2	7	100620416-100642779	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA011937, CAB016255	Enhanced				Liver cancer:2.48e-4 (favourable)	Tissue enriched	Tissue enriched	11	liver: 155.5	bone marrow: 13.9	Group enriched	14	HEL: 62.3;HMC-1: 81.2;K-562: 58.4
TFRC	CD71, p90, TFR1	ENSG00000072274	Transferrin receptor	3	196027183-196082189	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000153, HPA028598	Enhanced		Supported	Endosomes<br>Lysosomes	Liver cancer:1.15e-4 (unfavourable), Thyroid cancer:2.96e-4 (unfavourable), Cervical cancer:3.67e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 157.4	Expressed in all		
TGFA		ENSG00000163235	Transforming growth factor alpha	2	70447280-70554193	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA042297	Approved		Approved	Vesicles	Pancreatic cancer:1.20e-5 (unfavourable), Thyroid cancer:1.52e-4 (favourable)	Expressed in all	Mixed			esophagus: 27.2	Cell line enhanced		A-431: 58.1;CAPAN-2: 69.9;HBEC3-KT: 50.1;RPTEC TERT1: 52.1;U-87 MG: 63.0
TGFBR1	ACVRLK4, ALK-5, ALK5, ESS1, MSSE	ENSG00000106799	Transforming growth factor beta receptor 1	9	99104038-99154192	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002441, CAB031481, HPA056473	Uncertain		Supported	Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			placenta: 69.8	Expressed in all		
TGFBR2	MFS2	ENSG00000163513	Transforming growth factor beta receptor 2	3	30606502-30694142	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB073537			Supported	Plasma membrane		Expressed in all	Expressed in all			adipose tissue: 292.3	Cell line enhanced		ASC TERT1: 366.2;LHCN-M2: 371.8;TIME: 336.9
TGFBR3	betaglycan, BGCAN	ENSG00000069702	Transforming growth factor beta receptor 3	1	91680343-91906335	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008257, CAB018971	Supported		Uncertain	Cytosol	Thyroid cancer:3.14e-4 (unfavourable), Endometrial cancer:3.36e-4 (unfavourable), Head and neck cancer:4.84e-4 (favourable), Renal cancer:4.99e-4 (favourable)	Expressed in all	Expressed in all			ovary: 99.9	Cell line enhanced		ASC diff: 152.4;ASC TERT1: 75.3;U-2197: 71.9
TGFBR3L		ENSG00000260001	Transforming growth factor beta receptor 3 like	19	7916145-7919097	Predicted membrane proteins	Evidence at protein level	HPA074356	Supported		Approved	Vesicles		Mixed	Tissue enhanced		duodenum: 1.7;small intestine: 1.8	kidney: 1.0	Cell line enhanced		PC-3: 3.7;REH: 9.0
TGIF2-C20orf24		ENSG00000259399	TGIF2-C20orf24 readthrough	20	36574553-36612384	Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			appendix: 11.2	Mixed		
TGOLN2	TGN38, TGN46, TGN48, TGN51, TTGN2	ENSG00000152291	Trans-golgi network protein 2	2	85318020-85328425	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011489, HPA012609, HPA012723	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 146.3	Expressed in all		
THAP12	DAP4, P52rIPK, PRKRIR, THAP0	ENSG00000137492	THAP domain containing 12	11	76349956-76380971	Plasma proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA008758	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 42.8	Expressed in all		
THAP4	CGI-36	ENSG00000176946	THAP domain containing 4	2	241584405-241637449	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA044982, HPA053448	Uncertain		Approved	Nucleoplasm<br>Nuclear speckles	Renal cancer:1.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 83.1	Expressed in all		
THBD	CD141	ENSG00000178726	Thrombomodulin	20	23045633-23049741	Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB002425, HPA002982	Supported		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			lung: 73.3	Cell line enhanced		CAPAN-2: 33.8;EFO-21: 30.9;HaCaT: 28.6;hTCEpi: 30.3
THOC1	HPR1, P84	ENSG00000079134	THO complex 1	18	214520-268050	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019096, HPA019687	Enhanced		Enhanced	Nuclear speckles	Renal cancer:1.80e-6 (unfavourable), Liver cancer:1.83e-5 (unfavourable), Ovarian cancer:2.89e-5 (favourable), Breast cancer:8.43e-4 (favourable), Urothelial cancer:9.62e-4 (favourable)	Expressed in all	Mixed			testis: 29.3	Expressed in all		
THSD1	TMTSP	ENSG00000136114	Thrombospondin type 1 domain containing 1	13	52377167-52406494	Predicted membrane proteins	Evidence at protein level	HPA012611, CAB020796	Uncertain		Enhanced	Cytosol		Expressed in all	Mixed			lung: 16.6	Cell line enhanced		HUVEC TERT2: 34.0
THSD4	ADAMTSL6, FLJ13710, FVSY9334, PRO34005	ENSG00000187720	Thrombospondin type 1 domain containing 4	15	71096952-71783383	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026845			Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		cervix, uterine: 160.5	fallopian tube: 59.6	Cell line enhanced		BJ hTERT+: 43.1;TIME: 54.2
THSD7A	KIAA0960	ENSG00000005108	Thrombospondin type 1 domain containing 7A	7	11370357-11832198	Predicted membrane proteins	Evidence at protein level	HPA000923	Supported				Renal cancer:2.24e-6 (favourable)	Mixed	Mixed			kidney: 8.4	Cell line enhanced		A549: 9.2;HUVEC TERT2: 5.6;REH: 6.5;SH-SY5Y: 10.8;THP-1: 12.8
THSD7B	KIAA1679	ENSG00000144229	Thrombospondin type 1 domain containing 7B	2	136765545-137677717	Predicted membrane proteins	Evidence at transcript level	HPA051416, HPA056745	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		epididymis: 5.1	adipose tissue: 2.0	Group enriched	8	Daudi: 7.8;SCLC-21H: 25.8
THY1	CD90	ENSG00000154096	Thy-1 cell surface antigen	11	119417378-119424985	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003733, CAB068243, CAB068244	Enhanced		Approved	Nucleus<br>Plasma membrane	Renal cancer:2.40e-6 (unfavourable), Glioma:9.64e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 421.8;smooth muscle: 434.2	gallbladder: 161.0	Cell line enhanced		BJ: 643.3;BJ hTERT+: 686.4;fHDF/TERT166: 1040.5
TIE1	JTK14, TIE	ENSG00000066056	Tyrosine kinase with immunoglobulin like and EGF like domains 1	1	43300993-43323108	Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		placenta: 70.6	lung: 40.1	Cell line enhanced		EFO-21: 100.1;HUVEC TERT2: 199.8;TIME: 171.4
TIGIT	DKFZp667A205, FLJ39873, VSIG9, VSTM3	ENSG00000181847	T-cell immunoreceptor with Ig and ITIM domains	3	114276913-114310288	Predicted membrane proteins	Evidence at protein level						Head and neck cancer:3.96e-4 (favourable), Cervical cancer:5.43e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 44.3	spleen: 20.5	Cell line enhanced		HDLM-2: 1.2
TIMD4		ENSG00000145850	T-cell immunoglobulin and mucin domain containing 4	5	156919282-156963255	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA015625, CAB026027	Approved				Renal cancer:3.37e-4 (favourable)	Tissue enriched	Group enriched	6	lymph node: 63.6;testis: 163.0	adipose tissue: 17.9	Group enriched	16	U-266/70: 73.7;U-266/84: 19.8
TIMM17A	TIM17, TIM17A	ENSG00000134375	Translocase of inner mitochondrial membrane 17A	1	201955491-201970661	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA010083	Approved		Supported	Nucleoplasm<br>Mitochondria	Breast cancer:1.98e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 63.2	Expressed in all		
TIMM17B	DXS9822, JM3	ENSG00000126768	Translocase of inner mitochondrial membrane 17B	X	48893447-48898143	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029093	Approved		Approved	Microtubules<br>Mitochondria	Cervical cancer:6.63e-4 (favourable), Urothelial cancer:7.88e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 43.9	Expressed in all		
TIMM21	C18orf55, HSPC154, TIM21	ENSG00000075336	Translocase of inner mitochondrial membrane 21	18	74148511-74160530	Predicted membrane proteins	Evidence at protein level	HPA010587, HPA051543	Uncertain		Approved	Nucleoplasm	Renal cancer:1.38e-9 (favourable), Liver cancer:9.22e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 26.2	Expressed in all		
TIMM22	TEX4, TIM22	ENSG00000177370	Translocase of inner mitochondrial membrane 22	17	997117-1003671	Predicted membrane proteins	Evidence at protein level	HPA045138	Uncertain				Renal cancer:1.41e-4 (favourable), Pancreatic cancer:3.42e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 4.4	Expressed in all		
TIMM23	TIM23	ENSG00000265354	Translocase of inner mitochondrial membrane 23	10	45972449-46003734	Predicted membrane proteins	Evidence at protein level	HPA031408	Approved		Supported	Mitochondria	Liver cancer:2.77e-5 (unfavourable), Ovarian cancer:6.79e-4 (favourable)	Expressed in all	Expressed in all			testis: 142.2	Expressed in all		
TIMM23B	bA592B15.7	ENSG00000204152	Translocase of inner mitochondrial membrane 23 homolog B	10	49942033-49974850	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Mixed			bone marrow: 5.5	Mixed		
TIMM50	TIM50L	ENSG00000105197	Translocase of inner mitochondrial membrane 50	19	39480412-39493785	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048843, HPA056448	Enhanced		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			testis: 80.4	Expressed in all		
TIMMDC1	C3orf1, FLJ22597	ENSG00000113845	Translocase of inner mitochondrial membrane domain containing 1	3	119498532-119525090	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053214, HPA055846	Uncertain		Enhanced	Nucleus<br>Mitochondria	Liver cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 31.5	Expressed in all		
TLCD1		ENSG00000160606	TLC domain containing 1	17	28724348-28727935	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042366	Enhanced				Renal cancer:9.05e-5 (unfavourable), Liver cancer:3.28e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 23.4	Cell line enhanced		SK-BR-3: 86.3
TLCD2		ENSG00000185561	TLC domain containing 2	17	1702790-1710438	Predicted membrane proteins	Evidence at transcript level	HPA046063	Uncertain		Approved	Nucleoli<br>Vesicles	Renal cancer:4.36e-5 (unfavourable)	Expressed in all	Mixed			adipose tissue: 6.0	Cell line enhanced		SiHa: 6.2
TLR1	CD281, KIAA0012, rsc786	ENSG00000174125	Toll like receptor 1	4	38790677-38856817	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Mixed			appendix: 37.2	Cell line enhanced		Daudi: 8.0;HUVEC TERT2: 10.5;RPMI-8226: 9.8;U-698: 14.4
TLR10	CD290	ENSG00000174123	Toll like receptor 10	4	38772239-38782990	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	7	appendix: 21.1;lymph node: 51.7;spleen: 34.7;tonsil: 45.1	urinary bladder: 5.5	Group enriched	65	Daudi: 51.1;REH: 22.0;U-698: 17.6
TLR2	CD282, TIL4	ENSG00000137462	Toll like receptor 2	4	153701500-153705699	CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA060231, HPA071546			Supported	Nucleus<br>Mitochondria	Renal cancer:1.11e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 52.7	bone marrow: 34.8	Cell line enhanced		RT4: 8.5;THP-1: 25.3
TLR3	CD283	ENSG00000164342	Toll like receptor 3	4	186069152-186088069	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025658	Enhanced				Pancreatic cancer:3.09e-4 (unfavourable)	Mixed	Mixed			placenta: 24.5	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 29.4;CAPAN-2: 42.4
TLR4	ARMD10, CD284, hToll, TLR-4	ENSG00000136869	Toll like receptor 4	9	117704332-117716871	CD markers, Predicted membrane proteins	Evidence at protein level	CAB004025, HPA049174	Approved		Supported	Golgi apparatus<br>Cytosol	Testis cancer:3.79e-4 (unfavourable), Endometrial cancer:6.29e-4 (favourable)	Expressed in all	Mixed			spleen: 48.3	Cell line enhanced		Karpas-707: 40.8;TIME: 38.1
TLR5	FLJ10052, MGC126430, MGC126431, SLEB1, TIL3	ENSG00000187554	Toll like receptor 5	1	223109406-223143282	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009013			Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:4.95e-4 (unfavourable)	Mixed	Mixed			ovary: 25.2	Cell line enhanced		A-431: 1.9;HaCaT: 3.3;T-47d: 2.2
TLR6	CD286	ENSG00000174130	Toll like receptor 6	4	38823715-38856817	CD markers, Predicted membrane proteins	Evidence at protein level	HPA062733			Approved	Endoplasmic reticulum		Mixed	Mixed			appendix: 14.0	Cell line enhanced		CAPAN-2: 11.7
TLR7		ENSG00000196664	Toll like receptor 7	X	12867083-12890380	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA059613	Enhanced					Mixed	Mixed			placenta: 9.2	Group enriched	5	Daudi: 11.6;U-266/70: 12.4
TLR8	CD288	ENSG00000101916	Toll like receptor 8	X	12906620-12923169	CD markers, Predicted membrane proteins	Evidence at protein level	HPA001608	Enhanced					Mixed	Tissue enhanced		appendix: 23.2;lung: 15.6;spleen: 18.3	lymph node: 6.6	Not detected		
TLR9	CD289	ENSG00000239732	Toll like receptor 9	3	52221080-52226163	CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		lymph node: 3.0	spleen: 2.0	Group enriched	10	Daudi: 23.9;RPMI-8226: 14.8;U-698: 8.8
TM2D1	BBP	ENSG00000162604	TM2 domain containing 1	1	61681046-61725423	Predicted membrane proteins	Evidence at protein level	HPA046058, HPA055621	Approved		Enhanced	Nucleoplasm	Liver cancer:2.02e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 68.0	Expressed in all		
TM2D2	BLP1	ENSG00000169490	TM2 domain containing 2	8	38988808-38996824	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047152, HPA050547	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane	Colorectal cancer:1.71e-4 (favourable), Breast cancer:7.49e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.3	Expressed in all		
TM2D3	BLP2, FLJ22604	ENSG00000184277	TM2 domain containing 3	15	101621444-101652391	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054064	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 97.2	Expressed in all		
TM4SF1	L6, M3S1	ENSG00000169908	Transmembrane 4 L six family member 1	3	149369022-149377865	Predicted membrane proteins	Evidence at protein level	CAB002760, HPA002823	Uncertain				Urothelial cancer:3.43e-6 (unfavourable), Renal cancer:2.24e-4 (unfavourable), Pancreatic cancer:4.01e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 327.5	Cell line enhanced		CAPAN-2: 539.1;LHCN-M2: 495.4
TM4SF18	L6D	ENSG00000163762	Transmembrane 4 L six family member 18	3	149318498-149334414	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA053639, HPA069378	Approved		Uncertain	Nucleoli<br>Vesicles	Liver cancer:8.63e-4 (favourable)	Expressed in all	Mixed			spleen: 47.0	Group enriched	6	A549: 86.7;EFO-21: 184.5;HUVEC TERT2: 55.1;NTERA-2: 47.1
TM4SF19		ENSG00000145107	Transmembrane 4 L six family member 19	3	196319342-196338503	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 9.0	esophagus: 3.1	Cell line enhanced		hTEC/SVTERT24-B: 18.9;hTERT-HME1: 24.3;PC-3: 34.0;U-138 MG: 18.7;U-87 MG: 19.9
TM4SF20	FLJ22800, TCCE518	ENSG00000168955	Transmembrane 4 L six family member 20	2	227362156-227381995	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051838, HPA063184, HPA065531	Uncertain		Supported	Plasma membrane<br>Focal adhesion sites		Group enriched	Group enriched	35	duodenum: 277.2;small intestine: 163.8	testis: 6.3	Cell line enhanced		A549: 2.5;RPMI-8226: 1.2
TM4SF4	il-TMP	ENSG00000169903	Transmembrane 4 L six family member 4	3	149473974-149503281	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046430	Enhanced		Approved	Plasma membrane<br>Cytosol		Group enriched	Group enriched	34	duodenum: 579.6;gallbladder: 1319.6;liver: 346.9;small intestine: 504.0	stomach: 20.2	Group enriched	6	A549: 19.4;RPTEC TERT1: 24.4
TM4SF5		ENSG00000142484	Transmembrane 4 L six family member 5	17	4771884-4783213	Predicted membrane proteins	Evidence at protein level	HPA055674			Uncertain	Nucleoplasm<br>Plasma membrane<br>Cell Junctions		Tissue enriched	Group enriched	5	duodenum: 176.7;small intestine: 168.8	liver: 33.3	Group enriched	13	CACO-2: 45.1;Hep G2: 64.9
TM6SF1		ENSG00000136404	Transmembrane 6 superfamily member 1	15	83107407-83144854	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016051, HPA056857	Uncertain				Renal cancer:6.79e-4 (favourable)	Mixed	Mixed			thyroid gland: 13.3	Cell line enhanced		HEL: 16.0;HHSteC: 33.2;HUVEC TERT2: 18.1;TIME: 46.3
TM6SF2	Lpr4	ENSG00000213996	Transmembrane 6 superfamily member 2	19	19264364-19273391	Predicted membrane proteins	Evidence at protein level	HPA066026	Uncertain					Tissue enhanced	Group enriched	5	duodenum: 77.0;small intestine: 76.8	liver: 14.7	Cell line enhanced		HHSteC: 1.6;LHCN-M2: 1.2;SH-SY5Y: 1.8
TM7SF2	ANG1, DHCR14A, NET47	ENSG00000149809	Transmembrane 7 superfamily member 2	11	65111845-65116384	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030691, HPA072704	Approved		Supported	Endoplasmic reticulum<br>Vesicles	Renal cancer:8.49e-8 (favourable)	Expressed in all	Expressed in all			adrenal gland: 160.5	Cell line enhanced		T-47d: 122.6
TM7SF3		ENSG00000064115	Transmembrane 7 superfamily member 3	12	26973195-27014434	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057640			Supported	Nucleus<br>Cytosol	Renal cancer:1.32e-4 (favourable)	Expressed in all	Expressed in all			kidney: 190.9	Expressed in all		
TM9SF1	HMP70, MP70	ENSG00000100926	Transmembrane 9 superfamily member 1	14	24189143-24195687	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059249	Supported		Approved	Golgi apparatus	Lung cancer:2.04e-4 (unfavourable), Cervical cancer:8.94e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 73.0	Expressed in all		
TM9SF2	P76	ENSG00000125304	Transmembrane 9 superfamily member 2	13	99501417-99564006	Predicted membrane proteins, Transporters	Evidence at protein level	HPA005657	Supported				Renal cancer:5.21e-7 (favourable), Head and neck cancer:6.40e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 202.1	Expressed in all		
TM9SF3	SMBP	ENSG00000077147	Transmembrane 9 superfamily member 3	10	96518109-96587452	Predicted membrane proteins	Evidence at protein level	HPA039609	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			stomach: 180.7	Expressed in all		
TM9SF4	dJ836N17.2, KIAA0255	ENSG00000101337	Transmembrane 9 superfamily member 4	20	32109506-32167258	Predicted membrane proteins, Transporters	Evidence at protein level	HPA064099	Approved		Approved	Mitochondria	Endometrial cancer:6.37e-6 (unfavourable), Liver cancer:2.15e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 93.1	Expressed in all		
TMBIM1	LFG3, PP1201, RECS1	ENSG00000135926	Transmembrane BAX inhibitor motif containing 1	2	218274192-218292586	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012093, HPA070824	Approved		Supported	Vesicles	Renal cancer:3.38e-4 (favourable), Pancreatic cancer:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 269.0	Expressed in all		
TMBIM4	CGI-119, GAAP, LFG4, S1R, ZPRO	ENSG00000155957	Transmembrane BAX inhibitor motif containing 4	12	66135846-66170072	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA077642			Supported	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 164.3	Expressed in all		
TMBIM6	BAXI1, BI-1, TEGT	ENSG00000139644	Transmembrane BAX inhibitor motif containing 6	12	49707725-49764934	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017378	Approved				Renal cancer:1.00e-5 (favourable), Head and neck cancer:1.91e-4 (unfavourable), Breast cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 1188.4	Expressed in all		
TMC1	DFNA36, DFNB11, DFNB7	ENSG00000165091	Transmembrane channel like 1	9	72521801-72836351	Disease related genes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		cervix, uterine: 1.6	placenta: 1.0	Cell line enhanced		BEWO: 3.1;HAP1: 6.7;NTERA-2: 3.0;U-266/70: 1.6;U-266/84: 1.5
TMC2	C20orf145, dJ686C3.3	ENSG00000149488	Transmembrane channel like 2	20	2536607-2641784	Predicted membrane proteins	Evidence at transcript level	HPA046350	Uncertain					Not detected	Not detected			testis: 0.9	Not detected		
TMC3		ENSG00000188869	Transmembrane channel like 3	15	81331217-81374213	Predicted membrane proteins	Evidence at protein level	HPA040265, HPA040510	Enhanced		Supported	Cytosol		Tissue enhanced	Tissue enriched	137	parathyroid gland: 252.6	epididymis: 1.8	Mixed		
TMC4		ENSG00000167608	Transmembrane channel like 4	19	54160108-54173250	Predicted membrane proteins	Evidence at protein level	HPA048635	Approved				Renal cancer:1.54e-8 (favourable)	Expressed in all	Tissue enhanced		duodenum: 30.8	small intestine: 22.1	Cell line enriched	7	T-47d: 27.9
TMC5	FLJ13593	ENSG00000103534	Transmembrane channel like 5	16	19410496-19499113	Predicted membrane proteins	Evidence at protein level	HPA040810, HPA042037	Enhanced		Approved	Nucleus<br>Plasma membrane	Liver cancer:7.96e-4 (unfavourable)	Mixed	Tissue enhanced		small intestine: 59.1	duodenum: 45.4	Cell line enriched	6	CAPAN-2: 61.8
TMC6	EVER1, EVIN1, LAK-4P	ENSG00000141524	Transmembrane channel like 6	17	78110458-78132407	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051430	Uncertain				Stomach cancer:1.82e-4 (favourable), Urothelial cancer:3.20e-4 (favourable)	Expressed in all	Expressed in all			spleen: 82.8	Cell line enhanced		K-562: 99.9;SK-BR-3: 90.6
TMC7	FLJ21240	ENSG00000170537	Transmembrane channel like 7	16	18983934-19063942	Predicted membrane proteins	Evidence at protein level	HPA029465	Uncertain		Approved	Vesicles	Lung cancer:3.20e-4 (unfavourable), Pancreatic cancer:7.64e-4 (unfavourable), Urothelial cancer:9.20e-4 (favourable)	Mixed	Tissue enhanced		testis: 17.8	cerebral cortex: 10.7	Mixed		
TMC8	EVER2, EVIN2	ENSG00000167895	Transmembrane channel like 8	17	78130770-78142968	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047387, HPA054429	Uncertain		Uncertain	Golgi apparatus	Renal cancer:1.96e-7 (unfavourable), Cervical cancer:8.45e-6 (favourable), Head and neck cancer:4.19e-5 (favourable)	Expressed in all	Tissue enhanced		lymph node: 118.8;spleen: 104.5	appendix: 72.5	Cell line enhanced		HL-60: 50.1;HMC-1: 106.6;Karpas-707: 74.8;RPMI-8226: 46.3;U-266/70: 38.2;U-937: 41.2
TMCC1	KIAA0779	ENSG00000172765	Transmembrane and coiled-coil domain family 1	3	129647792-129893576	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053894	Uncertain				Renal cancer:1.77e-6 (unfavourable), Pancreatic cancer:1.87e-4 (unfavourable), Liver cancer:9.15e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 25.2	Expressed in all		
TMCC2	FLJ38497, HUCEP11	ENSG00000133069	Transmembrane and coiled-coil domain family 2	1	205228176-205273343	Predicted membrane proteins	Evidence at protein level	HPA014254	Approved					Mixed	Tissue enhanced		bone marrow: 52.4;cerebral cortex: 15.1	placenta: 7.8	Cell line enhanced		SCLC-21H: 41.5
TMCC3	KIAA1145	ENSG00000057704	Transmembrane and coiled-coil domain family 3	12	94567124-94650562	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014272	Approved		Approved	Endoplasmic reticulum<br>Vesicles	Endometrial cancer:4.87e-4 (unfavourable)	Expressed in all	Mixed			placenta: 25.7	Cell line enhanced		HUVEC TERT2: 26.1;Karpas-707: 30.1;U-266/84: 20.9
TMCO1	HP10122, TMCC4	ENSG00000143183	Transmembrane and coiled-coil domains 1	1	165724293-165827755	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA054768			Supported	Endoplasmic reticulum	Head and neck cancer:5.17e-7 (unfavourable), Renal cancer:1.25e-4 (unfavourable), Liver cancer:3.21e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 157.4	Expressed in all		
TMCO2	dJ39G22.2	ENSG00000188800	Transmembrane and coiled-coil domains 2	1	40245947-40251691	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	776	testis: 188.7	urinary bladder: 0.2	Not detected		
TMCO3	C13orf11, FLJ20623	ENSG00000150403	Transmembrane and coiled-coil domains 3	13	113490995-113554590	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039561, HPA048126	Uncertain		Approved	Cytosol	Liver cancer:1.14e-5 (unfavourable), Urothelial cancer:4.10e-4 (unfavourable), Cervical cancer:5.80e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 48.6	Expressed in all		
TMCO4	DKFZp686C23231	ENSG00000162542	Transmembrane and coiled-coil domains 4	1	19682213-19799945	Predicted membrane proteins	Evidence at protein level	HPA014601, HPA014620	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:4.12e-11 (favourable), Liver cancer:1.12e-4 (unfavourable), Urothelial cancer:3.64e-4 (favourable), Endometrial cancer:3.71e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 37.0	Cell line enhanced		CAPAN-2: 36.6
TMCO5A	MGC35118, TMCO5	ENSG00000166069	Transmembrane and coiled-coil domains 5A	15	37921939-37967724	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056530	Enhanced					Not detected	Tissue enriched	195	testis: 123.0	fallopian tube: 0.6	Not detected		
TMED1	Il1rl1l, IL1RL1LG, MGC1270, p24g1, p24gamma1, ST2L	ENSG00000099203	Transmembrane p24 trafficking protein 1	19	10832438-10836318	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018507	Uncertain				Renal cancer:8.66e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.6	Expressed in all		
TMED10	p23, P24(DELTA), p24d1, p24delta1, TMP21	ENSG00000170348	Transmembrane p24 trafficking protein 10	14	75131470-75176631	Predicted membrane proteins	Evidence at protein level	CAB034442, CAB037251, HPA047139, HPA050539	Enhanced		Supported	Golgi apparatus	Thyroid cancer:8.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 244.2	Expressed in all		
TMED2	P24A, p24b1, p24beta1, RNP24	ENSG00000086598	Transmembrane p24 trafficking protein 2	12	123584531-123598577	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA014060	Approved		Supported	Vesicles	Renal cancer:2.35e-7 (unfavourable), Head and neck cancer:3.36e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 328.1	Expressed in all		
TMED3	C15orf22, p24B, p24g4, p24gamma4	ENSG00000166557	Transmembrane p24 trafficking protein 3	15	79311062-79427432	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049314, HPA076949	Approved		Supported	Golgi apparatus	Renal cancer:3.73e-4 (unfavourable), Breast cancer:7.71e-4 (unfavourable)	Expressed in all	Mixed			salivary gland: 163.2	Mixed		
TMED4	HNLF, p24a3, p24alpha3	ENSG00000158604	Transmembrane p24 trafficking protein 4	7	44577894-44582287	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014650	Approved				Renal cancer:1.37e-4 (favourable), Endometrial cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 190.7	Expressed in all		
TMED5	CGI-100, p24g2, p24gamma2	ENSG00000117500	Transmembrane p24 trafficking protein 5	1	93149742-93180728	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050289	Approved					Expressed in all	Expressed in all			kidney: 28.2	Expressed in all		
TMED6	MGC23911, p24g5, p24gamma5	ENSG00000157315	Transmembrane p24 trafficking protein 6	16	69343248-69351809	Predicted membrane proteins	Evidence at protein level	HPA012532	Approved				Endometrial cancer:7.74e-5 (favourable)	Mixed	Tissue enhanced		fallopian tube: 35.3;pancreas: 61.2;stomach: 37.5	epididymis: 21.3	Cell line enhanced		Hep G2: 10.1
TMED7	CGI-109, FLJ90481, p24g3, p24gamma3	ENSG00000134970	Transmembrane p24 trafficking protein 7	5	115613508-115632992	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008960, CAB025883	Supported					Expressed in all	Expressed in all			thyroid gland: 138.8	Expressed in all		
TMED9	HSGP25L2G, p24a2, p24alpha2	ENSG00000184840	Transmembrane p24 trafficking protein 9	5	177592158-177596124	Predicted membrane proteins	Evidence at protein level	HPA014650	Approved				Renal cancer:5.88e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 212.7	Expressed in all		
TMEFF1	C9orf2, CT120.1, H7365	ENSG00000241697	Transmembrane protein with EGF like and two follistatin like domains 1	9	100473113-100577636	Predicted membrane proteins	Evidence at protein level	HPA051501	Uncertain					Tissue enhanced	Tissue enriched	5	cerebral cortex: 10.7	testis: 2.0	Cell line enhanced		NTERA-2: 28.1;REH: 17.9;SCLC-21H: 28.0;SH-SY5Y: 16.8
TMEFF2	CT120.2, HPP1, TENB2, TPEF, TR	ENSG00000144339	Transmembrane protein with EGF like and two follistatin like domains 2	2	191949043-192195709	Predicted membrane proteins	Evidence at protein level	HPA015587	Uncertain		Uncertain	Microtubules<br>Cytokinetic bridge		Tissue enriched	Tissue enhanced		cerebral cortex: 41.0;prostate: 64.1	seminal vesicle: 19.6	Group enriched	6	AF22: 38.8;LHCN-M2: 94.7
TMEM100	FLJ10970, FLJ37856	ENSG00000166292	Transmembrane protein 100	17	55719627-55732121	Predicted membrane proteins	Evidence at protein level	HPA055936	Approved		Uncertain	Nucleoplasm	Liver cancer:2.67e-5 (favourable), Renal cancer:1.32e-4 (unfavourable)	Mixed	Tissue enhanced		lung: 131.2;placenta: 78.3	epididymis: 44.5	Cell line enhanced		ASC diff: 19.9;ASC TERT1: 13.7;HHSteC: 37.7;HSkMC: 15.0;U-87 MG: 13.6;WM-115: 11.8
TMEM101	FLJ23987, MGC4251	ENSG00000091947	Transmembrane protein 101	17	44011188-44023946	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039739			Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:4.10e-5 (favourable), Endometrial cancer:4.29e-4 (favourable), Liver cancer:7.10e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 158.8	Mixed		
TMEM104	FLJ00021, FLJ20255	ENSG00000109066	Transmembrane protein 104	17	74776483-74839779	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044330	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Pancreatic cancer:1.97e-5 (favourable), Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 15.0	Expressed in all		
TMEM105	FLJ38792	ENSG00000185332	Transmembrane protein 105	17	81311270-81330674	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		thyroid gland: 1.0	kidney,liver: 0.6	Cell line enhanced		CAPAN-2: 2.9;MCF7: 1.1;U-937: 1.8
TMEM106A	MGC20235	ENSG00000184988	Transmembrane protein 106A	17	43211835-43220041	Predicted membrane proteins	Evidence at transcript level						Colorectal cancer:9.61e-5 (unfavourable)	Expressed in all	Mixed			kidney: 23.2	Mixed		
TMEM106B	FLJ11273, MGC33727	ENSG00000106460	Transmembrane protein 106B	7	12211241-12243367	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058342	Approved		Supported	Endosomes<br>Lysosomes		Expressed in all	Expressed in all			thyroid gland: 64.9	Expressed in all		
TMEM106C	MGC5576	ENSG00000134291	Transmembrane protein 106C	12	47963569-47968878	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047204	Enhanced				Liver cancer:5.27e-8 (unfavourable), Renal cancer:4.62e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 169.3	Expressed in all		
TMEM107	MGC10744	ENSG00000179029	Transmembrane protein 107	17	8173237-8176399	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA052555, HPA059653	Approved		Approved	Nucleoplasm<br>Midbody<br>Midbody ring<br>Cytosol	Endometrial cancer:9.39e-5 (favourable)	Expressed in all	Mixed			fallopian tube: 72.1	Expressed in all		
TMEM108	CT124, MGC3040	ENSG00000144868	Transmembrane protein 108	3	133038391-133397792	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA063350	Uncertain		Approved	Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 21.9;testis: 25.8	adrenal gland: 15.0	Cell line enhanced		HMC-1: 21.3;SCLC-21H: 24.8;SH-SY5Y: 98.2
TMEM109	MGC5508	ENSG00000110108	Transmembrane protein 109	11	60913874-60923443	Predicted membrane proteins, Transporters	Evidence at protein level	HPA011785	Approved		Approved	Nuclear membrane<br>Cytosol	Urothelial cancer:2.68e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 94.7	Expressed in all		
TMEM11	C17orf35, PM1, PMI	ENSG00000178307	Transmembrane protein 11	17	21197280-21214624	Predicted membrane proteins	Evidence at protein level	HPA051795, HPA062854	Uncertain		Supported	Mitochondria		Expressed in all	Mixed			skeletal muscle: 3.6	Mixed		
TMEM110	MGC52022	ENSG00000213533	Transmembrane protein 110	3	52836219-52897596	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051855	Uncertain		Approved	Cytosol		Mixed	Expressed in all			fallopian tube: 21.0	Expressed in all		
TMEM110-MUSTN1		ENSG00000248592	TMEM110-MUSTN1 readthrough	3	52833121-52897562	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA051855	Uncertain		Approved	Cytosol		Not detected	Tissue enhanced		skeletal muscle: 11.1	adipose tissue: 6.6	Cell line enhanced		HDLM-2: 5.2
TMEM114		ENSG00000232258	Transmembrane protein 114	16	8537605-8590193	Disease related genes, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	61	seminal vesicle: 28.7	epididymis: 0.4	Not detected		
TMEM115	PL6	ENSG00000126062	Transmembrane protein 115	3	50354749-50359610	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB006319, HPA015497	Supported		Supported	Golgi apparatus	Renal cancer:1.04e-7 (favourable), Liver cancer:3.73e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 37.3	Expressed in all		
TMEM116	FLJ90167	ENSG00000198270	Transmembrane protein 116	12	111931282-112013185	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA040720	Approved		Approved	Nucleoplasm<br>Microtubules	Renal cancer:1.08e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 57.3	testis: 48.2	Mixed		
TMEM117	DKFZp434K2435	ENSG00000139173	Transmembrane protein 117	12	43835967-44389762	Predicted membrane proteins	Evidence at transcript level	HPA039899, HPA046223	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytokinetic bridge	Melanoma:3.94e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 7.3	Mixed		
TMEM119		ENSG00000183160	Transmembrane protein 119	12	108589846-108598320	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051870, HPA052650	Enhanced				Renal cancer:2.06e-6 (unfavourable), Ovarian cancer:8.37e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 93.0	gallbladder: 55.2	Cell line enhanced		ASC diff: 378.8;ASC TERT1: 106.4;BJ hTERT+: 134.8;HSkMC: 171.1
TMEM120A	NET29, TMPIT	ENSG00000189077	Transmembrane protein 120A	7	75986837-75994659	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Expressed in all	Expressed in all			testis: 72.8	Expressed in all		
TMEM120B		ENSG00000188735	Transmembrane protein 120B	12	121712752-121783001	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014066	Uncertain		Approved	Nucleoli fibrillar center<br>Cytosol	Liver cancer:1.66e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 11.7	Expressed in all		
TMEM121	hole, MGC4659	ENSG00000184986	Transmembrane protein 121	14	105526603-105530202	Predicted membrane proteins	Evidence at transcript level	HPA049857	Uncertain		Approved	Cytosol	Thyroid cancer:5.87e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 4.8	spleen: 2.4	Cell line enhanced		EFO-21: 7.7;MCF7: 6.1;PC-3: 9.5;REH: 6.1;SCLC-21H: 6.2
TMEM123	KCT3, PORIMIN	ENSG00000152558	Transmembrane protein 123	11	102396332-102470384	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026001, HPA062862			Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Pancreatic cancer:2.66e-4 (unfavourable), Melanoma:5.36e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 575.8	Mixed		
TMEM125	MGC17299	ENSG00000179178	Transmembrane protein 125	1	43269994-43274002	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA015796			Approved	Midbody<br>Cytosol	Renal cancer:2.91e-9 (favourable), Lung cancer:5.11e-5 (favourable)	Mixed	Tissue enhanced		lung: 113.7	thyroid gland: 51.5	Cell line enhanced		A-431: 23.4;BEWO: 21.1;CAPAN-2: 42.6;SK-BR-3: 31.0;T-47d: 31.2
TMEM126A	DKFZp586C1924, OPA7	ENSG00000171202	Transmembrane protein 126A	11	85647967-85656547	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA046648	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:8.60e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 67.3	Expressed in all		
TMEM126B	HT007	ENSG00000171204	Transmembrane protein 126B	11	85628573-85636539	Predicted membrane proteins	Evidence at protein level	HPA014480, HPA019186	Uncertain		Supported	Mitochondria		Expressed in all	Expressed in all			epididymis: 39.6	Expressed in all		
TMEM127	FLJ20507, FLJ22257	ENSG00000135956	Transmembrane protein 127	2	96248516-96265994	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level						Renal cancer:6.69e-5 (favourable), Liver cancer:6.59e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 112.5	Expressed in all		
TMEM128	MGC13159	ENSG00000132406	Transmembrane protein 128	4	4235542-4248212	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044809	Uncertain					Expressed in all	Expressed in all			thyroid gland: 63.9	Expressed in all		
TMEM129	D4S2561E	ENSG00000168936	Transmembrane protein 129	4	1715952-1721358	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA060920			Approved	Vesicles	Renal cancer:9.64e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.1	Expressed in all		
TMEM130	DKFZp761L1417, FLJ42643	ENSG00000166448	Transmembrane protein 130	7	98846488-98870771	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012928	Uncertain		Supported	Golgi apparatus	Lung cancer:7.84e-4 (favourable)	Tissue enhanced	Group enriched	9	adrenal gland: 49.1;cerebral cortex: 183.0;testis: 70.7	epididymis: 11.5	Cell line enhanced		BJ hTERT+: 5.4;EFO-21: 6.0;NTERA-2: 3.8;SH-SY5Y: 8.3
TMEM131	CC28, KIAA0257, PRO1048, RW1, YR-23	ENSG00000075568	Transmembrane protein 131	2	97756333-97995891	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017678, HPA017682	Approved		Uncertain	Vesicles<br>Intermediate filaments		Expressed in all	Expressed in all			parathyroid gland: 47.6	Expressed in all		
TMEM132A	FLJ20539, GBP, HSPA5BP1	ENSG00000006118	Transmembrane protein 132A	11	60924463-60937159	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051979, HPA060492	Enhanced		Approved	Mitochondria	Renal cancer:1.55e-9 (unfavourable), Endometrial cancer:1.98e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 94.2	placenta: 25.0	Cell line enhanced		EFO-21: 167.6
TMEM132B	KIAA1786, KIAA1906	ENSG00000139364	Transmembrane protein 132B	12	125186836-125662377	Predicted membrane proteins	Evidence at protein level	HPA035661, HPA035662	Uncertain					Tissue enriched	Tissue enriched	7	cerebral cortex: 21.8	thyroid gland: 3.1	Cell line enhanced		HSkMC: 4.8;NTERA-2: 7.7;U-138 MG: 11.6
TMEM132C	DKFZp761O2018, PPP1R152	ENSG00000181234	Transmembrane protein 132C	12	128267403-128707915	Predicted membrane proteins	Evidence at protein level	HPA015633, HPA015984			Supported	Centrosome<br>Cytosol		Tissue enhanced	Tissue enhanced		adipose tissue: 34.8;cervix, uterine: 24.1	fallopian tube: 15.9	Group enriched	5	AF22: 3.7;ASC diff: 3.5;Daudi: 4.4
TMEM132D	KIAA1944, MOLT, PPP1R153	ENSG00000151952	Transmembrane protein 132D	12	129071725-129903666	Predicted membrane proteins	Evidence at protein level	HPA010739	Approved					Mixed	Tissue enriched	12	cerebral cortex: 12.3	testis: 1.0	Cell line enhanced		AF22: 2.6;MOLT-4: 3.9;NTERA-2: 1.8
TMEM132E	DFNB99	ENSG00000181291	Transmembrane protein 132E	17	34580749-34639318	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA070608	Approved				Renal cancer:1.55e-4 (unfavourable)	Group enriched	Group enriched	5	cerebral cortex: 4.8;duodenum: 1.7;kidney: 3.2;small intestine: 1.0;testis: 1.5	cervix, uterine: 0.4	Cell line enriched	7	RPMI-8226: 31.6
TMEM133	AD031	ENSG00000170647	Transmembrane protein 133	11	100991989-100993941	Predicted membrane proteins	Evidence at protein level	HPA060528, HPA065742	Uncertain		Approved	Endoplasmic reticulum<br>Golgi apparatus	Pancreatic cancer:1.76e-4 (unfavourable)	Expressed in all	Mixed			placenta: 18.3	Cell line enhanced		CAPAN-2: 12.4
TMEM134	FLJ21749	ENSG00000172663	Transmembrane protein 134	11	67461710-67469272	Predicted membrane proteins	Evidence at protein level	HPA043744	Approved		Supported	Cytosol		Expressed in all	Expressed in all			skin: 38.5	Expressed in all		
TMEM135	FLJ22104	ENSG00000166575	Transmembrane protein 135	11	87037844-87323758	Predicted membrane proteins	Evidence at protein level	HPA056685, HPA069473	Uncertain		Supported	Vesicles	Renal cancer:9.02e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 31.7	Expressed in all		
TMEM136	MGC17839	ENSG00000181264	Transmembrane protein 136	11	120325129-120333682	Predicted membrane proteins	Evidence at transcript level	HPA074432			Approved	Vesicles<br>Cytosol	Endometrial cancer:6.65e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 12.6	Mixed		
TMEM138	HSPC196, JBTS16	ENSG00000149483	Transmembrane protein 138	11	61362001-61369509	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA042373	Approved		Approved	Microtubules	Renal cancer:4.12e-6 (unfavourable), Liver cancer:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 24.9	Expressed in all		
TMEM139	FLJ90586	ENSG00000178826	Transmembrane protein 139	7	143279957-143288048	Predicted membrane proteins, Transporters	Evidence at protein level	HPA036982, HPA036983	Approved		Approved	Plasma membrane<br>Focal adhesion sites	Renal cancer:3.05e-5 (favourable), Pancreatic cancer:1.66e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 34.0;kidney: 34.6	small intestine: 20.7	Cell line enhanced		CAPAN-2: 35.7;EFO-21: 26.3;RPTEC TERT1: 53.2;T-47d: 64.1
TMEM140	FLJ11000	ENSG00000146859	Transmembrane protein 140	7	135148072-135166215	Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			spleen: 38.1	Mixed		
TMEM141	MGC14141	ENSG00000244187	Transmembrane protein 141	9	136791355-136793257	Predicted membrane proteins	Evidence at protein level	HPA014615, HPA050244	Approved		Supported	Cell Junctions<br>Mitochondria	Renal cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			prostate: 199.4	Expressed in all		
TMEM143	FLJ10922	ENSG00000161558	Transmembrane protein 143	19	48332356-48364237	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014476	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:1.53e-7 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 32.5	heart muscle: 15.5	Expressed in all		
TMEM144	FLJ11155	ENSG00000164124	Transmembrane protein 144	4	158201604-158255411	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA063554			Approved	Mitochondria	Endometrial cancer:2.89e-4 (favourable), Pancreatic cancer:8.48e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 90.5	testis: 46.9	Cell line enhanced		BEWO: 32.7
TMEM145	FLJ90805	ENSG00000167619	Transmembrane protein 145	19	42313325-42325062	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060462	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enriched	6	cerebral cortex: 38.3	adrenal gland: 5.9	Cell line enhanced		SCLC-21H: 32.9;SH-SY5Y: 14.2
TMEM147	MGC1936, NIFIE14	ENSG00000105677	Transmembrane protein 147	19	35545595-35547526	Predicted membrane proteins	Evidence at protein level	HPA067837			Uncertain	Golgi apparatus<br>Actin filaments<br>Cytosol	Liver cancer:4.98e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 120.6	Expressed in all		
TMEM14A	C6orf73, PTD011	ENSG00000096092	Transmembrane protein 14A	6	52671109-52686588	Predicted membrane proteins	Evidence at protein level	HPA072536	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum		Expressed in all	Expressed in all			cerebral cortex: 88.1	Expressed in all		
TMEM14B	MGC1223	ENSG00000137210	Transmembrane protein 14B	6	10747759-10852753	Predicted membrane proteins	Evidence at protein level						Liver cancer:9.35e-5 (unfavourable), Endometrial cancer:6.51e-4 (unfavourable), Ovarian cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 205.0	Expressed in all		
TMEM14C	bA421M1.6, C6orf53, HSPC194, NET26	ENSG00000111843	Transmembrane protein 14C	6	10722915-10731129	Predicted membrane proteins	Evidence at protein level						Liver cancer:3.66e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 148.2	Expressed in all		
TMEM150A	FLJ90024, TM6P1, TMEM150, TTN1	ENSG00000168890	Transmembrane protein 150A	2	85598548-85603196	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019015	Uncertain		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			placenta: 33.4	Mixed		
TMEM150B	TMEM224, TTN2	ENSG00000180061	Transmembrane protein 150B	19	55312801-55334048	Predicted membrane proteins	Evidence at transcript level						Renal cancer:6.14e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		duodenum: 69.8;small intestine: 66.5	lung: 18.9	Cell line enhanced		CACO-2: 7.6;HMC-1: 4.0;U-937: 16.3
TMEM150C	FLJ12993, TTN3	ENSG00000249242	Transmembrane protein 150C	4	82483170-82562357	Predicted membrane proteins	Evidence at protein level	HPA052921	Enhanced				Renal cancer:4.59e-6 (favourable), Pancreatic cancer:5.68e-4 (favourable), Head and neck cancer:7.87e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 181.6	ovary: 43.5	Cell line enhanced		AN3-CA: 11.7;MCF7: 27.5;SCLC-21H: 28.6
TMEM151A	MGC33486, TMEM151	ENSG00000179292	Transmembrane protein 151A	11	66291870-66296664	Predicted membrane proteins	Evidence at transcript level	HPA041035	Uncertain		Approved	Nucleoli<br>Cytosol		Tissue enhanced	Tissue enriched	24	cerebral cortex: 45.2	adrenal gland: 1.8	Group enriched	7	SCLC-21H: 17.8;SH-SY5Y: 3.7
TMEM151B	bA444E17.5, C6orf137, TMEM193	ENSG00000178233	Transmembrane protein 151B	6	44270466-44307506	Predicted membrane proteins	Evidence at transcript level	HPA055167	Uncertain					Tissue enhanced	Tissue enriched	10	cerebral cortex: 40.0	adrenal gland: 3.9	Cell line enriched	5	SCLC-21H: 33.6
TMEM154	FLJ32028	ENSG00000170006	Transmembrane protein 154	4	152618632-152680165	Predicted membrane proteins	Evidence at protein level	HPA019184, HPA055411	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Mixed	Tissue enhanced		esophagus: 64.3;skin: 69.5	tonsil: 24.1	Cell line enhanced		HMC-1: 62.0
TMEM156	FLJ23235	ENSG00000121895	Transmembrane protein 156	4	38966744-39032922	Predicted membrane proteins	Evidence at transcript level						Breast cancer:4.09e-4 (favourable)	Mixed	Group enriched	5	appendix: 11.8;lymph node: 27.8;spleen: 15.2;tonsil: 24.3;urinary bladder: 5.7	gallbladder: 3.0	Cell line enhanced		Daudi: 28.3;HBEC3-KT: 59.6;hTERT-HME1: 48.9;PC-3: 34.1;U-698: 30.9
TMEM158	p40BBp, RIS1	ENSG00000249992	Transmembrane protein 158 (gene/pseudogene)	3	45224466-45226278	Predicted membrane proteins	Evidence at transcript level	HPA074974	Approved				Renal cancer:5.42e-9 (unfavourable), Prostate cancer:6.43e-5 (favourable)	Mixed	Tissue enhanced		endometrium: 32.6;seminal vesicle: 32.1	smooth muscle: 25.7	Cell line enhanced		BJ hTERT+: 274.2;U-138 MG: 137.8;U-87 MG: 447.8
TMEM159	promethin	ENSG00000011638	Transmembrane protein 159	16	21158377-21180616	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018033, HPA063509	Approved		Approved	Vesicles	Renal cancer:8.11e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable)	Expressed in all	Mixed			skin: 45.2	Mixed		
TMEM160	FLJ20512	ENSG00000130748	Transmembrane protein 160	19	47045907-47048630	Predicted membrane proteins	Evidence at protein level	HPA055904	Uncertain					Expressed in all	Mixed			cerebral cortex: 21.0	Expressed in all		
TMEM161A	FLJ20422, FLJ39645	ENSG00000064545	Transmembrane protein 161A	19	19119169-19138513	Predicted membrane proteins	Evidence at protein level	HPA043365	Approved		Approved	Cytosol	Stomach cancer:2.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.7	Expressed in all		
TMEM161B	MGC33214	ENSG00000164180	Transmembrane protein 161B	5	88189633-88269476	Predicted membrane proteins	Evidence at protein level	HPA044562	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 59.9	Expressed in all		
TMEM163	DKFZP566N034, SV31	ENSG00000152128	Transmembrane protein 163	2	134455759-134719000	Predicted membrane proteins, Transporters	Evidence at protein level	HPA007224	Uncertain				Urothelial cancer:3.15e-4 (favourable), Lung cancer:7.94e-4 (favourable)	Mixed	Mixed			lung: 21.5	Cell line enhanced		HEL: 18.1;RPTEC TERT1: 50.5;SCLC-21H: 35.5
TMEM164	FLJ22679, RP13-360B22.2	ENSG00000157600	Transmembrane protein 164	X	110002631-110182734	Predicted membrane proteins	Evidence at protein level	HPA038784	Approved		Approved	Vesicles<br>Cell Junctions	Liver cancer:8.17e-6 (unfavourable), Stomach cancer:3.14e-4 (favourable)	Expressed in all	Expressed in all			lung: 26.7	Expressed in all		
TMEM165	GDT1, TMPT27, TPARL	ENSG00000134851	Transmembrane protein 165	4	55395957-55453397	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038299, HPA062424	Supported		Enhanced	Golgi apparatus<br>Vesicles	Renal cancer:1.18e-8 (unfavourable), Liver cancer:2.08e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 87.1	Expressed in all		
TMEM167A	FLJ30508, MGC23909, TMEM167	ENSG00000174695	Transmembrane protein 167A	5	83052846-83077863	Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			adrenal gland: 61.9	Expressed in all		
TMEM167B	AD-020, C1orf119, FLJ90710	ENSG00000215717	Transmembrane protein 167B	1	109089803-109096934	Predicted membrane proteins	Evidence at transcript level						Endometrial cancer:8.86e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 49.3	Expressed in all		
TMEM168	DKFZp564C012, FLJ13576	ENSG00000146802	Transmembrane protein 168	7	112762382-112790592	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA020389	Approved				Lung cancer:4.07e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.3	Expressed in all		
TMEM169	FLJ34263	ENSG00000163449	Transmembrane protein 169	2	216081866-216102783	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA062462, HPA062797, HPA070657	Uncertain		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 12.0	thyroid gland: 4.8	Cell line enhanced		AF22: 8.9;RPTEC TERT1: 10.0;SCLC-21H: 13.4;SH-SY5Y: 17.3
TMEM17	FLJ34583	ENSG00000186889	Transmembrane protein 17	2	62500221-62511894	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018100	Uncertain		Approved	Actin filaments		Expressed in all	Mixed			testis: 8.2	Mixed		
TMEM170A	FLJ37611, TMEM170	ENSG00000166822	Transmembrane protein 170A	16	75443054-75465497	Predicted membrane proteins, Transporters	Evidence at protein level	HPA055071	Uncertain				Renal cancer:2.36e-9 (favourable)	Expressed in all	Expressed in all			testis: 32.4	Expressed in all		
TMEM170B		ENSG00000205269	Transmembrane protein 170B	6	11538278-11583524	Predicted membrane proteins	Evidence at transcript level	HPA055134	Uncertain		Approved	Centrosome		Mixed	Tissue enhanced		cerebral cortex: 21.3	bone marrow: 16.8	Cell line enhanced		THP-1: 15.8
TMEM171	PRP2	ENSG00000157111	Transmembrane protein 171	5	73120292-73131817	Predicted membrane proteins	Evidence at protein level	HPA042308	Approved				Renal cancer:3.93e-10 (favourable)	Mixed	Tissue enhanced		colon: 32.4;rectum: 32.3;thyroid gland: 47.1	duodenum: 26.3	Cell line enhanced		LHCN-M2: 48.9;WM-115: 161.7
TMEM173	ERIS, FLJ38577, MITA, MPYS, NET23, STING	ENSG00000184584	Transmembrane protein 173	5	139475534-139482935	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA038116, HPA038534	Enhanced				Renal cancer:3.59e-8 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 70.7	Cell line enhanced		EFO-21: 150.4;HDLM-2: 331.0
TMEM174	FLJ31268, MGC13034	ENSG00000164325	Transmembrane protein 174	5	73173195-73175143	Predicted membrane proteins	Evidence at protein level	HPA037975	Enhanced				Renal cancer:3.30e-6 (favourable)	Tissue enriched	Tissue enriched	685	kidney: 159.4	thyroid gland: 0.2	Not detected		
TMEM175	MGC4618	ENSG00000127419	Transmembrane protein 175	4	932387-958656	Predicted membrane proteins, Transporters	Evidence at protein level	HPA057160	Approved		Approved	Nucleus<br>Nuclear membrane	Pancreatic cancer:9.85e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 20.7	Expressed in all		
TMEM176A	HCA112, MS4B1	ENSG00000002933	Transmembrane protein 176A	7	150800403-150805120	Predicted membrane proteins	Evidence at protein level	HPA008770	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			liver: 583.9	Cell line enriched	30	HSkMC: 493.9
TMEM176B	LR8, MS4B2	ENSG00000106565	Transmembrane protein 176B	7	150791285-150801360	Predicted membrane proteins	Evidence at protein level	HPA047509	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane		Expressed in all	Expressed in all			liver: 845.2	Group enriched	13	HSkMC: 462.2;THP-1: 144.5
TMEM177	MGC10993	ENSG00000144120	Transmembrane protein 177	2	119679167-119686507	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036689, HPA053816	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Mixed			fallopian tube: 16.9	Expressed in all		
TMEM178A	MGC33926, TMEM178	ENSG00000152154	Transmembrane protein 178A	2	39664982-39717963	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level	HPA052128	Uncertain		Approved	Nucleus<br>Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 55.4	kidney: 19.3	Cell line enhanced		AF22: 137.1;NTERA-2: 17.7;SCLC-21H: 30.2
TMEM178B	DKFZp547G036	ENSG00000261115	Transmembrane protein 178B	7	141074232-141480380	Predicted membrane proteins	Evidence at protein level	HPA048771	Uncertain		Uncertain	Nucleoli<br>Vesicles	Renal cancer:4.10e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 19.3;parathyroid gland: 28.9;thyroid gland: 14.4	heart muscle: 7.2	Cell line enhanced		HAP1: 6.3;RPTEC TERT1: 6.3;SCLC-21H: 7.7;WM-115: 8.9
TMEM179	C14orf90, FLJ42486, TMEM179A	ENSG00000258986	Transmembrane protein 179	14	104474678-104605647	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level	HPA002942			Uncertain	Mitochondria		Mixed	Group enriched	8	adrenal gland: 14.6;cerebral cortex: 27.9	testis: 2.5	Cell line enhanced		NTERA-2: 8.5;SCLC-21H: 42.8;SH-SY5Y: 12.2
TMEM179B		ENSG00000185475	Transmembrane protein 179B	11	62787415-62790405	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016585, HPA062068			Enhanced	Nuclear speckles		Expressed in all	Expressed in all			epididymis: 89.1	Expressed in all		
TMEM18	DKFZp434C1714	ENSG00000151353	Transmembrane protein 18	2	667335-677439	Predicted membrane proteins	Evidence at protein level	HPA040233	Approved		Approved	Mitochondria	Melanoma:3.21e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 43.8	Expressed in all		
TMEM181	GPR178, KIAA1423	ENSG00000146433	Transmembrane protein 181	6	158536436-158635428	Predicted membrane proteins	Evidence at protein level	HPA040189	Approved		Approved	Golgi apparatus<br>Vesicles	Ovarian cancer:1.09e-4 (unfavourable), Cervical cancer:7.26e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 41.5	Expressed in all		
TMEM182	FLJ30294	ENSG00000170417	Transmembrane protein 182	2	102736905-103019900	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045861	Uncertain		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Group enriched	9	heart muscle: 56.8;skeletal muscle: 44.4	prostate: 5.8	Mixed		
TMEM183A	C1orf37	ENSG00000163444	Transmembrane protein 183A	1	203007386-203024848	Predicted membrane proteins	Evidence at protein level	HPA072607			Approved	Nucleus<br>Plasma membrane<br>Cell Junctions	Liver cancer:2.62e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.1	Expressed in all		
TMEM184A	MGC9712, SDMG1	ENSG00000164855	Transmembrane protein 184A	7	1542235-1560821	Predicted membrane proteins	Evidence at protein level	HPA053790, HPA071312	Uncertain		Approved	Nucleoplasm	Colorectal cancer:1.12e-4 (unfavourable), Thyroid cancer:9.94e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 33.5	esophagus: 26.5	Cell line enhanced		SCLC-21H: 43.0;SK-BR-3: 42.7;T-47d: 47.5
TMEM184B	C22orf5, DKFZP586A1024, FM08, HS5O6A	ENSG00000198792	Transmembrane protein 184B	22	38219291-38273034	Predicted membrane proteins, Transporters	Evidence at protein level	HPA024076	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:5.94e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 57.4	Expressed in all		
TMEM184C	FLJ10846, TMEM34	ENSG00000164168	Transmembrane protein 184C	4	147617383-147672044	Predicted membrane proteins	Evidence at protein level	HPA054013	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:2.31e-7 (favourable), Pancreatic cancer:6.37e-4 (unfavourable)	Expressed in all	Group enriched	6	parathyroid gland: 253.9;thyroid gland: 53.2	placenta: 27.6	Expressed in all		
TMEM185A	CXorf13, FAM11A, FRAXF	ENSG00000269556	Transmembrane protein 185A	X	149596556-149631912	Predicted membrane proteins	Evidence at protein level	HPA048295, HPA071744	Uncertain		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			ovary: 36.4	Expressed in all		
TMEM185B	FAM11B, FLJ20979	ENSG00000226479	Transmembrane protein 185B	2	120221278-120223408	Predicted membrane proteins	Evidence at protein level	HPA048295, HPA071744	Uncertain		Approved	Endoplasmic reticulum	Liver cancer:5.71e-7 (unfavourable), Endometrial cancer:4.96e-6 (unfavourable), Colorectal cancer:5.44e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.6	Mixed		
TMEM186	C16orf51, DKFZP564K2062	ENSG00000184857	Transmembrane protein 186	16	8780384-8797648	Predicted membrane proteins	Evidence at protein level	HPA018226, HPA063559	Uncertain		Approved	Cell Junctions	Renal cancer:1.93e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.0	Expressed in all		
TMEM187	CXorf12, DXS9878E, ITBA1	ENSG00000177854	Transmembrane protein 187	X	153972327-153983195	Predicted membrane proteins	Evidence at transcript level	HPA038134	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:9.14e-8 (favourable)	Expressed in all	Expressed in all			fallopian tube: 11.4	Expressed in all		
TMEM189	Kua	ENSG00000240849	Transmembrane protein 189	20	50118254-50153734	Predicted membrane proteins	Evidence at protein level	HPA059549	Approved		Supported	Endoplasmic reticulum	Renal cancer:5.79e-11 (unfavourable), Endometrial cancer:7.51e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 31.3	Expressed in all		
TMEM189-UBE2V1	CROC-1B, Kua-UEV	ENSG00000124208	TMEM189-UBE2V1 readthrough	20	50081124-50153637	Predicted membrane proteins	Evidence at protein level	HPA052535, HPA053186			Supported	Nucleoplasm		Not detected	Mixed			placenta: 5.6	Mixed		
TMEM19	FLJ10936	ENSG00000139291	Transmembrane protein 19	12	71686087-71705046	Predicted membrane proteins	Evidence at protein level	HPA016830	Approved					Expressed in all	Expressed in all			kidney: 40.8	Expressed in all		
TMEM190	MDAC1	ENSG00000160472	Transmembrane protein 190	19	55376836-55378244	Predicted membrane proteins	Evidence at protein level							Group enriched	Tissue enriched	9	fallopian tube: 231.3	testis: 26.4	Cell line enhanced		Hep G2: 7.3;SCLC-21H: 6.1
TMEM191B		ENSG00000278558	Transmembrane protein 191B	22	18527802-18530573	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	15	testis: 14.7	spleen: 0.9	Cell line enhanced		BEWO: 1.4;CACO-2: 1.0
TMEM191C		ENSG00000206140	Transmembrane protein 191C	22	21466423-21471269	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	9	testis: 1.5	endometrium,lung,ovary: 0.1	Not detected		
TMEM192	FLJ38482	ENSG00000170088	Transmembrane protein 192	4	165070608-165208549	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014717, HPA024110	Enhanced		Enhanced	Nucleoplasm<br>Endosomes<br>Lysosomes	Renal cancer:2.33e-14 (favourable), Breast cancer:9.52e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 51.0	Expressed in all		
TMEM196	MGC42090	ENSG00000173452	Transmembrane protein 196	7	19719310-19773598	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA043163	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 9.2	endometrium: 2.2	Group enriched	7	ASC diff: 3.1;ASC TERT1: 3.1
TMEM198	MGC99813, TMEM198A	ENSG00000188760	Transmembrane protein 198	2	219543663-219550595	Predicted membrane proteins	Evidence at protein level	HPA042385, HPA056598	Uncertain		Approved	Vesicles	Pancreatic cancer:6.89e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 15.7	duodenum: 8.9	Cell line enhanced		SCLC-21H: 23.4;SH-SY5Y: 18.3
TMEM199	C17orf32, MGC45714, VMA12, VPH2	ENSG00000244045	Transmembrane protein 199	17	28357581-28363683	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA027051	Uncertain				Liver cancer:1.54e-4 (unfavourable), Endometrial cancer:5.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 19.3	Expressed in all		
TMEM2		ENSG00000135048	Transmembrane protein 2	9	71683366-71816690	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044889	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.31e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 94.6	Cell line enhanced		AF22: 107.2
TMEM200A	KIAA1913, TTMC	ENSG00000164484	Transmembrane protein 200A	6	130365734-130443063	Predicted membrane proteins	Evidence at protein level	HPA014396	Uncertain				Renal cancer:3.92e-4 (favourable)	Mixed	Tissue enhanced		endometrium: 65.1	smooth muscle: 29.4	Cell line enhanced		HBF TERT88: 39.5;hTEC/SVTERT24-B: 66.8
TMEM200B	TTMB	ENSG00000253304	Transmembrane protein 200B	1	29119428-29123935	Predicted membrane proteins	Evidence at transcript level	HPA055254	Uncertain					Mixed	Tissue enhanced		endometrium: 69.1	seminal vesicle: 54.2	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 28.3
TMEM200C	TTMA	ENSG00000206432	Transmembrane protein 200C	18	5882072-5895955	Predicted membrane proteins	Evidence at protein level	HPA047253, HPA050490	Uncertain		Approved	Microtubules		Tissue enhanced	Tissue enhanced		adrenal gland: 3.1;cerebral cortex: 3.5	salivary gland: 1.7	Cell line enhanced		AF22: 6.1;NTERA-2: 4.7;PC-3: 20.4;U-2 OS: 11.5
TMEM201	Ima1, NET5, RP13-15M17.2, SAMP1	ENSG00000188807	Transmembrane protein 201	1	9588922-9614873	Predicted membrane proteins	Evidence at protein level	CAB039039	Approved		Supported	Nucleus<br>Nuclear membrane	Liver cancer:9.61e-8 (unfavourable), Cervical cancer:5.36e-4 (favourable)	Expressed in all	Mixed			testis: 9.9	Expressed in all		
TMEM202	FLJ27523	ENSG00000187806	Transmembrane protein 202	15	72398273-72408029	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enriched	Tissue enriched	230	testis: 23.0	all non-specific tissues: 0.0	Not detected		
TMEM203	HBEBP1, MGC14327	ENSG00000187713	Transmembrane protein 203	9	137204082-137205638	Predicted membrane proteins, Transporters	Evidence at protein level						Pancreatic cancer:4.78e-6 (favourable), Renal cancer:1.50e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Expressed in all		
TMEM204	C16orf30, CLP24, FLJ20898	ENSG00000131634	Transmembrane protein 204	16	1528688-1555580	Predicted membrane proteins	Evidence at transcript level	HPA014028	Approved				Liver cancer:4.76e-4 (favourable), Melanoma:7.89e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 40.6	Cell line enhanced		BJ: 13.1;BJ hTERT+: 17.0;fHDF/TERT166: 11.0;HHSteC: 30.6;HSkMC: 10.6
TMEM205	MBC3205, UNQ501	ENSG00000105518	Transmembrane protein 205	19	11342776-11346518	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA041504	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 258.0	Expressed in all		
TMEM206	C1orf75, FLJ10874	ENSG00000065600	Transmembrane protein 206	1	212363931-212414901	Predicted membrane proteins	Evidence at protein level	HPA008540	Uncertain				Liver cancer:3.71e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 25.4	kidney: 10.7	Expressed in all		
TMEM207		ENSG00000198398	Transmembrane protein 207	3	190428655-190449876	Predicted membrane proteins	Evidence at protein level	HPA014332	Uncertain					Not detected	Tissue enriched	63	kidney: 18.7	testis: 0.2	Not detected		
TMEM208	HSPC171	ENSG00000168701	Transmembrane protein 208	16	67227103-67229278	Predicted membrane proteins, Transporters	Evidence at protein level	HPA041868, HPA041949	Supported				Head and neck cancer:9.63e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 89.7	Expressed in all		
TMEM209	FLJ14803, NET31	ENSG00000146842	Transmembrane protein 209	7	130164715-130207770	Predicted membrane proteins	Evidence at protein level	HPA031678	Uncertain		Approved	Nuclear membrane<br>Nuclear speckles<br>Vesicles		Expressed in all	Expressed in all			testis: 27.5	Expressed in all		
TMEM210		ENSG00000185863	Transmembrane protein 210	9	137170858-137172409	Predicted membrane proteins	Evidence at protein level	HPA066907	Enhanced					Tissue enhanced	Tissue enriched	11	testis: 10.1	salivary gland: 0.9	Cell line enriched	7	RPMI-8226: 7.9
TMEM211	bA9F11.1	ENSG00000206069	Transmembrane protein 211	22	24934954-24946695	Predicted membrane proteins	Evidence at transcript level	HPA066784	Uncertain					Tissue enhanced	Tissue enhanced		cervix, uterine: 3.7;stomach: 2.7	salivary gland: 1.4	Not detected		
TMEM212	FLJ23172	ENSG00000186329	Transmembrane protein 212	3	171843349-171938715	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA045736			Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum		Not detected	Tissue enriched	6	fallopian tube: 48.3	testis: 8.1	Mixed		
TMEM213		ENSG00000214128	Transmembrane protein 213	7	138797952-138838101	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054059	Enhanced				Renal cancer:5.54e-7 (favourable)	Tissue enriched	Group enriched	9	kidney: 80.7;salivary gland: 22.6	breast: 5.7	Not detected		
TMEM214	FLJ20254	ENSG00000119777	Transmembrane protein 214	2	27032910-27041695	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034551			Supported	Endoplasmic reticulum<br>Golgi apparatus<br>Cytosol	Renal cancer:2.39e-10 (unfavourable), Liver cancer:4.96e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 91.6	Expressed in all		
TMEM215		ENSG00000188133	Transmembrane protein 215	9	32783499-32787399	Predicted membrane proteins	Evidence at protein level	HPA052804, HPA063207	Uncertain		Supported	Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles		Tissue enriched	Group enriched	5	cervix, uterine: 1.0;endometrium: 4.8;testis: 4.2;thyroid gland: 1.8	cerebral cortex: 0.5	Cell line enhanced		NTERA-2: 1.9
TMEM216	CORS2, HSPC244, JBTS2, MGC13379, MKS2	ENSG00000187049	Transmembrane protein 216	11	61391687-61398863	Disease related genes, Predicted membrane proteins	Evidence at protein level							Expressed in all	Mixed			ovary: 32.4	Mixed		
TMEM217	C6orf128, dJ355M6.2	ENSG00000172738	Transmembrane protein 217	6	37212180-37258155	Predicted membrane proteins	Evidence at protein level	HPA045432, HPA071187, HPA074578			Supported	Nucleoli		Mixed	Tissue enriched	14	testis: 14.2	adrenal gland: 1.0	Cell line enhanced		HEL: 3.0;HUVEC TERT2: 2.8;TIME: 7.2
TMEM218		ENSG00000150433	Transmembrane protein 218	11	125096545-125111763	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038489	Uncertain		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.93e-5 (unfavourable), Stomach cancer:5.50e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 21.9	Expressed in all		
TMEM219		ENSG00000149932	Transmembrane protein 219	16	29940885-29973052	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059185	Approved				Endometrial cancer:5.79e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 198.4	Expressed in all		
TMEM220		ENSG00000187824	Transmembrane protein 220	17	10699015-10730316	Predicted membrane proteins	Evidence at protein level	HPA047680			Uncertain	Nucleoplasm	Liver cancer:2.23e-5 (favourable), Pancreatic cancer:1.72e-4 (favourable), Glioma:9.39e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 53.3	Mixed		
TMEM221		ENSG00000188051	Transmembrane protein 221	19	17435509-17448567	Predicted membrane proteins	Evidence at protein level	HPA041580	Approved					Tissue enhanced	Tissue enhanced		parathyroid gland: 6.8	fallopian tube: 4.2	Cell line enhanced		AN3-CA: 4.4;PC-3: 6.7;REH: 3.7
TMEM222	C1orf160, DKFZP564D0478	ENSG00000186501	Transmembrane protein 222	1	27322145-27336400	Predicted membrane proteins	Evidence at protein level	HPA016579, HPA059374	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 47.9	Expressed in all		
TMEM223	MGC3196	ENSG00000168569	Transmembrane protein 223	11	62771629-62792021	Predicted membrane proteins	Evidence at protein level	HPA014504	Approved		Approved	Nucleus<br>Nuclear membrane<br>Mitochondria		Expressed in all	Expressed in all			spleen: 15.1	Expressed in all		
TMEM225	PMP22CD, PPP1R154	ENSG00000204300	Transmembrane protein 225	11	123882926-123885642	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	398	testis: 39.8	all non-specific tissues: 0.0	Not detected		
TMEM229A		ENSG00000234224	Transmembrane protein 229A	7	124030916-124033023	Predicted membrane proteins	Evidence at protein level	HPA056391	Uncertain		Approved	Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 7.1;duodenum: 8.6;testis: 10.4	small intestine: 4.4	Cell line enriched	46	SH-SY5Y: 141.7
TMEM229B	C14orf83, FLJ33387	ENSG00000198133	Transmembrane protein 229B	14	67447084-67533739	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA046562	Approved				Endometrial cancer:1.21e-5 (favourable), Urothelial cancer:1.79e-5 (favourable), Breast cancer:5.38e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 16.0	Cell line enhanced		U-937: 26.9
TMEM230	C20orf30, HSPC274	ENSG00000089063	Transmembrane protein 230	20	5068232-5113103	Predicted membrane proteins	Evidence at protein level	HPA009078, HPA061421	Uncertain		Enhanced	Endoplasmic reticulum		Expressed in all	Expressed in all			thyroid gland: 227.2	Expressed in all		
TMEM231	ALYE870, FLJ22167, JBTS20, MKS11, PRO1886	ENSG00000205084	Transmembrane protein 231	16	75536744-75556286	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042081	Enhanced		Approved	Vesicles		Mixed	Tissue enriched	8	fallopian tube: 77.5	thyroid gland: 9.8	Mixed		
TMEM232	FLJ43080	ENSG00000186952	Transmembrane protein 232	5	110289233-110738956	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049386	Uncertain					Not detected	Tissue enhanced		fallopian tube: 26.4;testis: 35.5	thyroid gland: 7.3	Cell line enhanced		U-266/70: 2.1
TMEM233	IFITMD2	ENSG00000224982	Transmembrane protein 233	12	119593459-119643066	Predicted membrane proteins	Evidence at transcript level	HPA047506	Uncertain					Tissue enriched	Group enriched	5	cerebral cortex: 16.2;skeletal muscle: 11.5;thyroid gland: 21.4	parathyroid gland: 3.1	Cell line enhanced		hTEC/SVTERT24-B: 19.8;RH-30: 10.2;U-2197: 14.8;U-87 MG: 61.5
TMEM234	C1orf91, dJ622L5.7, FLJ90779, RP4-622L5	ENSG00000160055	Transmembrane protein 234	1	32214472-32222359	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015049	Uncertain		Approved	Vesicles	Liver cancer:2.35e-5 (unfavourable), Renal cancer:4.12e-5 (unfavourable)	Expressed in all	Mixed			epididymis: 12.8	Expressed in all		
TMEM235		ENSG00000204278	Transmembrane protein 235	17	78231310-78240987	Predicted membrane proteins	Evidence at transcript level	HPA053939	Uncertain					Tissue enriched	Tissue enriched	100	cerebral cortex: 15.6	placenta,testis: 0.1	Not detected		
TMEM236	bA162I21.2, bA16O1.2, FAM23A, FAM23B	ENSG00000148483	Transmembrane protein 236	10	17752252-17800868	Predicted membrane proteins	Evidence at protein level	HPA045096	Enhanced					Tissue enhanced	Group enriched	9	colon: 14.4;duodenum: 22.1;rectum: 15.5;small intestine: 37.7	appendix: 2.3	Cell line enriched	9	MOLT-4: 8.4
TMEM237	ALS2CR4, JBTS14	ENSG00000155755	Transmembrane protein 237	2	201620184-201643570	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA052596, HPA054732	Enhanced				Renal cancer:7.96e-6 (unfavourable), Melanoma:1.33e-4 (unfavourable), Endometrial cancer:2.51e-4 (unfavourable)	Expressed in all	Mixed			skin: 21.9	Expressed in all		
TMEM238		ENSG00000233493	Transmembrane protein 238	19	55379245-55384598	Predicted membrane proteins	Evidence at protein level						Renal cancer:8.84e-6 (favourable)	Expressed in all	Tissue enhanced		small intestine: 10.0;stomach: 9.9	colon: 9.1	Cell line enhanced		A-431: 17.0;HaCaT: 15.4
TMEM239		ENSG00000198326	Transmembrane protein 239	20	2816302-2820284	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	270	testis: 38.9	endometrium,placenta: 0.1	Cell line enriched	8	HDLM-2: 7.7
TMEM240	C1orf70, SCA21	ENSG00000205090	Transmembrane protein 240	1	1535174-1540453	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066721	Supported				Pancreatic cancer:2.52e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 18.6	endometrium: 7.7	Cell line enhanced		SCLC-21H: 12.1;SH-SY5Y: 13.3
TMEM241	C18orf45, FLJ44259, MGC11386	ENSG00000134490	Transmembrane protein 241	18	23197144-23437961	Predicted membrane proteins	Evidence at protein level	HPA029489, HPA059922	Uncertain		Approved	Golgi apparatus<br>Vesicles	Urothelial cancer:5.80e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 4.2	Mixed		
TMEM242	BM033, C6orf35	ENSG00000215712	Transmembrane protein 242	6	157289386-157323601	Predicted membrane proteins	Evidence at protein level	HPA025764	Approved					Expressed in all	Expressed in all			cerebral cortex: 16.9	Expressed in all		
TMEM243	C7orf23, MGC4175, MM-TRAG	ENSG00000135185	Transmembrane protein 243	7	87196160-87220587	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014918	Uncertain				Lung cancer:5.45e-4 (favourable), Melanoma:6.84e-4 (unfavourable), Urothelial cancer:9.13e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 103.9	Expressed in all		
TMEM244	bA174C7.4, C6orf191	ENSG00000203756	Transmembrane protein 244	6	129831244-129861547	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.7	lymph node: 0.6	Cell line enhanced		HDLM-2: 4.4;LHCN-M2: 4.4;U-251 MG: 3.4;U-266/70: 2.9;WM-115: 2.6
TMEM245	C9orf5, CG-2	ENSG00000106771	Transmembrane protein 245	9	109015152-109119945	Predicted membrane proteins	Evidence at protein level	HPA023892	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.46e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 124.0	Expressed in all		
TMEM246	C9orf125, MGC12992	ENSG00000165152	Transmembrane protein 246	9	101473171-101533537	Predicted membrane proteins	Evidence at protein level	HPA011318, HPA054041	Uncertain		Approved	Mitochondria	Renal cancer:1.55e-8 (favourable)	Mixed	Mixed			cerebral cortex: 46.5	Mixed		
TMEM247		ENSG00000187600	Transmembrane protein 247	2	46429190-46484425	Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	26	testis: 35.7	placenta: 1.3	Cell line enriched	13	U-266/84: 1.5
TMEM248	C7orf42, FLJ10099, FLJ13090	ENSG00000106609	Transmembrane protein 248	7	66921225-66958551	Predicted membrane proteins	Evidence at protein level	HPA016495	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 93.8	Expressed in all		
TMEM249	C8orfK29	ENSG00000261587	Transmembrane protein 249	8	144352219-144354914	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	27	testis: 9.3	epididymis: 0.3	Mixed		
TMEM25	FLJ14399	ENSG00000149582	Transmembrane protein 25	11	118531041-118547280	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012163, HPA051562	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			duodenum: 47.0	Cell line enhanced		T-47d: 41.7
TMEM251	C14orf109, DKFZP564F1123	ENSG00000153485	Transmembrane protein 251	14	93184951-93187089	Predicted membrane proteins	Evidence at transcript level	HPA048559	Uncertain		Approved	Golgi apparatus<br>Cell Junctions	Liver cancer:6.14e-7 (unfavourable), Renal cancer:1.10e-4 (favourable)	Expressed in all	Expressed in all			prostate: 27.0	Expressed in all		
TMEM252	C9orf71, MGC34760	ENSG00000181778	Transmembrane protein 252	9	68536580-68540867	Predicted membrane proteins	Evidence at transcript level						Renal cancer:1.75e-7 (favourable)	Tissue enriched	Tissue enhanced		kidney: 37.5;small intestine: 25.7	esophagus: 6.8	Cell line enhanced		PC-3: 1.1;RPTEC TERT1: 1.8;SK-BR-3: 1.0
TMEM253	C14orf176, C14orf95, NCRNA00220	ENSG00000232070	Transmembrane protein 253	14	21098937-21103724	Predicted membrane proteins	Evidence at protein level	HPA052329, HPA065092	Enhanced					Mixed	Group enriched	6	duodenum: 101.3;small intestine: 100.0	colon: 15.8	Mixed		
TMEM254	bA369J21.6, C10orf57, FLJ13263	ENSG00000133678	Transmembrane protein 254	10	80078646-80092557	Predicted membrane proteins	Evidence at protein level	HPA029105, HPA072613	Approved		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			skin: 85.7	Mixed		
TMEM255A	FAM70A, FLJ20716	ENSG00000125355	Transmembrane protein 255A	X	120258650-120311556	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA048470	Uncertain		Uncertain	Nucleus<br>Nuclear bodies		Group enriched	Tissue enhanced		ovary: 23.5	cervix, uterine: 10.5	Cell line enhanced		Karpas-707: 18.2;RPMI-8226: 11.7;SK-MEL-30: 21.1;U-2 OS: 11.8;U-87 MG: 27.9
TMEM255B	FAM70B, MGC20579	ENSG00000184497	Transmembrane protein 255B	13	113759240-113816995	Predicted membrane proteins, Transporters	Evidence at protein level	HPA043334	Approved		Approved	Nucleoplasm	Renal cancer:4.12e-5 (unfavourable)	Expressed in all	Mixed			lung: 8.3	Cell line enhanced		HMC-1: 25.9;HUVEC TERT2: 32.5;PC-3: 36.6;TIME: 30.0;U-87 MG: 39.8
TMEM256	C17orf61, MGC40107	ENSG00000205544	Transmembrane protein 256	17	7402975-7404137	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA062732			Approved	Vesicles	Renal cancer:9.36e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 68.3	Expressed in all		
TMEM257	CXorf1	ENSG00000221870	Transmembrane protein 257	X	145827410-145829850	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	10	cerebral cortex: 4.2	seminal vesicle: 0.4	Not detected		
TMEM258	C11orf10	ENSG00000134825	Transmembrane protein 258	11	61768501-61792802	Predicted membrane proteins	Evidence at protein level	HPA044602	Approved		Approved	Plasma membrane<br>Cytosol	Ovarian cancer:4.37e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 437.6	Expressed in all		
TMEM259	ASBABP1, C19orf6, MBRL, MGC4022	ENSG00000182087	Transmembrane protein 259	19	1009648-1021179	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042669, HPA054801	Approved		Approved	Nuclear speckles<br>Endoplasmic reticulum	Stomach cancer:8.92e-6 (favourable), Endometrial cancer:1.01e-4 (favourable)	Expressed in all	Expressed in all			spleen: 129.7	Expressed in all		
TMEM26	Em:AC068892.1, MGC35010	ENSG00000196932	Transmembrane protein 26	10	61406643-61453450	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 11.8	endometrium: 6.8	Cell line enhanced		BJ hTERT+: 3.7;HSkMC: 1.4;HUVEC TERT2: 1.2;MOLT-4: 1.8
TMEM260	C14orf101, FLJ20392	ENSG00000070269	Transmembrane protein 260	14	56488354-56650606	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003502	Uncertain		Approved	Nucleus<br>Focal adhesion sites<br>Cytosol	Lung cancer:7.11e-4 (favourable)	Expressed in all	Tissue enhanced		cervix, uterine: 63.5	thyroid gland: 14.1	Expressed in all		
TMEM261	C9orf123, MGC4730	ENSG00000137038	Transmembrane protein 261	9	7796490-7888380	Predicted membrane proteins	Evidence at protein level	HPA014585	Approved				Renal cancer:1.96e-11 (favourable), Endometrial cancer:4.15e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.3	Expressed in all		
TMEM262		ENSG00000187066	Transmembrane protein 262	11	65084979-65089375	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	57	testis: 13.6	cervix, uterine: 0.2	Not detected		
TMEM265		ENSG00000281991	Transmembrane protein 265	16	30740381-30744281	Predicted membrane proteins	Evidence at transcript level								Mixed			skin: 18.9	Cell line enhanced		CAPAN-2: 79.5;T-47d: 46.9
TMEM266	C15orf27, FLJ38190	ENSG00000169758	Transmembrane protein 266	15	76059837-76229121	Predicted membrane proteins	Evidence at protein level	HPA041921, HPA049425	Enhanced		Supported	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 1.9;skeletal muscle: 1.5	placenta: 1.2	Cell line enhanced		NTERA-2: 1.0
TMEM267	C5orf28, FLJ21657	ENSG00000151881	Transmembrane protein 267	5	43444252-43483893	Predicted membrane proteins	Evidence at protein level	HPA059946			Approved	Nucleoplasm	Liver cancer:1.59e-4 (unfavourable), Renal cancer:2.85e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 65.0	Expressed in all		
TMEM268	C9orf91, DKFZp547P234, FLJ38045	ENSG00000157693	Transmembrane protein 268	9	114611206-114646422	Predicted membrane proteins	Evidence at transcript level	HPA017199	Approved		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:3.61e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 22.3	Expressed in all		
TMEM269		ENSG00000274386	Transmembrane protein 269	1	42785007-42816619	Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.9	Mixed		
TMEM27	NX17	ENSG00000147003	Transmembrane protein 27	X	15627318-15665031	Predicted membrane proteins, Transporters	Evidence at protein level	HPA048543	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:6.78e-9 (favourable), Ovarian cancer:5.65e-4 (favourable)	Tissue enriched	Tissue enriched	16	kidney: 422.0	parathyroid gland: 26.6	Cell line enhanced		HaCaT: 6.8;RPTEC TERT1: 5.3
TMEM30A	C6orf67, CDC50A, FLJ10856	ENSG00000112697	Transmembrane protein 30A	6	75252924-75284968	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014561	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 167.6	Expressed in all		
TMEM30B	CDC50B	ENSG00000182107	Transmembrane protein 30B	14	61277370-61281840	Predicted membrane proteins, Transporters	Evidence at protein level	HPA043162	Uncertain				Renal cancer:5.89e-5 (favourable)	Mixed	Mixed			parathyroid gland: 82.1	Cell line enhanced		A-431: 53.2;CAPAN-2: 42.5;MCF7: 29.9;RT4: 66.7
TMEM31	MGC39655	ENSG00000179363	Transmembrane protein 31	X	103710909-103714028	Predicted membrane proteins	Evidence at protein level	HPA052760			Approved	Nucleoli fibrillar center		Tissue enhanced	Tissue enriched	64	testis: 85.3	ovary,placenta: 1.3	Cell line enhanced		BEWO: 4.1;MCF7: 4.9;NTERA-2: 1.9
TMEM33	FLJ10525	ENSG00000109133	Transmembrane protein 33	4	41935120-41960572	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.35e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Expressed in all		
TMEM35A	FLJ14084, TMEM35	ENSG00000126950	Transmembrane protein 35A	X	101078720-101096364	Predicted membrane proteins	Evidence at protein level	HPA048583	Enhanced		Supported	Vesicles<br>Focal adhesion sites<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 42.4;seminal vesicle: 65.5	prostate: 33.7	Cell line enhanced		HUVEC TERT2: 40.2;SH-SY5Y: 12.9
TMEM35B	ZMYM6NB	ENSG00000243749	Transmembrane protein 35B	1	34981535-34985353	Predicted membrane proteins	Evidence at protein level	HPA051024	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			placenta: 91.7	Mixed		
TMEM37	PR, PR1	ENSG00000171227	Transmembrane protein 37	2	119429901-119438520	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053794	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Expressed in all	Mixed			kidney: 108.5	Cell line enhanced		EFO-21: 25.4;Hep G2: 50.5;RPTEC TERT1: 45.1
TMEM38A	MGC3169, TRIC-A	ENSG00000072954	Transmembrane protein 38A	19	16661127-16690029	Predicted membrane proteins	Evidence at protein level	HPA048100, HPA050463	Enhanced		Approved	Nucleus	Renal cancer:2.99e-10 (favourable), Lung cancer:2.78e-5 (favourable), Ovarian cancer:7.96e-4 (unfavourable)	Expressed in all	Tissue enriched	9	skeletal muscle: 199.7	cerebral cortex: 23.1	Cell line enhanced		U-698: 18.5
TMEM38B	bA219P18.1, C9orf87, D4Ertd89e, FLJ10493, TRIC-B	ENSG00000095209	Transmembrane protein 38B	9	105694544-105776612	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018465	Uncertain				Renal cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			testis: 51.9	Expressed in all		
TMEM39A	FLJ10902	ENSG00000176142	Transmembrane protein 39A	3	119429500-119468830	Predicted membrane proteins	Evidence at protein level	HPA039140	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.00e-5 (unfavourable), Liver cancer:3.26e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 32.3	Expressed in all		
TMEM39B	FLJ10315	ENSG00000121775	Transmembrane protein 39B	1	32072031-32102866	Predicted membrane proteins	Evidence at protein level	HPA040191, HPA040224	Approved		Approved	Vesicles	Renal cancer:5.11e-9 (unfavourable), Liver cancer:2.82e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 10.1	Expressed in all		
TMEM40	FLJ11036	ENSG00000088726	Transmembrane protein 40	3	12733525-12769457	Predicted membrane proteins	Evidence at protein level	HPA044165	Enhanced		Approved	Cytosol		Tissue enhanced	Group enriched	8	esophagus: 88.8;placenta: 23.3;skin: 55.5;tonsil: 23.7	urinary bladder: 6.1	Cell line enhanced		HBEC3-KT: 182.0;hTCEpi: 40.5;hTERT-HME1: 54.0
TMEM41A	MGC15397	ENSG00000163900	Transmembrane protein 41A	3	185476496-185499057	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059101, HPA059790	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Endometrial cancer:6.70e-6 (unfavourable), Liver cancer:1.04e-4 (unfavourable), Pancreatic cancer:4.72e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 28.2	Expressed in all		
TMEM41B	KIAA0033	ENSG00000166471	Transmembrane protein 41B	11	9280654-9314780	Predicted membrane proteins	Evidence at protein level	HPA014946	Uncertain		Approved	Peroxisomes	Liver cancer:9.18e-6 (unfavourable)	Expressed in all	Mixed			thyroid gland: 22.3	Expressed in all		
TMEM42	MGC29956	ENSG00000169964	Transmembrane protein 42	3	44861869-44865670	Predicted membrane proteins	Evidence at transcript level	HPA052569	Uncertain		Uncertain	Nucleoplasm<br>Nucleoli	Renal cancer:1.10e-5 (favourable), Breast cancer:5.23e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 12.8	Mixed		
TMEM43	ARVD5, DKFZp586G1919, LUMA, MGC3222	ENSG00000170876	Transmembrane protein 43	3	14124940-14143679	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA019198	Approved				Pancreatic cancer:4.38e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 124.4	Expressed in all		
TMEM44	DKFZp686O18124	ENSG00000145014	Transmembrane protein 44	3	194587673-194633689	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043718	Uncertain		Approved	Cytosol	Renal cancer:6.55e-13 (unfavourable)	Expressed in all	Mixed			epididymis: 16.7	Mixed		
TMEM45A	DERP7, FLJ10134	ENSG00000181458	Transmembrane protein 45A	3	100492619-100577444	Predicted membrane proteins	Evidence at protein level	HPA062101	Uncertain		Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:6.18e-11 (unfavourable), Lung cancer:7.42e-4 (unfavourable)	Expressed in all	Tissue enriched	10	skin: 563.0	placenta: 58.7	Cell line enhanced		ASC diff: 279.1
TMEM45B	BC016153, FLJ40787	ENSG00000151715	Transmembrane protein 45B	11	129815819-129860003	Predicted membrane proteins	Evidence at protein level	HPA015878	Approved		Uncertain	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		duodenum: 136.2;small intestine: 139.1	rectum: 103.3	Cell line enhanced		CACO-2: 32.2;Hep G2: 27.4;PC-3: 45.6;RT4: 105.7;T-47d: 34.7
TMEM47	BCMP1, DKFZp564E153, DKFZP761J17121, TM4SF10, VAB-9	ENSG00000147027	Transmembrane protein 47	X	34627064-34657288	Predicted membrane proteins	Evidence at protein level	HPA046658	Approved		Approved	Nuclear membrane	Renal cancer:4.05e-6 (favourable), Melanoma:2.10e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 75.5	Cell line enhanced		BJ: 94.7;fHDF/TERT166: 268.6
TMEM50A	SMP1	ENSG00000183726	Transmembrane protein 50A	1	25337917-25362361	Predicted membrane proteins, Transporters	Evidence at protein level	HPA065192			Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Endometrial cancer:8.64e-5 (favourable), Liver cancer:3.34e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 71.2	Expressed in all		
TMEM50B	C21orf4	ENSG00000142188	Transmembrane protein 50B	21	33432485-33480011	Predicted membrane proteins, Transporters	Evidence at protein level	CAB034199, HPA068995	Approved		Approved	Nucleoli fibrillar center	Head and neck cancer:3.00e-4 (favourable), Lung cancer:3.33e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 74.6	Expressed in all		
TMEM51	C1orf72, FLJ10199	ENSG00000171729	Transmembrane protein 51	1	15152532-15220480	Predicted membrane proteins	Evidence at protein level	HPA014547, HPA019441	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:8.16e-8 (favourable)	Expressed in all	Mixed			gallbladder: 33.4	Mixed		
TMEM52		ENSG00000178821	Transmembrane protein 52	1	1917590-1919273	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		pancreas: 38.8;skeletal muscle: 105.7	adrenal gland: 24.4	Cell line enhanced		Hep G2: 13.9;RPMI-8226: 25.7
TMEM53	FLJ22353, NET4	ENSG00000126106	Transmembrane protein 53	1	44635238-44674555	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021134	Approved		Approved	Golgi apparatus<br>Focal adhesion sites	Renal cancer:1.02e-5 (favourable), Ovarian cancer:6.96e-4 (favourable)	Expressed in all	Mixed			testis: 23.3	Expressed in all		
TMEM54	CAC-1	ENSG00000121900	Transmembrane protein 54	1	32894594-32901438	Predicted membrane proteins	Evidence at transcript level	HPA061992			Approved	Vesicles	Liver cancer:3.08e-4 (unfavourable)	Expressed in all	Mixed			colon: 222.7	Mixed		
TMEM55A	DKFZp762O076	ENSG00000155099	Transmembrane protein 55A	8	90993796-91041064	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014591	Approved				Liver cancer:3.76e-5 (unfavourable), Cervical cancer:1.01e-4 (unfavourable), Head and neck cancer:1.54e-4 (unfavourable), Stomach cancer:8.01e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 21.7	Mixed		
TMEM55B	C14orf9, MGC26684	ENSG00000165782	Transmembrane protein 55B	14	20457719-20461612	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048528	Approved				Renal cancer:1.01e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.0	Expressed in all		
TMEM56	FLJ31842	ENSG00000152078	Transmembrane protein 56	1	95117338-95197607	Predicted membrane proteins	Evidence at protein level	HPA046762	Uncertain		Approved	Nuclear speckles		Tissue enhanced	Tissue enhanced		liver: 66.1	heart muscle: 16.7	Cell line enhanced		RH-30: 34.4
TMEM56-RWDD3		ENSG00000271092	TMEM56-RWDD3 readthrough	1	95117923-95247225	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			thyroid gland: 5.2	Cell line enhanced		RH-30: 11.5
TMEM57	FLJ10747	ENSG00000204178	Transmembrane protein 57	1	25430858-25500209	Predicted membrane proteins, Transporters	Evidence at protein level	HPA019680			Approved	Cytosol	Renal cancer:7.13e-4 (favourable)	Expressed in all	Expressed in all			testis: 36.1	Expressed in all		
TMEM59	C1orf8, HSPC001	ENSG00000116209	Transmembrane protein 59	1	54026681-54053504	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Expressed in all			fallopian tube: 650.0	Expressed in all		
TMEM59L	BSMAP, C19orf4	ENSG00000105696	Transmembrane protein 59 like	19	18607430-18621039	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA010661, HPA070701	Approved		Approved	Nucleoplasm<br>Actin filaments	Endometrial cancer:1.62e-4 (unfavourable), Pancreatic cancer:8.80e-4 (favourable)	Tissue enriched	Tissue enriched	16	cerebral cortex: 366.3	adrenal gland: 22.2	Cell line enhanced		AN3-CA: 33.4;ASC diff: 29.2;EFO-21: 24.0;Hep G2: 18.4;SH-SY5Y: 22.4
TMEM60	C7orf35, DC32	ENSG00000135211	Transmembrane protein 60	7	77793728-77798580	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA062625	Approved				Breast cancer:3.09e-4 (favourable), Glioma:8.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 56.4	Expressed in all		
TMEM61		ENSG00000143001	Transmembrane protein 61	1	54980792-54992293	Predicted membrane proteins	Evidence at transcript level	HPA030614	Uncertain				Renal cancer:1.78e-7 (favourable), Colorectal cancer:1.07e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 11.2;salivary gland: 10.1	seminal vesicle: 8.2	Cell line enriched	7	RPMI-8226: 16.2
TMEM62	FLJ23375	ENSG00000137842	Transmembrane protein 62	15	43123279-43185146	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044461, HPA062359	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Nuclear bodies<br>Cytoplasmic bodies	Endometrial cancer:9.72e-7 (favourable)	Expressed in all	Expressed in all			breast: 28.7	Mixed		
TMEM63A	KIAA0792	ENSG00000196187	Transmembrane protein 63A	1	225845536-225882369	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066504, HPA066936, HPA068918			Enhanced	Vesicles<br>Microtubule organizing center	Endometrial cancer:8.79e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 77.2	Mixed		
TMEM63B	C6orf110, dJ421H19.2, DKFZp434P0531	ENSG00000137216	Transmembrane protein 63B	6	44126914-44155519	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029249, HPA029250, HPA029251	Uncertain		Enhanced	Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			lung: 59.0	Expressed in all		
TMEM63C	C14orf171, CSC1, DKFZp434P0111, hsCSC1	ENSG00000165548	Transmembrane protein 63C	14	77116568-77259495	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030657	Uncertain		Approved	Centrosome		Mixed	Tissue enhanced		adrenal gland: 12.9;cerebral cortex: 18.5;testis: 13.8	epididymis: 5.6	Cell line enhanced		Daudi: 13.3;Karpas-707: 17.4;SCLC-21H: 38.5;SK-BR-3: 21.9
TMEM64	DKFZp762C1112	ENSG00000180694	Transmembrane protein 64	8	90621995-90791632	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	CAB034221	Uncertain					Expressed in all	Expressed in all			epididymis: 176.0	Mixed		
TMEM65		ENSG00000164983	Transmembrane protein 65	8	124306189-124372692	Predicted membrane proteins	Evidence at protein level	HPA025020	Uncertain		Approved	Nucleoplasm	Endometrial cancer:1.05e-4 (unfavourable), Breast cancer:2.17e-4 (unfavourable), Liver cancer:2.56e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 17.6	Mixed		
TMEM67	JBTS6, MGC26979, MKS3, NPHP11	ENSG00000164953	Transmembrane protein 67	8	93754844-93819234	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:7.62e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 21.5	testis: 12.5	Mixed		
TMEM68	FLJ32370	ENSG00000167904	Transmembrane protein 68	8	55696424-55773407	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018216, HPA019173	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			fallopian tube: 36.8	Expressed in all		
TMEM69	C1orf154, FLJ21029	ENSG00000159596	Transmembrane protein 69	1	45687214-45694443	Predicted membrane proteins	Evidence at transcript level	HPA026993	Approved		Approved	Nucleoplasm	Liver cancer:3.66e-8 (unfavourable), Breast cancer:2.24e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.9	Expressed in all		
TMEM70	FLJ20533	ENSG00000175606	Transmembrane protein 70	8	73972437-73982783	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023187, CAB034226	Uncertain		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 30.2	Expressed in all		
TMEM71	FLJ33069	ENSG00000165071	Transmembrane protein 71	8	132685007-132760712	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058401, HPA070655	Uncertain		Enhanced	Mitochondria		Mixed	Mixed			heart muscle: 27.1	Cell line enhanced		HDLM-2: 53.9;U-937: 26.7
TMEM72	bA285G1.3, C10orf127, KSP37	ENSG00000187783	Transmembrane protein 72	10	44911200-44937002	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039894, HPA062907	Enhanced				Renal cancer:1.01e-4 (favourable)	Tissue enriched	Tissue enriched	7	kidney: 54.3	rectum: 7.8	Group enriched	105	RPMI-8226: 24.8;U-937: 17.4
TMEM74	FLJ30668, NET36	ENSG00000164841	Transmembrane protein 74	8	108606850-108787615	Predicted membrane proteins	Evidence at protein level	HPA015672	Uncertain		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 6.2	heart muscle: 1.6	Cell line enhanced		HEK93: 3.6;NTERA-2: 4.9;SCLC-21H: 12.4
TMEM74B	C20orf46, FLJ11190	ENSG00000125895	Transmembrane protein 74B	20	1180561-1185415	Predicted membrane proteins	Evidence at transcript level	HPA045213	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:2.55e-7 (unfavourable), Pancreatic cancer:3.07e-5 (favourable)	Mixed	Mixed			small intestine: 27.0	Cell line enhanced		CACO-2: 6.6;Hep G2: 6.9;K-562: 15.6
TMEM78	FLJ40168	ENSG00000177800	Transmembrane protein 78	1	229249636-229251810	Predicted membrane proteins	Evidence at transcript level	HPA042351	Uncertain					Not detected	Not detected			bone marrow,cerebral cortex,skin,testis: 0.3	Not detected		
TMEM79	FLJ16057, FLJ32254, MATT, MGC13102	ENSG00000163472	Transmembrane protein 79	1	156282935-156293185	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055214	Enhanced		Approved	Nucleoli fibrillar center	Renal cancer:4.31e-7 (unfavourable), Liver cancer:2.61e-5 (unfavourable)	Expressed in all	Group enriched	6	esophagus: 61.6;prostate: 45.5;skin: 66.8	tonsil: 10.3	Mixed		
TMEM80	FLJ38216	ENSG00000177042	Transmembrane protein 80	11	695428-705028	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA059592, HPA067046	Uncertain		Approved	Golgi apparatus	Renal cancer:2.47e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 43.5	Expressed in all		
TMEM81	HC3107, KVLA2788, MGC75217, UNQ2788	ENSG00000174529	Transmembrane protein 81	1	205083129-205084460	Predicted membrane proteins	Evidence at protein level	HPA052515			Approved	Intermediate filaments	Renal cancer:6.65e-9 (unfavourable), Liver cancer:3.25e-6 (unfavourable), Urothelial cancer:2.67e-4 (favourable)	Expressed in all	Mixed			testis: 6.7	Expressed in all		
TMEM82		ENSG00000162460	Transmembrane protein 82	1	15742422-15747982	Predicted membrane proteins	Evidence at protein level	HPA060282	Uncertain		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:3.80e-7 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 23.0;liver: 9.0;small intestine: 19.4	kidney: 7.6	Cell line enriched	5	CACO-2: 2.6
TMEM86A	FLJ90119	ENSG00000151117	Transmembrane protein 86A	11	18693122-18704785	Predicted membrane proteins	Evidence at transcript level	HPA057119	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			skin: 13.3	Cell line enhanced		RPTEC TERT1: 13.2
TMEM86B	MGC30208	ENSG00000180089	Transmembrane protein 86B	19	55226639-55229264	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA057689	Uncertain		Approved	Midbody<br>Centrosome	Pancreatic cancer:9.97e-6 (favourable), Liver cancer:3.13e-4 (favourable)	Tissue enriched	Mixed			gallbladder: 6.6	Mixed		
TMEM87A	DKFZP564G2022	ENSG00000103978	Transmembrane protein 87A	15	42210452-42273663	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018104, HPA018189	Enhanced		Supported	Golgi apparatus		Expressed in all	Expressed in all			prostate: 124.3	Expressed in all		
TMEM87B	FLJ14681	ENSG00000153214	Transmembrane protein 87B	2	112055223-112119318	Predicted membrane proteins	Evidence at protein level	HPA035183	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.52e-7 (unfavourable), Cervical cancer:3.78e-4 (unfavourable), Head and neck cancer:4.28e-4 (unfavourable), Liver cancer:4.72e-4 (unfavourable)	Expressed in all	Mixed			prostate: 44.5	Expressed in all		
TMEM88	FLJ20025, MGC71744	ENSG00000167874	Transmembrane protein 88	17	7855065-7856099	Predicted membrane proteins	Evidence at protein level	HPA052991	Approved				Liver cancer:4.43e-6 (favourable), Colorectal cancer:1.16e-4 (unfavourable)	Expressed in all	Mixed			placenta: 34.2	Group enriched	5	AN3-CA: 60.4;HHSteC: 35.4;HUVEC TERT2: 42.7;NTERA-2: 26.4
TMEM88B		ENSG00000205116	Transmembrane protein 88B	1	1426128-1427787	Predicted membrane proteins	Evidence at protein level	HPA065743	Enhanced					Tissue enhanced	Tissue enriched	14	cerebral cortex: 11.8	testis: 0.8	Cell line enhanced		Hep G2: 2.8;SCLC-21H: 1.9
TMEM89		ENSG00000183396	Transmembrane protein 89	3	48620759-48621855	Predicted membrane proteins	Evidence at protein level	HPA053577	Uncertain					Not detected	Tissue enriched	10	testis: 9.4	bone marrow: 0.9	Not detected		
TMEM8A	M83, TMEM6, TMEM8	ENSG00000129925	Transmembrane protein 8A	16	370773-387113	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051281, HPA064673	Approved		Supported	Nucleoplasm<br>Cytokinetic bridge	Renal cancer:1.29e-5 (favourable)	Expressed in all	Expressed in all			testis: 57.1	Expressed in all		
TMEM8B	C9orf127, NAG-5, NGX6	ENSG00000137103	Transmembrane protein 8B	9	35814451-35854847	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052130, HPA062701	Approved		Approved	Vesicles	Renal cancer:1.89e-15 (favourable), Pancreatic cancer:3.14e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.1	Mixed		
TMEM8C	TMEM226	ENSG00000187616	Transmembrane protein 8C	9	133514586-133528612	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA051846, HPA055785	Uncertain					Not detected	Not detected			cerebral cortex,epididymis: 0.5	Group enriched	29	HSkMC: 11.3;RH-30: 6.9
TMEM9	TMEM9A	ENSG00000116857	Transmembrane protein 9	1	201134772-201171574	Predicted membrane proteins	Evidence at protein level						Head and neck cancer:3.93e-4 (unfavourable), Cervical cancer:6.57e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 122.7	Expressed in all		
TMEM91	FLJ27310, IFITMD6	ENSG00000142046	Transmembrane protein 91	19	41350911-41384083	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA053240	Uncertain				Renal cancer:3.52e-7 (unfavourable), Pancreatic cancer:3.54e-5 (favourable)	Expressed in all	Expressed in all			skin: 31.1	Mixed		
TMEM92	FLJ33318	ENSG00000167105	Transmembrane protein 92	17	50271406-50281485	Predicted membrane proteins	Evidence at protein level	HPA063009, HPA069820	Approved		Supported	Nucleoplasm	Renal cancer:1.14e-6 (unfavourable), Head and neck cancer:8.35e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 40.2;small intestine: 50.6	gallbladder: 21.8	Cell line enhanced		A549: 16.5;CACO-2: 25.7;CAPAN-2: 25.7;EFO-21: 56.2
TMEM94	KIAA0195	ENSG00000177728	Transmembrane protein 94	17	75441159-75500090	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008423, HPA050660	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 54.2	Expressed in all		
TMEM95	MGC129793, UNQ9390	ENSG00000182896	Transmembrane protein 95	17	7355123-7357219	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	48	testis: 9.9	gallbladder: 0.2	Not detected		
TMEM97	MAC30	ENSG00000109084	Transmembrane protein 97	17	28319095-28328685	Predicted membrane proteins	Evidence at protein level	HPA044795	Approved		Approved	Nuclear membrane<br>Plasma membrane<br>Cytosol	Renal cancer:1.24e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 110.0	Expressed in all		
TMEM98	DKFZP564K1964	ENSG00000006042	Transmembrane protein 98	17	32927910-32945106	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA040473, HPA053385	Uncertain		Supported	Nucleoplasm	Renal cancer:3.85e-4 (favourable), Lung cancer:7.10e-4 (favourable), Liver cancer:8.14e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 238.1	Mixed		
TMEM99	MGC21518	ENSG00000167920	Transmembrane protein 99	17	40819106-40836274	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Tissue enhanced		testis: 177.0	epididymis: 53.1	Mixed		
TMEM9B	C11orf15	ENSG00000175348	TMEM9 domain family member B	11	8947294-8965011	Predicted membrane proteins	Evidence at protein level	HPA037784	Uncertain				Renal cancer:4.26e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 129.7	Expressed in all		
TMIE	DFNB6	ENSG00000181585	Transmembrane inner ear	3	46701333-46710886	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038298	Uncertain		Uncertain	Vesicles<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 7.4;cerebral cortex: 5.2	testis: 1.6	Cell line enhanced		CAPAN-2: 2.2;EFO-21: 2.1;SH-SY5Y: 2.3
TMIGD1	TMIGD, UNQ9372	ENSG00000182271	Transmembrane and immunoglobulin domain containing 1	17	30316333-30334059	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA021946			Approved	Mitochondria		Tissue enhanced	Group enriched	23	colon: 81.8;rectum: 109.8;small intestine: 162.9	kidney: 5.1	Not detected		
TMIGD2	CD28H, IGPR-1, MGC23244	ENSG00000167664	Transmembrane and immunoglobulin domain containing 2	19	4292232-4302431	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011081	Approved					Mixed	Tissue enhanced		lymph node: 7.4	appendix: 5.5	Cell line enhanced		BEWO: 12.1;HEL: 26.9;MOLT-4: 21.9
TMIGD3	AD026	ENSG00000121933	Transmembrane and immunoglobulin domain containing 3	1	111483348-111563962	Predicted membrane proteins	Evidence at protein level						Breast cancer:3.58e-4 (unfavourable)	Tissue enriched	Tissue enriched	15	testis: 99.0	placenta: 6.6	Cell line enhanced		HDLM-2: 6.5;HMC-1: 1.5;NB-4: 2.4
TMPO	LAP2, LEMD4, TP	ENSG00000120802	Thymopoietin	12	98515512-98550379	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008150, CAB009847	Enhanced		Enhanced	Nuclear membrane	Renal cancer:9.34e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 91.3	Expressed in all		
TMPPE	FLJ45032	ENSG00000188167	Transmembrane protein with metallophosphoesterase domain	3	33090421-33096801	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027019	Uncertain		Approved	Nucleoplasm<br>Mitochondria		Mixed	Mixed			parathyroid gland: 4.1	Cell line enriched	6	BEWO: 26.4
TMPRSS11A	ECRG1	ENSG00000187054	Transmembrane protease, serine 11A	4	67909385-67964140	Enzymes, Predicted membrane proteins	Evidence at protein level							Group enriched	Group enriched	64	esophagus: 96.0;tonsil: 26.0	cervix, uterine: 0.9	Not detected		
TMPRSS11B		ENSG00000185873	Transmembrane protease, serine 11B	4	68226653-68245720	Enzymes, Predicted membrane proteins	Evidence at protein level						Head and neck cancer:6.91e-4 (favourable)	Group enriched	Group enriched	184	esophagus: 311.6;tonsil: 74.5	cervix, uterine: 1.0	Not detected		
TMPRSS11D		ENSG00000153802	Transmembrane protease, serine 11D	4	67820876-67884032	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052834	Uncertain					Group enriched	Group enriched	39	esophagus: 70.5;tonsil: 30.6	cervix, uterine: 1.3	Not detected		
TMPRSS11E	DESC1, TMPRSS11E2	ENSG00000087128	Transmembrane protease, serine 11E	4	68447449-68497604	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA051062	Uncertain				Lung cancer:6.73e-4 (unfavourable)	Group enriched	Tissue enriched	5	esophagus: 128.2	epididymis: 25.0	Cell line enhanced		HaCaT: 1.4
TMPRSS11F	FLJ16046	ENSG00000198092	Transmembrane protease, serine 11F	4	68053198-68129880	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA026911	Uncertain					Group enriched	Group enriched	7	esophagus: 16.7;skin: 11.0;tonsil: 3.7	breast: 1.5	Cell line enhanced		K-562: 1.4
TMPRSS12	CT151, MGC57341	ENSG00000186452	Transmembrane protease, serine 12	12	50842920-50887884	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	75	testis: 39.5	epididymis: 0.5	Not detected		
TMPRSS13	MSPL, TMPRSS11	ENSG00000137747	Transmembrane protease, serine 13	11	117900643-117929459	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 36.4	cervix, uterine,esophagus: 10.5	Cell line enhanced		BEWO: 32.1;MCF7: 22.3;SK-BR-3: 36.2;T-47d: 46.4
TMPRSS2	PRSS10	ENSG00000184012	Transmembrane protease, serine 2	21	41464551-41531116	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034493, HPA035787	Enhanced		Supported	Nucleoplasm<br>Cell Junctions	Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable)	Tissue enriched	Tissue enhanced		prostate: 489.3	stomach: 142.6	Cell line enhanced		CACO-2: 21.8;RT4: 50.4;SK-BR-3: 9.5
TMPRSS3	DFNB10, DFNB8	ENSG00000160183	Transmembrane protease, serine 3	21	42371890-42396846	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Colorectal cancer:3.64e-4 (unfavourable), Renal cancer:8.24e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 35.2	stomach: 13.7	Cell line enhanced		HEL: 58.2;SiHa: 35.3;U-266/84: 182.5
TMPRSS4	MT-SP2, TMPRSS3	ENSG00000137648	Transmembrane protease, serine 4	11	118077012-118121890	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006238	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.14e-4 (unfavourable)	Mixed	Tissue enhanced		rectum: 77.1;urinary bladder: 77.3	esophagus: 73.8	Group enriched	9	A-431: 25.3;CAPAN-2: 123.9;HaCaT: 53.5;RPTEC TERT1: 73.7;RT4: 99.4
TMPRSS4-AS1		ENSG00000255274	TMPRSS4 antisense RNA 1	11	118003634-118088299	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		kidney: 1.2	lymph node,spleen: 0.8	Cell line enhanced		Karpas-707: 7.8;RPMI-8226: 4.9;SCLC-21H: 1.7
TMPRSS5	MGC141886, MGC148044	ENSG00000166682	Transmembrane protease, serine 5	11	113687550-113706373	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010992			Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 10.1	salivary gland: 3.0	Cell line enhanced		CAPAN-2: 2.9;WM-115: 2.6
TMPRSS6	FLJ30744	ENSG00000187045	Transmembrane protease, serine 6	22	37065436-37109563	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Liver cancer:8.16e-6 (favourable)	Group enriched	Group enriched	6	liver: 40.8;testis: 8.6	stomach: 4.0	Cell line enhanced		Hep G2: 3.6;SCLC-21H: 10.1
TMPRSS7		ENSG00000176040	Transmembrane protease, serine 7	3	112034843-112081269	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA040630	Uncertain					Not detected	Tissue enhanced		testis: 2.5	fallopian tube: 0.6	Not detected		
TMPRSS9		ENSG00000178297	Transmembrane protease, serine 9	19	2389771-2426239	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA051483	Uncertain					Mixed	Tissue enhanced		spleen: 2.3;testis: 1.7	skin: 0.8	Cell line enhanced		Karpas-707: 1.8;U-266/70: 1.7
TMTC1	ARG99, FLJ31400, FLJ41625, OLF	ENSG00000133687	Transmembrane and tetratricopeptide repeat containing 1	12	29500840-29784759	Predicted membrane proteins	Evidence at protein level	HPA016720	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:1.90e-4 (unfavourable), Renal cancer:5.49e-4 (unfavourable)	Mixed	Tissue enhanced		spleen: 60.8	adipose tissue: 41.7	Cell line enhanced		HHSteC: 71.4;hTERT-HME1: 81.2;RH-30: 120.9
TMTC2	DKFZp762A217	ENSG00000179104	Transmembrane and tetratricopeptide repeat containing 2	12	82686880-83134870	Predicted membrane proteins	Evidence at protein level	HPA026954, HPA026955	Uncertain		Approved	Plasma membrane<br>Actin filaments	Renal cancer:2.84e-5 (favourable)	Mixed	Mixed			cerebral cortex: 16.4	Cell line enhanced		AF22: 31.2;WM-115: 76.7
TMTC3	FLJ90492, SMILE	ENSG00000139324	Transmembrane and tetratricopeptide repeat containing 3	12	88142296-88199887	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA038550	Approved					Expressed in all	Mixed			skin: 14.9	Expressed in all		
TMTC4	FLJ14624, FLJ22153	ENSG00000125247	Transmembrane and tetratricopeptide repeat containing 4	13	100603927-100675093	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016489	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			cerebral cortex: 26.4	Mixed		
TMUB1	C7orf21, SB144	ENSG00000164897	Transmembrane and ubiquitin like domain containing 1	7	151081080-151083546	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA029429	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			small intestine: 52.2	Expressed in all		
TMUB2	MGC3123	ENSG00000168591	Transmembrane and ubiquitin like domain containing 2	17	44186970-44191731	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043137	Approved		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 48.4	Expressed in all		
TMX1	PDIA11, TMX, TXNDC, TXNDC1	ENSG00000139921	Thioredoxin related transmembrane protein 1	14	51240162-51257546	Predicted membrane proteins	Evidence at protein level	HPA003085	Approved		Supported	Nucleoli<br>Endoplasmic reticulum	Liver cancer:1.29e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 19.8	Expressed in all		
TMX2	PDIA12, TXNDC14	ENSG00000213593	Thioredoxin related transmembrane protein 2	11	57712600-57740973	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040282, HPA063763	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.55e-5 (favourable), Urothelial cancer:3.37e-4 (unfavourable), Head and neck cancer:3.64e-4 (unfavourable), Liver cancer:4.11e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 129.2	Expressed in all		
TMX3	FLJ20793, KIAA1830, PDIA13, TXNDC10	ENSG00000166479	Thioredoxin related transmembrane protein 3	18	68673688-68715298	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014157	Uncertain				Renal cancer:2.87e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 31.4	Expressed in all		
TMX4	DJ971N18.2, KIAA1162, PDIA14, TXNDC13	ENSG00000125827	Thioredoxin related transmembrane protein 4	20	7977348-8019829	Predicted membrane proteins	Evidence at protein level	HPA000399, HPA015752	Enhanced		Supported	Nuclear membrane	Renal cancer:2.60e-5 (favourable)	Expressed in all	Expressed in all			testis: 118.2	Expressed in all		
TNFRSF10A	Apo2, CD261, DR4, TRAILR-1	ENSG00000104689	TNF receptor superfamily member 10a	8	23190452-23225126	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	HPA050958, HPA054475	Approved		Supported	Nucleoplasm	Pancreatic cancer:1.00e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 15.9	Mixed		
TNFRSF10B	CD262, DR5, KILLER, TRAIL-R2, TRICK2A, TRICKB	ENSG00000120889	TNF receptor superfamily member 10b	8	23020133-23069179	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA023625	Approved				Renal cancer:1.76e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 33.3	Mixed		
TNFRSF10C	CD263, DcR1, LIT, TRAILR3, TRID	ENSG00000173535	TNF receptor superfamily member 10c	8	23084355-23117437	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025635	Enhanced					Mixed	Tissue enhanced		appendix: 21.9	spleen: 18.2	Group enriched	5	BEWO: 78.5;HUVEC TERT2: 56.8
TNFRSF10D	CD264, DcR2, TRAILR4, TRUNDD	ENSG00000173530	TNF receptor superfamily member 10d	8	23135588-23164030	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	HPA070971			Approved	Plasma membrane<br>Actin filaments	Cervical cancer:1.70e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 12.7	Cell line enhanced		LHCN-M2: 208.5;WM-115: 234.5
TNFRSF11A	CD265, FEO, LOH18CR1, PDB2, RANK	ENSG00000141655	TNF receptor superfamily member 11a	18	62325287-62391292	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010391, HPA027728, HPA047976	Uncertain		Supported	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		duodenum: 30.6	small intestine: 20.5	Cell line enhanced		HDLM-2: 116.8;PC-3: 18.0;SCLC-21H: 24.0
TNFRSF12A	CD266, FN14, TweakR	ENSG00000006327	TNF receptor superfamily member 12A	16	3018445-3022383	Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007853	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:5.50e-4 (unfavourable), Renal cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 199.0	Mixed		
TNFRSF13B	CD267, IGAD2, TACI	ENSG00000240505	TNF receptor superfamily member 13B	17	16929816-16972118	CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030453	Uncertain					Not detected	Tissue enhanced		lymph node: 20.3;skeletal muscle: 22.1;spleen: 27.2;tonsil: 21.0	appendix: 12.1	Group enriched	8	Karpas-707: 120.9;RPMI-8226: 76.1;U-266/70: 56.5
TNFRSF13C	BAFFR, CD268	ENSG00000159958	TNF receptor superfamily member 13C	22	41922023-41926818	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA003246, CAB008380	Enhanced		Uncertain	Nucleus	Cervical cancer:4.44e-7 (favourable)	Mixed	Group enriched	10	appendix: 22.9;lymph node: 46.1;spleen: 43.5;tonsil: 49.9	bone marrow: 4.0	Cell line enhanced		REH: 19.1;U-698: 7.7
TNFRSF14	ATAR, CD270, HVEA, HVEM, LIGHTR, TR2	ENSG00000157873	TNF receptor superfamily member 14	1	2555639-2565382	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006404, CAB026150, CAB030007	Approved		Approved	Cytosol<br>Rods & Rings	Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 45.5	Cell line enhanced		CAPAN-2: 23.4;HDLM-2: 25.7;HHSteC: 25.4;SK-MEL-30: 41.0
TNFRSF17	BCM, BCMA, CD269, TNFRSF13A	ENSG00000048462	TNF receptor superfamily member 17	16	11965107-11968068	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Head and neck cancer:1.58e-6 (favourable), Breast cancer:1.35e-5 (favourable)	Mixed	Tissue enhanced		tonsil: 36.7	lymph node: 30.8	Group enriched	7	Karpas-707: 114.0;RPMI-8226: 179.8;U-266/70: 561.8;U-266/84: 274.9
TNFRSF18	AITR, CD357, GITR	ENSG00000186891	TNF receptor superfamily member 18	1	1203508-1206691	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008025	Approved				Renal cancer:4.40e-11 (unfavourable), Endometrial cancer:7.72e-6 (favourable), Head and neck cancer:4.12e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 43.3	parathyroid gland: 18.0	Group enriched	11	RPMI-8226: 148.8;SCLC-21H: 173.4
TNFRSF19	TAJ, TAJ-alpha, TRADE, TROY	ENSG00000127863	TNF receptor superfamily member 19	13	23570370-23676104	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA010135			Approved	Nucleoplasm<br>Mitochondria	Renal cancer:9.13e-7 (favourable), Lung cancer:3.87e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 128.9	fallopian tube: 50.5	Cell line enhanced		BJ hTERT+: 65.9;fHDF/TERT166: 48.4;Hep G2: 58.9;SK-MEL-30: 111.1;WM-115: 86.3
TNFRSF1A	CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60	ENSG00000067182	TNF receptor superfamily member 1A	12	6328757-6342114	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004102, CAB010309	Approved				Renal cancer:2.70e-7 (unfavourable), Head and neck cancer:3.68e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 141.2	Mixed		
TNFRSF1B	CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80	ENSG00000028137	TNF receptor superfamily member 1B	1	12167003-12209228	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004796	Approved				Renal cancer:8.35e-5 (unfavourable), Testis cancer:8.68e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 100.4	spleen: 77.8	Cell line enhanced		CAPAN-2: 31.7;K-562: 41.3;THP-1: 35.7;U-87 MG: 34.0
TNFRSF21	CD358, DR6	ENSG00000146072	TNF receptor superfamily member 21	6	47231532-47309905	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA006746, CAB009805	Approved				Renal cancer:7.23e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 105.2	Cell line enhanced		RT4: 416.8
TNFRSF25	APO-3, DDR3, DR3, LARD, TNFRSF12, TR3, TRAMP, WSL-1, WSL-LR	ENSG00000215788	TNF receptor superfamily member 25	1	6461151-6466195	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069834			Approved	Nucleus<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Renal cancer:1.65e-7 (unfavourable), Head and neck cancer:3.09e-4 (favourable), Colorectal cancer:4.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 29.6	spleen: 12.1	Cell line enhanced		HDLM-2: 24.6;RPMI-8226: 17.9
TNFRSF4	ACT35, CD134, OX40, TXGP1L	ENSG00000186827	TNF receptor superfamily member 4	1	1211326-1214138	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB016128	Enhanced				Head and neck cancer:3.50e-6 (favourable), Renal cancer:4.52e-6 (unfavourable), Liver cancer:6.03e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 9.7;appendix: 8.3	lymph node: 7.1	Group enriched	8	MOLT-4: 5.0;NB-4: 7.6
TNFRSF8	CD30, D1S166E, KI-1	ENSG00000120949	TNF receptor superfamily member 8	1	12063377-12144207	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000016, HPA032081, HPA032082	Approved					Tissue enriched	Tissue enhanced		appendix: 4.1	adipose tissue: 3.1	Cell line enriched	22	HDLM-2: 528.2
TNFRSF9	4-1BB, CD137, ILA	ENSG00000049249	TNF receptor superfamily member 9	1	7915894-7943165	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	HPA071425			Approved	Nucleoli<br>Plasma membrane	Renal cancer:2.69e-8 (unfavourable)	Mixed	Tissue enhanced		lymph node: 11.1;tonsil: 7.0	appendix: 5.2	Cell line enriched	8	HDLM-2: 92.4
TNFSF10	Apo-2L, CD253, TL2, TRAIL	ENSG00000121858	Tumor necrosis factor superfamily member 10	3	172505508-172523507	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054938	Uncertain		Approved	Microtubules	Pancreatic cancer:9.43e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 260.0	Cell line enhanced		BEWO: 70.1;HMC-1: 209.7;RPTEC TERT1: 91.4
TNFSF11	CD254, ODF, OPGL, RANKL, TRANCE	ENSG00000120659	Tumor necrosis factor superfamily member 11	13	42562736-42608013	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009193, HPA045142	Enhanced					Mixed	Tissue enhanced		lymph node: 17.3	appendix: 6.3	Cell line enhanced		HSkMC: 1.5;NTERA-2: 3.0
TNFSF13B	BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20	ENSG00000102524	Tumor necrosis factor superfamily member 13b	13	108251240-108308484	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009188	Enhanced				Renal cancer:2.53e-11 (unfavourable)	Expressed in all	Mixed			appendix: 35.3	Cell line enriched	9	U-937: 130.0
TNFSF14	CD258, HVEM-L, LIGHT, LTg	ENSG00000125735	Tumor necrosis factor superfamily member 14	19	6661253-6670588	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012700	Approved				Renal cancer:6.07e-13 (unfavourable)	Tissue enhanced	Mixed			adipose tissue: 6.8	Cell line enhanced		HDLM-2: 22.7;U-937: 10.8
TNFSF18	AITRL, hGITRL, TL6	ENSG00000120337	Tumor necrosis factor superfamily member 18	1	173039960-173050963	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 2.8;gallbladder: 3.0	parathyroid gland: 1.4	Group enriched	11	EFO-21: 48.3;HUVEC TERT2: 65.6;TIME: 89.7
TNFSF8	CD153, CD30LG	ENSG00000106952	Tumor necrosis factor superfamily member 8	9	114893343-114930595	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		lymph node: 34.4;tonsil: 26.7	appendix: 24.3	Group enriched	99	Daudi: 50.4;U-698: 39.7
TNMD	BRICD4, ChM1L, myodulin, TEM, tendin	ENSG00000000005	Tenomodulin	X	100584802-100599885	Predicted membrane proteins	Evidence at protein level	HPA034961, HPA055634	Uncertain					Mixed	Tissue enhanced		adipose tissue: 10.1;seminal vesicle: 33.2	breast: 4.3	Group enriched	19	HAP1: 6.2;NTERA-2: 14.2
TOM1L1	SRCASM	ENSG00000141198	Target of myb1 like 1 membrane trafficking protein	17	54899387-54968646	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022916	Uncertain				Renal cancer:3.81e-6 (favourable), Colorectal cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 116.9	Mixed		
TOMM20	KIAA0016, MAS20, MOM19, TOM20	ENSG00000173726	Translocase of outer mitochondrial membrane 20	1	235109336-235128936	Predicted membrane proteins	Evidence at protein level	CAB005585, HPA011562	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 230.8	Expressed in all		
TOMM20L	UNQ9438	ENSG00000196860	Translocase of outer mitochondrial membrane 20 like	14	58395916-58408701	Predicted membrane proteins	Evidence at transcript level	HPA044997	Uncertain					Mixed	Tissue enriched	11	testis: 13.1	epididymis: 1.2	Cell line enhanced		SCLC-21H: 1.1
TOMM22	TOM22	ENSG00000100216	Translocase of outer mitochondrial membrane 22	22	38681948-38685421	Predicted membrane proteins	Evidence at protein level	HPA003037	Enhanced		Enhanced	Mitochondria	Liver cancer:2.90e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 32.7	Expressed in all		
TOMM7	Tom7	ENSG00000196683	Translocase of outer mitochondrial membrane 7	7	22812628-22822852	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Head and neck cancer:6.30e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 677.6	Expressed in all		
TOMM70	KIAA0719, Tom70, TOMM70A	ENSG00000154174	Translocase of outer mitochondrial membrane 70	3	100363431-100401398	Predicted membrane proteins	Evidence at protein level	HPA014589, CAB017156, HPA048020	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 52.8	Expressed in all		
TOPORS-AS1	C9orf133	ENSG00000235453	TOPORS antisense RNA 1	9	32551144-32567005	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Breast cancer:4.18e-5 (favourable), Pancreatic cancer:7.33e-5 (favourable), Renal cancer:3.46e-4 (favourable), Cervical cancer:6.11e-4 (favourable), Ovarian cancer:8.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 35.7	Mixed		
TOR1AIP1	FLJ13142, LAP1B	ENSG00000143337	Torsin 1A interacting protein 1	1	179882042-179925000	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047151, HPA050546	Enhanced		Enhanced	Nuclear membrane		Expressed in all	Expressed in all			thyroid gland: 79.3	Expressed in all		
TOR1AIP2	IFRG15, LULL1, NET9	ENSG00000169905	Torsin 1A interacting protein 2	1	179839967-179877803	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051849, HPA058348, HPA070542	Uncertain		Enhanced	Endoplasmic reticulum	Renal cancer:2.29e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 34.1	Expressed in all		
TP53I11	PIG11	ENSG00000175274	Tumor protein p53 inducible protein 11	11	44885903-44951306	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059727, HPA061276	Uncertain		Supported	Endoplasmic reticulum<br>Golgi apparatus	Breast cancer:7.33e-5 (unfavourable), Renal cancer:4.65e-4 (unfavourable), Melanoma:6.12e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 58.4	Cell line enhanced		SCLC-21H: 453.7;T-47d: 206.4
TP53I13	DSCP1	ENSG00000167543	Tumor protein p53 inducible protein 13	17	29566052-29573157	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Renal cancer:2.10e-6 (unfavourable), Pancreatic cancer:3.13e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 53.3	Expressed in all		
TPBG	5T4, 5T4-AG	ENSG00000146242	Trophoblast glycoprotein	6	82363206-82370828	Predicted membrane proteins	Evidence at protein level	HPA010554	Enhanced		Approved	Nucleoplasm	Colorectal cancer:6.68e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 17.4	Cell line enhanced		hTEC/SVTERT24-B: 64.9
TPBGL		ENSG00000261594	Trophoblast glycoprotein-like	11	75240905-75243697	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		cerebral cortex: 3.1;testis: 5.0	adrenal gland: 2.3	Cell line enhanced		AF22: 1.5;HMC-1: 1.7;SCLC-21H: 2.2
TPCN1	FLJ20612, KIAA1169, TPC1	ENSG00000186815	Two pore segment channel 1	12	113221050-113298585	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA039757	Approved					Expressed in all	Expressed in all			thyroid gland: 53.5	Expressed in all		
TPCN2	TPC2	ENSG00000162341	Two pore segment channel 2	11	69048897-69162440	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA016561, HPA027080	Enhanced		Approved	Nucleoli	Ovarian cancer:1.49e-4 (unfavourable), Head and neck cancer:2.96e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 10.2	Expressed in all		
TPM1	C15orf13, CMH3	ENSG00000140416	Tropomyosin 1 (alpha)	15	63042632-63071915	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000261, HPA009066, CAB017698, HPA047089, HPA053624	Supported		Approved	Actin filaments<br>Cytosol	Urothelial cancer:7.30e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 7139.0	Expressed in all		
TPO	TPX	ENSG00000115705	Thyroid peroxidase	2	1374223-1543711	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007987, CAB009587	Enhanced					Tissue enriched	Tissue enriched	103	thyroid gland: 1817.4	spleen: 17.6	Cell line enhanced		Karpas-707: 6.9;RPMI-8226: 2.9
TPRA1	FLJ32197, GPR175, TMEM227, TPRA40	ENSG00000163870	Transmembrane protein adipocyte associated 1	3	127573069-127598251	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019784	Approved		Approved	Vesicles	Liver cancer:6.46e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 38.5	Expressed in all		
TPSG1	PRSS31, TMT	ENSG00000116176	Tryptase gamma 1	16	1221651-1225257	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA060458	Enhanced				Renal cancer:1.76e-8 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 14.6;duodenum: 14.3;rectum: 9.5;small intestine: 10.5	ovary: 2.5	Group enriched	8	HMC-1: 20.4;MCF7: 6.0
TPTE	CT44, PTEN2	ENSG00000274391	Transmembrane phosphatase with tensin homology	21	10521553-10606140	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA049690, HPA068342	Enhanced		Approved	Endoplasmic reticulum<br>Cytosol		Tissue enriched	Tissue enriched	247	testis: 191.3	placenta: 0.7	Cell line enhanced		BEWO: 6.4;K-562: 7.3;Karpas-707: 4.6;PC-3: 4.4;RPMI-8226: 6.2;U-2 OS: 4.3;U-266/70: 5.8
TPTE2	TPIP	ENSG00000132958	Transmembrane phosphoinositide 3-phosphatase and tensin homolog 2	13	19422877-19536762	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA068342			Approved	Endoplasmic reticulum<br>Cytosol		Tissue enriched	Tissue enriched	35	testis: 11.9	tonsil: 0.3	Cell line enhanced		HDLM-2: 4.4
TRABD	PP2447	ENSG00000170638	TraB domain containing	22	50185915-50199598	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA000822	Approved		Approved	Nucleus<br>Mitochondria	Endometrial cancer:1.19e-5 (favourable), Renal cancer:1.85e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 38.5	Expressed in all		
TRABD2A	C2orf89, TIKI1	ENSG00000186854	TraB domain containing 2A	2	84821650-84907008	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045817	Approved					Group enriched	Tissue enhanced		colon: 35.4;ovary: 30.7;rectum: 43.1	lymph node: 11.7	Cell line enhanced		BEWO: 38.1;HDLM-2: 29.0;hTEC/SVTERT24-B: 17.5;SiHa: 18.3
TRAF3IP3	T3JAM	ENSG00000009790	TRAF3 interacting protein 3	1	209756032-209782320	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040796	Enhanced		Approved	Vesicles	Breast cancer:4.11e-4 (favourable), Lung cancer:8.15e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 114.8;spleen: 82.5;tonsil: 82.8	appendix: 67.8	Cell line enhanced		HDLM-2: 106.9;Karpas-707: 33.1;MOLT-4: 48.2;NB-4: 43.3;THP-1: 43.1;U-266/70: 51.7
TRAM1	TRAM, TRAMP	ENSG00000067167	Translocation associated membrane protein 1	8	70573442-70608387	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA023929	Approved				Cervical cancer:2.06e-4 (unfavourable), Renal cancer:7.79e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 317.7	Expressed in all		
TRAM1L1	MGC26568	ENSG00000174599	Translocation associated membrane protein 1-like 1	4	117083554-117085576	Predicted membrane proteins	Evidence at transcript level	HPA044560	Uncertain		Approved	Mitochondria		Mixed	Mixed			cerebral cortex: 14.2	Cell line enhanced		SH-SY5Y: 9.5;U-138 MG: 10.8
TRAM2	KIAA0057	ENSG00000065308	Translocation associated membrane protein 2	6	52497402-52576915	Predicted membrane proteins	Evidence at protein level	HPA035092, HPA057925	Approved		Approved	Cytosol	Renal cancer:1.41e-9 (unfavourable), Endometrial cancer:1.88e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 52.1	Expressed in all		
TRAT1	HSPC062, TCRIM, TRIM	ENSG00000163519	T-cell receptor associated transmembrane adaptor 1	3	108822698-108855005	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002356, CAB026130	Enhanced					Mixed	Tissue enhanced		appendix: 14.0;lymph node: 26.4	spleen: 11.5	Cell line enriched	39	MOLT-4: 58.7
TRDN		ENSG00000186439	Triadin	6	123216339-123637093	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038226, HPA058226	Enhanced		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Group enriched	21	heart muscle: 273.5;skeletal muscle: 650.2	prostate: 22.2	Cell line enhanced		MCF7: 1.4
TREM1	CD354, TREM-1	ENSG00000124731	Triggering receptor expressed on myeloid cells 1	6	41267926-41286719	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005563	Uncertain					Tissue enhanced	Tissue enhanced		appendix: 67.7;bone marrow: 63.0;lung: 103.1	adipose tissue: 26.9	Cell line enriched	11	U-87 MG: 24.5
TREM2	TREM-2, Trem2a, Trem2b, Trem2c	ENSG00000095970	Triggering receptor expressed on myeloid cells 2	6	41158506-41163186	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010917, HPA012571	Approved				Liver cancer:4.24e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 37.0;lung: 40.5	adrenal gland: 16.1	Cell line enhanced		HBEC3-KT: 9.0;hTCEpi: 49.6;THP-1: 26.6
TREML1	dJ238O23.3, TLT1	ENSG00000161911	Triggering receptor expressed on myeloid cells like 1	6	41149342-41154337	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA016700, HPA017860	Enhanced					Mixed	Tissue enhanced		bone marrow: 5.0;lymph node: 6.5	tonsil: 4.4	Cell line enriched	176	HEL: 59.6
TREML2	C6orf76, dJ238O23.1, FLJ13693, TLT2	ENSG00000112195	Triggering receptor expressed on myeloid cells like 2	6	41190277-41201194	Plasma proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 9.3;bone marrow: 10.0;lymph node: 11.9	spleen: 8.8	Cell line enhanced		HEL: 26.9;HL-60: 5.6;U-698: 5.8;U-937: 4.3
TREML4	TLT4	ENSG00000188056	Triggering receptor expressed on myeloid cells like 4	6	41228324-41238882	Predicted membrane proteins	Evidence at transcript level	HPA065044	Uncertain					Not detected	Not detected			spleen: 0.4	Not detected		
TREX1	AGS1, DRN3	ENSG00000213689	Three prime repair exonuclease 1	3	48465811-48467645	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA035437, HPA046721	Supported		Supported	Cytosol		Not detected	Expressed in all			spleen: 30.9	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 66.5
TRHDE	PAP-II, PGPEP2, TRH-DE	ENSG00000072657	Thyrotropin releasing hormone degrading enzyme	12	72087266-72670757	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.53e-7 (favourable)	Tissue enhanced	Mixed			cerebral cortex: 7.9	Cell line enhanced		BJ: 25.6;BJ hTERT+: 23.6;EFO-21: 14.6
TRHR		ENSG00000174417	Thyrotropin releasing hormone receptor	8	109086621-109119584	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA055162	Supported					Not detected	Not detected			thyroid gland: 0.2	Not detected		
TRIB2	GS3955, TRB2	ENSG00000071575	Tribbles pseudokinase 2	2	12716889-12742734	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA001305	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			ovary: 117.2	Cell line enhanced		AN3-CA: 170.0;K-562: 229.8;WM-115: 243.3
TRIL	KIAA0644	ENSG00000255690	TLR4 interactor with leucine rich repeats	7	28953358-28958292	Predicted membrane proteins	Evidence at protein level						Endometrial cancer:3.23e-4 (unfavourable), Ovarian cancer:8.52e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 24.9	kidney: 5.7	Cell line enhanced		AF22: 22.0;SH-SY5Y: 42.6;SK-BR-3: 26.9;T-47d: 14.9
TRIM13	DLEU5, Leu5, RFP2, RNF77	ENSG00000204977	Tripartite motif containing 13	13	49995888-50020481	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000367	Enhanced					Expressed in all	Expressed in all			testis: 141.2	Expressed in all		
TRIM55	MURF-2, RNF29	ENSG00000147573	Tripartite motif containing 55	8	66126896-66175487	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038793, HPA053691	Approved		Approved	Golgi apparatus<br>Cytosol		Group enriched	Tissue enhanced		heart muscle: 40.0;liver: 19.7	testis: 13.2	Cell line enriched	17	LHCN-M2: 356.6
TRIM59	Mrf1, RNF104, TRIM57, TSBF1	ENSG00000213186	Tripartite motif containing 59	3	160432445-160485773	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017750	Uncertain		Approved	Rods & Rings	Pancreatic cancer:1.15e-5 (unfavourable), Cervical cancer:4.36e-4 (favourable)	Mixed	Mixed			cerebral cortex: 18.3	Mixed		
TRIQK	C8orf83, DKFZp779L1068, LOC286144, PRO0845	ENSG00000205133	Triple QxxK/R motif containing	8	92883530-93017673	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA076853			Supported	Endoplasmic reticulum		Expressed in all	Mixed			thyroid gland: 39.2	Mixed		
TRPA1	ANKTM1	ENSG00000104321	Transient receptor potential cation channel subfamily A member 1	8	72019917-72075617	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Colorectal cancer:6.57e-4 (favourable)	Mixed	Tissue enhanced		urinary bladder: 29.5	gallbladder: 11.4	Cell line enriched	5	HHSteC: 21.8
TRPC1	HTRP-1	ENSG00000144935	Transient receptor potential cation channel subfamily C member 1	3	142724074-142807888	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB009387, HPA021130	Supported		Approved	Vesicles	Renal cancer:2.72e-5 (unfavourable)	Mixed	Mixed			endometrium: 18.6	Mixed		
TRPC3		ENSG00000138741	Transient receptor potential cation channel subfamily C member 3	4	121879027-121951754	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA037969	Uncertain					Not detected	Tissue enhanced		smooth muscle: 4.1	cerebral cortex: 2.1	Cell line enhanced		HEK93: 1.6;HEL: 2.4;Karpas-707: 1.9;U-2 OS: 1.8
TRPC4	HTRP4, TRP4	ENSG00000133107	Transient receptor potential cation channel subfamily C member 4	13	37636636-37870425	Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enhanced		endometrium: 18.6;seminal vesicle: 12.1;smooth muscle: 18.5	prostate: 10.8	Cell line enhanced		AF22: 8.0;BJ: 16.3;BJ hTERT+ SV40 Large T+: 7.5;fHDF/TERT166: 14.3;U-2197: 8.0
TRPC5	PPP1R159	ENSG00000072315	Transient receptor potential cation channel subfamily C member 5	X	111774315-112082776	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 1.9	liver: 0.4	Cell line enriched	5	NTERA-2: 1.7
TRPC6	FSGS2, TRP6	ENSG00000137672	Transient receptor potential cation channel subfamily C member 6	11	101451564-101872562	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA045098, HPA062164	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		placenta: 30.1	lung: 20.0	Cell line enhanced		A549: 4.4;ASC diff: 6.0;BJ hTERT+: 3.9;HEL: 4.3;RPTEC TERT1: 16.5
TRPC7		ENSG00000069018	Transient receptor potential cation channel subfamily C member 7	5	136213320-136365537	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	CAB022592, HPA031126	Uncertain		Uncertain	Actin filaments<br>Focal adhesion sites		Not detected	Not detected			testis: 0.7	Not detected		
TRPM1	CSNB1C, LTRPC1, MLSN1	ENSG00000134160	Transient receptor potential cation channel subfamily M member 1	15	31001061-31161273	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA014779, HPA014785	Supported		Uncertain	Nucleoplasm<br>Cytosol		Tissue enriched	Group enriched	26	skin: 4.8;testis: 2.1	kidney: 0.1	Cell line enriched	91	SK-MEL-30: 9.1
TRPM2	EREG1, KNP3, LTRPC2, NUDT9H, NUDT9L1, TRPC7	ENSG00000142185	Transient receptor potential cation channel subfamily M member 2	21	44350163-44443081	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030976, HPA035260	Enhanced		Approved	Nuclear membrane	Renal cancer:4.39e-6 (unfavourable), Urothelial cancer:7.59e-4 (favourable), Endometrial cancer:9.28e-4 (favourable)	Expressed in all	Mixed			bone marrow: 18.8	Cell line enhanced		HL-60: 33.1;NB-4: 37.1;THP-1: 48.2;U-937: 52.8
TRPM3	GON-2, KIAA1616, LTRPC3	ENSG00000083067	Transient receptor potential cation channel subfamily M member 3	9	70529063-71446904	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enhanced		kidney: 17.6	testis: 5.6	Cell line enriched	5	HAP1: 17.8
TRPM4	FLJ20041	ENSG00000130529	Transient receptor potential cation channel subfamily M member 4	19	49157741-49211836	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA041169	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:2.53e-7 (favourable), Endometrial cancer:2.88e-7 (favourable)	Expressed in all	Mixed			prostate: 29.4	Cell line enhanced		RT4: 47.8
TRPM5	LTRPC5, MTR1	ENSG00000070985	Transient receptor potential cation channel subfamily M member 5	11	2404515-2423045	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA042115, HPA043315	Uncertain					Tissue enhanced	Group enriched	5	colon: 1.0;duodenum: 2.9;epididymis: 2.2;seminal vesicle: 2.5;small intestine: 2.9	testis,thyroid gland: 0.4	Not detected		
TRPM6	CHAK2, FLJ22628, HOMG, HSH	ENSG00000119121	Transient receptor potential cation channel subfamily M member 6	9	74722495-74888094	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enhanced		colon: 13.1;rectum: 18.2	small intestine: 8.7	Cell line enhanced		BEWO: 3.7;HeLa: 1.5;RT4: 3.0
TRPM7	CHAK1, LTRPC7, TRP-PLIK	ENSG00000092439	Transient receptor potential cation channel subfamily M member 7	15	50552473-50686815	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA052173	Enhanced		Approved	Nucleoplasm		Expressed in all	Tissue enriched	7	parathyroid gland: 216.4	thyroid gland: 29.0	Expressed in all		
TRPM8		ENSG00000144481	Transient receptor potential cation channel subfamily M member 8	2	233917398-234019522	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level						Liver cancer:7.15e-4 (favourable)	Tissue enriched	Tissue enriched	8	prostate: 127.3	liver: 16.2	Cell line enhanced		Karpas-707: 3.9;RPTEC TERT1: 6.2;SK-MEL-30: 6.6;WM-115: 5.0
TRPV1	VR1	ENSG00000196689	Transient receptor potential cation channel subfamily V member 1	17	3565444-3609411	FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Not detected	Mixed			duodenum: 7.8	Mixed		
TRPV2	VRL, VRL-1, VRL1	ENSG00000187688	Transient receptor potential cation channel subfamily V member 2	17	16415542-16437003	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044993	Uncertain		Supported	Plasma membrane	Renal cancer:1.19e-6 (unfavourable), Testis cancer:5.53e-4 (unfavourable)	Tissue enriched	Mixed			lung: 44.1	Cell line enhanced		fHDF/TERT166: 83.8;HMC-1: 77.5;SK-MEL-30: 73.0;TIME: 68.5
TRPV3	VRL3	ENSG00000167723	Transient receptor potential cation channel subfamily V member 3	17	3510502-3557995	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA069550			Approved	Plasma membrane<br>Centrosome<br>Cytosol		Mixed	Tissue enhanced		skin: 5.1;small intestine: 4.5	duodenum: 1.7	Cell line enhanced		BEWO: 3.6;RH-30: 9.0;T-47d: 3.7
TRPV4	CMT2C, OTRPC4, TRP12, VR-OAC, VRL-2, VROAC	ENSG00000111199	Transient receptor potential cation channel subfamily V member 4	12	109783085-109833401	Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA007150	Uncertain				Renal cancer:4.12e-5 (favourable), Ovarian cancer:8.10e-4 (unfavourable)	Expressed in all	Mixed			kidney: 11.8	Cell line enhanced		BEWO: 9.1;HaCaT: 13.9
TRPV5	CaT2, ECAC1	ENSG00000127412	Transient receptor potential cation channel subfamily V member 5	7	142908101-142933808	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA063175	Approved					Not detected	Not detected			kidney: 0.5	Not detected		
TRPV6	CaT1, ECAC2	ENSG00000165125	Transient receptor potential cation channel subfamily V member 6	7	142871203-142885762	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA062864	Approved					Tissue enriched	Tissue enhanced		prostate: 37.4;salivary gland: 28.9	placenta: 16.7	Cell line enhanced		HaCaT: 16.0;RT4: 26.0;SK-BR-3: 17.7;T-47d: 49.5
TRRAP	PAF400, TR-AP, Tra1	ENSG00000196367	Transformation/transcription domain associated protein	7	98877933-99013243	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054376			Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:8.77e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.6	Expressed in all		
TSC1	hamartin, KIAA0243, LAM, TSC	ENSG00000165699	Tuberous sclerosis 1	9	132891348-132944633	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011568, CAB012481, HPA074132	Supported		Enhanced	Cytosol	Liver cancer:6.03e-6 (unfavourable), Renal cancer:7.91e-4 (favourable), Pancreatic cancer:8.01e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.7	Expressed in all		
TSC2	LAM, PPP1R160, TSC4, tuberin	ENSG00000103197	Tuberous sclerosis 2	16	2047465-2088720	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002225, HPA030409, HPA049679	Approved		Enhanced	Cytosol	Pancreatic cancer:5.06e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 36.7	Expressed in all		
TSHR	LGR3	ENSG00000165409	Thyroid stimulating hormone receptor	14	80954989-81146302	Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000473	Approved					Tissue enriched	Tissue enriched	282	thyroid gland: 445.5	lymph node: 1.5	Cell line enhanced		MOLT-4: 18.4;SCLC-21H: 25.2;U-266/70: 7.9
TSN	BCLF-1, REHF-1, TRSLN	ENSG00000211460	Translin	2	121737103-121767853	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059561	Uncertain				Liver cancer:3.06e-4 (unfavourable), Endometrial cancer:7.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.1	Expressed in all		
TSNARE1	FLJ31164	ENSG00000171045	T-SNARE domain containing 1	8	142212080-142403240	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015890			Approved	Nucleus	Urothelial cancer:7.33e-4 (favourable)	Expressed in all	Expressed in all			skin: 29.2	Mixed		
TSPAN1	NET-1, TSPAN-1	ENSG00000117472	Tetraspanin 1	1	46175073-46185958	Predicted membrane proteins	Evidence at protein level	HPA011909	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:9.28e-6 (favourable)	Expressed in all	Tissue enhanced		colon: 525.0;rectum: 651.6	prostate: 311.2	Cell line enhanced		CAPAN-2: 191.2;HaCaT: 134.4;hTCEpi: 125.3;RPTEC TERT1: 474.4;RT4: 246.2
TSPAN10	OCSP	ENSG00000182612	Tetraspanin 10	17	81637171-81648749	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		skin: 1.5	lymph node: 1.0	Cell line enhanced		SK-MEL-30: 13.4;U-87 MG: 7.4
TSPAN11		ENSG00000110900	Tetraspanin 11	12	30926428-30996599	Predicted membrane proteins	Evidence at protein level	HPA066789			Approved	Vesicles	Lung cancer:3.43e-4 (favourable), Head and neck cancer:5.28e-4 (favourable)	Mixed	Mixed			cerebral cortex: 17.9	Group enriched	5	AF22: 26.8;HSkMC: 19.0;NTERA-2: 21.6;SCLC-21H: 12.2;SH-SY5Y: 21.8
TSPAN12	NET-2, TM4SF12	ENSG00000106025	Tetraspanin 12	7	120787320-120858402	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051570, HPA058244	Uncertain		Approved	Vesicles<br>Microtubules		Expressed in all	Mixed			kidney: 91.5	Cell line enhanced		HEK93: 47.4;HUVEC TERT2: 48.1;RH-30: 50.5;RPTEC TERT1: 63.2;RT4: 52.1
TSPAN13	NET-6, TM4SF13	ENSG00000106537	Tetraspanin 13	7	16753535-16784536	Predicted membrane proteins	Evidence at protein level	HPA007426	Uncertain		Approved	Nucleus	Glioma:5.27e-5 (unfavourable), Ovarian cancer:2.20e-4 (favourable), Renal cancer:2.43e-4 (unfavourable), Liver cancer:2.94e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 246.2	Cell line enhanced		SCLC-21H: 223.6;SK-BR-3: 207.6;T-47d: 488.1
TSPAN14	DC-TM4F2, MGC11352, TM4SF14	ENSG00000108219	Tetraspanin 14	10	80454166-80533123	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014773, HPA057174	Uncertain		Supported	Vesicles	Cervical cancer:3.56e-4 (favourable), Renal cancer:4.20e-4 (favourable)	Expressed in all	Expressed in all			placenta: 129.4	Mixed		
TSPAN15	NET-7, TM4SF15	ENSG00000099282	Tetraspanin 15	10	69451473-69507669	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044657	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.25e-4 (unfavourable), Liver cancer:8.00e-4 (unfavourable)	Expressed in all	Mixed			stomach: 72.3	Cell line enhanced		CAPAN-2: 136.3;EFO-21: 199.5;MCF7: 128.3;PC-3: 248.2
TSPAN16	TM-8, TM4-B, TM4SF16	ENSG00000130167	Tetraspanin 16	19	11296139-11326996	Predicted membrane proteins	Evidence at protein level	HPA041579	Approved					Not detected	Tissue enriched	46	testis: 154.0	bone marrow: 3.3	Not detected		
TSPAN17	FBX23, FBXO23, TM4SF17	ENSG00000048140	Tetraspanin 17	5	176647387-176659054	Predicted membrane proteins	Evidence at transcript level	HPA030447			Approved	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 34.7	Expressed in all		
TSPAN18	TSPAN	ENSG00000157570	Tetraspanin 18	11	44726465-44932421	Predicted membrane proteins	Evidence at protein level							Expressed in all	Mixed			smooth muscle: 69.3	Cell line enhanced		AF22: 36.4;CAPAN-2: 54.1;HDLM-2: 47.8;NTERA-2: 34.7;RH-30: 37.3;SCLC-21H: 38.6;SH-SY5Y: 39.5
TSPAN19		ENSG00000231738	Tetraspanin 19	12	85014311-85036277	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA057066	Uncertain					Not detected	Tissue enhanced		testis: 8.1	lung: 4.3	Cell line enhanced		SCLC-21H: 3.1
TSPAN2	FLJ12082, TSN2, TSPAN-2	ENSG00000134198	Tetraspanin 2	1	115048011-115089500	Predicted membrane proteins	Evidence at protein level	HPA015640	Uncertain		Approved	Nucleoplasm	Renal cancer:8.48e-7 (unfavourable), Endometrial cancer:8.89e-4 (unfavourable)	Mixed	Tissue enhanced		endometrium: 71.7;smooth muscle: 64.6	seminal vesicle: 40.5	Cell line enhanced		EFO-21: 58.1;U-937: 21.9
TSPAN3	TM4-A, TM4SF8, TSPAN-3	ENSG00000140391	Tetraspanin 3	15	77041404-77083984	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA015996	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			epididymis: 527.2	Expressed in all		
TSPAN31	SAS	ENSG00000135452	Tetraspanin 31	12	57738013-57750211	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057489	Approved				Renal cancer:9.91e-5 (favourable), Head and neck cancer:1.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.5	Expressed in all		
TSPAN32	PHEMX, TSSC6	ENSG00000064201	Tetraspanin 32	11	2301997-2318200	Predicted membrane proteins	Evidence at protein level	HPA024135	Uncertain					Mixed	Tissue enhanced		bone marrow: 12.0;heart muscle: 7.6	lymph node: 6.3	Group enriched	7	HEL: 13.1;HL-60: 5.1;NB-4: 3.3;THP-1: 3.8;U-937: 6.9
TSPAN33	MGC50844, Penumbra	ENSG00000158457	Tetraspanin 33	7	129144892-129169697	Predicted membrane proteins, Transporters	Evidence at protein level	HPA020357	Approved		Approved	Microtubules	Renal cancer:8.74e-5 (favourable), Pancreatic cancer:8.88e-4 (favourable)	Expressed in all	Expressed in all			kidney: 127.3	Cell line enhanced		AN3-CA: 48.8;HEL: 76.0;U-266/70: 73.4
TSPAN4	NAG-2, TETRASPAN, TM4SF7, TSPAN-4	ENSG00000214063	Tetraspanin 4	11	842808-867116	Predicted membrane proteins	Evidence at protein level						Liver cancer:1.02e-4 (unfavourable), Glioma:2.57e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 105.4	Expressed in all		
TSPAN5	NET-4, TM4SF9, Tspan-5	ENSG00000168785	Tetraspanin 5	4	98470367-98658629	Predicted membrane proteins	Evidence at protein level						Renal cancer:7.83e-5 (unfavourable), Stomach cancer:8.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 75.9	ovary: 57.2	Mixed		
TSPAN6	T245, TM4SF6, TSPAN-6	ENSG00000000003	Tetraspanin 6	X	100627109-100639991	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004109	Approved		Approved	Cytosol		Expressed in all	Mixed			fallopian tube: 102.1	Cell line enhanced		NTERA-2: 165.6;RT4: 203.5
TSPAN7	A15, CD231, DXS1692E, MRX58, MXS1, TALLA-1, TM4SF2	ENSG00000156298	Tetraspanin 7	X	38561370-38688920	CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003140, CAB062566, CAB068245	Enhanced				Renal cancer:5.48e-7 (favourable), Pancreatic cancer:1.70e-4 (favourable), Endometrial cancer:3.40e-4 (unfavourable)	Expressed in all	Tissue enriched	6	cerebral cortex: 574.4	adrenal gland: 99.2	Cell line enhanced		HDLM-2: 39.2;MOLT-4: 141.6;SCLC-21H: 109.6;U-266/70: 47.0
TSPAN8	CO-029, TM4SF3	ENSG00000127324	Tetraspanin 8	12	71125085-71441898	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	CAB026009, HPA044337	Enhanced		Approved	Nucleoplasm	Urothelial cancer:7.36e-5 (favourable), Renal cancer:9.66e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 910.6;duodenum: 905.9;rectum: 911.5;small intestine: 909.2	stomach: 573.4	Cell line enhanced		CACO-2: 36.0;HeLa: 34.8;PC-3: 151.7;RT4: 30.6
TSPAN9	NET-5	ENSG00000011105	Tetraspanin 9	12	3077355-3286564	Predicted membrane proteins	Evidence at protein level	HPA014002	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Melanoma:4.67e-4 (unfavourable)	Expressed in all	Mixed			heart muscle: 79.9	Cell line enhanced		RH-30: 185.6
TSPO	BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS	ENSG00000100300	Translocator protein	22	43151514-43163242	Cancer-related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB011232, HPA046260	Uncertain		Approved	Vesicles<br>Mitochondria<br>Cytosol	Liver cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 300.6	Mixed		
TSPO2	BZRPL1, dJ34B21.2	ENSG00000112212	Translocator protein 2	6	41042554-41044337	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA066996	Uncertain					Mixed	Tissue enriched	17	bone marrow: 30.8	placenta: 1.8	Cell line enhanced		CACO-2: 1.3
TSSK1B	FKSG81, SPOGA4, STK22D, TSSK1	ENSG00000212122	Testis specific serine kinase 1B	5	113432554-113435031	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA027827	Enhanced					Not detected	Tissue enriched	222	testis: 62.0	skin: 0.2	Not detected		
TSSK2	FLJ38613, SPOGA2, STK22B	ENSG00000206203	Testis specific serine kinase 2	22	19130808-19132623	Enzymes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	290	testis: 120.4	ovary: 0.4	Cell line enhanced		SCLC-21H: 1.0
TSSK4	C14orf20, STK22E	ENSG00000139908	Testis specific serine kinase 4	14	24205697-24208362	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060660, HPA077103	Enhanced		Approved	Cell Junctions		Mixed	Tissue enhanced		testis: 42.2	skin: 10.1	Mixed		
TTC13	FLJ22584	ENSG00000143643	Tetratricopeptide repeat domain 13	1	230906243-230978875	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018022, HPA051558	Uncertain		Approved	Nucleoplasm	Renal cancer:1.60e-11 (unfavourable), Pancreatic cancer:4.59e-5 (favourable), Head and neck cancer:7.66e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 23.0	Expressed in all		
TTC14	FLJ00166, KIAA1980	ENSG00000163728	Tetratricopeptide repeat domain 14	3	180602130-180617828	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009295	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 60.8	Expressed in all		
TTC3	DCRR1, RNF105, TPRD, TPRDI, TPRDII, TPRDIII	ENSG00000182670	Tetratricopeptide repeat domain 3	21	37073226-37203112	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016810, HPA023964, HPA036304	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 108.0	Expressed in all		
TTC33	OSRF	ENSG00000113638	Tetratricopeptide repeat domain 33	5	40512333-40755975	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038252, HPA038253	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:1.83e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 25.6	Expressed in all		
TTC39A	C1orf34, DEME-6, KIAA0452	ENSG00000085831	Tetratricopeptide repeat domain 39A	1	51287258-51345116	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028098, HPA043440	Uncertain		Approved	Centrosome	Liver cancer:5.05e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 87.4	breast: 53.8	Cell line enhanced		HDLM-2: 65.0;MCF7: 42.1;SK-BR-3: 123.3;T-47d: 112.3
TTC39B	C9orf52, FLJ33868	ENSG00000155158	Tetratricopeptide repeat domain 39B	9	15163622-15307360	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054804, HPA063162	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:4.08e-7 (favourable), Lung cancer:9.64e-6 (favourable)	Expressed in all	Mixed			gallbladder: 11.0	Cell line enhanced		HEL: 36.6
TTC39C	C18orf17, FLJ33761, HsT2697	ENSG00000168234	Tetratricopeptide repeat domain 39C	18	23992773-24135610	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065705, HPA065713	Approved		Approved	Nucleoplasm	Renal cancer:2.60e-5 (unfavourable), Breast cancer:1.48e-4 (favourable)	Expressed in all	Expressed in all			liver: 47.8	Mixed		
TTC8	BBS8, RP51	ENSG00000165533	Tetratricopeptide repeat domain 8	14	88824153-88881078	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:1.69e-5 (favourable), Renal cancer:4.89e-4 (favourable), Ovarian cancer:7.77e-4 (favourable)	Expressed in all	Expressed in all			ovary: 91.0	Expressed in all		
TTI2	C8orf41, FLJ23263	ENSG00000129696	TELO2 interacting protein 2	8	33473386-33513601	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023523, HPA029823	Approved		Enhanced	Centrosome		Expressed in all	Mixed			testis: 22.1	Expressed in all		
TTN	CMD1G, CMH9, CMPD4, FLJ32040, LGMD2J, MYLK5, TMD	ENSG00000155657	Titin	2	178525989-178830802	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007042, CAB022682, HPA030048	Enhanced					Tissue enhanced	Tissue enriched	7	skeletal muscle: 322.5	heart muscle: 46.7	Mixed		
TTYH1		ENSG00000167614	Tweety family member 1	19	54415219-54436900	Predicted membrane proteins, Transporters	Evidence at protein level	HPA023617, HPA050655	Approved				Breast cancer:3.64e-4 (favourable)	Tissue enriched	Tissue enriched	27	cerebral cortex: 57.7	fallopian tube,testis: 2.1	Group enriched	6	AF22: 5.8;AN3-CA: 17.4;U-2 OS: 7.0
TTYH2	C17orf29	ENSG00000141540	Tweety family member 2	17	74213514-74262020	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:9.74e-5 (unfavourable)	Group enriched	Tissue enriched	6	cerebral cortex: 129.2	testis: 21.8	Cell line enhanced		SK-MEL-30: 62.2
TTYH3	KIAA1691	ENSG00000136295	Tweety family member 3	7	2631951-2664802	Predicted membrane proteins	Evidence at protein level	HPA053520	Uncertain				Liver cancer:2.53e-5 (unfavourable), Renal cancer:2.58e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 62.2	Expressed in all		
TUBA8	TUBAL2	ENSG00000183785	Tubulin alpha 8	22	18110331-18146554	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043684, CAB046031, HPA063394	Approved		Supported	Microtubules		Not detected	Group enriched	6	cerebral cortex: 28.6;heart muscle: 83.0;skeletal muscle: 121.7;testis: 47.4	thyroid gland: 11.2	Group enriched	5	NB-4: 19.8;SCLC-21H: 17.4;TIME: 31.1
TUNAR	HI-LNC78, LINC00617, TUNA	ENSG00000250366	TCL1 upstream neural differentiation-associated RNA	14	95876392-95925571	Predicted membrane proteins	Evidence at transcript level						Renal cancer:1.55e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 4.0;endometrium: 1.8;fallopian tube: 2.5	seminal vesicle: 1.3	Cell line enhanced		AF22: 3.2;NTERA-2: 6.8;SCLC-21H: 7.9
TUSC3	MGC13453, MRT7, N33, OST3A	ENSG00000104723	Tumor suppressor candidate 3	8	15417215-15766649	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049851, HPA049974	Approved				Thyroid cancer:7.86e-4 (favourable)	Expressed in all	Mixed			epididymis: 143.1	Mixed		
TUSC5	IFITMD3, LOST1	ENSG00000184811	Tumor suppressor candidate 5	17	1279663-1300987	Predicted membrane proteins	Evidence at protein level	HPA050825	Approved					Tissue enhanced	Tissue enriched	18	adipose tissue: 110.0	breast: 6.1	Cell line enriched	207	ASC diff: 20.6
TVP23A	FAM18A, YDR084C	ENSG00000166676	Trans-golgi network vesicle protein 23 homolog A	16	10760919-10818794	Predicted membrane proteins	Evidence at transcript level	HPA060582	Uncertain		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.3	ovary: 3.2	Cell line enhanced		SH-SY5Y: 2.2
TVP23B	CGI-148, FAM18B, FAM18B1, YDR084C	ENSG00000171928	Trans-golgi network vesicle protein 23 homolog B	17	18780995-18806714	Predicted membrane proteins	Evidence at protein level	HPA019585, HPA065603	Uncertain		Approved	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 78.5	Expressed in all		
TVP23C	FAM18B2, MGC8763	ENSG00000175106	Trans-golgi network vesicle protein 23 homolog C	17	15502264-15563595	Predicted membrane proteins	Evidence at protein level	HPA019585, HPA065603	Uncertain		Enhanced	Golgi apparatus		Mixed	Mixed			thyroid gland: 10.3	Mixed		
TVP23C-CDRT4	FAM18B2-CDRT4	ENSG00000259024	TVP23C-CDRT4 readthrough	17	15436021-15563561	Predicted membrane proteins	Evidence at transcript level	HPA065603			Approved	Golgi apparatus		Not detected	Mixed			parathyroid gland: 11.8	Mixed		
TXNDC11	EFP1	ENSG00000153066	Thioredoxin domain containing 11	16	11679080-11742878	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041174, HPA041390	Supported		Supported	Plasma membrane<br>Cytosol	Endometrial cancer:2.12e-5 (favourable), Glioma:8.01e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 84.5	Expressed in all		
TXNDC15	2310047H23Rik, C5orf14, FLJ22625	ENSG00000113621	Thioredoxin domain containing 15	5	134873803-134901525	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015483	Approved		Approved	Golgi apparatus	Renal cancer:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 85.3	Expressed in all		
TXNDC16	KIAA1344	ENSG00000087301	Thioredoxin domain containing 16	14	52430590-52552522	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002543	Approved		Approved	Mitochondria	Renal cancer:6.79e-4 (favourable)	Expressed in all	Tissue enhanced		prostate: 43.0	seminal vesicle: 18.3	Cell line enhanced		SCLC-21H: 34.2
TYR	OCA1, OCA1A, OCAIA	ENSG00000077498	Tyrosinase	11	89177452-89295759	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB000079, HPA043241, HPA050889	Enhanced		Enhanced	Vesicles		Tissue enriched	Tissue enriched	33	skin: 29.8	breast: 0.9	Cell line enriched	1211	SK-MEL-30: 256.2
TYRO3	Brt, Dtk, Etk-2, Rek, RSE, Sky, Tif	ENSG00000092445	TYRO3 protein tyrosine kinase	15	41557675-41583586	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA071245	Approved					Expressed in all	Tissue enhanced		cerebral cortex: 67.4;ovary: 61.6	testis: 37.0	Cell line enhanced		BEWO: 66.6
TYROBP	DAP12, KARAP, PLO-SL, PLOSL	ENSG00000011600	TYRO protein tyrosine kinase binding protein	19	35904401-35908295	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB009493, HPA041899	Enhanced				Renal cancer:1.05e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 386.8	Group enriched	8	HMC-1: 603.3;THP-1: 266.6
TYRP1	b-PROTEIN, CAS2, CATB, GP75, OCA3, TRP, TYRP	ENSG00000107165	Tyrosinase related protein 1	9	12685439-12710290	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000937, CAB002520	Enhanced		Supported	Vesicles		Tissue enriched	Group enriched	6	heart muscle: 40.2;skin: 169.1	kidney: 17.0	Cell line enriched	51	SK-MEL-30: 1084.9
TYW1	FLJ10900, MGC23001, MGC60291, RSAFD1, TYW1A, YPL207W	ENSG00000198874	TRNA-yW synthesizing protein 1 homolog	7	66995173-67239519	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA013568, HPA014118, HPA015535, HPA043136, HPA047029, HPA047052, HPA052097	Approved		Approved	Nucleus<br>Nucleoli	Ovarian cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
TYW1B	LINC00069, MGC87315, NCRNA00069, RSAFD2	ENSG00000277149	TRNA-yW synthesizing protein 1 homolog B	7	72558744-72828198	Predicted membrane proteins	Evidence at protein level	HPA013568, HPA014118, HPA043136, HPA047029, HPA047052, HPA052097	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			ovary: 6.7	Mixed		
UBA1	A1S9T, CFAP124, GXP1, POC20, UBE1, UBE1X	ENSG00000130985	Ubiquitin like modifier activating enzyme 1	X	47190861-47215128	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000289, HPA001506, CAB019435, CAB073410	Approved		Enhanced	Nucleoplasm	Liver cancer:6.10e-5 (unfavourable), Thyroid cancer:1.78e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 239.4	Expressed in all		
UBA2	ARX, FLJ13058, HRIHFB2115, SAE2	ENSG00000126261	Ubiquitin like modifier activating enzyme 2	19	34428352-34471251	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041436	Supported		Supported	Nucleoplasm	Liver cancer:3.76e-4 (unfavourable), Renal cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 168.1	Expressed in all		
UBA5	FLJ23251, UBE1DC1	ENSG00000081307	Ubiquitin like modifier activating enzyme 5	3	132654446-132678097	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017235	Uncertain		Enhanced	Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 64.2	Expressed in all		
UBA7	D8, UBA1B, UBE1L, UBE2	ENSG00000182179	Ubiquitin like modifier activating enzyme 7	3	49805207-49813946	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB015444, HPA058182	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:1.04e-5 (unfavourable), Urothelial cancer:1.48e-4 (favourable), Breast cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			spleen: 65.5	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 55.3;HMC-1: 91.3
UBAC2	FLJ30548, PHGDHL1, RP11-178C10.1	ENSG00000134882	UBA domain containing 2	13	99200774-99386434	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013448	Approved		Approved	Cytosol	Pancreatic cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 35.8	Expressed in all		
UBE2J1	CGI-76, HSPC153, NCUBE1, UBC6	ENSG00000198833	Ubiquitin conjugating enzyme E2 J1	6	89326625-89352848	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA003509, CAB073419	Enhanced				Liver cancer:6.90e-5 (unfavourable), Renal cancer:1.11e-4 (unfavourable), Endometrial cancer:2.87e-4 (favourable), Ovarian cancer:7.43e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 102.3	Mixed		
UBE2J2	NCUBE2, Ubc6p	ENSG00000160087	Ubiquitin conjugating enzyme E2 J2	1	1253909-1273885	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.00e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 115.2	Expressed in all		
UBE3A	ANCR, AS, E6-AP, EPVE6AP, FLJ26981, HPVE6A	ENSG00000114062	Ubiquitin protein ligase E3A	15	25333728-25439056	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009723, HPA039410, HPA040380	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 86.1	Expressed in all		
UBIAD1	SCCD, TERE1	ENSG00000120942	UbiA prenyltransferase domain containing 1	1	11273206-11296049	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA044862			Approved	Vesicles	Renal cancer:6.80e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 15.8	Expressed in all		
UBR1		ENSG00000159459	Ubiquitin protein ligase E3 component n-recognin 1	15	42942897-43106113	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038838	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 27.4	Expressed in all		
UBR2	bA49A4.1, C6orf133, dJ392M17.3, KIAA0349	ENSG00000024048	Ubiquitin protein ligase E3 component n-recognin 2	6	42564062-42693504	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027869, HPA027880	Approved		Approved	Nucleoplasm<br>Plasma membrane	Ovarian cancer:1.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.5	Expressed in all		
UBR3	DKFZp434P117, FLJ37422, KIAA2024, ZNF650	ENSG00000144357	Ubiquitin protein ligase E3 component n-recognin 3 (putative)	2	169827458-170084131	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035390	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 39.6	Expressed in all		
UBR4	KIAA0462, KIAA1307, RBAF600, ZUBR1	ENSG00000127481	Ubiquitin protein ligase E3 component n-recognin 4	1	19074506-19210276	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013394, HPA021046	Approved		Supported	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			skin: 90.3	Expressed in all		
UBXN4	KIAA0242, UBXD2, UBXDC1	ENSG00000144224	UBX domain protein 4	2	135741619-135785055	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036325	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			thyroid gland: 105.0	Expressed in all		
UBXN8	D8S2298E, REP8, UBXD6	ENSG00000104691	UBX domain protein 8	8	30732247-30767006	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017725, HPA077538	Approved		Supported	Nucleoplasm<br>Nucleoli<br>Endoplasmic reticulum	Renal cancer:5.25e-5 (unfavourable), Colorectal cancer:6.13e-4 (favourable)	Expressed in all	Expressed in all			ovary: 109.4	Expressed in all		
UCP1	SLC25A7, UCP	ENSG00000109424	Uncoupling protein 1	4	140559434-140568805	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enhanced		adrenal gland: 3.7	breast: 0.9	Group enriched	16	BEWO: 4.9;HAP1: 3.8
UGCG	GCS	ENSG00000148154	UDP-glucose ceramide glucosyltransferase	9	111896766-111935369	Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA024124	Approved				Endometrial cancer:4.44e-5 (favourable), Cervical cancer:6.62e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 84.1	Expressed in all		
UGT1A1	GNT1, UGT1, UGT1A	ENSG00000241635	UDP glucuronosyltransferase family 1 member A1	2	233760248-233773299	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	33	duodenum: 199.5;liver: 155.8;small intestine: 81.9	kidney: 4.3	Cell line enhanced		HaCaT: 12.7;PC-3: 6.0;RT4: 27.4
UGT1A10	UGT1J	ENSG00000242515	UDP glucuronosyltransferase family 1 member A10	2	233636454-233773305	Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:4.55e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 49.7;duodenum: 80.9;small intestine: 59.1	rectum: 39.6	Cell line enriched	108	RT4: 416.9
UGT1A3	UGT1C	ENSG00000243135	UDP glucuronosyltransferase family 1 member A3	2	233729108-233773299	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	7	liver: 38.2	small intestine: 5.6	Cell line enriched	11	HaCaT: 10.9
UGT1A4	HUG-BR2, UGT1D	ENSG00000244474	UDP glucuronosyltransferase family 1 member A4	2	233718778-233773299	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	31	liver: 212.3	duodenum: 6.7	Not detected		
UGT1A5	UGT1E	ENSG00000240224	UDP glucuronosyltransferase family 1 member A5	2	233712992-233773299	Enzymes, Predicted membrane proteins	Evidence at transcript level							Not detected	Group enriched	7	duodenum: 7.5;gallbladder: 3.9;small intestine: 6.8	liver: 0.9	Not detected		
UGT1A6	GNT1, HLUGP, UGT1F	ENSG00000167165	UDP glucuronosyltransferase family 1 member A6	2	233691607-233773300	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009819, HPA054065	Enhanced				Liver cancer:2.89e-6 (unfavourable)	Tissue enhanced	Group enriched	6	kidney: 75.4;liver: 72.4;urinary bladder: 107.9	esophagus: 15.2	Cell line enhanced		CACO-2: 44.4;EFO-21: 75.2;HaCaT: 258.5;RT4: 119.0
UGT1A7	UGT1G	ENSG00000244122	UDP glucuronosyltransferase family 1 member A7	2	233681938-233773299	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Group enriched	Tissue enriched	13	esophagus: 61.4	tonsil: 4.6	Cell line enriched	21	SiHa: 118.8
UGT1A8	UGT1H	ENSG00000242366	UDP glucuronosyltransferase family 1 member A8	2	233617645-233773310	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		colon: 16.0;gallbladder: 10.3;rectum: 9.7;urinary bladder: 22.7	small intestine: 4.9	Cell line enriched	53	RT4: 96.7
UGT1A9	HLUGP4, LUGP4, UGT1AI	ENSG00000241119	UDP glucuronosyltransferase family 1 member A9	2	233671853-233773300	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level						Renal cancer:5.04e-5 (unfavourable)	Group enriched	Group enriched	592	kidney: 465.5;liver: 93.3	cerebral cortex,colon: 0.4	Cell line enhanced		A549: 1.2
UGT2A1		ENSG00000173610	UDP glucuronosyltransferase family 2 member A1 complex locus	4	69588417-69653249	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017261, HPA045108	Uncertain					Tissue enhanced	Group enriched	7	kidney: 8.1;liver: 5.5	skin: 0.9	Not detected		
UGT2A2		ENSG00000271271	UDP glucuronosyltransferase family 2 member A2	4	69589309-69639642	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Uncertain					Not detected	Not detected			cervix, uterine,skin: 0.2	Not detected		
UGT2A3	FLJ21934	ENSG00000135220	UDP glucuronosyltransferase family 2 member A3	4	68928463-68951791	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Supported				Renal cancer:6.07e-7 (favourable), Colorectal cancer:3.31e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 82.1;gallbladder: 46.3;kidney: 46.8;small intestine: 85.9	rectum: 23.9	Cell line enriched	8	Hep G2: 13.5
UGT2B10		ENSG00000109181	UDP glucuronosyltransferase family 2 member B10	4	68815993-68831196	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Uncertain					Tissue enriched	Tissue enriched	87	liver: 304.0	gallbladder: 3.4	Cell line enriched	33	Hep G2: 7.9
UGT2B11		ENSG00000213759	UDP glucuronosyltransferase family 2 member B11	4	69199951-69214731	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA045108	Uncertain					Group enriched	Tissue enriched	17	breast: 320.4	gallbladder: 18.3	Not detected		
UGT2B15	UGT2B8	ENSG00000196620	UDP glucuronosyltransferase family 2 member B15	4	68646630-68670628	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Approved				Urothelial cancer:4.50e-4 (favourable), Liver cancer:9.82e-4 (favourable)	Tissue enriched	Group enriched	5	gallbladder: 110.7;liver: 107.6	small intestine: 20.6	Not detected		
UGT2B17		ENSG00000197888	UDP glucuronosyltransferase family 2 member B17	4	68537184-68568527	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Supported					Group enriched	Tissue enhanced		colon: 372.4;duodenum: 371.2;small intestine: 522.5	rectum: 151.7	Cell line enhanced		RPMI-8226: 1.2
UGT2B28		ENSG00000135226	UDP glucuronosyltransferase family 2 member B28	4	69280499-69295050	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045108	Uncertain					Tissue enriched	Tissue enriched	12	breast: 267.2	gallbladder: 21.5	Group enriched	9	Daudi: 2.1;NB-4: 1.7
UGT2B4	UGT2B11	ENSG00000156096	UDP glucuronosyltransferase family 2 member B4	4	69480165-69526014	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033260, HPA045108	Enhanced					Tissue enriched	Tissue enriched	78	liver: 655.5	heart muscle: 8.3	Cell line enriched	11	RH-30: 4.5
UGT2B7	UGT2B9	ENSG00000171234	UDP glucuronosyltransferase family 2 member B7	4	69051363-69112987	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045108	Uncertain				Colorectal cancer:7.65e-5 (favourable), Renal cancer:3.79e-4 (favourable), Urothelial cancer:5.38e-4 (favourable)	Group enriched	Group enriched	13	kidney: 1326.3;liver: 825.7	fallopian tube: 79.7	Cell line enhanced		EFO-21: 73.2;RPTEC TERT1: 235.7;U-2197: 40.2
UGT3A1	FLJ34658	ENSG00000145626	UDP glycosyltransferase family 3 member A1	5	35951010-36001028	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047697, HPA056290	Uncertain		Approved	Vesicles<br>Cytosol		Group enriched	Tissue enhanced		kidney: 53.4;liver: 29.2	duodenum: 9.5	Cell line enriched	51	RH-30: 26.5
UGT3A2		ENSG00000168671	UDP glycosyltransferase family 3 member A2	5	36035017-36071358	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059475	Uncertain		Approved	Nucleus<br>Cytosol		Tissue enriched	Tissue enhanced		skin: 11.9;testis: 4.6	bone marrow: 3.2	Cell line enhanced		HDLM-2: 6.3;MOLT-4: 9.8;REH: 25.8;T-47d: 6.7;THP-1: 11.2
UGT8	CGT	ENSG00000174607	UDP glycosyltransferase 8	4	114598455-114678224	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014405, HPA065785	Approved		Approved	Mitochondria	Renal cancer:8.55e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 101.0	kidney: 29.8	Cell line enhanced		CAPAN-2: 44.4;RPTEC TERT1: 37.0;SCLC-21H: 32.8
ULBP1	RAET1I	ENSG00000111981	UL16 binding protein 1	6	149964007-149973710	Predicted membrane proteins	Evidence at protein level	HPA007547, HPA071005	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Mixed	Tissue enhanced		testis: 11.0	thyroid gland: 3.5	Cell line enhanced		HAP1: 35.9
ULBP2	RAET1H	ENSG00000131015	UL16 binding protein 2	6	149942000-149949235	Predicted membrane proteins	Evidence at protein level	CAB018974	Approved		Supported	Vesicles<br>Plasma membrane	Glioma:3.69e-4 (unfavourable), Cervical cancer:8.07e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex,esophagus: 3.0	Cell line enhanced		SiHa: 69.8
ULK4	FAM7C1, FLJ20574, REC01035	ENSG00000168038	Unc-51 like kinase 4	3	41246599-41962430	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017930	Uncertain		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Mixed	Tissue enhanced		testis: 38.1	parathyroid gland: 14.4	Mixed		
UMOD		ENSG00000169344	Uromodulin	16	20333052-20356301	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009446, HPA043420, HPA054721	Enhanced					Tissue enriched	Tissue enriched	726	kidney: 2392.4	cerebral cortex: 3.2	Not detected		
UMODL1		ENSG00000177398	Uromodulin like 1	21	42062959-42143453	Predicted membrane proteins	Evidence at protein level	HPA067245	Uncertain					Group enriched	Group enriched	7	fallopian tube: 1.7;testis: 1.7	small intestine: 0.2	Group enriched	6	SCLC-21H: 1.8;U-266/70: 2.9
UNC45A	GC-UNC45, SMAP-1	ENSG00000140553	Unc-45 myosin chaperone A	15	90930180-90954093	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039228	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:7.46e-7 (favourable), Liver cancer:7.72e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.3	Expressed in all		
UNC50	GMH1, UNCL, URP	ENSG00000115446	Unc-50 inner nuclear membrane RNA binding protein	2	98608579-98618515	Predicted membrane proteins	Evidence at protein level	HPA027009	Approved				Liver cancer:4.89e-5 (unfavourable), Breast cancer:4.79e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 106.2	Expressed in all		
UNC5A	KIAA1976, UNC5H1	ENSG00000113763	Unc-5 netrin receptor A	5	176810477-176880895	Predicted membrane proteins	Evidence at protein level	HPA071450			Approved	Plasma membrane<br>Cytosol	Endometrial cancer:2.23e-4 (unfavourable)	Tissue enhanced	Group enriched	22	adrenal gland: 10.3;cerebral cortex: 35.4	lymph node: 1.0	Cell line enriched	14	SCLC-21H: 104.8
UNC5B	p53RDL1, UNC5H2	ENSG00000107731	Unc-5 netrin receptor B	10	71212570-71302864	Plasma proteins, Predicted membrane proteins	Evidence at protein level						Liver cancer:3.01e-5 (unfavourable), Ovarian cancer:3.80e-5 (unfavourable), Renal cancer:1.54e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 38.5	cerebral cortex: 16.9	Cell line enhanced		HHSteC: 122.9;hTCEpi: 95.5;SH-SY5Y: 131.0
UNC5C		ENSG00000182168	Unc-5 netrin receptor C	4	95162504-95549206	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		thyroid gland: 20.0	adrenal gland: 11.6	Group enriched	6	AF22: 17.6;SH-SY5Y: 82.9
UNC5D	KIAA1777, Unc5h4	ENSG00000156687	Unc-5 netrin receptor D	8	35235457-35796550	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042940	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 9.2;duodenum: 6.1;prostate: 8.3	cervix, uterine: 3.4	Cell line enhanced		HEK93: 2.7;NTERA-2: 9.6;SH-SY5Y: 3.5;U-251 MG: 2.5
UNC79	KIAA1409	ENSG00000133958	Unc-79 homolog (C. elegans)	14	93333219-93707876	Predicted membrane proteins	Evidence at protein level	HPA071881			Approved	Nucleus<br>Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 5.2;testis: 3.0	adrenal gland: 1.0	Cell line enhanced		REH: 3.9;SCLC-21H: 3.6;SH-SY5Y: 2.0;U-937: 1.2
UNC93A	dJ366N23.1, dJ366N23.2	ENSG00000112494	Unc-93 homolog A (C. elegans)	6	167271169-167316019	Predicted membrane proteins	Evidence at protein level	HPA035729	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 9.7;liver: 7.1;skin: 17.8	esophagus: 5.6	Group enriched	9	CACO-2: 6.1;Hep G2: 2.1;SCLC-21H: 3.7
UNC93B1	UNC93	ENSG00000110057	Unc-93 homolog B1 (C. elegans)	11	67991104-68004982	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038716, HPA038717, HPA042803	Approved		Approved	Nucleoplasm	Pancreatic cancer:1.73e-4 (unfavourable), Renal cancer:7.38e-4 (unfavourable)	Expressed in all	Mixed			spleen: 54.4	Cell line enhanced		CAPAN-2: 111.1;RPMI-8226: 250.7
UPK1A	TSPAN21	ENSG00000105668	Uroplakin 1A	19	35666516-35678483	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049879	Enhanced					Tissue enriched	Tissue enhanced		esophagus: 26.9;urinary bladder: 108.7	skin: 15.6	Cell line enriched	9	RT4: 31.3
UPK1B	TSPAN20, UPK1	ENSG00000114638	Uroplakin 1B	3	119173517-119205153	Predicted membrane proteins, Transporters	Evidence at protein level	HPA031799, HPA031800	Enhanced				Endometrial cancer:3.87e-5 (favourable), Stomach cancer:7.76e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		stomach: 33.1;urinary bladder: 36.1	tonsil: 15.4	Cell line enhanced		CACO-2: 33.3;RPTEC TERT1: 27.6;RT4: 115.3
UPK2	MGC138598, UP2, UPII	ENSG00000110375	Uroplakin 2	11	118925164-118958559	Predicted membrane proteins, Transporters	Evidence at protein level	HPA043312, HPA061106	Enhanced				Renal cancer:7.30e-7 (unfavourable), Lung cancer:9.57e-4 (unfavourable)	Tissue enriched	Tissue enriched	44	urinary bladder: 68.5	adipose tissue: 1.5	Cell line enhanced		BEWO: 25.9;MCF7: 113.9;RT4: 131.8
UPK3A	UPK3	ENSG00000100373	Uroplakin 3A	22	45284982-45295874	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018407, HPA018415	Enhanced		Uncertain	Nuclear membrane<br>Nuclear bodies		Group enriched	Group enriched	7	parathyroid gland: 13.0;prostate: 35.0;skeletal muscle: 12.6;urinary bladder: 15.4	thyroid gland: 2.6	Group enriched	6	Hep G2: 20.8;RT4: 40.2
UPK3B	FLJ32198, MGC10902, p35, UPIIIb	ENSG00000243566	Uroplakin 3B	7	76510428-76516521	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA010506	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol		Group enriched	Group enriched	11	esophagus: 12.4;lung: 29.8;urinary bladder: 11.0	tonsil: 1.6	Group enriched	8	A549: 12.0;CAPAN-2: 41.9;HaCaT: 8.6;RT4: 26.3;T-47d: 25.4
UPK3BL	UPLP	ENSG00000267368	Uroplakin 3B-like	7	102637025-102642791	Predicted membrane proteins, Transporters	Evidence at protein level	HPA011403	Supported					Mixed	Expressed in all			esophagus: 138.6	Cell line enhanced		HaCaT: 109.3
UQCC1	BFZB, C20orf44, CBP3, FLJ10850, UQCC	ENSG00000101019	Ubiquinol-cytochrome c reductase complex assembly factor 1	20	35302566-35412141	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034875	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			parathyroid gland: 43.4	Expressed in all		
UQCC3	C11orf83, UNQ655	ENSG00000204922	Ubiquinol-cytochrome c reductase complex assembly factor 3	11	62670273-62673687	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA046851	Approved		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Liver cancer:2.55e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 8.8	Expressed in all		
UQCR10	HSPC051, QCR9, UCCR7.2, UCRC	ENSG00000184076	Ubiquinol-cytochrome c reductase, complex III subunit X	22	29767369-29770413	Predicted membrane proteins	Evidence at protein level						Renal cancer:5.45e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 205.9	Expressed in all		
UQCR11	QCR10, UQCR	ENSG00000127540	Ubiquinol-cytochrome c reductase, complex III subunit XI	19	1597172-1605490	Predicted membrane proteins	Evidence at protein level						Endometrial cancer:1.23e-4 (favourable), Renal cancer:1.65e-4 (favourable), Pancreatic cancer:1.86e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 111.9	Expressed in all		
URGCP	DKFZp666G166, DKFZp686O0457, FLJ20654, KIAA1507, URG4	ENSG00000106608	Upregulator of cell proliferation	7	43875894-43926411	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019879, HPA020134, HPA029468	Approved		Supported	Cytosol	Renal cancer:1.90e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.6	Expressed in all		
USE1	D12, MDS032, p31, SLT1	ENSG00000053501	Unconventional SNARE in the ER 1	19	17215346-17219829	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026851, HPA047562	Approved				Renal cancer:3.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 41.9	Expressed in all		
USH2A	RP39, USH2	ENSG00000042781	Usherin	1	215622894-216423396	Disease related genes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		liver: 3.6;testis: 1.0	epididymis: 0.7	Not detected		
USMG5	bA792D24.4, DAPIT, MGC14697	ENSG00000173915	Up-regulated during skeletal muscle growth 5 homolog (mouse)	10	103389041-103396466	Predicted membrane proteins	Evidence at protein level	HPA044798			Supported	Mitochondria		Expressed in all	Expressed in all			heart muscle: 554.9	Expressed in all		
USP19	KIAA0891, ZMYND9	ENSG00000172046	Ubiquitin specific peptidase 19	3	49108046-49120938	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.05e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 45.7	Expressed in all		
USP30	FLJ40511, MGC10702	ENSG00000135093	Ubiquitin specific peptidase 30	12	109023089-109088026	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016952	Approved				Renal cancer:5.23e-6 (favourable)	Expressed in all	Expressed in all			testis: 25.4	Expressed in all		
UST	2OST	ENSG00000111962	Uronyl 2-sulfotransferase	6	148747328-149076990	Predicted membrane proteins	Evidence at protein level	HPA032022	Approved					Expressed in all	Tissue enhanced		thyroid gland: 49.9	adrenal gland: 16.9	Mixed		
UTS2R	GPR14	ENSG00000181408	Urotensin 2 receptor	17	82374230-82375586	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Group enriched	Tissue enhanced		testis: 1.1;thyroid gland: 1.3	duodenum: 0.3	Cell line enhanced		Karpas-707: 5.1;SCLC-21H: 2.4;U-266/70: 13.2
VAMP1	SYB1, VAMP-1	ENSG00000139190	Vesicle associated membrane protein 1	12	6462237-6470987	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002779, CAB016119, CAB079000	Approved	Approved			Renal cancer:1.04e-11 (unfavourable), Colorectal cancer:6.37e-5 (unfavourable), Liver cancer:6.97e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 43.5	Cell line enriched	5	U-698: 140.4
VAMP2	SYB2, VAMP-2	ENSG00000220205	Vesicle associated membrane protein 2	17	8159149-8163546	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB078785		Supported			Renal cancer:9.76e-8 (favourable), Pancreatic cancer:3.83e-6 (favourable), Endometrial cancer:1.08e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 483.5	Expressed in all		
VAMP3	CEB	ENSG00000049245	Vesicle associated membrane protein 3	1	7771269-7781432	Cancer-related genes, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.36e-4 (favourable)	Expressed in all	Expressed in all			lung: 135.3	Expressed in all		
VAMP4		ENSG00000117533	Vesicle associated membrane protein 4	1	171700160-171742247	Predicted membrane proteins	Evidence at protein level	HPA050418	Enhanced		Approved	Golgi apparatus	Renal cancer:5.43e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 22.4	Expressed in all		
VAMP5		ENSG00000168899	Vesicle associated membrane protein 5	2	85584408-85593412	Predicted membrane proteins	Evidence at protein level	HPA035082	Supported				Renal cancer:1.28e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 119.8	Cell line enhanced		HUVEC TERT2: 284.0;LHCN-M2: 332.6;TIME: 191.2
VAMP7	SYBL1, TI-VAMP, VAMP-7	ENSG00000124333	Vesicle associated membrane protein 7	X	155881293-155943769	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036733	Approved		Supported	Vesicles	Renal cancer:2.83e-4 (favourable)	Expressed in all	Expressed in all			placenta: 57.2	Expressed in all		
VAMP8	EDB	ENSG00000118640	Vesicle associated membrane protein 8	2	85561562-85582031	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006882, CAB037132, CAB037147	Enhanced				Thyroid cancer:8.07e-9 (favourable), Urothelial cancer:1.59e-6 (favourable)	Expressed in all	Expressed in all			lung: 327.6	Cell line enhanced		HL-60: 584.2;NB-4: 722.5;U-937: 587.5
VANGL1	STB2	ENSG00000173218	VANGL planar cell polarity protein 1	1	115641953-115698224	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA025235, CAB076375	Approved		Approved	Plasma membrane	Colorectal cancer:7.53e-4 (favourable), Pancreatic cancer:7.89e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 19.4	Mixed		
VANGL2	KIAA1215, LPP1, LTAP, MGC119403, MGC119404, STB1, STBM, STBM1	ENSG00000162738	VANGL planar cell polarity protein 2	1	160400586-160428678	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA027043	Uncertain					Expressed in all	Tissue enhanced		skin: 44.6	cerebral cortex: 18.1	Cell line enhanced		AF22: 105.2;NTERA-2: 43.1;SH-SY5Y: 30.7
VAPA	hVAP-33, VAP-A	ENSG00000101558	VAMP associated protein A	18	9914002-9960021	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA009174	Approved		Enhanced	Endoplasmic reticulum	Renal cancer:5.72e-7 (favourable)	Expressed in all	Expressed in all			adrenal gland: 61.3	Expressed in all		
VAPB	ALS8, VAP-B, VAP-C	ENSG00000124164	VAMP associated protein B and C	20	58389122-58451101	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013144, CAB013722	Supported		Enhanced	Endoplasmic reticulum	Renal cancer:1.08e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 42.4	Expressed in all		
VASN	SLITL2	ENSG00000168140	Vasorin	16	4371848-4383528	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA011246, HPA016992	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Endometrial cancer:6.24e-5 (unfavourable)	Expressed in all	Mixed			placenta: 16.1	Cell line enriched	14	U-2197: 640.8
VCAM1	CD106	ENSG00000162692	Vascular cell adhesion molecule 1	1	100719742-100739045	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB000154, HPA034796, HPA069867	Enhanced		Approved	Cell Junctions	Head and neck cancer:7.19e-5 (favourable), Cervical cancer:3.82e-4 (favourable)	Tissue enriched	Tissue enriched	5	spleen: 549.1	lymph node: 109.7	Cell line enhanced		HHSteC: 144.7;HSkMC: 83.9;hTEC/SVTERT24-B: 31.1;U-138 MG: 25.9
VEZT	DKFZP761C241	ENSG00000028203	Vezatin, adherens junctions transmembrane protein	12	95217746-95302790	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004811, HPA017066	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.93e-5 (unfavourable), Liver cancer:1.71e-4 (unfavourable), Stomach cancer:3.68e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 31.4	Expressed in all		
VIPR1	HVR1, RDC1, VPAC1, VPAC1R	ENSG00000114812	Vasoactive intestinal peptide receptor 1	3	42489299-42537573	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026777	Approved					Tissue enhanced	Tissue enhanced		lung: 60.0	duodenum: 34.4	Cell line enhanced		CAPAN-2: 53.2;RT4: 34.8;WM-115: 77.3
VIPR2	VPAC2, VPAC2R	ENSG00000106018	Vasoactive intestinal peptide receptor 2	7	159028175-159144957	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062707	Approved					Tissue enhanced	Tissue enhanced		seminal vesicle: 28.3	epididymis: 14.9	Cell line enhanced		HMC-1: 7.8;MOLT-4: 10.2;U-266/70: 30.8
VKORC1	VKCFD2	ENSG00000167397	Vitamin K epoxide reductase complex subunit 1	16	31090842-31095980	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042720	Approved		Supported	Endoplasmic reticulum	Renal cancer:2.09e-10 (unfavourable)	Expressed in all	Expressed in all			liver: 141.4	Expressed in all		
VKORC1L1		ENSG00000196715	Vitamin K epoxide reductase complex subunit 1 like 1	7	65873267-65959563	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA053954	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			adipose tissue: 57.5	Expressed in all		
VLDLR	CARMQ1, CHRMQ1, VLDLRCH	ENSG00000147852	Very low density lipoprotein receptor	9	2621834-2660053	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB032462, HPA051312	Uncertain		Approved	Vesicles<br>Cytokinetic bridge<br>Microtubule organizing center	Endometrial cancer:5.95e-4 (favourable)	Expressed in all	Tissue enhanced		ovary: 110.0;parathyroid gland: 124.0	fallopian tube: 43.7	Cell line enhanced		BEWO: 60.5
VMA21	MEAX, XMEA	ENSG00000160131	VMA21, vacuolar ATPase assembly factor	X	151396515-151409364	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA010972	Uncertain				Cervical cancer:2.30e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 30.0	Expressed in all		
VMP1	EPG3, TANGO5, TMEM49	ENSG00000062716	Vacuole membrane protein 1	17	59707192-59842255	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030773, HPA064780	Uncertain		Approved	Nucleoli<br>Endoplasmic reticulum	Renal cancer:2.77e-8 (unfavourable), Endometrial cancer:1.56e-5 (unfavourable), Liver cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 63.4	Expressed in all		
VN1R1	V1RL1, VNR19I1, ZVNH1, ZVNR1	ENSG00000178201	Vomeronasal 1 receptor 1	19	57454790-57457142	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA062209			Uncertain	Nucleus<br>Vesicles		Mixed	Mixed			epididymis: 2.7	Cell line enhanced		HEK93: 2.6;U-266/70: 1.9;U-266/84: 2.3
VN1R2	V1RL2	ENSG00000196131	Vomeronasal 1 receptor 2	19	53258292-53261837	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA044551	Uncertain					Not detected	Mixed			small intestine: 2.4	Not detected		
VN1R4	V1RL4	ENSG00000228567	Vomeronasal 1 receptor 4	19	53266676-53267723	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA027018	Uncertain					Not detected	Not detected			testis: 0.5	Not detected		
VNN2	FOAP-4, GPI-80	ENSG00000112303	Vanin 2	6	132743870-132763459	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.72e-7 (unfavourable)	Mixed	Tissue enhanced		spleen: 76.9	lymph node: 45.0	Cell line enriched	6	Daudi: 40.8
VOPP1	DKFZp564K0822, ECop, FLJ20532, GASP	ENSG00000154978	Vesicular, overexpressed in cancer, prosurvival protein 1	7	55436056-55572988	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level						Renal cancer:6.99e-8 (unfavourable), Liver cancer:4.35e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 110.2	Mixed		
VRK1		ENSG00000100749	Vaccinia related kinase 1	14	96797304-96931722	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000660, HPA017929	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:4.15e-4 (unfavourable)	Expressed in all	Mixed			testis: 59.5	Expressed in all		
VRK2		ENSG00000028116	Vaccinia related kinase 2	2	57907651-58159920	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB046459, HPA047503	Approved		Supported	Endoplasmic reticulum	Liver cancer:6.32e-6 (unfavourable), Renal cancer:4.66e-5 (unfavourable), Pancreatic cancer:4.65e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 29.1	Mixed		
VSIG1	MGC44287	ENSG00000101842	V-set and immunoglobulin domain containing 1	X	108044970-108079184	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001445, HPA036310, HPA036311	Enhanced		Approved	Vesicles<br>Cytosol		Group enriched	Group enriched	10	stomach: 185.7;testis: 91.1	gallbladder: 14.3	Cell line enhanced		HBEC3-KT: 2.5;HUVEC TERT2: 5.9;PC-3: 2.2
VSIG10		ENSG00000176834	V-set and immunoglobulin domain containing 10	12	118063593-118136026	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062022			Approved	Microtubule organizing center<br>Cytosol	Liver cancer:1.76e-4 (unfavourable), Melanoma:7.53e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 27.7	Cell line enhanced		HAP1: 35.3
VSIG10L		ENSG00000186806	V-set and immunoglobulin domain containing 10 like	19	51331536-51342124	Predicted membrane proteins	Evidence at protein level	HPA060453, HPA066745	Uncertain		Enhanced	Nucleus	Liver cancer:8.75e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 31.4;salivary gland: 9.2	skin: 5.9	Group enriched	6	Hep G2: 3.2;T-47d: 7.9
VSIG2	CTH, CTXL	ENSG00000019102	V-set and immunoglobulin domain containing 2	11	124747472-124752238	Predicted membrane proteins	Evidence at protein level	HPA035919, HPA050147	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		stomach: 583.7	rectum: 151.1	Group enriched	7	HEL: 14.9;RT4: 55.8
VSIG4	Z39IG	ENSG00000155659	V-set and immunoglobulin domain containing 4	X	66021738-66040125	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA003903, CAB026000	Approved		Uncertain	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:1.95e-6 (unfavourable), Colorectal cancer:1.34e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 243.4	Not detected		
VSIG8		ENSG00000243284	V-set and immunoglobulin domain containing 8	1	159854316-159862657	Predicted membrane proteins	Evidence at protein level	HPA023219	Uncertain					Group enriched	Group enriched	6	skin: 13.6;tonsil: 5.8	kidney: 1.7	Not detected		
VSIR	B7-H5, B7H5, C10orf54, GI24, PD-1H, SISP1, VISTA	ENSG00000107738	V-set immunoregulatory receptor	10	71747559-71773498	Predicted membrane proteins	Evidence at protein level	HPA007968			Approved	Nucleoplasm	Testis cancer:6.93e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 184.9	Cell line enhanced		CAPAN-2: 162.4;HaCaT: 105.4;HMC-1: 173.0;U-937: 130.3
VSTM1	UNQ3033	ENSG00000189068	V-set and transmembrane domain containing 1	19	54040825-54063953	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059365			Approved	Vesicles		Mixed	Tissue enriched	38	bone marrow: 35.4	urinary bladder: 0.9	Not detected		
VSTM4	C10orf72, FLJ31737	ENSG00000165633	V-set and transmembrane domain containing 4	10	49014245-49115509	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA017279	Uncertain		Approved	Nucleus<br>Vesicles	Urothelial cancer:4.25e-4 (unfavourable)	Tissue enriched	Mixed			adrenal gland: 54.8	Cell line enhanced		RH-30: 9.1;U-138 MG: 10.5;U-2197: 22.4;U-87 MG: 11.4
VSTM5	C11orf90, LOC387804	ENSG00000214376	V-set and transmembrane domain containing 5	11	93818232-93850531	Predicted membrane proteins	Evidence at transcript level	HPA029525, HPA063591	Uncertain		Uncertain	Endoplasmic reticulum		Mixed	Tissue enhanced		placenta: 6.5	cerebral cortex: 2.8	Cell line enhanced		HaCaT: 1.1;PC-3: 5.1;SH-SY5Y: 2.3
VTCN1	B7-H4, B7H4, B7S1, B7X, FLJ22418	ENSG00000134258	V-set domain containing T-cell activation inhibitor 1	1	117143587-117210960	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054200	Approved		Approved	Plasma membrane<br>Cell Junctions<br>Focal adhesion sites		Group enriched	Tissue enhanced		breast: 129.4;fallopian tube: 51.3	cervix, uterine: 22.0	Group enriched	8	BEWO: 43.1;SK-BR-3: 182.1
VTI1A	MVti1, Vti1-rp2, Vti1a	ENSG00000151532	Vesicle transport through interaction with t-SNAREs 1A	10	112446998-112818744	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054108	Supported		Supported	Golgi apparatus<br>Vesicles	Liver cancer:6.50e-5 (unfavourable), Renal cancer:7.27e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.1	Expressed in all		
VTI1B	VTI2	ENSG00000100568	Vesicle transport through interaction with t-SNAREs 1B	14	67647075-67674831	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044121, HPA048150, HPA060118	Approved		Enhanced	Golgi apparatus<br>Vesicles	Renal cancer:3.53e-12 (favourable)	Expressed in all	Expressed in all			epididymis: 64.9	Expressed in all		
WAC	BM-016, FLJ31290, MGC10753, PRO1741, Wwp4	ENSG00000095787	WW domain containing adaptor with coiled-coil	10	28532493-28623112	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036528, HPA042609	Approved		Supported	Nucleoplasm	Liver cancer:9.27e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 132.1	Expressed in all		
WBP1	WBP-1	ENSG00000239779	WW domain binding protein 1	2	74458329-74460891	Predicted membrane proteins	Evidence at protein level	HPA057067	Approved		Approved	Cytosol	Colorectal cancer:1.04e-4 (unfavourable), Urothelial cancer:6.36e-4 (favourable), Pancreatic cancer:6.83e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 91.5	Expressed in all		
WBP1L	C10orf26, FLJ20154, OPAL1	ENSG00000166272	WW domain binding protein 1-like	10	102743970-102816267	Predicted membrane proteins	Evidence at protein level	HPA037635, HPA038371	Uncertain		Approved	Nucleoplasm<br>Microtubules	Renal cancer:1.56e-6 (favourable), Endometrial cancer:4.03e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 69.9	Expressed in all		
WBSCR28	MGC26719	ENSG00000175877	Williams-Beuren syndrome chromosome region 28	7	73861159-73865893	Predicted membrane proteins	Evidence at transcript level	HPA077196			Approved	Vesicles		Mixed	Tissue enriched	99	testis: 36.2	duodenum: 0.3	Cell line enhanced		MCF7: 1.2
WDFY4	C10orf64, Em:AC060234.3, FLJ45748, KIAA1607	ENSG00000128815	WDFY family member 4	10	48684876-48982956	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040634	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		lymph node: 33.0;spleen: 23.8	tonsil: 22.1	Cell line enhanced		Daudi: 43.5;HDLM-2: 52.1;HL-60: 17.1;U-698: 17.8;U-937: 19.6
WDHD1	AND-1, CHTF4, CTF4	ENSG00000198554	WD repeat and HMG-box DNA binding protein 1	14	54938950-55027105	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001122	Enhanced		Enhanced	Nucleoplasm	Pancreatic cancer:9.24e-4 (unfavourable)	Expressed in all	Mixed			testis: 9.8	Expressed in all		
WDR11	BRWD2, DR11, FLJ10506, HH14, KIAA1351, SRI1, WDR15	ENSG00000120008	WD repeat domain 11	10	120851175-120909524	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038980	Approved		Approved	Microtubules<br>Cytosol	Renal cancer:5.04e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 46.6	Expressed in all		
WDR17		ENSG00000150627	WD repeat domain 17	4	176065834-176182818	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042766, HPA054501	Approved		Approved	Nuclear speckles		Mixed	Tissue enhanced		cerebral cortex: 25.2;parathyroid gland: 19.3	thyroid gland: 11.0	Cell line enhanced		AF22: 7.7;SCLC-21H: 10.5
WDR33	FLJ11294, NET14, WDC146	ENSG00000136709	WD repeat domain 33	2	127701022-127811187	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026897, HPA046527	Supported		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Liver cancer:2.13e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 38.2	Expressed in all		
WDR45	JM5, NBIA5, WDRX1, WIPI4	ENSG00000196998	WD repeat domain 45	X	49071470-49101170	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027562	Uncertain		Approved	Nucleoli	Cervical cancer:1.21e-4 (favourable), Head and neck cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 258.8	Expressed in all		
WDR83OS	C19orf56, PTD008	ENSG00000105583	WD repeat domain 83 opposite strand	19	12668071-12671356	Predicted membrane proteins	Evidence at protein level	HPA065685	Approved		Approved	Endoplasmic reticulum	Lung cancer:2.09e-4 (favourable), Ovarian cancer:8.84e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 320.1	Expressed in all		
WFS1	DFNA14, DFNA38, DFNA6, DIDMOAD, WFS	ENSG00000109501	Wolframin ER transmembrane glycoprotein	4	6269849-6303265	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029128	Approved				Endometrial cancer:1.13e-6 (favourable), Thyroid cancer:3.13e-4 (unfavourable)	Expressed in all	Mixed			ovary: 61.5	Cell line enhanced		BEWO: 97.0
WHRN	CIP98, DFNB31, PDZD7B, USH2D	ENSG00000095397	Whirlin	9	114402080-114505450	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002480, CAB033194	Uncertain				Pancreatic cancer:2.28e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 73.0	testis: 44.4	Cell line enhanced		Karpas-707: 96.9;U-266/70: 64.0;U-266/84: 64.8
WLS	C1orf139, EVI, FLJ23091, GPR177, mig-14, MRP, wls	ENSG00000116729	Wntless Wnt ligand secretion mediator	1	68098473-68233120	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA069520	Approved				Renal cancer:3.67e-7 (favourable), Urothelial cancer:3.51e-4 (unfavourable), Breast cancer:4.03e-4 (favourable), Ovarian cancer:9.43e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 163.8	Cell line enhanced		AF22: 388.0
WNT10A		ENSG00000135925	Wnt family member 10A	2	218880363-218899581	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013898	Uncertain					Tissue enhanced	Tissue enhanced		skin: 8.3	placenta: 3.9	Cell line enhanced		CAPAN-2: 36.8;HaCaT: 106.8;HDLM-2: 47.5;U-266/70: 47.5
WNT2B	WNT13, XWNT2	ENSG00000134245	Wnt family member 2B	1	112466541-112530165	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047274, HPA060696, HPA066368	Uncertain		Approved	Nucleoplasm<br>Vesicles		Tissue enhanced	Mixed			seminal vesicle: 20.0	Cell line enhanced		HSkMC: 6.3
WNT4	WNT-4	ENSG00000162552	Wnt family member 4	1	22117305-22143969	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011397	Uncertain		Approved	Vesicles	Pancreatic cancer:4.90e-4 (favourable), Melanoma:5.34e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 49.2	ovary: 15.3	Cell line enhanced		HaCaT: 7.6;SCLC-21H: 12.2;SK-BR-3: 6.6
WRB	CHD5, GET1	ENSG00000182093	Tryptophan rich basic protein	21	39380244-39428528	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018527	Approved					Expressed in all	Expressed in all			fallopian tube: 109.1	Expressed in all		
WWP1	AIP5, DKFZP434D2111	ENSG00000123124	WW domain containing E3 ubiquitin protein ligase 1	8	86342738-86478420	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023180	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:5.45e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 183.6	Expressed in all		
XBP1	XBP2	ENSG00000100219	X-box binding protein 1	22	28794555-28800597	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level							Not detected	Expressed in all			breast: 918.6	Expressed in all		
XCR1	CCXCR1, GPR5	ENSG00000173578	X-C motif chemokine receptor 1	3	46017024-46027742	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013169	Uncertain					Mixed	Tissue enhanced		lymph node: 10.8	spleen: 9.1	Cell line enhanced		Karpas-707: 1.8
XG	PBDX	ENSG00000124343	Xg blood group	X	2752050-2815927	Blood group antigen proteins, Predicted membrane proteins	Evidence at transcript level						Breast cancer:4.25e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 41.1	breast: 15.4	Group enriched	6	ASC diff: 71.8;ASC TERT1: 49.4;fHDF/TERT166: 35.9;hTCEpi: 41.4;T-47d: 32.3
XK	Kx, NA, NAC, X1k, XKR1	ENSG00000047597	X-linked Kx blood group	X	37685759-37732130	Blood group antigen proteins, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019036	Approved		Approved	Nucleoplasm<br>Vesicles<br>Mitochondria		Mixed	Mixed			rectum: 12.1	Cell line enhanced		HEL: 39.5;K-562: 25.8
XKR3	MGC57211, XTES	ENSG00000172967	XK related 3	22	16783412-16821699	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA003379, HPA035081	Uncertain					Not detected	Tissue enriched	81	testis: 14.4	cerebral cortex: 0.1	Cell line enriched	12	Karpas-707: 165.9
XKR4	KIAA1889	ENSG00000206579	XK related 4	8	55102389-55542054	Predicted membrane proteins, Transporters	Evidence at protein level	HPA025072, HPA028083	Uncertain					Not detected	Tissue enriched	6	cerebral cortex: 4.7	seminal vesicle: 0.8	Group enriched	9	REH: 2.3;RPTEC TERT1: 7.5
XKR5		ENSG00000275591	XK related 5	8	6808517-6835644	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cervix, uterine: 1.0	testis: 0.6	Cell line enhanced		AF22: 3.0;NTERA-2: 1.9;SCLC-21H: 1.8;SH-SY5Y: 3.6
XKR6	C8orf21, C8orf5, C8orf7	ENSG00000171044	XK related 6	8	10896045-11201366	Predicted membrane proteins	Evidence at protein level	HPA024828, HPA064769	Uncertain		Approved	Actin filaments		Mixed	Mixed			testis: 1.8	Cell line enhanced		U-266/84: 4.8
XKR7	C20orf159, dJ310O13.4	ENSG00000260903	XK related 7	20	31968002-32003387	Predicted membrane proteins	Evidence at protein level	HPA040854	Uncertain					Not detected	Tissue enriched	10	cerebral cortex: 3.6	adrenal gland,testis: 0.3	Group enriched	18	SCLC-21H: 24.2;SH-SY5Y: 4.9
XKR8	FLJ10307	ENSG00000158156	XK related 8	1	27959462-27968096	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049984, HPA053529	Uncertain		Approved	Golgi apparatus	Breast cancer:8.63e-4 (favourable)	Expressed in all	Expressed in all			placenta: 13.7	Mixed		
XKR9		ENSG00000221947	XK related 9	8	70669365-70790371	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA044430	Uncertain		Approved	Mitochondria	Pancreatic cancer:7.20e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 13.8	small intestine: 6.1	Cell line enhanced		hTCEpi: 4.6
XKRX	XKR2, XPLAC	ENSG00000182489	XK related, X-linked	X	100913445-100929433	Predicted membrane proteins, Transporters	Evidence at transcript level						Thyroid cancer:3.52e-4 (favourable)	Mixed	Tissue enhanced		skin: 9.4	tonsil: 3.1	Cell line enriched	5	CACO-2: 6.8
XPO7	KIAA0745, RANBP16	ENSG00000130227	Exportin 7	8	21919671-22006585	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043727, HPA048153	Uncertain		Approved	Nucleus	Colorectal cancer:2.29e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 78.8	Expressed in all		
XPR1	SYG1, X3	ENSG00000143324	Xenotropic and polytropic retrovirus receptor 1	1	180632004-180890251	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA016557	Enhanced				Liver cancer:3.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 31.3	Expressed in all		
XXbac-BPG246D15.9		ENSG00000250264		6	32813767-32838822	Predicted membrane proteins	Evidence at transcript level	HPA001312	Approved		Approved	Nuclear speckles<br>Endoplasmic reticulum		Not detected	Tissue enhanced		appendix: 15.5;spleen: 9.5	lymph node: 6.5	Cell line enhanced		Daudi: 14.2;HDLM-2: 12.4;HEL: 12.9
XXbac-BPG32J3.19		ENSG00000250641		6	31706904-31717918	Predicted membrane proteins	No evidence	HPA008053	Uncertain					Tissue enriched	Not detected			testis: 0.5	Not detected		
YIF1A	54TM, FinGER7, YIF1, YIF1P	ENSG00000174851	Yip1 interacting factor homolog A, membrane trafficking protein	11	66284580-66289170	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014840	Approved		Supported	Golgi apparatus<br>Vesicles<br>Microtubule organizing center	Urothelial cancer:8.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.3	Expressed in all		
YIF1B	FinGER8	ENSG00000167645	Yip1 interacting factor homolog B, membrane trafficking protein	19	38305104-38317273	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039328, HPA055257, HPA062675	Approved		Approved	Golgi apparatus<br>Vesicles	Liver cancer:4.53e-5 (unfavourable), Pancreatic cancer:1.88e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 49.5	Expressed in all		
YIPF1	DJ167A19.1, FinGER1	ENSG00000058799	Yip1 domain family member 1	1	53851719-53889834	Predicted membrane proteins	Evidence at protein level	HPA014716	Approved		Approved	Nucleoplasm	Liver cancer:1.34e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 35.0	Expressed in all		
YIPF2	FinGER2, MGC3262	ENSG00000130733	Yip1 domain family member 2	19	10922185-10928681	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019902	Approved		Approved	Golgi apparatus<br>Mitochondria		Expressed in all	Expressed in all			testis: 72.9	Expressed in all		
YIPF3	C6orf109, dJ337H4.3, DKFZp566C243, FinGER3, KLIP1	ENSG00000137207	Yip1 domain family member 3	6	43511827-43516990	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014859, HPA063699	Supported		Enhanced	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 142.8	Expressed in all		
YIPF4	FinGER4, MGC11061	ENSG00000119820	Yip1 domain family member 4	2	32277910-32316594	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017884	Supported		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			cerebral cortex: 19.0	Expressed in all		
YIPF5	FinGER5, SMAP-5	ENSG00000145817	Yip1 domain family member 5	5	144158159-144170714	Predicted membrane proteins	Evidence at protein level	HPA042338, HPA073622	Enhanced		Supported	Nucleoplasm<br>Endoplasmic reticulum<br>Golgi apparatus<br>Vesicles	Head and neck cancer:1.12e-5 (unfavourable), Liver cancer:3.26e-5 (unfavourable), Breast cancer:7.83e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 43.2	Expressed in all		
YIPF6	FinGER6, MGC21416	ENSG00000181704	Yip1 domain family member 6	X	68498323-68537285	Predicted membrane proteins	Evidence at protein level	HPA003720	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			thyroid gland: 32.8	Mixed		
YIPF7	FinGER9, FLJ39576	ENSG00000177752	Yip1 domain family member 7	4	44622065-44678556	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA030642	Uncertain					Not detected	Tissue enriched	42	skeletal muscle: 29.6	esophagus: 0.6	Not detected		
YME1L1		ENSG00000136758	YME1 like 1 ATPase	10	27110112-27155266	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066953	Approved		Supported	Nuclear bodies<br>Mitochondria	Liver cancer:8.25e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 105.7	Expressed in all		
ZACN	L2, LGICZ, LGICZ1, ZAC, ZAC1	ENSG00000186919	Zinc activated ion channel	17	76071961-76083666	Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZAN		ENSG00000146839	Zonadhesin (gene/pseudogene)	7	100733626-100797797	Predicted membrane proteins	No evidence							Tissue enriched	Not detected			testis: 0.5	Not detected		
ZBTB11	ZNF-U69274, ZNF913	ENSG00000066422	Zinc finger and BTB domain containing 11	3	101648889-101677495	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA015328, HPA024138	Approved		Enhanced	Nucleoplasm	Endometrial cancer:7.49e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 23.4	Expressed in all		
ZDHHC1	C16orf1, HSU90653, ZNF377	ENSG00000159714	Zinc finger DHHC-type containing 1	16	67394419-67416833	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA042531, HPA048659	Uncertain		Approved	Cytosol	Endometrial cancer:1.25e-6 (favourable), Renal cancer:1.55e-6 (favourable), Pancreatic cancer:5.99e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 31.8	Mixed		
ZDHHC11	FLJ13153, ZNF399	ENSG00000188818	Zinc finger DHHC-type containing 11	5	795606-850986	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA057886, HPA069008	Uncertain		Approved	Lipid droplets		Mixed	Mixed			fallopian tube: 10.6	Cell line enhanced		T-47d: 10.8
ZDHHC11B		ENSG00000206077	Zinc finger DHHC-type containing 11B	5	710360-766952	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA057886, HPA069008	Uncertain		Approved	Lipid droplets	Lung cancer:3.98e-4 (favourable)	Mixed	Mixed			cerebral cortex: 6.2	Cell line enhanced		HAP1: 2.8;SCLC-21H: 4.1;THP-1: 2.7
ZDHHC12	FLJ14524, ZNF400	ENSG00000160446	Zinc finger DHHC-type containing 12	9	128720869-128724127	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA059339	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			small intestine: 35.8	Mixed		
ZDHHC13	FLJ10852, FLJ10941, HIP14L	ENSG00000177054	Zinc finger DHHC-type containing 13	11	19117099-19176422	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016759, HPA018791	Uncertain		Enhanced	Vesicles		Expressed in all	Mixed			esophagus: 40.4	Expressed in all		
ZDHHC14	FLJ20984, NEW1CP	ENSG00000175048	Zinc finger DHHC-type containing 14	6	157381133-157678146	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046033, HPA063754	Uncertain		Approved	Nucleoli<br>Mitochondria	Pancreatic cancer:6.93e-4 (favourable)	Expressed in all	Mixed			endometrium: 12.3	Cell line enhanced		HDLM-2: 47.1
ZDHHC15	FLJ31812, MRX91	ENSG00000102383	Zinc finger DHHC-type containing 15	X	75368427-75523502	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at transcript level	HPA003618	Uncertain		Approved	Nuclear speckles<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 4.8	Cell line enhanced		HEL: 2.8;MOLT-4: 1.9;NTERA-2: 2.0;RH-30: 3.0;SH-SY5Y: 2.7
ZDHHC16	APH2	ENSG00000171307	Zinc finger DHHC-type containing 16	10	97446131-97457370	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA039893, HPA040214	Uncertain		Supported	Nucleus<br>Nuclear membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland,placenta: 31.5	Expressed in all		
ZDHHC17	HIP14, HYPH, KIAA0946	ENSG00000186908	Zinc finger DHHC-type containing 17	12	76763588-76853696	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016807, HPA058674	Approved		Supported	Golgi apparatus<br>Vesicles<br>Aggresome	Renal cancer:7.11e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 45.2	Expressed in all		
ZDHHC18	DKFZp667O2416	ENSG00000204160	Zinc finger DHHC-type containing 18	1	26826710-26857602	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA040234	Approved		Approved	Microtubules	Renal cancer:1.36e-10 (unfavourable), Liver cancer:7.42e-7 (unfavourable), Glioma:9.53e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 75.2	Expressed in all		
ZDHHC19	MGC33345	ENSG00000163958	Zinc finger DHHC-type containing 19	3	196197449-196211437	Enzymes, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	44	testis: 29.2	adrenal gland: 0.6	Not detected		
ZDHHC2	ZNF372	ENSG00000104219	Zinc finger DHHC-type containing 2	8	17156029-17224799	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023331	Uncertain				Renal cancer:3.24e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.7	Mixed		
ZDHHC20	FLJ25952	ENSG00000180776	Zinc finger DHHC-type containing 20	13	21372573-21459370	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014483, HPA014702	Approved		Uncertain	Vesicles<br>Plasma membrane<br>Mitochondria	Renal cancer:1.01e-4 (unfavourable), Pancreatic cancer:6.55e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 60.5	Expressed in all		
ZDHHC21	DNZ1, HSPC097	ENSG00000175893	Zinc finger DHHC-type containing 21	9	14611071-14693471	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA065254	Approved		Approved	Golgi apparatus<br>Cytosol	Urothelial cancer:9.28e-6 (favourable), Renal cancer:1.29e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 16.0	Cell line enhanced		HEL: 26.6
ZDHHC22	C14orf59	ENSG00000177108	Zinc finger DHHC-type containing 22	14	77131270-77142734	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049471, HPA072213			Enhanced	Plasma membrane		Tissue enriched	Tissue enriched	113	cerebral cortex: 64.2	testis: 0.5	Cell line enhanced		AF22: 3.6;NTERA-2: 3.8;RH-30: 6.2;SCLC-21H: 8.2
ZDHHC23	MGC42530	ENSG00000184307	Zinc finger DHHC-type containing 23	3	113947901-113965401	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016808	Uncertain		Approved	Nucleus	Renal cancer:1.48e-7 (favourable), Endometrial cancer:2.85e-4 (unfavourable), Thyroid cancer:5.90e-4 (unfavourable)	Expressed in all	Mixed			testis: 22.5	Mixed		
ZDHHC24		ENSG00000174165	Zinc finger DHHC-type containing 24	11	66520637-66546238	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA016619	Approved		Approved	Vesicles<br>Cytosol	Glioma:2.39e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 10.9	Expressed in all		
ZDHHC3	GODZ, ZNF373	ENSG00000163812	Zinc finger DHHC-type containing 3	3	44915257-44976185	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB012465, HPA016616	Approved		Approved	Golgi apparatus	Renal cancer:1.81e-8 (favourable), Liver cancer:1.37e-4 (unfavourable), Colorectal cancer:3.43e-4 (favourable)	Expressed in all	Expressed in all			skin,testis: 65.5	Expressed in all		
ZDHHC4	FLJ10479, ZNF374	ENSG00000136247	Zinc finger DHHC-type containing 4	7	6577434-6589374	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA032124, HPA064358	Approved		Approved	Nuclear bodies	Renal cancer:1.18e-7 (favourable), Head and neck cancer:3.95e-6 (unfavourable), Urothelial cancer:8.94e-4 (unfavourable), Cervical cancer:9.35e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 77.7	Mixed		
ZDHHC5	KIAA1748, ZNF375	ENSG00000156599	Zinc finger DHHC-type containing 5	11	57667747-57701187	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014670	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Pancreatic cancer:6.74e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 87.5	Expressed in all		
ZDHHC6	FLJ21952, ZNF376	ENSG00000023041	Zinc finger DHHC-type containing 6	10	112424428-112446917	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014357	Approved					Expressed in all	Expressed in all			small intestine: 50.7	Expressed in all		
ZDHHC7	FLJ10792, FLJ20279, SERZ-B, SERZ1, ZNF370	ENSG00000153786	Zinc finger DHHC-type containing 7	16	84974181-85011535	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA019215, HPA059054, HPA059642	Uncertain		Enhanced	Golgi apparatus	Renal cancer:1.12e-5 (favourable), Liver cancer:4.20e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 64.8	Expressed in all		
ZDHHC8	KIAA1292, ZNF378	ENSG00000099904	Zinc finger DHHC-type containing 8	22	20129456-20148007	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA003422	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.04e-4 (unfavourable), Cervical cancer:9.68e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 29.7	Mixed		
ZDHHC9	CGI-89, CXorf11, ZDHHC10, ZNF379, ZNF380	ENSG00000188706	Zinc finger DHHC-type containing 9	X	129803288-129843909	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA031814	Uncertain		Supported	Golgi apparatus<br>Cytosol	Cervical cancer:4.64e-5 (unfavourable), Breast cancer:9.77e-5 (unfavourable), Head and neck cancer:2.45e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 71.1	Expressed in all		
ZFPL1	D11S750, MCG4	ENSG00000162300	Zinc finger protein like 1	11	65084223-65088400	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014909, HPA017347	Enhanced		Enhanced	Golgi apparatus	Liver cancer:9.12e-6 (unfavourable), Renal cancer:2.73e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 31.7	Expressed in all		
ZFYVE27	FLJ32919, SPG33	ENSG00000155256	Zinc finger FYVE-type containing 27	10	97737121-97760907	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA037523, HPA069876	Approved		Approved	Nucleoplasm<br>Cytosol	Colorectal cancer:6.91e-4 (unfavourable), Stomach cancer:7.54e-4 (favourable), Urothelial cancer:7.80e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 33.3	Expressed in all		
ZMPSTE24	FACE-1, HGPS, PRO1, STE24, Ste24p	ENSG00000084073	Zinc metallopeptidase STE24	1	40258107-40294184	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006988	Approved		Approved	Golgi apparatus<br>Cytosol	Liver cancer:5.73e-6 (unfavourable), Thyroid cancer:6.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 90.5	Expressed in all		
ZMYM5	MYM, ZNF198L1, ZNF237	ENSG00000132950	Zinc finger MYM-type containing 5	13	19823482-19863636	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020879	Uncertain					Expressed in all	Expressed in all			testis: 44.5	Expressed in all		
ZMYM6	Buster2, MYM, ZBED7, ZNF198L4, ZNF258	ENSG00000163867	Zinc finger MYM-type containing 6	1	34986165-35031968	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011004, HPA071865	Approved		Supported	Nucleoplasm	Breast cancer:1.30e-5 (favourable)	Expressed in all	Mixed			testis: 19.0	Expressed in all		
ZMYND11	BS69	ENSG00000015171	Zinc finger MYND-type containing 11	10	134465-254637	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015816			Supported	Nucleoplasm	Renal cancer:4.76e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 201.0	Mixed		
ZNF333	KIAA1806	ENSG00000160961	Zinc finger protein 333	19	14689801-14733746	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA043973, HPA054680	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			endometrium: 11.1	Mixed		
ZNF511	MGC30006	ENSG00000198546	Zinc finger protein 511	10	133308475-133313162	Predicted membrane proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA035360	Uncertain				Renal cancer:1.13e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 12.2	Expressed in all		
ZNF511-PRAP1		ENSG00000283496	ZNF511-PRAP1 readthrough	10	133309410-133352529	Predicted membrane proteins	Evidence at protein level	HPA035360, HPA038713, HPA052451	Supported		Uncertain	Nucleoplasm<br>Vesicles<br>Plasma membrane			Tissue enhanced		duodenum: 25.2;small intestine: 25.0	kidney: 10.7	Cell line enhanced		Hep G2: 11.3
ZNF584	FLJ39899	ENSG00000171574	Zinc finger protein 584	19	58401504-58418327	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at transcript level	HPA043408, HPA048075	Uncertain		Approved	Nuclear speckles		Expressed in all	Mixed			fallopian tube: 10.1	Mixed		
ZNF66	FLJ16537, ZNF66P	ENSG00000160229	Zinc finger protein 66	19	20776304-20807322	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		ovary: 9.5	thyroid gland: 4.2	Cell line enhanced		RT4: 11.8
ZNF816	ZNF816A	ENSG00000180257	Zinc finger protein 816	19	52949379-52962911	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA042466	Uncertain		Uncertain	Nucleoli		Expressed in all	Mixed			prostate: 20.8	Cell line enhanced		RT4: 42.8
ZNRF3	BK747E2.3, FLJ22057, KIAA1133, RNF203	ENSG00000183579	Zinc and ring finger 3	22	28883592-29057487	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA036702, HPA036703	Uncertain		Uncertain	Golgi apparatus		Not detected	Mixed			epididymis: 16.4	Cell line enhanced		Hep G2: 31.1
ZNRF4	RNF204, spzn, Ssrzf1	ENSG00000105428	Zinc and ring finger 4	19	5455431-5456856	Enzymes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	494	testis: 49.3	all non-specific tissues: 0.0	Not detected		
ZP1		ENSG00000149506	Zona pellucida glycoprotein 1	11	60867562-60875693	Disease related genes, Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			epididymis,prostate: 0.2	Group enriched	37	RPMI-8226: 8.4;SK-BR-3: 2.5
ZP2	ZPA	ENSG00000103310	Zona pellucida glycoprotein 2	16	21197450-21214510	Predicted membrane proteins	Evidence at protein level	HPA011296	Approved					Not detected	Not detected			placenta: 0.3	Cell line enriched	35	HDLM-2: 3.4
ZP3	ZP3-372, ZP3-424, ZP3A, ZP3B, ZPC	ENSG00000188372	Zona pellucida glycoprotein 3	7	76397518-76442071	Predicted membrane proteins	Evidence at protein level	HPA054061	Supported				Renal cancer:1.02e-6 (unfavourable)	Expressed in all	Mixed			fallopian tube: 6.2	Cell line enhanced		A549: 31.8;Karpas-707: 36.7;MCF7: 54.0
ZP4	ZPB	ENSG00000116996	Zona pellucida glycoprotein 4	1	237877864-237890922	Predicted membrane proteins	Evidence at protein level	HPA008547	Supported					Not detected	Not detected			tonsil: 0.2	Cell line enhanced		BJ hTERT+: 2.6
ZPLD1		ENSG00000170044	Zona pellucida like domain containing 1	3	102099244-102479841	Predicted membrane proteins	Evidence at transcript level	HPA077519			Approved	Nucleoplasm		Mixed	Tissue enhanced		gallbladder: 3.5;testis: 1.3	duodenum: 0.9	Cell line enriched	8	RPTEC TERT1: 5.0
ZZEF1	FLJ10821, KIAA0399, ZZZ4	ENSG00000074755	Zinc finger ZZ-type and EF-hand domain containing 1	17	4004445-4143020	Predicted membrane proteins	Evidence at protein level	HPA031778, HPA031790	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Head and neck cancer:1.02e-4 (favourable), Pancreatic cancer:6.08e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 25.8	Expressed in all		
